Dezapelisib
                    3D
 Structure written by MMmdl.
 46 50  0  0  1  0            999 V2000
   -5.2478   -0.9654   -0.0353 C   0  0  0  0  0  0
   -4.2579    0.1702    0.2133 C   0  0  0  0  0  0
   -4.6233    1.4431    0.4535 C   0  0  0  0  0  0
   -3.2671    2.5295    0.7003 S   0  0  0  0  0  0
   -2.1861    1.1502    0.4568 C   0  0  0  0  0  0
   -2.8808   -0.0167    0.2091 N   0  0  0  0  0  0
   -2.2263   -1.2231   -0.0068 C   0  0  0  0  0  0
   -2.7820   -2.3053   -0.2130 O   0  0  0  0  0  0
   -0.7556   -1.1258    0.0310 C   0  0  0  0  0  0
   -0.1733    0.0873    0.2883 C   0  0  0  0  0  0
   -0.9039    1.2265    0.5071 N   0  0  0  0  0  0
    1.3436    0.3521    0.3406 C   0  0  2  0  0  0
    1.8267    0.6179    1.7785 C   0  0  0  0  0  0
    1.8715    1.3725   -0.5718 N   0  0  0  0  0  0
    1.6731    1.3378   -1.9649 C   0  0  0  0  0  0
    2.2765    2.3162   -2.7796 C   0  0  0  0  0  0
    2.0270    2.2152   -4.1710 C   0  0  0  0  0  0
    2.7154    3.2673   -4.7236 N   0  0  0  0  0  0
    3.3218    3.9242   -3.6770 C   0  0  0  0  0  0
    3.0871    3.3904   -2.5024 N   0  0  0  0  0  0
    1.2794    1.2837   -4.7705 N   0  0  0  0  0  0
    0.7500    0.3936   -3.8878 C   0  0  0  0  0  0
    0.9028    0.3673   -2.5374 N   0  0  0  0  0  0
    0.0436   -2.3524   -0.1975 C   0  0  0  0  0  0
    0.7338   -2.9583    0.8597 C   0  0  0  0  0  0
    1.4835   -4.1154    0.6452 C   0  0  0  0  0  0
    1.5464   -4.6794   -0.6286 C   0  0  0  0  0  0
    0.8594   -4.0867   -1.6876 C   0  0  0  0  0  0
    0.1104   -2.9300   -1.4718 C   0  0  0  0  0  0
    0.9189   -4.6332   -2.9230 F   0  0  0  0  0  0
   -6.2754   -0.6024    0.0030 H   0  0  0  0  0  0
   -5.1461   -1.7429    0.7224 H   0  0  0  0  0  0
   -5.0932   -1.4092   -1.0193 H   0  0  0  0  0  0
   -5.6353    1.8179    0.5017 H   0  0  0  0  0  0
    1.8450   -0.5627    0.0264 H   0  0  0  0  0  0
    1.5218   -0.1844    2.4513 H   0  0  0  0  0  0
    1.4210    1.5507    2.1730 H   0  0  0  0  0  0
    2.9144    0.6843    1.8267 H   0  0  0  0  0  0
    2.6776    1.8914   -0.2551 H   0  0  0  0  0  0
    2.7930    3.5455   -5.6908 H   0  0  0  0  0  0
    3.9262    4.7981   -3.8726 H   0  0  0  0  0  0
    0.1343   -0.3872   -4.3100 H   0  0  0  0  0  0
    0.6894   -2.5317    1.8513 H   0  0  0  0  0  0
    2.0144   -4.5749    1.4657 H   0  0  0  0  0  0
    2.1263   -5.5753   -0.7944 H   0  0  0  0  0  0
   -0.4173   -2.4777   -2.2992 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 31  1  0  0  0
  1 32  1  0  0  0
  1 33  1  0  0  0
  2  3  2  0  0  0
  2  6  1  0  0  0
  3  4  1  0  0  0
  3 34  1  0  0  0
  4  5  1  0  0  0
  5  6  1  0  0  0
  5 11  2  0  0  0
  6  7  1  0  0  0
  7  8  2  0  0  0
  7  9  1  0  0  0
  9 10  2  0  0  0
  9 24  1  0  0  0
 10 11  1  0  0  0
 10 12  1  0  0  0
 12 13  1  0  0  0
 12 14  1  0  0  0
 12 35  1  0  0  0
 13 36  1  0  0  0
 13 37  1  0  0  0
 13 38  1  0  0  0
 14 15  1  0  0  0
 14 39  1  0  0  0
 15 16  1  0  0  0
 15 23  2  0  0  0
 16 17  2  0  0  0
 16 20  1  0  0  0
 17 18  1  0  0  0
 17 21  1  0  0  0
 18 19  1  0  0  0
 18 40  1  0  0  0
 19 20  2  0  0  0
 19 41  1  0  0  0
 21 22  2  0  0  0
 22 23  1  0  0  0
 22 42  1  0  0  0
 24 25  1  0  0  0
 24 29  2  0  0  0
 25 26  2  0  0  0
 25 43  1  0  0  0
 26 27  1  0  0  0
 26 44  1  0  0  0
 27 28  2  0  0  0
 27 45  1  0  0  0
 28 29  1  0  0  0
 28 30  1  0  0  0
 29 46  1  0  0  0
M  END
> <s_m_entry_id>
1

> <Applicants>
Incyte Corporation

> <CHEMBL_ID>
CHEMBL2216863

> <Canonical_Smiles>
S1C=C(N2C1=NC([C@@H](Nc1ncnc3[nH]cnc13)C)=C(c1cc(F)ccc1)C2=O)C

> <Chirality>
Single Stereoisomer

> <First_Approval>
nan

> <Phase>
0

> <SC_Patent>
None

> <Synonyms>
DEZAPELISIB | INCB040093

> <Indications>
nan

> <Type>
nan

> <targets_id>
nan

> <inchi>
InChI=1S/C20H16FN7OS/c1-10-7-30-20-27-15(11(2)26-18-16-17(23-8-22-16)24-9-25-18)14(19(29)28(10)20)12-4-3-5-13(21)6-12/h3-9,11H,1-2H3,(H2,22,23,24,25,26)/t11-/m0/s1

> <stdInchikey>
RSIWALKZYXPAGW-NSHDSACASA-N

> <csid>
28651137

> <Links>
|http://www.chemspider.com/Chemical-Structure.28651137.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2216863|http://pubchem.ncbi.nlm.nih.gov/compound/58111426|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9728|http://zinc15.docking.org/substances/ZINC000095564453|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=2K59L7G59M|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50004547

> <LinkName>
|ChemSpider|ChEMBL|PubChem|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
421.1

> <HBA>
8

> <HBD>
2

> <NRB>
4

> <TPSA>
100.9

> <LogP>
3.7

> <RoF>
0

> <Targets>
nan

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
0.955582

> <r_epik_Ionization_Penalty>
  0.0024

> <r_epik_State_Penalty>
  0.0207

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
1

$$$$
Toceranib
                    3D
 Structure written by MMmdl.
 55 58  0  0  1  0            999 V2000
   -0.7511   -3.0076    0.1651 C   0  0  0  0  0  0
   -0.9192   -1.5151   -0.0641 C   0  0  0  0  0  0
   -2.1051   -0.8694   -0.4345 C   0  0  0  0  0  0
   -1.8122    0.4633   -0.5250 N   0  0  0  0  0  0
   -0.4997    0.7182   -0.2490 C   0  0  0  0  0  0
    0.0764   -0.5126    0.0839 C   0  0  0  0  0  0
    1.4656   -0.7514    0.4019 C   0  0  0  0  0  0
    2.0679   -1.7311   -0.0404 O   0  0  0  0  0  0
    2.0212    0.1703    1.2108 N   0  0  0  0  0  0
    3.4129    0.1638    1.6578 C   0  0  0  0  0  0
    3.7202   -0.9276    2.7042 C   0  0  0  0  0  0
    5.2406   -1.0367    2.9408 N   0  3  0  0  0  0
    5.9007    0.2067    3.5727 C   0  0  0  0  0  0
    7.1015   -0.3328    4.3649 C   0  0  0  0  0  0
    7.0870   -1.8525    4.2049 C   0  0  0  0  0  0
    5.6393   -2.1909    3.8715 C   0  0  0  0  0  0
    0.0313    2.1338   -0.3498 C   0  0  0  0  0  0
   -3.4401   -1.4098   -0.7151 C   0  0  0  0  0  0
   -4.6419   -0.8911   -1.0785 C   0  0  0  0  0  0
   -5.8830   -1.6249   -1.3224 C   0  0  0  0  0  0
   -6.2122   -2.9826   -1.2636 C   0  0  0  0  0  0
   -7.5172   -3.3869   -1.5633 C   0  0  0  0  0  0
   -8.4830   -2.4389   -1.9184 C   0  0  0  0  0  0
   -8.1492   -1.0832   -1.9759 C   0  0  0  0  0  0
   -6.8421   -0.7033   -1.6724 C   0  0  0  0  0  0
   -6.2673    0.5431   -1.6551 N   0  0  0  0  0  0
   -4.9666    0.5153   -1.3104 C   0  0  0  0  0  0
   -4.2594    1.5168   -1.2297 O   0  0  0  0  0  0
   -7.8462   -4.6974   -1.5104 F   0  0  0  0  0  0
   -0.1080   -3.2149    1.0206 H   0  0  0  0  0  0
   -0.2991   -3.4942   -0.6991 H   0  0  0  0  0  0
   -1.6937   -3.5153    0.3665 H   0  0  0  0  0  0
   -2.4839    1.1700   -0.7926 H   0  0  0  0  0  0
    1.4439    0.9302    1.5413 H   0  0  0  0  0  0
    4.0696    0.0572    0.7914 H   0  0  0  0  0  0
    3.6306    1.1464    2.0773 H   0  0  0  0  0  0
    3.2607   -0.7303    3.6743 H   0  0  0  0  0  0
    3.4221   -1.9200    2.3620 H   0  0  0  0  0  0
    6.1709    0.8723    2.7519 H   0  0  0  0  0  0
    5.1619    0.6747    4.2259 H   0  0  0  0  0  0
    8.0429    0.0953    4.0181 H   0  0  0  0  0  0
    6.9941   -0.0618    5.4164 H   0  0  0  0  0  0
    7.7364   -2.1586    3.3830 H   0  0  0  0  0  0
    7.4335   -2.3618    5.1052 H   0  0  0  0  0  0
    4.9870   -2.1389    4.7458 H   0  0  0  0  0  0
    5.5050   -3.1318    3.3362 H   0  0  0  0  0  0
    1.1197    2.1739   -0.3725 H   0  0  0  0  0  0
   -0.2968    2.7444    0.4915 H   0  0  0  0  0  0
   -0.3134    2.6289   -1.2582 H   0  0  0  0  0  0
   -3.4396   -2.4832   -0.6016 H   0  0  0  0  0  0
   -5.4761   -3.7247   -0.9917 H   0  0  0  0  0  0
   -9.4895   -2.7554   -2.1495 H   0  0  0  0  0  0
   -8.8985   -0.3556   -2.2515 H   0  0  0  0  0  0
   -6.7622    1.3948   -1.8761 H   0  0  0  0  0  0
    5.6935   -1.2073    2.0535 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 30  1  0  0  0
  1 31  1  0  0  0
  1 32  1  0  0  0
  2  3  2  0  0  0
  2  6  1  0  0  0
  3  4  1  0  0  0
  3 18  1  0  0  0
  4  5  1  0  0  0
  4 33  1  0  0  0
  5  6  2  0  0  0
  5 17  1  0  0  0
  6  7  1  0  0  0
  7  8  2  0  0  0
  7  9  1  0  0  0
  9 10  1  0  0  0
  9 34  1  0  0  0
 10 11  1  0  0  0
 10 35  1  0  0  0
 10 36  1  0  0  0
 11 12  1  0  0  0
 11 37  1  0  0  0
 11 38  1  0  0  0
 12 13  1  0  0  0
 12 16  1  0  0  0
 12 55  1  0  0  0
 13 14  1  0  0  0
 13 39  1  0  0  0
 13 40  1  0  0  0
 14 15  1  0  0  0
 14 41  1  0  0  0
 14 42  1  0  0  0
 15 16  1  0  0  0
 15 43  1  0  0  0
 15 44  1  0  0  0
 16 45  1  0  0  0
 16 46  1  0  0  0
 17 47  1  0  0  0
 17 48  1  0  0  0
 17 49  1  0  0  0
 18 19  2  0  0  0
 18 50  1  0  0  0
 19 20  1  0  0  0
 19 27  1  0  0  0
 20 21  2  0  0  0
 20 25  1  0  0  0
 21 22  1  0  0  0
 21 51  1  0  0  0
 22 23  2  0  0  0
 22 29  1  0  0  0
 23 24  1  0  0  0
 23 52  1  0  0  0
 24 25  2  0  0  0
 24 53  1  0  0  0
 25 26  1  0  0  0
 26 27  1  0  0  0
 26 54  1  0  0  0
 27 28  2  0  0  0
M  CHG  1  12   1
M  END
> <s_m_entry_id>
3

> <Applicants>
Pfizer

> <CHEMBL_ID>
CHEMBL13608

> <Canonical_Smiles>
Fc1cc\2c(NC(=O)/C/2=C\c2[nH]c(C)c(C(=O)NCCN3CCCC3)c2C)cc1

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
0

> <SC_Patent>
None

> <Synonyms>
PHA-291639 | TOCERANIB

> <Indications>
nan

> <Type>
nan

> <targets_id>
O97799

> <inchi>
InChI=1S/C22H25FN4O2/c1-13-19(12-17-16-11-15(23)5-6-18(16)26-21(17)28)25-14(2)20(13)22(29)24-7-10-27-8-3-4-9-27/h5-6,11-12,25H,3-4,7-10H2,1-2H3,(H,24,29)(H,26,28)/b17-12-

> <stdInchikey>
SRSGVKWWVXWSJT-ATVHPVEESA-N

> <csid>
4486268

> <Links>
|http://www.chemspider.com/Chemical-Structure.4486268.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL13608|http://pubchem.ncbi.nlm.nih.gov/compound/5329106| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=BWC|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/BWC|http://zinc15.docking.org/substances/ZINC000003989258|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=59L7Y0530C|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=4818

> <LinkName>
|ChemSpider|ChEMBL|PubChem|RCSB|PDBe|ZINC|FDA SRS|BindingDB

> <MW>
396.2

> <HBA>
3

> <HBD>
3

> <NRB>
5

> <TPSA>
77.2

> <LogP>
3.1

> <RoF>
0

> <Targets>
KIT

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_epik_Ionization_Penalty>
  0.0038

> <r_epik_State_Penalty>
  0.0027

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
3

> <lig_pdbID>
'BWC'

> <pdbID>
6m13

> <Kinase families>
KIT

$$$$
Oclacitinib
                    3D
 Structure written by MMmdl.
 46 48  0  0  1  0            999 V2000
   -3.0997    2.3864   -0.1379 C   0  0  0  0  0  0
   -2.3769    1.7550   -1.2548 N   0  0  0  0  0  0
   -0.6160    1.7495   -1.2519 S   0  0  0  0  0  0
   -0.1876    1.4974   -2.6316 O   0  0  0  0  0  0
   -0.1610    2.9508   -0.5428 O   0  0  0  0  0  0
   -0.1949    0.2298   -0.1981 C   0  0  0  0  0  0
    1.3117    0.1505    0.1416 C   0  0  1  0  0  0
    1.5602   -0.8857    1.2675 C   0  0  0  0  0  0
    3.0496   -1.0079    1.6455 C   0  0  0  0  0  0
    3.9114   -1.3123    0.3953 C   0  0  1  0  0  0
    3.6954   -0.2747   -0.7340 C   0  0  0  0  0  0
    2.2004   -0.1511   -1.0940 C   0  0  0  0  0  0
    5.3442   -1.5057    0.7253 N   0  0  0  0  0  0
    6.1977   -0.4889    1.2575 C   0  0  0  0  0  0
    5.6503    0.7352    1.5108 N   0  0  0  0  0  0
    6.4313    1.7176    2.0177 C   0  0  0  0  0  0
    7.7484    1.6506    2.3228 N   0  0  0  0  0  0
    8.2776    0.4525    2.0698 C   0  0  0  0  0  0
    7.5842   -0.6798    1.5368 C   0  0  0  0  0  0
    8.5738   -1.7265    1.4420 C   0  0  0  0  0  0
    9.7700   -1.2118    1.9015 C   0  0  0  0  0  0
    9.5902    0.0945    2.2771 N   0  0  0  0  0  0
    5.8881   -2.8392    0.4656 C   0  0  0  0  0  0
   -4.1724    2.3051   -0.3137 H   0  0  0  0  0  0
   -2.8362    3.4424   -0.0716 H   0  0  0  0  0  0
   -2.8601    1.8761    0.7952 H   0  0  0  0  0  0
   -2.8317    1.7940   -2.1711 H   0  0  0  0  0  0
   -0.7876    0.3207    0.7126 H   0  0  0  0  0  0
   -0.5478   -0.6572   -0.7247 H   0  0  0  0  0  0
    1.6111    1.1241    0.5344 H   0  0  0  0  0  0
    0.9865   -0.6183    2.1561 H   0  0  0  0  0  0
    1.1898   -1.8629    0.9526 H   0  0  0  0  0  0
    3.3492   -0.0801    2.1297 H   0  0  0  0  0  0
    3.1738   -1.7963    2.3892 H   0  0  0  0  0  0
    3.5374   -2.2586    0.0017 H   0  0  0  0  0  0
    4.0542    0.7129   -0.4489 H   0  0  0  0  0  0
    4.2616   -0.5614   -1.6214 H   0  0  0  0  0  0
    1.8664   -1.0758   -1.5673 H   0  0  0  0  0  0
    2.0898    0.6308   -1.8445 H   0  0  0  0  0  0
    5.9460    2.6654    2.1997 H   0  0  0  0  0  0
    8.4595   -2.7386    1.0863 H   0  0  0  0  0  0
   10.7452   -1.6670    1.9935 H   0  0  0  0  0  0
   10.3352    0.6690    2.6435 H   0  0  0  0  0  0
    6.6749   -2.7857   -0.2870 H   0  0  0  0  0  0
    5.1416   -3.5463    0.1035 H   0  0  0  0  0  0
    6.3097   -3.2607    1.3781 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 24  1  0  0  0
  1 25  1  0  0  0
  1 26  1  0  0  0
  2  3  1  0  0  0
  2 27  1  0  0  0
  3  4  2  0  0  0
  3  5  2  0  0  0
  3  6  1  0  0  0
  6  7  1  0  0  0
  6 28  1  0  0  0
  6 29  1  0  0  0
  7  8  1  0  0  0
  7 12  1  0  0  0
  7 30  1  0  0  0
  8  9  1  0  0  0
  8 31  1  0  0  0
  8 32  1  0  0  0
  9 10  1  0  0  0
  9 33  1  0  0  0
  9 34  1  0  0  0
 10 11  1  0  0  0
 10 13  1  0  0  0
 10 35  1  0  0  0
 11 12  1  0  0  0
 11 36  1  0  0  0
 11 37  1  0  0  0
 12 38  1  0  0  0
 12 39  1  0  0  0
 13 14  1  0  0  0
 13 23  1  0  0  0
 14 15  1  0  0  0
 14 19  2  0  0  0
 15 16  2  0  0  0
 16 17  1  0  0  0
 16 40  1  0  0  0
 17 18  2  0  0  0
 18 19  1  0  0  0
 18 22  1  0  0  0
 19 20  1  0  0  0
 20 21  2  0  0  0
 20 41  1  0  0  0
 21 22  1  0  0  0
 21 42  1  0  0  0
 22 43  1  0  0  0
 23 44  1  0  0  0
 23 45  1  0  0  0
 23 46  1  0  0  0
M  END
> <s_m_entry_id>
4

> <Applicants>
Pfizer

> <CHEMBL_ID>
CHEMBL2103874

> <Canonical_Smiles>
S(=O)(=O)(NC)CC1CCC(N(C)c2ncnc3[nH]ccc23)CC1

> <Chirality>
Single Stereoisomer

> <First_Approval>
nan

> <Phase>
0

> <SC_Patent>
None

> <Synonyms>
JAKI | OCLACITINIB | PF-03394197

> <Indications>
nan

> <Type>
nan

> <targets_id>
P23458|O60674|P52333

> <inchi>
InChI=1S/C15H23N5O2S/c1-16-23(21,22)9-11-3-5-12(6-4-11)20(2)15-13-7-8-17-14(13)18-10-19-15/h7-8,10-12,16H,3-6,9H2,1-2H3,(H,17,18,19)/t11-,12-

> <stdInchikey>
HJWLJNBZVZDLAQ-HAQNSBGRSA-N

> <csid>
28528036

> <Links>
|http://www.chemspider.com/Chemical-Structure.28528036.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2103874|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9696|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=99GS5XTB51|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=185700

> <LinkName>
|ChemSpider|ChEMBL|Guide to Pharmacology|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
337.2

> <HBA>
5

> <HBD>
2

> <NRB>
5

> <TPSA>
91

> <LogP>
1.5

> <RoF>
0

> <Targets>
JAK1; JAK2; JAK3

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
0.999998

> <r_epik_Ionization_Penalty>
  0.0230

> <r_epik_State_Penalty>
  0.0172

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
4

> <Kinase families>
Tyr

$$$$
Cenisertib
                    3D
 Structure written by MMmdl.
 64 68  0  0  1  0            999 V2000
   -3.4069   -1.9193   -1.7132 C   0  0  0  0  0  0
   -2.3646   -1.0073   -1.0752 C   0  0  0  0  0  0
   -1.0099   -1.3335   -1.2057 C   0  0  0  0  0  0
   -0.0166   -0.5254   -0.6382 C   0  0  0  0  0  0
   -0.3987    0.6073    0.0812 C   0  0  0  0  0  0
   -1.7441    0.9427    0.2134 C   0  0  0  0  0  0
   -2.7405    0.1456   -0.3614 C   0  0  0  0  0  0
   -4.0737    0.4973   -0.2206 N   0  0  0  0  0  0
   -4.8062    0.3109    1.0346 C   0  0  0  0  0  0
   -4.8192    1.5960    1.8924 C   0  0  0  0  0  0
   -5.3792    2.7715    1.0591 N   0  3  0  0  0  0
   -4.6863    2.9100   -0.3154 C   0  0  0  0  0  0
   -4.6931    1.5443   -1.0361 C   0  0  0  0  0  0
   -5.2702    4.0900    1.8495 C   0  0  0  0  0  0
    1.3574   -0.8069   -0.7303 N   0  0  0  0  0  0
    2.1259   -1.5011   -1.6758 C   0  0  0  0  0  0
    1.5342   -2.0653   -2.7628 N   0  0  0  0  0  0
    2.3503   -2.6893   -3.6501 C   0  0  0  0  0  0
    3.7318   -2.7648   -3.4708 C   0  0  0  0  0  0
    4.2559   -2.1775   -2.3083 C   0  0  0  0  0  0
    3.4595   -1.5210   -1.4247 N   0  0  0  0  0  0
    5.6287   -2.1430   -2.0291 N   0  0  0  0  0  0
    6.3257   -3.4301   -1.9056 C   0  0  2  0  0  0
    5.8808   -4.2318   -0.6426 C   0  0  2  0  0  0
    6.8218   -3.7265    0.4397 C   0  0  0  0  0  0
    8.0804   -4.0896   -0.3430 C   0  0  2  0  0  0
    7.8909   -3.3598   -1.7107 C   0  0  2  0  0  0
    8.5377   -1.9481   -1.6970 C   0  0  0  0  0  0
    8.3325   -1.1577   -0.7771 O   0  0  0  0  0  0
    9.3269   -1.6259   -2.7256 N   0  0  0  0  0  0
    7.7644   -5.5657   -0.5709 C   0  0  0  0  0  0
    6.4312   -5.6508   -0.7613 C   0  0  0  0  0  0
    4.5121   -3.3651   -4.4004 F   0  0  0  0  0  0
   -3.9842   -1.3714   -2.4589 H   0  0  0  0  0  0
   -4.0954   -2.2970   -0.9563 H   0  0  0  0  0  0
   -2.9537   -2.7790   -2.2089 H   0  0  0  0  0  0
   -0.7447   -2.2339   -1.7379 H   0  0  0  0  0  0
    0.3476    1.2425    0.5369 H   0  0  0  0  0  0
   -2.0039    1.8318    0.7682 H   0  0  0  0  0  0
   -5.8310    0.0125    0.8077 H   0  0  0  0  0  0
   -4.3735   -0.5185    1.5962 H   0  0  0  0  0  0
   -5.4658    1.4930    2.7650 H   0  0  0  0  0  0
   -3.8188    1.8742    2.2272 H   0  0  0  0  0  0
   -5.2424    3.6645   -0.8733 H   0  0  0  0  0  0
   -3.6725    3.2745   -0.1413 H   0  0  0  0  0  0
   -4.1821    1.6170   -1.9974 H   0  0  0  0  0  0
   -5.7202    1.2564   -1.2667 H   0  0  0  0  0  0
   -4.2129    4.2922    2.0298 H   0  0  0  0  0  0
   -5.8183    3.9526    2.7825 H   0  0  0  0  0  0
   -5.7305    4.8691    1.2401 H   0  0  0  0  0  0
    1.9258   -0.2793   -0.0845 H   0  0  0  0  0  0
    1.8800   -3.1209   -4.5216 H   0  0  0  0  0  0
    5.8641   -1.4991   -1.2872 H   0  0  0  0  0  0
    6.1205   -4.0365   -2.7882 H   0  0  0  0  0  0
    4.8243   -4.1721   -0.3772 H   0  0  0  0  0  0
    6.7155   -2.6581    0.6350 H   0  0  0  0  0  0
    6.7238   -4.2470    1.3972 H   0  0  0  0  0  0
    9.0110   -3.8938    0.1926 H   0  0  0  0  0  0
    8.3925   -3.9179   -2.5052 H   0  0  0  0  0  0
    9.4836   -2.2819   -3.4766 H   0  0  0  0  0  0
    9.7677   -0.7184   -2.7576 H   0  0  0  0  0  0
    8.5027   -6.3535   -0.6036 H   0  0  0  0  0  0
    5.8349   -6.5239   -0.9824 H   0  0  0  0  0  0
   -6.3580    2.5857    0.8895 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 34  1  0  0  0
  1 35  1  0  0  0
  1 36  1  0  0  0
  2  3  2  0  0  0
  2  7  1  0  0  0
  3  4  1  0  0  0
  3 37  1  0  0  0
  4  5  2  0  0  0
  4 15  1  0  0  0
  5  6  1  0  0  0
  5 38  1  0  0  0
  6  7  2  0  0  0
  6 39  1  0  0  0
  7  8  1  0  0  0
  8  9  1  0  0  0
  8 13  1  0  0  0
  9 10  1  0  0  0
  9 40  1  0  0  0
  9 41  1  0  0  0
 10 11  1  0  0  0
 10 42  1  0  0  0
 10 43  1  0  0  0
 11 12  1  0  0  0
 11 14  1  0  0  0
 11 64  1  0  0  0
 12 13  1  0  0  0
 12 44  1  0  0  0
 12 45  1  0  0  0
 13 46  1  0  0  0
 13 47  1  0  0  0
 14 48  1  0  0  0
 14 49  1  0  0  0
 14 50  1  0  0  0
 15 16  1  0  0  0
 15 51  1  0  0  0
 16 17  1  0  0  0
 16 21  2  0  0  0
 17 18  2  0  0  0
 18 19  1  0  0  0
 18 52  1  0  0  0
 19 20  2  0  0  0
 19 33  1  0  0  0
 20 21  1  0  0  0
 20 22  1  0  0  0
 22 23  1  0  0  0
 22 53  1  0  0  0
 23 24  1  0  0  0
 23 27  1  0  0  0
 23 54  1  0  0  0
 24 25  1  0  0  0
 24 32  1  0  0  0
 24 55  1  0  0  0
 25 26  1  0  0  0
 25 56  1  0  0  0
 25 57  1  0  0  0
 26 27  1  0  0  0
 26 31  1  0  0  0
 26 58  1  0  0  0
 27 28  1  0  0  0
 27 59  1  0  0  0
 28 29  2  0  0  0
 28 30  1  0  0  0
 30 60  1  0  0  0
 30 61  1  0  0  0
 31 32  2  0  0  0
 31 62  1  0  0  0
 32 63  1  0  0  0
M  CHG  1  11   1
M  END
> <s_m_entry_id>
8

> <Applicants>
EMD Serono

> <CHEMBL_ID>
CHEMBL1967878

> <Canonical_Smiles>
Fc1cnc(nc1N[C@@H]1[C@H]2C=C[C@H](C2)[C@@H]1C(=O)N)Nc1cc(C)c(N2CCN(CC2)C)cc1

> <Chirality>
Racemic Mixture

> <First_Approval>
nan

> <Phase>
1

> <SC_Patent>
None

> <Synonyms>
AS-703569 | R-763

> <Indications>
nan

> <Type>
nan

> <targets_id>
O14965|Q96GD4|Q9UQB9

> <inchi>
InChI=1S/C24H30FN7O/c1-14-11-17(5-6-19(14)32-9-7-31(2)8-10-32)28-24-27-13-18(25)23(30-24)29-21-16-4-3-15(12-16)20(21)22(26)33/h3-6,11,13,15-16,20-21H,7-10,12H2,1-2H3,(H2,26,33)(H2,27,28,29,30)/t15-,16+,20+,21-/m1/s1

> <stdInchikey>
KSOVGRCOLZZTPF-QMKUDKLTSA-N

> <csid>
9744737

> <Links>
|http://www.chemspider.com/Chemical-Structure.9744737.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1614709|http://pubchem.ncbi.nlm.nih.gov/compound/11569967|http://www.drugbank.ca/drugs/DB06347|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9927|http://zinc15.docking.org/substances/ZINC000063298059|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=5277GPA358|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50389967

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
451.2

> <HBA>
7

> <HBD>
3

> <NRB>
6

> <TPSA>
99.4

> <LogP>
2.5

> <RoF>
0

> <Targets>
AURKA; AURKB; AURKC

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0655

> <r_epik_State_Penalty>
  0.3187

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
8

> <Kinase families>
Other

> <indicationDB>
Cenisertib is an aurora kinase inhibitor.

> <uniprotId>
O14965

$$$$
Alofanib
                    3D
 Structure written by MMmdl.
 42 44  0  0  1  0            999 V2000
   -4.1923    0.3047    0.1108 C   0  0  0  0  0  0
   -2.6981    0.0035    0.0920 C   0  0  0  0  0  0
   -1.8078    1.0760    0.1201 C   0  0  0  0  0  0
   -0.4250    0.8786    0.0652 C   0  0  0  0  0  0
    0.4411    2.0757    0.0871 N   0  3  0  0  0  0
    0.2914    2.8702    1.0104 O   0  0  0  0  0  0
    1.2388    2.2359   -0.8316 O   0  5  0  0  0  0
    0.1059   -0.4275   -0.0090 C   0  0  0  0  0  0
    1.4714   -0.6157   -0.0376 N   0  5  0  0  0  0
    2.1591   -2.0223   -0.1245 S   0  0  0  0  0  0
    2.0019   -2.8328    1.0893 O   0  0  0  0  0  0
    1.9728   -2.6927   -1.4169 O   0  0  0  0  0  0
    3.8739   -1.4883   -0.1034 C   0  0  0  0  0  0
    4.5032   -1.2236    1.1155 C   0  0  0  0  0  0
    5.8327   -0.8103    1.1402 C   0  0  0  0  0  0
    6.5405   -0.6608   -0.0517 C   0  0  0  0  0  0
    5.9314   -0.9219   -1.2907 C   0  0  0  0  0  0
    6.6954   -0.7605   -2.5729 C   0  0  0  0  0  0
    6.1091   -1.0297   -3.6465 O   0  0  0  0  0  0
    7.8823   -0.3660   -2.5048 O   0  5  0  0  0  0
    4.5887   -1.3379   -1.2974 C   0  0  0  0  0  0
   -0.8135   -1.4925   -0.0311 C   0  0  0  0  0  0
   -2.1995   -1.3085    0.0255 C   0  0  0  0  0  0
   -3.0829   -2.5087    0.0118 C   0  0  0  0  0  0
   -2.9779   -3.4734   -1.0004 C   0  0  0  0  0  0
   -3.8078   -4.5959   -0.9901 C   0  0  0  0  0  0
   -4.7297   -4.7300    0.0476 C   0  0  0  0  0  0
   -4.8508   -3.8204    1.0466 N   0  0  0  0  0  0
   -4.0330   -2.7368    1.0171 C   0  0  0  0  0  0
   -4.7393   -0.3619   -0.5567 H   0  0  0  0  0  0
   -4.3990    1.3248   -0.2157 H   0  0  0  0  0  0
   -4.5909    0.1912    1.1190 H   0  0  0  0  0  0
   -2.1937    2.0845    0.1705 H   0  0  0  0  0  0
    3.9620   -1.3322    2.0441 H   0  0  0  0  0  0
    6.3153   -0.6042    2.0839 H   0  0  0  0  0  0
    7.5705   -0.3379    0.0023 H   0  0  0  0  0  0
    4.0887   -1.5422   -2.2334 H   0  0  0  0  0  0
   -0.4525   -2.5095   -0.0793 H   0  0  0  0  0  0
   -2.2561   -3.3527   -1.7955 H   0  0  0  0  0  0
   -3.7364   -5.3431   -1.7666 H   0  0  0  0  0  0
   -5.3888   -5.5845    0.0911 H   0  0  0  0  0  0
   -4.1464   -2.0422    1.8364 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 30  1  0  0  0
  1 31  1  0  0  0
  1 32  1  0  0  0
  2  3  1  0  0  0
  2 23  2  0  0  0
  3  4  2  0  0  0
  3 33  1  0  0  0
  4  5  1  0  0  0
  4  8  1  0  0  0
  5  6  2  0  0  0
  5  7  1  0  0  0
  8  9  1  0  0  0
  8 22  2  0  0  0
  9 10  1  0  0  0
 10 11  2  0  0  0
 10 12  2  0  0  0
 10 13  1  0  0  0
 13 14  1  0  0  0
 13 21  2  0  0  0
 14 15  2  0  0  0
 14 34  1  0  0  0
 15 16  1  0  0  0
 15 35  1  0  0  0
 16 17  2  0  0  0
 16 36  1  0  0  0
 17 18  1  0  0  0
 17 21  1  0  0  0
 18 19  2  0  0  0
 18 20  1  0  0  0
 21 37  1  0  0  0
 22 23  1  0  0  0
 22 38  1  0  0  0
 23 24  1  0  0  0
 24 25  1  0  0  0
 24 29  2  0  0  0
 25 26  2  0  0  0
 25 39  1  0  0  0
 26 27  1  0  0  0
 26 40  1  0  0  0
 27 28  2  0  0  0
 27 41  1  0  0  0
 28 29  1  0  0  0
 29 42  1  0  0  0
M  CHG  4   5   1   7  -1   9  -1  20  -1
M  END
> <s_m_entry_id>
11

> <Applicants>
Russian Pharmaceutical Technologies

> <CHEMBL_ID>
CHEMBL4594436

> <Canonical_Smiles>
S(=O)(=O)(Nc1cc(-c2cccnc2)c(cc1[N+](=O)[O-])C)c1cc(ccc1)C(O)=O

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
1

> <SC_Patent>
None

> <Indications>
nan

> <Type>
nan

> <targets_id>
nan

> <inchi>
InChI=1S/C19H15N3O6S/c1-12-8-18(22(25)26)17(10-16(12)14-5-3-7-20-11-14)21-29(27,28)15-6-2-4-13(9-15)19(23)24/h2-11,21H,1H3,(H,23,24)

> <stdInchikey>
QUQGQIASFYWKAB-UHFFFAOYSA-N

> <csid>
44208820

> <Links>
|http://www.chemspider.com/Chemical-Structure.44208820.html|http://pubchem.ncbi.nlm.nih.gov/compound/86280646|http://zinc15.docking.org/substances/ZINC000219244618|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=LQX7RFK8MZ

> <LinkName>
|ChemSpider|PubChem|ZINC|FDA SRS

> <MW>
413.1

> <HBA>
6

> <HBD>
2

> <NRB>
6

> <TPSA>
139.5

> <LogP>
3.5

> <RoF>
0

> <Targets>
nan

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_epik_Ionization_Penalty>
  0.1042

> <r_epik_State_Penalty>
  0.0922

> <i_epik_Tot_Q>
-2

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
11

> <Kinase families>
(*)

$$$$
Balamapimod
                    3D
 Structure written by MMmdl.
 73 78  0  0  1  0            999 V2000
   -0.6609    6.6133    0.2737 C   0  0  0  0  0  0
   -1.6975    6.4683   -0.7350 N   0  0  0  0  0  0
   -1.6758    6.9812   -2.0060 C   0  0  0  0  0  0
   -2.8646    6.5772   -2.5851 C   0  0  0  0  0  0
   -3.5955    5.8626   -1.7499 N   0  0  0  0  0  0
   -2.8972    5.7915   -0.6381 C   0  0  0  0  0  0
   -3.4571    4.9257    0.7915 S   0  0  0  0  0  0
   -2.5047    3.4451    0.6077 C   0  0  0  0  0  0
   -1.3548    3.2958    1.3851 C   0  0  0  0  0  0
   -0.5491    2.1688    1.2383 C   0  0  0  0  0  0
   -0.8910    1.1763    0.3138 C   0  0  0  0  0  0
   -2.0661    1.3032   -0.4295 C   0  0  0  0  0  0
   -2.8760    2.4321   -0.2913 C   0  0  0  0  0  0
   -4.3116    2.5364   -1.2530 Cl  0  0  0  0  0  0
   -0.0597    0.0692    0.0939 N   0  0  0  0  0  0
    1.3540    0.0787    0.0746 C   0  0  0  0  0  0
    2.1099    1.0484   -0.6801 C   0  0  0  0  0  0
    1.5319    2.0518   -1.5071 C   0  0  0  0  0  0
    2.3124    2.9981   -2.1873 C   0  0  0  0  0  0
    3.7127    2.9456   -2.0842 C   0  0  0  0  0  0
    4.3095    1.9476   -1.3047 C   0  0  0  0  0  0
    3.5334    0.9991   -0.6032 C   0  0  0  0  0  0
    4.1894    0.0614    0.1280 N   0  0  0  0  0  0
    3.4617   -0.8582    0.7976 C   0  0  0  0  0  0
    2.0691   -0.8955    0.8041 C   0  0  0  0  0  0
    1.4219   -1.9453    1.5910 C   0  0  0  0  0  0
    0.9090   -2.7752    2.2131 N   0  0  0  0  0  0
    4.4942    3.8861   -2.7517 N   0  0  0  0  0  0
    4.5201    5.2486   -2.1915 C   0  0  0  0  0  0
    4.9128    6.2956   -3.2596 C   0  0  0  0  0  0
    6.2827    5.9867   -3.9089 C   0  0  0  0  0  0
    6.3077    4.5047   -4.3507 C   0  0  0  0  0  0
    5.8504    3.5508   -3.2233 C   0  0  0  0  0  0
    7.4007    6.2274   -2.8550 N   0  3  0  0  0  0
    8.8350    5.9211   -3.3249 C   0  0  0  0  0  0
    9.6893    6.6058   -2.2673 C   0  0  0  0  0  0
    8.9688    7.9212   -1.9998 C   0  0  0  0  0  0
    7.4874    7.6752   -2.3172 C   0  0  0  0  0  0
    1.7582    3.9938   -2.9787 O   0  0  0  0  0  0
    0.3424    4.1337   -3.0587 C   0  0  0  0  0  0
   -1.1134    6.7384    1.2578 H   0  0  0  0  0  0
   -0.0431    7.4837    0.0494 H   0  0  0  0  0  0
   -0.0330    5.7221    0.2696 H   0  0  0  0  0  0
   -0.8423    7.5645   -2.3692 H   0  0  0  0  0  0
   -3.1945    6.7969   -3.5900 H   0  0  0  0  0  0
   -1.0696    4.0638    2.0893 H   0  0  0  0  0  0
    0.3513    2.0822    1.8294 H   0  0  0  0  0  0
   -2.3416    0.5350   -1.1384 H   0  0  0  0  0  0
   -0.4369   -0.7639    0.5231 H   0  0  0  0  0  0
    0.4614    2.0764   -1.6130 H   0  0  0  0  0  0
    5.3851    1.8913   -1.2141 H   0  0  0  0  0  0
    4.0429   -1.5829    1.3517 H   0  0  0  0  0  0
    3.5371    5.5107   -1.7972 H   0  0  0  0  0  0
    5.2098    5.2844   -1.3463 H   0  0  0  0  0  0
    4.1473    6.3035   -4.0376 H   0  0  0  0  0  0
    4.8878    7.2966   -2.8298 H   0  0  0  0  0  0
    6.4949    6.6573   -4.7436 H   0  0  0  0  0  0
    5.6379    4.3818   -5.2037 H   0  0  0  0  0  0
    7.2880    4.2103   -4.7234 H   0  0  0  0  0  0
    6.5552    3.5774   -2.3904 H   0  0  0  0  0  0
    5.8545    2.5305   -3.6102 H   0  0  0  0  0  0
    8.9756    4.8407   -3.3640 H   0  0  0  0  0  0
    8.9501    6.3719   -4.3127 H   0  0  0  0  0  0
    9.7235    5.9937   -1.3644 H   0  0  0  0  0  0
   10.7161    6.7610   -2.6011 H   0  0  0  0  0  0
    9.1165    8.2576   -0.9727 H   0  0  0  0  0  0
    9.3555    8.7046   -2.6540 H   0  0  0  0  0  0
    7.1252    8.3467   -3.0976 H   0  0  0  0  0  0
    6.8405    7.7150   -1.4401 H   0  0  0  0  0  0
    0.1001    4.9949   -3.6811 H   0  0  0  0  0  0
   -0.1019    4.3028   -2.0765 H   0  0  0  0  0  0
   -0.1210    3.2582   -3.5156 H   0  0  0  0  0  0
    7.2197    5.6270   -2.0629 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 41  1  0  0  0
  1 42  1  0  0  0
  1 43  1  0  0  0
  2  3  1  0  0  0
  2  6  1  0  0  0
  3  4  2  0  0  0
  3 44  1  0  0  0
  4  5  1  0  0  0
  4 45  1  0  0  0
  5  6  2  0  0  0
  6  7  1  0  0  0
  7  8  1  0  0  0
  8  9  1  0  0  0
  8 13  2  0  0  0
  9 10  2  0  0  0
  9 46  1  0  0  0
 10 11  1  0  0  0
 10 47  1  0  0  0
 11 12  2  0  0  0
 11 15  1  0  0  0
 12 13  1  0  0  0
 12 48  1  0  0  0
 13 14  1  0  0  0
 15 16  1  0  0  0
 15 49  1  0  0  0
 16 17  1  0  0  0
 16 25  2  0  0  0
 17 18  1  0  0  0
 17 22  2  0  0  0
 18 19  2  0  0  0
 18 50  1  0  0  0
 19 20  1  0  0  0
 19 39  1  0  0  0
 20 21  2  0  0  0
 20 28  1  0  0  0
 21 22  1  0  0  0
 21 51  1  0  0  0
 22 23  1  0  0  0
 23 24  2  0  0  0
 24 25  1  0  0  0
 24 52  1  0  0  0
 25 26  1  0  0  0
 26 27  3  0  0  0
 28 29  1  0  0  0
 28 33  1  0  0  0
 29 30  1  0  0  0
 29 53  1  0  0  0
 29 54  1  0  0  0
 30 31  1  0  0  0
 30 55  1  0  0  0
 30 56  1  0  0  0
 31 32  1  0  0  0
 31 34  1  0  0  0
 31 57  1  0  0  0
 32 33  1  0  0  0
 32 58  1  0  0  0
 32 59  1  0  0  0
 33 60  1  0  0  0
 33 61  1  0  0  0
 34 35  1  0  0  0
 34 38  1  0  0  0
 34 73  1  0  0  0
 35 36  1  0  0  0
 35 62  1  0  0  0
 35 63  1  0  0  0
 36 37  1  0  0  0
 36 64  1  0  0  0
 36 65  1  0  0  0
 37 38  1  0  0  0
 37 66  1  0  0  0
 37 67  1  0  0  0
 38 68  1  0  0  0
 38 69  1  0  0  0
 39 40  1  0  0  0
 40 70  1  0  0  0
 40 71  1  0  0  0
 40 72  1  0  0  0
M  CHG  1  34   1
M  END
> <s_m_entry_id>
13

> <Applicants>
Wyeth

> <CHEMBL_ID>
CHEMBL2104954

> <Canonical_Smiles>
Clc1cc(Nc2c3cc(OC)c(N4CCC(N5CCCC5)CC4)cc3ncc2C#N)ccc1Sc1nccn1C

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
1

> <SC_Patent>
None

> <Synonyms>
BALAMAPIMOD | MKI-833

> <Indications>
nan

> <Type>
nan

> <targets_id>
P04049|Q02750|P36507

> <inchi>
InChI=1S/C30H32ClN7OS/c1-36-14-9-33-30(36)40-28-6-5-21(15-24(28)31)35-29-20(18-32)19-34-25-17-26(27(39-2)16-23(25)29)38-12-7-22(8-13-38)37-10-3-4-11-37/h5-6,9,14-17,19,22H,3-4,7-8,10-13H2,1-2H3,(H,34,35)

> <stdInchikey>
CVAKNHIXTWLGJO-UHFFFAOYSA-N

> <csid>
9653509

> <Links>
|http://www.chemspider.com/Chemical-Structure.9653509.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2104954|http://pubchem.ncbi.nlm.nih.gov/compound/11478684|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9925|http://zinc15.docking.org/substances/ZINC000011726212|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=7Y0IV7N95Q

> <LinkName>
|ChemSpider|ChEMBL|PubChem|Guide to Pharmacology|ZINC|FDA SRS

> <indicationG2P>
None

> <MW>
573.2

> <HBA>
9

> <HBD>
1

> <NRB>
7

> <TPSA>
82.2

> <LogP>
6.5

> <RoF>
2

> <Targets>
RAF1; MAP2K1; MAP2K2

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0383

> <r_epik_State_Penalty>
  0.0311

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
13

> <Kinase families>
STE<br>TKL

$$$$
Mubritinib
                    3D
 Structure written by MMmdl.
 57 60  0  0  1  0            999 V2000
   -2.0768   -0.7841   -0.4584 C   0  0  0  0  0  0
   -0.6865   -0.7408   -0.5089 C   0  0  0  0  0  0
    0.0064    0.3782   -0.0447 C   0  0  0  0  0  0
   -0.7155    1.4660    0.4722 C   0  0  0  0  0  0
   -2.1066    1.4252    0.5212 C   0  0  0  0  0  0
   -2.7893    0.2993    0.0582 C   0  0  0  0  0  0
   -4.3097    0.2541    0.1081 C   0  0  0  0  0  0
   -4.9605    0.7462   -1.1972 C   0  0  0  0  0  0
   -6.4971    0.6794   -1.1617 C   0  0  0  0  0  0
   -7.1428    1.1472   -2.4824 C   0  0  0  0  0  0
   -8.5947    1.0236   -2.4391 N   0  0  0  0  0  0
   -9.4017    0.1879   -3.1680 C   0  0  0  0  0  0
  -10.6811    0.4784   -2.7220 C   0  0  0  0  0  0
  -10.6443    1.4169   -1.7939 N   0  0  0  0  0  0
   -9.3209    1.7748   -1.6006 N   0  0  0  0  0  0
    1.3845    0.3284   -0.1347 O   0  0  0  0  0  0
    2.1608    1.4128    0.3688 C   0  0  0  0  0  0
    3.6300    1.0919    0.2006 C   0  0  0  0  0  0
    4.3291   -0.0504    0.5517 C   0  0  0  0  0  0
    5.6252    0.1406    0.2196 O   0  0  0  0  0  0
    5.6520    1.3913   -0.3087 C   0  0  0  0  0  0
    4.4695    1.9707   -0.3228 N   0  0  0  0  0  0
    6.9263    1.9124   -0.7632 C   0  0  0  0  0  0
    7.1495    3.1349   -1.2849 C   0  0  0  0  0  0
    8.4489    3.6781   -1.7322 C   0  0  0  0  0  0
    8.4530    4.8106   -2.5509 C   0  0  0  0  0  0
    9.6540    5.3529   -3.0000 C   0  0  0  0  0  0
   10.8704    4.7658   -2.6393 C   0  0  0  0  0  0
   10.8698    3.6333   -1.8192 C   0  0  0  0  0  0
    9.6680    3.0918   -1.3707 C   0  0  0  0  0  0
   12.1871    5.3741   -3.1212 C   0  0  0  0  0  0
   13.1971    5.0811   -2.2996 F   0  0  0  0  0  0
   12.4715    4.8905   -4.3301 F   0  0  0  0  0  0
   12.1015    6.7032   -3.2046 F   0  0  0  0  0  0
   -2.5977   -1.6576   -0.8227 H   0  0  0  0  0  0
   -0.1421   -1.5829   -0.9108 H   0  0  0  0  0  0
   -0.2165    2.3504    0.8378 H   0  0  0  0  0  0
   -2.6511    2.2698    0.9180 H   0  0  0  0  0  0
   -4.6272   -0.7677    0.3234 H   0  0  0  0  0  0
   -4.6615    0.8509    0.9516 H   0  0  0  0  0  0
   -4.6464    1.7725   -1.3948 H   0  0  0  0  0  0
   -4.5931    0.1476   -2.0322 H   0  0  0  0  0  0
   -6.8067   -0.3455   -0.9496 H   0  0  0  0  0  0
   -6.8622    1.2900   -0.3340 H   0  0  0  0  0  0
   -6.8959    2.1889   -2.6936 H   0  0  0  0  0  0
   -6.7730    0.5533   -3.3197 H   0  0  0  0  0  0
   -9.0060   -0.5019   -3.8988 H   0  0  0  0  0  0
  -11.6037    0.0267   -3.0559 H   0  0  0  0  0  0
    1.8959    2.3265   -0.1674 H   0  0  0  0  0  0
    1.9368    1.5874    1.4224 H   0  0  0  0  0  0
    4.0621   -0.9941    1.0040 H   0  0  0  0  0  0
    7.7422    1.2140   -0.6513 H   0  0  0  0  0  0
    6.3058    3.8051   -1.3776 H   0  0  0  0  0  0
    7.5237    5.2777   -2.8444 H   0  0  0  0  0  0
    9.6339    6.2291   -3.6320 H   0  0  0  0  0  0
   11.7985    3.1653   -1.5267 H   0  0  0  0  0  0
    9.7003    2.2197   -0.7351 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1  6  2  0  0  0
  1 35  1  0  0  0
  2  3  2  0  0  0
  2 36  1  0  0  0
  3  4  1  0  0  0
  3 16  1  0  0  0
  4  5  2  0  0  0
  4 37  1  0  0  0
  5  6  1  0  0  0
  5 38  1  0  0  0
  6  7  1  0  0  0
  7  8  1  0  0  0
  7 39  1  0  0  0
  7 40  1  0  0  0
  8  9  1  0  0  0
  8 41  1  0  0  0
  8 42  1  0  0  0
  9 10  1  0  0  0
  9 43  1  0  0  0
  9 44  1  0  0  0
 10 11  1  0  0  0
 10 45  1  0  0  0
 10 46  1  0  0  0
 11 12  1  0  0  0
 11 15  1  0  0  0
 12 13  2  0  0  0
 12 47  1  0  0  0
 13 14  1  0  0  0
 13 48  1  0  0  0
 14 15  2  0  0  0
 16 17  1  0  0  0
 17 18  1  0  0  0
 17 49  1  0  0  0
 17 50  1  0  0  0
 18 19  2  0  0  0
 18 22  1  0  0  0
 19 20  1  0  0  0
 19 51  1  0  0  0
 20 21  1  0  0  0
 21 22  2  0  0  0
 21 23  1  0  0  0
 23 24  2  0  0  0
 23 52  1  0  0  0
 24 25  1  0  0  0
 24 53  1  0  0  0
 25 26  1  0  0  0
 25 30  2  0  0  0
 26 27  2  0  0  0
 26 54  1  0  0  0
 27 28  1  0  0  0
 27 55  1  0  0  0
 28 29  2  0  0  0
 28 31  1  0  0  0
 29 30  1  0  0  0
 29 56  1  0  0  0
 30 57  1  0  0  0
 31 32  1  0  0  0
 31 33  1  0  0  0
 31 34  1  0  0  0
M  END
> <s_m_entry_id>
15

> <Applicants>
Takeda

> <CHEMBL_ID>
CHEMBL1614707

> <Canonical_Smiles>
FC(F)(F)c1ccc(cc1)\C=C\c1occ(n1)COc1ccc(cc1)CCCCn1nncc1

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
1

> <SC_Patent>
None

> <Synonyms>
MUBRITINIB | TAK-165

> <Indications>
nan

> <Type>
nan

> <targets_id>
P00533|P04626

> <inchi>
InChI=1S/C25H23F3N4O2/c26-25(27,28)21-9-4-20(5-10-21)8-13-24-30-22(18-34-24)17-33-23-11-6-19(7-12-23)3-1-2-15-32-16-14-29-31-32/h4-14,16,18H,1-3,15,17H2/b13-8+

> <stdInchikey>
ZTFBIUXIQYRUNT-MDWZMJQESA-N

> <csid>
4948554

> <Links>
|http://www.chemspider.com/Chemical-Structure.4948554.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1614707|http://pubchem.ncbi.nlm.nih.gov/compound/6444692|http://www.drugbank.ca/drugs/DB12682|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6011|http://zinc15.docking.org/substances/ZINC11679877|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=V734AZP9BR

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS

> <indicationG2P>
None

> <MW>
468.2

> <HBA>
6

> <HBD>
0

> <NRB>
10

> <TPSA>
66

> <LogP>
6.1

> <RoF>
1

> <Targets>
EGFR; ERBB2

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0000

> <r_epik_State_Penalty>
  0.0000

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
15

> <Kinase families>
Tyr

$$$$
Zotiraciclib
                    3D
 Structure written by MMmdl.
 53 56  0  0  1  0            999 V2000
   -0.2225    0.0946   -0.0968 C   0  0  0  0  0  0
    1.3148    0.0368    0.0377 N   0  3  2  0  0  0
    1.8327    0.7308    1.3198 C   0  0  0  0  0  0
    1.1567    0.2764    2.6049 C   0  0  0  0  0  0
    1.6435   -0.5940    3.5086 C   0  0  0  0  0  0
    2.9282   -1.3970    3.3900 C   0  0  0  0  0  0
    2.8631   -2.7858    4.0569 C   0  0  0  0  0  0
    1.7480   -3.5660    3.6191 O   0  0  0  0  0  0
    1.8502   -4.3523    2.4867 C   0  0  0  0  0  0
    0.8206   -5.2667    2.2577 C   0  0  0  0  0  0
    0.8539   -6.1147    1.1524 C   0  0  0  0  0  0
    1.9168   -6.0472    0.2533 C   0  0  0  0  0  0
    2.9533   -5.1250    0.4404 C   0  0  0  0  0  0
    2.9089   -4.2902    1.5670 C   0  0  0  0  0  0
    4.0724   -5.0232   -0.5362 C   0  0  0  0  0  0
    4.6921   -6.1421   -1.1056 C   0  0  0  0  0  0
    5.7529   -5.9041   -1.9828 C   0  0  0  0  0  0
    6.1778   -4.6513   -2.2940 N   0  0  0  0  0  0
    5.5079   -3.6205   -1.7184 C   0  0  0  0  0  0
    4.4790   -3.7617   -0.8417 N   0  0  0  0  0  0
    5.9467   -2.3306   -2.0530 N   0  0  0  0  0  0
    5.3992   -1.0760   -1.7326 C   0  0  0  0  0  0
    6.2596    0.0081   -1.5390 C   0  0  0  0  0  0
    5.7485    1.2666   -1.2185 C   0  0  0  0  0  0
    4.3711    1.4542   -1.1017 C   0  0  0  0  0  0
    3.4976    0.3834   -1.3109 C   0  0  0  0  0  0
    4.0156   -0.8735   -1.6314 C   0  0  0  0  0  0
    1.9907    0.5851   -1.2418 C   0  0  0  0  0  0
   -0.5148    1.1455   -0.1243 H   0  0  0  0  0  0
   -0.6526   -0.4223    0.7610 H   0  0  0  0  0  0
   -0.4921   -0.4222   -1.0187 H   0  0  0  0  0  0
    2.9047    0.5336    1.3374 H   0  0  0  0  0  0
    1.6781    1.8001    1.1677 H   0  0  0  0  0  0
    0.2201    0.7668    2.8279 H   0  0  0  0  0  0
    1.0598   -0.7805    4.3991 H   0  0  0  0  0  0
    3.2042   -1.4981    2.3410 H   0  0  0  0  0  0
    3.7253   -0.8210    3.8608 H   0  0  0  0  0  0
    3.8061   -3.3251    3.9530 H   0  0  0  0  0  0
    2.7356   -2.6440    5.1308 H   0  0  0  0  0  0
   -0.0068   -5.3288    2.9497 H   0  0  0  0  0  0
    0.0547   -6.8232    0.9913 H   0  0  0  0  0  0
    1.9213   -6.7051   -0.6038 H   0  0  0  0  0  0
    3.7180   -3.5922    1.7161 H   0  0  0  0  0  0
    4.3804   -7.1485   -0.8679 H   0  0  0  0  0  0
    6.2807   -6.7237   -2.4482 H   0  0  0  0  0  0
    6.8738   -2.3076   -2.4509 H   0  0  0  0  0  0
    7.3289   -0.1212   -1.6255 H   0  0  0  0  0  0
    6.4205    2.0981   -1.0648 H   0  0  0  0  0  0
    3.9856    2.4343   -0.8605 H   0  0  0  0  0  0
    3.3295   -1.6867   -1.8178 H   0  0  0  0  0  0
    1.5064    0.0602   -2.0673 H   0  0  0  0  0  0
    1.7124    1.6397   -1.2936 H   0  0  0  0  0  0
    1.5688   -0.9389    0.1090 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 29  1  0  0  0
  1 30  1  0  0  0
  1 31  1  0  0  0
  2  3  1  0  0  0
  2 28  1  0  0  0
  2 53  1  0  0  0
  3  4  1  0  0  0
  3 32  1  0  0  0
  3 33  1  0  0  0
  4  5  2  0  0  0
  4 34  1  0  0  0
  5  6  1  0  0  0
  5 35  1  0  0  0
  6  7  1  0  0  0
  6 36  1  0  0  0
  6 37  1  0  0  0
  7  8  1  0  0  0
  7 38  1  0  0  0
  7 39  1  0  0  0
  8  9  1  0  0  0
  9 10  1  0  0  0
  9 14  2  0  0  0
 10 11  2  0  0  0
 10 40  1  0  0  0
 11 12  1  0  0  0
 11 41  1  0  0  0
 12 13  2  0  0  0
 12 42  1  0  0  0
 13 14  1  0  0  0
 13 15  1  0  0  0
 14 43  1  0  0  0
 15 16  1  0  0  0
 15 20  2  0  0  0
 16 17  2  0  0  0
 16 44  1  0  0  0
 17 18  1  0  0  0
 17 45  1  0  0  0
 18 19  2  0  0  0
 19 20  1  0  0  0
 19 21  1  0  0  0
 21 22  1  0  0  0
 21 46  1  0  0  0
 22 23  1  0  0  0
 22 27  2  0  0  0
 23 24  2  0  0  0
 23 47  1  0  0  0
 24 25  1  0  0  0
 24 48  1  0  0  0
 25 26  2  0  0  0
 25 49  1  0  0  0
 26 27  1  0  0  0
 26 28  1  0  0  0
 27 50  1  0  0  0
 28 51  1  0  0  0
 28 52  1  0  0  0
M  CHG  1   2   1
M  END
> <s_m_entry_id>
16

> <Applicants>
S*BIO

> <CHEMBL_ID>
CHEMBL1944698

> <Canonical_Smiles>
O1CC\C=C\CN(Cc2cc(Nc3nc(-c4cc1ccc4)ccn3)ccc2)C

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
1

> <SC_Patent>
None

> <Synonyms>
EX45 | SB-1317 | SB1317 | TG-02 | TG02 | ZOTIRACICLIB

> <Indications>
nan

> <Type>
nan

> <targets_id>
nan

> <inchi>
InChI=1S/C23H24N4O/c1-27-13-3-2-4-14-28-21-10-6-8-19(16-21)22-11-12-24-23(26-22)25-20-9-5-7-18(15-20)17-27/h2-3,5-12,15-16H,4,13-14,17H2,1H3,(H,24,25,26)/b3-2+

> <stdInchikey>
VXBAJLGYBMTJCY-NSCUHMNNSA-N

> <csid>
20571045

> <Links>
|http://www.chemspider.com/Chemical-Structure.20571045.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1944698|http://pubchem.ncbi.nlm.nih.gov/compound/16739650|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9095|http://zinc15.docking.org/substances/ZINC000068251500|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=40D08182TT|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50363196

> <LinkName>
|ChemSpider|ChEMBL|PubChem|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
372.2

> <HBA>
5

> <HBD>
1

> <NRB>
0

> <TPSA>
50.3

> <LogP>
4.7

> <RoF>
0

> <Targets>
nan

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0504

> <r_epik_State_Penalty>
  0.0430

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
16

$$$$
Agerafenib
                    3D
 Structure written by MMmdl.
 59 62  0  0  1  0            999 V2000
   -7.0106    4.8464   -1.6242 C   0  0  0  0  0  0
   -6.7846    4.0455   -0.3169 C   0  0  0  0  0  0
   -7.7586    2.8393   -0.3165 C   0  0  0  0  0  0
   -5.3411    3.5404   -0.2715 C   0  0  0  0  0  0
   -4.7395    2.3232   -0.0162 C   0  0  0  0  0  0
   -3.3684    2.5409   -0.1347 C   0  0  0  0  0  0
   -3.1187    3.8017   -0.4398 N   0  0  0  0  0  0
   -4.3558    4.4408   -0.5250 O   0  0  0  0  0  0
   -2.4197    1.5424    0.0494 N   0  0  0  0  0  0
   -1.0821    1.6507   -0.0992 C   0  0  0  0  0  0
   -0.4879    2.6822   -0.4204 O   0  0  0  0  0  0
   -0.4915    0.4653    0.1571 N   0  0  0  0  0  0
    0.8664    0.1139    0.0416 C   0  0  0  0  0  0
    1.7996    0.8048   -0.7507 C   0  0  0  0  0  0
    3.1225    0.3677   -0.8208 C   0  0  0  0  0  0
    3.5254   -0.7621   -0.1107 C   0  0  0  0  0  0
    2.6065   -1.4601    0.6737 C   0  0  0  0  0  0
    1.2789   -1.0259    0.7395 C   0  0  0  0  0  0
    3.0130   -2.5849    1.3563 O   0  0  0  0  0  0
    3.2040   -2.5849    2.7294 C   0  0  0  0  0  0
    3.5846   -3.7961    3.3686 C   0  0  0  0  0  0
    3.7789   -5.0283    2.7016 C   0  0  0  0  0  0
    4.1562   -6.1773    3.4147 C   0  0  0  0  0  0
    4.3469   -6.1094    4.8019 C   0  0  0  0  0  0
    4.1570   -4.8934    5.4782 C   0  0  0  0  0  0
    3.7753   -3.7277    4.7790 C   0  0  0  0  0  0
    3.5992   -2.5654    5.4710 N   0  0  0  0  0  0
    3.2351   -1.4763    4.7503 C   0  0  0  0  0  0
    3.0280   -1.4204    3.4146 N   0  0  0  0  0  0
    4.7214   -7.2813    5.4368 O   0  0  0  0  0  0
    4.9504   -7.2796    6.8420 C   0  0  0  0  0  0
    4.3583   -7.4098    2.8168 O   0  0  0  0  0  0
    4.1788   -7.5487    1.4113 C   0  0  0  0  0  0
   -7.0598    4.9489    0.9227 C   0  0  0  0  0  0
   -8.3200    5.3877    0.9371 F   0  0  0  0  0  0
   -6.8713    4.2939    2.0703 F   0  0  0  0  0  0
   -6.2808    6.0324    0.9462 F   0  0  0  0  0  0
   -8.0406    5.1955   -1.7096 H   0  0  0  0  0  0
   -6.8014    4.2392   -2.5063 H   0  0  0  0  0  0
   -6.3687    5.7268   -1.6797 H   0  0  0  0  0  0
   -8.7996    3.1606   -0.3740 H   0  0  0  0  0  0
   -7.6575    2.2366    0.5873 H   0  0  0  0  0  0
   -7.5798    2.1798   -1.1671 H   0  0  0  0  0  0
   -5.2322    1.3930    0.2251 H   0  0  0  0  0  0
   -2.7855    0.6378    0.3075 H   0  0  0  0  0  0
   -1.0874   -0.2712    0.5055 H   0  0  0  0  0  0
    1.5210    1.6698   -1.3323 H   0  0  0  0  0  0
    3.8347    0.9025   -1.4315 H   0  0  0  0  0  0
    4.5503   -1.0980   -0.1700 H   0  0  0  0  0  0
    0.5752   -1.5798    1.3450 H   0  0  0  0  0  0
    3.6279   -5.0564    1.6330 H   0  0  0  0  0  0
    4.2971   -4.8174    6.5463 H   0  0  0  0  0  0
    3.0965   -0.5566    5.2999 H   0  0  0  0  0  0
    5.2374   -8.2819    7.1598 H   0  0  0  0  0  0
    4.0507   -7.0049    7.3946 H   0  0  0  0  0  0
    5.7620   -6.6031    7.1148 H   0  0  0  0  0  0
    4.3720   -8.5824    1.1252 H   0  0  0  0  0  0
    4.8738   -6.9176    0.8553 H   0  0  0  0  0  0
    3.1570   -7.3101    1.1120 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 38  1  0  0  0
  1 39  1  0  0  0
  1 40  1  0  0  0
  2  3  1  0  0  0
  2  4  1  0  0  0
  2 34  1  0  0  0
  3 41  1  0  0  0
  3 42  1  0  0  0
  3 43  1  0  0  0
  4  5  2  0  0  0
  4  8  1  0  0  0
  5  6  1  0  0  0
  5 44  1  0  0  0
  6  7  2  0  0  0
  6  9  1  0  0  0
  7  8  1  0  0  0
  9 10  1  0  0  0
  9 45  1  0  0  0
 10 11  2  0  0  0
 10 12  1  0  0  0
 12 13  1  0  0  0
 12 46  1  0  0  0
 13 14  1  0  0  0
 13 18  2  0  0  0
 14 15  2  0  0  0
 14 47  1  0  0  0
 15 16  1  0  0  0
 15 48  1  0  0  0
 16 17  2  0  0  0
 16 49  1  0  0  0
 17 18  1  0  0  0
 17 19  1  0  0  0
 18 50  1  0  0  0
 19 20  1  0  0  0
 20 21  1  0  0  0
 20 29  2  0  0  0
 21 22  1  0  0  0
 21 26  2  0  0  0
 22 23  2  0  0  0
 22 51  1  0  0  0
 23 24  1  0  0  0
 23 32  1  0  0  0
 24 25  2  0  0  0
 24 30  1  0  0  0
 25 26  1  0  0  0
 25 52  1  0  0  0
 26 27  1  0  0  0
 27 28  2  0  0  0
 28 29  1  0  0  0
 28 53  1  0  0  0
 30 31  1  0  0  0
 31 54  1  0  0  0
 31 55  1  0  0  0
 31 56  1  0  0  0
 32 33  1  0  0  0
 33 57  1  0  0  0
 33 58  1  0  0  0
 33 59  1  0  0  0
 34 35  1  0  0  0
 34 36  1  0  0  0
 34 37  1  0  0  0
M  END
> <s_m_entry_id>
22

> <Applicants>
Ignyta

> <CHEMBL_ID>
CHEMBL2029988

> <Canonical_Smiles>
FC(F)(F)C(C)(C)c1onc(NC(=O)Nc2cc(Oc3ncnc4c3cc(OC)c(OC)c4)ccc2)c1

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
1

> <SC_Patent>
None

> <Synonyms>
AB-024 | AC-013773 | AGERAFENIB | CEP-32496 | RXDX 105 | RXDX-105

> <Indications>
nan

> <Type>
nan

> <targets_id>
nan

> <inchi>
InChI=1S/C24H22F3N5O5/c1-23(2,24(25,26)27)19-11-20(32-37-19)31-22(33)30-13-6-5-7-14(8-13)36-21-15-9-17(34-3)18(35-4)10-16(15)28-12-29-21/h5-12H,1-4H3,(H2,30,31,32,33)

> <stdInchikey>
DKNUPRMJNUQNHR-UHFFFAOYSA-N

> <csid>
28506650

> <Links>
|http://www.chemspider.com/Chemical-Structure.28506650.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2029988|http://pubchem.ncbi.nlm.nih.gov/compound/56846693|http://www.drugbank.ca/drugs/DB15068|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7880|http://zinc15.docking.org/substances/ZINC000043207440|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=78I4VEX88N|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50382959

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
517.2

> <HBA>
8

> <HBD>
2

> <NRB>
7

> <TPSA>
120.6

> <LogP>
5.9

> <RoF>
2

> <Targets>
nan

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0008

> <r_epik_State_Penalty>
  0.0005

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
22

$$$$
Glumetinib
                    3D
 Structure written by MMmdl.
 50 55  0  0  1  0            999 V2000
   -2.7028   -8.2601    0.0025 C   0  0  0  0  0  0
   -2.0729   -6.9519    0.0041 N   0  0  0  0  0  0
   -2.6777   -5.7229   -0.0015 C   0  0  0  0  0  0
   -1.6581   -4.7783   -0.0007 C   0  0  0  0  0  0
   -1.7702   -3.2877   -0.0075 C   0  0  0  0  0  0
   -3.0268   -2.6657    0.0064 C   0  0  0  0  0  0
   -3.2243   -1.3206   -0.0001 N   0  0  0  0  0  0
   -2.1273   -0.5591   -0.0188 C   0  0  0  0  0  0
   -1.9403    0.8532   -0.0280 C   0  0  0  0  0  0
   -0.6661    1.1555   -0.0407 N   0  0  0  0  0  0
    0.0209   -0.0084   -0.0373 N   0  0  0  0  0  0
    1.7409    0.0324   -0.0270 S   0  0  0  0  0  0
    2.1825   -0.7998   -1.1516 O   0  0  0  0  0  0
    2.1555    1.4319    0.1302 O   0  0  0  0  0  0
    2.1632   -0.8422    1.4957 C   0  0  0  0  0  0
    2.8563   -2.0294    1.7037 C   0  0  0  0  0  0
    2.9423   -2.3641    2.9735 N   0  0  0  0  0  0
    2.2778   -1.3784    3.6333 C   0  0  0  0  0  0
    2.0307   -1.2104    5.0073 C   0  0  0  0  0  0
    1.2971   -0.1016    5.4356 C   0  0  0  0  0  0
    0.8069    0.8477    4.5328 C   0  0  0  0  0  0
    0.0121    2.0214    5.0056 C   0  0  0  0  0  0
   -0.5807    3.0463    4.2431 C   0  0  0  0  0  0
   -1.2199    3.9395    4.9639 N   0  0  0  0  0  0
   -1.0637    3.5223    6.2238 N   0  0  0  0  0  0
   -1.6530    4.2896    7.3064 C   0  0  0  0  0  0
   -0.3284    2.3694    6.3072 C   0  0  0  0  0  0
    1.0663    0.6793    3.1713 C   0  0  0  0  0  0
    1.7799   -0.4103    2.7415 N   0  0  0  0  0  0
   -0.8226   -1.1040   -0.0320 C   0  0  0  0  0  0
   -0.6180   -2.4881   -0.0283 C   0  0  0  0  0  0
   -0.4963   -5.5739    0.0074 C   0  0  0  0  0  0
   -0.7395   -6.8651    0.0096 N   0  0  0  0  0  0
   -3.7881   -8.1520    0.0023 H   0  0  0  0  0  0
   -2.3991   -8.8118    0.8931 H   0  0  0  0  0  0
   -2.3988   -8.8098   -0.8893 H   0  0  0  0  0  0
   -3.7542   -5.6344   -0.0062 H   0  0  0  0  0  0
   -3.9318   -3.2547    0.0239 H   0  0  0  0  0  0
   -2.6966    1.6239   -0.0242 H   0  0  0  0  0  0
    3.2935   -2.6438    0.9300 H   0  0  0  0  0  0
    2.3950   -1.9302    5.7254 H   0  0  0  0  0  0
    1.1083    0.0105    6.4932 H   0  0  0  0  0  0
   -0.5435    3.1352    3.1671 H   0  0  0  0  0  0
   -1.4408    3.8098    8.2626 H   0  0  0  0  0  0
   -2.7333    4.3462    7.1674 H   0  0  0  0  0  0
   -1.2320    5.2957    7.3106 H   0  0  0  0  0  0
   -0.1202    1.9118    7.2631 H   0  0  0  0  0  0
    0.7250    1.3667    2.4127 H   0  0  0  0  0  0
    0.3758   -2.9103   -0.0389 H   0  0  0  0  0  0
    0.5200   -5.2080    0.0106 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 34  1  0  0  0
  1 35  1  0  0  0
  1 36  1  0  0  0
  2  3  1  0  0  0
  2 33  1  0  0  0
  3  4  2  0  0  0
  3 37  1  0  0  0
  4  5  1  0  0  0
  4 32  1  0  0  0
  5  6  1  0  0  0
  5 31  2  0  0  0
  6  7  2  0  0  0
  6 38  1  0  0  0
  7  8  1  0  0  0
  8  9  1  0  0  0
  8 30  2  0  0  0
  9 10  2  0  0  0
  9 39  1  0  0  0
 10 11  1  0  0  0
 11 12  1  0  0  0
 11 30  1  0  0  0
 12 13  2  0  0  0
 12 14  2  0  0  0
 12 15  1  0  0  0
 15 16  2  0  0  0
 15 29  1  0  0  0
 16 17  1  0  0  0
 16 40  1  0  0  0
 17 18  2  0  0  0
 18 19  1  0  0  0
 18 29  1  0  0  0
 19 20  2  0  0  0
 19 41  1  0  0  0
 20 21  1  0  0  0
 20 42  1  0  0  0
 21 22  1  0  0  0
 21 28  2  0  0  0
 22 23  1  0  0  0
 22 27  2  0  0  0
 23 24  2  0  0  0
 23 43  1  0  0  0
 24 25  1  0  0  0
 25 26  1  0  0  0
 25 27  1  0  0  0
 26 44  1  0  0  0
 26 45  1  0  0  0
 26 46  1  0  0  0
 27 47  1  0  0  0
 28 29  1  0  0  0
 28 48  1  0  0  0
 30 31  1  0  0  0
 31 49  1  0  0  0
 32 33  2  0  0  0
 32 50  1  0  0  0
M  END
> <s_m_entry_id>
23

> <Applicants>
HaiHe Phaemaceutical

> <CHEMBL_ID>
CHEMBL4594400

> <Canonical_Smiles>
S(=O)(=O)(n1ncc2ncc(cc12)-c1cn(nc1)C)c1n2C=C(C=Cc2nc1)c1cn(nc1)C

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
1

> <SC_Patent>
None

> <Indications>
nan

> <Type>
nan

> <targets_id>
nan

> <inchi>
InChI=1S/C21H17N9O2S/c1-27-11-16(7-24-27)14-3-4-20-23-10-21(29(20)13-14)33(31,32)30-19-5-15(6-22-18(19)9-26-30)17-8-25-28(2)12-17/h3-13H,1-2H3

> <stdInchikey>
RYBLECYFLJXEJX-UHFFFAOYSA-N

> <csid>
68006902

> <Links>
|http://www.chemspider.com/Chemical-Structure.68006902.html|http://pubchem.ncbi.nlm.nih.gov/compound/117797905|http://www.drugbank.ca/drugs/DB15630|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=7JTT036WGX

> <LinkName>
|ChemSpider|PubChem|DrugBank|FDA SRS

> <MW>
459.1

> <HBA>
11

> <HBD>
0

> <NRB>
4

> <TPSA>
117.8

> <LogP>
2.1

> <RoF>
1

> <Targets>
nan

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0001

> <r_epik_State_Penalty>
  0.0000

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
23

> <Kinase families>
(*)

$$$$
Recilisib
                    3D
 Structure written by MMmdl.
 34 35  0  0  1  0            999 V2000
   -2.7400    1.9780    1.2174 C   0  0  0  0  0  0
   -4.1298    2.0638    1.2198 C   0  0  0  0  0  0
   -4.8221    2.1067    0.0105 C   0  0  0  0  0  0
   -4.1343    2.0638   -1.2014 C   0  0  0  0  0  0
   -2.7445    1.9782   -1.2043 C   0  0  0  0  0  0
   -2.0471    1.9341    0.0053 C   0  0  0  0  0  0
   -0.5309    1.8417    0.0027 C   0  0  0  0  0  0
    0.0609    0.0459   -0.0026 S   0  0  0  0  0  0
   -0.3316   -0.5720    1.2686 O   0  0  0  0  0  0
   -0.3378   -0.5658   -1.2749 O   0  0  0  0  0  0
    1.8481    0.1996   -0.0071 C   0  0  0  0  0  0
    2.6030   -0.9163    0.0028 C   0  0  0  0  0  0
    4.0824   -1.0006    0.0017 C   0  0  0  0  0  0
    4.6707   -2.2677    0.0008 C   0  0  0  0  0  0
    6.0557   -2.4082   -0.0001 C   0  0  0  0  0  0
    6.8896   -1.2807   -0.0003 C   0  0  0  0  0  0
    6.2967   -0.0097    0.0002 C   0  0  0  0  0  0
    4.9114    0.1292    0.0011 C   0  0  0  0  0  0
    8.3842   -1.4311   -0.0009 C   0  0  0  0  0  0
    9.0809   -0.3900   -0.0011 O   0  0  0  0  0  0
    8.8594   -2.5902   -0.0012 O   0  5  0  0  0  0
   -6.5449    2.2131    0.0138 Cl  0  0  0  0  0  0
   -2.2052    1.9415    2.1554 H   0  0  0  0  0  0
   -4.6660    2.0956    2.1569 H   0  0  0  0  0  0
   -4.6742    2.0956   -2.1365 H   0  0  0  0  0  0
   -2.2133    1.9417   -2.1444 H   0  0  0  0  0  0
   -0.1100    2.3312   -0.8762 H   0  0  0  0  0  0
   -0.1069    2.3272    0.8822 H   0  0  0  0  0  0
    2.2505    1.2007   -0.0180 H   0  0  0  0  0  0
    2.0831   -1.8646    0.0132 H   0  0  0  0  0  0
    4.0565   -3.1570    0.0009 H   0  0  0  0  0  0
    6.4704   -3.4063   -0.0006 H   0  0  0  0  0  0
    6.9024    0.8855   -0.0001 H   0  0  0  0  0  0
    4.4963    1.1259    0.0017 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1  6  2  0  0  0
  1 23  1  0  0  0
  2  3  2  0  0  0
  2 24  1  0  0  0
  3  4  1  0  0  0
  3 22  1  0  0  0
  4  5  2  0  0  0
  4 25  1  0  0  0
  5  6  1  0  0  0
  5 26  1  0  0  0
  6  7  1  0  0  0
  7  8  1  0  0  0
  7 27  1  0  0  0
  7 28  1  0  0  0
  8  9  2  0  0  0
  8 10  2  0  0  0
  8 11  1  0  0  0
 11 12  2  0  0  0
 11 29  1  0  0  0
 12 13  1  0  0  0
 12 30  1  0  0  0
 13 14  1  0  0  0
 13 18  2  0  0  0
 14 15  2  0  0  0
 14 31  1  0  0  0
 15 16  1  0  0  0
 15 32  1  0  0  0
 16 17  2  0  0  0
 16 19  1  0  0  0
 17 18  1  0  0  0
 17 33  1  0  0  0
 18 34  1  0  0  0
 19 20  2  0  0  0
 19 21  1  0  0  0
M  CHG  1  21  -1
M  END
> <s_m_entry_id>
24

> <Applicants>
Onconova Therapeutics

> <CHEMBL_ID>
CHEMBL2219421

> <Canonical_Smiles>
Clc1ccc(cc1)CS(=O)(=O)\C=C\c1ccc(cc1)C(O)=O

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
1

> <SC_Patent>
None

> <Synonyms>
EX-RAD | ON 01210 | ON 01210.NA | ON-01210 | RECILISIB

> <Indications>
nan

> <Type>
nan

> <targets_id>
nan

> <inchi>
InChI=1S/C16H13ClO4S/c17-15-7-3-13(4-8-15)11-22(20,21)10-9-12-1-5-14(6-2-12)16(18)19/h1-10H,11H2,(H,18,19)/b10-9+

> <stdInchikey>
KBEKQQJUNVQLDZ-MDZDMXLPSA-N

> <csid>
8059894

> <Links>
|http://www.chemspider.com/Chemical-Structure.8059894.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2219421|http://pubchem.ncbi.nlm.nih.gov/compound/9884220|http://zinc15.docking.org/substances/ZINC000034007613|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=F5V4K11SYV

> <LinkName>
|ChemSpider|ChEMBL|PubChem|ZINC|FDA SRS

> <MW>
336

> <HBA>
3

> <HBD>
1

> <NRB>
5

> <TPSA>
71.4

> <LogP>
3.6

> <RoF>
0

> <Targets>
nan

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_epik_Ionization_Penalty>
  0.0005

> <r_epik_State_Penalty>
  0.0003

> <i_epik_Tot_Q>
-1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
24

> <BrandName>
Ex-RAD;Ex-rad

$$$$
Lifirafenib
                    3D
 Structure written by MMmdl.
 52 58  0  0  1  0            999 V2000
   -4.0553    0.1212    1.6588 C   0  0  0  0  0  0
   -2.7236    0.3452    2.0167 C   0  0  0  0  0  0
   -1.7736    0.2079    1.0027 C   0  0  0  0  0  0
   -2.1249   -0.1398   -0.3243 C   0  0  0  0  0  0
   -3.4706   -0.3581   -0.6508 C   0  0  0  0  0  0
   -4.4381   -0.2222    0.3540 C   0  0  0  0  0  0
   -5.9087   -0.4702    0.0168 C   0  0  0  0  0  0
   -6.0352   -1.5106   -0.8088 F   0  0  0  0  0  0
   -6.6396   -0.7218    1.1047 F   0  0  0  0  0  0
   -6.4050    0.6113   -0.5835 F   0  0  0  0  0  0
   -1.0161   -0.2111   -1.1265 N   0  0  0  0  0  0
   -0.0097    0.0806   -0.3356 C   0  0  0  0  0  0
   -0.4052    0.3401    0.9558 N   0  0  0  0  0  0
    1.4506    0.1317   -0.7479 C   0  0  1  0  0  0
    1.9382   -0.9106   -1.7539 C   0  0  1  0  0  0
    1.7788    0.5254   -2.1787 C   0  0  2  0  0  0
    3.0793    1.0966   -2.3784 O   0  0  0  0  0  0
    4.0042    0.1059   -2.1733 C   0  0  0  0  0  0
    3.4259   -1.0932   -1.8031 C   0  0  0  0  0  0
    4.2369   -2.2049   -1.5742 C   0  0  0  0  0  0
    5.6263   -2.0960   -1.7155 C   0  0  0  0  0  0
    6.1924   -0.8559   -2.0682 C   0  0  0  0  0  0
    5.3807    0.2559   -2.3074 C   0  0  0  0  0  0
    6.3915   -3.2124   -1.4498 O   0  0  0  0  0  0
    7.5450   -3.4743   -2.1591 C   0  0  0  0  0  0
    7.5900   -3.3666   -3.5575 C   0  0  0  0  0  0
    8.7824   -3.6628   -4.2173 C   0  0  0  0  0  0
    9.9037   -4.0612   -3.5673 N   0  0  0  0  0  0
    9.8360   -4.1770   -2.2180 C   0  0  0  0  0  0
    8.6859   -3.9060   -1.4666 C   0  0  0  0  0  0
    8.7638   -4.0590    0.0485 C   0  0  0  0  0  0
    9.8789   -5.0494    0.4968 C   0  0  0  0  0  0
   11.1966   -4.9528   -0.3158 C   0  0  0  0  0  0
   12.3040   -5.2169    0.1468 O   0  0  0  0  0  0
   11.0121   -4.5979   -1.6037 N   0  0  0  0  0  0
   -4.8079    0.2234    2.4272 H   0  0  0  0  0  0
   -2.4520    0.6100    3.0279 H   0  0  0  0  0  0
   -3.7541   -0.6236   -1.6591 H   0  0  0  0  0  0
    2.1374    0.4557    0.0361 H   0  0  0  0  0  0
    1.3139   -1.6872   -2.1970 H   0  0  0  0  0  0
    1.0383    0.8488   -2.9115 H   0  0  0  0  0  0
    3.8031   -3.1522   -1.2892 H   0  0  0  0  0  0
    7.2638   -0.7524   -2.1574 H   0  0  0  0  0  0
    5.8213    1.2015   -2.5869 H   0  0  0  0  0  0
    6.7200   -3.0590   -4.1188 H   0  0  0  0  0  0
    8.8507   -3.5847   -5.2925 H   0  0  0  0  0  0
    8.9381   -3.0777    0.4920 H   0  0  0  0  0  0
    7.8059   -4.4038    0.4406 H   0  0  0  0  0  0
   10.1137   -4.8933    1.5504 H   0  0  0  0  0  0
    9.5274   -6.0774    0.3984 H   0  0  0  0  0  0
   11.8545   -4.5940   -2.1598 H   0  0  0  0  0  0
    0.2369    0.5798    1.6968 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1  6  2  0  0  0
  1 36  1  0  0  0
  2  3  2  0  0  0
  2 37  1  0  0  0
  3  4  1  0  0  0
  3 13  1  0  0  0
  4  5  2  0  0  0
  4 11  1  0  0  0
  5  6  1  0  0  0
  5 38  1  0  0  0
  6  7  1  0  0  0
  7  8  1  0  0  0
  7  9  1  0  0  0
  7 10  1  0  0  0
 11 12  2  0  0  0
 12 13  1  0  0  0
 12 14  1  0  0  0
 13 52  1  0  0  0
 14 15  1  0  0  0
 14 16  1  0  0  0
 14 39  1  0  0  0
 15 16  1  0  0  0
 15 19  1  0  0  0
 15 40  1  0  0  0
 16 17  1  0  0  0
 16 41  1  0  0  0
 17 18  1  0  0  0
 18 19  1  0  0  0
 18 23  2  0  0  0
 19 20  2  0  0  0
 20 21  1  0  0  0
 20 42  1  0  0  0
 21 22  2  0  0  0
 21 24  1  0  0  0
 22 23  1  0  0  0
 22 43  1  0  0  0
 23 44  1  0  0  0
 24 25  1  0  0  0
 25 26  1  0  0  0
 25 30  2  0  0  0
 26 27  2  0  0  0
 26 45  1  0  0  0
 27 28  1  0  0  0
 27 46  1  0  0  0
 28 29  2  0  0  0
 29 30  1  0  0  0
 29 35  1  0  0  0
 30 31  1  0  0  0
 31 32  1  0  0  0
 31 47  1  0  0  0
 31 48  1  0  0  0
 32 33  1  0  0  0
 32 49  1  0  0  0
 32 50  1  0  0  0
 33 34  2  0  0  0
 33 35  1  0  0  0
 35 51  1  0  0  0
M  END
> <s_m_entry_id>
25

> <Applicants>
BeiGene

> <CHEMBL_ID>
CHEMBL4209157

> <Canonical_Smiles>
FC(F)(F)c1cc2[nH]c(nc2cc1)[C@H]1[C@H]2[C@@H]1Oc1c2cc(Oc2c3CCC(=O)Nc3ncc2)cc1

> <Chirality>
Single Stereoisomer

> <First_Approval>
nan

> <Phase>
1

> <SC_Patent>
None

> <Synonyms>
BGB 283 | BGB-283 | LIFIRAFENIB

> <Indications>
nan

> <Type>
nan

> <targets_id>
nan

> <inchi>
InChI=1S/C25H17F3N4O3/c26-25(27,28)11-1-4-15-16(9-11)31-24(30-15)21-20-14-10-12(2-5-17(14)35-22(20)21)34-18-7-8-29-23-13(18)3-6-19(33)32-23/h1-2,4-5,7-10,20-22H,3,6H2,(H,30,31)(H,29,32,33)/t20-,21-,22-/m0/s1

> <stdInchikey>
NGFFVZQXSRKHBM-FKBYEOEOSA-N

> <csid>
58145118

> <Links>
|http://www.chemspider.com/Chemical-Structure.58145118.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4209157|http://pubchem.ncbi.nlm.nih.gov/compound/89670174|http://www.drugbank.ca/drugs/DB14773| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=3K3|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/3K3|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8958|http://zinc15.docking.org/substances/ZINC000068764621|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=8762XZS5ZF

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS

> <indicationG2P>
None

> <MW>
478.1

> <HBA>
5

> <HBD>
2

> <NRB>
3

> <TPSA>
89.1

> <LogP>
5.3

> <RoF>
1

> <Targets>
nan

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0768

> <r_epik_State_Penalty>
  0.3405

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
25

> <lig_pdbID>
'3K3'

> <pdbID>
4r5y

$$$$
Nedisertib
                    3D
 Structure written by MMmdl.
 55 59  0  0  1  0            999 V2000
   -5.1778    1.6930    0.5034 C   0  0  0  0  0  0
   -4.4992    0.6217   -0.1497 O   0  0  0  0  0  0
   -3.1249    0.5165   -0.0352 C   0  0  0  0  0  0
   -2.4774   -0.5374   -0.6796 C   0  0  0  0  0  0
   -1.0934   -0.6385   -0.5572 C   0  0  0  0  0  0
   -0.4253    0.3259    0.2062 C   0  0  0  0  0  0
   -1.0966    1.3406    0.8189 N   0  0  0  0  0  0
   -2.4315    1.4369    0.7001 N   0  0  0  0  0  0
    1.0915    0.3070    0.4081 C   0  0  2  0  0  0
    1.8026    1.3438   -0.4717 C   0  0  0  0  0  0
    2.1479    0.9998   -1.7858 C   0  0  0  0  0  0
    2.8048    1.8993   -2.6332 C   0  0  0  0  0  0
    3.1175    3.1740   -2.1439 C   0  0  0  0  0  0
    2.7786    3.5324   -0.8410 C   0  0  0  0  0  0
    2.1245    2.6300   -0.0028 C   0  0  0  0  0  0
    1.7327    3.1528    1.6004 Cl  0  0  0  0  0  0
    3.7411    4.0802   -2.9333 F   0  0  0  0  0  0
    3.1580    1.4941   -4.0211 C   0  0  0  0  0  0
    4.5020    1.4200   -4.4987 C   0  0  0  0  0  0
    5.6608    1.6837   -3.7274 C   0  0  0  0  0  0
    6.9241    1.5729   -4.3015 C   0  0  0  0  0  0
    7.0959    1.1947   -5.6408 C   0  0  0  0  0  0
    5.9571    0.9328   -6.4134 C   0  0  0  0  0  0
    4.6574    1.0320   -5.8640 C   0  0  0  0  0  0
    3.5840    0.7485   -6.6565 N   0  0  0  0  0  0
    2.3605    0.8431   -6.0814 C   0  0  0  0  0  0
    2.0893    1.1973   -4.8042 N   0  0  0  0  0  0
    8.3590    1.0872   -6.2223 N   0  0  0  0  0  0
    9.5642    1.6161   -5.5613 C   0  0  0  0  0  0
   10.7341    1.7974   -6.5524 C   0  0  0  0  0  0
   11.0275    0.5760   -7.2188 O   0  0  0  0  0  0
    9.8989    0.0087   -7.8716 C   0  0  0  0  0  0
    8.7280   -0.1772   -6.8826 C   0  0  0  0  0  0
    1.6598   -0.9886    0.3039 O   0  0  0  0  0  0
   -6.2478    1.6123    0.3123 H   0  0  0  0  0  0
   -4.8461    2.6625    0.1283 H   0  0  0  0  0  0
   -5.0308    1.6602    1.5841 H   0  0  0  0  0  0
   -3.0338   -1.2584   -1.2605 H   0  0  0  0  0  0
   -0.5605   -1.4402   -1.0475 H   0  0  0  0  0  0
    1.2738    0.5571    1.4534 H   0  0  0  0  0  0
    1.9011    0.0152   -2.1582 H   0  0  0  0  0  0
    3.0236    4.5210   -0.4809 H   0  0  0  0  0  0
    5.5678    1.9655   -2.6890 H   0  0  0  0  0  0
    7.7779    1.7767   -3.6726 H   0  0  0  0  0  0
    6.0530    0.6540   -7.4534 H   0  0  0  0  0  0
    1.5118    0.6125   -6.7086 H   0  0  0  0  0  0
    9.3408    2.5931   -5.1307 H   0  0  0  0  0  0
    9.8627    0.9688   -4.7350 H   0  0  0  0  0  0
   10.5091    2.5817   -7.2774 H   0  0  0  0  0  0
   11.6259    2.1250   -6.0181 H   0  0  0  0  0  0
    9.5970    0.6280   -8.7184 H   0  0  0  0  0  0
   10.1882   -0.9557   -8.2893 H   0  0  0  0  0  0
    8.9830   -0.9296   -6.1344 H   0  0  0  0  0  0
    7.8834   -0.5809   -7.4406 H   0  0  0  0  0  0
    1.3424   -1.5187    1.0387 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 35  1  0  0  0
  1 36  1  0  0  0
  1 37  1  0  0  0
  2  3  1  0  0  0
  3  4  1  0  0  0
  3  8  2  0  0  0
  4  5  2  0  0  0
  4 38  1  0  0  0
  5  6  1  0  0  0
  5 39  1  0  0  0
  6  7  2  0  0  0
  6  9  1  0  0  0
  7  8  1  0  0  0
  9 10  1  0  0  0
  9 34  1  0  0  0
  9 40  1  0  0  0
 10 11  1  0  0  0
 10 15  2  0  0  0
 11 12  2  0  0  0
 11 41  1  0  0  0
 12 13  1  0  0  0
 12 18  1  0  0  0
 13 14  2  0  0  0
 13 17  1  0  0  0
 14 15  1  0  0  0
 14 42  1  0  0  0
 15 16  1  0  0  0
 18 19  1  0  0  0
 18 27  2  0  0  0
 19 20  1  0  0  0
 19 24  2  0  0  0
 20 21  2  0  0  0
 20 43  1  0  0  0
 21 22  1  0  0  0
 21 44  1  0  0  0
 22 23  2  0  0  0
 22 28  1  0  0  0
 23 24  1  0  0  0
 23 45  1  0  0  0
 24 25  1  0  0  0
 25 26  2  0  0  0
 26 27  1  0  0  0
 26 46  1  0  0  0
 28 29  1  0  0  0
 28 33  1  0  0  0
 29 30  1  0  0  0
 29 47  1  0  0  0
 29 48  1  0  0  0
 30 31  1  0  0  0
 30 49  1  0  0  0
 30 50  1  0  0  0
 31 32  1  0  0  0
 32 33  1  0  0  0
 32 51  1  0  0  0
 32 52  1  0  0  0
 33 53  1  0  0  0
 33 54  1  0  0  0
 34 55  1  0  0  0
M  END
> <s_m_entry_id>
28

> <Applicants>
Merck

> <CHEMBL_ID>
CHEMBL4297629

> <Canonical_Smiles>
Clc1cc(F)c(cc1C(O)c1nnc(OC)cc1)-c1ncnc2c1ccc(N1CCOCC1)c2

> <Chirality>
Single Stereoisomer

> <First_Approval>
nan

> <Phase>
1

> <SC_Patent>
None

> <Synonyms>
|M3814|MSC2490484A|MSC 2490484A|MSC-2490484A|M-3814

> <Indications>
nan

> <Type>
nan

> <targets_id>
nan

> <inchi>
InChI=1S/C24H21ClFN5O3/c1-33-22-5-4-20(29-30-22)24(32)16-11-17(19(26)12-18(16)25)23-15-3-2-14(10-21(15)27-13-28-23)31-6-8-34-9-7-31/h2-5,10-13,24,32H,6-9H2,1H3

> <stdInchikey>
MOWXJLUYGFNTAL-UHFFFAOYSA-N

> <csid>
68007068

> <Links>
|http://www.chemspider.com/Chemical-Structure.68007068.html|http://pubchem.ncbi.nlm.nih.gov/compound/117696445|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=315705

> <LinkName>
|ChemSpider|PubChem|BindingDB

> <MW>
481.1

> <HBA>
8

> <HBD>
1

> <NRB>
5

> <TPSA>
93.5

> <LogP>
3.8

> <RoF>
0

> <Targets>
nan

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0024

> <r_epik_State_Penalty>
  0.0002

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
28

$$$$
Selatinib
                    3D
 Structure written by MMmdl.
 66 70  0  0  1  0            999 V2000
   -0.7649    5.9471    2.1772 C   0  0  0  0  0  0
    0.3589    4.5232    2.5599 S   0  0  1  0  0  0
   -0.0435    3.9844    3.9337 O   0  0  0  0  0  0
   -0.3194    3.3453    1.2975 C   0  0  0  0  0  0
    0.3531    1.9765    1.4596 C   0  0  0  0  0  0
   -0.2031    1.0135    0.3969 N   0  3  0  0  0  0
    0.3109   -0.4344    0.4826 C   0  0  0  0  0  0
    1.8066   -0.4598    0.2587 C   0  0  0  0  0  0
    2.9019   -0.6571    1.0835 C   0  0  0  0  0  0
    4.0354   -0.5406    0.2798 C   0  0  0  0  0  0
    3.5964   -0.2764   -1.0119 C   0  0  0  0  0  0
    2.2356   -0.2328   -1.0104 O   0  0  0  0  0  0
    4.2967   -0.0376   -2.3083 C   0  0  0  0  0  0
    3.5892   -0.0116   -3.5126 C   0  0  0  0  0  0
    4.2367    0.2170   -4.7235 C   0  0  0  0  0  0
    5.6341    0.4288   -4.7550 C   0  0  0  0  0  0
    6.3745    0.4038   -3.5326 C   0  0  0  0  0  0
    5.6790    0.1672   -2.3145 C   0  0  0  0  0  0
    7.7823    0.6253   -3.6464 C   0  0  0  0  0  0
    8.3780    0.8418   -4.8467 N   0  0  0  0  0  0
    7.5769    0.8454   -5.9354 C   0  0  0  0  0  0
    6.2374    0.6507   -5.9564 N   0  0  0  0  0  0
    8.5905    0.5961   -2.4925 N   0  0  0  0  0  0
    9.9737    0.7429   -2.2841 C   0  0  0  0  0  0
   10.5296    0.1245   -1.1629 C   0  0  0  0  0  0
   11.8934    0.2307   -0.8939 C   0  0  0  0  0  0
   12.7354    0.9720   -1.7396 C   0  0  0  0  0  0
   12.1722    1.6056   -2.8548 C   0  0  0  0  0  0
   10.8066    1.4944   -3.1224 C   0  0  0  0  0  0
   13.1571    2.5443   -3.9224 Cl  0  0  0  0  0  0
   14.0960    1.1202   -1.5376 O   0  0  0  0  0  0
   14.7161    0.4754   -0.4293 C   0  0  0  0  0  0
   16.2016    0.7921   -0.4429 C   0  0  0  0  0  0
   16.6996    1.8724    0.2933 C   0  0  0  0  0  0
   18.0651    2.1595    0.2831 C   0  0  0  0  0  0
   18.9389    1.3695   -0.4642 C   0  0  0  0  0  0
   18.4471    0.2931   -1.2033 C   0  0  0  0  0  0
   17.0816    0.0054   -1.1936 C   0  0  0  0  0  0
   19.2938   -0.4718   -1.9288 F   0  0  0  0  0  0
   -0.6313    6.2743    1.1461 H   0  0  0  0  0  0
   -0.5449    6.7853    2.8384 H   0  0  0  0  0  0
   -1.8068    5.6601    2.3207 H   0  0  0  0  0  0
   -1.3988    3.2626    1.4331 H   0  0  0  0  0  0
   -0.1428    3.7542    0.3019 H   0  0  0  0  0  0
    1.4307    2.0213    1.2966 H   0  0  0  0  0  0
    0.1340    1.5131    2.4231 H   0  0  0  0  0  0
   -1.2093    0.9950    0.4857 H   0  0  0  0  0  0
    0.0007   -0.7823    1.4689 H   0  0  0  0  0  0
   -0.2548   -0.9679   -0.2820 H   0  0  0  0  0  0
    2.8823   -0.8579    2.1445 H   0  0  0  0  0  0
    5.0609   -0.6360    0.6044 H   0  0  0  0  0  0
    2.5206   -0.1714   -3.5207 H   0  0  0  0  0  0
    3.6733    0.2333   -5.6457 H   0  0  0  0  0  0
    6.2323    0.1510   -1.3868 H   0  0  0  0  0  0
    8.0562    1.0201   -6.8876 H   0  0  0  0  0  0
    8.0979    0.2534   -1.6812 H   0  0  0  0  0  0
    9.9078   -0.4526   -0.4933 H   0  0  0  0  0  0
   12.2779   -0.2719   -0.0198 H   0  0  0  0  0  0
   10.4090    2.0171   -3.9784 H   0  0  0  0  0  0
   14.2776    0.8154    0.5111 H   0  0  0  0  0  0
   14.5760   -0.6059   -0.4851 H   0  0  0  0  0  0
   16.0305    2.4908    0.8741 H   0  0  0  0  0  0
   18.4457    2.9937    0.8542 H   0  0  0  0  0  0
   19.9958    1.5922   -0.4709 H   0  0  0  0  0  0
   16.7088   -0.8285   -1.7709 H   0  0  0  0  0  0
    0.0137    1.3774   -0.5205 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 40  1  0  0  0
  1 41  1  0  0  0
  1 42  1  0  0  0
  2  3  2  0  0  0
  2  4  1  0  0  0
  4  5  1  0  0  0
  4 43  1  0  0  0
  4 44  1  0  0  0
  5  6  1  0  0  0
  5 45  1  0  0  0
  5 46  1  0  0  0
  6  7  1  0  0  0
  6 47  1  0  0  0
  6 66  1  0  0  0
  7  8  1  0  0  0
  7 48  1  0  0  0
  7 49  1  0  0  0
  8  9  2  0  0  0
  8 12  1  0  0  0
  9 10  1  0  0  0
  9 50  1  0  0  0
 10 11  2  0  0  0
 10 51  1  0  0  0
 11 12  1  0  0  0
 11 13  1  0  0  0
 13 14  1  0  0  0
 13 18  2  0  0  0
 14 15  2  0  0  0
 14 52  1  0  0  0
 15 16  1  0  0  0
 15 53  1  0  0  0
 16 17  1  0  0  0
 16 22  2  0  0  0
 17 18  1  0  0  0
 17 19  2  0  0  0
 18 54  1  0  0  0
 19 20  1  0  0  0
 19 23  1  0  0  0
 20 21  2  0  0  0
 21 22  1  0  0  0
 21 55  1  0  0  0
 23 24  1  0  0  0
 23 56  1  0  0  0
 24 25  1  0  0  0
 24 29  2  0  0  0
 25 26  2  0  0  0
 25 57  1  0  0  0
 26 27  1  0  0  0
 26 58  1  0  0  0
 27 28  2  0  0  0
 27 31  1  0  0  0
 28 29  1  0  0  0
 28 30  1  0  0  0
 29 59  1  0  0  0
 31 32  1  0  0  0
 32 33  1  0  0  0
 32 60  1  0  0  0
 32 61  1  0  0  0
 33 34  1  0  0  0
 33 38  2  0  0  0
 34 35  2  0  0  0
 34 62  1  0  0  0
 35 36  1  0  0  0
 35 63  1  0  0  0
 36 37  2  0  0  0
 36 64  1  0  0  0
 37 38  1  0  0  0
 37 39  1  0  0  0
 38 65  1  0  0  0
M  CHG  1   6   1
M  END
> <s_m_entry_id>
30

> <Applicants>
Qilu Pharmaceutical

> <CHEMBL_ID>
nan

> <Canonical_Smiles>
Clc1cc(Nc2ncnc3c2cc(cc3)-c2oc(cc2)CNCCS(=O)C)ccc1OCc1cc(F)ccc1

> <Chirality>
nan

> <First_Approval>
nan

> <Phase>
1

> <SC_Patent>
nan

> <Indications>
nan

> <Type>
nan

> <targets_id>
P00533|P04626

> <inchi>
InChI=1S/C29H26ClFN4O3S/c1-39(36)12-11-32-16-23-7-10-27(38-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)37-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35)

> <stdInchikey>
OAMVGUFHZPRXOM-UHFFFAOYSA-N

> <csid>
30841488

> <Links>
|http://www.chemspider.com/Chemical-Structure.30841488.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3040548|http://pubchem.ncbi.nlm.nih.gov/compound/51348455|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9919|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=140985

> <LinkName>
|ChemSpider|ChEMBL|PubChem|Guide to Pharmacology|BindingDB

> <indicationG2P>
None

> <MW>
564.1

> <HBA>
7

> <HBD>
2

> <NRB>
11

> <TPSA>
89.3

> <LogP>
6.5

> <RoF>
2

> <Targets>
EGFR; ERBB2

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
0.999978

> <r_epik_Ionization_Penalty>
  0.0114

> <r_epik_State_Penalty>
  0.0082

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
30

> <Kinase families>
Tyr

$$$$
Allitinib
                    3D
 Structure written by MMmdl.
 50 53  0  0  1  0            999 V2000
   -6.4940   -2.7153    4.5139 C   0  0  0  0  0  0
   -5.3587   -2.0562    4.2153 C   0  0  0  0  0  0
   -5.3318   -0.8919    3.3588 C   0  0  0  0  0  0
   -6.3422   -0.4270    2.8256 O   0  0  0  0  0  0
   -4.0866   -0.3877    3.2196 N   0  0  0  0  0  0
   -3.6814    0.7567    2.5089 C   0  0  0  0  0  0
   -4.5121    1.8597    2.2697 C   0  0  0  0  0  0
   -4.0406    2.9736    1.5803 C   0  0  0  0  0  0
   -2.7056    3.0145    1.1171 C   0  0  0  0  0  0
   -1.8422    1.9026    1.3658 C   0  0  0  0  0  0
   -2.3558    0.7799    2.0728 C   0  0  0  0  0  0
   -0.5055    2.0229    0.8729 C   0  0  0  0  0  0
   -0.0860    3.1264    0.2031 N   0  0  0  0  0  0
   -0.9903    4.1158    0.0273 C   0  0  0  0  0  0
   -2.2772    4.1215    0.4476 N   0  0  0  0  0  0
    0.4067    0.9658    1.0614 N   0  0  0  0  0  0
    1.7537    0.7748    0.7043 C   0  0  0  0  0  0
    2.2099   -0.5392    0.5836 C   0  0  0  0  0  0
    3.5356   -0.8051    0.2445 C   0  0  0  0  0  0
    4.4439    0.2441    0.0272 C   0  0  0  0  0  0
    3.9871    1.5617    0.1592 C   0  0  0  0  0  0
    2.6581    1.8238    0.4966 C   0  0  0  0  0  0
    5.0633    2.8933   -0.0857 Cl  0  0  0  0  0  0
    5.7736    0.0574   -0.3057 O   0  0  0  0  0  0
    6.2853   -1.2648   -0.4444 C   0  0  0  0  0  0
    7.7645   -1.1853   -0.7795 C   0  0  0  0  0  0
    8.7220   -1.2399    0.2390 C   0  0  0  0  0  0
   10.0807   -1.1639   -0.0698 C   0  0  0  0  0  0
   10.4886   -1.0316   -1.3974 C   0  0  0  0  0  0
    9.5379   -0.9743   -2.4169 C   0  0  0  0  0  0
    8.1788   -1.0506   -2.1090 C   0  0  0  0  0  0
    9.9334   -0.8445   -3.7034 F   0  0  0  0  0  0
   -7.4589   -2.4139    4.1297 H   0  0  0  0  0  0
   -6.4696   -3.5811    5.1593 H   0  0  0  0  0  0
   -4.4171   -2.3968    4.6247 H   0  0  0  0  0  0
   -3.3313   -0.9505    3.5820 H   0  0  0  0  0  0
   -5.5305    1.8810    2.6263 H   0  0  0  0  0  0
   -4.6932    3.8164    1.4024 H   0  0  0  0  0  0
   -1.7081   -0.0629    2.2684 H   0  0  0  0  0  0
   -0.6507    4.9927   -0.5045 H   0  0  0  0  0  0
   -0.0366    0.1281    1.4073 H   0  0  0  0  0  0
    1.5355   -1.3678    0.7473 H   0  0  0  0  0  0
    3.8391   -1.8371    0.1569 H   0  0  0  0  0  0
    2.3553    2.8525    0.6131 H   0  0  0  0  0  0
    6.1500   -1.8317    0.4791 H   0  0  0  0  0  0
    5.7603   -1.7996   -1.2384 H   0  0  0  0  0  0
    8.4160   -1.3397    1.2707 H   0  0  0  0  0  0
   10.8166   -1.2073    0.7195 H   0  0  0  0  0  0
   11.5405   -0.9721   -1.6354 H   0  0  0  0  0  0
    7.4488   -1.0021   -2.9041 H   0  0  0  0  0  0
  1  2  2  0  0  0
  1 33  1  0  0  0
  1 34  1  0  0  0
  2  3  1  0  0  0
  2 35  1  0  0  0
  3  4  2  0  0  0
  3  5  1  0  0  0
  5  6  1  0  0  0
  5 36  1  0  0  0
  6  7  1  0  0  0
  6 11  2  0  0  0
  7  8  2  0  0  0
  7 37  1  0  0  0
  8  9  1  0  0  0
  8 38  1  0  0  0
  9 10  1  0  0  0
  9 15  2  0  0  0
 10 11  1  0  0  0
 10 12  2  0  0  0
 11 39  1  0  0  0
 12 13  1  0  0  0
 12 16  1  0  0  0
 13 14  2  0  0  0
 14 15  1  0  0  0
 14 40  1  0  0  0
 16 17  1  0  0  0
 16 41  1  0  0  0
 17 18  1  0  0  0
 17 22  2  0  0  0
 18 19  2  0  0  0
 18 42  1  0  0  0
 19 20  1  0  0  0
 19 43  1  0  0  0
 20 21  2  0  0  0
 20 24  1  0  0  0
 21 22  1  0  0  0
 21 23  1  0  0  0
 22 44  1  0  0  0
 24 25  1  0  0  0
 25 26  1  0  0  0
 25 45  1  0  0  0
 25 46  1  0  0  0
 26 27  1  0  0  0
 26 31  2  0  0  0
 27 28  2  0  0  0
 27 47  1  0  0  0
 28 29  1  0  0  0
 28 48  1  0  0  0
 29 30  2  0  0  0
 29 49  1  0  0  0
 30 31  1  0  0  0
 30 32  1  0  0  0
 31 50  1  0  0  0
M  END
> <s_m_entry_id>
34

> <Applicants>
Allist Pharmaceuticals

> <CHEMBL_ID>
CHEMBL3545244

> <Canonical_Smiles>
Clc1cc(Nc2ncnc3c2cc(NC(=O)C=C)cc3)ccc1OCc1cc(F)ccc1

> <Chirality>
Single Stereoisomer

> <First_Approval>
nan

> <Phase>
1

> <SC_Patent>
None

> <Synonyms>
ALL-3 | AST-1306

> <Indications>
nan

> <Type>
nan

> <targets_id>
P04626|P00533

> <inchi>
InChI=1S/C24H18ClFN4O2/c1-2-23(31)29-17-6-8-21-19(11-17)24(28-14-27-21)30-18-7-9-22(20(25)12-18)32-13-15-4-3-5-16(26)10-15/h2-12,14H,1,13H2,(H,29,31)(H,27,28,30)

> <stdInchikey>
MVZGYPSXNDCANY-UHFFFAOYSA-N

> <csid>
25027184

> <Links>
|http://www.chemspider.com/Chemical-Structure.25027184.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1947204|http://pubchem.ncbi.nlm.nih.gov/compound/24739943|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9912|http://zinc15.docking.org/substances/ZINC000052509434|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=CX0M5RO7CY

> <LinkName>
|ChemSpider|ChEMBL|PubChem|Guide to Pharmacology|ZINC|FDA SRS

> <indicationG2P>
None

> <MW>
448.1

> <HBA>
5

> <HBD>
2

> <NRB>
7

> <TPSA>
76.1

> <LogP>
5.9

> <RoF>
1

> <Targets>
ERBB2; EGFR

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0019

> <r_epik_State_Penalty>
  0.0000

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
34

> <Kinase families>
Tyr

$$$$
Theliatinib
                    3D
 Structure written by MMmdl.
 60 64  0  0  1  0            999 V2000
   -4.6024   -1.2168   -3.2887 C   0  0  0  0  0  0
   -5.0099   -0.1668   -2.2388 N   0  3  2  0  0  0
   -5.3754    1.2038   -2.8236 C   0  0  0  0  0  0
   -5.4414    2.0751   -1.5738 C   0  0  0  0  0  0
   -4.2990    1.5699   -0.6835 C   0  0  1  0  0  0
   -3.9802    0.1362   -1.1262 C   0  0  2  0  0  0
   -2.4983    0.1255   -1.5351 C   0  0  0  0  0  0
   -1.9676    1.3227   -0.8743 N   0  0  0  0  0  0
   -2.9940    2.3631   -0.8457 C   0  0  0  0  0  0
   -0.6860    1.5380   -0.4804 C   0  0  0  0  0  0
   -0.3196    2.6206   -0.0172 O   0  0  0  0  0  0
    0.1335    0.4695   -0.6230 N   0  0  0  0  0  0
    1.5106    0.3650   -0.3357 C   0  0  0  0  0  0
    2.3777    1.4638   -0.4242 C   0  0  0  0  0  0
    3.7618    1.3214   -0.1471 C   0  0  0  0  0  0
    4.2603    0.0341    0.2126 C   0  0  0  0  0  0
    3.3721   -1.0622    0.2767 C   0  0  0  0  0  0
    2.0052   -0.9057   -0.0019 C   0  0  0  0  0  0
    1.1016   -1.9569    0.0411 O   0  0  0  0  0  0
    1.5572   -3.2686    0.3557 C   0  0  0  0  0  0
    5.5782   -0.1741    0.4907 N   0  0  0  0  0  0
    6.3941    0.9026    0.4045 C   0  0  0  0  0  0
    6.0369    2.1625    0.0700 N   0  0  0  0  0  0
    4.7246    2.3771   -0.2016 C   0  0  0  0  0  0
    4.3163    3.6758   -0.5655 N   0  0  0  0  0  0
    4.9965    4.8934   -0.7489 C   0  0  0  0  0  0
    4.3928    5.8482   -1.5733 C   0  0  0  0  0  0
    5.0042    7.0807   -1.8009 C   0  0  0  0  0  0
    6.2261    7.3756   -1.1986 C   0  0  0  0  0  0
    6.8353    6.4384   -0.3603 C   0  0  0  0  0  0
    6.2192    5.2031   -0.1344 C   0  0  0  0  0  0
    8.1049    6.7494    0.2808 C   0  0  0  0  0  0
    9.1690    6.9986    0.8262 C   0  0  0  0  0  0
   -3.7823   -0.8166   -3.8848 H   0  0  0  0  0  0
   -5.4853   -1.3981   -3.9027 H   0  0  0  0  0  0
   -4.3100   -2.1145   -2.7428 H   0  0  0  0  0  0
   -4.5620    1.4924   -3.4922 H   0  0  0  0  0  0
   -6.3180    1.1137   -3.3651 H   0  0  0  0  0  0
   -5.3550    3.1367   -1.8098 H   0  0  0  0  0  0
   -6.4026    1.9328   -1.0773 H   0  0  0  0  0  0
   -4.5942    1.5808    0.3673 H   0  0  0  0  0  0
   -4.1857   -0.5926   -0.3401 H   0  0  0  0  0  0
   -1.9972   -0.7941   -1.2302 H   0  0  0  0  0  0
   -2.3688    0.2597   -2.6087 H   0  0  0  0  0  0
   -2.9688    2.9005   -1.7948 H   0  0  0  0  0  0
   -2.8511    3.0885   -0.0432 H   0  0  0  0  0  0
   -0.3000   -0.3963   -0.9088 H   0  0  0  0  0  0
    2.0119    2.4352   -0.7197 H   0  0  0  0  0  0
    3.7821   -2.0245    0.5448 H   0  0  0  0  0  0
    0.7127   -3.9570    0.3306 H   0  0  0  0  0  0
    1.9886   -3.3136    1.3567 H   0  0  0  0  0  0
    2.2917   -3.6222   -0.3696 H   0  0  0  0  0  0
    7.4391    0.7377    0.6234 H   0  0  0  0  0  0
    3.3617    3.7039   -0.8918 H   0  0  0  0  0  0
    3.4455    5.6379   -2.0495 H   0  0  0  0  0  0
    4.5300    7.8075   -2.4439 H   0  0  0  0  0  0
    6.6881    8.3352   -1.3843 H   0  0  0  0  0  0
    6.6923    4.5021    0.5361 H   0  0  0  0  0  0
   10.0989    7.2119    1.3037 H   0  0  0  0  0  0
   -5.8393   -0.5056   -1.7712 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 34  1  0  0  0
  1 35  1  0  0  0
  1 36  1  0  0  0
  2  3  1  0  0  0
  2  6  1  0  0  0
  2 60  1  0  0  0
  3  4  1  0  0  0
  3 37  1  0  0  0
  3 38  1  0  0  0
  4  5  1  0  0  0
  4 39  1  0  0  0
  4 40  1  0  0  0
  5  6  1  0  0  0
  5  9  1  0  0  0
  5 41  1  0  0  0
  6  7  1  0  0  0
  6 42  1  0  0  0
  7  8  1  0  0  0
  7 43  1  0  0  0
  7 44  1  0  0  0
  8  9  1  0  0  0
  8 10  1  0  0  0
  9 45  1  0  0  0
  9 46  1  0  0  0
 10 11  2  0  0  0
 10 12  1  0  0  0
 12 13  1  0  0  0
 12 47  1  0  0  0
 13 14  1  0  0  0
 13 18  2  0  0  0
 14 15  2  0  0  0
 14 48  1  0  0  0
 15 16  1  0  0  0
 15 24  1  0  0  0
 16 17  2  0  0  0
 16 21  1  0  0  0
 17 18  1  0  0  0
 17 49  1  0  0  0
 18 19  1  0  0  0
 19 20  1  0  0  0
 20 50  1  0  0  0
 20 51  1  0  0  0
 20 52  1  0  0  0
 21 22  2  0  0  0
 22 23  1  0  0  0
 22 53  1  0  0  0
 23 24  2  0  0  0
 24 25  1  0  0  0
 25 26  1  0  0  0
 25 54  1  0  0  0
 26 27  1  0  0  0
 26 31  2  0  0  0
 27 28  2  0  0  0
 27 55  1  0  0  0
 28 29  1  0  0  0
 28 56  1  0  0  0
 29 30  2  0  0  0
 29 57  1  0  0  0
 30 31  1  0  0  0
 30 32  1  0  0  0
 31 58  1  0  0  0
 32 33  3  0  0  0
 33 59  1  0  0  0
M  CHG  1   2   1
M  END
> <s_m_entry_id>
35

> <Applicants>
Hutchison MediPharma

> <CHEMBL_ID>
nan

> <Canonical_Smiles>
O(C)c1cc2ncnc(Nc3cc(ccc3)C#C)c2cc1NC(=O)N1C[C@@H]2[C@@H](N(CC2)C)C1

> <Chirality>
nan

> <First_Approval>
nan

> <Phase>
1

> <SC_Patent>
nan

> <Indications>
nan

> <Type>
nan

> <targets_id>
nan

> <inchi>
InChI=1S/C25H26N6O2/c1-4-16-6-5-7-18(10-16)28-24-19-11-21(23(33-3)12-20(19)26-15-27-24)29-25(32)31-13-17-8-9-30(2)22(17)14-31/h1,5-7,10-12,15,17,22H,8-9,13-14H2,2-3H3,(H,29,32)(H,26,27,28)/t17-,22+/m1/s1

> <stdInchikey>
FSXCKIBROURMFT-VGSWGCGISA-N

> <csid>
68025614

> <Links>
|http://www.chemspider.com/Chemical-Structure.68025614.html|http://pubchem.ncbi.nlm.nih.gov/compound/54759275|http://zinc15.docking.org/substances/ZINC000113384840|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=6ZZ3B7NZ0B

> <LinkName>
|ChemSpider|PubChem|ZINC|FDA SRS

> <MW>
442.2

> <HBA>
6

> <HBD>
2

> <NRB>
4

> <TPSA>
82.6

> <LogP>
3.5

> <RoF>
0

> <Targets>
nan

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0063

> <r_epik_State_Penalty>
  0.0000

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
35

$$$$
Empesertib
                    3D
 Structure written by MMmdl.
 66 70  0  0  1  0            999 V2000
  -11.6163    5.9463   -1.8294 C   0  0  0  0  0  0
  -10.8867    5.5300   -0.5308 C   0  0  2  0  0  0
  -10.8660    6.6396    0.5286 C   0  0  0  0  0  0
  -10.4434    7.9370    0.2078 C   0  0  0  0  0  0
  -10.4146    8.9270    1.1862 C   0  0  0  0  0  0
  -10.8027    8.6231    2.4888 C   0  0  0  0  0  0
  -11.2176    7.3357    2.8209 C   0  0  0  0  0  0
  -11.2471    6.3451    1.8429 C   0  0  0  0  0  0
  -10.7731    9.5846    3.4392 F   0  0  0  0  0  0
   -9.4542    5.0232   -0.8026 C   0  0  0  0  0  0
   -8.7031    5.6806   -1.5258 O   0  0  0  0  0  0
   -9.1230    3.8533   -0.2124 N   0  0  0  0  0  0
   -7.8980    3.1624   -0.2520 C   0  0  0  0  0  0
   -6.6630    3.7661   -0.5293 C   0  0  0  0  0  0
   -5.5002    3.0008   -0.5333 C   0  0  0  0  0  0
   -5.5425    1.6294   -0.2550 C   0  0  0  0  0  0
   -6.7782    1.0406    0.0386 C   0  0  0  0  0  0
   -7.9448    1.8000    0.0452 C   0  0  0  0  0  0
   -4.2946    0.8140   -0.2674 C   0  0  0  0  0  0
   -4.2817   -0.4800   -0.8129 C   0  0  0  0  0  0
   -3.1232   -1.2649   -0.8424 C   0  0  0  0  0  0
   -1.9379   -0.7341   -0.3070 C   0  0  0  0  0  0
   -0.6750   -1.2095   -0.1822 N   0  0  0  0  0  0
   -0.0435   -0.2144    0.4174 C   0  0  0  0  0  0
   -0.7516    0.8745    0.6808 N   0  0  0  0  0  0
   -1.9756    0.5497    0.2278 N   0  0  0  0  0  0
   -3.1028    1.3242    0.2619 C   0  0  0  0  0  0
    1.2964   -0.3381    0.7023 N   0  0  0  0  0  0
    2.0939    0.5853    1.4021 C   0  0  0  0  0  0
    3.2795    1.0033    0.7917 C   0  0  0  0  0  0
    4.1154    1.9232    1.4193 C   0  0  0  0  0  0
    3.7801    2.4250    2.6764 C   0  0  0  0  0  0
    2.6076    1.9969    3.3028 C   0  0  0  0  0  0
    1.7550    1.0646    2.6838 C   0  0  0  0  0  0
    0.6056    0.5754    3.2829 O   0  0  0  0  0  0
    0.2366    1.0283    4.5806 C   0  0  0  0  0  0
    4.8377    3.6282    3.4788 S   0  0  0  0  0  0
    4.6462    3.4893    4.9269 O   0  0  0  0  0  0
    6.1773    3.5046    2.8928 O   0  0  0  0  0  0
    4.0972    5.2744    2.9338 C   0  0  0  0  0  0
  -11.1080    6.7564   -2.3539 H   0  0  0  0  0  0
  -12.6315    6.2825   -1.6153 H   0  0  0  0  0  0
  -11.6950    5.1089   -2.5243 H   0  0  0  0  0  0
  -11.4691    4.7007   -0.1223 H   0  0  0  0  0  0
  -10.1299    8.1803   -0.7967 H   0  0  0  0  0  0
  -10.0890    9.9259    0.9360 H   0  0  0  0  0  0
  -11.5137    7.1057    3.8338 H   0  0  0  0  0  0
  -11.5655    5.3481    2.1111 H   0  0  0  0  0  0
   -9.8556    3.3835    0.2989 H   0  0  0  0  0  0
   -6.5770    4.8224   -0.7306 H   0  0  0  0  0  0
   -4.5606    3.4841   -0.7586 H   0  0  0  0  0  0
   -6.8404   -0.0126    0.2708 H   0  0  0  0  0  0
   -8.8846    1.3191    0.2770 H   0  0  0  0  0  0
   -5.1877   -0.8914   -1.2344 H   0  0  0  0  0  0
   -3.1430   -2.2559   -1.2713 H   0  0  0  0  0  0
   -3.0111    2.3050    0.7063 H   0  0  0  0  0  0
    1.8338   -1.0210    0.1896 H   0  0  0  0  0  0
    3.5532    0.6275   -0.1840 H   0  0  0  0  0  0
    5.0191    2.2446    0.9225 H   0  0  0  0  0  0
    2.3732    2.3953    4.2780 H   0  0  0  0  0  0
   -0.6897    0.5388    4.8806 H   0  0  0  0  0  0
    0.0591    2.1046    4.5941 H   0  0  0  0  0  0
    0.9968    0.7785    5.3223 H   0  0  0  0  0  0
    4.6754    6.0846    3.3770 H   0  0  0  0  0  0
    3.0628    5.3273    3.2723 H   0  0  0  0  0  0
    4.1384    5.3388    1.8469 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 41  1  0  0  0
  1 42  1  0  0  0
  1 43  1  0  0  0
  2  3  1  0  0  0
  2 10  1  0  0  0
  2 44  1  0  0  0
  3  4  1  0  0  0
  3  8  2  0  0  0
  4  5  2  0  0  0
  4 45  1  0  0  0
  5  6  1  0  0  0
  5 46  1  0  0  0
  6  7  2  0  0  0
  6  9  1  0  0  0
  7  8  1  0  0  0
  7 47  1  0  0  0
  8 48  1  0  0  0
 10 11  2  0  0  0
 10 12  1  0  0  0
 12 13  1  0  0  0
 12 49  1  0  0  0
 13 14  1  0  0  0
 13 18  2  0  0  0
 14 15  2  0  0  0
 14 50  1  0  0  0
 15 16  1  0  0  0
 15 51  1  0  0  0
 16 17  2  0  0  0
 16 19  1  0  0  0
 17 18  1  0  0  0
 17 52  1  0  0  0
 18 53  1  0  0  0
 19 20  1  0  0  0
 19 27  2  0  0  0
 20 21  2  0  0  0
 20 54  1  0  0  0
 21 22  1  0  0  0
 21 55  1  0  0  0
 22 23  2  0  0  0
 22 26  1  0  0  0
 23 24  1  0  0  0
 24 25  2  0  0  0
 24 28  1  0  0  0
 25 26  1  0  0  0
 26 27  1  0  0  0
 27 56  1  0  0  0
 28 29  1  0  0  0
 28 57  1  0  0  0
 29 30  1  0  0  0
 29 34  2  0  0  0
 30 31  2  0  0  0
 30 58  1  0  0  0
 31 32  1  0  0  0
 31 59  1  0  0  0
 32 33  2  0  0  0
 32 37  1  0  0  0
 33 34  1  0  0  0
 33 60  1  0  0  0
 34 35  1  0  0  0
 35 36  1  0  0  0
 36 61  1  0  0  0
 36 62  1  0  0  0
 36 63  1  0  0  0
 37 38  2  0  0  0
 37 39  2  0  0  0
 37 40  1  0  0  0
 40 64  1  0  0  0
 40 65  1  0  0  0
 40 66  1  0  0  0
M  END
> <s_m_entry_id>
39

> <Applicants>
Bayer

> <CHEMBL_ID>
CHEMBL3545425

> <Canonical_Smiles>
S(=O)(=O)(C)c1cc(OC)c(Nc2nc3n(n2)C=C(C=C3)c2ccc(NC(=O)[C@H](C)c3ccc(F)cc3)cc2)cc1

> <Chirality>
Single Stereoisomer

> <First_Approval>
nan

> <Phase>
1

> <SC_Patent>
None

> <Synonyms>
|MPS1-IN-5|(-)-BAY-1161909|BAY 1161909

> <Indications>
nan

> <Type>
nan

> <targets_id>
nan

> <inchi>
InChI=1S/C29H26FN5O4S/c1-18(19-4-9-22(30)10-5-19)28(36)31-23-11-6-20(7-12-23)21-8-15-27-33-29(34-35(27)17-21)32-25-14-13-24(40(3,37)38)16-26(25)39-2/h4-18H,1-3H3,(H,31,36)(H,32,34)/t18-/m1/s1

> <stdInchikey>
NRJKIOCCERLIDG-GOSISDBHSA-N

> <csid>
35308224

> <Links>
|http://www.chemspider.com/Chemical-Structure.35308224.html|http://pubchem.ncbi.nlm.nih.gov/compound/71599640| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=8QW|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/8QW|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9427|http://zinc15.docking.org/substances/ZINC000206769279|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=02Y3Z2756M|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=329334

> <LinkName>
|ChemSpider|PubChem|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
559.2

> <HBA>
8

> <HBD>
2

> <NRB>
8

> <TPSA>
114.7

> <LogP>
5.4

> <RoF>
2

> <Targets>
nan

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_epik_Ionization_Penalty>
  0.0045

> <r_epik_State_Penalty>
  0.0033

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
39

> <lig_pdbID>
'8QW'

> <pdbID>
5n9s 6tnb

$$$$
Pexmetinib
                    3D
 Structure written by MMmdl.
 74 78  0  0  1  0            999 V2000
    1.9161    8.0369   -1.0105 C   0  0  0  0  0  0
    0.9803    7.0118   -0.3965 C   0  0  0  0  0  0
    1.0991    5.6649   -0.7415 C   0  0  0  0  0  0
    0.2478    4.7238   -0.1709 C   0  0  0  0  0  0
   -0.7257    5.1226    0.7520 C   0  0  0  0  0  0
   -0.8403    6.4763    1.0951 C   0  0  0  0  0  0
    0.0115    7.4169    0.5229 C   0  0  0  0  0  0
   -1.5835    4.1676    1.3545 N   0  0  0  0  0  0
   -2.2589    3.1023    0.7918 C   0  0  0  0  0  0
   -2.9789    2.5355    1.8264 C   0  0  0  0  0  0
   -2.6887    3.2870    2.9745 C   0  0  0  0  0  0
   -1.8454    4.2557    2.6720 N   0  0  0  0  0  0
   -3.2051    3.1219    4.4114 C   0  0  0  0  0  0
   -4.2079    1.9468    4.5066 C   0  0  0  0  0  0
   -3.9221    4.4155    4.8664 C   0  0  0  0  0  0
   -2.0218    2.8348    5.3632 C   0  0  0  0  0  0
   -2.2076    2.7423   -0.5447 N   0  0  0  0  0  0
   -1.4345    1.7546   -1.0513 C   0  0  0  0  0  0
   -1.4125    1.5394   -2.2624 O   0  0  0  0  0  0
   -0.6894    1.0507   -0.1710 N   0  0  0  0  0  0
    0.3970    0.1391   -0.5205 C   0  0  0  0  0  0
    1.7179    0.8644   -0.7592 C   0  0  0  0  0  0
    2.1340    1.1288   -2.0689 C   0  0  0  0  0  0
    3.3542    1.7595   -2.3080 C   0  0  0  0  0  0
    4.1747    2.1167   -1.2396 C   0  0  0  0  0  0
    3.7720    1.8490    0.0680 C   0  0  0  0  0  0
    2.5362    1.2387    0.3189 C   0  0  0  0  0  0
    2.1320    0.9601    1.6081 O   0  0  0  0  0  0
    2.0030    1.9403    2.5756 C   0  0  0  0  0  0
    2.0585    3.3169    2.3075 C   0  0  0  0  0  0
    1.9001    4.2835    3.3006 C   0  0  0  0  0  0
    1.6819    3.8218    4.6018 C   0  0  0  0  0  0
    1.6119    2.4408    4.9064 C   0  0  0  0  0  0
    1.7713    1.4989    3.8799 C   0  0  0  0  0  0
    1.3703    2.3980    6.3117 C   0  0  0  0  0  0
    1.2913    3.5996    6.8217 N   0  0  0  0  0  0
    1.4959    4.4707    5.8119 N   0  0  0  0  0  0
    1.4476    5.9050    6.0864 C   0  0  0  0  0  0
    0.0117    6.4589    5.9988 C   0  0  0  0  0  0
   -0.4993    6.3735    4.6843 O   0  0  0  0  0  0
    3.7455    2.0172   -3.5764 F   0  0  0  0  0  0
    1.4157    8.9971   -1.1422 H   0  0  0  0  0  0
    2.2738    7.7127   -1.9887 H   0  0  0  0  0  0
    2.7812    8.1885   -0.3645 H   0  0  0  0  0  0
    1.8548    5.3421   -1.4432 H   0  0  0  0  0  0
    0.3803    3.6861   -0.4315 H   0  0  0  0  0  0
   -1.5843    6.8040    1.8071 H   0  0  0  0  0  0
   -0.0815    8.4576    0.7977 H   0  0  0  0  0  0
   -3.6354    1.6808    1.7573 H   0  0  0  0  0  0
   -4.5830    1.8202    5.5233 H   0  0  0  0  0  0
   -3.7487    1.0014    4.2137 H   0  0  0  0  0  0
   -5.0738    2.1043    3.8617 H   0  0  0  0  0  0
   -4.7615    4.6575    4.2128 H   0  0  0  0  0  0
   -3.2498    5.2745    4.8624 H   0  0  0  0  0  0
   -4.3154    4.3213    5.8796 H   0  0  0  0  0  0
   -2.3562    2.6907    6.3914 H   0  0  0  0  0  0
   -1.3067    3.6571    5.3718 H   0  0  0  0  0  0
   -1.4796    1.9357    5.0671 H   0  0  0  0  0  0
   -2.8057    3.2531   -1.1780 H   0  0  0  0  0  0
   -0.7595    1.2951    0.8063 H   0  0  0  0  0  0
    0.5189   -0.5741    0.2956 H   0  0  0  0  0  0
    0.1356   -0.4552   -1.3989 H   0  0  0  0  0  0
    1.5096    0.8467   -2.9045 H   0  0  0  0  0  0
    5.1241    2.5974   -1.4243 H   0  0  0  0  0  0
    4.4170    2.1224    0.8903 H   0  0  0  0  0  0
    2.2285    3.6641    1.3011 H   0  0  0  0  0  0
    1.9433    5.3369    3.0648 H   0  0  0  0  0  0
    1.7159    0.4412    4.0921 H   0  0  0  0  0  0
    1.2478    1.5241    6.9343 H   0  0  0  0  0  0
    1.8456    6.0772    7.0881 H   0  0  0  0  0  0
    2.1109    6.4219    5.3912 H   0  0  0  0  0  0
   -0.6538    5.9229    6.6772 H   0  0  0  0  0  0
   -0.0047    7.5051    6.3047 H   0  0  0  0  0  0
   -1.4113    6.6732    4.6882 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 42  1  0  0  0
  1 43  1  0  0  0
  1 44  1  0  0  0
  2  3  1  0  0  0
  2  7  2  0  0  0
  3  4  2  0  0  0
  3 45  1  0  0  0
  4  5  1  0  0  0
  4 46  1  0  0  0
  5  6  2  0  0  0
  5  8  1  0  0  0
  6  7  1  0  0  0
  6 47  1  0  0  0
  7 48  1  0  0  0
  8  9  1  0  0  0
  8 12  1  0  0  0
  9 10  2  0  0  0
  9 17  1  0  0  0
 10 11  1  0  0  0
 10 49  1  0  0  0
 11 12  2  0  0  0
 11 13  1  0  0  0
 13 14  1  0  0  0
 13 15  1  0  0  0
 13 16  1  0  0  0
 14 50  1  0  0  0
 14 51  1  0  0  0
 14 52  1  0  0  0
 15 53  1  0  0  0
 15 54  1  0  0  0
 15 55  1  0  0  0
 16 56  1  0  0  0
 16 57  1  0  0  0
 16 58  1  0  0  0
 17 18  1  0  0  0
 17 59  1  0  0  0
 18 19  2  0  0  0
 18 20  1  0  0  0
 20 21  1  0  0  0
 20 60  1  0  0  0
 21 22  1  0  0  0
 21 61  1  0  0  0
 21 62  1  0  0  0
 22 23  1  0  0  0
 22 27  2  0  0  0
 23 24  2  0  0  0
 23 63  1  0  0  0
 24 25  1  0  0  0
 24 41  1  0  0  0
 25 26  2  0  0  0
 25 64  1  0  0  0
 26 27  1  0  0  0
 26 65  1  0  0  0
 27 28  1  0  0  0
 28 29  1  0  0  0
 29 30  1  0  0  0
 29 34  2  0  0  0
 30 31  2  0  0  0
 30 66  1  0  0  0
 31 32  1  0  0  0
 31 67  1  0  0  0
 32 33  2  0  0  0
 32 37  1  0  0  0
 33 34  1  0  0  0
 33 35  1  0  0  0
 34 68  1  0  0  0
 35 36  2  0  0  0
 35 69  1  0  0  0
 36 37  1  0  0  0
 37 38  1  0  0  0
 38 39  1  0  0  0
 38 70  1  0  0  0
 38 71  1  0  0  0
 39 40  1  0  0  0
 39 72  1  0  0  0
 39 73  1  0  0  0
 40 74  1  0  0  0
M  END
> <s_m_entry_id>
40

> <Applicants>
Array BioPharma

> <CHEMBL_ID>
CHEMBL3545297

> <Canonical_Smiles>
Fc1cc(CNC(=O)Nc2n(nc(c2)C(C)(C)C)-c2ccc(cc2)C)c(Oc2cc3c(n(nc3)CCO)cc2)cc1

> <Chirality>
Single Stereoisomer

> <First_Approval>
nan

> <Phase>
1

> <SC_Patent>
None

> <Indications>
nan

> <Type>
nan

> <targets_id>
Q16539|Q02763

> <inchi>
InChI=1S/C31H33FN6O3/c1-20-5-8-24(9-6-20)38-29(17-28(36-38)31(2,3)4)35-30(40)33-18-22-15-23(32)7-12-27(22)41-25-10-11-26-21(16-25)19-34-37(26)13-14-39/h5-12,15-17,19,39H,13-14,18H2,1-4H3,(H2,33,35,40)

> <stdInchikey>
LNMRSSIMGCDUTP-UHFFFAOYSA-N

> <csid>
32702049

> <Links>
|http://www.chemspider.com/Chemical-Structure.32702049.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3991932|http://pubchem.ncbi.nlm.nih.gov/compound/24765037|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9917|http://zinc15.docking.org/substances/ZINC000041747181|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=3750D0U8B5

> <LinkName>
|ChemSpider|ChEMBL|PubChem|Guide to Pharmacology|ZINC|FDA SRS

> <indicationG2P>
None

> <MW>
556.3

> <HBA>
7

> <HBD>
3

> <NRB>
8

> <TPSA>
106.2

> <LogP>
6.1

> <RoF>
2

> <Targets>
MAPK14; TEK

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0000

> <r_epik_State_Penalty>
  0.0000

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
40

> <Kinase families>
Tyr<br>CMGC

$$$$
Altiratinib
                    3D
 Structure written by MMmdl.
 58 62  0  0  1  0            999 V2000
   -3.2011    2.5552   -4.1545 C   0  0  0  0  0  0
   -3.5421    2.6749   -5.4991 C   0  0  0  0  0  0
   -3.8929    1.5407   -6.2269 C   0  0  0  0  0  0
   -3.9001    0.2864   -5.6218 C   0  0  0  0  0  0
   -3.5591    0.1624   -4.2773 C   0  0  0  0  0  0
   -3.2175    1.3036   -3.5326 C   0  0  0  0  0  0
   -2.8492    1.2848   -2.1745 N   0  0  0  0  0  0
   -3.0657    0.3301   -1.2426 C   0  0  0  0  0  0
   -3.6772   -0.7205   -1.4442 O   0  0  0  0  0  0
   -2.5151    0.6464    0.1665 C   0  0  0  0  0  0
   -3.5446    1.2645    1.1089 C   0  0  0  0  0  0
   -3.0934   -0.1575    1.3281 C   0  0  0  0  0  0
   -1.0435    1.0703    0.3712 C   0  0  0  0  0  0
   -0.7759    2.0980    0.9974 O   0  0  0  0  0  0
   -0.1186    0.2539   -0.1798 N   0  0  0  0  0  0
    1.2804    0.3986   -0.1534 C   0  0  0  0  0  0
    1.9696    0.9410    0.9438 C   0  0  0  0  0  0
    3.3596    1.0528    0.9183 C   0  0  0  0  0  0
    4.0769    0.6249   -0.2017 C   0  0  0  0  0  0
    3.3966    0.0765   -1.2915 C   0  0  0  0  0  0
    2.0059   -0.0377   -1.2703 C   0  0  0  0  0  0
    1.3717   -0.5716   -2.3418 F   0  0  0  0  0  0
    5.4481    0.7238   -0.2231 O   0  0  0  0  0  0
    6.0746    1.8005   -0.8201 C   0  0  0  0  0  0
    5.3993    2.8607   -1.4484 C   0  0  0  0  0  0
    6.1465    3.8926   -2.0146 C   0  0  0  0  0  0
    7.5012    3.9218   -1.9843 N   0  0  0  0  0  0
    8.1604    2.8968   -1.3718 C   0  0  0  0  0  0
    7.4721    1.8280   -0.7873 C   0  0  0  0  0  0
    9.5650    2.8517   -1.2936 N   0  0  0  0  0  0
   10.4671    3.7602   -1.7252 C   0  0  0  0  0  0
   10.1789    4.8244   -2.2791 O   0  0  0  0  0  0
   11.9379    3.3771   -1.4725 C   0  0  0  0  0  0
   12.8824    4.5223   -1.1519 C   0  0  0  0  0  0
   12.9424    3.8596   -2.5048 C   0  0  0  0  0  0
    4.0095    1.5737    1.9847 F   0  0  0  0  0  0
   -4.2245    1.6577   -7.5325 F   0  0  0  0  0  0
   -2.9304    3.4423   -3.5996 H   0  0  0  0  0  0
   -3.5343    3.6441   -5.9755 H   0  0  0  0  0  0
   -4.1654   -0.5898   -6.1948 H   0  0  0  0  0  0
   -3.5559   -0.8261   -3.8462 H   0  0  0  0  0  0
   -2.3912    2.1255   -1.8538 H   0  0  0  0  0  0
   -3.2422    2.0211    1.8342 H   0  0  0  0  0  0
   -4.5621    1.4383    0.7547 H   0  0  0  0  0  0
   -3.8057   -0.9619    1.1397 H   0  0  0  0  0  0
   -2.4681   -0.3763    2.1953 H   0  0  0  0  0  0
   -0.4613   -0.5085   -0.7466 H   0  0  0  0  0  0
    1.4418    1.2640    1.8289 H   0  0  0  0  0  0
    3.9502   -0.2595   -2.1559 H   0  0  0  0  0  0
    4.3214    2.8940   -1.5017 H   0  0  0  0  0  0
    5.6587    4.7212   -2.5070 H   0  0  0  0  0  0
    8.0097    1.0227   -0.3071 H   0  0  0  0  0  0
    9.9348    2.0262   -0.8462 H   0  0  0  0  0  0
   12.1115    2.4128   -0.9926 H   0  0  0  0  0  0
   12.5046    5.5442   -1.0897 H   0  0  0  0  0  0
   13.6896    4.3411   -0.4421 H   0  0  0  0  0  0
   13.7904    3.2156   -2.7376 H   0  0  0  0  0  0
   12.6084    4.4272   -3.3750 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1  6  2  0  0  0
  1 38  1  0  0  0
  2  3  2  0  0  0
  2 39  1  0  0  0
  3  4  1  0  0  0
  3 37  1  0  0  0
  4  5  2  0  0  0
  4 40  1  0  0  0
  5  6  1  0  0  0
  5 41  1  0  0  0
  6  7  1  0  0  0
  7  8  1  0  0  0
  7 42  1  0  0  0
  8  9  2  0  0  0
  8 10  1  0  0  0
 10 11  1  0  0  0
 10 12  1  0  0  0
 10 13  1  0  0  0
 11 12  1  0  0  0
 11 43  1  0  0  0
 11 44  1  0  0  0
 12 45  1  0  0  0
 12 46  1  0  0  0
 13 14  2  0  0  0
 13 15  1  0  0  0
 15 16  1  0  0  0
 15 47  1  0  0  0
 16 17  1  0  0  0
 16 21  2  0  0  0
 17 18  2  0  0  0
 17 48  1  0  0  0
 18 19  1  0  0  0
 18 36  1  0  0  0
 19 20  2  0  0  0
 19 23  1  0  0  0
 20 21  1  0  0  0
 20 49  1  0  0  0
 21 22  1  0  0  0
 23 24  1  0  0  0
 24 25  1  0  0  0
 24 29  2  0  0  0
 25 26  2  0  0  0
 25 50  1  0  0  0
 26 27  1  0  0  0
 26 51  1  0  0  0
 27 28  2  0  0  0
 28 29  1  0  0  0
 28 30  1  0  0  0
 29 52  1  0  0  0
 30 31  1  0  0  0
 30 53  1  0  0  0
 31 32  2  0  0  0
 31 33  1  0  0  0
 33 34  1  0  0  0
 33 35  1  0  0  0
 33 54  1  0  0  0
 34 35  1  0  0  0
 34 55  1  0  0  0
 34 56  1  0  0  0
 35 57  1  0  0  0
 35 58  1  0  0  0
M  END
> <s_m_entry_id>
41

> <Applicants>
Deciphera Pharmaceuticals

> <CHEMBL_ID>
CHEMBL3545365

> <Canonical_Smiles>
Fc1cc(Oc2cc(ncc2)NC(=O)C2CC2)c(F)cc1NC(=O)C1(CC1)C(=O)Nc1ccc(F)cc1

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
1

> <SC_Patent>
None

> <Synonyms>
ALTIRATINIB | DCC-2701 | DP-5164

> <Indications>
nan

> <Type>
nan

> <targets_id>
P08581|Q02763|P35968|P04629

> <inchi>
InChI=1S/C26H21F3N4O4/c27-15-3-5-16(6-4-15)31-24(35)26(8-9-26)25(36)32-20-12-19(29)21(13-18(20)28)37-17-7-10-30-22(11-17)33-23(34)14-1-2-14/h3-7,10-14H,1-2,8-9H2,(H,31,35)(H,32,36)(H,30,33,34)

> <stdInchikey>
GNNDEPIMDAZHRQ-UHFFFAOYSA-N

> <csid>
33427355

> <Links>
|http://www.chemspider.com/Chemical-Structure.33427355.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3545365|http://pubchem.ncbi.nlm.nih.gov/compound/54576299|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9174|http://zinc15.docking.org/substances/ZINC000113198271|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=T678746713|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50193395

> <LinkName>
|ChemSpider|ChEMBL|PubChem|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
510.2

> <HBA>
5

> <HBD>
3

> <NRB>
8

> <TPSA>
109.4

> <LogP>
5

> <RoF>
1

> <Targets>
MET; TEK; KDR; NTRK1

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0029

> <r_epik_State_Penalty>
  0.0038

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
41

> <Kinase families>
Tyr

$$$$
Omipalisib
                    3D
 Structure written by MMmdl.
 53 57  0  0  1  0            999 V2000
   -0.6439    3.5957   -0.0934 C   0  0  0  0  0  0
    0.0465    2.3492   -0.0198 O   0  0  0  0  0  0
   -0.6722    1.1640    0.0097 C   0  0  0  0  0  0
    0.0209   -0.0533    0.0748 C   0  0  0  0  0  0
   -0.7299   -1.2358    0.1043 C   0  0  0  0  0  0
   -2.1301   -1.2025    0.0565 C   0  0  0  0  0  0
   -2.7322    0.0591   -0.0073 C   0  0  0  0  0  0
   -2.0349    1.2210   -0.0292 N   0  0  0  0  0  0
   -2.9325   -2.4588    0.0630 C   0  0  0  0  0  0
   -4.1439   -2.5386    0.7539 C   0  0  0  0  0  0
   -4.8983   -3.7080    0.7616 C   0  0  0  0  0  0
   -4.4426   -4.8565    0.0742 C   0  0  0  0  0  0
   -3.1946   -4.8131   -0.6234 C   0  0  0  0  0  0
   -2.4760   -3.5862   -0.6270 C   0  0  0  0  0  0
   -2.7489   -6.0029   -1.2942 C   0  0  0  0  0  0
   -3.5886   -7.1213   -1.2594 C   0  0  0  0  0  0
   -4.7913   -7.0677   -0.5656 C   0  0  0  0  0  0
   -5.2212   -5.9720    0.0998 N   0  0  0  0  0  0
   -1.4426   -6.0992   -2.0076 C   0  0  0  0  0  0
   -0.2357   -5.7303   -1.3999 C   0  0  0  0  0  0
    0.9456   -5.8481   -2.1304 C   0  0  0  0  0  0
    0.9634   -6.3209   -3.4035 N   0  0  0  0  0  0
   -0.1851   -6.6944   -3.9928 N   0  0  0  0  0  0
   -1.3597   -6.5911   -3.3158 C   0  0  0  0  0  0
    1.4254   -0.0556    0.1035 N   0  0  0  0  0  0
    2.4153   -1.5304    0.1008 S   0  0  0  0  0  0
    2.1678   -2.2182    1.3731 O   0  0  0  0  0  0
    2.1564   -2.2141   -1.1720 O   0  0  0  0  0  0
    4.1122   -0.9609    0.1098 C   0  0  0  0  0  0
    4.9558   -1.2463   -0.9693 C   0  0  0  0  0  0
    6.2759   -0.7955   -0.9637 C   0  0  0  0  0  0
    6.7575   -0.0571    0.1170 C   0  0  0  0  0  0
    5.9184    0.2323    1.1927 C   0  0  0  0  0  0
    4.5971   -0.2163    1.1921 C   0  0  0  0  0  0
    3.7962    0.0812    2.2415 F   0  0  0  0  0  0
    8.0370    0.3798    0.1208 F   0  0  0  0  0  0
    0.0807    4.4096   -0.1085 H   0  0  0  0  0  0
   -1.2920    3.7450    0.7717 H   0  0  0  0  0  0
   -1.2423    3.6674   -1.0030 H   0  0  0  0  0  0
   -0.2324   -2.1920    0.1640 H   0  0  0  0  0  0
   -3.8068    0.1601   -0.0544 H   0  0  0  0  0  0
   -4.5138   -1.6822    1.2986 H   0  0  0  0  0  0
   -5.8368   -3.7428    1.2965 H   0  0  0  0  0  0
   -1.5563   -3.5177   -1.1866 H   0  0  0  0  0  0
   -3.3032   -8.0390   -1.7536 H   0  0  0  0  0  0
   -5.4381   -7.9321   -0.5284 H   0  0  0  0  0  0
   -0.2110   -5.3591   -0.3856 H   0  0  0  0  0  0
    1.8955   -5.5652   -1.7014 H   0  0  0  0  0  0
   -2.2448   -6.9030   -3.8510 H   0  0  0  0  0  0
    1.8990    0.8359    0.0861 H   0  0  0  0  0  0
    4.5978   -1.8164   -1.8140 H   0  0  0  0  0  0
    6.9252   -1.0183   -1.7979 H   0  0  0  0  0  0
    6.2923    0.8069    2.0273 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 37  1  0  0  0
  1 38  1  0  0  0
  1 39  1  0  0  0
  2  3  1  0  0  0
  3  4  1  0  0  0
  3  8  2  0  0  0
  4  5  2  0  0  0
  4 25  1  0  0  0
  5  6  1  0  0  0
  5 40  1  0  0  0
  6  7  2  0  0  0
  6  9  1  0  0  0
  7  8  1  0  0  0
  7 41  1  0  0  0
  9 10  1  0  0  0
  9 14  2  0  0  0
 10 11  2  0  0  0
 10 42  1  0  0  0
 11 12  1  0  0  0
 11 43  1  0  0  0
 12 13  1  0  0  0
 12 18  2  0  0  0
 13 14  1  0  0  0
 13 15  2  0  0  0
 14 44  1  0  0  0
 15 16  1  0  0  0
 15 19  1  0  0  0
 16 17  2  0  0  0
 16 45  1  0  0  0
 17 18  1  0  0  0
 17 46  1  0  0  0
 19 20  1  0  0  0
 19 24  2  0  0  0
 20 21  2  0  0  0
 20 47  1  0  0  0
 21 22  1  0  0  0
 21 48  1  0  0  0
 22 23  2  0  0  0
 23 24  1  0  0  0
 24 49  1  0  0  0
 25 26  1  0  0  0
 25 50  1  0  0  0
 26 27  2  0  0  0
 26 28  2  0  0  0
 26 29  1  0  0  0
 29 30  1  0  0  0
 29 34  2  0  0  0
 30 31  2  0  0  0
 30 51  1  0  0  0
 31 32  1  0  0  0
 31 52  1  0  0  0
 32 33  2  0  0  0
 32 36  1  0  0  0
 33 34  1  0  0  0
 33 53  1  0  0  0
 34 35  1  0  0  0
M  END
> <s_m_entry_id>
42

> <Applicants>
GlaxosmithKline

> <CHEMBL_ID>
CHEMBL1236962

> <Canonical_Smiles>
S(=O)(=O)(Nc1cc(cnc1OC)-c1cc2c(nccc2-c2ccnnc2)cc1)c1ccc(F)cc1F

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
1

> <SC_Patent>
None

> <Synonyms>
GSK-2126458 | GSK2126458 | OMIPALISIB

> <Indications>
nan

> <Type>
1

> <targets_id>
P42336|P42345

> <inchi>
InChI=1S/C25H17F2N5O3S/c1-35-25-23(32-36(33,34)24-5-3-18(26)12-21(24)27)11-17(13-29-25)15-2-4-22-20(10-15)19(7-8-28-22)16-6-9-30-31-14-16/h2-14,32H,1H3

> <stdInchikey>
CGBJSGAELGCMKE-UHFFFAOYSA-N

> <csid>
25027388

> <Links>
|http://www.chemspider.com/Chemical-Structure.25027388.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1236962|http://pubchem.ncbi.nlm.nih.gov/compound/25167777|http://www.drugbank.ca/drugs/DB12703| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=ZIG|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/ZIG|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8974|http://zinc15.docking.org/substances/ZINC43208634|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=1X8F5A3NA0|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50145416

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
505.1

> <HBA>
7

> <HBD>
1

> <NRB>
6

> <TPSA>
107

> <LogP>
4.8

> <RoF>
1

> <Targets>
PIK3CA; MTOR

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.1066

> <r_epik_State_Penalty>
  0.0910

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
42

> <lig_pdbID>
'ZIG'

> <pdbID>
3l08

> <Kinase families>
Atypical

$$$$
Peposertib
                    3D
 Structure written by MMmdl.
 47 48  0  0  1  0            999 V2000
   -3.8872    0.3542    0.9717 C   0  0  0  0  0  0
   -2.4789    0.5261    1.0028 O   0  0  0  0  0  0
   -1.9909    1.3892   -0.0160 C   0  0  0  0  0  0
   -0.4631    1.4782    0.0829 C   0  0  0  0  0  0
    0.0970    0.1961   -0.1804 O   0  0  0  0  0  0
    1.4662    0.1406   -0.0746 C   0  0  0  0  0  0
    2.0563   -0.0959    1.1752 C   0  0  0  0  0  0
    3.4554   -0.1720    1.2603 C   0  0  0  0  0  0
    4.2495   -0.0298    0.1216 C   0  0  0  0  0  0
    3.6462    0.2142   -1.1129 C   0  0  0  0  0  0
    2.2491    0.2931   -1.2271 C   0  0  0  0  0  0
    1.5826    0.5168   -2.4187 O   0  0  0  0  0  0
    2.3300    0.6578   -3.6218 C   0  0  0  0  0  0
    5.7656   -0.1039    0.2354 C   0  0  0  0  0  0
    6.2978   -1.5344    0.1938 C   0  0  0  0  0  0
    6.4732   -2.2426    1.3921 C   0  0  0  0  0  0
    6.9615   -3.4984    1.3497 N   0  3  0  0  0  0
    7.2900   -4.0768    0.1817 C   0  0  0  0  0  0
    7.1597   -3.4542   -1.0154 N   0  0  0  0  0  0
    6.6669   -2.1855   -1.0028 C   0  0  0  0  0  0
    6.5433   -1.5663   -2.2461 N   0  0  0  0  0  0
    7.7978   -5.3860    0.1434 N   0  0  0  0  0  0
    1.2078   -0.2424    2.2582 O   0  0  0  0  0  0
    1.7570   -0.4519    3.5541 C   0  0  0  0  0  0
   -4.1882   -0.3207    1.7727 H   0  0  0  0  0  0
   -4.2149   -0.0824    0.0270 H   0  0  0  0  0  0
   -4.4075    1.3017    1.1197 H   0  0  0  0  0  0
   -2.2748    1.0105   -0.9998 H   0  0  0  0  0  0
   -2.4267    2.3840    0.0933 H   0  0  0  0  0  0
   -0.0873    2.2076   -0.6373 H   0  0  0  0  0  0
   -0.1781    1.8260    1.0781 H   0  0  0  0  0  0
    3.9418   -0.3502    2.2074 H   0  0  0  0  0  0
    4.2772    0.3336   -1.9803 H   0  0  0  0  0  0
    1.6440    0.8129   -4.4543 H   0  0  0  0  0  0
    2.9132   -0.2386   -3.8384 H   0  0  0  0  0  0
    2.9972    1.5202   -3.5796 H   0  0  0  0  0  0
    6.2297    0.4954   -0.5497 H   0  0  0  0  0  0
    6.0758    0.3709    1.1683 H   0  0  0  0  0  0
    6.2391   -1.8570    2.3742 H   0  0  0  0  0  0
    6.1761   -0.6279   -2.3026 H   0  0  0  0  0  0
    6.8166   -2.0720   -3.0763 H   0  0  0  0  0  0
    8.0400   -5.8025   -0.7440 H   0  0  0  0  0  0
    7.9193   -5.9111    0.9969 H   0  0  0  0  0  0
    0.9465   -0.5290    4.2789 H   0  0  0  0  0  0
    2.3928    0.3809    3.8585 H   0  0  0  0  0  0
    2.3302   -1.3789    3.6010 H   0  0  0  0  0  0
    7.0838   -4.0145    2.2088 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 25  1  0  0  0
  1 26  1  0  0  0
  1 27  1  0  0  0
  2  3  1  0  0  0
  3  4  1  0  0  0
  3 28  1  0  0  0
  3 29  1  0  0  0
  4  5  1  0  0  0
  4 30  1  0  0  0
  4 31  1  0  0  0
  5  6  1  0  0  0
  6  7  1  0  0  0
  6 11  2  0  0  0
  7  8  2  0  0  0
  7 23  1  0  0  0
  8  9  1  0  0  0
  8 32  1  0  0  0
  9 10  2  0  0  0
  9 14  1  0  0  0
 10 11  1  0  0  0
 10 33  1  0  0  0
 11 12  1  0  0  0
 12 13  1  0  0  0
 13 34  1  0  0  0
 13 35  1  0  0  0
 13 36  1  0  0  0
 14 15  1  0  0  0
 14 37  1  0  0  0
 14 38  1  0  0  0
 15 16  1  0  0  0
 15 20  2  0  0  0
 16 17  2  0  0  0
 16 39  1  0  0  0
 17 18  1  0  0  0
 17 47  1  0  0  0
 18 19  2  0  0  0
 18 22  1  0  0  0
 19 20  1  0  0  0
 20 21  1  0  0  0
 21 40  1  0  0  0
 21 41  1  0  0  0
 22 42  1  0  0  0
 22 43  1  0  0  0
 23 24  1  0  0  0
 24 44  1  0  0  0
 24 45  1  0  0  0
 24 46  1  0  0  0
M  CHG  1  17   1
M  END
> <s_m_entry_id>
44

> <Applicants>
Merck

> <CHEMBL_ID>
nan

> <Canonical_Smiles>
O(CCOC)c1c(OC)cc(cc1OC)Cc1cnc(nc1N)N

> <Chirality>
nan

> <First_Approval>
nan

> <Phase>
1

> <SC_Patent>
nan

> <Synonyms>
TETROXOPRIM

> <Indications>
nan

> <Type>
nan

> <targets_id>
nan

> <inchi>
InChI=1S/C16H22N4O4/c1-21-4-5-24-14-12(22-2)7-10(8-13(14)23-3)6-11-9-19-16(18)20-15(11)17/h7-9H,4-6H2,1-3H3,(H4,17,18,19,20)

> <stdInchikey>
WSWJIZXMAUYHOE-UHFFFAOYSA-N

> <csid>
58910

> <Links>
|http://www.chemspider.com/Chemical-Structure.58910.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL32039|http://pubchem.ncbi.nlm.nih.gov/compound/65450|http://zinc15.docking.org/substances/ZINC000002020087|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=5R6712AY0K|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50029760

> <LinkName>
|ChemSpider|ChEMBL|PubChem|ZINC|FDA SRS|BindingDB

> <MW>
334.2

> <HBA>
8

> <HBD>
2

> <NRB>
8

> <TPSA>
114.7

> <LogP>
1.3

> <RoF>
0

> <Targets>
nan

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
0.575011

> <r_epik_Ionization_Penalty>
  0.2380

> <r_epik_State_Penalty>
  0.4697

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
44

> <Melting point>
154.0 °C

$$$$
Panulisib
                    3D
 Structure written by MMmdl.
 60 64  0  0  1  0            999 V2000
   -4.6632   -1.3033    0.7530 C   0  0  0  0  0  0
   -4.1645   -0.0663   -0.0276 C   0  0  0  0  0  0
   -4.7908   -0.0484   -1.4406 C   0  0  0  0  0  0
   -4.6528    1.1358    0.6860 C   0  0  0  0  0  0
   -5.0367    2.0751    1.2439 N   0  0  0  0  0  0
   -2.6235   -0.0909   -0.1206 C   0  0  0  0  0  0
   -1.9618   -1.1208   -0.8077 C   0  0  0  0  0  0
   -0.5665   -1.1343   -0.8373 C   0  0  0  0  0  0
    0.1362   -0.1310   -0.1653 C   0  0  0  0  0  0
   -0.5794    0.8863    0.4695 C   0  0  0  0  0  0
   -1.9351    0.9080    0.5043 N   0  0  0  0  0  0
    1.5388   -0.1336   -0.1443 N   0  3  0  0  0  0
    2.3786   -0.7474    0.7932 C   0  0  0  0  0  0
    2.1062   -1.5248    1.9614 C   0  0  0  0  0  0
    0.7998   -1.8469    2.4163 C   0  0  0  0  0  0
    0.5976   -2.6152    3.5661 C   0  0  0  0  0  0
    1.7108   -3.0706    4.2782 C   0  0  0  0  0  0
    3.0077   -2.7752    3.8661 C   0  0  0  0  0  0
    3.2270   -2.0003    2.7036 C   0  0  0  0  0  0
    4.5091   -1.7321    2.3274 N   0  0  0  0  0  0
    4.7513   -0.9929    1.2139 C   0  0  0  0  0  0
    3.7063   -0.4917    0.4327 C   0  0  0  0  0  0
    3.6751    0.2723   -0.7306 N   0  0  0  0  0  0
    2.3521    0.4968   -1.0682 C   0  0  0  0  0  0
    1.9146    1.2093   -2.1398 N   0  0  0  0  0  0
    1.9968    2.5598   -2.1207 C   0  0  0  0  0  0
    2.0781    3.7134   -2.0996 N   0  0  0  0  0  0
    4.8509    0.7614   -1.4408 C   0  0  0  0  0  0
   -0.7866   -2.9417    4.0099 C   0  0  0  0  0  0
   -1.1227   -4.2134    4.4931 C   0  0  0  0  0  0
   -2.4360   -4.5127    4.8857 C   0  0  0  0  0  0
   -3.3948   -3.4880    4.7776 C   0  0  0  0  0  0
   -3.0931   -2.2499    4.3168 N   0  0  0  0  0  0
   -1.8158   -1.9947    3.9457 C   0  0  0  0  0  0
   -4.7275   -3.6848    5.1385 N   0  0  0  0  0  0
   -2.7934   -5.9106    5.4044 C   0  0  0  0  0  0
   -3.2671   -5.8238    6.6477 F   0  0  0  0  0  0
   -3.7281   -6.4569    4.6258 F   0  0  0  0  0  0
   -1.7433   -6.7337    5.4224 F   0  0  0  0  0  0
   -4.2435   -1.3317    1.7597 H   0  0  0  0  0  0
   -4.3919   -2.2373    0.2594 H   0  0  0  0  0  0
   -5.7493   -1.2978    0.8570 H   0  0  0  0  0  0
   -4.4456    0.8124   -2.0153 H   0  0  0  0  0  0
   -5.8791    0.0120   -1.3914 H   0  0  0  0  0  0
   -4.5467   -0.9444   -2.0123 H   0  0  0  0  0  0
   -2.5164   -1.9063   -1.2993 H   0  0  0  0  0  0
   -0.0438   -1.9287   -1.3510 H   0  0  0  0  0  0
   -0.0735    1.6892    0.9870 H   0  0  0  0  0  0
   -0.0643   -1.5100    1.8722 H   0  0  0  0  0  0
    1.5745   -3.6613    5.1726 H   0  0  0  0  0  0
    3.8520   -3.1381    4.4349 H   0  0  0  0  0  0
    5.7877   -0.8154    0.9663 H   0  0  0  0  0  0
    5.3626    1.4993   -0.8222 H   0  0  0  0  0  0
    4.5722    1.2213   -2.3893 H   0  0  0  0  0  0
    5.5255   -0.0723   -1.6394 H   0  0  0  0  0  0
   -0.3570   -4.9738    4.5492 H   0  0  0  0  0  0
   -1.6286   -0.9921    3.5882 H   0  0  0  0  0  0
   -5.0193   -4.5826    5.4966 H   0  0  0  0  0  0
   -5.3802   -2.9198    5.0485 H   0  0  0  0  0  0
    1.2777    0.7778   -2.7944 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 40  1  0  0  0
  1 41  1  0  0  0
  1 42  1  0  0  0
  2  3  1  0  0  0
  2  4  1  0  0  0
  2  6  1  0  0  0
  3 43  1  0  0  0
  3 44  1  0  0  0
  3 45  1  0  0  0
  4  5  3  0  0  0
  6  7  1  0  0  0
  6 11  2  0  0  0
  7  8  2  0  0  0
  7 46  1  0  0  0
  8  9  1  0  0  0
  8 47  1  0  0  0
  9 10  2  0  0  0
  9 12  1  0  0  0
 10 11  1  0  0  0
 10 48  1  0  0  0
 12 13  1  0  0  0
 12 24  2  0  0  0
 13 14  1  0  0  0
 13 22  2  0  0  0
 14 15  1  0  0  0
 14 19  2  0  0  0
 15 16  2  0  0  0
 15 49  1  0  0  0
 16 17  1  0  0  0
 16 29  1  0  0  0
 17 18  2  0  0  0
 17 50  1  0  0  0
 18 19  1  0  0  0
 18 51  1  0  0  0
 19 20  1  0  0  0
 20 21  2  0  0  0
 21 22  1  0  0  0
 21 52  1  0  0  0
 22 23  1  0  0  0
 23 24  1  0  0  0
 23 28  1  0  0  0
 24 25  1  0  0  0
 25 26  1  0  0  0
 25 60  1  0  0  0
 26 27  3  0  0  0
 28 53  1  0  0  0
 28 54  1  0  0  0
 28 55  1  0  0  0
 29 30  1  0  0  0
 29 34  2  0  0  0
 30 31  2  0  0  0
 30 56  1  0  0  0
 31 32  1  0  0  0
 31 36  1  0  0  0
 32 33  2  0  0  0
 32 35  1  0  0  0
 33 34  1  0  0  0
 34 57  1  0  0  0
 35 58  1  0  0  0
 35 59  1  0  0  0
 36 37  1  0  0  0
 36 38  1  0  0  0
 36 39  1  0  0  0
M  CHG  1  12   1
M  END
> <s_m_entry_id>
47

> <Applicants>
Piramal Enterprises

> <CHEMBL_ID>
CHEMBL3545322

> <Canonical_Smiles>
FC(F)(F)c1cc(cnc1N)-c1cc2c3N(c4ccc(nc4)C(C#N)(C)C)C(=NC#N)N(c3cnc2cc1)C

> <Chirality>
Single Stereoisomer

> <First_Approval>
nan

> <Phase>
1

> <SC_Patent>
None

> <Indications>
nan

> <Type>
nan

> <targets_id>
P42336|P42345

> <inchi>
InChI=1S/C27H20F3N9/c1-26(2,13-31)22-7-5-17(11-35-22)39-23-18-8-15(16-9-19(27(28,29)30)24(33)36-10-16)4-6-20(18)34-12-21(23)38(3)25(39)37-14-32/h4-12H,1-3H3,(H2,33,36)

> <stdInchikey>
VJLRLTSXTLICIR-UHFFFAOYSA-N

> <csid>
29165869

> <Links>
|http://www.chemspider.com/Chemical-Structure.29165869.html|http://pubchem.ncbi.nlm.nih.gov/compound/56947515|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9916|http://zinc15.docking.org/substances/ZINC000301055099

> <LinkName>
|ChemSpider|PubChem|Guide to Pharmacology|ZINC

> <indicationG2P>
None

> <MW>
527.2

> <HBA>
9

> <HBD>
1

> <NRB>
3

> <TPSA>
134.5

> <LogP>
4.8

> <RoF>
1

> <Targets>
PIK3CA; MTOR

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0310

> <r_epik_State_Penalty>
  0.0169

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
47

> <Kinase families>
Atypical

$$$$
Elimusertib
                    3D
 Structure written by MMmdl.
 49 53  0  0  1  0            999 V2000
   -0.1437   -2.3701    0.3646 C   0  0  0  0  0  0
   -0.7066   -0.9719    0.7064 C   0  0  2  0  0  0
   -2.1831   -0.8842    0.2340 C   0  0  0  0  0  0
   -2.7934    0.3264    0.6650 O   0  0  0  0  0  0
   -2.0797    1.4896    0.2695 C   0  0  0  0  0  0
   -0.6115    1.4025    0.7298 C   0  0  0  0  0  0
    0.0496    0.1973    0.1961 N   0  0  0  0  0  0
    1.4406    0.1530    0.1601 C   0  0  0  0  0  0
    2.0890   -0.5130   -0.8776 C   0  0  0  0  0  0
    3.4832   -0.5706   -0.9150 C   0  0  0  0  0  0
    4.2204    0.0765    0.1244 C   0  0  0  0  0  0
    5.6406    0.0745    0.1986 C   0  0  0  0  0  0
    6.2658    0.7339    1.2508 C   0  0  0  0  0  0
    5.5956    1.3861    2.2254 N   0  0  0  0  0  0
    4.2372    1.4017    2.1893 C   0  0  0  0  0  0
    3.4884    0.7538    1.1539 C   0  0  0  0  0  0
    2.1264    0.7783    1.1514 N   0  0  0  0  0  0
    3.6190    2.1610    3.3380 C   0  0  0  0  0  0
    2.3055    2.4409    3.7092 C   0  0  0  0  0  0
    2.3720    3.1954    4.8827 C   0  0  0  0  0  0
    3.6064    3.4041    5.2645 N   0  0  0  0  0  0
    4.3396    2.7825    4.3352 N   0  0  0  0  0  0
    4.1278   -1.2858   -2.0581 C   0  0  0  0  0  0
    5.0911   -0.8644   -2.9637 C   0  0  0  0  0  0
    5.3015   -1.9364   -3.8316 C   0  0  0  0  0  0
    4.5539   -2.9694   -3.5288 N   0  0  0  0  0  0
    3.8572   -2.5831   -2.4489 N   0  0  0  0  0  0
    2.9156   -3.5273   -1.8620 C   0  0  0  0  0  0
   -0.7680   -3.1590    0.7855 H   0  0  0  0  0  0
    0.8572   -2.5109    0.7737 H   0  0  0  0  0  0
   -0.0941   -2.5318   -0.7126 H   0  0  0  0  0  0
   -0.7035   -0.9104    1.7967 H   0  0  0  0  0  0
   -2.2548   -0.9704   -0.8521 H   0  0  0  0  0  0
   -2.7650   -1.7063    0.6522 H   0  0  0  0  0  0
   -2.1407    1.6261   -0.8117 H   0  0  0  0  0  0
   -2.5589    2.3615    0.7147 H   0  0  0  0  0  0
   -0.0873    2.2895    0.3704 H   0  0  0  0  0  0
   -0.5533    1.4295    1.8193 H   0  0  0  0  0  0
    1.5081   -0.9799   -1.6602 H   0  0  0  0  0  0
    6.2336   -0.4349   -0.5457 H   0  0  0  0  0  0
    7.3434    0.7438    1.3247 H   0  0  0  0  0  0
    1.3993    2.1436    3.2046 H   0  0  0  0  0  0
    1.5308    3.5807    5.4401 H   0  0  0  0  0  0
    5.3488    2.7797    4.3786 H   0  0  0  0  0  0
    5.5723    0.1018   -2.9983 H   0  0  0  0  0  0
    5.9850   -1.9539   -4.6677 H   0  0  0  0  0  0
    2.8247   -3.3437   -0.7913 H   0  0  0  0  0  0
    3.2622   -4.5516   -2.0086 H   0  0  0  0  0  0
    1.9413   -3.4045   -2.3354 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 29  1  0  0  0
  1 30  1  0  0  0
  1 31  1  0  0  0
  2  3  1  0  0  0
  2  7  1  0  0  0
  2 32  1  0  0  0
  3  4  1  0  0  0
  3 33  1  0  0  0
  3 34  1  0  0  0
  4  5  1  0  0  0
  5  6  1  0  0  0
  5 35  1  0  0  0
  5 36  1  0  0  0
  6  7  1  0  0  0
  6 37  1  0  0  0
  6 38  1  0  0  0
  7  8  1  0  0  0
  8  9  1  0  0  0
  8 17  2  0  0  0
  9 10  2  0  0  0
  9 39  1  0  0  0
 10 11  1  0  0  0
 10 23  1  0  0  0
 11 12  1  0  0  0
 11 16  2  0  0  0
 12 13  2  0  0  0
 12 40  1  0  0  0
 13 14  1  0  0  0
 13 41  1  0  0  0
 14 15  2  0  0  0
 15 16  1  0  0  0
 15 18  1  0  0  0
 16 17  1  0  0  0
 18 19  2  0  0  0
 18 22  1  0  0  0
 19 20  1  0  0  0
 19 42  1  0  0  0
 20 21  2  0  0  0
 20 43  1  0  0  0
 21 22  1  0  0  0
 22 44  1  0  0  0
 23 24  2  0  0  0
 23 27  1  0  0  0
 24 25  1  0  0  0
 24 45  1  0  0  0
 25 26  2  0  0  0
 25 46  1  0  0  0
 26 27  1  0  0  0
 27 28  1  0  0  0
 28 47  1  0  0  0
 28 48  1  0  0  0
 28 49  1  0  0  0
M  END
> <s_m_entry_id>
49

> <Applicants>
Bayer

> <CHEMBL_ID>
nan

> <Canonical_Smiles>
O1CC(N(CC1)c1nc2c(ccnc2-c2[nH]ncc2)c(c1)-c1n(ncc1)C)C

> <Chirality>
nan

> <First_Approval>
nan

> <Phase>
1

> <SC_Patent>
nan

> <Synonyms>
|BAY 1895344|BAY1895344|BAY-1895344

> <Indications>
nan

> <Type>
nan

> <targets_id>
nan

> <inchi>
InChI=1S/C20H21N7O/c1-13-12-28-10-9-27(13)18-11-15(17-5-8-23-26(17)2)14-3-6-21-20(19(14)24-18)16-4-7-22-25-16/h3-8,11,13H,9-10,12H2,1-2H3,(H,22,25)

> <stdInchikey>
YBXRSCXGRPSTMW-UHFFFAOYSA-N

> <csid>
64879752

> <Links>
|http://www.chemspider.com/Chemical-Structure.64879752.html|http://pubchem.ncbi.nlm.nih.gov/compound/134446438

> <LinkName>
|ChemSpider|PubChem

> <MW>
375.2

> <HBA>
7

> <HBD>
1

> <NRB>
3

> <TPSA>
84.8

> <LogP>
2.6

> <RoF>
0

> <Targets>
nan

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
0.5

> <r_epik_Ionization_Penalty>
  0.0009

> <r_epik_State_Penalty>
  0.3065

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
49

> <Kinase families>
(*)

$$$$
Ravoxertinib
                    3D
 Structure written by MMmdl.
 49 52  0  0  1  0            999 V2000
   -4.3796    4.4229   -1.8926 C   0  0  0  0  0  0
   -3.0146    4.4963   -1.3851 N   0  0  0  0  0  0
   -2.2760    3.5072   -0.7684 C   0  0  0  0  0  0
   -1.0495    4.1109   -0.5205 C   0  0  0  0  0  0
   -1.1483    5.4020   -1.0415 C   0  0  0  0  0  0
   -2.3263    5.6341   -1.5686 N   0  0  0  0  0  0
   -2.7971    2.2581   -0.5038 N   0  0  0  0  0  0
   -2.1017    1.0721   -0.2262 C   0  0  0  0  0  0
   -2.8790   -0.0027    0.0611 N   0  0  0  0  0  0
   -2.2368   -1.1697    0.3219 C   0  0  0  0  0  0
   -0.8462   -1.2810    0.3029 C   0  0  0  0  0  0
   -0.1116   -0.1229    0.0119 C   0  0  0  0  0  0
   -0.7416    1.0532   -0.2704 N   0  0  0  0  0  0
    1.3759   -0.1119   -0.0816 C   0  0  0  0  0  0
    2.1173   -1.3364   -0.3739 C   0  0  0  0  0  0
    3.4605   -1.2620   -0.4257 C   0  0  0  0  0  0
    4.2079   -0.1192   -0.2192 N   0  0  0  0  0  0
    3.5750    1.0856    0.0359 C   0  0  0  0  0  0
    4.1502    2.1617    0.2108 O   0  0  0  0  0  0
    2.1129    1.0209    0.1004 C   0  0  0  0  0  0
    5.6944   -0.1250   -0.2855 C   0  0  2  0  0  0
    6.2252   -0.0891   -1.7468 C   0  0  0  0  0  0
    5.6672    0.9663   -2.5048 O   0  0  0  0  0  0
    6.3274   -1.2065    0.6121 C   0  0  0  0  0  0
    5.9834   -1.2412    1.9702 C   0  0  0  0  0  0
    6.5260   -2.2033    2.8211 C   0  0  0  0  0  0
    7.4263   -3.1460    2.3262 C   0  0  0  0  0  0
    7.7821   -3.1229    0.9757 C   0  0  0  0  0  0
    7.2363   -2.1595    0.1259 C   0  0  0  0  0  0
    8.6546   -4.0315    0.4806 F   0  0  0  0  0  0
    8.0912   -4.3334    3.3907 Cl  0  0  0  0  0  0
   -4.9811    3.7817   -1.2478 H   0  0  0  0  0  0
   -4.3646    4.0091   -2.9013 H   0  0  0  0  0  0
   -4.8329    5.4155   -1.9157 H   0  0  0  0  0  0
   -0.1896    3.6772   -0.0326 H   0  0  0  0  0  0
   -0.3714    6.1525   -1.0324 H   0  0  0  0  0  0
   -3.7968    2.1396   -0.4344 H   0  0  0  0  0  0
   -2.8571   -2.0247    0.5479 H   0  0  0  0  0  0
   -0.3705   -2.2257    0.5188 H   0  0  0  0  0  0
    1.6178   -2.2741   -0.5676 H   0  0  0  0  0  0
    4.0768   -2.1216   -0.6480 H   0  0  0  0  0  0
    1.6087    1.9506    0.3233 H   0  0  0  0  0  0
    6.0765    0.7906    0.1699 H   0  0  0  0  0  0
    7.3078    0.0423   -1.7558 H   0  0  0  0  0  0
    6.0077   -1.0254   -2.2621 H   0  0  0  0  0  0
    6.0502    0.9488   -3.3850 H   0  0  0  0  0  0
    5.2883   -0.5176    2.3712 H   0  0  0  0  0  0
    6.2455   -2.2147    3.8642 H   0  0  0  0  0  0
    7.5305   -2.1734   -0.9123 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 32  1  0  0  0
  1 33  1  0  0  0
  1 34  1  0  0  0
  2  3  1  0  0  0
  2  6  1  0  0  0
  3  4  2  0  0  0
  3  7  1  0  0  0
  4  5  1  0  0  0
  4 35  1  0  0  0
  5  6  2  0  0  0
  5 36  1  0  0  0
  7  8  1  0  0  0
  7 37  1  0  0  0
  8  9  1  0  0  0
  8 13  2  0  0  0
  9 10  2  0  0  0
 10 11  1  0  0  0
 10 38  1  0  0  0
 11 12  2  0  0  0
 11 39  1  0  0  0
 12 13  1  0  0  0
 12 14  1  0  0  0
 14 15  1  0  0  0
 14 20  2  0  0  0
 15 16  2  0  0  0
 15 40  1  0  0  0
 16 17  1  0  0  0
 16 41  1  0  0  0
 17 18  1  0  0  0
 17 21  1  0  0  0
 18 19  2  0  0  0
 18 20  1  0  0  0
 20 42  1  0  0  0
 21 22  1  0  0  0
 21 24  1  0  0  0
 21 43  1  0  0  0
 22 23  1  0  0  0
 22 44  1  0  0  0
 22 45  1  0  0  0
 23 46  1  0  0  0
 24 25  2  0  0  0
 24 29  1  0  0  0
 25 26  1  0  0  0
 25 47  1  0  0  0
 26 27  2  0  0  0
 26 48  1  0  0  0
 27 28  1  0  0  0
 27 31  1  0  0  0
 28 29  2  0  0  0
 28 30  1  0  0  0
 29 49  1  0  0  0
M  END
> <s_m_entry_id>
53

> <Applicants>
Genentech

> <CHEMBL_ID>
CHEMBL3544964

> <Canonical_Smiles>
Clc1ccc(cc1F)[C@H](N1C=CC(=CC1=O)c1nc(ncc1)Nc1n(ncc1)C)CO

> <Chirality>
Single Stereoisomer

> <First_Approval>
nan

> <Phase>
1

> <SC_Patent>
None

> <Synonyms>
GDC-0994 | GDC0994 | RAVOXERTINIB | RG-7842

> <Indications>
nan

> <Type>
nan

> <targets_id>
nan

> <inchi>
InChI=1S/C21H18ClFN6O2/c1-28-19(5-8-25-28)27-21-24-7-4-17(26-21)13-6-9-29(20(31)11-13)18(12-30)14-2-3-15(22)16(23)10-14/h2-11,18,30H,12H2,1H3,(H,24,26,27)/t18-/m1/s1

> <stdInchikey>
RZUOCXOYPYGSKL-GOSISDBHSA-N

> <csid>
32501977

> <Links>
|http://www.chemspider.com/Chemical-Structure.32501977.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3544964|http://pubchem.ncbi.nlm.nih.gov/compound/71727581|http://www.drugbank.ca/drugs/DB15281| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=6QB|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/6QB|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9229|http://zinc15.docking.org/substances/ZINC000144904566|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=R6AXV96CRH|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=120095

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
440.1

> <HBA>
8

> <HBD>
2

> <NRB>
6

> <TPSA>
97.9

> <LogP>
3.2

> <RoF>
0

> <Targets>
nan

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0002

> <r_epik_State_Penalty>
  0.0000

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
53

> <lig_pdbID>
'6QB'

> <pdbID>
5k4i 5k4j 6oph

$$$$
Tafetinib
                    3D
 Structure written by MMmdl.
 61 64  0  0  1  0            999 V2000
   -2.3515   -1.4307   -0.6429 C   0  0  0  0  0  0
   -1.0179   -0.9318   -1.2233 C   0  0  0  0  0  0
   -0.2219   -0.1286   -0.1633 N   0  3  0  0  0  0
   -0.7922    1.2988    0.0360 C   0  0  0  0  0  0
   -0.4236    1.8456    1.4247 C   0  0  0  0  0  0
    1.2976   -0.1078   -0.4690 C   0  0  0  0  0  0
    1.9474   -1.4779   -0.1706 C   0  0  0  0  0  0
    3.4003   -1.4106   -0.0267 N   0  0  0  0  0  0
    4.2636   -1.1692   -1.0309 C   0  0  0  0  0  0
    3.9218   -0.9646   -2.1966 O   0  0  0  0  0  0
    5.6515   -1.1482   -0.6342 C   0  0  0  0  0  0
    6.2862   -2.0334    0.2424 C   0  0  0  0  0  0
    7.5957   -1.6475    0.2968 N   0  0  0  0  0  0
    7.8711   -0.6177   -0.5644 C   0  0  0  0  0  0
    6.6389   -0.2772   -1.1576 C   0  0  0  0  0  0
    6.4933    0.8799   -2.1423 C   0  0  0  0  0  0
    7.8788    1.3689   -2.5894 C   0  0  0  0  0  0
    8.8778    1.4855   -1.4236 C   0  0  0  0  0  0
    9.1514    0.0976   -0.8259 C   0  0  0  0  0  0
   10.4345   -0.3494   -0.6286 C   0  0  0  0  0  0
   11.7419    0.3538   -0.6775 C   0  0  0  0  0  0
   12.1415    1.6919   -0.8308 C   0  0  0  0  0  0
   13.4988    2.0277   -0.8241 C   0  0  0  0  0  0
   14.4671    1.0381   -0.6477 C   0  0  0  0  0  0
   14.0796   -0.2878   -0.4586 C   0  0  0  0  0  0
   12.7201   -0.5969   -0.4682 C   0  0  0  0  0  0
   12.1195   -1.8060   -0.2639 N   0  0  0  0  0  0
   10.7822   -1.7450   -0.3336 C   0  0  0  0  0  0
   10.0648   -2.7343   -0.2063 O   0  0  0  0  0  0
   13.8750    3.3176   -0.9768 F   0  0  0  0  0  0
    5.8139   -3.2174    1.0614 C   0  0  0  0  0  0
   -2.8606   -2.0743   -1.3609 H   0  0  0  0  0  0
   -3.0358   -0.6177   -0.4037 H   0  0  0  0  0  0
   -2.1951   -2.0156    0.2643 H   0  0  0  0  0  0
   -0.4014   -1.7834   -1.5074 H   0  0  0  0  0  0
   -1.1343   -0.2797   -2.0909 H   0  0  0  0  0  0
   -0.4142    1.9075   -0.7875 H   0  0  0  0  0  0
   -1.8750    1.2254   -0.0542 H   0  0  0  0  0  0
   -0.9069    2.8080    1.5945 H   0  0  0  0  0  0
    0.6479    2.0029    1.5422 H   0  0  0  0  0  0
   -0.7534    1.1717    2.2161 H   0  0  0  0  0  0
    1.4013    0.2042   -1.5099 H   0  0  0  0  0  0
    1.7331    0.6616    0.1678 H   0  0  0  0  0  0
    1.5538   -1.8762    0.7653 H   0  0  0  0  0  0
    1.6976   -2.2102   -0.9397 H   0  0  0  0  0  0
    3.7699   -1.5518    0.9024 H   0  0  0  0  0  0
    8.2965   -2.1097    0.8589 H   0  0  0  0  0  0
    5.9095    0.5956   -3.0179 H   0  0  0  0  0  0
    5.9493    1.6982   -1.6693 H   0  0  0  0  0  0
    8.2796    0.6897   -3.3445 H   0  0  0  0  0  0
    7.7742    2.3342   -3.0868 H   0  0  0  0  0  0
    9.7621    1.9296   -1.8618 H   0  0  0  0  0  0
    8.5108    2.1703   -0.6577 H   0  0  0  0  0  0
   11.4437    2.5064   -0.9218 H   0  0  0  0  0  0
   15.5145    1.3016   -0.6397 H   0  0  0  0  0  0
   14.8292   -1.0489   -0.2986 H   0  0  0  0  0  0
   12.6236   -2.6620   -0.0846 H   0  0  0  0  0  0
    4.8345   -3.5798    0.7505 H   0  0  0  0  0  0
    5.7447   -2.9688    2.1207 H   0  0  0  0  0  0
    6.4966   -4.0634    0.9744 H   0  0  0  0  0  0
   -0.3367   -0.6144    0.7152 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 32  1  0  0  0
  1 33  1  0  0  0
  1 34  1  0  0  0
  2  3  1  0  0  0
  2 35  1  0  0  0
  2 36  1  0  0  0
  3  4  1  0  0  0
  3  6  1  0  0  0
  3 61  1  0  0  0
  4  5  1  0  0  0
  4 37  1  0  0  0
  4 38  1  0  0  0
  5 39  1  0  0  0
  5 40  1  0  0  0
  5 41  1  0  0  0
  6  7  1  0  0  0
  6 42  1  0  0  0
  6 43  1  0  0  0
  7  8  1  0  0  0
  7 44  1  0  0  0
  7 45  1  0  0  0
  8  9  1  0  0  0
  8 46  1  0  0  0
  9 10  2  0  0  0
  9 11  1  0  0  0
 11 12  2  0  0  0
 11 15  1  0  0  0
 12 13  1  0  0  0
 12 31  1  0  0  0
 13 14  1  0  0  0
 13 47  1  0  0  0
 14 15  2  0  0  0
 14 19  1  0  0  0
 15 16  1  0  0  0
 16 17  1  0  0  0
 16 48  1  0  0  0
 16 49  1  0  0  0
 17 18  1  0  0  0
 17 50  1  0  0  0
 17 51  1  0  0  0
 18 19  1  0  0  0
 18 52  1  0  0  0
 18 53  1  0  0  0
 19 20  2  0  0  0
 20 21  1  0  0  0
 20 28  1  0  0  0
 21 22  2  0  0  0
 21 26  1  0  0  0
 22 23  1  0  0  0
 22 54  1  0  0  0
 23 24  2  0  0  0
 23 30  1  0  0  0
 24 25  1  0  0  0
 24 55  1  0  0  0
 25 26  2  0  0  0
 25 56  1  0  0  0
 26 27  1  0  0  0
 27 28  1  0  0  0
 27 57  1  0  0  0
 28 29  2  0  0  0
 31 58  1  0  0  0
 31 59  1  0  0  0
 31 60  1  0  0  0
M  CHG  1   3   1
M  END
> <s_m_entry_id>
54

> <Applicants>
Nanjing Yoko Biomedical

> <CHEMBL_ID>
CHEMBL2180602

> <Canonical_Smiles>
Fc1cc\2c(NC(=O)/C/2=C\2/CCCc3c/2[nH]c(C)c3C(=O)NCCN(CC)CC)cc1

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
1

> <SC_Patent>
None

> <Synonyms>
SIM 010603 | SIM-010603 | TAFETINIB

> <Indications>
nan

> <Type>
nan

> <targets_id>
P35968|P35916|P17948

> <inchi>
InChI=1S/C24H29FN4O2/c1-4-29(5-2)12-11-26-23(30)20-14(3)27-22-16(20)7-6-8-17(22)21-18-13-15(25)9-10-19(18)28-24(21)31/h9-10,13,27H,4-8,11-12H2,1-3H3,(H,26,30)(H,28,31)/b21-17-

> <stdInchikey>
KGSRYTUWXUESJK-FXBPSFAMSA-N

> <csid>
28664989

> <Links>
|http://www.chemspider.com/Chemical-Structure.28664989.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2180602|http://pubchem.ncbi.nlm.nih.gov/compound/56935577|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9921|http://zinc15.docking.org/substances/ZINC000095575309|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=H4X2M2NN5N|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50399535

> <LinkName>
|ChemSpider|ChEMBL|PubChem|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
424.2

> <HBA>
3

> <HBD>
3

> <NRB>
6

> <TPSA>
77.2

> <LogP>
3.7

> <RoF>
0

> <Targets>
KDR; FLT4; FLT1

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_epik_Ionization_Penalty>
  0.0058

> <r_epik_State_Penalty>
  0.0042

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
54

> <Kinase families>
Tyr

$$$$
Henatinib
                    3D
 Structure written by MMmdl.
 63 67  0  0  1  0            999 V2000
   -0.5441    3.8958    3.9186 C   0  0  0  0  0  0
   -0.3438    4.4974    2.5367 C   0  0  0  0  0  0
   -0.5099    5.8478    2.2163 C   0  0  0  0  0  0
   -0.2497    5.9604    0.8821 N   0  0  0  0  0  0
    0.0732    4.7610    0.3156 C   0  0  0  0  0  0
    0.0173    3.8056    1.3427 C   0  0  0  0  0  0
    0.3825    2.3906    1.2765 C   0  0  0  0  0  0
    0.9365    1.8926    2.2610 O   0  0  0  0  0  0
    0.0595    1.6953    0.1421 N   0  0  0  0  0  0
   -0.4997    2.2782   -1.0869 C   0  0  0  0  0  0
    0.4476    3.2860   -1.7619 C   0  0  0  0  0  0
    0.3680    4.6980   -1.1707 C   0  0  0  0  0  0
    0.3196    0.2406    0.1400 C   0  0  0  0  0  0
    1.7704   -0.1786   -0.2005 C   0  0  1  0  0  0
    1.9263   -1.7195   -0.1526 C   0  0  0  0  0  0
    3.2593   -2.2215   -0.5143 N   0  0  0  0  0  0
    3.2244   -3.6838   -0.6290 C   0  0  0  0  0  0
    4.6106   -4.2393   -1.0200 C   0  0  0  0  0  0
    5.6091   -3.8033   -0.1025 O   0  0  0  0  0  0
    5.6723   -2.3866    0.0342 C   0  0  0  0  0  0
    4.2992   -1.8055    0.4364 C   0  0  0  0  0  0
    2.1322    0.3164   -1.4780 O   0  0  0  0  0  0
   -0.8793    6.9933    3.0557 C   0  0  0  0  0  0
   -1.0464    8.3271    2.8618 C   0  0  0  0  0  0
   -1.4284    9.3226    3.8623 C   0  0  0  0  0  0
   -1.7252    9.2347    5.2260 C   0  0  0  0  0  0
   -2.0648   10.3936    5.9314 C   0  0  0  0  0  0
   -2.1057   11.6290    5.2761 C   0  0  0  0  0  0
   -1.8084   11.7119    3.9131 C   0  0  0  0  0  0
   -1.4732   10.5432    3.2299 C   0  0  0  0  0  0
   -1.1450   10.3556    1.9102 N   0  0  0  0  0  0
   -0.8807    9.0695    1.6137 C   0  0  0  0  0  0
   -0.5673    8.6771    0.4924 O   0  0  0  0  0  0
   -2.3544   10.3198    7.2501 F   0  0  0  0  0  0
   -0.9849    2.8998    3.8695 H   0  0  0  0  0  0
   -1.2131    4.4861    4.5440 H   0  0  0  0  0  0
    0.4013    3.8035    4.4534 H   0  0  0  0  0  0
   -0.2943    6.8328    0.3731 H   0  0  0  0  0  0
   -0.7104    1.4784   -1.7978 H   0  0  0  0  0  0
   -1.4655    2.7385   -0.8736 H   0  0  0  0  0  0
    1.4753    2.9252   -1.7023 H   0  0  0  0  0  0
    0.2244    3.3377   -2.8281 H   0  0  0  0  0  0
   -0.4246    5.2304   -1.6994 H   0  0  0  0  0  0
    1.2804    5.2448   -1.4118 H   0  0  0  0  0  0
    0.0533   -0.1774    1.1129 H   0  0  0  0  0  0
   -0.3603   -0.2371   -0.5668 H   0  0  0  0  0  0
    2.4287    0.2765    0.5396 H   0  0  0  0  0  0
    1.6712   -2.0772    0.8469 H   0  0  0  0  0  0
    1.1874   -2.1574   -0.8264 H   0  0  0  0  0  0
    2.8978   -4.1360    0.3093 H   0  0  0  0  0  0
    2.4961   -3.9770   -1.3864 H   0  0  0  0  0  0
    4.5868   -5.3290   -1.0178 H   0  0  0  0  0  0
    4.8742   -3.9438   -2.0371 H   0  0  0  0  0  0
    6.4153   -2.1421    0.7934 H   0  0  0  0  0  0
    6.0267   -1.9328   -0.8930 H   0  0  0  0  0  0
    4.3794   -0.7189    0.4564 H   0  0  0  0  0  0
    4.0438   -2.1205    1.4497 H   0  0  0  0  0  0
    1.5848   -0.1146   -2.1379 H   0  0  0  0  0  0
   -1.0522    6.6718    4.0715 H   0  0  0  0  0  0
   -1.6974    8.2872    5.7439 H   0  0  0  0  0  0
   -2.3678   12.5214    5.8252 H   0  0  0  0  0  0
   -1.8411   12.6682    3.4121 H   0  0  0  0  0  0
   -1.1044   11.0993    1.2288 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 35  1  0  0  0
  1 36  1  0  0  0
  1 37  1  0  0  0
  2  3  2  0  0  0
  2  6  1  0  0  0
  3  4  1  0  0  0
  3 23  1  0  0  0
  4  5  1  0  0  0
  4 38  1  0  0  0
  5  6  2  0  0  0
  5 12  1  0  0  0
  6  7  1  0  0  0
  7  8  2  0  0  0
  7  9  1  0  0  0
  9 10  1  0  0  0
  9 13  1  0  0  0
 10 11  1  0  0  0
 10 39  1  0  0  0
 10 40  1  0  0  0
 11 12  1  0  0  0
 11 41  1  0  0  0
 11 42  1  0  0  0
 12 43  1  0  0  0
 12 44  1  0  0  0
 13 14  1  0  0  0
 13 45  1  0  0  0
 13 46  1  0  0  0
 14 15  1  0  0  0
 14 22  1  0  0  0
 14 47  1  0  0  0
 15 16  1  0  0  0
 15 48  1  0  0  0
 15 49  1  0  0  0
 16 17  1  0  0  0
 16 21  1  0  0  0
 17 18  1  0  0  0
 17 50  1  0  0  0
 17 51  1  0  0  0
 18 19  1  0  0  0
 18 52  1  0  0  0
 18 53  1  0  0  0
 19 20  1  0  0  0
 20 21  1  0  0  0
 20 54  1  0  0  0
 20 55  1  0  0  0
 21 56  1  0  0  0
 21 57  1  0  0  0
 22 58  1  0  0  0
 23 24  2  0  0  0
 23 59  1  0  0  0
 24 25  1  0  0  0
 24 32  1  0  0  0
 25 26  2  0  0  0
 25 30  1  0  0  0
 26 27  1  0  0  0
 26 60  1  0  0  0
 27 28  2  0  0  0
 27 34  1  0  0  0
 28 29  1  0  0  0
 28 61  1  0  0  0
 29 30  2  0  0  0
 29 62  1  0  0  0
 30 31  1  0  0  0
 31 32  1  0  0  0
 31 63  1  0  0  0
 32 33  2  0  0  0
M  END
> <s_m_entry_id>
55

> <Applicants>
Jiangsu Hengrui Medicine

> <CHEMBL_ID>
CHEMBL3545416

> <Canonical_Smiles>
Fc1cc\2c(NC(=O)/C/2=C\c2[nH]c3c(c2C)C(=O)N(CCC3)C[C@H](O)CN2CCOCC2)cc1

> <Chirality>
Single Stereoisomer

> <First_Approval>
nan

> <Phase>
1

> <SC_Patent>
None

> <Indications>
nan

> <Type>
nan

> <targets_id>
P35968

> <inchi>
InChI=1S/C25H29FN4O4/c1-15-22(12-19-18-11-16(26)4-5-20(18)28-24(19)32)27-21-3-2-6-30(25(33)23(15)21)14-17(31)13-29-7-9-34-10-8-29/h4-5,11-12,17,27,31H,2-3,6-10,13-14H2,1H3,(H,28,32)/b19-12-/t17-/m1/s1

> <stdInchikey>
MCTXSDCWFQAGFS-UEXNTNOUSA-N

> <csid>
26354883

> <Links>
|http://www.chemspider.com/Chemical-Structure.26354883.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1277072|http://pubchem.ncbi.nlm.nih.gov/compound/25116064|http://www.drugbank.ca/drugs/DB13019|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9930|http://zinc15.docking.org/substances/ZINC000064454147|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=TE20GB753F|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50331032

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
468.2

> <HBA>
5

> <HBD>
3

> <NRB>
5

> <TPSA>
97.9

> <LogP>
2

> <RoF>
0

> <Targets>
KDR

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_epik_Ionization_Penalty>
  0.3045

> <r_epik_State_Penalty>
  0.2982

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
55

> <Kinase families>
Tyr

$$$$
Vecabrutinib
                    3D
 Structure written by MMmdl.
 60 63  0  0  1  0            999 V2000
   -4.4172   -2.4260    1.3133 C   0  0  0  0  0  0
   -5.3101   -3.3280    1.9059 C   0  0  0  0  0  0
   -5.7019   -4.4679    1.1930 C   0  0  0  0  0  0
   -5.2108   -4.6994   -0.0911 C   0  0  0  0  0  0
   -4.3243   -3.7939   -0.6722 C   0  0  0  0  0  0
   -3.9207   -2.6510    0.0221 C   0  0  0  0  0  0
   -3.0301   -1.7764   -0.6194 N   0  0  0  0  0  0
   -2.4503   -0.5219   -0.1724 C   0  0  2  0  0  0
   -2.9578    0.6090   -1.1017 C   0  0  0  0  0  0
   -2.0669    1.8680   -0.9917 C   0  0  0  0  0  0
   -1.0103    1.7856    0.1362 C   0  0  0  0  0  0
   -0.2362    0.5282    0.0007 N   0  0  0  0  0  0
   -0.9012   -0.6635   -0.0927 C   0  0  0  0  0  0
   -0.3648   -1.7762   -0.1260 O   0  0  0  0  0  0
    1.2409    0.5719    0.0681 C   0  0  1  0  0  0
    1.8655    1.2258   -1.1909 C   0  0  0  0  0  0
    3.3315    1.1118   -1.1997 N   0  0  0  0  0  0
    3.8665    1.8619   -0.0546 C   0  0  0  0  0  0
    3.3834    1.2542    1.2783 C   0  0  0  0  0  0
    1.8386    1.2254    1.3503 C   0  0  2  0  0  0
    1.3904    0.4749    2.6254 C   0  0  0  0  0  0
    1.6431   -0.7192    2.7771 O   0  0  0  0  0  0
    0.7161    1.1686    3.5468 N   0  0  0  0  0  0
    3.9851    1.2226   -2.4152 C   0  0  0  0  0  0
    4.6659    0.1273   -2.9655 C   0  0  0  0  0  0
    5.2969    0.3220   -4.2010 C   0  0  0  0  0  0
    5.2613    1.5131   -4.8523 N   0  0  0  0  0  0
    4.5792    2.5133   -4.2401 C   0  0  0  0  0  0
    3.9362    2.4296   -3.0486 N   0  0  0  0  0  0
    5.9933   -0.7158   -4.8173 N   0  0  0  0  0  0
    4.7112   -1.0696   -2.3292 F   0  0  0  0  0  0
   -5.7006   -6.1066   -0.9624 Cl  0  0  0  0  0  0
   -5.8325   -3.0568    3.3158 C   0  0  0  0  0  0
   -6.5499   -4.0728    3.7995 F   0  0  0  0  0  0
   -4.8110   -2.8395    4.1452 F   0  0  0  0  0  0
   -6.6053   -1.9706    3.2982 F   0  0  0  0  0  0
   -4.1237   -1.5533    1.8757 H   0  0  0  0  0  0
   -6.3892   -5.1787    1.6284 H   0  0  0  0  0  0
   -3.9505   -3.9849   -1.6683 H   0  0  0  0  0  0
   -2.7654   -2.0485   -1.5551 H   0  0  0  0  0  0
   -2.7714   -0.3052    0.8453 H   0  0  0  0  0  0
   -2.9762    0.2600   -2.1367 H   0  0  0  0  0  0
   -3.9860    0.8359   -0.8144 H   0  0  0  0  0  0
   -1.5496    2.0215   -1.9404 H   0  0  0  0  0  0
   -2.6875    2.7532   -0.8485 H   0  0  0  0  0  0
   -0.3472    2.6495    0.0861 H   0  0  0  0  0  0
   -1.4847    1.8057    1.1186 H   0  0  0  0  0  0
    1.6013   -0.4590    0.0568 H   0  0  0  0  0  0
    1.4700    0.7236   -2.0758 H   0  0  0  0  0  0
    1.5709    2.2738   -1.2712 H   0  0  0  0  0  0
    4.9572    1.8372   -0.0801 H   0  0  0  0  0  0
    3.5717    2.9107   -0.1264 H   0  0  0  0  0  0
    3.7967    0.2468    1.3668 H   0  0  0  0  0  0
    3.7942    1.8284    2.1103 H   0  0  0  0  0  0
    1.4755    2.2512    1.4399 H   0  0  0  0  0  0
    0.5169    2.1481    3.4073 H   0  0  0  0  0  0
    0.4042    0.7130    4.3920 H   0  0  0  0  0  0
    4.5448    3.4653   -4.7497 H   0  0  0  0  0  0
    6.0390   -1.6192   -4.3687 H   0  0  0  0  0  0
    6.4273   -0.5542   -5.7144 H   0  0  0  0  0  0
  1  2  2  0  0  0
  1  6  1  0  0  0
  1 37  1  0  0  0
  2  3  1  0  0  0
  2 33  1  0  0  0
  3  4  2  0  0  0
  3 38  1  0  0  0
  4  5  1  0  0  0
  4 32  1  0  0  0
  5  6  2  0  0  0
  5 39  1  0  0  0
  6  7  1  0  0  0
  7  8  1  0  0  0
  7 40  1  0  0  0
  8  9  1  0  0  0
  8 13  1  0  0  0
  8 41  1  0  0  0
  9 10  1  0  0  0
  9 42  1  0  0  0
  9 43  1  0  0  0
 10 11  1  0  0  0
 10 44  1  0  0  0
 10 45  1  0  0  0
 11 12  1  0  0  0
 11 46  1  0  0  0
 11 47  1  0  0  0
 12 13  1  0  0  0
 12 15  1  0  0  0
 13 14  2  0  0  0
 15 16  1  0  0  0
 15 20  1  0  0  0
 15 48  1  0  0  0
 16 17  1  0  0  0
 16 49  1  0  0  0
 16 50  1  0  0  0
 17 18  1  0  0  0
 17 24  1  0  0  0
 18 19  1  0  0  0
 18 51  1  0  0  0
 18 52  1  0  0  0
 19 20  1  0  0  0
 19 53  1  0  0  0
 19 54  1  0  0  0
 20 21  1  0  0  0
 20 55  1  0  0  0
 21 22  2  0  0  0
 21 23  1  0  0  0
 23 56  1  0  0  0
 23 57  1  0  0  0
 24 25  1  0  0  0
 24 29  2  0  0  0
 25 26  2  0  0  0
 25 31  1  0  0  0
 26 27  1  0  0  0
 26 30  1  0  0  0
 27 28  2  0  0  0
 28 29  1  0  0  0
 28 58  1  0  0  0
 30 59  1  0  0  0
 30 60  1  0  0  0
 33 34  1  0  0  0
 33 35  1  0  0  0
 33 36  1  0  0  0
M  END
> <s_m_entry_id>
57

> <Applicants>
Sunesis Pharmaceuticals

> <CHEMBL_ID>
CHEMBL4297640

> <Canonical_Smiles>
Clc1cc(cc(N[C@@H]2CCCN([C@H]3CN(CC[C@@H]3C(=O)N)c3ncnc(N)c3F)C2=O)c1)C(F)(F)F

> <Chirality>
Single Stereoisomer

> <First_Approval>
nan

> <Phase>
1

> <SC_Patent>
None

> <Synonyms>
BIIB-062 | BSK-4841 | FP-0182 | FP0182 | SNS-062 | VECABRUTINIB

> <Indications>
nan

> <Type>
nan

> <targets_id>
nan

> <inchi>
InChI=1S/C22H24ClF4N7O2/c23-12-6-11(22(25,26)27)7-13(8-12)32-15-2-1-4-34(21(15)36)16-9-33(5-3-14(16)19(29)35)20-17(24)18(28)30-10-31-20/h6-8,10,14-16,32H,1-5,9H2,(H2,29,35)(H2,28,30,31)/t14-,15+,16-/m0/s1

> <stdInchikey>
QLRRJMOBVVGXEJ-XHSDSOJGSA-N

> <csid>
64835225

> <Links>
|http://www.chemspider.com/Chemical-Structure.64835225.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4297640|http://pubchem.ncbi.nlm.nih.gov/compound/72547837|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10231|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=PQ7O0OB5GU

> <LinkName>
|ChemSpider|ChEMBL|PubChem|Guide to Pharmacology|FDA SRS

> <indicationG2P>
None

> <MW>
529.2

> <HBA>
7

> <HBD>
3

> <NRB>
5

> <TPSA>
130.5

> <LogP>
2.7

> <RoF>
1

> <Targets>
nan

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0074

> <r_epik_State_Penalty>
  0.0055

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
57

$$$$
Repotrectinib
                    3D
 Structure written by MMmdl.
 44 47  0  0  1  0            999 V2000
   -0.0613   -0.1411   -0.1021 C   0  0  0  0  0  0
    1.4694   -0.0022   -0.0699 C   0  0  2  0  0  0
    1.9626    0.9103   -1.2229 C   0  0  0  0  0  0
    3.3294    1.4119   -1.0533 N   0  0  0  0  0  0
    4.2518    1.6756   -2.0016 C   0  0  0  0  0  0
    5.1600    2.4785   -1.7960 O   0  0  0  0  0  0
    4.2049    0.9469   -3.2437 C   0  0  0  0  0  0
    4.0042   -0.4294   -3.5333 C   0  0  0  0  0  0
    3.7443   -1.5001   -2.7784 N   0  0  0  0  0  0
    3.6669   -2.7244   -3.3729 C   0  0  0  0  0  0
    3.8357   -2.8969   -4.7517 C   0  0  0  0  0  0
    4.0897   -1.7756   -5.5418 C   0  0  0  0  0  0
    4.1777   -0.5593   -4.9171 N   0  0  0  0  0  0
    4.4517    0.6231   -5.5043 N   0  0  0  0  0  0
    4.4883    1.4867   -4.5079 C   0  0  0  0  0  0
    3.4111   -3.8673   -2.5894 N   0  0  0  0  0  0
    2.8818   -3.8172   -1.2175 C   0  0  2  0  0  0
    3.7194   -2.9465   -0.2585 C   0  0  0  0  0  0
    3.2214   -1.7188    0.2244 C   0  0  0  0  0  0
    1.9578   -1.3406   -0.1940 O   0  0  0  0  0  0
    4.0220   -0.9490    1.0851 C   0  0  0  0  0  0
    5.2938   -1.3844    1.4518 C   0  0  0  0  0  0
    5.7846   -2.5928    0.9665 C   0  0  0  0  0  0
    5.0021   -3.3687    0.1157 C   0  0  0  0  0  0
    7.0208   -3.0119    1.3195 F   0  0  0  0  0  0
    2.6520   -5.2322   -0.6561 C   0  0  0  0  0  0
   -0.5507    0.8268    0.0121 H   0  0  0  0  0  0
   -0.4133   -0.7818    0.7074 H   0  0  0  0  0  0
   -0.4026   -0.5778   -1.0417 H   0  0  0  0  0  0
    1.7121    0.4367    0.8975 H   0  0  0  0  0  0
    1.8041    0.4154   -2.1809 H   0  0  0  0  0  0
    1.3357    1.8026   -1.2576 H   0  0  0  0  0  0
    3.4911    1.8574   -0.1618 H   0  0  0  0  0  0
    3.7702   -3.8755   -5.2053 H   0  0  0  0  0  0
    4.2370   -1.8078   -6.6118 H   0  0  0  0  0  0
    4.7254    2.5241   -4.6982 H   0  0  0  0  0  0
    3.1338   -4.6799   -3.1203 H   0  0  0  0  0  0
    1.8890   -3.3783   -1.3153 H   0  0  0  0  0  0
    3.6844   -0.0048    1.4803 H   0  0  0  0  0  0
    5.9005   -0.7812    2.1109 H   0  0  0  0  0  0
    5.3992   -4.3001   -0.2602 H   0  0  0  0  0  0
    2.1977   -5.1909    0.3346 H   0  0  0  0  0  0
    3.5821   -5.7954   -0.5711 H   0  0  0  0  0  0
    1.9795   -5.8051   -1.2958 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 27  1  0  0  0
  1 28  1  0  0  0
  1 29  1  0  0  0
  2  3  1  0  0  0
  2 20  1  0  0  0
  2 30  1  0  0  0
  3  4  1  0  0  0
  3 31  1  0  0  0
  3 32  1  0  0  0
  4  5  1  0  0  0
  4 33  1  0  0  0
  5  6  2  0  0  0
  5  7  1  0  0  0
  7  8  2  0  0  0
  7 15  1  0  0  0
  8  9  1  0  0  0
  8 13  1  0  0  0
  9 10  2  0  0  0
 10 11  1  0  0  0
 10 16  1  0  0  0
 11 12  2  0  0  0
 11 34  1  0  0  0
 12 13  1  0  0  0
 12 35  1  0  0  0
 13 14  1  0  0  0
 14 15  2  0  0  0
 15 36  1  0  0  0
 16 17  1  0  0  0
 16 37  1  0  0  0
 17 18  1  0  0  0
 17 26  1  0  0  0
 17 38  1  0  0  0
 18 19  1  0  0  0
 18 24  2  0  0  0
 19 20  1  0  0  0
 19 21  2  0  0  0
 21 22  1  0  0  0
 21 39  1  0  0  0
 22 23  2  0  0  0
 22 40  1  0  0  0
 23 24  1  0  0  0
 23 25  1  0  0  0
 24 41  1  0  0  0
 26 42  1  0  0  0
 26 43  1  0  0  0
 26 44  1  0  0  0
M  END
> <s_m_entry_id>
58

> <Applicants>
TP Therapeutics

> <CHEMBL_ID>
CHEMBL4298138

> <Canonical_Smiles>
Fc1cc2c(OC(CNC(=O)c3c4n(nc3)C=CC(NC2C)=N4)C)cc1

> <Chirality>
Single Stereoisomer

> <First_Approval>
nan

> <Phase>
1

> <SC_Patent>
None

> <Synonyms>
REPOTRECTINIB | TPX-0005 | TRX-0005

> <Indications>
nan

> <Type>
nan

> <targets_id>
nan

> <inchi>
InChI=1S/C18H18FN5O2/c1-10-8-20-18(25)14-9-21-24-6-5-16(23-17(14)24)22-11(2)13-7-12(19)3-4-15(13)26-10/h3-7,9-11,21H,8H2,1-2H3,(H,20,25)/b22-16-

> <stdInchikey>
FIKPXCOQUIZNHB-WDEREUQCSA-N

> <csid>
71084199

> <Links>
|http://www.chemspider.com/Chemical-Structure.71084199.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4298138|http://pubchem.ncbi.nlm.nih.gov/compound/135565923|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10316|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=08O3FQ4UNP

> <LinkName>
|ChemSpider|ChEMBL|PubChem|Guide to Pharmacology|FDA SRS

> <indicationG2P>
None

> <MW>
355.1

> <HBA>
6

> <HBD>
2

> <NRB>
0

> <TPSA>
80.6

> <LogP>
2.6

> <RoF>
0

> <Targets>
nan

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0000

> <r_epik_State_Penalty>
  0.0000

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
58

$$$$
Ningetinib
                    3D
 Structure written by MMmdl.
 70 74  0  0  1  0            999 V2000
   -1.5663   10.2220   -0.2595 C   0  0  0  0  0  0
   -2.7701    9.3411    0.0636 C   0  0  0  0  0  0
   -3.0432    8.0228   -0.1070 C   0  0  0  0  0  0
   -4.3410    7.7305    0.4843 C   0  0  0  0  0  0
   -4.9042    6.6363    0.5588 O   0  0  0  0  0  0
   -4.7922    8.9122    0.9548 N   0  0  0  0  0  0
   -3.8509    9.9071    0.7174 N   0  0  0  0  0  0
   -4.4629   11.1029    0.1294 C   0  0  0  0  0  0
   -5.9302    9.1082    1.7793 C   0  0  0  0  0  0
   -7.1500    8.4862    1.4729 C   0  0  0  0  0  0
   -8.2621    8.6864    2.2859 C   0  0  0  0  0  0
   -8.1603    9.5079    3.4057 C   0  0  0  0  0  0
   -6.9563   10.1328    3.7202 C   0  0  0  0  0  0
   -5.8426    9.9351    2.9087 C   0  0  0  0  0  0
   -2.0952    7.1383   -0.7718 C   0  0  0  0  0  0
   -1.3268    7.5325   -1.6520 O   0  0  0  0  0  0
   -2.1367    5.8603   -0.3299 N   0  0  0  0  0  0
   -1.4039    4.7533   -0.7917 C   0  0  0  0  0  0
   -1.1870    3.7139    0.1178 C   0  0  0  0  0  0
   -0.4902    2.5696   -0.2705 C   0  0  0  0  0  0
   -0.0106    2.4485   -1.5760 C   0  0  0  0  0  0
   -0.2412    3.4746   -2.4973 C   0  0  0  0  0  0
   -0.9345    4.6214   -2.1091 C   0  0  0  0  0  0
    0.2026    3.3587   -3.7704 F   0  0  0  0  0  0
    0.6566    1.3084   -1.9562 O   0  0  0  0  0  0
    2.0367    1.2293   -1.8918 C   0  0  0  0  0  0
    2.8519    2.2631   -1.4063 C   0  0  0  0  0  0
    4.2320    2.0959   -1.3852 C   0  0  0  0  0  0
    4.8565    0.9747   -1.8137 N   0  0  0  0  0  0
    4.0935   -0.0467   -2.2907 C   0  0  0  0  0  0
    2.6679    0.0344   -2.3466 C   0  0  0  0  0  0
    1.9450   -1.0747   -2.8542 C   0  0  0  0  0  0
    2.6162   -2.2127   -3.2910 C   0  0  0  0  0  0
    4.0056   -2.2997   -3.2478 C   0  0  0  0  0  0
    4.7447   -1.2189   -2.7451 C   0  0  0  0  0  0
    4.5620   -3.4746   -3.7149 O   0  0  0  0  0  0
    5.9827   -3.6092   -3.7665 C   0  0  0  0  0  0
    6.3850   -4.9794   -4.3634 C   0  0  0  0  0  0
    7.9191   -5.1275   -4.3993 C   0  0  0  0  0  0
    5.7395   -6.1560   -3.6025 C   0  0  0  0  0  0
    5.9377   -5.0275   -5.7063 O   0  0  0  0  0  0
   -0.6616    9.6384   -0.4236 H   0  0  0  0  0  0
   -1.3602   10.9050    0.5654 H   0  0  0  0  0  0
   -1.7581   10.8133   -1.1550 H   0  0  0  0  0  0
   -3.7079   11.8580   -0.0915 H   0  0  0  0  0  0
   -5.1764   11.5664    0.8109 H   0  0  0  0  0  0
   -4.9758   10.8647   -0.8040 H   0  0  0  0  0  0
   -7.2459    7.8536    0.6022 H   0  0  0  0  0  0
   -9.2004    8.2076    2.0474 H   0  0  0  0  0  0
   -9.0240    9.6619    4.0359 H   0  0  0  0  0  0
   -6.8862   10.7679    4.5909 H   0  0  0  0  0  0
   -4.9126   10.4216    3.1660 H   0  0  0  0  0  0
   -2.6956    5.6884    0.4933 H   0  0  0  0  0  0
   -1.5549    3.7873    1.1314 H   0  0  0  0  0  0
   -0.3252    1.7737    0.4411 H   0  0  0  0  0  0
   -1.1146    5.3868   -2.8485 H   0  0  0  0  0  0
    2.4308    3.1903   -1.0475 H   0  0  0  0  0  0
    4.8708    2.8844   -1.0149 H   0  0  0  0  0  0
    0.8665   -1.0358   -2.9053 H   0  0  0  0  0  0
    2.0442   -3.0444   -3.6761 H   0  0  0  0  0  0
    5.8229   -1.2539   -2.6939 H   0  0  0  0  0  0
    6.4127   -2.8018   -4.3635 H   0  0  0  0  0  0
    6.3900   -3.5191   -2.7574 H   0  0  0  0  0  0
    8.3410   -5.1075   -3.3936 H   0  0  0  0  0  0
    8.3888   -4.3206   -4.9642 H   0  0  0  0  0  0
    8.2236   -6.0687   -4.8599 H   0  0  0  0  0  0
    6.0420   -6.1601   -2.5547 H   0  0  0  0  0  0
    6.0276   -7.1179   -4.0288 H   0  0  0  0  0  0
    4.6501   -6.1046   -3.6258 H   0  0  0  0  0  0
    6.1835   -5.8771   -6.0791 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 42  1  0  0  0
  1 43  1  0  0  0
  1 44  1  0  0  0
  2  3  2  0  0  0
  2  7  1  0  0  0
  3  4  1  0  0  0
  3 15  1  0  0  0
  4  5  2  0  0  0
  4  6  1  0  0  0
  6  7  1  0  0  0
  6  9  1  0  0  0
  7  8  1  0  0  0
  8 45  1  0  0  0
  8 46  1  0  0  0
  8 47  1  0  0  0
  9 10  1  0  0  0
  9 14  2  0  0  0
 10 11  2  0  0  0
 10 48  1  0  0  0
 11 12  1  0  0  0
 11 49  1  0  0  0
 12 13  2  0  0  0
 12 50  1  0  0  0
 13 14  1  0  0  0
 13 51  1  0  0  0
 14 52  1  0  0  0
 15 16  2  0  0  0
 15 17  1  0  0  0
 17 18  1  0  0  0
 17 53  1  0  0  0
 18 19  1  0  0  0
 18 23  2  0  0  0
 19 20  2  0  0  0
 19 54  1  0  0  0
 20 21  1  0  0  0
 20 55  1  0  0  0
 21 22  2  0  0  0
 21 25  1  0  0  0
 22 23  1  0  0  0
 22 24  1  0  0  0
 23 56  1  0  0  0
 25 26  1  0  0  0
 26 27  2  0  0  0
 26 31  1  0  0  0
 27 28  1  0  0  0
 27 57  1  0  0  0
 28 29  2  0  0  0
 28 58  1  0  0  0
 29 30  1  0  0  0
 30 31  1  0  0  0
 30 35  2  0  0  0
 31 32  2  0  0  0
 32 33  1  0  0  0
 32 59  1  0  0  0
 33 34  2  0  0  0
 33 60  1  0  0  0
 34 35  1  0  0  0
 34 36  1  0  0  0
 35 61  1  0  0  0
 36 37  1  0  0  0
 37 38  1  0  0  0
 37 62  1  0  0  0
 37 63  1  0  0  0
 38 39  1  0  0  0
 38 40  1  0  0  0
 38 41  1  0  0  0
 39 64  1  0  0  0
 39 65  1  0  0  0
 39 66  1  0  0  0
 40 67  1  0  0  0
 40 68  1  0  0  0
 40 69  1  0  0  0
 41 70  1  0  0  0
M  END
> <s_m_entry_id>
62

> <Applicants>
HEC Pharm

> <CHEMBL_ID>
nan

> <Canonical_Smiles>
Fc1cc(NC(=O)C=2C(=O)N(N(C)C=2C)c2ccccc2)ccc1Oc1c2c(ncc1)cc(OCC(O)(C)C)cc2

> <Chirality>
nan

> <First_Approval>
nan

> <Phase>
1.5

> <SC_Patent>
nan

> <Indications>
Ningetinib, also known as CT-053 or DE-120, is a VEGF and PDGF inhibitor potentially for the treatment of wet age-related macular degeneration.

> <Type>
nan

> <targets_id>
nan

> <inchi>
InChI=1S/C31H29FN4O5/c1-19-28(30(38)36(35(19)4)21-8-6-5-7-9-21)29(37)34-20-10-13-27(24(32)16-20)41-26-14-15-33-25-17-22(11-12-23(25)26)40-18-31(2,3)39/h5-17,39H,18H2,1-4H3,(H,34,37)

> <stdInchikey>
VQYYQSZNRVQLIS-UHFFFAOYSA-N

> <csid>
61719564

> <Links>
|http://www.chemspider.com/Chemical-Structure.61719564.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3984441|http://pubchem.ncbi.nlm.nih.gov/compound/60165029|http://zinc15.docking.org/substances/ZINC000143426755|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=PW3Q92Z6A4|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=180270

> <LinkName>
|ChemSpider|ChEMBL|PubChem|ZINC|FDA SRS|BindingDB

> <MW>
556.2

> <HBA>
8

> <HBD>
2

> <NRB>
8

> <TPSA>
107.6

> <LogP>
5.4

> <RoF>
2

> <Targets>
nan

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.2722

> <r_epik_State_Penalty>
  0.2644

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
62

$$$$
Selitrectinib
                    3D
 Structure written by MMmdl.
 49 53  0  0  1  0            999 V2000
   -0.1219    0.1114   -0.3678 C   0  0  0  0  0  0
    1.3967   -0.0863   -0.2032 C   0  0  2  0  0  0
    2.1870    0.5080   -1.3974 C   0  0  0  0  0  0
    3.5866    1.0527   -1.0125 C   0  0  0  0  0  0
    3.5936    2.3457   -0.1787 C   0  0  0  0  0  0
    4.5962    2.6627    0.7672 C   0  0  0  0  0  0
    4.4722    3.8796    1.4588 C   0  0  0  0  0  0
    3.4028    4.7345    1.2043 C   0  0  0  0  0  0
    2.4667    4.3562    0.2492 C   0  0  0  0  0  0
    2.5552    3.1918   -0.4355 N   0  0  0  0  0  0
    3.2805    5.9066    1.8672 F   0  0  0  0  0  0
    5.8012    1.7508    1.0769 C   0  0  1  0  0  0
    7.1737    2.4200    0.8475 C   0  0  0  0  0  0
    7.9566    2.1340    2.1167 C   0  0  0  0  0  0
    6.8538    1.9565    3.1504 C   0  0  0  0  0  0
    5.7770    1.2453    2.4642 N   0  0  0  0  0  0
    4.6610    0.6586    3.0848 C   0  0  0  0  0  0
    4.4118    0.8236    4.4552 C   0  0  0  0  0  0
    3.2973    0.2036    5.0135 C   0  0  0  0  0  0
    2.5187   -0.5684    4.1949 N   0  0  0  0  0  0
    2.8144   -0.7330    2.8332 C   0  0  0  0  0  0
    3.8716   -0.1176    2.2830 N   0  0  0  0  0  0
    1.8338   -1.6424    2.3451 C   0  0  0  0  0  0
    1.0508   -1.9010    3.4790 C   0  0  0  0  0  0
    1.4278   -1.2662    4.5699 N   0  0  0  0  0  0
    1.6510   -2.2722    1.0665 C   0  0  0  0  0  0
    1.5106   -3.4914    0.9959 O   0  0  0  0  0  0
    1.7164   -1.5100   -0.0425 N   0  0  0  0  0  0
   -0.3734    1.1688   -0.4586 H   0  0  0  0  0  0
   -0.6677   -0.2769    0.4933 H   0  0  0  0  0  0
   -0.4984   -0.3974   -1.2562 H   0  0  0  0  0  0
    1.6770    0.4677    0.6925 H   0  0  0  0  0  0
    2.3011   -0.2487   -2.1756 H   0  0  0  0  0  0
    1.6118    1.2958   -1.8858 H   0  0  0  0  0  0
    4.1064    0.2456   -0.5019 H   0  0  0  0  0  0
    4.1549    1.2538   -1.9212 H   0  0  0  0  0  0
    5.2071    4.1714    2.1934 H   0  0  0  0  0  0
    1.6243    4.9913    0.0179 H   0  0  0  0  0  0
    5.7816    0.8688    0.4430 H   0  0  0  0  0  0
    7.6791    2.0317   -0.0376 H   0  0  0  0  0  0
    7.0801    3.4985    0.7115 H   0  0  0  0  0  0
    8.5232    1.2068    2.0120 H   0  0  0  0  0  0
    8.6585    2.9272    2.3762 H   0  0  0  0  0  0
    7.2029    1.3943    4.0175 H   0  0  0  0  0  0
    6.4887    2.9161    3.5185 H   0  0  0  0  0  0
    5.0526    1.4306    5.0771 H   0  0  0  0  0  0
    3.0194    0.2791    6.0548 H   0  0  0  0  0  0
    0.2011   -2.5687    3.5059 H   0  0  0  0  0  0
    1.7633   -2.0163   -0.9147 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 29  1  0  0  0
  1 30  1  0  0  0
  1 31  1  0  0  0
  2  3  1  0  0  0
  2 28  1  0  0  0
  2 32  1  0  0  0
  3  4  1  0  0  0
  3 33  1  0  0  0
  3 34  1  0  0  0
  4  5  1  0  0  0
  4 35  1  0  0  0
  4 36  1  0  0  0
  5  6  1  0  0  0
  5 10  2  0  0  0
  6  7  2  0  0  0
  6 12  1  0  0  0
  7  8  1  0  0  0
  7 37  1  0  0  0
  8  9  2  0  0  0
  8 11  1  0  0  0
  9 10  1  0  0  0
  9 38  1  0  0  0
 12 13  1  0  0  0
 12 16  1  0  0  0
 12 39  1  0  0  0
 13 14  1  0  0  0
 13 40  1  0  0  0
 13 41  1  0  0  0
 14 15  1  0  0  0
 14 42  1  0  0  0
 14 43  1  0  0  0
 15 16  1  0  0  0
 15 44  1  0  0  0
 15 45  1  0  0  0
 16 17  1  0  0  0
 17 18  1  0  0  0
 17 22  2  0  0  0
 18 19  2  0  0  0
 18 46  1  0  0  0
 19 20  1  0  0  0
 19 47  1  0  0  0
 20 21  1  0  0  0
 20 25  1  0  0  0
 21 22  1  0  0  0
 21 23  2  0  0  0
 23 24  1  0  0  0
 23 26  1  0  0  0
 24 25  2  0  0  0
 24 48  1  0  0  0
 26 27  2  0  0  0
 26 28  1  0  0  0
 28 49  1  0  0  0
M  END
> <s_m_entry_id>
64

> <Applicants>
Bayer

> <CHEMBL_ID>
CHEMBL4297627

> <Canonical_Smiles>
Fc1cc2[C@@H]3N(C4=Nc5n(ncc5C(=O)N[C@@H](CCc2nc1)C)C=C4)CCC3

> <Chirality>
Single Stereoisomer

> <First_Approval>
nan

> <Phase>
1.5

> <SC_Patent>
None

> <Synonyms>
LOXO-195 | SELITRECTINIB

> <Indications>
nan

> <Type>
nan

> <targets_id>
nan

> <inchi>
InChI=1S/C20H21FN6O/c1-12-4-5-16-14(9-13(21)10-22-16)17-3-2-7-26(17)18-6-8-27-19(25-18)15(11-23-27)20(28)24-12/h6,8-12,17H,2-5,7H2,1H3,(H,24,28)/t12-,17-/m1/s1

> <stdInchikey>
OEBIHOVSAMBXIB-SJKOYZFVSA-N

> <csid>
64853862

> <Links>
|http://www.chemspider.com/Chemical-Structure.64853862.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4297627|http://pubchem.ncbi.nlm.nih.gov/compound/129103609|http://www.drugbank.ca/drugs/DB14896|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10314|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=0J45910S3X

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|FDA SRS

> <indicationG2P>
None

> <MW>
380.2

> <HBA>
6

> <HBD>
1

> <NRB>
0

> <TPSA>
75.4

> <LogP>
2.7

> <RoF>
0

> <Targets>
nan

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_epik_Ionization_Penalty>
  0.0041

> <r_epik_State_Penalty>
  0.0027

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
64

$$$$
Lerociclib
                    3D
 Structure written by MMmdl.
 70 75  0  0  1  0            999 V2000
    1.5005   -1.5033    1.9495 C   0  0  0  0  0  0
    0.6675   -0.5644    1.0493 C   0  0  0  0  0  0
   -0.6790   -1.2245    0.6797 C   0  0  0  0  0  0
    1.4626   -0.1770   -0.2364 N   0  3  0  0  0  0
    2.8552    0.4281    0.1029 C   0  0  0  0  0  0
    3.5291    0.9820   -1.1716 C   0  0  0  0  0  0
    2.6655    1.9953   -1.7900 N   0  0  0  0  0  0
    1.5057    1.2752   -2.3294 C   0  0  0  0  0  0
    0.6310    0.7486   -1.1706 C   0  0  0  0  0  0
    2.6646    3.3515   -1.4457 C   0  0  0  0  0  0
    3.6943    3.9259   -0.6802 C   0  0  0  0  0  0
    3.6751    5.2840   -0.3627 C   0  0  0  0  0  0
    2.6205    6.0762   -0.8295 C   0  0  0  0  0  0
    1.6019    5.5446   -1.5485 N   0  0  0  0  0  0
    1.6381    4.2223   -1.8503 C   0  0  0  0  0  0
    2.5170    7.4501   -0.5605 N   0  0  0  0  0  0
    3.4704    8.4217   -0.2229 C   0  0  0  0  0  0
    2.9534    9.6126    0.1708 N   0  0  0  0  0  0
    3.8266   10.6044    0.4759 C   0  0  0  0  0  0
    5.2119   10.4101    0.3785 C   0  0  0  0  0  0
    6.3810   11.1931    0.5769 C   0  0  0  0  0  0
    7.4764   10.3986    0.2795 C   0  0  0  0  0  0
    7.0348    9.1158   -0.0716 N   0  0  0  0  0  0
    5.6374    9.1232   -0.0416 C   0  0  0  0  0  0
    4.7945    8.1279   -0.3534 N   0  0  0  0  0  0
    7.9668    8.0196   -0.4717 C   0  0  0  0  0  0
    8.1534    8.0396   -2.0197 C   0  0  0  0  0  0
    9.0580    6.9051   -2.5509 C   0  0  0  0  0  0
    8.5874    5.5161   -2.0791 C   0  0  0  0  0  0
    8.3957    5.4577   -0.5519 C   0  0  0  0  0  0
    7.4735    6.5941   -0.0615 C   0  0  0  0  0  0
    9.2850    8.3372    0.3139 C   0  0  0  0  0  0
    9.7051    9.7266    0.0958 N   0  0  0  0  0  0
    8.8769   10.7862    0.2320 C   0  0  0  0  0  0
    9.3381   11.9251    0.2558 O   0  0  0  0  0  0
    0.9070   -1.8690    2.7882 H   0  0  0  0  0  0
    2.3626   -0.9987    2.3857 H   0  0  0  0  0  0
    1.8593   -2.3739    1.3990 H   0  0  0  0  0  0
    0.4909    0.3828    1.5630 H   0  0  0  0  0  0
   -1.1871   -1.6022    1.5679 H   0  0  0  0  0  0
   -0.5398   -2.0665    0.0004 H   0  0  0  0  0  0
   -1.3685   -0.5219    0.2121 H   0  0  0  0  0  0
    2.7030    1.2053    0.8544 H   0  0  0  0  0  0
    3.4596   -0.3728    0.5279 H   0  0  0  0  0  0
    4.5221    1.3738   -0.9578 H   0  0  0  0  0  0
    3.7115    0.1627   -1.8700 H   0  0  0  0  0  0
    0.9281    1.8954   -3.0128 H   0  0  0  0  0  0
    1.8344    0.4356   -2.9451 H   0  0  0  0  0  0
   -0.1927    0.1537   -1.5641 H   0  0  0  0  0  0
    0.2316    1.5612   -0.5603 H   0  0  0  0  0  0
    4.5218    3.3411   -0.3111 H   0  0  0  0  0  0
    4.4627    5.6901    0.2516 H   0  0  0  0  0  0
    0.7979    3.8852   -2.4366 H   0  0  0  0  0  0
    1.5731    7.8048   -0.5957 H   0  0  0  0  0  0
    3.4082   11.5516    0.7832 H   0  0  0  0  0  0
    6.4308   12.2304    0.8754 H   0  0  0  0  0  0
    7.1766    7.9567   -2.5002 H   0  0  0  0  0  0
    8.5546    9.0004   -2.3457 H   0  0  0  0  0  0
    9.0838    6.9336   -3.6409 H   0  0  0  0  0  0
   10.0857    7.0708   -2.2261 H   0  0  0  0  0  0
    7.6423    5.2739   -2.5681 H   0  0  0  0  0  0
    9.2975    4.7518   -2.3972 H   0  0  0  0  0  0
    7.9711    4.4924   -0.2732 H   0  0  0  0  0  0
    9.3634    5.5110   -0.0527 H   0  0  0  0  0  0
    7.3373    6.5292    1.0191 H   0  0  0  0  0  0
    6.5036    6.3826   -0.5014 H   0  0  0  0  0  0
    9.1544    8.1773    1.3865 H   0  0  0  0  0  0
   10.1063    7.6893    0.0100 H   0  0  0  0  0  0
   10.6921    9.9155   -0.0021 H   0  0  0  0  0  0
    1.6355   -1.0287   -0.7519 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 36  1  0  0  0
  1 37  1  0  0  0
  1 38  1  0  0  0
  2  3  1  0  0  0
  2  4  1  0  0  0
  2 39  1  0  0  0
  3 40  1  0  0  0
  3 41  1  0  0  0
  3 42  1  0  0  0
  4  5  1  0  0  0
  4  9  1  0  0  0
  4 70  1  0  0  0
  5  6  1  0  0  0
  5 43  1  0  0  0
  5 44  1  0  0  0
  6  7  1  0  0  0
  6 45  1  0  0  0
  6 46  1  0  0  0
  7  8  1  0  0  0
  7 10  1  0  0  0
  8  9  1  0  0  0
  8 47  1  0  0  0
  8 48  1  0  0  0
  9 49  1  0  0  0
  9 50  1  0  0  0
 10 11  1  0  0  0
 10 15  2  0  0  0
 11 12  2  0  0  0
 11 51  1  0  0  0
 12 13  1  0  0  0
 12 52  1  0  0  0
 13 14  2  0  0  0
 13 16  1  0  0  0
 14 15  1  0  0  0
 15 53  1  0  0  0
 16 17  1  0  0  0
 16 54  1  0  0  0
 17 18  1  0  0  0
 17 25  2  0  0  0
 18 19  2  0  0  0
 19 20  1  0  0  0
 19 55  1  0  0  0
 20 21  1  0  0  0
 20 24  2  0  0  0
 21 22  2  0  0  0
 21 56  1  0  0  0
 22 23  1  0  0  0
 22 34  1  0  0  0
 23 24  1  0  0  0
 23 26  1  0  0  0
 24 25  1  0  0  0
 26 27  1  0  0  0
 26 31  1  0  0  0
 26 32  1  0  0  0
 27 28  1  0  0  0
 27 57  1  0  0  0
 27 58  1  0  0  0
 28 29  1  0  0  0
 28 59  1  0  0  0
 28 60  1  0  0  0
 29 30  1  0  0  0
 29 61  1  0  0  0
 29 62  1  0  0  0
 30 31  1  0  0  0
 30 63  1  0  0  0
 30 64  1  0  0  0
 31 65  1  0  0  0
 31 66  1  0  0  0
 32 33  1  0  0  0
 32 67  1  0  0  0
 32 68  1  0  0  0
 33 34  1  0  0  0
 33 69  1  0  0  0
 34 35  2  0  0  0
M  CHG  1   4   1
M  END
> <s_m_entry_id>
65

> <Applicants>
G1 Therapeutics

> <CHEMBL_ID>
CHEMBL3904602

> <Canonical_Smiles>
O=C1NCC2(n3c1cc1c3nc(nc1)Nc1ncc(N3CCN(CC3)C(C)C)cc1)CCCCC2

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
1.5

> <SC_Patent>
None

> <Synonyms>
G1T38 | G1T38 FREE BASE | LEROCICLIB

> <Indications>
nan

> <Type>
nan

> <targets_id>
nan

> <inchi>
InChI=1S/C26H34N8O/c1-18(2)32-10-12-33(13-11-32)20-6-7-22(27-16-20)30-25-28-15-19-14-21-24(35)29-17-26(8-4-3-5-9-26)34(21)23(19)31-25/h6-7,14-16,18H,3-5,8-13,17H2,1-2H3,(H,29,35)(H,27,28,30,31)

> <stdInchikey>
YPJRHEKCFKOVRT-UHFFFAOYSA-N

> <csid>
68007293

> <Links>
|http://www.chemspider.com/Chemical-Structure.68007293.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3904602|http://pubchem.ncbi.nlm.nih.gov/compound/86269224|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10313|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=WBH8AY6ENB|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=253941

> <LinkName>
|ChemSpider|ChEMBL|PubChem|Guide to Pharmacology|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
474.3

> <HBA>
8

> <HBD>
2

> <NRB>
4

> <TPSA>
91.2

> <LogP>
3.5

> <RoF>
0

> <Targets>
nan

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.1191

> <r_epik_State_Penalty>
  0.1308

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
65

$$$$
Dubermatinib
                    3D
 Structure written by MMmdl.
 66 69  0  0  1  0            999 V2000
    1.1578   10.5644   -3.2001 C   0  0  0  0  0  0
   -0.0371   10.4436   -2.3660 N   0  0  0  0  0  0
   -1.2763   10.5427   -3.1444 C   0  0  0  0  0  0
   -1.5751    9.2906   -4.0014 C   0  0  0  0  0  0
   -1.5482    8.0248   -3.1146 N   0  3  0  0  0  0
   -0.2437    7.9279   -2.2896 C   0  0  0  0  0  0
   -0.0087    9.2474   -1.5176 C   0  0  0  0  0  0
   -1.7652    6.7638   -3.9838 C   0  0  0  0  0  0
   -1.9482    5.4775   -3.1912 C   0  0  0  0  0  0
   -3.1932    5.1710   -2.6406 C   0  0  0  0  0  0
   -3.3658    3.9868   -1.9292 C   0  0  0  0  0  0
   -2.3000    3.0994   -1.7605 C   0  0  0  0  0  0
   -1.0565    3.4041   -2.3316 C   0  0  0  0  0  0
   -0.8826    4.5882   -3.0427 C   0  0  0  0  0  0
   -2.5544    1.9216   -1.0334 N   0  0  0  0  0  0
   -1.7287    1.0139   -0.3533 C   0  0  0  0  0  0
   -2.3777    0.0004    0.2753 N   0  0  0  0  0  0
   -1.6107   -0.8983    0.9453 C   0  0  0  0  0  0
   -0.2197   -0.7984    1.0094 C   0  0  0  0  0  0
    0.3640    0.3005    0.3595 C   0  0  0  0  0  0
   -0.3820    1.1931   -0.3394 N   0  0  0  0  0  0
    1.7485    0.4894    0.3017 N   0  0  0  0  0  0
    2.5344    1.1471    1.2630 C   0  0  0  0  0  0
    2.2229    1.0589    2.6276 C   0  0  0  0  0  0
    3.0031    1.7117    3.5799 C   0  0  0  0  0  0
    4.1036    2.4643    3.1801 C   0  0  0  0  0  0
    4.4225    2.5668    1.8278 C   0  0  0  0  0  0
    3.6466    1.9133    0.8631 C   0  0  0  0  0  0
    4.0911    2.1014   -0.8741 S   0  0  0  0  0  0
    2.9120    2.6651   -1.5428 O   0  0  0  0  0  0
    5.3792    2.8016   -0.9469 O   0  0  0  0  0  0
    4.3364    0.4579   -1.4897 N   0  0  0  0  0  0
    4.1997    0.2950   -2.9510 C   0  0  0  0  0  0
    5.4475   -0.2965   -0.8745 C   0  0  0  0  0  0
    0.7033   -2.0098    1.8326 Cl  0  0  0  0  0  0
    2.0569   10.5691   -2.5825 H   0  0  0  0  0  0
    1.1421   11.5019   -3.7576 H   0  0  0  0  0  0
    1.2464    9.7478   -3.9170 H   0  0  0  0  0  0
   -2.1025   10.7079   -2.4508 H   0  0  0  0  0  0
   -1.2453   11.4323   -3.7755 H   0  0  0  0  0  0
   -2.5686    9.3431   -4.4486 H   0  0  0  0  0  0
   -0.8405    9.1511   -4.7962 H   0  0  0  0  0  0
   -0.3589    7.0884   -1.6034 H   0  0  0  0  0  0
    0.5684    7.7045   -2.9833 H   0  0  0  0  0  0
    0.9363    9.2022   -0.9739 H   0  0  0  0  0  0
   -0.7787    9.3548   -0.7521 H   0  0  0  0  0  0
   -2.6579    6.9755   -4.5755 H   0  0  0  0  0  0
   -0.9085    6.7127   -4.6592 H   0  0  0  0  0  0
   -4.0271    5.8475   -2.7609 H   0  0  0  0  0  0
   -4.3356    3.7652   -1.5061 H   0  0  0  0  0  0
   -0.2147    2.7344   -2.2567 H   0  0  0  0  0  0
    0.0811    4.8086   -3.4787 H   0  0  0  0  0  0
   -3.5338    1.7630   -0.8490 H   0  0  0  0  0  0
   -2.1317   -1.7149    1.4238 H   0  0  0  0  0  0
    2.0557    0.7094   -0.6349 H   0  0  0  0  0  0
    1.3716    0.4880    2.9658 H   0  0  0  0  0  0
    2.7524    1.6358    4.6278 H   0  0  0  0  0  0
    4.7077    2.9722    3.9174 H   0  0  0  0  0  0
    5.2757    3.1621    1.5386 H   0  0  0  0  0  0
    4.1526   -0.7635   -3.2084 H   0  0  0  0  0  0
    5.0457    0.7630   -3.4558 H   0  0  0  0  0  0
    3.2849    0.7786   -3.2942 H   0  0  0  0  0  0
    5.3754   -1.3524   -1.1371 H   0  0  0  0  0  0
    5.4007   -0.2030    0.2105 H   0  0  0  0  0  0
    6.4022    0.1072   -1.2134 H   0  0  0  0  0  0
   -2.3196    8.0907   -2.4653 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 36  1  0  0  0
  1 37  1  0  0  0
  1 38  1  0  0  0
  2  3  1  0  0  0
  2  7  1  0  0  0
  3  4  1  0  0  0
  3 39  1  0  0  0
  3 40  1  0  0  0
  4  5  1  0  0  0
  4 41  1  0  0  0
  4 42  1  0  0  0
  5  6  1  0  0  0
  5  8  1  0  0  0
  5 66  1  0  0  0
  6  7  1  0  0  0
  6 43  1  0  0  0
  6 44  1  0  0  0
  7 45  1  0  0  0
  7 46  1  0  0  0
  8  9  1  0  0  0
  8 47  1  0  0  0
  8 48  1  0  0  0
  9 10  1  0  0  0
  9 14  2  0  0  0
 10 11  2  0  0  0
 10 49  1  0  0  0
 11 12  1  0  0  0
 11 50  1  0  0  0
 12 13  2  0  0  0
 12 15  1  0  0  0
 13 14  1  0  0  0
 13 51  1  0  0  0
 14 52  1  0  0  0
 15 16  1  0  0  0
 15 53  1  0  0  0
 16 17  1  0  0  0
 16 21  2  0  0  0
 17 18  2  0  0  0
 18 19  1  0  0  0
 18 54  1  0  0  0
 19 20  2  0  0  0
 19 35  1  0  0  0
 20 21  1  0  0  0
 20 22  1  0  0  0
 22 23  1  0  0  0
 22 55  1  0  0  0
 23 24  1  0  0  0
 23 28  2  0  0  0
 24 25  2  0  0  0
 24 56  1  0  0  0
 25 26  1  0  0  0
 25 57  1  0  0  0
 26 27  2  0  0  0
 26 58  1  0  0  0
 27 28  1  0  0  0
 27 59  1  0  0  0
 28 29  1  0  0  0
 29 30  2  0  0  0
 29 31  2  0  0  0
 29 32  1  0  0  0
 32 33  1  0  0  0
 32 34  1  0  0  0
 33 60  1  0  0  0
 33 61  1  0  0  0
 33 62  1  0  0  0
 34 63  1  0  0  0
 34 64  1  0  0  0
 34 65  1  0  0  0
M  CHG  1   5   1
M  END
> <s_m_entry_id>
69

> <Applicants>
Tolero Pharmaceuticals

> <CHEMBL_ID>
CHEMBL2022968

> <Canonical_Smiles>
Clc1cnc(nc1Nc1ccccc1S(=O)(=O)N(C)C)Nc1ccc(cc1)CN1CCN(CC1)C

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
1.5

> <SC_Patent>
None

> <Synonyms>
DUBERMATINIB | HCL-2084 | TP 0903 | TP-0903 | TP0903

> <Indications>
nan

> <Type>
nan

> <targets_id>
nan

> <inchi>
InChI=1S/C24H30ClN7O2S/c1-30(2)35(33,34)22-7-5-4-6-21(22)28-23-20(25)16-26-24(29-23)27-19-10-8-18(9-11-19)17-32-14-12-31(3)13-15-32/h4-11,16H,12-15,17H2,1-3H3,(H2,26,27,28,29)

> <stdInchikey>
YUAALFPUEOYPNX-UHFFFAOYSA-N

> <csid>
28516684

> <Links>
|http://www.chemspider.com/Chemical-Structure.28516684.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2022968|http://pubchem.ncbi.nlm.nih.gov/compound/56839178|http://www.drugbank.ca/drugs/DB15187|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8863|http://zinc15.docking.org/substances/ZINC000084617535|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=14D65TV20J|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50382425

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
515.2

> <HBA>
8

> <HBD>
2

> <NRB>
8

> <TPSA>
93.7

> <LogP>
3.6

> <RoF>
1

> <Targets>
nan

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0171

> <r_epik_State_Penalty>
  0.2066

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
69

$$$$
Berzosertib
                    3D
 Structure written by MMmdl.
 59 62  0  0  1  0            999 V2000
   -4.2229   -0.8401    2.8470 C   0  0  0  0  0  0
   -4.8551    0.1735    1.8778 C   0  0  0  0  0  0
   -6.3827    0.2557    2.0264 C   0  0  0  0  0  0
   -4.4347   -0.2909    0.0826 S   0  0  0  0  0  0
   -4.8063   -1.6930   -0.1423 O   0  0  0  0  0  0
   -4.9560    0.7584   -0.8010 O   0  0  0  0  0  0
   -2.6466   -0.1824    0.0169 C   0  0  0  0  0  0
   -1.8663   -1.3358    0.0921 C   0  0  0  0  0  0
   -0.4787   -1.2354    0.0484 C   0  0  0  0  0  0
    0.1524    0.0131   -0.0673 C   0  0  0  0  0  0
   -0.6504    1.1608   -0.1350 C   0  0  0  0  0  0
   -2.0386    1.0669   -0.0941 C   0  0  0  0  0  0
    1.6439    0.1246   -0.1134 C   0  0  0  0  0  0
    2.3127    1.1710   -0.7624 C   0  0  0  0  0  0
    3.6673    1.2466   -0.7958 N   0  0  0  0  0  0
    4.3736    0.2643   -0.1792 C   0  0  0  0  0  0
    3.7230   -0.8016    0.4740 C   0  0  0  0  0  0
    2.3622   -0.8597    0.4975 N   0  0  0  0  0  0
    4.3761   -1.9509    1.1793 C   0  0  0  0  0  0
    3.8974   -3.1011    1.7769 C   0  0  0  0  0  0
    5.0163   -3.7818    2.2661 C   0  0  0  0  0  0
    6.1166   -3.1063    1.9997 N   0  0  0  0  0  0
    5.7261   -1.9538    1.3177 O   0  0  0  0  0  0
    5.0484   -5.0925    2.9973 C   0  0  0  0  0  0
    6.2551   -5.7743    3.2072 C   0  0  0  0  0  0
    6.2720   -6.9882    3.8884 C   0  0  0  0  0  0
    5.0816   -7.5329    4.3710 C   0  0  0  0  0  0
    3.8738   -6.8665    4.1604 C   0  0  0  0  0  0
    3.8589   -5.6518    3.4799 C   0  0  0  0  0  0
    5.0975   -8.8642    5.1008 C   0  0  0  0  0  0
    5.2375   -8.7031    6.6214 N   0  3  0  0  0  0
    5.2594  -10.0364    7.3815 C   0  0  0  0  0  0
    5.7619    0.3800   -0.2444 N   0  0  0  0  0  0
   -4.4491   -0.5857    3.8830 H   0  0  0  0  0  0
   -3.1375   -0.8605    2.7497 H   0  0  0  0  0  0
   -4.5915   -1.8503    2.6650 H   0  0  0  0  0  0
   -4.4226    1.1594    2.0511 H   0  0  0  0  0  0
   -6.6655    0.5520    3.0370 H   0  0  0  0  0  0
   -6.8554   -0.7042    1.8151 H   0  0  0  0  0  0
   -6.8056    0.9901    1.3402 H   0  0  0  0  0  0
   -2.3260   -2.3088    0.1850 H   0  0  0  0  0  0
    0.1044   -2.1432    0.1024 H   0  0  0  0  0  0
   -0.2051    2.1418   -0.2104 H   0  0  0  0  0  0
   -2.6369    1.9649   -0.1445 H   0  0  0  0  0  0
    1.7804    1.9592   -1.2738 H   0  0  0  0  0  0
    2.8638   -3.4062    1.8425 H   0  0  0  0  0  0
    7.1877   -5.3700    2.8408 H   0  0  0  0  0  0
    7.2110   -7.5011    4.0386 H   0  0  0  0  0  0
    2.9459   -7.2842    4.5239 H   0  0  0  0  0  0
    2.9130   -5.1512    3.3342 H   0  0  0  0  0  0
    4.1711   -9.4227    4.9554 H   0  0  0  0  0  0
    5.9400   -9.4895    4.7992 H   0  0  0  0  0  0
    6.0902   -8.1977    6.8178 H   0  0  0  0  0  0
    5.3592   -9.7843    8.4375 H   0  0  0  0  0  0
    6.1183  -10.6034    7.0201 H   0  0  0  0  0  0
    4.3153  -10.5428    7.1766 H   0  0  0  0  0  0
    6.3407   -0.3219    0.1941 H   0  0  0  0  0  0
    6.1698    1.1651   -0.7309 H   0  0  0  0  0  0
    4.4665   -8.1449    6.9603 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 34  1  0  0  0
  1 35  1  0  0  0
  1 36  1  0  0  0
  2  3  1  0  0  0
  2  4  1  0  0  0
  2 37  1  0  0  0
  3 38  1  0  0  0
  3 39  1  0  0  0
  3 40  1  0  0  0
  4  5  2  0  0  0
  4  6  2  0  0  0
  4  7  1  0  0  0
  7  8  1  0  0  0
  7 12  2  0  0  0
  8  9  2  0  0  0
  8 41  1  0  0  0
  9 10  1  0  0  0
  9 42  1  0  0  0
 10 11  2  0  0  0
 10 13  1  0  0  0
 11 12  1  0  0  0
 11 43  1  0  0  0
 12 44  1  0  0  0
 13 14  1  0  0  0
 13 18  2  0  0  0
 14 15  2  0  0  0
 14 45  1  0  0  0
 15 16  1  0  0  0
 16 17  2  0  0  0
 16 33  1  0  0  0
 17 18  1  0  0  0
 17 19  1  0  0  0
 19 20  2  0  0  0
 19 23  1  0  0  0
 20 21  1  0  0  0
 20 46  1  0  0  0
 21 22  2  0  0  0
 21 24  1  0  0  0
 22 23  1  0  0  0
 24 25  1  0  0  0
 24 29  2  0  0  0
 25 26  2  0  0  0
 25 47  1  0  0  0
 26 27  1  0  0  0
 26 48  1  0  0  0
 27 28  2  0  0  0
 27 30  1  0  0  0
 28 29  1  0  0  0
 28 49  1  0  0  0
 29 50  1  0  0  0
 30 31  1  0  0  0
 30 51  1  0  0  0
 30 52  1  0  0  0
 31 32  1  0  0  0
 31 53  1  0  0  0
 31 59  1  0  0  0
 32 54  1  0  0  0
 32 55  1  0  0  0
 32 56  1  0  0  0
 33 57  1  0  0  0
 33 58  1  0  0  0
M  CHG  1  31   1
M  END
> <s_m_entry_id>
75

> <Applicants>
Vertex Pharmaceuticals

> <CHEMBL_ID>
CHEMBL3989870

> <Canonical_Smiles>
S(=O)(=O)(C(C)C)c1ccc(cc1)-c1nc(-c2onc(c2)-c2ccc(cc2)CNC)c(nc1)N

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
BERZOSERTIB | M-6620 | M6620 | VE-822 | VX-970 | VX970

> <Indications>
nan

> <Type>
nan

> <targets_id>
nan

> <inchi>
InChI=1S/C24H25N5O3S/c1-15(2)33(30,31)19-10-8-18(9-11-19)21-14-27-24(25)23(28-21)22-12-20(29-32-22)17-6-4-16(5-7-17)13-26-3/h4-12,14-15,26H,13H2,1-3H3,(H2,25,27)

> <stdInchikey>
JZCWLJDSIRUGIN-UHFFFAOYSA-N

> <csid>
30773968

> <Links>
|http://www.chemspider.com/Chemical-Structure.30773968.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3989870|http://pubchem.ncbi.nlm.nih.gov/compound/59472121|http://www.drugbank.ca/drugs/DB11794|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8003|http://zinc15.docking.org/substances/ZINC000096170459|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=L423PRV3V3|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50226746

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
463.2

> <HBA>
8

> <HBD>
2

> <NRB>
7

> <TPSA>
124

> <LogP>
3.9

> <RoF>
0

> <Targets>
nan

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0205

> <r_epik_State_Penalty>
  0.0165

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
75

$$$$
Entospletinib
                    3D
 Structure written by MMmdl.
 52 57  0  0  1  0            999 V2000
   -1.0246   -1.5846   -0.8549 C   0  0  0  0  0  0
   -2.3968   -1.3516   -0.8652 C   0  0  0  0  0  0
   -2.9876   -0.4752    0.0586 C   0  0  0  0  0  0
   -2.1561    0.1625    0.9901 C   0  0  0  0  0  0
   -0.7838   -0.0723    1.0052 C   0  0  0  0  0  0
   -0.2073   -0.9369    0.0762 C   0  0  0  0  0  0
    1.1826   -1.1370    0.1398 N   0  0  0  0  0  0
    2.1335   -1.4393   -0.8512 C   0  0  0  0  0  0
    3.4889   -1.5868   -0.4843 C   0  0  0  0  0  0
    4.1255   -1.5028    0.7170 N   0  0  0  0  0  0
    5.3901   -1.7388    0.4381 C   0  0  0  0  0  0
    5.6255   -1.9777   -0.9127 C   0  0  0  0  0  0
    4.3989   -1.8790   -1.5159 N   0  0  0  0  0  0
    4.0016   -2.0114   -2.8201 C   0  0  0  0  0  0
    2.6481   -1.8434   -3.1231 C   0  0  0  0  0  0
    1.7408   -1.5675   -2.1484 N   0  0  0  0  0  0
    2.1188   -1.9646   -4.5168 C   0  0  0  0  0  0
    2.9183   -1.5822   -5.6045 C   0  0  0  0  0  0
    2.4753   -1.6691   -6.9234 C   0  0  0  0  0  0
    1.1854   -2.1564   -7.1638 C   0  0  0  0  0  0
    0.3689   -2.3989   -8.3088 C   0  0  0  0  0  0
   -0.8011   -2.8763   -7.9702 N   0  0  0  0  0  0
   -0.8107   -2.9691   -6.6279 N   0  0  0  0  0  0
    0.3786   -2.5420   -6.0696 C   0  0  0  0  0  0
    0.8207   -2.4559   -4.7462 C   0  0  0  0  0  0
   -4.3599   -0.2149    0.0547 N   0  0  0  0  0  0
   -5.1155   -0.2686    1.3194 C   0  0  0  0  0  0
   -6.4411    0.5191    1.2403 C   0  0  0  0  0  0
   -7.2424    0.0540    0.1621 O   0  0  0  0  0  0
   -6.5683    0.0927   -1.0885 C   0  0  0  0  0  0
   -5.2416   -0.6942   -1.0244 C   0  0  0  0  0  0
   -0.6174   -2.2865   -1.5661 H   0  0  0  0  0  0
   -2.9911   -1.8787   -1.5962 H   0  0  0  0  0  0
   -2.5610    0.8613    1.7071 H   0  0  0  0  0  0
   -0.1705    0.4350    1.7361 H   0  0  0  0  0  0
    1.6017   -0.8280    1.0049 H   0  0  0  0  0  0
    6.1416   -1.7377    1.2140 H   0  0  0  0  0  0
    6.5332   -2.1978   -1.4551 H   0  0  0  0  0  0
    4.7655   -2.2434   -3.5477 H   0  0  0  0  0  0
    3.9116   -1.1942   -5.4321 H   0  0  0  0  0  0
    3.1154   -1.3627   -7.7376 H   0  0  0  0  0  0
    0.6190   -2.2327   -9.3463 H   0  0  0  0  0  0
   -1.6275   -3.3196   -6.1485 H   0  0  0  0  0  0
    0.1838   -2.7607   -3.9285 H   0  0  0  0  0  0
   -5.3115   -1.3072    1.5907 H   0  0  0  0  0  0
   -4.5342    0.1508    2.1393 H   0  0  0  0  0  0
   -7.0015    0.3958    2.1671 H   0  0  0  0  0  0
   -6.2512    1.5894    1.1404 H   0  0  0  0  0  0
   -7.2192   -0.3391   -1.8490 H   0  0  0  0  0  0
   -6.3907    1.1260   -1.3927 H   0  0  0  0  0  0
   -4.7429   -0.5662   -1.9858 H   0  0  0  0  0  0
   -5.4370   -1.7618   -0.9100 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1  6  2  0  0  0
  1 32  1  0  0  0
  2  3  2  0  0  0
  2 33  1  0  0  0
  3  4  1  0  0  0
  3 26  1  0  0  0
  4  5  2  0  0  0
  4 34  1  0  0  0
  5  6  1  0  0  0
  5 35  1  0  0  0
  6  7  1  0  0  0
  7  8  1  0  0  0
  7 36  1  0  0  0
  8  9  1  0  0  0
  8 16  2  0  0  0
  9 10  2  0  0  0
  9 13  1  0  0  0
 10 11  1  0  0  0
 11 12  2  0  0  0
 11 37  1  0  0  0
 12 13  1  0  0  0
 12 38  1  0  0  0
 13 14  1  0  0  0
 14 15  2  0  0  0
 14 39  1  0  0  0
 15 16  1  0  0  0
 15 17  1  0  0  0
 17 18  1  0  0  0
 17 25  2  0  0  0
 18 19  2  0  0  0
 18 40  1  0  0  0
 19 20  1  0  0  0
 19 41  1  0  0  0
 20 21  1  0  0  0
 20 24  2  0  0  0
 21 22  2  0  0  0
 21 42  1  0  0  0
 22 23  1  0  0  0
 23 24  1  0  0  0
 23 43  1  0  0  0
 24 25  1  0  0  0
 25 44  1  0  0  0
 26 27  1  0  0  0
 26 31  1  0  0  0
 27 28  1  0  0  0
 27 45  1  0  0  0
 27 46  1  0  0  0
 28 29  1  0  0  0
 28 47  1  0  0  0
 28 48  1  0  0  0
 29 30  1  0  0  0
 30 31  1  0  0  0
 30 49  1  0  0  0
 30 50  1  0  0  0
 31 51  1  0  0  0
 31 52  1  0  0  0
M  END
> <s_m_entry_id>
77

> <Applicants>
Gilead Sciences

> <CHEMBL_ID>
CHEMBL3265032

> <Canonical_Smiles>
O1CCN(CC1)c1ccc(NC2=NC(=Cn3c2ncc3)c2cc3[nH]ncc3cc2)cc1

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
ENTOSPLETINIB | GS-9973 | SYK INHIBITOR GS-9973

> <Indications>
nan

> <Type>
1

> <targets_id>
P43405

> <inchi>
InChI=1S/C23H21N7O/c1-2-17-14-25-28-20(17)13-16(1)21-15-30-8-7-24-23(30)22(27-21)26-18-3-5-19(6-4-18)29-9-11-31-12-10-29/h1-8,13-15H,9-12H2,(H,25,28)(H,26,27)

> <stdInchikey>
XSMSNFMDVXXHGJ-UHFFFAOYSA-N

> <csid>
31042596

> <Links>
|http://www.chemspider.com/Chemical-Structure.31042596.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3265032|http://pubchem.ncbi.nlm.nih.gov/compound/59473233|http://www.drugbank.ca/drugs/DB12121| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=CG9|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/CG9|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7889|http://zinc15.docking.org/substances/ZINC000098208742|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=6I3O3W6O3B|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50015448

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
411.2

> <HBA>
7

> <HBD>
2

> <NRB>
4

> <TPSA>
83.4

> <LogP>
3.9

> <RoF>
0

> <Targets>
SYK

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
0.980392

> <r_epik_Ionization_Penalty>
  0.0022

> <r_epik_State_Penalty>
  0.0090

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
77

> <lig_pdbID>
'CG9'

> <pdbID>
4puz

> <Kinase families>
Tyr

$$$$
Telatinib
                    3D
 Structure written by MMmdl.
 45 48  0  0  1  0            999 V2000
   -1.1917    7.1579    2.7445 C   0  0  0  0  0  0
   -1.0490    6.0879    1.7627 N   0  0  0  0  0  0
   -0.7756    4.7978    2.0443 C   0  0  0  0  0  0
   -0.6105    4.3864    3.1953 O   0  0  0  0  0  0
   -0.6785    3.8476    0.8658 C   0  0  0  0  0  0
   -0.3889    2.4888    1.0720 C   0  0  0  0  0  0
   -0.3064    1.6287   -0.0287 C   0  0  0  0  0  0
   -0.5116    2.1427   -1.3118 C   0  0  0  0  0  0
   -0.7948    3.5005   -1.4490 C   0  0  0  0  0  0
   -0.8797    4.3450   -0.3908 N   0  0  0  0  0  0
    0.0099    0.1566    0.1672 C   0  0  0  0  0  0
    1.4217   -0.0268    0.0845 O   0  0  0  0  0  0
    1.9405   -1.2978    0.2398 C   0  0  0  0  0  0
    3.3239   -1.4624    0.1533 C   0  0  0  0  0  0
    3.9064   -2.7375    0.3073 C   0  0  0  0  0  0
    5.3102   -2.5162    0.1137 C   0  0  0  0  0  0
    5.4590   -1.1548   -0.1064 C   0  0  0  0  0  0
    4.2633   -0.5015   -0.0857 O   0  0  0  0  0  0
    3.0228   -3.8107    0.5682 C   0  0  0  0  0  0
    1.6756   -3.6027    0.6078 N   0  0  0  0  0  0
    1.1396   -2.3783    0.4607 N   0  0  0  0  0  0
    3.4298   -5.1441    0.7298 N   0  0  0  0  0  0
    4.6551   -5.6925    1.1368 C   0  0  0  0  0  0
    5.0280   -6.9377    0.6265 C   0  0  0  0  0  0
    6.2274   -7.5243    1.0224 C   0  0  0  0  0  0
    7.0482   -6.8691    1.9387 C   0  0  0  0  0  0
    6.6746   -5.6346    2.4665 C   0  0  0  0  0  0
    5.4748   -5.0493    2.0709 C   0  0  0  0  0  0
    8.5351   -7.5954    2.4289 Cl  0  0  0  0  0  0
   -0.4343    7.9221    2.5695 H   0  0  0  0  0  0
   -1.0919    6.8128    3.7744 H   0  0  0  0  0  0
   -2.1713    7.6241    2.6400 H   0  0  0  0  0  0
   -1.1591    6.3514    0.7942 H   0  0  0  0  0  0
   -0.2272    2.0991    2.0674 H   0  0  0  0  0  0
   -0.4507    1.5065   -2.1829 H   0  0  0  0  0  0
   -0.9580    3.9326   -2.4253 H   0  0  0  0  0  0
   -0.3666   -0.1750    1.1373 H   0  0  0  0  0  0
   -0.5010   -0.4323   -0.5976 H   0  0  0  0  0  0
    6.1148   -3.2359    0.1279 H   0  0  0  0  0  0
    6.3225   -0.5343   -0.2954 H   0  0  0  0  0  0
    2.7678   -5.8156    0.3688 H   0  0  0  0  0  0
    4.3954   -7.4526   -0.0825 H   0  0  0  0  0  0
    6.5163   -8.4843    0.6200 H   0  0  0  0  0  0
    7.3078   -5.1328    3.1835 H   0  0  0  0  0  0
    5.1850   -4.1003    2.4982 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 30  1  0  0  0
  1 31  1  0  0  0
  1 32  1  0  0  0
  2  3  1  0  0  0
  2 33  1  0  0  0
  3  4  2  0  0  0
  3  5  1  0  0  0
  5  6  1  0  0  0
  5 10  2  0  0  0
  6  7  2  0  0  0
  6 34  1  0  0  0
  7  8  1  0  0  0
  7 11  1  0  0  0
  8  9  2  0  0  0
  8 35  1  0  0  0
  9 10  1  0  0  0
  9 36  1  0  0  0
 11 12  1  0  0  0
 11 37  1  0  0  0
 11 38  1  0  0  0
 12 13  1  0  0  0
 13 14  1  0  0  0
 13 21  2  0  0  0
 14 15  2  0  0  0
 14 18  1  0  0  0
 15 16  1  0  0  0
 15 19  1  0  0  0
 16 17  2  0  0  0
 16 39  1  0  0  0
 17 18  1  0  0  0
 17 40  1  0  0  0
 19 20  2  0  0  0
 19 22  1  0  0  0
 20 21  1  0  0  0
 22 23  1  0  0  0
 22 41  1  0  0  0
 23 24  1  0  0  0
 23 28  2  0  0  0
 24 25  2  0  0  0
 24 42  1  0  0  0
 25 26  1  0  0  0
 25 43  1  0  0  0
 26 27  2  0  0  0
 26 29  1  0  0  0
 27 28  1  0  0  0
 27 44  1  0  0  0
 28 45  1  0  0  0
M  END
> <s_m_entry_id>
79

> <Applicants>
Bayer

> <CHEMBL_ID>
CHEMBL2079588

> <Canonical_Smiles>
Clc1ccc(Nc2nnc(OCc3cc(ncc3)C(=O)NC)c3occc23)cc1

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
BAY 57-9352 | BAY-57-9352 | BAY-579352 | TELATINIB

> <Indications>
nan

> <Type>
nan

> <targets_id>
P35968|P35916

> <inchi>
InChI=1S/C20H16ClN5O3/c1-22-19(27)16-10-12(6-8-23-16)11-29-20-17-15(7-9-28-17)18(25-26-20)24-14-4-2-13(21)3-5-14/h2-10H,11H2,1H3,(H,22,27)(H,24,25)

> <stdInchikey>
QFCXANHHBCGMAS-UHFFFAOYSA-N

> <csid>
7984603

> <Links>
|http://www.chemspider.com/Chemical-Structure.7984603.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2079588|http://pubchem.ncbi.nlm.nih.gov/compound/9808844|http://www.drugbank.ca/drugs/DB15393|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10476|http://zinc15.docking.org/substances/ZINC00590964|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=18P7197Q7J|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50399538

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
409.1

> <HBA>
7

> <HBD>
2

> <NRB>
6

> <TPSA>
102.2

> <LogP>
4

> <RoF>
0

> <Targets>
KDR; FLT4

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0062

> <r_epik_State_Penalty>
  0.0000

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
79

> <Kinase families>
Tyr

$$$$
Riviciclib
                    3D
 Structure written by MMmdl.
 49 52  0  0  1  0            999 V2000
   -3.1963   -0.3317   -0.6292 C   0  0  0  0  0  0
   -2.0244   -1.3330   -0.7040 N   0  3  2  0  0  0
   -1.6498   -1.8975    0.6773 C   0  0  0  0  0  0
   -0.6587   -0.8842    1.2566 C   0  0  0  0  0  0
   -0.0409   -0.1371    0.0571 C   0  0  2  0  0  0
   -0.6939   -0.7330   -1.2133 C   0  0  2  0  0  0
   -0.7334    0.2259   -2.4234 C   0  0  0  0  0  0
   -1.2800   -0.4215   -3.5544 O   0  0  0  0  0  0
    1.5004   -0.0748    0.0282 C   0  0  0  0  0  0
    2.1771    1.1546   -0.0164 C   0  0  0  0  0  0
    3.5680    1.1899   -0.0535 C   0  0  0  0  0  0
    4.3166    0.0149   -0.0572 C   0  0  0  0  0  0
    3.6752   -1.2401   -0.0228 C   0  0  0  0  0  0
    2.2628   -1.2561    0.0254 C   0  0  0  0  0  0
    1.5557   -2.4441    0.0631 O   0  0  0  0  0  0
    2.2282   -3.6184    0.0250 C   0  0  0  0  0  0
    3.5695   -3.7275   -0.0341 C   0  0  0  0  0  0
    4.4325   -2.5508   -0.0423 C   0  0  0  0  0  0
    5.6605   -2.6255   -0.0718 O   0  0  0  0  0  0
    1.2875   -4.7468    0.0094 C   0  0  0  0  0  0
    0.8156   -5.2557    1.2245 C   0  0  0  0  0  0
   -0.0977   -6.3095    1.2451 C   0  0  0  0  0  0
   -0.5540   -6.8588    0.0483 C   0  0  0  0  0  0
   -0.0999   -6.3513   -1.1682 C   0  0  0  0  0  0
    0.8153   -5.2966   -1.1941 C   0  0  0  0  0  0
    1.3315   -4.6819   -2.7282 Cl  0  0  0  0  0  0
    5.6827    0.1468   -0.1007 O   0  0  0  0  0  0
    1.5056    2.3504   -0.0306 O   0  0  0  0  0  0
   -2.8914    0.5113   -0.0080 H   0  0  0  0  0  0
   -4.0432   -0.8651   -0.1958 H   0  0  0  0  0  0
   -3.4209   -0.0213   -1.6498 H   0  0  0  0  0  0
   -2.5495   -2.0607    1.2722 H   0  0  0  0  0  0
   -1.1748   -2.8561    0.4613 H   0  0  0  0  0  0
   -1.1741   -0.1908    1.9229 H   0  0  0  0  0  0
    0.0882   -1.3962    1.8644 H   0  0  0  0  0  0
   -0.4208    0.8814    0.1432 H   0  0  0  0  0  0
   -0.1572   -1.6338   -1.5177 H   0  0  0  0  0  0
   -1.3120    1.1236   -2.2033 H   0  0  0  0  0  0
    0.2751    0.5570   -2.6744 H   0  0  0  0  0  0
   -1.2512    0.1840   -4.2995 H   0  0  0  0  0  0
    4.0771    2.1432   -0.0853 H   0  0  0  0  0  0
    4.0100   -4.7134   -0.0767 H   0  0  0  0  0  0
    1.1583   -4.8354    2.1595 H   0  0  0  0  0  0
   -0.4519   -6.6997    2.1880 H   0  0  0  0  0  0
   -1.2618   -7.6747    0.0628 H   0  0  0  0  0  0
   -0.4635   -6.7764   -2.0927 H   0  0  0  0  0  0
    6.1342   -0.7012   -0.1063 H   0  0  0  0  0  0
    2.0957    3.1074   -0.0515 H   0  0  0  0  0  0
   -2.2939   -2.0928   -1.3135 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 29  1  0  0  0
  1 30  1  0  0  0
  1 31  1  0  0  0
  2  3  1  0  0  0
  2  6  1  0  0  0
  2 49  1  0  0  0
  3  4  1  0  0  0
  3 32  1  0  0  0
  3 33  1  0  0  0
  4  5  1  0  0  0
  4 34  1  0  0  0
  4 35  1  0  0  0
  5  6  1  0  0  0
  5  9  1  0  0  0
  5 36  1  0  0  0
  6  7  1  0  0  0
  6 37  1  0  0  0
  7  8  1  0  0  0
  7 38  1  0  0  0
  7 39  1  0  0  0
  8 40  1  0  0  0
  9 10  1  0  0  0
  9 14  2  0  0  0
 10 11  2  0  0  0
 10 28  1  0  0  0
 11 12  1  0  0  0
 11 41  1  0  0  0
 12 13  2  0  0  0
 12 27  1  0  0  0
 13 14  1  0  0  0
 13 18  1  0  0  0
 14 15  1  0  0  0
 15 16  1  0  0  0
 16 17  2  0  0  0
 16 20  1  0  0  0
 17 18  1  0  0  0
 17 42  1  0  0  0
 18 19  2  0  0  0
 20 21  1  0  0  0
 20 25  2  0  0  0
 21 22  2  0  0  0
 21 43  1  0  0  0
 22 23  1  0  0  0
 22 44  1  0  0  0
 23 24  2  0  0  0
 23 45  1  0  0  0
 24 25  1  0  0  0
 24 46  1  0  0  0
 25 26  1  0  0  0
 27 47  1  0  0  0
 28 48  1  0  0  0
M  CHG  1   2   1
M  END
> <s_m_entry_id>
80

> <Applicants>
Piramal Enterprises

> <CHEMBL_ID>
CHEMBL3545283

> <Canonical_Smiles>
Clc1ccccc1C=1Oc2c(C(=O)C=1)c(O)cc(O)c2[C@@H]1CCN(C)[C@H]1CO

> <Chirality>
Racemic Mixture

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Indications>
nan

> <Type>
nan

> <targets_id>
P06493|P11802|P50750

> <inchi>
InChI=1S/C21H20ClNO5/c1-23-7-6-12(14(23)10-24)19-15(25)8-16(26)20-17(27)9-18(28-21(19)20)11-4-2-3-5-13(11)22/h2-5,8-9,12,14,24-26H,6-7,10H2,1H3/t12-,14+/m1/s1

> <stdInchikey>
QLUYMIVVAYRECT-OCCSQVGLSA-N

> <csid>
29165868

> <Links>
|http://www.chemspider.com/Chemical-Structure.29165868.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3969723|http://pubchem.ncbi.nlm.nih.gov/compound/23643976|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7934|http://zinc15.docking.org/substances/ZINC000003937395|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=9EK26WE8QN|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50193086

> <LinkName>
|ChemSpider|ChEMBL|PubChem|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
401.1

> <HBA>
6

> <HBD>
3

> <NRB>
3

> <TPSA>
94.1

> <LogP>
3.3

> <RoF>
0

> <Targets>
CDK1; CDK4; CDK9

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_epik_Ionization_Penalty>
  0.1912

> <r_epik_State_Penalty>
  0.1679

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
80

> <Kinase families>
CMGC

$$$$
Gandotinib
                    3D
 Structure written by MMmdl.
 58 62  0  0  1  0            999 V2000
   -1.9509    5.0069    0.7576 C   0  0  0  0  0  0
   -1.5858    3.6467    0.2160 C   0  0  0  0  0  0
   -0.3839    3.0311   -0.0847 C   0  0  0  0  0  0
   -0.6909    1.7446   -0.5612 C   0  0  0  0  0  0
   -1.9921    1.5603   -0.5772 N   0  0  0  0  0  0
   -2.5164    2.6969   -0.1063 N   0  0  0  0  0  0
    0.1384    0.7361   -0.9931 N   0  0  0  0  0  0
    1.4877    0.5099   -0.6734 C   0  0  0  0  0  0
    2.1459   -0.5090   -1.3669 C   0  0  0  0  0  0
    3.4870   -0.8075   -1.0978 C   0  0  0  0  0  0
    4.1301   -0.0490   -0.0995 C   0  0  0  0  0  0
    5.3932   -0.0947    0.3912 N   0  0  0  0  0  0
    5.4404    0.8424    1.3165 C   0  0  0  0  0  0
    4.2269    1.5310    1.4514 C   0  0  0  0  0  0
    3.3775    0.9480    0.5361 N   0  0  0  0  0  0
    2.0906    1.2569    0.2918 N   0  0  0  0  0  0
    3.7935    2.6667    2.3675 C   0  0  0  0  0  0
    3.5554    3.9909    1.6456 C   0  0  0  0  0  0
    2.3430    4.6676    1.8230 C   0  0  0  0  0  0
    2.1108    5.8831    1.1794 C   0  0  0  0  0  0
    3.0922    6.4369    0.3583 C   0  0  0  0  0  0
    4.3092    5.7776    0.1874 C   0  0  0  0  0  0
    4.5449    4.5625    0.8314 C   0  0  0  0  0  0
    5.7394    3.9495    0.6632 F   0  0  0  0  0  0
    2.8028    7.9391   -0.4405 Cl  0  0  0  0  0  0
    6.7337    1.0504    2.0719 C   0  0  0  0  0  0
    4.1770   -1.9145   -1.8851 C   0  0  0  0  0  0
    4.5809   -1.4841   -3.2275 N   0  0  0  0  0  0
    5.6823   -0.5121   -3.1832 C   0  0  0  0  0  0
    6.1072   -0.1027   -4.6098 C   0  0  0  0  0  0
    6.4382   -1.2469   -5.3919 O   0  0  0  0  0  0
    5.3968   -2.2180   -5.4484 C   0  0  0  0  0  0
    4.9683   -2.6496   -4.0294 C   0  0  0  0  0  0
   -1.0686    5.6212    0.9356 H   0  0  0  0  0  0
   -2.4857    4.9331    1.7049 H   0  0  0  0  0  0
   -2.5894    5.5576    0.0664 H   0  0  0  0  0  0
    0.5987    3.4637    0.0203 H   0  0  0  0  0  0
   -3.5140    2.8217   -0.0106 H   0  0  0  0  0  0
   -0.2121    0.0820   -1.6771 H   0  0  0  0  0  0
    1.6205   -1.0727   -2.1254 H   0  0  0  0  0  0
    2.8964    2.3741    2.9157 H   0  0  0  0  0  0
    4.5455    2.8493    3.1350 H   0  0  0  0  0  0
    1.5714    4.2500    2.4536 H   0  0  0  0  0  0
    1.1699    6.3940    1.3193 H   0  0  0  0  0  0
    5.0742    6.2080   -0.4421 H   0  0  0  0  0  0
    6.6634    1.8565    2.8019 H   0  0  0  0  0  0
    7.5542    1.3060    1.4009 H   0  0  0  0  0  0
    7.0306    0.1540    2.6171 H   0  0  0  0  0  0
    5.0342   -2.2959   -1.3267 H   0  0  0  0  0  0
    3.4747   -2.7464   -1.9662 H   0  0  0  0  0  0
    5.3709    0.3812   -2.6407 H   0  0  0  0  0  0
    6.5385   -0.9217   -2.6439 H   0  0  0  0  0  0
    5.3188    0.4742   -5.0969 H   0  0  0  0  0  0
    6.9773    0.5526   -4.5635 H   0  0  0  0  0  0
    4.5445   -1.8277   -6.0080 H   0  0  0  0  0  0
    5.7554   -3.0829   -6.0068 H   0  0  0  0  0  0
    5.7802   -3.1985   -3.5481 H   0  0  0  0  0  0
    4.1262   -3.3393   -4.1054 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 34  1  0  0  0
  1 35  1  0  0  0
  1 36  1  0  0  0
  2  3  2  0  0  0
  2  6  1  0  0  0
  3  4  1  0  0  0
  3 37  1  0  0  0
  4  5  2  0  0  0
  4  7  1  0  0  0
  5  6  1  0  0  0
  6 38  1  0  0  0
  7  8  1  0  0  0
  7 39  1  0  0  0
  8  9  1  0  0  0
  8 16  2  0  0  0
  9 10  2  0  0  0
  9 40  1  0  0  0
 10 11  1  0  0  0
 10 27  1  0  0  0
 11 12  2  0  0  0
 11 15  1  0  0  0
 12 13  1  0  0  0
 13 14  2  0  0  0
 13 26  1  0  0  0
 14 15  1  0  0  0
 14 17  1  0  0  0
 15 16  1  0  0  0
 17 18  1  0  0  0
 17 41  1  0  0  0
 17 42  1  0  0  0
 18 19  1  0  0  0
 18 23  2  0  0  0
 19 20  2  0  0  0
 19 43  1  0  0  0
 20 21  1  0  0  0
 20 44  1  0  0  0
 21 22  2  0  0  0
 21 25  1  0  0  0
 22 23  1  0  0  0
 22 45  1  0  0  0
 23 24  1  0  0  0
 26 46  1  0  0  0
 26 47  1  0  0  0
 26 48  1  0  0  0
 27 28  1  0  0  0
 27 49  1  0  0  0
 27 50  1  0  0  0
 28 29  1  0  0  0
 28 33  1  0  0  0
 29 30  1  0  0  0
 29 51  1  0  0  0
 29 52  1  0  0  0
 30 31  1  0  0  0
 30 53  1  0  0  0
 30 54  1  0  0  0
 31 32  1  0  0  0
 32 33  1  0  0  0
 32 55  1  0  0  0
 32 56  1  0  0  0
 33 57  1  0  0  0
 33 58  1  0  0  0
M  END
> <s_m_entry_id>
94

> <Applicants>
Eli Lilly

> <CHEMBL_ID>
CHEMBL2107823

> <Canonical_Smiles>
Clc1cc(F)c(cc1)Cc1n2N=C(Nc3n[nH]c(c3)C)C=C(c2nc1C)CN1CCOCC1

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
GANDOTINIB | LY-2784544 | LY2784544

> <Indications>
nan

> <Type>
nan

> <targets_id>
O60674

> <inchi>
InChI=1S/C23H25ClFN7O/c1-14-9-21(29-28-14)27-22-11-17(13-31-5-7-33-8-6-31)23-26-15(2)20(32(23)30-22)10-16-3-4-18(24)12-19(16)25/h3-4,9,11-12H,5-8,10,13H2,1-2H3,(H2,27,28,29,30)

> <stdInchikey>
SQSZANZGUXWJEA-UHFFFAOYSA-N

> <csid>
25027412

> <Links>
|http://www.chemspider.com/Chemical-Structure.25027412.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2107823|http://pubchem.ncbi.nlm.nih.gov/compound/46213929|http://www.drugbank.ca/drugs/DB13040|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7909|http://zinc15.docking.org/substances/ZINC68245097|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=ANC71R916O

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS

> <indicationG2P>
None

> <MW>
469.2

> <HBA>
7

> <HBD>
2

> <NRB>
6

> <TPSA>
83.4

> <LogP>
4

> <RoF>
0

> <Targets>
JAK2

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
0.8426

> <r_epik_Ionization_Penalty>
  0.3051

> <r_epik_State_Penalty>
  0.3773

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
94

> <Kinase families>
Tyr

$$$$
Brepocitinib
                    3D
 Structure written by MMmdl.
 50 54  0  0  1  0            999 V2000
   -3.0857    3.8422   -2.5593 C   0  0  0  0  0  0
   -2.0132    3.1191   -1.9003 N   0  0  0  0  0  0
   -1.7046    1.7888   -1.9995 C   0  0  0  0  0  0
   -0.5936    1.5677   -1.1994 C   0  0  0  0  0  0
   -0.3330    2.8552   -0.6829 C   0  0  0  0  0  0
   -1.1717    3.7765   -1.0996 N   0  0  0  0  0  0
    0.0337    0.3691   -1.0167 N   0  0  0  0  0  0
    1.1408    0.0400   -0.1774 C   0  0  0  0  0  0
    1.5906   -1.2283   -0.1729 N   0  3  0  0  0  0
    2.6273   -1.6080    0.5983 C   0  0  0  0  0  0
    3.2479   -0.6559    1.4119 C   0  0  0  0  0  0
    2.7654    0.6677    1.3951 C   0  0  0  0  0  0
    1.7086    1.0046    0.5950 N   0  0  0  0  0  0
    3.3296    1.6825    2.1747 N   0  0  0  0  0  0
    4.3828    1.4073    3.1823 C   0  0  0  0  0  0
    5.1102    2.6308    3.8070 C   0  0  1  0  0  0
    5.8833    3.4695    2.7758 C   0  0  0  0  0  0
    4.8662    4.4727    2.2281 C   0  0  0  0  0  0
    3.5549    4.1506    2.9603 C   0  0  1  0  0  0
    2.7214    3.0345    2.2705 C   0  0  0  0  0  0
    4.0483    3.5547    4.1993 N   0  0  0  0  0  0
    3.5765    3.8243    5.4409 C   0  0  0  0  0  0
    2.6989    4.6716    5.6237 O   0  0  0  0  0  0
    4.1595    3.0444    6.6447 C   0  0  2  0  0  0
    3.3105    3.0238    7.9132 C   0  0  0  0  0  0
    4.5656    3.8527    7.8649 C   0  0  0  0  0  0
    5.6204    3.4299    8.5603 F   0  0  0  0  0  0
    4.4367    5.1810    7.8554 F   0  0  0  0  0  0
   -3.7412    3.1433   -3.0798 H   0  0  0  0  0  0
   -2.6615    4.5407   -3.2813 H   0  0  0  0  0  0
   -3.6681    4.3913   -1.8184 H   0  0  0  0  0  0
   -2.2938    1.1281   -2.6188 H   0  0  0  0  0  0
    0.4640    3.1284   -0.0089 H   0  0  0  0  0  0
   -0.3413   -0.4062   -1.5432 H   0  0  0  0  0  0
    2.9169   -2.6472    0.5367 H   0  0  0  0  0  0
    4.0762   -0.9581    2.0339 H   0  0  0  0  0  0
    3.9387    0.8068    3.9779 H   0  0  0  0  0  0
    5.1536    0.7882    2.7229 H   0  0  0  0  0  0
    5.7631    2.3182    4.6208 H   0  0  0  0  0  0
    6.7043    3.9996    3.2610 H   0  0  0  0  0  0
    6.3171    2.8526    1.9876 H   0  0  0  0  0  0
    5.1839    5.4906    2.4591 H   0  0  0  0  0  0
    4.7600    4.4033    1.1446 H   0  0  0  0  0  0
    2.9457    5.0427    3.1149 H   0  0  0  0  0  0
    2.4891    3.3856    1.2645 H   0  0  0  0  0  0
    1.7644    2.9329    2.7845 H   0  0  0  0  0  0
    4.7062    2.1303    6.4196 H   0  0  0  0  0  0
    2.3493    3.5385    7.9476 H   0  0  0  0  0  0
    3.3048    2.1137    8.5131 H   0  0  0  0  0  0
    1.1393   -1.9124   -0.7631 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 29  1  0  0  0
  1 30  1  0  0  0
  1 31  1  0  0  0
  2  3  1  0  0  0
  2  6  1  0  0  0
  3  4  2  0  0  0
  3 32  1  0  0  0
  4  5  1  0  0  0
  4  7  1  0  0  0
  5  6  2  0  0  0
  5 33  1  0  0  0
  7  8  1  0  0  0
  7 34  1  0  0  0
  8  9  1  0  0  0
  8 13  2  0  0  0
  9 10  2  0  0  0
  9 50  1  0  0  0
 10 11  1  0  0  0
 10 35  1  0  0  0
 11 12  2  0  0  0
 11 36  1  0  0  0
 12 13  1  0  0  0
 12 14  1  0  0  0
 14 15  1  0  0  0
 14 20  1  0  0  0
 15 16  1  0  0  0
 15 37  1  0  0  0
 15 38  1  0  0  0
 16 17  1  0  0  0
 16 21  1  0  0  0
 16 39  1  0  0  0
 17 18  1  0  0  0
 17 40  1  0  0  0
 17 41  1  0  0  0
 18 19  1  0  0  0
 18 42  1  0  0  0
 18 43  1  0  0  0
 19 20  1  0  0  0
 19 21  1  0  0  0
 19 44  1  0  0  0
 20 45  1  0  0  0
 20 46  1  0  0  0
 21 22  1  0  0  0
 22 23  2  0  0  0
 22 24  1  0  0  0
 24 25  1  0  0  0
 24 26  1  0  0  0
 24 47  1  0  0  0
 25 26  1  0  0  0
 25 48  1  0  0  0
 25 49  1  0  0  0
 26 27  1  0  0  0
 26 28  1  0  0  0
M  CHG  1   9   1
M  END
> <s_m_entry_id>
99

> <Applicants>
Pfizer

> <CHEMBL_ID>
CHEMBL4297477

> <Canonical_Smiles>
FC1(F)C[C@H]1C(=O)N1[C@H]2CC[C@@H]1CN(C2)c1nc(ncc1)Nc1cn(nc1)C

> <Chirality>
Single Stereoisomer

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
BREPOCITINIB | PF-06700841

> <Indications>
nan

> <Type>
nan

> <targets_id>
nan

> <inchi>
InChI=1S/C18H21F2N7O/c1-25-8-11(7-22-25)23-17-21-5-4-15(24-17)26-9-12-2-3-13(10-26)27(12)16(28)14-6-18(14,19)20/h4-5,7-8,12-14H,2-3,6,9-10H2,1H3,(H,21,23,24)/t12-,13+,14-/m0/s1

> <stdInchikey>
BUWBRTXGQRBBHG-MJBXVCDLSA-N

> <csid>
71107316

> <Links>
|http://www.chemspider.com/Chemical-Structure.71107316.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4297477|http://pubchem.ncbi.nlm.nih.gov/compound/118878093|http://www.drugbank.ca/drugs/DB15003| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=G4J|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/G4J|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10459|http://zinc15.docking.org/substances/ZINC000526061580|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=3X8387Q25N|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=329924

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
389.2

> <HBA>
7

> <HBD>
1

> <NRB>
4

> <TPSA>
79.2

> <LogP>
1.8

> <RoF>
0

> <Targets>
nan

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
0.575011

> <r_epik_Ionization_Penalty>
  0.0218

> <r_epik_State_Penalty>
  0.1552

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
99

> <lig_pdbID>
'G4J'

> <pdbID>
6dbm 6dbn

$$$$
Foretinib
                    3D
 Structure written by MMmdl.
 81 86  0  0  1  0            999 V2000
    0.7227    5.7100    1.1456 C   0  0  0  0  0  0
   -0.6250    5.4157    0.7927 O   0  0  0  0  0  0
   -1.1213    4.1382    0.9909 C   0  0  0  0  0  0
   -0.3635    3.0922    1.5398 C   0  0  0  0  0  0
   -0.9193    1.8016    1.7250 C   0  0  0  0  0  0
   -0.1851    0.7116    2.2805 C   0  0  0  0  0  0
   -0.8406   -0.5213    2.4235 C   0  0  0  0  0  0
   -2.1646   -0.6454    2.0187 C   0  0  0  0  0  0
   -2.8811    0.3707    1.4856 N   0  0  0  0  0  0
   -2.2746    1.5805    1.3391 C   0  0  0  0  0  0
   -3.0220    2.6441    0.7864 C   0  0  0  0  0  0
   -2.4509    3.9136    0.6145 C   0  0  0  0  0  0
   -3.1370    4.9913    0.0813 O   0  0  0  0  0  0
   -4.4985    4.8433   -0.3133 C   0  0  0  0  0  0
   -5.0190    6.1894   -0.8384 C   0  0  0  0  0  0
   -4.9962    7.2939    0.2354 C   0  0  0  0  0  0
   -5.6804    8.5873   -0.2702 N   0  3  0  0  0  0
   -5.9177    9.5469    0.9186 C   0  0  0  0  0  0
   -6.5436   10.8535    0.3957 C   0  0  0  0  0  0
   -5.7295   11.4364   -0.6176 O   0  0  0  0  0  0
   -5.5450   10.6089   -1.7622 C   0  0  0  0  0  0
   -4.8599    9.2814   -1.3835 C   0  0  0  0  0  0
    1.1301    0.9255    2.6560 O   0  0  0  0  0  0
    1.9023   -0.0953    3.1581 C   0  0  0  0  0  0
    2.5250   -0.9953    2.2900 C   0  0  0  0  0  0
    3.3063   -2.0341    2.7957 C   0  0  0  0  0  0
    3.4690   -2.1852    4.1830 C   0  0  0  0  0  0
    2.8617   -1.2669    5.0449 C   0  0  0  0  0  0
    2.0789   -0.2292    4.5377 C   0  0  0  0  0  0
    1.4901    0.6435    5.3876 F   0  0  0  0  0  0
    4.2458   -3.1930    4.7807 N   0  0  0  0  0  0
    4.5662   -4.4108    4.2907 C   0  0  0  0  0  0
    4.1951   -4.8426    3.1978 O   0  0  0  0  0  0
    5.4450   -5.2861    5.2125 C   0  0  0  0  0  0
    6.1585   -6.4683    4.5625 C   0  0  0  0  0  0
    6.9354   -5.2183    4.8906 C   0  0  0  0  0  0
    5.0605   -5.5219    6.6909 C   0  0  0  0  0  0
    5.8959   -5.3540    7.5807 O   0  0  0  0  0  0
    3.7904   -5.9349    6.8977 N   0  0  0  0  0  0
    3.1277   -6.2055    8.1093 C   0  0  0  0  0  0
    1.9580   -6.9641    8.0126 C   0  0  0  0  0  0
    1.2247   -7.2711    9.1556 C   0  0  0  0  0  0
    1.6559   -6.8123   10.3976 C   0  0  0  0  0  0
    2.8132   -6.0451   10.5051 C   0  0  0  0  0  0
    3.5497   -5.7361    9.3642 C   0  0  0  0  0  0
    0.9425   -7.1094   11.5072 F   0  0  0  0  0  0
    0.9338    6.7542    0.9157 H   0  0  0  0  0  0
    1.4274    5.0997    0.5788 H   0  0  0  0  0  0
    0.8982    5.5661    2.2128 H   0  0  0  0  0  0
    0.6629    3.2485    1.8353 H   0  0  0  0  0  0
   -0.3395   -1.3808    2.8430 H   0  0  0  0  0  0
   -2.6805   -1.5888    2.1215 H   0  0  0  0  0  0
   -4.0451    2.4466    0.5029 H   0  0  0  0  0  0
   -4.5793    4.0899   -1.0988 H   0  0  0  0  0  0
   -5.1100    4.5128    0.5284 H   0  0  0  0  0  0
   -4.4135    6.4788   -1.6967 H   0  0  0  0  0  0
   -6.0369    6.0608   -1.2079 H   0  0  0  0  0  0
   -5.5740    6.9824    1.1073 H   0  0  0  0  0  0
   -3.9873    7.5662    0.5517 H   0  0  0  0  0  0
   -6.5742    9.0344    1.6233 H   0  0  0  0  0  0
   -4.9436    9.7226    1.3794 H   0  0  0  0  0  0
   -7.5459   10.6734    0.0020 H   0  0  0  0  0  0
   -6.6504   11.5687    1.2117 H   0  0  0  0  0  0
   -6.5098   10.4240   -2.2383 H   0  0  0  0  0  0
   -4.9361   11.1490   -2.4878 H   0  0  0  0  0  0
   -3.8580    9.4435   -0.9812 H   0  0  0  0  0  0
   -4.8133    8.6042   -2.2355 H   0  0  0  0  0  0
    2.4019   -0.8876    1.2222 H   0  0  0  0  0  0
    3.7860   -2.6992    2.0941 H   0  0  0  0  0  0
    2.9863   -1.3569    6.1149 H   0  0  0  0  0  0
    4.5582   -2.9881    5.7187 H   0  0  0  0  0  0
    6.3501   -7.3687    5.1485 H   0  0  0  0  0  0
    5.9819   -6.7082    3.5131 H   0  0  0  0  0  0
    7.2798   -4.5895    4.0679 H   0  0  0  0  0  0
    7.6741   -5.2619    5.6922 H   0  0  0  0  0  0
    3.2354   -6.1013    6.0710 H   0  0  0  0  0  0
    1.6116   -7.3227    7.0537 H   0  0  0  0  0  0
    0.3238   -7.8619    9.0784 H   0  0  0  0  0  0
    3.1364   -5.6852   11.4709 H   0  0  0  0  0  0
    4.4290   -5.1226    9.4805 H   0  0  0  0  0  0
   -6.5840    8.3382   -0.6480 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 47  1  0  0  0
  1 48  1  0  0  0
  1 49  1  0  0  0
  2  3  1  0  0  0
  3  4  1  0  0  0
  3 12  2  0  0  0
  4  5  2  0  0  0
  4 50  1  0  0  0
  5  6  1  0  0  0
  5 10  1  0  0  0
  6  7  2  0  0  0
  6 23  1  0  0  0
  7  8  1  0  0  0
  7 51  1  0  0  0
  8  9  2  0  0  0
  8 52  1  0  0  0
  9 10  1  0  0  0
 10 11  2  0  0  0
 11 12  1  0  0  0
 11 53  1  0  0  0
 12 13  1  0  0  0
 13 14  1  0  0  0
 14 15  1  0  0  0
 14 54  1  0  0  0
 14 55  1  0  0  0
 15 16  1  0  0  0
 15 56  1  0  0  0
 15 57  1  0  0  0
 16 17  1  0  0  0
 16 58  1  0  0  0
 16 59  1  0  0  0
 17 18  1  0  0  0
 17 22  1  0  0  0
 17 81  1  0  0  0
 18 19  1  0  0  0
 18 60  1  0  0  0
 18 61  1  0  0  0
 19 20  1  0  0  0
 19 62  1  0  0  0
 19 63  1  0  0  0
 20 21  1  0  0  0
 21 22  1  0  0  0
 21 64  1  0  0  0
 21 65  1  0  0  0
 22 66  1  0  0  0
 22 67  1  0  0  0
 23 24  1  0  0  0
 24 25  1  0  0  0
 24 29  2  0  0  0
 25 26  2  0  0  0
 25 68  1  0  0  0
 26 27  1  0  0  0
 26 69  1  0  0  0
 27 28  2  0  0  0
 27 31  1  0  0  0
 28 29  1  0  0  0
 28 70  1  0  0  0
 29 30  1  0  0  0
 31 32  1  0  0  0
 31 71  1  0  0  0
 32 33  2  0  0  0
 32 34  1  0  0  0
 34 35  1  0  0  0
 34 36  1  0  0  0
 34 37  1  0  0  0
 35 36  1  0  0  0
 35 72  1  0  0  0
 35 73  1  0  0  0
 36 74  1  0  0  0
 36 75  1  0  0  0
 37 38  2  0  0  0
 37 39  1  0  0  0
 39 40  1  0  0  0
 39 76  1  0  0  0
 40 41  1  0  0  0
 40 45  2  0  0  0
 41 42  2  0  0  0
 41 77  1  0  0  0
 42 43  1  0  0  0
 42 78  1  0  0  0
 43 44  2  0  0  0
 43 46  1  0  0  0
 44 45  1  0  0  0
 44 79  1  0  0  0
 45 80  1  0  0  0
M  CHG  1  17   1
M  END
> <s_m_entry_id>
102

> <Applicants>
GlaxoSmithKline

> <CHEMBL_ID>
CHEMBL1230609

> <Canonical_Smiles>
Fc1cc(NC(=O)C2(CC2)C(=O)Nc2ccc(F)cc2)ccc1Oc1c2cc(OC)c(OCCCN3CCOCC3)cc2ncc1

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
EXEL-2880 | FORETINIB | GSK-089 | GSK-1363089 | GSK-1363089G | GSK089 | GSK1363089G | XL-880 | XL880

> <Indications>
nan

> <Type>
2

> <targets_id>
P08581|P35968

> <inchi>
InChI=1S/C34H34F2N4O6/c1-43-30-20-25-27(21-31(30)45-16-2-13-40-14-17-44-18-15-40)37-12-9-28(25)46-29-8-7-24(19-26(29)36)39-33(42)34(10-11-34)32(41)38-23-5-3-22(35)4-6-23/h3-9,12,19-21H,2,10-11,13-18H2,1H3,(H,38,41)(H,39,42)

> <stdInchikey>
CXQHYVUVSFXTMY-UHFFFAOYSA-N

> <csid>
24608641

> <Links>
|http://www.chemspider.com/Chemical-Structure.24608641.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1230609|http://pubchem.ncbi.nlm.nih.gov/compound/42642645|http://www.drugbank.ca/drugs/DB12307| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=88Z|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/88Z|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5679|http://zinc15.docking.org/substances/ZINC43204048|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=81FH7VK1C4|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50399540

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
632.2

> <HBA>
8

> <HBD>
2

> <NRB>
12

> <TPSA>
111.2

> <LogP>
5.8

> <RoF>
2

> <Targets>
MET; KDR

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.5539

> <r_epik_State_Penalty>
  0.5412

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
102

> <lig_pdbID>
'88Z'

> <pdbID>
3lq8 5ia4 6i2y 6sd9 6sdc

> <Kinase families>
Tyr

> <indicationDB>
Foretinib has been used in trials studying the treatment of Cancer, Breast Cancer, Carcinoma, Renal Cell, Recurrent Breast Cancer, and Neoplasms, Head and Neck, among others. Foretinib is an orally available small molecule compound designed to target multiple RTKs implicated in the development, progression and spread of cancer. It inhibits the activation of MET, RON, ERK and AKT, decreased proliferation and increased apoptosis.

> <uniprotId>
P14210|P35968

> <Withdrawn>
|Study NCT02034097 in nan was Withdrawn during Phase 2 because GSK has decided to terminate the Product Development of foretinib and conclude our Development
    Agreement with Exelixis

$$$$
Dilmapimod
                    3D
 Structure written by MMmdl.
 52 55  0  0  1  0            999 V2000
   -4.2498    2.7239    2.5068 C   0  0  0  0  0  0
   -4.9388    2.4302    1.1793 C   0  0  0  0  0  0
   -6.3336    2.3196    1.1582 C   0  0  0  0  0  0
   -7.0031    2.0263   -0.0279 C   0  0  0  0  0  0
   -6.2821    1.8397   -1.2041 C   0  0  0  0  0  0
   -4.8932    1.9540   -1.1934 C   0  0  0  0  0  0
   -4.2041    2.2546   -0.0112 C   0  0  0  0  0  0
   -2.7240    2.3932   -0.0554 C   0  0  0  0  0  0
   -2.0543    3.6196    0.0845 C   0  0  0  0  0  0
   -2.7020    4.9279    0.2569 C   0  0  0  0  0  0
   -1.9625    6.0473    0.3886 C   0  0  0  0  0  0
   -0.5060    6.0670    0.3756 C   0  0  0  0  0  0
    0.1038    7.1302    0.5162 O   0  0  0  0  0  0
    0.0778    4.8303    0.1992 N   0  0  0  0  0  0
   -0.6504    3.6025    0.0457 C   0  0  0  0  0  0
    0.0364    2.4384   -0.1320 N   0  0  0  0  0  0
   -0.6872    1.2953   -0.2650 C   0  0  0  0  0  0
   -2.0420    1.2298   -0.2373 N   0  0  0  0  0  0
   -0.0237    0.0703   -0.4333 N   0  0  0  0  0  0
    1.4323   -0.0712   -0.2991 C   0  0  0  0  0  0
    1.9990   -1.2975   -1.0723 C   0  0  0  0  0  0
    1.2348   -1.7031   -2.1945 O   0  0  0  0  0  0
    1.8456   -0.0666    1.1932 C   0  0  0  0  0  0
    3.2430   -0.2082    1.3565 O   0  0  0  0  0  0
    1.4928    4.7787    0.1889 C   0  0  0  0  0  0
    2.1952    4.9258   -1.0172 C   0  0  0  0  0  0
    3.5884    4.8485   -1.0246 C   0  0  0  0  0  0
    4.2845    4.6202    0.1623 C   0  0  0  0  0  0
    3.5895    4.4686    1.3619 C   0  0  0  0  0  0
    2.1965    4.5459    1.3806 C   0  0  0  0  0  0
    1.5377    4.3882    2.5532 F   0  0  0  0  0  0
    1.5354    5.1382   -2.1805 F   0  0  0  0  0  0
   -8.3510    1.9203   -0.0360 F   0  0  0  0  0  0
   -3.3458    2.1246    2.6219 H   0  0  0  0  0  0
   -4.8976    2.4976    3.3548 H   0  0  0  0  0  0
   -3.9742    3.7764    2.5691 H   0  0  0  0  0  0
   -6.9050    2.4562    2.0651 H   0  0  0  0  0  0
   -6.7982    1.6092   -2.1246 H   0  0  0  0  0  0
   -4.3471    1.8133   -2.1154 H   0  0  0  0  0  0
   -3.7796    5.0048    0.2740 H   0  0  0  0  0  0
   -2.4726    6.9919    0.5123 H   0  0  0  0  0  0
   -0.5824   -0.7700   -0.4096 H   0  0  0  0  0  0
    1.8631    0.8212   -0.7561 H   0  0  0  0  0  0
    2.9926   -1.0496   -1.4469 H   0  0  0  0  0  0
    2.1423   -2.1522   -0.4099 H   0  0  0  0  0  0
    1.6852   -2.4349   -2.6227 H   0  0  0  0  0  0
    1.5563    0.8716    1.6685 H   0  0  0  0  0  0
    1.3382   -0.8614    1.7420 H   0  0  0  0  0  0
    3.4453   -0.1705    2.2942 H   0  0  0  0  0  0
    4.1301    4.9626   -1.9521 H   0  0  0  0  0  0
    5.3627    4.5583    0.1524 H   0  0  0  0  0  0
    4.1321    4.2882    2.2783 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 34  1  0  0  0
  1 35  1  0  0  0
  1 36  1  0  0  0
  2  3  1  0  0  0
  2  7  2  0  0  0
  3  4  2  0  0  0
  3 37  1  0  0  0
  4  5  1  0  0  0
  4 33  1  0  0  0
  5  6  2  0  0  0
  5 38  1  0  0  0
  6  7  1  0  0  0
  6 39  1  0  0  0
  7  8  1  0  0  0
  8  9  2  0  0  0
  8 18  1  0  0  0
  9 10  1  0  0  0
  9 15  1  0  0  0
 10 11  2  0  0  0
 10 40  1  0  0  0
 11 12  1  0  0  0
 11 41  1  0  0  0
 12 13  2  0  0  0
 12 14  1  0  0  0
 14 15  1  0  0  0
 14 25  1  0  0  0
 15 16  2  0  0  0
 16 17  1  0  0  0
 17 18  2  0  0  0
 17 19  1  0  0  0
 19 20  1  0  0  0
 19 42  1  0  0  0
 20 21  1  0  0  0
 20 23  1  0  0  0
 20 43  1  0  0  0
 21 22  1  0  0  0
 21 44  1  0  0  0
 21 45  1  0  0  0
 22 46  1  0  0  0
 23 24  1  0  0  0
 23 47  1  0  0  0
 23 48  1  0  0  0
 24 49  1  0  0  0
 25 26  1  0  0  0
 25 30  2  0  0  0
 26 27  2  0  0  0
 26 32  1  0  0  0
 27 28  1  0  0  0
 27 50  1  0  0  0
 28 29  2  0  0  0
 28 51  1  0  0  0
 29 30  1  0  0  0
 29 52  1  0  0  0
 30 31  1  0  0  0
M  END
> <s_m_entry_id>
106

> <Applicants>
GlaxoSmithKline

> <CHEMBL_ID>
CHEMBL2103838

> <Canonical_Smiles>
Fc1cccc(F)c1N1c2nc(nc(c2C=CC1=O)-c1ccc(F)cc1C)NC(CO)CO

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
DILMAPIMOD | GW-681323 | SB-681323 | SB681323

> <Indications>
Dilmapimod has been used in trials studying the treatment and diagnostic of Nerve Trauma, Inflammation, Pain, Neuropathic, Arthritis, Rheumatoid, and Coronary Heart Disease, among others.

> <Type>
nan

> <targets_id>
Q16539|Q15759|O15264|P53778

> <inchi>
InChI=1S/C23H19F3N4O3/c1-12-9-13(24)5-6-15(12)20-16-7-8-19(33)30(21-17(25)3-2-4-18(21)26)22(16)29-23(28-20)27-14(10-31)11-32/h2-9,14,31-32H,10-11H2,1H3,(H,27,28,29)

> <stdInchikey>
ORVNHOYNEHYKJG-UHFFFAOYSA-N

> <csid>
8473450

> <Links>
|http://www.chemspider.com/Chemical-Structure.8473450.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2103838|http://pubchem.ncbi.nlm.nih.gov/compound/10297982|http://www.drugbank.ca/drugs/DB12140|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7815|http://zinc15.docking.org/substances/ZINC000034997404|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=Q3238VQW0N

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS

> <indicationG2P>
None

> <MW>
456.1

> <HBA>
7

> <HBD>
3

> <NRB>
6

> <TPSA>
100.3

> <LogP>
2.9

> <RoF>
0

> <Targets>
MAPK14; MAPK11; MAPK13; MAPK12

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0000

> <r_epik_State_Penalty>
  0.0000

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
106

> <Kinase families>
CMGC

> <indicationDB>
Dilmapimod has been used in trials studying the treatment and diagnostic of Nerve Trauma, Inflammation, Pain, Neuropathic, Arthritis, Rheumatoid, and Coronary Heart Disease, among others. Dilmapimod (SB-681323) is a p38 MAP-kinase inhibitor that has potential uses in inflammatory conditions such as RA (Rheumatoid Arthritis). Previous p38 MAP-kinase inhibitors have been hindered in development by liver toxicity. Methotrexate (common treatment for RA patients) also has potential liver toxicity.}

> <uniprotId>
P01375|P01584|P05231

$$$$
Bimiralisib
                    3D
 Structure written by MMmdl.
 49 52  0  0  1  0            999 V2000
   -1.7805   -1.4563    0.7132 C   0  0  0  0  0  0
   -0.3770   -1.4781    0.6595 C   0  0  0  0  0  0
    0.3066   -0.2941    0.2818 C   0  0  0  0  0  0
   -0.4745    0.8379    0.0040 C   0  0  0  0  0  0
   -1.8277    0.8605    0.0589 N   0  0  0  0  0  0
   -2.4636   -0.2801    0.4081 C   0  0  0  0  0  0
   -3.8546   -0.2448    0.4636 N   0  0  0  0  0  0
    1.7897   -0.1857    0.1619 C   0  0  0  0  0  0
    2.4384   -1.1169   -0.5842 N   0  0  0  0  0  0
    3.7905   -0.9709   -0.6672 C   0  0  0  0  0  0
    4.4780    0.0440   -0.0712 N   0  0  0  0  0  0
    3.7419    0.9370    0.6487 C   0  0  0  0  0  0
    2.3880    0.8633    0.7852 N   0  0  0  0  0  0
    4.4118    1.9967    1.2687 N   0  0  0  0  0  0
    5.8789    2.0242    1.4293 C   0  0  0  0  0  0
    6.4497    3.4538    1.5300 C   0  0  0  0  0  0
    5.8016    4.1894    2.5570 O   0  0  0  0  0  0
    4.3960    4.2625    2.3703 C   0  0  0  0  0  0
    3.7746    2.8526    2.2887 C   0  0  0  0  0  0
    4.5117   -1.9068   -1.4157 N   0  0  0  0  0  0
    5.9817   -2.0188   -1.3416 C   0  0  0  0  0  0
    6.6109   -2.6168   -2.6170 C   0  0  0  0  0  0
    6.0108   -3.8608   -2.9449 O   0  0  0  0  0  0
    4.6065   -3.7562   -3.1254 C   0  0  0  0  0  0
    3.9266   -3.1861   -1.8631 C   0  0  0  0  0  0
    0.3553   -2.7674    1.0667 C   0  0  0  0  0  0
    0.7603   -3.4154   -0.0255 F   0  0  0  0  0  0
    1.4138   -2.5039    1.8347 F   0  0  0  0  0  0
   -0.4316   -3.5931    1.7600 F   0  0  0  0  0  0
   -2.3376   -2.3381    0.9958 H   0  0  0  0  0  0
   -0.0101    1.7689   -0.2887 H   0  0  0  0  0  0
   -4.3651   -1.0744    0.7281 H   0  0  0  0  0  0
   -4.3338    0.6172    0.2474 H   0  0  0  0  0  0
    6.1620    1.4394    2.3055 H   0  0  0  0  0  0
    6.3644    1.5500    0.5759 H   0  0  0  0  0  0
    7.5164    3.4111    1.7511 H   0  0  0  0  0  0
    6.3603    3.9731    0.5740 H   0  0  0  0  0  0
    3.9605    4.8110    3.2057 H   0  0  0  0  0  0
    4.1603    4.8406    1.4749 H   0  0  0  0  0  0
    2.7158    2.9872    2.0653 H   0  0  0  0  0  0
    3.8208    2.3600    3.2610 H   0  0  0  0  0  0
    6.4306   -1.0353   -1.2004 H   0  0  0  0  0  0
    6.2605   -2.6098   -0.4681 H   0  0  0  0  0  0
    6.5266   -1.9199   -3.4530 H   0  0  0  0  0  0
    7.6787   -2.7736   -2.4632 H   0  0  0  0  0  0
    4.3791   -3.1410   -3.9979 H   0  0  0  0  0  0
    4.2077   -4.7469   -3.3441 H   0  0  0  0  0  0
    3.9662   -3.9116   -1.0494 H   0  0  0  0  0  0
    2.8714   -3.0569   -2.1048 H   0  0  0  0  0  0
  1  6  1  0  0  0
  1 30  1  0  0  0
  1  2  2  0  0  0
  2 26  1  0  0  0
  2  3  1  0  0  0
  3  8  1  0  0  0
  3  4  2  0  0  0
  4  5  1  0  0  0
  4 31  1  0  0  0
  5  6  2  0  0  0
  6  7  1  0  0  0
  7 33  1  0  0  0
  7 32  1  0  0  0
  8  9  1  0  0  0
  8 13  2  0  0  0
  9 10  2  0  0  0
 10 11  1  0  0  0
 10 20  1  0  0  0
 11 12  2  0  0  0
 12 13  1  0  0  0
 12 14  1  0  0  0
 14 15  1  0  0  0
 14 19  1  0  0  0
 15 16  1  0  0  0
 15 34  1  0  0  0
 15 35  1  0  0  0
 16 17  1  0  0  0
 16 36  1  0  0  0
 16 37  1  0  0  0
 17 18  1  0  0  0
 18 19  1  0  0  0
 18 38  1  0  0  0
 18 39  1  0  0  0
 19 40  1  0  0  0
 19 41  1  0  0  0
 20 21  1  0  0  0
 20 25  1  0  0  0
 21 22  1  0  0  0
 21 42  1  0  0  0
 21 43  1  0  0  0
 22 23  1  0  0  0
 22 44  1  0  0  0
 22 45  1  0  0  0
 23 24  1  0  0  0
 24 25  1  0  0  0
 24 46  1  0  0  0
 24 47  1  0  0  0
 25 48  1  0  0  0
 25 49  1  0  0  0
 26 27  1  0  0  0
 26 28  1  0  0  0
 26 29  1  0  0  0
M  END
> <s_m_entry_id>
107

> <Applicants>
Piqur Therapeutics

> <CHEMBL_ID>
CHEMBL4084907

> <Canonical_Smiles>
FC(F)(F)C1=CC(NC=C1c1nc(nc(n1)N1CCOCC1)N1CCOCC1)=N

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
BIMIRALISIB | NC-B5 | NCB5 | PI3K-IN-2 | PQR-309 | PQR309

> <Indications>
Bimiralisib (PQR309) is a novel dual inhibitor of phosphoinositol 3-kinase (PI3K) and mechanistic target of rapamycin (mTOR) kinases, with expected utility as an anti-cancer agent.

> <Type>
nan

> <targets_id>
nan

> <inchi>
InChI=1S/C17H20F3N7O2/c18-17(19,20)12-9-13(21)22-10-11(12)14-23-15(26-1-5-28-6-2-26)25-16(24-14)27-3-7-29-8-4-27/h9-10H,1-8H2,(H2,21,22)

> <stdInchikey>
ADGGYDAFIHSYFI-UHFFFAOYSA-N

> <csid>
35033288

> <Links>
|http://www.chemspider.com/Chemical-Structure.35033288.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4084907|http://pubchem.ncbi.nlm.nih.gov/compound/58507717|http://www.drugbank.ca/drugs/DB14846| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=A3W|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/A3W|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8383|http://zinc15.docking.org/substances/ZINC000068203488|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=6Z3QHB00LB|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50240975

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
411.2

> <HBA>
8

> <HBD>
2

> <NRB>
3

> <TPSA>
103.2

> <LogP>
1

> <RoF>
0

> <Targets>
nan

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0000

> <r_epik_State_Penalty>
  0.0000

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
107

> <lig_pdbID>
'A3W'

> <pdbID>
5oq4

$$$$
Galunisertib
                    3D
 Structure written by MMmdl.
 47 51  0  0  1  0            999 V2000
   -2.2949    2.9003    0.0883 C   0  0  0  0  0  0
   -1.7698    1.4845    0.2282 C   0  0  0  0  0  0
   -2.6184    0.4133    0.5186 C   0  0  0  0  0  0
   -2.0636   -0.8630    0.6238 C   0  0  0  0  0  0
   -0.6904   -1.0351    0.4371 C   0  0  0  0  0  0
    0.1024    0.0852    0.1480 C   0  0  0  0  0  0
   -0.4327    1.3331    0.0500 N   0  0  0  0  0  0
    1.5857   -0.0127   -0.0649 C   0  0  0  0  0  0
    2.4446    0.8672   -0.7825 C   0  0  0  0  0  0
    3.7065    0.3223   -0.6093 C   0  0  0  0  0  0
    3.5328   -0.8032    0.1342 N   0  0  0  0  0  0
    2.2624   -1.0126    0.4765 N   0  0  0  0  0  0
    4.7587   -1.5188    0.4177 C   0  0  0  0  0  0
    5.7041   -0.9157   -0.6322 C   0  0  0  0  0  0
    5.1681    0.4878   -0.9349 C   0  0  0  0  0  0
    2.1112    2.0913   -1.5691 C   0  0  0  0  0  0
    1.2167    1.9581   -2.6334 C   0  0  0  0  0  0
    0.8903    3.0716   -3.3979 C   0  0  0  0  0  0
    1.3994    4.3053   -3.1753 N   0  0  0  0  0  0
    2.2729    4.4670   -2.1433 C   0  0  0  0  0  0
    2.6642    3.3825   -1.2975 C   0  0  0  0  0  0
    3.5666    3.6471   -0.2313 C   0  0  0  0  0  0
    4.0853    4.9293   -0.0178 C   0  0  0  0  0  0
    3.6910    5.9736   -0.8627 C   0  0  0  0  0  0
    2.7999    5.7573   -1.9090 C   0  0  0  0  0  0
    5.0472    5.1649    1.1230 C   0  0  0  0  0  0
    5.0295    4.4628    2.1333 O   0  0  0  0  0  0
    5.9419    6.1472    0.9680 N   0  0  0  0  0  0
   -3.3816    2.9363    0.1726 H   0  0  0  0  0  0
   -2.0196    3.3149   -0.8824 H   0  0  0  0  0  0
   -1.8740    3.5400    0.8648 H   0  0  0  0  0  0
   -3.6790    0.5625    0.6580 H   0  0  0  0  0  0
   -2.6925   -1.7122    0.8461 H   0  0  0  0  0  0
   -0.2557   -2.0212    0.5129 H   0  0  0  0  0  0
    5.0915   -1.3057    1.4345 H   0  0  0  0  0  0
    4.6389   -2.5965    0.3014 H   0  0  0  0  0  0
    6.7416   -0.8998   -0.2964 H   0  0  0  0  0  0
    5.6724   -1.5204   -1.5409 H   0  0  0  0  0  0
    5.3638    0.7902   -1.9641 H   0  0  0  0  0  0
    5.6378    1.2246   -0.2817 H   0  0  0  0  0  0
    0.7765    0.9994   -2.8675 H   0  0  0  0  0  0
    0.1987    2.9824   -4.2227 H   0  0  0  0  0  0
    3.8524    2.8369    0.4236 H   0  0  0  0  0  0
    4.0665    6.9759   -0.7130 H   0  0  0  0  0  0
    2.5045    6.5786   -2.5464 H   0  0  0  0  0  0
    5.9431    6.7110    0.1307 H   0  0  0  0  0  0
    6.6202    6.3311    1.6927 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 29  1  0  0  0
  1 30  1  0  0  0
  1 31  1  0  0  0
  2  3  1  0  0  0
  2  7  2  0  0  0
  3  4  2  0  0  0
  3 32  1  0  0  0
  4  5  1  0  0  0
  4 33  1  0  0  0
  5  6  2  0  0  0
  5 34  1  0  0  0
  6  7  1  0  0  0
  6  8  1  0  0  0
  8  9  1  0  0  0
  8 12  2  0  0  0
  9 10  2  0  0  0
  9 16  1  0  0  0
 10 11  1  0  0  0
 10 15  1  0  0  0
 11 12  1  0  0  0
 11 13  1  0  0  0
 13 14  1  0  0  0
 13 35  1  0  0  0
 13 36  1  0  0  0
 14 15  1  0  0  0
 14 37  1  0  0  0
 14 38  1  0  0  0
 15 39  1  0  0  0
 15 40  1  0  0  0
 16 17  2  0  0  0
 16 21  1  0  0  0
 17 18  1  0  0  0
 17 41  1  0  0  0
 18 19  2  0  0  0
 18 42  1  0  0  0
 19 20  1  0  0  0
 20 21  1  0  0  0
 20 25  2  0  0  0
 21 22  2  0  0  0
 22 23  1  0  0  0
 22 43  1  0  0  0
 23 24  2  0  0  0
 23 26  1  0  0  0
 24 25  1  0  0  0
 24 44  1  0  0  0
 25 45  1  0  0  0
 26 27  2  0  0  0
 26 28  1  0  0  0
 28 46  1  0  0  0
 28 47  1  0  0  0
M  END
> <s_m_entry_id>
108

> <Applicants>
Eli Lilly

> <CHEMBL_ID>
CHEMBL2364611

> <Canonical_Smiles>
O=C(N)c1cc2c(nccc2-c2c3n(nc2-c2nc(ccc2)C)CCC3)cc1

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
GALUNISERTIB | LY-2157299 | LY2157299

> <Indications>
nan

> <Type>
nan

> <targets_id>
P36897

> <inchi>
InChI=1S/C22H19N5O/c1-13-4-2-5-18(25-13)21-20(19-6-3-11-27(19)26-21)15-9-10-24-17-8-7-14(22(23)28)12-16(15)17/h2,4-5,7-10,12H,3,6,11H2,1H3,(H2,23,28)

> <stdInchikey>
IVRXNBXKWIJUQB-UHFFFAOYSA-N

> <csid>
8266022

> <Links>
|http://www.chemspider.com/Chemical-Structure.8266022.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2364611|http://pubchem.ncbi.nlm.nih.gov/compound/10090485|http://www.drugbank.ca/drugs/DB11911|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7797|http://zinc15.docking.org/substances/ZINC03959536|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=3OKH1W5LZE|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50015640

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
369.2

> <HBA>
5

> <HBD>
1

> <NRB>
3

> <TPSA>
86.7

> <LogP>
3.5

> <RoF>
0

> <Targets>
TGFBR1

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0095

> <r_epik_State_Penalty>
  0.0069

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
108

> <Kinase families>
TKL

$$$$
Pamapimod
                    3D
 Structure written by MMmdl.
 49 51  0  0  1  0            999 V2000
   -4.6359    1.2320   -0.5289 C   0  0  0  0  0  0
   -3.9366    2.5250   -0.3855 N   0  0  0  0  0  0
   -2.5160    2.4855   -0.2257 C   0  0  0  0  0  0
   -1.8157    3.6891   -0.0722 C   0  0  0  0  0  0
   -2.5837    4.9340   -0.0996 C   0  0  0  0  0  0
   -3.9241    4.9219   -0.2678 C   0  0  0  0  0  0
   -4.6988    3.6723   -0.3803 C   0  0  0  0  0  0
   -5.9306    3.6783   -0.4499 O   0  0  0  0  0  0
   -4.5695    6.1227   -0.2703 O   0  0  0  0  0  0
   -5.3619    6.4726   -1.3439 C   0  0  0  0  0  0
   -4.8233    6.5802   -2.6321 C   0  0  0  0  0  0
   -5.6365    6.9442   -3.7057 C   0  0  0  0  0  0
   -6.9900    7.2088   -3.4973 C   0  0  0  0  0  0
   -7.5303    7.1107   -2.2151 C   0  0  0  0  0  0
   -6.7185    6.7463   -1.1400 C   0  0  0  0  0  0
   -7.2507    6.6568    0.1008 F   0  0  0  0  0  0
   -7.7777    7.5628   -4.5376 F   0  0  0  0  0  0
   -0.4323    3.6196    0.0912 C   0  0  0  0  0  0
    0.2297    2.4344    0.1018 N   0  0  0  0  0  0
   -0.5182    1.3058   -0.0562 C   0  0  0  0  0  0
   -1.8667    1.2848   -0.2204 N   0  0  0  0  0  0
    0.0989    0.0458   -0.0571 N   0  0  0  0  0  0
    1.5376   -0.1643    0.1330 C   0  0  0  0  0  0
    2.1774   -0.8589   -1.0904 C   0  0  0  0  0  0
    2.0593   -0.0554   -2.4003 C   0  0  0  0  0  0
    2.7110   -0.7392   -3.4495 O   0  0  0  0  0  0
    1.8342   -0.9162    1.4505 C   0  0  0  0  0  0
    1.3643   -0.1739    2.7168 C   0  0  0  0  0  0
    1.7342   -0.8994    3.8698 O   0  0  0  0  0  0
   -5.7160    1.3156   -0.6563 H   0  0  0  0  0  0
   -4.4618    0.6136    0.3524 H   0  0  0  0  0  0
   -4.2523    0.6950   -1.3972 H   0  0  0  0  0  0
   -2.0716    5.8803    0.0008 H   0  0  0  0  0  0
   -3.7751    6.3800   -2.7988 H   0  0  0  0  0  0
   -5.2169    7.0232   -4.6978 H   0  0  0  0  0  0
   -8.5779    7.3185   -2.0545 H   0  0  0  0  0  0
    0.1646    4.5116    0.2146 H   0  0  0  0  0  0
   -0.4865   -0.7689   -0.1680 H   0  0  0  0  0  0
    2.0409    0.7988    0.2226 H   0  0  0  0  0  0
    3.2358   -1.0279   -0.8843 H   0  0  0  0  0  0
    1.7359   -1.8485   -1.2215 H   0  0  0  0  0  0
    1.0160    0.0968   -2.6785 H   0  0  0  0  0  0
    2.5155    0.9289   -2.2875 H   0  0  0  0  0  0
    2.2062   -1.5282   -3.6599 H   0  0  0  0  0  0
    1.3821   -1.9091    1.4150 H   0  0  0  0  0  0
    2.9108   -1.0800    1.5254 H   0  0  0  0  0  0
    1.8146    0.8181    2.7686 H   0  0  0  0  0  0
    0.2818   -0.0430    2.7197 H   0  0  0  0  0  0
    1.2106   -1.7033    3.9062 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 30  1  0  0  0
  1 31  1  0  0  0
  1 32  1  0  0  0
  2  3  1  0  0  0
  2  7  1  0  0  0
  3  4  2  0  0  0
  3 21  1  0  0  0
  4  5  1  0  0  0
  4 18  1  0  0  0
  5  6  2  0  0  0
  5 33  1  0  0  0
  6  7  1  0  0  0
  6  9  1  0  0  0
  7  8  2  0  0  0
  9 10  1  0  0  0
 10 11  1  0  0  0
 10 15  2  0  0  0
 11 12  2  0  0  0
 11 34  1  0  0  0
 12 13  1  0  0  0
 12 35  1  0  0  0
 13 14  2  0  0  0
 13 17  1  0  0  0
 14 15  1  0  0  0
 14 36  1  0  0  0
 15 16  1  0  0  0
 18 19  2  0  0  0
 18 37  1  0  0  0
 19 20  1  0  0  0
 20 21  2  0  0  0
 20 22  1  0  0  0
 22 23  1  0  0  0
 22 38  1  0  0  0
 23 24  1  0  0  0
 23 27  1  0  0  0
 23 39  1  0  0  0
 24 25  1  0  0  0
 24 40  1  0  0  0
 24 41  1  0  0  0
 25 26  1  0  0  0
 25 42  1  0  0  0
 25 43  1  0  0  0
 26 44  1  0  0  0
 27 28  1  0  0  0
 27 45  1  0  0  0
 27 46  1  0  0  0
 28 29  1  0  0  0
 28 47  1  0  0  0
 28 48  1  0  0  0
 29 49  1  0  0  0
M  END
> <s_m_entry_id>
110

> <Applicants>
Hoffmann-La Roche

> <CHEMBL_ID>
CHEMBL1090089

> <Canonical_Smiles>
Fc1cc(F)ccc1OC1=Cc2c(nc(nc2)NC(CCO)CCO)N(C)C1=O

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
PAMAPIMOD | R-1503 | R1503 | RO 4402257 | RO-4402257

> <Indications>
nan

> <Type>
1

> <targets_id>
Q16539|Q15759

> <inchi>
InChI=1S/C19H20F2N4O4/c1-25-17-11(10-22-19(24-17)23-13(4-6-26)5-7-27)8-16(18(25)28)29-15-3-2-12(20)9-14(15)21/h2-3,8-10,13,26-27H,4-7H2,1H3,(H,22,23,24)

> <stdInchikey>
JYYLVUFNAHSSFE-UHFFFAOYSA-N

> <csid>
17347490

> <Links>
|http://www.chemspider.com/Chemical-Structure.17347490.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1090089|http://pubchem.ncbi.nlm.nih.gov/compound/16220188| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=FLW|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/FLW|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9915|http://zinc15.docking.org/substances/ZINC30691792|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=8S2C9V11K4|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50314070

> <LinkName>
|ChemSpider|ChEMBL|PubChem|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
406.1

> <HBA>
8

> <HBD>
3

> <NRB>
8

> <TPSA>
109.5

> <LogP>
1.9

> <RoF>
0

> <Targets>
MAPK14; MAPK11

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0000

> <r_epik_State_Penalty>
  0.0000

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
110

> <lig_pdbID>
'FLW'

> <pdbID>
3flw

> <Kinase families>
CMGC

$$$$
Mivavotinib
                    3D
 Structure written by MMmdl.
 47 50  0  0  1  0            999 V2000
   -5.0596    5.3011    0.5385 C   0  0  0  0  0  0
   -3.9931    4.3874    0.1708 N   0  0  0  0  0  0
   -3.8803    3.0562    0.4734 C   0  0  0  0  0  0
   -2.6907    2.6227   -0.0949 C   0  0  0  0  0  0
   -2.0764    1.2626   -0.0661 C   0  0  0  0  0  0
   -0.7250    1.2815    0.0950 N   0  0  0  0  0  0
   -0.0356    0.1063    0.1394 C   0  0  0  0  0  0
    1.3611    0.1281    0.3077 N   0  0  0  0  0  0
    2.1536    1.3368    0.0348 C   0  0  2  0  0  0
    2.3424    1.4961   -1.4955 C   0  0  0  0  0  0
    3.2781    0.4250   -2.1003 C   0  0  0  0  0  0
    4.6379    0.3710   -1.3727 C   0  0  0  0  0  0
    4.4785    0.1957    0.1518 C   0  0  0  0  0  0
    3.5367    1.2699    0.7442 C   0  0  2  0  0  0
    3.3393    0.9525    2.2349 N   0  3  0  0  0  0
   -0.6831   -1.1309    0.0177 C   0  0  0  0  0  0
    0.0100   -2.2942    0.0630 F   0  0  0  0  0  0
   -2.0676   -1.1450   -0.1606 C   0  0  0  0  0  0
   -2.7693    0.0494   -0.2113 C   0  0  0  0  0  0
   -4.2204   -0.2481   -0.4529 C   0  0  0  0  0  0
   -5.1654    0.5247   -0.5894 O   0  0  0  0  0  0
   -4.2870   -1.5897   -0.4987 N   0  0  0  0  0  0
   -3.0220   -2.2879   -0.3323 C   0  0  0  0  0  0
   -2.1789    3.7917   -0.6876 C   0  0  0  0  0  0
   -2.9529    4.8423   -0.5352 N   0  0  0  0  0  0
   -5.8562    4.7581    1.0487 H   0  0  0  0  0  0
   -5.4659    5.7686   -0.3593 H   0  0  0  0  0  0
   -4.6659    6.0694    1.2049 H   0  0  0  0  0  0
   -4.6379    2.5510    1.0543 H   0  0  0  0  0  0
    1.8315   -0.7545    0.1668 H   0  0  0  0  0  0
    1.6049    2.2004    0.4147 H   0  0  0  0  0  0
    1.3792    1.4870   -2.0082 H   0  0  0  0  0  0
    2.7641    2.4826   -1.6942 H   0  0  0  0  0  0
    2.7977   -0.5531   -2.0468 H   0  0  0  0  0  0
    3.4328    0.6254   -3.1613 H   0  0  0  0  0  0
    5.2456   -0.4382   -1.7798 H   0  0  0  0  0  0
    5.1879    1.2920   -1.5730 H   0  0  0  0  0  0
    4.0885   -0.8033    0.3564 H   0  0  0  0  0  0
    5.4575    0.2421    0.6313 H   0  0  0  0  0  0
    4.0198    2.2485    0.7208 H   0  0  0  0  0  0
    2.8944    0.0516    2.3385 H   0  0  0  0  0  0
    2.7517    1.6534    2.6634 H   0  0  0  0  0  0
   -5.1516   -2.0898   -0.6470 H   0  0  0  0  0  0
   -2.7996   -2.8921   -1.2126 H   0  0  0  0  0  0
   -3.0574   -2.9408    0.5408 H   0  0  0  0  0  0
   -1.2464    3.8630   -1.2286 H   0  0  0  0  0  0
    4.2296    0.9352    2.7114 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 26  1  0  0  0
  1 27  1  0  0  0
  1 28  1  0  0  0
  2  3  1  0  0  0
  2 25  1  0  0  0
  3  4  2  0  0  0
  3 29  1  0  0  0
  4  5  1  0  0  0
  4 24  1  0  0  0
  5  6  2  0  0  0
  5 19  1  0  0  0
  6  7  1  0  0  0
  7  8  1  0  0  0
  7 16  2  0  0  0
  8  9  1  0  0  0
  8 30  1  0  0  0
  9 10  1  0  0  0
  9 14  1  0  0  0
  9 31  1  0  0  0
 10 11  1  0  0  0
 10 32  1  0  0  0
 10 33  1  0  0  0
 11 12  1  0  0  0
 11 34  1  0  0  0
 11 35  1  0  0  0
 12 13  1  0  0  0
 12 36  1  0  0  0
 12 37  1  0  0  0
 13 14  1  0  0  0
 13 38  1  0  0  0
 13 39  1  0  0  0
 14 15  1  0  0  0
 14 40  1  0  0  0
 15 41  1  0  0  0
 15 42  1  0  0  0
 15 47  1  0  0  0
 16 17  1  0  0  0
 16 18  1  0  0  0
 18 19  2  0  0  0
 18 23  1  0  0  0
 19 20  1  0  0  0
 20 21  2  0  0  0
 20 22  1  0  0  0
 22 23  1  0  0  0
 22 43  1  0  0  0
 23 44  1  0  0  0
 23 45  1  0  0  0
 24 25  2  0  0  0
 24 46  1  0  0  0
M  CHG  1  15   1
M  END
> <s_m_entry_id>
111

> <Applicants>
Takeda

> <CHEMBL_ID>
CHEMBL3979920

> <Canonical_Smiles>
Fc1c2c(c(nc1N[C@@H]1CCCC[C@@H]1N)-c1cn(nc1)C)C(=O)NC2

> <Chirality>
Single Stereoisomer

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
MIVAVOTINIB | TAK-659F

> <Indications>
nan

> <Type>
nan

> <targets_id>
nan

> <inchi>
InChI=1S/C17H21FN6O/c1-24-8-9(6-21-24)15-13-10(7-20-17(13)25)14(18)16(23-15)22-12-5-3-2-4-11(12)19/h6,8,11-12H,2-5,7,19H2,1H3,(H,20,25)(H,22,23)/t11-,12+/m0/s1

> <stdInchikey>
MJHOMTRKVMKCNE-NWDGAFQWSA-N

> <csid>
57583808

> <Links>
|http://www.chemspider.com/Chemical-Structure.57583808.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3979920|http://pubchem.ncbi.nlm.nih.gov/compound/53252276| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=7KG|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/7KG|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9600|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=8QR88H79VX|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50204290

> <LinkName>
|ChemSpider|ChEMBL|PubChem|RCSB|PDBe|Guide to Pharmacology|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
344.2

> <HBA>
6

> <HBD>
3

> <NRB>
3

> <TPSA>
97.9

> <LogP>
1.5

> <RoF>
0

> <Targets>
nan

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0002

> <r_epik_State_Penalty>
  0.0000

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
111

> <lig_pdbID>
'7KG'

> <pdbID>
5tr6

> <Kinase families>
(*)

$$$$
Glesatinib
                    3D
 Structure written by MMmdl.
 70 74  0  0  1  0            999 V2000
   -2.9722    3.9345    1.5385 C   0  0  0  0  0  0
   -2.0882    2.9369    1.0496 O   0  0  0  0  0  0
   -2.4290    1.6225    1.4708 C   0  0  0  0  0  0
   -1.4077    0.6208    0.9136 C   0  0  0  0  0  0
   -1.4037    0.6876   -0.6234 N   0  3  0  0  0  0
   -0.4570   -0.3103   -1.3105 C   0  0  0  0  0  0
    1.0155   -0.0584   -1.0305 C   0  0  0  0  0  0
    1.7334    0.8896   -1.7650 C   0  0  0  0  0  0
    3.0860    1.0975   -1.4891 C   0  0  0  0  0  0
    3.7004    0.3424   -0.4790 C   0  0  0  0  0  0
    3.0094   -0.5924    0.2311 N   0  0  0  0  0  0
    1.6961   -0.7840   -0.0492 C   0  0  0  0  0  0
    5.1438    0.4945   -0.0956 C   0  0  0  0  0  0
    5.8630   -0.2141    0.8581 C   0  0  0  0  0  0
    7.2159    0.2042    0.9691 C   0  0  0  0  0  0
    7.5393    1.2603    0.0726 C   0  0  0  0  0  0
    6.1430    1.7073   -0.8938 S   0  0  0  0  0  0
    8.8380    1.7960    0.0555 C   0  0  0  0  0  0
    9.7667    1.2471    0.9501 C   0  0  0  0  0  0
    9.3669    0.2127    1.7935 C   0  0  0  0  0  0
    8.1146   -0.3144    1.8154 N   0  0  0  0  0  0
    9.0738    2.8200   -0.8395 O   0  0  0  0  0  0
   10.3214    3.3886   -0.9300 C   0  0  0  0  0  0
   11.3188    2.7743   -1.6932 C   0  0  0  0  0  0
   12.5854    3.3509   -1.7883 C   0  0  0  0  0  0
   12.8649    4.5415   -1.1125 C   0  0  0  0  0  0
   11.8585    5.1719   -0.3688 C   0  0  0  0  0  0
   10.5927    4.5930   -0.2730 C   0  0  0  0  0  0
    9.6297    5.2034    0.4559 F   0  0  0  0  0  0
   14.1427    5.1113   -1.2638 N   0  0  0  0  0  0
   15.0879    5.5197   -0.3580 C   0  0  0  0  0  0
   14.8508    5.1520    1.2897 S   0  0  0  0  0  0
   16.0874    6.2147   -0.8531 N   0  5  0  0  0  0
   17.2595    6.4813   -0.2912 C   0  0  0  0  0  0
   17.9185    5.7345    0.4397 O   0  0  0  0  0  0
   17.9078    7.8248   -0.6615 C   0  0  0  0  0  0
   17.6800    8.8682    0.4270 C   0  0  0  0  0  0
   16.5302    9.6632    0.3994 C   0  0  0  0  0  0
   16.3108   10.6050    1.4013 C   0  0  0  0  0  0
   17.2390   10.7474    2.4309 C   0  0  0  0  0  0
   18.3837    9.9534    2.4682 C   0  0  0  0  0  0
   18.6037    9.0107    1.4672 C   0  0  0  0  0  0
   17.0260   11.6625    3.4035 F   0  0  0  0  0  0
   -2.6524    4.9121    1.1778 H   0  0  0  0  0  0
   -2.9742    3.9658    2.6293 H   0  0  0  0  0  0
   -3.9928    3.7685    1.1905 H   0  0  0  0  0  0
   -2.4396    1.5645    2.5606 H   0  0  0  0  0  0
   -3.4306    1.3681    1.1179 H   0  0  0  0  0  0
   -0.3891    0.8598    1.2220 H   0  0  0  0  0  0
   -1.6503   -0.4114    1.1698 H   0  0  0  0  0  0
   -2.3431    0.5155   -0.9525 H   0  0  0  0  0  0
   -0.7843   -1.2963   -0.9756 H   0  0  0  0  0  0
   -0.6868   -0.2005   -2.3714 H   0  0  0  0  0  0
    1.2501    1.4659   -2.5405 H   0  0  0  0  0  0
    3.6335    1.8351   -2.0562 H   0  0  0  0  0  0
    1.1898   -1.5352    0.5397 H   0  0  0  0  0  0
    5.4387   -1.0036    1.4610 H   0  0  0  0  0  0
   10.7822    1.6119    0.9975 H   0  0  0  0  0  0
   10.0721   -0.2200    2.4882 H   0  0  0  0  0  0
   11.1100    1.8496   -2.2113 H   0  0  0  0  0  0
   13.3468    2.8668   -2.3834 H   0  0  0  0  0  0
   12.0551    6.1079    0.1341 H   0  0  0  0  0  0
   14.5067    4.9898   -2.1975 H   0  0  0  0  0  0
   18.9794    7.6738   -0.8039 H   0  0  0  0  0  0
   17.5320    8.1924   -1.6190 H   0  0  0  0  0  0
   15.8066    9.5482   -0.3947 H   0  0  0  0  0  0
   15.4231   11.2199    1.3813 H   0  0  0  0  0  0
   19.0964   10.0663    3.2717 H   0  0  0  0  0  0
   19.4878    8.3906    1.5011 H   0  0  0  0  0  0
   -1.1490    1.6243   -0.9046 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 44  1  0  0  0
  1 45  1  0  0  0
  1 46  1  0  0  0
  2  3  1  0  0  0
  3  4  1  0  0  0
  3 47  1  0  0  0
  3 48  1  0  0  0
  4  5  1  0  0  0
  4 49  1  0  0  0
  4 50  1  0  0  0
  5  6  1  0  0  0
  5 51  1  0  0  0
  5 70  1  0  0  0
  6  7  1  0  0  0
  6 52  1  0  0  0
  6 53  1  0  0  0
  7  8  1  0  0  0
  7 12  2  0  0  0
  8  9  2  0  0  0
  8 54  1  0  0  0
  9 10  1  0  0  0
  9 55  1  0  0  0
 10 11  2  0  0  0
 10 13  1  0  0  0
 11 12  1  0  0  0
 12 56  1  0  0  0
 13 14  2  0  0  0
 13 17  1  0  0  0
 14 15  1  0  0  0
 14 57  1  0  0  0
 15 16  1  0  0  0
 15 21  2  0  0  0
 16 17  1  0  0  0
 16 18  2  0  0  0
 18 19  1  0  0  0
 18 22  1  0  0  0
 19 20  2  0  0  0
 19 58  1  0  0  0
 20 21  1  0  0  0
 20 59  1  0  0  0
 22 23  1  0  0  0
 23 24  1  0  0  0
 23 28  2  0  0  0
 24 25  2  0  0  0
 24 60  1  0  0  0
 25 26  1  0  0  0
 25 61  1  0  0  0
 26 27  2  0  0  0
 26 30  1  0  0  0
 27 28  1  0  0  0
 27 62  1  0  0  0
 28 29  1  0  0  0
 30 31  1  0  0  0
 30 63  1  0  0  0
 31 32  2  0  0  0
 31 33  1  0  0  0
 33 34  1  0  0  0
 34 35  2  0  0  0
 34 36  1  0  0  0
 36 37  1  0  0  0
 36 64  1  0  0  0
 36 65  1  0  0  0
 37 38  1  0  0  0
 37 42  2  0  0  0
 38 39  2  0  0  0
 38 66  1  0  0  0
 39 40  1  0  0  0
 39 67  1  0  0  0
 40 41  2  0  0  0
 40 43  1  0  0  0
 41 42  1  0  0  0
 41 68  1  0  0  0
 42 69  1  0  0  0
M  CHG  2   5   1  33  -1
M  END
> <s_m_entry_id>
112

> <Applicants>
Mirati Therapeutics

> <CHEMBL_ID>
CHEMBL3989914

> <Canonical_Smiles>
s1c2c(nccc2Oc2ccc(NC(=S)NC(=O)Cc3ccc(F)cc3)cc2F)cc1-c1ncc(cc1)CNCCOC

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
GLESATINIB | MG-90265 | MG-90265X | MG90265 | MG90265GLY | MG90265H9 | MG90265X | MGCD-265 | MGCD265

> <Indications>
nan

> <Type>
nan

> <targets_id>
P08581|Q02763|P17948|P35968|P35916|Q04912

> <inchi>
InChI=1S/C31H27F2N5O3S2/c1-40-13-12-34-17-20-4-8-24(36-18-20)28-16-25-30(43-28)27(10-11-35-25)41-26-9-7-22(15-23(26)33)37-31(42)38-29(39)14-19-2-5-21(32)6-3-19/h2-11,15-16,18,34H,12-14,17H2,1H3,(H2,37,38,39,42)

> <stdInchikey>
YRCHYHRCBXNYNU-UHFFFAOYSA-N

> <csid>
52084900

> <Links>
|http://www.chemspider.com/Chemical-Structure.52084900.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3989914|http://pubchem.ncbi.nlm.nih.gov/compound/25181472|http://www.drugbank.ca/drugs/DB06302|http://zinc15.docking.org/substances/ZINC000113139653|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=7Q29OXD98N

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|ZINC|FDA SRS

> <MW>
619.2

> <HBA>
8

> <HBD>
3

> <NRB>
11

> <TPSA>
97.4

> <LogP>
6.2

> <RoF>
2

> <Targets>
MET; TEK; FLT1; KDR; FLT4; MST1R

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_epik_Ionization_Penalty>
  0.4996

> <r_epik_State_Penalty>
  0.4871

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
112

> <Kinase families>
Tyr

$$$$
Bemcentinib
                    3D
 Structure written by MMmdl.
 73 79  0  0  1  0            999 V2000
   -9.4992    4.2697    0.5284 C   0  0  0  0  0  0
   -9.2361    3.0188    1.0776 C   0  0  0  0  0  0
   -7.9828    2.4351    0.9072 C   0  0  0  0  0  0
   -6.9743    3.0916    0.1852 C   0  0  0  0  0  0
   -7.2471    4.3586   -0.3782 C   0  0  0  0  0  0
   -8.5101    4.9327   -0.1938 C   0  0  0  0  0  0
   -6.1683    5.0687   -1.1927 C   0  0  0  0  0  0
   -4.9545    5.5644   -0.3781 C   0  0  0  0  0  0
   -4.4396    4.5879    0.7003 C   0  0  0  0  0  0
   -4.4221    3.1211    0.2829 C   0  0  0  0  0  0
   -5.6325    2.4343    0.0656 C   0  0  0  0  0  0
   -5.6483    1.1161   -0.2822 N   0  0  0  0  0  0
   -4.5032    0.4340   -0.4357 N   0  0  0  0  0  0
   -3.3063    1.0505   -0.2414 C   0  0  0  0  0  0
   -3.2362    2.4028    0.1162 C   0  0  0  0  0  0
   -2.1313    0.2731   -0.4213 N   0  0  0  0  0  0
   -1.8916   -0.8720   -1.1532 C   0  0  0  0  0  0
   -0.6512   -1.2548   -1.0006 N   0  0  0  0  0  0
   -0.1525   -0.3530   -0.1714 C   0  0  0  0  0  0
   -0.9876    0.5947    0.2025 N   0  0  0  0  0  0
    1.1678   -0.4436    0.2090 N   0  0  0  0  0  0
    1.9200    0.3070    1.1333 C   0  0  0  0  0  0
    3.3043    0.1474    1.1055 C   0  0  0  0  0  0
    4.1162    0.8502    1.9906 C   0  0  0  0  0  0
    3.5702    1.7264    2.9346 C   0  0  0  0  0  0
    2.1703    1.8903    2.9828 C   0  0  0  0  0  0
    1.3678    1.1759    2.0838 C   0  0  0  0  0  0
    1.5309    2.8398    3.9941 C   0  0  0  0  0  0
    1.8908    4.3278    3.7974 C   0  0  0  0  0  0
    3.2657    4.7617    4.3642 C   0  0  2  0  0  0
    4.4656    4.0262    3.7159 C   0  0  0  0  0  0
    4.4816    2.4924    3.8914 C   0  0  0  0  0  0
    3.2994    4.5883    5.9097 N   0  3  0  0  0  0
    4.5957    5.0693    6.6001 C   0  0  0  0  0  0
    4.1898    5.4412    8.0333 C   0  0  0  0  0  0
    2.6811    5.2348    8.1270 C   0  0  0  0  0  0
    2.1890    5.3162    6.6883 C   0  0  0  0  0  0
   -2.8048   -1.5077   -1.9482 N   0  0  0  0  0  0
  -10.4697    4.7250    0.6608 H   0  0  0  0  0  0
  -10.0008    2.5034    1.6398 H   0  0  0  0  0  0
   -7.7946    1.4690    1.3534 H   0  0  0  0  0  0
   -8.7300    5.9014   -0.6184 H   0  0  0  0  0  0
   -5.8256    4.3752   -1.9624 H   0  0  0  0  0  0
   -6.6036    5.9038   -1.7437 H   0  0  0  0  0  0
   -4.1448    5.7941   -1.0721 H   0  0  0  0  0  0
   -5.2054    6.5103    0.1040 H   0  0  0  0  0  0
   -3.4460    4.8946    1.0304 H   0  0  0  0  0  0
   -5.0701    4.6682    1.5875 H   0  0  0  0  0  0
   -2.2842    2.8911    0.2677 H   0  0  0  0  0  0
    1.7413   -1.1200   -0.2727 H   0  0  0  0  0  0
    3.7634   -0.5207    0.3907 H   0  0  0  0  0  0
    5.1861    0.7092    1.9386 H   0  0  0  0  0  0
    0.3004    1.3043    2.1563 H   0  0  0  0  0  0
    0.4462    2.7413    3.9266 H   0  0  0  0  0  0
    1.7755    2.5074    5.0035 H   0  0  0  0  0  0
    1.8472    4.5691    2.7340 H   0  0  0  0  0  0
    1.1069    4.9412    4.2415 H   0  0  0  0  0  0
    3.3854    5.8380    4.2258 H   0  0  0  0  0  0
    4.5026    4.2663    2.6520 H   0  0  0  0  0  0
    5.3954    4.4308    4.1163 H   0  0  0  0  0  0
    4.2390    2.2146    4.9175 H   0  0  0  0  0  0
    5.5057    2.1447    3.7455 H   0  0  0  0  0  0
    5.3115    4.2484    6.5435 H   0  0  0  0  0  0
    4.9557    5.9389    6.0472 H   0  0  0  0  0  0
    4.7208    4.8422    8.7746 H   0  0  0  0  0  0
    4.4430    6.4853    8.2233 H   0  0  0  0  0  0
    2.4531    4.2504    8.5390 H   0  0  0  0  0  0
    2.2050    5.9781    8.7678 H   0  0  0  0  0  0
    2.1553    6.3408    6.3130 H   0  0  0  0  0  0
    1.2411    4.8035    6.5232 H   0  0  0  0  0  0
   -3.6915   -1.8145   -1.5752 H   0  0  0  0  0  0
   -2.5229   -1.9206   -2.8250 H   0  0  0  0  0  0
    3.2009    3.6040    6.1150 H   0  0  0  0  0  0
  1  2  2  0  0  0
  1  6  1  0  0  0
  1 39  1  0  0  0
  2  3  1  0  0  0
  2 40  1  0  0  0
  3  4  2  0  0  0
  3 41  1  0  0  0
  4  5  1  0  0  0
  4 11  1  0  0  0
  5  6  2  0  0  0
  5  7  1  0  0  0
  6 42  1  0  0  0
  7  8  1  0  0  0
  7 43  1  0  0  0
  7 44  1  0  0  0
  8  9  1  0  0  0
  8 45  1  0  0  0
  8 46  1  0  0  0
  9 10  1  0  0  0
  9 47  1  0  0  0
  9 48  1  0  0  0
 10 11  1  0  0  0
 10 15  2  0  0  0
 11 12  2  0  0  0
 12 13  1  0  0  0
 13 14  2  0  0  0
 14 15  1  0  0  0
 14 16  1  0  0  0
 15 49  1  0  0  0
 16 17  1  0  0  0
 16 20  1  0  0  0
 17 18  2  0  0  0
 17 38  1  0  0  0
 18 19  1  0  0  0
 19 20  2  0  0  0
 19 21  1  0  0  0
 21 22  1  0  0  0
 21 50  1  0  0  0
 22 23  1  0  0  0
 22 27  2  0  0  0
 23 24  2  0  0  0
 23 51  1  0  0  0
 24 25  1  0  0  0
 24 52  1  0  0  0
 25 26  2  0  0  0
 25 32  1  0  0  0
 26 27  1  0  0  0
 26 28  1  0  0  0
 27 53  1  0  0  0
 28 29  1  0  0  0
 28 54  1  0  0  0
 28 55  1  0  0  0
 29 30  1  0  0  0
 29 56  1  0  0  0
 29 57  1  0  0  0
 30 31  1  0  0  0
 30 33  1  0  0  0
 30 58  1  0  0  0
 31 32  1  0  0  0
 31 59  1  0  0  0
 31 60  1  0  0  0
 32 61  1  0  0  0
 32 62  1  0  0  0
 33 34  1  0  0  0
 33 37  1  0  0  0
 33 73  1  0  0  0
 34 35  1  0  0  0
 34 63  1  0  0  0
 34 64  1  0  0  0
 35 36  1  0  0  0
 35 65  1  0  0  0
 35 66  1  0  0  0
 36 37  1  0  0  0
 36 67  1  0  0  0
 36 68  1  0  0  0
 37 69  1  0  0  0
 37 70  1  0  0  0
 38 71  1  0  0  0
 38 72  1  0  0  0
M  CHG  1  33   1
M  END
> <s_m_entry_id>
116

> <Applicants>
BerGenBio

> <CHEMBL_ID>
CHEMBL3809489

> <Canonical_Smiles>
n1c(n(nc1Nc1cc2CC[C@@H](N3CCCC3)CCc2cc1)-c1nnc-2c(c1)CCCc1c-2cccc1)N

> <Chirality>
Single Stereoisomer

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
BEMCENTINIB | BGB 324 | BGB-324 | BGB324 | CS-1046 | HY-15150 | KB-80319 | QC-11751 | R 428 | R-428 | R428 | SYN-1131 | SYN1131 | W-5845

> <Indications>
nan

> <Type>
nan

> <targets_id>
P30530

> <inchi>
InChI=1S/C30H34N8/c31-29-33-30(32-24-13-10-20-11-14-25(15-12-22(20)18-24)37-16-3-4-17-37)36-38(29)27-19-23-8-5-7-21-6-1-2-9-26(21)28(23)35-34-27/h1-2,6,9-10,13,18-19,25H,3-5,7-8,11-12,14-17H2,(H3,31,32,33,36)/t25-/m0/s1

> <stdInchikey>
KXMZDGSRSGHMMK-VWLOTQADSA-N

> <csid>
28637805

> <Links>
|http://www.chemspider.com/Chemical-Structure.28637805.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3809489|http://pubchem.ncbi.nlm.nih.gov/compound/46215462|http://www.drugbank.ca/drugs/DB12411|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10478|http://zinc15.docking.org/substances/ZINC000051951669|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=0ICW2LX8AS|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50172079

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
506.3

> <HBA>
8

> <HBD>
2

> <NRB>
4

> <TPSA>
97.8

> <LogP>
4.9

> <RoF>
1

> <Targets>
AXL

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0018

> <r_epik_State_Penalty>
  0.0000

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
116

> <Kinase families>
Tyr

$$$$
Bafetinib
                    3D
 Structure written by MMmdl.
 74 78  0  0  1  0            999 V2000
   -5.9087   -1.9908    0.0081 C   0  0  0  0  0  0
   -4.4252   -1.6395    0.0633 C   0  0  0  0  0  0
   -3.4969   -2.5761   -0.4009 C   0  0  0  0  0  0
   -2.1332   -2.2976   -0.3720 C   0  0  0  0  0  0
   -1.6746   -1.0698    0.1050 C   0  0  0  0  0  0
   -2.6022   -0.1337    0.5882 C   0  0  0  0  0  0
   -3.9781   -0.4089    0.5810 C   0  0  0  0  0  0
   -4.9232    0.5250    1.0514 N   0  0  0  0  0  0
   -4.8695    1.5238    2.0354 C   0  0  0  0  0  0
   -3.7282    1.7288    2.7454 N   0  0  0  0  0  0
   -3.7614    2.7000    3.6915 C   0  0  0  0  0  0
   -4.9036    3.4602    3.9428 C   0  0  0  0  0  0
   -6.0425    3.1869    3.1721 C   0  0  0  0  0  0
   -6.0268    2.2095    2.2211 N   0  0  0  0  0  0
   -7.3288    3.9233    3.3546 C   0  0  0  0  0  0
   -7.3760    5.2318    3.8625 C   0  0  0  0  0  0
   -8.5317    5.9237    4.0388 N   0  0  0  0  0  0
   -9.6712    5.2760    3.6916 C   0  0  0  0  0  0
   -9.7551    4.0188    3.1910 N   0  0  0  0  0  0
   -8.5763    3.3629    3.0298 C   0  0  0  0  0  0
   -0.2825   -0.8698    0.1015 N   0  0  0  0  0  0
    0.4001    0.2971    0.0480 C   0  0  0  0  0  0
   -0.1219    1.4112   -0.0295 O   0  0  0  0  0  0
    1.9050    0.1725    0.1055 C   0  0  0  0  0  0
    2.6649    1.1872    0.6946 C   0  0  0  0  0  0
    4.0520    1.0929    0.7462 C   0  0  0  0  0  0
    4.7204   -0.0102    0.2037 C   0  0  0  0  0  0
    3.9711   -1.0524   -0.3860 C   0  0  0  0  0  0
    2.5722   -0.9391   -0.4307 C   0  0  0  0  0  0
    4.6391   -2.3063   -0.9704 C   0  0  0  0  0  0
    3.7582   -3.1751   -1.4714 F   0  0  0  0  0  0
    5.4698   -1.9679   -1.9561 F   0  0  0  0  0  0
    5.3265   -2.9402   -0.0196 F   0  0  0  0  0  0
    6.2503   -0.0319    0.2979 C   0  0  0  0  0  0
    6.8719    1.0963   -0.4002 N   0  0  0  0  0  0
    6.7770    1.0213   -1.8519 C   0  0  0  0  0  0
    7.8300    2.0037   -2.3715 C   0  0  0  0  0  0
    8.8173    2.1843   -1.2066 C   0  0  1  0  0  0
    8.3042    1.1881   -0.1561 C   0  0  0  0  0  0
   10.3247    2.1306   -1.5534 N   0  3  0  0  0  0
   11.2258    2.1798   -0.3026 C   0  0  0  0  0  0
   10.7359    3.2246   -2.5603 C   0  0  0  0  0  0
   -6.4570   -1.2443   -0.5673 H   0  0  0  0  0  0
   -6.3280   -2.0238    1.0142 H   0  0  0  0  0  0
   -6.0841   -2.9612   -0.4579 H   0  0  0  0  0  0
   -3.8293   -3.5285   -0.7878 H   0  0  0  0  0  0
   -1.4371   -3.0398   -0.7369 H   0  0  0  0  0  0
   -2.2536    0.8125    0.9665 H   0  0  0  0  0  0
   -5.8669    0.3305    0.7521 H   0  0  0  0  0  0
   -2.8535    2.8608    4.2541 H   0  0  0  0  0  0
   -4.8977    4.2188    4.7109 H   0  0  0  0  0  0
   -6.4742    5.7621    4.1310 H   0  0  0  0  0  0
  -10.5994    5.8120    3.8254 H   0  0  0  0  0  0
   -8.6521    2.3602    2.6343 H   0  0  0  0  0  0
    0.2669   -1.7162    0.0871 H   0  0  0  0  0  0
    2.1869    2.0589    1.1196 H   0  0  0  0  0  0
    4.6136    1.8927    1.2076 H   0  0  0  0  0  0
    1.9936   -1.7258   -0.8930 H   0  0  0  0  0  0
    6.5105    0.0311    1.3559 H   0  0  0  0  0  0
    6.6798   -0.9678   -0.0557 H   0  0  0  0  0  0
    7.0185    0.0144   -2.1977 H   0  0  0  0  0  0
    5.7732    1.2675   -2.2007 H   0  0  0  0  0  0
    8.3035    1.6066   -3.2700 H   0  0  0  0  0  0
    7.3778    2.9605   -2.6371 H   0  0  0  0  0  0
    8.7051    3.1919   -0.7991 H   0  0  0  0  0  0
    8.5116    1.5196    0.8623 H   0  0  0  0  0  0
    8.7754    0.2131   -0.3004 H   0  0  0  0  0  0
   11.0256    3.1188    0.2159 H   0  0  0  0  0  0
   12.2605    2.1221   -0.6432 H   0  0  0  0  0  0
   10.9798    1.3166    0.3161 H   0  0  0  0  0  0
   10.5567    4.1936   -2.0916 H   0  0  0  0  0  0
   10.1331    3.0965   -3.4594 H   0  0  0  0  0  0
   11.7934    3.0781   -2.7846 H   0  0  0  0  0  0
   10.4900    1.2393   -2.0003 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 43  1  0  0  0
  1 44  1  0  0  0
  1 45  1  0  0  0
  2  3  1  0  0  0
  2  7  2  0  0  0
  3  4  2  0  0  0
  3 46  1  0  0  0
  4  5  1  0  0  0
  4 47  1  0  0  0
  5  6  2  0  0  0
  5 21  1  0  0  0
  6  7  1  0  0  0
  6 48  1  0  0  0
  7  8  1  0  0  0
  8  9  1  0  0  0
  8 49  1  0  0  0
  9 10  1  0  0  0
  9 14  2  0  0  0
 10 11  2  0  0  0
 11 12  1  0  0  0
 11 50  1  0  0  0
 12 13  2  0  0  0
 12 51  1  0  0  0
 13 14  1  0  0  0
 13 15  1  0  0  0
 15 16  2  0  0  0
 15 20  1  0  0  0
 16 17  1  0  0  0
 16 52  1  0  0  0
 17 18  2  0  0  0
 18 19  1  0  0  0
 18 53  1  0  0  0
 19 20  2  0  0  0
 20 54  1  0  0  0
 21 22  1  0  0  0
 21 55  1  0  0  0
 22 23  2  0  0  0
 22 24  1  0  0  0
 24 25  2  0  0  0
 24 29  1  0  0  0
 25 26  1  0  0  0
 25 56  1  0  0  0
 26 27  2  0  0  0
 26 57  1  0  0  0
 27 28  1  0  0  0
 27 34  1  0  0  0
 28 29  2  0  0  0
 28 30  1  0  0  0
 29 58  1  0  0  0
 30 31  1  0  0  0
 30 32  1  0  0  0
 30 33  1  0  0  0
 34 35  1  0  0  0
 34 59  1  0  0  0
 34 60  1  0  0  0
 35 36  1  0  0  0
 35 39  1  0  0  0
 36 37  1  0  0  0
 36 61  1  0  0  0
 36 62  1  0  0  0
 37 38  1  0  0  0
 37 63  1  0  0  0
 37 64  1  0  0  0
 38 39  1  0  0  0
 38 40  1  0  0  0
 38 65  1  0  0  0
 39 66  1  0  0  0
 39 67  1  0  0  0
 40 41  1  0  0  0
 40 42  1  0  0  0
 40 74  1  0  0  0
 41 68  1  0  0  0
 41 69  1  0  0  0
 41 70  1  0  0  0
 42 71  1  0  0  0
 42 72  1  0  0  0
 42 73  1  0  0  0
M  CHG  1  40   1
M  END
> <s_m_entry_id>
117

> <Applicants>
Innovive Pharmaceuticals

> <CHEMBL_ID>
CHEMBL206834

> <Canonical_Smiles>
FC(F)(F)c1cc(ccc1CN1C[C@@H](N(C)C)CC1)C(=O)Nc1cc(Nc2nc(ccn2)-c2cncnc2)c(cc1)C

> <Chirality>
Single Stereoisomer

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
BAFETINIB | CNS-9 | INNO-406 | NS-187

> <Indications>
nan

> <Type>
2

> <targets_id>
P07948|P00519

> <inchi>
InChI=1S/C30H31F3N8O/c1-19-4-7-23(13-27(19)39-29-36-10-8-26(38-29)22-14-34-18-35-15-22)37-28(42)20-5-6-21(25(12-20)30(31,32)33)16-41-11-9-24(17-41)40(2)3/h4-8,10,12-15,18,24H,9,11,16-17H2,1-3H3,(H,37,42)(H,36,38,39)/t24-/m0/s1

> <stdInchikey>
ZGBAJMQHJDFTQJ-DEOSSOPVSA-N

> <csid>
9562515

> <Links>
|http://www.chemspider.com/Chemical-Structure.9562515.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL206834|http://pubchem.ncbi.nlm.nih.gov/compound/11387605|http://www.drugbank.ca/drugs/DB11851| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=406|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/406|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7906|http://zinc15.docking.org/substances/ZINC000022940637|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=NVW4Z03I9B|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50178612

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
576.3

> <HBA>
8

> <HBD>
2

> <NRB>
8

> <TPSA>
99.2

> <LogP>
5.4

> <RoF>
2

> <Targets>
LYN; ABL1

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0081

> <r_epik_State_Penalty>
  0.0733

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
117

> <lig_pdbID>
'406'

> <pdbID>
2e2b

> <Kinase families>
Tyr

$$$$
Silmitasertib
                    3D
 Structure written by MMmdl.
 36 39  0  0  1  0            999 V2000
   -2.9072    2.2263    0.2817 C   0  0  0  0  0  0
   -1.9844    1.2486   -0.0906 C   0  0  0  0  0  0
   -0.6269    1.5605   -0.2206 C   0  0  0  0  0  0
   -0.2102    2.8807    0.0076 C   0  0  0  0  0  0
   -1.1333    3.8599    0.3784 C   0  0  0  0  0  0
   -2.4814    3.5318    0.5193 C   0  0  0  0  0  0
   -0.6077    5.4802    0.6563 Cl  0  0  0  0  0  0
    0.2433    0.5234   -0.6040 N   0  0  0  0  0  0
    1.6239    0.2965   -0.4260 C   0  0  0  0  0  0
    2.2061   -0.9045   -0.9266 C   0  0  0  0  0  0
    1.4814   -1.9165   -1.6264 C   0  0  0  0  0  0
    2.1559   -3.0517   -2.0706 C   0  0  0  0  0  0
    3.4777   -3.2597   -1.8779 N   0  0  0  0  0  0
    4.1688   -2.3040   -1.2163 C   0  0  0  0  0  0
    3.6059   -1.0988   -0.7092 C   0  0  0  0  0  0
    4.3528   -0.1074   -0.0147 C   0  0  0  0  0  0
    5.7471   -0.2138    0.2451 C   0  0  0  0  0  0
    6.4173    0.7951    0.9312 C   0  0  0  0  0  0
    5.7534    1.9401    1.3883 C   0  0  0  0  0  0
    4.3787    2.0607    1.1412 C   0  0  0  0  0  0
    3.6668    1.0535    0.4454 C   0  0  0  0  0  0
    2.3373    1.2357    0.2409 N   0  0  0  0  0  0
    6.4982    3.0152    2.1273 C   0  0  0  0  0  0
    5.8547    4.0169    2.5162 O   0  0  0  0  0  0
    7.7262    2.8567    2.3182 O   0  5  0  0  0  0
   -3.9519    1.9722    0.3850 H   0  0  0  0  0  0
   -2.3325    0.2414   -0.2714 H   0  0  0  0  0  0
    0.8209    3.1726   -0.1165 H   0  0  0  0  0  0
   -3.1979    4.2875    0.8066 H   0  0  0  0  0  0
   -0.2409   -0.2888   -0.9571 H   0  0  0  0  0  0
    0.4232   -1.8090   -1.8129 H   0  0  0  0  0  0
    1.6248   -3.8282   -2.6012 H   0  0  0  0  0  0
    5.2171   -2.5231   -1.0913 H   0  0  0  0  0  0
    6.3109   -1.0727   -0.0819 H   0  0  0  0  0  0
    7.4768    0.6696    1.1047 H   0  0  0  0  0  0
    3.8320    2.9309    1.4789 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1  6  2  0  0  0
  1 26  1  0  0  0
  2  3  2  0  0  0
  2 27  1  0  0  0
  3  4  1  0  0  0
  3  8  1  0  0  0
  4  5  2  0  0  0
  4 28  1  0  0  0
  5  6  1  0  0  0
  5  7  1  0  0  0
  6 29  1  0  0  0
  8  9  1  0  0  0
  8 30  1  0  0  0
  9 10  1  0  0  0
  9 22  2  0  0  0
 10 11  1  0  0  0
 10 15  2  0  0  0
 11 12  2  0  0  0
 11 31  1  0  0  0
 12 13  1  0  0  0
 12 32  1  0  0  0
 13 14  2  0  0  0
 14 15  1  0  0  0
 14 33  1  0  0  0
 15 16  1  0  0  0
 16 17  1  0  0  0
 16 21  2  0  0  0
 17 18  2  0  0  0
 17 34  1  0  0  0
 18 19  1  0  0  0
 18 35  1  0  0  0
 19 20  2  0  0  0
 19 23  1  0  0  0
 20 21  1  0  0  0
 20 36  1  0  0  0
 21 22  1  0  0  0
 23 24  2  0  0  0
 23 25  1  0  0  0
M  CHG  1  25  -1
M  END
> <s_m_entry_id>
123

> <Applicants>
Senhwa Biosciences

> <CHEMBL_ID>
CHEMBL1230165

> <Canonical_Smiles>
Clc1cc(Nc2nc3cc(ccc3c3c2ccnc3)C(O)=O)ccc1

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
CX 4945 | CX-4945 | CX4945 | SILMITASERTIB

> <Indications>
nan

> <Type>
1

> <targets_id>
P68400|P19784

> <inchi>
InChI=1S/C19H12ClN3O2/c20-12-2-1-3-13(9-12)22-18-15-6-7-21-10-16(15)14-5-4-11(19(24)25)8-17(14)23-18/h1-10H,(H,22,23)(H,24,25)

> <stdInchikey>
MUOKSQABCJCOPU-UHFFFAOYSA-N

> <csid>
25057795

> <Links>
|http://www.chemspider.com/Chemical-Structure.25057795.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1230165|http://pubchem.ncbi.nlm.nih.gov/compound/24748573|http://www.drugbank.ca/drugs/DB15408| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=3NG|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/3NG|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8126|http://zinc15.docking.org/substances/ZINC000058638454|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=C6RWP0N0L2|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50335638

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
349.1

> <HBA>
4

> <HBD>
2

> <NRB>
3

> <TPSA>
75.1

> <LogP>
4.9

> <RoF>
0

> <Targets>
CSNK2A1; CSNK2A2

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0004

> <r_epik_State_Penalty>
  0.0000

> <i_epik_Tot_Q>
-1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
123

> <lig_pdbID>
'3NG'

> <pdbID>
3nga 3pe1 5o11 6fyl 6fyp 6fyv 6hmb 6isj 6k3l 6khd 6khe 6khf 6p5s

> <Kinase families>
Other

$$$$
Fenebrutinib
                    3D
 Structure written by MMmdl.
 94101  0  0  1  0            999 V2000
   -3.5083   -6.7186   -4.5320 C   0  0  0  0  0  0
   -2.5759   -7.7025   -3.7898 C   0  0  1  0  0  0
   -1.8985   -8.6265   -4.8396 C   0  0  0  0  0  0
   -0.9643   -9.6684   -4.1840 N   0  3  1  0  0  0
   -0.0039   -9.0045   -3.1752 C   0  0  0  0  0  0
   -0.7729   -8.0828   -2.2079 C   0  0  0  0  0  0
   -1.5724   -7.0701   -2.9075 N   0  0  0  0  0  0
   -1.8588   -5.9152   -2.1980 C   0  0  0  0  0  0
   -2.9220   -5.8454   -1.2883 C   0  0  0  0  0  0
   -3.1639   -4.6600   -0.5917 C   0  0  0  0  0  0
   -2.3285   -3.5601   -0.8099 C   0  0  0  0  0  0
   -1.2907   -3.6162   -1.6905 N   0  0  0  0  0  0
   -1.0685   -4.7741   -2.3613 C   0  0  0  0  0  0
   -2.6043   -2.3735   -0.1059 N   0  0  0  0  0  0
   -1.9053   -1.1730   -0.0703 C   0  0  0  0  0  0
   -0.5574   -1.0624   -0.1992 C   0  0  0  0  0  0
    0.1136    0.2297   -0.1490 C   0  0  0  0  0  0
   -0.7119    1.2715    0.0941 C   0  0  0  0  0  0
   -2.0778    1.2150    0.2511 N   0  0  0  0  0  0
   -2.7572    0.0124    0.1709 C   0  0  0  0  0  0
   -3.9861   -0.0681    0.2936 O   0  0  0  0  0  0
   -2.8548    2.4382    0.4948 C   0  0  0  0  0  0
    1.5898    0.3824   -0.2895 C   0  0  0  0  0  0
    2.2327    1.2619    0.5961 C   0  0  0  0  0  0
    3.6179    1.3684    0.5844 C   0  0  0  0  0  0
    4.3974    0.6503   -0.2510 N   0  0  0  0  0  0
    3.7934   -0.1747   -1.1471 C   0  0  0  0  0  0
    2.3863   -0.3247   -1.2296 C   0  0  0  0  0  0
    1.7588   -1.2009   -2.3312 C   0  0  0  0  0  0
    2.1798   -0.8746   -3.6402 O   0  0  0  0  0  0
    4.6609   -0.9110   -1.9770 N   0  0  0  0  0  0
    4.9477   -2.2965   -1.5250 C   0  0  0  0  0  0
    5.0669   -3.2473   -2.7361 C   0  0  0  0  0  0
    6.0181   -2.6217   -3.6348 N   0  0  0  0  0  0
    6.1483   -1.2466   -3.7737 C   0  0  0  0  0  0
    7.1149   -1.0215   -4.7586 C   0  0  0  0  0  0
    7.5821   -2.2607   -5.1965 C   0  0  0  0  0  0
    6.8916   -3.2176   -4.5094 C   0  0  0  0  0  0
    7.2797   -4.6156   -4.9023 C   0  0  0  0  0  0
    8.0207   -4.3701   -6.2466 C   0  0  0  0  0  0
    8.5424   -2.9046   -6.1628 C   0  0  0  0  0  0
    9.1843   -5.3678   -6.4321 C   0  0  0  0  0  0
    7.0295   -4.5122   -7.4293 C   0  0  0  0  0  0
    5.3050   -0.3144   -3.0402 C   0  0  0  0  0  0
    5.1438    0.8729   -3.3330 O   0  0  0  0  0  0
   -1.7639  -10.8221   -3.5309 C   0  0  0  0  0  0
   -0.9579  -12.0570   -3.1071 C   0  0  0  0  0  0
   -1.8550  -12.9426   -3.9006 O   0  0  0  0  0  0
   -2.5289  -11.7492   -4.4843 C   0  0  0  0  0  0
   -4.2124   -7.2489   -5.1744 H   0  0  0  0  0  0
   -2.9425   -6.0291   -5.1600 H   0  0  0  0  0  0
   -4.1040   -6.1223   -3.8406 H   0  0  0  0  0  0
   -3.2236   -8.3149   -3.1605 H   0  0  0  0  0  0
   -2.6160   -9.1796   -5.4472 H   0  0  0  0  0  0
   -1.2532   -8.0615   -5.5145 H   0  0  0  0  0  0
    0.5464   -9.7937   -2.6620 H   0  0  0  0  0  0
    0.7100   -8.4427   -3.7799 H   0  0  0  0  0  0
   -1.4093   -8.6641   -1.5391 H   0  0  0  0  0  0
   -0.0411   -7.5855   -1.5685 H   0  0  0  0  0  0
   -3.5599   -6.7016   -1.1229 H   0  0  0  0  0  0
   -3.9879   -4.6036    0.1052 H   0  0  0  0  0  0
   -0.2325   -4.7712   -3.0458 H   0  0  0  0  0  0
   -3.4920   -2.4070    0.3743 H   0  0  0  0  0  0
    0.0475   -1.9503   -0.3049 H   0  0  0  0  0  0
   -0.3518    2.2883    0.1731 H   0  0  0  0  0  0
   -3.9231    2.2764    0.6440 H   0  0  0  0  0  0
   -2.7418    3.1199   -0.3489 H   0  0  0  0  0  0
   -2.4772    2.9442    1.3838 H   0  0  0  0  0  0
    1.6726    1.8326    1.3226 H   0  0  0  0  0  0
    4.1270    2.0243    1.2751 H   0  0  0  0  0  0
    1.9842   -2.2485   -2.1309 H   0  0  0  0  0  0
    0.6779   -1.1116   -2.3777 H   0  0  0  0  0  0
    1.5958   -1.3072   -4.2674 H   0  0  0  0  0  0
    5.8638   -2.3074   -0.9325 H   0  0  0  0  0  0
    4.1512   -2.6539   -0.8704 H   0  0  0  0  0  0
    5.4284   -4.2299   -2.4310 H   0  0  0  0  0  0
    4.1121   -3.3735   -3.2480 H   0  0  0  0  0  0
    7.4391   -0.0574   -5.1222 H   0  0  0  0  0  0
    7.9389   -5.0493   -4.1489 H   0  0  0  0  0  0
    6.4304   -5.2919   -5.0084 H   0  0  0  0  0  0
    8.5696   -2.4161   -7.1380 H   0  0  0  0  0  0
    9.5573   -2.8635   -5.7641 H   0  0  0  0  0  0
    9.7233   -5.1815   -7.3619 H   0  0  0  0  0  0
    8.8248   -6.3973   -6.4609 H   0  0  0  0  0  0
    9.9068   -5.2983   -5.6181 H   0  0  0  0  0  0
    7.5136   -4.3010   -8.3836 H   0  0  0  0  0  0
    6.1859   -3.8270   -7.3347 H   0  0  0  0  0  0
    6.6216   -5.5223   -7.4895 H   0  0  0  0  0  0
   -2.3651  -10.3683   -2.7429 H   0  0  0  0  0  0
    0.0545  -12.1408   -3.5063 H   0  0  0  0  0  0
   -1.0153  -12.3353   -2.0541 H   0  0  0  0  0  0
   -3.6049  -11.8280   -4.3245 H   0  0  0  0  0  0
   -2.2676  -11.6858   -5.5420 H   0  0  0  0  0  0
   -0.4030  -10.0800   -4.9167 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 50  1  0  0  0
  1 51  1  0  0  0
  1 52  1  0  0  0
  2  3  1  0  0  0
  2  7  1  0  0  0
  2 53  1  0  0  0
  3  4  1  0  0  0
  3 54  1  0  0  0
  3 55  1  0  0  0
  4  5  1  0  0  0
  4 46  1  0  0  0
  4 94  1  0  0  0
  5  6  1  0  0  0
  5 56  1  0  0  0
  5 57  1  0  0  0
  6  7  1  0  0  0
  6 58  1  0  0  0
  6 59  1  0  0  0
  7  8  1  0  0  0
  8  9  2  0  0  0
  8 13  1  0  0  0
  9 10  1  0  0  0
  9 60  1  0  0  0
 10 11  2  0  0  0
 10 61  1  0  0  0
 11 12  1  0  0  0
 11 14  1  0  0  0
 12 13  2  0  0  0
 13 62  1  0  0  0
 14 15  1  0  0  0
 14 63  1  0  0  0
 15 16  2  0  0  0
 15 20  1  0  0  0
 16 17  1  0  0  0
 16 64  1  0  0  0
 17 18  2  0  0  0
 17 23  1  0  0  0
 18 19  1  0  0  0
 18 65  1  0  0  0
 19 20  1  0  0  0
 19 22  1  0  0  0
 20 21  2  0  0  0
 22 66  1  0  0  0
 22 67  1  0  0  0
 22 68  1  0  0  0
 23 24  2  0  0  0
 23 28  1  0  0  0
 24 25  1  0  0  0
 24 69  1  0  0  0
 25 26  2  0  0  0
 25 70  1  0  0  0
 26 27  1  0  0  0
 27 28  2  0  0  0
 27 31  1  0  0  0
 28 29  1  0  0  0
 29 30  1  0  0  0
 29 71  1  0  0  0
 29 72  1  0  0  0
 30 73  1  0  0  0
 31 32  1  0  0  0
 31 44  1  0  0  0
 32 33  1  0  0  0
 32 74  1  0  0  0
 32 75  1  0  0  0
 33 34  1  0  0  0
 33 76  1  0  0  0
 33 77  1  0  0  0
 34 35  1  0  0  0
 34 38  1  0  0  0
 35 36  2  0  0  0
 35 44  1  0  0  0
 36 37  1  0  0  0
 36 78  1  0  0  0
 37 38  2  0  0  0
 37 41  1  0  0  0
 38 39  1  0  0  0
 39 40  1  0  0  0
 39 79  1  0  0  0
 39 80  1  0  0  0
 40 41  1  0  0  0
 40 42  1  0  0  0
 40 43  1  0  0  0
 41 81  1  0  0  0
 41 82  1  0  0  0
 42 83  1  0  0  0
 42 84  1  0  0  0
 42 85  1  0  0  0
 43 86  1  0  0  0
 43 87  1  0  0  0
 43 88  1  0  0  0
 44 45  2  0  0  0
 46 47  1  0  0  0
 46 49  1  0  0  0
 46 89  1  0  0  0
 47 48  1  0  0  0
 47 90  1  0  0  0
 47 91  1  0  0  0
 48 49  1  0  0  0
 49 92  1  0  0  0
 49 93  1  0  0  0
M  CHG  1   4   1
M  END
> <s_m_entry_id>
124

> <Applicants>
Genentech

> <CHEMBL_ID>
CHEMBL4065122

> <Canonical_Smiles>
O1CC(N2C[C@@H](N(CC2)c2ccc(nc2)NC2=CC(=CN(C)C2=O)c2ccnc(N3CCn4c(cc5CC(Cc45)(C)C)C3=O)c2CO)C)C1

> <Chirality>
Single Stereoisomer

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
FENEBRUTINIB | G-02599853 | G02599853 | GDC-0853 | RG-7845 | RG7845 | RO-7010939 | RO7010939

> <Indications>
nan

> <Type>
nan

> <targets_id>
nan

> <inchi>
InChI=1S/C37H44N8O4/c1-23-18-42(27-21-49-22-27)9-10-43(23)26-5-6-33(39-17-26)40-30-13-25(19-41(4)35(30)47)28-7-8-38-34(29(28)20-46)45-12-11-44-31(36(45)48)14-24-15-37(2,3)16-32(24)44/h5-8,13-14,17,19,23,27,46H,9-12,15-16,18,20-22H2,1-4H3,(H,39,40)/t23-/m0/s1

> <stdInchikey>
WNEODWDFDXWOLU-QHCPKHFHSA-N

> <csid>
58145210

> <Links>
|http://www.chemspider.com/Chemical-Structure.58145210.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4065122|http://pubchem.ncbi.nlm.nih.gov/compound/86567195|http://www.drugbank.ca/drugs/DB14785| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=9AJ|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/9AJ|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9299|http://zinc15.docking.org/substances/ZINC000220197997|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=E9L2885WUL|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50244440

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
664.3

> <HBA>
11

> <HBD>
2

> <NRB>
7

> <TPSA>
121

> <LogP>
3.6

> <RoF>
2

> <Targets>
nan

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.1621

> <r_epik_State_Penalty>
  0.1758

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
124

> <lig_pdbID>
'9AJ'

> <pdbID>
5vfi

$$$$
Neflamapimod
                    3D
 Structure written by MMmdl.
 37 40  0  0  1  0            999 V2000
   -6.8200   -3.2212    0.0493 C   0  0  0  0  0  0
   -6.3746   -2.6949    1.2589 C   0  0  0  0  0  0
   -5.5388   -1.5776    1.2760 C   0  0  0  0  0  0
   -5.1395   -0.9709    0.0703 C   0  0  0  0  0  0
   -5.5953   -1.5126   -1.1463 C   0  0  0  0  0  0
   -6.4306   -2.6306   -1.1500 C   0  0  0  0  0  0
   -5.1373   -0.8260   -2.6691 Cl  0  0  0  0  0  0
   -4.2400    0.2145    0.0817 C   0  0  0  0  0  0
   -2.8814    0.0688    0.0329 C   0  0  0  0  0  0
   -2.1630   -1.2052   -0.0388 C   0  0  0  0  0  0
   -0.8137   -1.1897   -0.0842 C   0  0  0  0  0  0
   -0.0965    0.0699   -0.0608 C   0  0  0  0  0  0
   -0.7119    1.2066    0.0069 N   0  0  0  0  0  0
   -2.0638    1.2129    0.0497 N   0  0  0  0  0  0
   -2.6669    2.4663    0.1124 C   0  0  0  0  0  0
   -3.9380    2.6534    0.1575 N   0  0  0  0  0  0
   -4.8472    1.5692    0.1485 C   0  0  0  0  0  0
   -6.0747    1.6573    0.1905 O   0  0  0  0  0  0
    1.6942    0.0564   -0.1266 S   0  0  0  0  0  0
    1.9131   -0.0048   -1.8804 C   0  0  0  0  0  0
    1.9619    1.1877   -2.6069 C   0  0  0  0  0  0
    2.1337    1.1558   -3.9910 C   0  0  0  0  0  0
    2.2592   -0.0671   -4.6508 C   0  0  0  0  0  0
    2.2124   -1.2589   -3.9268 C   0  0  0  0  0  0
    2.0403   -1.2321   -2.5420 C   0  0  0  0  0  0
    1.9960   -2.3974   -1.8544 F   0  0  0  0  0  0
    2.4267   -0.0974   -5.9920 F   0  0  0  0  0  0
   -5.0103   -0.9730    2.8105 Cl  0  0  0  0  0  0
   -7.4657   -4.0868    0.0413 H   0  0  0  0  0  0
   -6.6791   -3.1581    2.1863 H   0  0  0  0  0  0
   -6.7780   -3.0441   -2.0857 H   0  0  0  0  0  0
   -2.6928   -2.1465   -0.0562 H   0  0  0  0  0  0
   -0.2834   -2.1293   -0.1375 H   0  0  0  0  0  0
   -1.9823    3.3116    0.1208 H   0  0  0  0  0  0
    1.8643    2.1381   -2.1020 H   0  0  0  0  0  0
    2.1700    2.0787   -4.5510 H   0  0  0  0  0  0
    2.3101   -2.2039   -4.4405 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1  6  2  0  0  0
  1 29  1  0  0  0
  2  3  2  0  0  0
  2 30  1  0  0  0
  3  4  1  0  0  0
  3 28  1  0  0  0
  4  5  2  0  0  0
  4  8  1  0  0  0
  5  6  1  0  0  0
  5  7  1  0  0  0
  6 31  1  0  0  0
  8  9  2  0  0  0
  8 17  1  0  0  0
  9 10  1  0  0  0
  9 14  1  0  0  0
 10 11  2  0  0  0
 10 32  1  0  0  0
 11 12  1  0  0  0
 11 33  1  0  0  0
 12 13  2  0  0  0
 12 19  1  0  0  0
 13 14  1  0  0  0
 14 15  1  0  0  0
 15 16  2  0  0  0
 15 34  1  0  0  0
 16 17  1  0  0  0
 17 18  2  0  0  0
 19 20  1  0  0  0
 20 21  1  0  0  0
 20 25  2  0  0  0
 21 22  2  0  0  0
 21 35  1  0  0  0
 22 23  1  0  0  0
 22 36  1  0  0  0
 23 24  2  0  0  0
 23 27  1  0  0  0
 24 25  1  0  0  0
 24 37  1  0  0  0
 25 26  1  0  0  0
M  END
> <s_m_entry_id>
136

> <Applicants>
EIP Pharma

> <CHEMBL_ID>
CHEMBL119385

> <Canonical_Smiles>
Clc1cccc(Cl)c1C1=C2N(N=C(Sc3ccc(F)cc3F)C=C2)C=NC1=O

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
745 | NEFLAMAPIMOD | VD-31 | VD-31,745 | VD-31745 | VRT-031745 | VX-745

> <Indications>
nan

> <Type>
nan

> <targets_id>
Q16539

> <inchi>
InChI=1S/C19H9Cl2F2N3OS/c20-11-2-1-3-12(21)17(11)18-14-5-7-16(25-26(14)9-24-19(18)27)28-15-6-4-10(22)8-13(15)23/h1-9H

> <stdInchikey>
VEPKQEUBKLEPRA-UHFFFAOYSA-N

> <csid>
2302086

> <Links>
|http://www.chemspider.com/Chemical-Structure.2302086.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL119385|http://pubchem.ncbi.nlm.nih.gov/compound/3038525|http://www.drugbank.ca/drugs/DB07138| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=52P|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/52P|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5719|http://zinc15.docking.org/substances/ZINC13493055|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=TYL52QM320|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=15244

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
435

> <HBA>
5

> <HBD>
0

> <NRB>
3

> <TPSA>
47.3

> <LogP>
5.5

> <RoF>
1

> <Targets>
MAPK14

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0000

> <r_epik_State_Penalty>
  0.0000

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
136

> <lig_pdbID>
'52P'

> <pdbID>
3fc1 3hp5 3zsi

> <Kinase families>
CMGC

> <indicationDB>
Neflamapimod has been used in trials studying the treatment of Alzheimer&#39;s Disease and Mild Cognitive Impairment.

> <uniprotId>
Q16539

$$$$
Vactosertib
                    3D
 Structure written by MMmdl.
 48 52  0  0  1  0            999 V2000
   -6.5352    2.0847    1.1417 C   0  0  0  0  0  0
   -5.1620    2.5025    0.6522 C   0  0  0  0  0  0
   -4.8846    3.8213    0.2830 C   0  0  0  0  0  0
   -3.5991    4.1282   -0.1662 C   0  0  0  0  0  0
   -2.6346    3.1206   -0.2373 C   0  0  0  0  0  0
   -2.9850    1.8200    0.1491 C   0  0  0  0  0  0
   -4.2332    1.5142    0.5939 N   0  0  0  0  0  0
   -2.0158    0.6818    0.0889 C   0  0  0  0  0  0
   -2.1531   -0.7187    0.0630 C   0  0  0  0  0  0
   -0.9713   -1.3255    0.0570 N   0  0  0  0  0  0
   -0.0742   -0.3729    0.0483 C   0  0  0  0  0  0
   -0.6564    0.8629    0.0653 N   0  0  0  0  0  0
    1.4223   -0.5896    0.0361 C   0  0  0  0  0  0
    2.0388   -0.2368    1.3102 N   0  0  0  0  0  0
    3.4279   -0.4158    1.4135 C   0  0  0  0  0  0
    4.3078    0.1317    0.4686 C   0  0  0  0  0  0
    5.6835   -0.0687    0.5849 C   0  0  0  0  0  0
    6.1924   -0.8183    1.6443 C   0  0  0  0  0  0
    5.3254   -1.3664    2.5889 C   0  0  0  0  0  0
    3.9481   -1.1678    2.4765 C   0  0  0  0  0  0
    3.1258   -1.7126    3.4052 F   0  0  0  0  0  0
   -3.4030   -1.5337    0.0333 C   0  0  0  0  0  0
   -3.5706   -2.6243    0.8979 C   0  0  0  0  0  0
   -4.7390   -3.3950    0.8914 C   0  0  0  0  0  0
   -5.7633   -3.0583   -0.0111 C   0  0  0  0  0  0
   -6.9888   -3.5797   -0.2653 N   0  0  0  0  0  0
   -7.4281   -2.7902   -1.2289 C   0  0  0  0  0  0
   -6.6474   -1.8113   -1.6457 N   0  0  0  0  0  0
   -5.5614   -1.9720   -0.8643 N   0  0  0  0  0  0
   -4.4212   -1.2168   -0.8694 C   0  0  0  0  0  0
   -7.2378    2.9187    1.1290 H   0  0  0  0  0  0
   -6.4762    1.7087    2.1637 H   0  0  0  0  0  0
   -6.9403    1.2931    0.5096 H   0  0  0  0  0  0
   -5.6429    4.5887    0.3395 H   0  0  0  0  0  0
   -3.3534    5.1378   -0.4609 H   0  0  0  0  0  0
   -1.6405    3.3497   -0.5918 H   0  0  0  0  0  0
   -0.1716    1.7483    0.0786 H   0  0  0  0  0  0
    1.6504   -1.6394   -0.1568 H   0  0  0  0  0  0
    1.8786   -0.0333   -0.7828 H   0  0  0  0  0  0
    1.5271   -0.5737    2.1136 H   0  0  0  0  0  0
    3.9345    0.7215   -0.3558 H   0  0  0  0  0  0
    6.3549    0.3577   -0.1460 H   0  0  0  0  0  0
    7.2575   -0.9738    1.7340 H   0  0  0  0  0  0
    5.7218   -1.9475    3.4088 H   0  0  0  0  0  0
   -2.7850   -2.8779    1.5954 H   0  0  0  0  0  0
   -4.8490   -4.2282    1.5696 H   0  0  0  0  0  0
   -8.4041   -2.9425   -1.6666 H   0  0  0  0  0  0
   -4.3706   -0.3981   -1.5731 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 31  1  0  0  0
  1 32  1  0  0  0
  1 33  1  0  0  0
  2  3  1  0  0  0
  2  7  2  0  0  0
  3  4  2  0  0  0
  3 34  1  0  0  0
  4  5  1  0  0  0
  4 35  1  0  0  0
  5  6  2  0  0  0
  5 36  1  0  0  0
  6  7  1  0  0  0
  6  8  1  0  0  0
  8  9  2  0  0  0
  8 12  1  0  0  0
  9 10  1  0  0  0
  9 22  1  0  0  0
 10 11  2  0  0  0
 11 12  1  0  0  0
 11 13  1  0  0  0
 12 37  1  0  0  0
 13 14  1  0  0  0
 13 38  1  0  0  0
 13 39  1  0  0  0
 14 15  1  0  0  0
 14 40  1  0  0  0
 15 16  1  0  0  0
 15 20  2  0  0  0
 16 17  2  0  0  0
 16 41  1  0  0  0
 17 18  1  0  0  0
 17 42  1  0  0  0
 18 19  2  0  0  0
 18 43  1  0  0  0
 19 20  1  0  0  0
 19 44  1  0  0  0
 20 21  1  0  0  0
 22 23  1  0  0  0
 22 30  2  0  0  0
 23 24  2  0  0  0
 23 45  1  0  0  0
 24 25  1  0  0  0
 24 46  1  0  0  0
 25 26  2  0  0  0
 25 29  1  0  0  0
 26 27  1  0  0  0
 27 28  2  0  0  0
 27 47  1  0  0  0
 28 29  1  0  0  0
 29 30  1  0  0  0
 30 48  1  0  0  0
M  END
> <s_m_entry_id>
137

> <Applicants>
MedPacto

> <CHEMBL_ID>
CHEMBL3260567

> <Canonical_Smiles>
Fc1ccccc1NCc1[nH]c(c(n1)C=1C=Cc2n(ncn2)C=1)-c1nc(ccc1)C

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
TEW 7197 | TEW-7197 | VACTOSERTIB

> <Indications>
Vactosertib (EW-7197) acts as in inhibitor of transforming growth factor beta receptor 1B (ALK5) and activin A receptor type IB (ALK4). The compound is potent, selective, and orally bioavailable, and exhibits experimental anti-tumour activity.

> <Type>
nan

> <targets_id>
nan

> <inchi>
InChI=1S/C22H18FN7/c1-14-5-4-8-18(27-14)22-21(15-9-10-20-25-13-26-30(20)12-15)28-19(29-22)11-24-17-7-3-2-6-16(17)23/h2-10,12-13,24H,11H2,1H3,(H,28,29)

> <stdInchikey>
FJCDSQATIJKQKA-UHFFFAOYSA-N

> <csid>
32813335

> <Links>
|http://www.chemspider.com/Chemical-Structure.32813335.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3260567|http://pubchem.ncbi.nlm.nih.gov/compound/54766013|http://www.drugbank.ca/drugs/DB15310|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8107|http://zinc15.docking.org/substances/ZINC000113391423|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=6T4O391P5Y|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50015639

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
399.2

> <HBA>
6

> <HBD>
2

> <NRB>
5

> <TPSA>
83.8

> <LogP>
4.2

> <RoF>
0

> <Targets>
nan

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
0.5

> <r_epik_Ionization_Penalty>
  0.0131

> <r_epik_State_Penalty>
  0.4107

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
137

$$$$
Ulixertinib
                    3D
 Structure written by MMmdl.
 51 53  0  0  1  0            999 V2000
   -5.0556    1.6471   -1.2819 C   0  0  0  0  0  0
   -4.4474    2.2033    0.0183 C   0  0  0  0  0  0
   -4.9939    3.6038    0.3372 C   0  0  0  0  0  0
   -2.9856    2.2112   -0.0278 N   0  0  0  0  0  0
   -2.2213    1.0518    0.1919 C   0  0  0  0  0  0
   -0.8506    1.1080   -0.0761 C   0  0  0  0  0  0
   -0.0525   -0.0266    0.1279 C   0  0  0  0  0  0
   -0.6660   -1.1949    0.6157 C   0  0  0  0  0  0
   -2.0390   -1.1740    0.8647 C   0  0  0  0  0  0
   -2.8127   -0.0802    0.6609 N   0  0  0  0  0  0
    0.2160   -2.6459    0.9495 Cl  0  0  0  0  0  0
    1.4045    0.0755   -0.1900 C   0  0  0  0  0  0
    2.2525    1.1689    0.0671 C   0  0  0  0  0  0
    3.5464    0.8815   -0.3730 C   0  0  0  0  0  0
    3.4745   -0.3625   -0.9487 N   0  0  0  0  0  0
    2.2051   -0.8628   -0.8324 C   0  0  0  0  0  0
    4.7330    1.6959   -0.3863 C   0  0  0  0  0  0
    5.6938    1.4250   -1.1094 O   0  0  0  0  0  0
    4.6875    2.7551    0.4450 N   0  0  0  0  0  0
    5.7534    3.7536    0.6290 C   0  0  2  0  0  0
    5.4368    4.7309    1.7854 C   0  0  0  0  0  0
    5.0815    4.0595    2.9799 O   0  0  0  0  0  0
    6.1311    4.5307   -0.6396 C   0  0  0  0  0  0
    5.1548    4.9353   -1.5610 C   0  0  0  0  0  0
    5.5166    5.6270   -2.7170 C   0  0  0  0  0  0
    6.8573    5.9192   -2.9645 C   0  0  0  0  0  0
    7.8371    5.5195   -2.0553 C   0  0  0  0  0  0
    7.4748    4.8280   -0.8983 C   0  0  0  0  0  0
    9.4972    5.8785   -2.3617 Cl  0  0  0  0  0  0
   -6.1439    1.6120   -1.2230 H   0  0  0  0  0  0
   -4.7107    0.6318   -1.4809 H   0  0  0  0  0  0
   -4.7899    2.2614   -2.1433 H   0  0  0  0  0  0
   -4.7624    1.5465    0.8307 H   0  0  0  0  0  0
   -6.0810    3.5923    0.4221 H   0  0  0  0  0  0
   -4.7306    4.3243   -0.4384 H   0  0  0  0  0  0
   -4.5993    3.9756    1.2838 H   0  0  0  0  0  0
   -2.5544    2.9382   -0.5797 H   0  0  0  0  0  0
   -0.4112    2.0221   -0.4505 H   0  0  0  0  0  0
   -2.5441   -2.0501    1.2446 H   0  0  0  0  0  0
    1.9451    2.0904    0.5401 H   0  0  0  0  0  0
    4.2481   -0.8382   -1.3911 H   0  0  0  0  0  0
    1.9751   -1.8401   -1.2306 H   0  0  0  0  0  0
    3.9029    2.8295    1.0757 H   0  0  0  0  0  0
    6.6345    3.1832    0.9344 H   0  0  0  0  0  0
    6.3037    5.3571    2.0003 H   0  0  0  0  0  0
    4.6218    5.4024    1.5120 H   0  0  0  0  0  0
    4.9312    4.7142    3.6662 H   0  0  0  0  0  0
    4.1122    4.7147   -1.3831 H   0  0  0  0  0  0
    4.7578    5.9348   -3.4214 H   0  0  0  0  0  0
    7.1337    6.4538   -3.8616 H   0  0  0  0  0  0
    8.2411    4.5204   -0.2013 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 30  1  0  0  0
  1 31  1  0  0  0
  1 32  1  0  0  0
  2  3  1  0  0  0
  2  4  1  0  0  0
  2 33  1  0  0  0
  3 34  1  0  0  0
  3 35  1  0  0  0
  3 36  1  0  0  0
  4  5  1  0  0  0
  4 37  1  0  0  0
  5  6  1  0  0  0
  5 10  2  0  0  0
  6  7  2  0  0  0
  6 38  1  0  0  0
  7  8  1  0  0  0
  7 12  1  0  0  0
  8  9  2  0  0  0
  8 11  1  0  0  0
  9 10  1  0  0  0
  9 39  1  0  0  0
 12 13  1  0  0  0
 12 16  2  0  0  0
 13 14  2  0  0  0
 13 40  1  0  0  0
 14 15  1  0  0  0
 14 17  1  0  0  0
 15 16  1  0  0  0
 15 41  1  0  0  0
 16 42  1  0  0  0
 17 18  2  0  0  0
 17 19  1  0  0  0
 19 20  1  0  0  0
 19 43  1  0  0  0
 20 21  1  0  0  0
 20 23  1  0  0  0
 20 44  1  0  0  0
 21 22  1  0  0  0
 21 45  1  0  0  0
 21 46  1  0  0  0
 22 47  1  0  0  0
 23 24  1  0  0  0
 23 28  2  0  0  0
 24 25  2  0  0  0
 24 48  1  0  0  0
 25 26  1  0  0  0
 25 49  1  0  0  0
 26 27  2  0  0  0
 26 50  1  0  0  0
 27 28  1  0  0  0
 27 29  1  0  0  0
 28 51  1  0  0  0
M  END
> <s_m_entry_id>
139

> <Applicants>
BioMed Valley Discoveries

> <CHEMBL_ID>
CHEMBL3545022

> <Canonical_Smiles>
Clc1cnc(NC(C)C)cc1-c1cc([nH]c1)C(=O)N[C@H](CO)c1cc(Cl)ccc1

> <Chirality>
Single Stereoisomer

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Indications>
nan

> <Type>
nan

> <targets_id>
P28482|P27361

> <inchi>
InChI=1S/C21H22Cl2N4O2/c1-12(2)26-20-8-16(17(23)10-25-20)14-7-18(24-9-14)21(29)27-19(11-28)13-4-3-5-15(22)6-13/h3-10,12,19,24,28H,11H2,1-2H3,(H,25,26)(H,27,29)/t19-/m1/s1

> <stdInchikey>
KSERXGMCDHOLSS-LJQANCHMSA-N

> <csid>
9893722

> <Links>
|http://www.chemspider.com/Chemical-Structure.9893722.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3590106|http://pubchem.ncbi.nlm.nih.gov/compound/11719003|http://www.drugbank.ca/drugs/DB13930| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=EVK|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/EVK|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9210|http://zinc15.docking.org/substances/ZINC000034642570|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=16ZDH50O1U

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS

> <indicationG2P>
None

> <MW>
432.1

> <HBA>
4

> <HBD>
4

> <NRB>
7

> <TPSA>
90

> <LogP>
4.7

> <RoF>
0

> <Targets>
MAPK1; MAPK3

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0015

> <r_epik_State_Penalty>
  0.0009

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
139

> <lig_pdbID>
'EVK'

> <pdbID>
6gdq

> <Kinase families>
CMGC

> <indicationDB>
Ulixertinib is a a novel, reversible, ATP-competitive ERK1/2 inhibitor with high potency and ERK1/2 selectivity <sup class="text-reference-group"><a class="reference-popover-link" data-content="Germann UA, Furey BF, Markland W, Hoover RR, Aronov AM, Roix JJ, Hale M, Boucher DM, Sorrell DA, Martinez-Botella G, Fitzgibbon M, Shapiro P, Wick MJ, Samadani R, Meshaw K, Groover A, DeCrescenzo G, Namchuk M, Emery CM, Saha S, Welsch DJ: Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib). Mol Cancer Ther. 2017 Nov;16(11):2351-2363. doi: 10.1158/1535-7163.MCT-17-0456. Epub 2017 Sep 22. (PubMed ID 28939558)" href="#reference-A31474">1</a></sup>. It is currently in clinical trials for the treatment of a wide range of tumors.

> <uniprotId>
P27361|P28482

$$$$
Foslinanib
                    3D
 Structure written by MMmdl.
 36 38  0  0  1  0            999 V2000
   -0.7079    1.1811   -0.1492 C   0  0  0  0  0  0
    0.0506   -0.0191   -0.0593 O   0  0  0  0  0  0
    1.4319    0.0395   -0.0844 C   0  0  0  0  0  0
    2.1534    1.2428   -0.0731 C   0  0  0  0  0  0
    3.5424    1.2350   -0.0522 C   0  0  0  0  0  0
    4.2288    0.0250   -0.0353 C   0  0  0  0  0  0
    3.5422   -1.2108   -0.0490 C   0  0  0  0  0  0
    2.1308   -1.1793   -0.0910 C   0  0  0  0  0  0
    1.4154   -2.3487   -0.1196 O   0  0  0  0  0  0
    0.5766   -3.0554   -1.4990 P   0  0  0  0  0  0
    0.0346   -4.4070   -0.9989 O   0  0  0  0  0  0
   -0.5441   -2.0756   -1.8925 O   0  5  0  0  0  0
    1.6442   -3.2111   -2.5980 O   0  5  0  0  0  0
    4.3139   -2.5193   -0.0240 C   0  0  0  0  0  0
    3.7819   -3.6288   -0.0211 O   0  0  0  0  0  0
    5.7740   -2.3382    0.0031 C   0  0  0  0  0  0
    6.3849   -1.1277    0.0201 C   0  0  0  0  0  0
    5.6330    0.0318   -0.0036 N   0  0  0  0  0  0
    7.8632   -0.9890    0.0280 C   0  0  0  0  0  0
    8.6733   -1.8576   -0.7195 C   0  0  0  0  0  0
   10.0630   -1.7326   -0.7041 C   0  0  0  0  0  0
   10.6647   -0.7374    0.0636 C   0  0  0  0  0  0
    9.8764    0.1308    0.8165 C   0  0  0  0  0  0
    8.4873    0.0039    0.7992 C   0  0  0  0  0  0
   10.4578    1.0949    1.5656 F   0  0  0  0  0  0
   -1.7694    0.9334   -0.1544 H   0  0  0  0  0  0
   -0.4914    1.7231   -1.0711 H   0  0  0  0  0  0
   -0.5267    1.8352    0.7050 H   0  0  0  0  0  0
    1.6519    2.1984   -0.0707 H   0  0  0  0  0  0
    4.0802    2.1721   -0.0404 H   0  0  0  0  0  0
    6.3906   -3.2250    0.0181 H   0  0  0  0  0  0
    6.1066    0.9232   -0.0009 H   0  0  0  0  0  0
    8.2271   -2.6328   -1.3256 H   0  0  0  0  0  0
   10.6727   -2.4067   -1.2874 H   0  0  0  0  0  0
   11.7404   -0.6404    0.0761 H   0  0  0  0  0  0
    7.8947    0.6821    1.3959 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 26  1  0  0  0
  1 27  1  0  0  0
  1 28  1  0  0  0
  2  3  1  0  0  0
  3  4  1  0  0  0
  3  8  2  0  0  0
  4  5  2  0  0  0
  4 29  1  0  0  0
  5  6  1  0  0  0
  5 30  1  0  0  0
  6  7  2  0  0  0
  6 18  1  0  0  0
  7  8  1  0  0  0
  7 14  1  0  0  0
  8  9  1  0  0  0
  9 10  1  0  0  0
 10 11  2  0  0  0
 10 12  1  0  0  0
 10 13  1  0  0  0
 14 15  2  0  0  0
 14 16  1  0  0  0
 16 17  2  0  0  0
 16 31  1  0  0  0
 17 18  1  0  0  0
 17 19  1  0  0  0
 18 32  1  0  0  0
 19 20  1  0  0  0
 19 24  2  0  0  0
 20 21  2  0  0  0
 20 33  1  0  0  0
 21 22  1  0  0  0
 21 34  1  0  0  0
 22 23  2  0  0  0
 22 35  1  0  0  0
 23 24  1  0  0  0
 23 25  1  0  0  0
 24 36  1  0  0  0
M  CHG  2  12  -1  13  -1
M  END
> <s_m_entry_id>
140

> <Applicants>
TaiRx

> <CHEMBL_ID>
CHEMBL1615993

> <Canonical_Smiles>
P(Oc1c2c(NC(=CC2=O)c2cc(F)ccc2)ccc1OC)(O)(O)=O

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
CVM-1118 | CVM-1118 FREE ACID | FOSLINANIB | TRX 818 | TRX-818 | TRX-818 FREE ACID

> <Indications>
nan

> <Type>
nan

> <targets_id>
nan

> <inchi>
InChI=1S/C16H13FNO6P/c1-23-14-6-5-11-15(16(14)24-25(20,21)22)13(19)8-12(18-11)9-3-2-4-10(17)7-9/h2-8H,1H3,(H,18,19)(H2,20,21,22)

> <stdInchikey>
ZDWFMAHQGDEALT-UHFFFAOYSA-N

> <csid>
26374637

> <Links>
|http://www.chemspider.com/Chemical-Structure.26374637.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1615993|http://pubchem.ncbi.nlm.nih.gov/compound/49840582|http://zinc15.docking.org/substances/ZINC000064447756|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=2X2DNM7NGX

> <LinkName>
|ChemSpider|ChEMBL|PubChem|ZINC|FDA SRS

> <MW>
365

> <HBA>
4

> <HBD>
3

> <NRB>
4

> <TPSA>
108.8

> <LogP>
2.8

> <RoF>
0

> <Targets>
nan

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_epik_Ionization_Penalty>
  0.0736

> <r_epik_State_Penalty>
  0.0645

> <i_epik_Tot_Q>
-2

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
140

$$$$
Mavelertinib
                    3D
 Structure written by MMmdl.
 52 55  0  0  1  0            999 V2000
   -2.0260    4.6350    1.3767 C   0  0  0  0  0  0
   -1.6218    3.3222    0.9076 N   0  0  0  0  0  0
   -0.4894    2.9833    0.2201 C   0  0  0  0  0  0
   -0.5563    1.6150   -0.0033 C   0  0  0  0  0  0
   -1.7947    1.2525    0.5599 C   0  0  0  0  0  0
   -2.4246    2.2758    1.1129 N   0  0  0  0  0  0
   -2.3114   -0.0257    0.5480 O   0  0  0  0  0  0
   -3.6072   -0.2247    1.1110 C   0  0  0  0  0  0
    0.3235    0.7942   -0.6676 N   0  0  0  0  0  0
    1.7282    0.8050   -0.6586 C   0  0  0  0  0  0
    2.5478    1.5481    0.2238 C   0  0  0  0  0  0
    3.9464    1.3914    0.0513 C   0  0  0  0  0  0
    4.5384    0.6103   -0.8576 N   0  0  0  0  0  0
    3.6619   -0.0680   -1.6506 C   0  0  0  0  0  0
    2.3030   -0.0208   -1.5716 N   0  0  0  0  0  0
    4.2126   -0.9606   -2.5837 N   0  0  0  0  0  0
    5.6027   -0.9740   -3.0403 C   0  0  0  0  0  0
    5.8118   -2.3014   -3.7756 C   0  0  2  0  0  0
    4.4468   -2.5105   -4.4421 C   0  0  1  0  0  0
    3.4796   -1.5914   -3.6836 C   0  0  0  0  0  0
    4.5106   -2.0858   -5.7063 F   0  0  0  0  0  0
    6.1260   -3.3674   -2.8183 N   0  0  0  0  0  0
    6.5759   -4.5917   -3.1439 C   0  0  0  0  0  0
    6.7840   -4.9503   -4.3054 O   0  0  0  0  0  0
    6.7887   -5.4389   -1.9934 C   0  0  0  0  0  0
    7.2148   -6.7114   -2.0970 C   0  0  0  0  0  0
    4.5237    2.1975    1.0101 N   0  0  0  0  0  0
    3.4721    2.7644    1.6961 C   0  0  0  0  0  0
    2.2890    2.4027    1.2666 N   0  0  0  0  0  0
    5.9402    2.3966    1.2672 C   0  0  0  0  0  0
   -1.2130    5.3478    1.2340 H   0  0  0  0  0  0
   -2.2735    4.5851    2.4377 H   0  0  0  0  0  0
   -2.8983    4.9682    0.8134 H   0  0  0  0  0  0
    0.2469    3.7287   -0.0420 H   0  0  0  0  0  0
   -3.8814   -1.2758    1.0231 H   0  0  0  0  0  0
   -4.3652    0.3601    0.5871 H   0  0  0  0  0  0
   -3.6284    0.0349    2.1707 H   0  0  0  0  0  0
   -0.0312   -0.0548   -1.0831 H   0  0  0  0  0  0
    5.7581   -0.1260   -3.7098 H   0  0  0  0  0  0
    6.3033   -0.8472   -2.2133 H   0  0  0  0  0  0
    6.6095   -2.1918   -4.5143 H   0  0  0  0  0  0
    4.1175   -3.5495   -4.4916 H   0  0  0  0  0  0
    2.6201   -2.1402   -3.2967 H   0  0  0  0  0  0
    3.0778   -0.8125   -4.3344 H   0  0  0  0  0  0
    5.9734   -3.1507   -1.8443 H   0  0  0  0  0  0
    6.5909   -5.0139   -1.0186 H   0  0  0  0  0  0
    7.4241   -7.1772   -3.0502 H   0  0  0  0  0  0
    7.3613   -7.3119   -1.2113 H   0  0  0  0  0  0
    3.6683    3.4405    2.5159 H   0  0  0  0  0  0
    6.0822    3.1585    2.0347 H   0  0  0  0  0  0
    6.4322    2.7168    0.3481 H   0  0  0  0  0  0
    6.3796    1.4574    1.6046 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 31  1  0  0  0
  1 32  1  0  0  0
  1 33  1  0  0  0
  2  3  1  0  0  0
  2  6  1  0  0  0
  3  4  2  0  0  0
  3 34  1  0  0  0
  4  5  1  0  0  0
  4  9  1  0  0  0
  5  6  2  0  0  0
  5  7  1  0  0  0
  7  8  1  0  0  0
  8 35  1  0  0  0
  8 36  1  0  0  0
  8 37  1  0  0  0
  9 10  1  0  0  0
  9 38  1  0  0  0
 10 11  2  0  0  0
 10 15  1  0  0  0
 11 12  1  0  0  0
 11 29  1  0  0  0
 12 13  2  0  0  0
 12 27  1  0  0  0
 13 14  1  0  0  0
 14 15  2  0  0  0
 14 16  1  0  0  0
 16 17  1  0  0  0
 16 20  1  0  0  0
 17 18  1  0  0  0
 17 39  1  0  0  0
 17 40  1  0  0  0
 18 19  1  0  0  0
 18 22  1  0  0  0
 18 41  1  0  0  0
 19 20  1  0  0  0
 19 21  1  0  0  0
 19 42  1  0  0  0
 20 43  1  0  0  0
 20 44  1  0  0  0
 22 23  1  0  0  0
 22 45  1  0  0  0
 23 24  2  0  0  0
 23 25  1  0  0  0
 25 26  2  0  0  0
 25 46  1  0  0  0
 26 47  1  0  0  0
 26 48  1  0  0  0
 27 28  1  0  0  0
 27 30  1  0  0  0
 28 29  2  0  0  0
 28 49  1  0  0  0
 30 50  1  0  0  0
 30 51  1  0  0  0
 30 52  1  0  0  0
M  END
> <s_m_entry_id>
142

> <Applicants>
Pfizer

> <CHEMBL_ID>
CHEMBL3989970

> <Canonical_Smiles>
F[C@@H]1CN(C[C@H]1NC(=O)C=C)c1nc(Nc2cn(nc2OC)C)c2ncn(c2n1)C

> <Chirality>
Single Stereoisomer

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
MAVELERTINIB | PF-06747775

> <Indications>
nan

> <Type>
nan

> <targets_id>
nan

> <inchi>
InChI=1S/C18H22FN9O2/c1-5-13(29)21-11-8-28(6-10(11)19)18-23-15(14-16(24-18)26(2)9-20-14)22-12-7-27(3)25-17(12)30-4/h5,7,9-11H,1,6,8H2,2-4H3,(H,21,29)(H,22,23,24)/t10-,11-/m1/s1

> <stdInchikey>
JYIUNVOCEFIUIU-GHMZBOCLSA-N

> <csid>
49070873

> <Links>
|http://www.chemspider.com/Chemical-Structure.49070873.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3989970|http://pubchem.ncbi.nlm.nih.gov/compound/91668194|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9765|http://zinc15.docking.org/substances/ZINC000231225813|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=YXX2180047|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50450870

> <LinkName>
|ChemSpider|ChEMBL|PubChem|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
415.2

> <HBA>
10

> <HBD>
2

> <NRB>
6

> <TPSA>
115

> <LogP>
0.7

> <RoF>
0

> <Targets>
nan

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
0.999997

> <r_epik_Ionization_Penalty>
  0.0391

> <r_epik_State_Penalty>
  0.0327

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
142

$$$$
Apitolisib
                    3D
 Structure written by MMmdl.
 66 70  0  0  1  0            999 V2000
   -0.0956   -2.2942   -0.4424 C   0  0  0  0  0  0
   -0.6717   -0.8917   -0.3535 C   0  0  0  0  0  0
    0.0521    0.2975   -0.3771 C   0  0  0  0  0  0
   -0.9862    1.7045   -0.2365 S   0  0  0  0  0  0
   -2.4345    0.7150   -0.1739 C   0  0  0  0  0  0
   -2.0773   -0.6620   -0.2191 C   0  0  0  0  0  0
   -3.0041   -1.6266   -0.1364 N   0  0  0  0  0  0
   -4.2974   -1.2299    0.0162 C   0  0  0  0  0  0
   -4.7206    0.0585    0.0736 N   0  0  0  0  0  0
   -3.8031    1.0555   -0.0448 C   0  0  0  0  0  0
   -4.2750    2.3698   -0.0078 N   0  0  0  0  0  0
   -3.8005    3.4221   -0.9210 C   0  0  0  0  0  0
   -3.8278    4.8099   -0.2478 C   0  0  0  0  0  0
   -5.1374    5.1135    0.2183 O   0  0  0  0  0  0
   -5.6675    4.1263    1.0950 C   0  0  0  0  0  0
   -5.6313    2.7240    0.4476 C   0  0  0  0  0  0
   -5.3420   -2.3020    0.1236 C   0  0  0  0  0  0
   -6.7041   -2.0161    0.3284 C   0  0  0  0  0  0
   -7.6658   -2.9704    0.4244 N   0  0  0  0  0  0
   -7.2499   -4.2543    0.3118 C   0  0  0  0  0  0
   -5.9714   -4.6561    0.1160 N   0  0  0  0  0  0
   -5.0393   -3.6725    0.0254 C   0  0  0  0  0  0
   -8.2196   -5.2456    0.4038 N   0  0  0  0  0  0
    1.5499    0.5073   -0.5054 C   0  0  0  0  0  0
    2.1725    0.7645    0.8884 N   0  3  0  0  0  0
    2.0703   -0.4745    1.8166 C   0  0  0  0  0  0
    2.7437   -0.1563    3.1717 C   0  0  0  0  0  0
    4.1444    0.1877    2.8732 N   0  0  0  0  0  0
    4.2688    1.4518    2.1250 C   0  0  0  0  0  0
    3.6516    1.1992    0.7296 C   0  0  0  0  0  0
    5.2034   -0.6544    3.0324 C   0  0  0  0  0  0
    6.3335   -0.3470    2.6401 O   0  0  0  0  0  0
    4.9904   -2.0280    3.7249 C   0  0  2  0  0  0
    4.9940   -1.9032    5.2603 C   0  0  0  0  0  0
    6.0257   -2.9259    3.3574 O   0  0  0  0  0  0
   -0.5003   -2.8372   -1.2971 H   0  0  0  0  0  0
   -0.3322   -2.8789    0.4470 H   0  0  0  0  0  0
    0.9884   -2.3096   -0.5468 H   0  0  0  0  0  0
   -2.7970    3.2320   -1.2878 H   0  0  0  0  0  0
   -4.4279    3.4325   -1.8139 H   0  0  0  0  0  0
   -3.1076    4.8591    0.5711 H   0  0  0  0  0  0
   -3.5286    5.5759   -0.9634 H   0  0  0  0  0  0
   -5.1192    4.1284    2.0389 H   0  0  0  0  0  0
   -6.6949    4.3944    1.3419 H   0  0  0  0  0  0
   -6.3371    2.6623   -0.3822 H   0  0  0  0  0  0
   -5.9729    2.0081    1.1965 H   0  0  0  0  0  0
   -7.0584   -0.9997    0.4216 H   0  0  0  0  0  0
   -4.0272   -4.0159   -0.1333 H   0  0  0  0  0  0
   -7.9455   -6.2134    0.3219 H   0  0  0  0  0  0
   -9.1827   -4.9804    0.5470 H   0  0  0  0  0  0
    2.0913   -0.3440   -0.9203 H   0  0  0  0  0  0
    1.7916    1.3879   -1.1031 H   0  0  0  0  0  0
    1.0103   -0.6875    1.9531 H   0  0  0  0  0  0
    2.5480   -1.3068    1.2953 H   0  0  0  0  0  0
    2.2581    0.7030    3.6367 H   0  0  0  0  0  0
    2.6356   -0.9868    3.8674 H   0  0  0  0  0  0
    3.7217    2.2383    2.6469 H   0  0  0  0  0  0
    5.3036    1.7864    2.0342 H   0  0  0  0  0  0
    4.1652    0.4044    0.1837 H   0  0  0  0  0  0
    3.6471    2.1100    0.1294 H   0  0  0  0  0  0
    4.0584   -2.4829    3.3898 H   0  0  0  0  0  0
    4.2021   -1.2420    5.6137 H   0  0  0  0  0  0
    5.9408   -1.5076    5.6320 H   0  0  0  0  0  0
    4.8360   -2.8727    5.7345 H   0  0  0  0  0  0
    5.9129   -3.7441    3.8469 H   0  0  0  0  0  0
    1.6686    1.5279    1.3180 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 36  1  0  0  0
  1 37  1  0  0  0
  1 38  1  0  0  0
  2  3  2  0  0  0
  2  6  1  0  0  0
  3  4  1  0  0  0
  3 24  1  0  0  0
  4  5  1  0  0  0
  5  6  2  0  0  0
  5 10  1  0  0  0
  6  7  1  0  0  0
  7  8  2  0  0  0
  8  9  1  0  0  0
  8 17  1  0  0  0
  9 10  2  0  0  0
 10 11  1  0  0  0
 11 12  1  0  0  0
 11 16  1  0  0  0
 12 13  1  0  0  0
 12 39  1  0  0  0
 12 40  1  0  0  0
 13 14  1  0  0  0
 13 41  1  0  0  0
 13 42  1  0  0  0
 14 15  1  0  0  0
 15 16  1  0  0  0
 15 43  1  0  0  0
 15 44  1  0  0  0
 16 45  1  0  0  0
 16 46  1  0  0  0
 17 18  2  0  0  0
 17 22  1  0  0  0
 18 19  1  0  0  0
 18 47  1  0  0  0
 19 20  2  0  0  0
 20 21  1  0  0  0
 20 23  1  0  0  0
 21 22  2  0  0  0
 22 48  1  0  0  0
 23 49  1  0  0  0
 23 50  1  0  0  0
 24 25  1  0  0  0
 24 51  1  0  0  0
 24 52  1  0  0  0
 25 26  1  0  0  0
 25 30  1  0  0  0
 25 66  1  0  0  0
 26 27  1  0  0  0
 26 53  1  0  0  0
 26 54  1  0  0  0
 27 28  1  0  0  0
 27 55  1  0  0  0
 27 56  1  0  0  0
 28 29  1  0  0  0
 28 31  1  0  0  0
 29 30  1  0  0  0
 29 57  1  0  0  0
 29 58  1  0  0  0
 30 59  1  0  0  0
 30 60  1  0  0  0
 31 32  2  0  0  0
 31 33  1  0  0  0
 33 34  1  0  0  0
 33 35  1  0  0  0
 33 61  1  0  0  0
 34 62  1  0  0  0
 34 63  1  0  0  0
 34 64  1  0  0  0
 35 65  1  0  0  0
M  CHG  1  25   1
M  END
> <s_m_entry_id>
144

> <Applicants>
Hoffmann-La Roche

> <CHEMBL_ID>
CHEMBL1922094

> <Canonical_Smiles>
s1c2c(nc(nc2N2CCOCC2)-c2cnc(nc2)N)c(C)c1CN1CCN(CC1)C(=O)[C@@H](O)C

> <Chirality>
Single Stereoisomer

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
APITOLISIB | G-038390 | G-038390.1 | GDC-0980 | GDC-0980.1 | RG-7422 | RG7422

> <Indications>
nan

> <Type>
nan

> <targets_id>
P42336|P42345

> <inchi>
InChI=1S/C23H30N8O3S/c1-14-17(13-29-3-5-31(6-4-29)22(33)15(2)32)35-19-18(14)27-20(16-11-25-23(24)26-12-16)28-21(19)30-7-9-34-10-8-30/h11-12,15,32H,3-10,13H2,1-2H3,(H2,24,25,26)/t15-/m0/s1

> <stdInchikey>
YOVVNQKCSKSHKT-HNNXBMFYSA-N

> <csid>
26325996

> <Links>
|http://www.chemspider.com/Chemical-Structure.26325996.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1922094|http://pubchem.ncbi.nlm.nih.gov/compound/25254071|http://www.drugbank.ca/drugs/DB12180| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=980|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/980|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7888|http://zinc15.docking.org/substances/ZINC000059224388|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=1C854K1MIJ|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50358204

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
498.2

> <HBA>
11

> <HBD>
2

> <NRB>
5

> <TPSA>
133.8

> <LogP>
0.9

> <RoF>
1

> <Targets>
PIK3CA; MTOR

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.1026

> <r_epik_State_Penalty>
  0.0923

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
144

> <lig_pdbID>
'980'

> <pdbID>
3tl5

> <Kinase families>
Atypical

$$$$
Talmapimod
                    3D
 Structure written by MMmdl.
 67 70  0  0  1  0            999 V2000
   -2.3262    2.6400   -1.0382 C   0  0  0  0  0  0
   -1.8661    1.5649   -0.0321 C   0  0  2  0  0  0
   -2.2737    1.8978    1.4258 C   0  0  0  0  0  0
   -1.4541    3.1028    1.9489 N   0  3  2  0  0  0
    0.0744    2.8288    1.8688 C   0  0  2  0  0  0
    0.4378    2.4505    0.4100 C   0  0  0  0  0  0
   -0.4056    1.3089   -0.0194 N   0  0  0  0  0  0
    0.0963    0.1323   -0.4927 C   0  0  0  0  0  0
   -0.6044   -0.7745   -0.9456 O   0  0  0  0  0  0
    1.5884   -0.0793   -0.4555 C   0  0  0  0  0  0
    2.1781   -0.4258    0.7630 C   0  0  0  0  0  0
    3.5689   -0.5976    0.8485 C   0  0  0  0  0  0
    4.3452   -0.4345   -0.3387 C   0  0  0  0  0  0
    3.7625   -0.1023   -1.5673 C   0  0  0  0  0  0
    2.3790    0.0784   -1.6058 C   0  0  0  0  0  0
    1.6851    0.5189   -3.1330 Cl  0  0  0  0  0  0
    5.6678   -0.6604    0.0026 N   0  0  0  0  0  0
    5.7395   -0.9420    1.3460 C   0  0  0  0  0  0
    4.4786   -0.9213    1.9183 C   0  0  0  0  0  0
    4.1270   -1.1373    3.3266 C   0  0  0  0  0  0
    3.0089   -0.9100    3.7893 O   0  0  0  0  0  0
    5.2338   -1.6935    4.3107 C   0  0  0  0  0  0
    5.6237   -0.9549    5.2170 O   0  0  0  0  0  0
    5.6923   -2.9542    4.0668 N   0  0  0  0  0  0
    5.1823   -3.9083    3.0720 C   0  0  0  0  0  0
    6.7646   -3.5258    4.8851 C   0  0  0  0  0  0
    6.8048   -0.5980   -0.9023 C   0  0  0  0  0  0
    0.5216    1.7917    2.9278 C   0  0  0  0  0  0
   -1.9251    3.5545    3.3524 C   0  0  0  0  0  0
   -3.3066    4.1917    3.3637 C   0  0  0  0  0  0
   -4.4160    3.4544    3.7870 C   0  0  0  0  0  0
   -5.6760    4.0469    3.8092 C   0  0  0  0  0  0
   -5.8224    5.3754    3.4144 C   0  0  0  0  0  0
   -4.7183    6.1169    2.9986 C   0  0  0  0  0  0
   -3.4578    5.5255    2.9758 C   0  0  0  0  0  0
   -7.0461    5.9503    3.4369 F   0  0  0  0  0  0
   -3.4124    2.7342   -1.0388 H   0  0  0  0  0  0
   -2.0221    2.3771   -2.0519 H   0  0  0  0  0  0
   -1.9137    3.6235   -0.8135 H   0  0  0  0  0  0
   -2.4053    0.6550   -0.3016 H   0  0  0  0  0  0
   -3.3256    2.1801    1.4777 H   0  0  0  0  0  0
   -2.1094    1.0634    2.1087 H   0  0  0  0  0  0
    0.5255    3.7953    2.0986 H   0  0  0  0  0  0
    0.2555    3.2936   -0.2564 H   0  0  0  0  0  0
    1.5057    2.2450    0.3443 H   0  0  0  0  0  0
    1.5642   -0.5589    1.6415 H   0  0  0  0  0  0
    4.3589    0.0219   -2.4596 H   0  0  0  0  0  0
    6.7037   -1.1342    1.7951 H   0  0  0  0  0  0
    4.2895   -3.5719    2.5465 H   0  0  0  0  0  0
    4.9262   -4.8506    3.5578 H   0  0  0  0  0  0
    5.9502   -4.1156    2.3262 H   0  0  0  0  0  0
    7.2251   -2.8018    5.5590 H   0  0  0  0  0  0
    7.5545   -3.9232    4.2469 H   0  0  0  0  0  0
    6.3781   -4.3452    5.4919 H   0  0  0  0  0  0
    7.7271   -0.8455   -0.3749 H   0  0  0  0  0  0
    6.8855    0.4098   -1.3111 H   0  0  0  0  0  0
    6.6580   -1.3081   -1.7168 H   0  0  0  0  0  0
    1.5936    1.6091    2.8492 H   0  0  0  0  0  0
    0.0231    0.8301    2.8112 H   0  0  0  0  0  0
    0.3458    2.1383    3.9456 H   0  0  0  0  0  0
   -1.8798    2.6716    3.9925 H   0  0  0  0  0  0
   -1.1737    4.2706    3.6900 H   0  0  0  0  0  0
   -4.3056    2.4249    4.0962 H   0  0  0  0  0  0
   -6.5363    3.4796    4.1333 H   0  0  0  0  0  0
   -4.8394    7.1471    2.6973 H   0  0  0  0  0  0
   -2.6029    6.1033    2.6554 H   0  0  0  0  0  0
   -1.6395    3.8749    1.3243 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 37  1  0  0  0
  1 38  1  0  0  0
  1 39  1  0  0  0
  2  3  1  0  0  0
  2  7  1  0  0  0
  2 40  1  0  0  0
  3  4  1  0  0  0
  3 41  1  0  0  0
  3 42  1  0  0  0
  4  5  1  0  0  0
  4 29  1  0  0  0
  4 67  1  0  0  0
  5  6  1  0  0  0
  5 28  1  0  0  0
  5 43  1  0  0  0
  6  7  1  0  0  0
  6 44  1  0  0  0
  6 45  1  0  0  0
  7  8  1  0  0  0
  8  9  2  0  0  0
  8 10  1  0  0  0
 10 11  1  0  0  0
 10 15  2  0  0  0
 11 12  2  0  0  0
 11 46  1  0  0  0
 12 13  1  0  0  0
 12 19  1  0  0  0
 13 14  2  0  0  0
 13 17  1  0  0  0
 14 15  1  0  0  0
 14 47  1  0  0  0
 15 16  1  0  0  0
 17 18  1  0  0  0
 17 27  1  0  0  0
 18 19  2  0  0  0
 18 48  1  0  0  0
 19 20  1  0  0  0
 20 21  2  0  0  0
 20 22  1  0  0  0
 22 23  2  0  0  0
 22 24  1  0  0  0
 24 25  1  0  0  0
 24 26  1  0  0  0
 25 49  1  0  0  0
 25 50  1  0  0  0
 25 51  1  0  0  0
 26 52  1  0  0  0
 26 53  1  0  0  0
 26 54  1  0  0  0
 27 55  1  0  0  0
 27 56  1  0  0  0
 27 57  1  0  0  0
 28 58  1  0  0  0
 28 59  1  0  0  0
 28 60  1  0  0  0
 29 30  1  0  0  0
 29 61  1  0  0  0
 29 62  1  0  0  0
 30 31  1  0  0  0
 30 35  2  0  0  0
 31 32  2  0  0  0
 31 63  1  0  0  0
 32 33  1  0  0  0
 32 64  1  0  0  0
 33 34  2  0  0  0
 33 36  1  0  0  0
 34 35  1  0  0  0
 34 65  1  0  0  0
 35 66  1  0  0  0
M  CHG  1   4   1
M  END
> <s_m_entry_id>
146

> <Applicants>
Scios inc

> <CHEMBL_ID>
CHEMBL514201

> <Canonical_Smiles>
Clc1cc2n(cc(c2cc1C(=O)N1C[C@@H](N(C[C@H]1C)Cc1ccc(F)cc1)C)C(=O)C(=O)N(C)C)C

> <Chirality>
Single Stereoisomer

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
SCIO 469 | SCIO-469 | TALMAPIMOD

> <Indications>
Investigated for use/treatment in pain (acute or chronic) and rheumatoid arthritis.

> <Type>
1

> <targets_id>
Q16539

> <inchi>
InChI=1S/C27H30ClFN4O3/c1-16-13-33(17(2)12-32(16)14-18-6-8-19(29)9-7-18)26(35)21-10-20-22(25(34)27(36)30(3)4)15-31(5)24(20)11-23(21)28/h6-11,15-17H,12-14H2,1-5H3/t16-,17+/m0/s1

> <stdInchikey>
ZMELOYOKMZBMRB-DLBZAZTESA-N

> <csid>
8046764

> <Links>
|http://www.chemspider.com/Chemical-Structure.8046764.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL514201|http://pubchem.ncbi.nlm.nih.gov/compound/9871074|http://www.drugbank.ca/drugs/DB05412| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=469|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/469|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7817|http://zinc15.docking.org/substances/ZINC000034001955|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=B1E00KQ6NT|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50266947

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
512.2

> <HBA>
5

> <HBD>
0

> <NRB>
5

> <TPSA>
65.9

> <LogP>
4

> <RoF>
1

> <Targets>
MAPK14

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_epik_Ionization_Penalty>
  0.2113

> <r_epik_State_Penalty>
  0.2014

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
146

> <lig_pdbID>
'469'

> <pdbID>
3hub 3zsh

> <Kinase families>
CMGC

> <indicationDB>
Talmapimod is the first-generation oral p38 MAP kinase inhibitor developed by Scios. It has shown to be effective to cure inflammatory diseases such as Rheumatoid Arthritis.

> <uniprotId>
Q16539|P01375|P01584|P00403

$$$$
Poseltinib
                    3D
 Structure written by MMmdl.
 62 66  0  0  1  0            999 V2000
   -2.4758    7.4104   -4.1593 C   0  0  0  0  0  0
   -2.8309    7.0494   -2.7041 N   0  3  0  0  0  0
   -1.5482    6.9396   -1.8434 C   0  0  0  0  0  0
   -1.9174    6.3922   -0.4456 C   0  0  0  0  0  0
   -2.5679    5.0787   -0.5832 N   0  0  0  0  0  0
   -3.8853    5.3283   -1.1907 C   0  0  0  0  0  0
   -3.7070    5.7734   -2.6602 C   0  0  0  0  0  0
   -1.8796    3.8600   -0.6577 C   0  0  0  0  0  0
   -2.5111    2.6942   -1.1215 C   0  0  0  0  0  0
   -1.8286    1.4829   -1.1912 C   0  0  0  0  0  0
   -0.4981    1.3967   -0.7865 C   0  0  0  0  0  0
    0.1490    2.5484   -0.3306 C   0  0  0  0  0  0
   -0.5351    3.7589   -0.2643 C   0  0  0  0  0  0
    0.1321    0.1435   -0.8860 N   0  0  0  0  0  0
    1.2115   -0.4397   -0.2055 C   0  0  0  0  0  0
    1.4883   -1.7209   -0.5851 N   0  0  0  0  0  0
    2.5078   -2.3104    0.0510 C   0  0  0  0  0  0
    3.1021   -3.6021   -0.0760 C   0  0  0  0  0  0
    4.1379   -3.6263    0.8501 C   0  0  0  0  0  0
    4.2354   -2.4555    1.5461 O   0  0  0  0  0  0
    3.2367   -1.6564    1.0653 C   0  0  0  0  0  0
    2.8751   -0.3449    1.4224 C   0  0  0  0  0  0
    1.8621    0.2689    0.7610 N   0  0  0  0  0  0
    3.5361    0.4179    2.3641 O   0  0  0  0  0  0
    4.2772   -0.1681    3.3634 C   0  0  0  0  0  0
    3.6802   -1.0178    4.3008 C   0  0  0  0  0  0
    4.4433   -1.5792    5.3230 C   0  0  0  0  0  0
    5.8050   -1.2929    5.4160 C   0  0  0  0  0  0
    6.4161   -0.4495    4.4831 C   0  0  0  0  0  0
    5.6384    0.1263    3.4646 C   0  0  0  0  0  0
    7.7875   -0.1940    4.6576 N   0  0  0  0  0  0
    8.6998    0.1238    3.7138 C   0  0  0  0  0  0
    8.4613    0.2033    2.5058 O   0  0  0  0  0  0
   10.0091    0.3672    4.2758 C   0  0  0  0  0  0
   11.0801    0.6759    3.5205 C   0  0  0  0  0  0
   -1.8787    6.5971   -4.5753 H   0  0  0  0  0  0
   -1.9165    8.3465   -4.1310 H   0  0  0  0  0  0
   -3.4158    7.5359   -4.6983 H   0  0  0  0  0  0
   -0.8510    6.2817   -2.3662 H   0  0  0  0  0  0
   -1.1234    7.9429   -1.7904 H   0  0  0  0  0  0
   -1.0483    6.3539    0.2081 H   0  0  0  0  0  0
   -2.5899    7.0944    0.0511 H   0  0  0  0  0  0
   -4.5401    4.4623   -1.1112 H   0  0  0  0  0  0
   -4.4121    6.1090   -0.6381 H   0  0  0  0  0  0
   -4.6579    6.0343   -3.1266 H   0  0  0  0  0  0
   -3.2109    5.0071   -3.2594 H   0  0  0  0  0  0
   -3.5402    2.6953   -1.4433 H   0  0  0  0  0  0
   -2.3474    0.6077   -1.5558 H   0  0  0  0  0  0
    1.1871    2.5342   -0.0377 H   0  0  0  0  0  0
    0.0163    4.6109    0.0993 H   0  0  0  0  0  0
   -0.3813   -0.5271   -1.4383 H   0  0  0  0  0  0
    2.8293   -4.4045   -0.7449 H   0  0  0  0  0  0
    4.8648   -4.3809    1.1136 H   0  0  0  0  0  0
    2.6246   -1.2384    4.2365 H   0  0  0  0  0  0
    3.9784   -2.2336    6.0457 H   0  0  0  0  0  0
    6.3819   -1.7346    6.2162 H   0  0  0  0  0  0
    6.0709    0.8097    2.7495 H   0  0  0  0  0  0
    8.1422   -0.3862    5.5828 H   0  0  0  0  0  0
   10.1129    0.2936    5.3503 H   0  0  0  0  0  0
   11.0268    0.7607    2.4438 H   0  0  0  0  0  0
   12.0412    0.8504    3.9814 H   0  0  0  0  0  0
   -3.3837    7.8040   -2.3215 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 36  1  0  0  0
  1 37  1  0  0  0
  1 38  1  0  0  0
  2  3  1  0  0  0
  2  7  1  0  0  0
  2 62  1  0  0  0
  3  4  1  0  0  0
  3 39  1  0  0  0
  3 40  1  0  0  0
  4  5  1  0  0  0
  4 41  1  0  0  0
  4 42  1  0  0  0
  5  6  1  0  0  0
  5  8  1  0  0  0
  6  7  1  0  0  0
  6 43  1  0  0  0
  6 44  1  0  0  0
  7 45  1  0  0  0
  7 46  1  0  0  0
  8  9  1  0  0  0
  8 13  2  0  0  0
  9 10  2  0  0  0
  9 47  1  0  0  0
 10 11  1  0  0  0
 10 48  1  0  0  0
 11 12  2  0  0  0
 11 14  1  0  0  0
 12 13  1  0  0  0
 12 49  1  0  0  0
 13 50  1  0  0  0
 14 15  1  0  0  0
 14 51  1  0  0  0
 15 16  1  0  0  0
 15 23  2  0  0  0
 16 17  2  0  0  0
 17 18  1  0  0  0
 17 21  1  0  0  0
 18 19  2  0  0  0
 18 52  1  0  0  0
 19 20  1  0  0  0
 19 53  1  0  0  0
 20 21  1  0  0  0
 21 22  2  0  0  0
 22 23  1  0  0  0
 22 24  1  0  0  0
 24 25  1  0  0  0
 25 26  1  0  0  0
 25 30  2  0  0  0
 26 27  2  0  0  0
 26 54  1  0  0  0
 27 28  1  0  0  0
 27 55  1  0  0  0
 28 29  2  0  0  0
 28 56  1  0  0  0
 29 30  1  0  0  0
 29 31  1  0  0  0
 30 57  1  0  0  0
 31 32  1  0  0  0
 31 58  1  0  0  0
 32 33  2  0  0  0
 32 34  1  0  0  0
 34 35  2  0  0  0
 34 59  1  0  0  0
 35 60  1  0  0  0
 35 61  1  0  0  0
M  CHG  1   2   1
M  END
> <s_m_entry_id>
152

> <Applicants>
Hanmi Pharmaceutical

> <CHEMBL_ID>
CHEMBL4163691

> <Canonical_Smiles>
o1c2c(nc(nc2Oc2cc(NC(=O)C=C)ccc2)Nc2ccc(N3CCN(CC3)C)cc2)cc1

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
HM71224 | LY3337641 | POSELTINIB

> <Indications>
nan

> <Type>
nan

> <targets_id>
nan

> <inchi>
InChI=1S/C26H26N6O3/c1-3-23(33)27-19-5-4-6-21(17-19)35-25-24-22(11-16-34-24)29-26(30-25)28-18-7-9-20(10-8-18)32-14-12-31(2)13-15-32/h3-11,16-17H,1,12-15H2,2H3,(H,27,33)(H,28,29,30)

> <stdInchikey>
LZMJNVRJMFMYQS-UHFFFAOYSA-N

> <csid>
58826582

> <Links>
|http://www.chemspider.com/Chemical-Structure.58826582.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4163691|http://pubchem.ncbi.nlm.nih.gov/compound/56644522|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9862|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=D01E4B1U35|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50369724

> <LinkName>
|ChemSpider|ChEMBL|PubChem|Guide to Pharmacology|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
470.2

> <HBA>
8

> <HBD>
2

> <NRB>
7

> <TPSA>
95.8

> <LogP>
4.6

> <RoF>
0

> <Targets>
nan

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0744

> <r_epik_State_Penalty>
  0.4007

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
152

$$$$
Inavolisib
                    3D
 Structure written by MMmdl.
 48 51  0  0  1  0            999 V2000
   -0.2770    1.5233    0.0804 C   0  0  0  0  0  0
    0.0090    0.0128   -0.0234 C   0  0  1  0  0  0
   -0.9509   -0.6395   -1.0492 C   0  0  0  0  0  0
   -2.0998   -1.1150   -0.5604 N   0  0  0  0  0  0
   -0.6623   -0.7004   -2.2448 O   0  0  0  0  0  0
    1.3931   -0.2601   -0.3640 N   0  0  0  0  0  0
    2.1002   -1.4709   -0.2655 C   0  0  0  0  0  0
    1.4701   -2.7128   -0.1283 C   0  0  0  0  0  0
    2.2265   -3.8792   -0.0355 C   0  0  0  0  0  0
    3.6236   -3.8280   -0.0632 C   0  0  0  0  0  0
    4.2655   -2.5817   -0.1988 C   0  0  0  0  0  0
    3.4949   -1.4216   -0.3062 C   0  0  0  0  0  0
    5.6341   -2.4781   -0.3241 O   0  0  0  0  0  0
    6.4801   -2.8512    0.7688 C   0  0  0  0  0  0
    6.0810   -4.0643    1.6331 C   0  0  0  0  0  0
    5.5441   -5.1555    0.8393 N   0  0  0  0  0  0
    4.4152   -5.0880    0.0561 C   0  0  0  0  0  0
    4.1409   -6.2440   -0.5086 N   0  0  0  0  0  0
    5.0965   -7.0872   -0.1410 C   0  0  0  0  0  0
    5.9914   -6.4433    0.7107 C   0  0  0  0  0  0
    5.1132   -8.4125   -0.5660 N   0  0  0  0  0  0
    4.0049   -9.0848   -1.2366 C   0  0  1  0  0  0
    4.7482  -10.2133   -1.9226 C   0  0  0  0  0  0
    5.8036  -10.4495   -1.0175 O   0  0  0  0  0  0
    6.1657   -9.3179   -0.3756 C   0  0  0  0  0  0
    7.2233   -9.2184    0.2451 O   0  0  0  0  0  0
    2.9222   -9.5796   -0.2477 C   0  0  0  0  0  0
    1.9682  -10.2882   -0.8514 F   0  0  0  0  0  0
    2.3418   -8.5930    0.4355 F   0  0  0  0  0  0
   -1.3094    1.7199    0.3740 H   0  0  0  0  0  0
   -0.1008    2.0354   -0.8674 H   0  0  0  0  0  0
    0.3634    1.9935    0.8277 H   0  0  0  0  0  0
   -0.1575   -0.3711    0.9854 H   0  0  0  0  0  0
   -2.7696   -1.5495   -1.1783 H   0  0  0  0  0  0
    2.0072    0.5261   -0.2084 H   0  0  0  0  0  0
    0.3951   -2.7941   -0.0881 H   0  0  0  0  0  0
    1.7205   -4.8283    0.0696 H   0  0  0  0  0  0
    3.9973   -0.4726   -0.4298 H   0  0  0  0  0  0
    7.4705   -3.0294    0.3484 H   0  0  0  0  0  0
    6.6000   -1.9822    1.4170 H   0  0  0  0  0  0
    6.9305   -4.4223    2.2165 H   0  0  0  0  0  0
    5.3146   -3.7761    2.3540 H   0  0  0  0  0  0
    6.8768   -6.7776    1.2308 H   0  0  0  0  0  0
    3.5405   -8.4340   -1.9788 H   0  0  0  0  0  0
    4.1361  -11.1009   -2.0855 H   0  0  0  0  0  0
    5.1570   -9.8933   -2.8828 H   0  0  0  0  0  0
    3.3555  -10.2437    0.5018 H   0  0  0  0  0  0
   -2.3034   -1.0478    0.4258 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 30  1  0  0  0
  1 31  1  0  0  0
  1 32  1  0  0  0
  2  3  1  0  0  0
  2  6  1  0  0  0
  2 33  1  0  0  0
  3  4  1  0  0  0
  3  5  2  0  0  0
  4 34  1  0  0  0
  4 48  1  0  0  0
  6  7  1  0  0  0
  6 35  1  0  0  0
  7  8  2  0  0  0
  7 12  1  0  0  0
  8  9  1  0  0  0
  8 36  1  0  0  0
  9 10  2  0  0  0
  9 37  1  0  0  0
 10 11  1  0  0  0
 10 17  1  0  0  0
 11 12  2  0  0  0
 11 13  1  0  0  0
 12 38  1  0  0  0
 13 14  1  0  0  0
 14 15  1  0  0  0
 14 39  1  0  0  0
 14 40  1  0  0  0
 15 16  1  0  0  0
 15 41  1  0  0  0
 15 42  1  0  0  0
 16 17  1  0  0  0
 16 20  1  0  0  0
 17 18  2  0  0  0
 18 19  1  0  0  0
 19 20  2  0  0  0
 19 21  1  0  0  0
 20 43  1  0  0  0
 21 22  1  0  0  0
 21 25  1  0  0  0
 22 23  1  0  0  0
 22 27  1  0  0  0
 22 44  1  0  0  0
 23 24  1  0  0  0
 23 45  1  0  0  0
 23 46  1  0  0  0
 24 25  1  0  0  0
 25 26  2  0  0  0
 27 28  1  0  0  0
 27 29  1  0  0  0
 27 47  1  0  0  0
M  END
> <s_m_entry_id>
155

> <Applicants>
Genentech

> <CHEMBL_ID>
CHEMBL4297757

> <Canonical_Smiles>
FC(F)[C@H]1N(c2nc-3n(c2)CCOc2cc(N[C@H](C(O)=N)C)ccc2-3)C(OC1)=O

> <Chirality>
Unknown

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
INAVOLISIB|RG6114|GDC-0077|GDC0077

> <Indications>
nan

> <Type>
nan

> <targets_id>
nan

> <inchi>
InChI=1S/C18H19F2N5O4/c1-9(16(21)26)22-10-2-3-11-13(6-10)28-5-4-24-7-14(23-17(11)24)25-12(15(19)20)8-29-18(25)27/h2-3,6-7,9,12,15,22H,4-5,8H2,1H3,(H2,21,26)/t9-,12-/m0/s1

> <stdInchikey>
SGEUNORSOZVTOL-CABZTGNLSA-N

> <csid>
59718498

> <Links>
|http://www.chemspider.com/Chemical-Structure.59718498.html|http://pubchem.ncbi.nlm.nih.gov/compound/124173720|http://www.drugbank.ca/drugs/DB15275|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9636|http://zinc15.docking.org/substances/ZINC000669678973|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=L4C1UY2NYH|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=295665

> <LinkName>
|ChemSpider|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
407.1

> <HBA>
7

> <HBD>
3

> <NRB>
5

> <TPSA>
112.7

> <LogP>
2.9

> <RoF>
0

> <Targets>
nan

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0001

> <r_epik_State_Penalty>
  0.0000

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
155

$$$$
Tirabrutinib
                    3D
 Structure written by MMmdl.
 56 60  0  0  1  0            999 V2000
   -1.8552   -2.1919   -5.4336 C   0  0  0  0  0  0
   -1.9600   -2.2846   -3.9705 C   0  0  0  0  0  0
   -2.0651   -2.3645   -2.7562 C   0  0  0  0  0  0
   -2.2830   -2.5202   -1.3197 C   0  0  0  0  0  0
   -2.9335   -3.4742   -0.8915 O   0  0  0  0  0  0
   -1.7338   -1.5662   -0.5204 N   0  0  0  0  0  0
   -1.8962   -1.5784    0.9332 C   0  0  0  0  0  0
   -0.5628   -1.0096    1.4017 C   0  0  0  0  0  0
   -0.1818    0.0234    0.3352 C   0  0  2  0  0  0
   -0.9740   -0.3721   -0.9265 C   0  0  0  0  0  0
    1.2737    0.0868    0.1125 N   0  0  0  0  0  0
    2.0953   -0.8915   -0.4172 C   0  0  0  0  0  0
    3.3693   -0.3976   -0.4023 C   0  0  0  0  0  0
    4.3946   -1.2157   -0.9000 C   0  0  0  0  0  0
    4.1165   -2.4598   -1.3808 N   0  0  0  0  0  0
    2.8113   -2.8539   -1.3487 C   0  0  0  0  0  0
    1.7616   -2.1238   -0.8829 N   0  0  0  0  0  0
    5.7286   -0.8165   -0.9315 N   0  0  0  0  0  0
    3.2914    0.8725    0.1441 N   0  0  0  0  0  0
    2.0045    1.1780    0.4714 C   0  0  0  0  0  0
    1.5936    2.2208    0.9864 O   0  0  0  0  0  0
    4.3841    1.7207    0.3538 C   0  0  0  0  0  0
    5.0977    1.6451    1.5522 C   0  0  0  0  0  0
    6.1909    2.4829    1.7539 C   0  0  0  0  0  0
    6.5656    3.3988    0.7701 C   0  0  0  0  0  0
    5.8579    3.4540   -0.4381 C   0  0  0  0  0  0
    4.7636    2.6193   -0.6457 C   0  0  0  0  0  0
    7.6697    4.1896    1.0111 O   0  0  0  0  0  0
    7.7002    5.5179    0.6388 C   0  0  0  0  0  0
    8.9157    6.0421    0.1961 C   0  0  0  0  0  0
    9.0099    7.3827   -0.1685 C   0  0  0  0  0  0
    7.8869    8.2020   -0.0793 C   0  0  0  0  0  0
    6.6726    7.6942    0.3769 C   0  0  0  0  0  0
    6.5795    6.3538    0.7423 C   0  0  0  0  0  0
   -2.2253   -3.1108   -5.8884 H   0  0  0  0  0  0
   -0.8144   -2.0443   -5.7215 H   0  0  0  0  0  0
   -2.4487   -1.3515   -5.7935 H   0  0  0  0  0  0
   -2.7219   -0.9208    1.2085 H   0  0  0  0  0  0
   -2.0893   -2.5708    1.3438 H   0  0  0  0  0  0
   -0.6281   -0.5696    2.3971 H   0  0  0  0  0  0
    0.1660   -1.8206    1.4555 H   0  0  0  0  0  0
   -0.5809    0.9855    0.6624 H   0  0  0  0  0  0
   -0.3259   -0.5700   -1.7814 H   0  0  0  0  0  0
   -1.6629    0.4240   -1.2111 H   0  0  0  0  0  0
    2.5887   -3.8399   -1.7296 H   0  0  0  0  0  0
    5.9832    0.0962   -0.5825 H   0  0  0  0  0  0
    6.4239   -1.4496   -1.2986 H   0  0  0  0  0  0
    4.8104    0.9426    2.3215 H   0  0  0  0  0  0
    6.7468    2.4255    2.6784 H   0  0  0  0  0  0
    6.1556    4.1427   -1.2151 H   0  0  0  0  0  0
    4.2188    2.6697   -1.5775 H   0  0  0  0  0  0
    9.7869    5.4066    0.1318 H   0  0  0  0  0  0
    9.9495    7.7856   -0.5165 H   0  0  0  0  0  0
    7.9596    9.2423   -0.3609 H   0  0  0  0  0  0
    5.8087    8.3381    0.4510 H   0  0  0  0  0  0
    5.6390    5.9677    1.1073 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 35  1  0  0  0
  1 36  1  0  0  0
  1 37  1  0  0  0
  2  3  3  0  0  0
  3  4  1  0  0  0
  4  5  2  0  0  0
  4  6  1  0  0  0
  6  7  1  0  0  0
  6 10  1  0  0  0
  7  8  1  0  0  0
  7 38  1  0  0  0
  7 39  1  0  0  0
  8  9  1  0  0  0
  8 40  1  0  0  0
  8 41  1  0  0  0
  9 10  1  0  0  0
  9 11  1  0  0  0
  9 42  1  0  0  0
 10 43  1  0  0  0
 10 44  1  0  0  0
 11 12  1  0  0  0
 11 20  1  0  0  0
 12 13  1  0  0  0
 12 17  2  0  0  0
 13 14  2  0  0  0
 13 19  1  0  0  0
 14 15  1  0  0  0
 14 18  1  0  0  0
 15 16  2  0  0  0
 16 17  1  0  0  0
 16 45  1  0  0  0
 18 46  1  0  0  0
 18 47  1  0  0  0
 19 20  1  0  0  0
 19 22  1  0  0  0
 20 21  2  0  0  0
 22 23  1  0  0  0
 22 27  2  0  0  0
 23 24  2  0  0  0
 23 48  1  0  0  0
 24 25  1  0  0  0
 24 49  1  0  0  0
 25 26  2  0  0  0
 25 28  1  0  0  0
 26 27  1  0  0  0
 26 50  1  0  0  0
 27 51  1  0  0  0
 28 29  1  0  0  0
 29 30  1  0  0  0
 29 34  2  0  0  0
 30 31  2  0  0  0
 30 52  1  0  0  0
 31 32  1  0  0  0
 31 53  1  0  0  0
 32 33  2  0  0  0
 32 54  1  0  0  0
 33 34  1  0  0  0
 33 55  1  0  0  0
 34 56  1  0  0  0
M  END
> <s_m_entry_id>
156

> <Applicants>
Ono Pharmaceutical

> <CHEMBL_ID>
CHEMBL4071161

> <Canonical_Smiles>
O(c1ccc(N2c3c(ncnc3N)N(C3CCN(C3)C(=O)C#CC)C2=O)cc1)c1ccccc1

> <Chirality>
Single Stereoisomer

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
|ONO-4059|GS-4059|ONO-4059(FREE BASE)

> <Indications>
nan

> <Type>
nan

> <targets_id>
nan

> <inchi>
InChI=1S/C25H22N6O3/c1-2-6-21(32)29-14-13-18(15-29)31-24-22(23(26)27-16-28-24)30(25(31)33)17-9-11-20(12-10-17)34-19-7-4-3-5-8-19/h3-5,7-12,16,18H,13-15H2,1H3,(H2,26,27,28)

> <stdInchikey>
SEJLPXCPMNSRAM-UHFFFAOYSA-N

> <csid>
34979967

> <Links>
|http://www.chemspider.com/Chemical-Structure.34979967.html|http://pubchem.ncbi.nlm.nih.gov/compound/54755435

> <LinkName>
|ChemSpider|PubChem

> <MW>
454.2

> <HBA>
8

> <HBD>
1

> <NRB>
4

> <TPSA>
108.3

> <LogP>
2.8

> <RoF>
0

> <Targets>
nan

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0044

> <r_epik_State_Penalty>
  0.0031

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
156

$$$$
Ilorasertib
                    3D
 Structure written by MMmdl.
 56 60  0  0  1  0            999 V2000
  -14.2887    3.1795    0.4349 C   0  0  0  0  0  0
  -12.9495    3.5430    0.2911 C   0  0  0  0  0  0
  -11.9457    2.5686    0.2868 C   0  0  0  0  0  0
  -12.3062    1.2148    0.4069 C   0  0  0  0  0  0
  -13.6468    0.8545    0.5489 C   0  0  0  0  0  0
  -14.6370    1.8359    0.5659 C   0  0  0  0  0  0
  -13.9873   -0.4492    0.6639 F   0  0  0  0  0  0
  -10.6258    3.0265    0.1195 N   0  0  0  0  0  0
   -9.4704    2.3992    0.4200 C   0  0  0  0  0  0
   -9.3838    1.3060    0.9820 O   0  0  0  0  0  0
   -8.4217    3.1401    0.0079 N   0  0  0  0  0  0
   -7.0499    2.8642    0.1493 C   0  0  0  0  0  0
   -6.1977    3.4528   -0.7876 C   0  0  0  0  0  0
   -4.8246    3.2353   -0.7184 C   0  0  0  0  0  0
   -4.2973    2.4321    0.2934 C   0  0  0  0  0  0
   -5.1395    1.8680    1.2528 C   0  0  0  0  0  0
   -6.5138    2.0800    1.1828 C   0  0  0  0  0  0
   -2.8297    2.2141    0.3707 C   0  0  0  0  0  0
   -1.9633    3.1738    0.8499 C   0  0  0  0  0  0
   -0.2882    2.7130    0.8537 S   0  0  0  0  0  0
   -0.7020    1.1462    0.1656 C   0  0  0  0  0  0
   -2.1205    1.0263   -0.0271 C   0  0  0  0  0  0
   -2.5767   -0.2015   -0.5643 C   0  0  0  0  0  0
   -1.7410   -1.2185   -0.8739 N   0  0  0  0  0  0
   -0.4150   -1.0652   -0.6756 C   0  0  0  0  0  0
    0.1776    0.0910   -0.1681 C   0  0  0  0  0  0
    1.6619    0.1467   -0.0131 C   0  0  0  0  0  0
    2.5388   -0.9077    0.2971 C   0  0  0  0  0  0
    3.8001   -0.5453    0.3535 N   0  0  0  0  0  0
    3.7850    0.7639    0.0721 N   0  0  0  0  0  0
    2.5171    1.2304   -0.1582 C   0  0  0  0  0  0
    5.0332    1.5180    0.0381 C   0  0  0  0  0  0
    5.6958    1.5646    1.4276 C   0  0  0  0  0  0
    6.8741    2.3394    1.3684 O   0  0  0  0  0  0
   -3.9271   -0.4423   -0.8111 N   0  0  0  0  0  0
  -15.0564    3.9392    0.4430 H   0  0  0  0  0  0
  -12.6983    4.5893    0.1879 H   0  0  0  0  0  0
  -11.5693    0.4273    0.3760 H   0  0  0  0  0  0
  -15.6745    1.5555    0.6747 H   0  0  0  0  0  0
  -10.5496    3.9626   -0.2503 H   0  0  0  0  0  0
   -8.6340    3.9706   -0.5250 H   0  0  0  0  0  0
   -6.5940    4.0740   -1.5784 H   0  0  0  0  0  0
   -4.1740    3.6877   -1.4531 H   0  0  0  0  0  0
   -4.7318    1.2627    2.0497 H   0  0  0  0  0  0
   -7.1406    1.6415    1.9444 H   0  0  0  0  0  0
   -2.2337    4.1542    1.2140 H   0  0  0  0  0  0
    0.1901   -1.9157   -0.9546 H   0  0  0  0  0  0
    2.2487   -1.9317    0.4823 H   0  0  0  0  0  0
    2.3440    2.2672   -0.4060 H   0  0  0  0  0  0
    5.6902    1.0486   -0.6962 H   0  0  0  0  0  0
    4.8137    2.5271   -0.3154 H   0  0  0  0  0  0
    5.0241    2.0053    2.1656 H   0  0  0  0  0  0
    5.9534    0.5641    1.7779 H   0  0  0  0  0  0
    7.2798    2.3463    2.2386 H   0  0  0  0  0  0
   -4.6073    0.2734   -0.5994 H   0  0  0  0  0  0
   -4.2065   -1.3348   -1.1914 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1  6  2  0  0  0
  1 36  1  0  0  0
  2  3  2  0  0  0
  2 37  1  0  0  0
  3  4  1  0  0  0
  3  8  1  0  0  0
  4  5  2  0  0  0
  4 38  1  0  0  0
  5  6  1  0  0  0
  5  7  1  0  0  0
  6 39  1  0  0  0
  8  9  1  0  0  0
  8 40  1  0  0  0
  9 10  2  0  0  0
  9 11  1  0  0  0
 11 12  1  0  0  0
 11 41  1  0  0  0
 12 13  1  0  0  0
 12 17  2  0  0  0
 13 14  2  0  0  0
 13 42  1  0  0  0
 14 15  1  0  0  0
 14 43  1  0  0  0
 15 16  2  0  0  0
 15 18  1  0  0  0
 16 17  1  0  0  0
 16 44  1  0  0  0
 17 45  1  0  0  0
 18 19  2  0  0  0
 18 22  1  0  0  0
 19 20  1  0  0  0
 19 46  1  0  0  0
 20 21  1  0  0  0
 21 22  1  0  0  0
 21 26  2  0  0  0
 22 23  2  0  0  0
 23 24  1  0  0  0
 23 35  1  0  0  0
 24 25  2  0  0  0
 25 26  1  0  0  0
 25 47  1  0  0  0
 26 27  1  0  0  0
 27 28  1  0  0  0
 27 31  2  0  0  0
 28 29  2  0  0  0
 28 48  1  0  0  0
 29 30  1  0  0  0
 30 31  1  0  0  0
 30 32  1  0  0  0
 31 49  1  0  0  0
 32 33  1  0  0  0
 32 50  1  0  0  0
 32 51  1  0  0  0
 33 34  1  0  0  0
 33 52  1  0  0  0
 33 53  1  0  0  0
 34 54  1  0  0  0
 35 55  1  0  0  0
 35 56  1  0  0  0
M  END
> <s_m_entry_id>
158

> <Applicants>
Abbott Laboratories

> <CHEMBL_ID>
CHEMBL1980297

> <Canonical_Smiles>
s1c2c(c(c1)-c1ccc(NC(=O)Nc3cc(F)ccc3)cc1)c(ncc2-c1cn(nc1)CCO)N

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
A-968660 | A-968660.0 | ABBOTT-968660 | ABT-348 | ABT-348, A-968660 | ILORASERTIB

> <Indications>
nan

> <Type>
nan

> <targets_id>
O14965|Q96GD4|Q9UQB9|P17948|P16234|P09619

> <inchi>
InChI=1S/C25H21FN6O2S/c26-17-2-1-3-19(10-17)31-25(34)30-18-6-4-15(5-7-18)21-14-35-23-20(12-28-24(27)22(21)23)16-11-29-32(13-16)8-9-33/h1-7,10-14,33H,8-9H2,(H2,27,28)(H2,30,31,34)

> <stdInchikey>
WPHKIQPVPYJNAX-UHFFFAOYSA-N

> <csid>
24809095

> <Links>
|http://www.chemspider.com/Chemical-Structure.24809095.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1980297|http://pubchem.ncbi.nlm.nih.gov/compound/46207586|http://www.drugbank.ca/drugs/DB11694|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9914|http://zinc15.docking.org/substances/ZINC000063298074|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=6L5D03D975|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50381716

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
488.1

> <HBA>
7

> <HBD>
4

> <NRB>
6

> <TPSA>
118.1

> <LogP>
5.2

> <RoF>
1

> <Targets>
AURKA; AURKB; AURKC; FLT1; PDGFRA; PDGFRB

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.3120

> <r_epik_State_Penalty>
  0.3057

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
158

> <Kinase families>
Tyr<br>Other

> <BrandName>
ABT-348, A-968660;Abt-348, a-968660

$$$$
Amuvatinib
                    3D
 Structure written by MMmdl.
 53 58  0  0  1  0            999 V2000
   -8.2259    2.0839   -3.8766 C   0  0  0  0  0  0
   -7.3559    2.4228   -4.9162 C   0  0  0  0  0  0
   -5.9716    2.3214   -4.7684 C   0  0  0  0  0  0
   -5.5002    1.8654   -3.5326 C   0  0  0  0  0  0
   -6.3610    1.5158   -2.4628 C   0  0  0  0  0  0
   -7.7494    1.6288   -2.6433 C   0  0  0  0  0  0
   -5.5331    1.1127   -1.4090 C   0  0  0  0  0  0
   -4.2053    1.2336   -1.8806 C   0  0  0  0  0  0
   -4.1848    1.6922   -3.1745 O   0  0  0  0  0  0
   -3.1357    0.8978   -1.0389 C   0  0  0  0  0  0
   -3.4024    0.4590    0.2252 N   0  0  0  0  0  0
   -4.7113    0.3759    0.5878 C   0  0  0  0  0  0
   -5.8040    0.6820   -0.1688 N   0  0  0  0  0  0
   -1.8263    1.0091   -1.4774 N   0  0  0  0  0  0
   -1.0388   -0.2363   -1.4880 C   0  0  0  0  0  0
    0.2859   -0.0689   -2.2727 C   0  0  0  0  0  0
    1.0708    0.9615   -1.5500 N   0  0  0  0  0  0
    0.3443    2.2539   -1.4956 C   0  0  0  0  0  0
   -0.9844    1.9749   -0.7498 C   0  0  0  0  0  0
    2.2248    0.6745   -0.8342 C   0  0  0  0  0  0
    3.0537    1.8181    0.0872 S   0  0  0  0  0  0
    2.6570   -0.6256   -0.9362 N   0  0  0  0  0  0
    3.7340   -1.2674   -0.1647 C   0  0  0  0  0  0
    3.3892   -1.5579    1.2919 C   0  0  0  0  0  0
    2.2661   -2.3486    1.6082 C   0  0  0  0  0  0
    1.9334   -2.6257    2.9412 C   0  0  0  0  0  0
    2.7515   -2.0949    3.9328 C   0  0  0  0  0  0
    3.8438   -1.3312    3.6324 C   0  0  0  0  0  0
    4.1975   -1.0416    2.3186 C   0  0  0  0  0  0
    4.4617   -0.9481    4.7795 O   0  0  0  0  0  0
    3.6937   -1.4745    5.8291 C   0  0  0  0  0  0
    2.6410   -2.2223    5.2805 O   0  0  0  0  0  0
   -9.2912    2.1758   -4.0293 H   0  0  0  0  0  0
   -7.7634    2.7709   -5.8539 H   0  0  0  0  0  0
   -5.2977    2.5833   -5.5709 H   0  0  0  0  0  0
   -8.4365    1.3713   -1.8506 H   0  0  0  0  0  0
   -4.9073    0.0273    1.5912 H   0  0  0  0  0  0
   -0.8401   -0.5832   -0.4712 H   0  0  0  0  0  0
   -1.6277   -1.0176   -1.9711 H   0  0  0  0  0  0
    0.7833   -1.0311   -2.3909 H   0  0  0  0  0  0
    0.0814    0.2906   -3.2826 H   0  0  0  0  0  0
    0.8842    3.0708   -1.0196 H   0  0  0  0  0  0
    0.1398    2.5838   -2.5154 H   0  0  0  0  0  0
   -1.5298    2.9156   -0.6587 H   0  0  0  0  0  0
   -0.7865    1.6330    0.2689 H   0  0  0  0  0  0
    2.2244   -1.2003   -1.6447 H   0  0  0  0  0  0
    3.9364   -2.2266   -0.6418 H   0  0  0  0  0  0
    4.6592   -0.6946   -0.2480 H   0  0  0  0  0  0
    1.6471   -2.7465    0.8174 H   0  0  0  0  0  0
    1.0705   -3.2302    3.1780 H   0  0  0  0  0  0
    5.0619   -0.4350    2.0912 H   0  0  0  0  0  0
    4.3112   -2.1045    6.4705 H   0  0  0  0  0  0
    3.2994   -0.6675    6.4481 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1  6  2  0  0  0
  1 33  1  0  0  0
  2  3  2  0  0  0
  2 34  1  0  0  0
  3  4  1  0  0  0
  3 35  1  0  0  0
  4  5  2  0  0  0
  4  9  1  0  0  0
  5  6  1  0  0  0
  5  7  1  0  0  0
  6 36  1  0  0  0
  7  8  1  0  0  0
  7 13  2  0  0  0
  8  9  1  0  0  0
  8 10  2  0  0  0
 10 11  1  0  0  0
 10 14  1  0  0  0
 11 12  2  0  0  0
 12 13  1  0  0  0
 12 37  1  0  0  0
 14 15  1  0  0  0
 14 19  1  0  0  0
 15 16  1  0  0  0
 15 38  1  0  0  0
 15 39  1  0  0  0
 16 17  1  0  0  0
 16 40  1  0  0  0
 16 41  1  0  0  0
 17 18  1  0  0  0
 17 20  1  0  0  0
 18 19  1  0  0  0
 18 42  1  0  0  0
 18 43  1  0  0  0
 19 44  1  0  0  0
 19 45  1  0  0  0
 20 21  2  0  0  0
 20 22  1  0  0  0
 22 23  1  0  0  0
 22 46  1  0  0  0
 23 24  1  0  0  0
 23 47  1  0  0  0
 23 48  1  0  0  0
 24 25  1  0  0  0
 24 29  2  0  0  0
 25 26  2  0  0  0
 25 49  1  0  0  0
 26 27  1  0  0  0
 26 50  1  0  0  0
 27 28  2  0  0  0
 27 32  1  0  0  0
 28 29  1  0  0  0
 28 30  1  0  0  0
 29 51  1  0  0  0
 30 31  1  0  0  0
 31 32  1  0  0  0
 31 52  1  0  0  0
 31 53  1  0  0  0
M  END
> <s_m_entry_id>
160

> <Applicants>
Supergen

> <CHEMBL_ID>
CHEMBL2103851

> <Canonical_Smiles>
S=C(NCc1cc2OCOc2cc1)N1CCN(CC1)c1ncnc2c1oc1c2cccc1

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
AMUVATINIB | HPK 56 | HPK-56 | HPK56 | MP 470 | MP-470 | MP470

> <Indications>
Amuvatinib is a selective multi-targeted tyrosine kinase inhibitor that suppresses c-MET, c-RET and the mutant forms of c-KIT, PDGFR and FLT3. Amuvatinib also suppresses Rad51 protein, a critical comp
onent of double-stranded DNA repair in cancer cells.

> <Type>
nan

> <targets_id>
P10721|P08581|P07949|P36888|P09619

> <inchi>
InChI=1S/C23H21N5O3S/c32-23(24-12-15-5-6-18-19(11-15)30-14-29-18)28-9-7-27(8-10-28)22-21-20(25-13-26-22)16-3-1-2-4-17(16)31-21/h1-6,11,13H,7-10,12,14H2,(H,24,32)

> <stdInchikey>
FOFDIMHVKGYHRU-UHFFFAOYSA-N

> <csid>
9457280

> <Links>
|http://www.chemspider.com/Chemical-Structure.9457280.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2103851|http://pubchem.ncbi.nlm.nih.gov/compound/11282283|http://www.drugbank.ca/drugs/DB12742|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7932|http://zinc15.docking.org/substances/ZINC34951302|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=SO9S6QZB4R|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50172081

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
447.1

> <HBA>
7

> <HBD>
1

> <NRB>
3

> <TPSA>
75.9

> <LogP>
3.3

> <RoF>
0

> <Targets>
KIT; MET; RET; FLT3; PDGFRB

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0024

> <r_epik_State_Penalty>
  0.0015

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
160

> <Kinase families>
Tyr

> <indicationDB>
Amuvatinib has been used in trials studying the treatment of Solid Tumors and Small Cell Lung Carcinoma. Amuvatinib is an oral, selective multi-targeted tyrosine kinase inhibitor that suppresses c-MET, c-RET and the mutant forms of c-KIT, PDGFR and FLT3. Amuvatinib also suppresses Rad51 protein, a critical component of double-stranded DNA repair in cancer cells.

> <uniprotId>
P10721|P08581|P07949|P16234|P36888|Q06609

$$$$
Amcasertib
                    3D
 Structure written by MMmdl.
 73 77  0  0  1  0            999 V2000
   -0.0440    3.0995    1.0963 C   0  0  0  0  0  0
   -1.3648    2.7472    0.3937 C   0  0  0  0  0  0
   -1.2129    1.4308   -0.4065 N   0  3  0  0  0  0
   -2.5586    0.6872   -0.5908 C   0  0  0  0  0  0
   -2.9440   -0.0547    0.6991 C   0  0  0  0  0  0
   -0.4686    1.6384   -1.7500 C   0  0  0  0  0  0
    0.2673    0.3489   -2.1819 C   0  0  0  0  0  0
    1.5917    0.1949   -1.5794 N   0  0  0  0  0  0
    1.8331   -0.2158   -0.3205 C   0  0  0  0  0  0
    0.9533   -0.5109    0.4901 O   0  0  0  0  0  0
    3.2337   -0.2728    0.0286 C   0  0  0  0  0  0
    4.2947   -0.7985   -0.7625 C   0  0  0  0  0  0
    5.4665   -0.6892   -0.0032 C   0  0  0  0  0  0
    5.1012   -0.1682    1.2071 N   0  0  0  0  0  0
    3.7603    0.0770    1.2739 C   0  0  0  0  0  0
    3.1596    0.6423    2.5444 C   0  0  0  0  0  0
    6.8498   -1.0647   -0.3176 C   0  0  0  0  0  0
    8.0565   -0.9141    0.2881 C   0  0  0  0  0  0
    9.3541   -1.3873   -0.1931 C   0  0  0  0  0  0
    9.7449   -2.0940   -1.3337 C   0  0  0  0  0  0
   11.0976   -2.4246   -1.5300 C   0  0  0  0  0  0
   12.0384   -2.0293   -0.5640 C   0  0  0  0  0  0
   11.6439   -1.3221    0.5739 C   0  0  0  0  0  0
   10.2955   -1.0150    0.7352 C   0  0  0  0  0  0
    9.6596   -0.3425    1.7486 N   0  0  0  0  0  0
    8.3322   -0.2374    1.5543 C   0  0  0  0  0  0
    7.5708    0.3339    2.3312 O   0  0  0  0  0  0
   11.5439   -3.1855   -2.7427 C   0  0  0  0  0  0
   12.7065   -3.9540   -2.8459 C   0  0  0  0  0  0
   12.8248   -4.6591   -4.4272 S   0  0  0  0  0  0
   11.3254   -3.8781   -4.8303 C   0  0  0  0  0  0
   10.8143   -3.1713   -3.8483 N   0  0  0  0  0  0
   10.6847   -4.0280   -6.1796 C   0  0  0  0  0  0
    9.3277   -3.7184   -6.3459 C   0  0  0  0  0  0
    8.7208   -3.8474   -7.5923 C   0  0  0  0  0  0
    9.4689   -4.2844   -8.6817 C   0  0  0  0  0  0
   10.8183   -4.5925   -8.5346 C   0  0  0  0  0  0
   11.4244   -4.4639   -7.2876 C   0  0  0  0  0  0
    4.1968   -1.3883   -2.1598 C   0  0  0  0  0  0
   -0.1593    4.0013    1.6978 H   0  0  0  0  0  0
    0.7685    3.2821    0.3937 H   0  0  0  0  0  0
    0.2691    2.2985    1.7664 H   0  0  0  0  0  0
   -2.1475    2.5832    1.1335 H   0  0  0  0  0  0
   -1.7037    3.5072   -0.3124 H   0  0  0  0  0  0
   -3.2908    1.4337   -0.9034 H   0  0  0  0  0  0
   -2.4182   -0.0260   -1.4029 H   0  0  0  0  0  0
   -3.8509   -0.6400    0.5460 H   0  0  0  0  0  0
   -3.1373    0.6245    1.5288 H   0  0  0  0  0  0
   -2.1580   -0.7454    1.0079 H   0  0  0  0  0  0
   -1.2226    1.9650   -2.4683 H   0  0  0  0  0  0
    0.2366    2.4577   -1.6094 H   0  0  0  0  0  0
   -0.3291   -0.5468   -2.0014 H   0  0  0  0  0  0
    0.4151    0.3839   -3.2616 H   0  0  0  0  0  0
    2.3808    0.4184   -2.1686 H   0  0  0  0  0  0
    5.7485    0.0065    1.9638 H   0  0  0  0  0  0
    2.0864    0.8094    2.4674 H   0  0  0  0  0  0
    3.6091    1.6005    2.8066 H   0  0  0  0  0  0
    3.3149   -0.0262    3.3916 H   0  0  0  0  0  0
    6.8923   -1.5797   -1.2654 H   0  0  0  0  0  0
    9.0062   -2.3923   -2.0633 H   0  0  0  0  0  0
   13.0853   -2.2637   -0.6904 H   0  0  0  0  0  0
   12.3808   -1.0258    1.3059 H   0  0  0  0  0  0
   10.1322    0.0403    2.5543 H   0  0  0  0  0  0
   13.4654   -4.1368   -2.0997 H   0  0  0  0  0  0
    8.7336   -3.3784   -5.5098 H   0  0  0  0  0  0
    7.6744   -3.6087   -7.7131 H   0  0  0  0  0  0
    8.9992   -4.3838   -9.6492 H   0  0  0  0  0  0
   11.3937   -4.9279   -9.3850 H   0  0  0  0  0  0
   12.4737   -4.7019   -7.1963 H   0  0  0  0  0  0
    5.0025   -2.0882   -2.3783 H   0  0  0  0  0  0
    4.2290   -0.6116   -2.9238 H   0  0  0  0  0  0
    3.2704   -1.9446   -2.3045 H   0  0  0  0  0  0
   -0.6251    0.8246    0.1505 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 40  1  0  0  0
  1 41  1  0  0  0
  1 42  1  0  0  0
  2  3  1  0  0  0
  2 43  1  0  0  0
  2 44  1  0  0  0
  3  4  1  0  0  0
  3  6  1  0  0  0
  3 73  1  0  0  0
  4  5  1  0  0  0
  4 45  1  0  0  0
  4 46  1  0  0  0
  5 47  1  0  0  0
  5 48  1  0  0  0
  5 49  1  0  0  0
  6  7  1  0  0  0
  6 50  1  0  0  0
  6 51  1  0  0  0
  7  8  1  0  0  0
  7 52  1  0  0  0
  7 53  1  0  0  0
  8  9  1  0  0  0
  8 54  1  0  0  0
  9 10  2  0  0  0
  9 11  1  0  0  0
 11 12  1  0  0  0
 11 15  2  0  0  0
 12 13  2  0  0  0
 12 39  1  0  0  0
 13 14  1  0  0  0
 13 17  1  0  0  0
 14 15  1  0  0  0
 14 55  1  0  0  0
 15 16  1  0  0  0
 16 56  1  0  0  0
 16 57  1  0  0  0
 16 58  1  0  0  0
 17 18  2  0  0  0
 17 59  1  0  0  0
 18 19  1  0  0  0
 18 26  1  0  0  0
 19 20  2  0  0  0
 19 24  1  0  0  0
 20 21  1  0  0  0
 20 60  1  0  0  0
 21 22  2  0  0  0
 21 28  1  0  0  0
 22 23  1  0  0  0
 22 61  1  0  0  0
 23 24  2  0  0  0
 23 62  1  0  0  0
 24 25  1  0  0  0
 25 26  1  0  0  0
 25 63  1  0  0  0
 26 27  2  0  0  0
 28 29  2  0  0  0
 28 32  1  0  0  0
 29 30  1  0  0  0
 29 64  1  0  0  0
 30 31  1  0  0  0
 31 32  2  0  0  0
 31 33  1  0  0  0
 33 34  1  0  0  0
 33 38  2  0  0  0
 34 35  2  0  0  0
 34 65  1  0  0  0
 35 36  1  0  0  0
 35 66  1  0  0  0
 36 37  2  0  0  0
 36 67  1  0  0  0
 37 38  1  0  0  0
 37 68  1  0  0  0
 38 69  1  0  0  0
 39 70  1  0  0  0
 39 71  1  0  0  0
 39 72  1  0  0  0
M  CHG  1   3   1
M  END
> <s_m_entry_id>
161

> <Applicants>
Boston Biomedical

> <CHEMBL_ID>
CHEMBL3707349

> <Canonical_Smiles>
s1cc(nc1-c1ccccc1)-c1cc\2c(NC(=O)/C/2=C\c2[nH]c(C)c(C(=O)NCCN(CC)CC)c2C)cc1

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
AMCASERTIB | BBI-503 | BBI503

> <Indications>
nan

> <Type>
nan

> <targets_id>
P16234

> <inchi>
InChI=1S/C31H33N5O2S/c1-5-36(6-2)15-14-32-30(38)28-19(3)26(33-20(28)4)17-24-23-16-22(12-13-25(23)34-29(24)37)27-18-39-31(35-27)21-10-8-7-9-11-21/h7-13,16-18,33H,5-6,14-15H2,1-4H3,(H,32,38)(H,34,37)/b24-17-

> <stdInchikey>
QDWKGEFGLQMDAM-ULJHMMPZSA-N

> <csid>
44208821

> <Links>
|http://www.chemspider.com/Chemical-Structure.44208821.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3707349|http://pubchem.ncbi.nlm.nih.gov/compound/25190990|http://www.drugbank.ca/drugs/DB14866|http://zinc15.docking.org/substances/ZINC000059029686|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=GLY8ABW25V

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|ZINC|FDA SRS

> <MW>
539.2

> <HBA>
5

> <HBD>
3

> <NRB>
9

> <TPSA>
90.1

> <LogP>
6

> <RoF>
2

> <Targets>
PDGFRA

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_epik_Ionization_Penalty>
  0.0058

> <r_epik_State_Penalty>
  0.0042

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
161

> <Kinase families>
Tyr

$$$$
Seletalisib
                    3D
 Structure written by MMmdl.
 48 52  0  0  1  0            999 V2000
   -4.2352    2.2864   -0.1462 C   0  0  0  0  0  0
   -2.8482    2.3654   -0.0699 C   0  0  0  0  0  0
   -2.0700    1.1835   -0.0449 C   0  0  0  0  0  0
   -0.6574    1.2098    0.0309 C   0  0  0  0  0  0
    0.0698    0.0144    0.0521 C   0  0  0  0  0  0
   -0.6472   -1.1920   -0.0004 C   0  0  0  0  0  0
   -2.0011   -1.2460   -0.0764 N   0  0  0  0  0  0
   -2.7186   -0.0875   -0.0985 C   0  0  0  0  0  0
   -4.1406   -0.1354   -0.1767 C   0  0  0  0  0  0
   -4.8722    1.0512   -0.1993 C   0  0  0  0  0  0
   -4.9960   -1.6400   -0.2448 Cl  0  0  0  0  0  0
    0.0037   -2.5221    0.0105 C   0  0  0  0  0  0
    0.3306   -3.1705   -1.1872 C   0  0  0  0  0  0
    0.9792   -4.4065   -1.1635 C   0  0  0  0  0  0
    1.2984   -4.9816    0.0670 C   0  0  0  0  0  0
    0.9781   -4.3357    1.2084 N   0  3  0  0  0  0
    0.3514   -3.1398    1.2171 C   0  0  0  0  0  0
    1.2793   -4.8688    2.3093 O   0  5  0  0  0  0
    1.6039    0.0444    0.1331 C   0  0  2  0  0  0
    2.1375    0.5749    1.4903 C   0  0  0  0  0  0
    3.4636    0.4749    1.5807 F   0  0  0  0  0  0
    1.8270    1.8561    1.6937 F   0  0  0  0  0  0
    1.6288   -0.1234    2.5062 F   0  0  0  0  0  0
    2.1269    0.7642   -1.0336 N   0  0  0  0  0  0
    3.3303    0.4180   -1.6828 C   0  0  0  0  0  0
    3.6801    1.0490   -2.9167 C   0  0  0  0  0  0
    4.9195    0.6383   -3.5041 C   0  0  0  0  0  0
    5.3108    1.2340   -4.7280 C   0  0  0  0  0  0
    4.4846    2.1898   -5.3153 C   0  0  0  0  0  0
    3.2934    2.5334   -4.6815 C   0  0  0  0  0  0
    2.8821    1.9882   -3.5101 N   0  0  0  0  0  0
    5.7202   -0.2992   -2.9235 N   0  0  0  0  0  0
    5.2793   -0.8260   -1.7561 C   0  0  0  0  0  0
    4.1317   -0.5192   -1.1084 N   0  0  0  0  0  0
   -4.8231    3.1923   -0.1643 H   0  0  0  0  0  0
   -2.3601    3.3286   -0.0287 H   0  0  0  0  0  0
   -0.1513    2.1641    0.0670 H   0  0  0  0  0  0
   -5.9503    1.0159   -0.2588 H   0  0  0  0  0  0
    0.0876   -2.7131   -2.1357 H   0  0  0  0  0  0
    1.2335   -4.9083   -2.0856 H   0  0  0  0  0  0
    1.8013   -5.9326    0.1731 H   0  0  0  0  0  0
    0.1500   -2.7108    2.1889 H   0  0  0  0  0  0
    1.9603   -0.9818    0.0564 H   0  0  0  0  0  0
    1.4502    1.2537   -1.6014 H   0  0  0  0  0  0
    6.2414    0.9462   -5.1958 H   0  0  0  0  0  0
    4.7640    2.6572   -6.2481 H   0  0  0  0  0  0
    2.6371    3.2716   -5.1188 H   0  0  0  0  0  0
    5.9109   -1.5697   -1.2923 H   0  0  0  0  0  0
  1  2  2  0  0  0
  1 10  1  0  0  0
  1 35  1  0  0  0
  2  3  1  0  0  0
  2 36  1  0  0  0
  3  4  1  0  0  0
  3  8  2  0  0  0
  4  5  2  0  0  0
  4 37  1  0  0  0
  5  6  1  0  0  0
  5 19  1  0  0  0
  6  7  2  0  0  0
  6 12  1  0  0  0
  7  8  1  0  0  0
  8  9  1  0  0  0
  9 10  2  0  0  0
  9 11  1  0  0  0
 10 38  1  0  0  0
 12 13  1  0  0  0
 12 17  2  0  0  0
 13 14  2  0  0  0
 13 39  1  0  0  0
 14 15  1  0  0  0
 14 40  1  0  0  0
 15 16  2  0  0  0
 15 41  1  0  0  0
 16 17  1  0  0  0
 16 18  1  0  0  0
 17 42  1  0  0  0
 19 20  1  0  0  0
 19 24  1  0  0  0
 19 43  1  0  0  0
 20 21  1  0  0  0
 20 22  1  0  0  0
 20 23  1  0  0  0
 24 25  1  0  0  0
 24 44  1  0  0  0
 25 26  1  0  0  0
 25 34  2  0  0  0
 26 27  1  0  0  0
 26 31  2  0  0  0
 27 28  2  0  0  0
 27 32  1  0  0  0
 28 29  1  0  0  0
 28 45  1  0  0  0
 29 30  2  0  0  0
 29 46  1  0  0  0
 30 31  1  0  0  0
 30 47  1  0  0  0
 32 33  2  0  0  0
 33 34  1  0  0  0
 33 48  1  0  0  0
M  CHG  2  16   1  18  -1
M  END
> <s_m_entry_id>
162

> <Applicants>
UCB

> <CHEMBL_ID>
CHEMBL4297648

> <Canonical_Smiles>
Clc1c2nc(-c3ccc[n+]([O-])c3)c(cc2ccc1)[C@@H](Nc1ncnc2c1nccc2)C(F)(F)F

> <Chirality>
Single Stereoisomer

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
SELETALISIB | UCB-5857 | UCB5857

> <Indications>
nan

> <Type>
nan

> <targets_id>
nan

> <inchi>
InChI=1S/C23H14ClF3N6O/c24-16-6-1-4-13-10-15(18(31-19(13)16)14-5-3-9-33(34)11-14)21(23(25,26)27)32-22-20-17(29-12-30-22)7-2-8-28-20/h1-12,21H,(H,29,30,32)/t21-/m1/s1

> <stdInchikey>
LNLJHGXOFYUARS-OAQYLSRUSA-N

> <csid>
34985875

> <Links>
|http://www.chemspider.com/Chemical-Structure.34985875.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4297648|http://pubchem.ncbi.nlm.nih.gov/compound/56928390|http://www.drugbank.ca/drugs/DB12706|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9800|http://zinc15.docking.org/substances/ZINC000144763934|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=64CW205BDD

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS

> <indicationG2P>
None

> <MW>
482.1

> <HBA>
6

> <HBD>
1

> <NRB>
4

> <TPSA>
90.5

> <LogP>
5.2

> <RoF>
1

> <Targets>
nan

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0000

> <r_epik_State_Penalty>
  0.0000

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
162

$$$$
Sonolisib
                    3D
 Structure written by MMmdl.
 72 75  0  0  1  0            999 V2000
   -4.4835    6.5844    1.7001 C   0  0  0  0  0  0
   -3.0867    6.4915    2.3002 C   0  0  0  0  0  0
   -2.8809    6.7287    3.4910 O   0  0  0  0  0  0
   -2.1637    6.1258    1.3833 O   0  0  0  0  0  0
   -0.7857    5.9560    1.7163 C   0  0  2  0  0  0
   -0.0734    7.3354    1.7623 C   0  0  0  0  0  0
    1.4383    7.1993    1.5422 C   0  0  1  0  0  0
    1.6233    6.6090    0.1295 C   0  0  1  0  0  0
    3.1063    6.8840   -0.1621 C   0  0  0  0  0  0
    3.3790    8.2727    0.4344 C   0  0  0  0  0  0
    2.2318    8.5149    1.4253 C   0  0  0  0  0  0
    1.9782    9.5779    1.9898 O   0  0  0  0  0  0
    0.9795    5.2018    0.0299 C   0  0  0  0  0  0
   -0.1323    4.8972    0.7756 C   0  0  0  0  0  0
   -0.7918    3.4823    0.7649 C   0  0  1  0  0  0
   -2.2138    3.4184    0.0995 C   0  0  2  0  0  0
   -2.7567    2.0902   -0.0785 O   0  0  0  0  0  0
   -1.9724    0.9783   -0.3170 C   0  0  0  0  0  0
   -2.5963   -0.0299   -0.6501 O   0  0  0  0  0  0
   -0.5202    1.1116   -0.0740 C   0  0  0  0  0  0
    0.1598   -0.0290    0.2217 C   0  0  0  0  0  0
    1.4637   -0.2674    0.6324 N   0  0  0  0  0  0
    2.2089   -1.3488   -0.0185 C   0  0  0  0  0  0
    2.5697   -1.1335   -1.4767 C   0  0  0  0  0  0
    2.1145   -1.8797   -2.4947 C   0  0  0  0  0  0
    2.2792    0.7309    1.3337 C   0  0  0  0  0  0
    3.2395    0.2385    2.4030 C   0  0  0  0  0  0
    3.0990    0.4787    3.7158 C   0  0  0  0  0  0
    0.0148    2.4810   -0.0733 C   0  0  0  0  0  0
    1.0592    2.8692   -0.8520 C   0  0  0  0  0  0
    1.5817    4.2477   -0.9365 C   0  0  0  0  0  0
    2.4443    4.5901   -1.7530 O   0  0  0  0  0  0
    1.6452    2.0447   -1.6549 O   0  5  0  0  0  0
   -2.3316    4.1651   -1.2539 C   0  0  0  0  0  0
   -3.7075    4.3435   -1.5646 O   0  0  0  0  0  0
   -3.9275    4.9949   -2.8060 C   0  0  0  0  0  0
   -0.8597    2.9815    2.2402 C   0  0  0  0  0  0
    2.1115    6.3966    2.7015 C   0  0  0  0  0  0
   -4.7706    5.6292    1.2594 H   0  0  0  0  0  0
   -4.5109    7.3471    0.9219 H   0  0  0  0  0  0
   -5.2156    6.8446    2.4650 H   0  0  0  0  0  0
   -0.7353    5.5435    2.7244 H   0  0  0  0  0  0
   -0.4966    7.9964    1.0025 H   0  0  0  0  0  0
   -0.2816    7.8248    2.7154 H   0  0  0  0  0  0
    1.0648    7.2124   -0.5937 H   0  0  0  0  0  0
    3.7459    6.1337    0.3060 H   0  0  0  0  0  0
    3.3300    6.8817   -1.2292 H   0  0  0  0  0  0
    4.3504    8.3176    0.9268 H   0  0  0  0  0  0
    3.3536    9.0410   -0.3388 H   0  0  0  0  0  0
   -2.9055    3.9034    0.7863 H   0  0  0  0  0  0
   -0.3586   -0.9783    0.1750 H   0  0  0  0  0  0
    3.1362   -1.5581    0.5123 H   0  0  0  0  0  0
    1.6225   -2.2648    0.0694 H   0  0  0  0  0  0
    3.2446   -0.3155   -1.6828 H   0  0  0  0  0  0
    1.4386   -2.7058   -2.3283 H   0  0  0  0  0  0
    2.4125   -1.6707   -3.5116 H   0  0  0  0  0  0
    2.8665    1.2816    0.5992 H   0  0  0  0  0  0
    1.6188    1.4587    1.8043 H   0  0  0  0  0  0
    4.0919   -0.3324    2.0654 H   0  0  0  0  0  0
    2.2635    1.0488    4.0958 H   0  0  0  0  0  0
    3.8193    0.1067    4.4294 H   0  0  0  0  0  0
   -1.8606    5.1473   -1.2045 H   0  0  0  0  0  0
   -1.8330    3.6013   -2.0450 H   0  0  0  0  0  0
   -4.9987    5.0992   -2.9773 H   0  0  0  0  0  0
   -3.5108    4.4207   -3.6347 H   0  0  0  0  0  0
   -3.4893    5.9941   -2.8157 H   0  0  0  0  0  0
    0.1149    3.0370    2.7273 H   0  0  0  0  0  0
   -1.2009    1.9504    2.3298 H   0  0  0  0  0  0
   -1.5591    3.5676    2.8361 H   0  0  0  0  0  0
    1.7730    5.3613    2.7345 H   0  0  0  0  0  0
    1.8748    6.8331    3.6732 H   0  0  0  0  0  0
    3.1998    6.3555    2.6269 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 39  1  0  0  0
  1 40  1  0  0  0
  1 41  1  0  0  0
  2  3  2  0  0  0
  2  4  1  0  0  0
  4  5  1  0  0  0
  5  6  1  0  0  0
  5 14  1  0  0  0
  5 42  1  0  0  0
  6  7  1  0  0  0
  6 43  1  0  0  0
  6 44  1  0  0  0
  7  8  1  0  0  0
  7 11  1  0  0  0
  7 38  1  0  0  0
  8  9  1  0  0  0
  8 13  1  0  0  0
  8 45  1  0  0  0
  9 10  1  0  0  0
  9 46  1  0  0  0
  9 47  1  0  0  0
 10 11  1  0  0  0
 10 48  1  0  0  0
 10 49  1  0  0  0
 11 12  2  0  0  0
 13 14  2  0  0  0
 13 31  1  0  0  0
 14 15  1  0  0  0
 15 16  1  0  0  0
 15 29  1  0  0  0
 15 37  1  0  0  0
 16 17  1  0  0  0
 16 34  1  0  0  0
 16 50  1  0  0  0
 17 18  1  0  0  0
 18 19  2  0  0  0
 18 20  1  0  0  0
 20 21  2  0  0  0
 20 29  1  0  0  0
 21 22  1  0  0  0
 21 51  1  0  0  0
 22 23  1  0  0  0
 22 26  1  0  0  0
 23 24  1  0  0  0
 23 52  1  0  0  0
 23 53  1  0  0  0
 24 25  2  0  0  0
 24 54  1  0  0  0
 25 55  1  0  0  0
 25 56  1  0  0  0
 26 27  1  0  0  0
 26 57  1  0  0  0
 26 58  1  0  0  0
 27 28  2  0  0  0
 27 59  1  0  0  0
 28 60  1  0  0  0
 28 61  1  0  0  0
 29 30  2  0  0  0
 30 31  1  0  0  0
 30 33  1  0  0  0
 31 32  2  0  0  0
 34 35  1  0  0  0
 34 62  1  0  0  0
 34 63  1  0  0  0
 35 36  1  0  0  0
 36 64  1  0  0  0
 36 65  1  0  0  0
 36 66  1  0  0  0
 37 67  1  0  0  0
 37 68  1  0  0  0
 37 69  1  0  0  0
 38 70  1  0  0  0
 38 71  1  0  0  0
 38 72  1  0  0  0
M  CHG  1  33  -1
M  END
> <s_m_entry_id>
163

> <Applicants>
Cascadian Therapeutics

> <CHEMBL_ID>
CHEMBL411907

> <Canonical_Smiles>
O1[C@H](COC)[C@]2(C(\C(=C/N(CC=C)CC=C)\C1=O)=C(O)C(=O)C=1[C@@H]3CCC(=O)[C@]3(C[C@@H](OC(=O)C)C=12)C)C

> <Chirality>
Single Stereoisomer

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
PX-866 | SONOLISIB

> <Indications>
nan

> <Type>
nan

> <targets_id>
P42336|P42338|P48736

> <inchi>
InChI=1S/C29H35NO8/c1-7-11-30(12-8-2)14-17-23-26(34)25(33)22-18-9-10-20(32)28(18,4)13-19(37-16(3)31)24(22)29(23,5)21(15-36-6)38-27(17)35/h7-8,14,18-19,21,34H,1-2,9-13,15H2,3-6H3/b17-14+/t18-,19+,21+,28-,29-/m0/s1

> <stdInchikey>
QIUASFSNWYMDFS-NILGECQDSA-N

> <csid>
8025448

> <Links>
|http://www.chemspider.com/Chemical-Structure.8025448.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL411907|http://pubchem.ncbi.nlm.nih.gov/compound/9849735|http://www.drugbank.ca/drugs/DB12601|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7941|http://zinc15.docking.org/substances/ZINC000029134545|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=987796874T

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS

> <indicationG2P>
None

> <MW>
525.2

> <HBA>
9

> <HBD>
1

> <NRB>
8

> <TPSA>
119.4

> <LogP>
3.1

> <RoF>
1

> <Targets>
PIK3CA; PIK3CB; PIK3CG

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
0.99995

> <r_epik_Ionization_Penalty>
  0.2311

> <r_epik_State_Penalty>
  0.2218

> <i_epik_Tot_Q>
-1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
163

> <Kinase families>
Atypical

$$$$
Tozasertib
                    3D
 Structure written by MMmdl.
 61 65  0  0  1  0            999 V2000
   -7.9091   -1.8138   -2.0905 C   0  0  0  0  0  0
   -6.5803   -2.0809   -1.4240 C   0  0  0  0  0  0
   -5.2889   -1.7658   -1.8725 C   0  0  0  0  0  0
   -4.4189   -2.2176   -0.8972 C   0  0  0  0  0  0
   -5.2390   -2.7609    0.0528 N   0  0  0  0  0  0
   -6.5384   -2.6853   -0.2554 N   0  0  0  0  0  0
   -3.0567   -2.1770   -0.7539 N   0  0  0  0  0  0
   -2.3224   -1.0425   -0.3801 C   0  0  0  0  0  0
   -2.9219    0.2009   -0.1267 C   0  0  0  0  0  0
   -2.0943    1.2710    0.2556 C   0  0  0  0  0  0
   -0.7472    1.0892    0.3699 N   0  0  0  0  0  0
   -0.2544   -0.1461    0.1128 C   0  0  0  0  0  0
   -0.9842   -1.2237   -0.2638 N   0  0  0  0  0  0
    1.4870   -0.3687    0.2907 S   0  0  0  0  0  0
    1.6879   -1.2357    1.8323 C   0  0  0  0  0  0
    2.9682   -1.6667    2.1773 C   0  0  0  0  0  0
    3.1776   -2.3552    3.3689 C   0  0  0  0  0  0
    2.1103   -2.6130    4.2319 C   0  0  0  0  0  0
    0.8213   -2.1786    3.8840 C   0  0  0  0  0  0
    0.6142   -1.4892    2.6925 C   0  0  0  0  0  0
    2.4262   -3.3305    5.4022 N   0  0  0  0  0  0
    1.6779   -3.5592    6.5026 C   0  0  0  0  0  0
    0.5386   -3.1248    6.6842 O   0  0  0  0  0  0
    2.3663   -4.4266    7.5740 C   0  0  0  0  0  0
    1.4628   -5.3658    8.3537 C   0  0  0  0  0  0
    2.0034   -4.1250    9.0180 C   0  0  0  0  0  0
   -2.5898    2.5542    0.5115 N   0  0  0  0  0  0
   -4.0111    2.8568    0.7753 C   0  0  0  0  0  0
   -4.4140    4.2473    0.2291 C   0  0  0  0  0  0
   -3.6027    5.2935    0.8558 N   0  0  0  0  0  0
   -2.1909    5.0283    0.5675 C   0  0  0  0  0  0
   -1.7853    3.6387    1.1137 C   0  0  0  0  0  0
   -3.9878    6.6070    0.3506 C   0  0  0  0  0  0
   -7.7862   -1.3463   -3.0676 H   0  0  0  0  0  0
   -8.5315   -1.1464   -1.4939 H   0  0  0  0  0  0
   -8.4761   -2.7322   -2.2457 H   0  0  0  0  0  0
   -5.0261   -1.2645   -2.7921 H   0  0  0  0  0  0
   -4.9177   -3.1809    0.9132 H   0  0  0  0  0  0
   -2.5295   -3.0324   -0.6563 H   0  0  0  0  0  0
   -3.9880    0.3123   -0.2352 H   0  0  0  0  0  0
    3.8046   -1.4743    1.5209 H   0  0  0  0  0  0
    4.1770   -2.6856    3.6149 H   0  0  0  0  0  0
   -0.0386   -2.3683    4.5055 H   0  0  0  0  0  0
   -0.3881   -1.1647    2.4599 H   0  0  0  0  0  0
    3.3596   -3.7145    5.4136 H   0  0  0  0  0  0
    3.3843   -4.7518    7.3532 H   0  0  0  0  0  0
    0.3957   -5.4125    8.1307 H   0  0  0  0  0  0
    1.8617   -6.3363    8.6494 H   0  0  0  0  0  0
    2.7785   -4.2316    9.7772 H   0  0  0  0  0  0
    1.3082   -3.3175    9.2535 H   0  0  0  0  0  0
   -4.6804    2.1298    0.3228 H   0  0  0  0  0  0
   -4.1793    2.8091    1.8528 H   0  0  0  0  0  0
   -4.2749    4.2750   -0.8540 H   0  0  0  0  0  0
   -5.4720    4.4266    0.4269 H   0  0  0  0  0  0
   -2.0225    5.0673   -0.5111 H   0  0  0  0  0  0
   -1.5669    5.7977    1.0243 H   0  0  0  0  0  0
   -1.9108    3.6033    2.1973 H   0  0  0  0  0  0
   -0.7222    3.5041    0.9156 H   0  0  0  0  0  0
   -3.3954    7.3900    0.8259 H   0  0  0  0  0  0
   -5.0364    6.8107    0.5713 H   0  0  0  0  0  0
   -3.8475    6.6819   -0.7293 H   0  0  0  0  0  0
  1 34  1  0  0  0
  1 35  1  0  0  0
  1 36  1  0  0  0
  1  2  1  0  0  0
  2  6  2  0  0  0
  2  3  1  0  0  0
  3  4  2  0  0  0
  3 37  1  0  0  0
  4  5  1  0  0  0
  4  7  1  0  0  0
  5  6  1  0  0  0
  5 38  1  0  0  0
  7  8  1  0  0  0
  7 39  1  0  0  0
  8 13  2  0  0  0
  8  9  1  0  0  0
  9 40  1  0  0  0
  9 10  2  0  0  0
 10 11  1  0  0  0
 10 27  1  0  0  0
 11 12  2  0  0  0
 12 14  1  0  0  0
 12 13  1  0  0  0
 14 15  1  0  0  0
 15 16  1  0  0  0
 15 20  2  0  0  0
 16 17  2  0  0  0
 16 41  1  0  0  0
 17 18  1  0  0  0
 17 42  1  0  0  0
 18 19  2  0  0  0
 18 21  1  0  0  0
 19 20  1  0  0  0
 19 43  1  0  0  0
 20 44  1  0  0  0
 21 22  1  0  0  0
 21 45  1  0  0  0
 22 23  2  0  0  0
 22 24  1  0  0  0
 24 25  1  0  0  0
 24 26  1  0  0  0
 24 46  1  0  0  0
 25 26  1  0  0  0
 25 47  1  0  0  0
 25 48  1  0  0  0
 26 49  1  0  0  0
 26 50  1  0  0  0
 27 28  1  0  0  0
 27 32  1  0  0  0
 28 29  1  0  0  0
 28 51  1  0  0  0
 28 52  1  0  0  0
 29 30  1  0  0  0
 29 53  1  0  0  0
 29 54  1  0  0  0
 30 31  1  0  0  0
 30 33  1  0  0  0
 31 32  1  0  0  0
 31 55  1  0  0  0
 31 56  1  0  0  0
 32 57  1  0  0  0
 32 58  1  0  0  0
 33 59  1  0  0  0
 33 60  1  0  0  0
 33 61  1  0  0  0
M  END
> <s_m_entry_id>
165

> <Applicants>
Merck

> <CHEMBL_ID>
CHEMBL572878

> <Canonical_Smiles>
S(c1ccc(NC(=O)C2CC2)cc1)c1nc(N2CCN(CC2)C)cc(n1)Nc1n[nH]c(c1)C

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
MK-045 | MK-0457 | TOZASERTIB | VX-68 | VX-680

> <Indications>
nan

> <Type>
1

> <targets_id>
O14965|Q96GD4|Q9UQB9

> <inchi>
InChI=1S/C23H28N8OS/c1-15-13-20(29-28-15)25-19-14-21(31-11-9-30(2)10-12-31)27-23(26-19)33-18-7-5-17(6-8-18)24-22(32)16-3-4-16/h5-8,13-14,16H,3-4,9-12H2,1-2H3,(H,24,32)(H2,25,26,27,28,29)

> <stdInchikey>
GCIKSSRWRFVXBI-UHFFFAOYSA-N

> <csid>
4591897

> <Links>
|http://www.chemspider.com/Chemical-Structure.4591897.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL572878|http://pubchem.ncbi.nlm.nih.gov/compound/5494449| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=VX6|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/VX6|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5718|http://zinc15.docking.org/substances/ZINC13125756|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=234335M86K|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50004205

> <LinkName>
|ChemSpider|ChEMBL|PubChem|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
464.2

> <HBA>
8

> <HBD>
3

> <NRB>
7

> <TPSA>
102.1

> <LogP>
3.5

> <RoF>
0

> <Targets>
AURKA; AURKB; AURKC

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
0.1574

> <r_epik_Ionization_Penalty>
  4.5244

> <r_epik_State_Penalty>
  0.2719

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
165

> <lig_pdbID>
'VX6'

> <pdbID>
2f4j 2xyn 3amb 3e5a 4af3 4b8m 4jbq 4zog 5wnm 6brj 6gr9

> <Kinase families>
Other

$$$$
Lucitanib
                    3D
 Structure written by MMmdl.
 60 64  0  0  1  0            999 V2000
   -2.1890    7.0848    3.0318 C   0  0  0  0  0  0
   -2.4727    6.0274    2.0678 N   0  0  0  0  0  0
   -2.6722    6.2147    0.7510 C   0  0  0  0  0  0
   -2.6678    7.3166    0.1997 O   0  0  0  0  0  0
   -2.9532    4.9632   -0.0439 C   0  0  0  0  0  0
   -4.1262    4.9245   -0.8052 C   0  0  0  0  0  0
   -4.4741    3.8036   -1.5458 C   0  0  0  0  0  0
   -3.6547    2.6836   -1.5561 C   0  0  0  0  0  0
   -2.4423    2.6740   -0.8270 C   0  0  0  0  0  0
   -2.0659    3.8262   -0.0625 C   0  0  0  0  0  0
   -0.8167    3.7773    0.6264 C   0  0  0  0  0  0
   -0.0076    2.6471    0.5749 C   0  0  0  0  0  0
   -0.3849    1.5254   -0.1673 C   0  0  0  0  0  0
   -1.5958    1.5375   -0.8524 C   0  0  0  0  0  0
    0.3701    0.3715   -0.2262 O   0  0  0  0  0  0
    1.7400    0.4154   -0.0867 C   0  0  0  0  0  0
    2.5253    1.1481   -0.9845 C   0  0  0  0  0  0
    3.9099    1.1702   -0.8467 C   0  0  0  0  0  0
    4.4905    0.4802    0.1497 N   0  3  0  0  0  0
    3.7977   -0.2714    1.0718 C   0  0  0  0  0  0
    2.3788   -0.3154    0.9585 C   0  0  0  0  0  0
    1.6679   -1.0893    1.9084 C   0  0  0  0  0  0
    2.3381   -1.7867    2.9283 C   0  0  0  0  0  0
    3.7366   -1.7280    3.0195 C   0  0  0  0  0  0
    4.4704   -0.9719    2.0919 C   0  0  0  0  0  0
    4.3223   -2.4405    4.0518 O   0  0  0  0  0  0
    5.7397   -2.4365    4.2057 C   0  0  0  0  0  0
    6.1124   -3.3082    5.4186 C   0  0  0  0  0  0
    7.4460   -3.0740    6.0904 C   0  0  0  0  0  0
    6.1658   -2.6453    6.7765 C   0  0  0  0  0  0
    5.5669   -4.7382    5.3360 N   0  3  0  0  0  0
    1.6856   -2.5521    3.8801 O   0  0  0  0  0  0
    0.2644   -2.6432    3.8592 C   0  0  0  0  0  0
   -3.0200    7.1813    3.7310 H   0  0  0  0  0  0
   -2.0242    8.0569    2.5643 H   0  0  0  0  0  0
   -1.2950    6.8317    3.6022 H   0  0  0  0  0  0
   -2.5393    5.0900    2.4371 H   0  0  0  0  0  0
   -4.7970    5.7728   -0.8170 H   0  0  0  0  0  0
   -5.3920    3.8018   -2.1155 H   0  0  0  0  0  0
   -3.9379    1.8152   -2.1339 H   0  0  0  0  0  0
   -0.4745    4.6254    1.1994 H   0  0  0  0  0  0
    0.9224    2.6497    1.1243 H   0  0  0  0  0  0
   -1.8951    0.6702   -1.4241 H   0  0  0  0  0  0
    2.0573    1.6978   -1.7882 H   0  0  0  0  0  0
    4.5785    1.7127   -1.4996 H   0  0  0  0  0  0
    0.5919   -1.1243    1.8262 H   0  0  0  0  0  0
    5.5474   -0.9064    2.1352 H   0  0  0  0  0  0
    6.2152   -2.8403    3.3100 H   0  0  0  0  0  0
    6.1024   -1.4150    4.3392 H   0  0  0  0  0  0
    7.9940   -3.9255    6.4954 H   0  0  0  0  0  0
    8.1104   -2.3013    5.7013 H   0  0  0  0  0  0
    5.9495   -1.5792    6.8570 H   0  0  0  0  0  0
    5.8336   -3.2016    7.6537 H   0  0  0  0  0  0
    5.8124   -5.2555    6.1680 H   0  0  0  0  0  0
    5.9517   -5.2124    4.5315 H   0  0  0  0  0  0
   -0.0672   -3.2769    4.6817 H   0  0  0  0  0  0
   -0.0946   -3.0936    2.9325 H   0  0  0  0  0  0
   -0.2025   -1.6656    3.9895 H   0  0  0  0  0  0
    5.4975    0.5162    0.2214 H   0  0  0  0  0  0
    4.5603   -4.7181    5.2496 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 34  1  0  0  0
  1 35  1  0  0  0
  1 36  1  0  0  0
  2  3  1  0  0  0
  2 37  1  0  0  0
  3  4  2  0  0  0
  3  5  1  0  0  0
  5  6  2  0  0  0
  5 10  1  0  0  0
  6  7  1  0  0  0
  6 38  1  0  0  0
  7  8  2  0  0  0
  7 39  1  0  0  0
  8  9  1  0  0  0
  8 40  1  0  0  0
  9 10  1  0  0  0
  9 14  2  0  0  0
 10 11  2  0  0  0
 11 12  1  0  0  0
 11 41  1  0  0  0
 12 13  2  0  0  0
 12 42  1  0  0  0
 13 14  1  0  0  0
 13 15  1  0  0  0
 14 43  1  0  0  0
 15 16  1  0  0  0
 16 17  2  0  0  0
 16 21  1  0  0  0
 17 18  1  0  0  0
 17 44  1  0  0  0
 18 19  2  0  0  0
 18 45  1  0  0  0
 19 20  1  0  0  0
 19 59  1  0  0  0
 20 21  1  0  0  0
 20 25  2  0  0  0
 21 22  2  0  0  0
 22 23  1  0  0  0
 22 46  1  0  0  0
 23 24  2  0  0  0
 23 32  1  0  0  0
 24 25  1  0  0  0
 24 26  1  0  0  0
 25 47  1  0  0  0
 26 27  1  0  0  0
 27 28  1  0  0  0
 27 48  1  0  0  0
 27 49  1  0  0  0
 28 29  1  0  0  0
 28 30  1  0  0  0
 28 31  1  0  0  0
 29 30  1  0  0  0
 29 50  1  0  0  0
 29 51  1  0  0  0
 30 52  1  0  0  0
 30 53  1  0  0  0
 31 54  1  0  0  0
 31 55  1  0  0  0
 31 60  1  0  0  0
 32 33  1  0  0  0
 33 56  1  0  0  0
 33 57  1  0  0  0
 33 58  1  0  0  0
M  CHG  2  19   1  31   1
M  END
> <s_m_entry_id>
168

> <Applicants>
Clovis Oncology

> <CHEMBL_ID>
CHEMBL2220486

> <Canonical_Smiles>
O(c1c2cc(OC)c(OCC3(N)CC3)cc2ncc1)c1cc2c(cc1)c(ccc2)C(=O)NC

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
AL-3810 | CO-3810 | E-3810 | LUCITANIB | S 80881 | S-80881

> <Indications>
nan

> <Type>
1

> <targets_id>
P17948|P35968|P35916|P11362|P21802

> <inchi>
InChI=1S/C26H25N3O4/c1-28-25(30)19-5-3-4-16-12-17(6-7-18(16)19)33-22-8-11-29-21-14-24(23(31-2)13-20(21)22)32-15-26(27)9-10-26/h3-8,11-14H,9-10,15,27H2,1-2H3,(H,28,30)

> <stdInchikey>
CUDVHEFYRIWYQD-UHFFFAOYSA-N

> <csid>
28189586

> <Links>
|http://www.chemspider.com/Chemical-Structure.28189586.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2220486|http://pubchem.ncbi.nlm.nih.gov/compound/25031915|http://www.drugbank.ca/drugs/DB11845| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=3ZC|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/3ZC|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7649|http://zinc15.docking.org/substances/ZINC000077024213|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=PP449XA4BH|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50399539

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
443.2

> <HBA>
6

> <HBD>
2

> <NRB>
7

> <TPSA>
95.7

> <LogP>
4.4

> <RoF>
0

> <Targets>
FLT1; KDR; FLT4; FGFR1; FGFR2

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_epik_Ionization_Penalty>
  0.0800

> <r_epik_State_Penalty>
  0.0675

> <i_epik_Tot_Q>
2

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
168

> <lig_pdbID>
'3ZC'

> <pdbID>
4rwl

> <Kinase families>
Tyr

> <Withdrawn>
|Study NCT02747797 in United States was Withdrawn during Phase 2 because Drug Supply No Longer Available

$$$$
Merestinib
                    3D
 Structure written by MMmdl.
 63 68  0  0  1  0            999 V2000
   -6.5341   -0.0523    0.2914 C   0  0  0  0  0  0
   -5.0405    0.2471    0.4429 C   0  0  0  0  0  0
   -4.1941   -0.7266    0.8339 C   0  0  0  0  0  0
   -2.7902   -0.4087    0.9701 C   0  0  0  0  0  0
   -2.3219    0.8418    0.7008 C   0  0  0  0  0  0
   -3.2519    1.9054    0.2569 C   0  0  0  0  0  0
   -2.8558    3.0444   -0.0217 O   0  0  0  0  0  0
   -4.5867    1.5405    0.1630 N   0  0  0  0  0  0
   -5.5128    2.5301   -0.2391 C   0  0  0  0  0  0
   -5.7813    2.7202   -1.5993 C   0  0  0  0  0  0
   -6.6947    3.6953   -1.9907 C   0  0  0  0  0  0
   -7.3334    4.4732   -1.0264 C   0  0  0  0  0  0
   -7.0677    4.2856    0.3291 C   0  0  0  0  0  0
   -6.1552    3.3124    0.7271 C   0  0  0  0  0  0
   -8.2199    5.4197   -1.4096 F   0  0  0  0  0  0
   -0.8977    1.1078    0.8740 C   0  0  0  0  0  0
   -0.4941    2.1220    1.4487 O   0  0  0  0  0  0
   -0.0765    0.1766    0.3317 N   0  0  0  0  0  0
    1.3271    0.2015    0.2836 C   0  0  0  0  0  0
    1.9939   -1.0251    0.3507 C   0  0  0  0  0  0
    3.3867   -1.0732    0.2920 C   0  0  0  0  0  0
    4.1268    0.1042    0.1509 C   0  0  0  0  0  0
    3.4639    1.3314    0.0594 C   0  0  0  0  0  0
    2.0711    1.3817    0.1242 C   0  0  0  0  0  0
    4.1691    2.4761   -0.0933 F   0  0  0  0  0  0
    5.4988    0.0555    0.0862 O   0  0  0  0  0  0
    6.2051   -0.2237    1.2361 C   0  0  0  0  0  0
    6.0270    0.5733    2.3743 C   0  0  0  0  0  0
    6.7639    0.2854    3.5295 C   0  0  0  0  0  0
    6.8684    0.8275    4.8451 C   0  0  0  0  0  0
    7.7330    0.1651    5.5696 N   0  0  0  0  0  0
    8.2345   -0.8099    4.7853 N   0  0  0  0  0  0
    7.6737   -0.7968    3.5197 C   0  0  0  0  0  0
    7.8650   -1.5992    2.3907 C   0  0  0  0  0  0
    7.1190   -1.2910    1.2455 C   0  0  0  0  0  0
    7.3254   -2.1488    0.0403 C   0  0  0  0  0  0
    7.3813   -1.7720   -1.2945 C   0  0  0  0  0  0
    7.5871   -2.9223   -2.0046 N   0  0  0  0  0  0
    7.6706   -4.0069   -1.2314 N   0  0  0  0  0  0
    7.5158   -3.5420   -0.0123 C   0  0  0  0  0  0
    9.2220   -1.7309    5.3250 C   0  0  0  0  0  0
   -6.7652   -1.0938    0.5188 H   0  0  0  0  0  0
   -6.8671    0.1405   -0.7289 H   0  0  0  0  0  0
   -7.1235    0.5686    0.9669 H   0  0  0  0  0  0
   -4.5471   -1.7256    1.0467 H   0  0  0  0  0  0
   -2.1288   -1.1943    1.3109 H   0  0  0  0  0  0
   -5.2848    2.1182   -2.3469 H   0  0  0  0  0  0
   -6.9062    3.8490   -3.0386 H   0  0  0  0  0  0
   -7.5670    4.8941    1.0687 H   0  0  0  0  0  0
   -5.9486    3.1680    1.7780 H   0  0  0  0  0  0
   -0.5002   -0.6944    0.0483 H   0  0  0  0  0  0
    1.4387   -1.9463    0.4564 H   0  0  0  0  0  0
    3.8948   -2.0247    0.3528 H   0  0  0  0  0  0
    1.5819    2.3405    0.0350 H   0  0  0  0  0  0
    5.3324    1.4003    2.3609 H   0  0  0  0  0  0
    6.3321    1.6697    5.2567 H   0  0  0  0  0  0
    8.5675   -2.4200    2.3998 H   0  0  0  0  0  0
    7.2947   -0.8163   -1.7904 H   0  0  0  0  0  0
    7.6719   -2.9724   -3.0099 H   0  0  0  0  0  0
    7.5365   -4.2043    0.8408 H   0  0  0  0  0  0
    8.7611   -2.7099    5.4578 H   0  0  0  0  0  0
    9.5990   -1.3780    6.2866 H   0  0  0  0  0  0
   10.0557   -1.8150    4.6272 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 42  1  0  0  0
  1 43  1  0  0  0
  1 44  1  0  0  0
  2  3  2  0  0  0
  2  8  1  0  0  0
  3  4  1  0  0  0
  3 45  1  0  0  0
  4  5  2  0  0  0
  4 46  1  0  0  0
  5  6  1  0  0  0
  5 16  1  0  0  0
  6  7  2  0  0  0
  6  8  1  0  0  0
  8  9  1  0  0  0
  9 10  1  0  0  0
  9 14  2  0  0  0
 10 11  2  0  0  0
 10 47  1  0  0  0
 11 12  1  0  0  0
 11 48  1  0  0  0
 12 13  2  0  0  0
 12 15  1  0  0  0
 13 14  1  0  0  0
 13 49  1  0  0  0
 14 50  1  0  0  0
 16 17  2  0  0  0
 16 18  1  0  0  0
 18 19  1  0  0  0
 18 51  1  0  0  0
 19 20  1  0  0  0
 19 24  2  0  0  0
 20 21  2  0  0  0
 20 52  1  0  0  0
 21 22  1  0  0  0
 21 53  1  0  0  0
 22 23  2  0  0  0
 22 26  1  0  0  0
 23 24  1  0  0  0
 23 25  1  0  0  0
 24 54  1  0  0  0
 26 27  1  0  0  0
 27 28  1  0  0  0
 27 35  2  0  0  0
 28 29  2  0  0  0
 28 55  1  0  0  0
 29 30  1  0  0  0
 29 33  1  0  0  0
 30 31  2  0  0  0
 30 56  1  0  0  0
 31 32  1  0  0  0
 32 33  1  0  0  0
 32 41  1  0  0  0
 33 34  2  0  0  0
 34 35  1  0  0  0
 34 57  1  0  0  0
 35 36  1  0  0  0
 36 37  2  0  0  0
 36 40  1  0  0  0
 37 38  1  0  0  0
 37 58  1  0  0  0
 38 39  1  0  0  0
 38 59  1  0  0  0
 39 40  2  0  0  0
 40 60  1  0  0  0
 41 61  1  0  0  0
 41 62  1  0  0  0
 41 63  1  0  0  0
M  END
> <s_m_entry_id>
171

> <Applicants>
Eli Lilly

> <CHEMBL_ID>
CHEMBL3545307

> <Canonical_Smiles>
Fc1cc(NC(=O)C2=CC=C(N(C2=O)c2ccc(F)cc2)C)ccc1Oc1cc2c(n(nc2)C)cc1-c1cn[nH]c1

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
LY-2801653 | LY2801653 | MERESTINIB

> <Indications>
nan

> <Type>
2

> <targets_id>
P08581

> <inchi>
InChI=1S/C30H22F2N6O3/c1-17-3-9-23(30(40)38(17)22-7-4-20(31)5-8-22)29(39)36-21-6-10-27(25(32)12-21)41-28-11-18-16-35-37(2)26(18)13-24(28)19-14-33-34-15-19/h3-16H,1-2H3,(H,33,34)(H,36,39)

> <stdInchikey>
QHADVLVFMKEIIP-UHFFFAOYSA-N

> <csid>
29361338

> <Links>
|http://www.chemspider.com/Chemical-Structure.29361338.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3545307|http://pubchem.ncbi.nlm.nih.gov/compound/44603533|http://www.drugbank.ca/drugs/DB12381| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=L1X|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/L1X|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9841|http://zinc15.docking.org/substances/ZINC000095926668|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=5OGS5K699E|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50172078

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
552.2

> <HBA>
7

> <HBD>
2

> <NRB>
6

> <TPSA>
106.8

> <LogP>
5.7

> <RoF>
2

> <Targets>
MET

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0000

> <r_epik_State_Penalty>
  0.0000

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
171

> <lig_pdbID>
'L1X'

> <pdbID>
4eev 7aay

> <Kinase families>
Tyr

$$$$
Miransertib
                    3D
 Structure written by MMmdl.
 58 63  0  0  1  0            999 V2000
   -0.7497   -7.3615    0.0379 C   0  0  0  0  0  0
   -1.8737   -6.8903   -0.6333 C   0  0  0  0  0  0
   -2.1620   -5.5282   -0.6244 C   0  0  0  0  0  0
   -1.3335   -4.6218    0.0533 C   0  0  0  0  0  0
   -0.2045   -5.1195    0.7232 C   0  0  0  0  0  0
    0.0867   -6.4810    0.7170 C   0  0  0  0  0  0
   -1.6507   -3.1604    0.0543 C   0  0  0  0  0  0
   -2.9774   -2.6967    0.0715 C   0  0  0  0  0  0
   -3.2464   -1.3255    0.0675 C   0  0  0  0  0  0
   -2.1472   -0.4556    0.0523 C   0  0  0  0  0  0
   -0.8506   -1.0123    0.0467 C   0  0  0  0  0  0
   -0.5718   -2.3215    0.0448 N   0  0  0  0  0  0
    0.0138    0.0710    0.0208 N   0  0  0  0  0  0
   -0.8089    1.1958    0.0408 C   0  0  0  0  0  0
   -2.0913    0.9082    0.0413 N   0  0  0  0  0  0
   -0.3164    2.6104    0.0889 C   0  0  0  0  0  0
    0.5432    2.9863    1.1307 C   0  0  0  0  0  0
    1.0279    4.2919    1.2030 C   0  0  0  0  0  0
    0.6320    5.2004    0.2236 C   0  0  0  0  0  0
   -0.2017    4.8681   -0.7931 N   0  0  0  0  0  0
   -0.6678    3.5945   -0.8551 C   0  0  0  0  0  0
   -1.5051    3.3087   -1.9333 N   0  0  0  0  0  0
    1.4273    0.0333    0.0010 C   0  0  0  0  0  0
    2.1159   -0.8268    0.8614 C   0  0  0  0  0  0
    3.5061   -0.8777    0.8245 C   0  0  0  0  0  0
    4.2145   -0.0930   -0.0904 C   0  0  0  0  0  0
    3.5227    0.7652   -0.9506 C   0  0  0  0  0  0
    2.1326    0.8180   -0.9166 C   0  0  0  0  0  0
    5.7400   -0.1027   -0.0794 C   0  0  0  0  0  0
    6.5381    1.1935   -0.3684 C   0  0  0  0  0  0
    7.5837    0.7742    0.6667 C   0  0  0  0  0  0
    6.5103   -0.1384    1.2636 C   0  0  0  0  0  0
    6.2002   -1.2421   -1.0030 N   0  3  0  0  0  0
   -0.5243   -8.4177    0.0304 H   0  0  0  0  0  0
   -2.5179   -7.5776   -1.1614 H   0  0  0  0  0  0
   -3.0330   -5.1806   -1.1606 H   0  0  0  0  0  0
    0.4538   -4.4504    1.2585 H   0  0  0  0  0  0
    0.9574   -6.8525    1.2369 H   0  0  0  0  0  0
   -3.8029   -3.3929    0.0926 H   0  0  0  0  0  0
   -4.2607   -0.9542    0.0769 H   0  0  0  0  0  0
    0.8376    2.2691    1.8833 H   0  0  0  0  0  0
    1.6922    4.5916    2.0000 H   0  0  0  0  0  0
    0.9849    6.2211    0.2444 H   0  0  0  0  0  0
   -1.9096    2.3873   -2.0158 H   0  0  0  0  0  0
   -1.7368    4.0440   -2.5849 H   0  0  0  0  0  0
    1.5813   -1.4433    1.5697 H   0  0  0  0  0  0
    4.0295   -1.5308    1.5075 H   0  0  0  0  0  0
    4.0569    1.3890   -1.6523 H   0  0  0  0  0  0
    1.6109    1.4722   -1.6004 H   0  0  0  0  0  0
    6.9077    1.3104   -1.3884 H   0  0  0  0  0  0
    6.0073    2.1081   -0.0943 H   0  0  0  0  0  0
    8.4381    0.2412    0.2457 H   0  0  0  0  0  0
    7.9435    1.5690    1.3214 H   0  0  0  0  0  0
    5.9680    0.3213    2.0930 H   0  0  0  0  0  0
    6.8577   -1.1199    1.5899 H   0  0  0  0  0  0
    7.2089   -1.2823   -1.0244 H   0  0  0  0  0  0
    5.8614   -1.0869   -1.9417 H   0  0  0  0  0  0
    5.8479   -2.1267   -0.6662 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1  6  2  0  0  0
  1 34  1  0  0  0
  2  3  2  0  0  0
  2 35  1  0  0  0
  3  4  1  0  0  0
  3 36  1  0  0  0
  4  5  2  0  0  0
  4  7  1  0  0  0
  5  6  1  0  0  0
  5 37  1  0  0  0
  6 38  1  0  0  0
  7  8  1  0  0  0
  7 12  2  0  0  0
  8  9  2  0  0  0
  8 39  1  0  0  0
  9 10  1  0  0  0
  9 40  1  0  0  0
 10 11  2  0  0  0
 10 15  1  0  0  0
 11 12  1  0  0  0
 11 13  1  0  0  0
 13 14  1  0  0  0
 13 23  1  0  0  0
 14 15  2  0  0  0
 14 16  1  0  0  0
 16 17  1  0  0  0
 16 21  2  0  0  0
 17 18  2  0  0  0
 17 41  1  0  0  0
 18 19  1  0  0  0
 18 42  1  0  0  0
 19 20  2  0  0  0
 19 43  1  0  0  0
 20 21  1  0  0  0
 21 22  1  0  0  0
 22 44  1  0  0  0
 22 45  1  0  0  0
 23 24  1  0  0  0
 23 28  2  0  0  0
 24 25  2  0  0  0
 24 46  1  0  0  0
 25 26  1  0  0  0
 25 47  1  0  0  0
 26 27  2  0  0  0
 26 29  1  0  0  0
 27 28  1  0  0  0
 27 48  1  0  0  0
 28 49  1  0  0  0
 29 30  1  0  0  0
 29 32  1  0  0  0
 29 33  1  0  0  0
 30 31  1  0  0  0
 30 50  1  0  0  0
 30 51  1  0  0  0
 31 32  1  0  0  0
 31 52  1  0  0  0
 31 53  1  0  0  0
 32 54  1  0  0  0
 32 55  1  0  0  0
 33 56  1  0  0  0
 33 57  1  0  0  0
 33 58  1  0  0  0
M  CHG  1  33   1
M  END
> <s_m_entry_id>
172

> <Applicants>
Merck

> <CHEMBL_ID>
CHEMBL4297188

> <Canonical_Smiles>
n1c2n(c(nc2ccc1-c1ccccc1)-c1cccnc1N)-c1ccc(cc1)C1(N)CCC1

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
ARQ 092 | ARQ 092 FREE BASE | ARQ-092 | MIRANSERTIB

> <Indications>
nan

> <Type>
nan

> <targets_id>
nan

> <inchi>
InChI=1S/C27H24N6/c28-24-21(8-4-17-30-24)25-32-23-14-13-22(18-6-2-1-3-7-18)31-26(23)33(25)20-11-9-19(10-12-20)27(29)15-5-16-27/h1-4,6-14,17H,5,15-16,29H2,(H2,28,30)

> <stdInchikey>
HNFMVVHMKGFCMB-UHFFFAOYSA-N

> <csid>
57251282

> <Links>
|http://www.chemspider.com/Chemical-Structure.57251282.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4297188|http://pubchem.ncbi.nlm.nih.gov/compound/53262401|http://www.drugbank.ca/drugs/DB14982| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=6S1|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/6S1|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9429|http://zinc15.docking.org/substances/ZINC000072315647|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=T1DQI1B52Y

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS

> <indicationG2P>
None

> <MW>
432.2

> <HBA>
6

> <HBD>
2

> <NRB>
4

> <TPSA>
95.6

> <LogP>
5.1

> <RoF>
1

> <Targets>
nan

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0317

> <r_epik_State_Penalty>
  0.0251

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
172

> <lig_pdbID>
'6S1'

> <pdbID>
5kcv

$$$$
Afuresertib
                    3D
 Structure written by MMmdl.
 45 47  0  0  1  0            999 V2000
   -4.1160   -3.5701   -0.7367 C   0  0  0  0  0  0
   -4.9766   -2.9922    0.2870 N   0  0  0  0  0  0
   -5.0348   -1.6831    0.7189 C   0  0  0  0  0  0
   -6.0036   -1.6892    1.7165 C   0  0  0  0  0  0
   -6.4299   -3.0183    1.7978 C   0  0  0  0  0  0
   -5.8097   -3.8035    0.9516 N   0  0  0  0  0  0
   -6.5530   -0.3656    2.6666 Cl  0  0  0  0  0  0
   -4.2196   -0.6021    0.1814 C   0  0  0  0  0  0
   -2.8161   -0.6215    0.1713 C   0  0  0  0  0  0
   -2.2355    0.5217   -0.3857 C   0  0  0  0  0  0
   -3.4603    1.6317   -0.9296 S   0  0  0  0  0  0
   -4.7178    0.5705   -0.3845 C   0  0  0  0  0  0
   -6.3605    1.0315   -0.6070 Cl  0  0  0  0  0  0
   -0.8392    0.8334   -0.5775 C   0  0  0  0  0  0
   -0.4722    1.8204   -1.2180 O   0  0  0  0  0  0
    0.0091   -0.0327    0.0081 N   0  0  0  0  0  0
    1.4744    0.0663    0.0218 C   0  0  1  0  0  0
    2.0508   -0.5111    1.3371 C   0  0  0  0  0  0
    1.4780    0.1287    2.5978 C   0  0  0  0  0  0
    2.0000    1.3369    3.0724 C   0  0  0  0  0  0
    1.4681    1.9305    4.2179 C   0  0  0  0  0  0
    0.4118    1.3200    4.8942 C   0  0  0  0  0  0
   -0.1132    0.1155    4.4256 C   0  0  0  0  0  0
    0.4189   -0.4794    3.2812 C   0  0  0  0  0  0
   -1.1391   -0.4750    5.0792 F   0  0  0  0  0  0
    2.1088   -0.6252   -1.2081 C   0  0  0  0  0  0
    1.9760    0.2594   -2.4532 N   0  3  0  0  0  0
   -3.9150   -2.8318   -1.5134 H   0  0  0  0  0  0
   -4.5983   -4.4339   -1.1971 H   0  0  0  0  0  0
   -3.1759   -3.8810   -0.2809 H   0  0  0  0  0  0
   -7.1795   -3.4004    2.4753 H   0  0  0  0  0  0
   -2.2447   -1.4494    0.5659 H   0  0  0  0  0  0
   -0.3839   -0.8168    0.5083 H   0  0  0  0  0  0
    1.7592    1.1222    0.0080 H   0  0  0  0  0  0
    1.8834   -1.5892    1.3799 H   0  0  0  0  0  0
    3.1350   -0.3867    1.3556 H   0  0  0  0  0  0
    2.8153    1.8197    2.5534 H   0  0  0  0  0  0
    1.8728    2.8642    4.5801 H   0  0  0  0  0  0
   -0.0007    1.7808    5.7798 H   0  0  0  0  0  0
    0.0026   -1.4102    2.9242 H   0  0  0  0  0  0
    3.1862   -0.7657   -1.1115 H   0  0  0  0  0  0
    1.6355   -1.5721   -1.4723 H   0  0  0  0  0  0
    2.3923   -0.1950   -3.2534 H   0  0  0  0  0  0
    2.4393    1.1441   -2.3024 H   0  0  0  0  0  0
    1.0006    0.4369   -2.6482 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 28  1  0  0  0
  1 29  1  0  0  0
  1 30  1  0  0  0
  2  3  1  0  0  0
  2  6  1  0  0  0
  3  4  2  0  0  0
  3  8  1  0  0  0
  4  5  1  0  0  0
  4  7  1  0  0  0
  5  6  2  0  0  0
  5 31  1  0  0  0
  8  9  1  0  0  0
  8 12  2  0  0  0
  9 10  2  0  0  0
  9 32  1  0  0  0
 10 11  1  0  0  0
 10 14  1  0  0  0
 11 12  1  0  0  0
 12 13  1  0  0  0
 14 15  2  0  0  0
 14 16  1  0  0  0
 16 17  1  0  0  0
 16 33  1  0  0  0
 17 18  1  0  0  0
 17 26  1  0  0  0
 17 34  1  0  0  0
 18 19  1  0  0  0
 18 35  1  0  0  0
 18 36  1  0  0  0
 19 20  1  0  0  0
 19 24  2  0  0  0
 20 21  2  0  0  0
 20 37  1  0  0  0
 21 22  1  0  0  0
 21 38  1  0  0  0
 22 23  2  0  0  0
 22 39  1  0  0  0
 23 24  1  0  0  0
 23 25  1  0  0  0
 24 40  1  0  0  0
 26 27  1  0  0  0
 26 41  1  0  0  0
 26 42  1  0  0  0
 27 43  1  0  0  0
 27 44  1  0  0  0
 27 45  1  0  0  0
M  CHG  1  27   1
M  END
> <s_m_entry_id>
175

> <Applicants>
GlaxoSmithKline

> <CHEMBL_ID>
CHEMBL2219422

> <Canonical_Smiles>
Clc1cnn(C)c1-c1cc(sc1Cl)C(=O)N[C@@H](Cc1cc(F)ccc1)CN

> <Chirality>
Single Stereoisomer

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
AFURESERTIB | ASB-183 | ASB183 | GSK-2110183 | GSK-2110183C | GSK2110183 | GSK2110183C

> <Indications>
nan

> <Type>
nan

> <targets_id>
P31749|P31751|Q9Y243

> <inchi>
InChI=1S/C18H17Cl2FN4OS/c1-25-16(14(19)9-23-25)13-7-15(27-17(13)20)18(26)24-12(8-22)6-10-3-2-4-11(21)5-10/h2-5,7,9,12H,6,8,22H2,1H3,(H,24,26)/t12-/m0/s1

> <stdInchikey>
AFJRDFWMXUECEW-LBPRGKRZSA-N

> <csid>
28651809

> <Links>
|http://www.chemspider.com/Chemical-Structure.28651809.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2219422|http://pubchem.ncbi.nlm.nih.gov/compound/46843057|http://www.drugbank.ca/drugs/DB11648|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7890|http://zinc15.docking.org/substances/ZINC000043197674|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=8739X25QI3

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS

> <indicationG2P>
None

> <MW>
426

> <HBA>
5

> <HBD>
2

> <NRB>
6

> <TPSA>
72.9

> <LogP>
3.9

> <RoF>
0

> <Targets>
AKT1; AKT2; AKT3

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0040

> <r_epik_State_Penalty>
  0.0029

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
175

> <Kinase families>
AGC

$$$$
Adavosertib
                    3D
 Structure written by MMmdl.
 70 74  0  0  1  0            999 V2000
   -2.3161    3.6880   -1.2404 C   0  0  0  0  0  0
   -3.0963    2.3707   -1.0260 C   0  0  0  0  0  0
   -3.2899    1.6233   -2.3641 C   0  0  0  0  0  0
   -2.3947    1.4670    0.0080 C   0  0  0  0  0  0
   -3.0289    1.0202    1.1749 C   0  0  0  0  0  0
   -2.3249    0.1942    2.0481 C   0  0  0  0  0  0
   -1.0129   -0.1681    1.7464 C   0  0  0  0  0  0
   -0.4171    0.3032    0.5670 C   0  0  0  0  0  0
   -1.1111    1.1133   -0.2825 N   0  0  0  0  0  0
    0.9191   -0.0270    0.2414 N   0  0  0  0  0  0
    2.0148   -0.2259    1.0778 C   0  0  0  0  0  0
    3.1559   -0.2099    0.3110 C   0  0  0  0  0  0
    4.3750   -0.3605    0.9683 C   0  0  0  0  0  0
    4.4250   -0.5084    2.3218 N   0  0  0  0  0  0
    3.2376   -0.4969    3.0013 C   0  0  0  0  0  0
    2.0109   -0.3438    2.4296 N   0  0  0  0  0  0
    3.2279   -0.6139    4.3988 N   0  0  0  0  0  0
    4.2555   -0.8075    5.3377 C   0  0  0  0  0  0
    4.0594   -0.3199    6.6280 C   0  0  0  0  0  0
    5.0393   -0.4898    7.6022 C   0  0  0  0  0  0
    6.2390   -1.1620    7.3172 C   0  0  0  0  0  0
    6.4112   -1.6672    6.0180 C   0  0  0  0  0  0
    5.4363   -1.4922    5.0403 C   0  0  0  0  0  0
    7.2211   -1.3383    8.3009 N   0  0  0  0  0  0
    8.5468   -1.9276    8.0525 C   0  0  0  0  0  0
    9.5272   -0.8379    7.5632 C   0  0  0  0  0  0
    9.6157    0.2823    8.6278 N   0  3  0  0  0  0
    8.2300    0.7585    9.1279 C   0  0  0  0  0  0
    7.3637   -0.4720    9.4828 C   0  0  0  0  0  0
   10.4350    1.4718    8.0912 C   0  0  0  0  0  0
    2.8073   -0.0250   -1.1204 C   0  0  0  0  0  0
    3.5574    0.0164   -2.0959 O   0  0  0  0  0  0
    1.4539    0.0294   -1.0897 N   0  0  0  0  0  0
    0.6560   -0.2059   -2.3080 C   0  0  0  0  0  0
    0.5419    1.0224   -3.1963 C   0  0  0  0  0  0
    0.9832    1.0977   -4.4614 C   0  0  0  0  0  0
   -4.3976    2.7692   -0.6230 O   0  0  0  0  0  0
   -1.3123    3.5050   -1.6245 H   0  0  0  0  0  0
   -2.2090    4.2444   -0.3077 H   0  0  0  0  0  0
   -2.8145    4.3431   -1.9567 H   0  0  0  0  0  0
   -2.3373    1.3199   -2.7977 H   0  0  0  0  0  0
   -3.7936    2.2439   -3.1069 H   0  0  0  0  0  0
   -3.8877    0.7197   -2.2342 H   0  0  0  0  0  0
   -4.0467    1.2957    1.4080 H   0  0  0  0  0  0
   -2.7939   -0.1672    2.9513 H   0  0  0  0  0  0
   -0.4862   -0.8227    2.4234 H   0  0  0  0  0  0
    5.3188   -0.3629    0.4421 H   0  0  0  0  0  0
    2.3393   -0.3616    4.8047 H   0  0  0  0  0  0
    3.1466    0.1993    6.8844 H   0  0  0  0  0  0
    4.8300   -0.0942    8.5831 H   0  0  0  0  0  0
    7.3038   -2.2004    5.7314 H   0  0  0  0  0  0
    5.6086   -1.9142    4.0621 H   0  0  0  0  0  0
    8.9350   -2.3778    8.9682 H   0  0  0  0  0  0
    8.4886   -2.7596    7.3519 H   0  0  0  0  0  0
   10.5387   -1.2258    7.4356 H   0  0  0  0  0  0
    9.1961   -0.3830    6.6275 H   0  0  0  0  0  0
    8.4155    1.3925    9.9960 H   0  0  0  0  0  0
    7.7778    1.3584    8.3353 H   0  0  0  0  0  0
    6.4016   -0.1681    9.8897 H   0  0  0  0  0  0
    7.8354   -1.0240   10.2982 H   0  0  0  0  0  0
    9.9073    1.8871    7.2310 H   0  0  0  0  0  0
   11.4170    1.0869    7.8131 H   0  0  0  0  0  0
   10.5172    2.1974    8.9015 H   0  0  0  0  0  0
    1.0995   -1.0234   -2.8818 H   0  0  0  0  0  0
   -0.3436   -0.5631   -2.0629 H   0  0  0  0  0  0
    0.0697    1.8875   -2.7555 H   0  0  0  0  0  0
    1.4639    0.2574   -4.9409 H   0  0  0  0  0  0
    0.8691    2.0054   -5.0355 H   0  0  0  0  0  0
   -4.7743    3.3175   -1.3148 H   0  0  0  0  0  0
   10.1054   -0.1008    9.4245 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 38  1  0  0  0
  1 39  1  0  0  0
  1 40  1  0  0  0
  2  3  1  0  0  0
  2  4  1  0  0  0
  2 37  1  0  0  0
  3 41  1  0  0  0
  3 42  1  0  0  0
  3 43  1  0  0  0
  4  5  1  0  0  0
  4  9  2  0  0  0
  5  6  2  0  0  0
  5 44  1  0  0  0
  6  7  1  0  0  0
  6 45  1  0  0  0
  7  8  2  0  0  0
  7 46  1  0  0  0
  8  9  1  0  0  0
  8 10  1  0  0  0
 10 11  1  0  0  0
 10 33  1  0  0  0
 11 12  2  0  0  0
 11 16  1  0  0  0
 12 13  1  0  0  0
 12 31  1  0  0  0
 13 14  2  0  0  0
 13 47  1  0  0  0
 14 15  1  0  0  0
 15 16  2  0  0  0
 15 17  1  0  0  0
 17 18  1  0  0  0
 17 48  1  0  0  0
 18 19  1  0  0  0
 18 23  2  0  0  0
 19 20  2  0  0  0
 19 49  1  0  0  0
 20 21  1  0  0  0
 20 50  1  0  0  0
 21 22  2  0  0  0
 21 24  1  0  0  0
 22 23  1  0  0  0
 22 51  1  0  0  0
 23 52  1  0  0  0
 24 25  1  0  0  0
 24 29  1  0  0  0
 25 26  1  0  0  0
 25 53  1  0  0  0
 25 54  1  0  0  0
 26 27  1  0  0  0
 26 55  1  0  0  0
 26 56  1  0  0  0
 27 28  1  0  0  0
 27 30  1  0  0  0
 27 70  1  0  0  0
 28 29  1  0  0  0
 28 57  1  0  0  0
 28 58  1  0  0  0
 29 59  1  0  0  0
 29 60  1  0  0  0
 30 61  1  0  0  0
 30 62  1  0  0  0
 30 63  1  0  0  0
 31 32  2  0  0  0
 31 33  1  0  0  0
 33 34  1  0  0  0
 34 35  1  0  0  0
 34 64  1  0  0  0
 34 65  1  0  0  0
 35 36  2  0  0  0
 35 66  1  0  0  0
 36 67  1  0  0  0
 36 68  1  0  0  0
 37 69  1  0  0  0
M  CHG  1  27   1
M  END
> <s_m_entry_id>
176

> <Applicants>
Astrazeneca

> <CHEMBL_ID>
CHEMBL1976040

> <Canonical_Smiles>
O=C1N(N(c2nc(ncc12)Nc1ccc(N2CCN(CC2)C)cc1)c1nc(ccc1)C(O)(C)C)CC=C

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
ADAVOSERTIB | AZD 1775 | AZD-1775 | AZD1775 | MK-1775 | MK1775

> <Indications>
nan

> <Type>
1

> <targets_id>
P30291

> <inchi>
InChI=1S/C27H32N8O2/c1-5-13-34-25(36)21-18-28-26(29-19-9-11-20(12-10-19)33-16-14-32(4)15-17-33)31-24(21)35(34)23-8-6-7-22(30-23)27(2,3)37/h5-12,18,37H,1,13-17H2,2-4H3,(H,28,29,31)

> <stdInchikey>
BKWJAKQVGHWELA-UHFFFAOYSA-N

> <csid>
24808590

> <Links>
|http://www.chemspider.com/Chemical-Structure.24808590.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1976040|http://pubchem.ncbi.nlm.nih.gov/compound/24856436|http://www.drugbank.ca/drugs/DB11740| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=8X7|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/8X7|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7702|http://zinc15.docking.org/substances/ZINC000063539231|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=K2T6HJX3I3|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50240826

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
500.3

> <HBA>
10

> <HBD>
2

> <NRB>
7

> <TPSA>
104.3

> <LogP>
2.9

> <RoF>
1

> <Targets>
WEE1

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_epik_Ionization_Penalty>
  0.0667

> <r_epik_State_Penalty>
  0.0564

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
176

> <lig_pdbID>
'8X7'

> <pdbID>
5v5y 5vd0 5vdk

> <Kinase families>
Other

> <indicationDB>
MK-1775 has been used in trials studying the treatment of LYMPHOMA, Neoplasms, Ovarian Cancer, Tongue Carcinoma, and Adult Glioblastoma, among others.

> <uniprotId>
P30291

$$$$
Milciclib
                    3D
 Structure written by MMmdl.
 67 71  0  0  1  0            999 V2000
   -4.4779    1.8560   -2.6308 C   0  0  0  0  0  0
   -4.9594    1.5640   -1.1921 C   0  0  0  0  0  0
   -4.5082    0.1135   -0.7800 C   0  0  0  0  0  0
   -3.0122   -0.0350   -0.5047 C   0  0  0  0  0  0
   -2.2783   -1.1934   -0.7786 C   0  0  0  0  0  0
   -0.9593   -1.3221   -0.4813 N   0  0  0  0  0  0
   -0.3621   -0.2650    0.1252 C   0  0  0  0  0  0
   -0.9862    0.9023    0.4351 N   0  0  0  0  0  0
   -2.3010    1.0045    0.1077 C   0  0  0  0  0  0
   -3.0594    2.2557    0.3723 C   0  0  0  0  0  0
   -4.2861    2.5689   -0.2196 C   0  0  0  0  0  0
   -4.5820    3.8823    0.2478 C   0  0  0  0  0  0
   -3.6664    4.2920    1.1068 N   0  0  0  0  0  0
   -2.7538    3.3235    1.1771 N   0  0  0  0  0  0
   -1.5927    3.5121    2.0351 C   0  0  0  0  0  0
   -5.6608    4.7351   -0.2022 C   0  0  0  0  0  0
   -6.0564    4.7130   -1.3681 O   0  0  0  0  0  0
   -6.1612    5.5505    0.7463 N   0  0  0  0  0  0
   -7.2383    6.5132    0.5451 C   0  0  0  0  0  0
    1.0054   -0.4243    0.3952 N   0  0  0  0  0  0
    1.9569    0.4329    0.9746 C   0  0  0  0  0  0
    3.2855    0.2959    0.5787 C   0  0  0  0  0  0
    4.2705    1.1180    1.1195 C   0  0  0  0  0  0
    3.9587    2.0922    2.0828 C   0  0  0  0  0  0
    2.6167    2.2062    2.4817 C   0  0  0  0  0  0
    1.6299    1.3872    1.9405 C   0  0  0  0  0  0
    4.9491    2.9257    2.6205 N   0  0  0  0  0  0
    4.7837    3.7424    3.8343 C   0  0  0  0  0  0
    5.1627    2.9107    5.0811 C   0  0  0  0  0  0
    6.6244    2.4186    4.9426 N   0  3  0  0  0  0
    6.9271    1.7871    3.5614 C   0  0  0  0  0  0
    6.3966    2.7197    2.4489 C   0  0  0  0  0  0
    6.9729    1.4335    6.0751 C   0  0  0  0  0  0
   -6.5024    1.5753   -1.0570 C   0  0  0  0  0  0
   -4.8939    1.1417   -3.3422 H   0  0  0  0  0  0
   -3.3914    1.8056   -2.7156 H   0  0  0  0  0  0
   -4.7821    2.8508   -2.9575 H   0  0  0  0  0  0
   -5.0241   -0.1934    0.1320 H   0  0  0  0  0  0
   -4.8140   -0.6016   -1.5461 H   0  0  0  0  0  0
   -2.7494   -2.0489   -1.2406 H   0  0  0  0  0  0
   -1.4782    2.6413    2.6810 H   0  0  0  0  0  0
   -1.7075    4.3989    2.6612 H   0  0  0  0  0  0
   -0.7029    3.6263    1.4153 H   0  0  0  0  0  0
   -5.7673    5.5055    1.6750 H   0  0  0  0  0  0
   -6.8902    7.5134    0.8033 H   0  0  0  0  0  0
   -8.0777    6.2685    1.1961 H   0  0  0  0  0  0
   -7.6043    6.5388   -0.4823 H   0  0  0  0  0  0
    1.4016   -1.2254   -0.0737 H   0  0  0  0  0  0
    3.5629   -0.4425   -0.1600 H   0  0  0  0  0  0
    5.2785    0.9697    0.7669 H   0  0  0  0  0  0
    2.3017    2.9257    3.2200 H   0  0  0  0  0  0
    0.6184    1.4971    2.2977 H   0  0  0  0  0  0
    5.4233    4.6257    3.7816 H   0  0  0  0  0  0
    3.7790    4.1516    3.9211 H   0  0  0  0  0  0
    5.1209    3.5036    5.9957 H   0  0  0  0  0  0
    4.5237    2.0324    5.1935 H   0  0  0  0  0  0
    8.0092    1.6611    3.5083 H   0  0  0  0  0  0
    6.4493    0.8058    3.5318 H   0  0  0  0  0  0
    6.6402    2.3395    1.4585 H   0  0  0  0  0  0
    6.9199    3.6767    2.4996 H   0  0  0  0  0  0
    6.3342    0.5549    5.9699 H   0  0  0  0  0  0
    6.7934    1.9503    7.0189 H   0  0  0  0  0  0
    8.0280    1.1789    5.9662 H   0  0  0  0  0  0
   -6.9494    0.7172   -1.5608 H   0  0  0  0  0  0
   -6.9607    2.4503   -1.5105 H   0  0  0  0  0  0
   -6.8180    1.5381   -0.0133 H   0  0  0  0  0  0
    7.2220    3.2278    5.0383 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 35  1  0  0  0
  1 36  1  0  0  0
  1 37  1  0  0  0
  2  3  1  0  0  0
  2 11  1  0  0  0
  2 34  1  0  0  0
  3  4  1  0  0  0
  3 38  1  0  0  0
  3 39  1  0  0  0
  4  5  1  0  0  0
  4  9  2  0  0  0
  5  6  2  0  0  0
  5 40  1  0  0  0
  6  7  1  0  0  0
  7  8  2  0  0  0
  7 20  1  0  0  0
  8  9  1  0  0  0
  9 10  1  0  0  0
 10 11  2  0  0  0
 10 14  1  0  0  0
 11 12  1  0  0  0
 12 13  2  0  0  0
 12 16  1  0  0  0
 13 14  1  0  0  0
 14 15  1  0  0  0
 15 41  1  0  0  0
 15 42  1  0  0  0
 15 43  1  0  0  0
 16 17  2  0  0  0
 16 18  1  0  0  0
 18 19  1  0  0  0
 18 44  1  0  0  0
 19 45  1  0  0  0
 19 46  1  0  0  0
 19 47  1  0  0  0
 20 21  1  0  0  0
 20 48  1  0  0  0
 21 22  1  0  0  0
 21 26  2  0  0  0
 22 23  2  0  0  0
 22 49  1  0  0  0
 23 24  1  0  0  0
 23 50  1  0  0  0
 24 25  2  0  0  0
 24 27  1  0  0  0
 25 26  1  0  0  0
 25 51  1  0  0  0
 26 52  1  0  0  0
 27 28  1  0  0  0
 27 32  1  0  0  0
 28 29  1  0  0  0
 28 53  1  0  0  0
 28 54  1  0  0  0
 29 30  1  0  0  0
 29 55  1  0  0  0
 29 56  1  0  0  0
 30 31  1  0  0  0
 30 33  1  0  0  0
 30 67  1  0  0  0
 31 32  1  0  0  0
 31 57  1  0  0  0
 31 58  1  0  0  0
 32 59  1  0  0  0
 32 60  1  0  0  0
 33 61  1  0  0  0
 33 62  1  0  0  0
 33 63  1  0  0  0
 34 64  1  0  0  0
 34 65  1  0  0  0
 34 66  1  0  0  0
M  CHG  1  30   1
M  END
> <s_m_entry_id>
178

> <Applicants>
Nerviano Medical Sciences

> <CHEMBL_ID>
CHEMBL564829

> <Canonical_Smiles>
O=C(NC)c1nn(c-2c1C(Cc1c-2nc(nc1)Nc1ccc(N2CCN(CC2)C)cc1)(C)C)C

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
MILCICLIB | PHA 848125 | PHA-848125

> <Indications>
nan

> <Type>
1

> <targets_id>
P06493|P04629

> <inchi>
InChI=1S/C25H32N8O/c1-25(2)14-16-15-27-24(29-20(16)22-19(25)21(23(34)26-3)30-32(22)5)28-17-6-8-18(9-7-17)33-12-10-31(4)11-13-33/h6-9,15H,10-14H2,1-5H3,(H,26,34)(H,27,28,29)

> <stdInchikey>
RXZMYLDMFYNEIM-UHFFFAOYSA-N

> <csid>
16788113

> <Links>
|http://www.chemspider.com/Chemical-Structure.16788113.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL564829|http://pubchem.ncbi.nlm.nih.gov/compound/16718576| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=P48|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/P48|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7938|http://zinc15.docking.org/substances/ZINC000053119602|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=688000M8S8|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=31545

> <LinkName>
|ChemSpider|ChEMBL|PubChem|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
460.3

> <HBA>
8

> <HBD>
2

> <NRB>
4

> <TPSA>
91.2

> <LogP>
2.6

> <RoF>
0

> <Targets>
CDK1; NTRK1

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0726

> <r_epik_State_Penalty>
  0.4007

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
178

> <lig_pdbID>
'P48'

> <pdbID>
2wih 5vc6 5vd1

> <Kinase families>
Tyr<br>CMGC

$$$$
Delgocitinib
                    3D
 Structure written by MMmdl.
 41 44  0  0  1  0            999 V2000
   -1.8113   -3.9112    1.0795 C   0  0  0  0  0  0
   -1.2296   -2.7056    0.3170 C   0  0  2  0  0  0
    0.2589   -2.4324    0.5888 C   0  0  0  0  0  0
   -0.1298   -1.0016    0.6922 N   0  0  0  0  0  0
   -1.5930   -1.2710    0.7968 C   0  0  2  0  0  0
   -2.2523   -1.0828    2.1700 C   0  0  0  0  0  0
   -3.6886   -0.6602    1.8396 C   0  0  0  0  0  0
   -3.8800   -0.7021    0.3891 N   0  0  0  0  0  0
   -2.5283   -0.4864   -0.1265 C   0  0  0  0  0  0
   -5.0561   -0.3465   -0.2970 C   0  0  0  0  0  0
   -6.3173   -0.2146    0.3374 C   0  0  0  0  0  0
   -6.8680   -0.2848    1.6661 C   0  0  0  0  0  0
   -8.2243   -0.0418    1.5573 C   0  0  0  0  0  0
   -8.5479    0.1765    0.2409 N   0  0  0  0  0  0
   -7.4119    0.0781   -0.5311 C   0  0  0  0  0  0
   -7.3429    0.2256   -1.8573 N   0  0  0  0  0  0
   -6.0882    0.0583   -2.3459 C   0  0  0  0  0  0
   -4.9595   -0.2255   -1.6517 N   0  0  0  0  0  0
    0.6041    0.1131    0.8739 C   0  0  0  0  0  0
    0.1226    1.1532    1.3218 O   0  0  0  0  0  0
    2.0913    0.0648    0.5097 C   0  0  0  0  0  0
    2.4190   -0.4659   -0.8237 C   0  0  0  0  0  0
    2.6770   -0.8836   -1.8716 N   0  0  0  0  0  0
   -1.4936   -3.9376    2.1218 H   0  0  0  0  0  0
   -1.4842   -4.8465    0.6247 H   0  0  0  0  0  0
   -2.9014   -3.8984    1.0563 H   0  0  0  0  0  0
   -1.4375   -2.8642   -0.7436 H   0  0  0  0  0  0
    0.6505   -2.8150    1.5324 H   0  0  0  0  0  0
    0.9332   -2.6441   -0.2412 H   0  0  0  0  0  0
   -2.2210   -1.9649    2.8062 H   0  0  0  0  0  0
   -1.7644   -0.2821    2.7273 H   0  0  0  0  0  0
   -4.4043   -1.3173    2.3321 H   0  0  0  0  0  0
   -3.8847    0.3499    2.2036 H   0  0  0  0  0  0
   -2.3078    0.5824   -0.1032 H   0  0  0  0  0  0
   -2.4361   -0.7992   -1.1673 H   0  0  0  0  0  0
   -6.3614   -0.4801    2.5982 H   0  0  0  0  0  0
   -8.9961   -0.0028    2.3123 H   0  0  0  0  0  0
   -9.4883    0.3744   -0.0685 H   0  0  0  0  0  0
   -5.9761    0.1579   -3.4157 H   0  0  0  0  0  0
    2.5184    1.0668    0.5692 H   0  0  0  0  0  0
    2.6161   -0.5396    1.2498 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 24  1  0  0  0
  1 25  1  0  0  0
  1 26  1  0  0  0
  2  3  1  0  0  0
  2  5  1  0  0  0
  2 27  1  0  0  0
  3  4  1  0  0  0
  3 28  1  0  0  0
  3 29  1  0  0  0
  4  5  1  0  0  0
  4 19  1  0  0  0
  5  6  1  0  0  0
  5  9  1  0  0  0
  6  7  1  0  0  0
  6 30  1  0  0  0
  6 31  1  0  0  0
  7  8  1  0  0  0
  7 32  1  0  0  0
  7 33  1  0  0  0
  8  9  1  0  0  0
  8 10  1  0  0  0
  9 34  1  0  0  0
  9 35  1  0  0  0
 10 11  1  0  0  0
 10 18  2  0  0  0
 11 12  1  0  0  0
 11 15  2  0  0  0
 12 13  2  0  0  0
 12 36  1  0  0  0
 13 14  1  0  0  0
 13 37  1  0  0  0
 14 15  1  0  0  0
 14 38  1  0  0  0
 15 16  1  0  0  0
 16 17  2  0  0  0
 17 18  1  0  0  0
 17 39  1  0  0  0
 19 20  2  0  0  0
 19 21  1  0  0  0
 21 22  1  0  0  0
 21 40  1  0  0  0
 21 41  1  0  0  0
 22 23  3  0  0  0
M  END
> <s_m_entry_id>
181

> <Applicants>
Japan Tobacco

> <CHEMBL_ID>
CHEMBL4297507

> <Canonical_Smiles>
O=C(N1CC(C)C12CCN(C2)c1ncnc2[nH]ccc12)CC#N

> <Chirality>
Single Stereoisomer

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Indications>
nan

> <Type>
nan

> <targets_id>
nan

> <inchi>
InChI=1S/C16H18N6O/c1-11-8-22(13(23)2-5-17)16(11)4-7-21(9-16)15-12-3-6-18-14(12)19-10-20-15/h3,6,10-11H,2,4,7-9H2,1H3,(H,18,19,20)

> <stdInchikey>
LOWWYYZBZNSPDT-UHFFFAOYSA-N

> <csid>
34960249

> <Links>
|http://www.chemspider.com/Chemical-Structure.34960249.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3689518|http://pubchem.ncbi.nlm.nih.gov/compound/50913622|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=109868

> <LinkName>
|ChemSpider|ChEMBL|PubChem|BindingDB

> <MW>
310.2

> <HBA>
5

> <HBD>
1

> <NRB>
2

> <TPSA>
88.9

> <LogP>
1.3

> <RoF>
0

> <Targets>
nan

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
0.999998

> <r_epik_Ionization_Penalty>
  0.0149

> <r_epik_State_Penalty>
  0.0108

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
181

$$$$
Voxtalisib
                    3D
 Structure written by MMmdl.
 34 36  0  0  1  0            999 V2000
   -0.6527    1.4772    0.1814 C   0  0  0  0  0  0
   -0.0892    0.0623   -0.0347 C   0  0  0  0  0  0
    1.3944    0.0149   -0.0538 N   0  0  0  0  0  0
    2.0792    0.0184    1.2026 C   0  0  0  0  0  0
    3.4812    0.0146    1.2165 C   0  0  0  0  0  0
    4.1650   -0.0046   -0.0810 C   0  0  0  0  0  0
    3.4860    0.0014   -1.2555 C   0  0  0  0  0  0
    2.0115    0.0534   -1.2867 C   0  0  0  0  0  0
    1.3770    0.1419   -2.3418 O   0  0  0  0  0  0
    4.2544   -0.0446   -2.5188 C   0  0  0  0  0  0
    3.8890   -0.2982   -3.8415 C   0  0  0  0  0  0
    5.0530   -0.2101   -4.6077 C   0  0  0  0  0  0
    6.1009    0.0704   -3.8766 N   0  0  0  0  0  0
    5.6122    0.1634   -2.6357 N   0  0  0  0  0  0
    4.1171    0.0194    2.4672 C   0  0  0  0  0  0
    3.4129    0.0235    3.6302 N   0  0  0  0  0  0
    2.0615    0.0204    3.5221 C   0  0  0  0  0  0
    1.3593    0.0168    2.3628 N   0  0  0  0  0  0
    1.3306    0.0194    4.7035 N   0  0  0  0  0  0
    5.6307    0.0144    2.6129 C   0  0  0  0  0  0
   -1.7426    1.4623    0.1757 H   0  0  0  0  0  0
   -0.3275    2.1555   -0.6083 H   0  0  0  0  0  0
   -0.3339    1.8969    1.1357 H   0  0  0  0  0  0
   -0.4631   -0.6033    0.7441 H   0  0  0  0  0  0
   -0.5111   -0.3483   -0.9534 H   0  0  0  0  0  0
    5.2444   -0.0479   -0.0880 H   0  0  0  0  0  0
    2.9036   -0.5261   -4.2185 H   0  0  0  0  0  0
    5.1248   -0.3524   -5.6760 H   0  0  0  0  0  0
    6.2140    0.3763   -1.8536 H   0  0  0  0  0  0
    0.3226    0.0126    4.6585 H   0  0  0  0  0  0
    1.8196    0.0190    5.5861 H   0  0  0  0  0  0
    6.0626    0.8788    2.1079 H   0  0  0  0  0  0
    6.0485   -0.8886    2.1672 H   0  0  0  0  0  0
    5.9453    0.0478    3.6573 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 21  1  0  0  0
  1 22  1  0  0  0
  1 23  1  0  0  0
  2  3  1  0  0  0
  2 24  1  0  0  0
  2 25  1  0  0  0
  3  4  1  0  0  0
  3  8  1  0  0  0
  4  5  2  0  0  0
  4 18  1  0  0  0
  5  6  1  0  0  0
  5 15  1  0  0  0
  6  7  2  0  0  0
  6 26  1  0  0  0
  7  8  1  0  0  0
  7 10  1  0  0  0
  8  9  2  0  0  0
 10 11  2  0  0  0
 10 14  1  0  0  0
 11 12  1  0  0  0
 11 27  1  0  0  0
 12 13  2  0  0  0
 12 28  1  0  0  0
 13 14  1  0  0  0
 14 29  1  0  0  0
 15 16  2  0  0  0
 15 20  1  0  0  0
 16 17  1  0  0  0
 17 18  2  0  0  0
 17 19  1  0  0  0
 19 30  1  0  0  0
 19 31  1  0  0  0
 20 32  1  0  0  0
 20 33  1  0  0  0
 20 34  1  0  0  0
M  END
> <s_m_entry_id>
189

> <Applicants>
Sanofi

> <CHEMBL_ID>
CHEMBL3545366

> <Canonical_Smiles>
O=C1N(c2nc(nc(c2C=C1c1[nH]ncc1)C)N)CC

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
SAR-245409 | SAR245409 | VOXTALISIB | XL-765 | XL765

> <Indications>
nan

> <Type>
nan

> <targets_id>
P42336|P42345

> <inchi>
InChI=1S/C13H14N6O/c1-3-19-11-8(7(2)16-13(14)17-11)6-9(12(19)20)10-4-5-15-18-10/h4-6H,3H2,1-2H3,(H,15,18)(H2,14,16,17)

> <stdInchikey>
RGHYDLZMTYDBDT-UHFFFAOYSA-N

> <csid>
17279963

> <Links>
|http://www.chemspider.com/Chemical-Structure.17279963.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3545366|http://pubchem.ncbi.nlm.nih.gov/compound/16123056|http://www.drugbank.ca/drugs/DB12400|http://zinc15.docking.org/substances/ZINC000035308805|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=CVL1685GPH

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|ZINC|FDA SRS

> <MW>
270.1

> <HBA>
6

> <HBD>
2

> <NRB>
2

> <TPSA>
102.5

> <LogP>
1.1

> <RoF>
0

> <Targets>
PIK3CA; MTOR

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
0.5

> <r_epik_Ionization_Penalty>
  0.0000

> <r_epik_State_Penalty>
  0.4107

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
189

> <Kinase families>
Atypical

$$$$
Rabusertib
                    3D
 Structure written by MMmdl.
 50 52  0  0  1  0            999 V2000
   -3.0602   -2.8518   -0.1678 C   0  0  0  0  0  0
   -2.3713   -1.4962   -0.1341 C   0  0  0  0  0  0
   -0.9758   -1.4309   -0.1142 C   0  0  0  0  0  0
   -0.3038   -0.1962   -0.0828 C   0  0  0  0  0  0
   -1.0608    0.9881   -0.0595 C   0  0  0  0  0  0
   -2.4627    0.9190   -0.0965 C   0  0  0  0  0  0
   -3.1152   -0.3113   -0.1287 C   0  0  0  0  0  0
   -5.0226   -0.3350   -0.1719 Br  0  0  0  0  0  0
   -0.3595    2.2119   -0.0427 N   0  0  0  0  0  0
   -0.7609    3.4037    0.4445 C   0  0  0  0  0  0
   -1.8407    3.6107    1.0022 O   0  0  0  0  0  0
    0.1978    4.3318    0.2443 N   0  0  0  0  0  0
    0.1920    5.6904    0.6093 C   0  0  0  0  0  0
    1.3349    6.4375    0.2957 C   0  0  0  0  0  0
    1.4381    7.7578    0.6033 N   0  0  0  0  0  0
    0.3791    8.3332    1.2325 C   0  0  0  0  0  0
   -0.7677    7.5991    1.5497 C   0  0  0  0  0  0
   -0.8671    6.2798    1.2412 N   0  0  0  0  0  0
    0.5108    9.8058    1.5682 C   0  0  0  0  0  0
    1.0777   -0.0821   -0.0694 O   0  0  0  0  0  0
    1.8890   -1.2539   -0.0471 C   0  0  0  0  0  0
    3.3678   -0.8336   -0.0034 C   0  0  2  0  0  0
    4.3114   -2.0504   -0.1636 C   0  0  0  0  0  0
    5.7679   -1.6277    0.0966 N   0  3  0  0  0  0
    5.9325   -0.8464    1.4083 C   0  0  0  0  0  0
    4.9431    0.3304    1.4026 C   0  0  0  0  0  0
    3.6138   -0.1462    1.2248 O   0  0  0  0  0  0
   -3.7003   -2.9733    0.7066 H   0  0  0  0  0  0
   -2.3454   -3.6756   -0.1742 H   0  0  0  0  0  0
   -3.6786   -2.9415   -1.0613 H   0  0  0  0  0  0
   -0.4222   -2.3573   -0.1257 H   0  0  0  0  0  0
   -3.0660    1.8138   -0.1164 H   0  0  0  0  0  0
    0.5896    2.1569   -0.3822 H   0  0  0  0  0  0
    1.0367    4.0241   -0.2246 H   0  0  0  0  0  0
    2.1830    5.9928   -0.2046 H   0  0  0  0  0  0
   -1.6126    8.0507    2.0485 H   0  0  0  0  0  0
   -0.3835   10.1840    2.0651 H   0  0  0  0  0  0
    0.6651   10.3912    0.6612 H   0  0  0  0  0  0
    1.3602    9.9708    2.2319 H   0  0  0  0  0  0
    1.6484   -1.8653    0.8251 H   0  0  0  0  0  0
    1.6970   -1.8442   -0.9453 H   0  0  0  0  0  0
    3.5426   -0.1505   -0.8376 H   0  0  0  0  0  0
    4.0973   -2.8473    0.5506 H   0  0  0  0  0  0
    4.3079   -2.4585   -1.1750 H   0  0  0  0  0  0
    6.3634   -2.4439    0.1071 H   0  0  0  0  0  0
    5.7311   -1.5603    2.2085 H   0  0  0  0  0  0
    6.9752   -0.5298    1.4495 H   0  0  0  0  0  0
    4.9970    0.8705    2.3483 H   0  0  0  0  0  0
    5.1864    1.0459    0.6147 H   0  0  0  0  0  0
    6.0783   -1.0444   -0.6677 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 28  1  0  0  0
  1 29  1  0  0  0
  1 30  1  0  0  0
  2  3  1  0  0  0
  2  7  2  0  0  0
  3  4  2  0  0  0
  3 31  1  0  0  0
  4  5  1  0  0  0
  4 20  1  0  0  0
  5  6  2  0  0  0
  5  9  1  0  0  0
  6  7  1  0  0  0
  6 32  1  0  0  0
  7  8  1  0  0  0
  9 10  1  0  0  0
  9 33  1  0  0  0
 10 11  2  0  0  0
 10 12  1  0  0  0
 12 13  1  0  0  0
 12 34  1  0  0  0
 13 14  1  0  0  0
 13 18  2  0  0  0
 14 15  2  0  0  0
 14 35  1  0  0  0
 15 16  1  0  0  0
 16 17  2  0  0  0
 16 19  1  0  0  0
 17 18  1  0  0  0
 17 36  1  0  0  0
 19 37  1  0  0  0
 19 38  1  0  0  0
 19 39  1  0  0  0
 20 21  1  0  0  0
 21 22  1  0  0  0
 21 40  1  0  0  0
 21 41  1  0  0  0
 22 23  1  0  0  0
 22 27  1  0  0  0
 22 42  1  0  0  0
 23 24  1  0  0  0
 23 43  1  0  0  0
 23 44  1  0  0  0
 24 25  1  0  0  0
 24 45  1  0  0  0
 24 50  1  0  0  0
 25 26  1  0  0  0
 25 46  1  0  0  0
 25 47  1  0  0  0
 26 27  1  0  0  0
 26 48  1  0  0  0
 26 49  1  0  0  0
M  CHG  1  24   1
M  END
> <s_m_entry_id>
191

> <Applicants>
Eli Lilly

> <CHEMBL_ID>
CHEMBL3039517

> <Canonical_Smiles>
Brc1cc(NC(=O)Nc2ncc(nc2)C)c(OC[C@H]2OCCNC2)cc1C

> <Chirality>
Single Stereoisomer

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
IC-83 | LY-2603618 | LY2603618 | RABUSERTIB

> <Indications>
nan

> <Type>
nan

> <targets_id>
O14757

> <inchi>
InChI=1S/C18H22BrN5O3/c1-11-5-16(27-10-13-8-20-3-4-26-13)15(6-14(11)19)23-18(25)24-17-9-21-12(2)7-22-17/h5-7,9,13,20H,3-4,8,10H2,1-2H3,(H2,22,23,24,25)/t13-/m0/s1

> <stdInchikey>
SYYBDNPGDKKJDU-ZDUSSCGKSA-N

> <csid>
10130131

> <Links>
|http://www.chemspider.com/Chemical-Structure.10130131.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3039517|http://pubchem.ncbi.nlm.nih.gov/compound/11955855|http://www.drugbank.ca/drugs/DB11662|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7960|http://zinc15.docking.org/substances/ZINC000070466463|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=3S9L1NU6U7

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS

> <indicationG2P>
None

> <MW>
435.1

> <HBA>
6

> <HBD>
3

> <NRB>
5

> <TPSA>
97.4

> <LogP>
2.9

> <RoF>
0

> <Targets>
CHEK1

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0285

> <r_epik_State_Penalty>
  0.0234

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
191

> <Kinase families>
CAMK

$$$$
Gedatolisib
                    3D
 Structure written by MMmdl.
 87 92  0  0  1  0            999 V2000
   -5.5127    4.4820   -3.6910 C   0  0  0  0  0  0
   -6.0841    3.2016   -4.3404 N   0  3  0  0  0  0
   -7.5073    3.4587   -4.8772 C   0  0  0  0  0  0
   -6.0000    1.8974   -3.4984 C   0  0  0  0  0  0
   -6.6111    2.0834   -2.0875 C   0  0  0  0  0  0
   -6.3960    0.8247   -1.2153 C   0  0  0  0  0  0
   -4.9457    0.5378   -1.2033 N   0  0  0  0  0  0
   -4.3832    0.1747   -2.5231 C   0  0  0  0  0  0
   -4.5327    1.4140   -3.4375 C   0  0  0  0  0  0
   -4.1763    0.9517   -0.1559 C   0  0  0  0  0  0
   -4.6252    1.6003    0.7921 O   0  0  0  0  0  0
   -2.7175    0.5696   -0.1290 C   0  0  0  0  0  0
   -2.3314   -0.7729   -0.2177 C   0  0  0  0  0  0
   -0.9846   -1.1206   -0.1615 C   0  0  0  0  0  0
   -0.0099   -0.1247   -0.0000 C   0  0  0  0  0  0
   -0.3960    1.2147    0.0802 C   0  0  0  0  0  0
   -1.7436    1.5605    0.0276 C   0  0  0  0  0  0
    1.3713   -0.3852    0.0546 N   0  0  0  0  0  0
    1.9941   -1.5074    0.4697 C   0  0  0  0  0  0
    1.4239   -2.5079    0.9075 O   0  0  0  0  0  0
    3.3306   -1.3587    0.3636 N   0  0  0  0  0  0
    4.3546   -2.2623    0.7066 C   0  0  0  0  0  0
    5.6293   -1.7188    0.8581 C   0  0  0  0  0  0
    6.7047   -2.5335    1.1995 C   0  0  0  0  0  0
    6.5414   -3.9154    1.3918 C   0  0  0  0  0  0
    5.2542   -4.4498    1.2158 C   0  0  0  0  0  0
    4.1732   -3.6415    0.8748 C   0  0  0  0  0  0
    7.7039   -4.7915    1.7737 C   0  0  0  0  0  0
    8.9197   -4.2032    1.9459 N   0  0  0  0  0  0
    9.9440   -5.0279    2.3001 C   0  0  0  0  0  0
    9.8015   -6.3690    2.4884 N   0  0  0  0  0  0
    8.5532   -6.8790    2.2979 C   0  0  0  0  0  0
    7.4779   -6.1247    1.9356 N   0  0  0  0  0  0
    8.3695   -8.2551    2.4688 N   0  0  0  0  0  0
    9.3683   -9.1132    3.1357 C   0  0  0  0  0  0
    9.3040  -10.5857    2.6800 C   0  0  0  0  0  0
    7.9911  -11.1064    2.8250 O   0  0  0  0  0  0
    7.0247  -10.3540    2.1069 C   0  0  0  0  0  0
    7.0331   -8.8761    2.5502 C   0  0  0  0  0  0
   11.2075   -4.4629    2.5008 N   0  0  0  0  0  0
   12.4332   -5.2757    2.6247 C   0  0  0  0  0  0
   13.5374   -4.5809    3.4483 C   0  0  0  0  0  0
   13.8219   -3.2894    2.9310 O   0  0  0  0  0  0
   12.6748   -2.4534    2.8914 C   0  0  0  0  0  0
   11.5490   -3.0976    2.0557 C   0  0  0  0  0  0
   -6.1768    4.7819   -2.8796 H   0  0  0  0  0  0
   -5.4863    5.2431   -4.4720 H   0  0  0  0  0  0
   -4.5060    4.2741   -3.3326 H   0  0  0  0  0  0
   -8.1556    3.6790   -4.0281 H   0  0  0  0  0  0
   -7.8271    2.5601   -5.4064 H   0  0  0  0  0  0
   -7.4460    4.3057   -5.5619 H   0  0  0  0  0  0
   -6.5753    1.1527   -4.0522 H   0  0  0  0  0  0
   -6.1625    2.9341   -1.5740 H   0  0  0  0  0  0
   -7.6778    2.2967   -2.1576 H   0  0  0  0  0  0
   -6.8031    0.9662   -0.2125 H   0  0  0  0  0  0
   -6.9172   -0.0267   -1.6550 H   0  0  0  0  0  0
   -3.3421   -0.1428   -2.4866 H   0  0  0  0  0  0
   -4.9576   -0.6587   -2.9295 H   0  0  0  0  0  0
   -4.1763    1.1737   -4.4398 H   0  0  0  0  0  0
   -3.8725    2.1968   -3.0644 H   0  0  0  0  0  0
   -3.0708   -1.5531   -0.3310 H   0  0  0  0  0  0
   -0.7192   -2.1626   -0.2541 H   0  0  0  0  0  0
    0.3437    1.9942    0.1965 H   0  0  0  0  0  0
   -2.0229    2.6018    0.1061 H   0  0  0  0  0  0
    1.9604    0.3969   -0.1901 H   0  0  0  0  0  0
    3.6577   -0.4581    0.0461 H   0  0  0  0  0  0
    5.7957   -0.6594    0.7220 H   0  0  0  0  0  0
    7.6731   -2.0691    1.3158 H   0  0  0  0  0  0
    5.0733   -5.5073    1.3414 H   0  0  0  0  0  0
    3.2129   -4.1133    0.7384 H   0  0  0  0  0  0
   10.3774   -8.7608    2.9212 H   0  0  0  0  0  0
    9.2450   -9.0449    4.2175 H   0  0  0  0  0  0
    9.6423  -10.6853    1.6469 H   0  0  0  0  0  0
    9.9871  -11.1880    3.2792 H   0  0  0  0  0  0
    7.1990  -10.4364    1.0323 H   0  0  0  0  0  0
    6.0407  -10.7881    2.2862 H   0  0  0  0  0  0
    6.6466   -8.7818    3.5659 H   0  0  0  0  0  0
    6.3292   -8.3489    1.9056 H   0  0  0  0  0  0
   12.2146   -6.2206    3.1229 H   0  0  0  0  0  0
   12.8042   -5.5333    1.6318 H   0  0  0  0  0  0
   13.2513   -4.5159    4.4999 H   0  0  0  0  0  0
   14.4495   -5.1772    3.4207 H   0  0  0  0  0  0
   12.3279   -2.2335    3.9028 H   0  0  0  0  0  0
   12.9561   -1.4951    2.4548 H   0  0  0  0  0  0
   11.8221   -3.1149    0.9996 H   0  0  0  0  0  0
   10.6816   -2.4419    2.1359 H   0  0  0  0  0  0
   -5.5148    3.0264   -5.1570 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 46  1  0  0  0
  1 47  1  0  0  0
  1 48  1  0  0  0
  2  3  1  0  0  0
  2  4  1  0  0  0
  2 87  1  0  0  0
  3 49  1  0  0  0
  3 50  1  0  0  0
  3 51  1  0  0  0
  4  5  1  0  0  0
  4  9  1  0  0  0
  4 52  1  0  0  0
  5  6  1  0  0  0
  5 53  1  0  0  0
  5 54  1  0  0  0
  6  7  1  0  0  0
  6 55  1  0  0  0
  6 56  1  0  0  0
  7  8  1  0  0  0
  7 10  1  0  0  0
  8  9  1  0  0  0
  8 57  1  0  0  0
  8 58  1  0  0  0
  9 59  1  0  0  0
  9 60  1  0  0  0
 10 11  2  0  0  0
 10 12  1  0  0  0
 12 13  1  0  0  0
 12 17  2  0  0  0
 13 14  2  0  0  0
 13 61  1  0  0  0
 14 15  1  0  0  0
 14 62  1  0  0  0
 15 16  2  0  0  0
 15 18  1  0  0  0
 16 17  1  0  0  0
 16 63  1  0  0  0
 17 64  1  0  0  0
 18 19  1  0  0  0
 18 65  1  0  0  0
 19 20  2  0  0  0
 19 21  1  0  0  0
 21 22  1  0  0  0
 21 66  1  0  0  0
 22 23  1  0  0  0
 22 27  2  0  0  0
 23 24  2  0  0  0
 23 67  1  0  0  0
 24 25  1  0  0  0
 24 68  1  0  0  0
 25 26  2  0  0  0
 25 28  1  0  0  0
 26 27  1  0  0  0
 26 69  1  0  0  0
 27 70  1  0  0  0
 28 29  1  0  0  0
 28 33  2  0  0  0
 29 30  2  0  0  0
 30 31  1  0  0  0
 30 40  1  0  0  0
 31 32  2  0  0  0
 32 33  1  0  0  0
 32 34  1  0  0  0
 34 35  1  0  0  0
 34 39  1  0  0  0
 35 36  1  0  0  0
 35 71  1  0  0  0
 35 72  1  0  0  0
 36 37  1  0  0  0
 36 73  1  0  0  0
 36 74  1  0  0  0
 37 38  1  0  0  0
 38 39  1  0  0  0
 38 75  1  0  0  0
 38 76  1  0  0  0
 39 77  1  0  0  0
 39 78  1  0  0  0
 40 41  1  0  0  0
 40 45  1  0  0  0
 41 42  1  0  0  0
 41 79  1  0  0  0
 41 80  1  0  0  0
 42 43  1  0  0  0
 42 81  1  0  0  0
 42 82  1  0  0  0
 43 44  1  0  0  0
 44 45  1  0  0  0
 44 83  1  0  0  0
 44 84  1  0  0  0
 45 85  1  0  0  0
 45 86  1  0  0  0
M  CHG  1   2   1
M  END
> <s_m_entry_id>
193

> <Applicants>
Pfizer

> <CHEMBL_ID>
CHEMBL592445

> <Canonical_Smiles>
O1CCN(CC1)c1nc(nc(n1)N1CCOCC1)-c1ccc(NC(=O)Nc2ccc(cc2)C(=O)N2CCC(N(C)C)CC2)cc1

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
GEDATOLISIB | PF-05212384 | PKI-587

> <Indications>
nan

> <Type>
nan

> <targets_id>
P42336|P42338|P48736|O00329|P42345

> <inchi>
InChI=1S/C32H41N9O4/c1-38(2)27-11-13-39(14-12-27)29(42)24-5-9-26(10-6-24)34-32(43)33-25-7-3-23(4-8-25)28-35-30(40-15-19-44-20-16-40)37-31(36-28)41-17-21-45-22-18-41/h3-10,27H,11-22H2,1-2H3,(H2,33,34,43)

> <stdInchikey>
DWZAEMINVBZMHQ-UHFFFAOYSA-N

> <csid>
24644946

> <Links>
|http://www.chemspider.com/Chemical-Structure.24644946.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL592445|http://pubchem.ncbi.nlm.nih.gov/compound/44516953|http://www.drugbank.ca/drugs/DB11896|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7940|http://zinc15.docking.org/substances/ZINC000049757175|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=96265TNH2R|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50308135

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
615.3

> <HBA>
10

> <HBD>
2

> <NRB>
7

> <TPSA>
128.3

> <LogP>
3

> <RoF>
1

> <Targets>
PIK3CA; PIK3CB; PIK3CG; PIK3CD; MTOR

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0014

> <r_epik_State_Penalty>
  0.0009

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
193

> <Kinase families>
Atypical

> <Withdrawn>
|Study NCT03400254 in United States was Withdrawn during Phase 1/Phase 2 because due to business decision regarding the study drug

$$$$
Bentamapimod
                    3D
 Structure written by MMmdl.
 56 60  0  0  1  0            999 V2000
   -2.2791   -3.8713    1.8044 N   0  0  0  0  0  0
   -2.5951   -3.0737    1.0273 C   0  0  0  0  0  0
   -2.9995   -2.0572    0.0379 C   0  0  2  0  0  0
   -3.1416   -2.6602   -1.3495 C   0  0  0  0  0  0
   -2.2011   -3.3744   -1.9124 N   0  0  0  0  0  0
   -2.5453   -3.7891   -3.1594 C   0  0  0  0  0  0
   -1.7382   -4.5720   -4.0000 C   0  0  0  0  0  0
   -2.2324   -4.9184   -5.2591 C   0  0  0  0  0  0
   -3.4952   -4.5030   -5.6824 C   0  0  0  0  0  0
   -4.3143   -3.7245   -4.8639 C   0  0  0  0  0  0
   -3.8279   -3.3710   -3.5976 C   0  0  0  0  0  0
   -4.5755   -2.4156   -2.3281 S   0  0  0  0  0  0
   -2.0625   -0.8537    0.0580 C   0  0  0  0  0  0
   -0.7302   -1.1032   -0.0718 N   0  0  0  0  0  0
    0.0971   -0.0183   -0.0638 C   0  0  0  0  0  0
    1.4625   -0.1900   -0.1912 O   0  0  0  0  0  0
    1.9952   -1.5108   -0.2969 C   0  0  0  0  0  0
    3.5106   -1.4345   -0.3823 C   0  0  0  0  0  0
    4.2409   -0.9554    0.7077 C   0  0  0  0  0  0
    5.6297   -0.8883    0.6396 C   0  0  0  0  0  0
    6.2918   -1.3019   -0.5187 C   0  0  0  0  0  0
    5.5617   -1.7829   -1.6084 C   0  0  0  0  0  0
    4.1724   -1.8468   -1.5415 C   0  0  0  0  0  0
    7.8131   -1.2375   -0.5891 C   0  0  0  0  0  0
    8.2983   -0.1781   -1.4796 N   0  0  0  0  0  0
    9.7364   -0.3457   -1.7166 C   0  0  0  0  0  0
   10.2687    0.7606   -2.6531 C   0  0  0  0  0  0
    9.9634    2.0538   -2.1387 O   0  0  0  0  0  0
    8.5754    2.2515   -1.8840 C   0  0  0  0  0  0
    8.0262    1.1607   -0.9390 C   0  0  0  0  0  0
   -0.2988    1.2740    0.0635 N   0  0  0  0  0  0
   -1.6342    1.4860    0.1941 C   0  0  0  0  0  0
   -2.5644    0.4445    0.1969 C   0  0  0  0  0  0
   -3.9796   -1.7215    0.3787 H   0  0  0  0  0  0
   -0.7580   -4.9012   -3.6864 H   0  0  0  0  0  0
   -1.6250   -5.5204   -5.9193 H   0  0  0  0  0  0
   -3.8456   -4.7899   -6.6631 H   0  0  0  0  0  0
   -5.2908   -3.4066   -5.1990 H   0  0  0  0  0  0
    1.7236   -2.1039    0.5787 H   0  0  0  0  0  0
    1.5877   -2.0160   -1.1754 H   0  0  0  0  0  0
    3.7330   -0.6341    1.6057 H   0  0  0  0  0  0
    6.1877   -0.5150    1.4860 H   0  0  0  0  0  0
    6.0699   -2.1039   -2.5064 H   0  0  0  0  0  0
    3.6155   -2.2186   -2.3893 H   0  0  0  0  0  0
    8.2367   -1.1213    0.4108 H   0  0  0  0  0  0
    8.1616   -2.2057   -0.9536 H   0  0  0  0  0  0
   10.2886   -0.3303   -0.7749 H   0  0  0  0  0  0
    9.9228   -1.3194   -2.1722 H   0  0  0  0  0  0
   11.3504    0.6720   -2.7540 H   0  0  0  0  0  0
    9.8598    0.6465   -3.6588 H   0  0  0  0  0  0
    8.4395    3.2349   -1.4338 H   0  0  0  0  0  0
    8.0168    2.2675   -2.8216 H   0  0  0  0  0  0
    6.9515    1.3043   -0.8223 H   0  0  0  0  0  0
    8.4658    1.2739    0.0539 H   0  0  0  0  0  0
   -1.9531    2.5129    0.2966 H   0  0  0  0  0  0
   -3.6219    0.6377    0.2984 H   0  0  0  0  0  0
  1  2  3  0  0  0
  2  3  1  0  0  0
  3  4  1  0  0  0
  3 13  1  0  0  0
  3 34  1  0  0  0
  4  5  2  0  0  0
  4 12  1  0  0  0
  5  6  1  0  0  0
  6  7  1  0  0  0
  6 11  2  0  0  0
  7  8  2  0  0  0
  7 35  1  0  0  0
  8  9  1  0  0  0
  8 36  1  0  0  0
  9 10  2  0  0  0
  9 37  1  0  0  0
 10 11  1  0  0  0
 10 38  1  0  0  0
 11 12  1  0  0  0
 13 14  1  0  0  0
 13 33  2  0  0  0
 14 15  2  0  0  0
 15 16  1  0  0  0
 15 31  1  0  0  0
 16 17  1  0  0  0
 17 18  1  0  0  0
 17 39  1  0  0  0
 17 40  1  0  0  0
 18 19  1  0  0  0
 18 23  2  0  0  0
 19 20  2  0  0  0
 19 41  1  0  0  0
 20 21  1  0  0  0
 20 42  1  0  0  0
 21 22  2  0  0  0
 21 24  1  0  0  0
 22 23  1  0  0  0
 22 43  1  0  0  0
 23 44  1  0  0  0
 24 25  1  0  0  0
 24 45  1  0  0  0
 24 46  1  0  0  0
 25 26  1  0  0  0
 25 30  1  0  0  0
 26 27  1  0  0  0
 26 47  1  0  0  0
 26 48  1  0  0  0
 27 28  1  0  0  0
 27 49  1  0  0  0
 27 50  1  0  0  0
 28 29  1  0  0  0
 29 30  1  0  0  0
 29 51  1  0  0  0
 29 52  1  0  0  0
 30 53  1  0  0  0
 30 54  1  0  0  0
 31 32  2  0  0  0
 32 33  1  0  0  0
 32 55  1  0  0  0
 33 56  1  0  0  0
M  END
> <s_m_entry_id>
194

> <Applicants>
PregLem

> <CHEMBL_ID>
CHEMBL3545213

> <Canonical_Smiles>
s1c2c(nc1C(C#N)c1nc(OCc3ccc(cc3)CN3CCOCC3)ncc1)cccc2

> <Chirality>
Racemic Mixture

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
AS-602801 | BENTAMAPIMOD | PGL-5001

> <Indications>
nan

> <Type>
nan

> <targets_id>
P45983|P45984

> <inchi>
InChI=1S/C25H23N5O2S/c26-15-20(24-28-22-3-1-2-4-23(22)33-24)21-9-10-27-25(29-21)32-17-19-7-5-18(6-8-19)16-30-11-13-31-14-12-30/h1-10,20H,11-14,16-17H2

> <stdInchikey>
XCPPIJCBCWUBNT-UHFFFAOYSA-N

> <csid>
8370750

> <Links>
|http://www.chemspider.com/Chemical-Structure.8370750.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3545213|http://pubchem.ncbi.nlm.nih.gov/compound/10195250|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9926

> <LinkName>
|ChemSpider|ChEMBL|PubChem|Guide to Pharmacology

> <indicationG2P>
None

> <MW>
457.2

> <HBA>
8

> <HBD>
0

> <NRB>
7

> <TPSA>
84.2

> <LogP>
4.2

> <RoF>
0

> <Targets>
MAPK8; MAPK9

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.2846

> <r_epik_State_Penalty>
  0.2773

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
194

> <Kinase families>
CMGC

$$$$
Tanzisertib
                    3D
 Structure written by MMmdl.
 55 59  0  0  1  0            999 V2000
   -8.3079    0.8431   -1.6130 C   0  0  0  0  0  0
   -7.3894    1.1618   -0.6122 C   0  0  0  0  0  0
   -6.3360    2.0481   -0.8797 C   0  0  0  0  0  0
   -6.2212    2.6164   -2.1564 C   0  0  0  0  0  0
   -7.1437    2.2935   -3.1525 C   0  0  0  0  0  0
   -8.1851    1.4073   -2.8819 C   0  0  0  0  0  0
   -9.0768    1.0964   -3.8493 F   0  0  0  0  0  0
   -5.2200    3.4820   -2.4413 F   0  0  0  0  0  0
   -5.4125    2.3680    0.1265 N   0  0  0  0  0  0
   -4.2245    1.6896    0.2518 C   0  0  0  0  0  0
   -2.9894    2.3235    0.1503 N   0  0  0  0  0  0
   -2.0543    1.3145    0.3123 C   0  0  0  0  0  0
   -0.7176    1.3777    0.3089 N   0  0  0  0  0  0
   -0.1000    0.1713    0.4814 C   0  0  0  0  0  0
   -0.7168   -1.0304    0.6492 N   0  0  0  0  0  0
   -2.0765   -1.0496    0.6542 C   0  0  0  0  0  0
   -2.8068    0.1345    0.4843 C   0  0  0  0  0  0
   -4.1468    0.3917    0.4456 N   0  0  0  0  0  0
    1.3029    0.1215    0.4952 N   0  0  0  0  0  0
    2.1396    1.2942    0.2350 C   0  0  1  0  0  0
    3.5324    1.0677    0.8615 C   0  0  0  0  0  0
    4.4809    2.2447    0.5557 C   0  0  0  0  0  0
    4.5838    2.5256   -0.9602 C   0  0  1  0  0  0
    3.1915    2.7160   -1.6022 C   0  0  0  0  0  0
    2.2466    1.5381   -1.2894 C   0  0  0  0  0  0
    5.4109    3.6436   -1.2094 O   0  0  0  0  0  0
   -2.7225    3.7547   -0.0935 C   0  0  2  0  0  0
   -2.0011    4.0097   -1.4280 C   0  0  0  0  0  0
   -1.1249    5.0873   -1.1139 O   0  0  0  0  0  0
   -0.5733    4.8106    0.1667 C   0  0  0  0  0  0
   -1.8161    4.4006    0.9549 C   0  0  0  0  0  0
   -7.5300    0.6049    0.6146 F   0  0  0  0  0  0
   -9.1166    0.1581   -1.4045 H   0  0  0  0  0  0
   -7.0522    2.7311   -4.1358 H   0  0  0  0  0  0
   -5.8374    2.7949    0.9370 H   0  0  0  0  0  0
   -2.5627   -2.0044    0.7899 H   0  0  0  0  0  0
    1.7450   -0.7857    0.5126 H   0  0  0  0  0  0
    1.6815    2.1659    0.7053 H   0  0  0  0  0  0
    3.4458    0.9436    1.9421 H   0  0  0  0  0  0
    3.9736    0.1453    0.4780 H   0  0  0  0  0  0
    4.1178    3.1362    1.0704 H   0  0  0  0  0  0
    5.4693    2.0359    0.9676 H   0  0  0  0  0  0
    5.0758    1.6775   -1.4396 H   0  0  0  0  0  0
    2.7398    3.6400   -1.2363 H   0  0  0  0  0  0
    3.2884    2.8311   -2.6829 H   0  0  0  0  0  0
    2.6163    0.6406   -1.7890 H   0  0  0  0  0  0
    1.2631    1.7448   -1.7143 H   0  0  0  0  0  0
    5.0129    4.4148   -0.7989 H   0  0  0  0  0  0
   -3.6939    4.2499   -0.0854 H   0  0  0  0  0  0
   -1.4173    3.1539   -1.7733 H   0  0  0  0  0  0
   -2.6888    4.2892   -2.2261 H   0  0  0  0  0  0
    0.1591    4.0042    0.0994 H   0  0  0  0  0  0
   -0.0787    5.6846    0.5907 H   0  0  0  0  0  0
   -2.3018    5.2869    1.3663 H   0  0  0  0  0  0
   -1.5702    3.7520    1.7970 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1  6  2  0  0  0
  1 33  1  0  0  0
  2  3  2  0  0  0
  2 32  1  0  0  0
  3  4  1  0  0  0
  3  9  1  0  0  0
  4  5  2  0  0  0
  4  8  1  0  0  0
  5  6  1  0  0  0
  5 34  1  0  0  0
  6  7  1  0  0  0
  9 10  1  0  0  0
  9 35  1  0  0  0
 10 11  1  0  0  0
 10 18  2  0  0  0
 11 12  1  0  0  0
 11 27  1  0  0  0
 12 13  2  0  0  0
 12 17  1  0  0  0
 13 14  1  0  0  0
 14 15  2  0  0  0
 14 19  1  0  0  0
 15 16  1  0  0  0
 16 17  2  0  0  0
 16 36  1  0  0  0
 17 18  1  0  0  0
 19 20  1  0  0  0
 19 37  1  0  0  0
 20 21  1  0  0  0
 20 25  1  0  0  0
 20 38  1  0  0  0
 21 22  1  0  0  0
 21 39  1  0  0  0
 21 40  1  0  0  0
 22 23  1  0  0  0
 22 41  1  0  0  0
 22 42  1  0  0  0
 23 24  1  0  0  0
 23 26  1  0  0  0
 23 43  1  0  0  0
 24 25  1  0  0  0
 24 44  1  0  0  0
 24 45  1  0  0  0
 25 46  1  0  0  0
 25 47  1  0  0  0
 26 48  1  0  0  0
 27 28  1  0  0  0
 27 31  1  0  0  0
 27 49  1  0  0  0
 28 29  1  0  0  0
 28 50  1  0  0  0
 28 51  1  0  0  0
 29 30  1  0  0  0
 30 31  1  0  0  0
 30 52  1  0  0  0
 30 53  1  0  0  0
 31 54  1  0  0  0
 31 55  1  0  0  0
M  END
> <s_m_entry_id>
198

> <Applicants>
Celgene

> <CHEMBL_ID>
CHEMBL1950289

> <Canonical_Smiles>
Fc1cc(F)cc(F)c1Nc1nc2c(nc(nc2)NC2CCC(O)CC2)n1[C@H]1CCOC1

> <Chirality>
Single Stereoisomer

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
CC-930 | JNK 930 | JNK-930 | TANZISERTIB

> <Indications>
nan

> <Type>
1

> <targets_id>
P45983

> <inchi>
InChI=1S/C21H23F3N6O2/c22-11-7-15(23)18(16(24)8-11)28-21-27-17-9-25-20(26-12-1-3-14(31)4-2-12)29-19(17)30(21)13-5-6-32-10-13/h7-9,12-14,31H,1-6,10H2,(H,27,28)(H,25,26,29)/t12-,13-,14-/m0/s1

> <stdInchikey>
IBGLGMOPHJQDJB-IHRRRGAJSA-N

> <csid>
28492361

> <Links>
|http://www.chemspider.com/Chemical-Structure.28492361.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1950289|http://www.drugbank.ca/drugs/DB11798| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=KBI|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/KBI|http://zinc15.docking.org/substances/ZINC000102930548|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=M5O06306UO|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50364378

> <LinkName>
|ChemSpider|ChEMBL|DrugBank|RCSB|PDBe|ZINC|FDA SRS|BindingDB

> <MW>
448.2

> <HBA>
8

> <HBD>
3

> <NRB>
5

> <TPSA>
97.1

> <LogP>
3.7

> <RoF>
0

> <Targets>
MAPK8

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_epik_Ionization_Penalty>
  0.0058

> <r_epik_State_Penalty>
  0.0041

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
198

> <lig_pdbID>
'KBI'

> <pdbID>
3tti

> <Kinase families>
CMGC

$$$$
Branebrutinib
                    3D
 Structure written by MMmdl.
 50 52  0  0  1  0            999 V2000
   -4.5802    7.3773   -0.3221 C   0  0  0  0  0  0
   -4.1562    6.0124    0.0213 C   0  0  0  0  0  0
   -3.7948    4.8800    0.3028 C   0  0  0  0  0  0
   -3.4570    3.5196    0.6809 C   0  0  0  0  0  0
   -4.0852    2.8833    1.5267 O   0  0  0  0  0  0
   -2.3908    3.0677   -0.0008 N   0  0  0  0  0  0
   -1.8022    1.7332    0.1303 C   0  0  1  0  0  0
   -2.6516    0.6065   -0.4970 C   0  0  0  0  0  0
   -1.9445   -0.7513   -0.3693 C   0  0  0  0  0  0
   -0.4751   -0.6875   -0.8420 C   0  0  0  0  0  0
    0.2825    0.3705   -0.1553 N   0  0  0  0  0  0
   -0.3589    1.6695   -0.4222 C   0  0  0  0  0  0
    1.6684    0.2554   -0.1262 C   0  0  0  0  0  0
    2.4882    0.8318   -1.1092 C   0  0  0  0  0  0
    3.8669    0.6629   -1.0955 C   0  0  0  0  0  0
    4.5283   -0.0994   -0.1253 C   0  0  0  0  0  0
    3.7036   -0.7026    0.8435 C   0  0  0  0  0  0
    2.2796   -0.5485    0.8683 C   0  0  0  0  0  0
    1.7912   -1.2995    2.0102 C   0  0  0  0  0  0
    2.8996   -1.8767    2.6125 C   0  0  0  0  0  0
    4.0172   -1.5122    1.9128 N   0  0  0  0  0  0
    3.0425   -2.7700    3.8246 C   0  0  0  0  0  0
    0.3517   -1.4327    2.4604 C   0  0  0  0  0  0
    6.0331   -0.2740   -0.1394 C   0  0  0  0  0  0
    6.5828   -1.1776    0.4884 O   0  0  0  0  0  0
    6.7457    0.6155   -0.8399 N   0  0  0  0  0  0
    1.9546    1.5596   -2.1188 F   0  0  0  0  0  0
   -5.6222    7.5230   -0.0376 H   0  0  0  0  0  0
   -4.4771    7.5366   -1.3954 H   0  0  0  0  0  0
   -3.9604    8.1006    0.2080 H   0  0  0  0  0  0
   -1.9620    3.6803   -0.6790 H   0  0  0  0  0  0
   -1.7344    1.5453    1.2055 H   0  0  0  0  0  0
   -3.6362    0.5564   -0.0304 H   0  0  0  0  0  0
   -2.8249    0.8258   -1.5519 H   0  0  0  0  0  0
   -1.9829   -1.0756    0.6707 H   0  0  0  0  0  0
   -2.4855   -1.5074   -0.9389 H   0  0  0  0  0  0
   -0.0051   -1.6554   -0.6611 H   0  0  0  0  0  0
   -0.4348   -0.5162   -1.9193 H   0  0  0  0  0  0
   -0.3657    1.8763   -1.4936 H   0  0  0  0  0  0
    0.2346    2.4560    0.0474 H   0  0  0  0  0  0
    4.4301    1.1373   -1.8866 H   0  0  0  0  0  0
    4.9403   -1.8233    2.1809 H   0  0  0  0  0  0
    2.0853   -2.9977    4.2922 H   0  0  0  0  0  0
    3.6672   -2.3100    4.5906 H   0  0  0  0  0  0
    3.5017   -3.7247    3.5666 H   0  0  0  0  0  0
    0.2598   -1.8654    3.4560 H   0  0  0  0  0  0
   -0.2133   -2.0771    1.7886 H   0  0  0  0  0  0
   -0.1537   -0.4675    2.4960 H   0  0  0  0  0  0
    6.2841    1.3591   -1.3424 H   0  0  0  0  0  0
    7.7529    0.5487   -0.8652 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 28  1  0  0  0
  1 29  1  0  0  0
  1 30  1  0  0  0
  2  3  3  0  0  0
  3  4  1  0  0  0
  4  5  2  0  0  0
  4  6  1  0  0  0
  6  7  1  0  0  0
  6 31  1  0  0  0
  7  8  1  0  0  0
  7 12  1  0  0  0
  7 32  1  0  0  0
  8  9  1  0  0  0
  8 33  1  0  0  0
  8 34  1  0  0  0
  9 10  1  0  0  0
  9 35  1  0  0  0
  9 36  1  0  0  0
 10 11  1  0  0  0
 10 37  1  0  0  0
 10 38  1  0  0  0
 11 12  1  0  0  0
 11 13  1  0  0  0
 12 39  1  0  0  0
 12 40  1  0  0  0
 13 14  2  0  0  0
 13 18  1  0  0  0
 14 15  1  0  0  0
 14 27  1  0  0  0
 15 16  2  0  0  0
 15 41  1  0  0  0
 16 17  1  0  0  0
 16 24  1  0  0  0
 17 18  2  0  0  0
 17 21  1  0  0  0
 18 19  1  0  0  0
 19 20  2  0  0  0
 19 23  1  0  0  0
 20 21  1  0  0  0
 20 22  1  0  0  0
 21 42  1  0  0  0
 22 43  1  0  0  0
 22 44  1  0  0  0
 22 45  1  0  0  0
 23 46  1  0  0  0
 23 47  1  0  0  0
 23 48  1  0  0  0
 24 25  2  0  0  0
 24 26  1  0  0  0
 26 49  1  0  0  0
 26 50  1  0  0  0
M  END
> <s_m_entry_id>
200

> <Applicants>
Bristol Myers Squibb

> <CHEMBL_ID>
CHEMBL4297674

> <Canonical_Smiles>
Fc1cc(c2[nH]c(C)c(c2c1N1C[C@@H](NC(=O)C#CC)CCC1)C)C(=O)N

> <Chirality>
Single Stereoisomer

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
BMS-986195 | BRANEBRUTINIB

> <Indications>
nan

> <Type>
nan

> <targets_id>
nan

> <inchi>
InChI=1S/C20H23FN4O2/c1-4-6-16(26)24-13-7-5-8-25(10-13)19-15(21)9-14(20(22)27)18-17(19)11(2)12(3)23-18/h9,13,23H,5,7-8,10H2,1-3H3,(H2,22,27)(H,24,26)/t13-/m0/s1

> <stdInchikey>
VJPPLCNBDLZIFG-ZDUSSCGKSA-N

> <csid>
64835069

> <Links>
|http://www.chemspider.com/Chemical-Structure.64835069.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4297674|http://pubchem.ncbi.nlm.nih.gov/compound/121293929|http://www.drugbank.ca/drugs/DB15347|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9869|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=7LBRZUYSHU|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=164638

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
370.2

> <HBA>
3

> <HBD>
3

> <NRB>
3

> <TPSA>
91.2

> <LogP>
2.1

> <RoF>
0

> <Targets>
nan

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0000

> <r_epik_State_Penalty>
  0.0000

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
200

$$$$
Defactinib
                    3D
 Structure written by MMmdl.
 56 58  0  0  1  0            999 V2000
    1.2607    7.0903    5.1502 C   0  0  0  0  0  0
    0.5019    6.1008    4.3942 N   0  0  0  0  0  0
   -0.8038    6.1917    4.0778 C   0  0  0  0  0  0
   -1.5166    7.1458    4.3953 O   0  0  0  0  0  0
   -1.3601    5.0568    3.2504 C   0  0  0  0  0  0
   -2.4213    5.2908    2.3659 C   0  0  0  0  0  0
   -2.9245    4.2589    1.5760 C   0  0  0  0  0  0
   -2.3665    2.9825    1.6500 C   0  0  0  0  0  0
   -1.3360    2.7343    2.5641 C   0  0  0  0  0  0
   -0.8355    3.7616    3.3557 C   0  0  0  0  0  0
   -2.8647    1.9780    0.7996 N   0  0  0  0  0  0
   -2.1768    0.9532    0.1309 C   0  0  0  0  0  0
   -2.9172    0.1323   -0.6517 N   0  0  0  0  0  0
   -2.2468   -0.8495   -1.3090 C   0  0  0  0  0  0
   -0.8579   -1.0265   -1.2134 C   0  0  0  0  0  0
   -0.1682   -0.1163   -0.3895 C   0  0  0  0  0  0
   -0.8331    0.8650    0.2755 N   0  0  0  0  0  0
    1.2281   -0.2008   -0.2176 N   0  0  0  0  0  0
    1.9559    0.9194    0.3846 C   0  0  0  0  0  0
    3.4068    0.5860    0.7286 C   0  0  0  0  0  0
    3.9947    0.9578    1.9549 C   0  0  0  0  0  0
    5.3102    0.6911    2.2011 N   0  0  0  0  0  0
    6.0297    0.0819    1.2241 C   0  0  0  0  0  0
    5.4480   -0.2683    0.0055 C   0  0  0  0  0  0
    4.1396   -0.0144   -0.2526 N   0  0  0  0  0  0
    3.2334    1.5646    2.9711 N   0  0  0  0  0  0
    3.0452    0.7082    4.1384 C   0  0  0  0  0  0
    3.5169    3.2860    3.3479 S   0  0  0  0  0  0
    2.6566    3.6383    4.4833 O   0  0  0  0  0  0
    4.9668    3.4964    3.4211 O   0  0  0  0  0  0
    2.8390    4.1511    1.8146 C   0  0  0  0  0  0
   -0.1509   -2.1493   -1.9769 C   0  0  0  0  0  0
    0.7636   -1.6320   -2.7979 F   0  0  0  0  0  0
    0.4565   -2.9670   -1.1166 F   0  0  0  0  0  0
   -0.9979   -2.8754   -2.7089 F   0  0  0  0  0  0
    1.6966    6.6217    6.0325 H   0  0  0  0  0  0
    0.6550    7.9349    5.4806 H   0  0  0  0  0  0
    2.0747    7.4764    4.5367 H   0  0  0  0  0  0
    1.0071    5.2715    4.1172 H   0  0  0  0  0  0
   -2.8558    6.2763    2.2723 H   0  0  0  0  0  0
   -3.7320    4.4654    0.8880 H   0  0  0  0  0  0
   -0.9130    1.7469    2.6740 H   0  0  0  0  0  0
   -0.0360    3.5360    4.0467 H   0  0  0  0  0  0
   -3.7908    2.1448    0.4352 H   0  0  0  0  0  0
   -2.8560   -1.4977   -1.9220 H   0  0  0  0  0  0
    1.7324   -0.7647   -0.8867 H   0  0  0  0  0  0
    1.9467    1.7638   -0.3058 H   0  0  0  0  0  0
    1.4298    1.2513    1.2794 H   0  0  0  0  0  0
    7.0705   -0.1200    1.4293 H   0  0  0  0  0  0
    6.0213   -0.7504   -0.7725 H   0  0  0  0  0  0
    3.9817    0.5822    4.6833 H   0  0  0  0  0  0
    2.6856   -0.2787    3.8434 H   0  0  0  0  0  0
    2.3090    1.1334    4.8205 H   0  0  0  0  0  0
    2.9392    5.2281    1.9459 H   0  0  0  0  0  0
    1.7883    3.8887    1.6941 H   0  0  0  0  0  0
    3.4078    3.8277    0.9432 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 36  1  0  0  0
  1 37  1  0  0  0
  1 38  1  0  0  0
  2  3  1  0  0  0
  2 39  1  0  0  0
  3  4  2  0  0  0
  3  5  1  0  0  0
  5  6  1  0  0  0
  5 10  2  0  0  0
  6  7  2  0  0  0
  6 40  1  0  0  0
  7  8  1  0  0  0
  7 41  1  0  0  0
  8  9  2  0  0  0
  8 11  1  0  0  0
  9 10  1  0  0  0
  9 42  1  0  0  0
 10 43  1  0  0  0
 11 12  1  0  0  0
 11 44  1  0  0  0
 12 13  1  0  0  0
 12 17  2  0  0  0
 13 14  2  0  0  0
 14 15  1  0  0  0
 14 45  1  0  0  0
 15 16  2  0  0  0
 15 32  1  0  0  0
 16 17  1  0  0  0
 16 18  1  0  0  0
 18 19  1  0  0  0
 18 46  1  0  0  0
 19 20  1  0  0  0
 19 47  1  0  0  0
 19 48  1  0  0  0
 20 21  1  0  0  0
 20 25  2  0  0  0
 21 22  2  0  0  0
 21 26  1  0  0  0
 22 23  1  0  0  0
 23 24  2  0  0  0
 23 49  1  0  0  0
 24 25  1  0  0  0
 24 50  1  0  0  0
 26 27  1  0  0  0
 26 28  1  0  0  0
 27 51  1  0  0  0
 27 52  1  0  0  0
 27 53  1  0  0  0
 28 29  2  0  0  0
 28 30  2  0  0  0
 28 31  1  0  0  0
 31 54  1  0  0  0
 31 55  1  0  0  0
 31 56  1  0  0  0
 32 33  1  0  0  0
 32 34  1  0  0  0
 32 35  1  0  0  0
M  END
> <s_m_entry_id>
201

> <Applicants>
Verastem

> <CHEMBL_ID>
CHEMBL3137331

> <Canonical_Smiles>
S(=O)(=O)(N(C)c1nccnc1CNc1nc(ncc1C(F)(F)F)Nc1ccc(cc1)C(=O)NC)C

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
DEFACTINIB | PF-04554878 | VS-6063

> <Indications>
nan

> <Type>
1

> <targets_id>
Q05397|Q14289

> <inchi>
InChI=1S/C20H21F3N8O3S/c1-24-18(32)12-4-6-13(7-5-12)29-19-28-10-14(20(21,22)23)16(30-19)27-11-15-17(26-9-8-25-15)31(2)35(3,33)34/h4-10H,11H2,1-3H3,(H,24,32)(H2,27,28,29,30)

> <stdInchikey>
FWLMVFUGMHIOAA-UHFFFAOYSA-N

> <csid>
32695161

> <Links>
|http://www.chemspider.com/Chemical-Structure.32695161.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3137331|http://pubchem.ncbi.nlm.nih.gov/compound/25117126|http://www.drugbank.ca/drugs/DB12282| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=7KD|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/7KD|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7910|http://zinc15.docking.org/substances/ZINC000103297739|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=53O87HA2QU|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=418817

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
510.1

> <HBA>
9

> <HBD>
3

> <NRB>
8

> <TPSA>
142.1

> <LogP>
2.4

> <RoF>
1

> <Targets>
PTK2; PTK2B

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0006

> <r_epik_State_Penalty>
  0.0000

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
201

> <lig_pdbID>
'7KD'

> <pdbID>
5mah

> <Kinase families>
Tyr

$$$$
Derazantinib
                    3D
 Structure written by MMmdl.
 65 69  0  0  1  0            999 V2000
   -4.1291   -1.0637    0.2399 C   0  0  0  0  0  0
   -2.8643   -0.5215    0.5888 O   0  0  0  0  0  0
   -2.5360    0.6634   -0.1263 C   0  0  0  0  0  0
   -1.1840    1.2042    0.3619 C   0  0  0  0  0  0
   -0.1025    0.1299    0.1701 N   0  3  0  0  0  0
    1.2896    0.5362    0.6831 C   0  0  0  0  0  0
    2.2530   -0.6625    0.5894 C   0  0  0  0  0  0
    1.8676   -1.8099    1.5150 C   0  0  0  0  0  0
    2.3805   -1.8744    2.8129 C   0  0  0  0  0  0
    2.0057   -2.9148    3.6613 C   0  0  0  0  0  0
    1.1060   -3.8856    3.2212 C   0  0  0  0  0  0
    0.5703   -3.8282    1.9308 C   0  0  0  0  0  0
    0.9768   -2.7944    1.0757 C   0  0  0  0  0  0
   -0.3479   -4.8258    1.5584 N   0  0  0  0  0  0
   -1.3702   -4.8735    0.5981 C   0  0  0  0  0  0
   -1.5809   -3.8242   -0.2382 N   0  0  0  0  0  0
   -2.5961   -3.9476   -1.1282 C   0  0  0  0  0  0
   -3.4191   -5.0753   -1.1962 C   0  0  0  0  0  0
   -3.1331   -6.1108   -0.2891 C   0  0  0  0  0  0
   -2.1089   -6.0100    0.6058 N   0  0  0  0  0  0
   -3.9619   -7.3601   -0.3078 C   0  0  0  0  0  0
   -3.5049   -8.5409    0.2991 C   0  0  0  0  0  0
   -4.2767   -9.6982    0.2867 C   0  0  0  0  0  0
   -5.5203   -9.6911   -0.3321 C   0  0  0  0  0  0
   -5.9858   -8.5277   -0.9381 C   0  0  0  0  0  0
   -5.2238   -7.3475   -0.9479 C   0  0  0  0  0  0
   -5.7239   -6.0414   -1.5993 C   0  0  1  0  0  0
   -4.5548   -5.2171   -2.1963 C   0  0  0  0  0  0
   -6.8663   -6.2069   -2.6134 C   0  0  0  0  0  0
   -8.0971   -5.5773   -2.3848 C   0  0  0  0  0  0
   -9.1429   -5.7106   -3.2981 C   0  0  0  0  0  0
   -8.9679   -6.4713   -4.4529 C   0  0  0  0  0  0
   -7.7465   -7.0985   -4.6940 C   0  0  0  0  0  0
   -6.6986   -6.9682   -3.7819 C   0  0  0  0  0  0
   -5.5244   -7.5910   -4.0360 F   0  0  0  0  0  0
   -4.2963   -1.9846    0.7987 H   0  0  0  0  0  0
   -4.1824   -1.3047   -0.8229 H   0  0  0  0  0  0
   -4.9381   -0.3734    0.4825 H   0  0  0  0  0  0
   -2.4858    0.4462   -1.1952 H   0  0  0  0  0  0
   -3.3068    1.4224    0.0199 H   0  0  0  0  0  0
   -0.8470    2.0753   -0.2017 H   0  0  0  0  0  0
   -1.1907    1.4214    1.4312 H   0  0  0  0  0  0
   -0.3951   -0.7020    0.6645 H   0  0  0  0  0  0
    1.5968    1.3725    0.0535 H   0  0  0  0  0  0
    1.1473    0.8751    1.7108 H   0  0  0  0  0  0
    2.3074   -1.0273   -0.4380 H   0  0  0  0  0  0
    3.2661   -0.3358    0.8298 H   0  0  0  0  0  0
    3.0684   -1.1203    3.1671 H   0  0  0  0  0  0
    2.4064   -2.9653    4.6631 H   0  0  0  0  0  0
    0.8190   -4.6792    3.8966 H   0  0  0  0  0  0
    0.6127   -2.7371    0.0624 H   0  0  0  0  0  0
   -0.3938   -5.5973    2.2074 H   0  0  0  0  0  0
   -2.7466   -3.1136   -1.7977 H   0  0  0  0  0  0
   -2.5412   -8.5718    0.7862 H   0  0  0  0  0  0
   -3.9110  -10.5982    0.7586 H   0  0  0  0  0  0
   -6.1260  -10.5853   -0.3404 H   0  0  0  0  0  0
   -6.9612   -8.5519   -1.4006 H   0  0  0  0  0  0
   -6.1360   -5.4564   -0.7742 H   0  0  0  0  0  0
   -4.9175   -4.2319   -2.4938 H   0  0  0  0  0  0
   -4.1620   -5.6907   -3.0965 H   0  0  0  0  0  0
   -8.2504   -4.9824   -1.4962 H   0  0  0  0  0  0
  -10.0886   -5.2235   -3.1106 H   0  0  0  0  0  0
   -9.7775   -6.5747   -5.1605 H   0  0  0  0  0  0
   -7.6116   -7.6878   -5.5890 H   0  0  0  0  0  0
   -0.0371   -0.1028   -0.8108 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 36  1  0  0  0
  1 37  1  0  0  0
  1 38  1  0  0  0
  2  3  1  0  0  0
  3  4  1  0  0  0
  3 39  1  0  0  0
  3 40  1  0  0  0
  4  5  1  0  0  0
  4 41  1  0  0  0
  4 42  1  0  0  0
  5  6  1  0  0  0
  5 43  1  0  0  0
  5 65  1  0  0  0
  6  7  1  0  0  0
  6 44  1  0  0  0
  6 45  1  0  0  0
  7  8  1  0  0  0
  7 46  1  0  0  0
  7 47  1  0  0  0
  8  9  1  0  0  0
  8 13  2  0  0  0
  9 10  2  0  0  0
  9 48  1  0  0  0
 10 11  1  0  0  0
 10 49  1  0  0  0
 11 12  2  0  0  0
 11 50  1  0  0  0
 12 13  1  0  0  0
 12 14  1  0  0  0
 13 51  1  0  0  0
 14 15  1  0  0  0
 14 52  1  0  0  0
 15 16  1  0  0  0
 15 20  2  0  0  0
 16 17  2  0  0  0
 17 18  1  0  0  0
 17 53  1  0  0  0
 18 19  2  0  0  0
 18 28  1  0  0  0
 19 20  1  0  0  0
 19 21  1  0  0  0
 21 22  1  0  0  0
 21 26  2  0  0  0
 22 23  2  0  0  0
 22 54  1  0  0  0
 23 24  1  0  0  0
 23 55  1  0  0  0
 24 25  2  0  0  0
 24 56  1  0  0  0
 25 26  1  0  0  0
 25 57  1  0  0  0
 26 27  1  0  0  0
 27 28  1  0  0  0
 27 29  1  0  0  0
 27 58  1  0  0  0
 28 59  1  0  0  0
 28 60  1  0  0  0
 29 30  1  0  0  0
 29 34  2  0  0  0
 30 31  2  0  0  0
 30 61  1  0  0  0
 31 32  1  0  0  0
 31 62  1  0  0  0
 32 33  2  0  0  0
 32 63  1  0  0  0
 33 34  1  0  0  0
 33 64  1  0  0  0
 34 35  1  0  0  0
M  CHG  1   5   1
M  END
> <s_m_entry_id>
202

> <Applicants>
ArQule

> <CHEMBL_ID>
CHEMBL4297187

> <Canonical_Smiles>
Fc1ccccc1[C@@H]1Cc2c(nc(nc2)Nc2cc(ccc2)CCNCCOC)-c2c1cccc2

> <Chirality>
Single Stereoisomer

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
ARQ 087 | ARQ-087 | ARQ087 | DERAZANTINIB

> <Indications>
Derazantinib (ARQ087) is an orally bioavailable, non-selective FGFR inhibitor being investigated for antineoplastic activity.

> <Type>
nan

> <targets_id>
nan

> <inchi>
InChI=1S/C29H29FN4O/c1-35-16-15-31-14-13-20-7-6-8-22(17-20)33-29-32-19-21-18-26(24-10-4-5-12-27(24)30)23-9-2-3-11-25(23)28(21)34-29/h2-12,17,19,26,31H,13-16,18H2,1H3,(H,32,33,34)/t26-/m1/s1

> <stdInchikey>
KPJDVVCDVBFRMU-AREMUKBSSA-N

> <csid>
59718644

> <Links>
|http://www.chemspider.com/Chemical-Structure.59718644.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4297187|http://pubchem.ncbi.nlm.nih.gov/compound/46834118|http://www.drugbank.ca/drugs/DB14889|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9785|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=N9B0H171MJ

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|FDA SRS

> <indicationG2P>
None

> <MW>
468.2

> <HBA>
5

> <HBD>
2

> <NRB>
9

> <TPSA>
59.1

> <LogP>
5.5

> <RoF>
1

> <Targets>
nan

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0032

> <r_epik_State_Penalty>
  0.0021

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
202

$$$$
Ceralasertib
                    3D
 Structure written by MMmdl.
 54 58  0  0  1  0            999 V2000
   -4.2065   -1.8758    2.1960 C   0  0  0  0  0  0
   -4.3159   -2.3354    0.7229 C   0  0  2  0  0  0
   -4.8836   -3.7813    0.7066 C   0  0  0  0  0  0
   -5.0668   -4.2559   -0.6195 O   0  0  0  0  0  0
   -3.8748   -4.2139   -1.3879 C   0  0  0  0  0  0
   -3.3034   -2.7839   -1.4020 C   0  0  0  0  0  0
   -3.0494   -2.2666   -0.0466 N   0  0  0  0  0  0
   -2.2272   -1.1459   -0.0227 C   0  0  0  0  0  0
   -0.8444   -1.2877   -0.1767 C   0  0  0  0  0  0
   -0.0771   -0.1217   -0.1591 C   0  0  0  0  0  0
   -0.6292    1.1088   -0.0021 N   0  0  0  0  0  0
   -1.9838    1.1707    0.1329 C   0  0  0  0  0  0
   -2.8004    0.0826    0.1205 N   0  0  0  0  0  0
   -2.6060    2.5304    0.3041 C   0  0  0  0  0  0
   -1.8229    3.6934    0.1817 C   0  0  0  0  0  0
   -2.3450    4.9228    0.3261 N   0  3  0  0  0  0
   -3.6349    5.1765    0.5972 C   0  0  0  0  0  0
   -4.4785    4.0735    0.7386 C   0  0  0  0  0  0
   -3.9878    2.7314    0.5961 C   0  0  0  0  0  0
   -5.1317    1.8797    0.8102 C   0  0  0  0  0  0
   -6.2199    2.6864    1.0615 C   0  0  0  0  0  0
   -5.8272    3.9975    1.0172 N   0  0  0  0  0  0
    1.4356   -0.1661   -0.2797 C   0  0  0  0  0  0
    2.1454   -1.0377   -1.2976 C   0  0  0  0  0  0
    2.1362    0.4610   -1.4685 C   0  0  0  0  0  0
    2.3307    0.0791    1.3801 S   0  0  2  0  0  0
    2.2873    1.5903    1.6379 N   0  0  0  0  0  0
    3.7014   -0.4425    1.3679 O   0  0  0  0  0  0
    1.2866   -0.6727    2.7608 C   0  0  0  0  0  0
   -5.1595   -1.9868    2.7143 H   0  0  0  0  0  0
   -3.9255   -0.8278    2.2886 H   0  0  0  0  0  0
   -3.4655   -2.4625    2.7405 H   0  0  0  0  0  0
   -5.0420   -1.6836    0.2328 H   0  0  0  0  0  0
   -4.2330   -4.4659    1.2550 H   0  0  0  0  0  0
   -5.8548   -3.8121    1.2017 H   0  0  0  0  0  0
   -3.1414   -4.9244   -1.0020 H   0  0  0  0  0  0
   -4.1042   -4.5338   -2.4045 H   0  0  0  0  0  0
   -2.3730   -2.8009   -1.9723 H   0  0  0  0  0  0
   -3.9795   -2.1165   -1.9398 H   0  0  0  0  0  0
   -0.3870   -2.2594   -0.2936 H   0  0  0  0  0  0
   -0.7642    3.6874   -0.0353 H   0  0  0  0  0  0
   -3.9266    6.2127    0.6884 H   0  0  0  0  0  0
   -5.1769    0.8016    0.7882 H   0  0  0  0  0  0
   -7.2507    2.4390    1.2706 H   0  0  0  0  0  0
   -6.4699    4.7612    1.1744 H   0  0  0  0  0  0
    3.0796   -1.5268   -1.0212 H   0  0  0  0  0  0
    1.5519   -1.6395   -1.9863 H   0  0  0  0  0  0
    1.5336    0.8900   -2.2696 H   0  0  0  0  0  0
    3.0626    1.0121   -1.3040 H   0  0  0  0  0  0
    1.7888    1.8330    2.4814 H   0  0  0  0  0  0
    0.2961   -0.2182    2.7519 H   0  0  0  0  0  0
    1.7742   -0.4839    3.7169 H   0  0  0  0  0  0
    1.2030   -1.7459    2.5932 H   0  0  0  0  0  0
   -1.7219    5.7118    0.2229 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 30  1  0  0  0
  1 31  1  0  0  0
  1 32  1  0  0  0
  2  3  1  0  0  0
  2  7  1  0  0  0
  2 33  1  0  0  0
  3  4  1  0  0  0
  3 34  1  0  0  0
  3 35  1  0  0  0
  4  5  1  0  0  0
  5  6  1  0  0  0
  5 36  1  0  0  0
  5 37  1  0  0  0
  6  7  1  0  0  0
  6 38  1  0  0  0
  6 39  1  0  0  0
  7  8  1  0  0  0
  8  9  1  0  0  0
  8 13  2  0  0  0
  9 10  2  0  0  0
  9 40  1  0  0  0
 10 11  1  0  0  0
 10 23  1  0  0  0
 11 12  2  0  0  0
 12 13  1  0  0  0
 12 14  1  0  0  0
 14 15  1  0  0  0
 14 19  2  0  0  0
 15 16  2  0  0  0
 15 41  1  0  0  0
 16 17  1  0  0  0
 16 54  1  0  0  0
 17 18  2  0  0  0
 17 42  1  0  0  0
 18 19  1  0  0  0
 18 22  1  0  0  0
 19 20  1  0  0  0
 20 21  2  0  0  0
 20 43  1  0  0  0
 21 22  1  0  0  0
 21 44  1  0  0  0
 22 45  1  0  0  0
 23 24  1  0  0  0
 23 25  1  0  0  0
 23 26  1  0  0  0
 24 25  1  0  0  0
 24 46  1  0  0  0
 24 47  1  0  0  0
 25 48  1  0  0  0
 25 49  1  0  0  0
 26 27  2  0  0  0
 26 28  2  0  0  0
 26 29  1  0  0  0
 27 50  1  0  0  0
 29 51  1  0  0  0
 29 52  1  0  0  0
 29 53  1  0  0  0
M  CHG  1  16   1
M  END
> <s_m_entry_id>
203

> <Applicants>
Astrazeneca

> <CHEMBL_ID>
CHEMBL4285417

> <Canonical_Smiles>
S(=O)(=[NH])(C)C1(CC1)c1nc(nc(N2CCOCC2C)c1)-c1c2c([nH]cc2)cnc1

> <Chirality>
Single Stereoisomer

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
AZD6738

> <Indications>
Ceralasertib, also known as AZD6738, is an orally available morpholino-pyrimidine-based inhibitor of ataxia telangiectasia and rad3 related (ATR) kinase, with potential antineoplastic activity. Upon oral administration, ATR kinase inhibitor Ceralasertib selectively inhibits ATR activity by blocking the downstream phosphorylation of the serine/threonine protein kinase CHK1. This prevents ATR-mediated signaling, and results in the inhibition of DNA damage checkpoint activation, disruption of DNA damage repair, and the induction of tumor cell apoptosis.

> <Type>
nan

> <targets_id>
nan

> <inchi>
InChI=1S/C20H24N6O2S/c1-13-12-28-8-7-26(13)18-9-17(20(4-5-20)29(2,21)27)24-19(25-18)15-10-22-11-16-14(15)3-6-23-16/h3,6,9-11,13,21,23H,4-5,7-8,12H2,1-2H3

> <stdInchikey>
DTTJKLNXNZAVSM-UHFFFAOYSA-N

> <csid>
64879993

> <Links>
|http://www.chemspider.com/Chemical-Structure.64879993.html|http://pubchem.ncbi.nlm.nih.gov/compound/76189946

> <LinkName>
|ChemSpider|PubChem

> <MW>
412.2

> <HBA>
7

> <HBD>
2

> <NRB>
4

> <TPSA>
107.8

> <LogP>
2.9

> <RoF>
0

> <Targets>
nan

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.3405

> <r_epik_State_Penalty>
  0.0913

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
203

$$$$
Vorolanib
                    3D
 Structure written by MMmdl.
 58 61  0  0  1  0            999 V2000
   -3.2784    0.7104   -2.8555 C   0  0  0  0  0  0
   -3.2962    0.1225   -1.4549 C   0  0  0  0  0  0
   -4.3969   -0.4789   -0.8345 C   0  0  0  0  0  0
   -3.9874   -0.8549    0.4151 N   0  0  0  0  0  0
   -2.6777   -0.5401    0.6372 C   0  0  0  0  0  0
   -2.2052    0.0337   -0.5492 C   0  0  0  0  0  0
   -0.8773    0.5558   -0.7814 C   0  0  0  0  0  0
   -0.6931    1.5972   -1.4133 O   0  0  0  0  0  0
    0.1121   -0.1975   -0.2678 N   0  0  0  0  0  0
    1.5395    0.0934   -0.3898 C   0  0  1  0  0  0
    2.3611   -0.7255    0.5990 C   0  0  0  0  0  0
    3.7429   -0.7863   -0.0409 C   0  0  0  0  0  0
    3.4270   -0.8698   -1.4732 N   0  0  0  0  0  0
    2.1116   -0.2834   -1.7662 C   0  0  0  0  0  0
    4.1261   -1.5818   -2.3978 C   0  0  0  0  0  0
    3.5837   -2.0088   -3.4212 O   0  0  0  0  0  0
    5.4401   -1.8193   -2.1464 N   0  0  0  0  0  0
    6.3696   -0.7690   -1.7209 C   0  0  0  0  0  0
    6.1105   -2.9924   -2.7075 C   0  0  0  0  0  0
   -2.0470   -0.8428    1.9814 C   0  0  0  0  0  0
   -5.7701   -0.6759   -1.3081 C   0  0  0  0  0  0
   -6.8401   -1.4004   -0.8908 C   0  0  0  0  0  0
   -8.1638   -1.4619   -1.5080 C   0  0  0  0  0  0
   -8.7192   -0.8413   -2.6310 C   0  0  0  0  0  0
  -10.0479   -1.1082   -2.9763 C   0  0  0  0  0  0
  -10.8124   -1.9886   -2.2030 C   0  0  0  0  0  0
  -10.2528   -2.6060   -1.0813 C   0  0  0  0  0  0
   -8.9263   -2.3248   -0.7557 C   0  0  0  0  0  0
   -8.1534   -2.7926    0.2779 N   0  0  0  0  0  0
   -6.9018   -2.2979    0.2609 C   0  0  0  0  0  0
   -6.0366   -2.5945    1.0814 O   0  0  0  0  0  0
  -10.5951   -0.5139   -4.0604 F   0  0  0  0  0  0
   -2.3485    0.4856   -3.3781 H   0  0  0  0  0  0
   -3.3777    1.7956   -2.8325 H   0  0  0  0  0  0
   -4.0806    0.3254   -3.4845 H   0  0  0  0  0  0
   -4.5870   -1.3046    1.0935 H   0  0  0  0  0  0
   -0.1326   -1.0424    0.2277 H   0  0  0  0  0  0
    1.7517    1.1495   -0.2036 H   0  0  0  0  0  0
    2.3819   -0.2828    1.5955 H   0  0  0  0  0  0
    1.9632   -1.7380    0.6972 H   0  0  0  0  0  0
    4.2923    0.1346    0.1567 H   0  0  0  0  0  0
    4.3318   -1.6314    0.3193 H   0  0  0  0  0  0
    1.4791   -1.0214   -2.2630 H   0  0  0  0  0  0
    2.1968    0.5850   -2.4202 H   0  0  0  0  0  0
    5.8686    0.1248   -1.3498 H   0  0  0  0  0  0
    6.9960   -0.4639   -2.5599 H   0  0  0  0  0  0
    7.0227   -1.1411   -0.9311 H   0  0  0  0  0  0
    5.4240   -3.8322   -2.8274 H   0  0  0  0  0  0
    6.9187   -3.3205   -2.0527 H   0  0  0  0  0  0
    6.5362   -2.7570   -3.6834 H   0  0  0  0  0  0
   -1.1021   -0.3213    2.1308 H   0  0  0  0  0  0
   -1.8489   -1.9084    2.0980 H   0  0  0  0  0  0
   -2.6956   -0.5451    2.8059 H   0  0  0  0  0  0
   -5.9408   -0.1057   -2.2090 H   0  0  0  0  0  0
   -8.1400   -0.1598   -3.2362 H   0  0  0  0  0  0
  -11.8380   -2.1923   -2.4737 H   0  0  0  0  0  0
  -10.8469   -3.2853   -0.4883 H   0  0  0  0  0  0
   -8.4796   -3.4469    0.9741 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 33  1  0  0  0
  1 34  1  0  0  0
  1 35  1  0  0  0
  2  3  2  0  0  0
  2  6  1  0  0  0
  3  4  1  0  0  0
  3 21  1  0  0  0
  4  5  1  0  0  0
  4 36  1  0  0  0
  5  6  2  0  0  0
  5 20  1  0  0  0
  6  7  1  0  0  0
  7  8  2  0  0  0
  7  9  1  0  0  0
  9 10  1  0  0  0
  9 37  1  0  0  0
 10 11  1  0  0  0
 10 14  1  0  0  0
 10 38  1  0  0  0
 11 12  1  0  0  0
 11 39  1  0  0  0
 11 40  1  0  0  0
 12 13  1  0  0  0
 12 41  1  0  0  0
 12 42  1  0  0  0
 13 14  1  0  0  0
 13 15  1  0  0  0
 14 43  1  0  0  0
 14 44  1  0  0  0
 15 16  2  0  0  0
 15 17  1  0  0  0
 17 18  1  0  0  0
 17 19  1  0  0  0
 18 45  1  0  0  0
 18 46  1  0  0  0
 18 47  1  0  0  0
 19 48  1  0  0  0
 19 49  1  0  0  0
 19 50  1  0  0  0
 20 51  1  0  0  0
 20 52  1  0  0  0
 20 53  1  0  0  0
 21 22  2  0  0  0
 21 54  1  0  0  0
 22 23  1  0  0  0
 22 30  1  0  0  0
 23 24  2  0  0  0
 23 28  1  0  0  0
 24 25  1  0  0  0
 24 55  1  0  0  0
 25 26  2  0  0  0
 25 32  1  0  0  0
 26 27  1  0  0  0
 26 56  1  0  0  0
 27 28  2  0  0  0
 27 57  1  0  0  0
 28 29  1  0  0  0
 29 30  1  0  0  0
 29 58  1  0  0  0
 30 31  2  0  0  0
M  END
> <s_m_entry_id>
211

> <Applicants>
Tyrogenex

> <CHEMBL_ID>
CHEMBL4297587

> <Canonical_Smiles>
Fc1cc\2c(NC(=O)/C/2=C\c2[nH]c(C)c(C(=O)N[C@H]3CCN(C3)C(=O)N(C)C)c2C)cc1

> <Chirality>
Single Stereoisomer

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
VOROLANIB

> <Indications>
nan

> <Type>
nan

> <targets_id>
nan

> <inchi>
InChI=1S/C23H26FN5O3/c1-12-19(10-17-16-9-14(24)5-6-18(16)27-21(17)30)25-13(2)20(12)22(31)26-15-7-8-29(11-15)23(32)28(3)4/h5-6,9-10,15,25H,7-8,11H2,1-4H3,(H,26,31)(H,27,30)/b17-10-/t15-/m0/s1

> <stdInchikey>
KMIOJWCYOHBUJS-HAKPAVFJSA-N

> <csid>
58827733

> <Links>
|http://www.chemspider.com/Chemical-Structure.58827733.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4297587|http://pubchem.ncbi.nlm.nih.gov/compound/59215954|http://www.drugbank.ca/drugs/DB15247|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=YP8G3I74EL

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|FDA SRS

> <MW>
439.2

> <HBA>
3

> <HBD>
3

> <NRB>
3

> <TPSA>
97.5

> <LogP>
2.7

> <RoF>
0

> <Targets>
nan

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0001

> <r_epik_State_Penalty>
  0.0000

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
211

$$$$
Pimasertib
                    3D
 Structure written by MMmdl.
 38 39  0  0  1  0            999 V2000
   -5.3463    4.9577   -2.6017 C   0  0  0  0  0  0
   -4.6318    3.8693   -2.1016 C   0  0  0  0  0  0
   -3.6527    4.0538   -1.1153 C   0  0  0  0  0  0
   -3.3995    5.3482   -0.6398 C   0  0  0  0  0  0
   -4.1164    6.4353   -1.1422 C   0  0  0  0  0  0
   -5.0901    6.2409   -2.1212 C   0  0  0  0  0  0
   -6.1633    7.8725   -2.8699 I   0  0  0  0  0  0
   -2.4598    5.5634    0.3120 F   0  0  0  0  0  0
   -2.9253    2.9757   -0.5821 N   0  0  0  0  0  0
   -3.2411    1.6040   -0.5062 C   0  0  0  0  0  0
   -4.5757    1.1971   -0.3557 C   0  0  0  0  0  0
   -4.9615   -0.0972   -0.2458 N   0  0  0  0  0  0
   -3.9959   -1.0447   -0.2767 C   0  0  0  0  0  0
   -2.6421   -0.7425   -0.4099 C   0  0  0  0  0  0
   -2.2407    0.6002   -0.5235 C   0  0  0  0  0  0
   -0.7686    0.9216   -0.6769 C   0  0  0  0  0  0
   -0.3859    1.7939   -1.4586 O   0  0  0  0  0  0
    0.0682    0.2085    0.1010 N   0  0  0  0  0  0
    1.5261    0.3546    0.1286 C   0  0  0  0  0  0
    2.2637   -0.1524   -1.1386 C   0  0  1  0  0  0
    3.7998   -0.1428   -0.9940 C   0  0  0  0  0  0
    4.2910    1.1727   -0.8297 O   0  0  0  0  0  0
    1.8541   -1.4726   -1.4497 O   0  0  0  0  0  0
   -6.0967    4.8037   -3.3633 H   0  0  0  0  0  0
   -4.8389    2.8858   -2.4968 H   0  0  0  0  0  0
   -3.9159    7.4294   -0.7703 H   0  0  0  0  0  0
   -1.9377    3.1710   -0.4947 H   0  0  0  0  0  0
   -5.3770    1.9194   -0.3012 H   0  0  0  0  0  0
   -4.3254   -2.0697   -0.1898 H   0  0  0  0  0  0
   -1.9227   -1.5489   -0.4305 H   0  0  0  0  0  0
   -0.3220   -0.4955    0.7104 H   0  0  0  0  0  0
    1.7761    1.4012    0.3140 H   0  0  0  0  0  0
    1.8847   -0.1948    1.0001 H   0  0  0  0  0  0
    1.9912    0.4756   -1.9883 H   0  0  0  0  0  0
    4.1175   -0.7487   -0.1443 H   0  0  0  0  0  0
    4.2725   -0.5699   -1.8796 H   0  0  0  0  0  0
    5.2475    1.1352   -0.7556 H   0  0  0  0  0  0
    0.9037   -1.4689   -1.5860 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1  6  2  0  0  0
  1 24  1  0  0  0
  2  3  2  0  0  0
  2 25  1  0  0  0
  3  4  1  0  0  0
  3  9  1  0  0  0
  4  5  2  0  0  0
  4  8  1  0  0  0
  5  6  1  0  0  0
  5 26  1  0  0  0
  6  7  1  0  0  0
  9 10  1  0  0  0
  9 27  1  0  0  0
 10 11  2  0  0  0
 10 15  1  0  0  0
 11 12  1  0  0  0
 11 28  1  0  0  0
 12 13  2  0  0  0
 13 14  1  0  0  0
 13 29  1  0  0  0
 14 15  2  0  0  0
 14 30  1  0  0  0
 15 16  1  0  0  0
 16 17  2  0  0  0
 16 18  1  0  0  0
 18 19  1  0  0  0
 18 31  1  0  0  0
 19 20  1  0  0  0
 19 32  1  0  0  0
 19 33  1  0  0  0
 20 21  1  0  0  0
 20 23  1  0  0  0
 20 34  1  0  0  0
 21 22  1  0  0  0
 21 35  1  0  0  0
 21 36  1  0  0  0
 22 37  1  0  0  0
 23 38  1  0  0  0
M  END
> <s_m_entry_id>
212

> <Applicants>
Merck

> <CHEMBL_ID>
CHEMBL2107832

> <Canonical_Smiles>
Ic1cc(F)c(Nc2cnccc2C(=O)NC[C@H](O)CO)cc1

> <Chirality>
Single Stereoisomer

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
AS 703026 | AS-703026 | AS703026 | EMD 1036239 | EMD-1036239 | G-02443714 | MSC-1936369A | MSC-1936369B | MSC1936369A | MSC1936369A; AS703026; EMD 1036239 | PIMASERTIB

> <Indications>
nan

> <Type>
nan

> <targets_id>
Q02750|P36507

> <inchi>
InChI=1S/C15H15FIN3O3/c16-12-5-9(17)1-2-13(12)20-14-7-18-4-3-11(14)15(23)19-6-10(22)8-21/h1-5,7,10,20-22H,6,8H2,(H,19,23)/t10-/m0/s1

> <stdInchikey>
VIUAUNHCRHHYNE-JTQLQIEISA-N

> <csid>
24747378

> <Links>
|http://www.chemspider.com/Chemical-Structure.24747378.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2107832|http://pubchem.ncbi.nlm.nih.gov/compound/44187362|http://www.drugbank.ca/drugs/DB14904| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=QOA|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/QOA|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7872|http://zinc15.docking.org/substances/ZINC38226009|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=6ON9RK82AL|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50014412

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
431

> <HBA>
5

> <HBD>
4

> <NRB>
6

> <TPSA>
94.5

> <LogP>
1.7

> <RoF>
0

> <Targets>
MAP2K1; MAP2K2

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0006

> <r_epik_State_Penalty>
  0.0000

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
212

> <lig_pdbID>
'QOA'

> <pdbID>
6v30

> <Kinase families>
STE

> <BrandName>
 AS703026; EMD 1036239;AS703026;MSC1936369A;Msc1936369a; as703026; emd 1036239

$$$$
Refametinib
                    3D
 Structure written by MMmdl.
 51 53  0  0  1  0            999 V2000
    1.9766    4.6288    0.6306 C   0  0  0  0  0  0
    1.4395    3.3242    0.8188 O   0  0  0  0  0  0
    0.1915    3.0120    0.3032 C   0  0  0  0  0  0
   -0.6132    3.9447   -0.3686 C   0  0  0  0  0  0
   -1.8792    3.5946   -0.8218 C   0  0  0  0  0  0
   -2.3653    2.3067   -0.6183 C   0  0  0  0  0  0
   -1.5668    1.3364    0.0106 C   0  0  0  0  0  0
   -0.2859    1.6992    0.4807 C   0  0  0  0  0  0
    0.5245    0.7716    1.1615 N   0  0  0  0  0  0
    1.9777    0.0539    0.4263 S   0  0  0  0  0  0
    2.4730    1.0030   -0.5778 O   0  0  0  0  0  0
    2.8356   -0.3632    1.5403 O   0  0  0  0  0  0
    1.3416   -1.5151   -0.4574 C   0  0  0  0  0  0
    0.4624   -1.2994   -1.6699 C   0  0  0  0  0  0
    1.9007   -1.7214   -1.8536 C   0  0  0  0  0  0
    1.1525   -2.7885    0.4086 C   0  0  0  0  0  0
   -0.1917   -2.8989    1.1600 C   0  0  1  0  0  0
   -0.4216   -4.3054    1.7544 C   0  0  0  0  0  0
   -1.7122   -4.4224    2.3220 O   0  0  0  0  0  0
   -0.2400   -1.9433    2.2022 O   0  0  0  0  0  0
   -2.0835    0.0547    0.2886 N   0  0  0  0  0  0
   -2.8954   -0.7947   -0.4826 C   0  0  0  0  0  0
   -2.9503   -0.6915   -1.8794 C   0  0  0  0  0  0
   -3.7601   -1.5512   -2.6208 C   0  0  0  0  0  0
   -4.5239   -2.5214   -1.9734 C   0  0  0  0  0  0
   -4.4788   -2.6297   -0.5838 C   0  0  0  0  0  0
   -3.6708   -1.7693    0.1609 C   0  0  0  0  0  0
   -3.6437   -1.8939    1.5095 F   0  0  0  0  0  0
   -5.7360   -3.8126   -3.0859 I   0  0  0  0  0  0
   -3.6305    2.0258   -1.0134 F   0  0  0  0  0  0
   -2.6475    4.5193   -1.4424 F   0  0  0  0  0  0
    2.9636    4.6791    1.0901 H   0  0  0  0  0  0
    1.3546    5.3901    1.1038 H   0  0  0  0  0  0
    2.0941    4.8646   -0.4283 H   0  0  0  0  0  0
   -0.2810    4.9585   -0.5315 H   0  0  0  0  0  0
    0.3576    0.6165    2.1450 H   0  0  0  0  0  0
   -0.3216   -2.0237   -1.8914 H   0  0  0  0  0  0
    0.1797   -0.2821   -1.9418 H   0  0  0  0  0  0
    2.6065   -0.9987   -2.2630 H   0  0  0  0  0  0
    2.1006   -2.7325   -2.2099 H   0  0  0  0  0  0
    1.2363   -3.6622   -0.2398 H   0  0  0  0  0  0
    1.9835   -2.8847    1.1089 H   0  0  0  0  0  0
   -0.9987   -2.6873    0.4602 H   0  0  0  0  0  0
   -0.3316   -5.0642    0.9763 H   0  0  0  0  0  0
    0.3275   -4.5373    2.5128 H   0  0  0  0  0  0
   -1.7670   -3.8254    3.0724 H   0  0  0  0  0  0
   -0.0934   -1.0742    1.8216 H   0  0  0  0  0  0
   -1.8155   -0.3241    1.1859 H   0  0  0  0  0  0
   -2.3593    0.0482   -2.3996 H   0  0  0  0  0  0
   -3.7925   -1.4643   -3.6970 H   0  0  0  0  0  0
   -5.0700   -3.3816   -0.0816 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 32  1  0  0  0
  1 33  1  0  0  0
  1 34  1  0  0  0
  2  3  1  0  0  0
  3  4  1  0  0  0
  3  8  2  0  0  0
  4  5  2  0  0  0
  4 35  1  0  0  0
  5  6  1  0  0  0
  5 31  1  0  0  0
  6  7  2  0  0  0
  6 30  1  0  0  0
  7  8  1  0  0  0
  7 21  1  0  0  0
  8  9  1  0  0  0
  9 10  1  0  0  0
  9 36  1  0  0  0
 10 11  2  0  0  0
 10 12  2  0  0  0
 10 13  1  0  0  0
 13 14  1  0  0  0
 13 15  1  0  0  0
 13 16  1  0  0  0
 14 15  1  0  0  0
 14 37  1  0  0  0
 14 38  1  0  0  0
 15 39  1  0  0  0
 15 40  1  0  0  0
 16 17  1  0  0  0
 16 41  1  0  0  0
 16 42  1  0  0  0
 17 18  1  0  0  0
 17 20  1  0  0  0
 17 43  1  0  0  0
 18 19  1  0  0  0
 18 44  1  0  0  0
 18 45  1  0  0  0
 19 46  1  0  0  0
 20 47  1  0  0  0
 21 22  1  0  0  0
 21 48  1  0  0  0
 22 23  1  0  0  0
 22 27  2  0  0  0
 23 24  2  0  0  0
 23 49  1  0  0  0
 24 25  1  0  0  0
 24 50  1  0  0  0
 25 26  2  0  0  0
 25 29  1  0  0  0
 26 27  1  0  0  0
 26 51  1  0  0  0
 27 28  1  0  0  0
M  END
> <s_m_entry_id>
213

> <Applicants>
Bayer

> <CHEMBL_ID>
CHEMBL1236682

> <Canonical_Smiles>
Ic1cc(F)c(Nc2c(NS(=O)(=O)C3(CC3)C[C@H](O)CO)c(OC)cc(F)c2F)cc1

> <Chirality>
Single Stereoisomer

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
BAY 869766 | BAY 8697661 | BAY-86-9766 | BAY-869766 | BAY-8697661 | BAY86-9766 | RDEA 119 | RDEA-119 | REFAMETINIB

> <Indications>
nan

> <Type>
nan

> <targets_id>
Q02750

> <inchi>
InChI=1S/C19H20F3IN2O5S/c1-30-15-7-13(21)16(22)18(24-14-3-2-10(23)6-12(14)20)17(15)25-31(28,29)19(4-5-19)8-11(27)9-26/h2-3,6-7,11,24-27H,4-5,8-9H2,1H3/t11-/m0/s1

> <stdInchikey>
RDSACQWTXKSHJT-NSHDSACASA-N

> <csid>
25058723

> <Links>
|http://www.chemspider.com/Chemical-Structure.25058723.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1236682|http://pubchem.ncbi.nlm.nih.gov/compound/44182295|http://www.drugbank.ca/drugs/DB06309| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=VRA|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/VRA|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7942|http://zinc15.docking.org/substances/ZINC39187987|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=JPX07AFM0N

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS

> <indicationG2P>
None

> <MW>
572

> <HBA>
6

> <HBD>
4

> <NRB>
9

> <TPSA>
107.9

> <LogP>
3.5

> <RoF>
1

> <Targets>
MAP2K1

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_epik_Ionization_Penalty>
  0.0025

> <r_epik_State_Penalty>
  0.0017

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
213

> <lig_pdbID>
'VRA'

> <pdbID>
3e8n

> <Kinase families>
STE

$$$$
Ralimetinib
                    3D
 Structure written by MMmdl.
 60 63  0  0  1  0            999 V2000
   -3.5403    4.3673   -1.8301 C   0  0  0  0  0  0
   -2.3236    4.3470   -0.8752 C   0  0  0  0  0  0
   -1.0939    3.8017   -1.6392 C   0  0  0  0  0  0
   -2.0156    5.7976   -0.4383 C   0  0  0  0  0  0
   -2.6262    3.5138    0.4106 C   0  0  0  0  0  0
   -2.9508    2.1003    0.1667 N   0  0  0  0  0  0
   -2.0572    1.0545    0.0377 C   0  0  0  0  0  0
   -2.8516   -0.0949   -0.1658 C   0  0  0  0  0  0
   -2.2030   -1.3294   -0.3195 C   0  0  0  0  0  0
   -0.8055   -1.3313   -0.2644 C   0  0  0  0  0  0
   -0.1038   -0.1294   -0.0618 C   0  0  0  0  0  0
   -0.7237    1.0747    0.0938 N   0  0  0  0  0  0
    1.4006   -0.0761   -0.0300 C   0  0  0  0  0  0
    2.2489    0.9860    0.3369 C   0  0  0  0  0  0
    3.5077    0.4980    0.1092 N   0  0  0  0  0  0
    3.3807   -0.7821   -0.3576 C   0  0  0  0  0  0
    2.1155   -1.1266   -0.4222 N   0  0  0  0  0  0
    4.5791   -1.6720   -0.7161 C   0  0  0  0  0  0
    4.1257   -2.9637   -1.4430 C   0  0  0  0  0  0
    5.3236   -2.0674    0.5788 C   0  0  0  0  0  0
    5.5462   -0.9038   -1.6481 C   0  0  0  0  0  0
    2.0095    2.3653    0.8463 C   0  0  0  0  0  0
    2.5602    3.4606    0.1751 C   0  0  0  0  0  0
    2.3091    4.7528    0.6294 C   0  0  0  0  0  0
    1.5123    4.9471    1.7558 C   0  0  0  0  0  0
    0.9706    3.8591    2.4365 C   0  0  0  0  0  0
    1.2225    2.5669    1.9835 C   0  0  0  0  0  0
    1.2616    6.2023    2.1915 F   0  0  0  0  0  0
   -4.1807    0.2274   -0.1729 N   0  0  0  0  0  0
   -4.2050    1.5230    0.0247 C   0  0  0  0  0  0
   -5.3619    2.2451    0.1015 N   0  0  0  0  0  0
   -3.3602    5.0085   -2.6941 H   0  0  0  0  0  0
   -4.4353    4.7403   -1.3306 H   0  0  0  0  0  0
   -3.7690    3.3728   -2.2146 H   0  0  0  0  0  0
   -1.2763    2.8081   -2.0489 H   0  0  0  0  0  0
   -0.2184    3.7364   -0.9923 H   0  0  0  0  0  0
   -0.8270    4.4432   -2.4801 H   0  0  0  0  0  0
   -1.7944    6.4384   -1.2931 H   0  0  0  0  0  0
   -1.1533    5.8405    0.2292 H   0  0  0  0  0  0
   -2.8584    6.2446    0.0908 H   0  0  0  0  0  0
   -1.7711    3.5396    1.0885 H   0  0  0  0  0  0
   -3.4514    3.9580    0.9698 H   0  0  0  0  0  0
   -2.7574   -2.2430   -0.4757 H   0  0  0  0  0  0
   -0.2760   -2.2651   -0.3841 H   0  0  0  0  0  0
    4.3745    0.9929    0.2596 H   0  0  0  0  0  0
    4.9743   -3.5954   -1.7095 H   0  0  0  0  0  0
    3.5890   -2.7364   -2.3656 H   0  0  0  0  0  0
    3.4610   -3.5644   -0.8203 H   0  0  0  0  0  0
    4.6725   -2.6141    1.2626 H   0  0  0  0  0  0
    5.6952   -1.1928    1.1144 H   0  0  0  0  0  0
    6.1827   -2.7060    0.3682 H   0  0  0  0  0  0
    6.4006   -1.5188   -1.9344 H   0  0  0  0  0  0
    5.9438   -0.0059   -1.1729 H   0  0  0  0  0  0
    5.0485   -0.5916   -2.5676 H   0  0  0  0  0  0
    3.1680    3.3140   -0.7061 H   0  0  0  0  0  0
    2.7258    5.6011    0.1069 H   0  0  0  0  0  0
    0.3536    4.0169    3.3085 H   0  0  0  0  0  0
    0.7944    1.7245    2.5077 H   0  0  0  0  0  0
   -6.1809    1.8526    0.5422 H   0  0  0  0  0  0
   -5.5197    3.0324   -0.5101 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 32  1  0  0  0
  1 33  1  0  0  0
  1 34  1  0  0  0
  2  3  1  0  0  0
  2  4  1  0  0  0
  2  5  1  0  0  0
  3 35  1  0  0  0
  3 36  1  0  0  0
  3 37  1  0  0  0
  4 38  1  0  0  0
  4 39  1  0  0  0
  4 40  1  0  0  0
  5  6  1  0  0  0
  5 41  1  0  0  0
  5 42  1  0  0  0
  6  7  1  0  0  0
  6 30  1  0  0  0
  7  8  1  0  0  0
  7 12  2  0  0  0
  8  9  2  0  0  0
  8 29  1  0  0  0
  9 10  1  0  0  0
  9 43  1  0  0  0
 10 11  2  0  0  0
 10 44  1  0  0  0
 11 12  1  0  0  0
 11 13  1  0  0  0
 13 14  2  0  0  0
 13 17  1  0  0  0
 14 22  1  0  0  0
 14 15  1  0  0  0
 15 45  1  0  0  0
 15 16  1  0  0  0
 16 18  1  0  0  0
 16 17  2  0  0  0
 18 19  1  0  0  0
 18 20  1  0  0  0
 18 21  1  0  0  0
 19 46  1  0  0  0
 19 47  1  0  0  0
 19 48  1  0  0  0
 20 49  1  0  0  0
 20 50  1  0  0  0
 20 51  1  0  0  0
 21 52  1  0  0  0
 21 53  1  0  0  0
 21 54  1  0  0  0
 22 23  1  0  0  0
 22 27  2  0  0  0
 23 24  2  0  0  0
 23 55  1  0  0  0
 24 25  1  0  0  0
 24 56  1  0  0  0
 25 26  2  0  0  0
 25 28  1  0  0  0
 26 27  1  0  0  0
 26 57  1  0  0  0
 27 58  1  0  0  0
 29 30  2  0  0  0
 30 31  1  0  0  0
 31 59  1  0  0  0
 31 60  1  0  0  0
M  END
> <s_m_entry_id>
214

> <Applicants>
Eli Lilly

> <CHEMBL_ID>
CHEMBL2364626

> <Canonical_Smiles>
Fc1ccc(cc1)-c1nc([nH]c1-c1nc2n(CC(C)(C)C)c(nc2cc1)N)C(C)(C)C

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
LSN-2322600 FREE BASE | LSN2322600 FREE BASE | LY-2228820 | LY2228820 | LY22288220 | RALIMETINIB

> <Indications>
nan

> <Type>
nan

> <targets_id>
Q16539|Q15759

> <inchi>
InChI=1S/C24H29FN6/c1-23(2,3)13-31-20-17(28-22(31)26)12-11-16(27-20)19-18(14-7-9-15(25)10-8-14)29-21(30-19)24(4,5)6/h7-12H,13H2,1-6H3,(H2,26,28)(H,29,30)

> <stdInchikey>
XPPBBJCBDOEXDN-UHFFFAOYSA-N

> <csid>
9713805

> <Links>
|http://www.chemspider.com/Chemical-Structure.9713805.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2364626|http://pubchem.ncbi.nlm.nih.gov/compound/11539025|http://www.drugbank.ca/drugs/DB11787|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7959|http://zinc15.docking.org/substances/ZINC34630490|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=73I34XW4HD

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS

> <indicationG2P>
None

> <MW>
420.2

> <HBA>
5

> <HBD>
2

> <NRB>
3

> <TPSA>
85.4

> <LogP>
5.6

> <RoF>
1

> <Targets>
MAPK14; MAPK11

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
0.5

> <r_epik_Ionization_Penalty>
  0.1185

> <r_epik_State_Penalty>
  0.4741

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
214

> <Kinase families>
CMGC

$$$$
Prexasertib
                    3D
 Structure written by MMmdl.
 47 49  0  0  1  0            999 V2000
   -4.1176    2.6468   -0.1813 C   0  0  0  0  0  0
   -2.7040    2.4785   -0.1833 O   0  0  0  0  0  0
   -2.1616    1.2098   -0.0620 C   0  0  0  0  0  0
   -2.9451    0.0524    0.0749 C   0  0  0  0  0  0
   -2.3511   -1.1995    0.1816 C   0  0  0  0  0  0
   -0.9666   -1.3180    0.1541 C   0  0  0  0  0  0
   -0.1523   -0.1822    0.0194 C   0  0  0  0  0  0
   -0.7590    1.0848   -0.0896 C   0  0  0  0  0  0
    0.0885    2.3133   -0.2235 C   0  0  0  0  0  0
    0.0389    3.5594    0.3834 C   0  0  0  0  0  0
    1.0972    4.3240   -0.1280 C   0  0  0  0  0  0
    1.7746    3.6190   -1.0107 N   0  0  0  0  0  0
    1.1649    2.4314   -1.0629 N   0  0  0  0  0  0
    1.3944    5.6236    0.2260 N   0  0  0  0  0  0
    2.4409    6.4683   -0.1895 C   0  0  0  0  0  0
    2.4937    7.7670    0.3338 C   0  0  0  0  0  0
    3.4723    8.6456   -0.0127 N   0  0  0  0  0  0
    4.4086    8.2105   -0.8957 C   0  0  0  0  0  0
    4.3702    6.9180   -1.4258 C   0  0  0  0  0  0
    3.3891    6.0453   -1.0750 N   0  0  0  0  0  0
    5.4490    9.1589   -1.2570 C   0  0  0  0  0  0
    6.2779    9.9135   -1.5451 N   0  0  0  0  0  0
    1.2313   -0.2428   -0.0002 O   0  0  0  0  0  0
    1.8940   -1.4986    0.1088 C   0  0  0  0  0  0
    3.4071   -1.2535    0.0287 C   0  0  0  0  0  0
    4.2211   -2.5501    0.1398 C   0  0  0  0  0  0
    5.7143   -2.2267    0.0389 N   0  3  0  0  0  0
   -4.3523    3.7059   -0.2871 H   0  0  0  0  0  0
   -4.5610    2.3038    0.7547 H   0  0  0  0  0  0
   -4.5842    2.1212   -1.0159 H   0  0  0  0  0  0
   -4.0229    0.1027    0.0996 H   0  0  0  0  0  0
   -2.9662   -2.0812    0.2870 H   0  0  0  0  0  0
   -0.5439   -2.3069    0.2439 H   0  0  0  0  0  0
   -0.6818    3.8797    1.1210 H   0  0  0  0  0  0
    1.4899    1.6948   -1.6723 H   0  0  0  0  0  0
    0.7874    6.0820    0.8889 H   0  0  0  0  0  0
    1.7550    8.1234    1.0369 H   0  0  0  0  0  0
    5.1114    6.5633   -2.1279 H   0  0  0  0  0  0
    1.6416   -1.9763    1.0575 H   0  0  0  0  0  0
    1.5825   -2.1616   -0.7008 H   0  0  0  0  0  0
    3.6409   -0.7540   -0.9128 H   0  0  0  0  0  0
    3.7034   -0.5668    0.8232 H   0  0  0  0  0  0
    4.1032   -3.0497    1.1020 H   0  0  0  0  0  0
    4.0268   -3.2491   -0.6744 H   0  0  0  0  0  0
    6.2601   -3.0736    0.1129 H   0  0  0  0  0  0
    5.9862   -1.5992    0.7825 H   0  0  0  0  0  0
    5.9171   -1.7866   -0.8476 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 28  1  0  0  0
  1 29  1  0  0  0
  1 30  1  0  0  0
  2  3  1  0  0  0
  3  4  1  0  0  0
  3  8  2  0  0  0
  4  5  2  0  0  0
  4 31  1  0  0  0
  5  6  1  0  0  0
  5 32  1  0  0  0
  6  7  2  0  0  0
  6 33  1  0  0  0
  7  8  1  0  0  0
  7 23  1  0  0  0
  8  9  1  0  0  0
  9 10  2  0  0  0
  9 13  1  0  0  0
 10 11  1  0  0  0
 10 34  1  0  0  0
 11 12  2  0  0  0
 11 14  1  0  0  0
 12 13  1  0  0  0
 13 35  1  0  0  0
 14 15  1  0  0  0
 14 36  1  0  0  0
 15 16  1  0  0  0
 15 20  2  0  0  0
 16 17  2  0  0  0
 16 37  1  0  0  0
 17 18  1  0  0  0
 18 19  2  0  0  0
 18 21  1  0  0  0
 19 20  1  0  0  0
 19 38  1  0  0  0
 21 22  3  0  0  0
 23 24  1  0  0  0
 24 25  1  0  0  0
 24 39  1  0  0  0
 24 40  1  0  0  0
 25 26  1  0  0  0
 25 41  1  0  0  0
 25 42  1  0  0  0
 26 27  1  0  0  0
 26 43  1  0  0  0
 26 44  1  0  0  0
 27 45  1  0  0  0
 27 46  1  0  0  0
 27 47  1  0  0  0
M  CHG  1  27   1
M  END
> <s_m_entry_id>
218

> <Applicants>
Eli Lilly

> <CHEMBL_ID>
CHEMBL3544911

> <Canonical_Smiles>
O(CCCN)c1cccc(OC)c1-c1[nH]nc(Nc2ncc(nc2)C#N)c1

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
LY2606368 | PREXASERTIB

> <Indications>
nan

> <Type>
nan

> <targets_id>
O14757|O96017

> <inchi>
InChI=1S/C18H19N7O2/c1-26-14-4-2-5-15(27-7-3-6-19)18(14)13-8-16(25-24-13)23-17-11-21-12(9-20)10-22-17/h2,4-5,8,10-11H,3,6-7,19H2,1H3,(H2,22,23,24,25)

> <stdInchikey>
DOTGPNHGTYJDEP-UHFFFAOYSA-N

> <csid>
32738771

> <Links>
|http://www.chemspider.com/Chemical-Structure.32738771.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3544911|http://pubchem.ncbi.nlm.nih.gov/compound/46700756|http://www.drugbank.ca/drugs/DB12008|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9549|http://zinc15.docking.org/substances/ZINC000095837013|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=820NH671E6

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS

> <indicationG2P>
None

> <MW>
365.2

> <HBA>
8

> <HBD>
3

> <NRB>
8

> <TPSA>
134.8

> <LogP>
2.2

> <RoF>
0

> <Targets>
CHEK1; CHEK2

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
0.8426

> <r_epik_Ionization_Penalty>
  0.0016

> <r_epik_State_Penalty>
  0.0915

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
218

> <Kinase families>
CAMK

$$$$
Poziotinib
                    3D
 Structure written by MMmdl.
 54 57  0  0  1  0            999 V2000
   -0.5939    3.6428    0.5398 C   0  0  0  0  0  0
   -0.0205    2.3417    0.4626 O   0  0  0  0  0  0
   -0.8268    1.2524    0.1781 C   0  0  0  0  0  0
   -2.2034    1.3612   -0.0753 C   0  0  0  0  0  0
   -2.9808    0.2184   -0.3621 C   0  0  0  0  0  0
   -2.3548   -1.0616   -0.3889 C   0  0  0  0  0  0
   -0.9649   -1.1483   -0.1277 C   0  0  0  0  0  0
   -0.2036   -0.0028    0.1486 C   0  0  0  0  0  0
    1.1610   -0.0155    0.4036 O   0  0  0  0  0  0
    1.9550   -1.2084    0.3845 C   0  0  0  0  0  0
    2.0938   -1.8737   -1.0146 C   0  0  0  0  0  0
    2.8482   -3.2232   -0.9746 C   0  0  0  0  0  0
    2.2077   -4.0359    0.0775 N   0  0  0  0  0  0
    2.4615   -3.5074    1.4331 C   0  0  0  0  0  0
    1.6570   -2.1941    1.5489 C   0  0  0  0  0  0
    1.2769   -4.9820   -0.2477 C   0  0  0  0  0  0
    1.0378   -5.2851   -1.4206 O   0  0  0  0  0  0
    0.5648   -5.6339    0.8358 C   0  0  0  0  0  0
    0.0331   -6.8644    0.7119 C   0  0  0  0  0  0
   -3.2038   -2.1705   -0.6880 C   0  0  0  0  0  0
   -4.5319   -2.0171   -0.9276 N   0  0  0  0  0  0
   -5.0146   -0.7551   -0.8774 C   0  0  0  0  0  0
   -4.3132    0.3715   -0.6065 N   0  0  0  0  0  0
   -2.6808   -3.4764   -0.7206 N   0  0  0  0  0  0
   -3.2931   -4.6862   -1.0839 C   0  0  0  0  0  0
   -3.1603   -5.7788   -0.2250 C   0  0  0  0  0  0
   -3.7041   -7.0154   -0.5660 C   0  0  0  0  0  0
   -4.3721   -7.1791   -1.7794 C   0  0  0  0  0  0
   -4.4871   -6.0972   -2.6627 C   0  0  0  0  0  0
   -3.9376   -4.8564   -2.3197 C   0  0  0  0  0  0
   -4.0169   -3.8282   -3.1994 F   0  0  0  0  0  0
   -5.2926   -6.2778   -4.1855 Cl  0  0  0  0  0  0
   -5.0332   -8.7310   -2.1631 Cl  0  0  0  0  0  0
    0.1852    4.3647    0.7847 H   0  0  0  0  0  0
   -1.3526    3.7001    1.3217 H   0  0  0  0  0  0
   -1.0335    3.9443   -0.4121 H   0  0  0  0  0  0
   -2.7025    2.3186   -0.0601 H   0  0  0  0  0  0
   -0.5168   -2.1267   -0.1557 H   0  0  0  0  0  0
    2.9445   -0.8040    0.6032 H   0  0  0  0  0  0
    1.1280   -2.0368   -1.4869 H   0  0  0  0  0  0
    2.6187   -1.1925   -1.6847 H   0  0  0  0  0  0
    2.8350   -3.7073   -1.9525 H   0  0  0  0  0  0
    3.8938   -3.0596   -0.7102 H   0  0  0  0  0  0
    2.2176   -4.2052    2.2327 H   0  0  0  0  0  0
    3.5266   -3.2914    1.5286 H   0  0  0  0  0  0
    1.8961   -1.7118    2.4971 H   0  0  0  0  0  0
    0.5994   -2.4381    1.6182 H   0  0  0  0  0  0
    0.4500   -5.1040    1.7682 H   0  0  0  0  0  0
    0.1116   -7.4407   -0.1999 H   0  0  0  0  0  0
   -0.4971   -7.3168    1.5370 H   0  0  0  0  0  0
   -6.0700   -0.6331   -1.0725 H   0  0  0  0  0  0
   -1.7135   -3.5547   -0.4427 H   0  0  0  0  0  0
   -2.6422   -5.6719    0.7173 H   0  0  0  0  0  0
   -3.6022   -7.8488    0.1139 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 34  1  0  0  0
  1 35  1  0  0  0
  1 36  1  0  0  0
  2  3  1  0  0  0
  3  4  1  0  0  0
  3  8  2  0  0  0
  4  5  2  0  0  0
  4 37  1  0  0  0
  5  6  1  0  0  0
  5 23  1  0  0  0
  6  7  2  0  0  0
  6 20  1  0  0  0
  7  8  1  0  0  0
  7 38  1  0  0  0
  8  9  1  0  0  0
  9 10  1  0  0  0
 10 11  1  0  0  0
 10 15  1  0  0  0
 10 39  1  0  0  0
 11 12  1  0  0  0
 11 40  1  0  0  0
 11 41  1  0  0  0
 12 13  1  0  0  0
 12 42  1  0  0  0
 12 43  1  0  0  0
 13 14  1  0  0  0
 13 16  1  0  0  0
 14 15  1  0  0  0
 14 44  1  0  0  0
 14 45  1  0  0  0
 15 46  1  0  0  0
 15 47  1  0  0  0
 16 17  2  0  0  0
 16 18  1  0  0  0
 18 19  2  0  0  0
 18 48  1  0  0  0
 19 49  1  0  0  0
 19 50  1  0  0  0
 20 21  2  0  0  0
 20 24  1  0  0  0
 21 22  1  0  0  0
 22 23  2  0  0  0
 22 51  1  0  0  0
 24 25  1  0  0  0
 24 52  1  0  0  0
 25 26  1  0  0  0
 25 30  2  0  0  0
 26 27  2  0  0  0
 26 53  1  0  0  0
 27 28  1  0  0  0
 27 54  1  0  0  0
 28 29  2  0  0  0
 28 33  1  0  0  0
 29 30  1  0  0  0
 29 32  1  0  0  0
 30 31  1  0  0  0
M  END
> <s_m_entry_id>
220

> <Applicants>
Hanmi Pharmaceutical

> <CHEMBL_ID>
CHEMBL3545154

> <Canonical_Smiles>
Clc1c(F)c(Nc2ncnc3c2cc(OC2CCN(CC2)C(=O)C=C)c(OC)c3)ccc1Cl

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
HM 781-36 | HM 781-36B | HM-781-36 | HM-781-36B | NOV-120101 | POZIOTINIB

> <Indications>
nan

> <Type>
nan

> <targets_id>
P00533

> <inchi>
InChI=1S/C23H21Cl2FN4O3/c1-3-20(31)30-8-6-13(7-9-30)33-19-10-14-17(11-18(19)32-2)27-12-28-23(14)29-16-5-4-15(24)21(25)22(16)26/h3-5,10-13H,1,6-9H2,2H3,(H,27,28,29)

> <stdInchikey>
LPFWVDIFUFFKJU-UHFFFAOYSA-N

> <csid>
30687714

> <Links>
|http://www.chemspider.com/Chemical-Structure.30687714.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3545154|http://pubchem.ncbi.nlm.nih.gov/compound/25127713|http://www.drugbank.ca/drugs/DB12114|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7903|http://zinc15.docking.org/substances/ZINC000095930125|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=OEI6OOU6IK|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50468247

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
490.1

> <HBA>
6

> <HBD>
1

> <NRB>
6

> <TPSA>
76.6

> <LogP>
5.4

> <RoF>
1

> <Targets>
EGFR

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0017

> <r_epik_State_Penalty>
  0.0000

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
220

> <Kinase families>
Tyr

$$$$
Solcitinib
                    3D
 Structure written by MMmdl.
 52 56  0  0  1  0            999 V2000
   -1.6053    4.1150    1.0920 C   0  0  0  0  0  0
   -1.5584    3.0129    0.0132 C   0  0  0  0  0  0
   -0.1357    2.4959   -0.2760 C   0  0  0  0  0  0
   -0.5467    1.2543    0.4323 N   0  0  0  0  0  0
   -1.9803    1.6248    0.5347 C   0  0  0  0  0  0
    0.1403    0.2241    0.9656 C   0  0  0  0  0  0
   -0.3978   -0.6221    1.6806 O   0  0  0  0  0  0
    1.6178    0.1391    0.6768 C   0  0  0  0  0  0
    2.5132   -0.1128    1.7200 C   0  0  0  0  0  0
    3.8798   -0.1922    1.4669 C   0  0  0  0  0  0
    4.3796   -0.0229    0.1708 C   0  0  0  0  0  0
    3.4733    0.1974   -0.8742 C   0  0  0  0  0  0
    2.1066    0.2788   -0.6267 C   0  0  0  0  0  0
    5.8508   -0.1145   -0.0786 C   0  0  0  0  0  0
    6.6479   -1.1076    0.5005 C   0  0  0  0  0  0
    8.0148   -1.1723    0.2300 C   0  0  0  0  0  0
    8.6291   -0.2508   -0.6218 C   0  0  0  0  0  0
    7.8414    0.7562   -1.2053 C   0  0  0  0  0  0
    6.4750    0.7908   -0.9142 N   0  0  0  0  0  0
    5.9379    1.8491   -1.5618 N   0  0  0  0  0  0
    6.9672    2.3723   -2.2135 C   0  0  0  0  0  0
    8.1345    1.7778   -2.0461 N   0  0  0  0  0  0
    6.9125    3.4831   -3.0439 N   0  0  0  0  0  0
    5.8203    4.2061   -3.3775 C   0  0  0  0  0  0
    4.6755    3.9752   -2.9769 O   0  0  0  0  0  0
    6.0978    5.3843   -4.3309 C   0  0  0  0  0  0
    5.2320    6.6176   -4.1415 C   0  0  0  0  0  0
    4.9984    5.7141   -5.3257 C   0  0  0  0  0  0
   -2.3204    3.4553   -1.2509 C   0  0  0  0  0  0
   -2.6322    4.3433    1.3797 H   0  0  0  0  0  0
   -1.1480    5.0384    0.7345 H   0  0  0  0  0  0
   -1.0722    3.8149    1.9954 H   0  0  0  0  0  0
    0.0957    2.3134   -1.3261 H   0  0  0  0  0  0
    0.6785    3.0216    0.2249 H   0  0  0  0  0  0
   -2.3557    1.5892    1.5583 H   0  0  0  0  0  0
   -2.6006    1.0303   -0.1371 H   0  0  0  0  0  0
    2.1585   -0.2389    2.7333 H   0  0  0  0  0  0
    4.5535   -0.3750    2.2914 H   0  0  0  0  0  0
    3.8222    0.2990   -1.8914 H   0  0  0  0  0  0
    1.4350    0.4415   -1.4573 H   0  0  0  0  0  0
    6.2068   -1.8429    1.1578 H   0  0  0  0  0  0
    8.6086   -1.9511    0.6860 H   0  0  0  0  0  0
    9.6886   -0.3119   -0.8219 H   0  0  0  0  0  0
    7.7961    3.7667   -3.4403 H   0  0  0  0  0  0
    7.1349    5.5216   -4.6408 H   0  0  0  0  0  0
    4.4790    6.6445   -3.3522 H   0  0  0  0  0  0
    5.6851    7.5952   -4.3078 H   0  0  0  0  0  0
    5.2887    6.0619   -6.3173 H   0  0  0  0  0  0
    4.0845    5.1183   -5.3523 H   0  0  0  0  0  0
   -2.2955    2.6859   -2.0238 H   0  0  0  0  0  0
   -1.8863    4.3602   -1.6778 H   0  0  0  0  0  0
   -3.3681    3.6625   -1.0298 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 30  1  0  0  0
  1 31  1  0  0  0
  1 32  1  0  0  0
  2  3  1  0  0  0
  2  5  1  0  0  0
  2 29  1  0  0  0
  3  4  1  0  0  0
  3 33  1  0  0  0
  3 34  1  0  0  0
  4  5  1  0  0  0
  4  6  1  0  0  0
  5 35  1  0  0  0
  5 36  1  0  0  0
  6  7  2  0  0  0
  6  8  1  0  0  0
  8  9  1  0  0  0
  8 13  2  0  0  0
  9 10  2  0  0  0
  9 37  1  0  0  0
 10 11  1  0  0  0
 10 38  1  0  0  0
 11 12  2  0  0  0
 11 14  1  0  0  0
 12 13  1  0  0  0
 12 39  1  0  0  0
 13 40  1  0  0  0
 14 15  2  0  0  0
 14 19  1  0  0  0
 15 16  1  0  0  0
 15 41  1  0  0  0
 16 17  2  0  0  0
 16 42  1  0  0  0
 17 18  1  0  0  0
 17 43  1  0  0  0
 18 19  1  0  0  0
 18 22  2  0  0  0
 19 20  1  0  0  0
 20 21  2  0  0  0
 21 22  1  0  0  0
 21 23  1  0  0  0
 23 24  1  0  0  0
 23 44  1  0  0  0
 24 25  2  0  0  0
 24 26  1  0  0  0
 26 27  1  0  0  0
 26 28  1  0  0  0
 26 45  1  0  0  0
 27 28  1  0  0  0
 27 46  1  0  0  0
 27 47  1  0  0  0
 28 48  1  0  0  0
 28 49  1  0  0  0
 29 50  1  0  0  0
 29 51  1  0  0  0
 29 52  1  0  0  0
M  END
> <s_m_entry_id>
221

> <Applicants>
GlaxoSmithKline

> <CHEMBL_ID>
CHEMBL3301606

> <Canonical_Smiles>
O=C(N1CC(C1)(C)C)c1ccc(cc1)C=1n2nc(nc2C=CC=1)NC(=O)C1CC1

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
G-154578 | G154578 | GLPG-0778 | GLPG-0788 | GLPG0778 | GSK-2586184 | GSK-2586184A | GSK2586184A | SOLCITINIB

> <Indications>
nan

> <Type>
nan

> <targets_id>
P23458

> <inchi>
InChI=1S/C22H23N5O2/c1-22(2)12-26(13-22)20(29)16-10-6-14(7-11-16)17-4-3-5-18-23-21(25-27(17)18)24-19(28)15-8-9-15/h3-7,10-11,15H,8-9,12-13H2,1-2H3,(H,24,25,28)

> <stdInchikey>
MPYACSQFXVMWNO-UHFFFAOYSA-N

> <csid>
31389944

> <Links>
|http://www.chemspider.com/Chemical-Structure.31389944.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3301606|http://pubchem.ncbi.nlm.nih.gov/compound/44603362|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9697|http://zinc15.docking.org/substances/ZINC000118401631|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=3V7GQ1260K|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=128101

> <LinkName>
|ChemSpider|ChEMBL|PubChem|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
389.2

> <HBA>
5

> <HBD>
1

> <NRB>
4

> <TPSA>
79.6

> <LogP>
3.2

> <RoF>
0

> <Targets>
JAK1

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_epik_Ionization_Penalty>
  0.3948

> <r_epik_State_Penalty>
  0.3938

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
221

> <Kinase families>
Tyr

$$$$
Roniciclib
                    3D
 Structure written by MMmdl.
 50 52  0  0  1  0            999 V2000
   -1.6232    0.4949   -2.5018 C   0  0  0  0  0  0
   -2.0501    1.0202   -1.1200 C   0  0  2  0  0  0
   -0.8591    1.2336   -0.1515 C   0  0  1  0  0  0
   -1.2917    1.8107    1.2143 C   0  0  0  0  0  0
   -0.1873   -0.0221    0.0229 O   0  0  0  0  0  0
    1.1297   -0.0873    0.4486 C   0  0  0  0  0  0
    1.7274   -1.3432    0.6302 C   0  0  0  0  0  0
    3.0608   -1.3433    1.0551 C   0  0  0  0  0  0
    3.7577   -0.2022    1.2837 N   0  0  0  0  0  0
    3.1013    0.9701    1.0861 C   0  0  0  0  0  0
    1.8149    1.0718    0.6711 N   0  0  0  0  0  0
    3.7541    2.1956    1.2849 N   0  0  0  0  0  0
    5.0630    2.5463    1.6620 C   0  0  0  0  0  0
    5.4920    3.8378    1.3458 C   0  0  0  0  0  0
    6.7727    4.2609    1.6902 C   0  0  0  0  0  0
    7.6342    3.3915    2.3625 C   0  0  0  0  0  0
    7.2101    2.1042    2.6917 C   0  0  0  0  0  0
    5.9286    1.6835    2.3468 C   0  0  0  0  0  0
    9.2895    3.9074    2.8324 S   0  0  2  0  0  0
    9.7468    4.9002    1.7536 N   0  0  0  0  0  0
   10.1782    2.7457    2.9446 O   0  0  0  0  0  0
    9.2213    4.9137    4.4417 C   0  0  0  0  0  0
    8.0231    4.7135    5.3404 C   0  0  0  0  0  0
    8.1636    5.9883    4.5368 C   0  0  0  0  0  0
    0.9621   -2.6396    0.3742 C   0  0  0  0  0  0
    1.7080   -3.7201    0.6117 F   0  0  0  0  0  0
   -0.1103   -2.6935    1.1645 F   0  0  0  0  0  0
    0.5624   -2.6816   -0.8971 F   0  0  0  0  0  0
   -3.0069    0.1308   -0.5724 O   0  0  0  0  0  0
   -0.9020    1.1648   -2.9706 H   0  0  0  0  0  0
   -2.4772    0.4128   -3.1752 H   0  0  0  0  0  0
   -1.1612   -0.4911   -2.4331 H   0  0  0  0  0  0
   -2.5539    1.9770   -1.2650 H   0  0  0  0  0  0
   -0.1926    1.9495   -0.6370 H   0  0  0  0  0  0
   -1.8466    2.7408    1.0891 H   0  0  0  0  0  0
   -0.4337    2.0308    1.8489 H   0  0  0  0  0  0
   -1.9284    1.1136    1.7597 H   0  0  0  0  0  0
    3.6008   -2.2646    1.2192 H   0  0  0  0  0  0
    3.2034    2.9777    0.9638 H   0  0  0  0  0  0
    4.8362    4.5215    0.8256 H   0  0  0  0  0  0
    7.0871    5.2620    1.4348 H   0  0  0  0  0  0
    7.8667    1.4303    3.2225 H   0  0  0  0  0  0
    5.6282    0.6903    2.6390 H   0  0  0  0  0  0
    9.9668    5.8128    2.1250 H   0  0  0  0  0  0
   10.2127    5.0954    4.8570 H   0  0  0  0  0  0
    7.2504    3.9986    5.0584 H   0  0  0  0  0  0
    8.1702    4.7597    6.4197 H   0  0  0  0  0  0
    8.4060    6.9114    5.0640 H   0  0  0  0  0  0
    7.4923    6.1558    3.6955 H   0  0  0  0  0  0
   -3.2725    0.4603    0.2893 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 30  1  0  0  0
  1 31  1  0  0  0
  1 32  1  0  0  0
  2  3  1  0  0  0
  2 29  1  0  0  0
  2 33  1  0  0  0
  3  4  1  0  0  0
  3  5  1  0  0  0
  3 34  1  0  0  0
  4 35  1  0  0  0
  4 36  1  0  0  0
  4 37  1  0  0  0
  5  6  1  0  0  0
  6  7  1  0  0  0
  6 11  2  0  0  0
  7  8  2  0  0  0
  7 25  1  0  0  0
  8  9  1  0  0  0
  8 38  1  0  0  0
  9 10  2  0  0  0
 10 11  1  0  0  0
 10 12  1  0  0  0
 12 13  1  0  0  0
 12 39  1  0  0  0
 13 14  1  0  0  0
 13 18  2  0  0  0
 14 15  2  0  0  0
 14 40  1  0  0  0
 15 16  1  0  0  0
 15 41  1  0  0  0
 16 17  2  0  0  0
 16 19  1  0  0  0
 17 18  1  0  0  0
 17 42  1  0  0  0
 18 43  1  0  0  0
 19 20  2  0  0  0
 19 21  2  0  0  0
 19 22  1  0  0  0
 20 44  1  0  0  0
 22 23  1  0  0  0
 22 24  1  0  0  0
 22 45  1  0  0  0
 23 24  1  0  0  0
 23 46  1  0  0  0
 23 47  1  0  0  0
 24 48  1  0  0  0
 24 49  1  0  0  0
 25 26  1  0  0  0
 25 27  1  0  0  0
 25 28  1  0  0  0
 29 50  1  0  0  0
M  END
> <s_m_entry_id>
223

> <Applicants>
Bayer

> <CHEMBL_ID>
CHEMBL3544942

> <Canonical_Smiles>
S(=O)(=[NH])(C1CC1)c1ccc(Nc2nc(O[C@@H]([C@H](O)C)C)c(cn2)C(F)(F)F)cc1

> <Chirality>
Single Stereoisomer

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Indications>
nan

> <Type>
nan

> <targets_id>
P06493|P24941|P11802|P50750

> <inchi>
InChI=1S/C18H21F3N4O3S/c1-10(26)11(2)28-16-15(18(19,20)21)9-23-17(25-16)24-12-3-5-13(6-4-12)29(22,27)14-7-8-14/h3-6,9-11,14,22,26H,7-8H2,1-2H3,(H,23,24,25)/t10-,11-,29+/m1/s1

> <stdInchikey>
UELYDGOOJPRWGF-SRQXXRKNSA-N

> <csid>
32697590

> <Links>
|http://www.chemspider.com/Chemical-Structure.32697590.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4282338|http://pubchem.ncbi.nlm.nih.gov/compound/71494949|http://www.drugbank.ca/drugs/DB12974|http://zinc15.docking.org/substances/ZINC000095616570|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=0W9Q8U337A|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50468265

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|ZINC|FDA SRS|BindingDB

> <MW>
430.1

> <HBA>
7

> <HBD>
3

> <NRB>
7

> <TPSA>
108.2

> <LogP>
4

> <RoF>
0

> <Targets>
CDK1; CDK2; CDK4; CDK9

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0002

> <r_epik_State_Penalty>
  0.0000

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
223

> <Kinase families>
CMGC

$$$$
Pictilisib
                    3D
 Structure written by MMmdl.
 62 67  0  0  1  0            999 V2000
   -4.1741    0.2707    3.6778 C   0  0  0  0  0  0
   -4.0801   -0.6299    2.0233 S   0  0  0  0  0  0
   -4.0988   -2.0706    2.3005 O   0  0  0  0  0  0
   -5.0767   -0.0411    1.1217 O   0  0  0  0  0  0
   -2.4695   -0.2002    1.4220 N   0  0  0  0  0  0
   -2.3457    1.1298    0.7811 C   0  0  0  0  0  0
   -0.8797    1.4937    0.4651 C   0  0  0  0  0  0
   -0.2317    0.4310   -0.3161 N   0  0  0  0  0  0
   -0.2577   -0.8457    0.4163 C   0  0  0  0  0  0
   -1.7059   -1.2720    0.7400 C   0  0  0  0  0  0
    1.1359    0.8214   -0.6735 C   0  0  0  0  0  0
    1.7132   -0.0459   -1.7757 C   0  0  0  0  0  0
    2.8075   -0.8940   -1.7131 C   0  0  0  0  0  0
    3.0721   -1.5774   -2.9287 C   0  0  0  0  0  0
    2.1525   -1.2397   -3.9531 C   0  0  0  0  0  0
    0.9777   -0.0705   -3.3759 S   0  0  0  0  0  0
    2.3012   -1.8521   -5.2080 C   0  0  0  0  0  0
    3.3064   -2.7443   -5.4136 N   0  0  0  0  0  0
    4.1473   -3.0059   -4.3777 C   0  0  0  0  0  0
    4.0653   -2.4527   -3.1314 N   0  0  0  0  0  0
    5.2516   -3.9946   -4.6206 C   0  0  0  0  0  0
    5.8318   -4.7095   -3.5590 C   0  0  0  0  0  0
    6.8527   -5.6369   -3.7499 C   0  0  0  0  0  0
    7.3669   -5.9143   -5.0134 C   0  0  0  0  0  0
    6.8097   -5.2127   -6.0835 C   0  0  0  0  0  0
    5.7674   -4.2616   -5.9152 C   0  0  0  0  0  0
    5.5265   -3.7984   -7.2502 C   0  0  0  0  0  0
    6.3025   -4.3850   -8.1230 N   0  0  0  0  0  0
    7.0790   -5.2390   -7.4372 N   0  0  0  0  0  0
    1.4293   -1.5593   -6.2445 N   0  0  0  0  0  0
    2.0302   -0.9737   -7.4534 C   0  0  0  0  0  0
    0.9422   -0.4339   -8.4080 C   0  0  0  0  0  0
    0.0429   -1.4727   -8.7824 O   0  0  0  0  0  0
   -0.5084   -2.1790   -7.6756 C   0  0  0  0  0  0
    0.6107   -2.6791   -6.7353 C   0  0  0  0  0  0
   -5.1401    0.0624    4.1370 H   0  0  0  0  0  0
   -4.0668    1.3418    3.5093 H   0  0  0  0  0  0
   -3.3714   -0.0881    4.3215 H   0  0  0  0  0  0
   -2.9474    1.1369   -0.1289 H   0  0  0  0  0  0
   -2.7936    1.8743    1.4396 H   0  0  0  0  0  0
   -0.8559    2.4329   -0.0895 H   0  0  0  0  0  0
   -0.3277    1.6504    1.3942 H   0  0  0  0  0  0
    0.2198   -1.6289   -0.1736 H   0  0  0  0  0  0
    0.3125   -0.7452    1.3419 H   0  0  0  0  0  0
   -1.7052   -2.1585    1.3744 H   0  0  0  0  0  0
   -2.2388   -1.5559   -0.1687 H   0  0  0  0  0  0
    1.1328    1.8580   -1.0149 H   0  0  0  0  0  0
    1.7664    0.7979    0.2175 H   0  0  0  0  0  0
    3.3996   -1.0256   -0.8195 H   0  0  0  0  0  0
    5.4805   -4.5548   -2.5492 H   0  0  0  0  0  0
    7.2552   -6.1569   -2.8931 H   0  0  0  0  0  0
    8.1588   -6.6363   -5.1488 H   0  0  0  0  0  0
    4.8111   -3.0587   -7.5771 H   0  0  0  0  0  0
    7.7631   -5.8036   -7.9198 H   0  0  0  0  0  0
    2.6808   -0.1470   -7.1636 H   0  0  0  0  0  0
    2.6630   -1.6960   -7.9733 H   0  0  0  0  0  0
    0.3981    0.3933   -7.9484 H   0  0  0  0  0  0
    1.4038   -0.0330   -9.3105 H   0  0  0  0  0  0
   -1.2148   -1.5461   -7.1355 H   0  0  0  0  0  0
   -1.0827   -3.0244   -8.0548 H   0  0  0  0  0  0
    1.2232   -3.4285   -7.2410 H   0  0  0  0  0  0
    0.1501   -3.1824   -5.8838 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 36  1  0  0  0
  1 37  1  0  0  0
  1 38  1  0  0  0
  2  3  2  0  0  0
  2  4  2  0  0  0
  2  5  1  0  0  0
  5  6  1  0  0  0
  5 10  1  0  0  0
  6  7  1  0  0  0
  6 39  1  0  0  0
  6 40  1  0  0  0
  7  8  1  0  0  0
  7 41  1  0  0  0
  7 42  1  0  0  0
  8  9  1  0  0  0
  8 11  1  0  0  0
  9 10  1  0  0  0
  9 43  1  0  0  0
  9 44  1  0  0  0
 10 45  1  0  0  0
 10 46  1  0  0  0
 11 12  1  0  0  0
 11 47  1  0  0  0
 11 48  1  0  0  0
 12 13  2  0  0  0
 12 16  1  0  0  0
 13 14  1  0  0  0
 13 49  1  0  0  0
 14 15  1  0  0  0
 14 20  2  0  0  0
 15 16  1  0  0  0
 15 17  2  0  0  0
 17 18  1  0  0  0
 17 30  1  0  0  0
 18 19  2  0  0  0
 19 20  1  0  0  0
 19 21  1  0  0  0
 21 22  1  0  0  0
 21 26  2  0  0  0
 22 23  2  0  0  0
 22 50  1  0  0  0
 23 24  1  0  0  0
 23 51  1  0  0  0
 24 25  2  0  0  0
 24 52  1  0  0  0
 25 26  1  0  0  0
 25 29  1  0  0  0
 26 27  1  0  0  0
 27 28  2  0  0  0
 27 53  1  0  0  0
 28 29  1  0  0  0
 29 54  1  0  0  0
 30 31  1  0  0  0
 30 35  1  0  0  0
 31 32  1  0  0  0
 31 55  1  0  0  0
 31 56  1  0  0  0
 32 33  1  0  0  0
 32 57  1  0  0  0
 32 58  1  0  0  0
 33 34  1  0  0  0
 34 35  1  0  0  0
 34 59  1  0  0  0
 34 60  1  0  0  0
 35 61  1  0  0  0
 35 62  1  0  0  0
M  END
> <s_m_entry_id>
224

> <Applicants>
Hoffmann-La Roche

> <CHEMBL_ID>
CHEMBL521851

> <Canonical_Smiles>
s1c2c(nc(nc2N2CCOCC2)-c2c3c([nH]nc3)ccc2)cc1CN1CCN(S(=O)(=O)C)CC1

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
CDC-0941 | GDC 0941 | GDC-0941 | PICTILISIB | RG-7321

> <Indications>
nan

> <Type>
1

> <targets_id>
P42336|P42338|O00329|P48736

> <inchi>
InChI=1S/C23H27N7O3S2/c1-35(31,32)30-7-5-28(6-8-30)15-16-13-20-21(34-16)23(29-9-11-33-12-10-29)26-22(25-20)17-3-2-4-19-18(17)14-24-27-19/h2-4,13-14H,5-12,15H2,1H3,(H,24,27)

> <stdInchikey>
LHNIIDJUOCFXAP-UHFFFAOYSA-N

> <csid>
21437049

> <Links>
|http://www.chemspider.com/Chemical-Structure.21437049.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL521851|http://pubchem.ncbi.nlm.nih.gov/compound/17755052|http://www.drugbank.ca/drugs/DB11663| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=GD9|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/GD9|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5682|http://zinc15.docking.org/substances/ZINC16052714|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=ICY00EMP8P|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=25028

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
513.2

> <HBA>
9

> <HBD>
1

> <NRB>
5

> <TPSA>
107.6

> <LogP>
2.1

> <RoF>
1

> <Targets>
PIK3CA; PIK3CB; PIK3CD; PIK3CG

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
0.980392

> <r_epik_Ionization_Penalty>
  0.2816

> <r_epik_State_Penalty>
  0.2831

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
224

> <lig_pdbID>
'GD9'

> <pdbID>
2wxp 2y3a 3dbs

> <Kinase families>
Atypical

$$$$
Verosudil
                    3D
 Structure written by MMmdl.
 41 43  0  0  1  0            999 V2000
   -0.6817   -0.3348    1.5847 C   0  0  0  0  0  0
   -0.2722   -0.1629    0.1019 N   0  3  0  0  0  0
   -1.0946   -1.1610   -0.7505 C   0  0  0  0  0  0
    1.2315   -0.2375   -0.1674 C   0  0  2  0  0  0
    2.0122    0.5077    0.8772 C   0  0  0  0  0  0
    2.0234    1.9050    1.0551 C   0  0  0  0  0  0
    2.8378    2.3110    2.1031 C   0  0  0  0  0  0
    3.6038    0.9718    2.8927 S   0  0  0  0  0  0
    2.8256   -0.1345    1.8073 C   0  0  0  0  0  0
    1.5469    0.3552   -1.5717 C   0  0  0  0  0  0
    0.6953    1.0046   -2.1846 O   0  0  0  0  0  0
    2.7939    0.0897   -2.0192 N   0  0  0  0  0  0
    3.3976    0.4985   -3.2212 C   0  0  0  0  0  0
    3.0229    1.6485   -3.9371 C   0  0  0  0  0  0
    3.6893    2.0001   -5.1115 C   0  0  0  0  0  0
    4.7438    1.2111   -5.5833 C   0  0  0  0  0  0
    5.1294    0.0630   -4.8607 C   0  0  0  0  0  0
    4.4613   -0.2820   -3.6847 C   0  0  0  0  0  0
    6.2434   -0.7433   -5.3816 C   0  0  0  0  0  0
    6.8316   -0.3373   -6.5199 C   0  0  0  0  0  0
    6.4724    0.7722   -7.2314 N   0  0  0  0  0  0
    5.4630    1.6140   -6.8721 C   0  0  0  0  0  0
    5.1945    2.5985   -7.5596 O   0  0  0  0  0  0
   -0.2804   -1.2894    1.9285 H   0  0  0  0  0  0
   -1.7712   -0.3168    1.6363 H   0  0  0  0  0  0
   -0.2733    0.5022    2.1507 H   0  0  0  0  0  0
   -0.8169   -2.1687   -0.4379 H   0  0  0  0  0  0
   -0.8704   -1.0017   -1.8044 H   0  0  0  0  0  0
   -2.1498   -0.9620   -0.5595 H   0  0  0  0  0  0
    1.4729   -1.3030   -0.1533 H   0  0  0  0  0  0
    1.4597    2.5928    0.4418 H   0  0  0  0  0  0
    3.0203    3.3199    2.4427 H   0  0  0  0  0  0
    3.0030   -1.1957    1.9031 H   0  0  0  0  0  0
    3.3667   -0.5062   -1.4395 H   0  0  0  0  0  0
    2.2298    2.2940   -3.5924 H   0  0  0  0  0  0
    3.3808    2.8905   -5.6415 H   0  0  0  0  0  0
    4.7688   -1.1620   -3.1367 H   0  0  0  0  0  0
    6.5807   -1.6340   -4.8714 H   0  0  0  0  0  0
    7.6554   -0.8563   -6.9878 H   0  0  0  0  0  0
    6.9629    1.0135   -8.0802 H   0  0  0  0  0  0
   -0.5374    0.7748   -0.1674 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 24  1  0  0  0
  1 25  1  0  0  0
  1 26  1  0  0  0
  2  3  1  0  0  0
  2  4  1  0  0  0
  2 41  1  0  0  0
  3 27  1  0  0  0
  3 28  1  0  0  0
  3 29  1  0  0  0
  4  5  1  0  0  0
  4 10  1  0  0  0
  4 30  1  0  0  0
  5  6  1  0  0  0
  5  9  2  0  0  0
  6  7  2  0  0  0
  6 31  1  0  0  0
  7  8  1  0  0  0
  7 32  1  0  0  0
  8  9  1  0  0  0
  9 33  1  0  0  0
 10 11  2  0  0  0
 10 12  1  0  0  0
 12 13  1  0  0  0
 12 34  1  0  0  0
 13 14  1  0  0  0
 13 18  2  0  0  0
 14 15  2  0  0  0
 14 35  1  0  0  0
 15 16  1  0  0  0
 15 36  1  0  0  0
 16 17  2  0  0  0
 16 22  1  0  0  0
 17 18  1  0  0  0
 17 19  1  0  0  0
 18 37  1  0  0  0
 19 20  2  0  0  0
 19 38  1  0  0  0
 20 21  1  0  0  0
 20 39  1  0  0  0
 21 22  1  0  0  0
 21 40  1  0  0  0
 22 23  2  0  0  0
M  CHG  1   2   1
M  END
> <s_m_entry_id>
226

> <Applicants>
Aerie Pharmaceutical

> <CHEMBL_ID>
CHEMBL3545065

> <Canonical_Smiles>
s1cc(cc1)C(N(C)C)C(=O)Nc1cc2c(cc1)C(=O)NC=C2

> <Chirality>
Racemic Mixture

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
AR-12286 | AR-12286 FREE BASE | VEROSUDIL

> <Indications>
nan

> <Type>
nan

> <targets_id>
nan

> <inchi>
InChI=1S/C17H17N3O2S/c1-20(2)15(12-6-8-23-10-12)17(22)19-13-3-4-14-11(9-13)5-7-18-16(14)21/h3-10,15H,1-2H3,(H,18,21)(H,19,22)

> <stdInchikey>
VDYRZXYYQMMFJW-UHFFFAOYSA-N

> <csid>
32742441

> <Links>
|http://www.chemspider.com/Chemical-Structure.32742441.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3545065|http://pubchem.ncbi.nlm.nih.gov/compound/66906051|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8911

> <LinkName>
|ChemSpider|ChEMBL|PubChem|Guide to Pharmacology

> <indicationG2P>
None

> <MW>
327.1

> <HBA>
4

> <HBD>
2

> <NRB>
4

> <TPSA>
65.2

> <LogP>
2.8

> <RoF>
0

> <Targets>
nan

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_epik_Ionization_Penalty>
  0.1794

> <r_epik_State_Penalty>
  0.1688

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
226

$$$$
Pelitinib
                    3D
 Structure written by MMmdl.
 57 59  0  0  1  0            999 V2000
    0.6765   -4.6024   -0.0450 C   0  0  0  0  0  0
   -0.4363   -3.5506   -0.0118 C   0  0  0  0  0  0
    0.1586   -2.2580    0.0645 O   0  0  0  0  0  0
   -0.6423   -1.1262    0.0879 C   0  0  0  0  0  0
   -2.0429   -1.1794    0.0502 C   0  0  0  0  0  0
   -2.8216   -0.0006    0.0777 C   0  0  0  0  0  0
   -2.1832    1.2729    0.1515 C   0  0  0  0  0  0
   -0.7615    1.3011    0.1945 C   0  0  0  0  0  0
   -0.0055    0.1213    0.1471 C   0  0  0  0  0  0
    1.4039    0.1307    0.2075 N   0  0  0  0  0  0
    2.2561    1.0762   -0.2445 C   0  0  0  0  0  0
    1.9148    2.1054   -0.8327 O   0  0  0  0  0  0
    3.6363    0.7559    0.0434 C   0  0  0  0  0  0
    4.6606    1.5604   -0.3054 C   0  0  0  0  0  0
    6.1195    1.2565   -0.0225 C   0  0  0  0  0  0
    6.7618    2.2233    0.9959 N   0  3  0  0  0  0
    6.1112    2.1417    2.3921 C   0  0  0  0  0  0
    8.2864    2.0176    1.0855 C   0  0  0  0  0  0
   -3.0064    2.4498    0.1916 C   0  0  0  0  0  0
   -4.4103    2.2787    0.1246 C   0  0  0  0  0  0
   -4.9278    0.9865    0.0575 C   0  0  0  0  0  0
   -4.1722   -0.1323    0.0381 N   0  0  0  0  0  0
   -5.3702    3.3806    0.0808 C   0  0  0  0  0  0
   -6.1301    4.2527    0.0462 N   0  0  0  0  0  0
   -2.3814    3.7159    0.2646 N   0  0  0  0  0  0
   -2.7583    4.8270    1.0317 C   0  0  0  0  0  0
   -3.1551    4.6829    2.3661 C   0  0  0  0  0  0
   -3.5196    5.8025    3.1140 C   0  0  0  0  0  0
   -3.4843    7.0721    2.5364 C   0  0  0  0  0  0
   -3.0801    7.2220    1.2064 C   0  0  0  0  0  0
   -2.7145    6.1006    0.4592 C   0  0  0  0  0  0
   -3.0283    8.7869    0.4761 Cl  0  0  0  0  0  0
   -3.8406    8.1507    3.2720 F   0  0  0  0  0  0
    0.2602   -5.6085   -0.1001 H   0  0  0  0  0  0
    1.2972   -4.5473    0.8497 H   0  0  0  0  0  0
    1.3236   -4.4623   -0.9113 H   0  0  0  0  0  0
   -1.0470   -3.6377   -0.9121 H   0  0  0  0  0  0
   -1.0801   -3.7246    0.8522 H   0  0  0  0  0  0
   -2.5637   -2.1241   -0.0001 H   0  0  0  0  0  0
   -0.2690    2.2574    0.2815 H   0  0  0  0  0  0
    1.8145   -0.7425    0.5053 H   0  0  0  0  0  0
    3.8296   -0.1733    0.5631 H   0  0  0  0  0  0
    4.4774    2.4886   -0.8304 H   0  0  0  0  0  0
    6.2660    0.2554    0.3884 H   0  0  0  0  0  0
    6.7040    1.3554   -0.9385 H   0  0  0  0  0  0
    6.2458    1.1250    2.7641 H   0  0  0  0  0  0
    5.0559    2.3928    2.2810 H   0  0  0  0  0  0
    6.6140    2.8720    3.0273 H   0  0  0  0  0  0
    8.4665    1.0064    1.4536 H   0  0  0  0  0  0
    8.6762    2.7711    1.7711 H   0  0  0  0  0  0
    8.6932    2.1599    0.0835 H   0  0  0  0  0  0
   -5.9943    0.8134    0.0032 H   0  0  0  0  0  0
   -1.3789    3.6526    0.1614 H   0  0  0  0  0  0
   -3.1861    3.7054    2.8257 H   0  0  0  0  0  0
   -3.8294    5.6850    4.1421 H   0  0  0  0  0  0
   -2.4038    6.2221   -0.5689 H   0  0  0  0  0  0
    6.6113    3.1607    0.6491 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 34  1  0  0  0
  1 35  1  0  0  0
  1 36  1  0  0  0
  2  3  1  0  0  0
  2 37  1  0  0  0
  2 38  1  0  0  0
  3  4  1  0  0  0
  4  5  1  0  0  0
  4  9  2  0  0  0
  5  6  2  0  0  0
  5 39  1  0  0  0
  6  7  1  0  0  0
  6 22  1  0  0  0
  7  8  2  0  0  0
  7 19  1  0  0  0
  8  9  1  0  0  0
  8 40  1  0  0  0
  9 10  1  0  0  0
 10 11  1  0  0  0
 10 41  1  0  0  0
 11 12  2  0  0  0
 11 13  1  0  0  0
 13 14  2  0  0  0
 13 42  1  0  0  0
 14 15  1  0  0  0
 14 43  1  0  0  0
 15 16  1  0  0  0
 15 44  1  0  0  0
 15 45  1  0  0  0
 16 17  1  0  0  0
 16 18  1  0  0  0
 16 57  1  0  0  0
 17 46  1  0  0  0
 17 47  1  0  0  0
 17 48  1  0  0  0
 18 49  1  0  0  0
 18 50  1  0  0  0
 18 51  1  0  0  0
 19 20  2  0  0  0
 19 25  1  0  0  0
 20 21  1  0  0  0
 20 23  1  0  0  0
 21 22  2  0  0  0
 21 52  1  0  0  0
 23 24  3  0  0  0
 25 26  1  0  0  0
 25 53  1  0  0  0
 26 27  2  0  0  0
 26 31  1  0  0  0
 27 28  1  0  0  0
 27 54  1  0  0  0
 28 29  2  0  0  0
 28 55  1  0  0  0
 29 30  1  0  0  0
 29 33  1  0  0  0
 30 31  2  0  0  0
 30 32  1  0  0  0
 31 56  1  0  0  0
M  CHG  1  16   1
M  END
> <s_m_entry_id>
230

> <Applicants>
Wyeth

> <CHEMBL_ID>
CHEMBL607707

> <Canonical_Smiles>
Clc1cc(Nc2c3cc(NC(=O)\C=C\CN(C)C)c(OCC)cc3ncc2C#N)ccc1F

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
EKB-569 | PELITINIB | WAY-EKB-569

> <Indications>
nan

> <Type>
1

> <targets_id>
P00533|P04626

> <inchi>
InChI=1S/C24H23ClFN5O2/c1-4-33-22-12-20-17(11-21(22)30-23(32)6-5-9-31(2)3)24(15(13-27)14-28-20)29-16-7-8-19(26)18(25)10-16/h5-8,10-12,14H,4,9H2,1-3H3,(H,28,29)(H,30,32)/b6-5+

> <stdInchikey>
WVUNYSQLFKLYNI-AATRIKPKSA-N

> <csid>
4949255

> <Links>
|http://www.chemspider.com/Chemical-Structure.4949255.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL607707|http://pubchem.ncbi.nlm.nih.gov/compound/6445562|http://www.drugbank.ca/drugs/DB05524| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=93J|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/93J|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7644|http://zinc15.docking.org/substances/ZINC000000602803|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=X5DWL380Z6|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=31090

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
467.2

> <HBA>
6

> <HBD>
2

> <NRB>
8

> <TPSA>
90.3

> <LogP>
5.1

> <RoF>
1

> <Targets>
EGFR; ERBB2

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_epik_Ionization_Penalty>
  0.1653

> <r_epik_State_Penalty>
  0.1823

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
230

> <lig_pdbID>
'93J'

> <pdbID>
5vcw 7axm

> <Kinase families>
Tyr

> <indicationDB>
Pelitinib (EKB-569) is a potent, low molecular weight, selective, and irreversible inhibitor of epidermal growth factor receptor (EGFR) that is being developed as an anticancer agent.

> <uniprotId>
P00533

$$$$
Doramapimod
                    3D
 Structure written by MMmdl.
 76 80  0  0  1  0            999 V2000
   -3.9587   -3.8437   -2.3413 C   0  0  0  0  0  0
   -3.9631   -2.4271   -1.7964 C   0  0  0  0  0  0
   -2.8008   -1.6547   -1.8453 C   0  0  0  0  0  0
   -2.8088   -0.3542   -1.3490 C   0  0  0  0  0  0
   -3.9811    0.1754   -0.8010 C   0  0  0  0  0  0
   -5.1481   -0.5957   -0.7611 C   0  0  0  0  0  0
   -5.1366   -1.8965   -1.2574 C   0  0  0  0  0  0
   -3.9935    1.4935   -0.2938 N   0  0  0  0  0  0
   -3.1557    2.0833    0.6292 C   0  0  0  0  0  0
   -3.6229    3.3762    0.7697 C   0  0  0  0  0  0
   -4.7215    3.5005   -0.0965 C   0  0  0  0  0  0
   -4.9336    2.3556   -0.7195 N   0  0  0  0  0  0
   -5.6270    4.7122   -0.3639 C   0  0  0  0  0  0
   -5.1402    5.9509    0.4268 C   0  0  0  0  0  0
   -7.0753    4.3880    0.0723 C   0  0  0  0  0  0
   -5.6132    5.0605   -1.8718 C   0  0  0  0  0  0
   -2.1218    1.4396    1.2787 N   0  0  0  0  0  0
   -0.8421    1.5332    0.8737 C   0  0  0  0  0  0
   -0.4630    2.1897   -0.1009 O   0  0  0  0  0  0
   -0.0415    0.7846    1.6576 N   0  0  0  0  0  0
    1.3409    0.5695    1.4933 C   0  0  0  0  0  0
    2.2011    1.6259    1.1796 C   0  0  0  0  0  0
    3.5664    1.4246    1.0423 C   0  0  0  0  0  0
    4.1393    0.1599    1.2229 C   0  0  0  0  0  0
    3.2944   -0.9377    1.5626 C   0  0  0  0  0  0
    1.8815   -0.7374    1.7047 C   0  0  0  0  0  0
    1.0691   -1.8598    2.0455 C   0  0  0  0  0  0
    1.6286   -3.1181    2.2365 C   0  0  0  0  0  0
    2.9958   -3.3083    2.0972 C   0  0  0  0  0  0
    3.8246   -2.2429    1.7651 C   0  0  0  0  0  0
    5.4954   -0.0875    1.0958 O   0  0  0  0  0  0
    6.3773    0.9563    0.6867 C   0  0  0  0  0  0
    7.8164    0.4147    0.5613 C   0  0  0  0  0  0
    7.9248   -0.7922   -0.2671 N   0  0  0  0  0  0
    9.2670   -1.3705   -0.1438 C   0  0  0  0  0  0
    9.3896   -2.6524   -0.9954 C   0  0  0  0  0  0
    9.0429   -2.3961   -2.3532 O   0  0  0  0  0  0
    7.7443   -1.8311   -2.5095 C   0  0  0  0  0  0
    7.5980   -0.5395   -1.6764 C   0  0  0  0  0  0
   -4.5333   -4.5096   -1.6965 H   0  0  0  0  0  0
   -2.9463   -4.2435   -2.4131 H   0  0  0  0  0  0
   -4.4036   -3.8643   -3.3365 H   0  0  0  0  0  0
   -1.8923   -2.0562   -2.2708 H   0  0  0  0  0  0
   -1.9073    0.2370   -1.4076 H   0  0  0  0  0  0
   -6.0599   -0.1935   -0.3431 H   0  0  0  0  0  0
   -6.0394   -2.4891   -1.2224 H   0  0  0  0  0  0
   -3.2175    4.1370    1.4198 H   0  0  0  0  0  0
   -5.7697    6.8215    0.2371 H   0  0  0  0  0  0
   -4.1205    6.2261    0.1538 H   0  0  0  0  0  0
   -5.1546    5.7731    1.5030 H   0  0  0  0  0  0
   -7.1254    4.1313    1.1315 H   0  0  0  0  0  0
   -7.4868    3.5454   -0.4854 H   0  0  0  0  0  0
   -7.7424    5.2361   -0.0885 H   0  0  0  0  0  0
   -6.2280    5.9356   -2.0872 H   0  0  0  0  0  0
   -5.9980    4.2413   -2.4809 H   0  0  0  0  0  0
   -4.6031    5.2783   -2.2216 H   0  0  0  0  0  0
   -2.3428    0.9186    2.1145 H   0  0  0  0  0  0
   -0.4844    0.2272    2.3731 H   0  0  0  0  0  0
    1.8157    2.6264    1.0459 H   0  0  0  0  0  0
    4.1740    2.2819    0.7968 H   0  0  0  0  0  0
    0.0012   -1.7422    2.1566 H   0  0  0  0  0  0
    0.9949   -3.9542    2.4934 H   0  0  0  0  0  0
    3.4187   -4.2908    2.2473 H   0  0  0  0  0  0
    4.8863   -2.4144    1.6607 H   0  0  0  0  0  0
    6.0563    1.3967   -0.2586 H   0  0  0  0  0  0
    6.3670    1.7616    1.4228 H   0  0  0  0  0  0
    8.4720    1.1957    0.1719 H   0  0  0  0  0  0
    8.1782    0.1954    1.5673 H   0  0  0  0  0  0
   10.0280   -0.6498   -0.4485 H   0  0  0  0  0  0
    9.4678   -1.6152    0.9002 H   0  0  0  0  0  0
   10.4135   -3.0244   -0.9609 H   0  0  0  0  0  0
    8.7639   -3.4483   -0.5879 H   0  0  0  0  0  0
    7.5825   -1.6115   -3.5649 H   0  0  0  0  0  0
    6.9792   -2.5580   -2.2310 H   0  0  0  0  0  0
    6.5716   -0.1843   -1.7672 H   0  0  0  0  0  0
    8.2389    0.2428   -2.0870 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 40  1  0  0  0
  1 41  1  0  0  0
  1 42  1  0  0  0
  2  3  1  0  0  0
  2  7  2  0  0  0
  3  4  2  0  0  0
  3 43  1  0  0  0
  4  5  1  0  0  0
  4 44  1  0  0  0
  5  6  2  0  0  0
  5  8  1  0  0  0
  6  7  1  0  0  0
  6 45  1  0  0  0
  7 46  1  0  0  0
  8  9  1  0  0  0
  8 12  1  0  0  0
  9 10  2  0  0  0
  9 17  1  0  0  0
 10 11  1  0  0  0
 10 47  1  0  0  0
 11 12  2  0  0  0
 11 13  1  0  0  0
 13 14  1  0  0  0
 13 15  1  0  0  0
 13 16  1  0  0  0
 14 48  1  0  0  0
 14 49  1  0  0  0
 14 50  1  0  0  0
 15 51  1  0  0  0
 15 52  1  0  0  0
 15 53  1  0  0  0
 16 54  1  0  0  0
 16 55  1  0  0  0
 16 56  1  0  0  0
 17 18  1  0  0  0
 17 57  1  0  0  0
 18 19  2  0  0  0
 18 20  1  0  0  0
 20 21  1  0  0  0
 20 58  1  0  0  0
 21 22  2  0  0  0
 21 26  1  0  0  0
 22 23  1  0  0  0
 22 59  1  0  0  0
 23 24  2  0  0  0
 23 60  1  0  0  0
 24 25  1  0  0  0
 24 31  1  0  0  0
 25 26  1  0  0  0
 25 30  2  0  0  0
 26 27  2  0  0  0
 27 28  1  0  0  0
 27 61  1  0  0  0
 28 29  2  0  0  0
 28 62  1  0  0  0
 29 30  1  0  0  0
 29 63  1  0  0  0
 30 64  1  0  0  0
 31 32  1  0  0  0
 32 33  1  0  0  0
 32 65  1  0  0  0
 32 66  1  0  0  0
 33 34  1  0  0  0
 33 67  1  0  0  0
 33 68  1  0  0  0
 34 35  1  0  0  0
 34 39  1  0  0  0
 35 36  1  0  0  0
 35 69  1  0  0  0
 35 70  1  0  0  0
 36 37  1  0  0  0
 36 71  1  0  0  0
 36 72  1  0  0  0
 37 38  1  0  0  0
 38 39  1  0  0  0
 38 73  1  0  0  0
 38 74  1  0  0  0
 39 75  1  0  0  0
 39 76  1  0  0  0
M  END
> <s_m_entry_id>
233

> <Applicants>
Boehringer Ingelheim

> <CHEMBL_ID>
CHEMBL103667

> <Canonical_Smiles>
O1CCN(CC1)CCOc1c2c(cccc2)c(NC(=O)Nc2n(nc(c2)C(C)(C)C)-c2ccc(cc2)C)cc1

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
BIRB 796 BS | BIRB-796 | BIRB-796 BS | DORAMAPIMOD

> <Indications>
nan

> <Type>
2

> <targets_id>
Q16539

> <inchi>
InChI=1S/C31H37N5O3/c1-22-9-11-23(12-10-22)36-29(21-28(34-36)31(2,3)4)33-30(37)32-26-13-14-27(25-8-6-5-7-24(25)26)39-20-17-35-15-18-38-19-16-35/h5-14,21H,15-20H2,1-4H3,(H2,32,33,37)

> <stdInchikey>
MVCOAUNKQVWQHZ-UHFFFAOYSA-N

> <csid>
137746

> <Links>
|http://www.chemspider.com/Chemical-Structure.137746.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL103667|http://pubchem.ncbi.nlm.nih.gov/compound/156422|http://www.drugbank.ca/drugs/DB03044| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=B96|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/B96|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5668|http://zinc15.docking.org/substances/ZINC24044436|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=HO1A8B3YVV|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=13533

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
527.3

> <HBA>
6

> <HBD>
2

> <NRB>
7

> <TPSA>
80.7

> <LogP>
6

> <RoF>
2

> <Targets>
MAPK14

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0641

> <r_epik_State_Penalty>
  0.0558

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
233

> <lig_pdbID>
'B96'

> <pdbID>
1kv2 3fzs 3npc 4jvg 4twn 5n66 6gtt

> <Kinase families>
CMGC

> <indicationDB>
Doramapimod is a P38 MAP kinase inhibitor.

> <uniprotId>
Q16539

$$$$
Simurosertib
                    3D
 Structure written by MMmdl.
 44 48  0  0  1  0            999 V2000
   -0.7099    2.5230    0.0978 C   0  0  0  0  0  0
   -0.9124    1.0254    0.0592 C   0  0  0  0  0  0
   -0.0444   -0.0636    0.0323 C   0  0  0  0  0  0
   -0.8919   -1.1834    0.0138 C   0  0  0  0  0  0
   -2.1645   -0.8680    0.0195 N   0  0  0  0  0  0
   -2.1638    0.4661    0.0441 N   0  0  0  0  0  0
    1.4080   -0.0609    0.0222 C   0  0  0  0  0  0
    2.2611    0.8518   -0.6010 C   0  0  0  0  0  0
    3.6184    0.5656   -0.4155 C   0  0  0  0  0  0
    3.8053   -0.5882    0.3538 C   0  0  0  0  0  0
    2.3096   -1.3066    0.8473 S   0  0  0  0  0  0
    5.1440   -1.0763    0.6653 C   0  0  0  0  0  0
    5.4678   -2.0639    1.3210 O   0  0  0  0  0  0
    6.0764   -0.2433    0.0971 N   0  0  0  0  0  0
    5.8615    0.8991   -0.6572 C   0  0  0  0  0  0
    4.6571    1.3013   -0.9140 N   0  0  0  0  0  0
    7.1027    1.6546   -1.1635 C   0  0  1  0  0  0
    6.9406    2.3333   -2.5674 C   0  0  0  0  0  0
    7.2762    3.8428   -2.4903 C   0  0  2  0  0  0
    8.7319    4.0011   -1.9894 C   0  0  0  0  0  0
    8.9098    3.3339   -0.5989 C   0  0  0  0  0  0
    7.5465    2.7462   -0.1404 N   0  3  1  0  0  0
    6.5258    3.9168   -0.0520 C   0  0  0  0  0  0
    6.3216    4.5111   -1.4709 C   0  0  0  0  0  0
    0.3254    2.7941    0.3025 H   0  0  0  0  0  0
   -1.3148    2.9910    0.8749 H   0  0  0  0  0  0
   -0.9838    2.9886   -0.8492 H   0  0  0  0  0  0
   -0.5734   -2.2157   -0.0086 H   0  0  0  0  0  0
   -3.0233    0.9963    0.0560 H   0  0  0  0  0  0
    1.9101    1.6973   -1.1742 H   0  0  0  0  0  0
    7.0342   -0.5162    0.2615 H   0  0  0  0  0  0
    7.9416    0.9553   -1.1773 H   0  0  0  0  0  0
    7.6040    1.8458   -3.2835 H   0  0  0  0  0  0
    5.9408    2.2097   -2.9871 H   0  0  0  0  0  0
    7.1616    4.3041   -3.4725 H   0  0  0  0  0  0
    9.4266    3.5573   -2.7039 H   0  0  0  0  0  0
    8.9958    5.0579   -1.9296 H   0  0  0  0  0  0
    9.6176    2.5037   -0.6158 H   0  0  0  0  0  0
    9.2217    4.0405    0.1719 H   0  0  0  0  0  0
    5.6073    3.5245    0.3845 H   0  0  0  0  0  0
    6.9508    4.6394    0.6465 H   0  0  0  0  0  0
    6.4938    5.5881   -1.4462 H   0  0  0  0  0  0
    5.2842    4.3788   -1.7820 H   0  0  0  0  0  0
    7.6706    2.3231    0.7687 H   0  0  0  0  0  0
  1 25  1  0  0  0
  1 26  1  0  0  0
  1 27  1  0  0  0
  1  2  1  0  0  0
  2  6  1  0  0  0
  2  3  2  0  0  0
  3  4  1  0  0  0
  3  7  1  0  0  0
  4 28  1  0  0  0
  4  5  2  0  0  0
  5  6  1  0  0  0
  6 29  1  0  0  0
  7  8  2  0  0  0
  7 11  1  0  0  0
  8  9  1  0  0  0
  8 30  1  0  0  0
  9 10  2  0  0  0
  9 16  1  0  0  0
 10 11  1  0  0  0
 10 12  1  0  0  0
 12 13  2  0  0  0
 12 14  1  0  0  0
 14 15  1  0  0  0
 14 31  1  0  0  0
 15 16  2  0  0  0
 15 17  1  0  0  0
 17 18  1  0  0  0
 17 22  1  0  0  0
 17 32  1  0  0  0
 18 19  1  0  0  0
 18 33  1  0  0  0
 18 34  1  0  0  0
 19 20  1  0  0  0
 19 24  1  0  0  0
 19 35  1  0  0  0
 20 21  1  0  0  0
 20 36  1  0  0  0
 20 37  1  0  0  0
 21 22  1  0  0  0
 21 38  1  0  0  0
 21 39  1  0  0  0
 22 23  1  0  0  0
 22 44  1  0  0  0
 23 24  1  0  0  0
 23 40  1  0  0  0
 23 41  1  0  0  0
 24 42  1  0  0  0
 24 43  1  0  0  0
M  CHG  1  22   1
M  END
> <s_m_entry_id>
235

> <Applicants>
Takeda

> <CHEMBL_ID>
CHEMBL4297644

> <Canonical_Smiles>
s1c2c(N=C(NC2=O)C2N3CCC(C2)CC3)cc1-c1c[nH]nc1C

> <Chirality>
Single Stereoisomer

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
|TAK-931

> <Indications>
nan

> <Type>
nan

> <targets_id>
nan

> <inchi>
InChI=1S/C17H19N5OS/c1-9-11(8-18-21-9)14-7-12-15(24-14)17(23)20-16(19-12)13-6-10-2-4-22(13)5-3-10/h7-8,10,13H,2-6H2,1H3,(H,18,21)(H,19,20,23)

> <stdInchikey>
XGVXKJKTISMIOW-UHFFFAOYSA-N

> <csid>
64879789

> <Links>
|http://www.chemspider.com/Chemical-Structure.64879789.html|http://pubchem.ncbi.nlm.nih.gov/compound/71147529

> <LinkName>
|ChemSpider|PubChem

> <MW>
341.1

> <HBA>
5

> <HBD>
2

> <NRB>
2

> <TPSA>
77.7

> <LogP>
2.8

> <RoF>
0

> <Targets>
nan

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
0.5

> <r_epik_Ionization_Penalty>
  0.1417

> <r_epik_State_Penalty>
  0.5503

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
235

$$$$
Olmutinib
                    3D
 Structure written by MMmdl.
 62 66  0  0  1  0            999 V2000
   -2.7534    7.0244   -4.1330 C   0  0  0  0  0  0
   -3.1643    6.6487   -2.6964 N   0  3  0  0  0  0
   -1.9469    6.7407   -1.7440 C   0  0  0  0  0  0
   -2.3385    6.1727   -0.3610 C   0  0  0  0  0  0
   -2.7865    4.7776   -0.5033 N   0  0  0  0  0  0
   -4.0772    4.8253   -1.2095 C   0  0  0  0  0  0
   -3.8533    5.2621   -2.6752 C   0  0  0  0  0  0
   -1.9299    3.6683   -0.5007 C   0  0  0  0  0  0
   -2.3908    2.3912   -0.8580 C   0  0  0  0  0  0
   -1.5395    1.2899   -0.8537 C   0  0  0  0  0  0
   -0.2004    1.4263   -0.4907 C   0  0  0  0  0  0
    0.2726    2.6926   -0.1277 C   0  0  0  0  0  0
   -0.5812    3.7915   -0.1308 C   0  0  0  0  0  0
    0.5868    0.2583   -0.5199 N   0  0  0  0  0  0
    1.9223   -0.0385   -0.2081 C   0  0  0  0  0  0
    2.2675   -1.3440   -0.3771 N   0  0  0  0  0  0
    3.5341   -1.6730   -0.0854 C   0  0  0  0  0  0
    4.0981   -2.9733   -0.1917 C   0  0  0  0  0  0
    5.4267   -2.9886    0.1821 C   0  0  0  0  0  0
    6.0467   -1.4280    0.6778 S   0  0  0  0  0  0
    4.4723   -0.7079    0.3786 C   0  0  0  0  0  0
    4.0295    0.6119    0.5242 C   0  0  0  0  0  0
    2.7463    0.9464    0.2254 N   0  0  0  0  0  0
    4.9270    1.5650    0.9711 O   0  0  0  0  0  0
    4.5310    2.8693    1.1677 C   0  0  0  0  0  0
    3.7000    3.2113    2.2389 C   0  0  0  0  0  0
    3.2960    4.5333    2.4172 C   0  0  0  0  0  0
    3.7207    5.5205    1.5283 C   0  0  0  0  0  0
    4.5531    5.1868    0.4470 C   0  0  0  0  0  0
    4.9661    3.8605    0.2857 C   0  0  0  0  0  0
    5.0438    6.1248   -0.4779 N   0  0  0  0  0  0
    4.4680    7.2805   -0.8733 C   0  0  0  0  0  0
    3.3594    7.6753   -0.5024 O   0  0  0  0  0  0
    5.3016    8.0220   -1.7925 C   0  0  0  0  0  0
    4.9533    9.2261   -2.2837 C   0  0  0  0  0  0
   -2.0200    6.2935   -4.4777 H   0  0  0  0  0  0
   -2.3323    8.0300   -4.0952 H   0  0  0  0  0  0
   -3.6582    7.0044   -4.7420 H   0  0  0  0  0  0
   -1.1263    6.1798   -2.1960 H   0  0  0  0  0  0
   -1.6734    7.7953   -1.6901 H   0  0  0  0  0  0
   -1.5237    6.2655    0.3551 H   0  0  0  0  0  0
   -3.1367    6.7822    0.0674 H   0  0  0  0  0  0
   -4.6096    3.8779   -1.1563 H   0  0  0  0  0  0
   -4.7477    5.5339   -0.7195 H   0  0  0  0  0  0
   -4.7936    5.3752   -3.2161 H   0  0  0  0  0  0
   -3.2107    4.5622   -3.2134 H   0  0  0  0  0  0
   -3.4151    2.2168   -1.1454 H   0  0  0  0  0  0
   -1.9336    0.3239   -1.1362 H   0  0  0  0  0  0
    1.2947    2.8692    0.1610 H   0  0  0  0  0  0
   -0.1553    4.7399    0.1556 H   0  0  0  0  0  0
    0.0749   -0.5581   -0.8196 H   0  0  0  0  0  0
    3.5540   -3.8451   -0.5241 H   0  0  0  0  0  0
    6.0825   -3.8465    0.1932 H   0  0  0  0  0  0
    3.3644    2.4495    2.9270 H   0  0  0  0  0  0
    2.6561    4.7945    3.2471 H   0  0  0  0  0  0
    3.4080    6.5387    1.7039 H   0  0  0  0  0  0
    5.6141    3.5867   -0.5349 H   0  0  0  0  0  0
    5.8692    5.8349   -0.9812 H   0  0  0  0  0  0
    6.2422    7.5747   -2.0854 H   0  0  0  0  0  0
    4.0252    9.7142   -2.0198 H   0  0  0  0  0  0
    5.6068    9.7471   -2.9682 H   0  0  0  0  0  0
   -3.8442    7.3255   -2.3788 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 36  1  0  0  0
  1 37  1  0  0  0
  1 38  1  0  0  0
  2  3  1  0  0  0
  2  7  1  0  0  0
  2 62  1  0  0  0
  3  4  1  0  0  0
  3 39  1  0  0  0
  3 40  1  0  0  0
  4  5  1  0  0  0
  4 41  1  0  0  0
  4 42  1  0  0  0
  5  6  1  0  0  0
  5  8  1  0  0  0
  6  7  1  0  0  0
  6 43  1  0  0  0
  6 44  1  0  0  0
  7 45  1  0  0  0
  7 46  1  0  0  0
  8  9  1  0  0  0
  8 13  2  0  0  0
  9 10  2  0  0  0
  9 47  1  0  0  0
 10 11  1  0  0  0
 10 48  1  0  0  0
 11 12  2  0  0  0
 11 14  1  0  0  0
 12 13  1  0  0  0
 12 49  1  0  0  0
 13 50  1  0  0  0
 14 15  1  0  0  0
 14 51  1  0  0  0
 15 16  1  0  0  0
 15 23  2  0  0  0
 16 17  2  0  0  0
 17 18  1  0  0  0
 17 21  1  0  0  0
 18 19  2  0  0  0
 18 52  1  0  0  0
 19 20  1  0  0  0
 19 53  1  0  0  0
 20 21  1  0  0  0
 21 22  2  0  0  0
 22 23  1  0  0  0
 22 24  1  0  0  0
 24 25  1  0  0  0
 25 26  1  0  0  0
 25 30  2  0  0  0
 26 27  2  0  0  0
 26 54  1  0  0  0
 27 28  1  0  0  0
 27 55  1  0  0  0
 28 29  2  0  0  0
 28 56  1  0  0  0
 29 30  1  0  0  0
 29 31  1  0  0  0
 30 57  1  0  0  0
 31 32  1  0  0  0
 31 58  1  0  0  0
 32 33  2  0  0  0
 32 34  1  0  0  0
 34 35  2  0  0  0
 34 59  1  0  0  0
 35 60  1  0  0  0
 35 61  1  0  0  0
M  CHG  1   2   1
M  END
> <s_m_entry_id>
247

> <Applicants>
Hanmi Pharmaceutical

> <CHEMBL_ID>
CHEMBL3786343

> <Canonical_Smiles>
s1c2c(nc(nc2Oc2cc(NC(=O)C=C)ccc2)Nc2ccc(N3CCN(CC3)C)cc2)cc1

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
BI 1482694 | BI-1482694 | HM-61713 | HM61713 | OLMUTINIB

> <Indications>
For use in treatment of metastatic T790M mutation positive non-small cell lung cancer

> <Type>
nan

> <targets_id>
P00533

> <inchi>
InChI=1S/C26H26N6O2S/c1-3-23(33)27-19-5-4-6-21(17-19)34-25-24-22(11-16-35-24)29-26(30-25)28-18-7-9-20(10-8-18)32-14-12-31(2)13-15-32/h3-11,16-17H,1,12-15H2,2H3,(H,27,33)(H,28,29,30)

> <stdInchikey>
FDMQDKQUTRLUBU-UHFFFAOYSA-N

> <csid>
45743494

> <Links>
|http://www.chemspider.com/Chemical-Structure.45743494.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3786343|http://pubchem.ncbi.nlm.nih.gov/compound/54758501|http://www.drugbank.ca/drugs/DB13164|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9196|http://zinc15.docking.org/substances/ZINC000198970879|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=CHL9B67L95|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50160871

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
486.2

> <HBA>
8

> <HBD>
2

> <NRB>
7

> <TPSA>
82.6

> <LogP>
5.1

> <RoF>
1

> <Targets>
EGFR

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0809

> <r_epik_State_Penalty>
  0.4007

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
247

> <Kinase families>
Tyr

> <indicationDB>
Olmutinib is an orally active epidermal growth factor receptor inhibitor used in the treatment of T790M mutation positive non-small cell lung cancer. It is available under the brand name Olita made by Hanmi Pharmaceuticals <sup class="text-reference-group"><a class="reference-popover-link" data-content="Kim ES: Olmutinib: First Global Approval. Drugs. 2016 Jul;76(11):1153-7. doi: 10.1007/s40265-016-0606-z. (PubMed ID 27357069)" href="#reference-A19196">4</a></sup>. Olmutinib was developed by Hanmi Pharmaceuticals and Boehringer Ingelheim. Olmutinib recieved breakthrough therapy designation in the United States in December 2015 and was approved for use in Korea in May 2016.

> <uniprotId>
P00533

$$$$
Leniolisib
                    3D
 Structure written by MMmdl.
 58 61  0  0  1  0            999 V2000
   -5.8071   -0.6619    1.4717 C   0  0  0  0  0  0
   -4.4219   -0.0121    1.2882 C   0  0  0  0  0  0
   -3.8549   -0.0928   -0.1451 C   0  0  0  0  0  0
   -4.4254   -0.7884   -0.9888 O   0  0  0  0  0  0
   -2.7328    0.6067   -0.4351 N   0  0  0  0  0  0
   -2.1228    0.6228   -1.7705 C   0  0  0  0  0  0
   -0.9178    1.5561   -1.5988 C   0  0  0  0  0  0
   -0.5853    1.5068   -0.1068 C   0  0  1  0  0  0
   -1.9882    1.4528    0.5063 C   0  0  0  0  0  0
    0.1938    0.3105    0.2278 N   0  0  0  0  0  0
    1.5812    0.2305    0.0058 C   0  0  0  0  0  0
    2.2241   -1.0195    0.1313 C   0  0  0  0  0  0
    3.6166   -1.0484   -0.0719 C   0  0  0  0  0  0
    4.2597    0.0909   -0.3967 N   0  3  0  0  0  0
    3.6051    1.2585   -0.5137 C   0  0  0  0  0  0
    2.2686    1.3662   -0.3173 N   0  0  0  0  0  0
    4.4242   -2.3363    0.0134 C   0  0  0  0  0  0
    3.6070   -3.4705    0.6769 C   0  0  0  0  0  0
    2.2488   -3.5348    0.1250 N   0  0  0  0  0  0
    1.5075   -2.3228    0.5052 C   0  0  0  0  0  0
    1.5876   -4.7483    0.0903 C   0  0  0  0  0  0
    1.0251   -5.3177    1.2388 C   0  0  0  0  0  0
    0.3593   -6.5498    1.1659 C   0  0  0  0  0  0
    0.2793   -7.1841   -0.0851 C   0  0  0  0  0  0
    0.8274   -6.6407   -1.2110 N   0  0  0  0  0  0
    1.4651   -5.4492   -1.1105 C   0  0  0  0  0  0
   -0.3776   -8.3997   -0.1844 O   0  0  0  0  0  0
   -0.4735   -9.0551   -1.4482 C   0  0  0  0  0  0
   -0.2611   -7.1859    2.4107 C   0  0  0  0  0  0
   -1.5779   -7.3080    2.2420 F   0  0  0  0  0  0
    0.2612   -8.3966    2.6088 F   0  0  0  0  0  0
   -0.0505   -6.4618    3.5117 F   0  0  0  0  0  0
   -6.1515   -0.5512    2.5001 H   0  0  0  0  0  0
   -5.7827   -1.7297    1.2494 H   0  0  0  0  0  0
   -6.5551   -0.2006    0.8254 H   0  0  0  0  0  0
   -4.4855    1.0352    1.5867 H   0  0  0  0  0  0
   -3.7128   -0.4893    1.9656 H   0  0  0  0  0  0
   -1.8023   -0.3842   -2.0417 H   0  0  0  0  0  0
   -2.8152    0.9868   -2.5310 H   0  0  0  0  0  0
   -0.0803    1.2834   -2.2426 H   0  0  0  0  0  0
   -1.2059    2.5728   -1.8725 H   0  0  0  0  0  0
   -0.0616    2.4132    0.2011 H   0  0  0  0  0  0
   -2.4368    2.4473    0.5237 H   0  0  0  0  0  0
   -1.9820    1.0668    1.5266 H   0  0  0  0  0  0
   -0.3139   -0.5602    0.2886 H   0  0  0  0  0  0
    4.1990    2.1230   -0.7741 H   0  0  0  0  0  0
    4.7021   -2.6355   -0.9983 H   0  0  0  0  0  0
    5.3562   -2.1768    0.5571 H   0  0  0  0  0  0
    4.1215   -4.4207    0.5229 H   0  0  0  0  0  0
    3.5543   -3.3204    1.7569 H   0  0  0  0  0  0
    1.3147   -2.3313    1.5793 H   0  0  0  0  0  0
    0.5322   -2.3529    0.0164 H   0  0  0  0  0  0
    1.1091   -4.7983    2.1827 H   0  0  0  0  0  0
    1.8814   -5.0565   -2.0274 H   0  0  0  0  0  0
   -1.0269   -9.9867   -1.3312 H   0  0  0  0  0  0
    0.5121   -9.3027   -1.8453 H   0  0  0  0  0  0
   -1.0069   -8.4421   -2.1763 H   0  0  0  0  0  0
    5.2568    0.0665   -0.5562 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 33  1  0  0  0
  1 34  1  0  0  0
  1 35  1  0  0  0
  2  3  1  0  0  0
  2 36  1  0  0  0
  2 37  1  0  0  0
  3  4  2  0  0  0
  3  5  1  0  0  0
  5  6  1  0  0  0
  5  9  1  0  0  0
  6  7  1  0  0  0
  6 38  1  0  0  0
  6 39  1  0  0  0
  7  8  1  0  0  0
  7 40  1  0  0  0
  7 41  1  0  0  0
  8  9  1  0  0  0
  8 10  1  0  0  0
  8 42  1  0  0  0
  9 43  1  0  0  0
  9 44  1  0  0  0
 10 11  1  0  0  0
 10 45  1  0  0  0
 11 12  1  0  0  0
 11 16  2  0  0  0
 12 13  2  0  0  0
 12 20  1  0  0  0
 13 14  1  0  0  0
 13 17  1  0  0  0
 14 15  2  0  0  0
 14 58  1  0  0  0
 15 16  1  0  0  0
 15 46  1  0  0  0
 17 18  1  0  0  0
 17 47  1  0  0  0
 17 48  1  0  0  0
 18 19  1  0  0  0
 18 49  1  0  0  0
 18 50  1  0  0  0
 19 20  1  0  0  0
 19 21  1  0  0  0
 20 51  1  0  0  0
 20 52  1  0  0  0
 21 22  2  0  0  0
 21 26  1  0  0  0
 22 23  1  0  0  0
 22 53  1  0  0  0
 23 24  2  0  0  0
 23 29  1  0  0  0
 24 25  1  0  0  0
 24 27  1  0  0  0
 25 26  2  0  0  0
 26 54  1  0  0  0
 27 28  1  0  0  0
 28 55  1  0  0  0
 28 56  1  0  0  0
 28 57  1  0  0  0
 29 30  1  0  0  0
 29 31  1  0  0  0
 29 32  1  0  0  0
M  CHG  1  14   1
M  END
> <s_m_entry_id>
250

> <Applicants>
Novartis

> <CHEMBL_ID>
CHEMBL3643413

> <Canonical_Smiles>
FC(F)(F)c1cc(N2Cc3c(ncnc3N[C@H]3CCN(C3)C(=O)CC)CC2)cnc1OC

> <Chirality>
Single Stereoisomer

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
CDZ173-NX | LENIOLISIB

> <Indications>
nan

> <Type>
nan

> <targets_id>
nan

> <inchi>
InChI=1S/C21H25F3N6O2/c1-3-18(31)30-6-4-13(10-30)28-19-15-11-29(7-5-17(15)26-12-27-19)14-8-16(21(22,23)24)20(32-2)25-9-14/h8-9,12-13H,3-7,10-11H2,1-2H3,(H,26,27,28)/t13-/m0/s1

> <stdInchikey>
MWKYMZXCGYXLPL-ZDUSSCGKSA-N

> <csid>
52083264

> <Links>
|http://www.chemspider.com/Chemical-Structure.52083264.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3643413|http://pubchem.ncbi.nlm.nih.gov/compound/57495353| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=9NQ|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/9NQ|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9424|http://zinc15.docking.org/substances/ZINC000113570569|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=L22772Z9CP|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=118299

> <LinkName>
|ChemSpider|ChEMBL|PubChem|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
450.2

> <HBA>
7

> <HBD>
1

> <NRB>
5

> <TPSA>
83.5

> <LogP>
2.9

> <RoF>
0

> <Targets>
nan

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
0.999336

> <r_epik_Ionization_Penalty>
  0.1144

> <r_epik_State_Penalty>
  0.1040

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
250

> <lig_pdbID>
'9NQ'

> <pdbID>
5o83

$$$$
Selonsertib
                    3D
 Structure written by MMmdl.
 57 61  0  0  1  0            999 V2000
   -6.5343   -0.5749   -0.0581 C   0  0  0  0  0  0
   -5.0530   -0.2259   -0.1453 C   0  0  0  0  0  0
   -4.4774   -0.0708   -1.4089 C   0  0  0  0  0  0
   -3.1342    0.2760   -1.5497 C   0  0  0  0  0  0
   -2.3329    0.4823   -0.4152 C   0  0  0  0  0  0
   -2.9070    0.3179    0.8540 C   0  0  0  0  0  0
   -4.2528   -0.0387    0.9974 C   0  0  0  0  0  0
   -4.7623   -0.1951    2.3022 N   0  0  0  0  0  0
   -4.6849    0.6899    3.3489 C   0  0  0  0  0  0
   -5.3184    0.0991    4.4354 C   0  0  0  0  0  0
   -5.7635   -1.1042    4.0971 N   0  0  0  0  0  0
   -5.4264   -1.2700    2.8413 C   0  0  0  0  0  0
   -5.5150    0.6753    5.8305 C   0  0  0  0  0  0
   -5.5588   -0.2676    7.0201 C   0  0  0  0  0  0
   -6.8209    0.4061    6.5554 C   0  0  0  0  0  0
   -0.8761    0.8517   -0.5550 C   0  0  0  0  0  0
   -0.5256    1.6739   -1.4030 O   0  0  0  0  0  0
   -0.0406    0.2177    0.2997 N   0  0  0  0  0  0
    1.3568    0.3322    0.4052 C   0  0  0  0  0  0
    1.9436   -0.2405    1.5375 C   0  0  0  0  0  0
    3.3275   -0.1631    1.6938 C   0  0  0  0  0  0
    4.0946    0.4776    0.7209 C   0  0  0  0  0  0
    3.4546    1.0297   -0.3968 C   0  0  0  0  0  0
    2.1055    0.9510   -0.5530 N   0  0  0  0  0  0
    4.2421    1.7101   -1.4833 C   0  0  0  0  0  0
    5.5051    1.4199   -1.7158 N   0  0  0  0  0  0
    5.9342    2.1633   -2.8071 N   0  0  0  0  0  0
    4.9112    2.8792   -3.1853 C   0  0  0  0  0  0
    3.8059    2.6698   -2.3902 N   0  0  0  0  0  0
    2.4940    3.3200   -2.5248 C   0  0  0  0  0  0
    1.6809    2.6129   -3.6245 C   0  0  0  0  0  0
    2.6414    4.8336   -2.7836 C   0  0  0  0  0  0
   -2.6268    0.4010   -2.7998 F   0  0  0  0  0  0
   -7.0261   -0.0109    0.7351 H   0  0  0  0  0  0
   -6.6624   -1.6387    0.1419 H   0  0  0  0  0  0
   -7.0565   -0.3456   -0.9879 H   0  0  0  0  0  0
   -5.0757   -0.2168   -2.2968 H   0  0  0  0  0  0
   -2.3061    0.4675    1.7410 H   0  0  0  0  0  0
   -4.2017    1.6488    3.2319 H   0  0  0  0  0  0
   -5.6184   -2.1468    2.2404 H   0  0  0  0  0  0
   -5.0498    1.6485    5.9906 H   0  0  0  0  0  0
   -5.4524   -1.3411    6.8606 H   0  0  0  0  0  0
   -5.1096    0.0579    7.9586 H   0  0  0  0  0  0
   -7.2464    1.1987    7.1708 H   0  0  0  0  0  0
   -7.5877   -0.1995    6.0709 H   0  0  0  0  0  0
   -0.4653   -0.4069    0.9687 H   0  0  0  0  0  0
    1.3447   -0.7360    2.2884 H   0  0  0  0  0  0
    3.8023   -0.5972    2.5614 H   0  0  0  0  0  0
    5.1668    0.5403    0.8373 H   0  0  0  0  0  0
    4.8785    3.5743   -4.0109 H   0  0  0  0  0  0
    1.9690    3.2272   -1.5759 H   0  0  0  0  0  0
    0.6812    3.0404   -3.7080 H   0  0  0  0  0  0
    1.5620    1.5500   -3.4103 H   0  0  0  0  0  0
    2.1607    2.7023   -4.5999 H   0  0  0  0  0  0
    1.6674    5.3243   -2.7745 H   0  0  0  0  0  0
    3.0982    5.0432   -3.7513 H   0  0  0  0  0  0
    3.2511    5.3103   -2.0148 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 34  1  0  0  0
  1 35  1  0  0  0
  1 36  1  0  0  0
  2  3  1  0  0  0
  2  7  2  0  0  0
  3  4  2  0  0  0
  3 37  1  0  0  0
  4  5  1  0  0  0
  4 33  1  0  0  0
  5  6  2  0  0  0
  5 16  1  0  0  0
  6  7  1  0  0  0
  6 38  1  0  0  0
  7  8  1  0  0  0
  8  9  1  0  0  0
  8 12  1  0  0  0
  9 10  2  0  0  0
  9 39  1  0  0  0
 10 11  1  0  0  0
 10 13  1  0  0  0
 11 12  2  0  0  0
 12 40  1  0  0  0
 13 14  1  0  0  0
 13 15  1  0  0  0
 13 41  1  0  0  0
 14 15  1  0  0  0
 14 42  1  0  0  0
 14 43  1  0  0  0
 15 44  1  0  0  0
 15 45  1  0  0  0
 16 17  2  0  0  0
 16 18  1  0  0  0
 18 19  1  0  0  0
 18 46  1  0  0  0
 19 20  1  0  0  0
 19 24  2  0  0  0
 20 21  2  0  0  0
 20 47  1  0  0  0
 21 22  1  0  0  0
 21 48  1  0  0  0
 22 23  2  0  0  0
 22 49  1  0  0  0
 23 24  1  0  0  0
 23 25  1  0  0  0
 25 26  2  0  0  0
 25 29  1  0  0  0
 26 27  1  0  0  0
 27 28  2  0  0  0
 28 29  1  0  0  0
 28 50  1  0  0  0
 29 30  1  0  0  0
 30 31  1  0  0  0
 30 32  1  0  0  0
 30 51  1  0  0  0
 31 52  1  0  0  0
 31 53  1  0  0  0
 31 54  1  0  0  0
 32 55  1  0  0  0
 32 56  1  0  0  0
 32 57  1  0  0  0
M  END
> <s_m_entry_id>
252

> <Applicants>
Gilead Sciences

> <CHEMBL_ID>
CHEMBL3916717

> <Canonical_Smiles>
Fc1cc(C)c(-n2cc(nc2)C2CC2)cc1C(=O)Nc1nc(ccc1)-c1nncn1C(C)C

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
GS-4997 | SELONSERTIB

> <Indications>
nan

> <Type>
nan

> <targets_id>
Q99683

> <inchi>
InChI=1S/C24H24FN7O/c1-14(2)32-13-27-30-23(32)19-5-4-6-22(28-19)29-24(33)17-10-21(15(3)9-18(17)25)31-11-20(26-12-31)16-7-8-16/h4-6,9-14,16H,7-8H2,1-3H3,(H,28,29,33)

> <stdInchikey>
YIDDLAAKOYYGJG-UHFFFAOYSA-N

> <csid>
44209497

> <Links>
|http://www.chemspider.com/Chemical-Structure.44209497.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3916717|http://pubchem.ncbi.nlm.nih.gov/compound/71245288|http://www.drugbank.ca/drugs/DB14916| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=NJV|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/NJV|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9040|http://zinc15.docking.org/substances/ZINC000149387856|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=NS3988A2TC|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50212258

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
445.2

> <HBA>
7

> <HBD>
1

> <NRB>
6

> <TPSA>
90.5

> <LogP>
4.7

> <RoF>
0

> <Targets>
MAP3K5

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0939

> <r_epik_State_Penalty>
  0.0840

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
252

> <lig_pdbID>
'NJV'

> <pdbID>
6oyt

> <Kinase families>
STE

$$$$
Rebastinib
                    3D
 Structure written by MMmdl.
 69 73  0  0  1  0            999 V2000
   -4.9547    6.0128   -1.1172 C   0  0  0  0  0  0
   -5.7019    4.8230   -0.4670 C   0  0  0  0  0  0
   -6.0970    5.2273    0.9742 C   0  0  0  0  0  0
   -6.9824    4.5375   -1.2858 C   0  0  0  0  0  0
   -4.8164    3.5677   -0.4430 C   0  0  0  0  0  0
   -3.5585    3.3479   -1.0279 C   0  0  0  0  0  0
   -3.1988    2.0516   -0.7127 C   0  0  0  0  0  0
   -4.2503    1.5539    0.0288 N   0  0  0  0  0  0
   -5.2188    2.4746    0.1796 N   0  0  0  0  0  0
   -4.4160    0.2719    0.5992 C   0  0  0  0  0  0
   -5.5849   -0.4543    0.3527 C   0  0  0  0  0  0
   -5.7636   -1.7248    0.8953 C   0  0  0  0  0  0
   -4.7593   -2.2993    1.7101 C   0  0  0  0  0  0
   -3.5668   -1.5574    1.9724 C   0  0  0  0  0  0
   -3.4144   -0.2676    1.4113 C   0  0  0  0  0  0
   -2.5779   -2.1547    2.7940 C   0  0  0  0  0  0
   -2.7975   -3.4299    3.3096 C   0  0  0  0  0  0
   -3.9882   -4.0831    3.0035 C   0  0  0  0  0  0
   -4.9590   -3.5461    2.2236 N   0  0  0  0  0  0
   -2.0790    1.3302   -1.0761 N   0  0  0  0  0  0
   -0.9256    1.3875   -0.3856 C   0  0  0  0  0  0
   -0.7428    2.0847    0.6173 O   0  0  0  0  0  0
   -0.0064    0.5589   -0.9170 N   0  0  0  0  0  0
    1.2779    0.3339   -0.4012 C   0  0  0  0  0  0
    2.3628    0.4795   -1.2696 C   0  0  0  0  0  0
    3.6595    0.2289   -0.8210 C   0  0  0  0  0  0
    3.8878   -0.1982    0.4883 C   0  0  0  0  0  0
    2.7976   -0.3531    1.3565 C   0  0  0  0  0  0
    1.4971   -0.1065    0.9154 C   0  0  0  0  0  0
    0.4647   -0.3137    1.7671 F   0  0  0  0  0  0
    5.1922   -0.4064    0.8859 O   0  0  0  0  0  0
    5.5262   -1.4239    1.7548 C   0  0  0  0  0  0
    4.9622   -2.7043    1.6729 C   0  0  0  0  0  0
    5.3797   -3.6792    2.5769 C   0  0  0  0  0  0
    6.3180   -3.4458    3.5277 N   0  0  0  0  0  0
    6.8851   -2.2052    3.6015 C   0  0  0  0  0  0
    6.5074   -1.1801    2.7193 C   0  0  0  0  0  0
    7.9400   -1.9531    4.6622 C   0  0  0  0  0  0
    8.4727   -0.8450    4.7647 O   0  0  0  0  0  0
    8.2513   -2.9890    5.4672 N   0  0  0  0  0  0
    9.2298   -2.9552    6.5489 C   0  0  0  0  0  0
   -5.5701    6.9137   -1.1310 H   0  0  0  0  0  0
   -4.6767    5.7993   -2.1503 H   0  0  0  0  0  0
   -4.0393    6.2559   -0.5754 H   0  0  0  0  0  0
   -5.2170    5.4170    1.5904 H   0  0  0  0  0  0
   -6.6785    4.4482    1.4696 H   0  0  0  0  0  0
   -6.7037    6.1340    0.9854 H   0  0  0  0  0  0
   -7.6301    5.4139   -1.3372 H   0  0  0  0  0  0
   -7.5694    3.7283   -0.8489 H   0  0  0  0  0  0
   -6.7445    4.2488   -2.3108 H   0  0  0  0  0  0
   -2.9812    4.0487   -1.6123 H   0  0  0  0  0  0
   -6.3625   -0.0368   -0.2713 H   0  0  0  0  0  0
   -6.6698   -2.2780    0.6940 H   0  0  0  0  0  0
   -2.5172    0.2912    1.6317 H   0  0  0  0  0  0
   -1.6641   -1.6213    3.0132 H   0  0  0  0  0  0
   -2.0568   -3.9036    3.9367 H   0  0  0  0  0  0
   -4.1822   -5.0724    3.3912 H   0  0  0  0  0  0
   -2.1314    0.7693   -1.9138 H   0  0  0  0  0  0
   -0.2123    0.1313   -1.8079 H   0  0  0  0  0  0
    2.2090    0.7978   -2.2909 H   0  0  0  0  0  0
    4.4923    0.3604   -1.4966 H   0  0  0  0  0  0
    2.9564   -0.6722    2.3763 H   0  0  0  0  0  0
    4.2189   -2.9389    0.9252 H   0  0  0  0  0  0
    4.9629   -4.6751    2.5450 H   0  0  0  0  0  0
    6.9594   -0.2001    2.7757 H   0  0  0  0  0  0
    7.7857   -3.8716    5.3118 H   0  0  0  0  0  0
    8.7884   -3.3678    7.4559 H   0  0  0  0  0  0
    9.5812   -1.9480    6.7766 H   0  0  0  0  0  0
   10.0942   -3.5649    6.2858 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 42  1  0  0  0
  1 43  1  0  0  0
  1 44  1  0  0  0
  2  3  1  0  0  0
  2  4  1  0  0  0
  2  5  1  0  0  0
  3 45  1  0  0  0
  3 46  1  0  0  0
  3 47  1  0  0  0
  4 48  1  0  0  0
  4 49  1  0  0  0
  4 50  1  0  0  0
  5  6  1  0  0  0
  5  9  2  0  0  0
  6  7  2  0  0  0
  6 51  1  0  0  0
  7  8  1  0  0  0
  7 20  1  0  0  0
  8  9  1  0  0  0
  8 10  1  0  0  0
 10 11  1  0  0  0
 10 15  2  0  0  0
 11 12  2  0  0  0
 11 52  1  0  0  0
 12 13  1  0  0  0
 12 53  1  0  0  0
 13 14  1  0  0  0
 13 19  2  0  0  0
 14 15  1  0  0  0
 14 16  2  0  0  0
 15 54  1  0  0  0
 16 17  1  0  0  0
 16 55  1  0  0  0
 17 18  2  0  0  0
 17 56  1  0  0  0
 18 19  1  0  0  0
 18 57  1  0  0  0
 20 21  1  0  0  0
 20 58  1  0  0  0
 21 22  2  0  0  0
 21 23  1  0  0  0
 23 24  1  0  0  0
 23 59  1  0  0  0
 24 25  1  0  0  0
 24 29  2  0  0  0
 25 26  2  0  0  0
 25 60  1  0  0  0
 26 27  1  0  0  0
 26 61  1  0  0  0
 27 28  2  0  0  0
 27 31  1  0  0  0
 28 29  1  0  0  0
 28 62  1  0  0  0
 29 30  1  0  0  0
 31 32  1  0  0  0
 32 33  1  0  0  0
 32 37  2  0  0  0
 33 34  2  0  0  0
 33 63  1  0  0  0
 34 35  1  0  0  0
 34 64  1  0  0  0
 35 36  2  0  0  0
 36 37  1  0  0  0
 36 38  1  0  0  0
 37 65  1  0  0  0
 38 39  2  0  0  0
 38 40  1  0  0  0
 40 41  1  0  0  0
 40 66  1  0  0  0
 41 67  1  0  0  0
 41 68  1  0  0  0
 41 69  1  0  0  0
M  END
> <s_m_entry_id>
254

> <Applicants>
Deciphera Pharmaceuticals

> <CHEMBL_ID>
CHEMBL1738757

> <Canonical_Smiles>
Fc1cc(Oc2cc(ncc2)C(=O)NC)ccc1NC(=O)Nc1n(nc(c1)C(C)(C)C)-c1cc2c(nccc2)cc1

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
DCC-2036 | DCC-2036 FREE BASE | DP-1919 | REBASTINIB

> <Indications>
nan

> <Type>
2

> <targets_id>
P36888|Q02763|P35968|P07948|P11274|P00519|P04629

> <inchi>
InChI=1S/C30H28FN7O3/c1-30(2,3)26-17-27(38(37-26)19-7-9-23-18(14-19)6-5-12-33-23)36-29(40)35-24-10-8-20(15-22(24)31)41-21-11-13-34-25(16-21)28(39)32-4/h5-17H,1-4H3,(H,32,39)(H2,35,36,40)

> <stdInchikey>
WVXNSAVVKYZVOE-UHFFFAOYSA-N

> <csid>
26325986

> <Links>
|http://www.chemspider.com/Chemical-Structure.26325986.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1738757|http://pubchem.ncbi.nlm.nih.gov/compound/25066467|http://www.drugbank.ca/drugs/DB13005| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=919|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/919|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9173|http://zinc15.docking.org/substances/ZINC63933734|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=75017Q6I97|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=185674

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
553.2

> <HBA>
7

> <HBD>
3

> <NRB>
6

> <TPSA>
123.1

> <LogP>
6

> <RoF>
2

> <Targets>
FLT3; TEK; KDR; LYN; BCR; ABL1; NTRK1

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0006

> <r_epik_State_Penalty>
  0.0004

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
254

> <lig_pdbID>
'919'

> <pdbID>
3qri 3qrj 5g6v 6cnh 6mwe

> <Kinase families>
Tyr<br>Atypical

> <BrandName>
DP-1919;Dp-1919

$$$$
Golvatinib
                    3D
 Structure written by MMmdl.
 84 89  0  0  1  0            999 V2000
   -7.2657   10.5019    1.8077 C   0  0  0  0  0  0
   -6.8051    9.8314    0.5929 N   0  0  0  0  0  0
   -5.4294    9.3445    0.7058 C   0  0  0  0  0  0
   -5.2752    8.1123    1.6256 C   0  0  0  0  0  0
   -6.2394    6.9737    1.1967 N   0  3  0  0  0  0
   -7.6881    7.5090    1.0373 C   0  0  0  0  0  0
   -7.7174    8.7755    0.1510 C   0  0  0  0  0  0
   -6.1766    5.7588    2.1783 C   0  0  0  0  0  0
   -4.7117    5.2475    2.2825 C   0  0  0  0  0  0
   -4.5962    3.8866    3.0043 C   0  0  0  0  0  0
   -5.4807    2.9424    2.2888 N   0  0  0  0  0  0
   -6.9097    3.2868    2.4071 C   0  0  0  0  0  0
   -7.1159    4.6293    1.6683 C   0  0  0  0  0  0
   -5.0607    2.0562    1.3384 C   0  0  0  0  0  0
   -5.8523    1.4544    0.6075 O   0  0  0  0  0  0
   -3.7186    1.8777    1.2723 N   0  0  0  0  0  0
   -2.9854    0.9989    0.4551 C   0  0  0  0  0  0
   -1.6127    1.2476    0.3499 C   0  0  0  0  0  0
   -0.8200    0.4083   -0.4374 C   0  0  0  0  0  0
   -1.4211   -0.6880   -1.0723 C   0  0  0  0  0  0
   -2.7940   -0.8797   -0.9224 C   0  0  0  0  0  0
   -3.5733   -0.0576   -0.1769 N   0  0  0  0  0  0
    0.5333    0.6649   -0.5087 O   0  0  0  0  0  0
    1.2483    0.4924   -1.6764 C   0  0  0  0  0  0
    2.5840    0.1014   -1.5718 C   0  0  0  0  0  0
    3.3680   -0.0628   -2.7134 C   0  0  0  0  0  0
    2.8237    0.1757   -3.9845 C   0  0  0  0  0  0
    1.4871    0.5792   -4.0934 C   0  0  0  0  0  0
    0.7102    0.7454   -2.9464 C   0  0  0  0  0  0
    0.9346    0.8218   -5.3064 F   0  0  0  0  0  0
    3.5673    0.0184   -5.1667 N   0  0  0  0  0  0
    4.8596    0.3560   -5.3699 C   0  0  0  0  0  0
    5.5857    0.8520   -4.5054 O   0  0  0  0  0  0
    5.4081    0.0867   -6.7910 C   0  0  0  0  0  0
    6.9214    0.1745   -6.9729 C   0  0  0  0  0  0
    6.2587   -1.1772   -6.8911 C   0  0  0  0  0  0
    4.6049    0.4886   -8.0504 C   0  0  0  0  0  0
    4.4545   -0.3173   -8.9705 O   0  0  0  0  0  0
    4.1315    1.7547   -8.0578 N   0  0  0  0  0  0
    3.3474    2.3986   -9.0325 C   0  0  0  0  0  0
    3.3652    3.7959   -9.0157 C   0  0  0  0  0  0
    2.6076    4.5171   -9.9349 C   0  0  0  0  0  0
    1.8229    3.8413  -10.8660 C   0  0  0  0  0  0
    1.7859    2.4492  -10.8826 C   0  0  0  0  0  0
    2.5426    1.7244   -9.9654 C   0  0  0  0  0  0
    1.0867    4.5424  -11.7574 F   0  0  0  0  0  0
   -8.2577   10.9292    1.6546 H   0  0  0  0  0  0
   -6.5960   11.3222    2.0695 H   0  0  0  0  0  0
   -7.3180    9.8248    2.6608 H   0  0  0  0  0  0
   -5.0723    9.0929   -0.2942 H   0  0  0  0  0  0
   -4.7810   10.1520    1.0494 H   0  0  0  0  0  0
   -4.2569    7.7339    1.5486 H   0  0  0  0  0  0
   -5.4888    8.3454    2.6702 H   0  0  0  0  0  0
   -8.2816    6.7274    0.5654 H   0  0  0  0  0  0
   -8.0802    7.6953    2.0387 H   0  0  0  0  0  0
   -8.7336    9.1689    0.0921 H   0  0  0  0  0  0
   -7.4536    8.5018   -0.8719 H   0  0  0  0  0  0
   -6.5173    6.1202    3.1509 H   0  0  0  0  0  0
   -4.2706    5.1638    1.2871 H   0  0  0  0  0  0
   -4.0965    5.9605    2.8308 H   0  0  0  0  0  0
   -3.5582    3.5565    3.0525 H   0  0  0  0  0  0
   -4.9455    3.9823    4.0335 H   0  0  0  0  0  0
   -7.5647    2.5129    2.0030 H   0  0  0  0  0  0
   -7.1602    3.3993    3.4629 H   0  0  0  0  0  0
   -8.1602    4.9142    1.7933 H   0  0  0  0  0  0
   -6.9686    4.4737    0.5977 H   0  0  0  0  0  0
   -3.1542    2.4653    1.8677 H   0  0  0  0  0  0
   -1.1604    2.0833    0.8646 H   0  0  0  0  0  0
   -0.8386   -1.3766   -1.6663 H   0  0  0  0  0  0
   -3.2904   -1.7113   -1.4009 H   0  0  0  0  0  0
    3.0161   -0.0820   -0.5989 H   0  0  0  0  0  0
    4.3925   -0.3853   -2.5990 H   0  0  0  0  0  0
   -0.3137    1.0738   -3.0481 H   0  0  0  0  0  0
    3.0432   -0.2998   -5.9690 H   0  0  0  0  0  0
    7.3309    0.4938   -7.9327 H   0  0  0  0  0  0
    7.5586    0.4906   -6.1458 H   0  0  0  0  0  0
    6.4264   -1.7849   -6.0003 H   0  0  0  0  0  0
    6.2258   -1.7937   -7.7904 H   0  0  0  0  0  0
    4.3935    2.3367   -7.2755 H   0  0  0  0  0  0
    3.9683    4.3308   -8.2957 H   0  0  0  0  0  0
    2.6272    5.5969   -9.9244 H   0  0  0  0  0  0
    1.1673    1.9321  -11.6012 H   0  0  0  0  0  0
    2.4750    0.6479   -9.9887 H   0  0  0  0  0  0
   -5.9373    6.6492    0.2885 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 47  1  0  0  0
  1 48  1  0  0  0
  1 49  1  0  0  0
  2  3  1  0  0  0
  2  7  1  0  0  0
  3  4  1  0  0  0
  3 50  1  0  0  0
  3 51  1  0  0  0
  4  5  1  0  0  0
  4 52  1  0  0  0
  4 53  1  0  0  0
  5  6  1  0  0  0
  5  8  1  0  0  0
  5 84  1  0  0  0
  6  7  1  0  0  0
  6 54  1  0  0  0
  6 55  1  0  0  0
  7 56  1  0  0  0
  7 57  1  0  0  0
  8  9  1  0  0  0
  8 13  1  0  0  0
  8 58  1  0  0  0
  9 10  1  0  0  0
  9 59  1  0  0  0
  9 60  1  0  0  0
 10 11  1  0  0  0
 10 61  1  0  0  0
 10 62  1  0  0  0
 11 12  1  0  0  0
 11 14  1  0  0  0
 12 13  1  0  0  0
 12 63  1  0  0  0
 12 64  1  0  0  0
 13 65  1  0  0  0
 13 66  1  0  0  0
 14 15  2  0  0  0
 14 16  1  0  0  0
 16 17  1  0  0  0
 16 67  1  0  0  0
 17 18  1  0  0  0
 17 22  2  0  0  0
 18 19  2  0  0  0
 18 68  1  0  0  0
 19 20  1  0  0  0
 19 23  1  0  0  0
 20 21  2  0  0  0
 20 69  1  0  0  0
 21 22  1  0  0  0
 21 70  1  0  0  0
 23 24  1  0  0  0
 24 25  1  0  0  0
 24 29  2  0  0  0
 25 26  2  0  0  0
 25 71  1  0  0  0
 26 27  1  0  0  0
 26 72  1  0  0  0
 27 28  2  0  0  0
 27 31  1  0  0  0
 28 29  1  0  0  0
 28 30  1  0  0  0
 29 73  1  0  0  0
 31 32  1  0  0  0
 31 74  1  0  0  0
 32 33  2  0  0  0
 32 34  1  0  0  0
 34 35  1  0  0  0
 34 36  1  0  0  0
 34 37  1  0  0  0
 35 36  1  0  0  0
 35 75  1  0  0  0
 35 76  1  0  0  0
 36 77  1  0  0  0
 36 78  1  0  0  0
 37 38  2  0  0  0
 37 39  1  0  0  0
 39 40  1  0  0  0
 39 79  1  0  0  0
 40 41  1  0  0  0
 40 45  2  0  0  0
 41 42  2  0  0  0
 41 80  1  0  0  0
 42 43  1  0  0  0
 42 81  1  0  0  0
 43 44  2  0  0  0
 43 46  1  0  0  0
 44 45  1  0  0  0
 44 82  1  0  0  0
 45 83  1  0  0  0
M  CHG  1   5   1
M  END
> <s_m_entry_id>
255

> <Applicants>
Eisai

> <CHEMBL_ID>
CHEMBL3039525

> <Canonical_Smiles>
Fc1cc(Oc2cc(ncc2)NC(=O)N2CCC(N3CCN(CC3)C)CC2)ccc1NC(=O)C1(CC1)C(=O)Nc1ccc(F)cc1

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
E-7050 | E7050 | GOLVATINIB

> <Indications>
nan

> <Type>
2

> <targets_id>
P08581|P35968

> <inchi>
InChI=1S/C33H37F2N7O4/c1-40-16-18-41(19-17-40)24-9-14-42(15-10-24)32(45)39-29-21-26(8-13-36-29)46-25-6-7-28(27(35)20-25)38-31(44)33(11-12-33)30(43)37-23-4-2-22(34)3-5-23/h2-8,13,20-21,24H,9-12,14-19H2,1H3,(H,37,43)(H,38,44)(H,36,39,45)

> <stdInchikey>
UQRCJCNVNUFYDX-UHFFFAOYSA-N

> <csid>
17275597

> <Links>
|http://www.chemspider.com/Chemical-Structure.17275597.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3039525|http://pubchem.ncbi.nlm.nih.gov/compound/16118392|http://www.drugbank.ca/drugs/DB11977| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=GV0|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/GV0|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7956|http://zinc15.docking.org/substances/ZINC000043195317|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=516Z3YP58E|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50100615

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
633.3

> <HBA>
7

> <HBD>
3

> <NRB>
8

> <TPSA>
119.1

> <LogP>
4.8

> <RoF>
1

> <Targets>
MET; KDR

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0036

> <r_epik_State_Penalty>
  0.0308

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
255

> <lig_pdbID>
'GV0'

> <pdbID>
5ia5

> <Kinase families>
Tyr

$$$$
Acumapimod
                    3D
 Structure written by MMmdl.
 48 51  0  0  1  0            999 V2000
    0.0821   -2.4607   -0.3280 C   0  0  0  0  0  0
   -0.6497   -1.1350   -0.1540 C   0  0  0  0  0  0
   -2.0472   -1.1373   -0.1506 C   0  0  0  0  0  0
   -2.7614    0.0524   -0.0219 C   0  0  0  0  0  0
   -2.0942    1.2768    0.1032 C   0  0  0  0  0  0
   -0.6913    1.2800    0.1117 C   0  0  0  0  0  0
    0.0345    0.0886   -0.0123 C   0  0  0  0  0  0
    1.4480    0.1622    0.0110 N   0  0  0  0  0  0
    2.2900    0.8889   -0.8133 C   0  0  0  0  0  0
    3.5820    0.6503   -0.3330 C   0  0  0  0  0  0
    3.3871   -0.2486    0.7251 C   0  0  0  0  0  0
    2.1250   -0.5140    0.9523 N   0  0  0  0  0  0
    4.8826    1.1214   -0.8259 C   0  0  0  0  0  0
    5.8561    0.3709   -0.7322 O   0  0  0  0  0  0
    4.9903    2.4323   -1.5454 C   0  0  0  0  0  0
    4.1869    3.5273   -1.1921 C   0  0  0  0  0  0
    4.3319    4.7543   -1.8383 C   0  0  0  0  0  0
    5.2944    4.9112   -2.8338 C   0  0  0  0  0  0
    6.1222    3.8405   -3.1793 C   0  0  0  0  0  0
    5.9755    2.6108   -2.5293 C   0  0  0  0  0  0
    7.1367    4.0062   -4.2096 C   0  0  0  0  0  0
    7.9433    4.1381   -5.0288 N   0  0  0  0  0  0
    1.8176    1.6078   -1.8822 N   0  0  0  0  0  0
   -2.8857    2.5555    0.2391 C   0  0  0  0  0  0
   -3.9982    2.5540    0.7704 O   0  0  0  0  0  0
   -2.3065    3.6633   -0.2614 N   0  0  0  0  0  0
   -2.9239    4.9852   -0.2559 C   0  0  0  0  0  0
   -2.0552    6.1727    0.0884 C   0  0  0  0  0  0
   -3.1160    5.7118    1.0586 C   0  0  0  0  0  0
    0.9154   -2.3587   -1.0241 H   0  0  0  0  0  0
   -0.5757   -3.2377   -0.7197 H   0  0  0  0  0  0
    0.4732   -2.8050    0.6297 H   0  0  0  0  0  0
   -2.5903   -2.0655   -0.2542 H   0  0  0  0  0  0
   -3.8418    0.0119   -0.0272 H   0  0  0  0  0  0
   -0.1532    2.2109    0.2277 H   0  0  0  0  0  0
    4.1653   -0.6869    1.3334 H   0  0  0  0  0  0
    3.4486    3.4424   -0.4076 H   0  0  0  0  0  0
    3.7025    5.5870   -1.5609 H   0  0  0  0  0  0
    5.3949    5.8699   -3.3237 H   0  0  0  0  0  0
    6.6247    1.7870   -2.7974 H   0  0  0  0  0  0
    1.4825    2.5547   -1.7791 H   0  0  0  0  0  0
    1.8157    1.2246   -2.8168 H   0  0  0  0  0  0
   -1.5304    3.5392   -0.8948 H   0  0  0  0  0  0
   -3.6798    5.1224   -1.0307 H   0  0  0  0  0  0
   -1.0083    6.0090    0.3467 H   0  0  0  0  0  0
   -2.2115    7.1070   -0.4511 H   0  0  0  0  0  0
   -4.0091    6.3233    1.1889 H   0  0  0  0  0  0
   -2.8037    5.2256    1.9835 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 30  1  0  0  0
  1 31  1  0  0  0
  1 32  1  0  0  0
  2  3  1  0  0  0
  2  7  2  0  0  0
  3  4  2  0  0  0
  3 33  1  0  0  0
  4  5  1  0  0  0
  4 34  1  0  0  0
  5  6  2  0  0  0
  5 24  1  0  0  0
  6  7  1  0  0  0
  6 35  1  0  0  0
  7  8  1  0  0  0
  8  9  1  0  0  0
  8 12  1  0  0  0
  9 10  2  0  0  0
  9 23  1  0  0  0
 10 11  1  0  0  0
 10 13  1  0  0  0
 11 12  2  0  0  0
 11 36  1  0  0  0
 13 14  2  0  0  0
 13 15  1  0  0  0
 15 16  1  0  0  0
 15 20  2  0  0  0
 16 17  2  0  0  0
 16 37  1  0  0  0
 17 18  1  0  0  0
 17 38  1  0  0  0
 18 19  2  0  0  0
 18 39  1  0  0  0
 19 20  1  0  0  0
 19 21  1  0  0  0
 20 40  1  0  0  0
 21 22  3  0  0  0
 23 41  1  0  0  0
 23 42  1  0  0  0
 24 25  2  0  0  0
 24 26  1  0  0  0
 26 27  1  0  0  0
 26 43  1  0  0  0
 27 28  1  0  0  0
 27 29  1  0  0  0
 27 44  1  0  0  0
 28 29  1  0  0  0
 28 45  1  0  0  0
 28 46  1  0  0  0
 29 47  1  0  0  0
 29 48  1  0  0  0
M  END
> <s_m_entry_id>
259

> <Applicants>
Mereo BioPharma

> <CHEMBL_ID>
CHEMBL3545226

> <Canonical_Smiles>
O=C(c1cnn(-c2cc(ccc2C)C(=O)NC2CC2)c1N)c1cc(ccc1)C#N

> <Chirality>
Single Stereoisomer

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Indications>
nan

> <Type>
nan

> <targets_id>
Q16539|Q15759|O15264|P53778

> <inchi>
InChI=1S/C22H19N5O2/c1-13-5-6-16(22(29)26-17-7-8-17)10-19(13)27-21(24)18(12-25-27)20(28)15-4-2-3-14(9-15)11-23/h2-6,9-10,12,17H,7-8,24H2,1H3,(H,26,29)

> <stdInchikey>
VGUSQKZDZHAAEE-UHFFFAOYSA-N

> <csid>
9513071

> <Links>
|http://www.chemspider.com/Chemical-Structure.9513071.html|http://pubchem.ncbi.nlm.nih.gov/compound/11338127|http://www.drugbank.ca/drugs/DB15448|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9203|http://zinc15.docking.org/substances/ZINC000116024237|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=2F16KW647L

> <LinkName>
|ChemSpider|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS

> <indicationG2P>
None

> <MW>
385.2

> <HBA>
6

> <HBD>
2

> <NRB>
5

> <TPSA>
113.8

> <LogP>
2.8

> <RoF>
0

> <Targets>
MAPK14; MAPK11; MAPK13; MAPK12

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0002

> <r_epik_State_Penalty>
  0.0000

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
259

> <Kinase families>
CMGC

$$$$
Ripasudil
                    3D
 Structure written by MMmdl.
 41 43  0  0  1  0            999 V2000
   -1.3105   -1.9592   -0.6296 C   0  0  0  0  0  0
   -0.4124   -0.9153   -1.3240 C   0  0  1  0  0  0
   -1.0798   -0.2557   -2.5524 C   0  0  0  0  0  0
   -2.5015    0.2582   -2.2739 N   0  3  0  0  0  0
   -2.6321    1.5544   -1.4642 C   0  0  0  0  0  0
   -1.9776    1.4806   -0.0760 C   0  0  0  0  0  0
   -0.4411    1.4110   -0.1004 C   0  0  0  0  0  0
    0.1474    0.0633   -0.3407 N   0  0  0  0  0  0
    1.8910   -0.0786   -0.0237 S   0  0  0  0  0  0
    2.2216   -1.4981    0.1475 O   0  0  0  0  0  0
    2.5608    0.6876   -1.0815 O   0  0  0  0  0  0
    2.2314    0.7408    1.5578 C   0  0  0  0  0  0
    3.1306    1.8132    1.5185 C   0  0  0  0  0  0
    3.4578    2.5375    2.6547 C   0  0  0  0  0  0
    2.8970    2.2137    3.8797 C   0  0  0  0  0  0
    1.9902    1.1361    3.9803 C   0  0  0  0  0  0
    1.6374    0.3673    2.8193 C   0  0  0  0  0  0
    0.7138   -0.7133    3.0241 C   0  0  0  0  0  0
    0.2099   -0.9557    4.3024 C   0  0  0  0  0  0
    0.5347   -0.2311    5.3947 N   0  0  0  0  0  0
    1.4053    0.7835    5.2181 C   0  0  0  0  0  0
    0.3063   -1.5230    2.0275 F   0  0  0  0  0  0
   -1.7343   -2.6529   -1.3562 H   0  0  0  0  0  0
   -2.1397   -1.5067   -0.0877 H   0  0  0  0  0  0
   -0.7412   -2.5613    0.0775 H   0  0  0  0  0  0
    0.4310   -1.4960   -1.6999 H   0  0  0  0  0  0
   -0.5183    0.5839   -2.9654 H   0  0  0  0  0  0
   -1.2407   -0.9866   -3.3457 H   0  0  0  0  0  0
   -2.9546    0.4100   -3.1641 H   0  0  0  0  0  0
   -2.2045    2.3362   -2.0934 H   0  0  0  0  0  0
   -3.7097    1.7052   -1.3961 H   0  0  0  0  0  0
   -2.2602    2.3887    0.4576 H   0  0  0  0  0  0
   -2.3955    0.6647    0.5132 H   0  0  0  0  0  0
   -0.0535    2.0861   -0.8646 H   0  0  0  0  0  0
   -0.0504    1.7894    0.8435 H   0  0  0  0  0  0
    3.5956    2.1090    0.5902 H   0  0  0  0  0  0
    4.1536    3.3608    2.5831 H   0  0  0  0  0  0
    3.1541    2.7837    4.7611 H   0  0  0  0  0  0
   -0.4843   -1.7671    4.4667 H   0  0  0  0  0  0
    1.6538    1.3477    6.1057 H   0  0  0  0  0  0
   -3.0141   -0.4723   -1.8005 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 23  1  0  0  0
  1 24  1  0  0  0
  1 25  1  0  0  0
  2  3  1  0  0  0
  2  8  1  0  0  0
  2 26  1  0  0  0
  3  4  1  0  0  0
  3 27  1  0  0  0
  3 28  1  0  0  0
  4  5  1  0  0  0
  4 29  1  0  0  0
  4 41  1  0  0  0
  5  6  1  0  0  0
  5 30  1  0  0  0
  5 31  1  0  0  0
  6  7  1  0  0  0
  6 32  1  0  0  0
  6 33  1  0  0  0
  7  8  1  0  0  0
  7 34  1  0  0  0
  7 35  1  0  0  0
  8  9  1  0  0  0
  9 10  2  0  0  0
  9 11  2  0  0  0
  9 12  1  0  0  0
 12 13  1  0  0  0
 12 17  2  0  0  0
 13 14  2  0  0  0
 13 36  1  0  0  0
 14 15  1  0  0  0
 14 37  1  0  0  0
 15 16  2  0  0  0
 15 38  1  0  0  0
 16 17  1  0  0  0
 16 21  1  0  0  0
 17 18  1  0  0  0
 18 19  2  0  0  0
 18 22  1  0  0  0
 19 20  1  0  0  0
 19 39  1  0  0  0
 20 21  2  0  0  0
 21 40  1  0  0  0
M  CHG  1   4   1
M  END
> <s_m_entry_id>
260

> <Applicants>
Kowa Pharmaceutical

> <CHEMBL_ID>
CHEMBL3426621

> <Canonical_Smiles>
S(=O)(=O)(N1CCCNC[C@@H]1C)c1c2c(ccc1)cncc2F

> <Chirality>
Single Stereoisomer

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
RIPASUDIL

> <Indications>
nan

> <Type>
nan

> <targets_id>
nan

> <inchi>
InChI=1S/C15H18FN3O2S/c1-11-8-17-6-3-7-19(11)22(20,21)14-5-2-4-12-9-18-10-13(16)15(12)14/h2,4-5,9-11,17H,3,6-8H2,1H3/t11-/m0/s1

> <stdInchikey>
QSKQVZWVLOIIEV-NSHDSACASA-N

> <csid>
8039366

> <Links>
|http://www.chemspider.com/Chemical-Structure.8039366.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3426621|http://pubchem.ncbi.nlm.nih.gov/compound/9863672|http://www.drugbank.ca/drugs/DB13165|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10423|http://zinc15.docking.org/substances/ZINC000003940873|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=11978226XX|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50087135

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
323.1

> <HBA>
4

> <HBD>
1

> <NRB>
2

> <TPSA>
62.3

> <LogP>
1.7

> <RoF>
0

> <Targets>
nan

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_epik_Ionization_Penalty>
  0.0080

> <r_epik_State_Penalty>
  0.0060

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
260

> <indicationDB>
Ripasudil, as hydrochloride hydrate (K-115), is a specifc Rho-associated coiled-coil containing protein kinase (ROCK) inhibitor used for the treatment of glaucoma and ocular hypertension. It was first approved for treatment in Japan in September 2014. This medication is available in the form of a 0.4% eye drop solution under the brand name Glanatec. Ripasudil is a well tolerated medication that is used when other drugs have been proven to be non-effective or cannot be administered.

> <uniprotId>
Q13464|O75116

$$$$
Tomivosertib
                    3D
 Structure written by MMmdl.
 45 48  0  0  1  0            999 V2000
   -2.4979   -2.4867    0.0077 C   0  0  0  0  0  0
   -1.9360   -1.0739   -0.0653 C   0  0  0  0  0  0
   -0.4986   -0.8539   -0.0991 C   0  0  0  0  0  0
    0.0268    0.3919   -0.0853 C   0  0  0  0  0  0
   -0.8319    1.5908   -0.0902 C   0  0  0  0  0  0
   -0.3869    2.7408   -0.1476 O   0  0  0  0  0  0
   -2.1873    1.3268   -0.0411 N   0  0  0  0  0  0
   -2.7090    0.0462   -0.0240 C   0  0  0  0  0  0
   -4.1558    0.1592    0.0370 C   0  0  0  0  0  0
   -5.0032   -0.7310    0.0706 O   0  0  0  0  0  0
   -4.4117    1.4724    0.0471 N   0  0  0  0  0  0
   -3.2500    2.3326   -0.0199 C   0  0  0  0  0  0
   -3.1954    3.2586    1.2344 C   0  0  0  0  0  0
   -4.3342    4.3018    1.2584 C   0  0  0  0  0  0
   -4.3741    5.1348   -0.0376 C   0  0  0  0  0  0
   -4.4349    4.2454   -1.2949 C   0  0  0  0  0  0
   -3.2961    3.2026   -1.3139 C   0  0  0  0  0  0
    1.3972    0.5962   -0.1344 N   0  0  0  0  0  0
    2.2207    1.2135    0.8240 C   0  0  0  0  0  0
    3.5877    1.3315    0.5499 C   0  0  0  0  0  0
    4.3852    1.9436    1.5208 C   0  0  0  0  0  0
    3.8784    2.4106    2.6896 N   0  0  0  0  0  0
    2.5433    2.2501    2.8682 C   0  0  0  0  0  0
    1.6855    1.6695    1.9926 N   0  0  0  0  0  0
    5.7528    2.0932    1.3106 N   0  0  0  0  0  0
   -3.2147   -2.5576    0.8260 H   0  0  0  0  0  0
   -1.7246   -3.2311    0.1999 H   0  0  0  0  0  0
   -3.0510   -2.7281   -0.9005 H   0  0  0  0  0  0
    0.1608   -1.7104   -0.1228 H   0  0  0  0  0  0
   -5.3466    1.8502    0.0881 H   0  0  0  0  0  0
   -3.2265    2.6628    2.1484 H   0  0  0  0  0  0
   -2.2474    3.7961    1.2670 H   0  0  0  0  0  0
   -5.2915    3.7967    1.3954 H   0  0  0  0  0  0
   -4.2157    4.9612    2.1190 H   0  0  0  0  0  0
   -5.2284    5.8124   -0.0191 H   0  0  0  0  0  0
   -3.4861    5.7669   -0.0867 H   0  0  0  0  0  0
   -5.3993    3.7368   -1.3349 H   0  0  0  0  0  0
   -4.3842    4.8656   -2.1906 H   0  0  0  0  0  0
   -2.3545    3.7366   -1.4438 H   0  0  0  0  0  0
   -3.3974    2.5677   -2.1960 H   0  0  0  0  0  0
    1.9216    0.1499   -0.8726 H   0  0  0  0  0  0
    4.0105    0.9673   -0.3756 H   0  0  0  0  0  0
    2.1246    2.6176    3.7936 H   0  0  0  0  0  0
    6.1657    1.7605    0.4518 H   0  0  0  0  0  0
    6.3122    2.5397    2.0226 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 26  1  0  0  0
  1 27  1  0  0  0
  1 28  1  0  0  0
  2  3  1  0  0  0
  2  8  2  0  0  0
  3  4  2  0  0  0
  3 29  1  0  0  0
  4  5  1  0  0  0
  4 18  1  0  0  0
  5  6  2  0  0  0
  5  7  1  0  0  0
  7  8  1  0  0  0
  7 12  1  0  0  0
  8  9  1  0  0  0
  9 10  2  0  0  0
  9 11  1  0  0  0
 11 12  1  0  0  0
 11 30  1  0  0  0
 12 13  1  0  0  0
 12 17  1  0  0  0
 13 14  1  0  0  0
 13 31  1  0  0  0
 13 32  1  0  0  0
 14 15  1  0  0  0
 14 33  1  0  0  0
 14 34  1  0  0  0
 15 16  1  0  0  0
 15 35  1  0  0  0
 15 36  1  0  0  0
 16 17  1  0  0  0
 16 37  1  0  0  0
 16 38  1  0  0  0
 17 39  1  0  0  0
 17 40  1  0  0  0
 18 19  1  0  0  0
 18 41  1  0  0  0
 19 20  1  0  0  0
 19 24  2  0  0  0
 20 21  2  0  0  0
 20 42  1  0  0  0
 21 22  1  0  0  0
 21 25  1  0  0  0
 22 23  2  0  0  0
 23 24  1  0  0  0
 23 43  1  0  0  0
 25 44  1  0  0  0
 25 45  1  0  0  0
M  END
> <s_m_entry_id>
262

> <Applicants>
Effector Therapeutics

> <CHEMBL_ID>
CHEMBL4073443

> <Canonical_Smiles>
O=C1N2C(=C(C=C1Nc1ncnc(N)c1)C)C(=O)NC12CCCCC1

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
EFT 508 | EFT-508 | EFT508 | TOMIVOSERTIB

> <Indications>
Tomivosertib, also known as eFT508 is a MNK1/2 inhibitor. Tomivosertib binds to and inhibits the activity of MNK1 and 2. This prevents MNK1/2-mediated signaling, and inhibits the phosphorylation of certain regulatory proteins, including eukaryotic translation initiation factor 4E (eIF4E), that regulate the translation of messenger RNAs (mRNAs) involved in tumor cell proliferation, angiogenesis, survival and immune signaling

> <Type>
nan

> <targets_id>
nan

> <inchi>
InChI=1S/C17H20N6O2/c1-10-7-11(21-13-8-12(18)19-9-20-13)16(25)23-14(10)15(24)22-17(23)5-3-2-4-6-17/h7-9H,2-6H2,1H3,(H,22,24)(H3,18,19,20,21)

> <stdInchikey>
HKTBYUWLRDZAJK-UHFFFAOYSA-N

> <csid>
57617704

> <Links>
|http://www.chemspider.com/Chemical-Structure.57617704.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4073443|http://pubchem.ncbi.nlm.nih.gov/compound/118598754|http://www.drugbank.ca/drugs/DB15219| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=N45|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/N45|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10167|http://zinc15.docking.org/substances/ZINC000575623807|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=U2H19X4WBV|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50263263

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
340.2

> <HBA>
7

> <HBD>
3

> <NRB>
2

> <TPSA>
114.9

> <LogP>
1.6

> <RoF>
0

> <Targets>
nan

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.1027

> <r_epik_State_Penalty>
  0.0889

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
262

> <lig_pdbID>
'N45'

> <pdbID>
6ck6

$$$$
Rogaratinib
                    3D
 Structure written by MMmdl.
 60 64  0  0  1  0            999 V2000
   -5.7896   -1.8155   -0.9471 C   0  0  0  0  0  0
   -4.5968   -0.9610   -0.5558 C   0  0  0  0  0  0
   -3.3034   -1.4525   -0.7436 C   0  0  0  0  0  0
   -2.1953   -0.6682   -0.3798 C   0  0  0  0  0  0
   -0.8066   -0.9617   -0.4790 C   0  0  0  0  0  0
    0.0020    0.0587   -0.0219 C   0  0  0  0  0  0
   -0.9125    1.4288    0.5649 S   0  0  0  0  0  0
   -2.4283    0.6223    0.1803 C   0  0  0  0  0  0
   -3.7298    1.1155    0.3729 C   0  0  0  0  0  0
   -4.8050    0.3016   -0.0039 C   0  0  0  0  0  0
   -3.8202    2.3778    0.9261 O   0  0  0  0  0  0
   -5.1110    2.9314    1.1524 C   0  0  0  0  0  0
    1.4497    0.0730    0.0387 C   0  0  0  0  0  0
    2.3072    0.9194   -0.6772 C   0  0  0  0  0  0
    3.6254    0.6244   -0.3099 C   0  0  0  0  0  0
    3.6074   -0.4208    0.5922 N   0  0  0  0  0  0
    2.2654   -0.7820    0.8286 C   0  0  0  0  0  0
    2.1009   -1.8380    1.7520 C   0  0  0  0  0  0
    3.1570   -2.4474    2.3439 N   0  0  0  0  0  0
    4.3892   -1.9981    2.0162 C   0  0  0  0  0  0
    4.6915   -0.9966    1.1564 N   0  0  0  0  0  0
    0.8355   -2.2994    2.1060 N   0  0  0  0  0  0
    4.9299    1.2566   -0.7753 C   0  0  0  0  0  0
    5.0852    2.6543   -0.1289 N   0  3  2  0  0  0
    6.1466    3.4604   -0.9178 C   0  0  0  0  0  0
    6.5593    4.6756   -0.0638 C   0  0  0  0  0  0
    7.1762    4.1542    1.1607 N   0  0  0  0  0  0
    6.5860    3.1968    1.9104 C   0  0  0  0  0  0
    7.0540    2.7330    2.9475 O   0  0  0  0  0  0
    5.2277    2.6761    1.3758 C   0  0  0  0  0  0
    1.9062    1.9965   -1.6675 C   0  0  0  0  0  0
    2.2307    1.5594   -2.9792 O   0  0  0  0  0  0
    1.8953    2.4988   -3.9891 C   0  0  0  0  0  0
   -6.6263   -1.1982   -1.2767 H   0  0  0  0  0  0
   -6.1199   -2.4108   -0.0955 H   0  0  0  0  0  0
   -5.5402   -2.4956   -1.7626 H   0  0  0  0  0  0
   -3.1565   -2.4354   -1.1680 H   0  0  0  0  0  0
   -0.4225   -1.8914   -0.8731 H   0  0  0  0  0  0
   -5.8197    0.6455    0.1306 H   0  0  0  0  0  0
   -5.0042    3.9251    1.5871 H   0  0  0  0  0  0
   -5.6889    2.3258    1.8522 H   0  0  0  0  0  0
   -5.6709    3.0368    0.2219 H   0  0  0  0  0  0
    5.2236   -2.4903    2.4949 H   0  0  0  0  0  0
    0.0164   -1.8688    1.7017 H   0  0  0  0  0  0
    0.7555   -3.0503    2.7764 H   0  0  0  0  0  0
    5.8398    0.7109   -0.5182 H   0  0  0  0  0  0
    4.9324    1.4271   -1.8533 H   0  0  0  0  0  0
    6.9879    2.7934   -1.1204 H   0  0  0  0  0  0
    5.6733    3.7531   -1.8561 H   0  0  0  0  0  0
    7.2824    5.2953   -0.5950 H   0  0  0  0  0  0
    5.7049    5.3095    0.1827 H   0  0  0  0  0  0
    8.0659    4.5271    1.4610 H   0  0  0  0  0  0
    4.4345    3.3223    1.7526 H   0  0  0  0  0  0
    5.0389    1.6831    1.7826 H   0  0  0  0  0  0
    0.8411    2.2224   -1.6091 H   0  0  0  0  0  0
    2.4245    2.9303   -1.4419 H   0  0  0  0  0  0
    2.1720    2.0988   -4.9645 H   0  0  0  0  0  0
    2.4294    3.4401   -3.8503 H   0  0  0  0  0  0
    0.8235    2.7024   -4.0042 H   0  0  0  0  0  0
    4.2127    3.1241   -0.3263 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 34  1  0  0  0
  1 35  1  0  0  0
  1 36  1  0  0  0
  2  3  1  0  0  0
  2 10  2  0  0  0
  3  4  2  0  0  0
  3 37  1  0  0  0
  4  5  1  0  0  0
  4  8  1  0  0  0
  5  6  2  0  0  0
  5 38  1  0  0  0
  6  7  1  0  0  0
  6 13  1  0  0  0
  7  8  1  0  0  0
  8  9  2  0  0  0
  9 10  1  0  0  0
  9 11  1  0  0  0
 10 39  1  0  0  0
 11 12  1  0  0  0
 12 40  1  0  0  0
 12 41  1  0  0  0
 12 42  1  0  0  0
 13 14  1  0  0  0
 13 17  2  0  0  0
 14 15  2  0  0  0
 14 31  1  0  0  0
 15 16  1  0  0  0
 15 23  1  0  0  0
 16 17  1  0  0  0
 16 21  1  0  0  0
 17 18  1  0  0  0
 18 19  2  0  0  0
 18 22  1  0  0  0
 19 20  1  0  0  0
 20 21  2  0  0  0
 20 43  1  0  0  0
 22 44  1  0  0  0
 22 45  1  0  0  0
 23 24  1  0  0  0
 23 46  1  0  0  0
 23 47  1  0  0  0
 24 25  1  0  0  0
 24 30  1  0  0  0
 24 60  1  0  0  0
 25 26  1  0  0  0
 25 48  1  0  0  0
 25 49  1  0  0  0
 26 27  1  0  0  0
 26 50  1  0  0  0
 26 51  1  0  0  0
 27 28  1  0  0  0
 27 52  1  0  0  0
 28 29  2  0  0  0
 28 30  1  0  0  0
 30 53  1  0  0  0
 30 54  1  0  0  0
 31 32  1  0  0  0
 31 55  1  0  0  0
 31 56  1  0  0  0
 32 33  1  0  0  0
 33 57  1  0  0  0
 33 58  1  0  0  0
 33 59  1  0  0  0
M  CHG  1  24   1
M  END
> <s_m_entry_id>
264

> <Applicants>
Bayer

> <CHEMBL_ID>
CHEMBL3963485

> <Canonical_Smiles>
s1c2c(cc1-c1c3n(N=CN=C3N)c(CN3CC(=O)NCC3)c1COC)cc(cc2OC)C

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
BAY-1163877 | ROGARATINIB

> <Indications>
Rogaratinib (BAY-1163877) is a FGFR-selective kinase inhibitor that is being investigated for antineoplastic activity.

> <Type>
nan

> <targets_id>
nan

> <inchi>
InChI=1S/C23H26N6O3S/c1-13-6-14-8-18(33-22(14)17(7-13)32-3)20-15(11-31-2)16(9-28-5-4-25-19(30)10-28)29-21(20)23(24)26-12-27-29/h6-8,12H,4-5,9-11H2,1-3H3,(H,25,30)(H2,24,26,27)

> <stdInchikey>
HNLRRJSKGXOYNO-UHFFFAOYSA-N

> <csid>
58828032

> <Links>
|http://www.chemspider.com/Chemical-Structure.58828032.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3963485|http://pubchem.ncbi.nlm.nih.gov/compound/71611869|http://www.drugbank.ca/drugs/DB15078|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9789|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=98BSN6N516|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=194820

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
466.2

> <HBA>
9

> <HBD>
2

> <NRB>
6

> <TPSA>
107

> <LogP>
2.6

> <RoF>
0

> <Targets>
nan

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_epik_Ionization_Penalty>
  0.4567

> <r_epik_State_Penalty>
  0.3724

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
264

$$$$
Parsaclisib
                    3D
 Structure written by MMmdl.
 52 55  0  0  1  0            999 V2000
    1.7168    3.2799    0.9223 C   0  0  0  0  0  0
    0.6007    2.2523    1.1260 C   0  0  0  0  0  0
    0.1270    1.8290   -0.1491 O   0  0  0  0  0  0
   -0.8151    0.8281   -0.1012 C   0  0  0  0  0  0
   -0.3978   -0.5147   -0.1733 C   0  0  0  0  0  0
   -1.3573   -1.5293   -0.0857 C   0  0  0  0  0  0
   -2.7073   -1.2247    0.0481 C   0  0  0  0  0  0
   -3.1228    0.1059    0.0887 C   0  0  0  0  0  0
   -2.1844    1.1481    0.0058 C   0  0  0  0  0  0
   -2.6512    2.6152    0.0323 C   0  0  1  0  0  0
   -3.6162    3.0451   -1.0704 C   0  0  0  0  0  0
   -4.4494    4.1768   -0.4674 C   0  0  0  0  0  0
   -5.1964    4.9355   -1.0800 O   0  0  0  0  0  0
   -4.1793    4.1739    0.8504 N   0  0  0  0  0  0
   -3.3440    3.0738    1.3111 C   0  0  0  0  0  0
   -4.4444    0.3762    0.2138 F   0  0  0  0  0  0
   -3.8590   -2.5082    0.1577 Cl  0  0  0  0  0  0
    1.0912   -0.8757   -0.3374 C   0  0  2  0  0  0
    1.3571   -1.9842   -1.3807 C   0  0  0  0  0  0
    1.7477   -1.2199    0.9298 N   0  0  0  0  0  0
    2.9197   -0.7125    1.4626 C   0  0  0  0  0  0
    3.1037   -1.3836    2.6928 C   0  0  0  0  0  0
    1.9975   -2.2852    2.7926 C   0  0  0  0  0  0
    1.2261   -2.1740    1.7361 N   0  0  0  0  0  0
    1.6669   -3.2637    3.8963 C   0  0  0  0  0  0
    4.2417   -1.0111    3.4309 C   0  0  0  0  0  0
    5.0959   -0.0646    2.9637 N   0  0  0  0  0  0
    4.7989    0.4950    1.7621 C   0  0  0  0  0  0
    3.7354    0.2245    0.9584 N   0  0  0  0  0  0
    4.5346   -1.5932    4.6615 N   0  0  0  0  0  0
    2.1171    3.6145    1.8794 H   0  0  0  0  0  0
    1.3503    4.1569    0.3880 H   0  0  0  0  0  0
    2.5406    2.8565    0.3467 H   0  0  0  0  0  0
    0.9811    1.4076    1.7016 H   0  0  0  0  0  0
   -0.2082    2.6949    1.7089 H   0  0  0  0  0  0
   -1.0583   -2.5666   -0.1161 H   0  0  0  0  0  0
   -1.7760    3.2562   -0.0866 H   0  0  0  0  0  0
   -3.0846    3.3855   -1.9600 H   0  0  0  0  0  0
   -4.2934    2.2493   -1.3791 H   0  0  0  0  0  0
   -4.5857    4.8366    1.4949 H   0  0  0  0  0  0
   -3.9853    2.3049    1.7438 H   0  0  0  0  0  0
   -2.6375    3.3931    2.0783 H   0  0  0  0  0  0
    1.6052    0.0074   -0.7191 H   0  0  0  0  0  0
    0.9177   -1.7282   -2.3455 H   0  0  0  0  0  0
    0.9511   -2.9490   -1.0760 H   0  0  0  0  0  0
    2.4274   -2.1225   -1.5403 H   0  0  0  0  0  0
    2.4675   -3.9906    4.0350 H   0  0  0  0  0  0
    0.7543   -3.8287    3.7014 H   0  0  0  0  0  0
    1.5280   -2.7540    4.8498 H   0  0  0  0  0  0
    5.4881    1.2456    1.4033 H   0  0  0  0  0  0
    3.9166   -2.2953    5.0408 H   0  0  0  0  0  0
    5.3599   -1.2960    5.1613 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 31  1  0  0  0
  1 32  1  0  0  0
  1 33  1  0  0  0
  2  3  1  0  0  0
  2 34  1  0  0  0
  2 35  1  0  0  0
  3  4  1  0  0  0
  4  5  2  0  0  0
  4  9  1  0  0  0
  5  6  1  0  0  0
  5 18  1  0  0  0
  6  7  2  0  0  0
  6 36  1  0  0  0
  7  8  1  0  0  0
  7 17  1  0  0  0
  8  9  2  0  0  0
  8 16  1  0  0  0
  9 10  1  0  0  0
 10 11  1  0  0  0
 10 15  1  0  0  0
 10 37  1  0  0  0
 11 12  1  0  0  0
 11 38  1  0  0  0
 11 39  1  0  0  0
 12 13  2  0  0  0
 12 14  1  0  0  0
 14 15  1  0  0  0
 14 40  1  0  0  0
 15 41  1  0  0  0
 15 42  1  0  0  0
 18 19  1  0  0  0
 18 20  1  0  0  0
 18 43  1  0  0  0
 19 44  1  0  0  0
 19 45  1  0  0  0
 19 46  1  0  0  0
 20 21  1  0  0  0
 20 24  1  0  0  0
 21 22  1  0  0  0
 21 29  2  0  0  0
 22 23  1  0  0  0
 22 26  2  0  0  0
 23 24  2  0  0  0
 23 25  1  0  0  0
 25 47  1  0  0  0
 25 48  1  0  0  0
 25 49  1  0  0  0
 26 27  1  0  0  0
 26 30  1  0  0  0
 27 28  2  0  0  0
 28 29  1  0  0  0
 28 50  1  0  0  0
 30 51  1  0  0  0
 30 52  1  0  0  0
M  END
> <s_m_entry_id>
270

> <Applicants>
Incyte Corporation

> <CHEMBL_ID>
CHEMBL4297615

> <Canonical_Smiles>
Clc1cc([C@@H](n2nc(c3c2ncnc3N)C)C)c(OCC)c([C@H]2CC(=O)NC2)c1F

> <Chirality>
Single Stereoisomer

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
INCB-050465 | INCB050465 | PARSACLISIB

> <Indications>
Parsaclisib (INCB050465) is a PI3K&delta; inhibitor that was developed by Incyte Corporation as an antineoplastic and immunomodulatory agent, as claimed in their patent WO2014134426A1 [<a href='javascript:callRef("ReferenceDisplayForward?referenceId=36232&displayId=1", 960, 600)' title="1. Li Y-L, Yao W, Combs AP, Yue EW, Mei S, Zhu W, Glenn J Jr, Maduskuie TP, Sparks RB, Douty B, He C. (2014) USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3Kδ RELATED DISORDERS. Patent no. WO2014134426A1.">1</a>]. The chemical structure is one of those claimed in patent WO2013033569A1, but it is not clear which example it is from a mixture of diastereoisomers 345-348 (although 347 and 348 had the highest inhibitory potency <i>vs</i>. PI3K&delta; and 347 was tested <i>in vivo</i> [<a href='javascript:callRef("ReferenceDisplayForward?referenceId=36233&displayId=2", 960, 600)' title="2. Li Y-L, Yao W, Combs AP, Yue EW, Mei S, Zhu W, Glenn J, Maduskuie TP Jr, Sparks RB, Douty B. (2013) Heterocyclylamines as pi3k inhibitors. Patent no. WO2013033569A1.">2</a>].

> <Type>
nan

> <targets_id>
nan

> <inchi>
InChI=1S/C20H22ClFN6O2/c1-4-30-18-12(6-13(21)17(22)16(18)11-5-14(29)24-7-11)10(3)28-20-15(9(2)27-28)19(23)25-8-26-20/h6,8,10-11H,4-5,7H2,1-3H3,(H,24,29)(H2,23,25,26)/t10-,11-/m0/s1

> <stdInchikey>
ZQPDJCIXJHUERQ-QWRGUYRKSA-N

> <csid>
64835232

> <Links>
|http://www.chemspider.com/Chemical-Structure.64835232.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4297615|http://pubchem.ncbi.nlm.nih.gov/compound/86677874|http://www.drugbank.ca/drugs/DB14867|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10098|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=OS7097575K|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=272573

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
432.1

> <HBA>
7

> <HBD>
2

> <NRB>
5

> <TPSA>
107.9

> <LogP>
3.1

> <RoF>
0

> <Targets>
nan

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0023

> <r_epik_State_Penalty>
  0.0016

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
270

$$$$
Sapanisertib
                    3D
 Structure written by MMmdl.
 38 41  0  0  1  0            999 V2000
   -0.4114   -0.8142    1.4231 C   0  0  0  0  0  0
    0.0245   -0.0734    0.1428 C   0  0  0  0  0  0
   -0.5402   -0.7221   -1.1363 C   0  0  0  0  0  0
    1.4882    0.0133    0.0658 N   0  0  0  0  0  0
    2.2868    1.1399   -0.0122 C   0  0  0  0  0  0
    3.6193    0.6673   -0.0864 C   0  0  0  0  0  0
    3.5040   -0.7635   -0.0311 C   0  0  0  0  0  0
    2.2389   -1.1122    0.0415 N   0  0  0  0  0  0
    4.5832   -1.7923   -0.0447 C   0  0  0  0  0  0
    4.4954   -2.8845   -0.9239 C   0  0  0  0  0  0
    5.4918   -3.8612   -0.9897 C   0  0  0  0  0  0
    6.5833   -3.6904   -0.1346 C   0  0  0  0  0  0
    6.7039   -2.6119    0.7560 C   0  0  0  0  0  0
    5.6896   -1.6448    0.8062 C   0  0  0  0  0  0
    7.8766   -2.7234    1.4507 N   0  0  0  0  0  0
    8.4071   -3.8269    0.9726 C   0  0  0  0  0  0
    7.6867   -4.4736    0.0090 O   0  0  0  0  0  0
    9.5934   -4.3912    1.3324 N   0  0  0  0  0  0
    4.6122    1.6620   -0.1957 C   0  0  0  0  0  0
    4.2820    2.9786   -0.2112 N   0  0  0  0  0  0
    2.9626    3.2859   -0.1237 C   0  0  0  0  0  0
    1.9135    2.4273   -0.0258 N   0  0  0  0  0  0
    5.9638    1.3484   -0.3097 N   0  0  0  0  0  0
   -1.4967   -0.8064    1.5280 H   0  0  0  0  0  0
    0.0049   -0.3426    2.3142 H   0  0  0  0  0  0
   -0.0905   -1.8569    1.4182 H   0  0  0  0  0  0
   -0.3595    0.9464    0.2007 H   0  0  0  0  0  0
   -1.6305   -0.7316   -1.1213 H   0  0  0  0  0  0
   -0.2047   -1.7539   -1.2494 H   0  0  0  0  0  0
   -0.2318   -0.1733   -2.0270 H   0  0  0  0  0  0
    3.6380   -2.9779   -1.5754 H   0  0  0  0  0  0
    5.4233   -4.6994   -1.6671 H   0  0  0  0  0  0
    5.7591   -0.8096    1.4880 H   0  0  0  0  0  0
   10.1818   -3.9732    2.0381 H   0  0  0  0  0  0
    9.9244   -5.2430    0.9040 H   0  0  0  0  0  0
    2.7173    4.3378   -0.1371 H   0  0  0  0  0  0
    6.2534    0.3811   -0.3040 H   0  0  0  0  0  0
    6.6365    2.0969   -0.3906 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 24  1  0  0  0
  1 25  1  0  0  0
  1 26  1  0  0  0
  2  3  1  0  0  0
  2  4  1  0  0  0
  2 27  1  0  0  0
  3 28  1  0  0  0
  3 29  1  0  0  0
  3 30  1  0  0  0
  4  5  1  0  0  0
  4  8  1  0  0  0
  5  6  1  0  0  0
  5 22  2  0  0  0
  6  7  1  0  0  0
  6 19  2  0  0  0
  7  8  2  0  0  0
  7  9  1  0  0  0
  9 10  1  0  0  0
  9 14  2  0  0  0
 10 11  2  0  0  0
 10 31  1  0  0  0
 11 12  1  0  0  0
 11 32  1  0  0  0
 12 13  2  0  0  0
 12 17  1  0  0  0
 13 14  1  0  0  0
 13 15  1  0  0  0
 14 33  1  0  0  0
 15 16  2  0  0  0
 16 17  1  0  0  0
 16 18  1  0  0  0
 18 34  1  0  0  0
 18 35  1  0  0  0
 19 20  1  0  0  0
 19 23  1  0  0  0
 20 21  2  0  0  0
 21 22  1  0  0  0
 21 36  1  0  0  0
 23 37  1  0  0  0
 23 38  1  0  0  0
M  END
> <s_m_entry_id>
271

> <Applicants>
Takeda

> <CHEMBL_ID>
CHEMBL3545097

> <Canonical_Smiles>
o1c2c(nc1N)cc(cc2)-c1nn(c2ncnc(N)c12)C(C)C

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
INK-128 | INK128 | MLN-0128 | MLN0128 | SAPANISERTIB | TAK-228

> <Indications>
nan

> <Type>
nan

> <targets_id>
P42345

> <inchi>
InChI=1S/C15H15N7O/c1-7(2)22-14-11(13(16)18-6-19-14)12(21-22)8-3-4-10-9(5-8)20-15(17)23-10/h3-7H,1-2H3,(H2,17,20)(H2,16,18,19)

> <stdInchikey>
GYLDXIAOMVERTK-UHFFFAOYSA-N

> <csid>
28189069

> <Links>
|http://www.chemspider.com/Chemical-Structure.28189069.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3545097|http://pubchem.ncbi.nlm.nih.gov/compound/45375953|http://www.drugbank.ca/drugs/DB11836| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=FE5|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/FE5|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7933|http://zinc15.docking.org/substances/ZINC000073069271|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=JGH0DF1U03|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=315477

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
309.1

> <HBA>
8

> <HBD>
2

> <NRB>
2

> <TPSA>
121.7

> <LogP>
2.4

> <RoF>
0

> <Targets>
MTOR

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0009

> <r_epik_State_Penalty>
  0.0000

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
271

> <lig_pdbID>
'FE5'

> <pdbID>
6gvf

> <Kinase families>
Atypical

$$$$
Tamatinib
                    3D
 Structure written by MMmdl.
 57 60  0  0  1  0            999 V2000
   -7.5702   -3.9199   -2.7945 C   0  0  0  0  0  0
   -6.8728   -3.0710   -1.7090 C   0  0  0  0  0  0
   -5.3190   -3.2140   -1.9320 C   0  0  0  0  0  0
   -4.7356   -4.2810   -2.1233 O   0  0  0  0  0  0
   -4.6508   -2.0507   -1.8269 N   0  0  0  0  0  0
   -5.2054   -0.8001   -1.6344 C   0  0  0  0  0  0
   -6.5865   -0.6521   -1.6573 C   0  0  0  0  0  0
   -7.1323    0.6211   -1.5031 C   0  0  0  0  0  0
   -6.2679    1.7033   -1.3115 C   0  0  0  0  0  0
   -4.8835    1.4807   -1.2842 C   0  0  0  0  0  0
   -4.3511    0.2357   -1.4479 N   0  0  0  0  0  0
   -4.0462    2.5935   -1.0964 N   0  0  0  0  0  0
   -2.6543    2.7324   -0.9485 C   0  0  0  0  0  0
   -2.1072    4.0222   -0.9157 C   0  0  0  0  0  0
   -0.7239    4.1285   -0.7679 C   0  0  0  0  0  0
    0.0798    3.0409   -0.6563 N   0  0  0  0  0  0
   -0.5244    1.8226   -0.7024 C   0  0  0  0  0  0
   -1.8611    1.6296   -0.8422 N   0  0  0  0  0  0
    0.2337    0.6502   -0.5630 N   0  0  0  0  0  0
    1.6045    0.4294   -0.3429 C   0  0  0  0  0  0
    2.6011    1.3001   -0.7959 C   0  0  0  0  0  0
    3.9578    1.0363   -0.5505 C   0  0  0  0  0  0
    4.3060   -0.1282    0.1463 C   0  0  0  0  0  0
    3.3235   -1.0171    0.6024 C   0  0  0  0  0  0
    1.9746   -0.7286    0.3413 C   0  0  0  0  0  0
    3.7551   -2.1371    1.2905 O   0  0  0  0  0  0
    2.7972   -3.0655    1.7865 C   0  0  0  0  0  0
    5.6303   -0.3901    0.4055 O   0  0  0  0  0  0
    6.2726   -1.1712   -0.5932 C   0  0  0  0  0  0
    4.9914    1.8596   -0.9609 O   0  0  0  0  0  0
    4.6924    3.0651   -1.6562 C   0  0  0  0  0  0
   -2.8762    5.1323   -1.0216 F   0  0  0  0  0  0
   -7.4144   -1.7312   -1.8794 O   0  0  0  0  0  0
   -7.1612   -3.5214   -0.2600 C   0  0  0  0  0  0
   -7.3090   -4.9771   -2.7223 H   0  0  0  0  0  0
   -7.3199   -3.5803   -3.8011 H   0  0  0  0  0  0
   -8.6545   -3.8560   -2.6956 H   0  0  0  0  0  0
   -3.6481   -2.1200   -1.9191 H   0  0  0  0  0  0
   -8.2016    0.7703   -1.5322 H   0  0  0  0  0  0
   -6.6729    2.6974   -1.1880 H   0  0  0  0  0  0
   -4.5422    3.4719   -1.0707 H   0  0  0  0  0  0
   -0.2417    5.0944   -0.7344 H   0  0  0  0  0  0
   -0.3418   -0.1647   -0.4103 H   0  0  0  0  0  0
    2.3221    2.1770   -1.3563 H   0  0  0  0  0  0
    1.1973   -1.3981    0.6792 H   0  0  0  0  0  0
    3.3149   -3.8728    2.3043 H   0  0  0  0  0  0
    2.2165   -3.5120    0.9781 H   0  0  0  0  0  0
    2.1189   -2.5978    2.5017 H   0  0  0  0  0  0
    7.3135   -1.3320   -0.3131 H   0  0  0  0  0  0
    6.2629   -0.6697   -1.5625 H   0  0  0  0  0  0
    5.8027   -2.1504   -0.7008 H   0  0  0  0  0  0
    5.6211    3.5886   -1.8825 H   0  0  0  0  0  0
    4.0761    3.7337   -1.0530 H   0  0  0  0  0  0
    4.1876    2.8663   -2.6028 H   0  0  0  0  0  0
   -6.8573   -4.5548   -0.0840 H   0  0  0  0  0  0
   -8.2281   -3.4618   -0.0437 H   0  0  0  0  0  0
   -6.6503   -2.8930    0.4715 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 35  1  0  0  0
  1 36  1  0  0  0
  1 37  1  0  0  0
  2  3  1  0  0  0
  2 33  1  0  0  0
  2 34  1  0  0  0
  3  4  2  0  0  0
  3  5  1  0  0  0
  5  6  1  0  0  0
  5 38  1  0  0  0
  6  7  1  0  0  0
  6 11  2  0  0  0
  7  8  2  0  0  0
  7 33  1  0  0  0
  8  9  1  0  0  0
  8 39  1  0  0  0
  9 10  2  0  0  0
  9 40  1  0  0  0
 10 11  1  0  0  0
 10 12  1  0  0  0
 12 13  1  0  0  0
 12 41  1  0  0  0
 13 14  1  0  0  0
 13 18  2  0  0  0
 14 15  2  0  0  0
 14 32  1  0  0  0
 15 16  1  0  0  0
 15 42  1  0  0  0
 16 17  2  0  0  0
 17 18  1  0  0  0
 17 19  1  0  0  0
 19 20  1  0  0  0
 19 43  1  0  0  0
 20 21  1  0  0  0
 20 25  2  0  0  0
 21 22  2  0  0  0
 21 44  1  0  0  0
 22 23  1  0  0  0
 22 30  1  0  0  0
 23 24  2  0  0  0
 23 28  1  0  0  0
 24 25  1  0  0  0
 24 26  1  0  0  0
 25 45  1  0  0  0
 26 27  1  0  0  0
 27 46  1  0  0  0
 27 47  1  0  0  0
 27 48  1  0  0  0
 28 29  1  0  0  0
 29 49  1  0  0  0
 29 50  1  0  0  0
 29 51  1  0  0  0
 30 31  1  0  0  0
 31 52  1  0  0  0
 31 53  1  0  0  0
 31 54  1  0  0  0
 34 55  1  0  0  0
 34 56  1  0  0  0
 34 57  1  0  0  0
M  END
> <s_m_entry_id>
272

> <Applicants>
Rigel Pharmaceuticals

> <CHEMBL_ID>
nan

> <Canonical_Smiles>
Fc1cnc(nc1Nc1nc2NC(=O)C(Oc2cc1)(C)C)Nc1cc(OC)c(OC)c(OC)c1

> <Chirality>
nan

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
nan

> <Synonyms>
R-406

> <Indications>
nan

> <Type>
1

> <targets_id>
P43405

> <inchi>
InChI=1S/C22H23FN6O5/c1-22(2)20(30)28-19-13(34-22)6-7-16(27-19)26-18-12(23)10-24-21(29-18)25-11-8-14(31-3)17(33-5)15(9-11)32-4/h6-10H,1-5H3,(H3,24,25,26,27,28,29,30)

> <stdInchikey>
NHHQJBCNYHBUSI-UHFFFAOYSA-N

> <csid>
9388620

> <Links>
|http://www.chemspider.com/Chemical-Structure.9388620.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL475251|http://pubchem.ncbi.nlm.nih.gov/compound/11213558|http://www.drugbank.ca/drugs/DB07159| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=585|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/585|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7425|http://zinc15.docking.org/substances/ZINC06745792|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=RC3A285J2G|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=60665

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
470.2

> <HBA>
10

> <HBD>
3

> <NRB>
7

> <TPSA>
128.8

> <LogP>
3.6

> <RoF>
0

> <Targets>
SYK

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0016

> <r_epik_State_Penalty>
  0.0000

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
272

> <lig_pdbID>
'585'

> <pdbID>
3fqs 3piy

> <Kinase families>
Tyr

> <uniprotId>
P43405

$$$$
Vistusertib
                    3D
 Structure written by MMmdl.
 64 68  0  0  1  0            999 V2000
   -5.5262   -0.4149   -2.2030 C   0  0  0  0  0  0
   -6.0830   -0.7174   -0.7938 C   0  0  1  0  0  0
   -6.7864   -2.1015   -0.8038 C   0  0  0  0  0  0
   -7.4034   -2.3760    0.4484 O   0  0  0  0  0  0
   -6.5113   -2.2770    1.5502 C   0  0  0  0  0  0
   -5.8090   -0.9047    1.5488 C   0  0  0  0  0  0
   -5.0764   -0.6775    0.2919 N   0  0  0  0  0  0
   -4.1622    0.3691    0.3160 C   0  0  0  0  0  0
   -2.7703    0.1292    0.1694 C   0  0  0  0  0  0
   -2.1515   -1.1362    0.0018 C   0  0  0  0  0  0
   -0.7665   -1.2000   -0.1333 C   0  0  0  0  0  0
   -0.0096   -0.0225   -0.1029 C   0  0  0  0  0  0
   -0.5853    1.2023    0.0525 N   0  0  0  0  0  0
   -1.9360    1.2829    0.1901 C   0  0  0  0  0  0
   -2.4447    2.5347    0.3448 N   0  0  0  0  0  0
   -3.7920    2.6639    0.4806 C   0  0  0  0  0  0
   -4.6662    1.6212    0.4713 N   0  0  0  0  0  0
   -4.3292    3.9502    0.6367 N   0  0  0  0  0  0
   -5.7509    4.2427    0.3721 C   0  0  0  0  0  0
   -5.9005    4.7201   -1.0891 C   0  0  0  0  0  0
   -5.0887    5.8698   -1.3300 O   0  0  0  0  0  0
   -3.7221    5.7371   -0.9337 C   0  0  0  0  0  0
   -3.6157    5.2467    0.5338 C   0  0  2  0  0  0
   -2.1778    5.3612    1.0829 C   0  0  0  0  0  0
    1.4766   -0.0392   -0.2584 C   0  0  0  0  0  0
    2.2387   -1.0878    0.2745 C   0  0  0  0  0  0
    3.6239   -1.1140    0.1311 C   0  0  0  0  0  0
    4.2739   -0.0914   -0.5547 C   0  0  0  0  0  0
    3.5461    0.9705   -1.1063 C   0  0  0  0  0  0
    2.1507    0.9855   -0.9430 C   0  0  0  0  0  0
    4.2664    2.0704   -1.8507 C   0  0  0  0  0  0
    5.4325    2.3577   -1.5713 O   0  0  0  0  0  0
    3.5690    2.6686   -2.8349 N   0  0  0  0  0  0
    4.0713    3.7310   -3.6995 C   0  0  0  0  0  0
   -6.3077   -0.4838   -2.9604 H   0  0  0  0  0  0
   -4.7354   -1.1143   -2.4776 H   0  0  0  0  0  0
   -5.1140    0.5927   -2.2654 H   0  0  0  0  0  0
   -6.8392    0.0439   -0.5889 H   0  0  0  0  0  0
   -7.5670   -2.1251   -1.5649 H   0  0  0  0  0  0
   -6.0828   -2.8991   -1.0512 H   0  0  0  0  0  0
   -7.0801   -2.4038    2.4714 H   0  0  0  0  0  0
   -5.7816   -3.0884    1.5262 H   0  0  0  0  0  0
   -6.5350   -0.1095    1.7293 H   0  0  0  0  0  0
   -5.1074   -0.8761    2.3841 H   0  0  0  0  0  0
   -2.7491   -2.0361   -0.0239 H   0  0  0  0  0  0
   -0.2917   -2.1605   -0.2704 H   0  0  0  0  0  0
   -6.3918    3.3821    0.5631 H   0  0  0  0  0  0
   -6.1184    5.0149    1.0502 H   0  0  0  0  0  0
   -5.6436    3.9210   -1.7868 H   0  0  0  0  0  0
   -6.9394    4.9808   -1.2921 H   0  0  0  0  0  0
   -3.1997    5.0605   -1.6127 H   0  0  0  0  0  0
   -3.2534    6.7157   -1.0422 H   0  0  0  0  0  0
   -4.1696    5.9582    1.1504 H   0  0  0  0  0  0
   -1.8934    6.4077    1.1977 H   0  0  0  0  0  0
   -1.4406    4.9088    0.4195 H   0  0  0  0  0  0
   -2.0892    4.8928    2.0637 H   0  0  0  0  0  0
    1.7605   -1.8909    0.8163 H   0  0  0  0  0  0
    4.1951   -1.9284    0.5522 H   0  0  0  0  0  0
    5.3493   -0.1356   -0.6561 H   0  0  0  0  0  0
    1.5736    1.8007   -1.3567 H   0  0  0  0  0  0
    2.6179    2.3722   -2.9984 H   0  0  0  0  0  0
    3.4257    4.6058   -3.6212 H   0  0  0  0  0  0
    4.0625    3.3967   -4.7370 H   0  0  0  0  0  0
    5.0880    4.0405   -3.4534 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 35  1  0  0  0
  1 36  1  0  0  0
  1 37  1  0  0  0
  2  3  1  0  0  0
  2  7  1  0  0  0
  2 38  1  0  0  0
  3  4  1  0  0  0
  3 39  1  0  0  0
  3 40  1  0  0  0
  4  5  1  0  0  0
  5  6  1  0  0  0
  5 41  1  0  0  0
  5 42  1  0  0  0
  6  7  1  0  0  0
  6 43  1  0  0  0
  6 44  1  0  0  0
  7  8  1  0  0  0
  8  9  2  0  0  0
  8 17  1  0  0  0
  9 10  1  0  0  0
  9 14  1  0  0  0
 10 11  2  0  0  0
 10 45  1  0  0  0
 11 12  1  0  0  0
 11 46  1  0  0  0
 12 13  2  0  0  0
 12 25  1  0  0  0
 13 14  1  0  0  0
 14 15  2  0  0  0
 15 16  1  0  0  0
 16 17  2  0  0  0
 16 18  1  0  0  0
 18 19  1  0  0  0
 18 23  1  0  0  0
 19 20  1  0  0  0
 19 47  1  0  0  0
 19 48  1  0  0  0
 20 21  1  0  0  0
 20 49  1  0  0  0
 20 50  1  0  0  0
 21 22  1  0  0  0
 22 23  1  0  0  0
 22 51  1  0  0  0
 22 52  1  0  0  0
 23 24  1  0  0  0
 23 53  1  0  0  0
 24 54  1  0  0  0
 24 55  1  0  0  0
 24 56  1  0  0  0
 25 26  1  0  0  0
 25 30  2  0  0  0
 26 27  2  0  0  0
 26 57  1  0  0  0
 27 28  1  0  0  0
 27 58  1  0  0  0
 28 29  2  0  0  0
 28 59  1  0  0  0
 29 30  1  0  0  0
 29 31  1  0  0  0
 30 60  1  0  0  0
 31 32  2  0  0  0
 31 33  1  0  0  0
 33 34  1  0  0  0
 33 61  1  0  0  0
 34 62  1  0  0  0
 34 63  1  0  0  0
 34 64  1  0  0  0
M  END
> <s_m_entry_id>
273

> <Applicants>
Astrazeneca

> <CHEMBL_ID>
CHEMBL2336325

> <Canonical_Smiles>
O1C[C@@H](N(CC1)c1nc(nc2nc(ccc12)-c1cc(ccc1)C(=O)NC)N1CCOC[C@@H]1C)C

> <Chirality>
Single Stereoisomer

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
AZD-2014 | AZD2014 | VISTUSERTIB

> <Indications>
nan

> <Type>
nan

> <targets_id>
P42345

> <inchi>
InChI=1S/C25H30N6O3/c1-16-14-33-11-9-30(16)23-20-7-8-21(18-5-4-6-19(13-18)24(32)26-3)27-22(20)28-25(29-23)31-10-12-34-15-17(31)2/h4-8,13,16-17H,9-12,14-15H2,1-3H3,(H,26,32)/t16-,17-/m0/s1

> <stdInchikey>
JUSFANSTBFGBAF-IRXDYDNUSA-N

> <csid>
28294977

> <Links>
|http://www.chemspider.com/Chemical-Structure.28294977.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2336325|http://pubchem.ncbi.nlm.nih.gov/compound/25262792|http://www.drugbank.ca/drugs/DB11925|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7699|http://zinc15.docking.org/substances/ZINC000059258964|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=0BSC3P4H5X|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50429701

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
462.2

> <HBA>
8

> <HBD>
1

> <NRB>
4

> <TPSA>
92.7

> <LogP>
2.5

> <RoF>
0

> <Targets>
MTOR

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0000

> <r_epik_State_Penalty>
  0.0000

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
273

> <Kinase families>
Atypical

> <Withdrawn>
|Study NCT03166904 in Korea, Republic of was Withdrawn during Phase 2 because Lack of efficacy|Study NCT03166176 in Korea, Republic of was Withdrawn during Phase 2 because lack of efficacy

$$$$
Tenalisib
                    3D
 Structure written by MMmdl.
 49 53  0  0  1  0            999 V2000
   -1.1136    1.1280   -0.3238 C   0  0  0  0  0  0
   -0.3298   -0.1859   -0.4805 C   0  0  0  0  0  0
    1.1861   -0.0547   -0.2076 C   0  0  1  0  0  0
    1.8550   -1.4269   -0.0746 C   0  0  0  0  0  0
    2.3745   -1.9772    1.0574 C   0  0  0  0  0  0
    2.9832   -3.3267    1.0243 C   0  0  0  0  0  0
    3.4443   -3.9147    2.0054 O   0  0  0  0  0  0
    3.0019   -3.9479   -0.3400 C   0  0  0  0  0  0
    3.5657   -5.2135   -0.5609 C   0  0  0  0  0  0
    3.5746   -5.7759   -1.8385 C   0  0  0  0  0  0
    3.0183   -5.0827   -2.9132 C   0  0  0  0  0  0
    2.4514   -3.8251   -2.7128 C   0  0  0  0  0  0
    2.4452   -3.2665   -1.4347 C   0  0  0  0  0  0
    1.8684   -2.0227   -1.3000 O   0  0  0  0  0  0
    2.2915   -1.2906    2.3692 C   0  0  0  0  0  0
    3.4548   -0.8721    3.0290 C   0  0  0  0  0  0
    3.3784   -0.2165    4.2580 C   0  0  0  0  0  0
    2.1362    0.0235    4.8436 C   0  0  0  0  0  0
    0.9715   -0.3937    4.2005 C   0  0  0  0  0  0
    1.0496   -1.0489    2.9714 C   0  0  0  0  0  0
   -0.2340   -0.1623    4.7676 F   0  0  0  0  0  0
    1.8260    0.8438   -1.1709 N   0  0  0  0  0  0
    3.1139    1.3704   -0.9672 C   0  0  0  0  0  0
    3.7457    2.0993   -1.9937 C   0  0  0  0  0  0
    5.0389    2.5998   -1.7019 C   0  0  0  0  0  0
    5.4215    3.2575   -2.8454 N   0  0  0  0  0  0
    4.3793    3.1240   -3.7345 C   0  0  0  0  0  0
    3.3615    2.4411   -3.2676 N   0  0  0  0  0  0
    5.7020    2.4429   -0.5520 N   0  0  0  0  0  0
    4.9945    1.7274    0.3643 C   0  0  0  0  0  0
    3.7529    1.1913    0.2258 N   0  0  0  0  0  0
   -2.1782    0.9678   -0.4959 H   0  0  0  0  0  0
   -0.7764    1.8841   -1.0334 H   0  0  0  0  0  0
   -0.9996    1.5372    0.6807 H   0  0  0  0  0  0
   -0.7584   -0.9162    0.2075 H   0  0  0  0  0  0
   -0.4949   -0.5898   -1.4808 H   0  0  0  0  0  0
    1.2731    0.4477    0.7557 H   0  0  0  0  0  0
    4.0031   -5.7718    0.2547 H   0  0  0  0  0  0
    4.0135   -6.7504   -1.9948 H   0  0  0  0  0  0
    3.0266   -5.5204   -3.9006 H   0  0  0  0  0  0
    2.0198   -3.2875   -3.5444 H   0  0  0  0  0  0
    4.4232   -1.0487    2.5830 H   0  0  0  0  0  0
    4.2814    0.1063    4.7548 H   0  0  0  0  0  0
    2.0770    0.5322    5.7947 H   0  0  0  0  0  0
    0.1400   -1.3678    2.4836 H   0  0  0  0  0  0
    1.4530    0.8658   -2.1092 H   0  0  0  0  0  0
    6.2782    3.7528   -3.0438 H   0  0  0  0  0  0
    4.4544    3.5673   -4.7169 H   0  0  0  0  0  0
    5.4764    1.5656    1.3175 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 32  1  0  0  0
  1 33  1  0  0  0
  1 34  1  0  0  0
  2  3  1  0  0  0
  2 35  1  0  0  0
  2 36  1  0  0  0
  3  4  1  0  0  0
  3 22  1  0  0  0
  3 37  1  0  0  0
  4  5  2  0  0  0
  4 14  1  0  0  0
  5  6  1  0  0  0
  5 15  1  0  0  0
  6  7  2  0  0  0
  6  8  1  0  0  0
  8  9  1  0  0  0
  8 13  2  0  0  0
  9 10  2  0  0  0
  9 38  1  0  0  0
 10 11  1  0  0  0
 10 39  1  0  0  0
 11 12  2  0  0  0
 11 40  1  0  0  0
 12 13  1  0  0  0
 12 41  1  0  0  0
 13 14  1  0  0  0
 15 16  1  0  0  0
 15 20  2  0  0  0
 16 17  2  0  0  0
 16 42  1  0  0  0
 17 18  1  0  0  0
 17 43  1  0  0  0
 18 19  2  0  0  0
 18 44  1  0  0  0
 19 20  1  0  0  0
 19 21  1  0  0  0
 20 45  1  0  0  0
 22 23  1  0  0  0
 22 46  1  0  0  0
 23 24  1  0  0  0
 23 31  2  0  0  0
 24 25  2  0  0  0
 24 28  1  0  0  0
 25 26  1  0  0  0
 25 29  1  0  0  0
 26 27  1  0  0  0
 26 47  1  0  0  0
 27 28  2  0  0  0
 27 48  1  0  0  0
 29 30  2  0  0  0
 30 31  1  0  0  0
 30 49  1  0  0  0
M  END
> <s_m_entry_id>
274

> <Applicants>
Rhizen Pharmaceuticals

> <CHEMBL_ID>
CHEMBL4297584

> <Canonical_Smiles>
Fc1cc(ccc1)C=1C(=O)c2c(OC=1[C@@H](Nc1ncnc3[nH]cnc13)CC)cccc2

> <Chirality>
Single Stereoisomer

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
TENALISIB

> <Indications>
nan

> <Type>
nan

> <targets_id>
nan

> <inchi>
InChI=1S/C23H18FN5O2/c1-2-16(29-23-19-22(26-11-25-19)27-12-28-23)21-18(13-6-5-7-14(24)10-13)20(30)15-8-3-4-9-17(15)31-21/h3-12,16H,2H2,1H3,(H2,25,26,27,28,29)/t16-/m0/s1

> <stdInchikey>
HDXDQPRPFRKGKZ-INIZCTEOSA-N

> <csid>
52083673

> <Links>
|http://www.chemspider.com/Chemical-Structure.52083673.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4297584|http://pubchem.ncbi.nlm.nih.gov/compound/86291103|http://www.drugbank.ca/drugs/DB15295|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9907|http://zinc15.docking.org/substances/ZINC000220062787|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=2261HH611H

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS

> <indicationG2P>
None

> <MW>
415.1

> <HBA>
6

> <HBD>
2

> <NRB>
5

> <TPSA>
96.7

> <LogP>
4.8

> <RoF>
0

> <Targets>
nan

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
0.955582

> <r_epik_Ionization_Penalty>
  0.0022

> <r_epik_State_Penalty>
  0.0207

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
274

$$$$
Tepotinib
                    3D
 Structure written by MMmdl.
 66 70  0  0  1  0            999 V2000
  -10.5070    1.2241   -1.4560 C   0  0  0  0  0  0
   -9.0009    1.4982   -1.2732 N   0  3  2  0  0  0
   -8.1870    0.2418   -1.6552 C   0  0  0  0  0  0
   -6.6881    0.5415   -1.4797 C   0  0  0  0  0  0
   -6.3460    1.0242   -0.0515 C   0  0  2  0  0  0
   -7.2170    2.2412    0.3303 C   0  0  0  0  0  0
   -8.7216    1.9588    0.1748 C   0  0  0  0  0  0
   -4.8432    1.3281    0.1193 C   0  0  0  0  0  0
   -4.0866    0.1487   -0.1423 O   0  0  0  0  0  0
   -2.7095    0.2087   -0.0679 C   0  0  0  0  0  0
   -1.9767   -0.9426   -0.3650 C   0  0  0  0  0  0
   -0.6204   -0.9863   -0.3251 N   0  0  0  0  0  0
    0.0265    0.1607    0.0285 C   0  0  0  0  0  0
   -0.5994    1.3317    0.3392 N   0  0  0  0  0  0
   -1.9564    1.3407    0.2858 C   0  0  0  0  0  0
    1.5291    0.1327    0.0743 C   0  0  0  0  0  0
    2.2564   -0.9485   -0.4551 C   0  0  0  0  0  0
    3.6494   -0.9767   -0.4161 C   0  0  0  0  0  0
    4.3517    0.0793    0.1561 C   0  0  0  0  0  0
    3.6620    1.1712    0.6849 C   0  0  0  0  0  0
    2.2640    1.1860    0.6483 C   0  0  0  0  0  0
    4.4263    2.3149    1.3418 C   0  0  0  0  0  0
    4.7656    3.3982    0.4023 N   0  0  0  0  0  0
    3.9257    4.4912    0.3248 C   0  0  0  0  0  0
    2.9065    4.6750    0.9926 O   0  0  0  0  0  0
    4.3762    5.4449   -0.6744 C   0  0  0  0  0  0
    5.4725    5.2351   -1.4369 C   0  0  0  0  0  0
    6.2748    4.0325   -1.2991 C   0  0  0  0  0  0
    5.8911    3.1826   -0.4009 N   0  0  0  0  0  0
    7.4691    3.8266   -2.1480 C   0  0  0  0  0  0
    7.9123    2.5235   -2.4283 C   0  0  0  0  0  0
    9.0257    2.3069   -3.2392 C   0  0  0  0  0  0
    9.7142    3.3879   -3.7853 C   0  0  0  0  0  0
    9.2902    4.6916   -3.5191 C   0  0  0  0  0  0
    8.1733    4.9078   -2.7051 C   0  0  0  0  0  0
   10.0098    5.8224   -4.0862 C   0  0  0  0  0  0
   10.5815    6.7219   -4.5367 N   0  0  0  0  0  0
  -10.7914    0.4150   -0.7810 H   0  0  0  0  0  0
  -10.6610    0.9488   -2.5003 H   0  0  0  0  0  0
  -11.0347    2.1490   -1.2195 H   0  0  0  0  0  0
   -8.5216   -0.5696   -1.0057 H   0  0  0  0  0  0
   -8.4321    0.0048   -2.6918 H   0  0  0  0  0  0
   -6.1194   -0.3585   -1.7177 H   0  0  0  0  0  0
   -6.3829    1.2925   -2.2103 H   0  0  0  0  0  0
   -6.5908    0.2162    0.6410 H   0  0  0  0  0  0
   -7.0155    2.5339    1.3618 H   0  0  0  0  0  0
   -6.9483    3.1013   -0.2855 H   0  0  0  0  0  0
   -9.3202    2.8550    0.3458 H   0  0  0  0  0  0
   -9.0603    1.1606    0.8382 H   0  0  0  0  0  0
   -4.5431    2.1295   -0.5589 H   0  0  0  0  0  0
   -4.6486    1.6661    1.1392 H   0  0  0  0  0  0
   -2.4775   -1.8577   -0.6455 H   0  0  0  0  0  0
   -2.4216    2.2824    0.5348 H   0  0  0  0  0  0
    1.7466   -1.7851   -0.9102 H   0  0  0  0  0  0
    4.1842   -1.8189   -0.8298 H   0  0  0  0  0  0
    5.4314    0.0488    0.1842 H   0  0  0  0  0  0
    1.7504    2.0350    1.0761 H   0  0  0  0  0  0
    3.8570    2.6728    2.2033 H   0  0  0  0  0  0
    5.3465    1.9224    1.7801 H   0  0  0  0  0  0
    3.7994    6.3483   -0.8113 H   0  0  0  0  0  0
    5.7164    5.9940   -2.1652 H   0  0  0  0  0  0
    7.3958    1.6633   -2.0255 H   0  0  0  0  0  0
    9.3537    1.2988   -3.4460 H   0  0  0  0  0  0
   10.5754    3.2022   -4.4125 H   0  0  0  0  0  0
    7.8689    5.9246   -2.4988 H   0  0  0  0  0  0
   -8.7388    2.2470   -1.8995 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 38  1  0  0  0
  1 39  1  0  0  0
  1 40  1  0  0  0
  2  3  1  0  0  0
  2  7  1  0  0  0
  2 66  1  0  0  0
  3  4  1  0  0  0
  3 41  1  0  0  0
  3 42  1  0  0  0
  4  5  1  0  0  0
  4 43  1  0  0  0
  4 44  1  0  0  0
  5  6  1  0  0  0
  5  8  1  0  0  0
  5 45  1  0  0  0
  6  7  1  0  0  0
  6 46  1  0  0  0
  6 47  1  0  0  0
  7 48  1  0  0  0
  7 49  1  0  0  0
  8  9  1  0  0  0
  8 50  1  0  0  0
  8 51  1  0  0  0
  9 10  1  0  0  0
 10 11  1  0  0  0
 10 15  2  0  0  0
 11 12  2  0  0  0
 11 52  1  0  0  0
 12 13  1  0  0  0
 13 14  2  0  0  0
 13 16  1  0  0  0
 14 15  1  0  0  0
 15 53  1  0  0  0
 16 17  1  0  0  0
 16 21  2  0  0  0
 17 18  2  0  0  0
 17 54  1  0  0  0
 18 19  1  0  0  0
 18 55  1  0  0  0
 19 20  2  0  0  0
 19 56  1  0  0  0
 20 21  1  0  0  0
 20 22  1  0  0  0
 21 57  1  0  0  0
 22 23  1  0  0  0
 22 58  1  0  0  0
 22 59  1  0  0  0
 23 24  1  0  0  0
 23 29  1  0  0  0
 24 25  2  0  0  0
 24 26  1  0  0  0
 26 27  2  0  0  0
 26 60  1  0  0  0
 27 28  1  0  0  0
 27 61  1  0  0  0
 28 29  2  0  0  0
 28 30  1  0  0  0
 30 31  1  0  0  0
 30 35  2  0  0  0
 31 32  2  0  0  0
 31 62  1  0  0  0
 32 33  1  0  0  0
 32 63  1  0  0  0
 33 34  2  0  0  0
 33 64  1  0  0  0
 34 35  1  0  0  0
 34 36  1  0  0  0
 35 65  1  0  0  0
 36 37  3  0  0  0
M  CHG  1   2   1
M  END
> <s_m_entry_id>
276

> <Applicants>
Merck

> <CHEMBL_ID>
CHEMBL3402762

> <Canonical_Smiles>
O(CC1CCN(CC1)C)c1cnc(nc1)-c1cc(ccc1)CN1N=C(C=CC1=O)c1cc(ccc1)C#N

> <Chirality>
Achiral Molecule

> <First_Approval>
2021

> <Phase>
4

> <SC_Patent>
None

> <Synonyms>
EMD 1214063 | EMD-1214063 | EMD1214063 | MSC-2156119 | MSC-2156119J | MSC2156119 | TEPOTINIB

> <Indications>
On February 2021, FDA approved tepotinib to treat non-small cell lung cancer

> <Type>
1

> <targets_id>
P08581

> <inchi>
InChI=1S/C29H28N6O2/c1-34-12-10-21(11-13-34)20-37-26-17-31-29(32-18-26)25-7-3-5-23(15-25)19-35-28(36)9-8-27(33-35)24-6-2-4-22(14-24)16-30/h2-9,14-15,17-18,21H,10-13,19-20H2,1H3

> <stdInchikey>
AHYMHWXQRWRBKT-UHFFFAOYSA-N

> <csid>
28637823

> <Links>
|http://www.chemspider.com/Chemical-Structure.28637823.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3402762|http://pubchem.ncbi.nlm.nih.gov/compound/25171648|http://www.drugbank.ca/drugs/DB15133| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=3E8|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/3E8|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8293|http://zinc15.docking.org/substances/ZINC000043202335|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=1IJV77EI07|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50065457

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
492.2

> <HBA>
8

> <HBD>
0

> <NRB>
7

> <TPSA>
96.9

> <LogP>
4

> <RoF>
0

> <Targets>
MET

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0016

> <r_epik_State_Penalty>
  0.0011

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
276

> <lig_pdbID>
'3E8'

> <pdbID>
4r1v

> <Kinase families>
Tyr

> <indicationDB>
Tepotinib is a MET tyrosine kinase inhibitor intended to treat a variety of MET-overexpressing solid tumors.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Markham A: Tepotinib: First Approval. Drugs. 2020 Jun;80(8):829-833. doi: 10.1007/s40265-020-01317-9. (PubMed ID 32361823)" href="#reference-A228058">6</a></sup> It was originally developed in partnership between EMD Serono and the University of Texas M.D. Anderson Cancer Center in 2009 and has since been investigated in the treatment of neuroblastoma,<sup class="text-reference-group"><a class="reference-popover-link" data-content="Scorsone K, Zhang L, Woodfield SE, Hicks J, Zage PE: The novel kinase inhibitor EMD1214063 is effective against neuroblastoma. Invest New Drugs. 2014 Oct;32(5):815-24. doi: 10.1007/s10637-014-0107-4. Epub 2014 May 16. (PubMed ID 24832869)" href="#reference-A228053">5</a></sup> gastric cancers,<sup class="text-reference-group"><a class="reference-popover-link" data-content="Sohn SH, Sul HJ, Kim B, Kim BJ, Kim HS, Zang DY: Tepotinib Inhibits the Epithelial-Mesenchymal Transition and Tumor Growth of Gastric Cancers by Increasing GSK3beta, E-Cadherin, and Mucin 5AC and 6 Levels. Int J Mol Sci. 2020 Aug 21;21(17). pii: ijms21176027. doi: 10.3390/ijms21176027. (PubMed ID 32825724)" href="#reference-A228033">2</a></sup> non-small cell lung cancer, and hepatocellular carcinoma.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Markham A: Tepotinib: First Approval. Drugs. 2020 Jun;80(8):829-833. doi: 10.1007/s40265-020-01317-9. (PubMed ID 32361823)" href="#reference-A228058">6</a></sup> MET is a desirable target in the treatment of certain solid tumors as it appears to play a critical role, both directly and indirectly, in the growth and proliferation of tumors in which it is overexpressed and/or mutated.</p><p>Tepotinib was first approved in Japan in March 2020 for the treatment of non-small cell lung cancers (NSCLC) with <em>MET</em> alterations, and was subsequently granted accelerated approval by the US FDA in February 2021, under the brand name Tepmetko, for the treatment of adult patients with metastatic NSCLC and <em>MET</em> exon 14 skipping alterations.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA Approved Drug Products: Tepmetko (tepotinib) tablets for oral use" href="#reference-L31443">7</a>,<a class="reference-popover-link" data-content="PR Newswire: FDA Approves TEPMETKO® as the First and Only Once-daily Oral MET Inhibitor for Patients with Metastatic NSCLC with METex14 Skipping Alterations" href="#reference-L31473">9</a></sup> It is the first oral MET-targeted tyrosine kinase inhibitor to allow for once-daily dosing,<sup class="text-reference-group"><a class="reference-popover-link" data-content="PR Newswire: FDA Approves TEPMETKO® as the First and Only Once-daily Oral MET Inhibitor for Patients with Metastatic NSCLC with METex14 Skipping Alterations" href="#reference-L31473">9</a></sup> an advantage that may aid in easing the pill burden often associated with chemotherapeutic regimens.

> <uniprotId>
P08581|Q9Y2I1|P49286|P08684|P10632|P02768|P02763|P08183|Q9UNQ0

> <FDA_approved>
Y

$$$$
Tarloxotinib
                    3D
 Structure written by MMmdl.
 62 65  0  0  1  0            999 V2000
   -2.3685    1.6163    2.6179 C   0  0  0  0  0  0
   -2.8867    1.4980    1.2624 N   0  0  0  0  0  0
   -4.2102    1.4920    0.9106 C   0  0  0  0  0  0
   -4.4026    1.4112   -0.3774 N   0  0  0  0  0  0
   -3.1899    1.3766   -0.9161 C   0  0  0  0  0  0
   -2.1894    1.3781    0.0751 C   0  0  0  0  0  0
   -0.6603    1.3388    0.0012 C   0  0  0  0  0  0
   -0.0738   -0.1098   -0.0406 N   0  3  0  0  0  0
   -0.4467   -0.8914    1.2439 C   0  0  0  0  0  0
   -0.6085   -0.9133   -1.2543 C   0  0  0  0  0  0
    1.4815   -0.0409   -0.1097 C   0  0  0  0  0  0
    2.0581    0.6487   -1.3381 C   0  0  0  0  0  0
    2.7123    1.8272   -1.3119 C   0  0  0  0  0  0
    3.2397    2.4536   -2.5037 C   0  0  0  0  0  0
    3.0473    2.0038   -3.6357 O   0  0  0  0  0  0
    3.9362    3.5770   -2.2258 N   0  0  0  0  0  0
    4.6125    4.4394   -3.1051 C   0  0  0  0  0  0
    5.0349    4.0721   -4.3952 C   0  0  0  0  0  0
    5.7122    5.0310   -5.2037 C   0  0  0  0  0  0
    5.9464    6.3326   -4.6637 C   0  0  0  0  0  0
    5.4864    6.5810   -3.3537 C   0  0  0  0  0  0
    4.8404    5.6722   -2.5878 N   0  0  0  0  0  0
    6.5866    7.3084   -5.3657 N   0  0  0  0  0  0
    6.9910    6.9780   -6.6154 C   0  0  0  0  0  0
    6.8254    5.7856   -7.2329 N   0  0  0  0  0  0
    6.1914    4.8103   -6.5316 C   0  0  0  0  0  0
    5.9844    3.5618   -7.1512 N   0  0  0  0  0  0
    6.2930    3.0586   -8.4282 C   0  0  0  0  0  0
    5.5030    2.0174   -8.9232 C   0  0  0  0  0  0
    5.7545    1.4708  -10.1813 C   0  0  0  0  0  0
    6.8077    1.9518  -10.9591 C   0  0  0  0  0  0
    7.6172    2.9826  -10.4671 C   0  0  0  0  0  0
    7.3597    3.5278   -9.2079 C   0  0  0  0  0  0
    9.0831    3.6623  -11.4804 Br  0  0  0  0  0  0
    7.0884    1.2529  -12.5154 Cl  0  0  0  0  0  0
   -3.0239    1.3448   -2.3436 N   0  3  0  0  0  0
   -3.9816    1.0061   -3.0344 O   0  0  0  0  0  0
   -1.9332    1.6665   -2.8018 O   0  5  0  0  0  0
   -1.4943    2.2668    2.6336 H   0  0  0  0  0  0
   -2.1052    0.6293    2.9959 H   0  0  0  0  0  0
   -3.1325    2.0429    3.2693 H   0  0  0  0  0  0
   -4.9760    1.5626    1.6697 H   0  0  0  0  0  0
   -0.2949    1.8055   -0.9123 H   0  0  0  0  0  0
   -0.1658    1.8339    0.8373 H   0  0  0  0  0  0
    0.0346   -1.8696    1.1985 H   0  0  0  0  0  0
   -1.5305   -1.0067    1.2748 H   0  0  0  0  0  0
   -0.0839   -0.3212    2.1002 H   0  0  0  0  0  0
   -0.1017   -1.8796   -1.2669 H   0  0  0  0  0  0
   -0.3891   -0.3511   -2.1616 H   0  0  0  0  0  0
   -1.6835   -1.0498   -1.1328 H   0  0  0  0  0  0
    1.7918    0.4663    0.8063 H   0  0  0  0  0  0
    1.8397   -1.0711   -0.0667 H   0  0  0  0  0  0
    1.9215    0.1210   -2.2725 H   0  0  0  0  0  0
    2.8582    2.3462   -0.3737 H   0  0  0  0  0  0
    3.9536    3.8723   -1.2609 H   0  0  0  0  0  0
    4.8750    3.0807   -4.7887 H   0  0  0  0  0  0
    5.6462    7.5520   -2.9074 H   0  0  0  0  0  0
    7.4979    7.7478   -7.1789 H   0  0  0  0  0  0
    5.3606    2.9661   -6.6269 H   0  0  0  0  0  0
    4.6812    1.6291   -8.3380 H   0  0  0  0  0  0
    5.1288    0.6716  -10.5511 H   0  0  0  0  0  0
    8.0152    4.3044   -8.8468 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 39  1  0  0  0
  1 40  1  0  0  0
  1 41  1  0  0  0
  2  3  1  0  0  0
  2  6  1  0  0  0
  3  4  2  0  0  0
  3 42  1  0  0  0
  4  5  1  0  0  0
  5  6  2  0  0  0
  5 36  1  0  0  0
  6  7  1  0  0  0
  7  8  1  0  0  0
  7 43  1  0  0  0
  7 44  1  0  0  0
  8  9  1  0  0  0
  8 10  1  0  0  0
  8 11  1  0  0  0
  9 45  1  0  0  0
  9 46  1  0  0  0
  9 47  1  0  0  0
 10 48  1  0  0  0
 10 49  1  0  0  0
 10 50  1  0  0  0
 11 12  1  0  0  0
 11 51  1  0  0  0
 11 52  1  0  0  0
 12 13  2  0  0  0
 12 53  1  0  0  0
 13 14  1  0  0  0
 13 54  1  0  0  0
 14 15  2  0  0  0
 14 16  1  0  0  0
 16 17  1  0  0  0
 16 55  1  0  0  0
 17 18  2  0  0  0
 17 22  1  0  0  0
 18 19  1  0  0  0
 18 56  1  0  0  0
 19 20  2  0  0  0
 19 26  1  0  0  0
 20 21  1  0  0  0
 20 23  1  0  0  0
 21 22  2  0  0  0
 21 57  1  0  0  0
 23 24  2  0  0  0
 24 25  1  0  0  0
 24 58  1  0  0  0
 25 26  2  0  0  0
 26 27  1  0  0  0
 27 28  1  0  0  0
 27 59  1  0  0  0
 28 29  2  0  0  0
 28 33  1  0  0  0
 29 30  1  0  0  0
 29 60  1  0  0  0
 30 31  2  0  0  0
 30 61  1  0  0  0
 31 32  1  0  0  0
 31 35  1  0  0  0
 32 33  2  0  0  0
 32 34  1  0  0  0
 33 62  1  0  0  0
 36 37  2  0  0  0
 36 38  1  0  0  0
M  CHG  3   8   1  36   1  38  -1
M  END
> <s_m_entry_id>
280

> <Applicants>
Threshold Pharmaceuticals

> <CHEMBL_ID>
CHEMBL4297661

> <Canonical_Smiles>
Brc1cc(Nc2ncnc3c2cc(nc3)NC(=O)\C=C\C[N+](Cc2n(cnc2[N+](=O)[O-])C)(C)C)ccc1Cl.[Br-]

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
TARLOXOTINIB BROMIDE

> <Indications>
nan

> <Type>
nan

> <targets_id>
P00533

> <inchi>
InChI=1S/C24H23BrClN9O3.BrH/c1-33-14-30-24(34(37)38)20(33)12-35(2,3)8-4-5-22(36)32-21-10-16-19(11-27-21)28-13-29-23(16)31-15-6-7-18(26)17(25)9-15;/h4-7,9-11,13-14H,8,12H2,1-3H3,(H-,27,28,29,31,32,36);1H/b5-4+;

> <stdInchikey>
WAKIMVYUBWMMHJ-FXRZFVDSSA-N

> <csid>
46518771

> <Links>
|http://www.chemspider.com/Chemical-Structure.46518771.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4297662|http://pubchem.ncbi.nlm.nih.gov/compound/51038315|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=3Y31FJ8K50

> <LinkName>
|ChemSpider|ChEMBL|PubChem|FDA SRS

> <MW>
679

> <HBA>
9

> <HBD>
2

> <NRB>
9

> <TPSA>
140.8

> <LogP>
1.6

> <RoF>
1

> <Targets>
EGFR

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0000

> <r_epik_State_Penalty>
  0.0000

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
280

> <Kinase families>
Tyr

$$$$
Tandutinib
                    3D
 Structure written by MMmdl.
 85 89  0  0  1  0            999 V2000
  -11.2676    0.3690    5.7341 C   0  0  0  0  0  0
  -10.5599    0.4341    4.3726 C   0  0  0  0  0  0
  -11.5382    0.1383    3.2188 C   0  0  0  0  0  0
   -9.5118   -0.5373    4.4079 O   0  0  0  0  0  0
   -8.4688   -0.4955    3.4998 C   0  0  0  0  0  0
   -7.5531   -1.5452    3.5678 C   0  0  0  0  0  0
   -6.4667   -1.5975    2.6998 C   0  0  0  0  0  0
   -6.2737   -0.5891    1.7549 C   0  0  0  0  0  0
   -7.1939    0.4662    1.6728 C   0  0  0  0  0  0
   -8.2797    0.5141    2.5433 C   0  0  0  0  0  0
   -5.1585   -0.7356    0.9090 N   0  0  0  0  0  0
   -4.5016    0.2027    0.1855 C   0  0  0  0  0  0
   -4.7987    1.3999    0.2033 O   0  0  0  0  0  0
   -3.5057   -0.2866   -0.6074 N   0  0  0  0  0  0
   -2.7760   -1.5442   -0.3397 C   0  0  0  0  0  0
   -1.3975   -1.1385    0.2384 C   0  0  0  0  0  0
   -0.6232   -0.3313   -0.7214 N   0  0  0  0  0  0
   -1.4116    0.8985   -0.9174 C   0  0  0  0  0  0
   -2.7930    0.5954   -1.5499 C   0  0  0  0  0  0
    0.7318   -0.1729   -0.4603 C   0  0  0  0  0  0
    1.7185   -0.6685   -1.3727 C   0  0  0  0  0  0
    1.4385   -1.3426   -2.5897 C   0  0  0  0  0  0
    2.4750   -1.7976   -3.4233 C   0  0  0  0  0  0
    3.8145   -1.5910   -3.0601 C   0  0  0  0  0  0
    4.1245   -0.9243   -1.8642 C   0  0  0  0  0  0
    3.0869   -0.4682   -1.0288 C   0  0  0  0  0  0
    3.3525    0.1875    0.1533 N   0  3  0  0  0  0
    2.3770    0.6298    0.9657 C   0  0  0  0  0  0
    1.0607    0.4699    0.6961 N   0  0  0  0  0  0
    4.7758   -2.0743   -3.9311 O   0  0  0  0  0  0
    6.1593   -1.8989   -3.6342 C   0  0  0  0  0  0
    7.0045   -2.5600   -4.7340 C   0  0  0  0  0  0
    6.8043   -1.9142   -6.1192 C   0  0  0  0  0  0
    7.4918   -2.7419   -7.2336 N   0  3  0  0  0  0
    6.9894   -2.2534   -8.6148 C   0  0  0  0  0  0
    7.6377   -3.0985   -9.7248 C   0  0  0  0  0  0
    9.1715   -3.0691   -9.6434 C   0  0  0  0  0  0
    9.6655   -3.5102   -8.2569 C   0  0  0  0  0  0
    9.0366   -2.6782   -7.1250 C   0  0  0  0  0  0
    2.2517   -2.4587   -4.6191 O   0  0  0  0  0  0
    0.9174   -2.6938   -5.0582 C   0  0  0  0  0  0
  -12.0669    1.1075    5.8003 H   0  0  0  0  0  0
  -10.5695    0.5677    6.5478 H   0  0  0  0  0  0
  -11.7069   -0.6140    5.9087 H   0  0  0  0  0  0
  -10.1510    1.4408    4.2734 H   0  0  0  0  0  0
  -12.3620    0.8523    3.2105 H   0  0  0  0  0  0
  -11.9659   -0.8604    3.3117 H   0  0  0  0  0  0
  -11.0509    0.1952    2.2460 H   0  0  0  0  0  0
   -7.6871   -2.3289    4.2992 H   0  0  0  0  0  0
   -5.7749   -2.4248    2.7721 H   0  0  0  0  0  0
   -7.0997    1.2488    0.9365 H   0  0  0  0  0  0
   -8.9651    1.3417    2.4514 H   0  0  0  0  0  0
   -4.7799   -1.6708    0.8768 H   0  0  0  0  0  0
   -3.2976   -2.2171    0.3411 H   0  0  0  0  0  0
   -2.6427   -2.0803   -1.2803 H   0  0  0  0  0  0
   -1.5209   -0.6062    1.1845 H   0  0  0  0  0  0
   -0.8393   -2.0481    0.4655 H   0  0  0  0  0  0
   -1.5322    1.4382    0.0247 H   0  0  0  0  0  0
   -0.8666    1.5647   -1.5880 H   0  0  0  0  0  0
   -2.6640    0.0687   -2.4964 H   0  0  0  0  0  0
   -3.3385    1.5153   -1.7659 H   0  0  0  0  0  0
    0.4044   -1.4973   -2.8581 H   0  0  0  0  0  0
    5.1449   -0.7483   -1.5578 H   0  0  0  0  0  0
    2.6951    1.1315    1.8684 H   0  0  0  0  0  0
    6.4037   -0.8373   -3.5616 H   0  0  0  0  0  0
    6.3963   -2.3616   -2.6745 H   0  0  0  0  0  0
    8.0508   -2.4888   -4.4386 H   0  0  0  0  0  0
    6.7697   -3.6242   -4.7822 H   0  0  0  0  0  0
    5.7449   -1.9073   -6.3805 H   0  0  0  0  0  0
    7.1959   -0.8975   -6.1831 H   0  0  0  0  0  0
    5.9036   -2.3601   -8.6211 H   0  0  0  0  0  0
    7.2526   -1.1970   -8.6959 H   0  0  0  0  0  0
    7.2824   -4.1277   -9.6535 H   0  0  0  0  0  0
    7.3132   -2.7329  -10.6998 H   0  0  0  0  0  0
    9.5987   -3.7128  -10.4136 H   0  0  0  0  0  0
    9.5303   -2.0607   -9.8565 H   0  0  0  0  0  0
    9.4357   -4.5656   -8.1019 H   0  0  0  0  0  0
   10.7521   -3.4276   -8.2106 H   0  0  0  0  0  0
    9.3184   -1.6253   -7.1823 H   0  0  0  0  0  0
    9.3199   -3.0799   -6.1530 H   0  0  0  0  0  0
    0.9412   -3.2174   -6.0139 H   0  0  0  0  0  0
    0.3746   -1.7593   -5.2090 H   0  0  0  0  0  0
    0.3677   -3.3202   -4.3542 H   0  0  0  0  0  0
    4.3122    0.3451    0.4258 H   0  0  0  0  0  0
    7.2038   -3.7045   -7.1267 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 42  1  0  0  0
  1 43  1  0  0  0
  1 44  1  0  0  0
  2  3  1  0  0  0
  2  4  1  0  0  0
  2 45  1  0  0  0
  3 46  1  0  0  0
  3 47  1  0  0  0
  3 48  1  0  0  0
  4  5  1  0  0  0
  5  6  1  0  0  0
  5 10  2  0  0  0
  6  7  2  0  0  0
  6 49  1  0  0  0
  7  8  1  0  0  0
  7 50  1  0  0  0
  8  9  2  0  0  0
  8 11  1  0  0  0
  9 10  1  0  0  0
  9 51  1  0  0  0
 10 52  1  0  0  0
 11 12  1  0  0  0
 11 53  1  0  0  0
 12 13  2  0  0  0
 12 14  1  0  0  0
 14 15  1  0  0  0
 14 19  1  0  0  0
 15 16  1  0  0  0
 15 54  1  0  0  0
 15 55  1  0  0  0
 16 17  1  0  0  0
 16 56  1  0  0  0
 16 57  1  0  0  0
 17 18  1  0  0  0
 17 20  1  0  0  0
 18 19  1  0  0  0
 18 58  1  0  0  0
 18 59  1  0  0  0
 19 60  1  0  0  0
 19 61  1  0  0  0
 20 21  1  0  0  0
 20 29  2  0  0  0
 21 22  1  0  0  0
 21 26  2  0  0  0
 22 23  2  0  0  0
 22 62  1  0  0  0
 23 24  1  0  0  0
 23 40  1  0  0  0
 24 25  2  0  0  0
 24 30  1  0  0  0
 25 26  1  0  0  0
 25 63  1  0  0  0
 26 27  1  0  0  0
 27 28  2  0  0  0
 27 84  1  0  0  0
 28 29  1  0  0  0
 28 64  1  0  0  0
 30 31  1  0  0  0
 31 32  1  0  0  0
 31 65  1  0  0  0
 31 66  1  0  0  0
 32 33  1  0  0  0
 32 67  1  0  0  0
 32 68  1  0  0  0
 33 34  1  0  0  0
 33 69  1  0  0  0
 33 70  1  0  0  0
 34 35  1  0  0  0
 34 39  1  0  0  0
 34 85  1  0  0  0
 35 36  1  0  0  0
 35 71  1  0  0  0
 35 72  1  0  0  0
 36 37  1  0  0  0
 36 73  1  0  0  0
 36 74  1  0  0  0
 37 38  1  0  0  0
 37 75  1  0  0  0
 37 76  1  0  0  0
 38 39  1  0  0  0
 38 77  1  0  0  0
 38 78  1  0  0  0
 39 79  1  0  0  0
 39 80  1  0  0  0
 40 41  1  0  0  0
 41 81  1  0  0  0
 41 82  1  0  0  0
 41 83  1  0  0  0
M  CHG  2  27   1  34   1
M  END
> <s_m_entry_id>
281

> <Applicants>
Takeda

> <CHEMBL_ID>
CHEMBL124660

> <Canonical_Smiles>
O(CCCN1CCCCC1)c1cc2ncnc(N3CCN(CC3)C(=O)Nc3ccc(OC(C)C)cc3)c2cc1OC

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
CT 53518 | CT-53518 | CT53518 | MLN-0518 | MLN-518 | TANDUTINIB

> <Indications>
Investigated for use/treatment in leukemia (myeloid).

> <Type>
nan

> <targets_id>
P36888|Q9GZP0

> <inchi>
InChI=1S/C31H42N6O4/c1-23(2)41-25-10-8-24(9-11-25)34-31(38)37-17-15-36(16-18-37)30-26-20-28(39-3)29(21-27(26)32-22-33-30)40-19-7-14-35-12-5-4-6-13-35/h8-11,20-23H,4-7,12-19H2,1-3H3,(H,34,38)

> <stdInchikey>
UXXQOJXBIDBUAC-UHFFFAOYSA-N

> <csid>
2302085

> <Links>
|http://www.chemspider.com/Chemical-Structure.2302085.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL124660|http://pubchem.ncbi.nlm.nih.gov/compound/3038522|http://www.drugbank.ca/drugs/DB05465|http://zinc15.docking.org/substances/ZINC000003966243|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=E1IO3ICJ9A|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=13535

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|ZINC|FDA SRS|BindingDB

> <MW>
562.3

> <HBA>
8

> <HBD>
1

> <NRB>
10

> <TPSA>
92.3

> <LogP>
5

> <RoF>
2

> <Targets>
FLT3; PDGFD

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
0.993508

> <r_epik_Ionization_Penalty>
  0.0022

> <r_epik_State_Penalty>
  0.0015

> <i_epik_Tot_Q>
2

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
281

> <Kinase families>
Tyr<br>(*)

> <indicationDB>
MLN518 is a novel, oral, small molecule designed to inhibit type III receptor tyrosine kinases, including FLT3, (platelet-derived growth-factor receptor) PDGFR and c-KIT. Tyrosine kinases are enzymes involved in several cellular processes and are known to be activated in cancer cells to drive tumor growth. AML patients with FLT3 mutations experience earlier disease relapse and shorter survival rates compared to patients without these mutations. Approximately 25 to 30 percent of all adult AML patients have a mutation of the FLT3 gene. The use of MLN518 to treat AML has been granted fast-track status by the U.S. Food and Drug Administration. Phase I/II trials are underway.

> <uniprotId>
P36888|Q9GZP0

$$$$
Nemiralisib
                    3D
 Structure written by MMmdl.
 62 67  0  0  1  0            999 V2000
   -2.7148   -3.5123   -1.2766 C   0  0  0  0  0  0
   -1.9991   -2.9536   -0.0236 C   0  0  0  0  0  0
   -2.3748   -3.8303    1.1948 C   0  0  0  0  0  0
   -2.3238   -1.5237    0.2064 N   0  0  0  0  0  0
   -1.7097   -0.9409    1.4124 C   0  0  0  0  0  0
   -0.1755   -0.7761    1.3082 C   0  0  0  0  0  0
    0.1750    0.0700    0.0599 N   0  3  0  0  0  0
   -0.5318   -0.4494   -1.2131 C   0  0  0  0  0  0
   -2.0415   -0.6344   -0.9343 C   0  0  0  0  0  0
    1.7010    0.1687   -0.1816 C   0  0  0  0  0  0
    2.3592    0.8779    0.9816 C   0  0  0  0  0  0
    2.6344    2.1945    1.3092 C   0  0  0  0  0  0
    3.2251    2.2750    2.4866 N   0  0  0  0  0  0
    3.3355    1.0251    2.8811 C   0  0  0  0  0  0
    2.8271    0.1210    2.0018 O   0  0  0  0  0  0
    3.9243    0.5180    4.1552 C   0  0  0  0  0  0
    4.4433   -0.7788    4.2263 C   0  0  0  0  0  0
    5.0142   -1.3002    5.3935 C   0  0  0  0  0  0
    5.0685   -0.5240    6.5589 C   0  0  0  0  0  0
    4.5479    0.7710    6.4990 C   0  0  0  0  0  0
    3.9779    1.3076    5.3194 C   0  0  0  0  0  0
    3.5786    2.6271    5.7003 C   0  0  0  0  0  0
    3.8661    2.8786    6.9505 N   0  0  0  0  0  0
    4.4503    1.7731    7.4442 N   0  0  0  0  0  0
    5.5632   -2.6848    5.4026 C   0  0  0  0  0  0
    5.2231   -3.5799    6.4237 C   0  0  0  0  0  0
    5.7154   -4.8808    6.4585 C   0  0  0  0  0  0
    6.5781   -5.3671    5.4795 C   0  0  0  0  0  0
    6.9348   -4.4857    4.4557 C   0  0  0  0  0  0
    6.4440   -3.1425    4.3956 C   0  0  0  0  0  0
    7.0349   -2.5494    3.2262 C   0  0  0  0  0  0
    7.8223   -3.5087    2.6278 C   0  0  0  0  0  0
    7.7601   -4.6632    3.3641 N   0  0  0  0  0  0
   -2.5646   -4.5886   -1.3689 H   0  0  0  0  0  0
   -2.3318   -3.0784   -2.1997 H   0  0  0  0  0  0
   -3.7908   -3.3362   -1.2381 H   0  0  0  0  0  0
   -0.9257   -3.0573   -0.1845 H   0  0  0  0  0  0
   -2.2540   -4.8908    0.9706 H   0  0  0  0  0  0
   -3.4122   -3.6776    1.4965 H   0  0  0  0  0  0
   -1.7379   -3.6339    2.0569 H   0  0  0  0  0  0
   -2.1598    0.0381    1.5864 H   0  0  0  0  0  0
   -1.9694   -1.5134    2.3015 H   0  0  0  0  0  0
    0.2144   -0.2453    2.1770 H   0  0  0  0  0  0
    0.3429   -1.7318    1.2188 H   0  0  0  0  0  0
   -0.3601    0.2950   -1.9917 H   0  0  0  0  0  0
   -0.0477   -1.3825   -1.5064 H   0  0  0  0  0  0
   -2.5541   -0.9742   -1.8330 H   0  0  0  0  0  0
   -2.4858    0.3411   -0.7278 H   0  0  0  0  0  0
    2.0529   -0.8528   -0.3370 H   0  0  0  0  0  0
    1.8002    0.7314   -1.1110 H   0  0  0  0  0  0
    2.4028    3.0688    0.7188 H   0  0  0  0  0  0
    4.4060   -1.4029    3.3446 H   0  0  0  0  0  0
    5.5054   -0.9114    7.4681 H   0  0  0  0  0  0
    3.0956    3.3743    5.0882 H   0  0  0  0  0  0
    4.7578    1.7468    8.4057 H   0  0  0  0  0  0
    4.5522   -3.2639    7.2097 H   0  0  0  0  0  0
    5.4181   -5.5324    7.2672 H   0  0  0  0  0  0
    6.9519   -6.3797    5.5202 H   0  0  0  0  0  0
    6.9052   -1.5422    2.8590 H   0  0  0  0  0  0
    8.4301   -3.4700    1.7356 H   0  0  0  0  0  0
    8.2675   -5.4979    3.1072 H   0  0  0  0  0  0
   -0.1672    1.0057    0.2279 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 34  1  0  0  0
  1 35  1  0  0  0
  1 36  1  0  0  0
  2  3  1  0  0  0
  2  4  1  0  0  0
  2 37  1  0  0  0
  3 38  1  0  0  0
  3 39  1  0  0  0
  3 40  1  0  0  0
  4  5  1  0  0  0
  4  9  1  0  0  0
  5  6  1  0  0  0
  5 41  1  0  0  0
  5 42  1  0  0  0
  6  7  1  0  0  0
  6 43  1  0  0  0
  6 44  1  0  0  0
  7  8  1  0  0  0
  7 10  1  0  0  0
  7 62  1  0  0  0
  8  9  1  0  0  0
  8 45  1  0  0  0
  8 46  1  0  0  0
  9 47  1  0  0  0
  9 48  1  0  0  0
 10 11  1  0  0  0
 10 49  1  0  0  0
 10 50  1  0  0  0
 11 12  2  0  0  0
 11 15  1  0  0  0
 12 13  1  0  0  0
 12 51  1  0  0  0
 13 14  2  0  0  0
 14 15  1  0  0  0
 14 16  1  0  0  0
 16 17  1  0  0  0
 16 21  2  0  0  0
 17 18  2  0  0  0
 17 52  1  0  0  0
 18 19  1  0  0  0
 18 25  1  0  0  0
 19 20  2  0  0  0
 19 53  1  0  0  0
 20 21  1  0  0  0
 20 24  1  0  0  0
 21 22  1  0  0  0
 22 23  2  0  0  0
 22 54  1  0  0  0
 23 24  1  0  0  0
 24 55  1  0  0  0
 25 26  1  0  0  0
 25 30  2  0  0  0
 26 27  2  0  0  0
 26 56  1  0  0  0
 27 28  1  0  0  0
 27 57  1  0  0  0
 28 29  2  0  0  0
 28 58  1  0  0  0
 29 30  1  0  0  0
 29 33  1  0  0  0
 30 31  1  0  0  0
 31 32  2  0  0  0
 31 59  1  0  0  0
 32 33  1  0  0  0
 32 60  1  0  0  0
 33 61  1  0  0  0
M  CHG  1   7   1
M  END
> <s_m_entry_id>
282

> <Applicants>
GlaxosmithKline

> <CHEMBL_ID>
CHEMBL2216859

> <Canonical_Smiles>
o1c(ncc1CN1CCN(CC1)C(C)C)-c1cc(cc2[nH]ncc12)-c1c2c([nH]cc2)ccc1

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
GSK-2269557 | GSK-2269557 FREE BASE | GSK-2269557A | GSK2269557A | NEMIRALISIB

> <Indications>
nan

> <Type>
nan

> <targets_id>
nan

> <inchi>
InChI=1S/C26H28N6O/c1-17(2)32-10-8-31(9-11-32)16-19-14-28-26(33-19)22-12-18(13-25-23(22)15-29-30-25)20-4-3-5-24-21(20)6-7-27-24/h3-7,12-15,17,27H,8-11,16H2,1-2H3,(H,29,30)

> <stdInchikey>
MCIDWGZGWVSZMK-UHFFFAOYSA-N

> <csid>
28651123

> <Links>
|http://www.chemspider.com/Chemical-Structure.28651123.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2216859|http://pubchem.ncbi.nlm.nih.gov/compound/49784002| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=VVX|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/VVX|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9425|http://zinc15.docking.org/substances/ZINC000095564436|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=OEP8JJ3OZR|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50004529

> <LinkName>
|ChemSpider|ChEMBL|PubChem|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
440.2

> <HBA>
5

> <HBD>
2

> <NRB>
5

> <TPSA>
77

> <LogP>
4.9

> <RoF>
0

> <Targets>
nan

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
0.980392

> <r_epik_Ionization_Penalty>
  0.0245

> <r_epik_State_Penalty>
  0.2856

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
282

> <lig_pdbID>
'VVX'

> <pdbID>
5ae8

$$$$
Pilaralisib
                    3D
 Structure written by MMmdl.
 63 66  0  0  1  0            999 V2000
   -6.1287    3.5166   -1.2716 C   0  0  0  0  0  0
   -5.0934    3.5275   -0.1247 C   0  0  0  0  0  0
   -5.7541    3.9186    1.2165 C   0  0  0  0  0  0
   -4.3822    2.1462   -0.0094 C   0  0  0  0  0  0
   -5.0745    1.1658    0.2688 O   0  0  0  0  0  0
   -3.0421    2.0825   -0.2001 N   0  0  0  0  0  0
   -2.1900    0.9636   -0.1520 C   0  0  0  0  0  0
   -2.6121   -0.3684   -0.3060 C   0  0  0  0  0  0
   -1.6845   -1.4091   -0.2579 C   0  0  0  0  0  0
   -0.3318   -1.1349   -0.0652 C   0  0  0  0  0  0
    0.0988    0.1857    0.0763 C   0  0  0  0  0  0
   -0.8289    1.2296    0.0261 C   0  0  0  0  0  0
    1.8415    0.5345    0.2821 S   0  0  0  0  0  0
    1.9957    1.9381    0.6843 O   0  0  0  0  0  0
    2.4049   -0.5468    1.0981 O   0  0  0  0  0  0
    2.5317    0.3436   -1.3450 N   0  0  0  0  0  0
    2.2704    1.2098   -2.4233 C   0  0  0  0  0  0
    2.7088    0.8863   -3.7226 C   0  0  0  0  0  0
    2.4496    1.7090   -4.7756 N   0  0  0  0  0  0
    1.7642    2.8610   -4.5429 C   0  0  0  0  0  0
    1.4796    3.7429   -5.6121 C   0  0  0  0  0  0
    0.7763    4.9220   -5.3710 C   0  0  0  0  0  0
    0.3478    5.2446   -4.0852 C   0  0  0  0  0  0
    0.6131    4.3950   -3.0124 C   0  0  0  0  0  0
    1.3254    3.1913   -3.2269 C   0  0  0  0  0  0
    1.5844    2.3601   -2.1818 N   0  0  0  0  0  0
    3.3980   -0.3182   -3.9667 N   0  0  0  0  0  0
    4.0306   -0.8097   -5.1229 C   0  0  0  0  0  0
    4.7414    0.0439   -5.9770 C   0  0  0  0  0  0
    5.3635   -0.4345   -7.1320 C   0  0  0  0  0  0
    5.2625   -1.8013   -7.4350 C   0  0  0  0  0  0
    4.5565   -2.6602   -6.5953 C   0  0  0  0  0  0
    3.9405   -2.1733   -5.4425 C   0  0  0  0  0  0
    3.0732   -3.2871   -4.4374 Cl  0  0  0  0  0  0
    6.0446    0.4891   -7.9012 O   0  0  0  0  0  0
    6.7054    0.0537   -9.0844 C   0  0  0  0  0  0
   -4.0775    4.6375   -0.4567 N   0  3  0  0  0  0
   -6.9196    2.7861   -1.0915 H   0  0  0  0  0  0
   -5.6722    3.2695   -2.2319 H   0  0  0  0  0  0
   -6.6144    4.4873   -1.3837 H   0  0  0  0  0  0
   -6.5303    3.2072    1.5043 H   0  0  0  0  0  0
   -6.2291    4.8992    1.1601 H   0  0  0  0  0  0
   -5.0304    3.9556    2.0329 H   0  0  0  0  0  0
   -2.5651    2.9570   -0.3598 H   0  0  0  0  0  0
   -3.6455   -0.6231   -0.4804 H   0  0  0  0  0  0
   -2.0148   -2.4304   -0.3783 H   0  0  0  0  0  0
    0.3790   -1.9481   -0.0372 H   0  0  0  0  0  0
   -0.4885    2.2507    0.1249 H   0  0  0  0  0  0
    2.9257   -0.5576   -1.5700 H   0  0  0  0  0  0
    1.8100    3.4966   -6.6112 H   0  0  0  0  0  0
    0.5622    5.5932   -6.1899 H   0  0  0  0  0  0
   -0.1945    6.1639   -3.9192 H   0  0  0  0  0  0
    0.2807    4.6498   -2.0163 H   0  0  0  0  0  0
    3.4052   -0.9600   -3.1879 H   0  0  0  0  0  0
    4.8301    1.0945   -5.7408 H   0  0  0  0  0  0
    5.7263   -2.2157   -8.3171 H   0  0  0  0  0  0
    4.4879   -3.7094   -6.8438 H   0  0  0  0  0  0
    7.1879    0.9067   -9.5612 H   0  0  0  0  0  0
    6.0025   -0.3706   -9.8028 H   0  0  0  0  0  0
    7.4807   -0.6814   -8.8630 H   0  0  0  0  0  0
   -4.5557    5.5240   -0.5334 H   0  0  0  0  0  0
   -3.6207    4.4439   -1.3366 H   0  0  0  0  0  0
   -3.3860    4.7115    0.2757 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 38  1  0  0  0
  1 39  1  0  0  0
  1 40  1  0  0  0
  2  3  1  0  0  0
  2  4  1  0  0  0
  2 37  1  0  0  0
  3 41  1  0  0  0
  3 42  1  0  0  0
  3 43  1  0  0  0
  4  5  2  0  0  0
  4  6  1  0  0  0
  6  7  1  0  0  0
  6 44  1  0  0  0
  7  8  1  0  0  0
  7 12  2  0  0  0
  8  9  2  0  0  0
  8 45  1  0  0  0
  9 10  1  0  0  0
  9 46  1  0  0  0
 10 11  2  0  0  0
 10 47  1  0  0  0
 11 12  1  0  0  0
 11 13  1  0  0  0
 12 48  1  0  0  0
 13 14  2  0  0  0
 13 15  2  0  0  0
 13 16  1  0  0  0
 16 17  1  0  0  0
 16 49  1  0  0  0
 17 18  1  0  0  0
 17 26  2  0  0  0
 18 19  2  0  0  0
 18 27  1  0  0  0
 19 20  1  0  0  0
 20 21  1  0  0  0
 20 25  2  0  0  0
 21 22  2  0  0  0
 21 50  1  0  0  0
 22 23  1  0  0  0
 22 51  1  0  0  0
 23 24  2  0  0  0
 23 52  1  0  0  0
 24 25  1  0  0  0
 24 53  1  0  0  0
 25 26  1  0  0  0
 27 28  1  0  0  0
 27 54  1  0  0  0
 28 29  1  0  0  0
 28 33  2  0  0  0
 29 30  2  0  0  0
 29 55  1  0  0  0
 30 31  1  0  0  0
 30 35  1  0  0  0
 31 32  2  0  0  0
 31 56  1  0  0  0
 32 33  1  0  0  0
 32 57  1  0  0  0
 33 34  1  0  0  0
 35 36  1  0  0  0
 36 58  1  0  0  0
 36 59  1  0  0  0
 36 60  1  0  0  0
 37 61  1  0  0  0
 37 62  1  0  0  0
 37 63  1  0  0  0
M  CHG  1  37   1
M  END
> <s_m_entry_id>
288

> <Applicants>
Sanofi

> <CHEMBL_ID>
CHEMBL3360203

> <Canonical_Smiles>
Clc1ccc(OC)cc1Nc1nc2c(nc1NS(=O)(=O)c1cc(NC(=O)C(N)(C)C)ccc1)cccc2

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
PILARALISIB | SAR-245408 | SAR245408 | XL-147 | XL147

> <Indications>
nan

> <Type>
nan

> <targets_id>
P42336|P42338|O00329|P48736

> <inchi>
InChI=1S/C25H25ClN6O4S/c1-25(2,27)24(33)28-15-7-6-8-17(13-15)37(34,35)32-23-22(29-19-9-4-5-10-20(19)30-23)31-21-14-16(36-3)11-12-18(21)26/h4-14H,27H2,1-3H3,(H,28,33)(H,29,31)(H,30,32)

> <stdInchikey>
QINPEPAQOBZPOF-UHFFFAOYSA-N

> <csid>
29340997

> <Links>
|http://www.chemspider.com/Chemical-Structure.29340997.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3360203|http://pubchem.ncbi.nlm.nih.gov/compound/56599306|http://www.drugbank.ca/drugs/DB11772|http://zinc15.docking.org/substances/ZINC000100472223|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=60ES45KTMK|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50197062

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|ZINC|FDA SRS|BindingDB

> <MW>
540.1

> <HBA>
8

> <HBD>
4

> <NRB>
8

> <TPSA>
148.3

> <LogP>
4.5

> <RoF>
1

> <Targets>
PIK3CA; PIK3CB; PIK3CD; PIK3CG

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_epik_Ionization_Penalty>
  0.2817

> <r_epik_State_Penalty>
  0.2610

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
288

> <Kinase families>
Atypical

> <indicationDB>
Pilaralisib is an orally available small molecule that selectively inhibits the activity of phosphoinositide-3 kinase (PI3K). Pilaralisib has been used in trials studying the treatment of Cancer, Lymphoma, Solid Tumors, Glioblastoma, and Breast Cancer, among others.

> <uniprotId>
P42336

$$$$
Seliciclib
                    3D
 Structure written by MMmdl.
 52 54  0  0  1  0            999 V2000
   -1.6915    1.2497    1.7664 C   0  0  0  0  0  0
   -1.7546    1.5115    0.2517 C   0  0  0  0  0  0
   -0.3742    1.5780   -0.4401 C   0  0  2  0  0  0
   -0.5054    2.0463   -1.9176 C   0  0  0  0  0  0
    0.5451    1.6358   -2.7748 O   0  0  0  0  0  0
    0.3602    0.3160   -0.2825 N   0  0  0  0  0  0
    1.7475    0.2401   -0.0883 C   0  0  0  0  0  0
    2.4624    1.3849    0.1036 N   0  0  0  0  0  0
    3.8087    1.2865    0.2872 C   0  0  0  0  0  0
    4.5885    2.4406    0.4807 N   0  0  0  0  0  0
    4.0049    3.7776    0.5764 C   0  0  0  0  0  0
    3.5562    4.3062   -0.7813 C   0  0  0  0  0  0
    2.2021    4.5573   -1.0186 C   0  0  0  0  0  0
    1.7925    5.0513   -2.2544 C   0  0  0  0  0  0
    2.7381    5.2968   -3.2477 C   0  0  0  0  0  0
    4.0908    5.0565   -3.0155 C   0  0  0  0  0  0
    4.5011    4.5636   -1.7795 C   0  0  0  0  0  0
    4.4213    0.0203    0.2793 C   0  0  0  0  0  0
    5.7237   -0.3782    0.4356 N   0  0  0  0  0  0
    5.6687   -1.6828    0.3323 C   0  0  0  0  0  0
    4.4047   -2.1951    0.1136 N   0  0  0  0  0  0
    4.0676   -3.6146   -0.0348 C   0  0  0  0  0  0
    3.4671   -3.8841   -1.4280 C   0  0  0  0  0  0
    3.1438   -4.0696    1.1110 C   0  0  0  0  0  0
    3.5695   -1.0911    0.0749 C   0  0  0  0  0  0
    2.2457   -1.0253   -0.1095 N   0  0  0  0  0  0
   -2.6899    1.2592    2.2041 H   0  0  0  0  0  0
   -1.1005    2.0127    2.2740 H   0  0  0  0  0  0
   -1.2458    0.2795    1.9888 H   0  0  0  0  0  0
   -2.3733    0.7482   -0.2230 H   0  0  0  0  0  0
   -2.2759    2.4568    0.0941 H   0  0  0  0  0  0
    0.1901    2.3574    0.0728 H   0  0  0  0  0  0
   -1.4581    1.7376   -2.3492 H   0  0  0  0  0  0
   -0.5173    3.1360   -1.9403 H   0  0  0  0  0  0
    0.3954    2.0120   -3.6451 H   0  0  0  0  0  0
   -0.1216   -0.5390   -0.5172 H   0  0  0  0  0  0
    5.5299    2.3139    0.8229 H   0  0  0  0  0  0
    3.1738    3.7698    1.2835 H   0  0  0  0  0  0
    4.7558    4.4516    0.9895 H   0  0  0  0  0  0
    1.4670    4.3672   -0.2501 H   0  0  0  0  0  0
    0.7464    5.2430   -2.4420 H   0  0  0  0  0  0
    2.4196    5.6789   -4.2064 H   0  0  0  0  0  0
    4.8177    5.2525   -3.7900 H   0  0  0  0  0  0
    5.5502    4.3790   -1.5988 H   0  0  0  0  0  0
    6.5122   -2.3542    0.4048 H   0  0  0  0  0  0
    4.9980   -4.1802    0.0420 H   0  0  0  0  0  0
    3.2969   -4.9507   -1.5779 H   0  0  0  0  0  0
    4.1367   -3.5472   -2.2204 H   0  0  0  0  0  0
    2.5099   -3.3802   -1.5659 H   0  0  0  0  0  0
    2.9543   -5.1420    1.0556 H   0  0  0  0  0  0
    2.1767   -3.5665    1.0800 H   0  0  0  0  0  0
    3.5918   -3.8689    2.0851 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 27  1  0  0  0
  1 28  1  0  0  0
  1 29  1  0  0  0
  2  3  1  0  0  0
  2 30  1  0  0  0
  2 31  1  0  0  0
  3  4  1  0  0  0
  3  6  1  0  0  0
  3 32  1  0  0  0
  4  5  1  0  0  0
  4 33  1  0  0  0
  4 34  1  0  0  0
  5 35  1  0  0  0
  6  7  1  0  0  0
  6 36  1  0  0  0
  7  8  1  0  0  0
  7 26  2  0  0  0
  8  9  2  0  0  0
  9 10  1  0  0  0
  9 18  1  0  0  0
 10 11  1  0  0  0
 10 37  1  0  0  0
 11 12  1  0  0  0
 11 38  1  0  0  0
 11 39  1  0  0  0
 12 13  1  0  0  0
 12 17  2  0  0  0
 13 14  2  0  0  0
 13 40  1  0  0  0
 14 15  1  0  0  0
 14 41  1  0  0  0
 15 16  2  0  0  0
 15 42  1  0  0  0
 16 17  1  0  0  0
 16 43  1  0  0  0
 17 44  1  0  0  0
 18 19  1  0  0  0
 18 25  2  0  0  0
 19 20  2  0  0  0
 20 21  1  0  0  0
 20 45  1  0  0  0
 21 22  1  0  0  0
 21 25  1  0  0  0
 22 23  1  0  0  0
 22 24  1  0  0  0
 22 46  1  0  0  0
 23 47  1  0  0  0
 23 48  1  0  0  0
 23 49  1  0  0  0
 24 50  1  0  0  0
 24 51  1  0  0  0
 24 52  1  0  0  0
 25 26  1  0  0  0
M  END
> <s_m_entry_id>
292

> <Applicants>
Cyclacel pharmaceuticals

> <CHEMBL_ID>
CHEMBL14762

> <Canonical_Smiles>
OC[C@H](Nc1nc(NCc2ccccc2)c2ncn(c2n1)C(C)C)CC

> <Chirality>
Single Stereoisomer

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
AL-39256 | CYC-202 | NSC-701554 | SELICICLIB

> <Indications>
nan

> <Type>
1

> <targets_id>
P24941|P50613|P50750

> <inchi>
InChI=1S/C19H26N6O/c1-4-15(11-26)22-19-23-17(20-10-14-8-6-5-7-9-14)16-18(24-19)25(12-21-16)13(2)3/h5-9,12-13,15,26H,4,10-11H2,1-3H3,(H2,20,22,23,24)/t15-/m1/s1

> <stdInchikey>
BTIHMVBBUGXLCJ-OAHLLOKOSA-N

> <csid>
140922

> <Links>
|http://www.chemspider.com/Chemical-Structure.140922.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL14762|http://pubchem.ncbi.nlm.nih.gov/compound/160355|http://www.drugbank.ca/drugs/DB06195| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=RRC|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/RRC|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6035|http://zinc15.docking.org/substances/ZINC01649340|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=0ES1C2KQ94|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=7533

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
354.2

> <HBA>
7

> <HBD>
3

> <NRB>
8

> <TPSA>
87.9

> <LogP>
3.2

> <RoF>
0

> <Targets>
CDK2; CDK7; CDK9

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_epik_Ionization_Penalty>
  0.0134

> <r_epik_State_Penalty>
  0.0065

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
292

> <lig_pdbID>
'RRC'

> <pdbID>
1unl 1ygk 2a4l 3ddq

> <Kinase families>
CMGC

> <indicationDB>
R-roscovitine (Seliciclib or CYC202) is a cyclin-dependent kinase (CDK) inhibitor that preferentially inhibits multiple enzyme targets including CDK2, CDK7 and CDK9, which alter the growth phase of treated cells. Developed by Cyclacel, seliciclib is being researched for the treatment of non-small cell lung cancer (NSCLC), leukemia, HIV infection, herpes simplex infection, and the mechanisms of chronic inflammation disorders.

> <uniprotId>
P06493|P24941|P27361|P28482|P50613|P50750|P49674|P35354

$$$$
Uprosertib
                    3D
 Structure written by MMmdl.
 45 47  0  0  1  0            999 V2000
   -5.8455    3.1291   -0.9509 C   0  0  0  0  0  0
   -6.4807    2.0964   -0.1422 N   0  0  0  0  0  0
   -5.9129    0.9615    0.4003 C   0  0  0  0  0  0
   -6.9542    0.3491    1.0902 C   0  0  0  0  0  0
   -8.0554    1.1896    0.9037 C   0  0  0  0  0  0
   -7.7741    2.2418    0.1754 N   0  0  0  0  0  0
   -6.9117   -1.1097    1.9997 Cl  0  0  0  0  0  0
   -4.5191    0.5742    0.2323 C   0  0  0  0  0  0
   -3.3909    1.3752    0.4470 C   0  0  0  0  0  0
   -2.2676    0.6075    0.1738 C   0  0  0  0  0  0
   -2.6642   -0.6374   -0.2063 O   0  0  0  0  0  0
   -4.0217   -0.6609   -0.1716 C   0  0  0  0  0  0
   -4.7937   -2.1272   -0.6296 Cl  0  0  0  0  0  0
   -0.8692    0.9406    0.2281 C   0  0  0  0  0  0
   -0.4973    2.0773    0.5223 O   0  0  0  0  0  0
   -0.0359   -0.0769   -0.0655 N   0  0  0  0  0  0
    1.4323   -0.0150   -0.0548 C   0  0  1  0  0  0
    2.0279   -0.6584    1.2228 C   0  0  0  0  0  0
    1.5099   -0.0558    2.5245 C   0  0  0  0  0  0
    2.0345    1.1515    2.9977 C   0  0  0  0  0  0
    1.5443    1.7169    4.1754 C   0  0  0  0  0  0
    0.5281    1.0785    4.8871 C   0  0  0  0  0  0
    0.0029   -0.1281    4.4214 C   0  0  0  0  0  0
    0.4934   -0.6940    3.2440 C   0  0  0  0  0  0
   -0.9830   -0.7499    5.1075 F   0  0  0  0  0  0
    0.0533    1.6313    6.0266 F   0  0  0  0  0  0
    2.0119   -0.6735   -1.3243 C   0  0  0  0  0  0
    1.7051    0.1883   -2.5552 N   0  3  0  0  0  0
   -5.1037    2.6775   -1.6100 H   0  0  0  0  0  0
   -5.3568    3.8486   -0.2935 H   0  0  0  0  0  0
   -6.5856    3.6455   -1.5647 H   0  0  0  0  0  0
   -9.0454    1.0309    1.3060 H   0  0  0  0  0  0
   -3.3944    2.4059    0.7715 H   0  0  0  0  0  0
   -0.4434   -0.9793   -0.2646 H   0  0  0  0  0  0
    1.7614    1.0278   -0.0579 H   0  0  0  0  0  0
    1.8333   -1.7327    1.2270 H   0  0  0  0  0  0
    3.1151   -0.5618    1.2151 H   0  0  0  0  0  0
    2.8164    1.6579    2.4505 H   0  0  0  0  0  0
    1.9504    2.6512    4.5345 H   0  0  0  0  0  0
    0.0754   -1.6245    2.8882 H   0  0  0  0  0  0
    3.1011   -0.7326   -1.3162 H   0  0  0  0  0  0
    1.5858   -1.6534   -1.5454 H   0  0  0  0  0  0
    2.0853   -0.2409   -3.3868 H   0  0  0  0  0  0
    2.1113    1.1069   -2.4470 H   0  0  0  0  0  0
    0.7059    0.2875   -2.6672 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 29  1  0  0  0
  1 30  1  0  0  0
  1 31  1  0  0  0
  2  3  1  0  0  0
  2  6  1  0  0  0
  3  4  2  0  0  0
  3  8  1  0  0  0
  4  5  1  0  0  0
  4  7  1  0  0  0
  5  6  2  0  0  0
  5 32  1  0  0  0
  8  9  1  0  0  0
  8 12  2  0  0  0
  9 10  2  0  0  0
  9 33  1  0  0  0
 10 11  1  0  0  0
 10 14  1  0  0  0
 11 12  1  0  0  0
 12 13  1  0  0  0
 14 15  2  0  0  0
 14 16  1  0  0  0
 16 17  1  0  0  0
 16 34  1  0  0  0
 17 18  1  0  0  0
 17 27  1  0  0  0
 17 35  1  0  0  0
 18 19  1  0  0  0
 18 36  1  0  0  0
 18 37  1  0  0  0
 19 20  2  0  0  0
 19 24  1  0  0  0
 20 21  1  0  0  0
 20 38  1  0  0  0
 21 22  2  0  0  0
 21 39  1  0  0  0
 22 23  1  0  0  0
 22 26  1  0  0  0
 23 24  2  0  0  0
 23 25  1  0  0  0
 24 40  1  0  0  0
 27 28  1  0  0  0
 27 41  1  0  0  0
 27 42  1  0  0  0
 28 43  1  0  0  0
 28 44  1  0  0  0
 28 45  1  0  0  0
M  CHG  1  28   1
M  END
> <s_m_entry_id>
294

> <Applicants>
GlaxoSmithKline

> <CHEMBL_ID>
CHEMBL3137336

> <Canonical_Smiles>
Clc1cnn(C)c1-c1cc(oc1Cl)C(=O)N[C@@H](Cc1cc(F)c(F)cc1)CN

> <Chirality>
Single Stereoisomer

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
GSK-2141795 | GSK-2141795C | GSK2141795 | GSK2141795C | UPROSERTIB

> <Indications>
nan

> <Type>
nan

> <targets_id>
P31749|P31751|Q9Y243

> <inchi>
InChI=1S/C18H16Cl2F2N4O2/c1-26-16(12(19)8-24-26)11-6-15(28-17(11)20)18(27)25-10(7-23)4-9-2-3-13(21)14(22)5-9/h2-3,5-6,8,10H,4,7,23H2,1H3,(H,25,27)/t10-/m0/s1

> <stdInchikey>
AXTAPYRUEKNRBA-JTQLQIEISA-N

> <csid>
32701836

> <Links>
|http://www.chemspider.com/Chemical-Structure.32701836.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3137336|http://pubchem.ncbi.nlm.nih.gov/compound/51042438|http://www.drugbank.ca/drugs/DB11969|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7902|http://zinc15.docking.org/substances/ZINC000043197676|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=ZXM835LQ5E|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50170284

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
428.1

> <HBA>
5

> <HBD>
2

> <NRB>
6

> <TPSA>
86.1

> <LogP>
3.6

> <RoF>
0

> <Targets>
AKT1; AKT2; AKT3

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0029

> <r_epik_State_Penalty>
  0.0020

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
294

> <Kinase families>
AGC

$$$$
Samotolisib
                    3D
 Structure written by MMmdl.
 56 59  0  0  1  0            999 V2000
   -2.1578    1.3133    0.1424 C   0  0  0  0  0  0
   -0.6211    1.3879    0.0895 C   0  0  1  0  0  0
   -0.0013   -0.0274    0.1292 C   0  0  0  0  0  0
    1.4649   -0.0488    0.0270 N   0  0  0  0  0  0
    2.2624   -0.0100   -1.1164 C   0  0  0  0  0  0
    2.0163    0.0171   -2.5272 C   0  0  0  0  0  0
    0.7325    0.0137   -3.1340 C   0  0  0  0  0  0
    0.5744    0.0659   -4.5231 C   0  0  0  0  0  0
    1.7147    0.0977   -5.3297 C   0  0  0  0  0  0
    2.9935    0.0892   -4.7815 C   0  0  0  0  0  0
    3.1682    0.0536   -3.3796 C   0  0  0  0  0  0
    4.4436    0.0581   -2.8896 N   0  0  0  0  0  0
    4.6228    0.0296   -1.5463 C   0  0  0  0  0  0
    3.5527   -0.0045   -0.6597 C   0  0  0  0  0  0
    3.5058   -0.0340    0.7139 N   0  0  0  0  0  0
    2.2249   -0.0448    1.1572 C   0  0  0  0  0  0
    1.8363   -0.0485    2.3283 O   0  0  0  0  0  0
    4.6541   -0.0315    1.6181 C   0  0  0  0  0  0
   -0.7898    0.0974   -5.1254 C   0  0  0  0  0  0
   -1.0917   -0.5949   -6.3082 C   0  0  0  0  0  0
   -2.3824   -0.5513   -6.8616 C   0  0  0  0  0  0
   -3.3435    0.2045   -6.1772 C   0  0  0  0  0  0
   -3.0875    0.8858   -5.0344 N   0  0  0  0  0  0
   -1.8304    0.8253   -4.5322 C   0  0  0  0  0  0
   -2.7573   -1.2941   -8.1588 C   0  0  0  0  0  0
   -3.8011   -2.3960   -7.8765 C   0  0  0  0  0  0
   -3.2663   -0.3090   -9.2345 C   0  0  0  0  0  0
   -1.6566   -1.9602   -8.7570 O   0  0  0  0  0  0
   -0.1850    2.0606   -1.0900 O   0  0  0  0  0  0
   -0.3428    3.4732   -1.0919 C   0  0  0  0  0  0
   -2.4930    0.7385    1.0064 H   0  0  0  0  0  0
   -2.5597    0.8347   -0.7514 H   0  0  0  0  0  0
   -2.6091    2.3017    0.2225 H   0  0  0  0  0  0
   -0.2552    1.9299    0.9644 H   0  0  0  0  0  0
   -0.3119   -0.5129    1.0562 H   0  0  0  0  0  0
   -0.4217   -0.6640   -0.6460 H   0  0  0  0  0  0
   -0.1488   -0.0182   -2.5194 H   0  0  0  0  0  0
    1.6155    0.1401   -6.4047 H   0  0  0  0  0  0
    3.8595    0.1180   -5.4276 H   0  0  0  0  0  0
    5.6468    0.0360   -1.2025 H   0  0  0  0  0  0
    4.3617   -0.0640    2.6687 H   0  0  0  0  0  0
    5.2497    0.8684    1.4630 H   0  0  0  0  0  0
    5.2877   -0.8961    1.4194 H   0  0  0  0  0  0
   -0.3168   -1.1720   -6.7911 H   0  0  0  0  0  0
   -4.3572    0.2766   -6.5436 H   0  0  0  0  0  0
   -1.6665    1.3907   -3.6260 H   0  0  0  0  0  0
   -4.7230   -1.9810   -7.4679 H   0  0  0  0  0  0
   -3.4271   -3.1266   -7.1575 H   0  0  0  0  0  0
   -4.0721   -2.9397   -8.7831 H   0  0  0  0  0  0
   -4.1655    0.2155   -8.9099 H   0  0  0  0  0  0
   -3.5186   -0.8200  -10.1651 H   0  0  0  0  0  0
   -2.5165    0.4478   -9.4710 H   0  0  0  0  0  0
   -1.9637   -2.3958   -9.5553 H   0  0  0  0  0  0
    0.0636    3.8773   -2.0188 H   0  0  0  0  0  0
    0.1976    3.9346   -0.2642 H   0  0  0  0  0  0
   -1.3904    3.7692   -1.0377 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 31  1  0  0  0
  1 32  1  0  0  0
  1 33  1  0  0  0
  2  3  1  0  0  0
  2 29  1  0  0  0
  2 34  1  0  0  0
  3  4  1  0  0  0
  3 35  1  0  0  0
  3 36  1  0  0  0
  4  5  1  0  0  0
  4 16  1  0  0  0
  5  6  1  0  0  0
  5 14  2  0  0  0
  6  7  1  0  0  0
  6 11  2  0  0  0
  7  8  2  0  0  0
  7 37  1  0  0  0
  8  9  1  0  0  0
  8 19  1  0  0  0
  9 10  2  0  0  0
  9 38  1  0  0  0
 10 11  1  0  0  0
 10 39  1  0  0  0
 11 12  1  0  0  0
 12 13  2  0  0  0
 13 14  1  0  0  0
 13 40  1  0  0  0
 14 15  1  0  0  0
 15 16  1  0  0  0
 15 18  1  0  0  0
 16 17  2  0  0  0
 18 41  1  0  0  0
 18 42  1  0  0  0
 18 43  1  0  0  0
 19 20  2  0  0  0
 19 24  1  0  0  0
 20 21  1  0  0  0
 20 44  1  0  0  0
 21 22  2  0  0  0
 21 25  1  0  0  0
 22 23  1  0  0  0
 22 45  1  0  0  0
 23 24  2  0  0  0
 24 46  1  0  0  0
 25 26  1  0  0  0
 25 27  1  0  0  0
 25 28  1  0  0  0
 26 47  1  0  0  0
 26 48  1  0  0  0
 26 49  1  0  0  0
 27 50  1  0  0  0
 27 51  1  0  0  0
 27 52  1  0  0  0
 28 53  1  0  0  0
 29 30  1  0  0  0
 30 54  1  0  0  0
 30 55  1  0  0  0
 30 56  1  0  0  0
M  END
> <s_m_entry_id>
295

> <Applicants>
Eli Lilly

> <CHEMBL_ID>
CHEMBL4297181

> <Canonical_Smiles>
O=C1N(c2c3cc(ccc3ncc2N1C)-c1cc(cnc1)C(O)(C)C)C[C@@H](OC)C

> <Chirality>
Single Stereoisomer

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
LY 3023414 | LY-3023414 | LY3023414 | SAMOTOLISIB

> <Indications>
LY3023414 is a dual inhibitor of phosphoinositide 3-kinase &alpha; (PI3K&alpha;) and the serine/threonine kinase mTOR (mechanistic target of rapamycin), with potential antineoplastic activity.

> <Type>
nan

> <targets_id>
nan

> <inchi>
InChI=1S/C23H26N4O3/c1-14(30-5)13-27-21-18-9-15(16-8-17(11-24-10-16)23(2,3)29)6-7-19(18)25-12-20(21)26(4)22(27)28/h6-12,14,29H,13H2,1-5H3/t14-/m0/s1

> <stdInchikey>
ACCFLVVUVBJNGT-AWEZNQCLSA-N

> <csid>
35142771

> <Links>
|http://www.chemspider.com/Chemical-Structure.35142771.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4297181|http://pubchem.ncbi.nlm.nih.gov/compound/57519748|http://www.drugbank.ca/drugs/DB12167|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8918|http://zinc15.docking.org/substances/ZINC000143116580|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=C88817F47Y

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS

> <indicationG2P>
None

> <MW>
406.2

> <HBA>
7

> <HBD>
1

> <NRB>
5

> <TPSA>
82.2

> <LogP>
3.2

> <RoF>
0

> <Targets>
nan

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0029

> <r_epik_State_Penalty>
  0.0000

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
295

$$$$
Spebrutinib
                    3D
 Structure written by MMmdl.
 53 55  0  0  1  0            999 V2000
   -8.2654   -0.4419    1.5738 C   0  0  0  0  0  0
   -6.9243   -0.0318    1.3568 O   0  0  0  0  0  0
   -6.7865    0.9245    0.3142 C   0  0  0  0  0  0
   -5.3043    1.2790    0.1388 C   0  0  0  0  0  0
   -4.5938    0.1236   -0.3010 O   0  0  0  0  0  0
   -3.2312    0.2056   -0.5150 C   0  0  0  0  0  0
   -2.5942   -0.9656   -0.9239 C   0  0  0  0  0  0
   -1.2227   -0.9821   -1.1625 C   0  0  0  0  0  0
   -0.4648    0.1816   -0.9882 C   0  0  0  0  0  0
   -1.1016    1.3592   -0.5932 C   0  0  0  0  0  0
   -2.4728    1.3747   -0.3531 C   0  0  0  0  0  0
    0.9216    0.2425   -1.2156 N   0  0  0  0  0  0
    1.9398   -0.7225   -1.1953 C   0  0  0  0  0  0
    1.6522   -2.0242   -0.9254 N   0  0  0  0  0  0
    2.6968   -2.8907   -0.9044 C   0  0  0  0  0  0
    4.0102   -2.4833   -1.1414 C   0  0  0  0  0  0
    4.2240   -1.1245   -1.4079 C   0  0  0  0  0  0
    3.1871   -0.2419   -1.4324 N   0  0  0  0  0  0
    5.5346   -0.6779   -1.6530 N   0  0  0  0  0  0
    6.0523    0.5810   -2.0060 C   0  0  0  0  0  0
    5.3172    1.5385   -2.7177 C   0  0  0  0  0  0
    5.8912    2.7636   -3.0524 C   0  0  0  0  0  0
    7.2043    3.0470   -2.6824 C   0  0  0  0  0  0
    7.9550    2.1002   -1.9678 C   0  0  0  0  0  0
    7.3745    0.8677   -1.6515 C   0  0  0  0  0  0
    9.2928    2.2908   -1.5771 N   0  0  0  0  0  0
    9.9408    3.4535   -1.3475 C   0  0  0  0  0  0
    9.4227    4.5712   -1.4084 O   0  0  0  0  0  0
   11.3333    3.2497   -1.0172 C   0  0  0  0  0  0
   12.1784    4.2671   -0.7649 C   0  0  0  0  0  0
    5.0266   -3.3781   -1.1104 F   0  0  0  0  0  0
   -8.2967   -1.1695    2.3846 H   0  0  0  0  0  0
   -8.6860   -0.9147    0.6850 H   0  0  0  0  0  0
   -8.8990    0.4004    1.8561 H   0  0  0  0  0  0
   -7.1827    0.5239   -0.6209 H   0  0  0  0  0  0
   -7.3546    1.8252    0.5536 H   0  0  0  0  0  0
   -5.2064    2.0835   -0.5922 H   0  0  0  0  0  0
   -4.8972    1.6350    1.0871 H   0  0  0  0  0  0
   -3.1681   -1.8703   -1.0618 H   0  0  0  0  0  0
   -0.7759   -1.9042   -1.4986 H   0  0  0  0  0  0
   -0.5356    2.2708   -0.4629 H   0  0  0  0  0  0
   -2.9280    2.3028   -0.0428 H   0  0  0  0  0  0
    1.2836    1.1837   -1.2542 H   0  0  0  0  0  0
    2.4661   -3.9243   -0.6924 H   0  0  0  0  0  0
    6.2364   -1.3340   -1.3429 H   0  0  0  0  0  0
    4.3064    1.3433   -3.0408 H   0  0  0  0  0  0
    5.3202    3.4911   -3.6100 H   0  0  0  0  0  0
    7.6247    3.9962   -2.9772 H   0  0  0  0  0  0
    7.9528    0.1285   -1.1139 H   0  0  0  0  0  0
    9.7904    1.4441   -1.3446 H   0  0  0  0  0  0
   11.6928    2.2301   -0.9766 H   0  0  0  0  0  0
   11.8658    5.3021   -0.7937 H   0  0  0  0  0  0
   13.2126    4.0718   -0.5223 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 32  1  0  0  0
  1 33  1  0  0  0
  1 34  1  0  0  0
  2  3  1  0  0  0
  3  4  1  0  0  0
  3 35  1  0  0  0
  3 36  1  0  0  0
  4  5  1  0  0  0
  4 37  1  0  0  0
  4 38  1  0  0  0
  5  6  1  0  0  0
  6  7  1  0  0  0
  6 11  2  0  0  0
  7  8  2  0  0  0
  7 39  1  0  0  0
  8  9  1  0  0  0
  8 40  1  0  0  0
  9 10  2  0  0  0
  9 12  1  0  0  0
 10 11  1  0  0  0
 10 41  1  0  0  0
 11 42  1  0  0  0
 12 13  1  0  0  0
 12 43  1  0  0  0
 13 14  1  0  0  0
 13 18  2  0  0  0
 14 15  2  0  0  0
 15 16  1  0  0  0
 15 44  1  0  0  0
 16 17  2  0  0  0
 16 31  1  0  0  0
 17 18  1  0  0  0
 17 19  1  0  0  0
 19 20  1  0  0  0
 19 45  1  0  0  0
 20 21  1  0  0  0
 20 25  2  0  0  0
 21 22  2  0  0  0
 21 46  1  0  0  0
 22 23  1  0  0  0
 22 47  1  0  0  0
 23 24  2  0  0  0
 23 48  1  0  0  0
 24 25  1  0  0  0
 24 26  1  0  0  0
 25 49  1  0  0  0
 26 27  1  0  0  0
 26 50  1  0  0  0
 27 28  2  0  0  0
 27 29  1  0  0  0
 29 30  2  0  0  0
 29 51  1  0  0  0
 30 52  1  0  0  0
 30 53  1  0  0  0
M  END
> <s_m_entry_id>
296

> <Applicants>
Celgene

> <CHEMBL_ID>
CHEMBL3301625

> <Canonical_Smiles>
Fc1cnc(nc1Nc1cc(NC(=O)C=C)ccc1)Nc1ccc(OCCOC)cc1

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
AVL-292 | CC-292 | SPEBRUTINIB

> <Indications>
nan

> <Type>
nan

> <targets_id>
Q06187

> <inchi>
InChI=1S/C22H22FN5O3/c1-3-20(29)25-16-5-4-6-17(13-16)26-21-19(23)14-24-22(28-21)27-15-7-9-18(10-8-15)31-12-11-30-2/h3-10,13-14H,1,11-12H2,2H3,(H,25,29)(H2,24,26,27,28)

> <stdInchikey>
KXBDTLQSDKGAEB-UHFFFAOYSA-N

> <csid>
29361342

> <Links>
|http://www.chemspider.com/Chemical-Structure.29361342.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3301625|http://pubchem.ncbi.nlm.nih.gov/compound/59174488|http://www.drugbank.ca/drugs/DB11764|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7837|http://zinc15.docking.org/substances/ZINC000072319585|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=DRU6NG543J|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50161162

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
423.2

> <HBA>
7

> <HBD>
3

> <NRB>
10

> <TPSA>
97.4

> <LogP>
4.3

> <RoF>
0

> <Targets>
BTK

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0020

> <r_epik_State_Penalty>
  0.0000

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
296

> <Kinase families>
Tyr

$$$$
Sotrastaurin
                    3D
 Structure written by MMmdl.
 56 61  0  0  1  0            999 V2000
   -1.0803    2.0614    3.9186 C   0  0  0  0  0  0
   -1.1460    1.3121    2.5739 N   0  3  0  0  0  0
   -0.4870   -0.0828    2.6995 C   0  0  0  0  0  0
   -0.4068   -0.7377    1.3027 C   0  0  0  0  0  0
    0.3559    0.1264    0.3879 N   0  0  0  0  0  0
   -0.4451    1.3371    0.1487 C   0  0  0  0  0  0
   -0.5312    2.1742    1.4447 C   0  0  0  0  0  0
    1.7408    0.0578    0.2172 C   0  0  0  0  0  0
    2.3427    1.0613   -0.4774 N   0  0  0  0  0  0
    3.6916    0.9908   -0.6572 C   0  0  0  0  0  0
    4.3379    2.0181   -1.3857 C   0  0  0  0  0  0
    5.7132    1.9653   -1.5986 C   0  0  0  0  0  0
    6.4670    0.9048   -1.1054 C   0  0  0  0  0  0
    5.8629   -0.1214   -0.3831 C   0  0  0  0  0  0
    4.4638   -0.0925   -0.1366 C   0  0  0  0  0  0
    3.7284   -1.0805    0.5827 C   0  0  0  0  0  0
    2.3858   -1.0082    0.7557 N   0  0  0  0  0  0
    4.3341   -2.2708    1.2276 C   0  0  0  0  0  0
    4.0109   -3.5629    1.0531 C   0  0  0  0  0  0
    4.8198   -4.3485    1.9445 C   0  0  0  0  0  0
    4.8500   -5.5698    2.0934 O   0  0  0  0  0  0
    5.5680   -3.4559    2.6083 N   0  0  0  0  0  0
    5.3292   -2.1851    2.2574 C   0  0  0  0  0  0
    5.8610   -1.1853    2.7383 O   0  0  0  0  0  0
    3.0426   -4.1642    0.1307 C   0  0  0  0  0  0
    2.1763   -5.2009    0.4363 C   0  0  0  0  0  0
    1.3690   -5.4710   -0.6367 N   0  0  0  0  0  0
    1.6866   -4.6362   -1.6850 C   0  0  0  0  0  0
    2.7580   -3.7995   -1.2379 C   0  0  0  0  0  0
    3.2935   -2.8683   -2.1463 C   0  0  0  0  0  0
    2.7536   -2.7729   -3.4268 C   0  0  0  0  0  0
    1.7001   -3.5897   -3.8256 C   0  0  0  0  0  0
    1.1434   -4.5402   -2.9708 C   0  0  0  0  0  0
   -0.0299    2.2258    4.1647 H   0  0  0  0  0  0
   -1.5745    1.4335    4.6611 H   0  0  0  0  0  0
   -1.6155    3.0030    3.7877 H   0  0  0  0  0  0
    0.5032    0.0551    3.1391 H   0  0  0  0  0  0
   -1.1066   -0.6605    3.3867 H   0  0  0  0  0  0
    0.0352   -1.7328    1.3630 H   0  0  0  0  0  0
   -1.4136   -0.8990    0.9130 H   0  0  0  0  0  0
   -0.0316    1.9284   -0.6687 H   0  0  0  0  0  0
   -1.4491    1.0631   -0.1808 H   0  0  0  0  0  0
   -1.1792    3.0437    1.3273 H   0  0  0  0  0  0
    0.4547    2.5045    1.7784 H   0  0  0  0  0  0
    3.7586    2.8415   -1.7790 H   0  0  0  0  0  0
    6.1994    2.7526   -2.1561 H   0  0  0  0  0  0
    7.5316    0.8766   -1.2863 H   0  0  0  0  0  0
    6.4624   -0.9411   -0.0163 H   0  0  0  0  0  0
    6.2380   -3.7159    3.3167 H   0  0  0  0  0  0
    2.0504   -5.7646    1.3493 H   0  0  0  0  0  0
    0.6580   -6.1877   -0.6139 H   0  0  0  0  0  0
    4.1211   -2.2346   -1.8693 H   0  0  0  0  0  0
    3.1624   -2.0559   -4.1237 H   0  0  0  0  0  0
    1.3077   -3.4889   -4.8270 H   0  0  0  0  0  0
    0.3314   -5.1728   -3.2976 H   0  0  0  0  0  0
   -2.1192    1.1654    2.3447 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 34  1  0  0  0
  1 35  1  0  0  0
  1 36  1  0  0  0
  2  3  1  0  0  0
  2  7  1  0  0  0
  2 56  1  0  0  0
  3  4  1  0  0  0
  3 37  1  0  0  0
  3 38  1  0  0  0
  4  5  1  0  0  0
  4 39  1  0  0  0
  4 40  1  0  0  0
  5  6  1  0  0  0
  5  8  1  0  0  0
  6  7  1  0  0  0
  6 41  1  0  0  0
  6 42  1  0  0  0
  7 43  1  0  0  0
  7 44  1  0  0  0
  8  9  1  0  0  0
  8 17  2  0  0  0
  9 10  2  0  0  0
 10 11  1  0  0  0
 10 15  1  0  0  0
 11 12  2  0  0  0
 11 45  1  0  0  0
 12 13  1  0  0  0
 12 46  1  0  0  0
 13 14  2  0  0  0
 13 47  1  0  0  0
 14 15  1  0  0  0
 14 48  1  0  0  0
 15 16  2  0  0  0
 16 17  1  0  0  0
 16 18  1  0  0  0
 18 19  2  0  0  0
 18 23  1  0  0  0
 19 20  1  0  0  0
 19 25  1  0  0  0
 20 21  2  0  0  0
 20 22  1  0  0  0
 22 23  1  0  0  0
 22 49  1  0  0  0
 23 24  2  0  0  0
 25 26  2  0  0  0
 25 29  1  0  0  0
 26 27  1  0  0  0
 26 50  1  0  0  0
 27 28  1  0  0  0
 27 51  1  0  0  0
 28 29  1  0  0  0
 28 33  2  0  0  0
 29 30  2  0  0  0
 30 31  1  0  0  0
 30 52  1  0  0  0
 31 32  2  0  0  0
 31 53  1  0  0  0
 32 33  1  0  0  0
 32 54  1  0  0  0
 33 55  1  0  0  0
M  CHG  1   2   1
M  END
> <s_m_entry_id>
297

> <Applicants>
Novartis

> <CHEMBL_ID>
CHEMBL565612

> <Canonical_Smiles>
O=C1NC(=O)C(=C1c1c2c([nH]c1)cccc2)c1nc(nc2c1cccc2)N1CCN(CC1)C

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
AEB-071 | AEB071 | NVP-AEB071 | SOTRASTAURIN

> <Indications>
nan

> <Type>
nan

> <targets_id>
nan

> <inchi>
InChI=1S/C25H22N6O2/c1-30-10-12-31(13-11-30)25-27-19-9-5-3-7-16(19)22(28-25)21-20(23(32)29-24(21)33)17-14-26-18-8-4-2-6-15(17)18/h2-9,14,26H,10-13H2,1H3,(H,29,32,33)

> <stdInchikey>
OAVGBZOFDPFGPJ-UHFFFAOYSA-N

> <csid>
8472351

> <Links>
|http://www.chemspider.com/Chemical-Structure.8472351.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL565612|http://pubchem.ncbi.nlm.nih.gov/compound/10296883|http://www.drugbank.ca/drugs/DB12369| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=LW4|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/LW4|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7946|http://zinc15.docking.org/substances/ZINC000003973984|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=7I279E1NZ8|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=33971

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
438.2

> <HBA>
6

> <HBD>
2

> <NRB>
3

> <TPSA>
94.2

> <LogP>
2.4

> <RoF>
0

> <Targets>
nan

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_epik_Ionization_Penalty>
  0.4702

> <r_epik_State_Penalty>
  0.4385

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
297

> <lig_pdbID>
'LW4'

> <pdbID>
3iw4

$$$$
Danusertib
                    3D
 Structure written by MMmdl.
 66 70  0  0  1  0            999 V2000
   -7.7538   -0.6642    4.4141 C   0  0  0  0  0  0
   -7.8221   -0.5715    2.8777 N   0  3  0  0  0  0
   -6.9645   -1.6847    2.2272 C   0  0  0  0  0  0
   -6.9010   -1.4541    0.6998 C   0  0  0  0  0  0
   -6.3331   -0.1248    0.4196 N   0  0  0  0  0  0
   -7.3347    0.8597    0.8608 C   0  0  0  0  0  0
   -7.4357    0.8504    2.4026 C   0  0  0  0  0  0
   -4.9631    0.1408    0.2876 C   0  0  0  0  0  0
   -4.4656    1.4519    0.3634 C   0  0  0  0  0  0
   -3.1066    1.7188    0.2241 C   0  0  0  0  0  0
   -2.1967    0.6810    0.0023 C   0  0  0  0  0  0
   -2.6802   -0.6303   -0.0814 C   0  0  0  0  0  0
   -4.0402   -0.8927    0.0602 C   0  0  0  0  0  0
   -0.7263    0.9931   -0.1606 C   0  0  0  0  0  0
   -0.3759    2.0888   -0.6041 O   0  0  0  0  0  0
    0.1232    0.0146    0.2245 N   0  0  0  0  0  0
    1.5057    0.0731    0.1906 C   0  0  0  0  0  0
    2.3743    1.1862    0.2189 C   0  0  0  0  0  0
    3.6296    0.6750    0.2068 C   0  0  0  0  0  0
    3.4901   -0.6815    0.1911 N   0  0  0  0  0  0
    2.1999   -1.0520    0.1973 N   0  0  0  0  0  0
    4.6988    1.7208    0.2359 C   0  0  0  0  0  0
    3.8977    2.9332    0.4679 N   0  0  0  0  0  0
    2.4559    2.6886    0.2723 C   0  0  0  0  0  0
    4.3985    4.1700    0.7082 C   0  0  0  0  0  0
    3.6655    5.1546    0.8327 O   0  0  0  0  0  0
    5.9379    4.3627    0.8203 C   0  0  1  0  0  0
    6.5597    4.5759   -0.5625 C   0  0  0  0  0  0
    6.2731    5.7313   -1.3011 C   0  0  0  0  0  0
    6.8389    5.9161   -2.5595 C   0  0  0  0  0  0
    7.6944    4.9480   -3.0797 C   0  0  0  0  0  0
    7.9898    3.7974   -2.3522 C   0  0  0  0  0  0
    7.4241    3.6123   -1.0935 C   0  0  0  0  0  0
    6.2664    5.4935    1.6377 O   0  0  0  0  0  0
    6.0237    5.3571    3.0357 C   0  0  0  0  0  0
   -6.7183   -0.5034    4.7184 H   0  0  0  0  0  0
   -8.1051   -1.6590    4.6914 H   0  0  0  0  0  0
   -8.4148    0.1066    4.8129 H   0  0  0  0  0  0
   -5.9734   -1.6520    2.6845 H   0  0  0  0  0  0
   -7.4443   -2.6316    2.4782 H   0  0  0  0  0  0
   -6.3518   -2.2508    0.2025 H   0  0  0  0  0  0
   -7.9071   -1.5271    0.2820 H   0  0  0  0  0  0
   -7.1206    1.8569    0.4801 H   0  0  0  0  0  0
   -8.3105    0.6190    0.4340 H   0  0  0  0  0  0
   -8.2155    1.5214    2.7650 H   0  0  0  0  0  0
   -6.4869    1.1138    2.8747 H   0  0  0  0  0  0
   -5.1134    2.2965    0.5348 H   0  0  0  0  0  0
   -2.7694    2.7440    0.2900 H   0  0  0  0  0  0
   -2.0126   -1.4600   -0.2660 H   0  0  0  0  0  0
   -4.3495   -1.9221   -0.0204 H   0  0  0  0  0  0
   -0.2713   -0.8941    0.4164 H   0  0  0  0  0  0
    4.2483   -1.3489    0.1926 H   0  0  0  0  0  0
    5.4235    1.5549    1.0332 H   0  0  0  0  0  0
    5.2327    1.7849   -0.7128 H   0  0  0  0  0  0
    2.1249    3.1445   -0.6619 H   0  0  0  0  0  0
    1.8684    3.1201    1.0841 H   0  0  0  0  0  0
    6.4018    3.4868    1.2770 H   0  0  0  0  0  0
    5.6099    6.4843   -0.9000 H   0  0  0  0  0  0
    6.6147    6.8059   -3.1292 H   0  0  0  0  0  0
    8.1333    5.0917   -4.0561 H   0  0  0  0  0  0
    8.6548    3.0520   -2.7627 H   0  0  0  0  0  0
    7.6570    2.7173   -0.5353 H   0  0  0  0  0  0
    6.3574    6.2591    3.5485 H   0  0  0  0  0  0
    6.5771    4.5143    3.4517 H   0  0  0  0  0  0
    4.9653    5.2235    3.2606 H   0  0  0  0  0  0
   -8.7804   -0.7299    2.5983 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 36  1  0  0  0
  1 37  1  0  0  0
  1 38  1  0  0  0
  2  3  1  0  0  0
  2  7  1  0  0  0
  2 66  1  0  0  0
  3  4  1  0  0  0
  3 39  1  0  0  0
  3 40  1  0  0  0
  4  5  1  0  0  0
  4 41  1  0  0  0
  4 42  1  0  0  0
  5  6  1  0  0  0
  5  8  1  0  0  0
  6  7  1  0  0  0
  6 43  1  0  0  0
  6 44  1  0  0  0
  7 45  1  0  0  0
  7 46  1  0  0  0
  8  9  1  0  0  0
  8 13  2  0  0  0
  9 10  2  0  0  0
  9 47  1  0  0  0
 10 11  1  0  0  0
 10 48  1  0  0  0
 11 12  2  0  0  0
 11 14  1  0  0  0
 12 13  1  0  0  0
 12 49  1  0  0  0
 13 50  1  0  0  0
 14 15  2  0  0  0
 14 16  1  0  0  0
 16 17  1  0  0  0
 16 51  1  0  0  0
 17 18  1  0  0  0
 17 21  2  0  0  0
 18 19  2  0  0  0
 18 24  1  0  0  0
 19 20  1  0  0  0
 19 22  1  0  0  0
 20 21  1  0  0  0
 20 52  1  0  0  0
 22 23  1  0  0  0
 22 53  1  0  0  0
 22 54  1  0  0  0
 23 24  1  0  0  0
 23 25  1  0  0  0
 24 55  1  0  0  0
 24 56  1  0  0  0
 25 26  2  0  0  0
 25 27  1  0  0  0
 27 28  1  0  0  0
 27 34  1  0  0  0
 27 57  1  0  0  0
 28 29  1  0  0  0
 28 33  2  0  0  0
 29 30  2  0  0  0
 29 58  1  0  0  0
 30 31  1  0  0  0
 30 59  1  0  0  0
 31 32  2  0  0  0
 31 60  1  0  0  0
 32 33  1  0  0  0
 32 61  1  0  0  0
 33 62  1  0  0  0
 34 35  1  0  0  0
 35 63  1  0  0  0
 35 64  1  0  0  0
 35 65  1  0  0  0
M  CHG  1   2   1
M  END
> <s_m_entry_id>
301

> <Applicants>
Nerviano Medical Sciences

> <CHEMBL_ID>
CHEMBL402548

> <Canonical_Smiles>
O([C@@H](C(=O)N1Cc2c([nH]nc2NC(=O)c2ccc(N3CCN(CC3)C)cc2)C1)c1ccccc1)C

> <Chirality>
Single Stereoisomer

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
DANUSERTIB | PHA-739358

> <Indications>
nan

> <Type>
1

> <targets_id>
O14965|Q96GD4|Q9UQB9

> <inchi>
InChI=1S/C26H30N6O3/c1-30-12-14-31(15-13-30)20-10-8-19(9-11-20)25(33)27-24-21-16-32(17-22(21)28-29-24)26(34)23(35-2)18-6-4-3-5-7-18/h3-11,23H,12-17H2,1-2H3,(H2,27,28,29,33)/t23-/m1/s1

> <stdInchikey>
XKFTZKGMDDZMJI-HSZRJFAPSA-N

> <csid>
9617754

> <Links>
|http://www.chemspider.com/Chemical-Structure.9617754.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL402548|http://pubchem.ncbi.nlm.nih.gov/compound/11442891|http://www.drugbank.ca/drugs/DB11778| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=627|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/627|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7937|http://zinc15.docking.org/substances/ZINC000006718723|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=M3X659D0FY|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=209858

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
474.2

> <HBA>
6

> <HBD>
2

> <NRB>
6

> <TPSA>
93.8

> <LogP>
2.6

> <RoF>
0

> <Targets>
AURKA; AURKB; AURKC

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
0.5

> <r_epik_Ionization_Penalty>
  0.0648

> <r_epik_State_Penalty>
  0.4671

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
301

> <lig_pdbID>
'627'

> <pdbID>
2j50 2v7a 4qo9 5i9z

> <Kinase families>
Other

$$$$
Edicotinib
                    3D
 Structure written by MMmdl.
 68 71  0  0  1  0            999 V2000
   -5.4503    4.3152    1.0496 C   0  0  0  0  0  0
   -4.3875    4.9459    0.1138 C   0  0  0  0  0  0
   -2.9871    4.8833    0.7851 C   0  0  0  0  0  0
   -2.4825    3.4484    1.0731 C   0  0  0  0  0  0
   -2.7955    2.4848   -0.0734 C   0  0  0  0  0  0
   -3.6098    2.8249   -1.0976 C   0  0  0  0  0  0
   -4.3358    4.1585   -1.2314 C   0  0  0  0  0  0
   -2.2323    1.1175   -0.0124 C   0  0  0  0  0  0
   -3.0069   -0.0472    0.1454 C   0  0  0  0  0  0
   -2.3289   -1.2761    0.2045 C   0  0  0  0  0  0
   -0.9394   -1.3113    0.0888 C   0  0  0  0  0  0
   -0.2364   -0.1136   -0.0952 C   0  0  0  0  0  0
   -0.8791    1.0850   -0.1177 N   0  0  0  0  0  0
    1.3035   -0.0754   -0.1971 C   0  0  0  0  0  0
    1.9288    1.2081   -0.8036 C   0  0  0  0  0  0
    1.9519    1.2663   -2.3610 C   0  0  0  0  0  0
    2.4198    0.0227   -2.9126 O   0  0  0  0  0  0
    1.9849   -1.2621   -2.4326 C   0  0  0  0  0  0
    1.9825   -1.2904   -0.8768 C   0  0  0  0  0  0
    0.6117   -1.6456   -3.0271 C   0  0  0  0  0  0
    3.0921   -2.2126   -2.9344 C   0  0  0  0  0  0
    0.5836    1.6545   -2.9648 C   0  0  0  0  0  0
    3.0450    2.2673   -2.7887 C   0  0  0  0  0  0
   -4.4037    0.0937    0.2739 N   0  0  0  0  0  0
   -5.3889   -0.8299    0.1855 C   0  0  0  0  0  0
   -5.2107   -2.0346   -0.0115 O   0  0  0  0  0  0
   -6.7311   -0.2789    0.3266 C   0  0  0  0  0  0
   -6.9908    1.0047    0.5111 N   0  5  0  0  0  0
   -8.2919    1.0834    0.5761 C   0  0  0  0  0  0
   -8.7949   -0.1858    0.4268 C   0  0  0  0  0  0
   -7.8120   -1.0297    0.2724 N   0  0  0  0  0  0
   -9.0107    2.3317    0.7720 C   0  0  0  0  0  0
   -9.5826    3.3260    0.9278 N   0  0  0  0  0  0
   -4.7149    6.4229   -0.1991 C   0  0  0  0  0  0
   -6.4495    4.3861    0.6182 H   0  0  0  0  0  0
   -5.4791    4.8229    2.0144 H   0  0  0  0  0  0
   -5.2641    3.2590    1.2449 H   0  0  0  0  0  0
   -2.2599    5.3738    0.1349 H   0  0  0  0  0  0
   -2.9812    5.4579    1.7129 H   0  0  0  0  0  0
   -1.4079    3.4791    1.2578 H   0  0  0  0  0  0
   -2.9383    3.0632    1.9862 H   0  0  0  0  0  0
   -3.7891    2.0858   -1.8664 H   0  0  0  0  0  0
   -5.3454    3.9855   -1.6072 H   0  0  0  0  0  0
   -3.8210    4.7319   -2.0038 H   0  0  0  0  0  0
   -2.8464   -2.2096    0.3566 H   0  0  0  0  0  0
   -0.4370   -2.2633    0.1523 H   0  0  0  0  0  0
    1.5898   -0.0998    0.8559 H   0  0  0  0  0  0
    1.4730    2.1094   -0.3914 H   0  0  0  0  0  0
    2.9585    1.2452   -0.4428 H   0  0  0  0  0  0
    3.0195   -1.2903   -0.5345 H   0  0  0  0  0  0
    1.5901   -2.2379   -0.5109 H   0  0  0  0  0  0
    0.4001   -2.7024   -2.8602 H   0  0  0  0  0  0
    0.5929   -1.4788   -4.1045 H   0  0  0  0  0  0
   -0.2218   -1.1002   -2.5977 H   0  0  0  0  0  0
    2.9153   -3.2386   -2.6086 H   0  0  0  0  0  0
    4.0768   -1.9166   -2.5699 H   0  0  0  0  0  0
    3.1416   -2.2208   -4.0240 H   0  0  0  0  0  0
    0.2937    2.6585   -2.6527 H   0  0  0  0  0  0
   -0.2288    0.9970   -2.6775 H   0  0  0  0  0  0
    0.6247    1.6545   -4.0545 H   0  0  0  0  0  0
    2.8364    3.2694   -2.4115 H   0  0  0  0  0  0
    3.1158    2.3360   -3.8751 H   0  0  0  0  0  0
    4.0295    1.9746   -2.4211 H   0  0  0  0  0  0
   -4.7135    1.0464    0.4045 H   0  0  0  0  0  0
   -9.8325   -0.4871    0.4288 H   0  0  0  0  0  0
   -3.9695    6.8772   -0.8536 H   0  0  0  0  0  0
   -4.7569    7.0217    0.7118 H   0  0  0  0  0  0
   -5.6832    6.5178   -0.6925 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 35  1  0  0  0
  1 36  1  0  0  0
  1 37  1  0  0  0
  2  3  1  0  0  0
  2  7  1  0  0  0
  2 34  1  0  0  0
  3  4  1  0  0  0
  3 38  1  0  0  0
  3 39  1  0  0  0
  4  5  1  0  0  0
  4 40  1  0  0  0
  4 41  1  0  0  0
  5  6  2  0  0  0
  5  8  1  0  0  0
  6  7  1  0  0  0
  6 42  1  0  0  0
  7 43  1  0  0  0
  7 44  1  0  0  0
  8  9  1  0  0  0
  8 13  2  0  0  0
  9 10  2  0  0  0
  9 24  1  0  0  0
 10 11  1  0  0  0
 10 45  1  0  0  0
 11 12  2  0  0  0
 11 46  1  0  0  0
 12 13  1  0  0  0
 12 14  1  0  0  0
 14 15  1  0  0  0
 14 19  1  0  0  0
 14 47  1  0  0  0
 15 16  1  0  0  0
 15 48  1  0  0  0
 15 49  1  0  0  0
 16 17  1  0  0  0
 16 22  1  0  0  0
 16 23  1  0  0  0
 17 18  1  0  0  0
 18 19  1  0  0  0
 18 20  1  0  0  0
 18 21  1  0  0  0
 19 50  1  0  0  0
 19 51  1  0  0  0
 20 52  1  0  0  0
 20 53  1  0  0  0
 20 54  1  0  0  0
 21 55  1  0  0  0
 21 56  1  0  0  0
 21 57  1  0  0  0
 22 58  1  0  0  0
 22 59  1  0  0  0
 22 60  1  0  0  0
 23 61  1  0  0  0
 23 62  1  0  0  0
 23 63  1  0  0  0
 24 25  1  0  0  0
 24 64  1  0  0  0
 25 26  2  0  0  0
 25 27  1  0  0  0
 27 28  1  0  0  0
 27 31  2  0  0  0
 28 29  1  0  0  0
 29 30  2  0  0  0
 29 32  1  0  0  0
 30 31  1  0  0  0
 30 65  1  0  0  0
 32 33  3  0  0  0
 34 66  1  0  0  0
 34 67  1  0  0  0
 34 68  1  0  0  0
M  CHG  1  28  -1
M  END
> <s_m_entry_id>
305

> <Applicants>
Janssen

> <CHEMBL_ID>
CHEMBL3674570

> <Canonical_Smiles>
O1C(CC(CC1(C)C)c1nc(C=2CCC(CC=2)(C)C)c(NC(=O)c2[nH]c(cn2)C#N)cc1)(C)C

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
EDICOTINIB | JNJ-40346527

> <Indications>
nan

> <Type>
nan

> <targets_id>
nan

> <inchi>
InChI=1S/C27H35N5O2/c1-25(2)11-9-17(10-12-25)22-21(32-24(33)23-29-16-19(15-28)30-23)8-7-20(31-22)18-13-26(3,4)34-27(5,6)14-18/h7-9,16,18H,10-14H2,1-6H3,(H,29,30)(H,32,33)

> <stdInchikey>
BNVPFDRNGHMRJS-UHFFFAOYSA-N

> <csid>
34951020

> <Links>
|http://www.chemspider.com/Chemical-Structure.34951020.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3674570|http://pubchem.ncbi.nlm.nih.gov/compound/25230468|http://www.drugbank.ca/drugs/DB12504|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8942|http://zinc15.docking.org/substances/ZINC000043208574|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=3NU609VYNF|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=98634

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
461.3

> <HBA>
5

> <HBD>
2

> <NRB>
4

> <TPSA>
103.7

> <LogP>
6

> <RoF>
1

> <Targets>
nan

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_epik_Ionization_Penalty>
  0.1784

> <r_epik_State_Penalty>
  0.0968

> <i_epik_Tot_Q>
-1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
305

$$$$
Onvansertib
                    3D
 Structure written by MMmdl.
 66 70  0  0  1  0            999 V2000
   -4.8725    4.3852    3.4270 C   0  0  0  0  0  0
   -4.6860    3.9546    1.9595 N   0  3  0  0  0  0
   -5.1087    2.4771    1.7684 C   0  0  0  0  0  0
   -4.7351    2.0177    0.3404 C   0  0  0  0  0  0
   -3.2876    2.1809    0.1277 N   0  0  0  0  0  0
   -3.0309    3.6298    0.0869 C   0  0  0  0  0  0
   -3.2384    4.2399    1.4912 C   0  0  0  0  0  0
   -2.3279    1.2126    0.4520 C   0  0  0  0  0  0
   -2.6787   -0.1378    0.6100 C   0  0  0  0  0  0
   -1.7249   -1.1008    0.9278 C   0  0  0  0  0  0
   -0.3853   -0.7460    1.0799 C   0  0  0  0  0  0
    0.0017    0.5931    0.9301 C   0  0  0  0  0  0
   -0.9746    1.5524    0.6252 C   0  0  0  0  0  0
    1.3567    0.9256    1.1210 N   0  0  0  0  0  0
    2.1741    1.9403    0.6016 C   0  0  0  0  0  0
    1.6525    2.8993   -0.2081 N   0  0  0  0  0  0
    2.5132    3.8366   -0.6804 C   0  0  0  0  0  0
    3.8769    3.8468   -0.3711 C   0  0  0  0  0  0
    4.3183    2.8071    0.4652 C   0  0  0  0  0  0
    3.4809    1.8535    0.9504 N   0  0  0  0  0  0
    5.7700    2.7952    0.8032 C   0  0  0  0  0  0
    6.6070    3.8898    0.6155 C   0  0  0  0  0  0
    7.8845    3.4896    1.0738 C   0  0  0  0  0  0
    7.8407    2.2424    1.5076 N   0  0  0  0  0  0
    6.5820    1.8203    1.3363 N   0  0  0  0  0  0
    6.2561    0.4484    1.7312 C   0  0  0  0  0  0
    6.1623    0.2899    3.2626 C   0  0  0  0  0  0
    5.1574    1.1168    3.8146 O   0  0  0  0  0  0
    9.0684    4.3301    1.0986 C   0  0  0  0  0  0
    9.0388    5.5191    0.7861 O   0  0  0  0  0  0
   10.2032    3.7327    1.4839 N   0  0  0  0  0  0
    6.0475    5.1865    0.0299 C   0  0  0  0  0  0
    4.8575    4.8838   -0.9254 C   0  0  0  0  0  0
    0.5326   -1.7189    1.4069 O   0  0  0  0  0  0
    1.0770   -2.4508    0.3095 C   0  0  0  0  0  0
    2.0023   -3.2756    0.7965 F   0  0  0  0  0  0
    0.1453   -3.1907   -0.2943 F   0  0  0  0  0  0
    1.6743   -1.6513   -0.5769 F   0  0  0  0  0  0
   -4.2090    3.7787    4.0456 H   0  0  0  0  0  0
   -5.9209    4.2203    3.6790 H   0  0  0  0  0  0
   -4.6213    5.4452    3.4860 H   0  0  0  0  0  0
   -4.6005    1.8835    2.5312 H   0  0  0  0  0  0
   -6.1849    2.4387    1.9417 H   0  0  0  0  0  0
   -5.0677    0.9983    0.1563 H   0  0  0  0  0  0
   -5.2899    2.6128   -0.3876 H   0  0  0  0  0  0
   -2.0408    3.8540   -0.3073 H   0  0  0  0  0  0
   -3.7101    4.1110   -0.6196 H   0  0  0  0  0  0
   -3.1221    5.3244    1.4870 H   0  0  0  0  0  0
   -2.5574    3.8081    2.2275 H   0  0  0  0  0  0
   -3.6949   -0.4775    0.4896 H   0  0  0  0  0  0
   -2.0273   -2.1307    1.0504 H   0  0  0  0  0  0
   -0.6744    2.5832    0.5555 H   0  0  0  0  0  0
    1.8921    0.1902    1.5587 H   0  0  0  0  0  0
    2.0888    4.5903   -1.3276 H   0  0  0  0  0  0
    5.3342    0.1304    1.2474 H   0  0  0  0  0  0
    7.0325   -0.2095    1.3371 H   0  0  0  0  0  0
    5.9382   -0.7461    3.5185 H   0  0  0  0  0  0
    7.1152    0.5294    3.7361 H   0  0  0  0  0  0
    5.1384    0.9834    4.7651 H   0  0  0  0  0  0
   10.2041    2.7547    1.7341 H   0  0  0  0  0  0
   11.0636    4.2590    1.5255 H   0  0  0  0  0  0
    5.7184    5.8476    0.8324 H   0  0  0  0  0  0
    6.8078    5.7401   -0.5211 H   0  0  0  0  0  0
    5.2403    4.5259   -1.8824 H   0  0  0  0  0  0
    4.3336    5.8153   -1.1440 H   0  0  0  0  0  0
   -5.3010    4.5178    1.3887 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 39  1  0  0  0
  1 40  1  0  0  0
  1 41  1  0  0  0
  2  3  1  0  0  0
  2  7  1  0  0  0
  2 66  1  0  0  0
  3  4  1  0  0  0
  3 42  1  0  0  0
  3 43  1  0  0  0
  4  5  1  0  0  0
  4 44  1  0  0  0
  4 45  1  0  0  0
  5  6  1  0  0  0
  5  8  1  0  0  0
  6  7  1  0  0  0
  6 46  1  0  0  0
  6 47  1  0  0  0
  7 48  1  0  0  0
  7 49  1  0  0  0
  8  9  1  0  0  0
  8 13  2  0  0  0
  9 10  2  0  0  0
  9 50  1  0  0  0
 10 11  1  0  0  0
 10 51  1  0  0  0
 11 12  2  0  0  0
 11 34  1  0  0  0
 12 13  1  0  0  0
 12 14  1  0  0  0
 13 52  1  0  0  0
 14 15  1  0  0  0
 14 53  1  0  0  0
 15 16  1  0  0  0
 15 20  2  0  0  0
 16 17  2  0  0  0
 17 18  1  0  0  0
 17 54  1  0  0  0
 18 19  2  0  0  0
 18 33  1  0  0  0
 19 20  1  0  0  0
 19 21  1  0  0  0
 21 22  2  0  0  0
 21 25  1  0  0  0
 22 23  1  0  0  0
 22 32  1  0  0  0
 23 24  2  0  0  0
 23 29  1  0  0  0
 24 25  1  0  0  0
 25 26  1  0  0  0
 26 27  1  0  0  0
 26 55  1  0  0  0
 26 56  1  0  0  0
 27 28  1  0  0  0
 27 57  1  0  0  0
 27 58  1  0  0  0
 28 59  1  0  0  0
 29 30  2  0  0  0
 29 31  1  0  0  0
 31 60  1  0  0  0
 31 61  1  0  0  0
 32 33  1  0  0  0
 32 62  1  0  0  0
 32 63  1  0  0  0
 33 64  1  0  0  0
 33 65  1  0  0  0
 34 35  1  0  0  0
 35 36  1  0  0  0
 35 37  1  0  0  0
 35 38  1  0  0  0
M  CHG  1   2   1
M  END
> <s_m_entry_id>
308

> <Applicants>
Cardiff Oncology

> <CHEMBL_ID>
CHEMBL1738758

> <Canonical_Smiles>
FC(F)(F)Oc1ccc(N2CCN(CC2)C)cc1Nc1nc-2c(CCc3c-2n(nc3C(=O)N)CCO)cn1

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
NMS-1286937 | NMS-P937 | ONVANSERTIB | PCM-075

> <Indications>
nan

> <Type>
nan

> <targets_id>
nan

> <inchi>
InChI=1S/C24H27F3N8O3/c1-33-6-8-34(9-7-33)15-3-5-18(38-24(25,26)27)17(12-15)30-23-29-13-14-2-4-16-20(22(28)37)32-35(10-11-36)21(16)19(14)31-23/h3,5,12-13,36H,2,4,6-11H2,1H3,(H2,28,37)(H,29,30,31)

> <stdInchikey>
QHLVBNKYJGBCQJ-UHFFFAOYSA-N

> <csid>
26325993

> <Links>
|http://www.chemspider.com/Chemical-Structure.26325993.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1738758|http://pubchem.ncbi.nlm.nih.gov/compound/49792852|http://www.drugbank.ca/drugs/DB15110| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=937|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/937|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7918|http://zinc15.docking.org/substances/ZINC000043196885|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=67RM91WDHQ|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50343559

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
532.2

> <HBA>
10

> <HBD>
3

> <NRB>
7

> <TPSA>
134.7

> <LogP>
1.9

> <RoF>
1

> <Targets>
nan

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0424

> <r_epik_State_Penalty>
  0.0358

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
308

> <lig_pdbID>
'937'

> <pdbID>
2yac

$$$$
Serabelisib
                    3D
 Structure written by MMmdl.
 44 48  0  0  1  0            999 V2000
   -0.6778   -1.1530   -0.3986 C   0  0  0  0  0  0
   -2.0709   -1.2272   -0.4629 C   0  0  0  0  0  0
   -2.7652   -0.0433   -0.2100 C   0  0  0  0  0  0
   -2.1315    1.1692    0.0969 C   0  0  0  0  0  0
   -0.7310    1.2154    0.1587 C   0  0  0  0  0  0
    0.0020    0.0408   -0.0945 C   0  0  0  0  0  0
    1.4923    0.0617   -0.0412 C   0  0  0  0  0  0
    2.2170    1.1384   -0.5662 C   0  0  0  0  0  0
    3.6116    1.1805   -0.5288 C   0  0  0  0  0  0
    4.3120    0.1097    0.0513 C   0  0  0  0  0  0
    5.6462   -0.0810    0.2060 N   0  0  0  0  0  0
    5.7413   -1.2424    0.8142 C   0  0  0  0  0  0
    4.5115   -1.8586    1.0613 C   0  0  0  0  0  0
    3.5755   -0.9694    0.5750 N   0  0  0  0  0  0
    2.2025   -0.9974    0.5336 C   0  0  0  0  0  0
    4.2486   -3.1159    1.7127 C   0  0  0  0  0  0
    3.5861   -3.1132    2.7518 O   0  0  0  0  0  0
    4.7704   -4.2425    1.1498 N   0  0  0  0  0  0
    4.5416   -5.5602    1.7687 C   0  0  0  0  0  0
    3.5717   -6.3200    0.8362 C   0  0  0  0  0  0
    4.0888   -6.3879   -0.4920 O   0  0  0  0  0  0
    4.3710   -5.1143   -1.0699 C   0  0  0  0  0  0
    5.3680   -4.3173   -0.1986 C   0  0  0  0  0  0
   -3.0754    2.1403    0.2904 N   0  0  0  0  0  0
   -4.2088    1.5022    0.1005 C   0  0  0  0  0  0
   -4.1081    0.1755   -0.2072 O   0  0  0  0  0  0
   -5.4666    2.0198    0.1757 N   0  0  0  0  0  0
   -0.1134   -2.0524   -0.5986 H   0  0  0  0  0  0
   -2.5812   -2.1493   -0.6981 H   0  0  0  0  0  0
   -0.2285    2.1403    0.4018 H   0  0  0  0  0  0
    1.6929    1.9657   -1.0229 H   0  0  0  0  0  0
    4.1404    2.0267   -0.9423 H   0  0  0  0  0  0
    6.7071   -1.6494    1.0773 H   0  0  0  0  0  0
    1.7225   -1.8641    0.9646 H   0  0  0  0  0  0
    5.4922   -6.0912    1.8303 H   0  0  0  0  0  0
    4.1407   -5.4971    2.7815 H   0  0  0  0  0  0
    3.4187   -7.3346    1.2042 H   0  0  0  0  0  0
    2.5923   -5.8376    0.8203 H   0  0  0  0  0  0
    4.7844   -5.2663   -2.0670 H   0  0  0  0  0  0
    3.4389   -4.5596   -1.1961 H   0  0  0  0  0  0
    5.5712   -3.3492   -0.6527 H   0  0  0  0  0  0
    6.3176   -4.8500   -0.1356 H   0  0  0  0  0  0
   -5.6222    2.9905    0.4045 H   0  0  0  0  0  0
   -6.2827    1.4534   -0.0033 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1  6  2  0  0  0
  1 28  1  0  0  0
  2  3  2  0  0  0
  2 29  1  0  0  0
  3  4  1  0  0  0
  3 26  1  0  0  0
  4  5  2  0  0  0
  4 24  1  0  0  0
  5  6  1  0  0  0
  5 30  1  0  0  0
  6  7  1  0  0  0
  7  8  1  0  0  0
  7 15  2  0  0  0
  8  9  2  0  0  0
  8 31  1  0  0  0
  9 10  1  0  0  0
  9 32  1  0  0  0
 10 11  2  0  0  0
 10 14  1  0  0  0
 11 12  1  0  0  0
 12 13  2  0  0  0
 12 33  1  0  0  0
 13 14  1  0  0  0
 13 16  1  0  0  0
 14 15  1  0  0  0
 15 34  1  0  0  0
 16 17  2  0  0  0
 16 18  1  0  0  0
 18 19  1  0  0  0
 18 23  1  0  0  0
 19 20  1  0  0  0
 19 35  1  0  0  0
 19 36  1  0  0  0
 20 21  1  0  0  0
 20 37  1  0  0  0
 20 38  1  0  0  0
 21 22  1  0  0  0
 22 23  1  0  0  0
 22 39  1  0  0  0
 22 40  1  0  0  0
 23 41  1  0  0  0
 23 42  1  0  0  0
 24 25  2  0  0  0
 25 26  1  0  0  0
 25 27  1  0  0  0
 27 43  1  0  0  0
 27 44  1  0  0  0
M  END
> <s_m_entry_id>
310

> <Applicants>
Takeda

> <CHEMBL_ID>
CHEMBL3935857

> <Canonical_Smiles>
o1c2c(nc1N)cc(cc2)C=1C=Cc2n(C=1)c(cn2)C(=O)N1CCOCC1

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
AGN-PC-0DB6FL | INK1117 | MLN-1117 | MLN1117 | SERABELISIB | TAK-117

> <Indications>
nan

> <Type>
nan

> <targets_id>
nan

> <inchi>
InChI=1S/C19H17N5O3/c20-19-22-14-9-12(1-3-16(14)27-19)13-2-4-17-21-10-15(24(17)11-13)18(25)23-5-7-26-8-6-23/h1-4,9-11H,5-8H2,(H2,20,22)

> <stdInchikey>
BLGWHBSBBJNKJO-UHFFFAOYSA-N

> <csid>
35143228

> <Links>
|http://www.chemspider.com/Chemical-Structure.35143228.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3935857|http://pubchem.ncbi.nlm.nih.gov/compound/70798655|http://www.drugbank.ca/drugs/DB14935|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8969|http://zinc15.docking.org/substances/ZINC000146965425|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=43J9Q56T3W|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=119531

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
363.1

> <HBA>
7

> <HBD>
1

> <NRB>
2

> <TPSA>
98.9

> <LogP>
2.2

> <RoF>
0

> <Targets>
nan

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_epik_Ionization_Penalty>
  0.0047

> <r_epik_State_Penalty>
  0.0034

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
310

$$$$
Acalisib
                    3D
 Structure written by MMmdl.
 46 50  0  0  1  0            999 V2000
   -0.5820   -1.0737   -1.0504 C   0  0  0  0  0  0
   -0.0919   -0.1501    0.0864 C   0  0  1  0  0  0
    1.4506   -0.0184    0.1450 C   0  0  0  0  0  0
    2.0951    0.1331   -0.9628 N   0  0  0  0  0  0
    3.4922    0.2197   -0.9706 C   0  0  0  0  0  0
    4.1457    0.3746   -2.1951 C   0  0  0  0  0  0
    5.5392    0.4587   -2.2308 C   0  0  0  0  0  0
    6.2793    0.3900   -1.0481 C   0  0  0  0  0  0
    5.6306    0.2358    0.1789 C   0  0  0  0  0  0
    4.2338    0.1502    0.2151 C   0  0  0  0  0  0
    3.4954   -0.0110    1.5318 C   0  0  0  0  0  0
    4.0814   -0.0685    2.6193 O   0  0  0  0  0  0
    2.1166   -0.0726    1.3775 N   0  0  0  0  0  0
    1.3757   -0.1373    2.5820 C   0  0  0  0  0  0
    0.8335    1.0334    3.1279 C   0  0  0  0  0  0
    0.0775    0.9658    4.2946 C   0  0  0  0  0  0
   -0.1308   -0.2659    4.9120 C   0  0  0  0  0  0
    0.4092   -1.4335    4.3756 C   0  0  0  0  0  0
    1.1641   -1.3725    3.2074 C   0  0  0  0  0  0
    7.6282    0.4740   -1.0915 F   0  0  0  0  0  0
   -0.6001    1.2143   -0.0620 N   0  0  0  0  0  0
   -1.7867    1.6561    0.5487 C   0  0  0  0  0  0
   -2.2246    2.9801    0.3524 C   0  0  0  0  0  0
   -3.4171    3.3512    1.0217 C   0  0  0  0  0  0
   -3.6162    4.6641    0.6712 N   0  0  0  0  0  0
   -2.5727    5.0046   -0.1593 C   0  0  0  0  0  0
   -1.7205    4.0312   -0.3744 N   0  0  0  0  0  0
   -4.1528    2.5640    1.8125 N   0  0  0  0  0  0
   -3.6348    1.3107    1.9274 C   0  0  0  0  0  0
   -2.5081    0.8168    1.3482 N   0  0  0  0  0  0
   -0.1661   -2.0773   -0.9524 H   0  0  0  0  0  0
   -0.3115   -0.6951   -2.0375 H   0  0  0  0  0  0
   -1.6679   -1.1715   -1.0282 H   0  0  0  0  0  0
   -0.4676   -0.5877    1.0099 H   0  0  0  0  0  0
    3.5827    0.4292   -3.1158 H   0  0  0  0  0  0
    6.0461    0.5782   -3.1771 H   0  0  0  0  0  0
    6.2164    0.1861    1.0861 H   0  0  0  0  0  0
    0.9889    1.9876    2.6450 H   0  0  0  0  0  0
   -0.3475    1.8641    4.7173 H   0  0  0  0  0  0
   -0.7186   -0.3164    5.8167 H   0  0  0  0  0  0
    0.2402   -2.3825    4.8626 H   0  0  0  0  0  0
    1.5773   -2.2784    2.7875 H   0  0  0  0  0  0
   -0.1204    1.8339   -0.6992 H   0  0  0  0  0  0
   -2.5172    6.0039   -0.5664 H   0  0  0  0  0  0
   -4.3579    5.2939    0.9394 H   0  0  0  0  0  0
   -4.1838    0.6250    2.5561 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 31  1  0  0  0
  1 32  1  0  0  0
  1 33  1  0  0  0
  2  3  1  0  0  0
  2 34  1  0  0  0
  2 21  1  0  0  0
  3  4  2  0  0  0
  3 13  1  0  0  0
  4  5  1  0  0  0
  5  6  1  0  0  0
  5 10  2  0  0  0
  6  7  2  0  0  0
  6 35  1  0  0  0
  7  8  1  0  0  0
  7 36  1  0  0  0
  8  9  2  0  0  0
  8 20  1  0  0  0
  9 10  1  0  0  0
  9 37  1  0  0  0
 10 11  1  0  0  0
 11 12  2  0  0  0
 11 13  1  0  0  0
 13 14  1  0  0  0
 14 15  1  0  0  0
 14 19  2  0  0  0
 15 16  2  0  0  0
 15 38  1  0  0  0
 16 17  1  0  0  0
 16 39  1  0  0  0
 17 18  2  0  0  0
 17 40  1  0  0  0
 18 19  1  0  0  0
 18 41  1  0  0  0
 19 42  1  0  0  0
 21 22  1  0  0  0
 21 43  1  0  0  0
 22 30  1  0  0  0
 22 23  2  0  0  0
 23 27  1  0  0  0
 23 24  1  0  0  0
 24 25  1  0  0  0
 24 28  2  0  0  0
 25 26  1  0  0  0
 25 45  1  0  0  0
 26 27  2  0  0  0
 26 44  1  0  0  0
 28 29  1  0  0  0
 29 46  1  0  0  0
 29 30  2  0  0  0
M  END
> <s_m_entry_id>
311

> <Applicants>
Gilead Sciences

> <CHEMBL_ID>
CHEMBL3545397

> <Canonical_Smiles>
Fc1cc2c(N=C(N(C2=O)c2ccccc2)[C@@H](Nc2ncnc3nc[nH]c23)C)cc1

> <Chirality>
Single Stereoisomer

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
|CAL-120|GS9820|CAL120|GS-9820

> <Indications>
nan

> <Type>
nan

> <targets_id>
P42336

> <inchi>
InChI=1S/C21H16FN7O/c1-12(27-19-17-18(24-10-23-17)25-11-26-19)20-28-16-8-7-13(22)9-15(16)21(30)29(20)14-5-3-2-4-6-14/h2-12H,1H3,(H2,23,24,25,26,27)/t12-/m0/s1

> <stdInchikey>
DOCINCLJNAXZQF-LBPRGKRZSA-N

> <csid>
9793017

> <Links>
|http://www.chemspider.com/Chemical-Structure.9793017.html|http://pubchem.ncbi.nlm.nih.gov/compound/11618268|http://www.drugbank.ca/drugs/DB15407|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10096|http://zinc15.docking.org/substances/ZINC000035943170|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=OVW60IDW1D|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=217352

> <LinkName>
|ChemSpider|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
401.1

> <HBA>
7

> <HBD>
2

> <NRB>
4

> <TPSA>
101.4

> <LogP>
3.4

> <RoF>
0

> <Targets>
PIK3CA

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
0.955582

> <r_epik_Ionization_Penalty>
  0.0023

> <r_epik_State_Penalty>
  0.0207

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
311

> <Kinase families>
Atypical

$$$$
Sapitinib
                    3D
 Structure written by MMmdl.
 59 62  0  0  1  0            999 V2000
    1.6004    7.4069    1.5644 C   0  0  0  0  0  0
    0.6214    6.6258    0.8169 N   0  0  0  0  0  0
   -0.6756    6.5082    1.1548 C   0  0  0  0  0  0
   -1.1719    7.0716    2.1291 O   0  0  0  0  0  0
   -1.5713    5.6365    0.2606 C   0  0  0  0  0  0
   -0.9555    4.2729    0.1457 N   0  3  2  0  0  0
   -1.1437    3.6131   -1.2410 C   0  0  0  0  0  0
   -0.2774    2.3456   -1.3401 C   0  0  0  0  0  0
   -0.4811    1.3763   -0.1515 C   0  0  2  0  0  0
   -0.4700    2.0562    1.2371 C   0  0  0  0  0  0
   -1.3586    3.3077    1.2867 C   0  0  0  0  0  0
    0.2944    0.1726   -0.2284 O   0  0  0  0  0  0
    1.6738    0.1317   -0.0746 C   0  0  0  0  0  0
    2.4837    1.2651    0.0850 C   0  0  0  0  0  0
    3.8894    1.1528    0.2242 C   0  0  0  0  0  0
    4.4799   -0.1439    0.2089 C   0  0  0  0  0  0
    3.6522   -1.2767    0.0514 C   0  0  0  0  0  0
    2.2620   -1.1407   -0.0921 C   0  0  0  0  0  0
    1.4077   -2.2182   -0.2537 O   0  0  0  0  0  0
    1.9363   -3.5401   -0.2807 C   0  0  0  0  0  0
    5.8254   -0.3201    0.3388 N   0  0  0  0  0  0
    6.5747    0.7999    0.4778 C   0  0  0  0  0  0
    6.1269    2.0760    0.5007 N   0  0  0  0  0  0
    4.7869    2.2536    0.3787 C   0  0  0  0  0  0
    4.2849    3.5693    0.3741 N   0  0  0  0  0  0
    4.9025    4.8240    0.5192 C   0  0  0  0  0  0
    6.0112    5.0179    1.3543 C   0  0  0  0  0  0
    6.6023    6.2761    1.4636 C   0  0  0  0  0  0
    6.0934    7.3518    0.7388 C   0  0  0  0  0  0
    4.9910    7.1718   -0.0965 C   0  0  0  0  0  0
    4.3961    5.9109   -0.2080 C   0  0  0  0  0  0
    3.3219    5.7476   -1.0199 F   0  0  0  0  0  0
    4.3683    8.5159   -0.9856 Cl  0  0  0  0  0  0
    1.9899    8.2075    0.9358 H   0  0  0  0  0  0
    2.4357    6.7698    1.8548 H   0  0  0  0  0  0
    1.1966    7.8591    2.4713 H   0  0  0  0  0  0
    0.9607    6.1601   -0.0125 H   0  0  0  0  0  0
   -2.5783    5.5105    0.6636 H   0  0  0  0  0  0
   -1.6471    6.0696   -0.7379 H   0  0  0  0  0  0
   -2.2097    3.4019   -1.3428 H   0  0  0  0  0  0
   -0.8407    4.3443   -1.9919 H   0  0  0  0  0  0
   -0.5239    1.8233   -2.2655 H   0  0  0  0  0  0
    0.7591    2.6487   -1.4588 H   0  0  0  0  0  0
   -1.4894    0.9759   -0.2717 H   0  0  0  0  0  0
   -0.8205    1.3432    1.9844 H   0  0  0  0  0  0
    0.5310    2.3343    1.5565 H   0  0  0  0  0  0
   -1.2236    3.8435    2.2274 H   0  0  0  0  0  0
   -2.4159    3.0759    1.1462 H   0  0  0  0  0  0
    2.0662    2.2556    0.1070 H   0  0  0  0  0  0
    4.1245   -2.2480    0.0421 H   0  0  0  0  0  0
    1.1202   -4.2502   -0.4129 H   0  0  0  0  0  0
    2.4406   -3.7892    0.6543 H   0  0  0  0  0  0
    2.6291   -3.6774   -1.1121 H   0  0  0  0  0  0
    7.6413    0.6597    0.5773 H   0  0  0  0  0  0
    3.2961    3.6231    0.1813 H   0  0  0  0  0  0
    6.4159    4.2046    1.9380 H   0  0  0  0  0  0
    7.4540    6.4171    2.1127 H   0  0  0  0  0  0
    6.5553    8.3244    0.8279 H   0  0  0  0  0  0
    0.0238    4.4983    0.2500 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 34  1  0  0  0
  1 35  1  0  0  0
  1 36  1  0  0  0
  2  3  1  0  0  0
  2 37  1  0  0  0
  3  4  2  0  0  0
  3  5  1  0  0  0
  5  6  1  0  0  0
  5 38  1  0  0  0
  5 39  1  0  0  0
  6  7  1  0  0  0
  6 11  1  0  0  0
  6 59  1  0  0  0
  7  8  1  0  0  0
  7 40  1  0  0  0
  7 41  1  0  0  0
  8  9  1  0  0  0
  8 42  1  0  0  0
  8 43  1  0  0  0
  9 10  1  0  0  0
  9 12  1  0  0  0
  9 44  1  0  0  0
 10 11  1  0  0  0
 10 45  1  0  0  0
 10 46  1  0  0  0
 11 47  1  0  0  0
 11 48  1  0  0  0
 12 13  1  0  0  0
 13 14  1  0  0  0
 13 18  2  0  0  0
 14 15  2  0  0  0
 14 49  1  0  0  0
 15 16  1  0  0  0
 15 24  1  0  0  0
 16 17  2  0  0  0
 16 21  1  0  0  0
 17 18  1  0  0  0
 17 50  1  0  0  0
 18 19  1  0  0  0
 19 20  1  0  0  0
 20 51  1  0  0  0
 20 52  1  0  0  0
 20 53  1  0  0  0
 21 22  2  0  0  0
 22 23  1  0  0  0
 22 54  1  0  0  0
 23 24  2  0  0  0
 24 25  1  0  0  0
 25 26  1  0  0  0
 25 55  1  0  0  0
 26 27  1  0  0  0
 26 31  2  0  0  0
 27 28  2  0  0  0
 27 56  1  0  0  0
 28 29  1  0  0  0
 28 57  1  0  0  0
 29 30  2  0  0  0
 29 58  1  0  0  0
 30 31  1  0  0  0
 30 33  1  0  0  0
 31 32  1  0  0  0
M  CHG  1   6   1
M  END
> <s_m_entry_id>
313

> <Applicants>
Astrazeneca

> <CHEMBL_ID>
CHEMBL2408045

> <Canonical_Smiles>
Clc1cccc(Nc2ncnc3c2cc(OC2CCN(CC2)CC(=O)NC)c(OC)c3)c1F

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
AZD-8931 | AZD8931 | SAPITINIB

> <Indications>
nan

> <Type>
nan

> <targets_id>
P00533|P04626|Q15303|P21860

> <inchi>
InChI=1S/C23H25ClFN5O3/c1-26-21(31)12-30-8-6-14(7-9-30)33-20-10-15-18(11-19(20)32-2)27-13-28-23(15)29-17-5-3-4-16(24)22(17)25/h3-5,10-11,13-14H,6-9,12H2,1-2H3,(H,26,31)(H,27,28,29)

> <stdInchikey>
DFJSJLGUIXFDJP-UHFFFAOYSA-N

> <csid>
9663133

> <Links>
|http://www.chemspider.com/Chemical-Structure.9663133.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2408045|http://pubchem.ncbi.nlm.nih.gov/compound/11488320|http://www.drugbank.ca/drugs/DB12183|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7717|http://zinc15.docking.org/substances/ZINC000034587071|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=3499328002|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50437353

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
473.2

> <HBA>
7

> <HBD>
2

> <NRB>
7

> <TPSA>
88.6

> <LogP>
3.8

> <RoF>
0

> <Targets>
EGFR; ERBB2; ERBB4; ERBB3

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
0.999978

> <r_epik_Ionization_Penalty>
  0.1790

> <r_epik_State_Penalty>
  0.1672

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
313

> <Kinase families>
Tyr

$$$$
Voruciclib
                    3D
 Structure written by MMmdl.
 52 55  0  0  1  0            999 V2000
   -3.1911   -0.3567   -0.5191 C   0  0  0  0  0  0
   -2.0072   -1.3407   -0.6329 N   0  3  2  0  0  0
   -1.5860   -1.9054    0.7347 C   0  0  0  0  0  0
   -0.5960   -0.8795    1.2889 C   0  0  0  0  0  0
   -0.0134   -0.1277    0.0751 C   0  0  2  0  0  0
   -0.7036   -0.7184   -1.1834 C   0  0  2  0  0  0
   -0.8282    0.2392   -2.3909 C   0  0  0  0  0  0
    0.4405    0.5716   -2.9159 O   0  0  0  0  0  0
    1.5275   -0.0635    0.0218 C   0  0  0  0  0  0
    2.2029    1.1672    0.0100 C   0  0  0  0  0  0
    3.5933    1.2053   -0.0371 C   0  0  0  0  0  0
    4.3432    0.0314   -0.0765 C   0  0  0  0  0  0
    3.7032   -1.2251   -0.0720 C   0  0  0  0  0  0
    2.2907   -1.2433   -0.0230 C   0  0  0  0  0  0
    1.5837   -2.4321   -0.0153 O   0  0  0  0  0  0
    2.2562   -3.6067   -0.0664 C   0  0  0  0  0  0
    3.5989   -3.7127   -0.1048 C   0  0  0  0  0  0
    4.4609   -2.5356   -0.1161 C   0  0  0  0  0  0
    5.6881   -2.6134   -0.1586 O   0  0  0  0  0  0
    1.3174   -4.7394   -0.0318 C   0  0  0  0  0  0
    0.4957   -4.9635   -1.1410 C   0  0  0  0  0  0
   -0.4282   -6.0068   -1.1431 C   0  0  0  0  0  0
   -0.5560   -6.8427   -0.0294 C   0  0  0  0  0  0
    0.2590   -6.6151    1.0859 C   0  0  0  0  0  0
    1.1846   -5.5696    1.0934 C   0  0  0  0  0  0
    2.1374   -5.3223    2.5176 Cl  0  0  0  0  0  0
   -1.5633   -7.9910   -0.0495 C   0  0  0  0  0  0
   -1.3060   -8.9018    0.8909 F   0  0  0  0  0  0
   -2.7846   -7.5005    0.1604 F   0  0  0  0  0  0
   -1.5480   -8.6064   -1.2330 F   0  0  0  0  0  0
    5.7089    0.1686   -0.1193 O   0  0  0  0  0  0
    1.5306    2.3626    0.0406 O   0  0  0  0  0  0
   -2.8792    0.4888    0.0953 H   0  0  0  0  0  0
   -4.0168   -0.9030   -0.0615 H   0  0  0  0  0  0
   -3.4513   -0.0466   -1.5313 H   0  0  0  0  0  0
   -2.4656   -2.0839    1.3549 H   0  0  0  0  0  0
   -1.1030   -2.8562    0.5041 H   0  0  0  0  0  0
   -1.1046   -0.1913    1.9660 H   0  0  0  0  0  0
    0.1709   -1.3823    1.8796 H   0  0  0  0  0  0
   -0.3928    0.8898    0.1724 H   0  0  0  0  0  0
   -0.1777   -1.6130   -1.5211 H   0  0  0  0  0  0
   -1.4150   -0.2253   -3.1839 H   0  0  0  0  0  0
   -1.3424    1.1591   -2.1109 H   0  0  0  0  0  0
    0.3203    1.1637   -3.6626 H   0  0  0  0  0  0
    4.0987    2.1609   -0.0433 H   0  0  0  0  0  0
    4.0420   -4.6981   -0.1278 H   0  0  0  0  0  0
    0.5728   -4.3266   -2.0108 H   0  0  0  0  0  0
   -1.0481   -6.1619   -2.0145 H   0  0  0  0  0  0
    0.1723   -7.2457    1.9592 H   0  0  0  0  0  0
    5.9944    1.0847   -0.1145 H   0  0  0  0  0  0
    2.1192    3.1207    0.0239 H   0  0  0  0  0  0
   -2.2854   -2.1042   -1.2334 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 33  1  0  0  0
  1 34  1  0  0  0
  1 35  1  0  0  0
  2  3  1  0  0  0
  2  6  1  0  0  0
  2 52  1  0  0  0
  3  4  1  0  0  0
  3 36  1  0  0  0
  3 37  1  0  0  0
  4  5  1  0  0  0
  4 38  1  0  0  0
  4 39  1  0  0  0
  5  6  1  0  0  0
  5  9  1  0  0  0
  5 40  1  0  0  0
  6  7  1  0  0  0
  6 41  1  0  0  0
  7  8  1  0  0  0
  7 42  1  0  0  0
  7 43  1  0  0  0
  8 44  1  0  0  0
  9 10  1  0  0  0
  9 14  2  0  0  0
 10 11  2  0  0  0
 10 32  1  0  0  0
 11 12  1  0  0  0
 11 45  1  0  0  0
 12 13  2  0  0  0
 12 31  1  0  0  0
 13 14  1  0  0  0
 13 18  1  0  0  0
 14 15  1  0  0  0
 15 16  1  0  0  0
 16 17  2  0  0  0
 16 20  1  0  0  0
 17 18  1  0  0  0
 17 46  1  0  0  0
 18 19  2  0  0  0
 20 21  1  0  0  0
 20 25  2  0  0  0
 21 22  2  0  0  0
 21 47  1  0  0  0
 22 23  1  0  0  0
 22 48  1  0  0  0
 23 24  2  0  0  0
 23 27  1  0  0  0
 24 25  1  0  0  0
 24 49  1  0  0  0
 25 26  1  0  0  0
 27 28  1  0  0  0
 27 29  1  0  0  0
 27 30  1  0  0  0
 31 50  1  0  0  0
 32 51  1  0  0  0
M  CHG  1   2   1
M  END
> <s_m_entry_id>
319

> <Applicants>
Piramal Enterprises

> <CHEMBL_ID>
CHEMBL3545218

> <Canonical_Smiles>
Clc1cc(ccc1C=1Oc2c(C(=O)C=1)c(O)cc(O)c2[C@@H]1CCN(C)[C@H]1CO)C(F)(F)F

> <Chirality>
Single Stereoisomer

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Indications>
nan

> <Type>
nan

> <targets_id>
P11802

> <inchi>
InChI=1S/C22H19ClF3NO5/c1-27-5-4-12(14(27)9-28)19-15(29)7-16(30)20-17(31)8-18(32-21(19)20)11-3-2-10(6-13(11)23)22(24,25)26/h2-3,6-8,12,14,28-30H,4-5,9H2,1H3/t12-,14+/m1/s1

> <stdInchikey>
MRPGRAKIAJJGMM-OCCSQVGLSA-N

> <csid>
29165867

> <Links>
|http://www.chemspider.com/Chemical-Structure.29165867.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3905910|http://pubchem.ncbi.nlm.nih.gov/compound/67409219|http://www.drugbank.ca/drugs/DB15157|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9923|http://zinc15.docking.org/substances/ZINC000118905502|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=W66XP666AM|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50193104

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
469.1

> <HBA>
6

> <HBD>
3

> <NRB>
3

> <TPSA>
94.1

> <LogP>
4.3

> <RoF>
0

> <Targets>
CDK4

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_epik_Ionization_Penalty>
  0.1912

> <r_epik_State_Penalty>
  0.1679

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
319

> <Kinase families>
CMGC

$$$$
Decernotinib
                    3D
 Structure written by MMmdl.
 47 49  0  0  1  0            999 V2000
   -0.4167    0.1429    2.7817 C   0  0  0  0  0  0
   -0.7974   -0.5660    1.4632 C   0  0  0  0  0  0
   -0.0913   -0.0691    0.1617 C   0  0  2  0  0  0
   -0.6864   -0.8891   -1.0246 C   0  0  0  0  0  0
    1.4547   -0.2945    0.2975 C   0  0  0  0  0  0
    2.1943    0.6107    0.6956 O   0  0  0  0  0  0
    1.9339   -1.5146   -0.0177 N   0  0  0  0  0  0
    3.3455   -1.9062    0.0003 C   0  0  0  0  0  0
    4.1163   -1.5359   -1.2838 C   0  0  0  0  0  0
    5.3779   -1.9591   -1.2142 F   0  0  0  0  0  0
    3.5638   -2.0962   -2.3606 F   0  0  0  0  0  0
    4.1466   -0.2190   -1.4899 F   0  0  0  0  0  0
   -0.3814    1.3709   -0.0083 N   0  0  0  0  0  0
    0.0301    2.1891   -1.0792 C   0  0  0  0  0  0
   -0.3039    3.5466   -1.0348 C   0  0  0  0  0  0
    0.1121    4.3450   -2.1023 C   0  0  0  0  0  0
    0.8141    3.8500   -3.1539 N   0  0  0  0  0  0
    1.0980    2.5216   -3.1161 C   0  0  0  0  0  0
    0.7339    1.6687   -2.1223 N   0  0  0  0  0  0
    1.8750    1.9363   -4.2546 C   0  0  0  0  0  0
    2.3179    0.6220   -4.3585 C   0  0  0  0  0  0
    3.0014    0.4275   -5.5311 N   0  0  0  0  0  0
    3.0238    1.6051   -6.2380 C   0  0  0  0  0  0
    2.3241    2.5832   -5.4687 C   0  0  0  0  0  0
    2.2308    3.8736   -6.0272 C   0  0  0  0  0  0
    2.8181    4.1023   -7.2731 C   0  0  0  0  0  0
    3.4756    3.0577   -7.9233 C   0  0  0  0  0  0
    3.5961    1.7970   -7.4308 N   0  0  0  0  0  0
   -0.9914   -0.2620    3.6151 H   0  0  0  0  0  0
   -0.6185    1.2133    2.7370 H   0  0  0  0  0  0
    0.6382    0.0109    3.0226 H   0  0  0  0  0  0
   -0.6233   -1.6361    1.5929 H   0  0  0  0  0  0
   -1.8779   -0.4704    1.3385 H   0  0  0  0  0  0
   -0.6732   -1.9616   -0.8248 H   0  0  0  0  0  0
   -0.1455   -0.7444   -1.9597 H   0  0  0  0  0  0
   -1.7269   -0.6186   -1.2108 H   0  0  0  0  0  0
    1.2793   -2.2220   -0.3183 H   0  0  0  0  0  0
    3.8474   -1.4800    0.8716 H   0  0  0  0  0  0
    3.3810   -2.9877    0.1349 H   0  0  0  0  0  0
   -0.7343    1.8474    0.8084 H   0  0  0  0  0  0
   -0.8608    3.9689   -0.2112 H   0  0  0  0  0  0
   -0.1156    5.4006   -2.1253 H   0  0  0  0  0  0
    2.2001   -0.2061   -3.6749 H   0  0  0  0  0  0
    3.4060   -0.4596   -5.7925 H   0  0  0  0  0  0
    1.7183    4.6739   -5.5152 H   0  0  0  0  0  0
    2.7634    5.0792   -7.7301 H   0  0  0  0  0  0
    3.9317    3.2286   -8.8874 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 29  1  0  0  0
  1 30  1  0  0  0
  1 31  1  0  0  0
  2  3  1  0  0  0
  2 32  1  0  0  0
  2 33  1  0  0  0
  3  4  1  0  0  0
  3  5  1  0  0  0
  3 13  1  0  0  0
  4 34  1  0  0  0
  4 35  1  0  0  0
  4 36  1  0  0  0
  5  6  2  0  0  0
  5  7  1  0  0  0
  7  8  1  0  0  0
  7 37  1  0  0  0
  8  9  1  0  0  0
  8 38  1  0  0  0
  8 39  1  0  0  0
  9 10  1  0  0  0
  9 11  1  0  0  0
  9 12  1  0  0  0
 13 14  1  0  0  0
 13 40  1  0  0  0
 14 15  1  0  0  0
 14 19  2  0  0  0
 15 16  2  0  0  0
 15 41  1  0  0  0
 16 17  1  0  0  0
 16 42  1  0  0  0
 17 18  2  0  0  0
 18 19  1  0  0  0
 18 20  1  0  0  0
 20 21  2  0  0  0
 20 24  1  0  0  0
 21 22  1  0  0  0
 21 43  1  0  0  0
 22 23  1  0  0  0
 22 44  1  0  0  0
 23 24  1  0  0  0
 23 28  2  0  0  0
 24 25  2  0  0  0
 25 26  1  0  0  0
 25 45  1  0  0  0
 26 27  2  0  0  0
 26 46  1  0  0  0
 27 28  1  0  0  0
 27 47  1  0  0  0
M  END
> <s_m_entry_id>
333

> <Applicants>
Vertex Pharmaceuticals

> <CHEMBL_ID>
CHEMBL3039513

> <Canonical_Smiles>
FC(F)(F)CNC(=O)[C@](Nc1nc(ncc1)-c1c2cccnc2[nH]c1)(CC)C

> <Chirality>
Single Stereoisomer

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
ADELATINIB | DECERNOTINIB | VRT-831509 | VX-509

> <Indications>
nan

> <Type>
1

> <targets_id>
P52333

> <inchi>
InChI=1S/C18H19F3N6O/c1-3-17(2,16(28)25-10-18(19,20)21)27-13-6-8-23-15(26-13)12-9-24-14-11(12)5-4-7-22-14/h4-9H,3,10H2,1-2H3,(H,22,24)(H,25,28)(H,23,26,27)/t17-/m1/s1

> <stdInchikey>
ASUGUQWIHMTFJL-QGZVFWFLSA-N

> <csid>
30843790

> <Links>
|http://www.chemspider.com/Chemical-Structure.30843790.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3039513|http://pubchem.ncbi.nlm.nih.gov/compound/59422203|http://www.drugbank.ca/drugs/DB12566| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=VJK|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/VJK|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8309|http://zinc15.docking.org/substances/ZINC000096941867|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=MZK2GP0RHK|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50021655

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
392.2

> <HBA>
5

> <HBD>
3

> <NRB>
6

> <TPSA>
95.6

> <LogP>
3.3

> <RoF>
0

> <Targets>
JAK3

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
0.999998

> <r_epik_Ionization_Penalty>
  0.0209

> <r_epik_State_Penalty>
  0.0159

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
333

> <lig_pdbID>
'VJK'

> <pdbID>
4yti

> <Kinase families>
Tyr

$$$$
Ilginatinib
                    3D
 Structure written by MMmdl.
 49 52  0  0  1  0            999 V2000
   -2.1423    1.0337    0.9569 C   0  0  0  0  0  0
   -0.7516    1.2471    0.3367 C   0  0  2  0  0  0
   -0.8644    1.6953   -1.1255 C   0  0  0  0  0  0
   -0.6717    3.0429   -1.4444 C   0  0  0  0  0  0
   -0.7707    3.4698   -2.7659 C   0  0  0  0  0  0
   -1.0685    2.5503   -3.7692 C   0  0  0  0  0  0
   -1.2708    1.2070   -3.4610 C   0  0  0  0  0  0
   -1.1718    0.7795   -2.1400 C   0  0  0  0  0  0
   -1.1644    2.9656   -5.0524 F   0  0  0  0  0  0
    0.0856    0.0525    0.4799 N   0  0  0  0  0  0
    1.4472    0.0243    0.1314 C   0  0  0  0  0  0
    2.1060   -1.2060    0.1353 C   0  0  0  0  0  0
    3.4607   -1.2580   -0.2092 C   0  0  0  0  0  0
    4.1164   -0.0686   -0.5477 C   0  0  0  0  0  0
    3.4008    1.1370   -0.5371 C   0  0  0  0  0  0
    2.0896    1.1782   -0.1943 N   0  0  0  0  0  0
    3.9523    2.3892   -0.8533 N   0  0  0  0  0  0
    5.1891    2.8156   -1.3649 C   0  0  0  0  0  0
    5.4283    4.1921   -1.4665 C   0  0  0  0  0  0
    6.5943    4.6869   -1.9612 N   0  0  0  0  0  0
    7.5287    3.7857   -2.3614 C   0  0  0  0  0  0
    7.3000    2.4115   -2.2687 C   0  0  0  0  0  0
    6.1329    1.9222   -1.7734 N   0  0  0  0  0  0
    4.1914   -2.5567   -0.2140 C   0  0  0  0  0  0
    3.6774   -3.8495   -0.4187 C   0  0  0  0  0  0
    4.5899   -4.7930   -0.3586 N   0  0  0  0  0  0
    5.7299   -4.1377   -0.1157 N   0  0  0  0  0  0
    5.5467   -2.7835   -0.0176 C   0  0  0  0  0  0
    6.9665   -4.8858    0.0203 C   0  0  0  0  0  0
   -2.7416    1.9429    0.8987 H   0  0  0  0  0  0
   -2.0673    0.7620    2.0104 H   0  0  0  0  0  0
   -2.6940    0.2417    0.4485 H   0  0  0  0  0  0
   -0.2590    2.0406    0.9020 H   0  0  0  0  0  0
   -0.4387    3.7598   -0.6706 H   0  0  0  0  0  0
   -0.6166    4.5100   -3.0119 H   0  0  0  0  0  0
   -1.5031    0.4992   -4.2430 H   0  0  0  0  0  0
   -1.3304   -0.2632   -1.9063 H   0  0  0  0  0  0
   -0.3676   -0.8136    0.7314 H   0  0  0  0  0  0
    1.5740   -2.1081    0.4024 H   0  0  0  0  0  0
    5.1619   -0.1064   -0.8035 H   0  0  0  0  0  0
    3.3171    3.1493   -0.6614 H   0  0  0  0  0  0
    4.6916    4.9179   -1.1539 H   0  0  0  0  0  0
    8.4559    4.1754   -2.7548 H   0  0  0  0  0  0
    8.0421    1.6948   -2.5879 H   0  0  0  0  0  0
    2.6422   -4.0916   -0.6107 H   0  0  0  0  0  0
    6.3754   -2.1193    0.1795 H   0  0  0  0  0  0
    7.8030   -4.2006    0.1632 H   0  0  0  0  0  0
    7.1382   -5.4754   -0.8811 H   0  0  0  0  0  0
    6.8963   -5.5493    0.8830 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 30  1  0  0  0
  1 31  1  0  0  0
  1 32  1  0  0  0
  2  3  1  0  0  0
  2 10  1  0  0  0
  2 33  1  0  0  0
  3  4  1  0  0  0
  3  8  2  0  0  0
  4  5  2  0  0  0
  4 34  1  0  0  0
  5  6  1  0  0  0
  5 35  1  0  0  0
  6  7  2  0  0  0
  6  9  1  0  0  0
  7  8  1  0  0  0
  7 36  1  0  0  0
  8 37  1  0  0  0
 10 11  1  0  0  0
 10 38  1  0  0  0
 11 12  1  0  0  0
 11 16  2  0  0  0
 12 13  2  0  0  0
 12 39  1  0  0  0
 13 14  1  0  0  0
 13 24  1  0  0  0
 14 15  2  0  0  0
 14 40  1  0  0  0
 15 16  1  0  0  0
 15 17  1  0  0  0
 17 18  1  0  0  0
 17 41  1  0  0  0
 18 19  1  0  0  0
 18 23  2  0  0  0
 19 20  2  0  0  0
 19 42  1  0  0  0
 20 21  1  0  0  0
 21 22  2  0  0  0
 21 43  1  0  0  0
 22 23  1  0  0  0
 22 44  1  0  0  0
 24 25  1  0  0  0
 24 28  2  0  0  0
 25 26  2  0  0  0
 25 45  1  0  0  0
 26 27  1  0  0  0
 27 28  1  0  0  0
 27 29  1  0  0  0
 28 46  1  0  0  0
 29 47  1  0  0  0
 29 48  1  0  0  0
 29 49  1  0  0  0
M  END
> <s_m_entry_id>
335

> <Applicants>
Nippon Shinyaku

> <CHEMBL_ID>
CHEMBL3545217

> <Canonical_Smiles>
Fc1ccc(cc1)C(Nc1nc(Nc2nccnc2)cc(c1)-c1cn(nc1)C)C

> <Chirality>
Single Stereoisomer

> <First_Approval>
nan

> <Phase>
2

> <SC_Patent>
None

> <Synonyms>
|NS-018

> <Indications>
nan

> <Type>
nan

> <targets_id>
nan

> <inchi>
InChI=1S/C21H20FN7/c1-14(15-3-5-18(22)6-4-15)26-19-9-16(17-11-25-29(2)13-17)10-20(27-19)28-21-12-23-7-8-24-21/h3-14H,1-2H3,(H2,24,26,27,28)

> <stdInchikey>
UQTPDWDAYHAZNT-UHFFFAOYSA-N

> <csid>
64880076

> <Links>
|http://www.chemspider.com/Chemical-Structure.64880076.html|http://pubchem.ncbi.nlm.nih.gov/compound/75236651

> <LinkName>
|ChemSpider|PubChem

> <MW>
389.2

> <HBA>
7

> <HBD>
2

> <NRB>
6

> <TPSA>
80.6

> <LogP>
4.3

> <RoF>
0

> <Targets>
nan

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0042

> <r_epik_State_Penalty>
  0.0029

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
335

$$$$
Varlitinib
                    3D
 Structure written by MMmdl.
 51 55  0  0  1  0            999 V2000
   -4.7458   -4.8702   -2.7090 C   0  0  0  0  0  0
   -3.5361   -4.1974   -3.3843 C   0  0  2  0  0  0
   -2.4494   -3.7503   -2.4095 C   0  0  0  0  0  0
   -2.7862   -2.3983   -2.1358 O   0  0  0  0  0  0
   -3.5334   -1.8619   -3.1545 C   0  0  0  0  0  0
   -3.8795   -2.9206   -3.9616 N   0  0  0  0  0  0
   -3.8684   -0.6392   -3.2736 N   0  0  0  0  0  0
   -3.4328    0.3438   -2.3717 C   0  0  0  0  0  0
   -4.3643    1.2642   -1.8858 C   0  0  0  0  0  0
   -4.0020    2.3000   -1.0288 C   0  0  0  0  0  0
   -2.6541    2.4613   -0.6405 C   0  0  0  0  0  0
   -1.6707    1.5575   -1.1452 C   0  0  0  0  0  0
   -2.0843    0.5155   -2.0195 C   0  0  0  0  0  0
   -0.3258    1.7898   -0.7205 C   0  0  0  0  0  0
   -0.0065    2.8056    0.1214 N   0  0  0  0  0  0
   -1.0213    3.5968    0.5365 C   0  0  0  0  0  0
   -2.3279    3.4821    0.2013 N   0  0  0  0  0  0
    0.7025    0.9346   -1.1633 N   0  0  0  0  0  0
    2.0880    0.8789   -0.9276 C   0  0  0  0  0  0
    2.8573    1.9852   -0.5460 C   0  0  0  0  0  0
    4.2311    1.8569   -0.3441 C   0  0  0  0  0  0
    4.8714    0.6197   -0.5257 C   0  0  0  0  0  0
    4.0996   -0.4814   -0.9170 C   0  0  0  0  0  0
    2.7253   -0.3486   -1.1191 C   0  0  0  0  0  0
    4.8332   -2.0284   -1.1614 Cl  0  0  0  0  0  0
    6.2281    0.4179   -0.3482 O   0  0  0  0  0  0
    7.0641    1.5096    0.0301 C   0  0  0  0  0  0
    8.5031    1.0475    0.1447 C   0  0  0  0  0  0
    9.5029    1.8963    0.1979 N   0  0  0  0  0  0
   10.6729    1.2971    0.2967 C   0  0  0  0  0  0
   10.6503   -0.0902    0.3310 C   0  0  0  0  0  0
    9.0012   -0.6207    0.2257 S   0  0  0  0  0  0
   -4.4563   -5.8108   -2.2396 H   0  0  0  0  0  0
   -5.5265   -5.0945   -3.4365 H   0  0  0  0  0  0
   -5.1838   -4.2367   -1.9361 H   0  0  0  0  0  0
   -3.1248   -4.8619   -4.1451 H   0  0  0  0  0  0
   -2.4195   -4.3465   -1.4965 H   0  0  0  0  0  0
   -1.4597   -3.7910   -2.8693 H   0  0  0  0  0  0
   -5.4022    1.1720   -2.1728 H   0  0  0  0  0  0
   -4.7504    2.9871   -0.6607 H   0  0  0  0  0  0
   -1.3401   -0.1584   -2.4188 H   0  0  0  0  0  0
   -0.7623    4.4047    1.2051 H   0  0  0  0  0  0
    0.3484    0.1221   -1.6463 H   0  0  0  0  0  0
    2.4169    2.9614   -0.4195 H   0  0  0  0  0  0
    4.7839    2.7364   -0.0515 H   0  0  0  0  0  0
    2.1522   -1.2133   -1.4233 H   0  0  0  0  0  0
    6.9818    2.3073   -0.7106 H   0  0  0  0  0  0
    6.7272    1.9128    0.9866 H   0  0  0  0  0  0
   11.5675    1.9005    0.3452 H   0  0  0  0  0  0
   11.4724   -0.7859    0.4081 H   0  0  0  0  0  0
   -4.5141   -2.9731   -4.7447 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 33  1  0  0  0
  1 34  1  0  0  0
  1 35  1  0  0  0
  2  3  1  0  0  0
  2  6  1  0  0  0
  2 36  1  0  0  0
  3  4  1  0  0  0
  3 37  1  0  0  0
  3 38  1  0  0  0
  4  5  1  0  0  0
  5  6  1  0  0  0
  5  7  2  0  0  0
  6 51  1  0  0  0
  7  8  1  0  0  0
  8  9  1  0  0  0
  8 13  2  0  0  0
  9 10  2  0  0  0
  9 39  1  0  0  0
 10 11  1  0  0  0
 10 40  1  0  0  0
 11 12  2  0  0  0
 11 17  1  0  0  0
 12 13  1  0  0  0
 12 14  1  0  0  0
 13 41  1  0  0  0
 14 15  2  0  0  0
 14 18  1  0  0  0
 15 16  1  0  0  0
 16 17  2  0  0  0
 16 42  1  0  0  0
 18 19  1  0  0  0
 18 43  1  0  0  0
 19 20  2  0  0  0
 19 24  1  0  0  0
 20 21  1  0  0  0
 20 44  1  0  0  0
 21 22  2  0  0  0
 21 45  1  0  0  0
 22 23  1  0  0  0
 22 26  1  0  0  0
 23 24  2  0  0  0
 23 25  1  0  0  0
 24 46  1  0  0  0
 26 27  1  0  0  0
 27 28  1  0  0  0
 27 47  1  0  0  0
 27 48  1  0  0  0
 28 29  2  0  0  0
 28 32  1  0  0  0
 29 30  1  0  0  0
 30 31  2  0  0  0
 30 49  1  0  0  0
 31 32  1  0  0  0
 31 50  1  0  0  0
M  END
> <s_m_entry_id>
337

> <Applicants>
Array Biopharma

> <CHEMBL_ID>
CHEMBL2103842

> <Canonical_Smiles>
Clc1cc(Nc2ncnc3c2cc(NC=2OC[C@H](N=2)C)cc3)ccc1OCc1sccn1

> <Chirality>
Single Stereoisomer

> <First_Approval>
nan

> <Phase>
2.5

> <SC_Patent>
None

> <Synonyms>
AR-00334543 | ARRY-334543 | ARRY-543 | ASLAN-001 | ASLAN001 | VARLITINIB

> <Indications>
Investigated for use/treatment in cancer/tumors (unspecified).

> <Type>
nan

> <targets_id>
P00533|P04626

> <inchi>
InChI=1S/C22H19ClN6O2S/c1-13-10-31-22(27-13)29-14-2-4-18-16(8-14)21(26-12-25-18)28-15-3-5-19(17(23)9-15)30-11-20-24-6-7-32-20/h2-9,12-13H,10-11H2,1H3,(H,27,29)(H,25,26,28)/t13-/m1/s1

> <stdInchikey>
UWXSAYUXVSFDBQ-CYBMUJFWSA-N

> <csid>
25027380

> <Links>
|http://www.chemspider.com/Chemical-Structure.25027380.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2103842|http://pubchem.ncbi.nlm.nih.gov/compound/42642648|http://www.drugbank.ca/drugs/DB05944|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7645|http://zinc15.docking.org/substances/ZINC000013980035|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=846Y8197W1|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50205268

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
466.1

> <HBA>
9

> <HBD>
2

> <NRB>
6

> <TPSA>
93.5

> <LogP>
5.2

> <RoF>
1

> <Targets>
EGFR; ERBB2

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_epik_Ionization_Penalty>
  0.3460

> <r_epik_State_Penalty>
  0.3511

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
337

> <Kinase families>
Tyr

> <indicationDB>
Varlitinib is an oral, selective, reversible, small molecule tyrosine kinase inhibitor of both ErbB-2 (Her-2/neu) and EGFR. Over-expression of ErbB-2 and EGFR receptors in tumors is predictive of poor prognosis in cancer patients. Varlitinib has shown significant anti-tumor activity in preclinical models of human breast, lung, and epidermal carcinoma tumors.

> <uniprotId>
P04626|P00533

$$$$
Opaganib
                    3D
 Structure written by MMmdl.
 52 56  0  0  1  0            999 V2000
   -2.2299   -0.5626    3.7608 C   0  0  0  0  0  0
   -2.5591   -1.0825    5.0092 C   0  0  0  0  0  0
   -3.1767   -2.3263    5.0978 C   0  0  0  0  0  0
   -3.4657   -3.0510    3.9454 C   0  0  0  0  0  0
   -3.1358   -2.5295    2.6972 C   0  0  0  0  0  0
   -2.5121   -1.2755    2.5850 C   0  0  0  0  0  0
   -2.1293   -0.6624    1.2134 C   0  0  1  0  0  0
   -2.5163   -1.5685   -0.0072 C   0  0  0  0  0  0
   -2.1204   -0.9142   -1.3553 C   0  0  1  0  0  0
   -2.8481    0.4448   -1.4999 C   0  0  0  0  0  0
   -2.4470    1.3735   -0.3278 C   0  0  1  0  0  0
   -2.8490    0.7125    1.0161 C   0  0  0  0  0  0
   -0.9144    1.6064   -0.3524 C   0  0  0  0  0  0
   -0.1651    0.2433   -0.2138 C   0  0  2  0  0  0
   -0.5882   -0.6903   -1.3896 C   0  0  0  0  0  0
   -0.5849   -0.4251    1.1402 C   0  0  0  0  0  0
    1.3686    0.5074   -0.3152 C   0  0  0  0  0  0
    1.8239    1.0439   -1.3281 O   0  0  0  0  0  0
    2.1590    0.1344    0.7119 N   0  0  0  0  0  0
    3.6088    0.3207    0.7987 C   0  0  0  0  0  0
    4.0691    1.7741    0.7642 C   0  0  0  0  0  0
    3.9034    2.5955    1.8859 C   0  0  0  0  0  0
    4.3516    3.9163    1.8215 C   0  0  0  0  0  0
    4.9486    4.4405    0.7206 N   0  0  0  0  0  0
    5.1111    3.6300   -0.3566 C   0  0  0  0  0  0
    4.6926    2.2982   -0.3745 C   0  0  0  0  0  0
   -3.5864   -2.9734    6.6445 Cl  0  0  0  0  0  0
   -1.7511    0.4043    3.7165 H   0  0  0  0  0  0
   -2.3348   -0.5198    5.9036 H   0  0  0  0  0  0
   -3.9448   -4.0167    4.0153 H   0  0  0  0  0  0
   -3.3773   -3.1233    1.8299 H   0  0  0  0  0  0
   -2.0298   -2.5425    0.0709 H   0  0  0  0  0  0
   -3.5901   -1.7645   -0.0104 H   0  0  0  0  0  0
   -2.4099   -1.5704   -2.1773 H   0  0  0  0  0  0
   -2.5977    0.9094   -2.4551 H   0  0  0  0  0  0
   -3.9291    0.2961   -1.5124 H   0  0  0  0  0  0
   -2.9614    2.3300   -0.4306 H   0  0  0  0  0  0
   -3.9317    0.5786    1.0527 H   0  0  0  0  0  0
   -2.6114    1.3993    1.8296 H   0  0  0  0  0  0
   -0.6447    2.1139   -1.2812 H   0  0  0  0  0  0
   -0.6320    2.2870    0.4537 H   0  0  0  0  0  0
   -0.0734   -1.6512   -1.3260 H   0  0  0  0  0  0
   -0.3093   -0.2635   -2.3556 H   0  0  0  0  0  0
   -0.2640    0.2054    1.9714 H   0  0  0  0  0  0
   -0.0681   -1.3785    1.2711 H   0  0  0  0  0  0
    1.7361   -0.3802    1.4703 H   0  0  0  0  0  0
    3.9409   -0.1213    1.7388 H   0  0  0  0  0  0
    4.0980   -0.2608    0.0148 H   0  0  0  0  0  0
    3.4343    2.2211    2.7841 H   0  0  0  0  0  0
    4.2352    4.5786    2.6671 H   0  0  0  0  0  0
    5.5888    4.0675   -1.2208 H   0  0  0  0  0  0
    4.8422    1.6912   -1.2555 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1  6  2  0  0  0
  1 28  1  0  0  0
  2  3  2  0  0  0
  2 29  1  0  0  0
  3  4  1  0  0  0
  3 27  1  0  0  0
  4  5  2  0  0  0
  4 30  1  0  0  0
  5  6  1  0  0  0
  5 31  1  0  0  0
  6  7  1  0  0  0
  7  8  1  0  0  0
  7 12  1  0  0  0
  7 16  1  0  0  0
  8  9  1  0  0  0
  8 32  1  0  0  0
  8 33  1  0  0  0
  9 10  1  0  0  0
  9 15  1  0  0  0
  9 34  1  0  0  0
 10 11  1  0  0  0
 10 35  1  0  0  0
 10 36  1  0  0  0
 11 12  1  0  0  0
 11 13  1  0  0  0
 11 37  1  0  0  0
 12 38  1  0  0  0
 12 39  1  0  0  0
 13 14  1  0  0  0
 13 40  1  0  0  0
 13 41  1  0  0  0
 14 15  1  0  0  0
 14 16  1  0  0  0
 14 17  1  0  0  0
 15 42  1  0  0  0
 15 43  1  0  0  0
 16 44  1  0  0  0
 16 45  1  0  0  0
 17 18  2  0  0  0
 17 19  1  0  0  0
 19 20  1  0  0  0
 19 46  1  0  0  0
 20 21  1  0  0  0
 20 47  1  0  0  0
 20 48  1  0  0  0
 21 22  1  0  0  0
 21 26  2  0  0  0
 22 23  2  0  0  0
 22 49  1  0  0  0
 23 24  1  0  0  0
 23 50  1  0  0  0
 24 25  2  0  0  0
 25 26  1  0  0  0
 25 51  1  0  0  0
 26 52  1  0  0  0
M  END
> <s_m_entry_id>
340

> <Applicants>
RedHill Biopharma

> <CHEMBL_ID>
CHEMBL2158685

> <Canonical_Smiles>
Clc1ccc(cc1)C12CC3(CC(C1)CC(C2)C3)C(=O)NCc1ccncc1

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
2.5

> <SC_Patent>
None

> <Synonyms>
ABC 294640 | ABC-294640 | OPAGANIB

> <Indications>
nan

> <Type>
nan

> <targets_id>
nan

> <inchi>
InChI=1S/C23H25ClN2O/c24-20-3-1-19(2-4-20)22-10-17-9-18(11-22)13-23(12-17,15-22)21(27)26-14-16-5-7-25-8-6-16/h1-8,17-18H,9-15H2,(H,26,27)

> <stdInchikey>
CAOTVXGYTWCKQE-UHFFFAOYSA-N

> <csid>
13079494

> <Links>
|http://www.chemspider.com/Chemical-Structure.13079494.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2158685|http://pubchem.ncbi.nlm.nih.gov/compound/15604015|http://www.drugbank.ca/drugs/DB12764|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6624|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=DRG21OQ517|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50393642

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
380.2

> <HBA>
2

> <HBD>
1

> <NRB>
4

> <TPSA>
42

> <LogP>
4.9

> <RoF>
0

> <Targets>
nan

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_epik_Ionization_Penalty>
  0.0103

> <r_epik_State_Penalty>
  0.0079

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
340

> <indicationDB>
Opaganib, also known as ABC294640, is a selective <a href="https://go.drugbank.com/polypeptides/Q9NRA0">sphingosine kinase-2 (SK2)</a> inhibitor that is orally administered.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Opaganib (Yeliva®, ABC294640)" href="#reference-L27436">2</a></sup> This drug has potential anticancer, anti-inflammatory, and antiviral activities, with potential applications in oncology, inflammation, the gastrointestinal system, and COVID-19.

> <uniprotId>
Q9NRA0

$$$$
Cerdulatinib
                    3D
 Structure written by MMmdl.
 58 61  0  0  1  0            999 V2000
  -10.6702   -2.8290   -1.5419 C   0  0  0  0  0  0
   -9.1519   -2.7269   -1.3531 C   0  0  0  0  0  0
   -8.7147   -1.1281   -0.4420 S   0  0  0  0  0  0
   -9.0633    0.0061   -1.3054 O   0  0  0  0  0  0
   -9.2740   -1.2183    0.9117 O   0  0  0  0  0  0
   -6.9485   -1.2055   -0.3198 N   0  0  0  0  0  0
   -6.1909   -0.8033   -1.5252 C   0  0  0  0  0  0
   -4.6765   -1.0623   -1.3742 C   0  0  0  0  0  0
   -4.1299   -0.4205   -0.1634 N   0  0  0  0  0  0
   -4.8263   -1.0005    1.0007 C   0  0  0  0  0  0
   -6.3475   -0.7408    0.9499 C   0  0  0  0  0  0
   -2.7704   -0.1401   -0.0372 C   0  0  0  0  0  0
   -1.8074   -0.7105   -0.8815 C   0  0  0  0  0  0
   -0.4584   -0.4015   -0.7308 C   0  0  0  0  0  0
   -0.0376    0.4855    0.2613 C   0  0  0  0  0  0
   -0.9943    1.0628    1.1052 C   0  0  0  0  0  0
   -2.3430    0.7517    0.9536 C   0  0  0  0  0  0
    1.3456    0.7363    0.3399 N   0  0  0  0  0  0
    2.1628    1.5321    1.1571 C   0  0  0  0  0  0
    1.6269    2.2986    2.1374 N   0  0  0  0  0  0
    2.4876    3.0371    2.8778 C   0  0  0  0  0  0
    3.8753    3.0335    2.6733 C   0  0  0  0  0  0
    4.3483    2.2029    1.6299 C   0  0  0  0  0  0
    3.4861    1.4591    0.8785 N   0  0  0  0  0  0
    5.7245    2.1117    1.3349 N   0  0  0  0  0  0
    6.2444    1.1029    0.4195 C   0  0  0  0  0  0
    7.4849    1.4465   -0.3719 C   0  0  0  0  0  0
    6.1493    1.3585   -1.0686 C   0  0  0  0  0  0
    4.7737    3.8930    3.5354 C   0  0  0  0  0  0
    5.7561    4.4708    3.0742 O   0  0  0  0  0  0
    4.4503    3.9785    4.8300 N   0  0  0  0  0  0
  -10.9365   -3.7469   -2.0662 H   0  0  0  0  0  0
  -11.0517   -1.9905   -2.1253 H   0  0  0  0  0  0
  -11.1880   -2.8321   -0.5823 H   0  0  0  0  0  0
   -8.7643   -3.5597   -0.7662 H   0  0  0  0  0  0
   -8.6308   -2.7195   -2.3102 H   0  0  0  0  0  0
   -6.5925   -1.3457   -2.3813 H   0  0  0  0  0  0
   -6.3815    0.2524   -1.7239 H   0  0  0  0  0  0
   -4.4774   -2.1350   -1.3393 H   0  0  0  0  0  0
   -4.1759   -0.6665   -2.2588 H   0  0  0  0  0  0
   -4.6311   -2.0740    1.0322 H   0  0  0  0  0  0
   -4.4380   -0.5866    1.9317 H   0  0  0  0  0  0
   -6.5653    0.3209    1.0740 H   0  0  0  0  0  0
   -6.8470   -1.2483    1.7754 H   0  0  0  0  0  0
   -2.0884   -1.4073   -1.6572 H   0  0  0  0  0  0
    0.2596   -0.8609   -1.3952 H   0  0  0  0  0  0
   -0.7311    1.7562    1.8858 H   0  0  0  0  0  0
   -3.0597    1.2204    1.6125 H   0  0  0  0  0  0
    1.8789    0.2267   -0.3486 H   0  0  0  0  0  0
    2.0302    3.6471    3.6442 H   0  0  0  0  0  0
    6.3610    2.4734    2.0305 H   0  0  0  0  0  0
    6.1371    0.0763    0.7722 H   0  0  0  0  0  0
    7.9428    2.4285   -0.2462 H   0  0  0  0  0  0
    8.2209    0.6627   -0.5519 H   0  0  0  0  0  0
    5.9575    0.5126   -1.7288 H   0  0  0  0  0  0
    5.6797    2.2780   -1.4197 H   0  0  0  0  0  0
    3.6515    3.4796    5.1932 H   0  0  0  0  0  0
    5.0167    4.5324    5.4560 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 32  1  0  0  0
  1 33  1  0  0  0
  1 34  1  0  0  0
  2  3  1  0  0  0
  2 35  1  0  0  0
  2 36  1  0  0  0
  3  4  2  0  0  0
  3  5  2  0  0  0
  3  6  1  0  0  0
  6  7  1  0  0  0
  6 11  1  0  0  0
  7  8  1  0  0  0
  7 37  1  0  0  0
  7 38  1  0  0  0
  8  9  1  0  0  0
  8 39  1  0  0  0
  8 40  1  0  0  0
  9 10  1  0  0  0
  9 12  1  0  0  0
 10 11  1  0  0  0
 10 41  1  0  0  0
 10 42  1  0  0  0
 11 43  1  0  0  0
 11 44  1  0  0  0
 12 13  1  0  0  0
 12 17  2  0  0  0
 13 14  2  0  0  0
 13 45  1  0  0  0
 14 15  1  0  0  0
 14 46  1  0  0  0
 15 16  2  0  0  0
 15 18  1  0  0  0
 16 17  1  0  0  0
 16 47  1  0  0  0
 17 48  1  0  0  0
 18 19  1  0  0  0
 18 49  1  0  0  0
 19 20  1  0  0  0
 19 24  2  0  0  0
 20 21  2  0  0  0
 21 22  1  0  0  0
 21 50  1  0  0  0
 22 23  2  0  0  0
 22 29  1  0  0  0
 23 24  1  0  0  0
 23 25  1  0  0  0
 25 26  1  0  0  0
 25 51  1  0  0  0
 26 27  1  0  0  0
 26 28  1  0  0  0
 26 52  1  0  0  0
 27 28  1  0  0  0
 27 53  1  0  0  0
 27 54  1  0  0  0
 28 55  1  0  0  0
 28 56  1  0  0  0
 29 30  2  0  0  0
 29 31  1  0  0  0
 31 57  1  0  0  0
 31 58  1  0  0  0
M  END
> <s_m_entry_id>
342

> <Applicants>
Portola pharmaceuticals

> <CHEMBL_ID>
CHEMBL3545284

> <Canonical_Smiles>
S(=O)(=O)(N1CCN(CC1)c1ccc(Nc2nc(NC3CC3)c(cn2)C(=O)N)cc1)CC

> <Chirality>
Single Stereoisomer

> <First_Approval>
nan

> <Phase>
2.5

> <SC_Patent>
None

> <Indications>
nan

> <Type>
nan

> <targets_id>
P23458|P43405

> <inchi>
InChI=1S/C20H27N7O3S/c1-2-31(29,30)27-11-9-26(10-12-27)16-7-5-15(6-8-16)24-20-22-13-17(18(21)28)19(25-20)23-14-3-4-14/h5-8,13-14H,2-4,9-12H2,1H3,(H2,21,28)(H2,22,23,24,25)

> <stdInchikey>
BGLPECHZZQDNCD-UHFFFAOYSA-N

> <csid>
32822046

> <Links>
|http://www.chemspider.com/Chemical-Structure.32822046.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4116008|http://pubchem.ncbi.nlm.nih.gov/compound/44595079|http://www.drugbank.ca/drugs/DB15499|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8957|http://zinc15.docking.org/substances/ZINC000114483165|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=D1LXQ45S1O|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50468574

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
445.2

> <HBA>
8

> <HBD>
3

> <NRB>
8

> <TPSA>
133.6

> <LogP>
1.4

> <RoF>
0

> <Targets>
JAK1; SYK

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0031

> <r_epik_State_Penalty>
  0.0000

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
342

> <Kinase families>
Tyr

> <Withdrawn>
Study NCT04021082 in nan was Withdrawn during Phase 2/Phase 3 because Sponsor decision to not initiate the trial

$$$$
Tivantinib
                    3D
 Structure written by MMmdl.
 47 52  0  0  1  0            999 V2000
   -1.9490    3.3028   -0.2247 C   0  0  0  0  0  0
   -3.2096    2.7136   -0.2080 C   0  0  0  0  0  0
   -3.3743    1.3335   -0.0953 C   0  0  0  0  0  0
   -2.2122    0.5606    0.0017 C   0  0  0  0  0  0
   -0.9026    1.1346   -0.0125 C   0  0  0  0  0  0
   -0.7924    2.5319   -0.1291 C   0  0  0  0  0  0
    0.0548    0.0562    0.1044 C   0  0  0  0  0  0
   -0.7083   -1.0960    0.1795 C   0  0  0  0  0  0
   -2.0439   -0.7992    0.1210 N   0  0  0  0  0  0
    1.5795    0.1411    0.1237 C   0  0  1  0  0  0
    2.1882    0.8010   -1.0992 C   0  0  1  0  0  0
    2.9996    1.9654   -0.5422 C   0  0  0  0  0  0
    3.6583    2.7644   -1.2061 O   0  0  0  0  0  0
    2.8523    1.9611    0.7984 N   0  0  0  0  0  0
    2.0657    0.9853    1.2966 C   0  0  0  0  0  0
    1.7933    0.7947    2.4809 O   0  0  0  0  0  0
    3.0667   -0.1179   -1.9438 C   0  0  0  0  0  0
    2.8916   -0.4291   -3.2889 C   0  0  0  0  0  0
    3.8579   -1.3018   -3.7252 N   0  0  0  0  0  0
    4.7017   -1.5637   -2.6696 C   0  0  0  0  0  0
    4.2393   -0.8591   -1.5308 C   0  0  0  0  0  0
    4.9617   -1.0160   -0.3339 C   0  0  0  0  0  0
    6.0838   -1.8489   -0.3204 C   0  0  0  0  0  0
    6.5016   -2.5255   -1.4680 C   0  0  0  0  0  0
    5.8177   -2.4041   -2.6794 C   0  0  0  0  0  0
    6.1644   -3.0671   -4.0080 C   0  0  0  0  0  0
    4.8986   -3.2044   -4.8972 C   0  0  0  0  0  0
    4.1035   -1.8741   -5.0552 C   0  0  0  0  0  0
   -1.8659    4.3762   -0.3130 H   0  0  0  0  0  0
   -4.0842    3.3428   -0.2848 H   0  0  0  0  0  0
   -4.3592    0.8903   -0.0850 H   0  0  0  0  0  0
    0.1744    3.0122   -0.1444 H   0  0  0  0  0  0
   -0.4015   -2.1276    0.2711 H   0  0  0  0  0  0
   -2.7616   -1.5085    0.1618 H   0  0  0  0  0  0
    1.9559   -0.8739    0.2671 H   0  0  0  0  0  0
    1.4239    1.2134   -1.7611 H   0  0  0  0  0  0
    3.2981    2.6470    1.3898 H   0  0  0  0  0  0
    2.1377   -0.0893   -3.9839 H   0  0  0  0  0  0
    4.6596   -0.5027    0.5669 H   0  0  0  0  0  0
    6.6408   -1.9710    0.5970 H   0  0  0  0  0  0
    7.3762   -3.1572   -1.4155 H   0  0  0  0  0  0
    6.9079   -2.4560   -4.5215 H   0  0  0  0  0  0
    6.6213   -4.0431   -3.8395 H   0  0  0  0  0  0
    5.1806   -3.5805   -5.8812 H   0  0  0  0  0  0
    4.2412   -3.9632   -4.4686 H   0  0  0  0  0  0
    3.1532   -2.0448   -5.5626 H   0  0  0  0  0  0
    4.6703   -1.1531   -5.6457 H   0  0  0  0  0  0
  1  2  2  0  0  0
  1  6  1  0  0  0
  1 29  1  0  0  0
  2  3  1  0  0  0
  2 30  1  0  0  0
  3  4  2  0  0  0
  3 31  1  0  0  0
  4  5  1  0  0  0
  4  9  1  0  0  0
  5  6  2  0  0  0
  5  7  1  0  0  0
  6 32  1  0  0  0
  7  8  2  0  0  0
  7 10  1  0  0  0
  8  9  1  0  0  0
  8 33  1  0  0  0
  9 34  1  0  0  0
 10 11  1  0  0  0
 10 15  1  0  0  0
 10 35  1  0  0  0
 11 12  1  0  0  0
 11 17  1  0  0  0
 11 36  1  0  0  0
 12 13  2  0  0  0
 12 14  1  0  0  0
 14 15  1  0  0  0
 14 37  1  0  0  0
 15 16  2  0  0  0
 17 18  2  0  0  0
 17 21  1  0  0  0
 18 19  1  0  0  0
 18 38  1  0  0  0
 19 20  1  0  0  0
 19 28  1  0  0  0
 20 21  2  0  0  0
 20 25  1  0  0  0
 21 22  1  0  0  0
 22 23  2  0  0  0
 22 39  1  0  0  0
 23 24  1  0  0  0
 23 40  1  0  0  0
 24 25  2  0  0  0
 24 41  1  0  0  0
 25 26  1  0  0  0
 26 27  1  0  0  0
 26 42  1  0  0  0
 26 43  1  0  0  0
 27 28  1  0  0  0
 27 44  1  0  0  0
 27 45  1  0  0  0
 28 46  1  0  0  0
 28 47  1  0  0  0
M  END
> <s_m_entry_id>
343

> <Applicants>
Daiichi Sankyo

> <CHEMBL_ID>
CHEMBL2103882

> <Canonical_Smiles>
O=C1NC(=O)[C@H]([C@@H]1c1c2c3n(c1)CCCc3ccc2)c1c2c([nH]c1)cccc2

> <Chirality>
Single Stereoisomer

> <First_Approval>
nan

> <Phase>
3

> <SC_Patent>
None

> <Synonyms>
ARQ 197 | ARQ-197 | TIVANTINIB

> <Indications>
nan

> <Type>
nan

> <targets_id>
P08581

> <inchi>
InChI=1S/C23H19N3O2/c27-22-19(16-11-24-18-9-2-1-7-14(16)18)20(23(28)25-22)17-12-26-10-4-6-13-5-3-8-15(17)21(13)26/h1-3,5,7-9,11-12,19-20,24H,4,6,10H2,(H,25,27,28)/t19-,20-/m0/s1

> <stdInchikey>
UCEQXRCJXIVODC-PMACEKPBSA-N

> <csid>
9669218

> <Links>
|http://www.chemspider.com/Chemical-Structure.9669218.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2103882|http://pubchem.ncbi.nlm.nih.gov/compound/11494412|http://www.drugbank.ca/drugs/DB12200| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=TIV|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/TIV|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7948|http://zinc15.docking.org/substances/ZINC000100016063|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=PJ4H73IL17|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50146168

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
369.1

> <HBA>
3

> <HBD>
2

> <NRB>
2

> <TPSA>
66.9

> <LogP>
3.6

> <RoF>
0

> <Targets>
MET

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0724

> <r_epik_State_Penalty>
  0.0636

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
343

> <lig_pdbID>
'TIV'

> <pdbID>
5cb4

> <Kinase families>
Tyr

> <indicationDB>
Tivantinib has been investigated in Solid Tumors.

> <uniprotId>
P08581

$$$$
Tesevatinib
                    3D
 Structure written by MMmdl.
 59 63  0  0  1  0            999 V2000
   -5.8291    2.7492    3.7857 C   0  0  0  0  0  0
   -4.8546    2.3197    2.6755 N   0  3  2  0  0  0
   -5.1741    2.9152    1.2942 C   0  0  0  0  0  0
   -4.3881    2.0214    0.3226 C   0  0  1  0  0  0
   -2.9897    2.5505   -0.0513 C   0  0  0  0  0  0
   -2.0922    1.3088   -0.0828 C   0  0  2  0  0  0
   -2.6380    0.4648    1.0751 C   0  0  0  0  0  0
   -4.1622    0.6807    1.0418 C   0  0  1  0  0  0
   -4.8212    0.8033    2.4238 C   0  0  0  0  0  0
   -0.5855    1.6126    0.0059 C   0  0  0  0  0  0
    0.1266    0.3786    0.0160 O   0  0  0  0  0  0
    1.5001    0.3733    0.1818 C   0  0  0  0  0  0
    2.2772    1.5408    0.2179 C   0  0  0  0  0  0
    3.6766    1.4742    0.3945 C   0  0  0  0  0  0
    4.3041    0.2012    0.5391 C   0  0  0  0  0  0
    3.4994   -0.9670    0.4933 C   0  0  0  0  0  0
    2.1103   -0.8800    0.3150 C   0  0  0  0  0  0
    1.2786   -1.9859    0.2659 O   0  0  0  0  0  0
    1.8315   -3.2906    0.4046 C   0  0  0  0  0  0
    5.7213    0.2170    0.7244 C   0  0  0  0  0  0
    6.4303    1.3751    0.7459 N   0  0  0  0  0  0
    5.7288    2.5209    0.5954 C   0  0  0  0  0  0
    4.3907    2.6349    0.4231 N   0  0  0  0  0  0
    6.4249   -0.9941    0.8707 N   0  0  0  0  0  0
    7.7758   -1.2757    1.1444 C   0  0  0  0  0  0
    8.5535   -0.4517    1.9676 C   0  0  0  0  0  0
    9.8925   -0.7532    2.2068 C   0  0  0  0  0  0
   10.4746   -1.8801    1.6278 C   0  0  0  0  0  0
    9.7074   -2.7135    0.8034 C   0  0  0  0  0  0
    8.3625   -2.4088    0.5643 C   0  0  0  0  0  0
    7.6266   -3.2194   -0.2359 F   0  0  0  0  0  0
   10.4025   -4.1215    0.0724 Cl  0  0  0  0  0  0
   12.1404   -2.2167    1.9513 Cl  0  0  0  0  0  0
   -6.8302    2.4188    3.5042 H   0  0  0  0  0  0
   -5.7676    3.8356    3.8576 H   0  0  0  0  0  0
   -5.4892    2.2708    4.7049 H   0  0  0  0  0  0
   -6.2527    2.8158    1.1561 H   0  0  0  0  0  0
   -4.8813    3.9661    1.3025 H   0  0  0  0  0  0
   -4.9647    1.8649   -0.5911 H   0  0  0  0  0  0
   -2.9914    3.0842   -1.0029 H   0  0  0  0  0  0
   -2.6279    3.2463    0.7086 H   0  0  0  0  0  0
   -2.2789    0.7753   -1.0176 H   0  0  0  0  0  0
   -2.3682   -0.5883    0.9825 H   0  0  0  0  0  0
   -2.2193    0.8230    2.0179 H   0  0  0  0  0  0
   -4.6241   -0.1318    0.4775 H   0  0  0  0  0  0
   -4.2752    0.3357    3.2446 H   0  0  0  0  0  0
   -5.8602    0.4675    2.4106 H   0  0  0  0  0  0
   -0.2777    2.2145   -0.8510 H   0  0  0  0  0  0
   -0.3705    2.1823    0.9122 H   0  0  0  0  0  0
    1.8277    2.5167    0.1110 H   0  0  0  0  0  0
    3.9827   -1.9259    0.6015 H   0  0  0  0  0  0
    1.0311   -4.0278    0.3438 H   0  0  0  0  0  0
    2.3224   -3.4172    1.3706 H   0  0  0  0  0  0
    2.5429   -3.5107   -0.3928 H   0  0  0  0  0  0
    6.2946    3.4409    0.6156 H   0  0  0  0  0  0
    5.8536   -1.8160    0.7400 H   0  0  0  0  0  0
    8.1276    0.4196    2.4424 H   0  0  0  0  0  0
   10.4772   -0.1088    2.8470 H   0  0  0  0  0  0
   -3.9193    2.6097    2.9259 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 34  1  0  0  0
  1 35  1  0  0  0
  1 36  1  0  0  0
  2  3  1  0  0  0
  2  9  1  0  0  0
  2 59  1  0  0  0
  3  4  1  0  0  0
  3 37  1  0  0  0
  3 38  1  0  0  0
  4  5  1  0  0  0
  4  8  1  0  0  0
  4 39  1  0  0  0
  5  6  1  0  0  0
  5 40  1  0  0  0
  5 41  1  0  0  0
  6  7  1  0  0  0
  6 10  1  0  0  0
  6 42  1  0  0  0
  7  8  1  0  0  0
  7 43  1  0  0  0
  7 44  1  0  0  0
  8  9  1  0  0  0
  8 45  1  0  0  0
  9 46  1  0  0  0
  9 47  1  0  0  0
 10 11  1  0  0  0
 10 48  1  0  0  0
 10 49  1  0  0  0
 11 12  1  0  0  0
 12 13  1  0  0  0
 12 17  2  0  0  0
 13 14  2  0  0  0
 13 50  1  0  0  0
 14 15  1  0  0  0
 14 23  1  0  0  0
 15 16  2  0  0  0
 15 20  1  0  0  0
 16 17  1  0  0  0
 16 51  1  0  0  0
 17 18  1  0  0  0
 18 19  1  0  0  0
 19 52  1  0  0  0
 19 53  1  0  0  0
 19 54  1  0  0  0
 20 21  2  0  0  0
 20 24  1  0  0  0
 21 22  1  0  0  0
 22 23  2  0  0  0
 22 55  1  0  0  0
 24 25  1  0  0  0
 24 56  1  0  0  0
 25 26  2  0  0  0
 25 30  1  0  0  0
 26 27  1  0  0  0
 26 57  1  0  0  0
 27 28  2  0  0  0
 27 58  1  0  0  0
 28 29  1  0  0  0
 28 33  1  0  0  0
 29 30  2  0  0  0
 29 32  1  0  0  0
 30 31  1  0  0  0
M  CHG  1   2   1
M  END
> <s_m_entry_id>
345

> <Applicants>
Kadmon Corporation

> <CHEMBL_ID>
CHEMBL3544983

> <Canonical_Smiles>
Clc1c(F)c(Nc2ncnc3c2cc(OC)c(OCC2C[C@@H]4[C@H](C2)CN(C4)C)c3)ccc1Cl

> <Chirality>
Racemic Mixture

> <First_Approval>
nan

> <Phase>
3

> <SC_Patent>
None

> <Synonyms>
EXEL-7647 | KD-019 | KD-020 | KD019 | TESEVATINIB | XL-647 | XL647

> <Indications>
nan

> <Type>
nan

> <targets_id>
P00533|P04626|P35968|P35916|P54760

> <inchi>
InChI=1S/C24H25Cl2FN4O2/c1-31-9-14-5-13(6-15(14)10-31)11-33-21-8-19-16(7-20(21)32-2)24(29-12-28-19)30-18-4-3-17(25)22(26)23(18)27/h3-4,7-8,12-15H,5-6,9-11H2,1-2H3,(H,28,29,30)/t13-,14-,15+

> <stdInchikey>
HVXKQKFEHMGHSL-QKDCVEJESA-N

> <csid>
32699556

> <Links>
|http://www.chemspider.com/Chemical-Structure.32699556.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3544983|http://www.drugbank.ca/drugs/DB11973|http://zinc15.docking.org/substances/ZINC000114456300|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=F6XM2TN5A1

> <LinkName>
|ChemSpider|ChEMBL|DrugBank|ZINC|FDA SRS

> <MW>
490.1

> <HBA>
6

> <HBD>
1

> <NRB>
6

> <TPSA>
59.5

> <LogP>
5.8

> <RoF>
1

> <Targets>
EGFR; ERBB2; KDR; FLT4; EPHB4

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0024

> <r_epik_State_Penalty>
  0.0000

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
345

> <Kinase families>
Tyr

> <indicationDB>
Tesevatinib has been used in trials studying the treatment of Cancer, Stomach Cancer, Brain Metastases, Esophageal Cancer, and Leptomeningeal Metastases, among others.</p><p>Tesevatinib is a potent inhibitor of multiple RTKs implicated in driving tumor cell proliferation and tumor vascularization (blood vessel formation). Tesevatinib inhibits the EGF, HER2, and VEGF RTKs, each of which is a target of currently approved cancer therapies. In addition, tesevatinib inhibits EphB4, an RTK that is highly expressed in many human tumors and plays a role in promoting angiogenesis. In a broad array of preclinical tumor models including breast, lung, colon and prostate cancer, XL647 demonstrated potent inhibition of tumor growth and causes tumor regression. In cell culture models, tesevatinib retains significant potency against mutant EGFRs that are resistant to current EGFR inhibitors.

> <uniprotId>
P01133|P54760|P04626

$$$$
Taselisib
                    3D
 Structure written by MMmdl.
 62 66  0  0  1  0            999 V2000
   -3.1257   -1.4979    0.3536 C   0  0  0  0  0  0
   -1.9361   -0.5693    0.2628 C   0  0  0  0  0  0
   -0.6952   -1.0240    0.3307 N   0  0  0  0  0  0
    0.0321    0.0608    0.2018 C   0  0  0  0  0  0
   -0.8046    1.1511    0.0920 N   0  0  0  0  0  0
   -2.0765    0.7284    0.1089 N   0  0  0  0  0  0
   -0.4880    2.5801   -0.0660 C   0  0  0  0  0  0
   -1.3647    3.4612    0.8504 C   0  0  0  0  0  0
   -0.6071    2.9788   -1.5489 C   0  0  0  0  0  0
    1.4952    0.0520    0.1598 C   0  0  0  0  0  0
    2.3448   -0.8313    0.7930 C   0  0  0  0  0  0
    3.6266   -0.4638    0.4697 N   0  0  0  0  0  0
    3.4808    0.6344   -0.3717 C   0  0  0  0  0  0
    2.2021    0.9206   -0.5371 N   0  0  0  0  0  0
    4.5842    1.4298   -1.0341 C   0  0  0  0  0  0
    4.2675    2.6997   -1.5467 C   0  0  0  0  0  0
    5.2048    3.4657   -2.2351 C   0  0  0  0  0  0
    6.4953    2.9802   -2.4411 C   0  0  0  0  0  0
    6.8298    1.7260   -1.9289 C   0  0  0  0  0  0
    5.9028    0.9599   -1.2174 C   0  0  0  0  0  0
    6.3383   -0.2452   -0.7315 O   0  0  0  0  0  0
    6.1469   -0.4539    0.6562 C   0  0  0  0  0  0
    4.8212   -1.1571    0.9372 C   0  0  0  0  0  0
    7.4989    3.7855   -3.1925 C   0  0  0  0  0  0
    8.5838    3.3348   -3.9577 C   0  0  0  0  0  0
    9.2790    4.3062   -4.5010 N   0  0  0  0  0  0
    8.6761    5.4441   -4.1035 N   0  0  0  0  0  0
    7.5845    5.1647   -3.3101 C   0  0  0  0  0  0
    9.1949    6.7730   -4.5459 C   0  0  0  0  0  0
    8.6883    7.8761   -3.5674 C   0  0  0  0  0  0
   10.7496    6.7739   -4.4640 C   0  0  0  0  0  0
    8.7799    7.1077   -6.0122 C   0  0  0  0  0  0
    8.4475    8.2480   -6.3346 O   0  0  0  0  0  0
    8.8195    6.1348   -6.9300 N   0  0  0  0  0  0
   -4.0786   -0.9672    0.3452 H   0  0  0  0  0  0
   -3.0979   -2.0913    1.2679 H   0  0  0  0  0  0
   -3.1409   -2.2069   -0.4745 H   0  0  0  0  0  0
    0.5422    2.7295    0.2547 H   0  0  0  0  0  0
   -1.0596    4.5066    0.7945 H   0  0  0  0  0  0
   -1.2806    3.1535    1.8935 H   0  0  0  0  0  0
   -2.4188    3.4151    0.5736 H   0  0  0  0  0  0
   -0.3271    4.0220   -1.6981 H   0  0  0  0  0  0
   -1.6260    2.8542   -1.9180 H   0  0  0  0  0  0
    0.0497    2.3738   -2.1756 H   0  0  0  0  0  0
    2.1536   -1.6766    1.4380 H   0  0  0  0  0  0
    3.2736    3.1066   -1.4278 H   0  0  0  0  0  0
    4.9153    4.4330   -2.6195 H   0  0  0  0  0  0
    7.8293    1.3392   -2.0677 H   0  0  0  0  0  0
    6.9588   -1.0954    1.0000 H   0  0  0  0  0  0
    6.2392    0.4657    1.2394 H   0  0  0  0  0  0
    4.7158   -1.3112    2.0122 H   0  0  0  0  0  0
    4.8261   -2.1493    0.4839 H   0  0  0  0  0  0
    8.8551    2.3015   -4.1175 H   0  0  0  0  0  0
    6.9663    5.9500   -2.9027 H   0  0  0  0  0  0
    9.1446    8.8453   -3.7770 H   0  0  0  0  0  0
    8.9284    7.6349   -2.5305 H   0  0  0  0  0  0
    7.6081    8.0185   -3.6292 H   0  0  0  0  0  0
   11.1667    7.7549   -4.6985 H   0  0  0  0  0  0
   11.2068    6.0639   -5.1557 H   0  0  0  0  0  0
   11.0947    6.5125   -3.4623 H   0  0  0  0  0  0
    9.0955    5.1993   -6.6683 H   0  0  0  0  0  0
    8.5692    6.3313   -7.8881 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 35  1  0  0  0
  1 36  1  0  0  0
  1 37  1  0  0  0
  2  3  1  0  0  0
  2  6  2  0  0  0
  3  4  2  0  0  0
  4  5  1  0  0  0
  4 10  1  0  0  0
  5  6  1  0  0  0
  5  7  1  0  0  0
  7  8  1  0  0  0
  7  9  1  0  0  0
  7 38  1  0  0  0
  8 39  1  0  0  0
  8 40  1  0  0  0
  8 41  1  0  0  0
  9 42  1  0  0  0
  9 43  1  0  0  0
  9 44  1  0  0  0
 10 11  2  0  0  0
 10 14  1  0  0  0
 11 12  1  0  0  0
 11 45  1  0  0  0
 12 13  1  0  0  0
 12 23  1  0  0  0
 13 14  2  0  0  0
 13 15  1  0  0  0
 15 16  1  0  0  0
 15 20  2  0  0  0
 16 17  2  0  0  0
 16 46  1  0  0  0
 17 18  1  0  0  0
 17 47  1  0  0  0
 18 19  2  0  0  0
 18 24  1  0  0  0
 19 20  1  0  0  0
 19 48  1  0  0  0
 20 21  1  0  0  0
 21 22  1  0  0  0
 22 23  1  0  0  0
 22 49  1  0  0  0
 22 50  1  0  0  0
 23 51  1  0  0  0
 23 52  1  0  0  0
 24 25  1  0  0  0
 24 28  2  0  0  0
 25 26  2  0  0  0
 25 53  1  0  0  0
 26 27  1  0  0  0
 27 28  1  0  0  0
 27 29  1  0  0  0
 28 54  1  0  0  0
 29 30  1  0  0  0
 29 31  1  0  0  0
 29 32  1  0  0  0
 30 55  1  0  0  0
 30 56  1  0  0  0
 30 57  1  0  0  0
 31 58  1  0  0  0
 31 59  1  0  0  0
 31 60  1  0  0  0
 32 33  2  0  0  0
 32 34  1  0  0  0
 34 61  1  0  0  0
 34 62  1  0  0  0
M  END
> <s_m_entry_id>
349

> <Applicants>
Hoffmann-La Roche

> <CHEMBL_ID>
CHEMBL2387080

> <Canonical_Smiles>
O1CCn2cc(nc2-c2c1cc(cc2)-c1cn(nc1)C(C(=O)N)(C)C)-c1nc(nn1C(C)C)C

> <Chirality>
Racemic Mixture

> <First_Approval>
nan

> <Phase>
3

> <SC_Patent>
None

> <Synonyms>
GDC-0032 | RG-7604 | TASELISIB

> <Indications>
nan

> <Type>
1

> <targets_id>
P42336|O00329|P48736

> <inchi>
InChI=1S/C24H28N8O2/c1-14(2)32-22(27-15(3)29-32)19-13-30-8-9-34-20-10-16(6-7-18(20)21(30)28-19)17-11-26-31(12-17)24(4,5)23(25)33/h6-7,10-14H,8-9H2,1-5H3,(H2,25,33)

> <stdInchikey>
BEUQXVWXFDOSAQ-UHFFFAOYSA-N

> <csid>
29315044

> <Links>
|http://www.chemspider.com/Chemical-Structure.29315044.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2387080|http://pubchem.ncbi.nlm.nih.gov/compound/51001932|http://www.drugbank.ca/drugs/DB12108| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=799|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/799|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7794|http://zinc15.docking.org/substances/ZINC000068267049|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=L08J2O299M|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50434806

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
460.2

> <HBA>
9

> <HBD>
1

> <NRB>
5

> <TPSA>
118.7

> <LogP>
3.2

> <RoF>
0

> <Targets>
PIK3CA; PIK3CD; PIK3CG

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0227

> <r_epik_State_Penalty>
  0.0183

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
349

> <lig_pdbID>
'799'

> <pdbID>
5t8f

> <Kinase families>
Atypical

$$$$
Rociletinib
                    3D
 Structure written by MMmdl.
 68 71  0  0  1  0            999 V2000
   -3.0473   10.5472   -0.9486 C   0  0  0  0  0  0
   -3.9013    9.4292   -0.3423 C   0  0  0  0  0  0
   -4.7363    9.7440    0.5070 O   0  0  0  0  0  0
   -3.7167    8.1486   -0.7570 N   0  0  0  0  0  0
   -2.6400    7.7238   -1.6653 C   0  0  0  0  0  0
   -1.6737    6.8538   -0.8250 C   0  0  0  0  0  0
   -2.3426    5.6767   -0.2395 N   0  0  0  0  0  0
   -3.4276    6.1803    0.6232 C   0  0  0  0  0  0
   -4.4599    7.0278   -0.1599 C   0  0  0  0  0  0
   -1.6191    4.5701    0.2000 C   0  0  0  0  0  0
   -2.2841    3.3619    0.4329 C   0  0  0  0  0  0
   -1.5907    2.2341    0.8619 C   0  0  0  0  0  0
   -0.2096    2.2797    1.0562 C   0  0  0  0  0  0
    0.4848    3.4883    0.8573 C   0  0  0  0  0  0
   -0.2337    4.6156    0.4188 C   0  0  0  0  0  0
    1.8402    3.5204    1.1411 O   0  0  0  0  0  0
    2.5915    4.7023    0.8878 C   0  0  0  0  0  0
    0.4207    1.0976    1.4842 N   0  0  0  0  0  0
    1.5711    0.4584    1.0002 C   0  0  0  0  0  0
    2.2149    0.9604   -0.0850 N   0  0  0  0  0  0
    3.3124    0.2873   -0.5073 C   0  0  0  0  0  0
    3.7826   -0.8742    0.1194 C   0  0  0  0  0  0
    3.0474   -1.3262    1.2348 C   0  0  0  0  0  0
    1.9373   -0.6653    1.6632 N   0  0  0  0  0  0
    3.4551   -2.4907    1.9134 N   0  0  0  0  0  0
    2.9839   -3.1685    3.0526 C   0  0  0  0  0  0
    2.1951   -2.5689    4.0441 C   0  0  0  0  0  0
    1.7833   -3.3008    5.1567 C   0  0  0  0  0  0
    2.1545   -4.6367    5.2956 C   0  0  0  0  0  0
    2.9430   -5.2545    4.3123 C   0  0  0  0  0  0
    3.3601   -4.5070    3.2062 C   0  0  0  0  0  0
    3.3917   -6.5865    4.3806 N   0  0  0  0  0  0
    2.8625   -7.6206    5.0701 C   0  0  0  0  0  0
    1.8325   -7.5639    5.7461 O   0  0  0  0  0  0
    3.6456   -8.8281    4.9318 C   0  0  0  0  0  0
    3.3060   -9.9889    5.5233 C   0  0  0  0  0  0
    5.0323   -1.5923   -0.4004 C   0  0  0  0  0  0
    5.9638   -1.6279    0.5530 F   0  0  0  0  0  0
    4.7251   -2.8424   -0.7482 F   0  0  0  0  0  0
    5.5590   -0.9874   -1.4669 F   0  0  0  0  0  0
   -1.9921   10.3910   -0.7227 H   0  0  0  0  0  0
   -3.3358   11.5167   -0.5410 H   0  0  0  0  0  0
   -3.1765   10.5885   -2.0304 H   0  0  0  0  0  0
   -3.0755    7.1293   -2.4696 H   0  0  0  0  0  0
   -2.1067    8.5507   -2.1323 H   0  0  0  0  0  0
   -0.8735    6.5166   -1.4851 H   0  0  0  0  0  0
   -1.2061    7.4511   -0.0394 H   0  0  0  0  0  0
   -3.9612    5.3475    1.0817 H   0  0  0  0  0  0
   -3.0045    6.7607    1.4457 H   0  0  0  0  0  0
   -5.2701    7.3537    0.4940 H   0  0  0  0  0  0
   -4.9064    6.4346   -0.9588 H   0  0  0  0  0  0
   -3.3500    3.2857    0.2725 H   0  0  0  0  0  0
   -2.1359    1.3154    1.0265 H   0  0  0  0  0  0
    0.2846    5.5490    0.2670 H   0  0  0  0  0  0
    3.6377    4.5195    1.1321 H   0  0  0  0  0  0
    2.2498    5.5340    1.5055 H   0  0  0  0  0  0
    2.5446    4.9891   -0.1638 H   0  0  0  0  0  0
   -0.1429    0.5065    2.0770 H   0  0  0  0  0  0
    3.8112    0.7065   -1.3689 H   0  0  0  0  0  0
    4.1529   -3.0114    1.4027 H   0  0  0  0  0  0
    1.9088   -1.5309    3.9886 H   0  0  0  0  0  0
    1.1850   -2.8269    5.9208 H   0  0  0  0  0  0
    1.8377   -5.1632    6.1826 H   0  0  0  0  0  0
    3.9801   -4.9738    2.4527 H   0  0  0  0  0  0
    4.1549   -6.8065    3.7580 H   0  0  0  0  0  0
    4.5390   -8.7769    4.3238 H   0  0  0  0  0  0
    2.4234  -10.0895    6.1398 H   0  0  0  0  0  0
    3.9198  -10.8684    5.3945 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 41  1  0  0  0
  1 42  1  0  0  0
  1 43  1  0  0  0
  2  3  2  0  0  0
  2  4  1  0  0  0
  4  5  1  0  0  0
  4  9  1  0  0  0
  5  6  1  0  0  0
  5 44  1  0  0  0
  5 45  1  0  0  0
  6  7  1  0  0  0
  6 46  1  0  0  0
  6 47  1  0  0  0
  7  8  1  0  0  0
  7 10  1  0  0  0
  8  9  1  0  0  0
  8 48  1  0  0  0
  8 49  1  0  0  0
  9 50  1  0  0  0
  9 51  1  0  0  0
 10 11  1  0  0  0
 10 15  2  0  0  0
 11 12  2  0  0  0
 11 52  1  0  0  0
 12 13  1  0  0  0
 12 53  1  0  0  0
 13 14  2  0  0  0
 13 18  1  0  0  0
 14 15  1  0  0  0
 14 16  1  0  0  0
 15 54  1  0  0  0
 16 17  1  0  0  0
 17 55  1  0  0  0
 17 56  1  0  0  0
 17 57  1  0  0  0
 18 19  1  0  0  0
 18 58  1  0  0  0
 19 20  1  0  0  0
 19 24  2  0  0  0
 20 21  2  0  0  0
 21 22  1  0  0  0
 21 59  1  0  0  0
 22 23  2  0  0  0
 22 37  1  0  0  0
 23 24  1  0  0  0
 23 25  1  0  0  0
 25 26  1  0  0  0
 25 60  1  0  0  0
 26 27  1  0  0  0
 26 31  2  0  0  0
 27 28  2  0  0  0
 27 61  1  0  0  0
 28 29  1  0  0  0
 28 62  1  0  0  0
 29 30  2  0  0  0
 29 63  1  0  0  0
 30 31  1  0  0  0
 30 32  1  0  0  0
 31 64  1  0  0  0
 32 33  1  0  0  0
 32 65  1  0  0  0
 33 34  2  0  0  0
 33 35  1  0  0  0
 35 36  2  0  0  0
 35 66  1  0  0  0
 36 67  1  0  0  0
 36 68  1  0  0  0
 37 38  1  0  0  0
 37 39  1  0  0  0
 37 40  1  0  0  0
M  END
> <s_m_entry_id>
351

> <Applicants>
Clovis Oncology

> <CHEMBL_ID>
CHEMBL3545308

> <Canonical_Smiles>
FC(F)(F)c1cnc(nc1Nc1cc(NC(=O)C=C)ccc1)Nc1ccc(N2CCN(CC2)C(=O)C)cc1OC

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
3

> <SC_Patent>
None

> <Synonyms>
AVL-301 | CNX-419 | CO-1686 | CS-1631 | ROCILETINIB

> <Indications>
nan

> <Type>
1

> <targets_id>
P00533

> <inchi>
InChI=1S/C27H28F3N7O3/c1-4-24(39)32-18-6-5-7-19(14-18)33-25-21(27(28,29)30)16-31-26(35-25)34-22-9-8-20(15-23(22)40-3)37-12-10-36(11-13-37)17(2)38/h4-9,14-16H,1,10-13H2,2-3H3,(H,32,39)(H2,31,33,34,35)

> <stdInchikey>
HUFOZJXAKZVRNJ-UHFFFAOYSA-N

> <csid>
30646712

> <Links>
|http://www.chemspider.com/Chemical-Structure.30646712.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3545308|http://pubchem.ncbi.nlm.nih.gov/compound/57335384|http://www.drugbank.ca/drugs/DB11907| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=8JC|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/8JC|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7966|http://zinc15.docking.org/substances/ZINC000098043800|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=72AH61702G|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=149404

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
555.2

> <HBA>
8

> <HBD>
3

> <NRB>
8

> <TPSA>
111.7

> <LogP>
4.8

> <RoF>
1

> <Targets>
EGFR

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0144

> <r_epik_State_Penalty>
  0.0099

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
351

> <lig_pdbID>
'8JC'

> <pdbID>
5xdk 5xdl

> <Kinase families>
Tyr

$$$$
Masitinib
                    3D
 Structure written by MMmdl.
 67 71  0  0  1  0            999 V2000
   -4.4742    0.0918   -0.4582 C   0  0  0  0  0  0
   -2.9542    0.1511   -0.3479 C   0  0  0  0  0  0
   -2.2035   -0.9345   -0.8090 C   0  0  0  0  0  0
   -0.8132   -0.9218   -0.7290 C   0  0  0  0  0  0
   -0.1469    0.1828   -0.1980 C   0  0  0  0  0  0
   -0.8973    1.2679    0.2799 C   0  0  0  0  0  0
   -2.2996    1.2648    0.2104 C   0  0  0  0  0  0
   -3.0570    2.3548    0.6818 N   0  0  0  0  0  0
   -2.5735    3.4522    1.3462 C   0  0  0  0  0  0
   -2.5891    4.6694    0.8682 N   0  0  0  0  0  0
   -2.0988    5.5660    1.7127 C   0  0  0  0  0  0
   -1.6937    5.0231    2.9375 C   0  0  0  0  0  0
   -1.9709    3.3089    2.9629 S   0  0  0  0  0  0
   -2.0198    7.0120    1.3221 C   0  0  0  0  0  0
   -2.1336    7.4310   -0.0135 C   0  0  0  0  0  0
   -2.0564    8.7878   -0.3331 C   0  0  0  0  0  0
   -1.8654    9.7039    0.7005 C   0  0  0  0  0  0
   -1.7515    9.3334    2.0002 N   0  0  0  0  0  0
   -1.8288    8.0091    2.2902 C   0  0  0  0  0  0
    1.2564    0.1088   -0.1386 N   0  0  0  0  0  0
    2.1520    1.1218   -0.0825 C   0  0  0  0  0  0
    1.8610    2.3180   -0.1458 O   0  0  0  0  0  0
    3.5998    0.7031    0.0274 C   0  0  0  0  0  0
    4.5995    1.5029   -0.5424 C   0  0  0  0  0  0
    5.9394    1.1401   -0.4366 C   0  0  0  0  0  0
    6.2953   -0.0232    0.2474 C   0  0  0  0  0  0
    5.3073   -0.8304    0.8120 C   0  0  0  0  0  0
    3.9674   -0.4678    0.7077 C   0  0  0  0  0  0
    7.7577   -0.4291    0.3579 C   0  0  0  0  0  0
    8.4113   -0.0833    1.7162 N   0  3  0  0  0  0
    8.4811    1.4455    1.9390 C   0  0  0  0  0  0
    9.2294    1.7537    3.2572 C   0  0  0  0  0  0
   10.5481    1.1183    3.3529 N   0  0  0  0  0  0
   10.4824   -0.3325    3.1489 C   0  0  0  0  0  0
    9.8048   -0.7434    1.8212 C   0  0  0  0  0  0
   11.5408    1.7596    2.4922 C   0  0  0  0  0  0
   -4.8409    0.9023   -1.0889 H   0  0  0  0  0  0
   -4.9322    0.1887    0.5268 H   0  0  0  0  0  0
   -4.8182   -0.8478   -0.8922 H   0  0  0  0  0  0
   -2.6960   -1.7980   -1.2326 H   0  0  0  0  0  0
   -0.2582   -1.7757   -1.0911 H   0  0  0  0  0  0
   -0.3974    2.1156    0.7214 H   0  0  0  0  0  0
   -4.0509    2.2509    0.5399 H   0  0  0  0  0  0
   -1.2656    5.5255    3.7918 H   0  0  0  0  0  0
   -2.2792    6.7127   -0.8071 H   0  0  0  0  0  0
   -2.1424    9.1195   -1.3572 H   0  0  0  0  0  0
   -1.8008   10.7620    0.4931 H   0  0  0  0  0  0
   -1.7379    7.7614    3.3374 H   0  0  0  0  0  0
    1.6330   -0.8267   -0.1806 H   0  0  0  0  0  0
    4.3461    2.4106   -1.0726 H   0  0  0  0  0  0
    6.6974    1.7675   -0.8830 H   0  0  0  0  0  0
    5.5753   -1.7356    1.3378 H   0  0  0  0  0  0
    3.2231   -1.1029    1.1671 H   0  0  0  0  0  0
    7.8582   -1.5117    0.2590 H   0  0  0  0  0  0
    8.3785    0.0457   -0.4050 H   0  0  0  0  0  0
    8.9780    1.8813    1.0707 H   0  0  0  0  0  0
    7.4549    1.8123    1.9760 H   0  0  0  0  0  0
    9.3280    2.8321    3.3903 H   0  0  0  0  0  0
    8.6252    1.4127    4.0995 H   0  0  0  0  0  0
   11.4847   -0.7597    3.2082 H   0  0  0  0  0  0
    9.9314   -0.7695    3.9831 H   0  0  0  0  0  0
    9.6497   -1.8220    1.7720 H   0  0  0  0  0  0
   10.3833   -0.4328    0.9497 H   0  0  0  0  0  0
   12.5242    1.3126    2.6436 H   0  0  0  0  0  0
   11.6262    2.8201    2.7322 H   0  0  0  0  0  0
   11.2901    1.6726    1.4348 H   0  0  0  0  0  0
    7.8332   -0.4743    2.4469 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 37  1  0  0  0
  1 38  1  0  0  0
  1 39  1  0  0  0
  2  3  1  0  0  0
  2  7  2  0  0  0
  3  4  2  0  0  0
  3 40  1  0  0  0
  4  5  1  0  0  0
  4 41  1  0  0  0
  5  6  2  0  0  0
  5 20  1  0  0  0
  6  7  1  0  0  0
  6 42  1  0  0  0
  7  8  1  0  0  0
  8  9  1  0  0  0
  8 43  1  0  0  0
  9 10  2  0  0  0
  9 13  1  0  0  0
 10 11  1  0  0  0
 11 12  2  0  0  0
 11 14  1  0  0  0
 12 13  1  0  0  0
 12 44  1  0  0  0
 14 15  1  0  0  0
 14 19  2  0  0  0
 15 16  2  0  0  0
 15 45  1  0  0  0
 16 17  1  0  0  0
 16 46  1  0  0  0
 17 18  2  0  0  0
 17 47  1  0  0  0
 18 19  1  0  0  0
 19 48  1  0  0  0
 20 21  1  0  0  0
 20 49  1  0  0  0
 21 22  2  0  0  0
 21 23  1  0  0  0
 23 24  1  0  0  0
 23 28  2  0  0  0
 24 25  2  0  0  0
 24 50  1  0  0  0
 25 26  1  0  0  0
 25 51  1  0  0  0
 26 27  2  0  0  0
 26 29  1  0  0  0
 27 28  1  0  0  0
 27 52  1  0  0  0
 28 53  1  0  0  0
 29 30  1  0  0  0
 29 54  1  0  0  0
 29 55  1  0  0  0
 30 31  1  0  0  0
 30 35  1  0  0  0
 30 67  1  0  0  0
 31 32  1  0  0  0
 31 56  1  0  0  0
 31 57  1  0  0  0
 32 33  1  0  0  0
 32 58  1  0  0  0
 32 59  1  0  0  0
 33 34  1  0  0  0
 33 36  1  0  0  0
 34 35  1  0  0  0
 34 60  1  0  0  0
 34 61  1  0  0  0
 35 62  1  0  0  0
 35 63  1  0  0  0
 36 64  1  0  0  0
 36 65  1  0  0  0
 36 66  1  0  0  0
M  CHG  1  30   1
M  END
> <s_m_entry_id>
353

> <Applicants>
AB Science

> <CHEMBL_ID>
CHEMBL1908391

> <Canonical_Smiles>
s1cc(nc1Nc1cc(NC(=O)c2ccc(cc2)CN2CCN(CC2)C)ccc1C)-c1cccnc1

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
3

> <SC_Patent>
None

> <Synonyms>
AB-1010 | KINAVET | MASITINIB | MASIVET

> <Indications>
nan

> <Type>
nan

> <targets_id>
P10721|P16234|P09619|P11362|P21802|P22607

> <inchi>
InChI=1S/C28H30N6OS/c1-20-5-10-24(16-25(20)31-28-32-26(19-36-28)23-4-3-11-29-17-23)30-27(35)22-8-6-21(7-9-22)18-34-14-12-33(2)13-15-34/h3-11,16-17,19H,12-15,18H2,1-2H3,(H,30,35)(H,31,32)

> <stdInchikey>
WJEOLQLKVOPQFV-UHFFFAOYSA-N

> <csid>
8250179

> <Links>
|http://www.chemspider.com/Chemical-Structure.8250179.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1908391|http://pubchem.ncbi.nlm.nih.gov/compound/10074640|http://www.drugbank.ca/drugs/DB11526| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=G65|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/G65|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5656|http://zinc15.docking.org/substances/ZINC34177219|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=M59NC4E26P|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50355495

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
498.2

> <HBA>
7

> <HBD>
2

> <NRB>
7

> <TPSA>
73.4

> <LogP>
5.3

> <RoF>
1

> <Targets>
KIT; PDGFRA; PDGFRB; FGFR1; FGFR2; FGFR3

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_epik_Ionization_Penalty>
  0.0178

> <r_epik_State_Penalty>
  0.2066

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
353

> <lig_pdbID>
'G65'

> <pdbID>
5mql 7ju7

> <Kinase families>
Tyr

> <BrandName>
Kinavet;Masivet

$$$$
Fruquintinib
                    3D
 Structure written by MMmdl.
 48 51  0  0  1  0            999 V2000
   -4.2649    4.7975   -2.5981 C   0  0  0  0  0  0
   -3.2806    4.4742   -1.4930 C   0  0  0  0  0  0
   -2.7448    5.2004   -0.4153 C   0  0  0  0  0  0
   -1.8500    4.2724    0.2390 C   0  0  0  0  0  0
   -0.9870    4.3013    1.3516 C   0  0  0  0  0  0
   -0.2600    3.1543    1.6788 C   0  0  0  0  0  0
   -0.3553    1.9827    0.9186 C   0  0  0  0  0  0
   -1.2072    1.9190   -0.1842 C   0  0  0  0  0  0
   -1.9325    3.0728   -0.5012 C   0  0  0  0  0  0
   -2.7937    3.2019   -1.5434 O   0  0  0  0  0  0
    0.3563    0.8551    1.2672 O   0  0  0  0  0  0
    1.7425    0.8150    1.2716 C   0  0  0  0  0  0
    2.3918   -0.3489    1.7650 C   0  0  0  0  0  0
    1.7218   -1.4919    2.2608 C   0  0  0  0  0  0
    2.4460   -2.5979    2.7336 C   0  0  0  0  0  0
    3.8476   -2.5756    2.7180 C   0  0  0  0  0  0
    4.5265   -1.4490    2.2264 C   0  0  0  0  0  0
    3.8163   -0.3276    1.7462 C   0  0  0  0  0  0
    4.5118    0.7482    1.2774 N   0  0  0  0  0  0
    3.7803    1.7972    0.8280 C   0  0  0  0  0  0
    2.4311    1.8910    0.7977 N   0  0  0  0  0  0
    4.4946   -3.6997    3.2025 O   0  0  0  0  0  0
    5.9176   -3.7315    3.2412 C   0  0  0  0  0  0
    1.8459   -3.7425    3.2299 O   0  0  0  0  0  0
    0.4255   -3.8290    3.2782 C   0  0  0  0  0  0
   -3.0456    6.5852   -0.1270 C   0  0  0  0  0  0
   -3.5467    7.3325   -0.9689 O   0  0  0  0  0  0
   -2.7262    6.9684    1.1212 N   0  0  0  0  0  0
   -2.9217    8.3075    1.6651 C   0  0  0  0  0  0
   -4.9320    5.6187   -2.3388 H   0  0  0  0  0  0
   -4.9021    3.9443   -2.8320 H   0  0  0  0  0  0
   -3.7509    5.0762   -3.5179 H   0  0  0  0  0  0
   -0.8795    5.1910    1.9536 H   0  0  0  0  0  0
    0.3966    3.1758    2.5364 H   0  0  0  0  0  0
   -1.2968    1.0172   -0.7718 H   0  0  0  0  0  0
    0.6424   -1.4861    2.2640 H   0  0  0  0  0  0
    5.6053   -1.4096    2.2030 H   0  0  0  0  0  0
    4.3323    2.6483    0.4564 H   0  0  0  0  0  0
    6.2439   -4.6848    3.6562 H   0  0  0  0  0  0
    6.3184   -2.9410    3.8777 H   0  0  0  0  0  0
    6.3481   -3.6429    2.2427 H   0  0  0  0  0  0
    0.1387   -4.7942    3.6952 H   0  0  0  0  0  0
   -0.0146   -3.7573    2.2825 H   0  0  0  0  0  0
   -0.0010   -3.0544    3.9174 H   0  0  0  0  0  0
   -2.3132    6.2886    1.7427 H   0  0  0  0  0  0
   -3.4270    8.2418    2.6287 H   0  0  0  0  0  0
   -3.5195    8.9496    1.0167 H   0  0  0  0  0  0
   -1.9557    8.7874    1.8222 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 30  1  0  0  0
  1 31  1  0  0  0
  1 32  1  0  0  0
  2  3  2  0  0  0
  2 10  1  0  0  0
  3  4  1  0  0  0
  3 26  1  0  0  0
  4  5  1  0  0  0
  4  9  2  0  0  0
  5  6  2  0  0  0
  5 33  1  0  0  0
  6  7  1  0  0  0
  6 34  1  0  0  0
  7  8  2  0  0  0
  7 11  1  0  0  0
  8  9  1  0  0  0
  8 35  1  0  0  0
  9 10  1  0  0  0
 11 12  1  0  0  0
 12 13  1  0  0  0
 12 21  2  0  0  0
 13 14  1  0  0  0
 13 18  2  0  0  0
 14 15  2  0  0  0
 14 36  1  0  0  0
 15 16  1  0  0  0
 15 24  1  0  0  0
 16 17  2  0  0  0
 16 22  1  0  0  0
 17 18  1  0  0  0
 17 37  1  0  0  0
 18 19  1  0  0  0
 19 20  2  0  0  0
 20 21  1  0  0  0
 20 38  1  0  0  0
 22 23  1  0  0  0
 23 39  1  0  0  0
 23 40  1  0  0  0
 23 41  1  0  0  0
 24 25  1  0  0  0
 25 42  1  0  0  0
 25 43  1  0  0  0
 25 44  1  0  0  0
 26 27  2  0  0  0
 26 28  1  0  0  0
 28 29  1  0  0  0
 28 45  1  0  0  0
 29 46  1  0  0  0
 29 47  1  0  0  0
 29 48  1  0  0  0
M  END
> <s_m_entry_id>
359

> <Applicants>
Hutchison MediPharma

> <CHEMBL_ID>
CHEMBL3545339

> <Canonical_Smiles>
o1c2c(ccc(Oc3ncnc4c3cc(OC)c(OC)c4)c2)c(C(=O)NC)c1C

> <Chirality>
Single Stereoisomer

> <First_Approval>
nan

> <Phase>
3

> <SC_Patent>
None

> <Synonyms>
HMP-013|HMPL-013

> <Indications>
nan

> <Type>
nan

> <targets_id>
P17948|P35968|P35916

> <inchi>
InChI=1S/C21H19N3O5/c1-11-19(20(25)22-2)13-6-5-12(7-16(13)28-11)29-21-14-8-17(26-3)18(27-4)9-15(14)23-10-24-21/h5-10H,1-4H3,(H,22,25)

> <stdInchikey>
BALLNEJQLSTPIO-UHFFFAOYSA-N

> <csid>
39625837

> <Links>
|http://www.chemspider.com/Chemical-Structure.39625837.html|http://pubchem.ncbi.nlm.nih.gov/compound/44480399|http://www.drugbank.ca/drugs/DB11679|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9428|http://zinc15.docking.org/substances/ZINC000114898570|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=49DXG3M5ZW

> <LinkName>
|ChemSpider|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS

> <indicationG2P>
None

> <MW>
393.1

> <HBA>
7

> <HBD>
1

> <NRB>
5

> <TPSA>
95.7

> <LogP>
3.9

> <RoF>
0

> <Targets>
FLT1; KDR; FLT4

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0007

> <r_epik_State_Penalty>
  0.0005

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
359

> <Kinase families>
Tyr

$$$$
Motesanib
                    3D
 Structure written by MMmdl.
 51 54  0  0  1  0            999 V2000
   -6.7644   -2.6080   -1.4355 C   0  0  0  0  0  0
   -6.0082   -2.7834   -0.1005 C   0  0  0  0  0  0
   -5.6683   -4.2769    0.1388 C   0  0  0  0  0  0
   -4.2163   -4.3556    0.1956 N   0  0  0  0  0  0
   -3.6547   -3.0928    0.0251 C   0  0  0  0  0  0
   -4.6420   -2.1325   -0.1496 C   0  0  0  0  0  0
   -4.2841   -0.7946   -0.3299 C   0  0  0  0  0  0
   -2.9370   -0.4302   -0.3411 C   0  0  0  0  0  0
   -1.9358   -1.4047   -0.1808 C   0  0  0  0  0  0
   -2.3052   -2.7395    0.0171 C   0  0  0  0  0  0
   -0.5597   -1.1169   -0.1630 N   0  0  0  0  0  0
    0.0849   -0.0851   -0.7533 C   0  0  0  0  0  0
   -0.4543    0.7697   -1.4589 O   0  0  0  0  0  0
    1.5746   -0.0267   -0.4901 C   0  0  0  0  0  0
    2.3384   -1.2034   -0.5750 C   0  0  0  0  0  0
    3.7134   -1.1696   -0.3536 C   0  0  0  0  0  0
    4.3043    0.0519   -0.0489 C   0  0  0  0  0  0
    3.5982    1.2037    0.0427 N   0  0  0  0  0  0
    2.2516    1.1781   -0.1746 C   0  0  0  0  0  0
    1.5442    2.3914   -0.0428 N   0  0  0  0  0  0
    2.2249    3.6766    0.0703 C   0  0  0  0  0  0
    1.2038    4.7753    0.3054 C   0  0  0  0  0  0
    0.9026    5.1986    1.6048 C   0  0  0  0  0  0
   -0.0451    6.2097    1.7762 C   0  0  0  0  0  0
   -0.6881    6.8031    0.7379 N   0  0  0  0  0  0
   -0.3838    6.3832   -0.5169 C   0  0  0  0  0  0
    0.5514    5.3793   -0.7758 C   0  0  0  0  0  0
   -6.8590   -2.2288    1.0630 C   0  0  0  0  0  0
   -7.7152   -3.1428   -1.4286 H   0  0  0  0  0  0
   -6.1828   -2.9867   -2.2774 H   0  0  0  0  0  0
   -6.9815   -1.5580   -1.6365 H   0  0  0  0  0  0
   -6.0890   -4.6602    1.0695 H   0  0  0  0  0  0
   -6.0374   -4.9244   -0.6580 H   0  0  0  0  0  0
   -3.8210   -5.2726    0.3469 H   0  0  0  0  0  0
   -5.0390   -0.0327   -0.4565 H   0  0  0  0  0  0
   -2.6932    0.6144   -0.4597 H   0  0  0  0  0  0
   -1.5458   -3.4959    0.1562 H   0  0  0  0  0  0
    0.0115   -1.7946    0.3200 H   0  0  0  0  0  0
    1.8763   -2.1490   -0.8218 H   0  0  0  0  0  0
    4.3065   -2.0697   -0.4207 H   0  0  0  0  0  0
    5.3676    0.1217    0.1283 H   0  0  0  0  0  0
    0.6104    2.4061   -0.4281 H   0  0  0  0  0  0
    2.9500    3.6552    0.8854 H   0  0  0  0  0  0
    2.7802    3.8772   -0.8472 H   0  0  0  0  0  0
    1.3874    4.7532    2.4614 H   0  0  0  0  0  0
   -0.3034    6.5591    2.7651 H   0  0  0  0  0  0
   -0.9080    6.8680   -1.3275 H   0  0  0  0  0  0
    0.7598    5.0748   -1.7913 H   0  0  0  0  0  0
   -7.8142   -2.7496    1.1412 H   0  0  0  0  0  0
   -7.0756   -1.1679    0.9297 H   0  0  0  0  0  0
   -6.3480   -2.3383    2.0208 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 29  1  0  0  0
  1 30  1  0  0  0
  1 31  1  0  0  0
  2  3  1  0  0  0
  2  6  1  0  0  0
  2 28  1  0  0  0
  3  4  1  0  0  0
  3 32  1  0  0  0
  3 33  1  0  0  0
  4  5  1  0  0  0
  4 34  1  0  0  0
  5  6  1  0  0  0
  5 10  2  0  0  0
  6  7  2  0  0  0
  7  8  1  0  0  0
  7 35  1  0  0  0
  8  9  2  0  0  0
  8 36  1  0  0  0
  9 10  1  0  0  0
  9 11  1  0  0  0
 10 37  1  0  0  0
 11 12  1  0  0  0
 11 38  1  0  0  0
 12 13  2  0  0  0
 12 14  1  0  0  0
 14 15  1  0  0  0
 14 19  2  0  0  0
 15 16  2  0  0  0
 15 39  1  0  0  0
 16 17  1  0  0  0
 16 40  1  0  0  0
 17 18  2  0  0  0
 17 41  1  0  0  0
 18 19  1  0  0  0
 19 20  1  0  0  0
 20 21  1  0  0  0
 20 42  1  0  0  0
 21 22  1  0  0  0
 21 43  1  0  0  0
 21 44  1  0  0  0
 22 23  1  0  0  0
 22 27  2  0  0  0
 23 24  2  0  0  0
 23 45  1  0  0  0
 24 25  1  0  0  0
 24 46  1  0  0  0
 25 26  2  0  0  0
 26 27  1  0  0  0
 26 47  1  0  0  0
 27 48  1  0  0  0
 28 49  1  0  0  0
 28 50  1  0  0  0
 28 51  1  0  0  0
M  END
> <s_m_entry_id>
360

> <Applicants>
Amgen

> <CHEMBL_ID>
CHEMBL572881

> <Canonical_Smiles>
O=C(Nc1cc2NCC(c2cc1)(C)C)c1cccnc1NCc1ccncc1

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
3

> <SC_Patent>
None

> <Synonyms>
AMG 706 | AMG-706 | MOTESANIB

> <Indications>
nan

> <Type>
2

> <targets_id>
P17948|P35968|P35916|P16234|P09619|P10721|P07949

> <inchi>
InChI=1S/C22H23N5O/c1-22(2)14-26-19-12-16(5-6-18(19)22)27-21(28)17-4-3-9-24-20(17)25-13-15-7-10-23-11-8-15/h3-12,26H,13-14H2,1-2H3,(H,24,25)(H,27,28)

> <stdInchikey>
RAHBGWKEPAQNFF-UHFFFAOYSA-N

> <csid>
9842625

> <Links>
|http://www.chemspider.com/Chemical-Structure.9842625.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL572881|http://pubchem.ncbi.nlm.nih.gov/compound/11667893|http://www.drugbank.ca/drugs/DB05575| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=706|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/706|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5660|http://zinc15.docking.org/substances/ZINC18710082|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=U1JK633AYI|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=24773

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
373.2

> <HBA>
5

> <HBD>
3

> <NRB>
5

> <TPSA>
78.9

> <LogP>
4

> <RoF>
0

> <Targets>
FLT1; KDR; FLT4; PDGFRA; PDGFRB; KIT; RET

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.2364

> <r_epik_State_Penalty>
  0.2125

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
360

> <lig_pdbID>
'706'

> <pdbID>
3efl

> <Kinase families>
Tyr

$$$$
Momelotinib
                    3D
 Structure written by MMmdl.
 53 56  0  0  1  0            999 V2000
   -0.9248   -0.8375   -0.3857 C   0  0  0  0  0  0
   -2.3103   -0.7179   -0.4393 C   0  0  0  0  0  0
   -2.9209    0.5279   -0.2617 C   0  0  0  0  0  0
   -2.1167    1.6501   -0.0227 C   0  0  0  0  0  0
   -0.7311    1.5250    0.0288 C   0  0  0  0  0  0
   -0.1131    0.2814   -0.1527 C   0  0  0  0  0  0
    1.3756    0.1563   -0.0957 C   0  0  0  0  0  0
    2.2348    1.1856   -0.5054 C   0  0  0  0  0  0
    3.6069    0.9495   -0.4161 C   0  0  0  0  0  0
    4.1157   -0.2221    0.0418 N   0  0  0  0  0  0
    3.2233   -1.1753    0.4117 C   0  0  0  0  0  0
    1.8727   -1.0272    0.3636 N   0  0  0  0  0  0
    3.7888   -2.3671    0.8901 N   0  0  0  0  0  0
    3.2403   -3.5576    1.4006 C   0  0  0  0  0  0
    4.0665   -4.3519    2.1958 C   0  0  0  0  0  0
    3.5934   -5.5448    2.7353 C   0  0  0  0  0  0
    2.2802   -5.9718    2.4893 C   0  0  0  0  0  0
    1.4637   -5.1781    1.6740 C   0  0  0  0  0  0
    1.9353   -3.9856    1.1327 C   0  0  0  0  0  0
    1.7780   -7.1630    3.0111 N   0  0  0  0  0  0
    0.5457   -7.1125    3.8162 C   0  0  0  0  0  0
   -0.1397   -8.4930    3.9079 C   0  0  0  0  0  0
    0.7548   -9.4688    4.4282 O   0  0  0  0  0  0
    1.9730   -9.5580    3.6997 C   0  0  0  0  0  0
    2.6613   -8.1791    3.6072 C   0  0  0  0  0  0
   -4.4259    0.6382   -0.3145 C   0  0  0  0  0  0
   -5.1411   -0.3094    0.0156 O   0  0  0  0  0  0
   -4.9208    1.8009   -0.7778 N   0  0  0  0  0  0
   -6.3447    2.0988   -0.9047 C   0  0  0  0  0  0
   -6.9917    2.3160    0.4007 C   0  0  0  0  0  0
   -7.5000    2.4872    1.4260 N   0  0  0  0  0  0
   -0.4843   -1.8130   -0.5333 H   0  0  0  0  0  0
   -2.9024   -1.6036   -0.6235 H   0  0  0  0  0  0
   -2.5534    2.6263    0.1338 H   0  0  0  0  0  0
   -0.1403    2.4078    0.2246 H   0  0  0  0  0  0
    1.8632    2.1257   -0.8846 H   0  0  0  0  0  0
    4.3195    1.7037   -0.7165 H   0  0  0  0  0  0
    4.7873   -2.2953    1.0167 H   0  0  0  0  0  0
    5.0814   -4.0465    2.4078 H   0  0  0  0  0  0
    4.2620   -6.1238    3.3549 H   0  0  0  0  0  0
    0.4556   -5.4882    1.4397 H   0  0  0  0  0  0
    1.2729   -3.4250    0.4934 H   0  0  0  0  0  0
    0.7670   -6.7346    4.8160 H   0  0  0  0  0  0
   -0.1684   -6.4137    3.3804 H   0  0  0  0  0  0
   -1.0082   -8.4331    4.5641 H   0  0  0  0  0  0
   -0.5172   -8.8039    2.9320 H   0  0  0  0  0  0
    2.6293  -10.2670    4.2043 H   0  0  0  0  0  0
    1.7914   -9.9671    2.7043 H   0  0  0  0  0  0
    3.5507   -8.2925    2.9859 H   0  0  0  0  0  0
    3.0042   -7.8584    4.5924 H   0  0  0  0  0  0
   -4.2852    2.5714   -0.9230 H   0  0  0  0  0  0
   -6.4719    2.9998   -1.5047 H   0  0  0  0  0  0
   -6.8708    1.2909   -1.4165 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1  6  2  0  0  0
  1 32  1  0  0  0
  2  3  2  0  0  0
  2 33  1  0  0  0
  3  4  1  0  0  0
  3 26  1  0  0  0
  4  5  2  0  0  0
  4 34  1  0  0  0
  5  6  1  0  0  0
  5 35  1  0  0  0
  6  7  1  0  0  0
  7  8  1  0  0  0
  7 12  2  0  0  0
  8  9  2  0  0  0
  8 36  1  0  0  0
  9 10  1  0  0  0
  9 37  1  0  0  0
 10 11  2  0  0  0
 11 12  1  0  0  0
 11 13  1  0  0  0
 13 14  1  0  0  0
 13 38  1  0  0  0
 14 15  1  0  0  0
 14 19  2  0  0  0
 15 16  2  0  0  0
 15 39  1  0  0  0
 16 17  1  0  0  0
 16 40  1  0  0  0
 17 18  2  0  0  0
 17 20  1  0  0  0
 18 19  1  0  0  0
 18 41  1  0  0  0
 19 42  1  0  0  0
 20 21  1  0  0  0
 20 25  1  0  0  0
 21 22  1  0  0  0
 21 43  1  0  0  0
 21 44  1  0  0  0
 22 23  1  0  0  0
 22 45  1  0  0  0
 22 46  1  0  0  0
 23 24  1  0  0  0
 24 25  1  0  0  0
 24 47  1  0  0  0
 24 48  1  0  0  0
 25 49  1  0  0  0
 25 50  1  0  0  0
 26 27  2  0  0  0
 26 28  1  0  0  0
 28 29  1  0  0  0
 28 51  1  0  0  0
 29 30  1  0  0  0
 29 52  1  0  0  0
 29 53  1  0  0  0
 30 31  3  0  0  0
M  END
> <s_m_entry_id>
364

> <Applicants>
Ym Biosciences Australia

> <CHEMBL_ID>
CHEMBL1078178

> <Canonical_Smiles>
O1CCN(CC1)c1ccc(Nc2nc(ccn2)-c2ccc(cc2)C(=O)NCC#N)cc1

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
3

> <SC_Patent>
None

> <Synonyms>
CYT-0387 | CYT-11387 | CYT-387 | CYT387 | GS-0387 | MOMELOTINIB

> <Indications>
nan

> <Type>
nan

> <targets_id>
P23458|O60674|P52333

> <inchi>
InChI=1S/C23H22N6O2/c24-10-12-25-22(30)18-3-1-17(2-4-18)21-9-11-26-23(28-21)27-19-5-7-20(8-6-19)29-13-15-31-16-14-29/h1-9,11H,12-16H2,(H,25,30)(H,26,27,28)

> <stdInchikey>
ZVHNDZWQTBEVRY-UHFFFAOYSA-N

> <csid>
24676202

> <Links>
|http://www.chemspider.com/Chemical-Structure.24676202.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1078178|http://pubchem.ncbi.nlm.nih.gov/compound/25062766|http://www.drugbank.ca/drugs/DB11763| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=C87|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/C87|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7791|http://zinc15.docking.org/substances/ZINC43199890|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=6O01GMS00P|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50311017

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
414.2

> <HBA>
7

> <HBD>
2

> <NRB>
6

> <TPSA>
103.2

> <LogP>
3

> <RoF>
0

> <Targets>
JAK1; JAK2; JAK3

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0002

> <r_epik_State_Penalty>
  0.0000

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
364

> <lig_pdbID>
'C87'

> <pdbID>
6fdz

> <Kinase families>
Tyr

$$$$
Brivanib alaninate
                    3D
 Structure written by MMmdl.
 57 60  0  0  1  0            999 V2000
  -10.1679    6.8477   -3.0733 C   0  0  0  0  0  0
   -8.8759    6.0818   -2.9234 C   0  0  0  0  0  0
   -8.3194    5.4243   -1.8418 C   0  0  0  0  0  0
   -7.0673    4.8638   -2.2580 C   0  0  0  0  0  0
   -6.0674    4.1057   -1.6269 C   0  0  0  0  0  0
   -6.1918    3.7542   -0.3256 F   0  0  0  0  0  0
   -4.9408    3.7231   -2.3591 C   0  0  0  0  0  0
   -3.9530    2.9805   -1.7534 O   0  0  0  0  0  0
   -2.8185    3.5820   -1.2397 C   0  0  0  0  0  0
   -2.6644    4.9360   -1.2927 N   0  0  0  0  0  0
   -1.5216    5.4365   -0.7683 C   0  0  0  0  0  0
   -0.5075    4.7426   -0.1948 N   0  0  0  0  0  0
   -0.7183    3.4122   -0.1730 N   0  0  0  0  0  0
    0.1424    2.4798    0.3428 C   0  0  0  0  0  0
   -0.4246    1.2135    0.1777 C   0  0  0  0  0  0
    0.1165    0.0079    0.5485 O   0  0  0  0  0  0
    1.5420   -0.0567    0.5602 C   0  0  0  0  0  0
    2.0009   -1.5180    0.7213 C   0  0  1  0  0  0
    1.4683   -2.1675    2.0161 C   0  0  0  0  0  0
    1.5575   -2.2346   -0.4328 O   0  0  0  0  0  0
    2.1225   -3.4002   -0.8287 C   0  0  0  0  0  0
    3.0849   -3.9379   -0.2698 O   0  0  0  0  0  0
    1.4238   -3.9263   -2.0774 C   0  0  2  0  0  0
   -0.0675   -4.2350   -1.8347 C   0  0  0  0  0  0
    2.1728   -5.1619   -2.4855 N   0  3  0  0  0  0
   -1.6661    1.3392   -0.4503 C   0  0  0  0  0  0
   -2.6299    0.2374   -0.8302 C   0  0  0  0  0  0
   -1.8490    2.7332   -0.6731 C   0  0  0  0  0  0
   -4.8086    4.0786   -3.7019 C   0  0  0  0  0  0
   -5.7771    4.8294   -4.3678 C   0  0  0  0  0  0
   -6.9006    5.2137   -3.6290 C   0  0  0  0  0  0
   -8.0140    5.9452   -3.9856 N   0  0  0  0  0  0
  -10.7339    6.8748   -2.1419 H   0  0  0  0  0  0
  -10.8155    6.4010   -3.8281 H   0  0  0  0  0  0
   -9.9911    7.8821   -3.3693 H   0  0  0  0  0  0
   -8.7705    5.3598   -0.8627 H   0  0  0  0  0  0
   -1.4041    6.5096   -0.8124 H   0  0  0  0  0  0
    1.0849    2.7667    0.7853 H   0  0  0  0  0  0
    1.9588    0.3520   -0.3635 H   0  0  0  0  0  0
    1.9378    0.5429    1.3817 H   0  0  0  0  0  0
    3.0923   -1.5200    0.7475 H   0  0  0  0  0  0
    1.7662   -1.5924    2.8933 H   0  0  0  0  0  0
    1.8569   -3.1777    2.1449 H   0  0  0  0  0  0
    0.3795   -2.2296    2.0145 H   0  0  0  0  0  0
    1.5493   -3.2360   -2.9126 H   0  0  0  0  0  0
   -0.6250   -3.3363   -1.5647 H   0  0  0  0  0  0
   -0.2104   -4.9646   -1.0352 H   0  0  0  0  0  0
   -0.5345   -4.6385   -2.7339 H   0  0  0  0  0  0
    3.1431   -4.9242   -2.6363 H   0  0  0  0  0  0
    1.7712   -5.5276   -3.3370 H   0  0  0  0  0  0
   -3.5917    0.3581   -0.3312 H   0  0  0  0  0  0
   -2.2536   -0.7511   -0.5654 H   0  0  0  0  0  0
   -2.8238    0.2288   -1.9028 H   0  0  0  0  0  0
   -3.9267    3.7675   -4.2427 H   0  0  0  0  0  0
   -5.6546    5.0984   -5.4065 H   0  0  0  0  0  0
   -8.2133    6.3467   -4.8905 H   0  0  0  0  0  0
    2.1014   -5.8484   -1.7477 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 33  1  0  0  0
  1 34  1  0  0  0
  1 35  1  0  0  0
  2  3  2  0  0  0
  2 32  1  0  0  0
  3  4  1  0  0  0
  3 36  1  0  0  0
  4  5  2  0  0  0
  4 31  1  0  0  0
  5  6  1  0  0  0
  5  7  1  0  0  0
  7  8  1  0  0  0
  7 29  2  0  0  0
  8  9  1  0  0  0
  9 10  2  0  0  0
  9 28  1  0  0  0
 10 11  1  0  0  0
 11 12  2  0  0  0
 11 37  1  0  0  0
 12 13  1  0  0  0
 13 14  1  0  0  0
 13 28  1  0  0  0
 14 15  2  0  0  0
 14 38  1  0  0  0
 15 16  1  0  0  0
 15 26  1  0  0  0
 16 17  1  0  0  0
 17 18  1  0  0  0
 17 39  1  0  0  0
 17 40  1  0  0  0
 18 19  1  0  0  0
 18 20  1  0  0  0
 18 41  1  0  0  0
 19 42  1  0  0  0
 19 43  1  0  0  0
 19 44  1  0  0  0
 20 21  1  0  0  0
 21 22  2  0  0  0
 21 23  1  0  0  0
 23 24  1  0  0  0
 23 25  1  0  0  0
 23 45  1  0  0  0
 24 46  1  0  0  0
 24 47  1  0  0  0
 24 48  1  0  0  0
 25 49  1  0  0  0
 25 50  1  0  0  0
 25 57  1  0  0  0
 26 27  1  0  0  0
 26 28  2  0  0  0
 27 51  1  0  0  0
 27 52  1  0  0  0
 27 53  1  0  0  0
 29 30  1  0  0  0
 29 54  1  0  0  0
 30 31  2  0  0  0
 30 55  1  0  0  0
 31 32  1  0  0  0
 32 56  1  0  0  0
M  CHG  1  25   1
M  END
> <s_m_entry_id>
365

> <Applicants>
Bristol Myers Squibb

> <CHEMBL_ID>
CHEMBL270995

> <Canonical_Smiles>
Fc1c2cc([nH]c2ccc1OC1=NC=Nn2c1c(C)c(OC[C@H](OC(=O)[C@@H](N)C)C)c2)C

> <Chirality>
Single Stereoisomer

> <First_Approval>
nan

> <Phase>
3

> <SC_Patent>
None

> <Synonyms>
BMS-582664 | BMS-582664-02 | BRIVANIB ALANINATE | BRIVANIB L-ALANINE ESTER

> <Indications>
nan

> <Type>
nan

> <targets_id>
nan

> <inchi>
InChI=1S/C22H24FN5O4/c1-11-7-15-16(27-11)5-6-17(19(15)23)32-21-20-13(3)18(8-28(20)26-10-25-21)30-9-12(2)31-22(29)14(4)24/h5-8,10,12,14,27H,9,24H2,1-4H3/t12-,14+/m1/s1

> <stdInchikey>
LTEJRLHKIYCEOX-OCCSQVGLSA-N

> <csid>
9330033

> <Links>
|http://www.chemspider.com/Chemical-Structure.9330033.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL270995|http://pubchem.ncbi.nlm.nih.gov/compound/11154925|http://www.drugbank.ca/drugs/DB11865|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8097|http://zinc15.docking.org/substances/ZINC29134440|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=U2Y5OFN795

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS

> <indicationG2P>
None

> <MW>
441.2

> <HBA>
8

> <HBD>
2

> <NRB>
7

> <TPSA>
116.8

> <LogP>
3.4

> <RoF>
0

> <Targets>
nan

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_epik_Ionization_Penalty>
  0.3111

> <r_epik_State_Penalty>
  0.3051

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
365

$$$$
Rigosertib
                    3D
 Structure written by MMmdl.
 55 56  0  0  1  0            999 V2000
   -1.3697    4.3547   -4.4618 C   0  0  0  0  0  0
   -2.2370    3.3387   -3.9701 O   0  0  0  0  0  0
   -1.9611    2.7293   -2.7558 C   0  0  0  0  0  0
   -0.8485    3.0640   -1.9628 C   0  0  0  0  0  0
   -0.6162    2.4206   -0.7502 C   0  0  0  0  0  0
   -1.4877    1.4283   -0.3049 C   0  0  0  0  0  0
   -2.5976    1.0904   -1.0796 C   0  0  0  0  0  0
   -2.8433    1.7296   -2.3048 C   0  0  0  0  0  0
   -3.9550    1.3960   -3.1025 N   0  0  0  0  0  0
   -4.9510    0.4045   -2.7019 C   0  0  0  0  0  0
   -6.0915    0.0773   -3.6731 C   0  0  0  0  0  0
   -6.9276   -0.7674   -3.2842 O   0  0  0  0  0  0
   -6.1221    0.6631   -4.7789 O   0  5  0  0  0  0
   -1.2368    0.7247    1.0193 C   0  0  0  0  0  0
   -0.2925   -0.9049    0.8135 S   0  0  0  0  0  0
   -0.2183   -1.5476    2.1307 O   0  0  0  0  0  0
   -0.8591   -1.6385   -0.3234 O   0  0  0  0  0  0
    1.3605   -0.3705    0.3413 C   0  0  0  0  0  0
    2.4196   -0.5851    1.1461 C   0  0  0  0  0  0
    3.8261   -0.2028    0.8625 C   0  0  0  0  0  0
    4.5573    0.4293    1.8846 C   0  0  0  0  0  0
    5.8843    0.8136    1.6403 C   0  0  0  0  0  0
    6.4949    0.5841    0.4117 C   0  0  0  0  0  0
    5.7610   -0.0543   -0.5952 C   0  0  0  0  0  0
    4.4321   -0.4568   -0.3858 C   0  0  0  0  0  0
    3.6870   -1.1155   -1.3507 O   0  0  0  0  0  0
    4.2585   -1.4013   -2.6228 C   0  0  0  0  0  0
    7.8030    1.0098    0.2809 O   0  0  0  0  0  0
    8.4788    0.8161   -0.9569 C   0  0  0  0  0  0
    3.9175    0.6524    3.0940 O   0  0  0  0  0  0
    4.6119    1.3018    4.1536 C   0  0  0  0  0  0
   -1.7415    4.7092   -5.4230 H   0  0  0  0  0  0
   -0.3586    3.9763   -4.6194 H   0  0  0  0  0  0
   -1.3334    5.2109   -3.7867 H   0  0  0  0  0  0
   -0.1479    3.8246   -2.2714 H   0  0  0  0  0  0
    0.2465    2.6939   -0.1599 H   0  0  0  0  0  0
   -3.2612    0.3190   -0.7176 H   0  0  0  0  0  0
   -4.1285    1.9242   -3.9461 H   0  0  0  0  0  0
   -4.4342   -0.5324   -2.4908 H   0  0  0  0  0  0
   -5.4009    0.7320   -1.7639 H   0  0  0  0  0  0
   -0.6681    1.3554    1.7035 H   0  0  0  0  0  0
   -2.1837    0.4862    1.5046 H   0  0  0  0  0  0
    1.4428    0.1254   -0.6144 H   0  0  0  0  0  0
    2.2623   -1.0939    2.0862 H   0  0  0  0  0  0
    6.4675    1.3043    2.4048 H   0  0  0  0  0  0
    6.2315   -0.2429   -1.5464 H   0  0  0  0  0  0
    3.5211   -1.9154   -3.2389 H   0  0  0  0  0  0
    5.1265   -2.0562   -2.5339 H   0  0  0  0  0  0
    4.5458   -0.4888   -3.1472 H   0  0  0  0  0  0
    9.4887    1.2188   -0.8813 H   0  0  0  0  0  0
    7.9772    1.3378   -1.7733 H   0  0  0  0  0  0
    8.5645   -0.2429   -1.2052 H   0  0  0  0  0  0
    3.9503    1.3889    5.0151 H   0  0  0  0  0  0
    4.9191    2.3100    3.8721 H   0  0  0  0  0  0
    5.4877    0.7322    4.4680 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 32  1  0  0  0
  1 33  1  0  0  0
  1 34  1  0  0  0
  2  3  1  0  0  0
  3  4  1  0  0  0
  3  8  2  0  0  0
  4  5  2  0  0  0
  4 35  1  0  0  0
  5  6  1  0  0  0
  5 36  1  0  0  0
  6  7  2  0  0  0
  6 14  1  0  0  0
  7  8  1  0  0  0
  7 37  1  0  0  0
  8  9  1  0  0  0
  9 10  1  0  0  0
  9 38  1  0  0  0
 10 11  1  0  0  0
 10 39  1  0  0  0
 10 40  1  0  0  0
 11 12  2  0  0  0
 11 13  1  0  0  0
 14 15  1  0  0  0
 14 41  1  0  0  0
 14 42  1  0  0  0
 15 16  2  0  0  0
 15 17  2  0  0  0
 15 18  1  0  0  0
 18 19  2  0  0  0
 18 43  1  0  0  0
 19 20  1  0  0  0
 19 44  1  0  0  0
 20 21  1  0  0  0
 20 25  2  0  0  0
 21 22  2  0  0  0
 21 30  1  0  0  0
 22 23  1  0  0  0
 22 45  1  0  0  0
 23 24  2  0  0  0
 23 28  1  0  0  0
 24 25  1  0  0  0
 24 46  1  0  0  0
 25 26  1  0  0  0
 26 27  1  0  0  0
 27 47  1  0  0  0
 27 48  1  0  0  0
 27 49  1  0  0  0
 28 29  1  0  0  0
 29 50  1  0  0  0
 29 51  1  0  0  0
 29 52  1  0  0  0
 30 31  1  0  0  0
 31 53  1  0  0  0
 31 54  1  0  0  0
 31 55  1  0  0  0
M  CHG  1  13  -1
M  END
> <s_m_entry_id>
367

> <Applicants>
Onconova Therapeutics

> <CHEMBL_ID>
CHEMBL1241855

> <Canonical_Smiles>
S(=O)(=O)(\C=C\c1c(OC)cc(OC)cc1OC)Cc1cc(NCC(O)=O)c(OC)cc1

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
3

> <SC_Patent>
None

> <Synonyms>
ON 01910 | RIGOSERTIB

> <Indications>
nan

> <Type>
3

> <targets_id>
P42336|P53350

> <inchi>
InChI=1S/C21H25NO8S/c1-27-15-10-19(29-3)16(20(11-15)30-4)7-8-31(25,26)13-14-5-6-18(28-2)17(9-14)22-12-21(23)24/h5-11,22H,12-13H2,1-4H3,(H,23,24)/b8-7+

> <stdInchikey>
OWBFCJROIKNMGD-BQYQJAHWSA-N

> <csid>
5293927

> <Links>
|http://www.chemspider.com/Chemical-Structure.5293927.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1241855|http://pubchem.ncbi.nlm.nih.gov/compound/6918736|http://www.drugbank.ca/drugs/DB12146| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=6FS|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/6FS|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7833|http://zinc15.docking.org/substances/ZINC000003942646|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=67DOW7F9GL|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50060917

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
451.1

> <HBA>
8

> <HBD>
2

> <NRB>
11

> <TPSA>
120.4

> <LogP>
2.8

> <RoF>
0

> <Targets>
PIK3CA; PLK1

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_epik_Ionization_Penalty>
  0.0075

> <r_epik_State_Penalty>
  0.0055

> <i_epik_Tot_Q>
-1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
367

> <lig_pdbID>
'6FS'

> <pdbID>
5j18 5j2r 5ov7

> <Kinase families>
Other<br>Atypical

$$$$
Dinaciclib
                    3D
 Structure written by MMmdl.
 57 60  0  0  1  0            999 V2000
   -2.4551   -4.3567   -1.2068 C   0  0  0  0  0  0
   -3.0362   -3.7891    0.0956 C   0  0  0  0  0  0
   -3.1922   -2.2837    0.0452 C   0  0  0  0  0  0
   -4.3653   -1.5241    0.0123 C   0  0  0  0  0  0
   -4.1807   -0.2216   -0.0302 N   0  0  0  0  0  0
   -2.8351   -0.0585   -0.0255 N   0  0  0  0  0  0
   -2.1718   -1.2966    0.0193 C   0  0  0  0  0  0
   -0.8353   -1.3659    0.0259 N   0  0  0  0  0  0
   -0.1353   -0.1940    0.0057 C   0  0  0  0  0  0
   -0.7528    1.0588   -0.0439 C   0  0  0  0  0  0
   -2.1499    1.1357   -0.0637 C   0  0  0  0  0  0
   -2.8561    2.3538   -0.1269 N   0  0  0  0  0  0
   -2.2013    3.6614   -0.1169 C   0  0  0  0  0  0
   -1.4074    3.9592   -1.3882 C   0  0  0  0  0  0
   -0.1982    4.6595   -1.3031 C   0  0  0  0  0  0
    0.5314    4.9433   -2.4594 C   0  0  0  0  0  0
    0.0364    4.5250   -3.6951 C   0  0  0  0  0  0
   -1.1365    3.8591   -3.7536 N   0  3  0  0  0  0
   -1.8663    3.5710   -2.6545 C   0  0  0  0  0  0
   -1.5677    3.4931   -4.8791 O   0  5  0  0  0  0
    1.2520   -0.2667   -0.0230 N   0  0  0  0  0  0
    1.7914   -0.2010   -1.3951 C   0  0  0  0  0  0
    3.2740    0.2033   -1.4314 C   0  0  0  0  0  0
    4.1184   -0.7929   -0.6378 C   0  0  0  0  0  0
    3.5284   -0.9778    0.7649 C   0  0  0  0  0  0
    2.0007   -1.2894    0.7594 C   0  0  1  0  0  0
    1.5113   -1.4697    2.2283 C   0  0  0  0  0  0
    2.0327   -2.7440    2.9206 C   0  0  0  0  0  0
    1.4595   -2.8670    4.2054 O   0  0  0  0  0  0
   -2.3663   -5.4420   -1.1523 H   0  0  0  0  0  0
   -1.4611   -3.9549   -1.4077 H   0  0  0  0  0  0
   -3.0904   -4.1193   -2.0608 H   0  0  0  0  0  0
   -3.9984   -4.2655    0.2879 H   0  0  0  0  0  0
   -2.3938   -4.0731    0.9299 H   0  0  0  0  0  0
   -5.3649   -1.9338    0.0177 H   0  0  0  0  0  0
   -0.1416    1.9486   -0.0688 H   0  0  0  0  0  0
   -3.8638    2.3264   -0.0591 H   0  0  0  0  0  0
   -2.9671    4.4283    0.0017 H   0  0  0  0  0  0
   -1.5533    3.7299    0.7583 H   0  0  0  0  0  0
    0.1798    4.9822   -0.3437 H   0  0  0  0  0  0
    1.4661    5.4812   -2.3978 H   0  0  0  0  0  0
    0.5385    4.7044   -4.6354 H   0  0  0  0  0  0
   -2.7902    3.0353   -2.8227 H   0  0  0  0  0  0
    1.6536   -1.1666   -1.8857 H   0  0  0  0  0  0
    1.2305    0.5280   -1.9833 H   0  0  0  0  0  0
    3.6240    0.2488   -2.4631 H   0  0  0  0  0  0
    3.3929    1.2077   -1.0218 H   0  0  0  0  0  0
    4.1317   -1.7532   -1.1556 H   0  0  0  0  0  0
    5.1544   -0.4575   -0.5783 H   0  0  0  0  0  0
    4.0829   -1.7742    1.2602 H   0  0  0  0  0  0
    3.7134   -0.0759    1.3513 H   0  0  0  0  0  0
    1.8532   -2.2448    0.2514 H   0  0  0  0  0  0
    1.7869   -0.5932    2.8171 H   0  0  0  0  0  0
    0.4238   -1.5153    2.2656 H   0  0  0  0  0  0
    1.7796   -3.6314    2.3393 H   0  0  0  0  0  0
    3.1160   -2.7270    3.0349 H   0  0  0  0  0  0
    1.7984   -3.6658    4.6159 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 30  1  0  0  0
  1 31  1  0  0  0
  1 32  1  0  0  0
  2  3  1  0  0  0
  2 33  1  0  0  0
  2 34  1  0  0  0
  3  4  1  0  0  0
  3  7  2  0  0  0
  4  5  2  0  0  0
  4 35  1  0  0  0
  5  6  1  0  0  0
  6  7  1  0  0  0
  6 11  1  0  0  0
  7  8  1  0  0  0
  8  9  2  0  0  0
  9 10  1  0  0  0
  9 21  1  0  0  0
 10 11  2  0  0  0
 10 36  1  0  0  0
 11 12  1  0  0  0
 12 13  1  0  0  0
 12 37  1  0  0  0
 13 14  1  0  0  0
 13 38  1  0  0  0
 13 39  1  0  0  0
 14 15  1  0  0  0
 14 19  2  0  0  0
 15 16  2  0  0  0
 15 40  1  0  0  0
 16 17  1  0  0  0
 16 41  1  0  0  0
 17 18  2  0  0  0
 17 42  1  0  0  0
 18 19  1  0  0  0
 18 20  1  0  0  0
 19 43  1  0  0  0
 21 22  1  0  0  0
 21 26  1  0  0  0
 22 23  1  0  0  0
 22 44  1  0  0  0
 22 45  1  0  0  0
 23 24  1  0  0  0
 23 46  1  0  0  0
 23 47  1  0  0  0
 24 25  1  0  0  0
 24 48  1  0  0  0
 24 49  1  0  0  0
 25 26  1  0  0  0
 25 50  1  0  0  0
 25 51  1  0  0  0
 26 27  1  0  0  0
 26 52  1  0  0  0
 27 28  1  0  0  0
 27 53  1  0  0  0
 27 54  1  0  0  0
 28 29  1  0  0  0
 28 55  1  0  0  0
 28 56  1  0  0  0
 29 57  1  0  0  0
M  CHG  2  18   1  20  -1
M  END
> <s_m_entry_id>
368

> <Applicants>
Schering-Plough

> <CHEMBL_ID>
CHEMBL2103840

> <Canonical_Smiles>
OCC[C@H]1N(CCCC1)C1=Nc2n(ncc2CC)C(NCc2ccc[n+]([O-])c2)=C1

> <Chirality>
Single Stereoisomer

> <First_Approval>
nan

> <Phase>
3

> <SC_Patent>
None

> <Synonyms>
DINACICLIB | MK-7965 | SCH 727965 | SCH-727965

> <Indications>
nan

> <Type>
nan

> <targets_id>
P11802|Q00534|Q58F21

> <inchi>
InChI=1S/C21H28N6O2/c1-2-17-14-23-27-19(22-13-16-6-5-9-25(29)15-16)12-20(24-21(17)27)26-10-4-3-7-18(26)8-11-28/h5-6,9,12,14-15,18,22,28H,2-4,7-8,10-11,13H2,1H3/t18-/m0/s1

> <stdInchikey>
PIMQWRZWLQKKBJ-SFHVURJKSA-N

> <csid>
25027387

> <Links>
|http://www.chemspider.com/Chemical-Structure.25027387.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2103840|http://pubchem.ncbi.nlm.nih.gov/compound/46926350|http://www.drugbank.ca/drugs/DB12021|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7379|http://zinc15.docking.org/substances/ZINC000034894449|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=4V8ECV0NBQ|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50139171

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
396.2

> <HBA>
7

> <HBD>
2

> <NRB>
7

> <TPSA>
92.6

> <LogP>
2.3

> <RoF>
0

> <Targets>
CDK4; CDK6; BRDT

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0002

> <r_epik_State_Penalty>
  0.0000

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
368

> <Kinase families>
CMGC<br>(*)

$$$$
Surufatinib
                    3D
 Structure written by MMmdl.
 63 66  0  0  1  0            999 V2000
   -4.5072   -3.5706    1.0379 C   0  0  0  0  0  0
   -3.9017   -2.8929   -0.1667 C   0  0  0  0  0  0
   -4.2884   -1.7732   -0.8796 C   0  0  0  0  0  0
   -3.3297   -1.5597   -1.9224 C   0  0  0  0  0  0
   -3.1762   -0.6015   -2.9353 C   0  0  0  0  0  0
   -2.0772   -0.6884   -3.7961 C   0  0  0  0  0  0
   -1.1602   -1.7312   -3.6723 C   0  0  0  0  0  0
   -1.2783   -2.7095   -2.6848 C   0  0  0  0  0  0
   -2.3676   -2.6038   -1.8145 C   0  0  0  0  0  0
   -2.7553   -3.3833   -0.7454 N   0  0  0  0  0  0
   -1.8992    0.2352   -4.8037 O   0  0  0  0  0  0
   -1.6590    1.5731   -4.5424 C   0  0  0  0  0  0
   -1.5984    2.4679   -5.6118 C   0  0  0  0  0  0
   -1.3611    3.8077   -5.3046 C   0  0  0  0  0  0
   -1.1938    4.2438   -4.0294 N   0  0  0  0  0  0
   -1.2653    3.3109   -3.0452 C   0  0  0  0  0  0
   -1.4851    1.9871   -3.2530 N   0  0  0  0  0  0
   -1.0854    3.8072   -1.7451 N   0  0  0  0  0  0
   -1.0518    3.2282   -0.4624 C   0  0  0  0  0  0
   -0.6657    4.0584    0.5952 C   0  0  0  0  0  0
   -0.6008    3.5706    1.8995 C   0  0  0  0  0  0
   -0.9215    2.2412    2.1627 C   0  0  0  0  0  0
   -1.3084    1.3953    1.1211 C   0  0  0  0  0  0
   -1.3819    1.8919   -0.1844 C   0  0  0  0  0  0
   -1.6477   -0.0585    1.4054 C   0  0  0  0  0  0
   -0.2006   -1.2246    1.0422 S   0  0  0  0  0  0
   -0.5949   -2.5752    1.4556 O   0  0  0  0  0  0
    0.2682   -0.9775   -0.3261 O   0  0  0  0  0  0
    1.0568   -0.6913    2.1591 N   0  0  0  0  0  0
    2.0204    0.3451    1.7393 C   0  0  0  0  0  0
    3.2171   -0.2770    0.9975 C   0  0  0  0  0  0
    4.1252    0.8178    0.3922 N   0  3  0  0  0  0
    4.7981    1.7124    1.4537 C   0  0  0  0  0  0
    5.1770    0.2095   -0.5563 C   0  0  0  0  0  0
   -5.4172   -3.0701    1.3696 H   0  0  0  0  0  0
   -3.8190   -3.5749    1.8834 H   0  0  0  0  0  0
   -4.7700   -4.6078    0.8285 H   0  0  0  0  0  0
   -5.1588   -1.1731   -0.6588 H   0  0  0  0  0  0
   -3.8891    0.2027   -3.0443 H   0  0  0  0  0  0
   -0.3275   -1.7815   -4.3587 H   0  0  0  0  0  0
   -0.5524   -3.5045   -2.5990 H   0  0  0  0  0  0
   -2.2859   -4.2038   -0.3900 H   0  0  0  0  0  0
   -1.7328    2.1389   -6.6315 H   0  0  0  0  0  0
   -1.3042    4.5529   -6.0847 H   0  0  0  0  0  0
   -0.8831    4.7957   -1.7409 H   0  0  0  0  0  0
   -0.4113    5.0928    0.4120 H   0  0  0  0  0  0
   -0.3006    4.2230    2.7062 H   0  0  0  0  0  0
   -0.8629    1.8693    3.1754 H   0  0  0  0  0  0
   -1.6960    1.2128   -0.9596 H   0  0  0  0  0  0
   -1.9329   -0.2023    2.4480 H   0  0  0  0  0  0
   -2.4863   -0.3795    0.7890 H   0  0  0  0  0  0
    1.4187   -1.4057    2.7973 H   0  0  0  0  0  0
    1.5029    1.0647    1.1045 H   0  0  0  0  0  0
    2.3560    0.8558    2.6416 H   0  0  0  0  0  0
    3.8454   -0.8977    1.6389 H   0  0  0  0  0  0
    2.8852   -0.8722    0.1453 H   0  0  0  0  0  0
    5.3886    1.0682    2.1070 H   0  0  0  0  0  0
    4.0116    2.2316    2.0007 H   0  0  0  0  0  0
    5.4263    2.4297    0.9237 H   0  0  0  0  0  0
    5.8232   -0.4418    0.0344 H   0  0  0  0  0  0
    5.7341    1.0370   -0.9976 H   0  0  0  0  0  0
    4.6398   -0.3463   -1.3259 H   0  0  0  0  0  0
    3.5339    1.4124   -0.1725 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 35  1  0  0  0
  1 36  1  0  0  0
  1 37  1  0  0  0
  2  3  2  0  0  0
  2 10  1  0  0  0
  3  4  1  0  0  0
  3 38  1  0  0  0
  4  5  1  0  0  0
  4  9  2  0  0  0
  5  6  2  0  0  0
  5 39  1  0  0  0
  6  7  1  0  0  0
  6 11  1  0  0  0
  7  8  2  0  0  0
  7 40  1  0  0  0
  8  9  1  0  0  0
  8 41  1  0  0  0
  9 10  1  0  0  0
 10 42  1  0  0  0
 11 12  1  0  0  0
 12 13  1  0  0  0
 12 17  2  0  0  0
 13 14  2  0  0  0
 13 43  1  0  0  0
 14 15  1  0  0  0
 14 44  1  0  0  0
 15 16  2  0  0  0
 16 17  1  0  0  0
 16 18  1  0  0  0
 18 19  1  0  0  0
 18 45  1  0  0  0
 19 20  1  0  0  0
 19 24  2  0  0  0
 20 21  2  0  0  0
 20 46  1  0  0  0
 21 22  1  0  0  0
 21 47  1  0  0  0
 22 23  2  0  0  0
 22 48  1  0  0  0
 23 24  1  0  0  0
 23 25  1  0  0  0
 24 49  1  0  0  0
 25 26  1  0  0  0
 25 50  1  0  0  0
 25 51  1  0  0  0
 26 27  2  0  0  0
 26 28  2  0  0  0
 26 29  1  0  0  0
 29 30  1  0  0  0
 29 52  1  0  0  0
 30 31  1  0  0  0
 30 53  1  0  0  0
 30 54  1  0  0  0
 31 32  1  0  0  0
 31 55  1  0  0  0
 31 56  1  0  0  0
 32 33  1  0  0  0
 32 34  1  0  0  0
 32 63  1  0  0  0
 33 57  1  0  0  0
 33 58  1  0  0  0
 33 59  1  0  0  0
 34 60  1  0  0  0
 34 61  1  0  0  0
 34 62  1  0  0  0
M  CHG  1  32   1
M  END
> <s_m_entry_id>
369

> <Applicants>
Hutchison MediPharma

> <CHEMBL_ID>
CHEMBL4297190

> <Canonical_Smiles>
S(=O)(=O)(NCCN(C)C)Cc1cc(Nc2nc(Oc3cc4cc([nH]c4cc3)C)ccn2)ccc1

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
3

> <SC_Patent>
None

> <Synonyms>
HMPL-012 | SULFATINIB | SURUFATINIB

> <Indications>
nan

> <Type>
nan

> <targets_id>
nan

> <inchi>
InChI=1S/C24H28N6O3S/c1-17-13-19-15-21(7-8-22(19)27-17)33-23-9-10-25-24(29-23)28-20-6-4-5-18(14-20)16-34(31,32)26-11-12-30(2)3/h4-10,13-15,26-27H,11-12,16H2,1-3H3,(H,25,28,29)

> <stdInchikey>
TTZSNFLLYPYKIL-UHFFFAOYSA-N

> <csid>
57583328

> <Links>
|http://www.chemspider.com/Chemical-Structure.57583328.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4297190|http://pubchem.ncbi.nlm.nih.gov/compound/52920501|http://www.drugbank.ca/drugs/DB15106|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9769|http://zinc15.docking.org/substances/ZINC000117218067|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=B2K5L1L8S9

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS

> <indicationG2P>
None

> <MW>
480.2

> <HBA>
7

> <HBD>
3

> <NRB>
10

> <TPSA>
112.2

> <LogP>
3.8

> <RoF>
0

> <Targets>
nan

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0252

> <r_epik_State_Penalty>
  0.0154

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
369

$$$$
Dovitinib
                    3D
 Structure written by MMmdl.
 51 55  0  0  1  0            999 V2000
   -1.8224    1.4025    3.7782 C   0  0  0  0  0  0
   -1.6190    0.9317    2.3252 N   0  3  0  0  0  0
   -0.9264   -0.4526    2.2976 C   0  0  0  0  0  0
   -0.5510   -0.8065    0.8402 C   0  0  0  0  0  0
    0.3292    0.2309    0.2773 N   0  0  0  0  0  0
   -0.5042    1.4348    0.1174 C   0  0  0  0  0  0
   -0.8650    2.0084    1.5071 C   0  0  0  0  0  0
    1.7193    0.2699    0.4558 C   0  0  0  0  0  0
    2.3880   -0.7733    1.1253 C   0  0  0  0  0  0
    3.7669   -0.7737    1.3349 C   0  0  0  0  0  0
    4.5085    0.3059    0.8475 C   0  0  0  0  0  0
    3.8487    1.3460    0.1622 C   0  0  0  0  0  0
    2.4676    1.3538   -0.0467 C   0  0  0  0  0  0
    4.8659    2.2069   -0.1753 N   0  0  0  0  0  0
    6.0499    1.6848    0.3060 C   0  0  0  0  0  0
    5.8552    0.5413    0.9266 N   0  0  0  0  0  0
    7.3737    2.3241    0.1502 C   0  0  0  0  0  0
    8.4823    1.6116   -0.2198 C   0  0  0  0  0  0
    9.8202    2.2714   -0.3770 C   0  0  0  0  0  0
    9.8485    3.6563   -0.1292 C   0  0  0  0  0  0
   11.0327    4.3855   -0.2440 C   0  0  0  0  0  0
   12.2117    3.7403   -0.6069 C   0  0  0  0  0  0
   12.2064    2.3697   -0.8533 C   0  0  0  0  0  0
   11.0258    1.6331   -0.7415 C   0  0  0  0  0  0
   11.0856    0.3042   -0.9922 F   0  0  0  0  0  0
    8.6712    4.3172    0.2420 N   0  0  0  0  0  0
    7.4444    3.7711    0.4079 C   0  0  0  0  0  0
    6.5038    4.4858    0.7544 O   0  0  0  0  0  0
    8.4571    0.2639   -0.4986 N   0  0  0  0  0  0
   -0.8397    1.5196    4.2380 H   0  0  0  0  0  0
   -2.4143    0.6383    4.2835 H   0  0  0  0  0  0
   -2.3625    2.3494    3.7378 H   0  0  0  0  0  0
   -0.0468   -0.3974    2.9421 H   0  0  0  0  0  0
   -1.6368   -1.1635    2.7211 H   0  0  0  0  0  0
   -0.0952   -1.7933    0.7697 H   0  0  0  0  0  0
   -1.4615   -0.8916    0.2435 H   0  0  0  0  0  0
   -0.0249    2.1890   -0.5030 H   0  0  0  0  0  0
   -1.4209    1.1901   -0.4228 H   0  0  0  0  0  0
   -1.5340    2.8669    1.4345 H   0  0  0  0  0  0
    0.0249    2.2938    2.0720 H   0  0  0  0  0  0
    1.8452   -1.6170    1.5210 H   0  0  0  0  0  0
    4.2450   -1.5867    1.8614 H   0  0  0  0  0  0
    2.0161    2.1708   -0.5865 H   0  0  0  0  0  0
    4.8147    3.0835   -0.6738 H   0  0  0  0  0  0
   11.0442    5.4489   -0.0527 H   0  0  0  0  0  0
   13.1299    4.3018   -0.6962 H   0  0  0  0  0  0
   13.1248    1.8743   -1.1326 H   0  0  0  0  0  0
    8.7158    5.3100    0.4186 H   0  0  0  0  0  0
    7.6041   -0.2693   -0.4074 H   0  0  0  0  0  0
    9.2948   -0.2281   -0.7750 H   0  0  0  0  0  0
   -2.5300    0.8184    1.9029 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 30  1  0  0  0
  1 31  1  0  0  0
  1 32  1  0  0  0
  2  3  1  0  0  0
  2  7  1  0  0  0
  2 51  1  0  0  0
  3  4  1  0  0  0
  3 33  1  0  0  0
  3 34  1  0  0  0
  4  5  1  0  0  0
  4 35  1  0  0  0
  4 36  1  0  0  0
  5  6  1  0  0  0
  5  8  1  0  0  0
  6  7  1  0  0  0
  6 37  1  0  0  0
  6 38  1  0  0  0
  7 39  1  0  0  0
  7 40  1  0  0  0
  8  9  1  0  0  0
  8 13  2  0  0  0
  9 10  2  0  0  0
  9 41  1  0  0  0
 10 11  1  0  0  0
 10 42  1  0  0  0
 11 12  2  0  0  0
 11 16  1  0  0  0
 12 13  1  0  0  0
 12 14  1  0  0  0
 13 43  1  0  0  0
 14 15  1  0  0  0
 14 44  1  0  0  0
 15 16  2  0  0  0
 15 17  1  0  0  0
 17 18  2  0  0  0
 17 27  1  0  0  0
 18 19  1  0  0  0
 18 29  1  0  0  0
 19 20  1  0  0  0
 19 24  2  0  0  0
 20 21  2  0  0  0
 20 26  1  0  0  0
 21 22  1  0  0  0
 21 45  1  0  0  0
 22 23  2  0  0  0
 22 46  1  0  0  0
 23 24  1  0  0  0
 23 47  1  0  0  0
 24 25  1  0  0  0
 26 27  1  0  0  0
 26 48  1  0  0  0
 27 28  2  0  0  0
 29 49  1  0  0  0
 29 50  1  0  0  0
M  CHG  1   2   1
M  END
> <s_m_entry_id>
371

> <Applicants>
Novartis

> <CHEMBL_ID>
CHEMBL522892

> <Canonical_Smiles>
Fc1c2c(NC(=O)C(c3[nH]c4cc(N5CCN(CC5)C)ccc4n3)=C2N)ccc1

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
3

> <SC_Patent>
None

> <Synonyms>
CHIR-258 | DOVITINIB | GFKI-258 | NVP-TKI258 | TKI-258

> <Indications>
nan

> <Type>
1

> <targets_id>
P22607|P15692|P11362|P16234|P10721|P07333

> <inchi>
InChI=1S/C21H21FN6O/c1-27-7-9-28(10-8-27)12-5-6-14-16(11-12)25-20(24-14)18-19(23)17-13(22)3-2-4-15(17)26-21(18)29/h2-6,11H,7-10H2,1H3,(H,24,25)(H3,23,26,29)

> <stdInchikey>
PIQCTGMSNWUMAF-UHFFFAOYSA-N

> <csid>
11530944

> <Links>
|http://www.chemspider.com/Chemical-Structure.11530944.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL522892|http://pubchem.ncbi.nlm.nih.gov/compound/135398510|http://www.drugbank.ca/drugs/DB05928| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=38O|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/38O|http://zinc15.docking.org/substances/ZINC000003816310|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=I35H55G906|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=25118

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|ZINC|FDA SRS|BindingDB

> <MW>
392.2

> <HBA>
5

> <HBD>
3

> <NRB>
2

> <TPSA>
94

> <LogP>
2.5

> <RoF>
0

> <Targets>
FGFR3; VEGFA; FGFR1; PDGFRA; KIT; CSF1R

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_epik_Ionization_Penalty>
  0.0655

> <r_epik_State_Penalty>
  0.2229

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
371

> <lig_pdbID>
'38O'

> <pdbID>
4tyi 5a46 5am6 5am7 5owq 7akg

> <Kinase families>
Tyr<br>(*)

> <indicationDB>
Dovitinib is an orally active small molecule that exhibits potent inhibitory activity against multiple RTKs involved in tumor growth and angiogenesis. Preclinical data show that dovitinib works to inhibit multiple kinases associated with different cancers, including acute myeloid leukemia (AML) and multiple myeloma. Chiron currently has three ongoing Phase I clinical trials for dovitinib.

> <uniprotId>
O75469|P04798|P05177|P35503|P16662|P33261|P08684|O15438|Q9UNQ0|Q9Y6L6|O94956|Q9NPD5|P08183

> <Withdrawn>
|Study NCT02065323 in United States was Withdrawn during Phase 2 because Terminated due to budgetary considerations and length of development|Study NCT02048943 in United States was Withdrawn during Phase 1 because Lack of funding|Study NCT02268435 in nan was Withdrawn during Phase 1 because Dovitinib Production stopped

$$$$
Naquotinib
                    3D
 Structure written by MMmdl.
 84 88  0  0  1  0            999 V2000
   -5.1181    1.2070    0.7135 C   0  0  0  0  0  0
   -3.9345    0.7473    1.5763 C   0  0  0  0  0  0
   -2.6590    0.5551    0.7662 C   0  0  0  0  0  0
   -2.2456   -0.6931    0.2958 C   0  0  0  0  0  0
   -1.0971   -0.8089   -0.4254 N   0  0  0  0  0  0
   -0.3576    0.3044   -0.6865 C   0  0  0  0  0  0
   -0.7905    1.5761   -0.2264 C   0  0  0  0  0  0
   -1.9423    1.6773    0.5041 N   0  0  0  0  0  0
   -0.0434    2.8787   -0.4977 C   0  0  0  0  0  0
    0.9492    2.9324   -1.2223 O   0  0  0  0  0  0
   -0.5080    3.9926    0.0844 N   0  0  0  0  0  0
    0.8236    0.1385   -1.4377 N   0  0  0  0  0  0
    1.4953   -0.9971   -1.9227 C   0  0  0  0  0  0
    2.2702   -0.8499   -3.0728 C   0  0  0  0  0  0
    2.9722   -1.9345   -3.5907 C   0  0  0  0  0  0
    2.9222   -3.1847   -2.9630 C   0  0  0  0  0  0
    2.1514   -3.3226   -1.7993 C   0  0  0  0  0  0
    1.4465   -2.2395   -1.2824 C   0  0  0  0  0  0
    3.6485   -4.2426   -3.5036 N   0  0  0  0  0  0
    3.2658   -4.7117   -4.8456 C   0  0  0  0  0  0
    4.4393   -5.4138   -5.5611 C   0  0  0  0  0  0
    4.9941   -6.6097   -4.7474 C   0  0  0  0  0  0
    5.1999   -6.1826   -3.2725 C   0  0  0  0  0  0
    3.9775   -5.4334   -2.7021 C   0  0  0  0  0  0
    6.3540   -7.0762   -5.3595 N   0  3  0  0  0  0
    6.1975   -7.4913   -6.8467 C   0  0  0  0  0  0
    7.5254   -8.0499   -7.4071 C   0  0  0  0  0  0
    8.0940   -9.1380   -6.6098 N   0  0  0  0  0  0
    8.2808   -8.7444   -5.2124 C   0  0  0  0  0  0
    6.9957   -8.2211   -4.5311 C   0  0  0  0  0  0
    7.3459  -10.3864   -6.7472 C   0  0  0  0  0  0
   -3.0107   -1.8202    0.5476 O   0  0  0  0  0  0
   -2.5920   -3.1085    0.0754 C   0  0  2  0  0  0
   -3.7491   -4.0689    0.3028 C   0  0  0  0  0  0
   -3.6483   -4.4598    1.7794 C   0  0  0  0  0  0
   -2.2346   -4.2291    2.1175 N   0  0  0  0  0  0
   -1.4920   -3.6812    0.9748 C   0  0  0  0  0  0
   -1.6277   -4.5158    3.2996 C   0  0  0  0  0  0
   -0.4160   -4.3415    3.4611 O   0  0  0  0  0  0
   -2.4669   -5.0247    4.3715 C   0  0  0  0  0  0
   -1.9755   -5.3872    5.5717 C   0  0  0  0  0  0
   -6.0135    1.3404    1.3210 H   0  0  0  0  0  0
   -5.3492    0.4747   -0.0611 H   0  0  0  0  0  0
   -4.9069    2.1579    0.2231 H   0  0  0  0  0  0
   -3.7510    1.4740    2.3695 H   0  0  0  0  0  0
   -4.1923   -0.1810    2.0877 H   0  0  0  0  0  0
   -1.3184    3.9523    0.6848 H   0  0  0  0  0  0
   -0.0456    4.8766   -0.0705 H   0  0  0  0  0  0
    1.1578    1.0068   -1.8311 H   0  0  0  0  0  0
    2.3305    0.1057   -3.5739 H   0  0  0  0  0  0
    3.5671   -1.7935   -4.4819 H   0  0  0  0  0  0
    2.0870   -4.2680   -1.2815 H   0  0  0  0  0  0
    0.8855   -2.3789   -0.3720 H   0  0  0  0  0  0
    2.4103   -5.3857   -4.7681 H   0  0  0  0  0  0
    2.9385   -3.8738   -5.4628 H   0  0  0  0  0  0
    4.0861   -5.7441   -6.5376 H   0  0  0  0  0  0
    5.2299   -4.6850   -5.7501 H   0  0  0  0  0  0
    4.3096   -7.4586   -4.8036 H   0  0  0  0  0  0
    5.3824   -7.0531   -2.6427 H   0  0  0  0  0  0
    6.0825   -5.5464   -3.1824 H   0  0  0  0  0  0
    4.2118   -5.1310   -1.6802 H   0  0  0  0  0  0
    3.1130   -6.0979   -2.6464 H   0  0  0  0  0  0
    5.3870   -8.2203   -6.8985 H   0  0  0  0  0  0
    5.9118   -6.6051   -7.4114 H   0  0  0  0  0  0
    7.3879   -8.3823   -8.4373 H   0  0  0  0  0  0
    8.2597   -7.2444   -7.4588 H   0  0  0  0  0  0
    8.6905   -9.5823   -4.6462 H   0  0  0  0  0  0
    9.0471   -7.9685   -5.1756 H   0  0  0  0  0  0
    7.2456   -7.8208   -3.5495 H   0  0  0  0  0  0
    6.2417   -9.0011   -4.4140 H   0  0  0  0  0  0
    7.8434  -11.1909   -6.2042 H   0  0  0  0  0  0
    7.2922  -10.6862   -7.7947 H   0  0  0  0  0  0
    6.3272  -10.3034   -6.3673 H   0  0  0  0  0  0
   -2.3119   -3.0370   -0.9775 H   0  0  0  0  0  0
   -4.7178   -3.6341    0.0531 H   0  0  0  0  0  0
   -3.6196   -4.9533   -0.3232 H   0  0  0  0  0  0
   -4.2801   -3.8139    2.3908 H   0  0  0  0  0  0
   -3.9446   -5.4970    1.9411 H   0  0  0  0  0  0
   -0.9749   -4.4976    0.4690 H   0  0  0  0  0  0
   -0.7532   -2.9345    1.2691 H   0  0  0  0  0  0
   -3.5286   -5.1129    4.1979 H   0  0  0  0  0  0
   -0.9234   -5.3235    5.8130 H   0  0  0  0  0  0
   -2.6353   -5.7592    6.3419 H   0  0  0  0  0  0
    6.9892   -6.2910   -5.3305 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 42  1  0  0  0
  1 43  1  0  0  0
  1 44  1  0  0  0
  2  3  1  0  0  0
  2 45  1  0  0  0
  2 46  1  0  0  0
  3  4  2  0  0  0
  3  8  1  0  0  0
  4  5  1  0  0  0
  4 32  1  0  0  0
  5  6  2  0  0  0
  6  7  1  0  0  0
  6 12  1  0  0  0
  7  8  2  0  0  0
  7  9  1  0  0  0
  9 10  2  0  0  0
  9 11  1  0  0  0
 11 47  1  0  0  0
 11 48  1  0  0  0
 12 13  1  0  0  0
 12 49  1  0  0  0
 13 14  1  0  0  0
 13 18  2  0  0  0
 14 15  2  0  0  0
 14 50  1  0  0  0
 15 16  1  0  0  0
 15 51  1  0  0  0
 16 17  2  0  0  0
 16 19  1  0  0  0
 17 18  1  0  0  0
 17 52  1  0  0  0
 18 53  1  0  0  0
 19 20  1  0  0  0
 19 24  1  0  0  0
 20 21  1  0  0  0
 20 54  1  0  0  0
 20 55  1  0  0  0
 21 22  1  0  0  0
 21 56  1  0  0  0
 21 57  1  0  0  0
 22 23  1  0  0  0
 22 25  1  0  0  0
 22 58  1  0  0  0
 23 24  1  0  0  0
 23 59  1  0  0  0
 23 60  1  0  0  0
 24 61  1  0  0  0
 24 62  1  0  0  0
 25 26  1  0  0  0
 25 30  1  0  0  0
 25 84  1  0  0  0
 26 27  1  0  0  0
 26 63  1  0  0  0
 26 64  1  0  0  0
 27 28  1  0  0  0
 27 65  1  0  0  0
 27 66  1  0  0  0
 28 29  1  0  0  0
 28 31  1  0  0  0
 29 30  1  0  0  0
 29 67  1  0  0  0
 29 68  1  0  0  0
 30 69  1  0  0  0
 30 70  1  0  0  0
 31 71  1  0  0  0
 31 72  1  0  0  0
 31 73  1  0  0  0
 32 33  1  0  0  0
 33 34  1  0  0  0
 33 37  1  0  0  0
 33 74  1  0  0  0
 34 35  1  0  0  0
 34 75  1  0  0  0
 34 76  1  0  0  0
 35 36  1  0  0  0
 35 77  1  0  0  0
 35 78  1  0  0  0
 36 37  1  0  0  0
 36 38  1  0  0  0
 37 79  1  0  0  0
 37 80  1  0  0  0
 38 39  2  0  0  0
 38 40  1  0  0  0
 40 41  2  0  0  0
 40 81  1  0  0  0
 41 82  1  0  0  0
 41 83  1  0  0  0
M  CHG  1  25   1
M  END
> <s_m_entry_id>
375

> <Applicants>
Astellas Pharma

> <CHEMBL_ID>
CHEMBL3663929

> <Canonical_Smiles>
O([C@@H]1CCN(C1)C(=O)C=C)c1nc(Nc2ccc(N3CCC(N4CCN(CC4)C)CC3)cc2)c(nc1CC)C(=O)N

> <Chirality>
Single Stereoisomer

> <First_Approval>
nan

> <Phase>
3

> <SC_Patent>
None

> <Synonyms>
ASP-8273 | ASP8273 | NAQUOTINIB

> <Indications>
nan

> <Type>
nan

> <targets_id>
P00533

> <inchi>
InChI=1S/C30H42N8O3/c1-4-25-30(41-24-12-15-38(20-24)26(39)5-2)34-29(27(33-25)28(31)40)32-21-6-8-22(9-7-21)36-13-10-23(11-14-36)37-18-16-35(3)17-19-37/h5-9,23-24H,2,4,10-20H2,1,3H3,(H2,31,40)(H,32,34)/t24-/m1/s1

> <stdInchikey>
QKDCLUARMDUUKN-XMMPIXPASA-N

> <csid>
44210447

> <Links>
|http://www.chemspider.com/Chemical-Structure.44210447.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3663929|http://pubchem.ncbi.nlm.nih.gov/compound/71667668|http://www.drugbank.ca/drugs/DB12036| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=8RC|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/8RC|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9248|http://zinc15.docking.org/substances/ZINC000205341959|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=47DD4548PB|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=170514

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
562.3

> <HBA>
9

> <HBD>
2

> <NRB>
9

> <TPSA>
120.2

> <LogP>
2.3

> <RoF>
1

> <Targets>
EGFR

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0115

> <r_epik_State_Penalty>
  0.0264

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
375

> <lig_pdbID>
'8RC'

> <pdbID>
5y9t

> <Kinase families>
Tyr

> <Withdrawn>
|Study NCT02674555 in nan was Withdrawn during Phase 1 because Following recommendation by SOLAR Study IDMC, Astellas closed enrollment in ASP8273 studies

$$$$
Sitravatinib
                    3D
 Structure written by MMmdl.
 75 80  0  0  1  0            999 V2000
   -6.8190    1.6149   -4.9814 C   0  0  0  0  0  0
   -6.5385    0.9420   -3.7630 O   0  0  0  0  0  0
   -6.8975   -0.4337   -3.7806 C   0  0  0  0  0  0
   -6.5873   -1.0677   -2.4171 C   0  0  0  0  0  0
   -5.0884   -0.9223   -2.1082 N   0  3  0  0  0  0
   -4.6673   -1.5377   -0.7660 C   0  0  0  0  0  0
   -3.1812   -1.3900   -0.4981 C   0  0  0  0  0  0
   -2.2729   -2.3566   -0.9394 C   0  0  0  0  0  0
   -0.9131   -2.2037   -0.6630 C   0  0  0  0  0  0
   -0.4864   -1.0813    0.0600 C   0  0  0  0  0  0
   -1.3670   -0.1385    0.4990 N   0  0  0  0  0  0
   -2.6853   -0.3003    0.2222 C   0  0  0  0  0  0
    0.9635   -0.8683    0.3904 C   0  0  0  0  0  0
    2.0472   -1.6520    0.0199 C   0  0  0  0  0  0
    3.2896   -1.1623    0.5044 C   0  0  0  0  0  0
    3.1514    0.0299    1.2681 C   0  0  0  0  0  0
    1.4673    0.5175    1.3623 S   0  0  0  0  0  0
    4.2861    0.6454    1.8229 C   0  0  0  0  0  0
    5.5241    0.0318    1.5882 C   0  0  0  0  0  0
    5.5702   -1.1344    0.8273 C   0  0  0  0  0  0
    4.4793   -1.7361    0.2852 N   0  0  0  0  0  0
    4.0721    1.7964    2.5541 O   0  0  0  0  0  0
    5.1339    2.4854    3.0885 C   0  0  0  0  0  0
    5.8475    3.3914    2.3010 C   0  0  0  0  0  0
    6.9245    4.0935    2.8410 C   0  0  0  0  0  0
    7.2932    3.9098    4.1773 C   0  0  0  0  0  0
    6.5777    2.9914    4.9645 C   0  0  0  0  0  0
    5.5012    2.2879    4.4223 C   0  0  0  0  0  0
    4.8204    1.4074    5.1918 F   0  0  0  0  0  0
    8.4009    4.6492    4.6288 N   0  0  0  0  0  0
    8.7633    4.9506    5.8953 C   0  0  0  0  0  0
    8.1175    4.6454    6.8992 O   0  0  0  0  0  0
   10.0730    5.7594    6.0317 C   0  0  0  0  0  0
    9.8623    7.2670    6.1420 C   0  0  0  0  0  0
   10.3004    6.4854    7.3550 C   0  0  0  0  0  0
   11.3729    5.2868    5.3431 C   0  0  0  0  0  0
   11.9995    6.0567    4.6132 O   0  0  0  0  0  0
   11.7260    4.0066    5.5942 N   0  0  0  0  0  0
   12.8348    3.2825    5.1196 C   0  0  0  0  0  0
   12.7313    1.8900    5.1804 C   0  0  0  0  0  0
   13.7822    1.0893    4.7409 C   0  0  0  0  0  0
   14.9427    1.6805    4.2481 C   0  0  0  0  0  0
   15.0631    3.0672    4.1963 C   0  0  0  0  0  0
   14.0140    3.8717    4.6345 C   0  0  0  0  0  0
   15.9627    0.9021    3.8213 F   0  0  0  0  0  0
   -6.5187    2.6596   -4.8989 H   0  0  0  0  0  0
   -7.8853    1.5916   -5.2123 H   0  0  0  0  0  0
   -6.2701    1.1752   -5.8158 H   0  0  0  0  0  0
   -7.9606   -0.5457   -4.0014 H   0  0  0  0  0  0
   -6.3426   -0.9510   -4.5661 H   0  0  0  0  0  0
   -7.1033   -0.5646   -1.5979 H   0  0  0  0  0  0
   -6.7967   -2.1381   -2.3976 H   0  0  0  0  0  0
   -4.5584   -1.3622   -2.8472 H   0  0  0  0  0  0
   -5.2740   -1.0307   -0.0133 H   0  0  0  0  0  0
   -4.9696   -2.5850   -0.8217 H   0  0  0  0  0  0
   -2.6138   -3.2202   -1.4920 H   0  0  0  0  0  0
   -0.2137   -2.9513   -1.0058 H   0  0  0  0  0  0
   -3.3459    0.4698    0.5935 H   0  0  0  0  0  0
    1.9659   -2.5476   -0.5778 H   0  0  0  0  0  0
    6.4386    0.4450    1.9866 H   0  0  0  0  0  0
    6.5173   -1.6185    0.6370 H   0  0  0  0  0  0
    5.5682    3.5466    1.2690 H   0  0  0  0  0  0
    7.4666    4.7863    2.2129 H   0  0  0  0  0  0
    6.8455    2.7955    5.9910 H   0  0  0  0  0  0
    8.9817    5.0266    3.8944 H   0  0  0  0  0  0
   10.5733    7.9561    5.6843 H   0  0  0  0  0  0
    8.8489    7.6716    6.1229 H   0  0  0  0  0  0
    9.5934    6.3652    8.1771 H   0  0  0  0  0  0
   11.3177    6.6264    7.7240 H   0  0  0  0  0  0
   11.0888    3.4714    6.1661 H   0  0  0  0  0  0
   11.8358    1.4200    5.5619 H   0  0  0  0  0  0
   13.6973    0.0134    4.7830 H   0  0  0  0  0  0
   15.9701    3.5185    3.8217 H   0  0  0  0  0  0
   14.1466    4.9418    4.6010 H   0  0  0  0  0  0
   -4.8529    0.0604   -2.1046 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 46  1  0  0  0
  1 47  1  0  0  0
  1 48  1  0  0  0
  2  3  1  0  0  0
  3  4  1  0  0  0
  3 49  1  0  0  0
  3 50  1  0  0  0
  4  5  1  0  0  0
  4 51  1  0  0  0
  4 52  1  0  0  0
  5  6  1  0  0  0
  5 53  1  0  0  0
  5 75  1  0  0  0
  6  7  1  0  0  0
  6 54  1  0  0  0
  6 55  1  0  0  0
  7  8  1  0  0  0
  7 12  2  0  0  0
  8  9  2  0  0  0
  8 56  1  0  0  0
  9 10  1  0  0  0
  9 57  1  0  0  0
 10 11  2  0  0  0
 10 13  1  0  0  0
 11 12  1  0  0  0
 12 58  1  0  0  0
 13 14  2  0  0  0
 13 17  1  0  0  0
 14 15  1  0  0  0
 14 59  1  0  0  0
 15 16  1  0  0  0
 15 21  2  0  0  0
 16 17  1  0  0  0
 16 18  2  0  0  0
 18 19  1  0  0  0
 18 22  1  0  0  0
 19 20  2  0  0  0
 19 60  1  0  0  0
 20 21  1  0  0  0
 20 61  1  0  0  0
 22 23  1  0  0  0
 23 24  1  0  0  0
 23 28  2  0  0  0
 24 25  2  0  0  0
 24 62  1  0  0  0
 25 26  1  0  0  0
 25 63  1  0  0  0
 26 27  2  0  0  0
 26 30  1  0  0  0
 27 28  1  0  0  0
 27 64  1  0  0  0
 28 29  1  0  0  0
 30 31  1  0  0  0
 30 65  1  0  0  0
 31 32  2  0  0  0
 31 33  1  0  0  0
 33 34  1  0  0  0
 33 35  1  0  0  0
 33 36  1  0  0  0
 34 35  1  0  0  0
 34 66  1  0  0  0
 34 67  1  0  0  0
 35 68  1  0  0  0
 35 69  1  0  0  0
 36 37  2  0  0  0
 36 38  1  0  0  0
 38 39  1  0  0  0
 38 70  1  0  0  0
 39 40  1  0  0  0
 39 44  2  0  0  0
 40 41  2  0  0  0
 40 71  1  0  0  0
 41 42  1  0  0  0
 41 72  1  0  0  0
 42 43  2  0  0  0
 42 45  1  0  0  0
 43 44  1  0  0  0
 43 73  1  0  0  0
 44 74  1  0  0  0
M  CHG  1   5   1
M  END
> <s_m_entry_id>
387

> <Applicants>
Mirati Therapeutics

> <CHEMBL_ID>
CHEMBL3989926

> <Canonical_Smiles>
s1c2c(nccc2Oc2ccc(NC(=O)C3(CC3)C(=O)Nc3ccc(F)cc3)cc2F)cc1-c1ncc(cc1)CNCCOC

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
3

> <SC_Patent>
None

> <Synonyms>
MG-516 | MG-91516 | MGCD-516 | MGCD516 | SITRAVATINIB

> <Indications>
nan

> <Type>
nan

> <targets_id>
P07949|Q16832|P04629|Q16620|Q16288

> <inchi>
InChI=1S/C33H29F2N5O4S/c1-43-15-14-36-18-20-2-8-25(38-19-20)29-17-26-30(45-29)28(10-13-37-26)44-27-9-7-23(16-24(27)35)40-32(42)33(11-12-33)31(41)39-22-5-3-21(34)4-6-22/h2-10,13,16-17,19,36H,11-12,14-15,18H2,1H3,(H,39,41)(H,40,42)

> <stdInchikey>
WLAVZAAODLTUSW-UHFFFAOYSA-N

> <csid>
52083477

> <Links>
|http://www.chemspider.com/Chemical-Structure.52083477.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3989926|http://pubchem.ncbi.nlm.nih.gov/compound/25212148|http://www.drugbank.ca/drugs/DB15036|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9920|http://zinc15.docking.org/substances/ZINC000164334830|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=CWG62Q1VTB|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50467574

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
629.2

> <HBA>
8

> <HBD>
3

> <NRB>
12

> <TPSA>
114.5

> <LogP>
6.5

> <RoF>
2

> <Targets>
RET; DDR2; NTRK1; NTRK2; NTRK3

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0903

> <r_epik_State_Penalty>
  0.0778

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
387

> <Kinase families>
Tyr

$$$$
Ensartinib
                    3D
 Structure written by MMmdl.
 66 69  0  0  1  0            999 V2000
  -10.3273   -2.7865    2.2956 C   0  0  0  0  0  0
   -8.8488   -2.4356    2.0742 C   0  0  2  0  0  0
   -8.0371   -3.5862    1.4266 C   0  0  0  0  0  0
   -6.6305   -3.1483    1.3569 N   0  0  0  0  0  0
   -6.0175   -2.9777    2.6894 C   0  0  0  0  0  0
   -6.7502   -1.7995    3.3801 C   0  0  1  0  0  0
   -8.2563   -2.1236    3.4641 N   0  3  0  0  0  0
   -6.2731   -1.5474    4.8177 C   0  0  0  0  0  0
   -6.1260   -2.6044    0.2135 C   0  0  0  0  0  0
   -6.8014   -2.4394   -0.8048 O   0  0  0  0  0  0
   -4.6706   -2.2118    0.1775 C   0  0  0  0  0  0
   -3.6723   -3.1468    0.4749 C   0  0  0  0  0  0
   -2.3309   -2.7790    0.4206 C   0  0  0  0  0  0
   -1.9744   -1.4748    0.0736 C   0  0  0  0  0  0
   -2.9716   -0.5443   -0.2536 C   0  0  0  0  0  0
   -4.3125   -0.9147   -0.2021 C   0  0  0  0  0  0
   -0.5988   -1.1886    0.0282 N   0  0  0  0  0  0
    0.0175    0.0019    0.2229 C   0  0  0  0  0  0
   -0.5775    1.0425    0.5139 O   0  0  0  0  0  0
    1.5279    0.0047    0.0875 C   0  0  0  0  0  0
    2.2632    1.1729    0.3270 C   0  0  0  0  0  0
    3.6614    1.1406    0.2126 C   0  0  0  0  0  0
    4.2366   -0.0806   -0.1628 C   0  0  0  0  0  0
    3.4941   -1.1931   -0.3958 N   0  0  0  0  0  0
    2.1588   -1.1523   -0.2682 N   0  0  0  0  0  0
    5.6186   -0.2087   -0.3069 N   0  0  0  0  0  0
    4.4902    2.2288    0.4396 O   0  0  0  0  0  0
    3.9918    3.4112    1.0767 C   0  0  2  0  0  0
    5.0796    4.4955    1.0053 C   0  0  0  0  0  0
    3.5314    3.1458    2.5278 C   0  0  0  0  0  0
    4.3295    2.3992    3.4226 C   0  0  0  0  0  0
    3.8882    2.1525    4.7225 C   0  0  0  0  0  0
    2.6630    2.6441    5.1576 C   0  0  0  0  0  0
    1.8708    3.3951    4.2957 C   0  0  0  0  0  0
    2.2970    3.6538    2.9889 C   0  0  0  0  0  0
    1.2668    4.6162    1.9785 Cl  0  0  0  0  0  0
    0.6844    3.8732    4.7387 F   0  0  0  0  0  0
    5.8796    1.7614    2.9845 Cl  0  0  0  0  0  0
  -10.8219   -2.9992    1.3472 H   0  0  0  0  0  0
  -10.8676   -1.9631    2.7649 H   0  0  0  0  0  0
  -10.4433   -3.6657    2.9311 H   0  0  0  0  0  0
   -8.7582   -1.5068    1.5065 H   0  0  0  0  0  0
   -8.1043   -4.4888    2.0360 H   0  0  0  0  0  0
   -8.4385   -3.8395    0.4435 H   0  0  0  0  0  0
   -6.1480   -3.8948    3.2658 H   0  0  0  0  0  0
   -4.9472   -2.7809    2.6526 H   0  0  0  0  0  0
   -6.6848   -0.8816    2.7914 H   0  0  0  0  0  0
   -8.7474   -1.3399    3.8706 H   0  0  0  0  0  0
   -5.2155   -1.2809    4.8340 H   0  0  0  0  0  0
   -6.3992   -2.4299    5.4466 H   0  0  0  0  0  0
   -6.8205   -0.7262    5.2826 H   0  0  0  0  0  0
   -3.9292   -4.1609    0.7468 H   0  0  0  0  0  0
   -1.5729   -3.5133    0.6545 H   0  0  0  0  0  0
   -2.7268    0.4597   -0.5655 H   0  0  0  0  0  0
   -5.0688   -0.1865   -0.4597 H   0  0  0  0  0  0
   -0.0001   -1.9888   -0.1147 H   0  0  0  0  0  0
    1.7512    2.0823    0.5997 H   0  0  0  0  0  0
    6.2092    0.5913   -0.1311 H   0  0  0  0  0  0
    6.0105   -1.1002   -0.5735 H   0  0  0  0  0  0
    3.1728    3.7727    0.4568 H   0  0  0  0  0  0
    4.7253    5.4351    1.4304 H   0  0  0  0  0  0
    5.3662    4.6915   -0.0282 H   0  0  0  0  0  0
    5.9812    4.2079    1.5458 H   0  0  0  0  0  0
    4.5005    1.5773    5.4017 H   0  0  0  0  0  0
    2.3311    2.4480    6.1667 H   0  0  0  0  0  0
   -8.3934   -2.9190    4.0713 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 39  1  0  0  0
  1 40  1  0  0  0
  1 41  1  0  0  0
  2  3  1  0  0  0
  2  7  1  0  0  0
  2 42  1  0  0  0
  3  4  1  0  0  0
  3 43  1  0  0  0
  3 44  1  0  0  0
  4  5  1  0  0  0
  4  9  1  0  0  0
  5  6  1  0  0  0
  5 45  1  0  0  0
  5 46  1  0  0  0
  6  7  1  0  0  0
  6  8  1  0  0  0
  6 47  1  0  0  0
  7 48  1  0  0  0
  7 66  1  0  0  0
  8 49  1  0  0  0
  8 50  1  0  0  0
  8 51  1  0  0  0
  9 10  2  0  0  0
  9 11  1  0  0  0
 11 12  1  0  0  0
 11 16  2  0  0  0
 12 13  2  0  0  0
 12 52  1  0  0  0
 13 14  1  0  0  0
 13 53  1  0  0  0
 14 15  2  0  0  0
 14 17  1  0  0  0
 15 16  1  0  0  0
 15 54  1  0  0  0
 16 55  1  0  0  0
 17 18  1  0  0  0
 17 56  1  0  0  0
 18 19  2  0  0  0
 18 20  1  0  0  0
 20 21  1  0  0  0
 20 25  2  0  0  0
 21 22  2  0  0  0
 21 57  1  0  0  0
 22 23  1  0  0  0
 22 27  1  0  0  0
 23 24  2  0  0  0
 23 26  1  0  0  0
 24 25  1  0  0  0
 26 58  1  0  0  0
 26 59  1  0  0  0
 27 28  1  0  0  0
 28 29  1  0  0  0
 28 30  1  0  0  0
 28 60  1  0  0  0
 29 61  1  0  0  0
 29 62  1  0  0  0
 29 63  1  0  0  0
 30 31  2  0  0  0
 30 35  1  0  0  0
 31 32  1  0  0  0
 31 38  1  0  0  0
 32 33  2  0  0  0
 32 64  1  0  0  0
 33 34  1  0  0  0
 33 65  1  0  0  0
 34 35  2  0  0  0
 34 37  1  0  0  0
 35 36  1  0  0  0
M  CHG  1   7   1
M  END
> <s_m_entry_id>
389

> <Applicants>
Xcovery

> <CHEMBL_ID>
CHEMBL4113131

> <Canonical_Smiles>
Clc1c([C@H](Oc2cc(nnc2N)C(=O)Nc2ccc(cc2)C(=O)N2C[C@H](N[C@H](C2)C)C)C)c(Cl)ccc1F

> <Chirality>
Single Stereoisomer

> <First_Approval>
nan

> <Phase>
3

> <SC_Patent>
None

> <Synonyms>
ENSARTINIB | X-396

> <Indications>
nan

> <Type>
nan

> <targets_id>
Q9UM73

> <inchi>
InChI=1S/C26H27Cl2FN6O3/c1-13-11-35(12-14(2)31-13)26(37)16-4-6-17(7-5-16)32-25(36)20-10-21(24(30)34-33-20)38-15(3)22-18(27)8-9-19(29)23(22)28/h4-10,13-15,31H,11-12H2,1-3H3,(H2,30,34)(H,32,36)/t13-,14+,15-/m1/s1

> <stdInchikey>
GLYMPHUVMRFTFV-QLFBSQMISA-N

> <csid>
58828042

> <Links>
|http://www.chemspider.com/Chemical-Structure.58828042.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4113131|http://pubchem.ncbi.nlm.nih.gov/compound/56960363|http://www.drugbank.ca/drugs/DB14860|http://zinc15.docking.org/substances/ZINC000199407645|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=SMA5ZS5B22|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=179297

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|ZINC|FDA SRS|BindingDB

> <MW>
560.2

> <HBA>
7

> <HBD>
3

> <NRB>
6

> <TPSA>
122.5

> <LogP>
4.7

> <RoF>
1

> <Targets>
ALK

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
0.999839

> <r_epik_Ionization_Penalty>
  0.0553

> <r_epik_State_Penalty>
  0.0444

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
389

> <Kinase families>
Tyr

$$$$
Savolitinib
                    3D
 Structure written by MMmdl.
 41 45  0  0  1  0            999 V2000
   -0.6085    1.7136   -0.0508 C   0  0  0  0  0  0
    0.0262    0.3077    0.0629 C   0  0  1  0  0  0
   -0.4489   -0.6220   -1.0540 C   0  0  0  0  0  0
   -1.3582   -1.6474   -0.7778 C   0  0  0  0  0  0
   -1.8117   -2.5101   -1.7785 C   0  0  0  0  0  0
   -1.3419   -2.3391   -3.0932 C   0  0  0  0  0  0
   -1.6251   -3.0290   -4.2292 N   0  0  0  0  0  0
   -0.9072   -2.4383   -5.1612 C   0  0  0  0  0  0
   -0.1494   -1.3719   -4.6862 C   0  0  0  0  0  0
   -0.4270   -1.3007   -3.3457 N   0  0  0  0  0  0
    0.0160   -0.4572   -2.3613 C   0  0  0  0  0  0
    1.4927    0.3457    0.1756 N   0  0  0  0  0  0
    2.3470   -0.6485    0.6225 C   0  0  0  0  0  0
    3.6497   -0.1183    0.4659 C   0  0  0  0  0  0
    4.7355   -0.8182    0.8141 N   0  0  0  0  0  0
    4.4873   -2.0611    1.3170 C   0  0  0  0  0  0
    3.1885   -2.5791    1.4617 C   0  0  0  0  0  0
    2.0773   -1.8665    1.1091 N   0  0  0  0  0  0
    2.9392   -3.9484    2.0007 C   0  0  0  0  0  0
    1.7283   -4.6640    2.0660 C   0  0  0  0  0  0
    1.8485   -5.8574    2.6024 N   0  0  0  0  0  0
    3.1474   -5.9567    2.9019 N   0  0  0  0  0  0
    3.8520   -4.8316    2.5627 C   0  0  0  0  0  0
    3.6441   -7.1706    3.5243 C   0  0  0  0  0  0
    3.5681    1.1300   -0.0710 N   0  0  0  0  0  0
    2.2265    1.3980   -0.2629 N   0  0  0  0  0  0
   -1.6968    1.6543   -0.0123 H   0  0  0  0  0  0
   -0.3411    2.2063   -0.9868 H   0  0  0  0  0  0
   -0.2910    2.3600    0.7684 H   0  0  0  0  0  0
   -0.3184   -0.1058    1.0128 H   0  0  0  0  0  0
   -1.7238   -1.7850    0.2297 H   0  0  0  0  0  0
   -2.5143   -3.2952   -1.5408 H   0  0  0  0  0  0
   -0.9334   -2.7803   -6.1856 H   0  0  0  0  0  0
    0.5299   -0.6962   -5.1848 H   0  0  0  0  0  0
    0.7172    0.3116   -2.6526 H   0  0  0  0  0  0
    5.3556   -2.6381    1.5991 H   0  0  0  0  0  0
    0.7693   -4.3067    1.7195 H   0  0  0  0  0  0
    4.9140   -4.7627    2.7474 H   0  0  0  0  0  0
    4.7248   -7.1065    3.6570 H   0  0  0  0  0  0
    3.4132   -8.0275    2.8899 H   0  0  0  0  0  0
    3.1709   -7.2995    4.4987 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 27  1  0  0  0
  1 28  1  0  0  0
  1 29  1  0  0  0
  2  3  1  0  0  0
  2 12  1  0  0  0
  2 30  1  0  0  0
  3  4  1  0  0  0
  3 11  2  0  0  0
  4  5  2  0  0  0
  4 31  1  0  0  0
  5  6  1  0  0  0
  5 32  1  0  0  0
  6  7  2  0  0  0
  6 10  1  0  0  0
  7  8  1  0  0  0
  8  9  2  0  0  0
  8 33  1  0  0  0
  9 10  1  0  0  0
  9 34  1  0  0  0
 10 11  1  0  0  0
 11 35  1  0  0  0
 12 13  1  0  0  0
 12 26  1  0  0  0
 13 14  2  0  0  0
 13 18  1  0  0  0
 14 15  1  0  0  0
 14 25  1  0  0  0
 15 16  2  0  0  0
 16 17  1  0  0  0
 16 36  1  0  0  0
 17 18  2  0  0  0
 17 19  1  0  0  0
 19 20  1  0  0  0
 19 23  2  0  0  0
 20 21  2  0  0  0
 20 37  1  0  0  0
 21 22  1  0  0  0
 22 23  1  0  0  0
 22 24  1  0  0  0
 23 38  1  0  0  0
 24 39  1  0  0  0
 24 40  1  0  0  0
 24 41  1  0  0  0
 25 26  2  0  0  0
M  END
> <s_m_entry_id>
391

> <Applicants>
Astrazeneca

> <CHEMBL_ID>
CHEMBL3334567

> <Canonical_Smiles>
n1c2n(nnc2ncc1-c1cn(nc1)C)[C@@H](C)C=1C=Cc2n(C=1)ccn2

> <Chirality>
Single Stereoisomer

> <First_Approval>
nan

> <Phase>
3

> <SC_Patent>
None

> <Synonyms>
AZD-6094 | AZD6094 | HMPL-504 | SAVOLITINIB | VOLITINIB

> <Indications>
nan

> <Type>
nan

> <targets_id>
P08581

> <inchi>
InChI=1S/C17H15N9/c1-11(12-3-4-15-18-5-6-25(15)10-12)26-17-16(22-23-26)19-8-14(21-17)13-7-20-24(2)9-13/h3-11H,1-2H3/t11-/m0/s1

> <stdInchikey>
XYDNMOZJKOGZLS-NSHDSACASA-N

> <csid>
34501055

> <Links>
|http://www.chemspider.com/Chemical-Structure.34501055.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3334567|http://pubchem.ncbi.nlm.nih.gov/compound/68289010|http://www.drugbank.ca/drugs/DB12048| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=V0L|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/V0L|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9918|http://zinc15.docking.org/substances/ZINC000149738712|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=2A2DA6857R|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50023342

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
345.1

> <HBA>
9

> <HBD>
0

> <NRB>
3

> <TPSA>
91.6

> <LogP>
1.9

> <RoF>
0

> <Targets>
MET

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0892

> <r_epik_State_Penalty>
  0.0796

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
391

> <lig_pdbID>
'V0L'

> <pdbID>
5lbw 6sde

> <Kinase families>
Tyr

$$$$
Saracatinib
                    3D
 Structure written by MMmdl.
 71 76  0  0  1  0            999 V2000
   -5.7884    3.3451    2.4949 C   0  0  0  0  0  0
   -4.8791    2.1120    2.3286 N   0  3  0  0  0  0
   -3.3986    2.5059    2.5198 C   0  0  0  0  0  0
   -2.4995    1.2787    2.2467 C   0  0  0  0  0  0
   -2.7302    0.6631    0.9315 N   0  0  0  0  0  0
   -4.1350    0.2684    0.7671 C   0  0  0  0  0  0
   -5.1344    1.4332    0.9651 C   0  0  0  0  0  0
   -2.2467    1.4540   -0.2112 C   0  0  0  0  0  0
   -0.7212    1.6775   -0.2142 C   0  0  0  0  0  0
   -0.0399    0.4321   -0.0759 O   0  0  0  0  0  0
    1.3372    0.4180    0.0325 C   0  0  0  0  0  0
    2.1435    1.5563   -0.0340 C   0  0  0  0  0  0
    3.5433    1.4531    0.0983 C   0  0  0  0  0  0
    4.1525    0.1727    0.3010 C   0  0  0  0  0  0
    3.3159   -0.9945    0.3548 C   0  0  0  0  0  0
    1.9299   -0.8254    0.2201 C   0  0  0  0  0  0
    3.9235   -2.2275    0.5408 O   0  0  0  0  0  0
    3.2334   -3.4829    0.5407 C   0  0  0  0  0  0
    2.5724   -3.8863   -0.7977 C   0  0  0  0  0  0
    1.9100   -5.2732   -0.6888 C   0  0  0  0  0  0
    1.0304   -5.3249    0.4347 O   0  0  0  0  0  0
    1.6806   -5.1357    1.6916 C   0  0  0  0  0  0
    2.3287   -3.7396    1.7673 C   0  0  0  0  0  0
    5.5860    0.1992    0.4300 C   0  0  0  0  0  0
    6.3011    1.3502    0.3439 N   0  0  0  0  0  0
    5.6069    2.4893    0.1496 C   0  0  0  0  0  0
    4.2674    2.6045    0.0249 N   0  0  0  0  0  0
    6.3247   -0.9814    0.6297 N   0  0  0  0  0  0
    7.7016   -1.1936    0.8212 C   0  0  0  0  0  0
    8.3776   -2.1863    0.0809 C   0  0  0  0  0  0
    9.7597   -2.3854    0.2476 C   0  0  0  0  0  0
   10.4962   -1.6081    1.1492 C   0  0  0  0  0  0
    9.8111   -0.6372    1.8688 C   0  0  0  0  0  0
    8.4678   -0.4348    1.7123 C   0  0  0  0  0  0
    8.0660    0.5459    2.5657 O   0  0  0  0  0  0
    9.2309    1.0525    3.1568 C   0  0  0  0  0  0
   10.2996    0.2176    2.8047 O   0  0  0  0  0  0
    7.5359   -3.1899   -1.0531 Cl  0  0  0  0  0  0
   -5.5305    4.0662    1.7174 H   0  0  0  0  0  0
   -5.6055    3.7469    3.4925 H   0  0  0  0  0  0
   -6.8192    3.0012    2.3988 H   0  0  0  0  0  0
   -3.1842    3.3338    1.8419 H   0  0  0  0  0  0
   -3.2968    2.8581    3.5472 H   0  0  0  0  0  0
   -1.4495    1.5436    2.3685 H   0  0  0  0  0  0
   -2.6865    0.5233    3.0116 H   0  0  0  0  0  0
   -4.2801   -0.1901   -0.2123 H   0  0  0  0  0  0
   -4.3554   -0.5201    1.4887 H   0  0  0  0  0  0
   -6.1665    1.0803    0.9767 H   0  0  0  0  0  0
   -5.0341    2.1971    0.1923 H   0  0  0  0  0  0
   -2.5098    0.9413   -1.1380 H   0  0  0  0  0  0
   -2.7532    2.4185   -0.2539 H   0  0  0  0  0  0
   -0.4331    2.1530   -1.1533 H   0  0  0  0  0  0
   -0.4454    2.3733    0.5796 H   0  0  0  0  0  0
    1.7173    2.5369   -0.1868 H   0  0  0  0  0  0
    1.2604   -1.6664    0.2597 H   0  0  0  0  0  0
    4.0785   -4.1634    0.6598 H   0  0  0  0  0  0
    1.8175   -3.1700   -1.1123 H   0  0  0  0  0  0
    3.3193   -3.8952   -1.5923 H   0  0  0  0  0  0
    1.3399   -5.4882   -1.5928 H   0  0  0  0  0  0
    2.6648   -6.0575   -0.6049 H   0  0  0  0  0  0
    0.9465   -5.2515    2.4893 H   0  0  0  0  0  0
    2.4275   -5.9173    1.8427 H   0  0  0  0  0  0
    2.9140   -3.6554    2.6836 H   0  0  0  0  0  0
    1.5401   -2.9963    1.8542 H   0  0  0  0  0  0
    6.1811    3.4022    0.0870 H   0  0  0  0  0  0
    5.7711   -1.8251    0.5855 H   0  0  0  0  0  0
   10.2655   -3.1482   -0.3262 H   0  0  0  0  0  0
   11.5569   -1.7680    1.2752 H   0  0  0  0  0  0
    9.4167    2.0687    2.8049 H   0  0  0  0  0  0
    9.1204    1.0957    4.2409 H   0  0  0  0  0  0
   -5.1152    1.4467    3.0517 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 39  1  0  0  0
  1 40  1  0  0  0
  1 41  1  0  0  0
  2  3  1  0  0  0
  2  7  1  0  0  0
  2 71  1  0  0  0
  3  4  1  0  0  0
  3 42  1  0  0  0
  3 43  1  0  0  0
  4  5  1  0  0  0
  4 44  1  0  0  0
  4 45  1  0  0  0
  5  6  1  0  0  0
  5  8  1  0  0  0
  6  7  1  0  0  0
  6 46  1  0  0  0
  6 47  1  0  0  0
  7 48  1  0  0  0
  7 49  1  0  0  0
  8  9  1  0  0  0
  8 50  1  0  0  0
  8 51  1  0  0  0
  9 10  1  0  0  0
  9 52  1  0  0  0
  9 53  1  0  0  0
 10 11  1  0  0  0
 11 12  1  0  0  0
 11 16  2  0  0  0
 12 13  2  0  0  0
 12 54  1  0  0  0
 13 14  1  0  0  0
 13 27  1  0  0  0
 14 15  2  0  0  0
 14 24  1  0  0  0
 15 16  1  0  0  0
 15 17  1  0  0  0
 16 55  1  0  0  0
 17 18  1  0  0  0
 18 19  1  0  0  0
 18 23  1  0  0  0
 18 56  1  0  0  0
 19 20  1  0  0  0
 19 57  1  0  0  0
 19 58  1  0  0  0
 20 21  1  0  0  0
 20 59  1  0  0  0
 20 60  1  0  0  0
 21 22  1  0  0  0
 22 23  1  0  0  0
 22 61  1  0  0  0
 22 62  1  0  0  0
 23 63  1  0  0  0
 23 64  1  0  0  0
 24 25  2  0  0  0
 24 28  1  0  0  0
 25 26  1  0  0  0
 26 27  2  0  0  0
 26 65  1  0  0  0
 28 29  1  0  0  0
 28 66  1  0  0  0
 29 30  1  0  0  0
 29 34  2  0  0  0
 30 31  2  0  0  0
 30 38  1  0  0  0
 31 32  1  0  0  0
 31 67  1  0  0  0
 32 33  2  0  0  0
 32 68  1  0  0  0
 33 34  1  0  0  0
 33 37  1  0  0  0
 34 35  1  0  0  0
 35 36  1  0  0  0
 36 37  1  0  0  0
 36 69  1  0  0  0
 36 70  1  0  0  0
M  CHG  1   2   1
M  END
> <s_m_entry_id>
393

> <Applicants>
Astrazeneca

> <CHEMBL_ID>
CHEMBL217092

> <Canonical_Smiles>
Clc1ccc2OCOc2c1Nc1ncnc2c1c(OC1CCOCC1)cc(OCCN1CCN(CC1)C)c2

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
3

> <SC_Patent>
None

> <Synonyms>
AZ-10353926 | AZD-0530 | AZD0530 | SARACATINIB

> <Indications>
nan

> <Type>
1

> <targets_id>
P12931|P00519

> <inchi>
InChI=1S/C27H32ClN5O5/c1-32-6-8-33(9-7-32)10-13-35-19-14-21-24(23(15-19)38-18-4-11-34-12-5-18)27(30-16-29-21)31-25-20(28)2-3-22-26(25)37-17-36-22/h2-3,14-16,18H,4-13,17H2,1H3,(H,29,30,31)

> <stdInchikey>
OUKYUETWWIPKQR-UHFFFAOYSA-N

> <csid>
8477917

> <Links>
|http://www.chemspider.com/Chemical-Structure.8477917.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL217092|http://pubchem.ncbi.nlm.nih.gov/compound/10302451|http://www.drugbank.ca/drugs/DB11805| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=H8H|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/H8H|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7731|http://zinc15.docking.org/substances/ZINC24811973|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=9KD24QGH76|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=12255

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
541.2

> <HBA>
10

> <HBD>
1

> <NRB>
8

> <TPSA>
90.4

> <LogP>
3.9

> <RoF>
1

> <Targets>
SRC; ABL1

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
0.999978

> <r_epik_Ionization_Penalty>
  0.0557

> <r_epik_State_Penalty>
  0.1518

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
393

> <lig_pdbID>
'H8H'

> <pdbID>
2h8h 4qmx 5vcx 5vd3 6zgc

> <Kinase families>
Tyr

$$$$
Enzastaurin
                    3D
 Structure written by MMmdl.
 69 75  0  0  1  0            999 V2000
   -0.7813    5.8712   -1.3538 C   0  0  0  0  0  0
   -0.4256    4.6483   -0.6513 N   0  0  0  0  0  0
   -1.0619    3.4390   -0.7951 C   0  0  0  0  0  0
   -0.4714    2.4744    0.0010 C   0  0  0  0  0  0
    0.5829    3.1494    0.7175 C   0  0  0  0  0  0
    0.5996    4.5088    0.2681 C   0  0  0  0  0  0
    1.5301    5.4407    0.7486 C   0  0  0  0  0  0
    2.4457    4.9970    1.7014 C   0  0  0  0  0  0
    2.4384    3.6880    2.1706 C   0  0  0  0  0  0
    1.5153    2.7600    1.6966 C   0  0  0  0  0  0
   -0.8494    1.0576    0.0540 C   0  0  0  0  0  0
   -0.0663   -0.0308    0.1279 C   0  0  0  0  0  0
   -0.9065   -1.1938    0.1730 C   0  0  0  0  0  0
   -0.5902   -2.3821    0.2118 O   0  0  0  0  0  0
   -2.1566   -0.7122    0.1508 N   0  0  0  0  0  0
   -2.2193    0.6244    0.0733 C   0  0  0  0  0  0
   -3.2481    1.2987    0.0346 O   0  0  0  0  0  0
    1.3928   -0.1055    0.0965 C   0  0  0  0  0  0
    2.1993    0.6269   -0.7482 C   0  0  0  0  0  0
    3.5306    0.3829   -0.4981 N   0  0  0  0  0  0
    3.6199   -0.5722    0.5060 C   0  0  0  0  0  0
    2.2817   -0.8994    0.9027 C   0  0  0  0  0  0
    2.0958   -1.8378    1.9330 C   0  0  0  0  0  0
    3.2080   -2.4304    2.5245 C   0  0  0  0  0  0
    4.4967   -2.1031    2.1185 C   0  0  0  0  0  0
    4.7358   -1.1711    1.1099 C   0  0  0  0  0  0
    4.6516    1.0427   -1.1782 C   0  0  2  0  0  0
    4.6095    2.5668   -0.9259 C   0  0  0  0  0  0
    5.7511    3.2961   -1.6535 C   0  0  0  0  0  0
    5.6865    2.9588   -3.1633 N   0  3  2  0  0  0
    5.7809    1.4376   -3.4284 C   0  0  0  0  0  0
    4.6352    0.7260   -2.6891 C   0  0  0  0  0  0
    6.8020    3.7037   -3.9363 C   0  0  0  0  0  0
    6.6823    5.2222   -3.9701 C   0  0  0  0  0  0
    7.8152    6.0325   -3.8421 C   0  0  0  0  0  0
    7.6532    7.4190   -3.8861 C   0  0  0  0  0  0
    6.3765    7.9578   -4.0581 C   0  0  0  0  0  0
    5.2957    7.0830   -4.1822 C   0  0  0  0  0  0
    5.4320    5.7326   -4.1420 N   0  0  0  0  0  0
   -1.0684    6.6331   -0.6283 H   0  0  0  0  0  0
   -1.6155    5.6921   -2.0335 H   0  0  0  0  0  0
    0.0777    6.2221   -1.9264 H   0  0  0  0  0  0
   -1.8896    3.3538   -1.4844 H   0  0  0  0  0  0
    1.5429    6.4650    0.4056 H   0  0  0  0  0  0
    3.1748    5.6910    2.0934 H   0  0  0  0  0  0
    3.1585    3.3871    2.9173 H   0  0  0  0  0  0
    1.5255    1.7527    2.0845 H   0  0  0  0  0  0
   -2.9748   -1.3022    0.1782 H   0  0  0  0  0  0
    1.9230    1.3465   -1.5053 H   0  0  0  0  0  0
    1.1050   -2.1013    2.2713 H   0  0  0  0  0  0
    3.0679   -3.1545    3.3139 H   0  0  0  0  0  0
    5.3362   -2.5818    2.6013 H   0  0  0  0  0  0
    5.7477   -0.9318    0.8196 H   0  0  0  0  0  0
    5.5860    0.6606   -0.7655 H   0  0  0  0  0  0
    3.6583    2.9892   -1.2544 H   0  0  0  0  0  0
    4.6778    2.7695    0.1440 H   0  0  0  0  0  0
    5.6549    4.3782   -1.5560 H   0  0  0  0  0  0
    6.7341    2.9842   -1.2959 H   0  0  0  0  0  0
    5.7081    1.2937   -4.5073 H   0  0  0  0  0  0
    6.7628    1.1109   -3.0809 H   0  0  0  0  0  0
    4.7195   -0.3506   -2.8456 H   0  0  0  0  0  0
    3.6869    1.0272   -3.1372 H   0  0  0  0  0  0
    7.7472    3.3775   -3.4975 H   0  0  0  0  0  0
    6.7651    3.3221   -4.9579 H   0  0  0  0  0  0
    8.7974    5.6020   -3.7116 H   0  0  0  0  0  0
    8.5098    8.0698   -3.7891 H   0  0  0  0  0  0
    6.2290    9.0272   -4.0962 H   0  0  0  0  0  0
    4.2936    7.4622   -4.3192 H   0  0  0  0  0  0
    4.7996    3.2853   -3.5214 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 40  1  0  0  0
  1 41  1  0  0  0
  1 42  1  0  0  0
  2  3  1  0  0  0
  2  6  1  0  0  0
  3  4  2  0  0  0
  3 43  1  0  0  0
  4  5  1  0  0  0
  4 11  1  0  0  0
  5  6  1  0  0  0
  5 10  2  0  0  0
  6  7  2  0  0  0
  7  8  1  0  0  0
  7 44  1  0  0  0
  8  9  2  0  0  0
  8 45  1  0  0  0
  9 10  1  0  0  0
  9 46  1  0  0  0
 10 47  1  0  0  0
 11 12  2  0  0  0
 11 16  1  0  0  0
 12 13  1  0  0  0
 12 18  1  0  0  0
 13 14  2  0  0  0
 13 15  1  0  0  0
 15 16  1  0  0  0
 15 48  1  0  0  0
 16 17  2  0  0  0
 18 19  2  0  0  0
 18 22  1  0  0  0
 19 20  1  0  0  0
 19 49  1  0  0  0
 20 21  1  0  0  0
 20 27  1  0  0  0
 21 22  1  0  0  0
 21 26  2  0  0  0
 22 23  2  0  0  0
 23 24  1  0  0  0
 23 50  1  0  0  0
 24 25  2  0  0  0
 24 51  1  0  0  0
 25 26  1  0  0  0
 25 52  1  0  0  0
 26 53  1  0  0  0
 27 28  1  0  0  0
 27 32  1  0  0  0
 27 54  1  0  0  0
 28 29  1  0  0  0
 28 55  1  0  0  0
 28 56  1  0  0  0
 29 30  1  0  0  0
 29 57  1  0  0  0
 29 58  1  0  0  0
 30 31  1  0  0  0
 30 33  1  0  0  0
 30 69  1  0  0  0
 31 32  1  0  0  0
 31 59  1  0  0  0
 31 60  1  0  0  0
 32 61  1  0  0  0
 32 62  1  0  0  0
 33 34  1  0  0  0
 33 63  1  0  0  0
 33 64  1  0  0  0
 34 35  1  0  0  0
 34 39  2  0  0  0
 35 36  2  0  0  0
 35 65  1  0  0  0
 36 37  1  0  0  0
 36 66  1  0  0  0
 37 38  2  0  0  0
 37 67  1  0  0  0
 38 39  1  0  0  0
 38 68  1  0  0  0
M  CHG  1  30   1
M  END
> <s_m_entry_id>
399

> <Applicants>
Eli Lilly

> <CHEMBL_ID>
CHEMBL300138

> <Canonical_Smiles>
O=C1NC(=O)C(=C1c1c2c(n(c1)C1CCN(CC1)Cc1ncccc1)cccc2)c1c2c(n(c1)C)cccc2

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
3

> <SC_Patent>
None

> <Synonyms>
ENZASTAURIN | LY-317615 | LY317615

> <Indications>
nan

> <Type>
nan

> <targets_id>
nan

> <inchi>
InChI=1S/C32H29N5O2/c1-35-19-25(23-9-2-4-11-27(23)35)29-30(32(39)34-31(29)38)26-20-37(28-12-5-3-10-24(26)28)22-13-16-36(17-14-22)18-21-8-6-7-15-33-21/h2-12,15,19-20,22H,13-14,16-18H2,1H3,(H,34,38,39)

> <stdInchikey>
AXRCEOKUDYDWLF-UHFFFAOYSA-N

> <csid>
153463

> <Links>
|http://www.chemspider.com/Chemical-Structure.153463.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL300138|http://pubchem.ncbi.nlm.nih.gov/compound/176167|http://www.drugbank.ca/drugs/DB06486|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5693|http://zinc15.docking.org/substances/ZINC000001494900|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=UC96G28EQF|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50128285

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
515.2

> <HBA>
6

> <HBD>
1

> <NRB>
5

> <TPSA>
72.2

> <LogP>
4.9

> <RoF>
1

> <Targets>
nan

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_epik_Ionization_Penalty>
  0.1295

> <r_epik_State_Penalty>
  0.1137

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
399

> <indicationDB>
Enzastaurin, an investigational, targeted, oral agent, will be evaluated at more than 100 sites worldwide for the treatment of relapsed glioblastoma multiforme (GBM), an aggressive and malignant form of brain cancer.

> <uniprotId>
P05771|Q96GD4|O14965|Q96Q40|O14757|O96017|P31749|P27986

$$$$
Evobrutinib
                    3D
 Structure written by MMmdl.
 59 62  0  0  1  0            999 V2000
   -4.1929    2.7304   -6.3459 C   0  0  0  0  0  0
   -3.6837    2.2276   -5.2054 C   0  0  0  0  0  0
   -4.0939    2.6967   -3.8938 C   0  0  0  0  0  0
   -4.5855    3.8216   -3.7608 O   0  0  0  0  0  0
   -3.8991    1.8659   -2.8275 N   0  0  0  0  0  0
   -3.3620    0.4907   -2.8919 C   0  0  0  0  0  0
   -1.9188    0.5532   -2.3446 C   0  0  0  0  0  0
   -1.8589    1.1431   -0.9118 C   0  0  0  0  0  0
   -2.6451    2.4742   -0.8424 C   0  0  0  0  0  0
   -4.0647    2.3659   -1.4476 C   0  0  0  0  0  0
   -0.4169    1.3138   -0.3878 C   0  0  0  0  0  0
    0.3318    0.0613   -0.3322 N   0  0  0  0  0  0
    1.6888    0.0211    0.0435 C   0  0  0  0  0  0
    2.3224   -1.2261    0.2507 C   0  0  0  0  0  0
    3.6787   -1.1712    0.6374 C   0  0  0  0  0  0
    4.3489   -0.0050    0.8054 N   0  0  0  0  0  0
    3.6506    1.1292    0.5751 C   0  0  0  0  0  0
    2.3540    1.2005    0.1985 N   0  0  0  0  0  0
    4.4315   -2.3261    0.8517 N   0  0  0  0  0  0
    1.6021   -2.5251    0.0706 C   0  0  0  0  0  0
    1.4543   -3.4082    1.1456 C   0  0  0  0  0  0
    0.7727   -4.6109    0.9831 C   0  0  0  0  0  0
    0.2203   -4.9376   -0.2539 C   0  0  0  0  0  0
    0.3791   -4.0702   -1.3389 C   0  0  0  0  0  0
    1.0637   -2.8700   -1.1740 C   0  0  0  0  0  0
   -0.4415   -6.1387   -0.3826 O   0  0  0  0  0  0
   -1.7085   -6.2013   -0.9282 C   0  0  0  0  0  0
   -2.0770   -7.3861   -1.5678 C   0  0  0  0  0  0
   -3.3505   -7.5226   -2.1143 C   0  0  0  0  0  0
   -4.2609   -6.4735   -2.0116 C   0  0  0  0  0  0
   -3.9108   -5.2912   -1.3640 C   0  0  0  0  0  0
   -2.6375   -5.1558   -0.8172 C   0  0  0  0  0  0
   -4.9442    3.5083   -6.3517 H   0  0  0  0  0  0
   -3.8573    2.3620   -7.3041 H   0  0  0  0  0  0
   -2.9309    1.4571   -5.2631 H   0  0  0  0  0  0
   -3.9694   -0.1480   -2.2492 H   0  0  0  0  0  0
   -3.3972    0.0434   -3.8839 H   0  0  0  0  0  0
   -1.4934   -0.4510   -2.3550 H   0  0  0  0  0  0
   -1.3001    1.1492   -3.0181 H   0  0  0  0  0  0
   -2.3674    0.4391   -0.2498 H   0  0  0  0  0  0
   -2.7217    2.8056    0.1939 H   0  0  0  0  0  0
   -2.0930    3.2563   -1.3670 H   0  0  0  0  0  0
   -4.5779    3.3272   -1.3959 H   0  0  0  0  0  0
   -4.6631    1.6521   -0.8800 H   0  0  0  0  0  0
    0.1278    2.0299   -1.0053 H   0  0  0  0  0  0
   -0.4293    1.7466    0.6137 H   0  0  0  0  0  0
   -0.2005   -0.7735   -0.1348 H   0  0  0  0  0  0
    4.1772    2.0638    0.7029 H   0  0  0  0  0  0
    3.9996   -3.2296    0.7243 H   0  0  0  0  0  0
    5.4036   -2.2397    1.1101 H   0  0  0  0  0  0
    1.8646   -3.1596    2.1138 H   0  0  0  0  0  0
    0.6639   -5.2848    1.8202 H   0  0  0  0  0  0
   -0.0297   -4.3253   -2.3055 H   0  0  0  0  0  0
    1.1748   -2.2045   -2.0181 H   0  0  0  0  0  0
   -1.3725   -8.2016   -1.6427 H   0  0  0  0  0  0
   -3.6317   -8.4389   -2.6122 H   0  0  0  0  0  0
   -5.2496   -6.5794   -2.4334 H   0  0  0  0  0  0
   -4.6253   -4.4854   -1.2817 H   0  0  0  0  0  0
   -2.3788   -4.2410   -0.3048 H   0  0  0  0  0  0
  1  2  2  0  0  0
  1 33  1  0  0  0
  1 34  1  0  0  0
  2  3  1  0  0  0
  2 35  1  0  0  0
  3  4  2  0  0  0
  3  5  1  0  0  0
  5  6  1  0  0  0
  5 10  1  0  0  0
  6  7  1  0  0  0
  6 36  1  0  0  0
  6 37  1  0  0  0
  7  8  1  0  0  0
  7 38  1  0  0  0
  7 39  1  0  0  0
  8  9  1  0  0  0
  8 11  1  0  0  0
  8 40  1  0  0  0
  9 10  1  0  0  0
  9 41  1  0  0  0
  9 42  1  0  0  0
 10 43  1  0  0  0
 10 44  1  0  0  0
 11 12  1  0  0  0
 11 45  1  0  0  0
 11 46  1  0  0  0
 12 13  1  0  0  0
 12 47  1  0  0  0
 13 14  1  0  0  0
 13 18  2  0  0  0
 14 15  2  0  0  0
 14 20  1  0  0  0
 15 16  1  0  0  0
 15 19  1  0  0  0
 16 17  2  0  0  0
 17 18  1  0  0  0
 17 48  1  0  0  0
 19 49  1  0  0  0
 19 50  1  0  0  0
 20 21  1  0  0  0
 20 25  2  0  0  0
 21 22  2  0  0  0
 21 51  1  0  0  0
 22 23  1  0  0  0
 22 52  1  0  0  0
 23 24  2  0  0  0
 23 26  1  0  0  0
 24 25  1  0  0  0
 24 53  1  0  0  0
 25 54  1  0  0  0
 26 27  1  0  0  0
 27 28  1  0  0  0
 27 32  2  0  0  0
 28 29  2  0  0  0
 28 55  1  0  0  0
 29 30  1  0  0  0
 29 56  1  0  0  0
 30 31  2  0  0  0
 30 57  1  0  0  0
 31 32  1  0  0  0
 31 58  1  0  0  0
 32 59  1  0  0  0
M  END
> <s_m_entry_id>
409

> <Applicants>
Merck

> <CHEMBL_ID>
CHEMBL4072833

> <Canonical_Smiles>
O(c1ccc(cc1)-c1c(ncnc1N)NCC1CCN(CC1)C(=O)C=C)c1ccccc1

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
3

> <SC_Patent>
None

> <Synonyms>
EVOBRUTINIB | M-2951

> <Indications>
nan

> <Type>
nan

> <targets_id>
Q06187

> <inchi>
InChI=1S/C25H27N5O2/c1-2-22(31)30-14-12-18(13-15-30)16-27-25-23(24(26)28-17-29-25)19-8-10-21(11-9-19)32-20-6-4-3-5-7-20/h2-11,17-18H,1,12-16H2,(H3,26,27,28,29)

> <stdInchikey>
QUIWHXQETADMGN-UHFFFAOYSA-N

> <csid>
58827807

> <Links>
|http://www.chemspider.com/Chemical-Structure.58827807.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4072833|http://pubchem.ncbi.nlm.nih.gov/compound/71479709|http://www.drugbank.ca/drugs/DB15170| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=MZJ|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/MZJ|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9752|http://zinc15.docking.org/substances/ZINC000205623965|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=ZA45457L1K|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=291522

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
429.2

> <HBA>
6

> <HBD>
2

> <NRB>
7

> <TPSA>
93.4

> <LogP>
4.4

> <RoF>
0

> <Targets>
BTK

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0239

> <r_epik_State_Penalty>
  0.0188

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
409

> <lig_pdbID>
'MZJ'

> <pdbID>
6omu

> <Kinase families>
Tyr

$$$$
Famitinib
                    3D
 Structure written by MMmdl.
 58 61  0  0  1  0            999 V2000
   -1.8405   -1.0729    0.5304 C   0  0  0  0  0  0
   -0.8777   -0.8477   -0.6463 C   0  0  0  0  0  0
    0.3657   -0.0497   -0.1839 N   0  3  0  0  0  0
    0.0833    1.4639   -0.0249 C   0  0  0  0  0  0
    1.0666    2.0891    0.9786 C   0  0  0  0  0  0
    1.6047   -0.3299   -1.0710 C   0  0  0  0  0  0
    2.2647   -1.6624   -0.6556 C   0  0  0  0  0  0
    2.9015   -1.6049    0.6704 N   0  0  0  0  0  0
    2.2207   -2.3377    1.7737 C   0  0  0  0  0  0
    2.2855   -1.5496    3.1047 C   0  0  0  0  0  0
    3.7338   -1.1756    3.2600 C   0  0  0  0  0  0
    4.5894   -0.9792    2.1916 C   0  0  0  0  0  0
    5.8563   -0.6585    2.7413 C   0  0  0  0  0  0
    5.7314   -0.6865    4.1412 C   0  0  0  0  0  0
    4.4269   -0.9984    4.4185 N   0  0  0  0  0  0
    6.7295   -0.4382    5.1869 C   0  0  0  0  0  0
    6.7335   -0.4316    6.5451 C   0  0  0  0  0  0
    7.8697   -0.1555    7.4230 C   0  0  0  0  0  0
    9.2080    0.1640    7.1742 C   0  0  0  0  0  0
   10.0763    0.3719    8.2507 C   0  0  0  0  0  0
    9.6073    0.2613    9.5640 C   0  0  0  0  0  0
    8.2689   -0.0575    9.8076 C   0  0  0  0  0  0
    7.4214   -0.2609    8.7190 C   0  0  0  0  0  0
    6.0866   -0.5803    8.6877 N   0  0  0  0  0  0
    5.6060   -0.6998    7.4362 C   0  0  0  0  0  0
    4.4382   -0.9805    7.1764 O   0  0  0  0  0  0
   11.3728    0.6799    8.0215 F   0  0  0  0  0  0
    7.1258   -0.3526    1.9690 C   0  0  0  0  0  0
    4.1390   -1.0104    0.8065 C   0  0  0  0  0  0
    4.7373   -0.5173   -0.1520 O   0  0  0  0  0  0
   -2.6814   -1.6948    0.2224 H   0  0  0  0  0  0
   -2.2555   -0.1415    0.9139 H   0  0  0  0  0  0
   -1.3426   -1.5829    1.3560 H   0  0  0  0  0  0
   -0.5165   -1.8055   -1.0211 H   0  0  0  0  0  0
   -1.3186   -0.2907   -1.4750 H   0  0  0  0  0  0
    0.1385    1.9004   -1.0236 H   0  0  0  0  0  0
   -0.9373    1.5606    0.3434 H   0  0  0  0  0  0
    0.8265    3.1397    1.1437 H   0  0  0  0  0  0
    2.0996    2.0469    0.6347 H   0  0  0  0  0  0
    1.0174    1.5875    1.9457 H   0  0  0  0  0  0
    1.2562   -0.3234   -2.1049 H   0  0  0  0  0  0
    2.2933    0.5043   -0.9414 H   0  0  0  0  0  0
    1.5282   -2.4657   -0.6664 H   0  0  0  0  0  0
    3.0059   -1.9441   -1.4057 H   0  0  0  0  0  0
    1.1781   -2.5235    1.5125 H   0  0  0  0  0  0
    2.6876   -3.3177    1.8839 H   0  0  0  0  0  0
    1.6483   -0.6656    3.0661 H   0  0  0  0  0  0
    1.9323   -2.1694    3.9293 H   0  0  0  0  0  0
    4.0411   -1.0904    5.3485 H   0  0  0  0  0  0
    7.6850   -0.2068    4.7402 H   0  0  0  0  0  0
    9.5833    0.2519    6.1654 H   0  0  0  0  0  0
   10.2816    0.4223   10.3922 H   0  0  0  0  0  0
    7.9118   -0.1423   10.8234 H   0  0  0  0  0  0
    5.5195   -0.7136    9.5121 H   0  0  0  0  0  0
    8.0196   -0.6828    2.4981 H   0  0  0  0  0  0
    7.2338    0.7168    1.7878 H   0  0  0  0  0  0
    7.1494   -0.8487    0.9987 H   0  0  0  0  0  0
    0.5985   -0.3923    0.7379 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 31  1  0  0  0
  1 32  1  0  0  0
  1 33  1  0  0  0
  2  3  1  0  0  0
  2 34  1  0  0  0
  2 35  1  0  0  0
  3  4  1  0  0  0
  3  6  1  0  0  0
  3 58  1  0  0  0
  4  5  1  0  0  0
  4 36  1  0  0  0
  4 37  1  0  0  0
  5 38  1  0  0  0
  5 39  1  0  0  0
  5 40  1  0  0  0
  6  7  1  0  0  0
  6 41  1  0  0  0
  6 42  1  0  0  0
  7  8  1  0  0  0
  7 43  1  0  0  0
  7 44  1  0  0  0
  8  9  1  0  0  0
  8 29  1  0  0  0
  9 10  1  0  0  0
  9 45  1  0  0  0
  9 46  1  0  0  0
 10 11  1  0  0  0
 10 47  1  0  0  0
 10 48  1  0  0  0
 11 12  2  0  0  0
 11 15  1  0  0  0
 12 13  1  0  0  0
 12 29  1  0  0  0
 13 14  2  0  0  0
 13 28  1  0  0  0
 14 15  1  0  0  0
 14 16  1  0  0  0
 15 49  1  0  0  0
 16 17  2  0  0  0
 16 50  1  0  0  0
 17 18  1  0  0  0
 17 25  1  0  0  0
 18 19  2  0  0  0
 18 23  1  0  0  0
 19 20  1  0  0  0
 19 51  1  0  0  0
 20 21  2  0  0  0
 20 27  1  0  0  0
 21 22  1  0  0  0
 21 52  1  0  0  0
 22 23  2  0  0  0
 22 53  1  0  0  0
 23 24  1  0  0  0
 24 25  1  0  0  0
 24 54  1  0  0  0
 25 26  2  0  0  0
 28 55  1  0  0  0
 28 56  1  0  0  0
 28 57  1  0  0  0
 29 30  2  0  0  0
M  CHG  1   3   1
M  END
> <s_m_entry_id>
411

> <Applicants>
Jiangsu Hengrui Medicine

> <CHEMBL_ID>
CHEMBL3545026

> <Canonical_Smiles>
Fc1cc\2c(NC(=O)/C/2=C\c2[nH]c3c(c2C)C(=O)N(CC3)CCN(CC)CC)cc1

> <Chirality>
Single Stereoisomer

> <First_Approval>
nan

> <Phase>
3

> <SC_Patent>
None

> <Synonyms>
SHR-1020

> <Indications>
nan

> <Type>
nan

> <targets_id>
P10721|P35968|P35916|P16234|P09619|P17948|P36888

> <inchi>
InChI=1S/C23H27FN4O2/c1-4-27(5-2)10-11-28-9-8-19-21(23(28)30)14(3)20(25-19)13-17-16-12-15(24)6-7-18(16)26-22(17)29/h6-7,12-13,25H,4-5,8-11H2,1-3H3,(H,26,29)/b17-13-

> <stdInchikey>
GKEYKDOLBLYGRB-LGMDPLHJSA-N

> <csid>
17595500

> <Links>
|http://www.chemspider.com/Chemical-Structure.17595500.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1278146|http://pubchem.ncbi.nlm.nih.gov/compound/16662431|http://www.drugbank.ca/drugs/DB11741|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7886|http://zinc15.docking.org/substances/ZINC000064453767|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=768FW21J3L|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50331023

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
410.2

> <HBA>
3

> <HBD>
2

> <NRB>
6

> <TPSA>
68.4

> <LogP>
3.3

> <RoF>
0

> <Targets>
KIT; KDR; FLT4; PDGFRA; PDGFRB; FLT1; FLT3

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_epik_Ionization_Penalty>
  0.0096

> <r_epik_State_Penalty>
  0.0073

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
411

> <Kinase families>
Tyr

> <Withdrawn>
|Study NCT04044378 in China was Withdrawn during Phase 1/Phase 2 because toxicity

$$$$
Ruboxistaurin
                    3D
 Structure written by MMmdl.
 64 69  0  0  1  0            999 V2000
    0.0352    0.9062   -0.6815 C   0  0  0  0  0  0
    1.5613    0.9281   -0.4617 N   0  3  0  0  0  0
    2.0766    2.3758   -0.3382 C   0  0  0  0  0  0
    2.0160    0.0584    0.7347 C   0  0  0  0  0  0
    1.8436   -1.4544    0.4496 C   0  0  2  0  0  0
    2.5291   -2.3988    1.4786 C   0  0  0  0  0  0
    3.8382   -1.9357    2.1725 C   0  0  0  0  0  0
    4.9481   -1.6621    1.2570 N   0  0  0  0  0  0
    5.4779   -2.5652    0.3685 C   0  0  0  0  0  0
    6.5572   -2.0415   -0.3220 C   0  0  0  0  0  0
    6.7020   -0.7004    0.1868 C   0  0  0  0  0  0
    5.6967   -0.4970    1.1875 C   0  0  0  0  0  0
    5.5920    0.7097    1.8968 C   0  0  0  0  0  0
    6.4928    1.7233    1.5763 C   0  0  0  0  0  0
    7.4634    1.5571    0.5953 C   0  0  0  0  0  0
    7.5799    0.3592   -0.1039 C   0  0  0  0  0  0
    7.3486   -2.7292   -1.3422 C   0  0  0  0  0  0
    6.9125   -3.5177   -2.3409 C   0  0  0  0  0  0
    5.5342   -3.8422   -2.6822 C   0  0  0  0  0  0
    4.4852   -2.9465   -2.7302 C   0  0  0  0  0  0
    3.2953   -3.5726   -2.9938 N   0  0  0  0  0  0
    3.5393   -4.9235   -3.1738 C   0  0  0  0  0  0
    4.9471   -5.1210   -2.9971 C   0  0  0  0  0  0
    5.4592   -6.4251   -3.1194 C   0  0  0  0  0  0
    4.5933   -7.4749   -3.4140 C   0  0  0  0  0  0
    3.2302   -7.2562   -3.5806 C   0  0  0  0  0  0
    2.6701   -5.9852   -3.4628 C   0  0  0  0  0  0
    2.0008   -2.9038   -3.0170 C   0  0  0  0  0  0
    1.4710   -2.6815   -1.5889 C   0  0  0  0  0  0
    2.2887   -1.7503   -0.8766 O   0  0  0  0  0  0
    8.0561   -3.9857   -3.0735 C   0  0  0  0  0  0
    8.0924   -4.7102   -4.0673 O   0  0  0  0  0  0
    9.1139   -3.4577   -2.4521 N   0  0  0  0  0  0
    8.7850   -2.6995   -1.4025 C   0  0  0  0  0  0
    9.5769   -2.1207   -0.6599 O   0  0  0  0  0  0
   -0.4366    1.3112    0.2149 H   0  0  0  0  0  0
   -0.2634   -0.1256   -0.8621 H   0  0  0  0  0  0
   -0.1753    1.5212   -1.5575 H   0  0  0  0  0  0
    1.6438    2.8085    0.5651 H   0  0  0  0  0  0
    1.7605    2.9124   -1.2338 H   0  0  0  0  0  0
    3.1651    2.3296   -0.2809 H   0  0  0  0  0  0
    3.0618    0.3220    0.8684 H   0  0  0  0  0  0
    1.4444    0.4033    1.5981 H   0  0  0  0  0  0
    0.7710   -1.6484    0.5285 H   0  0  0  0  0  0
    1.8098   -2.5890    2.2768 H   0  0  0  0  0  0
    2.6886   -3.3774    1.0236 H   0  0  0  0  0  0
    3.6447   -1.0524    2.7807 H   0  0  0  0  0  0
    4.1776   -2.7055    2.8671 H   0  0  0  0  0  0
    5.0356   -3.5484    0.2957 H   0  0  0  0  0  0
    4.8441    0.8683    2.6593 H   0  0  0  0  0  0
    6.4345    2.6651    2.1023 H   0  0  0  0  0  0
    8.1404    2.3695    0.3747 H   0  0  0  0  0  0
    8.3434    0.2544   -0.8601 H   0  0  0  0  0  0
    4.4879   -1.8814   -2.5482 H   0  0  0  0  0  0
    6.5121   -6.6221   -2.9820 H   0  0  0  0  0  0
    4.9857   -8.4767   -3.5095 H   0  0  0  0  0  0
    2.5877   -8.0951   -3.8048 H   0  0  0  0  0  0
    1.6080   -5.8399   -3.5921 H   0  0  0  0  0  0
    2.0990   -1.9562   -3.5491 H   0  0  0  0  0  0
    1.3029   -3.5110   -3.5942 H   0  0  0  0  0  0
    0.4566   -2.2866   -1.6606 H   0  0  0  0  0  0
    1.4000   -3.6319   -1.0564 H   0  0  0  0  0  0
   10.0666   -3.6186   -2.7437 H   0  0  0  0  0  0
    1.9923    0.5341   -1.2871 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 36  1  0  0  0
  1 37  1  0  0  0
  1 38  1  0  0  0
  2  3  1  0  0  0
  2  4  1  0  0  0
  2 64  1  0  0  0
  3 39  1  0  0  0
  3 40  1  0  0  0
  3 41  1  0  0  0
  4  5  1  0  0  0
  4 42  1  0  0  0
  4 43  1  0  0  0
  5  6  1  0  0  0
  5 30  1  0  0  0
  5 44  1  0  0  0
  6  7  1  0  0  0
  6 45  1  0  0  0
  6 46  1  0  0  0
  7  8  1  0  0  0
  7 47  1  0  0  0
  7 48  1  0  0  0
  8  9  1  0  0  0
  8 12  1  0  0  0
  9 10  2  0  0  0
  9 49  1  0  0  0
 10 11  1  0  0  0
 10 17  1  0  0  0
 11 12  2  0  0  0
 11 16  1  0  0  0
 12 13  1  0  0  0
 13 14  2  0  0  0
 13 50  1  0  0  0
 14 15  1  0  0  0
 14 51  1  0  0  0
 15 16  2  0  0  0
 15 52  1  0  0  0
 16 53  1  0  0  0
 17 18  2  0  0  0
 17 34  1  0  0  0
 18 19  1  0  0  0
 18 31  1  0  0  0
 19 20  2  0  0  0
 19 23  1  0  0  0
 20 21  1  0  0  0
 20 54  1  0  0  0
 21 22  1  0  0  0
 21 28  1  0  0  0
 22 23  2  0  0  0
 22 27  1  0  0  0
 23 24  1  0  0  0
 24 25  2  0  0  0
 24 55  1  0  0  0
 25 26  1  0  0  0
 25 56  1  0  0  0
 26 27  2  0  0  0
 26 57  1  0  0  0
 27 58  1  0  0  0
 28 29  1  0  0  0
 28 59  1  0  0  0
 28 60  1  0  0  0
 29 30  1  0  0  0
 29 61  1  0  0  0
 29 62  1  0  0  0
 31 32  2  0  0  0
 31 33  1  0  0  0
 33 34  1  0  0  0
 33 63  1  0  0  0
 34 35  2  0  0  0
M  CHG  1   2   1
M  END
> <s_m_entry_id>
413

> <Applicants>
Eli Lilly

> <CHEMBL_ID>
CHEMBL91829

> <Canonical_Smiles>
O1CCn2c3c(c(C4=C(c5c6c(n(CC[C@H]1CN(C)C)c5)cccc6)C(=O)NC4=O)c2)cccc3

> <Chirality>
Single Stereoisomer

> <First_Approval>
nan

> <Phase>
3

> <SC_Patent>
None

> <Synonyms>
ARXXANT | LY-333531 | RUBOXISTAURIN

> <Indications>
nan

> <Type>
nan

> <targets_id>
nan

> <inchi>
InChI=1S/C28H28N4O3/c1-30(2)15-18-11-12-31-16-21(19-7-3-5-9-23(19)31)25-26(28(34)29-27(25)33)22-17-32(13-14-35-18)24-10-6-4-8-20(22)24/h3-10,16-18H,11-15H2,1-2H3,(H,29,33,34)/t18-/m0/s1

> <stdInchikey>
ZCBUQCWBWNUWSU-SFHVURJKSA-N

> <csid>
135727

> <Links>
|http://www.chemspider.com/Chemical-Structure.135727.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL91829|http://pubchem.ncbi.nlm.nih.gov/compound/153999|http://www.drugbank.ca/drugs/DB11829| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=LY4|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/LY4|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5263|http://zinc15.docking.org/substances/ZINC000003812168|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=721809WQCP|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50128281

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
468.2

> <HBA>
6

> <HBD>
1

> <NRB>
2

> <TPSA>
68.5

> <LogP>
3.5

> <RoF>
0

> <Targets>
nan

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_epik_Ionization_Penalty>
  0.0507

> <r_epik_State_Penalty>
  0.0416

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
413

> <lig_pdbID>
'LY4'

> <pdbID>
1uu3 2j2i

> <BrandName>
Arxxant

$$$$
Simotinib
                    3D
 Structure written by MMmdl.
 62 67  0  0  1  0            999 V2000
   -0.1355    3.3181   -0.2906 C   0  0  0  0  0  0
    0.3497    1.9799   -0.3275 O   0  0  0  0  0  0
   -0.5460    0.9296   -0.4347 C   0  0  0  0  0  0
   -1.9350    1.1065   -0.5220 C   0  0  0  0  0  0
   -2.8021   -0.0022   -0.6308 C   0  0  0  0  0  0
   -2.2561   -1.3204   -0.6503 C   0  0  0  0  0  0
   -0.8477   -1.4769   -0.5626 C   0  0  0  0  0  0
   -0.0032   -0.3610   -0.4581 C   0  0  0  0  0  0
    1.3745   -0.4548   -0.3709 O   0  0  0  0  0  0
    2.0140   -1.7220   -0.5048 C   0  0  0  0  0  0
    3.5389   -1.5238   -0.4629 C   0  0  0  0  0  0
    3.9878   -0.4972   -1.5247 N   0  3  2  0  0  0
    3.8081   -0.9332   -2.9781 C   0  0  0  0  0  0
    4.6762    0.0489   -3.7803 C   0  0  0  0  0  0
    4.8604   -0.2118   -5.2605 C   0  0  0  0  0  0
    3.9980    0.9403   -4.8016 C   0  0  0  0  0  0
    5.7928    0.5088   -2.8257 C   0  0  0  0  0  0
    5.4802   -0.1685   -1.4823 C   0  0  0  0  0  0
    7.0584    0.1987   -3.3077 O   0  0  0  0  0  0
    7.9844    0.9792   -2.5774 C   0  0  0  0  0  0
    7.1649    2.2362   -2.2726 C   0  0  0  0  0  0
    5.8672    1.8929   -2.7268 O   0  0  0  0  0  0
   -3.1996   -2.3901   -0.7598 C   0  0  0  0  0  0
   -4.5351   -2.1605   -0.8372 N   0  0  0  0  0  0
   -4.9366   -0.8702   -0.8120 C   0  0  0  0  0  0
   -4.1436    0.2222   -0.7128 N   0  0  0  0  0  0
   -2.7489   -3.7251   -0.7641 N   0  0  0  0  0  0
   -3.4124   -4.9640   -0.8273 C   0  0  0  0  0  0
   -4.6597   -5.1435   -1.4433 C   0  0  0  0  0  0
   -5.2568   -6.4039   -1.4770 C   0  0  0  0  0  0
   -4.6142   -7.5002   -0.9034 C   0  0  0  0  0  0
   -3.3660   -7.3350   -0.2986 C   0  0  0  0  0  0
   -2.7699   -6.0730   -0.2673 C   0  0  0  0  0  0
   -2.5501   -8.6815    0.4125 Cl  0  0  0  0  0  0
   -5.2041   -8.7177   -0.9428 F   0  0  0  0  0  0
    0.7073    4.0027   -0.1967 H   0  0  0  0  0  0
   -0.7907    3.4838    0.5660 H   0  0  0  0  0  0
   -0.6685    3.5760   -1.2070 H   0  0  0  0  0  0
   -2.3762    2.0921   -0.5081 H   0  0  0  0  0  0
   -0.4418   -2.4766   -0.5771 H   0  0  0  0  0  0
    1.7102   -2.3867    0.3054 H   0  0  0  0  0  0
    1.7256   -2.1917   -1.4469 H   0  0  0  0  0  0
    3.8572   -1.0894    0.4860 H   0  0  0  0  0  0
    4.0951   -2.4429   -0.6534 H   0  0  0  0  0  0
    4.1656   -1.9620   -3.0560 H   0  0  0  0  0  0
    2.7421   -0.8791   -3.2036 H   0  0  0  0  0  0
    5.8224    0.0139   -5.7217 H   0  0  0  0  0  0
    4.3770   -1.0798   -5.7097 H   0  0  0  0  0  0
    2.9184    0.8708   -4.9381 H   0  0  0  0  0  0
    4.3702    1.9542   -4.9502 H   0  0  0  0  0  0
    5.6586    0.4814   -0.6244 H   0  0  0  0  0  0
    6.0271   -1.1094   -1.3882 H   0  0  0  0  0  0
    8.2994    0.4643   -1.6684 H   0  0  0  0  0  0
    8.8707    1.1954   -3.1744 H   0  0  0  0  0  0
    7.1608    2.4762   -1.2085 H   0  0  0  0  0  0
    7.5329    3.1063   -2.8177 H   0  0  0  0  0  0
   -6.0004   -0.6929   -0.8757 H   0  0  0  0  0  0
   -1.7720   -3.8060   -0.5247 H   0  0  0  0  0  0
   -5.1757   -4.3245   -1.9192 H   0  0  0  0  0  0
   -6.2175   -6.5298   -1.9542 H   0  0  0  0  0  0
   -1.8039   -5.9585    0.2041 H   0  0  0  0  0  0
    3.4752    0.3637   -1.3904 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 36  1  0  0  0
  1 37  1  0  0  0
  1 38  1  0  0  0
  2  3  1  0  0  0
  3  4  1  0  0  0
  3  8  2  0  0  0
  4  5  2  0  0  0
  4 39  1  0  0  0
  5  6  1  0  0  0
  5 26  1  0  0  0
  6  7  2  0  0  0
  6 23  1  0  0  0
  7  8  1  0  0  0
  7 40  1  0  0  0
  8  9  1  0  0  0
  9 10  1  0  0  0
 10 11  1  0  0  0
 10 41  1  0  0  0
 10 42  1  0  0  0
 11 12  1  0  0  0
 11 43  1  0  0  0
 11 44  1  0  0  0
 12 13  1  0  0  0
 12 18  1  0  0  0
 12 62  1  0  0  0
 13 14  1  0  0  0
 13 45  1  0  0  0
 13 46  1  0  0  0
 14 15  1  0  0  0
 14 16  1  0  0  0
 14 17  1  0  0  0
 15 16  1  0  0  0
 15 47  1  0  0  0
 15 48  1  0  0  0
 16 49  1  0  0  0
 16 50  1  0  0  0
 17 18  1  0  0  0
 17 19  1  0  0  0
 17 22  1  0  0  0
 18 51  1  0  0  0
 18 52  1  0  0  0
 19 20  1  0  0  0
 20 21  1  0  0  0
 20 53  1  0  0  0
 20 54  1  0  0  0
 21 22  1  0  0  0
 21 55  1  0  0  0
 21 56  1  0  0  0
 23 24  2  0  0  0
 23 27  1  0  0  0
 24 25  1  0  0  0
 25 26  2  0  0  0
 25 57  1  0  0  0
 27 28  1  0  0  0
 27 58  1  0  0  0
 28 29  1  0  0  0
 28 33  2  0  0  0
 29 30  2  0  0  0
 29 59  1  0  0  0
 30 31  1  0  0  0
 30 60  1  0  0  0
 31 32  2  0  0  0
 31 35  1  0  0  0
 32 33  1  0  0  0
 32 34  1  0  0  0
 33 61  1  0  0  0
M  CHG  1  12   1
M  END
> <s_m_entry_id>
416

> <Applicants>
Advenchen Laboratories

> <CHEMBL_ID>
CHEMBL3545235

> <Canonical_Smiles>
Clc1cc(Nc2ncnc3c2cc(OCCN2CC4(CC4)C4(OCCO4)C2)c(OC)c3)ccc1F

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
3

> <SC_Patent>
None

> <Synonyms>
SIM-6802 | SIMOTINIB

> <Indications>
nan

> <Type>
nan

> <targets_id>
P00533

> <inchi>
InChI=1S/C25H26ClFN4O4/c1-32-21-12-20-17(23(29-15-28-20)30-16-2-3-19(27)18(26)10-16)11-22(21)33-7-6-31-13-24(4-5-24)25(14-31)34-8-9-35-25/h2-3,10-12,15H,4-9,13-14H2,1H3,(H,28,29,30)

> <stdInchikey>
OXWUWXCJDBRCCG-UHFFFAOYSA-N

> <csid>
20566604

> <Links>
|http://www.chemspider.com/Chemical-Structure.20566604.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3545235|http://pubchem.ncbi.nlm.nih.gov/compound/16735117|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7640|http://zinc15.docking.org/substances/ZINC000137136675|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=58K797D5IK

> <LinkName>
|ChemSpider|ChEMBL|PubChem|Guide to Pharmacology|ZINC|FDA SRS

> <indicationG2P>
None

> <MW>
500.2

> <HBA>
8

> <HBD>
1

> <NRB>
7

> <TPSA>
78

> <LogP>
4.4

> <RoF>
1

> <Targets>
EGFR

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
0.999978

> <r_epik_Ionization_Penalty>
  0.2679

> <r_epik_State_Penalty>
  0.2590

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
416

> <Kinase families>
Tyr

$$$$
Losmapimod
                    3D
 Structure written by MMmdl.
 54 56  0  0  1  0            999 V2000
   -0.1572    2.7421   -0.4078 C   0  0  0  0  0  0
   -0.8742    1.3994   -0.2873 C   0  0  0  0  0  0
   -0.1690    0.1856   -0.1413 C   0  0  0  0  0  0
   -0.9003   -1.0019    0.0090 C   0  0  0  0  0  0
   -2.3002   -1.0159   -0.0065 C   0  0  0  0  0  0
   -2.9784    0.1982   -0.1666 C   0  0  0  0  0  0
   -2.2743    1.3913   -0.3050 C   0  0  0  0  0  0
   -2.9652    2.5461   -0.4518 F   0  0  0  0  0  0
   -3.0451   -2.3197    0.1548 C   0  0  0  0  0  0
   -2.5647   -3.2403    0.8195 O   0  0  0  0  0  0
   -4.2331   -2.4033   -0.4741 N   0  0  0  0  0  0
   -5.0840   -3.5885   -0.4613 C   0  0  0  0  0  0
   -6.5770   -3.3914   -0.3362 C   0  0  0  0  0  0
   -5.7970   -3.9756    0.8169 C   0  0  0  0  0  0
    1.3200    0.1117   -0.1657 C   0  0  0  0  0  0
    2.0728    0.6116   -1.2348 C   0  0  0  0  0  0
    3.4628    0.4918   -1.1999 C   0  0  0  0  0  0
    4.0846   -0.1286   -0.1049 C   0  0  0  0  0  0
    3.2592   -0.6003    0.9242 C   0  0  0  0  0  0
    1.9064   -0.4942    0.9023 N   0  0  0  0  0  0
    5.5821   -0.2836   -0.0167 C   0  0  0  0  0  0
    6.1485   -0.3033    1.0778 O   0  0  0  0  0  0
    6.2293   -0.4215   -1.1901 N   0  0  0  0  0  0
    7.6755   -0.6034   -1.3539 C   0  0  0  0  0  0
    8.4729    0.6890   -1.7006 C   0  0  0  0  0  0
    7.9332    1.3293   -3.0021 C   0  0  0  0  0  0
    9.9576    0.3118   -1.9092 C   0  0  0  0  0  0
    8.3811    1.7222   -0.5524 C   0  0  0  0  0  0
   -0.7197    3.5342    0.0879 H   0  0  0  0  0  0
   -0.0432    3.0149   -1.4571 H   0  0  0  0  0  0
    0.8294    2.7295    0.0551 H   0  0  0  0  0  0
   -0.3615   -1.9331    0.1223 H   0  0  0  0  0  0
   -4.0587    0.2323   -0.1764 H   0  0  0  0  0  0
   -4.4294   -1.7240   -1.1946 H   0  0  0  0  0  0
   -4.7353   -4.3900   -1.1143 H   0  0  0  0  0  0
   -6.9735   -2.3802   -0.2376 H   0  0  0  0  0  0
   -7.2391   -4.0463   -0.9029 H   0  0  0  0  0  0
   -5.9140   -5.0349    1.0462 H   0  0  0  0  0  0
   -5.6509   -3.3676    1.7104 H   0  0  0  0  0  0
    1.5908    1.0806   -2.0802 H   0  0  0  0  0  0
    4.0429    0.8841   -2.0232 H   0  0  0  0  0  0
    3.6734   -1.0863    1.7964 H   0  0  0  0  0  0
    5.6820   -0.4408   -2.0381 H   0  0  0  0  0  0
    8.1028   -1.0774   -0.4668 H   0  0  0  0  0  0
    7.8035   -1.3319   -2.1560 H   0  0  0  0  0  0
    8.5120    2.2098   -3.2849 H   0  0  0  0  0  0
    6.8954    1.6481   -2.8973 H   0  0  0  0  0  0
    7.9756    0.6307   -3.8391 H   0  0  0  0  0  0
   10.0786   -0.4083   -2.7199 H   0  0  0  0  0  0
   10.3870   -0.1353   -1.0114 H   0  0  0  0  0  0
   10.5641    1.1839   -2.1579 H   0  0  0  0  0  0
    8.9930    2.6022   -0.7555 H   0  0  0  0  0  0
    8.7226    1.3000    0.3937 H   0  0  0  0  0  0
    7.3596    2.0730   -0.4022 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 29  1  0  0  0
  1 30  1  0  0  0
  1 31  1  0  0  0
  2  3  1  0  0  0
  2  7  2  0  0  0
  3  4  2  0  0  0
  3 15  1  0  0  0
  4  5  1  0  0  0
  4 32  1  0  0  0
  5  6  2  0  0  0
  5  9  1  0  0  0
  6  7  1  0  0  0
  6 33  1  0  0  0
  7  8  1  0  0  0
  9 10  2  0  0  0
  9 11  1  0  0  0
 11 12  1  0  0  0
 11 34  1  0  0  0
 12 13  1  0  0  0
 12 14  1  0  0  0
 12 35  1  0  0  0
 13 14  1  0  0  0
 13 36  1  0  0  0
 13 37  1  0  0  0
 14 38  1  0  0  0
 14 39  1  0  0  0
 15 16  1  0  0  0
 15 20  2  0  0  0
 16 17  2  0  0  0
 16 40  1  0  0  0
 17 18  1  0  0  0
 17 41  1  0  0  0
 18 19  2  0  0  0
 18 21  1  0  0  0
 19 20  1  0  0  0
 19 42  1  0  0  0
 21 22  2  0  0  0
 21 23  1  0  0  0
 23 24  1  0  0  0
 23 43  1  0  0  0
 24 25  1  0  0  0
 24 44  1  0  0  0
 24 45  1  0  0  0
 25 26  1  0  0  0
 25 27  1  0  0  0
 25 28  1  0  0  0
 26 46  1  0  0  0
 26 47  1  0  0  0
 26 48  1  0  0  0
 27 49  1  0  0  0
 27 50  1  0  0  0
 27 51  1  0  0  0
 28 52  1  0  0  0
 28 53  1  0  0  0
 28 54  1  0  0  0
M  END
> <s_m_entry_id>
422

> <Applicants>
GlaxoSmithKline

> <CHEMBL_ID>
CHEMBL1088752

> <Canonical_Smiles>
Fc1cc(cc(-c2ncc(cc2)C(=O)NCC(C)(C)C)c1C)C(=O)NC1CC1

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
3

> <SC_Patent>
None

> <Synonyms>
FTX-1821 | FTX1821 | GSK-AHAB | GSKAHAB | GW-856553 | GW-856553X | GW856553X | LOSMAPIMOD

> <Indications>
nan

> <Type>
nan

> <targets_id>
Q16539|Q15759|O15264|P53778

> <inchi>
InChI=1S/C22H26FN3O2/c1-13-17(9-15(10-18(13)23)21(28)26-16-6-7-16)19-8-5-14(11-24-19)20(27)25-12-22(2,3)4/h5,8-11,16H,6-7,12H2,1-4H3,(H,25,27)(H,26,28)

> <stdInchikey>
KKYABQBFGDZVNQ-UHFFFAOYSA-N

> <csid>
9727484

> <Links>
|http://www.chemspider.com/Chemical-Structure.9727484.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1088752|http://pubchem.ncbi.nlm.nih.gov/compound/11552706|http://www.drugbank.ca/drugs/DB12270|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7835|http://zinc15.docking.org/substances/ZINC000035793138|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=F2DQF16BXE|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50418610

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
383.2

> <HBA>
3

> <HBD>
2

> <NRB>
5

> <TPSA>
71.1

> <LogP>
3.9

> <RoF>
0

> <Targets>
MAPK14; MAPK11; MAPK13; MAPK12

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0000

> <r_epik_State_Penalty>
  0.0000

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
422

> <Kinase families>
CMGC

$$$$
Barasertib
                    3D
 Structure written by MMmdl.
 71 74  0  0  1  0            999 V2000
   -0.3258    1.8177   -2.7978 C   0  0  0  0  0  0
   -1.1346    1.7489   -1.4917 C   0  0  0  0  0  0
   -0.1986    1.5253   -0.2768 N   0  3  2  0  0  0
    0.2930    0.0568   -0.1922 C   0  0  0  0  0  0
    1.6129   -0.0514    0.5946 C   0  0  0  0  0  0
    2.2019   -1.4696    0.5803 C   0  0  0  0  0  0
    1.2839   -2.3738    1.1918 O   0  0  0  0  0  0
    1.6042   -3.7154    1.2775 C   0  0  0  0  0  0
    2.8101   -4.2719    0.8282 C   0  0  0  0  0  0
    3.0648   -5.6357    0.9479 C   0  0  0  0  0  0
    2.0986   -6.4980    1.5324 C   0  0  0  0  0  0
    0.8677   -5.9357    1.9915 C   0  0  0  0  0  0
    0.6441   -4.5457    1.8547 C   0  0  0  0  0  0
   -0.1043   -6.7018    2.5612 N   0  0  0  0  0  0
    0.1545   -8.0258    2.6721 C   0  0  0  0  0  0
    1.2769   -8.6663    2.2767 N   0  0  0  0  0  0
    2.2503   -7.9096    1.7051 C   0  0  0  0  0  0
    3.4428   -8.5372    1.2841 N   0  0  0  0  0  0
    3.8016   -9.8690    1.2347 C   0  0  0  0  0  0
    5.0501  -10.3619    0.8275 C   0  0  0  0  0  0
    4.9981  -11.7425    0.9133 C   0  0  0  0  0  0
    3.7216  -11.9787    1.3484 N   0  0  0  0  0  0
    3.0022  -10.8702    1.5449 N   0  0  0  0  0  0
    5.9923  -12.8414    0.5981 C   0  0  0  0  0  0
    5.7320  -13.4809   -0.7712 C   0  0  0  0  0  0
    4.7426  -14.1999   -0.9173 O   0  0  0  0  0  0
    6.6424  -13.2108   -1.7317 N   0  0  0  0  0  0
    6.6461  -13.6244   -3.0757 C   0  0  0  0  0  0
    7.8834  -13.6287   -3.7282 C   0  0  0  0  0  0
    7.9759  -14.0102   -5.0670 C   0  0  0  0  0  0
    6.8292  -14.3805   -5.7683 C   0  0  0  0  0  0
    5.5881  -14.3647   -5.1327 C   0  0  0  0  0  0
    5.4923  -13.9854   -3.7932 C   0  0  0  0  0  0
    4.4750  -14.7120   -5.8175 F   0  0  0  0  0  0
   -0.8122    2.0041    1.0666 C   0  0  0  0  0  0
   -1.0904    3.5226    1.0824 C   0  0  0  0  0  0
   -0.0396    4.2805    0.5060 O   0  0  0  0  0  0
    1.5131    4.5003    1.3086 P   0  0  0  0  0  0
    2.2781    5.5183    0.4445 O   0  0  0  0  0  0
    1.1880    5.0296    2.7173 O   0  5  0  0  0  0
    2.1820    3.1138    1.3272 O   0  5  0  0  0  0
   -0.9759    2.0762   -3.6339 H   0  0  0  0  0  0
    0.1540    0.8727   -3.0479 H   0  0  0  0  0  0
    0.4497    2.5828   -2.7399 H   0  0  0  0  0  0
   -1.6407    2.6996   -1.3394 H   0  0  0  0  0  0
   -1.8749    0.9473   -1.4722 H   0  0  0  0  0  0
   -0.5229   -0.5214    0.2446 H   0  0  0  0  0  0
    0.4500   -0.2830   -1.2142 H   0  0  0  0  0  0
    2.3419    0.6394    0.1694 H   0  0  0  0  0  0
    1.4744    0.2529    1.6313 H   0  0  0  0  0  0
    2.4102   -1.7731   -0.4475 H   0  0  0  0  0  0
    3.1482   -1.4722    1.1244 H   0  0  0  0  0  0
    3.5731   -3.6553    0.3782 H   0  0  0  0  0  0
    4.0031   -6.0361    0.5930 H   0  0  0  0  0  0
   -0.2888   -4.1268    2.2047 H   0  0  0  0  0  0
   -0.6154   -8.6339    3.1243 H   0  0  0  0  0  0
    4.1063   -7.8616    0.9360 H   0  0  0  0  0  0
    5.8965   -9.7741    0.5045 H   0  0  0  0  0  0
    3.3337  -12.8982    1.5046 H   0  0  0  0  0  0
    5.9455  -13.6301    1.3503 H   0  0  0  0  0  0
    7.0119  -12.4553    0.6500 H   0  0  0  0  0  0
    7.4459  -12.6666   -1.4540 H   0  0  0  0  0  0
    8.7823  -13.3424   -3.2005 H   0  0  0  0  0  0
    8.9364  -14.0181   -5.5609 H   0  0  0  0  0  0
    6.9016  -14.6742   -6.8053 H   0  0  0  0  0  0
    4.5139  -13.9642   -3.3387 H   0  0  0  0  0  0
   -1.7111    1.4078    1.2291 H   0  0  0  0  0  0
   -0.0787    1.7589    1.8321 H   0  0  0  0  0  0
   -2.0071    3.7516    0.5401 H   0  0  0  0  0  0
   -1.2614    3.8595    2.1055 H   0  0  0  0  0  0
    0.6155    2.1055   -0.4315 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 42  1  0  0  0
  1 43  1  0  0  0
  1 44  1  0  0  0
  2  3  1  0  0  0
  2 45  1  0  0  0
  2 46  1  0  0  0
  3  4  1  0  0  0
  3 35  1  0  0  0
  3 71  1  0  0  0
  4  5  1  0  0  0
  4 47  1  0  0  0
  4 48  1  0  0  0
  5  6  1  0  0  0
  5 49  1  0  0  0
  5 50  1  0  0  0
  6  7  1  0  0  0
  6 51  1  0  0  0
  6 52  1  0  0  0
  7  8  1  0  0  0
  8  9  1  0  0  0
  8 13  2  0  0  0
  9 10  2  0  0  0
  9 53  1  0  0  0
 10 11  1  0  0  0
 10 54  1  0  0  0
 11 12  1  0  0  0
 11 17  2  0  0  0
 12 13  1  0  0  0
 12 14  2  0  0  0
 13 55  1  0  0  0
 14 15  1  0  0  0
 15 16  2  0  0  0
 15 56  1  0  0  0
 16 17  1  0  0  0
 17 18  1  0  0  0
 18 19  1  0  0  0
 18 57  1  0  0  0
 19 23  2  0  0  0
 19 20  1  0  0  0
 20 21  2  0  0  0
 20 58  1  0  0  0
 21 24  1  0  0  0
 21 22  1  0  0  0
 22 59  1  0  0  0
 22 23  1  0  0  0
 24 25  1  0  0  0
 24 60  1  0  0  0
 24 61  1  0  0  0
 25 26  2  0  0  0
 25 27  1  0  0  0
 27 28  1  0  0  0
 27 62  1  0  0  0
 28 29  1  0  0  0
 28 33  2  0  0  0
 29 30  2  0  0  0
 29 63  1  0  0  0
 30 31  1  0  0  0
 30 64  1  0  0  0
 31 32  2  0  0  0
 31 65  1  0  0  0
 32 33  1  0  0  0
 32 34  1  0  0  0
 33 66  1  0  0  0
 35 36  1  0  0  0
 35 67  1  0  0  0
 35 68  1  0  0  0
 36 37  1  0  0  0
 36 69  1  0  0  0
 36 70  1  0  0  0
 37 38  1  0  0  0
 38 39  2  0  0  0
 38 40  1  0  0  0
 38 41  1  0  0  0
M  CHG  3   3   1  40  -1  41  -1
M  END
> <s_m_entry_id>
423

> <Applicants>
Astrazeneca

> <CHEMBL_ID>
CHEMBL415049

> <Canonical_Smiles>
P(OCCN(CCCOc1cc2ncnc(Nc3[nH]nc(c3)CC(=O)Nc3cc(F)ccc3)c2cc1)CC)(O)(O)=O

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
3

> <SC_Patent>
None

> <Synonyms>
AZD 1152 | AZD-1152 | AZD1152 | BARASERTIB

> <Indications>
nan

> <Type>
nan

> <targets_id>
Q96GD4

> <inchi>
InChI=1S/C26H31FN7O6P/c1-2-34(10-12-40-41(36,37)38)9-4-11-39-21-7-8-22-23(16-21)28-17-29-26(22)31-24-14-20(32-33-24)15-25(35)30-19-6-3-5-18(27)13-19/h3,5-8,13-14,16-17H,2,4,9-12,15H2,1H3,(H,30,35)(H2,36,37,38)(H2,28,29,31,32,33)

> <stdInchikey>
GBJVVSCPOBPEIT-UHFFFAOYSA-N

> <csid>
9672789

> <Links>
|http://www.chemspider.com/Chemical-Structure.9672789.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL415049|http://pubchem.ncbi.nlm.nih.gov/compound/11497983|http://www.drugbank.ca/drugs/DB11747|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7332|http://zinc15.docking.org/substances/ZINC000043129461|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=16XC2U7W8N|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50241089

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
587.2

> <HBA>
9

> <HBD>
5

> <NRB>
15

> <TPSA>
174.8

> <LogP>
3.6

> <RoF>
1

> <Targets>
AURKB

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
0.842584

> <r_epik_Ionization_Penalty>
  0.1397

> <r_epik_State_Penalty>
  0.2011

> <i_epik_Tot_Q>
-1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
423

> <Kinase families>
Other

$$$$
Canertinib
                    3D
 Structure written by MMmdl.
 59 62  0  0  1  0            999 V2000
    0.8698    5.4936    1.4716 C   0  0  0  0  0  0
    0.8607    4.2860    0.8768 C   0  0  0  0  0  0
   -0.1363    3.2797    1.1644 C   0  0  0  0  0  0
   -1.0671    3.4603    1.9538 O   0  0  0  0  0  0
    0.0714    2.1400    0.4701 N   0  0  0  0  0  0
   -0.7087    0.9650    0.4696 C   0  0  0  0  0  0
   -2.1007    0.9985    0.6327 C   0  0  0  0  0  0
   -2.8630   -0.1980    0.6101 C   0  0  0  0  0  0
   -2.1879   -1.4378    0.4023 C   0  0  0  0  0  0
   -0.7865   -1.4453    0.2230 C   0  0  0  0  0  0
   -0.0468   -0.2530    0.2515 C   0  0  0  0  0  0
    1.3271   -0.2114    0.0757 O   0  0  0  0  0  0
    2.0722   -1.4211   -0.0388 C   0  0  0  0  0  0
    3.5675   -1.0802   -0.1349 C   0  0  0  0  0  0
    4.0952   -0.3479    1.1186 C   0  0  0  0  0  0
    5.5485   -0.1516    1.1045 N   0  0  0  0  0  0
    5.9712    0.8214    0.0876 C   0  0  0  0  0  0
    7.5001    1.0346    0.1348 C   0  0  0  0  0  0
    7.9241    1.4108    1.4418 O   0  0  0  0  0  0
    7.5304    0.4879    2.4527 C   0  0  0  0  0  0
    6.0020    0.2721    2.4345 C   0  0  0  0  0  0
   -2.8595   -2.6233    0.3646 N   0  0  0  0  0  0
   -4.2015   -2.5666    0.5325 C   0  0  0  0  0  0
   -4.9447   -1.4557    0.7344 N   0  0  0  0  0  0
   -4.2809   -0.2729    0.7782 C   0  0  0  0  0  0
   -5.0234    0.9079    0.9778 N   0  0  0  0  0  0
   -6.3922    1.1785    1.1560 C   0  0  0  0  0  0
   -6.8353    2.4716    0.8607 C   0  0  0  0  0  0
   -8.1769    2.8183    1.0204 C   0  0  0  0  0  0
   -9.0920    1.8753    1.4859 C   0  0  0  0  0  0
   -8.6608    0.5834    1.7965 C   0  0  0  0  0  0
   -7.3171    0.2389    1.6351 C   0  0  0  0  0  0
   -9.7776   -0.5942    2.3894 Cl  0  0  0  0  0  0
  -10.3911    2.2226    1.6383 F   0  0  0  0  0  0
    0.1298    5.7855    2.2042 H   0  0  0  0  0  0
    1.6335    6.2175    1.2274 H   0  0  0  0  0  0
    1.6236    4.0395    0.1503 H   0  0  0  0  0  0
    0.9615    2.0539    0.0015 H   0  0  0  0  0  0
   -2.6171    1.9370    0.7664 H   0  0  0  0  0  0
   -0.3055   -2.3983    0.0601 H   0  0  0  0  0  0
    1.8946   -2.0659    0.8240 H   0  0  0  0  0  0
    1.7634   -1.9672   -0.9319 H   0  0  0  0  0  0
    4.1283   -2.0047   -0.2810 H   0  0  0  0  0  0
    3.7268   -0.4768   -1.0288 H   0  0  0  0  0  0
    3.5854    0.6092    1.2469 H   0  0  0  0  0  0
    3.8321   -0.9513    1.9894 H   0  0  0  0  0  0
    5.7034    0.4686   -0.9079 H   0  0  0  0  0  0
    5.4596    1.7751    0.2305 H   0  0  0  0  0  0
    8.0256    0.1343   -0.1894 H   0  0  0  0  0  0
    7.7869    1.8200   -0.5645 H   0  0  0  0  0  0
    8.0571   -0.4602    2.3282 H   0  0  0  0  0  0
    7.8382    0.8799    3.4223 H   0  0  0  0  0  0
    5.4968    1.1903    2.7407 H   0  0  0  0  0  0
    5.7411   -0.4884    3.1720 H   0  0  0  0  0  0
   -4.7337   -3.5062    0.5003 H   0  0  0  0  0  0
   -4.4695    1.7409    0.8427 H   0  0  0  0  0  0
   -6.1410    3.2171    0.4996 H   0  0  0  0  0  0
   -8.5053    3.8197    0.7840 H   0  0  0  0  0  0
   -7.0117   -0.7586    1.9080 H   0  0  0  0  0  0
  1  2  2  0  0  0
  1 35  1  0  0  0
  1 36  1  0  0  0
  2  3  1  0  0  0
  2 37  1  0  0  0
  3  4  2  0  0  0
  3  5  1  0  0  0
  5  6  1  0  0  0
  5 38  1  0  0  0
  6  7  1  0  0  0
  6 11  2  0  0  0
  7  8  2  0  0  0
  7 39  1  0  0  0
  8  9  1  0  0  0
  8 25  1  0  0  0
  9 10  2  0  0  0
  9 22  1  0  0  0
 10 11  1  0  0  0
 10 40  1  0  0  0
 11 12  1  0  0  0
 12 13  1  0  0  0
 13 14  1  0  0  0
 13 41  1  0  0  0
 13 42  1  0  0  0
 14 15  1  0  0  0
 14 43  1  0  0  0
 14 44  1  0  0  0
 15 16  1  0  0  0
 15 45  1  0  0  0
 15 46  1  0  0  0
 16 17  1  0  0  0
 16 21  1  0  0  0
 17 18  1  0  0  0
 17 47  1  0  0  0
 17 48  1  0  0  0
 18 19  1  0  0  0
 18 49  1  0  0  0
 18 50  1  0  0  0
 19 20  1  0  0  0
 20 21  1  0  0  0
 20 51  1  0  0  0
 20 52  1  0  0  0
 21 53  1  0  0  0
 21 54  1  0  0  0
 22 23  2  0  0  0
 23 24  1  0  0  0
 23 55  1  0  0  0
 24 25  2  0  0  0
 25 26  1  0  0  0
 26 27  1  0  0  0
 26 56  1  0  0  0
 27 28  1  0  0  0
 27 32  2  0  0  0
 28 29  2  0  0  0
 28 57  1  0  0  0
 29 30  1  0  0  0
 29 58  1  0  0  0
 30 31  2  0  0  0
 30 34  1  0  0  0
 31 32  1  0  0  0
 31 33  1  0  0  0
 32 59  1  0  0  0
M  END
> <s_m_entry_id>
443

> <Applicants>
Pfizer

> <CHEMBL_ID>
CHEMBL31965

> <Canonical_Smiles>
Clc1cc(Nc2ncnc3c2cc(NC(=O)C=C)c(OCCCN2CCOCC2)c3)ccc1F

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
3

> <SC_Patent>
None

> <Synonyms>
CANERTINIB | CI-1033

> <Indications>
Investigated for use/treatment in breast cancer and lung cancer.

> <Type>
nan

> <targets_id>
P00533

> <inchi>
InChI=1S/C24H25ClFN5O3/c1-2-23(32)30-21-13-17-20(14-22(21)34-9-3-6-31-7-10-33-11-8-31)27-15-28-24(17)29-16-4-5-19(26)18(25)12-16/h2,4-5,12-15H,1,3,6-11H2,(H,30,32)(H,27,28,29)

> <stdInchikey>
OMZCMEYTWSXEPZ-UHFFFAOYSA-N

> <csid>
137741

> <Links>
|http://www.chemspider.com/Chemical-Structure.137741.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL31965|http://pubchem.ncbi.nlm.nih.gov/compound/156414|http://www.drugbank.ca/drugs/DB05424|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5675|http://zinc15.docking.org/substances/ZINC27439698|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=C78W1K5ASF|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=4779

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
485.2

> <HBA>
7

> <HBD>
2

> <NRB>
9

> <TPSA>
88.6

> <LogP>
4.4

> <RoF>
0

> <Targets>
EGFR

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
0.999978

> <r_epik_Ionization_Penalty>
  0.3841

> <r_epik_State_Penalty>
  0.3798

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
443

> <Kinase families>
Tyr

> <indicationDB>
Canertinib is a pan-erbB tyrosine kinase inhibitor which work against esophageal squamous cell carcinoma in vitro and in vivo. Canertinib treatment significantly affects tumour metabolism, proliferation and hypoxia as determined by PET.

> <uniprotId>
P00533

$$$$
Orantinib
                    3D
 Structure written by MMmdl.
 40 42  0  0  1  0            999 V2000
   -0.5547    2.5396   -0.1660 C   0  0  0  0  0  0
   -0.8630    1.0871    0.1373 C   0  0  0  0  0  0
    0.0624    0.0168    0.1123 C   0  0  0  0  0  0
   -0.6315   -1.1362    0.4664 C   0  0  0  0  0  0
   -1.9258   -0.7712    0.6968 N   0  0  0  0  0  0
   -2.1070    0.5707    0.5127 C   0  0  0  0  0  0
   -3.4021    1.2349    0.6867 C   0  0  0  0  0  0
   -4.6348    0.8583    1.1146 C   0  0  0  0  0  0
   -5.8303    1.6945    1.2133 C   0  0  0  0  0  0
   -6.0772    3.0395    0.9213 C   0  0  0  0  0  0
   -7.3578    3.5625    1.1270 C   0  0  0  0  0  0
   -8.3808    2.7462    1.6214 C   0  0  0  0  0  0
   -8.1290    1.4025    1.9114 C   0  0  0  0  0  0
   -6.8450    0.9021    1.6976 C   0  0  0  0  0  0
   -6.3463   -0.3610    1.8985 N   0  0  0  0  0  0
   -5.0431   -0.4659    1.5797 C   0  0  0  0  0  0
   -4.3944   -1.5038    1.6881 O   0  0  0  0  0  0
   -0.1993   -2.5764    0.6188 C   0  0  0  0  0  0
    1.5351    0.0969   -0.2450 C   0  0  0  0  0  0
    2.4215    0.2708    1.0110 C   0  0  0  0  0  0
    3.9026   -0.0322    0.7325 C   0  0  0  0  0  0
    4.5446   -0.5965    1.6455 O   0  0  0  0  0  0
    4.3816    0.3204   -0.3689 O   0  5  0  0  0  0
   -1.1590    3.2210    0.4327 H   0  0  0  0  0  0
   -0.7411    2.7768   -1.2136 H   0  0  0  0  0  0
    0.4855    2.7917    0.0421 H   0  0  0  0  0  0
   -2.6584   -1.4089    0.9770 H   0  0  0  0  0  0
   -3.3268    2.2739    0.4017 H   0  0  0  0  0  0
   -5.2969    3.6813    0.5402 H   0  0  0  0  0  0
   -7.5576    4.6003    0.9041 H   0  0  0  0  0  0
   -9.3676    3.1556    1.7795 H   0  0  0  0  0  0
   -8.9214    0.7755    2.2934 H   0  0  0  0  0  0
   -6.8925   -1.1331    2.2508 H   0  0  0  0  0  0
    0.8699   -2.7038    0.4484 H   0  0  0  0  0  0
   -0.7157   -3.2275   -0.0867 H   0  0  0  0  0  0
   -0.4072   -2.9548    1.6200 H   0  0  0  0  0  0
    1.8223   -0.8020   -0.7939 H   0  0  0  0  0  0
    1.7106    0.9248   -0.9333 H   0  0  0  0  0  0
    2.3547    1.2969    1.3742 H   0  0  0  0  0  0
    2.0701   -0.3750    1.8182 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 24  1  0  0  0
  1 25  1  0  0  0
  1 26  1  0  0  0
  2  3  1  0  0  0
  2  6  2  0  0  0
  3  4  2  0  0  0
  3 19  1  0  0  0
  4  5  1  0  0  0
  4 18  1  0  0  0
  5  6  1  0  0  0
  5 27  1  0  0  0
  6  7  1  0  0  0
  7  8  2  0  0  0
  7 28  1  0  0  0
  8  9  1  0  0  0
  8 16  1  0  0  0
  9 10  1  0  0  0
  9 14  2  0  0  0
 10 11  2  0  0  0
 10 29  1  0  0  0
 11 12  1  0  0  0
 11 30  1  0  0  0
 12 13  2  0  0  0
 12 31  1  0  0  0
 13 14  1  0  0  0
 13 32  1  0  0  0
 14 15  1  0  0  0
 15 16  1  0  0  0
 15 33  1  0  0  0
 16 17  2  0  0  0
 18 34  1  0  0  0
 18 35  1  0  0  0
 18 36  1  0  0  0
 19 20  1  0  0  0
 19 37  1  0  0  0
 19 38  1  0  0  0
 20 21  1  0  0  0
 20 39  1  0  0  0
 20 40  1  0  0  0
 21 22  2  0  0  0
 21 23  1  0  0  0
M  CHG  1  23  -1
M  END
> <s_m_entry_id>
445

> <Applicants>
Pfizer

> <CHEMBL_ID>
CHEMBL274654

> <Canonical_Smiles>
O=C/1Nc2c(cccc2)\C\1=C\c1[nH]c(C)c(CCC(O)=O)c1C

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
3

> <SC_Patent>
None

> <Synonyms>
NSC-702827 | ORANTINIB | SU-6668 | TSU-68

> <Indications>
nan

> <Type>
1

> <targets_id>
P35968|P09619|P11362

> <inchi>
InChI=1S/C18H18N2O3/c1-10-12(7-8-17(21)22)11(2)19-16(10)9-14-13-5-3-4-6-15(13)20-18(14)23/h3-6,9,19H,7-8H2,1-2H3,(H,20,23)(H,21,22)/b14-9-

> <stdInchikey>
NHFDRBXTEDBWCZ-ZROIWOOFSA-N

> <csid>
4486261

> <Links>
|http://www.chemspider.com/Chemical-Structure.4486261.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL274654|http://pubchem.ncbi.nlm.nih.gov/compound/5329099|http://www.drugbank.ca/drugs/DB12072| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=SU6|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/SU6|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7816|http://zinc15.docking.org/substances/ZINC000003834032|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=9RL37ZZ665|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=4811

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
310.1

> <HBA>
2

> <HBD>
3

> <NRB>
4

> <TPSA>
82.2

> <LogP>
3.1

> <RoF>
0

> <Targets>
KDR; PDGFRB; FGFR1

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_epik_Ionization_Penalty>
  0.0023

> <r_epik_State_Penalty>
  0.0016

> <i_epik_Tot_Q>
-1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
445

> <lig_pdbID>
'SU6'

> <pdbID>
4jlc 5yvc

> <Kinase families>
Tyr

$$$$
Semaxanib
                    3D
 Structure written by MMmdl.
 32 34  0  0  1  0            999 V2000
    0.1179    0.2959   -0.8436 C   0  0  0  0  0  0
    1.5280    0.0813   -0.3423 C   0  0  0  0  0  0
    2.2565   -1.1180   -0.3874 C   0  0  0  0  0  0
    3.5117   -0.9256    0.1601 C   0  0  0  0  0  0
    3.5454    0.3880    0.5376 N   0  0  0  0  0  0
    2.3674    1.0305    0.2494 C   0  0  0  0  0  0
    2.1305    2.4461    0.5446 C   0  0  0  0  0  0
    2.8535    3.4586    1.0890 C   0  0  0  0  0  0
    2.4217    4.8399    1.2969 C   0  0  0  0  0  0
    1.2259    5.5128    1.0287 C   0  0  0  0  0  0
    1.1164    6.8704    1.3458 C   0  0  0  0  0  0
    2.1944    7.5470    1.9268 C   0  0  0  0  0  0
    3.3869    6.8694    2.1944 C   0  0  0  0  0  0
    3.4738    5.5160    1.8694 C   0  0  0  0  0  0
    4.5162    4.6368    2.0256 N   0  0  0  0  0  0
    4.2268    3.3981    1.5862 C   0  0  0  0  0  0
    5.0151    2.4566    1.6286 O   0  0  0  0  0  0
    4.6898   -1.8457    0.3673 C   0  0  0  0  0  0
    0.0689    1.1172   -1.5591 H   0  0  0  0  0  0
   -0.5621    0.5431   -0.0280 H   0  0  0  0  0  0
   -0.2824   -0.5874   -1.3422 H   0  0  0  0  0  0
    1.8922   -2.0517   -0.7901 H   0  0  0  0  0  0
    4.3407    0.8350    0.9732 H   0  0  0  0  0  0
    1.1305    2.7219    0.2430 H   0  0  0  0  0  0
    0.3860    5.0032    0.5800 H   0  0  0  0  0  0
    0.1969    7.3984    1.1405 H   0  0  0  0  0  0
    2.1049    8.5957    2.1689 H   0  0  0  0  0  0
    4.2168    7.3956    2.6427 H   0  0  0  0  0  0
    5.4087    4.8862    2.4258 H   0  0  0  0  0  0
    4.4872   -2.8518   -0.0004 H   0  0  0  0  0  0
    4.9494   -1.9355    1.4226 H   0  0  0  0  0  0
    5.5773   -1.4865   -0.1542 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 19  1  0  0  0
  1 20  1  0  0  0
  1 21  1  0  0  0
  2  3  1  0  0  0
  2  6  2  0  0  0
  3  4  2  0  0  0
  3 22  1  0  0  0
  4  5  1  0  0  0
  4 18  1  0  0  0
  5  6  1  0  0  0
  5 23  1  0  0  0
  6  7  1  0  0  0
  7  8  2  0  0  0
  7 24  1  0  0  0
  8  9  1  0  0  0
  8 16  1  0  0  0
  9 10  1  0  0  0
  9 14  2  0  0  0
 10 11  2  0  0  0
 10 25  1  0  0  0
 11 12  1  0  0  0
 11 26  1  0  0  0
 12 13  2  0  0  0
 12 27  1  0  0  0
 13 14  1  0  0  0
 13 28  1  0  0  0
 14 15  1  0  0  0
 15 16  1  0  0  0
 15 29  1  0  0  0
 16 17  2  0  0  0
 18 30  1  0  0  0
 18 31  1  0  0  0
 18 32  1  0  0  0
M  END
> <s_m_entry_id>
446

> <Applicants>
Sugen

> <CHEMBL_ID>
CHEMBL276711

> <Canonical_Smiles>
O=C/1Nc2c(cccc2)\C\1=C\c1[nH]c(cc1C)C

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
3

> <SC_Patent>
None

> <Synonyms>
NSC-696819 | SEMAXANIB | SEMAXINIB | SU-5416 | SU005416 | SU5416

> <Indications>
Investigated for use/treatment in colorectal cancer and lung cancer.

> <Type>
1

> <targets_id>
P35968

> <inchi>
InChI=1S/C15H14N2O/c1-9-7-10(2)16-14(9)8-12-11-5-3-4-6-13(11)17-15(12)18/h3-8,16H,1-2H3,(H,17,18)/b12-8-

> <stdInchikey>
WUWDLXZGHZSWQZ-WQLSENKSSA-N

> <csid>
4486260

> <Links>
|http://www.chemspider.com/Chemical-Structure.4486260.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL276711|http://pubchem.ncbi.nlm.nih.gov/compound/5329098|http://www.drugbank.ca/drugs/DB06436| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=X2M|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/X2M|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5056|http://zinc15.docking.org/substances/ZINC12410091|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=71IA9S35AJ|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=4810

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
238.1

> <HBA>
1

> <HBD>
2

> <NRB>
1

> <TPSA>
44.9

> <LogP>
3.1

> <RoF>
0

> <Targets>
KDR

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0000

> <r_epik_State_Penalty>
  0.0000

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
446

> <lig_pdbID>
'X2M'

> <pdbID>
2x2m

> <Kinase families>
Tyr

> <uniprotId>
P35968|P35354

$$$$
Pacritinib
                    3D
 Structure written by MMmdl.
 68 72  0  0  1  0            999 V2000
   -7.8316    3.9577   -4.1271 C   0  0  0  0  0  0
   -7.9382    2.6294   -3.7224 C   0  0  0  0  0  0
   -7.2417    2.1844   -2.5976 C   0  0  0  0  0  0
   -6.4378    3.0798   -1.8842 C   0  0  0  0  0  0
   -6.3154    4.4217   -2.2778 C   0  0  0  0  0  0
   -7.0280    4.8436   -3.4103 C   0  0  0  0  0  0
   -5.4532    5.3779   -1.5207 C   0  0  0  0  0  0
   -5.7798    6.7350   -1.3920 C   0  0  0  0  0  0
   -4.8997    7.5414   -0.6710 C   0  0  0  0  0  0
   -3.7650    7.0563   -0.1076 N   0  0  0  0  0  0
   -3.5204    5.7308   -0.2652 C   0  0  0  0  0  0
   -4.3232    4.8701   -0.9490 N   0  0  0  0  0  0
   -2.3193    5.2801    0.3010 N   0  0  0  0  0  0
   -1.6922    4.0229    0.3107 C   0  0  0  0  0  0
   -0.2972    3.9911    0.3506 C   0  0  0  0  0  0
    0.3853    2.7764    0.3615 C   0  0  0  0  0  0
   -0.3188    1.5631    0.3494 C   0  0  0  0  0  0
   -1.7208    1.5902    0.3423 C   0  0  0  0  0  0
   -2.3992    2.8141    0.3141 C   0  0  0  0  0  0
   -2.5122    0.2897    0.3468 C   0  0  0  0  0  0
   -2.4913   -0.2649   -0.9609 O   0  0  0  0  0  0
   -3.1507   -1.5190   -1.0671 C   0  0  0  0  0  0
   -3.4847   -1.8093   -2.5173 C   0  0  0  0  0  0
   -4.3443   -1.1047   -3.2772 C   0  0  0  0  0  0
   -5.1258    0.1189   -2.8348 C   0  0  0  0  0  0
   -6.5239   -0.1317   -2.9278 O   0  0  0  0  0  0
   -7.3547    0.7311   -2.1522 C   0  0  0  0  0  0
    0.3007    0.3293    0.3575 O   0  0  0  0  0  0
    1.6254    0.2190   -0.1545 C   0  0  0  0  0  0
    1.9333   -1.2657   -0.4155 C   0  0  0  0  0  0
    0.8343   -1.9083   -1.2911 N   0  3  0  0  0  0
    0.6617   -1.2984   -2.6977 C   0  0  0  0  0  0
    0.1577   -2.4514   -3.5785 C   0  0  0  0  0  0
    0.0535   -3.6799   -2.6753 C   0  0  0  0  0  0
    1.0369   -3.4088   -1.5443 C   0  0  0  0  0  0
   -8.3687    4.3010   -4.9989 H   0  0  0  0  0  0
   -8.5600    1.9476   -4.2845 H   0  0  0  0  0  0
   -5.9028    2.7256   -1.0144 H   0  0  0  0  0  0
   -6.9552    5.8654   -3.7526 H   0  0  0  0  0  0
   -6.6768    7.1511   -1.8259 H   0  0  0  0  0  0
   -5.0959    8.5954   -0.5383 H   0  0  0  0  0  0
   -1.7175    6.0406    0.5798 H   0  0  0  0  0  0
    0.2698    4.9111    0.3626 H   0  0  0  0  0  0
    1.4644    2.7926    0.3866 H   0  0  0  0  0  0
   -3.4789    2.8141    0.3141 H   0  0  0  0  0  0
   -2.0760   -0.4043    1.0681 H   0  0  0  0  0  0
   -3.5404    0.4737    0.6653 H   0  0  0  0  0  0
   -2.5108   -2.3090   -0.6716 H   0  0  0  0  0  0
   -4.0803   -1.5351   -0.4939 H   0  0  0  0  0  0
   -3.0000   -2.6719   -2.9498 H   0  0  0  0  0  0
   -4.5141   -1.4202   -4.2964 H   0  0  0  0  0  0
   -4.8509    0.4047   -1.8185 H   0  0  0  0  0  0
   -4.8596    0.9543   -3.4834 H   0  0  0  0  0  0
   -7.1227    0.6284   -1.0902 H   0  0  0  0  0  0
   -8.3886    0.4026   -2.2659 H   0  0  0  0  0  0
    1.7230    0.7809   -1.0858 H   0  0  0  0  0  0
    2.3412    0.6316    0.5577 H   0  0  0  0  0  0
    2.8813   -1.4186   -0.9341 H   0  0  0  0  0  0
    1.9182   -1.8461    0.5083 H   0  0  0  0  0  0
   -0.0460   -0.4744   -2.5941 H   0  0  0  0  0  0
    1.6386   -0.9359   -3.0217 H   0  0  0  0  0  0
   -0.7984   -2.2157   -4.0473 H   0  0  0  0  0  0
    0.8724   -2.6323   -4.3829 H   0  0  0  0  0  0
   -0.9542   -3.7775   -2.2695 H   0  0  0  0  0  0
    0.2833   -4.6023   -3.2101 H   0  0  0  0  0  0
    2.0750   -3.5454   -1.8542 H   0  0  0  0  0  0
    0.8265   -3.9499   -0.6209 H   0  0  0  0  0  0
   -0.0501   -1.8058   -0.8124 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1  6  2  0  0  0
  1 36  1  0  0  0
  2  3  2  0  0  0
  2 37  1  0  0  0
  3  4  1  0  0  0
  3 27  1  0  0  0
  4  5  2  0  0  0
  4 38  1  0  0  0
  5  6  1  0  0  0
  5  7  1  0  0  0
  6 39  1  0  0  0
  7  8  1  0  0  0
  7 12  2  0  0  0
  8  9  2  0  0  0
  8 40  1  0  0  0
  9 10  1  0  0  0
  9 41  1  0  0  0
 10 11  2  0  0  0
 11 12  1  0  0  0
 11 13  1  0  0  0
 13 14  1  0  0  0
 13 42  1  0  0  0
 14 15  1  0  0  0
 14 19  2  0  0  0
 15 16  2  0  0  0
 15 43  1  0  0  0
 16 17  1  0  0  0
 16 44  1  0  0  0
 17 18  2  0  0  0
 17 28  1  0  0  0
 18 19  1  0  0  0
 18 20  1  0  0  0
 19 45  1  0  0  0
 20 21  1  0  0  0
 20 46  1  0  0  0
 20 47  1  0  0  0
 21 22  1  0  0  0
 22 23  1  0  0  0
 22 48  1  0  0  0
 22 49  1  0  0  0
 23 24  2  0  0  0
 23 50  1  0  0  0
 24 25  1  0  0  0
 24 51  1  0  0  0
 25 26  1  0  0  0
 25 52  1  0  0  0
 25 53  1  0  0  0
 26 27  1  0  0  0
 27 54  1  0  0  0
 27 55  1  0  0  0
 28 29  1  0  0  0
 29 30  1  0  0  0
 29 56  1  0  0  0
 29 57  1  0  0  0
 30 31  1  0  0  0
 30 58  1  0  0  0
 30 59  1  0  0  0
 31 32  1  0  0  0
 31 35  1  0  0  0
 31 68  1  0  0  0
 32 33  1  0  0  0
 32 60  1  0  0  0
 32 61  1  0  0  0
 33 34  1  0  0  0
 33 62  1  0  0  0
 33 63  1  0  0  0
 34 35  1  0  0  0
 34 64  1  0  0  0
 34 65  1  0  0  0
 35 66  1  0  0  0
 35 67  1  0  0  0
M  CHG  1  31   1
M  END
> <s_m_entry_id>
447

> <Applicants>
Cell Therapeutics

> <CHEMBL_ID>
CHEMBL2035187

> <Canonical_Smiles>
O1Cc2cc(Nc3nc(-c4cc(COC\C=C\C1)ccc4)ccn3)ccc2OCCN1CCCC1

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
3

> <SC_Patent>
None

> <Synonyms>
ONX-0803 | PACRITINIB | SB-1518 | SB1518

> <Indications>
nan

> <Type>
nan

> <targets_id>
O60674

> <inchi>
InChI=1S/C28H32N4O3/c1-2-13-32(12-1)14-17-35-27-9-8-25-19-24(27)21-34-16-4-3-15-33-20-22-6-5-7-23(18-22)26-10-11-29-28(30-25)31-26/h3-11,18-19H,1-2,12-17,20-21H2,(H,29,30,31)/b4-3+

> <stdInchikey>
HWXVIOGONBBTBY-ONEGZZNKSA-N

> <csid>
28518965

> <Links>
|http://www.chemspider.com/Chemical-Structure.28518965.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2035187|http://pubchem.ncbi.nlm.nih.gov/compound/46216796|http://www.drugbank.ca/drugs/DB11697| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=6T3|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/6T3|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7793|http://zinc15.docking.org/substances/ZINC000043153645|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=G22N65IL3O|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50400312

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
472.2

> <HBA>
7

> <HBD>
1

> <NRB>
4

> <TPSA>
68.7

> <LogP>
5

> <RoF>
0

> <Targets>
JAK2

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0072

> <r_epik_State_Penalty>
  0.0051

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
447

> <lig_pdbID>
'6T3'

> <pdbID>
5lbz

> <Kinase families>
Tyr

> <Withdrawn>
|Study NCT02677948 in United States was Withdrawn during Phase 1/Phase 2 because FDA has placed all trials involving Pacritinib on Full Clinical Hold

$$$$
Alisertib
                    3D
 Structure written by MMmdl.
 56 60  0  0  1  0            999 V2000
   -2.1459    4.4120    3.3070 C   0  0  0  0  0  0
   -3.0592    3.4940    2.7166 O   0  0  0  0  0  0
   -4.4075    3.5605    3.0356 C   0  0  0  0  0  0
   -4.9359    4.5047    3.9342 C   0  0  0  0  0  0
   -6.2980    4.5347    4.2222 C   0  0  0  0  0  0
   -7.1581    3.6240    3.6179 C   0  0  0  0  0  0
   -6.6607    2.6786    2.7241 C   0  0  0  0  0  0
   -5.2863    2.6373    2.4304 C   0  0  0  0  0  0
   -4.7748    1.6434    1.4670 C   0  0  0  0  0  0
   -4.7045    0.4253    1.8659 N   0  0  0  0  0  0
   -4.2253   -0.5998    0.9586 C   0  0  0  0  0  0
   -2.7400   -0.4401    0.6683 C   0  0  0  0  0  0
   -1.7639   -1.3479    1.0920 C   0  0  0  0  0  0
   -0.4436   -1.1917    0.8214 N   0  0  0  0  0  0
   -0.0937   -0.0958    0.1035 C   0  0  0  0  0  0
   -0.9683    0.8441   -0.3385 N   0  0  0  0  0  0
   -2.2917    0.6721   -0.0629 C   0  0  0  0  0  0
   -3.2274    1.7270   -0.5836 C   0  0  0  0  0  0
   -4.3749    2.1749    0.1262 C   0  0  0  0  0  0
   -5.1568    3.1928   -0.4513 C   0  0  0  0  0  0
   -4.8407    3.7479   -1.6879 C   0  0  0  0  0  0
   -3.7263    3.2971   -2.3822 C   0  0  0  0  0  0
   -2.9315    2.2969   -1.8348 C   0  0  0  0  0  0
   -5.8330    4.9908   -2.3582 Cl  0  0  0  0  0  0
    1.2787    0.0398   -0.1579 N   0  0  0  0  0  0
    2.0330    1.0142   -0.8374 C   0  0  0  0  0  0
    3.3845    1.1219   -0.5198 C   0  0  0  0  0  0
    4.1876    2.0627   -1.1565 C   0  0  0  0  0  0
    3.6655    2.9221   -2.1351 C   0  0  0  0  0  0
    2.2950    2.8244   -2.4695 C   0  0  0  0  0  0
    1.5040    1.8573   -1.8215 C   0  0  0  0  0  0
    1.7721    3.6923   -3.4170 O   0  0  0  0  0  0
    0.3765    3.6876   -3.7008 C   0  0  0  0  0  0
    4.5834    3.9128   -2.7923 C   0  0  0  0  0  0
    4.3678    4.2207   -3.9863 O   0  0  0  0  0  0
    5.5346    4.3606   -2.1112 O   0  5  0  0  0  0
   -7.5279    1.8129    2.1443 F   0  0  0  0  0  0
   -1.1423    4.2077    2.9344 H   0  0  0  0  0  0
   -2.1209    4.3094    4.3928 H   0  0  0  0  0  0
   -2.3897    5.4433    3.0471 H   0  0  0  0  0  0
   -4.3029    5.2296    4.4223 H   0  0  0  0  0  0
   -6.6876    5.2670    4.9138 H   0  0  0  0  0  0
   -8.2145    3.6535    3.8410 H   0  0  0  0  0  0
   -4.4084   -1.5742    1.4132 H   0  0  0  0  0  0
   -4.7935   -0.5999    0.0247 H   0  0  0  0  0  0
   -2.0335   -2.2248    1.6624 H   0  0  0  0  0  0
   -6.0367    3.5646    0.0545 H   0  0  0  0  0  0
   -3.4739    3.7202   -3.3434 H   0  0  0  0  0  0
   -2.0717    1.9667   -2.4000 H   0  0  0  0  0  0
    1.8403   -0.6176    0.3623 H   0  0  0  0  0  0
    3.8243    0.4775    0.2281 H   0  0  0  0  0  0
    5.2322    2.1108   -0.8821 H   0  0  0  0  0  0
    0.4701    1.7527   -2.1003 H   0  0  0  0  0  0
    0.1575    4.4643   -4.4332 H   0  0  0  0  0  0
   -0.2154    3.9004   -2.8089 H   0  0  0  0  0  0
    0.0568    2.7357   -4.1274 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 38  1  0  0  0
  1 39  1  0  0  0
  1 40  1  0  0  0
  2  3  1  0  0  0
  3  4  1  0  0  0
  3  8  2  0  0  0
  4  5  2  0  0  0
  4 41  1  0  0  0
  5  6  1  0  0  0
  5 42  1  0  0  0
  6  7  2  0  0  0
  6 43  1  0  0  0
  7  8  1  0  0  0
  7 37  1  0  0  0
  8  9  1  0  0  0
  9 10  2  0  0  0
  9 19  1  0  0  0
 10 11  1  0  0  0
 11 12  1  0  0  0
 11 44  1  0  0  0
 11 45  1  0  0  0
 12 13  1  0  0  0
 12 17  2  0  0  0
 13 14  2  0  0  0
 13 46  1  0  0  0
 14 15  1  0  0  0
 15 16  2  0  0  0
 15 25  1  0  0  0
 16 17  1  0  0  0
 17 18  1  0  0  0
 18 19  1  0  0  0
 18 23  2  0  0  0
 19 20  2  0  0  0
 20 21  1  0  0  0
 20 47  1  0  0  0
 21 22  2  0  0  0
 21 24  1  0  0  0
 22 23  1  0  0  0
 22 48  1  0  0  0
 23 49  1  0  0  0
 25 26  1  0  0  0
 25 50  1  0  0  0
 26 27  1  0  0  0
 26 31  2  0  0  0
 27 28  2  0  0  0
 27 51  1  0  0  0
 28 29  1  0  0  0
 28 52  1  0  0  0
 29 30  2  0  0  0
 29 34  1  0  0  0
 30 31  1  0  0  0
 30 32  1  0  0  0
 31 53  1  0  0  0
 32 33  1  0  0  0
 33 54  1  0  0  0
 33 55  1  0  0  0
 33 56  1  0  0  0
 34 35  2  0  0  0
 34 36  1  0  0  0
M  CHG  1  36  -1
M  END
> <s_m_entry_id>
448

> <Applicants>
Millennium Pharmaceuticals

> <CHEMBL_ID>
CHEMBL483158

> <Canonical_Smiles>
Clc1cc2c(-c3nc(ncc3CN=C2c2c(OC)cccc2F)Nc2cc(OC)c(cc2)C(O)=O)cc1

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
3

> <SC_Patent>
None

> <Synonyms>
ALISERTIB | MLN 8237 | MLN-8237 | MLN8237

> <Indications>
For the treatment of various forms of cancer.

> <Type>
1

> <targets_id>
O14965

> <inchi>
InChI=1S/C27H20ClFN4O4/c1-36-21-5-3-4-20(29)23(21)25-19-10-15(28)6-8-17(19)24-14(12-30-25)13-31-27(33-24)32-16-7-9-18(26(34)35)22(11-16)37-2/h3-11,13H,12H2,1-2H3,(H,34,35)(H,31,32,33)

> <stdInchikey>
ZLHFILGSQDJULK-UHFFFAOYSA-N

> <csid>
24700147

> <Links>
|http://www.chemspider.com/Chemical-Structure.24700147.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL483158|http://pubchem.ncbi.nlm.nih.gov/compound/24771867|http://www.drugbank.ca/drugs/DB05220| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=A5B|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/A5B|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7790|http://zinc15.docking.org/substances/ZINC40939534|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=T66ES73M18|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50277545

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
518.1

> <HBA>
7

> <HBD>
2

> <NRB>
6

> <TPSA>
105.9

> <LogP>
5.7

> <RoF>
2

> <Targets>
AURKA

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.1921

> <r_epik_State_Penalty>
  0.1810

> <i_epik_Tot_Q>
-1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
448

> <lig_pdbID>
'A5B'

> <pdbID>
5ia0

> <Kinase families>
Other

> <indicationDB>
Alisertib is a novel aurora A kinase inhibitor under investigation for the treatment of various forms of cancer.

> <uniprotId>
O14965

$$$$
Brivanib
                    3D
 Structure written by MMmdl.
 46 49  0  0  1  0            999 V2000
   -9.1286    6.3805    3.0506 C   0  0  0  0  0  0
   -7.9006    5.5188    2.8820 C   0  0  0  0  0  0
   -7.1012    5.2677    1.7821 C   0  0  0  0  0  0
   -6.0584    4.3702    2.1851 C   0  0  0  0  0  0
   -6.2686    4.0967    3.5675 C   0  0  0  0  0  0
   -7.3880    4.8100    3.9427 N   0  0  0  0  0  0
   -5.4293    3.2495    4.2981 C   0  0  0  0  0  0
   -4.3596    2.6738    3.6128 C   0  0  0  0  0  0
   -4.1288    2.9190    2.2581 C   0  0  0  0  0  0
   -4.9696    3.7676    1.5339 C   0  0  0  0  0  0
   -4.7382    4.0065    0.2219 F   0  0  0  0  0  0
   -3.0541    2.3304    1.6304 O   0  0  0  0  0  0
   -3.0862    1.0044    1.2384 C   0  0  0  0  0  0
   -1.9179    0.4872    0.6474 C   0  0  0  0  0  0
   -0.6177    0.9493    0.2973 C   0  0  0  0  0  0
    0.0395   -0.1489   -0.2634 C   0  0  0  0  0  0
   -0.8206   -1.2507   -0.2680 C   0  0  0  0  0  0
   -2.0162   -0.8720    0.2834 N   0  0  0  0  0  0
   -3.0898   -1.6699    0.4460 N   0  0  0  0  0  0
   -4.1434   -1.0398    1.0219 C   0  0  0  0  0  0
   -4.2057    0.2494    1.4294 N   0  0  0  0  0  0
    1.3330   -0.1049   -0.7222 O   0  0  0  0  0  0
    2.0740   -1.3179   -0.6024 C   0  0  0  0  0  0
    3.5424   -1.0700   -0.9975 C   0  0  1  0  0  0
    4.4246   -2.3113   -0.7892 C   0  0  0  0  0  0
    3.6174   -0.6920   -2.3589 O   0  0  0  0  0  0
   -0.0793    2.3472    0.5042 C   0  0  0  0  0  0
   -9.4381    6.8332    2.1081 H   0  0  0  0  0  0
   -8.9558    7.1948    3.7547 H   0  0  0  0  0  0
   -9.9776    5.8061    3.4222 H   0  0  0  0  0  0
   -7.2568    5.6892    0.8001 H   0  0  0  0  0  0
   -7.8102    4.8399    4.8595 H   0  0  0  0  0  0
   -5.5927    3.0452    5.3461 H   0  0  0  0  0  0
   -3.6912    2.0145    4.1474 H   0  0  0  0  0  0
   -0.6589   -2.2578   -0.6232 H   0  0  0  0  0  0
   -5.0328   -1.6339    1.1744 H   0  0  0  0  0  0
    2.0356   -1.6675    0.4320 H   0  0  0  0  0  0
    1.6445   -2.1007   -1.2309 H   0  0  0  0  0  0
    3.9434   -0.2540   -0.3944 H   0  0  0  0  0  0
    4.4215   -2.6235    0.2557 H   0  0  0  0  0  0
    5.4610   -2.1111   -1.0644 H   0  0  0  0  0  0
    4.0793   -3.1564   -1.3866 H   0  0  0  0  0  0
    3.2349   -1.3928   -2.8920 H   0  0  0  0  0  0
    0.9397    2.4575    0.1329 H   0  0  0  0  0  0
   -0.0664    2.6188    1.5600 H   0  0  0  0  0  0
   -0.6890    3.0895   -0.0113 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 28  1  0  0  0
  1 29  1  0  0  0
  1 30  1  0  0  0
  2  3  2  0  0  0
  2  6  1  0  0  0
  3  4  1  0  0  0
  3 31  1  0  0  0
  4  5  2  0  0  0
  4 10  1  0  0  0
  5  6  1  0  0  0
  5  7  1  0  0  0
  6 32  1  0  0  0
  7  8  2  0  0  0
  7 33  1  0  0  0
  8  9  1  0  0  0
  8 34  1  0  0  0
  9 10  2  0  0  0
  9 12  1  0  0  0
 10 11  1  0  0  0
 12 13  1  0  0  0
 13 14  1  0  0  0
 13 21  2  0  0  0
 14 15  2  0  0  0
 14 18  1  0  0  0
 15 16  1  0  0  0
 15 27  1  0  0  0
 16 17  2  0  0  0
 16 22  1  0  0  0
 17 18  1  0  0  0
 17 35  1  0  0  0
 18 19  1  0  0  0
 19 20  2  0  0  0
 20 21  1  0  0  0
 20 36  1  0  0  0
 22 23  1  0  0  0
 23 24  1  0  0  0
 23 37  1  0  0  0
 23 38  1  0  0  0
 24 25  1  0  0  0
 24 26  1  0  0  0
 24 39  1  0  0  0
 25 40  1  0  0  0
 25 41  1  0  0  0
 25 42  1  0  0  0
 26 43  1  0  0  0
 27 44  1  0  0  0
 27 45  1  0  0  0
 27 46  1  0  0  0
M  END
> <s_m_entry_id>
450

> <Applicants>
Bristol Myers Squibb

> <CHEMBL_ID>
CHEMBL377300

> <Canonical_Smiles>
Fc1c2cc([nH]c2ccc1OC1=NC=Nn2c1c(C)c(OC[C@H](O)C)c2)C

> <Chirality>
Single Stereoisomer

> <First_Approval>
nan

> <Phase>
3

> <SC_Patent>
None

> <Synonyms>
BMS-540215 | BRIVANIB

> <Indications>
nan

> <Type>
nan

> <targets_id>
P35968

> <inchi>
InChI=1S/C19H19FN4O3/c1-10-6-13-14(23-10)4-5-15(17(13)20)27-19-18-12(3)16(26-8-11(2)25)7-24(18)22-9-21-19/h4-7,9,11,23,25H,8H2,1-3H3/t11-/m1/s1

> <stdInchikey>
WCWUXEGQKLTGDX-LLVKDONJSA-N

> <csid>
9409099

> <Links>
|http://www.chemspider.com/Chemical-Structure.9409099.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL377300|http://pubchem.ncbi.nlm.nih.gov/compound/11234052|http://www.drugbank.ca/drugs/DB11958|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5671|http://zinc15.docking.org/substances/ZINC13684256|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=DDU33B674I|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50184807

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
370.1

> <HBA>
6

> <HBD>
2

> <NRB>
5

> <TPSA>
84.7

> <LogP>
3.5

> <RoF>
0

> <Targets>
KDR

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0000

> <r_epik_State_Penalty>
  0.0000

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
450

> <Kinase families>
Tyr

$$$$
Volasertib
                    3D
 Structure written by MMmdl.
 96101  0  0  1  0            999 V2000
   -4.7713    4.3868   -3.2643 C   0  0  0  0  0  0
   -5.8255    4.1894   -2.1551 C   0  0  0  0  0  0
   -5.2744    4.0255   -0.7040 C   0  0  1  0  0  0
   -4.3482    2.8508   -0.5874 N   0  0  0  0  0  0
   -2.9608    3.0134   -0.5506 C   0  0  0  0  0  0
   -2.1383    1.9386   -0.6973 N   0  0  0  0  0  0
   -0.8019    2.1484   -0.6579 C   0  0  0  0  0  0
   -0.2189    3.3571   -0.4636 N   0  0  0  0  0  0
   -1.0476    4.4176   -0.3072 C   0  0  0  0  0  0
   -2.4493    4.3106   -0.3392 C   0  0  0  0  0  0
   -3.3071    5.4230   -0.1482 N   0  0  0  0  0  0
   -4.6616    5.3889   -0.2630 C   0  0  0  0  0  0
   -5.4380    6.3278   -0.0647 O   0  0  0  0  0  0
   -2.6908    6.7158    0.2039 C   0  0  0  0  0  0
   -0.0174    0.9951   -0.8046 N   0  0  0  0  0  0
    1.3731    0.7681   -0.7770 C   0  0  0  0  0  0
    1.8409   -0.4992   -0.3856 C   0  0  0  0  0  0
    3.2272   -0.7376   -0.3592 C   0  0  0  0  0  0
    4.1471    0.2530   -0.7249 C   0  0  0  0  0  0
    3.6610    1.5040   -1.1233 C   0  0  0  0  0  0
    2.2926    1.7554   -1.1539 C   0  0  0  0  0  0
    5.6289   -0.0360   -0.6776 C   0  0  0  0  0  0
    6.0877   -0.8490    0.1277 O   0  0  0  0  0  0
    6.3884    0.6244   -1.5741 N   0  0  0  0  0  0
    7.8390    0.4972   -1.7296 C   0  0  2  0  0  0
    8.4482    1.6773   -2.5086 C   0  0  0  0  0  0
    9.9811    1.5819   -2.6361 C   0  0  0  0  0  0
   10.4814    0.2444   -3.2570 C   0  0  2  0  0  0
    9.8240   -0.9430   -2.4935 C   0  0  0  0  0  0
    8.2921   -0.8341   -2.3660 C   0  0  0  0  0  0
   11.9589    0.1496   -3.3657 N   0  0  0  0  0  0
   12.4609   -1.1182   -3.9206 C   0  0  0  0  0  0
   12.1374   -1.3031   -5.4213 C   0  0  0  0  0  0
   12.6850   -0.1027   -6.2300 N   0  3  0  0  0  0
   12.2880    1.2572   -5.6085 C   0  0  0  0  0  0
   12.6008    1.2572   -4.0939 C   0  0  0  0  0  0
   12.2490   -0.1442   -7.7148 C   0  0  0  0  0  0
   12.8581   -1.3580   -8.4426 C   0  0  0  0  0  0
   12.1885   -1.8315   -9.7107 C   0  0  0  0  0  0
   12.0993   -2.6661   -8.4516 C   0  0  0  0  0  0
    0.8998   -1.4561   -0.0367 O   0  0  0  0  0  0
    1.3265   -2.7548    0.3611 C   0  0  0  0  0  0
   -5.0813    1.5646   -0.5915 C   0  0  0  0  0  0
   -4.7877    0.7513    0.6854 C   0  0  0  0  0  0
   -4.8381    0.7524   -1.8812 C   0  0  0  0  0  0
   -5.2496    4.4641   -4.2408 H   0  0  0  0  0  0
   -4.0718    3.5520   -3.3092 H   0  0  0  0  0  0
   -4.1926    5.2980   -3.1124 H   0  0  0  0  0  0
   -6.5295    5.0231   -2.1951 H   0  0  0  0  0  0
   -6.4286    3.3166   -2.4069 H   0  0  0  0  0  0
   -6.1574    3.8970   -0.0740 H   0  0  0  0  0  0
   -0.5447    5.3600   -0.1499 H   0  0  0  0  0  0
   -3.4067    7.5171    0.3928 H   0  0  0  0  0  0
   -2.0404    7.0533   -0.6038 H   0  0  0  0  0  0
   -2.0872    6.6108    1.1062 H   0  0  0  0  0  0
   -0.5644    0.1491   -0.7429 H   0  0  0  0  0  0
    3.6035   -1.7035   -0.0553 H   0  0  0  0  0  0
    4.3365    2.2964   -1.4130 H   0  0  0  0  0  0
    1.9669    2.7262   -1.4927 H   0  0  0  0  0  0
    5.9265    1.2492   -2.2187 H   0  0  0  0  0  0
    8.2489    0.5435   -0.7170 H   0  0  0  0  0  0
    8.0063    1.7228   -3.5056 H   0  0  0  0  0  0
    8.1854    2.6177   -2.0213 H   0  0  0  0  0  0
   10.2983    2.4322   -3.2384 H   0  0  0  0  0  0
   10.4327    1.7173   -1.6518 H   0  0  0  0  0  0
   10.0854    0.2094   -4.2722 H   0  0  0  0  0  0
   10.0283   -1.8877   -2.9958 H   0  0  0  0  0  0
   10.2626   -1.0231   -1.4974 H   0  0  0  0  0  0
    7.9237   -1.6764   -1.7789 H   0  0  0  0  0  0
    7.8388   -0.9378   -3.3533 H   0  0  0  0  0  0
   13.5437   -1.1467   -3.7867 H   0  0  0  0  0  0
   12.1033   -1.9693   -3.3437 H   0  0  0  0  0  0
   12.6247   -2.1961   -5.8119 H   0  0  0  0  0  0
   11.0651   -1.3726   -5.6109 H   0  0  0  0  0  0
   12.8661    2.0195   -6.1325 H   0  0  0  0  0  0
   11.2284    1.4213   -5.8111 H   0  0  0  0  0  0
   12.3484    2.2191   -3.6509 H   0  0  0  0  0  0
   13.6806    1.1789   -3.9555 H   0  0  0  0  0  0
   11.1569   -0.1315   -7.7185 H   0  0  0  0  0  0
   12.6228    0.7837   -8.1509 H   0  0  0  0  0  0
   13.9479   -1.3916   -8.4038 H   0  0  0  0  0  0
   11.2911   -1.3215  -10.0628 H   0  0  0  0  0  0
   12.8132   -2.1894  -10.5297 H   0  0  0  0  0  0
   12.6639   -3.5975   -8.4010 H   0  0  0  0  0  0
   11.1377   -2.7324   -7.9415 H   0  0  0  0  0  0
    0.4529   -3.3658    0.5882 H   0  0  0  0  0  0
    1.9432   -2.7158    1.2603 H   0  0  0  0  0  0
    1.8797   -3.2556   -0.4347 H   0  0  0  0  0  0
   -6.1535    1.7661   -0.5648 H   0  0  0  0  0  0
   -5.4326   -0.1263    0.7405 H   0  0  0  0  0  0
   -4.9715    1.3434    1.5829 H   0  0  0  0  0  0
   -3.7583    0.3955    0.7269 H   0  0  0  0  0  0
   -5.4936   -0.1181   -1.9142 H   0  0  0  0  0  0
   -3.8163    0.3824   -1.9580 H   0  0  0  0  0  0
   -5.0449    1.3416   -2.7743 H   0  0  0  0  0  0
   13.6937   -0.1548   -6.2036 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 46  1  0  0  0
  1 47  1  0  0  0
  1 48  1  0  0  0
  2  3  1  0  0  0
  2 49  1  0  0  0
  2 50  1  0  0  0
  3  4  1  0  0  0
  3 12  1  0  0  0
  3 51  1  0  0  0
  4  5  1  0  0  0
  4 43  1  0  0  0
  5  6  2  0  0  0
  5 10  1  0  0  0
  6  7  1  0  0  0
  7  8  2  0  0  0
  7 15  1  0  0  0
  8  9  1  0  0  0
  9 10  2  0  0  0
  9 52  1  0  0  0
 10 11  1  0  0  0
 11 12  1  0  0  0
 11 14  1  0  0  0
 12 13  2  0  0  0
 14 53  1  0  0  0
 14 54  1  0  0  0
 14 55  1  0  0  0
 15 16  1  0  0  0
 15 56  1  0  0  0
 16 17  2  0  0  0
 16 21  1  0  0  0
 17 18  1  0  0  0
 17 41  1  0  0  0
 18 19  2  0  0  0
 18 57  1  0  0  0
 19 20  1  0  0  0
 19 22  1  0  0  0
 20 21  2  0  0  0
 20 58  1  0  0  0
 21 59  1  0  0  0
 22 23  2  0  0  0
 22 24  1  0  0  0
 24 25  1  0  0  0
 24 60  1  0  0  0
 25 26  1  0  0  0
 25 30  1  0  0  0
 25 61  1  0  0  0
 26 27  1  0  0  0
 26 62  1  0  0  0
 26 63  1  0  0  0
 27 28  1  0  0  0
 27 64  1  0  0  0
 27 65  1  0  0  0
 28 29  1  0  0  0
 28 31  1  0  0  0
 28 66  1  0  0  0
 29 30  1  0  0  0
 29 67  1  0  0  0
 29 68  1  0  0  0
 30 69  1  0  0  0
 30 70  1  0  0  0
 31 32  1  0  0  0
 31 36  1  0  0  0
 32 33  1  0  0  0
 32 71  1  0  0  0
 32 72  1  0  0  0
 33 34  1  0  0  0
 33 73  1  0  0  0
 33 74  1  0  0  0
 34 35  1  0  0  0
 34 37  1  0  0  0
 34 96  1  0  0  0
 35 36  1  0  0  0
 35 75  1  0  0  0
 35 76  1  0  0  0
 36 77  1  0  0  0
 36 78  1  0  0  0
 37 38  1  0  0  0
 37 79  1  0  0  0
 37 80  1  0  0  0
 38 39  1  0  0  0
 38 40  1  0  0  0
 38 81  1  0  0  0
 39 40  1  0  0  0
 39 82  1  0  0  0
 39 83  1  0  0  0
 40 84  1  0  0  0
 40 85  1  0  0  0
 41 42  1  0  0  0
 42 86  1  0  0  0
 42 87  1  0  0  0
 42 88  1  0  0  0
 43 44  1  0  0  0
 43 45  1  0  0  0
 43 89  1  0  0  0
 44 90  1  0  0  0
 44 91  1  0  0  0
 44 92  1  0  0  0
 45 93  1  0  0  0
 45 94  1  0  0  0
 45 95  1  0  0  0
M  CHG  1  34   1
M  END
> <s_m_entry_id>
451

> <Applicants>
Boehringer Ingelheim

> <CHEMBL_ID>
CHEMBL1233528

> <Canonical_Smiles>
O(C)c1cc(ccc1Nc1nc2N(C(C)C)[C@H](CC)C(=O)N(c2cn1)C)C(=O)NC1CCC(N2CCN(CC2)CC2CC2)CC1

> <Chirality>
Single Stereoisomer

> <First_Approval>
nan

> <Phase>
3

> <SC_Patent>
None

> <Synonyms>
BI 6727 | BI-6727 | VOLASERTIB

> <Indications>
nan

> <Type>
1

> <targets_id>
P53350

> <inchi>
InChI=1S/C34H50N8O3/c1-6-28-33(44)39(4)29-20-35-34(38-31(29)42(28)22(2)3)37-27-14-9-24(19-30(27)45-5)32(43)36-25-10-12-26(13-11-25)41-17-15-40(16-18-41)21-23-7-8-23/h9,14,19-20,22-23,25-26,28H,6-8,10-13,15-18,21H2,1-5H3,(H,36,43)(H,35,37,38)/t25-,26-,28-/m1/s1

> <stdInchikey>
SXNJFOWDRLKDSF-STROYTFGSA-N

> <csid>
26327706

> <Links>
|http://www.chemspider.com/Chemical-Structure.26327706.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1233528|http://www.drugbank.ca/drugs/DB12062| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=IBI|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/IBI|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7947|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=6EM57086EA|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50402023

> <LinkName>
|ChemSpider|ChEMBL|DrugBank|RCSB|PDBe|Guide to Pharmacology|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
618.4

> <HBA>
9

> <HBD>
2

> <NRB>
10

> <TPSA>
106.2

> <LogP>
4.3

> <RoF>
1

> <Targets>
PLK1

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.2056

> <r_epik_State_Penalty>
  0.4377

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
451

> <lig_pdbID>
'IBI'

> <pdbID>
3fc2 5v67 5vbr

> <Kinase families>
Other

> <Withdrawn>
|Study NCT02905994 in United States was Withdrawn during Phase 1 because Funding Withdrawn|Study NCT02527174 in Canada was Withdrawn during Phase 1 because Volasertib no longer available

$$$$
Buparlisib
                    3D
 Structure written by MMmdl.
 50 53  0  0  1  0            999 V2000
   -2.0478    1.7996    0.0006 C   0  0  0  0  0  0
   -0.6703    1.6806   -0.2459 C   0  0  0  0  0  0
    0.0056    0.5307    0.2299 C   0  0  0  0  0  0
   -0.7477   -0.4169    0.9374 C   0  0  0  0  0  0
   -2.0761   -0.3020    1.1778 N   0  0  0  0  0  0
   -2.7095    0.7965    0.7078 C   0  0  0  0  0  0
   -4.0747    0.9038    0.9600 N   0  0  0  0  0  0
    1.4538    0.2716    0.0044 C   0  0  0  0  0  0
    2.0112    0.1826   -1.2749 C   0  0  0  0  0  0
    3.3894   -0.0670   -1.3835 C   0  0  0  0  0  0
    4.1450   -0.2180   -0.2580 N   0  0  0  0  0  0
    3.5381   -0.1276    0.9571 C   0  0  0  0  0  0
    2.2078    0.1053    1.1220 N   0  0  0  0  0  0
    4.3247   -0.3008    2.1009 N   0  0  0  0  0  0
    3.8465    0.0433    3.4545 C   0  0  0  0  0  0
    4.5453   -0.7639    4.5685 C   0  0  0  0  0  0
    5.9573   -0.6505    4.4706 O   0  0  0  0  0  0
    6.4512   -1.0750    3.2089 C   0  0  0  0  0  0
    5.8002   -0.2733    2.0628 C   0  0  0  0  0  0
    4.0477   -0.1647   -2.6159 N   0  0  0  0  0  0
    5.4245   -0.6890   -2.7366 C   0  0  0  0  0  0
    6.1734   -0.2158   -3.9988 C   0  0  0  0  0  0
    5.4088   -0.4727   -5.1649 O   0  0  0  0  0  0
    4.1497    0.1783   -5.1263 C   0  0  0  0  0  0
    3.3268   -0.2690   -3.8997 C   0  0  0  0  0  0
    0.0528    2.8260   -0.9725 C   0  0  0  0  0  0
    1.2451    3.0777   -0.4302 F   0  0  0  0  0  0
    0.2205    2.5035   -2.2544 F   0  0  0  0  0  0
   -0.6441    3.9636   -0.9257 F   0  0  0  0  0  0
   -2.5995    2.6619   -0.3458 H   0  0  0  0  0  0
   -0.2827   -1.3137    1.3215 H   0  0  0  0  0  0
   -4.5836    1.7085    0.6247 H   0  0  0  0  0  0
   -4.5375    0.1718    1.4792 H   0  0  0  0  0  0
    1.3737    0.2935   -2.1368 H   0  0  0  0  0  0
    3.9717    1.1134    3.6256 H   0  0  0  0  0  0
    2.7783   -0.1564    3.5429 H   0  0  0  0  0  0
    4.2325   -0.3939    5.5450 H   0  0  0  0  0  0
    4.2440   -1.8125    4.5330 H   0  0  0  0  0  0
    7.5319   -0.9334    3.1916 H   0  0  0  0  0  0
    6.2859   -2.1456    3.0743 H   0  0  0  0  0  0
    6.1652   -0.7033    1.1297 H   0  0  0  0  0  0
    6.1474    0.7607    2.0789 H   0  0  0  0  0  0
    6.0251   -0.3703   -1.8842 H   0  0  0  0  0  0
    5.3987   -1.7789   -2.7002 H   0  0  0  0  0  0
    6.4198    0.8453   -3.9279 H   0  0  0  0  0  0
    7.1260   -0.7393   -4.0816 H   0  0  0  0  0  0
    4.2822    1.2618   -5.1271 H   0  0  0  0  0  0
    3.6057   -0.0559   -6.0415 H   0  0  0  0  0  0
    2.9692   -1.2907   -4.0343 H   0  0  0  0  0  0
    2.4446    0.3688   -3.8922 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1  6  2  0  0  0
  1 30  1  0  0  0
  2  3  2  0  0  0
  2 26  1  0  0  0
  3  4  1  0  0  0
  3  8  1  0  0  0
  4  5  2  0  0  0
  4 31  1  0  0  0
  5  6  1  0  0  0
  6  7  1  0  0  0
  7 32  1  0  0  0
  7 33  1  0  0  0
  8  9  1  0  0  0
  8 13  2  0  0  0
  9 10  2  0  0  0
  9 34  1  0  0  0
 10 11  1  0  0  0
 10 20  1  0  0  0
 11 12  2  0  0  0
 12 13  1  0  0  0
 12 14  1  0  0  0
 14 15  1  0  0  0
 14 19  1  0  0  0
 15 16  1  0  0  0
 15 35  1  0  0  0
 15 36  1  0  0  0
 16 17  1  0  0  0
 16 37  1  0  0  0
 16 38  1  0  0  0
 17 18  1  0  0  0
 18 19  1  0  0  0
 18 39  1  0  0  0
 18 40  1  0  0  0
 19 41  1  0  0  0
 19 42  1  0  0  0
 20 21  1  0  0  0
 20 25  1  0  0  0
 21 22  1  0  0  0
 21 43  1  0  0  0
 21 44  1  0  0  0
 22 23  1  0  0  0
 22 45  1  0  0  0
 22 46  1  0  0  0
 23 24  1  0  0  0
 24 25  1  0  0  0
 24 47  1  0  0  0
 24 48  1  0  0  0
 25 49  1  0  0  0
 25 50  1  0  0  0
 26 27  1  0  0  0
 26 28  1  0  0  0
 26 29  1  0  0  0
M  END
> <s_m_entry_id>
475

> <Applicants>
Novartis

> <CHEMBL_ID>
CHEMBL2017974

> <Canonical_Smiles>
FC(F)(F)c1cc(ncc1-c1nc(nc(N2CCOCC2)c1)N1CCOCC1)N

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
3

> <SC_Patent>
None

> <Synonyms>
BKM-120 | BKM-120NX | BKM120-NX | BUPARLISIB | NVP-BKM-120 | NVP-BKM120

> <Indications>
nan

> <Type>
1

> <targets_id>
P42336

> <inchi>
InChI=1S/C18H21F3N6O2/c19-18(20,21)13-9-15(22)23-11-12(13)14-10-16(26-1-5-28-6-2-26)25-17(24-14)27-3-7-29-8-4-27/h9-11H,1-8H2,(H2,22,23)

> <stdInchikey>
CWHUFRVAEUJCEF-UHFFFAOYSA-N

> <csid>
17588300

> <Links>
|http://www.chemspider.com/Chemical-Structure.17588300.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2017974|http://pubchem.ncbi.nlm.nih.gov/compound/16654980|http://www.drugbank.ca/drugs/DB11666| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=SD5|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/SD5|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7878|http://zinc15.docking.org/substances/ZINC43154039|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=0ZM2Z182GD|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50380363

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
410.2

> <HBA>
8

> <HBD>
1

> <NRB>
3

> <TPSA>
89.6

> <LogP>
1.8

> <RoF>
0

> <Targets>
PIK3CA

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0014

> <r_epik_State_Penalty>
  0.0009

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
475

> <lig_pdbID>
'SD5'

> <pdbID>
3sd5 5m7e

> <Kinase families>
Atypical

$$$$
Capivasertib
                    3D
 Structure written by MMmdl.
 55 58  0  0  1  0            999 V2000
   -1.4589   -1.6566   -1.8447 C   0  0  0  0  0  0
   -1.7732   -1.9261   -3.1740 C   0  0  0  0  0  0
   -1.2122   -1.1520   -4.1879 C   0  0  0  0  0  0
   -0.3391   -0.1102   -3.8814 C   0  0  0  0  0  0
   -0.0254    0.1594   -2.5521 C   0  0  0  0  0  0
   -0.5857   -0.6116   -1.5252 C   0  0  0  0  0  0
   -0.2396   -0.3440   -0.0533 C   0  0  2  0  0  0
   -1.2221    0.6784    0.5627 C   0  0  0  0  0  0
   -1.0970    0.8281    2.0910 C   0  0  0  0  0  0
   -2.0553    1.7486    2.5678 O   0  0  0  0  0  0
    1.1557    0.0589    0.1780 N   0  0  0  0  0  0
    2.2524   -0.6943   -0.0559 C   0  0  0  0  0  0
    2.1602   -1.8475   -0.4858 O   0  0  0  0  0  0
    3.6637   -0.0766    0.2225 C   0  0  0  0  0  0
    4.4124   -1.0144    1.2065 C   0  0  0  0  0  0
    5.9136   -0.6716    1.3253 C   0  0  0  0  0  0
    6.6224   -0.7062    0.0286 N   0  0  0  0  0  0
    5.9643    0.2015   -0.9271 C   0  0  0  0  0  0
    4.4571   -0.0938   -1.1109 C   0  0  0  0  0  0
    7.9829   -1.0263   -0.0239 C   0  0  0  0  0  0
    8.9173   -0.3912   -0.8864 C   0  0  0  0  0  0
    8.9445    0.6814   -1.8488 C   0  0  0  0  0  0
   10.2374    0.7691   -2.3285 C   0  0  0  0  0  0
   11.0197   -0.1741   -1.7108 N   0  0  0  0  0  0
   10.2534   -0.8924   -0.8206 C   0  0  0  0  0  0
   10.6830   -1.8813   -0.0322 N   0  0  0  0  0  0
    9.7040   -2.3988    0.7504 C   0  0  0  0  0  0
    8.4006   -2.0320    0.7983 N   0  0  0  0  0  0
    3.5925    1.2830    0.7587 N   0  0  0  0  0  0
   -1.6006   -1.4864   -5.8360 Cl  0  0  0  0  0  0
   -1.8954   -2.2623   -1.0636 H   0  0  0  0  0  0
   -2.4483   -2.7343   -3.4149 H   0  0  0  0  0  0
    0.0956    0.4872   -4.6695 H   0  0  0  0  0  0
    0.6529    0.9685   -2.3238 H   0  0  0  0  0  0
   -0.3713   -1.2835    0.4904 H   0  0  0  0  0  0
   -1.0747    1.6510    0.0890 H   0  0  0  0  0  0
   -2.2445    0.3799    0.3221 H   0  0  0  0  0  0
   -1.2582   -0.1307    2.5849 H   0  0  0  0  0  0
   -0.1045    1.1805    2.3730 H   0  0  0  0  0  0
   -1.8219    2.6255    2.2540 H   0  0  0  0  0  0
    1.2891    0.9852    0.5556 H   0  0  0  0  0  0
    3.9548   -0.9708    2.1966 H   0  0  0  0  0  0
    4.3411   -2.0595    0.8963 H   0  0  0  0  0  0
    6.0404    0.3194    1.7637 H   0  0  0  0  0  0
    6.3541   -1.3728    2.0342 H   0  0  0  0  0  0
    6.1253    1.2361   -0.6197 H   0  0  0  0  0  0
    6.4124    0.0727   -1.9110 H   0  0  0  0  0  0
    4.3778   -1.0656   -1.6039 H   0  0  0  0  0  0
    4.0340    0.6247   -1.8155 H   0  0  0  0  0  0
    8.1393    1.3270   -2.1639 H   0  0  0  0  0  0
   10.6756    1.4347   -3.0579 H   0  0  0  0  0  0
   12.0046   -0.2829   -1.9041 H   0  0  0  0  0  0
    9.9968   -3.2012    1.4118 H   0  0  0  0  0  0
    3.0869    1.8747    0.1153 H   0  0  0  0  0  0
    3.0713    1.2791    1.6236 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1  6  2  0  0  0
  1 31  1  0  0  0
  2  3  2  0  0  0
  2 32  1  0  0  0
  3  4  1  0  0  0
  3 30  1  0  0  0
  4  5  2  0  0  0
  4 33  1  0  0  0
  5  6  1  0  0  0
  5 34  1  0  0  0
  6  7  1  0  0  0
  7  8  1  0  0  0
  7 11  1  0  0  0
  7 35  1  0  0  0
  8  9  1  0  0  0
  8 36  1  0  0  0
  8 37  1  0  0  0
  9 10  1  0  0  0
  9 38  1  0  0  0
  9 39  1  0  0  0
 10 40  1  0  0  0
 11 12  1  0  0  0
 11 41  1  0  0  0
 12 13  2  0  0  0
 12 14  1  0  0  0
 14 15  1  0  0  0
 14 19  1  0  0  0
 14 29  1  0  0  0
 15 16  1  0  0  0
 15 42  1  0  0  0
 15 43  1  0  0  0
 16 17  1  0  0  0
 16 44  1  0  0  0
 16 45  1  0  0  0
 17 18  1  0  0  0
 17 20  1  0  0  0
 18 19  1  0  0  0
 18 46  1  0  0  0
 18 47  1  0  0  0
 19 48  1  0  0  0
 19 49  1  0  0  0
 20 21  1  0  0  0
 20 28  2  0  0  0
 21 22  1  0  0  0
 21 25  2  0  0  0
 22 23  2  0  0  0
 22 50  1  0  0  0
 23 24  1  0  0  0
 23 51  1  0  0  0
 24 25  1  0  0  0
 24 52  1  0  0  0
 25 26  1  0  0  0
 26 27  2  0  0  0
 27 28  1  0  0  0
 27 53  1  0  0  0
 29 54  1  0  0  0
 29 55  1  0  0  0
M  END
> <s_m_entry_id>
476

> <Applicants>
Astrazeneca

> <CHEMBL_ID>
CHEMBL2325741

> <Canonical_Smiles>
Clc1ccc(cc1)[C@@H](NC(=O)C1(N)CCN(CC1)c1ncnc2[nH]ccc12)CCO

> <Chirality>
Single Stereoisomer

> <First_Approval>
nan

> <Phase>
3

> <SC_Patent>
None

> <Synonyms>
AZC5363 | AZD 5363 | AZD-5363 | AZD5363 | CAPIVASERTIB

> <Indications>
nan

> <Type>
nan

> <targets_id>
P31749

> <inchi>
InChI=1S/C21H25ClN6O2/c22-15-3-1-14(2-4-15)17(6-12-29)27-20(30)21(23)7-10-28(11-8-21)19-16-5-9-24-18(16)25-13-26-19/h1-5,9,13,17,29H,6-8,10-12,23H2,(H,27,30)(H,24,25,26)/t17-/m0/s1

> <stdInchikey>
JDUBGYFRJFOXQC-KRWDZBQOSA-N

> <csid>
28189073

> <Links>
|http://www.chemspider.com/Chemical-Structure.28189073.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2325741|http://pubchem.ncbi.nlm.nih.gov/compound/25227436|http://www.drugbank.ca/drugs/DB12218| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=0XZ|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/0XZ|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7709|http://zinc15.docking.org/substances/ZINC000043204023|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=WFR23M21IE|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50427349

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
428.2

> <HBA>
6

> <HBD>
4

> <NRB>
6

> <TPSA>
120.2

> <LogP>
2.1

> <RoF>
0

> <Targets>
AKT1

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
0.999998

> <r_epik_Ionization_Penalty>
  0.1491

> <r_epik_State_Penalty>
  0.3964

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
476

> <lig_pdbID>
'0XZ'

> <pdbID>
4gv1

> <Kinase families>
AGC

$$$$
Almonertinib
                    3D
 Structure written by MMmdl.
 75 79  0  0  1  0            999 V2000
   -2.4606   -3.8160    0.4439 C   0  0  0  0  0  0
   -0.9766   -3.6125    0.8117 N   0  3  0  0  0  0
   -0.2081   -4.9472    0.7487 C   0  0  0  0  0  0
   -0.2806   -2.5245   -0.0366 C   0  0  0  0  0  0
   -0.8554   -1.1250    0.2847 C   0  0  0  0  0  0
   -0.1457    0.0007   -0.3326 N   0  0  0  0  0  0
   -0.7125    1.3243   -0.1007 C   0  0  0  0  0  0
    1.2679    0.0021   -0.3724 C   0  0  0  0  0  0
    1.8657    0.1869   -1.6226 C   0  0  0  0  0  0
    3.2613    0.1875   -1.7834 C   0  0  0  0  0  0
    3.8773    0.2999   -3.0190 O   0  0  0  0  0  0
    3.0948    0.5298   -4.1856 C   0  0  0  0  0  0
    4.0723    0.0333   -0.6436 C   0  0  0  0  0  0
    3.4839   -0.1686    0.6054 C   0  0  0  0  0  0
    2.0918   -0.1864    0.7566 C   0  0  0  0  0  0
    1.5320   -0.3317    2.0391 N   0  0  0  0  0  0
    1.8033   -1.3331    2.9022 C   0  0  0  0  0  0
    2.5850   -2.2579    2.6628 O   0  0  0  0  0  0
    1.0799   -1.2079    4.1466 C   0  0  0  0  0  0
    1.1758   -2.1142    5.1374 C   0  0  0  0  0  0
    5.4781    0.0533   -0.6966 N   0  0  0  0  0  0
    6.3391    0.9909   -1.2858 C   0  0  0  0  0  0
    5.8141    2.0683   -1.9282 N   0  0  0  0  0  0
    6.6773    2.9575   -2.4850 C   0  0  0  0  0  0
    8.0635    2.7828   -2.3835 C   0  0  0  0  0  0
    8.5145    1.6580   -1.6901 C   0  0  0  0  0  0
    7.6670    0.7542   -1.1339 N   0  0  0  0  0  0
    6.0604    4.1177   -3.2057 C   0  0  0  0  0  0
    6.7416    5.0739   -3.9380 C   0  0  0  0  0  0
    5.8810    5.9981   -4.4772 N   0  0  0  0  0  0
    6.2765    7.1176   -5.3204 C   0  0  0  0  0  0
    7.4225    8.0097   -4.8888 C   0  0  0  0  0  0
    6.0069    8.5283   -4.8421 C   0  0  0  0  0  0
    4.5875    5.6634   -4.1209 C   0  0  0  0  0  0
    3.3666    6.2776   -4.4339 C   0  0  0  0  0  0
    2.2096    5.7063   -3.9081 C   0  0  0  0  0  0
    2.2536    4.5747   -3.1024 C   0  0  0  0  0  0
    3.4635    3.9607   -2.7914 C   0  0  0  0  0  0
    4.6646    4.4897   -3.3027 C   0  0  0  0  0  0
   -2.5083   -4.0940   -0.6102 H   0  0  0  0  0  0
   -2.9851   -2.8812    0.6395 H   0  0  0  0  0  0
   -2.8490   -4.6089    1.0848 H   0  0  0  0  0  0
   -0.2126   -5.2859   -0.2886 H   0  0  0  0  0  0
   -0.7221   -5.6506    1.4054 H   0  0  0  0  0  0
    0.8046   -4.7565    1.1067 H   0  0  0  0  0  0
    0.7723   -2.6021    0.2359 H   0  0  0  0  0  0
   -0.4036   -2.8125   -1.0821 H   0  0  0  0  0  0
   -1.8844   -1.0774   -0.0725 H   0  0  0  0  0  0
   -0.9140   -0.9697    1.3625 H   0  0  0  0  0  0
   -0.1902    2.0866   -0.6814 H   0  0  0  0  0  0
   -0.6389    1.5998    0.9521 H   0  0  0  0  0  0
   -1.7603    1.3514   -0.4016 H   0  0  0  0  0  0
    1.2211    0.3108   -2.4802 H   0  0  0  0  0  0
    3.7570    0.6351   -5.0447 H   0  0  0  0  0  0
    2.5131    1.4492   -4.1055 H   0  0  0  0  0  0
    2.4231   -0.3055   -4.3875 H   0  0  0  0  0  0
    4.1161   -0.2868    1.4751 H   0  0  0  0  0  0
    0.7304    0.2489    2.2376 H   0  0  0  0  0  0
    0.4405   -0.3437    4.2672 H   0  0  0  0  0  0
    1.8014   -2.9931    5.0621 H   0  0  0  0  0  0
    0.6184   -1.9841    6.0534 H   0  0  0  0  0  0
    5.9385   -0.5321   -0.0154 H   0  0  0  0  0  0
    8.7636    3.4811   -2.8166 H   0  0  0  0  0  0
    9.5711    1.4670   -1.5732 H   0  0  0  0  0  0
    7.8002    5.1723   -4.1299 H   0  0  0  0  0  0
    6.1603    6.9129   -6.3852 H   0  0  0  0  0  0
    7.9314    7.8095   -3.9452 H   0  0  0  0  0  0
    8.0982    8.3938   -5.6532 H   0  0  0  0  0  0
    5.6938    9.2729   -5.5741 H   0  0  0  0  0  0
    5.5378    8.6774   -3.8688 H   0  0  0  0  0  0
    3.3131    7.1602   -5.0541 H   0  0  0  0  0  0
    1.2529    6.1563   -4.1293 H   0  0  0  0  0  0
    1.3340    4.1646   -2.7110 H   0  0  0  0  0  0
    3.4595    3.0843   -2.1626 H   0  0  0  0  0  0
   -0.9428   -3.3049    1.7739 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 40  1  0  0  0
  1 41  1  0  0  0
  1 42  1  0  0  0
  2  3  1  0  0  0
  2  4  1  0  0  0
  2 75  1  0  0  0
  3 43  1  0  0  0
  3 44  1  0  0  0
  3 45  1  0  0  0
  4  5  1  0  0  0
  4 46  1  0  0  0
  4 47  1  0  0  0
  5  6  1  0  0  0
  5 48  1  0  0  0
  5 49  1  0  0  0
  6  7  1  0  0  0
  6  8  1  0  0  0
  7 50  1  0  0  0
  7 51  1  0  0  0
  7 52  1  0  0  0
  8  9  1  0  0  0
  8 15  2  0  0  0
  9 10  2  0  0  0
  9 53  1  0  0  0
 10 11  1  0  0  0
 10 13  1  0  0  0
 11 12  1  0  0  0
 12 54  1  0  0  0
 12 55  1  0  0  0
 12 56  1  0  0  0
 13 14  2  0  0  0
 13 21  1  0  0  0
 14 15  1  0  0  0
 14 57  1  0  0  0
 15 16  1  0  0  0
 16 17  1  0  0  0
 16 58  1  0  0  0
 17 18  2  0  0  0
 17 19  1  0  0  0
 19 20  2  0  0  0
 19 59  1  0  0  0
 20 60  1  0  0  0
 20 61  1  0  0  0
 21 22  1  0  0  0
 21 62  1  0  0  0
 22 23  1  0  0  0
 22 27  2  0  0  0
 23 24  2  0  0  0
 24 25  1  0  0  0
 24 28  1  0  0  0
 25 26  2  0  0  0
 25 63  1  0  0  0
 26 27  1  0  0  0
 26 64  1  0  0  0
 28 29  2  0  0  0
 28 39  1  0  0  0
 29 30  1  0  0  0
 29 65  1  0  0  0
 30 31  1  0  0  0
 30 34  1  0  0  0
 31 32  1  0  0  0
 31 33  1  0  0  0
 31 66  1  0  0  0
 32 33  1  0  0  0
 32 67  1  0  0  0
 32 68  1  0  0  0
 33 69  1  0  0  0
 33 70  1  0  0  0
 34 35  1  0  0  0
 34 39  2  0  0  0
 35 36  2  0  0  0
 35 71  1  0  0  0
 36 37  1  0  0  0
 36 72  1  0  0  0
 37 38  2  0  0  0
 37 73  1  0  0  0
 38 39  1  0  0  0
 38 74  1  0  0  0
M  CHG  1   2   1
M  END
> <s_m_entry_id>
479

> <Applicants>
Jiangsu Hansoh Pharmaceutical

> <CHEMBL_ID>
CHEMBL4594354

> <Canonical_Smiles>
O(C)c1cc(N(CCN(C)C)C)c(NC(=O)C=C)cc1Nc1nc(ccn1)-c1c2c(n(c1)C1CC1)cccc2

> <Chirality>
Unknown

> <First_Approval>
nan

> <Phase>
3

> <SC_Patent>
None

> <Synonyms>
HS-10296||AMEILE

> <Indications>
nan

> <Type>
nan

> <targets_id>
nan

> <inchi>
InChI=1S/C30H35N7O2/c1-6-29(38)32-24-17-25(28(39-5)18-27(24)36(4)16-15-35(2)3)34-30-31-14-13-23(33-30)22-19-37(20-11-12-20)26-10-8-7-9-21(22)26/h6-10,13-14,17-20H,1,11-12,15-16H2,2-5H3,(H,32,38)(H,31,33,34)

> <stdInchikey>
DOEOECWDNSEFDN-UHFFFAOYSA-N

> <csid>
75535991

> <Links>
|http://www.chemspider.com/Chemical-Structure.75535991.html|http://pubchem.ncbi.nlm.nih.gov/compound/121280087|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11136|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=T4RS462G19

> <LinkName>
|ChemSpider|PubChem|Guide to Pharmacology|FDA SRS

> <indicationG2P>
None

> <MW>
525.3

> <HBA>
8

> <HBD>
2

> <NRB>
11

> <TPSA>
87.6

> <LogP>
5.3

> <RoF>
2

> <Targets>
nan

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0134

> <r_epik_State_Penalty>
  0.0077

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
479

$$$$
Asciminib
                    3D
 Structure written by MMmdl.
 49 52  0  0  1  0            999 V2000
   -2.2948   -2.8387    0.3363 C   0  0  0  0  0  0
   -3.6186   -3.2694    0.3365 C   0  0  0  0  0  0
   -4.6558   -2.3719    0.0392 C   0  0  0  0  0  0
   -4.3405   -1.0470   -0.2626 C   0  0  0  0  0  0
   -3.0186   -0.6115   -0.2638 C   0  0  0  0  0  0
   -1.9866   -1.5082    0.0490 C   0  0  0  0  0  0
   -0.6216   -1.1679    0.0592 N   0  0  0  0  0  0
   -0.0527    0.0505    0.2064 C   0  0  0  0  0  0
   -0.6740    1.1010    0.3767 O   0  0  0  0  0  0
    1.4543    0.0725    0.1309 C   0  0  0  0  0  0
    2.2397   -1.0165    0.5388 C   0  0  0  0  0  0
    3.6380   -0.9596    0.4598 C   0  0  0  0  0  0
    4.2208    0.2231   -0.0346 C   0  0  0  0  0  0
    3.4721    1.2883   -0.4330 N   0  0  0  0  0  0
    2.1232    1.2053   -0.3437 C   0  0  0  0  0  0
    5.6079    0.3504   -0.1744 N   0  0  0  0  0  0
    6.3315    1.4270    0.4993 C   0  0  0  0  0  0
    7.7979    1.2600    0.1021 C   0  0  0  0  0  0
    7.7157    0.6624   -1.3035 C   0  0  2  0  0  0
    6.2038    0.5020   -1.5021 C   0  0  0  0  0  0
    8.4078   -0.5660   -1.4153 O   0  0  0  0  0  0
    4.4333   -2.1458    0.9075 C   0  0  0  0  0  0
    5.6479   -2.2683    1.5696 C   0  0  0  0  0  0
    5.8799   -3.6397    1.7052 C   0  0  0  0  0  0
    4.9151   -4.3583    1.1843 N   0  0  0  0  0  0
    4.0537   -3.4517    0.7093 N   0  0  0  0  0  0
   -5.9997   -2.7005    0.0151 O   0  0  0  0  0  0
   -6.4395   -4.0258    0.3164 C   0  0  0  0  0  0
   -5.9440   -4.9028   -0.5593 F   0  0  0  0  0  0
   -6.0968   -4.3718    1.5591 F   0  0  0  0  0  0
   -8.2148   -4.1068    0.2091 Cl  0  0  0  0  0  0
   -1.5118   -3.5471    0.5678 H   0  0  0  0  0  0
   -3.8165   -4.3041    0.5695 H   0  0  0  0  0  0
   -5.1283   -0.3481   -0.5035 H   0  0  0  0  0  0
   -2.8223    0.4169   -0.5240 H   0  0  0  0  0  0
    0.0081   -1.9535   -0.0099 H   0  0  0  0  0  0
    1.7690   -1.9080    0.9295 H   0  0  0  0  0  0
    1.5811    2.0812   -0.6718 H   0  0  0  0  0  0
    5.9460    2.4007    0.1872 H   0  0  0  0  0  0
    6.1902    1.3678    1.5793 H   0  0  0  0  0  0
    8.3337    2.2096    0.1255 H   0  0  0  0  0  0
    8.2970    0.5839    0.7991 H   0  0  0  0  0  0
    8.1048    1.3702   -2.0367 H   0  0  0  0  0  0
    5.9533   -0.3426   -2.1459 H   0  0  0  0  0  0
    5.7873    1.3823   -1.9978 H   0  0  0  0  0  0
    8.0381   -1.1812   -0.7775 H   0  0  0  0  0  0
    6.2861   -1.4674    1.9127 H   0  0  0  0  0  0
    6.7384   -4.0961    2.1758 H   0  0  0  0  0  0
    3.2033   -3.7288    0.2408 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1  6  2  0  0  0
  1 32  1  0  0  0
  2  3  2  0  0  0
  2 33  1  0  0  0
  3  4  1  0  0  0
  3 27  1  0  0  0
  4  5  2  0  0  0
  4 34  1  0  0  0
  5  6  1  0  0  0
  5 35  1  0  0  0
  6  7  1  0  0  0
  7  8  1  0  0  0
  7 36  1  0  0  0
  8  9  2  0  0  0
  8 10  1  0  0  0
 10 11  2  0  0  0
 10 15  1  0  0  0
 11 12  1  0  0  0
 11 37  1  0  0  0
 12 13  2  0  0  0
 12 22  1  0  0  0
 13 14  1  0  0  0
 13 16  1  0  0  0
 14 15  2  0  0  0
 15 38  1  0  0  0
 16 17  1  0  0  0
 16 20  1  0  0  0
 17 18  1  0  0  0
 17 39  1  0  0  0
 17 40  1  0  0  0
 18 19  1  0  0  0
 18 41  1  0  0  0
 18 42  1  0  0  0
 19 20  1  0  0  0
 19 21  1  0  0  0
 19 43  1  0  0  0
 20 44  1  0  0  0
 20 45  1  0  0  0
 21 46  1  0  0  0
 22 23  2  0  0  0
 22 26  1  0  0  0
 23 24  1  0  0  0
 23 47  1  0  0  0
 24 25  2  0  0  0
 24 48  1  0  0  0
 25 26  1  0  0  0
 26 49  1  0  0  0
 27 28  1  0  0  0
 28 29  1  0  0  0
 28 30  1  0  0  0
 28 31  1  0  0  0
M  END
> <s_m_entry_id>
480

> <Applicants>
Novartis

> <CHEMBL_ID>
CHEMBL4208229

> <Canonical_Smiles>
ClC(F)(F)Oc1ccc(NC(=O)c2cc(-c3[nH]ncc3)c(nc2)N2C[C@H](O)CC2)cc1

> <Chirality>
Single Stereoisomer

> <First_Approval>
nan

> <Phase>
3

> <SC_Patent>
None

> <Synonyms>
ABL-001 | ABL001 | ABL001-NX | ASCIMINIB | NVP-ABL001

> <Indications>
nan

> <Type>
nan

> <targets_id>
nan

> <inchi>
InChI=1S/C20H18ClF2N5O3/c21-20(22,23)31-15-3-1-13(2-4-15)26-19(30)12-9-16(17-5-7-25-27-17)18(24-10-12)28-8-6-14(29)11-28/h1-5,7,9-10,14,29H,6,8,11H2,(H,25,27)(H,26,30)/t14-/m1/s1

> <stdInchikey>
VOVZXURTCKPRDQ-CQSZACIVSA-N

> <csid>
52085218

> <Links>
|http://www.chemspider.com/Chemical-Structure.52085218.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4208229|http://pubchem.ncbi.nlm.nih.gov/compound/72165228|http://www.drugbank.ca/drugs/DB12597| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=AY7|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/AY7|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8962|http://zinc15.docking.org/substances/ZINC000150275965|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=L1F3R18W77

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS

> <indicationG2P>
None

> <MW>
449.1

> <HBA>
6

> <HBD>
3

> <NRB>
6

> <TPSA>
103.4

> <LogP>
3.5

> <RoF>
0

> <Targets>
nan

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
0.5

> <r_epik_Ionization_Penalty>
  0.0013

> <r_epik_State_Penalty>
  0.3631

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
480

> <lig_pdbID>
'AY7'

> <pdbID>
5mo4

$$$$
Umbralisib
                    3D
 Structure written by MMmdl.
 66 71  0  0  1  0            999 V2000
   -2.3536   -2.0577   -2.0904 C   0  0  0  0  0  0
   -2.4023   -2.0354   -0.5443 C   0  0  1  0  0  0
   -2.5986   -3.4261    0.0653 C   0  0  0  0  0  0
   -3.6718   -3.8675    0.7775 C   0  0  0  0  0  0
   -3.7056   -5.2496    1.3067 C   0  0  0  0  0  0
   -4.6460   -5.7385    1.9370 O   0  0  0  0  0  0
   -2.4658   -6.0396    1.0122 C   0  0  0  0  0  0
   -2.3172   -7.3627    1.4553 C   0  0  0  0  0  0
   -1.1561   -8.0835    1.1698 C   0  0  0  0  0  0
   -0.1274   -7.4921    0.4365 C   0  0  0  0  0  0
   -0.2570   -6.1789   -0.0126 C   0  0  0  0  0  0
   -1.4188   -5.4629    0.2749 C   0  0  0  0  0  0
   -1.4883   -4.1710   -0.1976 O   0  0  0  0  0  0
   -1.0284   -9.3575    1.6047 F   0  0  0  0  0  0
   -4.8660   -3.0188    0.9968 C   0  0  0  0  0  0
   -5.1929   -2.5663    2.2818 C   0  0  0  0  0  0
   -6.3154   -1.7640    2.4874 C   0  0  0  0  0  0
   -7.1255   -1.4094    1.4093 C   0  0  0  0  0  0
   -6.8138   -1.8589    0.1266 C   0  0  0  0  0  0
   -5.6909   -2.6610   -0.0777 C   0  0  0  0  0  0
   -7.5988   -1.5161   -0.9196 F   0  0  0  0  0  0
   -1.2512   -1.3468    0.0618 N   0  0  0  0  0  0
   -1.1461   -0.8479    1.3479 C   0  0  0  0  0  0
    0.1743   -0.3543    1.4716 C   0  0  0  0  0  0
    0.7907   -0.6442    0.2069 C   0  0  0  0  0  0
   -0.0733   -1.2275   -0.5934 N   0  0  0  0  0  0
    2.1907   -0.3890   -0.2375 C   0  0  0  0  0  0
    2.4442    0.2001   -1.4799 C   0  0  0  0  0  0
    3.7527    0.4537   -1.8904 C   0  0  0  0  0  0
    4.8394    0.1267   -1.0612 C   0  0  0  0  0  0
    4.5782   -0.4612    0.1815 C   0  0  0  0  0  0
    3.2685   -0.7154    0.5893 C   0  0  0  0  0  0
    5.6014   -0.7921    1.0035 F   0  0  0  0  0  0
    6.1685    0.3400   -1.3855 O   0  0  0  0  0  0
    6.5373    0.9719   -2.6136 C   0  0  0  0  0  0
    8.0093    0.6167   -2.8689 C   0  0  0  0  0  0
    6.3367    2.4971   -2.5196 C   0  0  0  0  0  0
    0.4866    0.2412    2.7106 C   0  0  0  0  0  0
   -0.4331    0.3000    3.7079 N   0  0  0  0  0  0
   -1.6563   -0.2308    3.4531 C   0  0  0  0  0  0
   -2.0856   -0.8142    2.3033 N   0  0  0  0  0  0
    1.7327    0.8065    2.9665 N   0  0  0  0  0  0
   -3.2712   -2.4799   -2.5016 H   0  0  0  0  0  0
   -1.5229   -2.6585   -2.4632 H   0  0  0  0  0  0
   -2.2485   -1.0520   -2.4996 H   0  0  0  0  0  0
   -3.2582   -1.4137   -0.2835 H   0  0  0  0  0  0
   -3.0999   -7.8434    2.0252 H   0  0  0  0  0  0
    0.7699   -8.0516    0.2163 H   0  0  0  0  0  0
    0.5394   -5.7200   -0.5804 H   0  0  0  0  0  0
   -4.5707   -2.8321    3.1243 H   0  0  0  0  0  0
   -6.5562   -1.4167    3.4814 H   0  0  0  0  0  0
   -7.9945   -0.7880    1.5680 H   0  0  0  0  0  0
   -5.4595   -3.0040   -1.0759 H   0  0  0  0  0  0
    1.6254    0.4661   -2.1328 H   0  0  0  0  0  0
    3.8970    0.9094   -2.8574 H   0  0  0  0  0  0
    3.0955   -1.1787    1.5498 H   0  0  0  0  0  0
    5.9630    0.5647   -3.4471 H   0  0  0  0  0  0
    8.3654    1.0517   -3.8035 H   0  0  0  0  0  0
    8.1445   -0.4633   -2.9375 H   0  0  0  0  0  0
    8.6522    0.9798   -2.0661 H   0  0  0  0  0  0
    6.6454    2.9906   -3.4415 H   0  0  0  0  0  0
    6.9225    2.9228   -1.7040 H   0  0  0  0  0  0
    5.2943    2.7611   -2.3448 H   0  0  0  0  0  0
   -2.3753   -0.1785    4.2577 H   0  0  0  0  0  0
    2.4407    0.7996    2.2467 H   0  0  0  0  0  0
    1.9044    1.2315    3.8661 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 43  1  0  0  0
  1 44  1  0  0  0
  1 45  1  0  0  0
  2  3  1  0  0  0
  2 22  1  0  0  0
  2 46  1  0  0  0
  3  4  2  0  0  0
  3 13  1  0  0  0
  4  5  1  0  0  0
  4 15  1  0  0  0
  5  6  2  0  0  0
  5  7  1  0  0  0
  7  8  2  0  0  0
  7 12  1  0  0  0
  8  9  1  0  0  0
  8 47  1  0  0  0
  9 10  2  0  0  0
  9 14  1  0  0  0
 10 11  1  0  0  0
 10 48  1  0  0  0
 11 12  2  0  0  0
 11 49  1  0  0  0
 12 13  1  0  0  0
 15 16  1  0  0  0
 15 20  2  0  0  0
 16 17  2  0  0  0
 16 50  1  0  0  0
 17 18  1  0  0  0
 17 51  1  0  0  0
 18 19  2  0  0  0
 18 52  1  0  0  0
 19 20  1  0  0  0
 19 21  1  0  0  0
 20 53  1  0  0  0
 22 23  1  0  0  0
 22 26  1  0  0  0
 23 24  1  0  0  0
 23 41  2  0  0  0
 24 25  1  0  0  0
 24 38  2  0  0  0
 25 26  2  0  0  0
 25 27  1  0  0  0
 27 28  2  0  0  0
 27 32  1  0  0  0
 28 29  1  0  0  0
 28 54  1  0  0  0
 29 30  2  0  0  0
 29 55  1  0  0  0
 30 31  1  0  0  0
 30 34  1  0  0  0
 31 32  2  0  0  0
 31 33  1  0  0  0
 32 56  1  0  0  0
 34 35  1  0  0  0
 35 36  1  0  0  0
 35 37  1  0  0  0
 35 57  1  0  0  0
 36 58  1  0  0  0
 36 59  1  0  0  0
 36 60  1  0  0  0
 37 61  1  0  0  0
 37 62  1  0  0  0
 37 63  1  0  0  0
 38 39  1  0  0  0
 38 42  1  0  0  0
 39 40  2  0  0  0
 40 41  1  0  0  0
 40 64  1  0  0  0
 42 65  1  0  0  0
 42 66  1  0  0  0
M  END
> <s_m_entry_id>
482

> <Applicants>
TG Therapeutics

> <CHEMBL_ID>
CHEMBL3948730

> <Canonical_Smiles>
Fc1cc(ccc1OC(C)C)-c1nn(c2ncnc(N)c12)[C@@H](C)C=1Oc2c(cc(F)cc2)C(=O)C=1c1cc(F)ccc1

> <Chirality>
Single Stereoisomer

> <First_Approval>
2021

> <Phase>
4

> <SC_Patent>
None

> <Synonyms>
RP-5264 | RP5264 | TGR 1202 | TGR-1202 BASE | TGR-1202 FREE BASE | UMBRALISIB

> <Indications>
On February 2021, FDA approved umbralisib for the treatment of certain patients with marginal zone lymphoma and follicular lymphoma

> <Type>
nan

> <targets_id>
nan

> <inchi>
InChI=1S/C31H24F3N5O3/c1-15(2)41-24-9-7-18(12-22(24)34)27-26-30(35)36-14-37-31(26)39(38-27)16(3)29-25(17-5-4-6-19(32)11-17)28(40)21-13-20(33)8-10-23(21)42-29/h4-16H,1-3H3,(H2,35,36,37)/t16-/m0/s1

> <stdInchikey>
IUVCFHHAEHNCFT-INIZCTEOSA-N

> <csid>
34979945

> <Links>
|http://www.chemspider.com/Chemical-Structure.34979945.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3948730|http://pubchem.ncbi.nlm.nih.gov/compound/72950888|http://www.drugbank.ca/drugs/DB14989|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8916|http://zinc15.docking.org/substances/ZINC000141831516|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=38073MQB2A|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=184556

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
571.2

> <HBA>
8

> <HBD>
1

> <NRB>
6

> <TPSA>
109.1

> <LogP>
6.7

> <RoF>
2

> <Targets>
nan

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0016

> <r_epik_State_Penalty>
  0.0011

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
482

> <indicationDB>
Marginal zone lymphoma is a rare, slowly progressing type of non-Hodgkin lymphoma initially treated with <a href="https://go.drugbank.com/drugs/DB00073">rituximab</a> (an anti-CD20 drug), either alone or in combination with chemotherapy. Unfortunately, many patients experience a relapse or develop resistance to these drugs. Treatment options then become limited, and alternate treatments for the lymphoma are required to control disease progression.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Burris HA 3rd, Flinn IW, Patel MR, Fenske TS, Deng C, Brander DM, Gutierrez M, Essell JH, Kuhn JG, Miskin HP, Sportelli P, Weiss MS, Vakkalanka S, Savona MR, O&#39;Connor OA: Umbralisib, a novel PI3Kdelta and casein kinase-1epsilon inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study. Lancet Oncol. 2018 Apr;19(4):486-496. doi: 10.1016/S1470-2045(18)30082-2. Epub 2018 Feb 20. (PubMed ID 29475723)" href="#reference-A229363">1</a></sup> Follicular lymphoma is also treated with rituximab and other chemotherapeutic agents, but may show similar progression.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Freedman A, Jacobsen E: Follicular lymphoma: 2020 update on diagnosis and management. Am J Hematol. 2020 Mar;95(3):316-327. doi: 10.1002/ajh.25696. Epub 2019 Dec 22. (PubMed ID 31814159)" href="#reference-A229668">5</a></sup></p><p>On February 5, 2021, the Food and Drug Administration granted accelerated approval to umbralisib, a kinase inhibitor for PI3K-delta and casein kinase CK1-epsilon, based on promising results from clinical trials. It is marketed as Ukoniq by TG Therapeutics and is approved for treating relapsing and refractory marginal cell lymphoma and follicular lymphoma in adults.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA: FDA grants accelerated approval to umbralisib for marginal zone lymphoma and follicular lymphoma" href="#reference-L31863">6</a></sup> Umbralisib inhibits casein kinase, a primary regulator of protein translation, kinase-1ε, distinguishing it from other lymphoma treatments and offering a promising therapy for patients experiencing relapsing or refractory disease.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Burris HA 3rd, Flinn IW, Patel MR, Fenske TS, Deng C, Brander DM, Gutierrez M, Essell JH, Kuhn JG, Miskin HP, Sportelli P, Weiss MS, Vakkalanka S, Savona MR, O&#39;Connor OA: Umbralisib, a novel PI3Kdelta and casein kinase-1epsilon inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study. Lancet Oncol. 2018 Apr;19(4):486-496. doi: 10.1016/S1470-2045(18)30082-2. Epub 2018 Feb 20. (PubMed ID 29475723)" href="#reference-A229363">1</a></sup> Continued approval may depend on confirmation of efficacy in clinical trials.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA Approved Drug Products: UKONIQ (umbralisib) tablets, for oral use" href="#reference-L31878">7</a></sup>

> <uniprotId>
P49674|O00329|P00519|P11712|P05177|P08684|O00329|P49674|P00519|P08183

> <FDA_approved>
Y

$$$$
Crenolanib
                    3D
 Structure written by MMmdl.
 63 68  0  0  1  0            999 V2000
   -2.4931   -0.3750   -1.1120 C   0  0  0  0  0  0
   -2.1240    0.5453    0.0706 C   0  0  0  0  0  0
   -3.0613    1.7537    0.2321 C   0  0  0  0  0  0
   -3.5371    1.2455    1.5502 O   0  0  0  0  0  0
   -2.6427    0.0585    1.4339 C   0  0  0  0  0  0
   -0.6249    0.9152    0.0570 C   0  0  0  0  0  0
    0.1636   -0.2630    0.2168 O   0  0  0  0  0  0
    1.5418   -0.1698    0.1850 C   0  0  0  0  0  0
    2.2422   -1.3717    0.3124 C   0  0  0  0  0  0
    3.6360   -1.4421    0.2914 C   0  0  0  0  0  0
    4.3277   -0.2372    0.1270 C   0  0  0  0  0  0
    3.6464    1.0014    0.0073 C   0  0  0  0  0  0
    2.2455    1.0376    0.0360 C   0  0  0  0  0  0
    4.5252    2.0403   -0.1270 N   0  0  0  0  0  0
    5.7000    1.4689   -0.0982 C   0  0  0  0  0  0
    5.6725    0.0953    0.0423 N   0  0  0  0  0  0
    6.7932   -0.7593    0.0834 C   0  0  0  0  0  0
    7.9300   -0.4060    0.8098 C   0  0  0  0  0  0
    9.0230   -1.2673    0.8047 C   0  0  0  0  0  0
    8.9599   -2.4772    0.0681 C   0  0  0  0  0  0
   10.0487   -3.3754    0.0140 C   0  0  0  0  0  0
    9.9527   -4.5432   -0.7312 C   0  0  0  0  0  0
    8.7871   -4.8494   -1.4228 C   0  0  0  0  0  0
    7.6671   -4.0062   -1.3942 C   0  0  0  0  0  0
    7.7546   -2.7838   -0.6414 C   0  0  0  0  0  0
    6.6977   -1.9141   -0.6225 N   0  0  0  0  0  0
    6.5034   -4.3536   -2.0803 N   0  0  0  0  0  0
    5.3222   -4.7201   -1.2793 C   0  0  0  0  0  0
    4.0195   -4.3898   -2.0370 C   0  0  0  0  0  0
    3.9798   -5.1223   -3.3901 C   0  0  0  0  0  0
    5.2909   -4.9280   -4.1755 C   0  0  0  0  0  0
    6.5229   -5.2044   -3.2837 C   0  0  0  0  0  0
    2.8346   -4.5275   -4.2178 N   0  3  0  0  0  0
   -1.9416   -1.3150   -1.0711 H   0  0  0  0  0  0
   -2.2670    0.0997   -2.0674 H   0  0  0  0  0  0
   -3.5556   -0.6224   -1.1141 H   0  0  0  0  0  0
   -2.5898    2.7265    0.3805 H   0  0  0  0  0  0
   -3.9115    1.8121   -0.4495 H   0  0  0  0  0  0
   -3.2551   -0.8445    1.4326 H   0  0  0  0  0  0
   -1.9328    0.0700    2.2625 H   0  0  0  0  0  0
   -0.3797    1.4123   -0.8838 H   0  0  0  0  0  0
   -0.4020    1.6156    0.8648 H   0  0  0  0  0  0
    1.6847   -2.2893    0.4325 H   0  0  0  0  0  0
    4.1449   -2.3876    0.3969 H   0  0  0  0  0  0
    1.7344    1.9836   -0.0574 H   0  0  0  0  0  0
    6.6476    1.9804   -0.1891 H   0  0  0  0  0  0
    7.9729    0.5190    1.3665 H   0  0  0  0  0  0
    9.9201   -1.0161    1.3523 H   0  0  0  0  0  0
   10.9588   -3.1460    0.5496 H   0  0  0  0  0  0
   10.7910   -5.2234   -0.7709 H   0  0  0  0  0  0
    8.7600   -5.7768   -1.9763 H   0  0  0  0  0  0
    5.3617   -5.7832   -1.0337 H   0  0  0  0  0  0
    5.3249   -4.1928   -0.3254 H   0  0  0  0  0  0
    3.1554   -4.6644   -1.4306 H   0  0  0  0  0  0
    3.9579   -3.3086   -2.1797 H   0  0  0  0  0  0
    3.7513   -6.1814   -3.2588 H   0  0  0  0  0  0
    5.3091   -5.5819   -5.0485 H   0  0  0  0  0  0
    5.3582   -3.9085   -4.5610 H   0  0  0  0  0  0
    7.4242   -4.9961   -3.8623 H   0  0  0  0  0  0
    6.5633   -6.2573   -2.9985 H   0  0  0  0  0  0
    2.9965   -3.5428   -4.3740 H   0  0  0  0  0  0
    1.9576   -4.6389   -3.7295 H   0  0  0  0  0  0
    2.7720   -4.9927   -5.1120 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 34  1  0  0  0
  1 35  1  0  0  0
  1 36  1  0  0  0
  2  3  1  0  0  0
  2  5  1  0  0  0
  2  6  1  0  0  0
  3  4  1  0  0  0
  3 37  1  0  0  0
  3 38  1  0  0  0
  4  5  1  0  0  0
  5 39  1  0  0  0
  5 40  1  0  0  0
  6  7  1  0  0  0
  6 41  1  0  0  0
  6 42  1  0  0  0
  7  8  1  0  0  0
  8  9  1  0  0  0
  8 13  2  0  0  0
  9 10  2  0  0  0
  9 43  1  0  0  0
 10 11  1  0  0  0
 10 44  1  0  0  0
 11 12  2  0  0  0
 11 16  1  0  0  0
 12 13  1  0  0  0
 12 14  1  0  0  0
 13 45  1  0  0  0
 14 15  2  0  0  0
 15 16  1  0  0  0
 15 46  1  0  0  0
 16 17  1  0  0  0
 17 18  1  0  0  0
 17 26  2  0  0  0
 18 19  2  0  0  0
 18 47  1  0  0  0
 19 20  1  0  0  0
 19 48  1  0  0  0
 20 21  1  0  0  0
 20 25  2  0  0  0
 21 22  2  0  0  0
 21 49  1  0  0  0
 22 23  1  0  0  0
 22 50  1  0  0  0
 23 24  2  0  0  0
 23 51  1  0  0  0
 24 25  1  0  0  0
 24 27  1  0  0  0
 25 26  1  0  0  0
 27 28  1  0  0  0
 27 32  1  0  0  0
 28 29  1  0  0  0
 28 52  1  0  0  0
 28 53  1  0  0  0
 29 30  1  0  0  0
 29 54  1  0  0  0
 29 55  1  0  0  0
 30 31  1  0  0  0
 30 33  1  0  0  0
 30 56  1  0  0  0
 31 32  1  0  0  0
 31 57  1  0  0  0
 31 58  1  0  0  0
 32 59  1  0  0  0
 32 60  1  0  0  0
 33 61  1  0  0  0
 33 62  1  0  0  0
 33 63  1  0  0  0
M  CHG  1  33   1
M  END
> <s_m_entry_id>
483

> <Applicants>
Arog Pharmaceuticals

> <CHEMBL_ID>
CHEMBL2105728

> <Canonical_Smiles>
O1CC(C1)(COc1cc2ncn(c2cc1)-c1nc2c(cc1)cccc2N1CCC(N)CC1)C

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
3

> <SC_Patent>
None

> <Synonyms>
ARO 002 | ARO-002 | CP 868596 | CP-868,596 | CP-868596 | CRENOLANIB

> <Indications>
nan

> <Type>
1

> <targets_id>
P36888|P16234|P09619

> <inchi>
InChI=1S/C26H29N5O2/c1-26(14-32-15-26)16-33-20-6-7-22-21(13-20)28-17-31(22)24-8-5-18-3-2-4-23(25(18)29-24)30-11-9-19(27)10-12-30/h2-8,13,17,19H,9-12,14-16,27H2,1H3

> <stdInchikey>
DYNHJHQFHQTFTP-UHFFFAOYSA-N

> <csid>
8541584

> <Links>
|http://www.chemspider.com/Chemical-Structure.8541584.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2105728|http://pubchem.ncbi.nlm.nih.gov/compound/10366136|http://www.drugbank.ca/drugs/DB11832| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=6T2|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/6T2|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7882|http://zinc15.docking.org/substances/ZINC000003820043|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=LQF7I567TQ|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=185149

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
443.2

> <HBA>
7

> <HBD>
1

> <NRB>
5

> <TPSA>
78.4

> <LogP>
3.9

> <RoF>
0

> <Targets>
FLT3; PDGFRA; PDGFRB

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_epik_Ionization_Penalty>
  0.0214

> <r_epik_State_Penalty>
  0.0131

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
483

> <lig_pdbID>
'6T2'

> <pdbID>
5lby 6bqp 6joi 6joj

> <Kinase families>
Tyr

$$$$
Abivertinib
                    3D
 Structure written by MMmdl.
 63 67  0  0  1  0            999 V2000
   -6.4066    3.1831   -2.5837 C   0  0  0  0  0  0
   -5.4617    4.3499   -2.2363 N   0  3  0  0  0  0
   -4.1246    4.2081   -2.9940 C   0  0  0  0  0  0
   -3.1652    5.3254   -2.5308 C   0  0  0  0  0  0
   -2.8989    5.2541   -1.0831 N   0  0  0  0  0  0
   -4.1783    5.5162   -0.3999 C   0  0  0  0  0  0
   -5.2576    4.4492   -0.7094 C   0  0  0  0  0  0
   -1.9105    4.4077   -0.5695 C   0  0  0  0  0  0
   -2.1798    3.5257    0.4907 C   0  0  0  0  0  0
   -1.1966    2.6776    0.9972 C   0  0  0  0  0  0
    0.0919    2.6847    0.4647 C   0  0  0  0  0  0
    0.3872    3.5858   -0.5634 C   0  0  0  0  0  0
   -0.5942    4.4385   -1.0704 C   0  0  0  0  0  0
   -0.2298    5.3208   -2.0308 F   0  0  0  0  0  0
    1.0353    1.8023    1.0193 N   0  0  0  0  0  0
    2.1964    1.2038    0.5083 C   0  0  0  0  0  0
    2.5940    1.4836   -0.7662 N   0  0  0  0  0  0
    3.7022    0.8407   -1.1481 C   0  0  0  0  0  0
    4.4447   -0.0693   -0.3504 C   0  0  0  0  0  0
    5.5494   -0.5252   -1.1419 C   0  0  0  0  0  0
    5.4417    0.1098   -2.3668 C   0  0  0  0  0  0
    4.3354    0.9277   -2.3683 N   0  0  0  0  0  0
    3.9370   -0.2794    0.9392 C   0  0  0  0  0  0
    2.8076    0.3515    1.3706 N   0  0  0  0  0  0
    4.6211   -1.1623    1.7554 O   0  0  0  0  0  0
    4.2720   -1.3620    3.0733 C   0  0  0  0  0  0
    3.9601   -2.6531    3.5016 C   0  0  0  0  0  0
    3.6378   -2.8922    4.8369 C   0  0  0  0  0  0
    3.6273   -1.8405    5.7529 C   0  0  0  0  0  0
    3.9330   -0.5408    5.3394 C   0  0  0  0  0  0
    4.2765   -0.3104    3.9977 C   0  0  0  0  0  0
    3.9221    0.4641    6.3214 N   0  0  0  0  0  0
    3.6495    1.7802    6.1581 C   0  0  0  0  0  0
    3.3290    2.2962    5.0869 O   0  0  0  0  0  0
    3.7822    2.5917    7.3477 C   0  0  0  0  0  0
    3.5551    2.1540    8.6025 C   0  0  0  0  0  0
   -5.9348    2.2547   -2.2573 H   0  0  0  0  0  0
   -6.5550    3.2005   -3.6643 H   0  0  0  0  0  0
   -7.3465    3.3629   -2.0601 H   0  0  0  0  0  0
   -3.7252    3.2125   -2.7896 H   0  0  0  0  0  0
   -4.3607    4.2907   -4.0558 H   0  0  0  0  0  0
   -2.2464    5.2730   -3.1110 H   0  0  0  0  0  0
   -3.5947    6.2989   -2.7751 H   0  0  0  0  0  0
   -4.0142    5.5973    0.6754 H   0  0  0  0  0  0
   -4.5499    6.4977   -0.7005 H   0  0  0  0  0  0
   -6.2252    4.7150   -0.2817 H   0  0  0  0  0  0
   -4.9771    3.4558   -0.3569 H   0  0  0  0  0  0
   -3.1582    3.4753    0.9421 H   0  0  0  0  0  0
   -1.4480    2.0075    1.8072 H   0  0  0  0  0  0
    1.3849    3.6622   -0.9667 H   0  0  0  0  0  0
    0.7450    1.3922    1.8945 H   0  0  0  0  0  0
    6.3244   -1.2236   -0.8623 H   0  0  0  0  0  0
    6.0642    0.0501   -3.2476 H   0  0  0  0  0  0
    4.0665    1.4881   -3.1637 H   0  0  0  0  0  0
    3.9694   -3.4721    2.7974 H   0  0  0  0  0  0
    3.3977   -3.8936    5.1623 H   0  0  0  0  0  0
    3.3755   -2.0429    6.7843 H   0  0  0  0  0  0
    4.5575    0.6750    3.6575 H   0  0  0  0  0  0
    4.0088    0.1340    7.2712 H   0  0  0  0  0  0
    4.0738    3.6180    7.1757 H   0  0  0  0  0  0
    3.2517    1.1395    8.8199 H   0  0  0  0  0  0
    3.6718    2.8233    9.4420 H   0  0  0  0  0  0
   -5.8955    5.2095   -2.5433 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 37  1  0  0  0
  1 38  1  0  0  0
  1 39  1  0  0  0
  2  3  1  0  0  0
  2  7  1  0  0  0
  2 63  1  0  0  0
  3  4  1  0  0  0
  3 40  1  0  0  0
  3 41  1  0  0  0
  4  5  1  0  0  0
  4 42  1  0  0  0
  4 43  1  0  0  0
  5  6  1  0  0  0
  5  8  1  0  0  0
  6  7  1  0  0  0
  6 44  1  0  0  0
  6 45  1  0  0  0
  7 46  1  0  0  0
  7 47  1  0  0  0
  8  9  1  0  0  0
  8 13  2  0  0  0
  9 10  2  0  0  0
  9 48  1  0  0  0
 10 11  1  0  0  0
 10 49  1  0  0  0
 11 12  2  0  0  0
 11 15  1  0  0  0
 12 13  1  0  0  0
 12 50  1  0  0  0
 13 14  1  0  0  0
 15 16  1  0  0  0
 15 51  1  0  0  0
 16 17  1  0  0  0
 16 24  2  0  0  0
 17 18  2  0  0  0
 18 19  1  0  0  0
 18 22  1  0  0  0
 19 20  1  0  0  0
 19 23  2  0  0  0
 20 21  2  0  0  0
 20 52  1  0  0  0
 21 22  1  0  0  0
 21 53  1  0  0  0
 22 54  1  0  0  0
 23 24  1  0  0  0
 23 25  1  0  0  0
 25 26  1  0  0  0
 26 27  1  0  0  0
 26 31  2  0  0  0
 27 28  2  0  0  0
 27 55  1  0  0  0
 28 29  1  0  0  0
 28 56  1  0  0  0
 29 30  2  0  0  0
 29 57  1  0  0  0
 30 31  1  0  0  0
 30 32  1  0  0  0
 31 58  1  0  0  0
 32 33  1  0  0  0
 32 59  1  0  0  0
 33 34  2  0  0  0
 33 35  1  0  0  0
 35 36  2  0  0  0
 35 60  1  0  0  0
 36 61  1  0  0  0
 36 62  1  0  0  0
M  CHG  1   2   1
M  END
> <s_m_entry_id>
485

> <Applicants>
ACEA Biosciences

> <CHEMBL_ID>
CHEMBL4297865

> <Canonical_Smiles>
Fc1cc(Nc2nc(Oc3cc(NC(=O)C=C)ccc3)c3cc[nH]c3n2)ccc1N1CCN(CC1)C

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
3

> <SC_Patent>
None

> <Synonyms>
A610 | ABIVERTINIB | AC-0010 | AC0010 | ACEA100610 | AVITINIB | EX-ACEA0010

> <Indications>
AC0010 is an orally active, irreversible EGFR inhibitor that selectively targets mutated EGFRs, and was designed to overcome T790M-induced resistance in tumours [<a href='javascript:callRef("ReferenceDisplayForward?referenceId=35960&displayId=2", 960, 600)' title="2. Xu X, Mao L, Xu W, Tang W, Zhang X, Xi B, Xu R, Fang X, Liu J, Fang C et al.. (2016) Mol. Cancer Ther. 15 (11): 2586-2597">2</a>]. It may also inhibit BTK, thus offering extended clinical utility [<a href='javascript:callRef("ReferenceDisplayForward?referenceId=35961&displayId=3", 960, 600)' title="3. Yan X, Zhou Y, Huang S, Li X, Yu M, Huang J, Wang J, Ma Z, Jin J, Pan J et al.. (2018) J. Cancer Res. Clin. Oncol. 144 (4): 697-706">3</a>]. We show the structure for the free base form of the compound.

> <Type>
nan

> <targets_id>
nan

> <inchi>
InChI=1S/C26H26FN7O2/c1-3-23(35)29-17-5-4-6-19(15-17)36-25-20-9-10-28-24(20)31-26(32-25)30-18-7-8-22(21(27)16-18)34-13-11-33(2)12-14-34/h3-10,15-16H,1,11-14H2,2H3,(H,29,35)(H2,28,30,31,32)

> <stdInchikey>
UOFYSRZSLXWIQB-UHFFFAOYSA-N

> <csid>
57490375

> <Links>
|http://www.chemspider.com/Chemical-Structure.57490375.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4297865|http://pubchem.ncbi.nlm.nih.gov/compound/72734520|http://www.drugbank.ca/drugs/DB15327|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10044|http://zinc15.docking.org/substances/ZINC000142081723|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=CER0OPG92L|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=294480

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
487.2

> <HBA>
7

> <HBD>
3

> <NRB>
7

> <TPSA>
98.4

> <LogP>
4.5

> <RoF>
0

> <Targets>
nan

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0727

> <r_epik_State_Penalty>
  0.0564

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
485

> <indicationDB>
Abivertinib is a tyrosine kinase inhibitor targeted against mutant forms of both human epidermal growth factor receptor (EGFR) and Bruton&#39;s tyrosine kinase (BTK).<sup class="text-reference-group"><a class="reference-popover-link" data-content="Sorrento Therapeutics: Abivertinib" href="#reference-L17383">1</a></sup> It has been investigated for use in the treatment of non-small cell lung cancer (NSCLC) and B-cell malignancies. In binding to and inhibiting EGFR and BTK receptors, abivertinib exerts immunomodulatory effects by preventing the production and release of pro-inflammatory cytokines (e.g. TNF-alpha, interleukins).<sup class="text-reference-group"><a class="reference-popover-link" data-content="Sorrento Therapeutics: Abivertinib COVID-19 Trial" href="#reference-L17388">2</a></sup></p><p>Abivertinib&#39;s potential to depress cytokine production has led to its investigation in the treatment of hospitalized patients with moderate-to-severe COVID-19.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Sorrento Therapeutics: Abivertinib COVID-19 Trial" href="#reference-L17388">2</a>,<a class="reference-popover-link" data-content="NCT04440007: Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate) With SOC Versus SOC in Subjects With COVID-19 (SOC)" href="#reference-L17393">3</a></sup> The cytokine storm associated with COVID-19 is thought to contribute to disease progression and is associated with poor outcomes in patients - as abivertinib inhibits the release of multiple cytokines at once, it may provide more pronounced clinical benefits as compared to agents targeting single pathways (e.g. interleukin-6 inhibitors). The study is expected to be completed in March 2021.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Targeted Oncology: FDA Clears Phase 2 Study of Abivertinib in Hospitalized Patients With COVID-19" href="#reference-L17398">4</a></sup>

> <uniprotId>
P00533|Q06187

$$$$
Peficitinib
                    3D
 Structure written by MMmdl.
 46 50  0  0  1  0            999 V2000
   -0.7281    2.7353    0.3707 C   0  0  0  0  0  0
   -1.9520    3.3138    0.1020 C   0  0  0  0  0  0
   -2.8208    2.3505   -0.3382 N   0  0  0  0  0  0
   -2.1791    1.1332   -0.3613 C   0  0  0  0  0  0
   -0.8340    1.3266    0.0736 C   0  0  0  0  0  0
    0.0094    0.1819    0.1162 C   0  0  0  0  0  0
   -0.5669   -1.0631   -0.2494 C   0  0  0  0  0  0
   -1.9088   -1.0896   -0.6569 C   0  0  0  0  0  0
   -2.7333   -0.0188   -0.7271 N   0  0  0  0  0  0
    0.2120   -2.3633   -0.2396 C   0  0  0  0  0  0
    1.3658   -2.4330   -0.6592 O   0  0  0  0  0  0
   -0.4204   -3.4306    0.2599 N   0  0  0  0  0  0
    1.3577    0.2355    0.5360 N   0  0  0  0  0  0
    2.2327    1.3864    0.3029 C   0  0  2  0  0  0
    2.3360    1.7675   -1.2099 C   0  0  2  0  0  0
    3.0176    0.6324   -2.0253 C   0  0  0  0  0  0
    4.4389    0.3624   -1.4656 C   0  0  2  0  0  0
    4.3396   -0.0536    0.0254 C   0  0  0  0  0  0
    3.6606    1.0814    0.8464 C   0  0  1  0  0  0
    4.5179    2.3706    0.7226 C   0  0  0  0  0  0
    4.6224    2.8031   -0.7688 C   0  0  1  0  0  0
    5.2885    1.6562   -1.5804 C   0  0  0  0  0  0
    3.1931    3.0564   -1.3300 C   0  0  0  0  0  0
    5.3971    3.9810   -0.8735 O   0  0  0  0  0  0
    0.1188    3.2931    0.7355 H   0  0  0  0  0  0
   -2.2841    4.3379    0.1901 H   0  0  0  0  0  0
   -3.7780    2.5475   -0.5912 H   0  0  0  0  0  0
   -2.3720   -2.0176   -0.9617 H   0  0  0  0  0  0
   -1.3529   -3.3430    0.6362 H   0  0  0  0  0  0
    0.0459   -4.3255    0.2904 H   0  0  0  0  0  0
    1.8325   -0.6537    0.4660 H   0  0  0  0  0  0
    1.8351    2.2165    0.8801 H   0  0  0  0  0  0
    1.3470    1.9642   -1.6248 H   0  0  0  0  0  0
    2.4177   -0.2774   -1.9922 H   0  0  0  0  0  0
    3.0744    0.9085   -3.0794 H   0  0  0  0  0  0
    4.9108   -0.4375   -2.0377 H   0  0  0  0  0  0
    3.7820   -0.9864    0.1209 H   0  0  0  0  0  0
    5.3333   -0.2633    0.4244 H   0  0  0  0  0  0
    3.6054    0.7881    1.8962 H   0  0  0  0  0  0
    4.0769    3.1699    1.3211 H   0  0  0  0  0  0
    5.5115    2.1974    1.1399 H   0  0  0  0  0  0
    6.3014    1.4699   -1.2185 H   0  0  0  0  0  0
    5.3912    1.9398   -2.6292 H   0  0  0  0  0  0
    3.2435    3.3730   -2.3735 H   0  0  0  0  0  0
    2.7106    3.8746   -0.7921 H   0  0  0  0  0  0
    5.4607    4.2219   -1.8006 H   0  0  0  0  0  0
  1  2  2  0  0  0
  1  5  1  0  0  0
  1 25  1  0  0  0
  2  3  1  0  0  0
  2 26  1  0  0  0
  3  4  1  0  0  0
  3 27  1  0  0  0
  4  5  1  0  0  0
  4  9  2  0  0  0
  5  6  2  0  0  0
  6  7  1  0  0  0
  6 13  1  0  0  0
  7  8  2  0  0  0
  7 10  1  0  0  0
  8  9  1  0  0  0
  8 28  1  0  0  0
 10 11  2  0  0  0
 10 12  1  0  0  0
 12 29  1  0  0  0
 12 30  1  0  0  0
 13 14  1  0  0  0
 13 31  1  0  0  0
 14 15  1  0  0  0
 14 19  1  0  0  0
 14 32  1  0  0  0
 15 16  1  0  0  0
 15 23  1  0  0  0
 15 33  1  0  0  0
 16 17  1  0  0  0
 16 34  1  0  0  0
 16 35  1  0  0  0
 17 18  1  0  0  0
 17 22  1  0  0  0
 17 36  1  0  0  0
 18 19  1  0  0  0
 18 37  1  0  0  0
 18 38  1  0  0  0
 19 20  1  0  0  0
 19 39  1  0  0  0
 20 21  1  0  0  0
 20 40  1  0  0  0
 20 41  1  0  0  0
 21 22  1  0  0  0
 21 23  1  0  0  0
 21 24  1  0  0  0
 22 42  1  0  0  0
 22 43  1  0  0  0
 23 44  1  0  0  0
 23 45  1  0  0  0
 24 46  1  0  0  0
M  END
> <s_m_entry_id>
487

> <Applicants>
Astellas Pharma

> <CHEMBL_ID>
CHEMBL3137308

> <Canonical_Smiles>
OC12CC3C[C@H](C1)C(Nc1c4cc[nH]c4ncc1C(=O)N)[C@H](C2)C3

> <Chirality>
Racemic Mixture

> <First_Approval>
nan

> <Phase>
3

> <SC_Patent>
None

> <Synonyms>
|ASP-015K|JNJ-54781532|ASP015K

> <Indications>
nan

> <Type>
nan

> <targets_id>
P23458|O60674|P52333|P29597

> <inchi>
InChI=1S/C18H22N4O2/c19-16(23)13-8-21-17-12(1-2-20-17)15(13)22-14-10-3-9-4-11(14)7-18(24,5-9)6-10/h1-2,8-11,14,24H,3-7H2,(H2,19,23)(H2,20,21,22)/t9-,10-,11+,14-,18-

> <stdInchikey>
DREIJXJRTLTGJC-ZKVNVPQCSA-N

> <csid>
32742439

> <Links>
|http://www.chemspider.com/Chemical-Structure.32742439.html| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=9T6|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/9T6|http://zinc15.docking.org/substances/ZINC000146784326

> <LinkName>
|ChemSpider|RCSB|PDBe|ZINC

> <MW>
326.2

> <HBA>
4

> <HBD>
4

> <NRB>
3

> <TPSA>
104

> <LogP>
2

> <RoF>
0

> <Targets>
JAK1; JAK2; JAK3; TYK2

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_epik_Ionization_Penalty>
  0.0130

> <r_epik_State_Penalty>
  0.0101

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
487

> <lig_pdbID>
'9T6'

> <pdbID>
6aah 6aaj 6aak 6aam

> <Kinase families>
Tyr

$$$$
Linsitinib
                    3D
 Structure written by MMmdl.
 55 60  0  0  1  0            999 V2000
   -1.7155   -3.0785    0.3380 C   0  0  0  0  0  0
   -1.5513   -1.6006   -0.0634 C   0  0  1  0  0  0
   -0.7032   -0.7840    0.9275 C   0  0  0  0  0  0
    0.0239   -0.1589   -0.2816 C   0  0  2  0  0  0
   -0.4461   -1.3684   -1.1086 C   0  0  0  0  0  0
    1.5295    0.0510   -0.1822 C   0  0  0  0  0  0
    2.2378    0.8522   -1.0504 N   0  0  0  0  0  0
    3.5830    0.7799   -0.6370 C   0  0  0  0  0  0
    4.5049    1.5630   -1.3703 C   0  0  0  0  0  0
    4.1298    2.3221   -2.4315 N   0  0  0  0  0  0
    2.8273    2.3395   -2.7984 C   0  0  0  0  0  0
    1.8505    1.6163   -2.1240 C   0  0  0  0  0  0
    5.8530    1.6098   -1.0263 N   0  0  0  0  0  0
    3.5597   -0.1212    0.4686 C   0  0  0  0  0  0
    2.3242   -0.5189    0.7010 N   0  0  0  0  0  0
    4.6930   -0.6214    1.2998 C   0  0  0  0  0  0
    5.8615   -1.0788    0.6861 C   0  0  0  0  0  0
    6.9535   -1.5325    1.4632 C   0  0  0  0  0  0
    8.0772   -1.9674    0.8289 N   0  0  0  0  0  0
    9.1353   -2.4005    1.5684 C   0  0  0  0  0  0
    9.0989   -2.4218    2.9671 C   0  0  0  0  0  0
    7.9583   -1.9818    3.6345 C   0  0  0  0  0  0
    6.8493   -1.5213    2.8855 C   0  0  0  0  0  0
    5.6560   -1.0570    3.4875 C   0  0  0  0  0  0
    4.6005   -0.6138    2.6940 C   0  0  0  0  0  0
   10.3315   -2.8651    0.8006 C   0  0  0  0  0  0
   11.6235   -2.6737    1.3121 C   0  0  0  0  0  0
   12.7428   -3.1030    0.6038 C   0  0  0  0  0  0
   12.5807   -3.7307   -0.6275 C   0  0  0  0  0  0
   11.3088   -3.9307   -1.1550 C   0  0  0  0  0  0
   10.1921   -3.4996   -0.4440 C   0  0  0  0  0  0
   -2.8241   -1.0655   -0.3776 O   0  0  0  0  0  0
   -0.7609   -3.5391    0.5962 H   0  0  0  0  0  0
   -2.1487   -3.6621   -0.4755 H   0  0  0  0  0  0
   -2.3712   -3.1816    1.2037 H   0  0  0  0  0  0
   -1.2545   -0.0814    1.5539 H   0  0  0  0  0  0
   -0.0659   -1.3907    1.5743 H   0  0  0  0  0  0
   -0.4564    0.7723   -0.5900 H   0  0  0  0  0  0
    0.2914   -2.1721   -1.1699 H   0  0  0  0  0  0
   -0.7897   -1.1392   -2.1182 H   0  0  0  0  0  0
    2.5717    2.9545   -3.6488 H   0  0  0  0  0  0
    0.8058    1.6223   -2.3964 H   0  0  0  0  0  0
    6.1859    1.0746   -0.2374 H   0  0  0  0  0  0
    6.4789    2.1874   -1.5682 H   0  0  0  0  0  0
    5.9422   -1.0976   -0.3918 H   0  0  0  0  0  0
    9.9415   -2.7818    3.5391 H   0  0  0  0  0  0
    7.9137   -1.9912    4.7141 H   0  0  0  0  0  0
    5.5700   -1.0454    4.5646 H   0  0  0  0  0  0
    3.6997   -0.2572    3.1727 H   0  0  0  0  0  0
   11.7705   -2.1799    2.2614 H   0  0  0  0  0  0
   13.7325   -2.9475    1.0071 H   0  0  0  0  0  0
   13.4483   -4.0635   -1.1779 H   0  0  0  0  0  0
   11.1879   -4.4187   -2.1109 H   0  0  0  0  0  0
    9.2119   -3.6672   -0.8665 H   0  0  0  0  0  0
   -2.7149   -0.1415   -0.6135 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 33  1  0  0  0
  1 34  1  0  0  0
  1 35  1  0  0  0
  2  3  1  0  0  0
  2  5  1  0  0  0
  2 32  1  0  0  0
  3  4  1  0  0  0
  3 36  1  0  0  0
  3 37  1  0  0  0
  4  5  1  0  0  0
  4  6  1  0  0  0
  4 38  1  0  0  0
  5 39  1  0  0  0
  5 40  1  0  0  0
  6  7  1  0  0  0
  6 15  2  0  0  0
  7  8  1  0  0  0
  7 12  1  0  0  0
  8  9  1  0  0  0
  8 14  2  0  0  0
  9 10  2  0  0  0
  9 13  1  0  0  0
 10 11  1  0  0  0
 11 12  2  0  0  0
 11 41  1  0  0  0
 12 42  1  0  0  0
 13 43  1  0  0  0
 13 44  1  0  0  0
 14 15  1  0  0  0
 14 16  1  0  0  0
 16 17  1  0  0  0
 16 25  2  0  0  0
 17 18  2  0  0  0
 17 45  1  0  0  0
 18 19  1  0  0  0
 18 23  1  0  0  0
 19 20  2  0  0  0
 20 21  1  0  0  0
 20 26  1  0  0  0
 21 22  2  0  0  0
 21 46  1  0  0  0
 22 23  1  0  0  0
 22 47  1  0  0  0
 23 24  2  0  0  0
 24 25  1  0  0  0
 24 48  1  0  0  0
 25 49  1  0  0  0
 26 27  1  0  0  0
 26 31  2  0  0  0
 27 28  2  0  0  0
 27 50  1  0  0  0
 28 29  1  0  0  0
 28 51  1  0  0  0
 29 30  2  0  0  0
 29 52  1  0  0  0
 30 31  1  0  0  0
 30 53  1  0  0  0
 31 54  1  0  0  0
 32 55  1  0  0  0
M  END
> <s_m_entry_id>
489

> <Applicants>
Osi Pharmaceuticals

> <CHEMBL_ID>
CHEMBL1091644

> <Canonical_Smiles>
OC1(CC(C1)c1nc(c2n1C=CN=C2N)-c1cc2nc(ccc2cc1)-c1ccccc1)C

> <Chirality>
Single Stereoisomer

> <First_Approval>
nan

> <Phase>
3

> <SC_Patent>
None

> <Synonyms>
ASP-7487 | LINSITINIB | OSI-906 | OSI-906AA

> <Indications>
nan

> <Type>
nan

> <targets_id>
P08069

> <inchi>
InChI=1S/C26H23N5O/c1-26(32)14-19(15-26)25-30-22(23-24(27)28-11-12-31(23)25)18-8-7-17-9-10-20(29-21(17)13-18)16-5-3-2-4-6-16/h2-13,19,32H,14-15H2,1H3,(H2,27,28)/t19-,26+

> <stdInchikey>
PKCDDUHJAFVJJB-VLZXCDOPSA-N

> <csid>
21391708

> <Links>
|http://www.chemspider.com/Chemical-Structure.21391708.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1091644|http://www.drugbank.ca/drugs/DB06075|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7423|http://zinc15.docking.org/substances/ZINC000100071817|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=15A52GPT8T|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50315887

> <LinkName>
|ChemSpider|ChEMBL|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
421.2

> <HBA>
6

> <HBD>
2

> <NRB>
3

> <TPSA>
89.3

> <LogP>
4.8

> <RoF>
0

> <Targets>
IGF1R

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_epik_Ionization_Penalty>
  0.0248

> <r_epik_State_Penalty>
  0.0172

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
489

> <Kinase families>
Tyr

> <indicationDB>
An orally bioavailable small molecule inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic activity. IGF-1R inhibitor OSI-906 selectively inhibits IGF-1R, which may result in the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis.

> <uniprotId>
P08069

> <Withdrawn>
|Study NCT01465815 in United States was Withdrawn during Phase 1/Phase 2 because Drug manufacturer, Astellas Pharma, informed us that safety and efficacy of Erlotinib and
    OSI-906 in other oncology studies was determined to be unfavorable

$$$$
Cediranib
                    3D
 Structure written by MMmdl.
 61 65  0  0  1  0            999 V2000
  -12.0605    1.5697   -2.1028 C   0  0  0  0  0  0
  -10.5638    1.4239   -2.2349 C   0  0  0  0  0  0
   -9.5462    1.5400   -1.3060 C   0  0  0  0  0  0
   -8.3024    1.2981   -1.9762 C   0  0  0  0  0  0
   -8.6191    1.0347   -3.3402 C   0  0  0  0  0  0
   -9.9914    1.1221   -3.4479 N   0  0  0  0  0  0
   -7.6368    0.7541   -4.2953 C   0  0  0  0  0  0
   -6.3129    0.7393   -3.8562 C   0  0  0  0  0  0
   -5.9711    0.9887   -2.5264 C   0  0  0  0  0  0
   -6.9560    1.2739   -1.5774 C   0  0  0  0  0  0
   -6.6177    1.5205   -0.2902 F   0  0  0  0  0  0
   -4.6469    0.9615   -2.1486 O   0  0  0  0  0  0
   -4.0025   -0.2228   -1.8257 C   0  0  0  0  0  0
   -2.6293   -0.1789   -1.4623 C   0  0  0  0  0  0
   -1.8525    1.0018   -1.4033 C   0  0  0  0  0  0
   -0.4989    0.9510   -1.0344 C   0  0  0  0  0  0
    0.0951   -0.2789   -0.7199 C   0  0  0  0  0  0
   -0.6628   -1.4595   -0.7732 C   0  0  0  0  0  0
   -2.0255   -1.4290   -1.1418 C   0  0  0  0  0  0
   -2.7291   -2.5970   -1.1818 N   0  0  0  0  0  0
   -4.0333   -2.5101   -1.5415 C   0  0  0  0  0  0
   -4.7116   -1.3859   -1.8674 N   0  0  0  0  0  0
    1.4325   -0.2492   -0.3641 O   0  0  0  0  0  0
    2.1198   -1.4643   -0.0754 C   0  0  0  0  0  0
    3.5830   -1.1480    0.2688 C   0  0  0  0  0  0
    4.3433   -0.4853   -0.8940 C   0  0  0  0  0  0
    5.7770   -0.1171   -0.4608 N   0  3  0  0  0  0
    6.6991   -1.3122   -0.1410 C   0  0  0  0  0  0
    8.1201   -0.8215   -0.4576 C   0  0  0  0  0  0
    7.9836    0.6004   -1.0007 C   0  0  0  0  0  0
    6.5532    0.6801   -1.5192 C   0  0  0  0  0  0
    0.3117    2.0711   -0.9609 O   0  0  0  0  0  0
   -0.2292    3.3524   -1.2664 C   0  0  0  0  0  0
  -12.3556    1.8015   -1.0792 H   0  0  0  0  0  0
  -12.5810    0.6545   -2.3854 H   0  0  0  0  0  0
  -12.4453    2.3699   -2.7353 H   0  0  0  0  0  0
   -9.6908    1.7726   -0.2611 H   0  0  0  0  0  0
  -10.5453    0.9899   -4.2818 H   0  0  0  0  0  0
   -7.8821    0.5557   -5.3283 H   0  0  0  0  0  0
   -5.5291    0.5238   -4.5677 H   0  0  0  0  0  0
   -2.3319    1.9372   -1.6499 H   0  0  0  0  0  0
   -0.2272   -2.4182   -0.5338 H   0  0  0  0  0  0
   -4.5895   -3.4356   -1.5717 H   0  0  0  0  0  0
    1.6494   -1.9673    0.7714 H   0  0  0  0  0  0
    2.0775   -2.1416   -0.9306 H   0  0  0  0  0  0
    3.6161   -0.5010    1.1466 H   0  0  0  0  0  0
    4.0819   -2.0746    0.5540 H   0  0  0  0  0  0
    4.4339   -1.1299   -1.7699 H   0  0  0  0  0  0
    3.8870    0.4626   -1.1839 H   0  0  0  0  0  0
    6.5387   -1.5674    0.9072 H   0  0  0  0  0  0
    6.4024   -2.1370   -0.7914 H   0  0  0  0  0  0
    8.7655   -0.8521    0.4211 H   0  0  0  0  0  0
    8.5698   -1.4724   -1.2089 H   0  0  0  0  0  0
    8.1285    1.3316   -0.2037 H   0  0  0  0  0  0
    8.7169    0.8130   -1.7798 H   0  0  0  0  0  0
    6.4261    0.1596   -2.4706 H   0  0  0  0  0  0
    6.1433    1.6897   -1.5661 H   0  0  0  0  0  0
    0.5494    4.1068   -1.1542 H   0  0  0  0  0  0
   -1.0427    3.6158   -0.5886 H   0  0  0  0  0  0
   -0.5879    3.4006   -2.2957 H   0  0  0  0  0  0
    5.7263    0.4626    0.3654 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 34  1  0  0  0
  1 35  1  0  0  0
  1 36  1  0  0  0
  2  3  2  0  0  0
  2  6  1  0  0  0
  3  4  1  0  0  0
  3 37  1  0  0  0
  4  5  1  0  0  0
  4 10  2  0  0  0
  5  6  1  0  0  0
  5  7  2  0  0  0
  6 38  1  0  0  0
  7  8  1  0  0  0
  7 39  1  0  0  0
  8  9  2  0  0  0
  8 40  1  0  0  0
  9 10  1  0  0  0
  9 12  1  0  0  0
 10 11  1  0  0  0
 12 13  1  0  0  0
 13 14  1  0  0  0
 13 22  2  0  0  0
 14 15  1  0  0  0
 14 19  2  0  0  0
 15 16  2  0  0  0
 15 41  1  0  0  0
 16 17  1  0  0  0
 16 32  1  0  0  0
 17 18  2  0  0  0
 17 23  1  0  0  0
 18 19  1  0  0  0
 18 42  1  0  0  0
 19 20  1  0  0  0
 20 21  2  0  0  0
 21 22  1  0  0  0
 21 43  1  0  0  0
 23 24  1  0  0  0
 24 25  1  0  0  0
 24 44  1  0  0  0
 24 45  1  0  0  0
 25 26  1  0  0  0
 25 46  1  0  0  0
 25 47  1  0  0  0
 26 27  1  0  0  0
 26 48  1  0  0  0
 26 49  1  0  0  0
 27 28  1  0  0  0
 27 31  1  0  0  0
 27 61  1  0  0  0
 28 29  1  0  0  0
 28 50  1  0  0  0
 28 51  1  0  0  0
 29 30  1  0  0  0
 29 52  1  0  0  0
 29 53  1  0  0  0
 30 31  1  0  0  0
 30 54  1  0  0  0
 30 55  1  0  0  0
 31 56  1  0  0  0
 31 57  1  0  0  0
 32 33  1  0  0  0
 33 58  1  0  0  0
 33 59  1  0  0  0
 33 60  1  0  0  0
M  CHG  1  27   1
M  END
> <s_m_entry_id>
493

> <Applicants>
Astrazeneca

> <CHEMBL_ID>
CHEMBL491473

> <Canonical_Smiles>
Fc1c2cc([nH]c2ccc1Oc1ncnc2c1cc(OC)c(OCCCN1CCCC1)c2)C

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
3

> <SC_Patent>
None

> <Synonyms>
AZD-2171 | AZD2171 | CEDIRANIB | RECENTIN | ZD-2171

> <Indications>
For the treatment of liver cancer, advanced non-small cell lung cancer (NSCLC), advanced colorectal cancer (CRC) and other solid tumors.

> <Type>
nan

> <targets_id>
P35968

> <inchi>
InChI=1S/C25H27FN4O3/c1-16-12-17-19(29-16)6-7-21(24(17)26)33-25-18-13-22(31-2)23(14-20(18)27-15-28-25)32-11-5-10-30-8-3-4-9-30/h6-7,12-15,29H,3-5,8-11H2,1-2H3

> <stdInchikey>
XXJWYDDUDKYVKI-UHFFFAOYSA-N

> <csid>
8109103

> <Links>
|http://www.chemspider.com/Chemical-Structure.8109103.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL491473|http://pubchem.ncbi.nlm.nih.gov/compound/9933475|http://www.drugbank.ca/drugs/DB04849|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5664|http://zinc15.docking.org/substances/ZINC000003948085|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=NQU9IPY4K9|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50331096

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
450.2

> <HBA>
6

> <HBD>
1

> <NRB>
8

> <TPSA>
72.5

> <LogP>
5.2

> <RoF>
1

> <Targets>
KDR

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0011

> <r_epik_State_Penalty>
  0.0007

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
493

> <Kinase families>
Tyr

> <indicationDB>
The novel indole-ether quinazoline Cediranib is a highly potent (IC<sub>50</sub> &lt; 1 nmol/L) ATP-competitive inhibitor of recombinant KDR tyrosine kinase in vitro. It is being developed clinically as a once-daily oral therapy for the treatment of cancer.

> <uniprotId>
P35968

> <BrandName>
Recentin

> <Withdrawn>
|Study NCT04184518 in Spain was Withdrawn during Phase 2 because The Cediranib producer laboratory decided to stop the development of this product

$$$$
Trilaciclib
                    3D
 Structure written by MMmdl.
 64 69  0  0  1  0            999 V2000
   -1.7250   -0.0867    2.7616 C   0  0  0  0  0  0
   -1.2882    0.7821    1.5662 N   0  3  0  0  0  0
   -0.7793   -0.1084    0.4060 C   0  0  0  0  0  0
   -0.1751    0.7890   -0.6980 C   0  0  0  0  0  0
    0.9209    1.5952   -0.1378 N   0  0  0  0  0  0
    0.3058    2.5719    0.7745 C   0  0  0  0  0  0
   -0.2569    1.8455    2.0177 C   0  0  0  0  0  0
    2.2474    1.1585   -0.0450 C   0  0  0  0  0  0
    3.1961    1.8164    0.7585 C   0  0  0  0  0  0
    4.5135    1.3601    0.8280 C   0  0  0  0  0  0
    4.8839    0.2387    0.0851 C   0  0  0  0  0  0
    3.9891   -0.4145   -0.7013 N   0  0  0  0  0  0
    2.7138    0.0415   -0.7588 C   0  0  0  0  0  0
    6.2184   -0.1980    0.1688 N   0  0  0  0  0  0
    6.9159   -1.2603   -0.4282 C   0  0  0  0  0  0
    8.2338   -1.3269   -0.1098 N   0  0  0  0  0  0
    8.9642   -2.3251   -0.6682 C   0  0  0  0  0  0
    8.3786   -3.2569   -1.5380 C   0  0  0  0  0  0
    8.8106   -4.3697   -2.3102 C   0  0  0  0  0  0
    7.7112   -4.8576   -3.0004 C   0  0  0  0  0  0
    6.5775   -4.1180   -2.6406 N   0  0  0  0  0  0
    6.9907   -3.0999   -1.7795 C   0  0  0  0  0  0
    6.2514   -2.1157   -1.2526 N   0  0  0  0  0  0
    5.2175   -4.3755   -3.1985 C   0  0  0  0  0  0
    4.0670   -4.1473   -2.1621 C   0  0  0  0  0  0
    2.6556   -4.3058   -2.7666 C   0  0  0  0  0  0
    2.4571   -3.3719   -3.9747 C   0  0  0  0  0  0
    3.5651   -3.5516   -5.0295 C   0  0  0  0  0  0
    4.9777   -3.4318   -4.4160 C   0  0  0  0  0  0
    5.2347   -5.8938   -3.5865 C   0  0  0  0  0  0
    6.4210   -6.2280   -4.3820 N   0  0  0  0  0  0
    7.6787   -5.9043   -4.0087 C   0  0  0  0  0  0
    8.6376   -6.4404   -4.5599 O   0  0  0  0  0  0
   -0.8474   -0.6184    3.1335 H   0  0  0  0  0  0
   -2.4882   -0.7757    2.3974 H   0  0  0  0  0  0
   -2.1367    0.5865    3.5150 H   0  0  0  0  0  0
   -0.0412   -0.8008    0.8162 H   0  0  0  0  0  0
   -1.6407   -0.6734    0.0473 H   0  0  0  0  0  0
    0.1492    0.2013   -1.5550 H   0  0  0  0  0  0
   -0.9529    1.4411   -1.1004 H   0  0  0  0  0  0
    1.0035    3.3591    1.0550 H   0  0  0  0  0  0
   -0.5035    3.1006    0.2670 H   0  0  0  0  0  0
   -0.7858    2.5272    2.6850 H   0  0  0  0  0  0
    0.5279    1.3322    2.5771 H   0  0  0  0  0  0
    2.9396    2.6856    1.3429 H   0  0  0  0  0  0
    5.2300    1.8766    1.4506 H   0  0  0  0  0  0
    2.0753   -0.5345   -1.4097 H   0  0  0  0  0  0
    6.7978    0.3693    0.7690 H   0  0  0  0  0  0
   10.0157   -2.3612   -0.4246 H   0  0  0  0  0  0
    9.8154   -4.7582   -2.3921 H   0  0  0  0  0  0
    4.1837   -4.8153   -1.3074 H   0  0  0  0  0  0
    4.0955   -3.1412   -1.7533 H   0  0  0  0  0  0
    2.4867   -5.3407   -3.0658 H   0  0  0  0  0  0
    1.9027   -4.0889   -2.0077 H   0  0  0  0  0  0
    1.4794   -3.5455   -4.4258 H   0  0  0  0  0  0
    2.4540   -2.3363   -3.6306 H   0  0  0  0  0  0
    3.4539   -4.5224   -5.5135 H   0  0  0  0  0  0
    3.4431   -2.8107   -5.8206 H   0  0  0  0  0  0
    5.1290   -2.3969   -4.1028 H   0  0  0  0  0  0
    5.7242   -3.6119   -5.1911 H   0  0  0  0  0  0
    5.2265   -6.5290   -2.6978 H   0  0  0  0  0  0
    4.3548   -6.1745   -4.1644 H   0  0  0  0  0  0
    6.3162   -6.8959   -5.1321 H   0  0  0  0  0  0
   -2.1009    1.2781    1.2277 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 34  1  0  0  0
  1 35  1  0  0  0
  1 36  1  0  0  0
  2  3  1  0  0  0
  2  7  1  0  0  0
  2 64  1  0  0  0
  3  4  1  0  0  0
  3 37  1  0  0  0
  3 38  1  0  0  0
  4  5  1  0  0  0
  4 39  1  0  0  0
  4 40  1  0  0  0
  5  6  1  0  0  0
  5  8  1  0  0  0
  6  7  1  0  0  0
  6 41  1  0  0  0
  6 42  1  0  0  0
  7 43  1  0  0  0
  7 44  1  0  0  0
  8  9  1  0  0  0
  8 13  2  0  0  0
  9 10  2  0  0  0
  9 45  1  0  0  0
 10 11  1  0  0  0
 10 46  1  0  0  0
 11 12  2  0  0  0
 11 14  1  0  0  0
 12 13  1  0  0  0
 13 47  1  0  0  0
 14 15  1  0  0  0
 14 48  1  0  0  0
 15 16  1  0  0  0
 15 23  2  0  0  0
 16 17  2  0  0  0
 17 18  1  0  0  0
 17 49  1  0  0  0
 18 19  1  0  0  0
 18 22  2  0  0  0
 19 20  2  0  0  0
 19 50  1  0  0  0
 20 21  1  0  0  0
 20 32  1  0  0  0
 21 22  1  0  0  0
 21 24  1  0  0  0
 22 23  1  0  0  0
 24 25  1  0  0  0
 24 29  1  0  0  0
 24 30  1  0  0  0
 25 26  1  0  0  0
 25 51  1  0  0  0
 25 52  1  0  0  0
 26 27  1  0  0  0
 26 53  1  0  0  0
 26 54  1  0  0  0
 27 28  1  0  0  0
 27 55  1  0  0  0
 27 56  1  0  0  0
 28 29  1  0  0  0
 28 57  1  0  0  0
 28 58  1  0  0  0
 29 59  1  0  0  0
 29 60  1  0  0  0
 30 31  1  0  0  0
 30 61  1  0  0  0
 30 62  1  0  0  0
 31 32  1  0  0  0
 31 63  1  0  0  0
 32 33  2  0  0  0
M  CHG  1   2   1
M  END
> <s_m_entry_id>
494

> <Applicants>
G1 Therapeutics

> <CHEMBL_ID>
CHEMBL3894860

> <Canonical_Smiles>
O=C1NCC2(n3c1cc1c3nc(nc1)Nc1ncc(N3CCN(CC3)C)cc1)CCCCC2

> <Chirality>
Achiral Molecule

> <First_Approval>
2021

> <Phase>
4

> <SC_Patent>
None

> <Synonyms>
G1T28 | TRILACICLIB

> <Indications>
On February 2021, FDA approved trilaciclib to mitigate chemotherapy-induced myelosuppression in adult patients with small cell lung cancer

> <Type>
nan

> <targets_id>
P11802|Q00534

> <inchi>
InChI=1S/C24H30N8O/c1-30-9-11-31(12-10-30)18-5-6-20(25-15-18)28-23-26-14-17-13-19-22(33)27-16-24(7-3-2-4-8-24)32(19)21(17)29-23/h5-6,13-15H,2-4,7-12,16H2,1H3,(H,27,33)(H,25,26,28,29)

> <stdInchikey>
PDGKHKMBHVFCMG-UHFFFAOYSA-N

> <csid>
58825997

> <Links>
|http://www.chemspider.com/Chemical-Structure.58825997.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3894860|http://pubchem.ncbi.nlm.nih.gov/compound/68029831|http://www.drugbank.ca/drugs/DB15442|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9626|http://zinc15.docking.org/substances/ZINC000143683854|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=U6072DO9XG|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=253928

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
446.3

> <HBA>
8

> <HBD>
2

> <NRB>
3

> <TPSA>
91.2

> <LogP>
2.7

> <RoF>
0

> <Targets>
CDK4; CDK6

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.1224

> <r_epik_State_Penalty>
  0.1348

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
494

> <Kinase families>
CMGC

> <indicationDB>
Trilaciclib, or G1T28, is a CDK4 and CDK6 inhibitor, indicated to reduce the incidence of chemotherapy induced myelosuppression in patients before topotecan-containing or platinum and etoposide-containing chemotherapy for extensive stage small cell lung cancer.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA Approved Drug Products: Cosela (Trilaciclib) Intravenous Injection" href="#reference-L31828">5</a></sup> CDK4 and CDK6 inhibitors have been investigated since the mid 1990s for their use in tumorigenesis and chemotherapy.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Peters G: The D-type cyclins and their role in tumorigenesis. J Cell Sci Suppl. 1994;18:89-96. doi: 10.1242/jcs.1994.supplement_18.13. (PubMed ID 7883799)" href="#reference-A229323">3</a></sup> Trilaciclib was first described in the literature in 2016.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Bisi JE, Sorrentino JA, Roberts PJ, Tavares FX, Strum JC: Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression. Mol Cancer Ther. 2016 May;15(5):783-93. doi: 10.1158/1535-7163.MCT-15-0775. Epub 2016 Jan 29. (PubMed ID 26826116)" href="#reference-A229313">1</a></sup></p><p>Trilaciclib was granted FDA approval on 12 February 2021.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA News Release: FDA Approves Drug to Reduce Bone Marrow Suppression Caused by Chemotherapy" href="#reference-L31823">4</a></sup>

> <uniprotId>
P11802|Q00534|P50750|P24941|Q00535|P50613|P05177|O15244|Q96FL8|Q86VL8|Q9UNQ0|P08183

> <FDA_approved>
Y

$$$$
Dactolisib
                    3D
 Structure written by MMmdl.
 59 64  0  0  1  0            999 V2000
   -0.6599   -0.6245   -1.2908 C   0  0  0  0  0  0
    0.0165    0.1105   -0.1071 C   0  0  0  0  0  0
   -0.3890    1.5997   -0.1385 C   0  0  0  0  0  0
   -0.5172   -0.4985    1.1304 C   0  0  0  0  0  0
   -0.9360   -0.9748    2.0992 N   0  0  0  0  0  0
    1.5582    0.0048   -0.1199 C   0  0  0  0  0  0
    2.2689   -0.2179   -1.3097 C   0  0  0  0  0  0
    3.6596   -0.2736   -1.3069 C   0  0  0  0  0  0
    4.3540   -0.0992   -0.1093 C   0  0  0  0  0  0
    3.6654    0.1198    1.0844 C   0  0  0  0  0  0
    2.2755    0.1771    1.0735 C   0  0  0  0  0  0
    5.7525   -0.0850   -0.1130 N   0  0  0  0  0  0
    6.5402    1.0590   -0.2149 C   0  0  0  0  0  0
    6.2698    2.4542   -0.3724 C   0  0  0  0  0  0
    4.9733    3.0216   -0.4811 C   0  0  0  0  0  0
    4.7849    4.4001   -0.6178 C   0  0  0  0  0  0
    5.9073    5.2324   -0.6586 C   0  0  0  0  0  0
    7.1981    4.7188   -0.5662 C   0  0  0  0  0  0
    7.4038    3.3277   -0.4211 C   0  0  0  0  0  0
    8.6870    2.8656   -0.3303 N   0  0  0  0  0  0
    8.8893    1.5315   -0.1872 C   0  0  0  0  0  0
    7.8343    0.6269   -0.1278 C   0  0  0  0  0  0
    7.7998   -0.7418    0.0113 N   0  0  0  0  0  0
    6.5226   -1.2005    0.0127 C   0  0  0  0  0  0
    6.1416   -2.3693    0.1145 O   0  0  0  0  0  0
    8.9551   -1.6271    0.1404 C   0  0  0  0  0  0
    3.4072    4.9616   -0.7171 C   0  0  0  0  0  0
    3.1100    6.0182   -1.5858 C   0  0  0  0  0  0
    1.7888    6.5239   -1.6679 C   0  0  0  0  0  0
    1.4284    7.5893   -2.5290 C   0  0  0  0  0  0
    0.1110    8.0410   -2.5667 C   0  0  0  0  0  0
   -0.8635    7.4549   -1.7639 C   0  0  0  0  0  0
   -0.5400    6.4055   -0.9063 C   0  0  0  0  0  0
    0.7899    5.9233   -0.8438 C   0  0  0  0  0  0
    1.0795    4.8978    0.0021 N   0  0  0  0  0  0
    2.3560    4.4458    0.0495 C   0  0  0  0  0  0
   -0.3369   -1.6649   -1.3516 H   0  0  0  0  0  0
   -0.4455   -0.1498   -2.2489 H   0  0  0  0  0  0
   -1.7457   -0.6307   -1.1833 H   0  0  0  0  0  0
    0.0099    2.1412    0.7205 H   0  0  0  0  0  0
   -1.4732    1.7200   -0.1194 H   0  0  0  0  0  0
   -0.0211    2.0976   -1.0371 H   0  0  0  0  0  0
    1.7596   -0.3375   -2.2530 H   0  0  0  0  0  0
    4.1923   -0.4319   -2.2337 H   0  0  0  0  0  0
    4.2022    0.2669    2.0109 H   0  0  0  0  0  0
    1.7577    0.3708    2.0013 H   0  0  0  0  0  0
    4.1079    2.3817   -0.4644 H   0  0  0  0  0  0
    5.7838    6.3011   -0.7584 H   0  0  0  0  0  0
    8.0494    5.3839   -0.6011 H   0  0  0  0  0  0
    9.9188    1.2111   -0.1207 H   0  0  0  0  0  0
    8.6717   -2.6767    0.2331 H   0  0  0  0  0  0
    9.5350   -1.3572    1.0233 H   0  0  0  0  0  0
    9.5999   -1.5297   -0.7331 H   0  0  0  0  0  0
    3.8776    6.4541   -2.2095 H   0  0  0  0  0  0
    2.1800    8.0487   -3.1550 H   0  0  0  0  0  0
   -0.1575    8.8539   -3.2254 H   0  0  0  0  0  0
   -1.8800    7.8177   -1.8062 H   0  0  0  0  0  0
   -1.3021    5.9558   -0.2858 H   0  0  0  0  0  0
    2.5266    3.6341    0.7420 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 37  1  0  0  0
  1 38  1  0  0  0
  1 39  1  0  0  0
  2  3  1  0  0  0
  2  4  1  0  0  0
  2  6  1  0  0  0
  3 40  1  0  0  0
  3 41  1  0  0  0
  3 42  1  0  0  0
  4  5  3  0  0  0
  6  7  1  0  0  0
  6 11  2  0  0  0
  7  8  2  0  0  0
  7 43  1  0  0  0
  8  9  1  0  0  0
  8 44  1  0  0  0
  9 10  2  0  0  0
  9 12  1  0  0  0
 10 11  1  0  0  0
 10 45  1  0  0  0
 11 46  1  0  0  0
 12 13  1  0  0  0
 12 24  1  0  0  0
 13 14  1  0  0  0
 13 22  2  0  0  0
 14 15  1  0  0  0
 14 19  2  0  0  0
 15 16  2  0  0  0
 15 47  1  0  0  0
 16 17  1  0  0  0
 16 27  1  0  0  0
 17 18  2  0  0  0
 17 48  1  0  0  0
 18 19  1  0  0  0
 18 49  1  0  0  0
 19 20  1  0  0  0
 20 21  2  0  0  0
 21 22  1  0  0  0
 21 50  1  0  0  0
 22 23  1  0  0  0
 23 24  1  0  0  0
 23 26  1  0  0  0
 24 25  2  0  0  0
 26 51  1  0  0  0
 26 52  1  0  0  0
 26 53  1  0  0  0
 27 28  1  0  0  0
 27 36  2  0  0  0
 28 29  2  0  0  0
 28 54  1  0  0  0
 29 30  1  0  0  0
 29 34  1  0  0  0
 30 31  2  0  0  0
 30 55  1  0  0  0
 31 32  1  0  0  0
 31 56  1  0  0  0
 32 33  2  0  0  0
 32 57  1  0  0  0
 33 34  1  0  0  0
 33 58  1  0  0  0
 34 35  2  0  0  0
 35 36  1  0  0  0
 36 59  1  0  0  0
M  END
> <s_m_entry_id>
498

> <Applicants>
Novartis

> <CHEMBL_ID>
CHEMBL1879463

> <Canonical_Smiles>
O=C1N(c2c3cc(ccc3ncc2N1C)-c1cc2c(nc1)cccc2)c1ccc(cc1)C(C#N)(C)C

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
3

> <SC_Patent>
None

> <Synonyms>
BEZ-235 | BEZ235 | DACTOLISIB | NVP-BEZ235 | NVP-BEZ235-NX

> <Indications>
nan

> <Type>
nan

> <targets_id>
P42336|P42338|P48736|O00329|P42345

> <inchi>
InChI=1S/C30H23N5O/c1-30(2,18-31)22-9-11-23(12-10-22)35-28-24-15-19(21-14-20-6-4-5-7-25(20)32-16-21)8-13-26(24)33-17-27(28)34(3)29(35)36/h4-17H,1-3H3

> <stdInchikey>
JOGKUKXHTYWRGZ-UHFFFAOYSA-N

> <csid>
10151099

> <Links>
|http://www.chemspider.com/Chemical-Structure.10151099.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1879463|http://pubchem.ncbi.nlm.nih.gov/compound/11977753|http://www.drugbank.ca/drugs/DB11651|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7950|http://zinc15.docking.org/substances/ZINC24760115|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=RUJ6Z9Y0DT|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=92862

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
469.2

> <HBA>
6

> <HBD>
0

> <NRB>
3

> <TPSA>
76.5

> <LogP>
5.9

> <RoF>
1

> <Targets>
PIK3CA; PIK3CB; PIK3CG; PIK3CD; MTOR

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0033

> <r_epik_State_Penalty>
  0.0000

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
498

> <Kinase families>
Atypical

$$$$
Linifanib
                    3D
 Structure written by MMmdl.
 46 49  0  0  1  0            999 V2000
   -4.5459    4.8826   -1.8043 C   0  0  0  0  0  0
   -4.4382    3.6739   -0.8924 C   0  0  0  0  0  0
   -5.5255    3.3020   -0.0989 C   0  0  0  0  0  0
   -5.4362    2.1889    0.7354 C   0  0  0  0  0  0
   -4.2588    1.4423    0.7875 C   0  0  0  0  0  0
   -3.1558    1.8110    0.0055 C   0  0  0  0  0  0
   -3.2559    2.9295   -0.8390 C   0  0  0  0  0  0
   -1.9935    1.0229    0.0975 N   0  0  0  0  0  0
   -0.7118    1.4280   -0.0085 C   0  0  0  0  0  0
   -0.3589    2.5921   -0.2054 O   0  0  0  0  0  0
    0.1178    0.3760    0.1473 N   0  0  0  0  0  0
    1.5232    0.3269    0.0753 C   0  0  0  0  0  0
    2.3302    1.3411   -0.4628 C   0  0  0  0  0  0
    3.7130    1.1838   -0.4979 C   0  0  0  0  0  0
    4.3109    0.0161   -0.0154 C   0  0  0  0  0  0
    3.5017   -0.9908    0.5187 C   0  0  0  0  0  0
    2.1187   -0.8395    0.5589 C   0  0  0  0  0  0
    5.7877   -0.1484   -0.0478 C   0  0  0  0  0  0
    6.4867   -0.4111    1.1363 C   0  0  0  0  0  0
    7.8713   -0.5529    1.1606 C   0  0  0  0  0  0
    8.6412   -0.4437    0.0048 C   0  0  0  0  0  0
    7.9551   -0.1964   -1.1869 C   0  0  0  0  0  0
    6.5414   -0.0525   -1.2431 C   0  0  0  0  0  0
    6.2849    0.1517   -2.6429 C   0  0  0  0  0  0
    7.3888    0.1708   -3.3423 N   0  0  0  0  0  0
    8.3999   -0.0417   -2.4842 N   0  0  0  0  0  0
    5.0598    0.3207   -3.2202 N   0  0  0  0  0  0
   -4.1985    0.3634    1.6047 F   0  0  0  0  0  0
   -3.7399    4.9080   -2.5388 H   0  0  0  0  0  0
   -4.4998    5.8011   -1.2186 H   0  0  0  0  0  0
   -5.4912    4.8712   -2.3484 H   0  0  0  0  0  0
   -6.4428    3.8719   -0.1302 H   0  0  0  0  0  0
   -6.2830    1.9043    1.3428 H   0  0  0  0  0  0
   -2.4272    3.2191   -1.4683 H   0  0  0  0  0  0
   -2.1482    0.0658    0.3795 H   0  0  0  0  0  0
   -0.3172   -0.5069    0.3707 H   0  0  0  0  0  0
    1.9172    2.2508   -0.8680 H   0  0  0  0  0  0
    4.3233    1.9760   -0.9076 H   0  0  0  0  0  0
    3.9448   -1.8998    0.8994 H   0  0  0  0  0  0
    1.5152   -1.6355    0.9717 H   0  0  0  0  0  0
    5.9442   -0.4969    2.0669 H   0  0  0  0  0  0
    8.3618   -0.7494    2.1027 H   0  0  0  0  0  0
    9.7152   -0.5526    0.0375 H   0  0  0  0  0  0
    9.3524   -0.0755   -2.8182 H   0  0  0  0  0  0
    4.2662    0.6432   -2.6853 H   0  0  0  0  0  0
    4.9397    0.2640   -4.2211 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 29  1  0  0  0
  1 30  1  0  0  0
  1 31  1  0  0  0
  2  3  1  0  0  0
  2  7  2  0  0  0
  3  4  2  0  0  0
  3 32  1  0  0  0
  4  5  1  0  0  0
  4 33  1  0  0  0
  5  6  2  0  0  0
  5 28  1  0  0  0
  6  7  1  0  0  0
  6  8  1  0  0  0
  7 34  1  0  0  0
  8  9  1  0  0  0
  8 35  1  0  0  0
  9 10  2  0  0  0
  9 11  1  0  0  0
 11 12  1  0  0  0
 11 36  1  0  0  0
 12 13  1  0  0  0
 12 17  2  0  0  0
 13 14  2  0  0  0
 13 37  1  0  0  0
 14 15  1  0  0  0
 14 38  1  0  0  0
 15 16  2  0  0  0
 15 18  1  0  0  0
 16 17  1  0  0  0
 16 39  1  0  0  0
 17 40  1  0  0  0
 18 19  1  0  0  0
 18 23  2  0  0  0
 19 20  2  0  0  0
 19 41  1  0  0  0
 20 21  1  0  0  0
 20 42  1  0  0  0
 21 22  2  0  0  0
 21 43  1  0  0  0
 22 23  1  0  0  0
 22 26  1  0  0  0
 23 24  1  0  0  0
 24 25  2  0  0  0
 24 27  1  0  0  0
 25 26  1  0  0  0
 26 44  1  0  0  0
 27 45  1  0  0  0
 27 46  1  0  0  0
M  END
> <s_m_entry_id>
499

> <Applicants>
Abbott Laboratories

> <CHEMBL_ID>
CHEMBL223360

> <Canonical_Smiles>
Fc1ccc(cc1NC(=O)Nc1ccc(cc1)-c1c2c([nH]nc2N)ccc1)C

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
3

> <SC_Patent>
None

> <Synonyms>
A-741439 | ABT-869 | AL-39324 | LINIFANIB | RG-3635

> <Indications>
nan

> <Type>
nan

> <targets_id>
P36888|P07333|P35968

> <inchi>
InChI=1S/C21H18FN5O/c1-12-5-10-16(22)18(11-12)25-21(28)24-14-8-6-13(7-9-14)15-3-2-4-17-19(15)20(23)27-26-17/h2-11H,1H3,(H3,23,26,27)(H2,24,25,28)

> <stdInchikey>
MPVGZUGXCQEXTM-UHFFFAOYSA-N

> <csid>
9660475

> <Links>
|http://www.chemspider.com/Chemical-Structure.9660475.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL223360|http://pubchem.ncbi.nlm.nih.gov/compound/11485656|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5657|http://zinc15.docking.org/substances/ZINC06718813|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=CO93X137CW|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=21079

> <LinkName>
|ChemSpider|ChEMBL|PubChem|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
375.1

> <HBA>
3

> <HBD>
4

> <NRB>
3

> <TPSA>
95.8

> <LogP>
4.9

> <RoF>
0

> <Targets>
FLT3; CSF1R; KDR

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0001

> <r_epik_State_Penalty>
  0.0000

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
499

> <Kinase families>
Tyr

$$$$
Alvocidib
                    3D
 Structure written by MMmdl.
 49 52  0  0  1  0            999 V2000
   -1.7368   -3.8124   -1.3479 C   0  0  0  0  0  0
   -1.2491   -2.9088   -0.1975 N   0  3  2  0  0  0
   -0.8741   -1.5160   -0.7442 C   0  0  0  0  0  0
   -0.5307   -0.6153    0.4488 C   0  0  0  0  0  0
    0.6469   -1.1445    1.2958 C   0  0  1  0  0  0
    0.5116   -2.6649    1.6454 C   0  0  1  0  0  0
   -0.0811   -3.5934    0.5506 C   0  0  0  0  0  0
    1.6932   -3.2232    2.1867 O   0  0  0  0  0  0
    2.0229   -0.5934    0.8209 C   0  0  0  0  0  0
    2.8189   -1.2384   -0.1426 C   0  0  0  0  0  0
    4.0466   -0.7063   -0.5226 C   0  0  0  0  0  0
    4.5135    0.4856    0.0212 C   0  0  0  0  0  0
    3.7384    1.1878    0.9647 C   0  0  0  0  0  0
    2.4943    0.6303    1.3434 C   0  0  0  0  0  0
    1.6657    1.2800    2.2442 O   0  0  0  0  0  0
    2.0594    2.4576    2.7888 C   0  0  0  0  0  0
    3.2224    3.0740    2.5035 C   0  0  0  0  0  0
    4.1850    2.5012    1.5719 C   0  0  0  0  0  0
    5.2551    3.0481    1.3078 O   0  0  0  0  0  0
    1.0276    2.9891    3.6953 C   0  0  0  0  0  0
    0.7708    2.3124    4.8938 C   0  0  0  0  0  0
   -0.2089    2.7702    5.7743 C   0  0  0  0  0  0
   -0.9495    3.9078    5.4609 C   0  0  0  0  0  0
   -0.7126    4.5839    4.2652 C   0  0  0  0  0  0
    0.2672    4.1294    3.3795 C   0  0  0  0  0  0
    0.5023    4.9942    1.8978 Cl  0  0  0  0  0  0
    5.7372    0.9289   -0.4172 O   0  0  0  0  0  0
    2.4337   -2.3918   -0.7651 O   0  0  0  0  0  0
   -0.9193   -3.9255   -2.0621 H   0  0  0  0  0  0
   -2.6004   -3.3229   -1.8001 H   0  0  0  0  0  0
   -2.0223   -4.7693   -0.9090 H   0  0  0  0  0  0
   -0.0441   -1.6416   -1.4406 H   0  0  0  0  0  0
   -1.7462   -1.1413   -1.2821 H   0  0  0  0  0  0
   -0.3329    0.4015    0.1056 H   0  0  0  0  0  0
   -1.4167   -0.5374    1.0812 H   0  0  0  0  0  0
    0.5175   -0.6912    2.2786 H   0  0  0  0  0  0
   -0.1987   -2.7266    2.4726 H   0  0  0  0  0  0
   -0.5222   -4.4869    0.9957 H   0  0  0  0  0  0
    0.6402   -3.9101   -0.1997 H   0  0  0  0  0  0
    1.9965   -2.6625    2.9049 H   0  0  0  0  0  0
    4.6455   -1.2236   -1.2593 H   0  0  0  0  0  0
    3.4386    4.0199    2.9789 H   0  0  0  0  0  0
    1.3358    1.4270    5.1488 H   0  0  0  0  0  0
   -0.3939    2.2425    6.6985 H   0  0  0  0  0  0
   -1.7091    4.2633    6.1415 H   0  0  0  0  0  0
   -1.2953    5.4614    4.0248 H   0  0  0  0  0  0
    6.1395    0.3442   -1.0631 H   0  0  0  0  0  0
    3.0938   -2.7175   -1.3814 H   0  0  0  0  0  0
   -2.0141   -2.7912    0.4522 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 29  1  0  0  0
  1 30  1  0  0  0
  1 31  1  0  0  0
  2  3  1  0  0  0
  2  7  1  0  0  0
  2 49  1  0  0  0
  3  4  1  0  0  0
  3 32  1  0  0  0
  3 33  1  0  0  0
  4  5  1  0  0  0
  4 34  1  0  0  0
  4 35  1  0  0  0
  5  6  1  0  0  0
  5  9  1  0  0  0
  5 36  1  0  0  0
  6  7  1  0  0  0
  6  8  1  0  0  0
  6 37  1  0  0  0
  7 38  1  0  0  0
  7 39  1  0  0  0
  8 40  1  0  0  0
  9 10  1  0  0  0
  9 14  2  0  0  0
 10 11  2  0  0  0
 10 28  1  0  0  0
 11 12  1  0  0  0
 11 41  1  0  0  0
 12 13  2  0  0  0
 12 27  1  0  0  0
 13 14  1  0  0  0
 13 18  1  0  0  0
 14 15  1  0  0  0
 15 16  1  0  0  0
 16 17  2  0  0  0
 16 20  1  0  0  0
 17 18  1  0  0  0
 17 42  1  0  0  0
 18 19  2  0  0  0
 20 21  1  0  0  0
 20 25  2  0  0  0
 21 22  2  0  0  0
 21 43  1  0  0  0
 22 23  1  0  0  0
 22 44  1  0  0  0
 23 24  2  0  0  0
 23 45  1  0  0  0
 24 25  1  0  0  0
 24 46  1  0  0  0
 25 26  1  0  0  0
 27 47  1  0  0  0
 28 48  1  0  0  0
M  CHG  1   2   1
M  END
> <s_m_entry_id>
500

> <Applicants>
Sanofi

> <CHEMBL_ID>
CHEMBL428690

> <Canonical_Smiles>
Clc1ccccc1C=1Oc2c(C(=O)C=1)c(O)cc(O)c2[C@H]1CCN(C[C@H]1O)C

> <Chirality>
Single Stereoisomer

> <First_Approval>
nan

> <Phase>
3

> <SC_Patent>
None

> <Synonyms>
ALVOCIDIB | FLAVOPIRIDOL | HL 275 | HL-275 | HMR 1275 | HMR-1275 | L 86 8275 | L-868275 | L86-8275 | MDL 107,826A | MDL-107826A | NSC-649890

> <Indications>
Investigated for use/treatment in esophageal cancer, leukemia (lymphoid), lung cancer, liver cancer, and lymphoma (unspecified).

> <Type>
nan

> <targets_id>
nan

> <inchi>
InChI=1S/C21H20ClNO5/c1-23-7-6-12(17(27)10-23)19-14(24)8-15(25)20-16(26)9-18(28-21(19)20)11-4-2-3-5-13(11)22/h2-5,8-9,12,17,24-25,27H,6-7,10H2,1H3/t12-,17+/m0/s1

> <stdInchikey>
BIIVYFLTOXDAOV-YVEFUNNKSA-N

> <csid>
4450222

> <Links>
|http://www.chemspider.com/Chemical-Structure.4450222.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL428690|http://pubchem.ncbi.nlm.nih.gov/compound/5287969|http://www.drugbank.ca/drugs/DB03496| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=CPB|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/CPB|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5680|http://zinc15.docking.org/substances/ZINC000021288966|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=45AD6X575G|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=5655

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
401.1

> <HBA>
6

> <HBD>
3

> <NRB>
2

> <TPSA>
94.1

> <LogP>
3.3

> <RoF>
0

> <Targets>
nan

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_epik_Ionization_Penalty>
  0.0511

> <r_epik_State_Penalty>
  0.0382

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
500

> <lig_pdbID>
'CPB'

> <pdbID>
1c8k 1e1y 3blr 3ebp 4o71

> <indicationDB>
Alvocidib is a synthetic flavonoid based on an extract from an Indian plant for the potential treatment of cancer. It works by inhibiting cyclin-dependent kinases, arresting cell division and causing apoptosis in non-small lung cancer cells.

> <uniprotId>
P24941|Q00535|P50750|P06493|Q00534|P00533|P11802|P49336|P50613|P11217|P11216|P06737|P22309|Q9UNQ0

> <Withdrawn>
|Study NCT04493099 in United States was Withdrawn during Phase 1/Phase 2 because The original sponsor was acquired by a new company and has elected to end funding for all
    Investigator Sponsored Trials (ISTs)

$$$$
Filgotinib
                    3D
 Structure written by MMmdl.
 54 58  0  0  1  0            999 V2000
   -1.8871   -1.1606   -0.4681 C   0  0  0  0  0  0
   -0.4992   -1.0789   -0.3409 C   0  0  0  0  0  0
    0.1376    0.1520   -0.1400 C   0  0  0  0  0  0
   -0.6543    1.2837   -0.0810 N   0  0  0  0  0  0
   -2.0581    1.2136   -0.2111 C   0  0  0  0  0  0
   -2.6923   -0.0216   -0.4034 C   0  0  0  0  0  0
   -2.4591    2.5047   -0.1067 N   0  3  0  0  0  0
   -1.3406    3.2942    0.0674 C   0  0  0  0  0  0
   -0.2322    2.5787    0.0742 N   0  0  0  0  0  0
   -1.4619    4.6483    0.1986 N   0  0  0  0  0  0
   -0.3476    5.5684    0.4919 C   0  0  0  0  0  0
    0.8151    5.2026    0.6791 O   0  0  0  0  0  0
   -0.7772    7.0441    0.5447 C   0  0  0  0  0  0
    0.2665    8.0598    0.1195 C   0  0  0  0  0  0
   -0.0781    7.9021    1.5819 C   0  0  0  0  0  0
    1.6204    0.2596    0.0179 C   0  0  0  0  0  0
    2.4664   -0.4375   -0.8533 C   0  0  0  0  0  0
    3.8497   -0.3564   -0.7196 C   0  0  0  0  0  0
    4.4064    0.4167    0.2998 C   0  0  0  0  0  0
    3.5750    1.1073    1.1822 C   0  0  0  0  0  0
    2.1929    1.0231    1.0445 C   0  0  0  0  0  0
    5.9208    0.5129    0.4483 C   0  0  0  0  0  0
    6.4248   -0.1924    1.6351 N   0  0  0  0  0  0
    7.7999    0.2543    1.9058 C   0  0  0  0  0  0
    8.3246   -0.2150    3.2737 C   0  0  0  0  0  0
    8.3526   -2.0933    3.3252 S   0  0  0  0  0  0
    9.2969   -2.5891    2.3181 O   0  0  0  0  0  0
    8.5083   -2.5431    4.7123 O   0  0  0  0  0  0
    6.5977   -2.4359    2.7473 C   0  0  0  0  0  0
    6.3207   -1.6505    1.4541 C   0  0  0  0  0  0
   -2.3470   -2.1267   -0.6178 H   0  0  0  0  0  0
    0.0847   -1.9869   -0.3891 H   0  0  0  0  0  0
   -3.7654   -0.0944   -0.5041 H   0  0  0  0  0  0
   -2.3730    5.0636    0.0729 H   0  0  0  0  0  0
   -1.8241    7.2508    0.3185 H   0  0  0  0  0  0
    1.2494    7.7289   -0.2207 H   0  0  0  0  0  0
   -0.0688    8.9541   -0.4062 H   0  0  0  0  0  0
   -0.6529    8.6869    2.0742 H   0  0  0  0  0  0
    0.6673    7.4620    2.2466 H   0  0  0  0  0  0
    2.0530   -1.0394   -1.6498 H   0  0  0  0  0  0
    4.4852   -0.8963   -1.4064 H   0  0  0  0  0  0
    3.9984    1.7034    1.9779 H   0  0  0  0  0  0
    1.5683    1.5531    1.7488 H   0  0  0  0  0  0
    6.4206    0.1533   -0.4540 H   0  0  0  0  0  0
    6.1581    1.5762    0.5187 H   0  0  0  0  0  0
    8.4735   -0.0652    1.1083 H   0  0  0  0  0  0
    7.8294    1.3454    1.9084 H   0  0  0  0  0  0
    9.3362    0.1456    3.4573 H   0  0  0  0  0  0
    7.6885    0.1474    4.0817 H   0  0  0  0  0  0
    6.4939   -3.5094    2.5916 H   0  0  0  0  0  0
    5.9058   -2.1439    3.5376 H   0  0  0  0  0  0
    5.3102   -1.9082    1.1361 H   0  0  0  0  0  0
    6.9838   -1.9867    0.6545 H   0  0  0  0  0  0
   -3.4099    2.8419   -0.1495 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1  6  2  0  0  0
  1 31  1  0  0  0
  2  3  2  0  0  0
  2 32  1  0  0  0
  3  4  1  0  0  0
  3 16  1  0  0  0
  4  5  1  0  0  0
  4  9  1  0  0  0
  5  6  1  0  0  0
  5  7  2  0  0  0
  6 33  1  0  0  0
  7  8  1  0  0  0
  7 54  1  0  0  0
  8  9  2  0  0  0
  8 10  1  0  0  0
 10 11  1  0  0  0
 10 34  1  0  0  0
 11 12  2  0  0  0
 11 13  1  0  0  0
 13 14  1  0  0  0
 13 15  1  0  0  0
 13 35  1  0  0  0
 14 15  1  0  0  0
 14 36  1  0  0  0
 14 37  1  0  0  0
 15 38  1  0  0  0
 15 39  1  0  0  0
 16 17  1  0  0  0
 16 21  2  0  0  0
 17 18  2  0  0  0
 17 40  1  0  0  0
 18 19  1  0  0  0
 18 41  1  0  0  0
 19 20  2  0  0  0
 19 22  1  0  0  0
 20 21  1  0  0  0
 20 42  1  0  0  0
 21 43  1  0  0  0
 22 23  1  0  0  0
 22 44  1  0  0  0
 22 45  1  0  0  0
 23 24  1  0  0  0
 23 30  1  0  0  0
 24 25  1  0  0  0
 24 46  1  0  0  0
 24 47  1  0  0  0
 25 26  1  0  0  0
 25 48  1  0  0  0
 25 49  1  0  0  0
 26 27  2  0  0  0
 26 28  2  0  0  0
 26 29  1  0  0  0
 29 30  1  0  0  0
 29 50  1  0  0  0
 29 51  1  0  0  0
 30 52  1  0  0  0
 30 53  1  0  0  0
M  CHG  1   7   1
M  END
> <s_m_entry_id>
510

> <Applicants>
Galapagos

> <CHEMBL_ID>
CHEMBL3301607

> <Canonical_Smiles>
S1(=O)(=O)CCN(CC1)Cc1ccc(cc1)C=1n2nc(nc2C=CC=1)NC(=O)C1CC1

> <Chirality>
Single Stereoisomer

> <First_Approval>
nan

> <Phase>
3

> <SC_Patent>
None

> <Synonyms>
FILGOTINIB | G-146034 | G146034 | GLPG-0634 | GLPG0634 | GS-6034 FREE BASE

> <Indications>
nan

> <Type>
1

> <targets_id>
P23458

> <inchi>
InChI=1S/C21H23N5O3S/c27-20(17-8-9-17)23-21-22-19-3-1-2-18(26(19)24-21)16-6-4-15(5-7-16)14-25-10-12-30(28,29)13-11-25/h1-7,17H,8-14H2,(H,23,24,27)

> <stdInchikey>
RIJLVEAXPNLDTC-UHFFFAOYSA-N

> <csid>
28189566

> <Links>
|http://www.chemspider.com/Chemical-Structure.28189566.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3301607|http://pubchem.ncbi.nlm.nih.gov/compound/49831257|http://www.drugbank.ca/drugs/DB14845| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=2HB|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/2HB|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7913|http://zinc15.docking.org/substances/ZINC000096174616|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=3XVL385Q0M|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=103727

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
425.2

> <HBA>
7

> <HBD>
1

> <NRB>
5

> <TPSA>
96.7

> <LogP>
2

> <RoF>
0

> <Targets>
JAK1

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_epik_Ionization_Penalty>
  0.3061

> <r_epik_State_Penalty>
  0.3928

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
510

> <lig_pdbID>
'2HB'

> <pdbID>
4p7e 5ut5

> <Kinase families>
Tyr

> <indicationDB>
Rheumatoid arthritis (RA) is a chronic, autoimmune, systemic, and inflammatory disease that causes synovial joint symptoms and can limit range of motion in severe cases.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Wasserman AM: Diagnosis and management of rheumatoid arthritis. Am Fam Physician. 2011 Dec 1;84(11):1245-52. (PubMed ID 22150658)" href="#reference-A221451">4</a>,<a class="reference-popover-link" data-content="Guo Q, Wang Y, Xu D, Nossent J, Pavlos NJ, Xu J: Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Bone Res. 2018 Apr 27;6:15. doi: 10.1038/s41413-018-0016-9. eCollection 2018. (PubMed ID 29736302)" href="#reference-A221456">5</a></sup> The disease is associated with extra-articular manifestations, progressive disability, and comorbidities including cardiovascular disease and mental disorders.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Biggioggero M, Becciolini A, Crotti C, Agape E, Favalli EG: Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis. Drugs Context. 2019 Oct 24;8:212595. doi: 10.7573/dic.212595. eCollection 2019. (PubMed ID 31692920)" href="#reference-A189165">3</a></sup> 50-70% of patients with RA are unable to achieve sustained clinical remission despite the availability of several treatments including disease-modifying anti-rheumatic drugs (DMARDS) like <a href="https://go.drugbank.com/drugs/DB00563">methotrexate</a>, interleukin-6 (IL-6) blockers, and tumor necrosis factor (TNF) inhibitors.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Biggioggero M, Becciolini A, Crotti C, Agape E, Favalli EG: Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis. Drugs Context. 2019 Oct 24;8:212595. doi: 10.7573/dic.212595. eCollection 2019. (PubMed ID 31692920)" href="#reference-A189165">3</a></sup> New therapeutic developments target other inflammatory pathways implicated in RA including the Janus kinase (JAK) signaling pathway as seen with filgotinib.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Guo Q, Wang Y, Xu D, Nossent J, Pavlos NJ, Xu J: Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Bone Res. 2018 Apr 27;6:15. doi: 10.1038/s41413-018-0016-9. eCollection 2018. (PubMed ID 29736302)" href="#reference-A221456">5</a></sup> </p><p>There are four JAK subtypes which include JAK1, JAK2, JAK3, and tyrosine kinase 2.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Biggioggero M, Becciolini A, Crotti C, Agape E, Favalli EG: Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis. Drugs Context. 2019 Oct 24;8:212595. doi: 10.7573/dic.212595. eCollection 2019. (PubMed ID 31692920)" href="#reference-A189165">3</a></sup> Non-selective JAK inhibitors like <a href="https://go.drugbank.com/drugs/DB08895">tofacitinib</a> target JAK1 and JAK3 subtypes with minimal activity at JAK2. In contrast, the newly approved filgotinib is a highly selective JAK1 inhibitor.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Biggioggero M, Becciolini A, Crotti C, Agape E, Favalli EG: Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis. Drugs Context. 2019 Oct 24;8:212595. doi: 10.7573/dic.212595. eCollection 2019. (PubMed ID 31692920)" href="#reference-A189165">3</a></sup> JAK2 and JAK3 play important roles in both immune and hematologic functions; therefore, selectivity for JAK1 aims to improve the safety profile of filgotinib while maintaining clinical efficacy.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Biggioggero M, Becciolini A, Crotti C, Agape E, Favalli EG: Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis. Drugs Context. 2019 Oct 24;8:212

> <uniprotId>
P23458|O00748|P23141|P08183

$$$$
Abrocitinib
                    3D
 Structure written by MMmdl.
 43 45  0  0  1  0            999 V2000
   -0.6651    4.0323   -0.7470 C   0  0  0  0  0  0
   -0.5804    2.5282   -1.0345 C   0  0  0  0  0  0
   -0.4931    1.6843    0.2495 C   0  0  0  0  0  0
   -0.2130   -0.1510   -0.1401 S   0  0  0  0  0  0
   -0.5806   -0.9115    1.0586 O   0  0  0  0  0  0
   -0.8288   -0.4647   -1.4344 O   0  0  0  0  0  0
    1.5362   -0.2968   -0.3125 N   0  0  0  0  0  0
    2.2225    0.2757   -1.4899 C   0  0  2  0  0  0
    3.6038   -0.2919   -1.8560 C   0  0  0  0  0  0
    4.2247    0.9006   -1.1073 C   0  0  2  0  0  0
    2.8966    1.6496   -1.3316 C   0  0  0  0  0  0
    5.4947    1.4450   -1.6184 N   0  0  0  0  0  0
    6.6524    0.6284   -1.2514 C   0  0  0  0  0  0
    5.5110    1.9742   -2.9302 C   0  0  0  0  0  0
    5.0630    3.2904   -3.1778 C   0  0  0  0  0  0
    4.5306    4.3869   -2.4177 C   0  0  0  0  0  0
    4.2950    5.4153   -3.3115 C   0  0  0  0  0  0
    4.6623    5.0196   -4.5757 N   0  0  0  0  0  0
    5.1439    3.7299   -4.5300 C   0  0  0  0  0  0
    5.6090    3.0121   -5.5569 N   0  0  0  0  0  0
    6.0332    1.7747   -5.1918 C   0  0  0  0  0  0
    6.0200    1.2247   -3.9519 N   0  0  0  0  0  0
   -0.7419    4.6018   -1.6734 H   0  0  0  0  0  0
    0.2204    4.3830   -0.2161 H   0  0  0  0  0  0
   -1.5378    4.2703   -0.1382 H   0  0  0  0  0  0
   -1.4566    2.2243   -1.6086 H   0  0  0  0  0  0
    0.2780    2.3376   -1.6757 H   0  0  0  0  0  0
    0.3124    2.0122    0.9068 H   0  0  0  0  0  0
   -1.4289    1.7500    0.8048 H   0  0  0  0  0  0
    2.0679   -0.2422    0.5603 H   0  0  0  0  0  0
    1.5191    0.2460   -2.3231 H   0  0  0  0  0  0
    3.8389   -1.2742   -1.4447 H   0  0  0  0  0  0
    3.7958   -0.3074   -2.9306 H   0  0  0  0  0  0
    4.3828    0.6735   -0.0504 H   0  0  0  0  0  0
    2.8274    2.2438   -2.2417 H   0  0  0  0  0  0
    2.5568    2.2549   -0.4906 H   0  0  0  0  0  0
    7.5786    1.0987   -1.5852 H   0  0  0  0  0  0
    6.5981   -0.3620   -1.7057 H   0  0  0  0  0  0
    6.7214    0.5188   -0.1686 H   0  0  0  0  0  0
    4.3368    4.4246   -1.3559 H   0  0  0  0  0  0
    3.8974    6.4074   -3.1551 H   0  0  0  0  0  0
    4.5809    5.6187   -5.3843 H   0  0  0  0  0  0
    6.4303    1.1551   -5.9827 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 23  1  0  0  0
  1 24  1  0  0  0
  1 25  1  0  0  0
  2  3  1  0  0  0
  2 26  1  0  0  0
  2 27  1  0  0  0
  3  4  1  0  0  0
  3 28  1  0  0  0
  3 29  1  0  0  0
  4  5  2  0  0  0
  4  6  2  0  0  0
  4  7  1  0  0  0
  7  8  1  0  0  0
  7 30  1  0  0  0
  8  9  1  0  0  0
  8 11  1  0  0  0
  8 31  1  0  0  0
  9 10  1  0  0  0
  9 32  1  0  0  0
  9 33  1  0  0  0
 10 11  1  0  0  0
 10 12  1  0  0  0
 10 34  1  0  0  0
 11 35  1  0  0  0
 11 36  1  0  0  0
 12 13  1  0  0  0
 12 14  1  0  0  0
 13 37  1  0  0  0
 13 38  1  0  0  0
 13 39  1  0  0  0
 14 15  1  0  0  0
 14 22  2  0  0  0
 15 16  1  0  0  0
 15 19  2  0  0  0
 16 17  2  0  0  0
 16 40  1  0  0  0
 17 18  1  0  0  0
 17 41  1  0  0  0
 18 19  1  0  0  0
 18 42  1  0  0  0
 19 20  1  0  0  0
 20 21  2  0  0  0
 21 22  1  0  0  0
 21 43  1  0  0  0
M  END
> <s_m_entry_id>
514

> <Applicants>
Pfizer

> <CHEMBL_ID>
CHEMBL3655081

> <Canonical_Smiles>
S(=O)(=O)(NC1CC(N(C)c2ncnc3[nH]ccc23)C1)CCC

> <Chirality>
Single Stereoisomer

> <First_Approval>
nan

> <Phase>
3

> <SC_Patent>
None

> <Synonyms>
|PF-04965842

> <Indications>
nan

> <Type>
nan

> <targets_id>
nan

> <inchi>
InChI=1S/C14H21N5O2S/c1-3-6-22(20,21)18-10-7-11(8-10)19(2)14-12-4-5-15-13(12)16-9-17-14/h4-5,9-11,18H,3,6-8H2,1-2H3,(H,15,16,17)

> <stdInchikey>
IUEWXNHSKRWHDY-UHFFFAOYSA-N

> <csid>
68006894

> <Links>
|http://www.chemspider.com/Chemical-Structure.68006894.html|http://pubchem.ncbi.nlm.nih.gov/compound/78323835

> <LinkName>
|ChemSpider|PubChem

> <MW>
323.1

> <HBA>
5

> <HBD>
2

> <NRB>
6

> <TPSA>
91

> <LogP>
1.3

> <RoF>
0

> <Targets>
nan

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
0.999998

> <r_epik_Ionization_Penalty>
  0.0152

> <r_epik_State_Penalty>
  0.0111

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
514

$$$$
Lazertinib
                    3D
 Structure written by MMmdl.
 76 80  0  0  1  0            999 V2000
   -6.6499    4.9549   -0.2649 C   0  0  0  0  0  0
   -6.4739    4.5965    1.2261 N   0  3  0  0  0  0
   -7.5249    5.3200    2.0910 C   0  0  0  0  0  0
   -5.0435    4.8447    1.7589 C   0  0  0  0  0  0
   -4.0521    3.9529    1.0343 C   0  0  0  0  0  0
   -3.7257    2.6407    1.3387 C   0  0  0  0  0  0
   -2.7919    2.2223    0.4253 N   0  0  0  0  0  0
   -2.5073    3.2040   -0.4435 N   0  0  0  0  0  0
   -3.2397    4.2386   -0.0855 C   0  0  0  0  0  0
   -3.1532    5.5125   -0.8570 C   0  0  0  0  0  0
   -3.2767    5.4962   -2.2510 C   0  0  0  0  0  0
   -3.2036    6.6844   -2.9729 C   0  0  0  0  0  0
   -3.0030    7.8881   -2.3012 C   0  0  0  0  0  0
   -2.8720    7.9136   -0.9147 C   0  0  0  0  0  0
   -2.9464    6.7253   -0.1928 C   0  0  0  0  0  0
   -2.1672    0.9561    0.3398 C   0  0  0  0  0  0
   -2.8522   -0.2039    0.7262 C   0  0  0  0  0  0
   -2.1619   -1.4120    0.6145 C   0  0  0  0  0  0
   -0.8838   -1.4830    0.1624 N   0  0  0  0  0  0
   -0.2921   -0.3072   -0.1868 C   0  0  0  0  0  0
   -0.8827    0.9127   -0.1177 N   0  0  0  0  0  0
    1.0340   -0.3164   -0.6348 N   0  0  0  0  0  0
    1.8538   -1.4261   -0.8895 C   0  0  0  0  0  0
    2.9321   -1.6597   -0.0384 C   0  0  0  0  0  0
    3.7892   -2.7509   -0.2411 C   0  0  0  0  0  0
    3.5819   -3.6045   -1.3455 C   0  0  0  0  0  0
    2.4959   -3.3488   -2.1974 C   0  0  0  0  0  0
    1.6229   -2.2691   -1.9856 C   0  0  0  0  0  0
    0.5450   -1.9822   -2.8075 O   0  0  0  0  0  0
    0.2664   -2.8215   -3.9225 C   0  0  0  0  0  0
    4.4263   -4.6880   -1.5861 N   0  0  0  0  0  0
    4.2580   -5.8788   -0.7410 C   0  0  0  0  0  0
    5.5244   -6.7621   -0.7685 C   0  0  0  0  0  0
    5.8544   -7.1351   -2.1026 O   0  0  0  0  0  0
    5.9757   -6.0292   -2.9913 C   0  0  0  0  0  0
    4.7041   -5.1544   -2.9529 C   0  0  0  0  0  0
    4.8974   -2.9704    0.6062 N   0  0  0  0  0  0
    4.9530   -2.8013    1.9445 C   0  0  0  0  0  0
    4.0041   -2.4315    2.6412 O   0  0  0  0  0  0
    6.2608   -3.0973    2.4834 C   0  0  0  0  0  0
    6.5464   -2.9975    3.7952 C   0  0  0  0  0  0
   -6.3845    6.0061   -0.3886 H   0  0  0  0  0  0
   -7.6930    4.7701   -0.5248 H   0  0  0  0  0  0
   -5.9947    4.3038   -0.8431 H   0  0  0  0  0  0
   -7.3437    6.3929    2.0077 H   0  0  0  0  0  0
   -7.4008    4.9693    3.1164 H   0  0  0  0  0  0
   -8.5083    5.0466    1.7063 H   0  0  0  0  0  0
   -4.8745    5.9140    1.6313 H   0  0  0  0  0  0
   -5.0934    4.6230    2.8260 H   0  0  0  0  0  0
   -4.0744    1.9803    2.1191 H   0  0  0  0  0  0
   -3.4342    4.5649   -2.7759 H   0  0  0  0  0  0
   -3.3013    6.6725   -4.0486 H   0  0  0  0  0  0
   -2.9441    8.8100   -2.8609 H   0  0  0  0  0  0
   -2.7092    8.8503   -0.4022 H   0  0  0  0  0  0
   -2.8321    6.7507    0.8810 H   0  0  0  0  0  0
   -3.8696   -0.1796    1.0878 H   0  0  0  0  0  0
   -2.6305   -2.3453    0.8907 H   0  0  0  0  0  0
    1.4190    0.5860   -0.8712 H   0  0  0  0  0  0
    3.1038   -0.9776    0.7821 H   0  0  0  0  0  0
    2.3298   -4.0093   -3.0341 H   0  0  0  0  0  0
   -0.6128   -2.4438   -4.4443 H   0  0  0  0  0  0
    0.0497   -3.8437   -3.6087 H   0  0  0  0  0  0
    1.0931   -2.8297   -4.6343 H   0  0  0  0  0  0
    4.0668   -5.5817    0.2910 H   0  0  0  0  0  0
    3.3864   -6.4535   -1.0588 H   0  0  0  0  0  0
    6.3646   -6.2470   -0.2994 H   0  0  0  0  0  0
    5.3589   -7.6677   -0.1847 H   0  0  0  0  0  0
    6.8598   -5.4384   -2.7446 H   0  0  0  0  0  0
    6.1355   -6.4085   -4.0008 H   0  0  0  0  0  0
    3.8546   -5.7087   -3.3559 H   0  0  0  0  0  0
    4.8541   -4.2916   -3.6034 H   0  0  0  0  0  0
    5.6700   -3.4587    0.1774 H   0  0  0  0  0  0
    7.0279   -3.4110    1.7879 H   0  0  0  0  0  0
    5.8124   -2.6884    4.5269 H   0  0  0  0  0  0
    7.5369   -3.2285    4.1583 H   0  0  0  0  0  0
   -6.6522    3.6060    1.3160 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 42  1  0  0  0
  1 43  1  0  0  0
  1 44  1  0  0  0
  2  3  1  0  0  0
  2  4  1  0  0  0
  2 76  1  0  0  0
  3 45  1  0  0  0
  3 46  1  0  0  0
  3 47  1  0  0  0
  4  5  1  0  0  0
  4 48  1  0  0  0
  4 49  1  0  0  0
  5  6  2  0  0  0
  5  9  1  0  0  0
  6  7  1  0  0  0
  6 50  1  0  0  0
  7  8  1  0  0  0
  7 16  1  0  0  0
  8  9  2  0  0  0
  9 10  1  0  0  0
 10 11  1  0  0  0
 10 15  2  0  0  0
 11 12  2  0  0  0
 11 51  1  0  0  0
 12 13  1  0  0  0
 12 52  1  0  0  0
 13 14  2  0  0  0
 13 53  1  0  0  0
 14 15  1  0  0  0
 14 54  1  0  0  0
 15 55  1  0  0  0
 16 17  1  0  0  0
 16 21  2  0  0  0
 17 18  2  0  0  0
 17 56  1  0  0  0
 18 19  1  0  0  0
 18 57  1  0  0  0
 19 20  2  0  0  0
 20 21  1  0  0  0
 20 22  1  0  0  0
 22 23  1  0  0  0
 22 58  1  0  0  0
 23 24  1  0  0  0
 23 28  2  0  0  0
 24 25  2  0  0  0
 24 59  1  0  0  0
 25 26  1  0  0  0
 25 37  1  0  0  0
 26 27  2  0  0  0
 26 31  1  0  0  0
 27 28  1  0  0  0
 27 60  1  0  0  0
 28 29  1  0  0  0
 29 30  1  0  0  0
 30 61  1  0  0  0
 30 62  1  0  0  0
 30 63  1  0  0  0
 31 32  1  0  0  0
 31 36  1  0  0  0
 32 33  1  0  0  0
 32 64  1  0  0  0
 32 65  1  0  0  0
 33 34  1  0  0  0
 33 66  1  0  0  0
 33 67  1  0  0  0
 34 35  1  0  0  0
 35 36  1  0  0  0
 35 68  1  0  0  0
 35 69  1  0  0  0
 36 70  1  0  0  0
 36 71  1  0  0  0
 37 38  1  0  0  0
 37 72  1  0  0  0
 38 39  2  0  0  0
 38 40  1  0  0  0
 40 41  2  0  0  0
 40 73  1  0  0  0
 41 74  1  0  0  0
 41 75  1  0  0  0
M  CHG  1   2   1
M  END
> <s_m_entry_id>
518

> <Applicants>
Genosco

> <CHEMBL_ID>
CHEMBL4558324

> <Canonical_Smiles>
O1CCN(CC1)c1cc(OC)c(Nc2nc(-n3nc(-c4ccccc4)c(c3)CN(C)C)ccn2)cc1NC(=O)C=C

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
3

> <SC_Patent>
None

> <Synonyms>
YH25448|GNS1480|GNS-1480|YH-25448|JNJ-73841937

> <Indications>
Lazertinib (YH-25448, GNS-1480) is an inhibitor of the aberrant activity of EGFR mutant kinases, that was originally developed by Yuhan Corporation for antineoplastic potential in cancers with (acquired) resistance to existing EGFR tyrosine kinase inhibitors, in particular for EGFR mutation positive, advanced non-small cell lung cancer (NSCLC). In addition to predicted efficacy for the treatment of primary lung and extracranial lesions, lazertinib is expected to be beneficial for NSCLC brain metastases as it is able to cross the blood brain barrier.

> <Type>
nan

> <targets_id>
nan

> <inchi>
InChI=1S/C30H34N8O3/c1-5-28(39)32-23-17-24(26(40-4)18-25(23)37-13-15-41-16-14-37)33-30-31-12-11-27(34-30)38-20-22(19-36(2)3)29(35-38)21-9-7-6-8-10-21/h5-12,17-18,20H,1,13-16,19H2,2-4H3,(H,32,39)(H,31,33,34)

> <stdInchikey>
RRMJMHOQSALEJJ-UHFFFAOYSA-N

> <csid>
64835231

> <Links>
|http://www.chemspider.com/Chemical-Structure.64835231.html|http://pubchem.ncbi.nlm.nih.gov/compound/121269225|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10136|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=4A2Y23XK11

> <LinkName>
|ChemSpider|PubChem|Guide to Pharmacology|FDA SRS

> <indicationG2P>
None

> <MW>
554.3

> <HBA>
10

> <HBD>
2

> <NRB>
10

> <TPSA>
109.7

> <LogP>
4.1

> <RoF>
1

> <Targets>
nan

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0330

> <r_epik_State_Penalty>
  0.0194

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
518

$$$$
Itacitinib
                    3D
 Structure written by MMmdl.
 63 68  0  0  1  0            999 V2000
   -5.5761    3.0524    2.3984 C   0  0  0  0  0  0
   -6.2817    3.8375    3.2914 C   0  0  0  0  0  0
   -7.4049    3.1655    3.7089 N   0  0  0  0  0  0
   -7.4527    1.9323    3.0976 C   0  0  0  0  0  0
   -8.3997    1.0018    3.2552 N   0  0  0  0  0  0
   -8.1751   -0.1155    2.5163 C   0  0  0  0  0  0
   -7.1359   -0.3640    1.6803 N   0  0  0  0  0  0
   -6.1872    0.6049    1.5478 C   0  0  0  0  0  0
   -6.3042    1.8209    2.2587 C   0  0  0  0  0  0
   -5.0619    0.2737    0.6189 C   0  0  0  0  0  0
   -4.9225   -0.8508   -0.2172 C   0  0  0  0  0  0
   -3.8113   -0.8584   -0.9162 N   0  0  0  0  0  0
   -3.1754    0.2602   -0.5487 N   0  0  0  0  0  0
   -3.8967    0.9850    0.3651 C   0  0  0  0  0  0
   -1.8750    0.5927   -1.1431 C   0  0  0  0  0  0
   -0.8509    1.3167   -0.2628 C   0  0  0  0  0  0
   -0.1444    0.0609   -0.0120 N   0  0  0  0  0  0
   -0.8124   -0.5119   -1.1806 C   0  0  0  0  0  0
    1.3178    0.0602    0.0562 C   0  0  0  0  0  0
    1.9133   -1.3666    0.1251 C   0  0  0  0  0  0
    1.6332   -2.0626    1.4785 C   0  0  0  0  0  0
    2.1815   -1.1869    2.5354 N   0  0  0  0  0  0
    1.5735    0.1590    2.6138 C   0  0  0  0  0  0
    1.8569    0.8625    1.2650 C   0  0  0  0  0  0
    3.2125   -1.6110    3.3192 C   0  0  0  0  0  0
    3.6914   -2.7450    3.2536 O   0  0  0  0  0  0
    3.8008   -0.6556    4.3245 C   0  0  0  0  0  0
    4.5387    0.4553    3.8943 C   0  0  0  0  0  0
    5.0652    1.3232    4.8500 C   0  0  0  0  0  0
    4.8969    1.1410    6.1829 N   0  0  0  0  0  0
    4.1816    0.0602    6.6012 C   0  0  0  0  0  0
    3.6186   -0.8582    5.7021 C   0  0  0  0  0  0
    2.9074   -1.9173    6.1622 F   0  0  0  0  0  0
    4.0139   -0.1108    8.1124 C   0  0  0  0  0  0
    4.5200   -1.2857    8.4887 F   0  0  0  0  0  0
    4.6258    0.8465    8.8150 F   0  0  0  0  0  0
    2.7173   -0.0859    8.4230 F   0  0  0  0  0  0
   -2.0506    1.2793   -2.5175 C   0  0  0  0  0  0
   -2.6201    0.4110   -3.5620 C   0  0  0  0  0  0
   -3.0673   -0.2702   -4.3831 N   0  0  0  0  0  0
   -4.6565    3.3492    1.9191 H   0  0  0  0  0  0
   -6.0800    4.8294    3.6690 H   0  0  0  0  0  0
   -8.0671    3.5552    4.3638 H   0  0  0  0  0  0
   -8.9117   -0.9006    2.6055 H   0  0  0  0  0  0
   -5.6372   -1.6557   -0.3095 H   0  0  0  0  0  0
   -3.5153    1.9182    0.7472 H   0  0  0  0  0  0
   -0.2427    2.0491   -0.7982 H   0  0  0  0  0  0
   -1.2341    1.7833    0.6449 H   0  0  0  0  0  0
   -1.1707   -1.5295   -1.0197 H   0  0  0  0  0  0
   -0.1906   -0.4989   -2.0785 H   0  0  0  0  0  0
    1.6775    0.5359   -0.8580 H   0  0  0  0  0  0
    1.5333   -1.9802   -0.6924 H   0  0  0  0  0  0
    2.9920   -1.3153   -0.0333 H   0  0  0  0  0  0
    0.5591   -2.1723    1.6337 H   0  0  0  0  0  0
    2.0622   -3.0657    1.4857 H   0  0  0  0  0  0
    0.4981    0.0452    2.7572 H   0  0  0  0  0  0
    1.9366    0.7589    3.4473 H   0  0  0  0  0  0
    2.9328    1.0048    1.1519 H   0  0  0  0  0  0
    1.4352    1.8681    1.2761 H   0  0  0  0  0  0
    4.7052    0.6447    2.8434 H   0  0  0  0  0  0
    5.6390    2.1883    4.5514 H   0  0  0  0  0  0
   -2.6952    2.1542   -2.4256 H   0  0  0  0  0  0
   -1.0934    1.6372   -2.8992 H   0  0  0  0  0  0
  1  9  1  0  0  0
  1 41  1  0  0  0
  1  2  2  0  0  0
  2 42  1  0  0  0
  2  3  1  0  0  0
  3 43  1  0  0  0
  3  4  1  0  0  0
  4  9  2  0  0  0
  4  5  1  0  0  0
  5  6  2  0  0  0
  6 44  1  0  0  0
  6  7  1  0  0  0
  7  8  2  0  0  0
  8 10  1  0  0  0
  8  9  1  0  0  0
 10 11  1  0  0  0
 10 14  2  0  0  0
 11 12  2  0  0  0
 11 45  1  0  0  0
 12 13  1  0  0  0
 13 14  1  0  0  0
 13 15  1  0  0  0
 14 46  1  0  0  0
 15 16  1  0  0  0
 15 18  1  0  0  0
 15 38  1  0  0  0
 16 17  1  0  0  0
 16 47  1  0  0  0
 16 48  1  0  0  0
 17 18  1  0  0  0
 17 19  1  0  0  0
 18 49  1  0  0  0
 18 50  1  0  0  0
 19 20  1  0  0  0
 19 24  1  0  0  0
 19 51  1  0  0  0
 20 21  1  0  0  0
 20 52  1  0  0  0
 20 53  1  0  0  0
 21 22  1  0  0  0
 21 54  1  0  0  0
 21 55  1  0  0  0
 22 23  1  0  0  0
 22 25  1  0  0  0
 23 24  1  0  0  0
 23 56  1  0  0  0
 23 57  1  0  0  0
 24 58  1  0  0  0
 24 59  1  0  0  0
 25 26  2  0  0  0
 25 27  1  0  0  0
 27 28  1  0  0  0
 27 32  2  0  0  0
 28 29  2  0  0  0
 28 60  1  0  0  0
 29 30  1  0  0  0
 29 61  1  0  0  0
 30 31  2  0  0  0
 31 32  1  0  0  0
 31 34  1  0  0  0
 32 33  1  0  0  0
 34 35  1  0  0  0
 34 36  1  0  0  0
 34 37  1  0  0  0
 38 39  1  0  0  0
 38 62  1  0  0  0
 38 63  1  0  0  0
 39 40  3  0  0  0
M  END
> <s_m_entry_id>
520

> <Applicants>
Incyte Corporation

> <CHEMBL_ID>
CHEMBL3622820

> <Canonical_Smiles>
Fc1c(ccnc1C(F)(F)F)C(=O)N1CCC(N2CC(n3ncc(c3)-c3nc[nH]c-4nccc3-4)(C2)CC#N)CC1

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
3

> <SC_Patent>
None

> <Synonyms>
INCB-039110 | INCB-39110 | INCB039110 | ITACITINIB

> <Indications>
nan

> <Type>
nan

> <targets_id>
P23458

> <inchi>
InChI=1S/C26H23F4N9O/c27-20-18(1-7-32-22(20)26(28,29)30)24(40)37-9-3-17(4-10-37)38-13-25(14-38,5-6-31)39-12-16(11-36-39)21-19-2-8-33-23(19)35-15-34-21/h1-2,7-8,11-12,15,17H,3-5,9-10,13-14H2,(H,33,34,35)

> <stdInchikey>
KTBSXLIQKWEBRB-UHFFFAOYSA-N

> <csid>
35033258

> <Links>
|http://www.chemspider.com/Chemical-Structure.35033258.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3622820|http://pubchem.ncbi.nlm.nih.gov/compound/53380437|http://www.drugbank.ca/drugs/DB12154|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8364|http://zinc15.docking.org/substances/ZINC000118795962|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=19J3781LPM|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=246868

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
553.2

> <HBA>
8

> <HBD>
1

> <NRB>
5

> <TPSA>
119.6

> <LogP>
3.6

> <RoF>
1

> <Targets>
JAK1

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
0.999998

> <r_epik_Ionization_Penalty>
  0.1178

> <r_epik_State_Penalty>
  0.1074

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
520

> <Kinase families>
Tyr

> <Withdrawn>
|Study NCT03627052 in nan was Withdrawn during Phase 2 because Study withdrawn due to lack of recruitment No patients enrolled No safety concerns|Study NCT02355431 in United States was Withdrawn during Phase 2 because Study withdrawn before enrolling first patient

$$$$
Ipatasertib
                    3D
 Structure written by MMmdl.
 65 68  0  0  1  0            999 V2000
   -6.9242   -1.7933   -1.1912 C   0  0  0  0  0  0
   -7.2913   -2.0680    0.2781 C   0  0  2  0  0  0
   -8.7977   -2.3101    0.4801 C   0  0  0  0  0  0
   -9.3998   -0.9522    0.8613 C   0  0  2  0  0  0
   -8.2361   -0.2818    1.5618 C   0  0  0  0  0  0
   -7.0327   -0.9016    1.2184 C   0  0  0  0  0  0
   -5.8635   -0.3978    1.8088 C   0  0  0  0  0  0
   -5.9074    0.6502    2.6837 N   0  0  0  0  0  0
   -7.1310    1.1766    2.9502 C   0  0  0  0  0  0
   -8.3137    0.7605    2.4303 N   0  0  0  0  0  0
   -4.6240   -0.9478    1.5193 N   0  0  0  0  0  0
   -3.8864   -0.3271    0.4067 C   0  0  0  0  0  0
   -2.7623   -1.2542   -0.1175 C   0  0  0  0  0  0
   -1.8452   -1.4673    1.0160 N   0  0  0  0  0  0
   -2.5033   -2.1057    2.1703 C   0  0  0  0  0  0
   -3.6449   -1.1511    2.6028 C   0  0  0  0  0  0
   -0.6184   -0.8870    1.1365 C   0  0  0  0  0  0
    0.0263   -0.9434    2.1875 O   0  0  0  0  0  0
    0.0073   -0.1160   -0.0648 C   0  0  2  0  0  0
    1.5559   -0.0003   -0.0207 C   0  0  0  0  0  0
    2.2174   -1.3912    0.0538 N   0  3  0  0  0  0
    3.7575   -1.4000    0.0503 C   0  0  0  0  0  0
    4.2188   -2.8389   -0.2276 C   0  0  0  0  0  0
    4.2916   -0.8508    1.3862 C   0  0  0  0  0  0
   -0.6231    1.2754   -0.2238 C   0  0  0  0  0  0
   -1.1581    1.6539   -1.4604 C   0  0  0  0  0  0
   -1.7293    2.9131   -1.6224 C   0  0  0  0  0  0
   -1.7591    3.8022   -0.5502 C   0  0  0  0  0  0
   -1.2169    3.4426    0.6818 C   0  0  0  0  0  0
   -0.6453    2.1839    0.8437 C   0  0  0  0  0  0
   -2.4687    5.3624   -0.7514 Cl  0  0  0  0  0  0
  -10.5705   -1.0530    1.6483 O   0  0  0  0  0  0
   -5.8476   -1.6879   -1.3185 H   0  0  0  0  0  0
   -7.3964   -0.8822   -1.5607 H   0  0  0  0  0  0
   -7.2409   -2.6149   -1.8342 H   0  0  0  0  0  0
   -6.7426   -2.9535    0.6032 H   0  0  0  0  0  0
   -9.2858   -2.7491   -0.3914 H   0  0  0  0  0  0
   -8.9335   -3.0181    1.3008 H   0  0  0  0  0  0
   -9.6368   -0.3988   -0.0488 H   0  0  0  0  0  0
   -7.1660    2.0051    3.6424 H   0  0  0  0  0  0
   -4.5704   -0.1073   -0.4128 H   0  0  0  0  0  0
   -3.4748    0.6352    0.7194 H   0  0  0  0  0  0
   -3.1831   -2.2156   -0.4156 H   0  0  0  0  0  0
   -2.2940   -0.8282   -1.0015 H   0  0  0  0  0  0
   -2.9155   -3.0664    1.8577 H   0  0  0  0  0  0
   -1.8224   -2.3013    2.9998 H   0  0  0  0  0  0
   -3.2374   -0.1943    2.9367 H   0  0  0  0  0  0
   -4.1557   -1.5894    3.4613 H   0  0  0  0  0  0
   -0.2145   -0.6972   -0.9610 H   0  0  0  0  0  0
    1.9589    0.4569   -0.9258 H   0  0  0  0  0  0
    1.9048    0.5507    0.8532 H   0  0  0  0  0  0
    1.8916   -1.8643    0.8854 H   0  0  0  0  0  0
    4.0358   -0.7540   -0.7843 H   0  0  0  0  0  0
    5.3066   -2.8959   -0.2844 H   0  0  0  0  0  0
    3.8260   -3.2078   -1.1761 H   0  0  0  0  0  0
    3.8933   -3.5249    0.5557 H   0  0  0  0  0  0
    5.3800   -0.9103    1.4228 H   0  0  0  0  0  0
    3.9035   -1.4146    2.2356 H   0  0  0  0  0  0
    4.0289    0.1966    1.5330 H   0  0  0  0  0  0
   -1.1393    0.9725   -2.2988 H   0  0  0  0  0  0
   -2.1464    3.1974   -2.5777 H   0  0  0  0  0  0
   -1.2371    4.1356    1.5104 H   0  0  0  0  0  0
   -0.2241    1.9150    1.8016 H   0  0  0  0  0  0
  -10.9420   -0.1739    1.7545 H   0  0  0  0  0  0
    1.9022   -1.9233   -0.7447 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 33  1  0  0  0
  1 34  1  0  0  0
  1 35  1  0  0  0
  2  3  1  0  0  0
  2  6  1  0  0  0
  2 36  1  0  0  0
  3  4  1  0  0  0
  3 37  1  0  0  0
  3 38  1  0  0  0
  4  5  1  0  0  0
  4 32  1  0  0  0
  4 39  1  0  0  0
  5  6  2  0  0  0
  5 10  1  0  0  0
  6  7  1  0  0  0
  7  8  2  0  0  0
  7 11  1  0  0  0
  8  9  1  0  0  0
  9 10  2  0  0  0
  9 40  1  0  0  0
 11 12  1  0  0  0
 11 16  1  0  0  0
 12 13  1  0  0  0
 12 41  1  0  0  0
 12 42  1  0  0  0
 13 14  1  0  0  0
 13 43  1  0  0  0
 13 44  1  0  0  0
 14 15  1  0  0  0
 14 17  1  0  0  0
 15 16  1  0  0  0
 15 45  1  0  0  0
 15 46  1  0  0  0
 16 47  1  0  0  0
 16 48  1  0  0  0
 17 18  2  0  0  0
 17 19  1  0  0  0
 19 20  1  0  0  0
 19 25  1  0  0  0
 19 49  1  0  0  0
 20 21  1  0  0  0
 20 50  1  0  0  0
 20 51  1  0  0  0
 21 22  1  0  0  0
 21 52  1  0  0  0
 21 65  1  0  0  0
 22 23  1  0  0  0
 22 24  1  0  0  0
 22 53  1  0  0  0
 23 54  1  0  0  0
 23 55  1  0  0  0
 23 56  1  0  0  0
 24 57  1  0  0  0
 24 58  1  0  0  0
 24 59  1  0  0  0
 25 26  1  0  0  0
 25 30  2  0  0  0
 26 27  2  0  0  0
 26 60  1  0  0  0
 27 28  1  0  0  0
 27 61  1  0  0  0
 28 29  2  0  0  0
 28 31  1  0  0  0
 29 30  1  0  0  0
 29 62  1  0  0  0
 30 63  1  0  0  0
 32 64  1  0  0  0
M  CHG  1  21   1
M  END
> <s_m_entry_id>
526

> <Applicants>
Hoffmann-La Roche

> <CHEMBL_ID>
CHEMBL2177390

> <Canonical_Smiles>
Clc1ccc(cc1)[C@H](C(=O)N1CCN(CC1)c1ncnc2c1[C@@H](C[C@H]2O)C)CNC(C)C

> <Chirality>
Single Stereoisomer

> <First_Approval>
nan

> <Phase>
3

> <SC_Patent>
None

> <Synonyms>
GDC-0068 | IPATASERTIB | RG-7440 | RG7440

> <Indications>
nan

> <Type>
1

> <targets_id>
P31749|P31751|Q9Y243

> <inchi>
InChI=1S/C24H32ClN5O2/c1-15(2)26-13-19(17-4-6-18(25)7-5-17)24(32)30-10-8-29(9-11-30)23-21-16(3)12-20(31)22(21)27-14-28-23/h4-7,14-16,19-20,26,31H,8-13H2,1-3H3/t16-,19-,20-/m1/s1

> <stdInchikey>
GRZXWCHAXNAUHY-NSISKUIASA-N

> <csid>
28189084

> <Links>
|http://www.chemspider.com/Chemical-Structure.28189084.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2177390|http://pubchem.ncbi.nlm.nih.gov/compound/24788740|http://www.drugbank.ca/drugs/DB11743| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=0RF|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/0RF|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7887|http://zinc15.docking.org/substances/ZINC000068250459|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=524Y3IB4HQ|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50398379

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
457.2

> <HBA>
6

> <HBD>
2

> <NRB>
6

> <TPSA>
81.6

> <LogP>
3.1

> <RoF>
0

> <Targets>
AKT1; AKT2; AKT3

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0051

> <r_epik_State_Penalty>
  0.0000

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
526

> <lig_pdbID>
'0RF'

> <pdbID>
4ekl

> <Kinase families>
AGC

$$$$
Lestaurtinib
                    3D
 Structure written by MMmdl.
 54 61  0  0  1  0            999 V2000
    0.6059   -1.4484    2.1042 C   0  0  0  0  0  0
   -0.4954   -0.7730    1.2683 C   0  0  1  0  0  0
    0.0007   -0.0221   -0.0398 C   0  0  2  0  0  0
   -0.5717   -0.9026   -1.1622 C   0  0  0  0  0  0
   -1.7108   -1.6208   -0.4828 C   0  0  1  0  0  0
   -1.2278   -1.8733    0.7917 O   0  0  0  0  0  0
   -2.9839   -0.9210   -0.4353 N   0  0  0  0  0  0
   -3.9975   -0.9973   -1.3825 C   0  0  0  0  0  0
   -4.0491   -1.7082   -2.5912 C   0  0  0  0  0  0
   -5.2132   -1.6066   -3.3498 C   0  0  0  0  0  0
   -6.2905   -0.8329   -2.9352 C   0  0  0  0  0  0
   -6.2477   -0.1231   -1.7384 C   0  0  0  0  0  0
   -5.0926   -0.1931   -0.9374 C   0  0  0  0  0  0
   -4.7273    0.3838    0.3023 C   0  0  0  0  0  0
   -3.4125   -0.0618    0.5629 C   0  0  0  0  0  0
   -2.7235    0.3391    1.7107 C   0  0  0  0  0  0
   -1.4186    0.0355    2.1027 N   0  0  0  0  0  0
   -1.2130    0.6938    3.3314 C   0  0  0  0  0  0
   -0.0969    0.7801    4.1875 C   0  0  0  0  0  0
   -0.2175    1.5286    5.3576 C   0  0  0  0  0  0
   -1.3921    2.1880    5.6914 C   0  0  0  0  0  0
   -2.5015    2.1304    4.8578 C   0  0  0  0  0  0
   -2.4206    1.3878    3.6687 C   0  0  0  0  0  0
   -3.3480    1.1762    2.6436 C   0  0  0  0  0  0
   -4.6618    1.6152    2.4042 C   0  0  0  0  0  0
   -5.3422    1.2363    1.2505 C   0  0  0  0  0  0
   -6.7024    1.8727    1.2761 C   0  0  0  0  0  0
   -7.6179    1.7996    0.4619 O   0  0  0  0  0  0
   -6.7330    2.5788    2.4187 N   0  0  0  0  0  0
   -5.5344    2.5062    3.2338 C   0  0  0  0  0  0
    1.5473    0.1557   -0.1396 C   0  0  0  0  0  0
    1.9593    0.7278   -1.3698 O   0  0  0  0  0  0
   -0.5060    1.3065   -0.1446 O   0  0  0  0  0  0
    1.4120   -0.7579    2.3383 H   0  0  0  0  0  0
    1.0496   -2.2715    1.5413 H   0  0  0  0  0  0
    0.1947   -1.8631    3.0258 H   0  0  0  0  0  0
   -0.9096   -0.3646   -2.0499 H   0  0  0  0  0  0
    0.1518   -1.6563   -1.4783 H   0  0  0  0  0  0
   -1.9200   -2.5675   -0.9829 H   0  0  0  0  0  0
   -3.2241   -2.3146   -2.9345 H   0  0  0  0  0  0
   -5.2804   -2.1438   -4.2844 H   0  0  0  0  0  0
   -7.1754   -0.7811   -3.5523 H   0  0  0  0  0  0
   -7.1024    0.4659   -1.4545 H   0  0  0  0  0  0
    0.8460    0.3034    3.9937 H   0  0  0  0  0  0
    0.6295    1.5999    6.0241 H   0  0  0  0  0  0
   -1.4414    2.7586    6.6071 H   0  0  0  0  0  0
   -3.4046    2.6575    5.1266 H   0  0  0  0  0  0
   -7.5338    3.1234    2.7035 H   0  0  0  0  0  0
   -5.7615    2.0802    4.2118 H   0  0  0  0  0  0
   -5.1074    3.4998    3.3738 H   0  0  0  0  0  0
    1.9232    0.7834    0.6701 H   0  0  0  0  0  0
    2.0571   -0.8043   -0.0565 H   0  0  0  0  0  0
    2.9141    0.8274   -1.3567 H   0  0  0  0  0  0
   -0.1877    1.6849   -0.9679 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 34  1  0  0  0
  1 35  1  0  0  0
  1 36  1  0  0  0
  2  3  1  0  0  0
  2  6  1  0  0  0
  2 17  1  0  0  0
  3  4  1  0  0  0
  3 31  1  0  0  0
  3 33  1  0  0  0
  4  5  1  0  0  0
  4 37  1  0  0  0
  4 38  1  0  0  0
  5  6  1  0  0  0
  5  7  1  0  0  0
  5 39  1  0  0  0
  7  8  1  0  0  0
  7 15  1  0  0  0
  8  9  1  0  0  0
  8 13  2  0  0  0
  9 10  2  0  0  0
  9 40  1  0  0  0
 10 11  1  0  0  0
 10 41  1  0  0  0
 11 12  2  0  0  0
 11 42  1  0  0  0
 12 13  1  0  0  0
 12 43  1  0  0  0
 13 14  1  0  0  0
 14 15  2  0  0  0
 14 26  1  0  0  0
 15 16  1  0  0  0
 16 17  1  0  0  0
 16 24  2  0  0  0
 17 18  1  0  0  0
 18 19  2  0  0  0
 18 23  1  0  0  0
 19 20  1  0  0  0
 19 44  1  0  0  0
 20 21  2  0  0  0
 20 45  1  0  0  0
 21 22  1  0  0  0
 21 46  1  0  0  0
 22 23  2  0  0  0
 22 47  1  0  0  0
 23 24  1  0  0  0
 24 25  1  0  0  0
 25 26  2  0  0  0
 25 30  1  0  0  0
 26 27  1  0  0  0
 27 28  2  0  0  0
 27 29  1  0  0  0
 29 30  1  0  0  0
 29 48  1  0  0  0
 30 49  1  0  0  0
 30 50  1  0  0  0
 31 32  1  0  0  0
 31 51  1  0  0  0
 31 52  1  0  0  0
 32 53  1  0  0  0
 33 54  1  0  0  0
M  END
> <s_m_entry_id>
527

> <Applicants>
Cephalon

> <CHEMBL_ID>
CHEMBL603469

> <Canonical_Smiles>
O1[C@H]2n3c4c(c5c(CNC5=O)c5c6c(n(c45)[C@]1(C)[C@](O)(C2)CO)cccc6)c1c3cccc1

> <Chirality>
Single Stereoisomer

> <First_Approval>
nan

> <Phase>
3

> <SC_Patent>
None

> <Synonyms>
A-154475 | A-154475.0 | CEP-701 | KT-555 | KT-5555 | KT5555 | LESTAURTINIB | SP-924 | SP924 | SPM-924

> <Indications>
nan

> <Type>
nan

> <targets_id>
P36888

> <inchi>
InChI=1S/C26H21N3O4/c1-25-26(32,12-30)10-18(33-25)28-16-8-4-2-6-13(16)20-21-15(11-27-24(21)31)19-14-7-3-5-9-17(14)29(25)23(19)22(20)28/h2-9,18,30,32H,10-12H2,1H3,(H,27,31)/t18-,25+,26+/m1/s1

> <stdInchikey>
UIARLYUEJFELEN-LROUJFHJSA-N

> <csid>
112457

> <Links>
|http://www.chemspider.com/Chemical-Structure.112457.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL603469|http://pubchem.ncbi.nlm.nih.gov/compound/126565|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5672|http://zinc15.docking.org/substances/ZINC03781738|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=DO989GC5D1|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50308060

> <LinkName>
|ChemSpider|ChEMBL|PubChem|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
439.2

> <HBA>
6

> <HBD>
3

> <NRB>
1

> <TPSA>
88.7

> <LogP>
3.5

> <RoF>
0

> <Targets>
FLT3

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0000

> <r_epik_State_Penalty>
  0.0000

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
527

> <Kinase families>
Tyr

$$$$
Infigratinib
                    3D
 Structure written by MMmdl.
 70 73  0  0  1  0            999 V2000
   -3.5204   -9.8810   -5.4992 C   0  0  0  0  0  0
   -2.5957   -8.6611   -5.3617 C   0  0  0  0  0  0
   -1.7892   -8.7111   -4.0421 N   0  3  0  0  0  0
   -2.7044   -8.5936   -2.7940 C   0  0  0  0  0  0
   -1.8374   -8.4222   -1.5257 C   0  0  0  0  0  0
   -0.9833   -7.2323   -1.6634 N   0  0  0  0  0  0
    0.0151   -7.5608   -2.6923 C   0  0  0  0  0  0
   -0.6700   -7.6385   -4.0745 C   0  0  0  0  0  0
   -1.3878   -5.9298   -1.3406 C   0  0  0  0  0  0
   -2.4923   -5.6977   -0.5041 C   0  0  0  0  0  0
   -2.8901   -4.4043   -0.1768 C   0  0  0  0  0  0
   -2.1865   -3.3072   -0.6681 C   0  0  0  0  0  0
   -1.0968   -3.5167   -1.5149 C   0  0  0  0  0  0
   -0.6993   -4.8107   -1.8379 C   0  0  0  0  0  0
   -2.6309   -2.0213   -0.3217 N   0  0  0  0  0  0
   -1.9255   -0.8295   -0.0981 C   0  0  0  0  0  0
   -0.5288   -0.7769    0.0212 C   0  0  0  0  0  0
    0.0471    0.4752    0.2681 C   0  0  0  0  0  0
   -0.6989    1.6058    0.3984 N   0  0  0  0  0  0
   -2.0410    1.4497    0.2838 C   0  0  0  0  0  0
   -2.6923    0.2829    0.0476 N   0  0  0  0  0  0
    1.4430    0.5777    0.4015 N   0  0  0  0  0  0
    2.1926    0.6933   -0.8551 C   0  0  0  0  0  0
    2.0888    0.5436    1.6064 C   0  0  0  0  0  0
    3.3191    0.6032    1.6988 O   0  0  0  0  0  0
    1.3006    0.4308    2.7036 N   0  0  0  0  0  0
    1.7868    0.3217    4.0140 C   0  0  0  0  0  0
    2.0304   -0.9471    4.5634 C   0  0  0  0  0  0
    2.5194   -1.0663    5.8697 C   0  0  0  0  0  0
    2.7515    0.0994    6.6172 C   0  0  0  0  0  0
    2.4985    1.3741    6.0860 C   0  0  0  0  0  0
    2.0092    1.4781    4.7785 C   0  0  0  0  0  0
    1.6835    3.0521    4.1192 Cl  0  0  0  0  0  0
    2.7063    2.5517    6.7835 O   0  0  0  0  0  0
    3.2258    2.5049    8.1080 C   0  0  0  0  0  0
    2.7481   -2.3445    6.3492 O   0  0  0  0  0  0
    3.2667   -2.5230    7.6626 C   0  0  0  0  0  0
    1.7305   -2.3862    3.6369 Cl  0  0  0  0  0  0
   -3.9892   -9.8941   -6.4835 H   0  0  0  0  0  0
   -4.3245   -9.8702   -4.7635 H   0  0  0  0  0  0
   -2.9687  -10.8152   -5.3870 H   0  0  0  0  0  0
   -1.8492   -8.6575   -6.1579 H   0  0  0  0  0  0
   -3.1361   -7.7127   -5.3681 H   0  0  0  0  0  0
   -3.3699   -7.7421   -2.9492 H   0  0  0  0  0  0
   -3.2955   -9.5080   -2.7453 H   0  0  0  0  0  0
   -2.4519   -8.3837   -0.6287 H   0  0  0  0  0  0
   -1.2231   -9.3139   -1.3855 H   0  0  0  0  0  0
    0.8415   -6.8520   -2.6929 H   0  0  0  0  0  0
    0.4887   -8.5192   -2.4694 H   0  0  0  0  0  0
    0.0290   -7.9423   -4.8548 H   0  0  0  0  0  0
   -1.1284   -6.6876   -4.3540 H   0  0  0  0  0  0
   -3.0676   -6.5074   -0.0851 H   0  0  0  0  0  0
   -3.7451   -4.2623    0.4689 H   0  0  0  0  0  0
   -0.5585   -2.6841   -1.9430 H   0  0  0  0  0  0
    0.1488   -4.9127   -2.4962 H   0  0  0  0  0  0
   -3.5622   -1.9994    0.0675 H   0  0  0  0  0  0
    0.0909   -1.6578   -0.0483 H   0  0  0  0  0  0
   -2.6480    2.3364    0.3946 H   0  0  0  0  0  0
    3.2654    0.8287   -0.7119 H   0  0  0  0  0  0
    1.8304    1.5464   -1.4298 H   0  0  0  0  0  0
    2.0515   -0.2036   -1.4591 H   0  0  0  0  0  0
    0.2985    0.4011    2.5832 H   0  0  0  0  0  0
    3.1283    0.0135    7.6232 H   0  0  0  0  0  0
    3.3304    3.5211    8.4882 H   0  0  0  0  0  0
    4.2130    2.0411    8.1343 H   0  0  0  0  0  0
    2.5568    1.9684    8.7824 H   0  0  0  0  0  0
    3.3875   -3.5885    7.8578 H   0  0  0  0  0  0
    2.5890   -2.1244    8.4190 H   0  0  0  0  0  0
    4.2462   -2.0553    7.7730 H   0  0  0  0  0  0
   -1.3292   -9.6095   -3.9947 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 39  1  0  0  0
  1 40  1  0  0  0
  1 41  1  0  0  0
  2  3  1  0  0  0
  2 42  1  0  0  0
  2 43  1  0  0  0
  3  4  1  0  0  0
  3  8  1  0  0  0
  3 70  1  0  0  0
  4  5  1  0  0  0
  4 44  1  0  0  0
  4 45  1  0  0  0
  5  6  1  0  0  0
  5 46  1  0  0  0
  5 47  1  0  0  0
  6  7  1  0  0  0
  6  9  1  0  0  0
  7  8  1  0  0  0
  7 48  1  0  0  0
  7 49  1  0  0  0
  8 50  1  0  0  0
  8 51  1  0  0  0
  9 10  1  0  0  0
  9 14  2  0  0  0
 10 11  2  0  0  0
 10 52  1  0  0  0
 11 12  1  0  0  0
 11 53  1  0  0  0
 12 13  2  0  0  0
 12 15  1  0  0  0
 13 14  1  0  0  0
 13 54  1  0  0  0
 14 55  1  0  0  0
 15 16  1  0  0  0
 15 56  1  0  0  0
 16 17  1  0  0  0
 16 21  2  0  0  0
 17 18  2  0  0  0
 17 57  1  0  0  0
 18 19  1  0  0  0
 18 22  1  0  0  0
 19 20  2  0  0  0
 20 21  1  0  0  0
 20 58  1  0  0  0
 22 23  1  0  0  0
 22 24  1  0  0  0
 23 59  1  0  0  0
 23 60  1  0  0  0
 23 61  1  0  0  0
 24 25  2  0  0  0
 24 26  1  0  0  0
 26 27  1  0  0  0
 26 62  1  0  0  0
 27 28  1  0  0  0
 27 32  2  0  0  0
 28 29  2  0  0  0
 28 38  1  0  0  0
 29 30  1  0  0  0
 29 36  1  0  0  0
 30 31  2  0  0  0
 30 63  1  0  0  0
 31 32  1  0  0  0
 31 34  1  0  0  0
 32 33  1  0  0  0
 34 35  1  0  0  0
 35 64  1  0  0  0
 35 65  1  0  0  0
 35 66  1  0  0  0
 36 37  1  0  0  0
 37 67  1  0  0  0
 37 68  1  0  0  0
 37 69  1  0  0  0
M  CHG  1   3   1
M  END
> <s_m_entry_id>
528

> <Applicants>
Novartis

> <CHEMBL_ID>
CHEMBL1852688

> <Canonical_Smiles>
Clc1c(NC(=O)N(C)c2ncnc(Nc3ccc(N4CCN(CC4)CC)cc3)c2)c(Cl)c(OC)cc1OC

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
3

> <SC_Patent>
None

> <Synonyms>
BGJ-398 | BGJ398 | INFIGRATINIB | MVP-BGJ398 | NVP-BGJ398

> <Indications>
nan

> <Type>
1

> <targets_id>
P11362|P21802|P22607

> <inchi>
InChI=1S/C26H31Cl2N7O3/c1-5-34-10-12-35(13-11-34)18-8-6-17(7-9-18)31-21-15-22(30-16-29-21)33(2)26(36)32-25-23(27)19(37-3)14-20(38-4)24(25)28/h6-9,14-16H,5,10-13H2,1-4H3,(H,32,36)(H,29,30,31)

> <stdInchikey>
QADPYRIHXKWUSV-UHFFFAOYSA-N

> <csid>
26333103

> <Links>
|http://www.chemspider.com/Chemical-Structure.26333103.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1852688|http://pubchem.ncbi.nlm.nih.gov/compound/53235510|http://www.drugbank.ca/drugs/DB11886| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=07J|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/07J|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7877|http://zinc15.docking.org/substances/ZINC000072105034|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=A4055ME1VK|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50355393

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
559.2

> <HBA>
8

> <HBD>
2

> <NRB>
8

> <TPSA>
95.1

> <LogP>
5.4

> <RoF>
2

> <Targets>
FGFR1; FGFR2; FGFR3

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.1179

> <r_epik_State_Penalty>
  0.5668

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
528

> <lig_pdbID>
'07J'

> <pdbID>
3tt0

> <Kinase families>
Tyr

$$$$
Quizartinib
                    3D
 Structure written by MMmdl.
 72 77  0  0  1  0            999 V2000
  -11.4593   -2.7543    0.8387 C   0  0  0  0  0  0
  -10.9787   -2.7368   -0.6298 C   0  0  0  0  0  0
  -11.4183   -4.0545   -1.3140 C   0  0  0  0  0  0
  -11.6326   -1.5473   -1.3663 C   0  0  0  0  0  0
   -9.4586   -2.5655   -0.6594 C   0  0  0  0  0  0
   -8.5855   -1.6486   -0.1081 C   0  0  0  0  0  0
   -7.3104   -2.0419   -0.5093 C   0  0  0  0  0  0
   -7.3702   -3.1256   -1.2620 N   0  0  0  0  0  0
   -8.7200   -3.4626   -1.3638 O   0  0  0  0  0  0
   -6.1532   -1.3627   -0.1479 N   0  0  0  0  0  0
   -4.8845   -1.6740   -0.4899 C   0  0  0  0  0  0
   -4.5574   -2.6287   -1.1983 O   0  0  0  0  0  0
   -4.0268   -0.7825    0.0483 N   0  0  0  0  0  0
   -2.6211   -0.7666   -0.0207 C   0  0  0  0  0  0
   -2.0020    0.4661    0.1894 C   0  0  0  0  0  0
   -0.6146    0.5714    0.1438 C   0  0  0  0  0  0
    0.1783   -0.5559   -0.1017 C   0  0  0  0  0  0
   -0.4472   -1.7952   -0.2913 C   0  0  0  0  0  0
   -1.8342   -1.9049   -0.2482 C   0  0  0  0  0  0
    1.6740   -0.4209   -0.1600 C   0  0  0  0  0  0
    2.4291    0.7413    0.0534 C   0  0  0  0  0  0
    3.7390    0.3472   -0.1314 N   0  0  0  0  0  0
    4.9340    0.9340   -0.0908 C   0  0  0  0  0  0
    5.1881    2.2809    0.1874 C   0  0  0  0  0  0
    6.5263    2.6810    0.1722 C   0  0  0  0  0  0
    7.5791    1.8029   -0.1018 C   0  0  0  0  0  0
    7.3107    0.4509   -0.3795 C   0  0  0  0  0  0
    5.9775    0.0216   -0.3724 C   0  0  0  0  0  0
    5.3059   -1.5826   -0.6774 S   0  0  0  0  0  0
    3.6827   -0.9887   -0.4259 C   0  0  0  0  0  0
    2.4569   -1.4562   -0.4426 N   0  0  0  0  0  0
    8.8467    2.3518   -0.0795 O   0  0  0  0  0  0
    9.9801    1.5176   -0.3138 C   0  0  0  0  0  0
   11.2800    2.3425   -0.2160 C   0  0  0  0  0  0
   11.4037    3.1111    1.0284 N   0  0  0  0  0  0
   12.5380    4.0366    0.9342 C   0  0  0  0  0  0
   12.6821    4.8621    2.2309 C   0  0  0  0  0  0
   12.7859    4.0088    3.3670 O   0  0  0  0  0  0
   11.6991    3.0961    3.4906 C   0  0  0  0  0  0
   11.5378    2.2486    2.2098 C   0  0  0  0  0  0
  -12.5430   -2.8615    0.9047 H   0  0  0  0  0  0
  -11.1944   -1.8343    1.3622 H   0  0  0  0  0  0
  -11.0173   -3.5829    1.3945 H   0  0  0  0  0  0
  -10.9795   -4.9261   -0.8258 H   0  0  0  0  0  0
  -11.1196   -4.0829   -2.3631 H   0  0  0  0  0  0
  -12.5017   -4.1797   -1.2854 H   0  0  0  0  0  0
  -12.7210   -1.6223   -1.3621 H   0  0  0  0  0  0
  -11.3146   -1.4987   -2.4088 H   0  0  0  0  0  0
  -11.3728   -0.5943   -0.9029 H   0  0  0  0  0  0
   -8.8426   -0.8002    0.5086 H   0  0  0  0  0  0
   -6.2899   -0.5511    0.4359 H   0  0  0  0  0  0
   -4.4341    0.0072    0.5271 H   0  0  0  0  0  0
   -2.5910    1.3521    0.3800 H   0  0  0  0  0  0
   -0.1651    1.5409    0.2986 H   0  0  0  0  0  0
    0.1365   -2.6860   -0.4717 H   0  0  0  0  0  0
   -2.2728   -2.8818   -0.3810 H   0  0  0  0  0  0
    2.1409    1.7523    0.3004 H   0  0  0  0  0  0
    4.3988    2.9864    0.4029 H   0  0  0  0  0  0
    6.7544    3.7161    0.3822 H   0  0  0  0  0  0
    8.0995   -0.2529   -0.5964 H   0  0  0  0  0  0
   10.0080    0.6834    0.3889 H   0  0  0  0  0  0
    9.9177    1.0793   -1.3112 H   0  0  0  0  0  0
   12.1429    1.6850   -0.3355 H   0  0  0  0  0  0
   11.3055    3.0256   -1.0669 H   0  0  0  0  0  0
   13.4642    3.4936    0.7377 H   0  0  0  0  0  0
   12.3896    4.7159    0.0934 H   0  0  0  0  0  0
   13.5765    5.4830    2.1779 H   0  0  0  0  0  0
   11.8421    5.5494    2.3479 H   0  0  0  0  0  0
   11.8855    2.4454    4.3450 H   0  0  0  0  0  0
   10.7769    3.6351    3.7159 H   0  0  0  0  0  0
   10.6531    1.6215    2.3196 H   0  0  0  0  0  0
   12.3890    1.5742    2.1008 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 41  1  0  0  0
  1 42  1  0  0  0
  1 43  1  0  0  0
  2  3  1  0  0  0
  2  4  1  0  0  0
  2  5  1  0  0  0
  3 44  1  0  0  0
  3 45  1  0  0  0
  3 46  1  0  0  0
  4 47  1  0  0  0
  4 48  1  0  0  0
  4 49  1  0  0  0
  5  6  2  0  0  0
  5  9  1  0  0  0
  6  7  1  0  0  0
  6 50  1  0  0  0
  7  8  2  0  0  0
  7 10  1  0  0  0
  8  9  1  0  0  0
 10 11  1  0  0  0
 10 51  1  0  0  0
 11 12  2  0  0  0
 11 13  1  0  0  0
 13 14  1  0  0  0
 13 52  1  0  0  0
 14 15  1  0  0  0
 14 19  2  0  0  0
 15 16  2  0  0  0
 15 53  1  0  0  0
 16 17  1  0  0  0
 16 54  1  0  0  0
 17 18  2  0  0  0
 17 20  1  0  0  0
 18 19  1  0  0  0
 18 55  1  0  0  0
 19 56  1  0  0  0
 20 21  2  0  0  0
 20 31  1  0  0  0
 21 22  1  0  0  0
 21 57  1  0  0  0
 22 23  1  0  0  0
 22 30  1  0  0  0
 23 24  1  0  0  0
 23 28  2  0  0  0
 24 25  2  0  0  0
 24 58  1  0  0  0
 25 26  1  0  0  0
 25 59  1  0  0  0
 26 27  2  0  0  0
 26 32  1  0  0  0
 27 28  1  0  0  0
 27 60  1  0  0  0
 28 29  1  0  0  0
 29 30  1  0  0  0
 30 31  2  0  0  0
 32 33  1  0  0  0
 33 34  1  0  0  0
 33 61  1  0  0  0
 33 62  1  0  0  0
 34 35  1  0  0  0
 34 63  1  0  0  0
 34 64  1  0  0  0
 35 36  1  0  0  0
 35 40  1  0  0  0
 36 37  1  0  0  0
 36 65  1  0  0  0
 36 66  1  0  0  0
 37 38  1  0  0  0
 37 67  1  0  0  0
 37 68  1  0  0  0
 38 39  1  0  0  0
 39 40  1  0  0  0
 39 69  1  0  0  0
 39 70  1  0  0  0
 40 71  1  0  0  0
 40 72  1  0  0  0
M  END
> <s_m_entry_id>
531

> <Applicants>
Ambit Biosciences

> <CHEMBL_ID>
CHEMBL576982

> <Canonical_Smiles>
S1c2cc(OCCN3CCOCC3)ccc2-n2cc(nc12)-c1ccc(NC(=O)Nc2noc(c2)C(C)(C)C)cc1

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
3

> <SC_Patent>
None

> <Synonyms>
AC-010220 | AC-220 | AC010220 | AC220 | ASP-2689 | QUIZARTINIB

> <Indications>
nan

> <Type>
2

> <targets_id>
P36888|P07333|P10721

> <inchi>
InChI=1S/C29H32N6O4S/c1-29(2,3)25-17-26(33-39-25)32-27(36)30-20-6-4-19(5-7-20)22-18-35-23-9-8-21(16-24(23)40-28(35)31-22)38-15-12-34-10-13-37-14-11-34/h4-9,16-18H,10-15H2,1-3H3,(H2,30,32,33,36)

> <stdInchikey>
CVWXJKQAOSCOAB-UHFFFAOYSA-N

> <csid>
24640357

> <Links>
|http://www.chemspider.com/Chemical-Structure.24640357.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL576982|http://pubchem.ncbi.nlm.nih.gov/compound/24889392|http://www.drugbank.ca/drugs/DB12874| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=P30|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/P30|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5658|http://zinc15.docking.org/substances/ZINC43204002|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=7LA4O6Q0D3|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50300690

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
560.2

> <HBA>
9

> <HBD>
2

> <NRB>
7

> <TPSA>
106.2

> <LogP>
5.9

> <RoF>
2

> <Targets>
FLT3; CSF1R; KIT

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_epik_Ionization_Penalty>
  0.0642

> <r_epik_State_Penalty>
  0.0558

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
531

> <lig_pdbID>
'P30'

> <pdbID>
4rt7 4xuf

> <Kinase families>
Tyr

> <indicationDB>
Quizartinib is under investigation in Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies. It is a potent inhibitor of FLT3.

> <uniprotId>
P36888

$$$$
Radotinib
                    3D
 Structure written by MMmdl.
 60 64  0  0  1  0            999 V2000
   -4.6428   -0.0218    0.4705 C   0  0  0  0  0  0
   -3.1198    0.0050    0.3981 C   0  0  0  0  0  0
   -2.4103   -1.1654    0.6813 C   0  0  0  0  0  0
   -1.0185   -1.1832    0.6261 C   0  0  0  0  0  0
   -0.3013   -0.0271    0.2951 C   0  0  0  0  0  0
   -1.0195    1.1459    0.0147 C   0  0  0  0  0  0
   -2.4210    1.1726    0.0436 C   0  0  0  0  0  0
   -3.1280    2.3562   -0.2447 N   0  0  0  0  0  0
   -2.8733    3.3838   -1.1654 C   0  0  0  0  0  0
   -3.7717    4.4003   -1.1711 N   0  0  0  0  0  0
   -3.5550    5.4011   -2.0617 C   0  0  0  0  0  0
   -2.4743    5.3981   -2.9446 C   0  0  0  0  0  0
   -1.5951    4.3048   -2.8905 C   0  0  0  0  0  0
   -1.7990    3.2964   -1.9958 N   0  0  0  0  0  0
   -0.4066    4.1650   -3.7924 C   0  0  0  0  0  0
    0.2875    2.9543   -3.9680 C   0  0  0  0  0  0
    1.3608    2.8482   -4.7953 N   0  0  0  0  0  0
    1.7490    3.9696   -5.4544 C   0  0  0  0  0  0
    1.0727    5.1792   -5.2920 C   0  0  0  0  0  0
   -0.0023    5.2815   -4.4674 N   0  0  0  0  0  0
    1.2111   -0.0541    0.2661 C   0  0  0  0  0  0
    1.8235   -0.8852    0.9385 O   0  0  0  0  0  0
    1.7886    0.8599   -0.5481 N   0  0  0  0  0  0
    3.1500    1.1306   -0.7845 C   0  0  0  0  0  0
    3.4219    2.0490   -1.8025 C   0  0  0  0  0  0
    4.7353    2.4028   -2.1299 C   0  0  0  0  0  0
    5.7921    1.8332   -1.4110 C   0  0  0  0  0  0
    5.5388    0.9214   -0.3807 C   0  0  0  0  0  0
    4.2207    0.5700   -0.0688 C   0  0  0  0  0  0
    6.6077    0.3640    0.3482 N   0  0  0  0  0  0
    6.6670    0.0893    1.6931 C   0  0  0  0  0  0
    7.9217   -0.4509    1.9414 C   0  0  0  0  0  0
    8.6240   -0.5180    0.8221 N   0  0  0  0  0  0
    7.8407   -0.0350   -0.1124 C   0  0  0  0  0  0
    8.5138   -0.9279    3.2462 C   0  0  0  0  0  0
    4.9938    3.4159   -3.2444 C   0  0  0  0  0  0
    6.2274    3.9217   -3.1889 F   0  0  0  0  0  0
    4.8376    2.8152   -4.4239 F   0  0  0  0  0  0
    4.1310    4.4306   -3.1655 F   0  0  0  0  0  0
   -5.0740    0.2314   -0.4986 H   0  0  0  0  0  0
   -5.0010    0.7003    1.2049 H   0  0  0  0  0  0
   -5.0230   -1.0031    0.7573 H   0  0  0  0  0  0
   -2.9359   -2.0713    0.9467 H   0  0  0  0  0  0
   -0.5036   -2.1070    0.8506 H   0  0  0  0  0  0
   -0.4814    2.0557   -0.2068 H   0  0  0  0  0  0
   -4.0675    2.3802    0.1234 H   0  0  0  0  0  0
   -4.2678    6.2127   -2.0621 H   0  0  0  0  0  0
   -2.3377    6.2087   -3.6450 H   0  0  0  0  0  0
   -0.0064    2.0502   -3.4551 H   0  0  0  0  0  0
    2.6041    3.8873   -6.1090 H   0  0  0  0  0  0
    1.3817    6.0713   -5.8164 H   0  0  0  0  0  0
    1.1543    1.4436   -1.0730 H   0  0  0  0  0  0
    2.6054    2.4961   -2.3504 H   0  0  0  0  0  0
    6.8113    2.1046   -1.6469 H   0  0  0  0  0  0
    4.0559   -0.1306    0.7338 H   0  0  0  0  0  0
    5.8319    0.2994    2.3454 H   0  0  0  0  0  0
    8.0851    0.0588   -1.1606 H   0  0  0  0  0  0
    7.8172   -0.8079    4.0763 H   0  0  0  0  0  0
    9.4169   -0.3748    3.5054 H   0  0  0  0  0  0
    8.7814   -1.9841    3.2054 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 40  1  0  0  0
  1 41  1  0  0  0
  1 42  1  0  0  0
  2  3  1  0  0  0
  2  7  2  0  0  0
  3  4  2  0  0  0
  3 43  1  0  0  0
  4  5  1  0  0  0
  4 44  1  0  0  0
  5  6  2  0  0  0
  5 21  1  0  0  0
  6  7  1  0  0  0
  6 45  1  0  0  0
  7  8  1  0  0  0
  8  9  1  0  0  0
  8 46  1  0  0  0
  9 10  1  0  0  0
  9 14  2  0  0  0
 10 11  2  0  0  0
 11 12  1  0  0  0
 11 47  1  0  0  0
 12 13  2  0  0  0
 12 48  1  0  0  0
 13 14  1  0  0  0
 13 15  1  0  0  0
 15 16  1  0  0  0
 15 20  2  0  0  0
 16 17  2  0  0  0
 16 49  1  0  0  0
 17 18  1  0  0  0
 18 19  2  0  0  0
 18 50  1  0  0  0
 19 20  1  0  0  0
 19 51  1  0  0  0
 21 22  2  0  0  0
 21 23  1  0  0  0
 23 24  1  0  0  0
 23 52  1  0  0  0
 24 25  1  0  0  0
 24 29  2  0  0  0
 25 26  2  0  0  0
 25 53  1  0  0  0
 26 27  1  0  0  0
 26 36  1  0  0  0
 27 28  2  0  0  0
 27 54  1  0  0  0
 28 29  1  0  0  0
 28 30  1  0  0  0
 29 55  1  0  0  0
 30 31  1  0  0  0
 30 34  1  0  0  0
 31 32  2  0  0  0
 31 56  1  0  0  0
 32 33  1  0  0  0
 32 35  1  0  0  0
 33 34  2  0  0  0
 34 57  1  0  0  0
 35 58  1  0  0  0
 35 59  1  0  0  0
 35 60  1  0  0  0
 36 37  1  0  0  0
 36 38  1  0  0  0
 36 39  1  0  0  0
M  END
> <s_m_entry_id>
533

> <Applicants>
Il-Yang Pharmaceutical

> <CHEMBL_ID>
CHEMBL4297524

> <Canonical_Smiles>
FC(F)(F)c1cc(NC(=O)c2cc(Nc3nc(ccn3)-c3nccnc3)c(cc2)C)cc(-n2cc(nc2)C)c1

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
3

> <SC_Patent>
None

> <Synonyms>
IY5511 | RADOTINIB

> <Indications>
Radotinib is indicated for the treatment of different types of cancer, most notably Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) with resistance or intolerance of other Bcr-Abl tyrosine-kinase inhibitors, such as patients resistant or intolerant to imatinib.

> <Type>
nan

> <targets_id>
P00519|P09619

> <inchi>
InChI=1S/C27H21F3N8O/c1-16-3-4-18(9-23(16)37-26-33-6-5-22(36-26)24-13-31-7-8-32-24)25(39)35-20-10-19(27(28,29)30)11-21(12-20)38-14-17(2)34-15-38/h3-15H,1-2H3,(H,35,39)(H,33,36,37)

> <stdInchikey>
DUPWHXBITIZIKZ-UHFFFAOYSA-N

> <csid>
17222861

> <Links>
|http://www.chemspider.com/Chemical-Structure.17222861.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4297524|http://pubchem.ncbi.nlm.nih.gov/compound/16063245|http://www.drugbank.ca/drugs/DB12323|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7814|http://zinc15.docking.org/substances/ZINC000059749972|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=I284LJY110

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS

> <indicationG2P>
None

> <MW>
530.2

> <HBA>
8

> <HBD>
2

> <NRB>
6

> <TPSA>
110.5

> <LogP>
5.8

> <RoF>
2

> <Targets>
ABL1; PDGFRB

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.1504

> <r_epik_State_Penalty>
  0.1396

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
533

> <Kinase families>
Tyr

> <indicationDB>
Radotinib is under investigation for the treatment of Leukemia, Myelogenous, Chronic, BCR-ABL Positive.

> <uniprotId>
P00519

$$$$
Futibatinib
                    3D
 Structure written by MMmdl.
 53 56  0  0  1  0            999 V2000
   -4.0769    2.5479    0.0060 C   0  0  0  0  0  0
   -2.6557    2.4670   -0.0019 O   0  0  0  0  0  0
   -2.0501    1.2249   -0.0088 C   0  0  0  0  0  0
   -0.6542    1.2094   -0.0221 C   0  0  0  0  0  0
    0.0481    0.0028   -0.0285 C   0  0  0  0  0  0
   -0.6531   -1.2044   -0.0235 C   0  0  0  0  0  0
   -2.0490   -1.2215   -0.0102 C   0  0  0  0  0  0
   -2.7417    0.0014   -0.0023 C   0  0  0  0  0  0
   -2.6533   -2.4642   -0.0047 O   0  0  0  0  0  0
   -4.0744   -2.5471    0.0044 C   0  0  0  0  0  0
    1.5038    0.0036   -0.0382 C   0  0  0  0  0  0
    2.7254    0.0134   -0.0338 C   0  0  0  0  0  0
    4.1789    0.0491   -0.0190 C   0  0  0  0  0  0
    5.0290    1.1444    0.3431 C   0  0  0  0  0  0
    4.9247    2.4779    0.7846 C   0  0  0  0  0  0
    6.0351    3.2187    1.0322 N   0  0  0  0  0  0
    7.2359    2.6160    0.8352 C   0  0  0  0  0  0
    7.4694    1.3443    0.4139 N   0  0  0  0  0  0
    6.3452    0.6521    0.1811 C   0  0  0  0  0  0
    6.2091   -0.6540   -0.2552 N   0  0  0  0  0  0
    4.9023   -0.9930   -0.3569 N   0  0  0  0  0  0
    7.2561   -1.6337   -0.5672 C   0  0  2  0  0  0
    7.1442   -2.2463   -1.9602 C   0  0  0  0  0  0
    7.9691   -3.5246   -1.8473 C   0  0  0  0  0  0
    7.7641   -3.9435   -0.4538 N   0  0  0  0  0  0
    7.2734   -2.8363    0.3835 C   0  0  0  0  0  0
    8.0906   -5.1924   -0.0265 C   0  0  0  0  0  0
    8.5842   -6.0275   -0.7904 O   0  0  0  0  0  0
    7.8201   -5.5107    1.3655 C   0  0  0  0  0  0
    8.2014   -6.6701    1.9345 C   0  0  0  0  0  0
    3.6895    3.0882    0.9872 N   0  0  0  0  0  0
   -4.3768    3.5956    0.0070 H   0  0  0  0  0  0
   -4.5002    2.0835    0.8980 H   0  0  0  0  0  0
   -4.5090    2.0824   -0.8812 H   0  0  0  0  0  0
   -0.1198    2.1495   -0.0267 H   0  0  0  0  0  0
   -0.1175   -2.1437   -0.0290 H   0  0  0  0  0  0
   -3.8197    0.0009    0.0094 H   0  0  0  0  0  0
   -4.3724   -3.5955    0.0048 H   0  0  0  0  0  0
   -4.5083   -2.0818   -0.8820 H   0  0  0  0  0  0
   -4.4979   -2.0845    0.8973 H   0  0  0  0  0  0
    8.1094    3.2187    1.0377 H   0  0  0  0  0  0
    8.1970   -1.0866   -0.4831 H   0  0  0  0  0  0
    6.1122   -2.5058   -2.2040 H   0  0  0  0  0  0
    7.5147   -1.5828   -2.7422 H   0  0  0  0  0  0
    7.6549   -4.2843   -2.5650 H   0  0  0  0  0  0
    9.0277   -3.3140   -2.0053 H   0  0  0  0  0  0
    7.9203   -2.6538    1.2429 H   0  0  0  0  0  0
    6.2724   -3.0748    0.7460 H   0  0  0  0  0  0
    7.2890   -4.7872    1.9652 H   0  0  0  0  0  0
    8.7354   -7.4365    1.3900 H   0  0  0  0  0  0
    7.9790   -6.8683    2.9726 H   0  0  0  0  0  0
    2.8427    2.5640    0.8204 H   0  0  0  0  0  0
    3.6599    4.0448    1.3086 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 32  1  0  0  0
  1 33  1  0  0  0
  1 34  1  0  0  0
  2  3  1  0  0  0
  3  4  1  0  0  0
  3  8  2  0  0  0
  4  5  2  0  0  0
  4 35  1  0  0  0
  5  6  1  0  0  0
  5 11  1  0  0  0
  6  7  2  0  0  0
  6 36  1  0  0  0
  7  8  1  0  0  0
  7  9  1  0  0  0
  8 37  1  0  0  0
  9 10  1  0  0  0
 10 38  1  0  0  0
 10 39  1  0  0  0
 10 40  1  0  0  0
 11 12  3  0  0  0
 12 13  1  0  0  0
 13 14  1  0  0  0
 13 21  2  0  0  0
 14 15  1  0  0  0
 14 19  2  0  0  0
 15 16  2  0  0  0
 15 31  1  0  0  0
 16 17  1  0  0  0
 17 18  2  0  0  0
 17 41  1  0  0  0
 18 19  1  0  0  0
 19 20  1  0  0  0
 20 21  1  0  0  0
 20 22  1  0  0  0
 22 23  1  0  0  0
 22 26  1  0  0  0
 22 42  1  0  0  0
 23 24  1  0  0  0
 23 43  1  0  0  0
 23 44  1  0  0  0
 24 25  1  0  0  0
 24 45  1  0  0  0
 24 46  1  0  0  0
 25 26  1  0  0  0
 25 27  1  0  0  0
 26 47  1  0  0  0
 26 48  1  0  0  0
 27 28  2  0  0  0
 27 29  1  0  0  0
 29 30  2  0  0  0
 29 49  1  0  0  0
 30 50  1  0  0  0
 30 51  1  0  0  0
 31 52  1  0  0  0
 31 53  1  0  0  0
M  END
> <s_m_entry_id>
535

> <Applicants>
Taiho Pharmaceutical

> <CHEMBL_ID>
CHEMBL3701238

> <Canonical_Smiles>
O(C)c1cc(cc(OC)c1)C#Cc1nn(c2ncnc(N)c12)C1CCN(C1)C(=O)C=C

> <Chirality>
Single Stereoisomer

> <First_Approval>
nan

> <Phase>
3

> <SC_Patent>
None

> <Indications>
nan

> <Type>
nan

> <targets_id>
nan

> <inchi>
InChI=1S/C22H22N6O3/c1-4-19(29)27-8-7-15(12-27)28-22-20(21(23)24-13-25-22)18(26-28)6-5-14-9-16(30-2)11-17(10-14)31-3/h4,9-11,13,15H,1,7-8,12H2,2-3H3,(H2,23,24,25)

> <stdInchikey>
KEIPNCCJPRMIAX-UHFFFAOYSA-N

> <csid>
58877815

> <Links>
|http://www.chemspider.com/Chemical-Structure.58877815.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3701237|http://pubchem.ncbi.nlm.nih.gov/compound/78137072|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=161388

> <LinkName>
|ChemSpider|ChEMBL|PubChem|BindingDB

> <MW>
418.2

> <HBA>
8

> <HBD>
1

> <NRB>
4

> <TPSA>
108.4

> <LogP>
1.8

> <RoF>
0

> <Targets>
nan

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0003

> <r_epik_State_Penalty>
  0.0000

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
535

$$$$
Nazartinib
                    3D
 Structure written by MMmdl.
 66 69  0  0  1  0            999 V2000
    0.5651   -3.3018   -0.3785 C   0  0  0  0  0  0
   -0.5764   -3.5123    0.6399 C   0  0  0  0  0  0
   -1.6831   -4.5750    0.0782 C   0  0  0  0  0  0
   -2.9920   -4.8785    0.9771 C   0  0  0  0  0  0
   -3.2220   -4.2416    2.4450 C   0  0  0  0  0  0
   -2.1953   -3.1821    3.0698 C   0  0  0  0  0  0
   -0.9004   -2.7983    2.2516 N   0  0  0  0  0  0
   -4.2188   -5.2801    0.2286 C   0  0  0  0  0  0
   -4.3428   -6.4148   -0.2266 O   0  0  0  0  0  0
   -5.1734   -4.2856   -0.0141 N   0  0  0  0  0  0
   -5.1022   -3.0395    0.3319 C   0  0  0  0  0  0
   -6.1619   -2.1266    0.1640 N   0  0  0  0  0  0
   -5.9342   -0.9325    0.8294 C   0  0  0  0  0  0
   -6.7661    0.1700    1.0182 C   0  0  0  0  0  0
   -6.3433    1.2133    1.8370 C   0  0  0  0  0  0
   -5.1153    1.1288    2.4898 C   0  0  0  0  0  0
   -4.2827    0.0219    2.3027 C   0  0  0  0  0  0
   -4.6635   -0.9970    1.4045 C   0  0  0  0  0  0
   -4.0882   -2.1963    0.9458 N   0  0  0  0  0  0
   -2.6143   -2.5385    0.8428 C   0  0  2  0  0  0
   -0.9833   -5.0289    2.2758 C   0  0  0  0  0  0
    0.7396   -4.6951    2.5144 C   0  0  0  0  0  0
    1.5273   -3.1228    2.5100 C   0  0  0  0  0  0
    1.2442   -1.5949    1.6551 C   0  0  0  0  0  0
   -0.0830   -0.7237    1.1340 N   0  0  0  0  0  0
   -1.5938   -1.0998    0.5486 C   0  0  0  0  0  0
    0.1070    0.6377    1.1263 C   0  0  0  0  0  0
   -0.8135    1.4542    1.1965 O   0  0  0  0  0  0
    1.4497    1.1663    1.0179 C   0  0  0  0  0  0
    2.2789    0.8391    0.0069 C   0  0  0  0  0  0
    3.6959    1.3613   -0.1445 C   0  0  0  0  0  0
    4.7447    0.3660    0.0901 N   0  0  0  0  0  0
    4.7620   -0.6631   -0.9483 C   0  0  0  0  0  0
    6.0493    1.0201    0.1371 C   0  0  0  0  0  0
   -2.8486   -0.0425    3.2616 Cl  0  0  0  0  0  0
    0.4086   -3.9419   -1.2465 H   0  0  0  0  0  0
    1.5450   -3.5932   -0.0063 H   0  0  0  0  0  0
    0.5979   -2.2944   -0.7890 H   0  0  0  0  0  0
   -1.6099   -4.9679   -0.9256 H   0  0  0  0  0  0
   -4.1482   -4.4302    2.9681 H   0  0  0  0  0  0
   -2.3547   -2.7192    4.0320 H   0  0  0  0  0  0
   -7.7427    0.2160    0.5592 H   0  0  0  0  0  0
   -6.9822    2.0694    1.9965 H   0  0  0  0  0  0
   -4.8180    1.9206    3.1623 H   0  0  0  0  0  0
   -2.7285   -2.6653   -0.2431 H   0  0  0  0  0  0
   -1.2821   -5.3393    3.2882 H   0  0  0  0  0  0
   -1.0156   -6.0269    1.8151 H   0  0  0  0  0  0
    1.0497   -5.2109    3.4235 H   0  0  0  0  0  0
    1.2447   -5.2620    1.7312 H   0  0  0  0  0  0
    1.4580   -2.8231    3.5568 H   0  0  0  0  0  0
    2.5911   -3.3289    2.3915 H   0  0  0  0  0  0
    1.7583   -0.9089    2.3287 H   0  0  0  0  0  0
    1.9223   -1.6158    0.8042 H   0  0  0  0  0  0
   -1.4259   -1.0968   -0.5293 H   0  0  0  0  0  0
   -2.2546   -0.2440    0.6549 H   0  0  0  0  0  0
    1.7503    1.8523    1.7969 H   0  0  0  0  0  0
    1.9455    0.1642   -0.7699 H   0  0  0  0  0  0
    3.8040    1.7954   -1.1402 H   0  0  0  0  0  0
    3.8258    2.1810    0.5648 H   0  0  0  0  0  0
    5.5530   -1.3897   -0.7569 H   0  0  0  0  0  0
    4.9282   -0.2336   -1.9378 H   0  0  0  0  0  0
    3.8217   -1.2145   -0.9705 H   0  0  0  0  0  0
    6.8379    0.2949    0.3429 H   0  0  0  0  0  0
    6.0792    1.7651    0.9334 H   0  0  0  0  0  0
    6.2842    1.5200   -0.8045 H   0  0  0  0  0  0
   -7.0372   -2.3724   -0.2753 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 36  1  0  0  0
  1 37  1  0  0  0
  1 38  1  0  0  0
  2  3  1  0  0  0
  2  7  2  0  0  0
  3  4  2  0  0  0
  3 39  1  0  0  0
  4  5  1  0  0  0
  4  8  1  0  0  0
  5  6  2  0  0  0
  5 40  1  0  0  0
  6  7  1  0  0  0
  6 41  1  0  0  0
  8  9  2  0  0  0
  8 10  1  0  0  0
 10 11  2  0  0  0
 11 12  1  0  0  0
 11 19  1  0  0  0
 12 13  1  0  0  0
 12 66  1  0  0  0
 13 14  1  0  0  0
 13 18  2  0  0  0
 14 15  2  0  0  0
 14 42  1  0  0  0
 15 16  1  0  0  0
 15 43  1  0  0  0
 16 17  2  0  0  0
 16 44  1  0  0  0
 17 18  1  0  0  0
 17 35  1  0  0  0
 18 19  1  0  0  0
 19 20  1  0  0  0
 20 21  1  0  0  0
 20 26  1  0  0  0
 20 45  1  0  0  0
 21 22  1  0  0  0
 21 46  1  0  0  0
 21 47  1  0  0  0
 22 23  1  0  0  0
 22 48  1  0  0  0
 22 49  1  0  0  0
 23 24  1  0  0  0
 23 50  1  0  0  0
 23 51  1  0  0  0
 24 25  1  0  0  0
 24 52  1  0  0  0
 24 53  1  0  0  0
 25 26  1  0  0  0
 25 27  1  0  0  0
 26 54  1  0  0  0
 26 55  1  0  0  0
 27 28  2  0  0  0
 27 29  1  0  0  0
 29 30  2  0  0  0
 29 56  1  0  0  0
 30 31  1  0  0  0
 30 57  1  0  0  0
 31 32  1  0  0  0
 31 58  1  0  0  0
 31 59  1  0  0  0
 32 33  1  0  0  0
 32 34  1  0  0  0
 33 60  1  0  0  0
 33 61  1  0  0  0
 33 62  1  0  0  0
 34 63  1  0  0  0
 34 64  1  0  0  0
 34 65  1  0  0  0
M  END
> <s_m_entry_id>
537

> <Applicants>
Novartis

> <CHEMBL_ID>
CHEMBL3787344

> <Canonical_Smiles>
Clc1c2n([C@@H]3CCCCN(C3)C(=O)\C=C\CN(C)C)c(nc2ccc1)NC(=O)c1cc(ncc1)C

> <Chirality>
Single Stereoisomer

> <First_Approval>
nan

> <Phase>
3

> <SC_Patent>
None

> <Synonyms>
EGF-816 | EGF816 | NAZARTINIB | NVP-EGF816-NX

> <Indications>
nan

> <Type>
nan

> <targets_id>
nan

> <inchi>
InChI=1S/C26H31ClN6O2/c1-18-16-19(12-13-28-18)25(35)30-26-29-22-10-6-9-21(27)24(22)33(26)20-8-4-5-15-32(17-20)23(34)11-7-14-31(2)3/h6-7,9-13,16,20H,4-5,8,14-15,17H2,1-3H3,(H,29,30,35)/b11-7+/t20-/m1/s1

> <stdInchikey>
IOMMMLWIABWRKL-WUTDNEBXSA-N

> <csid>
35308229

> <Links>
|http://www.chemspider.com/Chemical-Structure.35308229.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3787344|http://pubchem.ncbi.nlm.nih.gov/compound/72703790|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9204|http://zinc15.docking.org/substances/ZINC000210610738|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=KE7K32EME8|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50160870

> <LinkName>
|ChemSpider|ChEMBL|PubChem|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
494.2

> <HBA>
6

> <HBD>
1

> <NRB>
6

> <TPSA>
83.4

> <LogP>
4.3

> <RoF>
0

> <Targets>
nan

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_epik_Ionization_Penalty>
  1.2502

> <r_epik_State_Penalty>
  0.0030

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
537

> <Withdrawn>
|Study NCT03529084 in nan was Withdrawn during Phase 3 because Decision by Sponsor not to continue with the trial

$$$$
Vatalanib
                    3D
 Structure written by MMmdl.
 40 43  0  0  1  0            999 V2000
   -0.7234   -3.3370    0.6909 C   0  0  0  0  0  0
   -2.1085   -3.3296    0.5843 C   0  0  0  0  0  0
   -2.7779   -2.1940    0.1390 C   0  0  0  0  0  0
   -2.0554   -1.0183   -0.2145 C   0  0  0  0  0  0
   -0.6295   -1.0268   -0.0972 C   0  0  0  0  0  0
    0.0189   -2.2084    0.3578 C   0  0  0  0  0  0
    0.0405    0.1765   -0.4625 C   0  0  0  0  0  0
   -0.6021    1.2838   -0.9075 N   0  0  0  0  0  0
   -1.9355    1.2834   -1.0120 N   0  0  0  0  0  0
   -2.6667    0.1850   -0.6878 C   0  0  0  0  0  0
   -4.0698    0.2591   -0.8094 N   0  0  0  0  0  0
   -4.9556    1.2797   -1.2021 C   0  0  0  0  0  0
   -6.2673    1.2053   -0.7258 C   0  0  0  0  0  0
   -7.2000    2.1787   -1.0738 C   0  0  0  0  0  0
   -6.8238    3.2281   -1.9090 C   0  0  0  0  0  0
   -5.5237    3.3051   -2.4030 C   0  0  0  0  0  0
   -4.5914    2.3312   -2.0544 C   0  0  0  0  0  0
   -7.9780    4.4367   -2.3404 Cl  0  0  0  0  0  0
    1.5616    0.3041   -0.3778 C   0  0  0  0  0  0
    2.2820   -0.1132   -1.6526 C   0  0  0  0  0  0
    3.0417   -1.2885   -1.6867 C   0  0  0  0  0  0
    3.7005   -1.6274   -2.8700 C   0  0  0  0  0  0
    3.6436   -0.8645   -3.9914 N   0  0  0  0  0  0
    2.9111    0.2773   -3.9420 C   0  0  0  0  0  0
    2.2229    0.6888   -2.7991 C   0  0  0  0  0  0
   -0.2187   -4.2279    1.0348 H   0  0  0  0  0  0
   -2.6696   -4.2144    0.8470 H   0  0  0  0  0  0
   -3.8551   -2.2121    0.0601 H   0  0  0  0  0  0
    1.0933   -2.2453    0.4460 H   0  0  0  0  0  0
   -4.5374   -0.5350   -0.3973 H   0  0  0  0  0  0
   -6.5702    0.3961   -0.0766 H   0  0  0  0  0  0
   -8.2100    2.1174   -0.6961 H   0  0  0  0  0  0
   -5.2366    4.1141   -3.0586 H   0  0  0  0  0  0
   -3.6005    2.4050   -2.4734 H   0  0  0  0  0  0
    1.8238    1.3455   -0.1795 H   0  0  0  0  0  0
    1.9485   -0.2349    0.4872 H   0  0  0  0  0  0
    3.1217   -1.9270   -0.8193 H   0  0  0  0  0  0
    4.2925   -2.5288   -2.9302 H   0  0  0  0  0  0
    2.8823    0.8703   -4.8442 H   0  0  0  0  0  0
    1.6543    1.6075   -2.8063 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1  6  2  0  0  0
  1 26  1  0  0  0
  2  3  2  0  0  0
  2 27  1  0  0  0
  3  4  1  0  0  0
  3 28  1  0  0  0
  4  5  1  0  0  0
  4 10  2  0  0  0
  5  6  1  0  0  0
  5  7  2  0  0  0
  6 29  1  0  0  0
  7  8  1  0  0  0
  7 19  1  0  0  0
  8  9  2  0  0  0
  9 10  1  0  0  0
 10 11  1  0  0  0
 11 12  1  0  0  0
 11 30  1  0  0  0
 12 13  1  0  0  0
 12 17  2  0  0  0
 13 14  2  0  0  0
 13 31  1  0  0  0
 14 15  1  0  0  0
 14 32  1  0  0  0
 15 16  2  0  0  0
 15 18  1  0  0  0
 16 17  1  0  0  0
 16 33  1  0  0  0
 17 34  1  0  0  0
 19 20  1  0  0  0
 19 35  1  0  0  0
 19 36  1  0  0  0
 20 21  1  0  0  0
 20 25  2  0  0  0
 21 22  2  0  0  0
 21 37  1  0  0  0
 22 23  1  0  0  0
 22 38  1  0  0  0
 23 24  2  0  0  0
 24 25  1  0  0  0
 24 39  1  0  0  0
 25 40  1  0  0  0
M  END
> <s_m_entry_id>
538

> <Applicants>
Novartis

> <CHEMBL_ID>
CHEMBL101253

> <Canonical_Smiles>
Clc1ccc(Nc2nnc(c3c2cccc3)Cc2ccncc2)cc1

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
3

> <SC_Patent>
None

> <Synonyms>
BAY-86-5127 | CGP-79787 | K-222584 | NVP-PTK787 | PTK-787 | PTK787 | VATALANIB | ZK-222584

> <Indications>
Used in combination with first- and second-line chemotherapy for the treatment of metastatic colorectal cancer and non-small cell lung cancer (NSCLC).

> <Type>
nan

> <targets_id>
P17948|P35968|P35916

> <inchi>
InChI=1S/C20H15ClN4/c21-15-5-7-16(8-6-15)23-20-18-4-2-1-3-17(18)19(24-25-20)13-14-9-11-22-12-10-14/h1-12H,13H2,(H,23,25)

> <stdInchikey>
YCOYDOIWSSHVCK-UHFFFAOYSA-N

> <csid>
133257

> <Links>
|http://www.chemspider.com/Chemical-Structure.133257.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL101253|http://pubchem.ncbi.nlm.nih.gov/compound/151194|http://www.drugbank.ca/drugs/DB04879|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5705|http://zinc15.docking.org/substances/ZINC00007460|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=5DX9U76296|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=4851

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
346.1

> <HBA>
4

> <HBD>
1

> <NRB>
4

> <TPSA>
50.7

> <LogP>
5

> <RoF>
1

> <Targets>
FLT1; KDR; FLT4

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_epik_Ionization_Penalty>
  0.0476

> <r_epik_State_Penalty>
  0.0347

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
538

> <Kinase families>
Tyr

> <indicationDB>
Vatalanib (PTK787/ZK-222584) is a new oral antiangiogenic molecule that inhibits all known vascular endothelial growth factor receptors. Vatalanib is under investigation for the treatment of solid tumors.

> <uniprotId>
P17948|P35968|P35916

$$$$
Pyrotinib
                    3D
 Structure written by MMmdl.
 74 78  0  0  1  0            999 V2000
   -4.6349   -6.3637   -0.6902 C   0  0  0  0  0  0
   -4.2189   -4.8915   -0.6241 C   0  0  0  0  0  0
   -2.8123   -4.8240   -0.4073 O   0  0  0  0  0  0
   -2.1850   -3.5920   -0.3015 C   0  0  0  0  0  0
   -2.8696   -2.3731   -0.4081 C   0  0  0  0  0  0
   -2.1910   -1.1394   -0.2898 C   0  0  0  0  0  0
   -0.7852   -1.1202   -0.0480 C   0  0  0  0  0  0
   -0.1130   -2.3695    0.0596 C   0  0  0  0  0  0
   -0.8001   -3.5831   -0.0837 C   0  0  0  0  0  0
   -0.1514   -4.8304    0.0306 N   0  0  0  0  0  0
    1.1207   -5.1456   -0.2971 C   0  0  0  0  0  0
    1.9356   -4.3583   -0.7850 O   0  0  0  0  0  0
    1.4367   -6.5269   -0.0097 C   0  0  0  0  0  0
    2.6410   -7.0705   -0.2782 C   0  0  0  0  0  0
    3.0081   -8.5200    0.0017 C   0  0  1  0  0  0
    3.5944   -9.2707   -1.2033 C   0  0  0  0  0  0
    4.5132  -10.3553   -0.6295 C   0  0  0  0  0  0
    4.5187  -10.1668    0.8924 C   0  0  0  0  0  0
    4.0658   -8.7111    1.1119 N   0  3  1  0  0  0
    5.2521   -7.7218    1.0862 C   0  0  0  0  0  0
   -0.1315    0.1519    0.0863 C   0  0  0  0  0  0
   -0.9167    1.3198   -0.0676 C   0  0  0  0  0  0
   -2.2838    1.1850   -0.3017 C   0  0  0  0  0  0
   -2.9211   -0.0008   -0.4069 N   0  0  0  0  0  0
   -0.3797    2.6794   -0.0378 C   0  0  0  0  0  0
    0.0445    3.7558   -0.0144 N   0  0  0  0  0  0
    1.2597    0.1797    0.3359 N   0  0  0  0  0  0
    1.9689    1.0096    1.2158 C   0  0  0  0  0  0
    1.4633    1.3258    2.4799 C   0  0  0  0  0  0
    2.1882    2.1478    3.3412 C   0  0  0  0  0  0
    3.4389    2.6627    2.9581 C   0  0  0  0  0  0
    3.9422    2.3305    1.6926 C   0  0  0  0  0  0
    3.2136    1.5081    0.8315 C   0  0  0  0  0  0
    5.4774    2.9320    1.1707 Cl  0  0  0  0  0  0
    4.2130    3.4829    3.7590 O   0  0  0  0  0  0
    3.7400    3.8562    5.0513 C   0  0  0  0  0  0
    4.7535    4.7757    5.7128 C   0  0  0  0  0  0
    5.4313    4.3942    6.8759 C   0  0  0  0  0  0
    6.3514    5.2844    7.4340 C   0  0  0  0  0  0
    6.5708    6.5208    6.8230 C   0  0  0  0  0  0
    5.8543    6.8276    5.6648 C   0  0  0  0  0  0
    4.9545    5.9773    5.1071 N   0  0  0  0  0  0
   -5.7090   -6.4580   -0.8520 H   0  0  0  0  0  0
   -4.3909   -6.8835    0.2368 H   0  0  0  0  0  0
   -4.1285   -6.8790   -1.5071 H   0  0  0  0  0  0
   -4.4848   -4.3939   -1.5584 H   0  0  0  0  0  0
   -4.7543   -4.3965    0.1880 H   0  0  0  0  0  0
   -3.9348   -2.3455   -0.5834 H   0  0  0  0  0  0
    0.9455   -2.3679    0.2699 H   0  0  0  0  0  0
   -0.7644   -5.6007    0.2550 H   0  0  0  0  0  0
    0.6569   -7.1292    0.4381 H   0  0  0  0  0  0
    3.4217   -6.4721   -0.7290 H   0  0  0  0  0  0
    2.1505   -9.0741    0.3917 H   0  0  0  0  0  0
    2.8075   -9.6895   -1.8322 H   0  0  0  0  0  0
    4.1794   -8.5977   -1.8329 H   0  0  0  0  0  0
    4.1516  -11.3519   -0.8867 H   0  0  0  0  0  0
    5.5227  -10.2655   -1.0334 H   0  0  0  0  0  0
    3.7510  -10.7698    1.3805 H   0  0  0  0  0  0
    5.4809  -10.3378    1.3778 H   0  0  0  0  0  0
    5.7199   -7.7710    0.1020 H   0  0  0  0  0  0
    5.9408   -8.0299    1.8738 H   0  0  0  0  0  0
    4.8521   -6.7294    1.2956 H   0  0  0  0  0  0
   -2.9179    2.0526   -0.4262 H   0  0  0  0  0  0
    1.6790   -0.7362    0.2641 H   0  0  0  0  0  0
    0.5051    0.9409    2.7979 H   0  0  0  0  0  0
    1.7602    2.3734    4.3058 H   0  0  0  0  0  0
    3.6176    1.2634   -0.1409 H   0  0  0  0  0  0
    2.7845    4.3797    4.9806 H   0  0  0  0  0  0
    3.5858    2.9680    5.6672 H   0  0  0  0  0  0
    5.2533    3.4335    7.3364 H   0  0  0  0  0  0
    6.8900    5.0178    8.3314 H   0  0  0  0  0  0
    7.2785    7.2237    7.2372 H   0  0  0  0  0  0
    5.9963    7.7741    5.1640 H   0  0  0  0  0  0
    3.6116   -8.6396    2.0118 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 43  1  0  0  0
  1 44  1  0  0  0
  1 45  1  0  0  0
  2  3  1  0  0  0
  2 46  1  0  0  0
  2 47  1  0  0  0
  3  4  1  0  0  0
  4  5  1  0  0  0
  4  9  2  0  0  0
  5  6  2  0  0  0
  5 48  1  0  0  0
  6  7  1  0  0  0
  6 24  1  0  0  0
  7  8  2  0  0  0
  7 21  1  0  0  0
  8  9  1  0  0  0
  8 49  1  0  0  0
  9 10  1  0  0  0
 10 11  1  0  0  0
 10 50  1  0  0  0
 11 12  2  0  0  0
 11 13  1  0  0  0
 13 14  2  0  0  0
 13 51  1  0  0  0
 14 15  1  0  0  0
 14 52  1  0  0  0
 15 16  1  0  0  0
 15 19  1  0  0  0
 15 53  1  0  0  0
 16 17  1  0  0  0
 16 54  1  0  0  0
 16 55  1  0  0  0
 17 18  1  0  0  0
 17 56  1  0  0  0
 17 57  1  0  0  0
 18 19  1  0  0  0
 18 58  1  0  0  0
 18 59  1  0  0  0
 19 20  1  0  0  0
 19 74  1  0  0  0
 20 60  1  0  0  0
 20 61  1  0  0  0
 20 62  1  0  0  0
 21 22  2  0  0  0
 21 27  1  0  0  0
 22 23  1  0  0  0
 22 25  1  0  0  0
 23 24  2  0  0  0
 23 63  1  0  0  0
 25 26  3  0  0  0
 27 28  1  0  0  0
 27 64  1  0  0  0
 28 29  2  0  0  0
 28 33  1  0  0  0
 29 30  1  0  0  0
 29 65  1  0  0  0
 30 31  2  0  0  0
 30 66  1  0  0  0
 31 32  1  0  0  0
 31 35  1  0  0  0
 32 33  2  0  0  0
 32 34  1  0  0  0
 33 67  1  0  0  0
 35 36  1  0  0  0
 36 37  1  0  0  0
 36 68  1  0  0  0
 36 69  1  0  0  0
 37 38  1  0  0  0
 37 42  2  0  0  0
 38 39  2  0  0  0
 38 70  1  0  0  0
 39 40  1  0  0  0
 39 71  1  0  0  0
 40 41  2  0  0  0
 40 72  1  0  0  0
 41 42  1  0  0  0
 41 73  1  0  0  0
M  CHG  1  19   1
M  END
> <s_m_entry_id>
541

> <Applicants>
Hengrui Therapeutics

> <CHEMBL_ID>
CHEMBL3544956

> <Canonical_Smiles>
Clc1cc(Nc2c3cc(NC(=O)\C=C\[C@@H]4N(CCC4)C)c(OCC)cc3ncc2C#N)ccc1OCc1ncccc1

> <Chirality>
Single Stereoisomer

> <First_Approval>
nan

> <Phase>
3

> <SC_Patent>
None

> <Indications>
nan

> <Type>
nan

> <targets_id>
P00533|P04626

> <inchi>
InChI=1S/C32H31ClN6O3/c1-3-41-30-17-27-25(16-28(30)38-31(40)12-10-24-8-6-14-39(24)2)32(21(18-34)19-36-27)37-22-9-11-29(26(33)15-22)42-20-23-7-4-5-13-35-23/h4-5,7,9-13,15-17,19,24H,3,6,8,14,20H2,1-2H3,(H,36,37)(H,38,40)/b12-10+/t24-/m1/s1

> <stdInchikey>
SADXACCFNXBCFY-IYNHSRRRSA-N

> <csid>
52083721

> <Links>
|http://www.chemspider.com/Chemical-Structure.52083721.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3647420|http://pubchem.ncbi.nlm.nih.gov/compound/51039030|http://www.drugbank.ca/drugs/DB14993|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9662|http://zinc15.docking.org/substances/ZINC000068250550|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=CJN36EQM0H|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=139991

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
582.2

> <HBA>
8

> <HBD>
2

> <NRB>
10

> <TPSA>
112.4

> <LogP>
6.5

> <RoF>
2

> <Targets>
EGFR; ERBB2

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_epik_Ionization_Penalty>
  0.1026

> <r_epik_State_Penalty>
  0.0891

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
541

> <Kinase families>
Tyr

$$$$
Selpercatinib
                    3D
 Structure written by MMmdl.
 71 76  0  0  1  0            999 V2000
  -10.6810   -0.8639   -5.2382 C   0  0  0  0  0  0
  -10.8447   -1.3149   -3.8947 O   0  0  0  0  0  0
  -10.2357   -0.6227   -2.8637 C   0  0  0  0  0  0
  -10.4241   -1.0781   -1.5569 C   0  0  0  0  0  0
   -9.8198   -0.3860   -0.5061 C   0  0  0  0  0  0
   -9.0354    0.7392   -0.7797 C   0  0  0  0  0  0
   -8.3885    1.5314    0.3433 C   0  0  0  0  0  0
   -6.9240    1.1323    0.6170 N   0  3  2  0  0  0
   -6.6347   -0.2308    1.2612 C   0  0  1  0  0  0
   -5.1834   -0.6291    0.8655 C   0  0  0  0  0  0
   -4.1737    0.4448    1.0604 N   0  0  0  0  0  0
   -4.7194    1.7116    1.6187 C   0  0  0  0  0  0
   -6.2527    1.6946    1.8773 C   0  0  2  0  0  0
   -6.7004    0.4379    2.6456 C   0  0  0  0  0  0
   -2.8170    0.2638    0.7814 C   0  0  0  0  0  0
   -2.3162   -0.9425    0.2668 C   0  0  0  0  0  0
   -0.9486   -1.0650    0.0180 C   0  0  0  0  0  0
   -0.0873    0.0073    0.2733 C   0  0  0  0  0  0
   -0.6561    1.1754    0.7900 C   0  0  0  0  0  0
   -1.9832    1.3121    1.0370 N   0  0  0  0  0  0
    1.3740   -0.0991    0.0328 C   0  0  0  0  0  0
    2.2661    0.1003    1.0964 C   0  0  0  0  0  0
    3.6474   -0.0191    0.9548 C   0  0  0  0  0  0
    4.1662   -0.3408   -0.3027 C   0  0  0  0  0  0
    3.3084   -0.5192   -1.3539 N   0  0  0  0  0  0
    3.7098   -0.8211   -2.6067 N   0  0  0  0  0  0
    2.6028   -0.8882   -3.3089 C   0  0  0  0  0  0
    1.4427   -0.6405   -2.5765 C   0  0  0  0  0  0
    0.0830   -0.6208   -3.0904 C   0  0  0  0  0  0
   -0.9993   -0.6051   -3.4985 N   0  0  0  0  0  0
    1.9080   -0.4045   -1.2462 C   0  0  0  0  0  0
    4.4142    0.1887    2.0846 O   0  0  0  0  0  0
    5.8285   -0.0013    2.0141 C   0  0  0  0  0  0
    6.4914    0.2439    3.3914 C   0  0  0  0  0  0
    5.8455   -0.6023    4.5080 C   0  0  0  0  0  0
    8.0091   -0.0177    3.3180 C   0  0  0  0  0  0
    6.3265    1.6096    3.7275 O   0  0  0  0  0  0
   -8.8953    1.1379   -2.1121 C   0  0  0  0  0  0
   -9.4771    0.4773   -3.1449 N   0  0  0  0  0  0
  -11.2310   -1.5224   -5.9104 H   0  0  0  0  0  0
   -9.6327   -0.8818   -5.5404 H   0  0  0  0  0  0
  -11.0722    0.1460   -5.3704 H   0  0  0  0  0  0
  -11.0322   -1.9490   -1.3610 H   0  0  0  0  0  0
   -9.9630   -0.7231    0.5102 H   0  0  0  0  0  0
   -8.3341    2.5953    0.1072 H   0  0  0  0  0  0
   -8.9268    1.4102    1.2846 H   0  0  0  0  0  0
   -7.3842   -0.9767    0.9937 H   0  0  0  0  0  0
   -4.8850   -1.5033    1.4459 H   0  0  0  0  0  0
   -5.1717   -0.9306   -0.1830 H   0  0  0  0  0  0
   -4.2024    1.9369    2.5527 H   0  0  0  0  0  0
   -4.4820    2.5235    0.9297 H   0  0  0  0  0  0
   -6.6645    2.6657    2.1569 H   0  0  0  0  0  0
   -7.7019    0.4975    3.0749 H   0  0  0  0  0  0
   -6.0078    0.0588    3.3989 H   0  0  0  0  0  0
   -2.9612   -1.7830    0.0593 H   0  0  0  0  0  0
   -0.5607   -1.9946   -0.3729 H   0  0  0  0  0  0
   -0.0429    2.0368    1.0134 H   0  0  0  0  0  0
    1.8713    0.3393    2.0740 H   0  0  0  0  0  0
    5.2193   -0.4555   -0.5142 H   0  0  0  0  0  0
    2.6365   -1.1108   -4.3661 H   0  0  0  0  0  0
    6.0369   -1.0231    1.6895 H   0  0  0  0  0  0
    6.2592    0.6688    1.2667 H   0  0  0  0  0  0
    5.9330   -1.6685    4.2961 H   0  0  0  0  0  0
    4.7836   -0.3796    4.6226 H   0  0  0  0  0  0
    6.3193   -0.4224    5.4742 H   0  0  0  0  0  0
    8.2182   -1.0590    3.0692 H   0  0  0  0  0  0
    8.5020    0.1931    4.2684 H   0  0  0  0  0  0
    8.4891    0.6004    2.5574 H   0  0  0  0  0  0
    6.7437    1.7666    4.5776 H   0  0  0  0  0  0
   -8.3083    2.0064   -2.3737 H   0  0  0  0  0  0
   -6.3598    1.2863   -0.2070 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 40  1  0  0  0
  1 41  1  0  0  0
  1 42  1  0  0  0
  2  3  1  0  0  0
  3  4  1  0  0  0
  3 39  2  0  0  0
  4  5  2  0  0  0
  4 43  1  0  0  0
  5  6  1  0  0  0
  5 44  1  0  0  0
  6  7  1  0  0  0
  6 38  2  0  0  0
  7  8  1  0  0  0
  7 45  1  0  0  0
  7 46  1  0  0  0
  8  9  1  0  0  0
  8 13  1  0  0  0
  8 71  1  0  0  0
  9 10  1  0  0  0
  9 14  1  0  0  0
  9 47  1  0  0  0
 10 11  1  0  0  0
 10 48  1  0  0  0
 10 49  1  0  0  0
 11 12  1  0  0  0
 11 15  1  0  0  0
 12 13  1  0  0  0
 12 50  1  0  0  0
 12 51  1  0  0  0
 13 14  1  0  0  0
 13 52  1  0  0  0
 14 53  1  0  0  0
 14 54  1  0  0  0
 15 16  1  0  0  0
 15 20  2  0  0  0
 16 17  2  0  0  0
 16 55  1  0  0  0
 17 18  1  0  0  0
 17 56  1  0  0  0
 18 19  2  0  0  0
 18 21  1  0  0  0
 19 20  1  0  0  0
 19 57  1  0  0  0
 21 22  2  0  0  0
 21 31  1  0  0  0
 22 23  1  0  0  0
 22 58  1  0  0  0
 23 24  2  0  0  0
 23 32  1  0  0  0
 24 25  1  0  0  0
 24 59  1  0  0  0
 25 26  1  0  0  0
 25 31  1  0  0  0
 26 27  2  0  0  0
 27 28  1  0  0  0
 27 60  1  0  0  0
 28 29  1  0  0  0
 28 31  2  0  0  0
 29 30  3  0  0  0
 32 33  1  0  0  0
 33 34  1  0  0  0
 33 61  1  0  0  0
 33 62  1  0  0  0
 34 35  1  0  0  0
 34 36  1  0  0  0
 34 37  1  0  0  0
 35 63  1  0  0  0
 35 64  1  0  0  0
 35 65  1  0  0  0
 36 66  1  0  0  0
 36 67  1  0  0  0
 36 68  1  0  0  0
 37 69  1  0  0  0
 38 39  1  0  0  0
 38 70  1  0  0  0
M  CHG  1   8   1
M  END
> <s_m_entry_id>
547

> <Applicants>
Loxo Oncology

> <CHEMBL_ID>
CHEMBL4559134

> <Canonical_Smiles>
O(CC(O)(C)C)C=1C=C(c2n(ncc2C#N)C=1)c1ccc(nc1)N1CC2N(C(C2)C1)Cc1ccc(OC)nc1

> <Chirality>
Achiral Molecule

> <First_Approval>
2020

> <Phase>
4

> <SC_Patent>
US-10112942-B2

> <Synonyms>
LY-3527723|LY3527723|RETEVMO|LOXO-292|WHO 10967

> <Indications>
On May 2020 FDA approved selpercatinib to treat lung and thyroid cancers.

> <Type>
nan

> <targets_id>
nan

> <inchi>
InChI=1S/C29H31N7O3/c1-29(2,37)18-39-24-9-25(28-21(10-30)13-33-36(28)17-24)20-5-6-26(31-12-20)34-15-22-8-23(16-34)35(22)14-19-4-7-27(38-3)32-11-19/h4-7,9,11-13,17,22-23,37H,8,14-16,18H2,1-3H3

> <stdInchikey>
XIIOFHFUYBLOLW-UHFFFAOYSA-N

> <csid>
72379991

> <Links>
|http://www.chemspider.com/Chemical-Structure.72379991.html|http://pubchem.ncbi.nlm.nih.gov/compound/134436906|http://www.drugbank.ca/drugs/DB15685|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10318|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=296429

> <LinkName>
|ChemSpider|PubChem|DrugBank|Guide to Pharmacology|BindingDB

> <indicationG2P>
None

> <MW>
525.2

> <HBA>
10

> <HBD>
1

> <NRB>
8

> <TPSA>
112

> <LogP>
3.3

> <RoF>
1

> <Targets>
nan

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0847

> <r_epik_State_Penalty>
  0.0305

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
547

> <indicationDB>
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Subbiah V, Yang D, Velcheti V, Drilon A, Meric-Bernstam F: State-of-the-Art Strategies for Targeting RET-Dependent Cancers. J Clin Oncol. 2020 Apr 10;38(11):1209-1221. doi: 10.1200/JCO.19.02551. Epub 2020 Feb 21. (PubMed ID 32083997)" href="#reference-A202055">4</a>,<a class="reference-popover-link" data-content="Solomon BJ, Tan L, Lin JJ, Wong SQ, Hollizeck S, Ebata K, Tuch BB, Yoda S, Gainor JF, Sequist LV, Oxnard GR, Gautschi O, Drilon A, Subbiah V, Khoo C, Zhu EY, Nguyen M, Henry D, Condroski KR, Kolakowski GR, Gomez E, Ballard J, Metcalf AT, Blake JF, Dawson SJ, Blosser W, Stancato LF, Brandhuber BJ, Andrews S, Robinson BG, Rothenberg SM: RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies. J Thorac Oncol. 2020 Apr;15(4):541-549. doi: 10.1016/j.jtho.2020.01.006. Epub 2020 Jan 24. (PubMed ID 31988000)" href="#reference-A202052">3</a>,<a class="reference-popover-link" data-content="FDA Approved Drug Products: Retevmo (selpercatinib) capsules" href="#reference-L13604">7</a></sup> Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including <a href="https://go.drugbank.com/drugs/DB08875">cabozantinib</a>, <a href="https://go.drugbank.com/drugs/DB08901">ponatinib</a>, <a href="https://go.drugbank.com/drugs/DB00398">sorafenib</a>, <a href="https://go.drugbank.com/drugs/DB01268">sunitinib</a>, and <a href="https://go.drugbank.com/drugs/DB05294">vandetanib</a>, have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Russo A, Lopes AR, McCusker MG, Garrigues SG, Ricciardi GR, Arensmeyer KE, Scilla KA, Mehra R, Rolfo C: New Targets in Lung Cancer (Excluding EGFR, ALK, ROS1). Curr Oncol Rep. 2020 Apr 16;22(5):48. doi: 10.1007/s11912-020-00909-8. (PubMed ID 32296961)" href="#reference-A202049">2</a>,<a class="reference-popover-link" data-content="Subbiah V, Yang D, Velcheti V, Drilon A, Meric-Bernstam F: State-of-the-Art Strategies for Targeting RET-Dependent Cancers. J Clin Oncol. 2020 Apr 10;38(11):1209-1221. doi: 10.1200/JCO.19.02551. Epub 2020 Feb 21. (PubMed ID 32083997)" href="#reference-A202055">4</a>,<a class="reference-popover-link" data-content="Solomon BJ, Tan L, Lin JJ, Wong SQ, Hollizeck S, Ebata K, Tuch BB, Yoda S, Gainor JF, Sequist LV, Oxnard GR, Gautschi O, Drilon A, Subbiah V, Khoo C, Zhu EY, Nguyen M, Henry D, Condroski KR, Kolakowski GR, Gomez E, Ballard J, Metcalf AT, Blake JF, Dawson SJ, Blosser W, Stancato LF, Brandhuber BJ, Andrews S, Robinson BG, Rothenberg SM: RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies. J Thorac Oncol. 2020 Apr;15(4):541-549. doi: 10.1016/j.jtho.2020.01.006. Epub 2020 Jan 24. (PubMed ID 31988000)" href="#reference-A202052">3</a>,<a class="reference-popover-link" data-content="FDA Approved Drug Products: Retevmo (selpercatinib) capsules" href="#reference-L13604">7</a></sup></p><p>Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA Approved Drug Products: Retevmo (selpercatinib) capsules" href="#reference-L13604">7</a></sup>

> <uniprotId>
P07949|P17948|P35916|P11362|P21802|P22607|P08684|P10632|P08684|Q9HB55|P20815|P24462|P08183|Q9UNQ0|Q96FL8

> <BrandName>
Retevmo

> <FDA_approved>
Y

$$$$
Regorafenib
                    3D
 Structure written by MMmdl.
 48 50  0  0  1  0            999 V2000
   -1.0845    6.9650   -2.0509 C   0  0  0  0  0  0
   -1.3996    5.6663   -1.4656 N   0  0  0  0  0  0
   -0.6243    4.5655   -1.5399 C   0  0  0  0  0  0
    0.4575    4.5497   -2.1327 O   0  0  0  0  0  0
   -1.1437    3.3170   -0.8526 C   0  0  0  0  0  0
   -0.4099    2.1210   -0.9059 C   0  0  0  0  0  0
   -0.9015    0.9765   -0.2582 C   0  0  0  0  0  0
   -2.1284    1.0546    0.4028 C   0  0  0  0  0  0
   -2.8091    2.2705    0.4194 C   0  0  0  0  0  0
   -2.3358    3.3858   -0.1895 N   0  0  0  0  0  0
   -0.2566   -0.2427   -0.2901 O   0  0  0  0  0  0
    1.1190   -0.3307   -0.3103 C   0  0  0  0  0  0
    1.7103   -1.2633   -1.1635 C   0  0  0  0  0  0
    3.0964   -1.4088   -1.2012 C   0  0  0  0  0  0
    3.9085   -0.6434   -0.3603 C   0  0  0  0  0  0
    3.3212    0.3094    0.4905 C   0  0  0  0  0  0
    1.9329    0.4482    0.5230 C   0  0  0  0  0  0
    4.0782    1.1147    1.2726 F   0  0  0  0  0  0
    5.2967   -0.8120   -0.4732 N   0  0  0  0  0  0
    6.1430   -1.0646    0.5444 C   0  0  0  0  0  0
    5.8105   -1.1105    1.7306 O   0  0  0  0  0  0
    7.3923   -1.2621    0.0766 N   0  0  0  0  0  0
    8.5540   -1.6225    0.7850 C   0  0  0  0  0  0
    9.7712   -1.3700    0.1509 C   0  0  0  0  0  0
   10.9719   -1.7062    0.7703 C   0  0  0  0  0  0
   10.9751   -2.3073    2.0288 C   0  0  0  0  0  0
    9.7599   -2.5843    2.6821 C   0  0  0  0  0  0
    8.5567   -2.2405    2.0466 C   0  0  0  0  0  0
    9.7357   -3.2538    4.0617 C   0  0  0  0  0  0
    8.4976   -3.4373    4.5251 F   0  0  0  0  0  0
   10.3256   -4.4480    3.9963 F   0  0  0  0  0  0
   10.3907   -2.4980    4.9437 F   0  0  0  0  0  0
   12.5062   -2.6966    2.7375 Cl  0  0  0  0  0  0
   -0.0757    7.0166   -2.4625 H   0  0  0  0  0  0
   -1.1763    7.7418   -1.2918 H   0  0  0  0  0  0
   -1.7888    7.1900   -2.8518 H   0  0  0  0  0  0
   -2.2810    5.5971   -0.9773 H   0  0  0  0  0  0
    0.5260    2.0718   -1.4441 H   0  0  0  0  0  0
   -2.5439    0.1883    0.8963 H   0  0  0  0  0  0
   -3.7582    2.3635    0.9266 H   0  0  0  0  0  0
    1.0913   -1.8729   -1.8055 H   0  0  0  0  0  0
    3.5328   -2.1292   -1.8785 H   0  0  0  0  0  0
    1.4884    1.1700    1.1926 H   0  0  0  0  0  0
    5.6521   -0.9287   -1.4106 H   0  0  0  0  0  0
    7.5343   -1.1032   -0.9099 H   0  0  0  0  0  0
    9.7961   -0.9056   -0.8250 H   0  0  0  0  0  0
   11.9057   -1.4986    0.2681 H   0  0  0  0  0  0
    7.6253   -2.4742    2.5373 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 34  1  0  0  0
  1 35  1  0  0  0
  1 36  1  0  0  0
  2  3  1  0  0  0
  2 37  1  0  0  0
  3  4  2  0  0  0
  3  5  1  0  0  0
  5  6  1  0  0  0
  5 10  2  0  0  0
  6  7  2  0  0  0
  6 38  1  0  0  0
  7  8  1  0  0  0
  7 11  1  0  0  0
  8  9  2  0  0  0
  8 39  1  0  0  0
  9 10  1  0  0  0
  9 40  1  0  0  0
 11 12  1  0  0  0
 12 13  1  0  0  0
 12 17  2  0  0  0
 13 14  2  0  0  0
 13 41  1  0  0  0
 14 15  1  0  0  0
 14 42  1  0  0  0
 15 16  2  0  0  0
 15 19  1  0  0  0
 16 17  1  0  0  0
 16 18  1  0  0  0
 17 43  1  0  0  0
 19 20  1  0  0  0
 19 44  1  0  0  0
 20 21  2  0  0  0
 20 22  1  0  0  0
 22 23  1  0  0  0
 22 45  1  0  0  0
 23 24  1  0  0  0
 23 28  2  0  0  0
 24 25  2  0  0  0
 24 46  1  0  0  0
 25 26  1  0  0  0
 25 47  1  0  0  0
 26 27  2  0  0  0
 26 33  1  0  0  0
 27 28  1  0  0  0
 27 29  1  0  0  0
 28 48  1  0  0  0
 29 30  1  0  0  0
 29 31  1  0  0  0
 29 32  1  0  0  0
M  END
> <s_m_entry_id>
551

> <Applicants>
Bayer

> <CHEMBL_ID>
CHEMBL1946170

> <Canonical_Smiles>
Clc1ccc(NC(=O)Nc2ccc(Oc3cc(ncc3)C(=O)NC)cc2F)cc1C(F)(F)F

> <Chirality>
Achiral Molecule

> <First_Approval>
2012

> <Phase>
4

> <SC_Patent>
US-7351834-B1

> <Synonyms>
BAY 73-4506 | BAY 73-4506 MONOHYDRATE | BAY-73-4506 | BAY-734506 | REGORAFENIB | STIVARGA

> <Indications>
Regorafenib is indicated for the treatment of patients with metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild type, an anti-EGFR therapy. Regorafenib is also indicated for the treatment of patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.

> <Type>
2

> <targets_id>
P17948|P35968|P35916|P10721|P16234|P09619|P11362|P21802|Q02763|Q16832|P04629|P29317|P04049|P15056|Q15759|P42685|P00519|P07949

> <inchi>
InChI=1S/C21H15ClF4N4O3/c1-27-19(31)18-10-13(6-7-28-18)33-12-3-5-17(16(23)9-12)30-20(32)29-11-2-4-15(22)14(8-11)21(24,25)26/h2-10H,1H3,(H,27,31)(H2,29,30,32)

> <stdInchikey>
FNHKPVJBJVTLMP-UHFFFAOYSA-N

> <csid>
9342697

> <Links>
|http://www.chemspider.com/Chemical-Structure.9342697.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1946170|http://pubchem.ncbi.nlm.nih.gov/compound/11167602|http://www.drugbank.ca/drugs/DB08896|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5891|http://zinc15.docking.org/substances/ZINC06745272|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=24T2A1DOYB|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50363397

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
482.1

> <HBA>
4

> <HBD>
3

> <NRB>
5

> <TPSA>
92.3

> <LogP>
5.7

> <RoF>
1

> <Targets>
FLT1; KDR; FLT4; KIT; PDGFRA; PDGFRB; FGFR1; FGFR2; TEK; DDR2; NTRK1; EPHA2; RAF1; BRAF; MAPK11; FRK; ABL1; RET

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0000

> <r_epik_State_Penalty>
  0.0000

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
551

> <Kinase families>
Tyr<br>CMGC<br>TKL

> <indicationDB>
Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in April 2017.

> <uniprotId>
P17948|P35968|P35916|P10721|P16234|P09619|P11362|P21802|Q02763|Q16832|P04629|P29317|P04049|P15056|Q15759|P42685|P00519|P07949

> <BrandName>
Stivarga

> <FDA_approved>
Y

$$$$
Ribociclib
                    3D
 Structure written by MMmdl.
 63 67  0  0  1  0            999 V2000
   -1.1581   -1.9287    0.3604 C   0  0  0  0  0  0
   -1.2522   -0.4713    0.5039 N   0  0  0  0  0  0
   -2.5666   -0.0360    0.9849 C   0  0  0  0  0  0
   -0.2748    0.4283    0.1994 C   0  0  0  0  0  0
   -0.4482    1.6485    0.2459 O   0  0  0  0  0  0
    1.0356   -0.0812   -0.1667 C   0  0  0  0  0  0
    1.7830   -1.0007    0.5639 C   0  0  0  0  0  0
    3.0571   -1.1175   -0.0564 C   0  0  0  0  0  0
    4.2382   -1.8405    0.1604 C   0  0  0  0  0  0
    5.3166   -1.6818   -0.6462 N   0  0  0  0  0  0
    5.2135   -0.7930   -1.6710 C   0  0  0  0  0  0
    4.1190   -0.0438   -1.9706 N   0  0  0  0  0  0
    3.0654   -0.2279   -1.1590 C   0  0  0  0  0  0
    1.8200    0.3968   -1.2232 N   0  0  0  0  0  0
    1.4262    1.4135   -2.2283 C   0  0  0  0  0  0
    1.7196    1.0237   -3.6975 C   0  0  0  0  0  0
    2.6589    2.1084   -4.2392 C   0  0  0  0  0  0
    2.3479    3.3425   -3.3914 C   0  0  0  0  0  0
    2.1096    2.7745   -1.9910 C   0  0  0  0  0  0
    6.3012   -0.5910   -2.5346 N   0  0  0  0  0  0
    7.6061   -1.1112   -2.5780 C   0  0  0  0  0  0
    8.4369   -0.7077   -3.6264 C   0  0  0  0  0  0
    9.7388   -1.2073   -3.6914 C   0  0  0  0  0  0
   10.2061   -2.1005   -2.7165 C   0  0  0  0  0  0
    9.3069   -2.4482   -1.6958 C   0  0  0  0  0  0
    8.0381   -1.9748   -1.6212 N   0  0  0  0  0  0
   11.5079   -2.5912   -2.7803 N   0  0  0  0  0  0
   12.1402   -3.2218   -1.6091 C   0  0  0  0  0  0
   13.6812   -3.2137   -1.6948 C   0  0  0  0  0  0
   14.1303   -3.9226   -2.9807 N   0  3  0  0  0  0
   13.4118   -3.3664   -4.2187 C   0  0  0  0  0  0
   11.8877   -3.3629   -3.9758 C   0  0  0  0  0  0
   -0.3579   -2.2411   -0.3103 H   0  0  0  0  0  0
   -2.0837   -2.3311   -0.0532 H   0  0  0  0  0  0
   -0.9956   -2.3937    1.3332 H   0  0  0  0  0  0
   -2.6194    1.0347    1.1873 H   0  0  0  0  0  0
   -2.8179   -0.5539    1.9112 H   0  0  0  0  0  0
   -3.3347   -0.2729    0.2479 H   0  0  0  0  0  0
    1.4466   -1.5100    1.4554 H   0  0  0  0  0  0
    4.3328   -2.5403    0.9775 H   0  0  0  0  0  0
    0.3454    1.5158   -2.1433 H   0  0  0  0  0  0
    2.1349    0.0229   -3.8207 H   0  0  0  0  0  0
    0.7887    1.0365   -4.2669 H   0  0  0  0  0  0
    3.6979    1.8112   -4.0876 H   0  0  0  0  0  0
    2.5241    2.2869   -5.3066 H   0  0  0  0  0  0
    3.1492    4.0820   -3.4144 H   0  0  0  0  0  0
    1.4405    3.8265   -3.7573 H   0  0  0  0  0  0
    1.5050    3.4392   -1.3729 H   0  0  0  0  0  0
    3.0703    2.6510   -1.4875 H   0  0  0  0  0  0
    6.1010    0.0694   -3.2702 H   0  0  0  0  0  0
    8.0864   -0.0179   -4.3808 H   0  0  0  0  0  0
   10.3829   -0.8887   -4.4983 H   0  0  0  0  0  0
    9.5824   -3.1344   -0.9087 H   0  0  0  0  0  0
   11.8574   -2.6728   -0.7096 H   0  0  0  0  0  0
   11.7689   -4.2404   -1.4814 H   0  0  0  0  0  0
   14.0926   -2.2037   -1.7362 H   0  0  0  0  0  0
   14.1509   -3.7516   -0.8706 H   0  0  0  0  0  0
   15.1308   -3.8370   -3.0926 H   0  0  0  0  0  0
   13.8108   -2.3648   -4.3877 H   0  0  0  0  0  0
   13.7027   -4.0072   -5.0515 H   0  0  0  0  0  0
   11.5142   -4.3852   -3.8894 H   0  0  0  0  0  0
   11.4095   -2.9444   -4.8621 H   0  0  0  0  0  0
   13.9203   -4.9075   -2.8986 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 33  1  0  0  0
  1 34  1  0  0  0
  1 35  1  0  0  0
  2  3  1  0  0  0
  2  4  1  0  0  0
  3 36  1  0  0  0
  3 37  1  0  0  0
  3 38  1  0  0  0
  4  5  2  0  0  0
  4  6  1  0  0  0
  6  7  2  0  0  0
  6 14  1  0  0  0
  7  8  1  0  0  0
  7 39  1  0  0  0
  8  9  1  0  0  0
  8 13  2  0  0  0
  9 10  2  0  0  0
  9 40  1  0  0  0
 10 11  1  0  0  0
 11 12  2  0  0  0
 11 20  1  0  0  0
 12 13  1  0  0  0
 13 14  1  0  0  0
 14 15  1  0  0  0
 15 16  1  0  0  0
 15 19  1  0  0  0
 15 41  1  0  0  0
 16 17  1  0  0  0
 16 42  1  0  0  0
 16 43  1  0  0  0
 17 18  1  0  0  0
 17 44  1  0  0  0
 17 45  1  0  0  0
 18 19  1  0  0  0
 18 46  1  0  0  0
 18 47  1  0  0  0
 19 48  1  0  0  0
 19 49  1  0  0  0
 20 21  1  0  0  0
 20 50  1  0  0  0
 21 22  1  0  0  0
 21 26  2  0  0  0
 22 23  2  0  0  0
 22 51  1  0  0  0
 23 24  1  0  0  0
 23 52  1  0  0  0
 24 25  2  0  0  0
 24 27  1  0  0  0
 25 26  1  0  0  0
 25 53  1  0  0  0
 27 28  1  0  0  0
 27 32  1  0  0  0
 28 29  1  0  0  0
 28 54  1  0  0  0
 28 55  1  0  0  0
 29 30  1  0  0  0
 29 56  1  0  0  0
 29 57  1  0  0  0
 30 31  1  0  0  0
 30 58  1  0  0  0
 30 63  1  0  0  0
 31 32  1  0  0  0
 31 59  1  0  0  0
 31 60  1  0  0  0
 32 61  1  0  0  0
 32 62  1  0  0  0
M  CHG  1  30   1
M  END
> <s_m_entry_id>
552

> <Applicants>
Novartis

> <CHEMBL_ID>
CHEMBL3545110

> <Canonical_Smiles>
O=C(N(C)C)c1n(c2nc(ncc2c1)Nc1ncc(N2CCNCC2)cc1)C1CCCC1

> <Chirality>
Achiral Molecule

> <First_Approval>
2017

> <Phase>
4

> <SC_Patent>
US-8324225-B2

> <Synonyms>
LEE-011 | LEE-011A | LEE011 | LEE011A | NVP-LEE011 | RIBOCICLIB

> <Indications>
Kisqali (ribociclib) is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced precision may play a role in ensuring that cancer cells do not continue to replicate uncontrollably.

> <Type>
1

> <targets_id>
P11802|Q00534

> <inchi>
InChI=1S/C23H30N8O/c1-29(2)22(32)19-13-16-14-26-23(28-21(16)31(19)17-5-3-4-6-17)27-20-8-7-18(15-25-20)30-11-9-24-10-12-30/h7-8,13-15,17,24H,3-6,9-12H2,1-2H3,(H,25,26,27,28)

> <stdInchikey>
RHXHGRAEPCAFML-UHFFFAOYSA-N

> <csid>
30798107

> <Links>
|http://www.chemspider.com/Chemical-Structure.30798107.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3545110|http://pubchem.ncbi.nlm.nih.gov/compound/44631912|http://www.drugbank.ca/drugs/DB11730| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=6ZZ|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/6ZZ|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7383|http://zinc15.docking.org/substances/ZINC000072316335|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=TK8ERE8P56|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=148264

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
434.3

> <HBA>
8

> <HBD>
2

> <NRB>
5

> <TPSA>
91.2

> <LogP>
2.8

> <RoF>
0

> <Targets>
CDK4; CDK6

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0633

> <r_epik_State_Penalty>
  0.0690

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
552

> <lig_pdbID>
'6ZZ'

> <pdbID>
5l2t

> <Kinase families>
CMGC

> <indicationDB>
Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced precision may play a role in ensuring that cancer cells do not continue to replicate uncontrollably. Ribociclib was approved by the U.S. FDA in March, 2017 as Kisqali.

> <uniprotId>
P11802|Q00534|P08684

> <BrandName>
Kisqali

> <FDA_approved>
Y

$$$$
Ruxolitinib
                    3D
 Structure written by MMmdl.
 41 44  0  0  1  0            999 V2000
   -5.2236    0.4883    0.0077 C   0  0  0  0  0  0
   -6.5940    0.3272    0.0969 C   0  0  0  0  0  0
   -6.8955   -1.0091    0.2000 N   0  0  0  0  0  0
   -5.7304   -1.7430    0.1800 C   0  0  0  0  0  0
   -4.6445   -0.8266    0.0515 C   0  0  0  0  0  0
   -3.3586   -1.4115    0.0104 C   0  0  0  0  0  0
   -3.2132   -2.7631    0.1061 N   0  0  0  0  0  0
   -4.3402   -3.5089    0.2252 C   0  0  0  0  0  0
   -5.6258   -3.0731    0.2666 N   0  0  0  0  0  0
   -2.0825   -0.6421   -0.1227 C   0  0  0  0  0  0
   -1.8844    0.7076   -0.4667 C   0  0  0  0  0  0
   -0.6219    1.0691   -0.4926 N   0  0  0  0  0  0
    0.0538   -0.0427   -0.1796 N   0  0  0  0  0  0
   -0.7834   -1.1024    0.0581 C   0  0  0  0  0  0
    1.5192   -0.0086   -0.0990 C   0  0  2  0  0  0
    2.1247   -1.1649   -0.9266 C   0  0  0  0  0  0
    1.7031   -1.1790   -2.3378 C   0  0  0  0  0  0
    1.3717   -1.1901   -3.4460 N   0  0  0  0  0  0
    1.9758   -0.0272    1.3844 C   0  0  0  0  0  0
    1.4339    1.1213    2.2491 C   0  0  0  0  0  0
    2.3347    1.1226    3.4852 C   0  0  0  0  0  0
    3.7122    0.6593    2.9905 C   0  0  0  0  0  0
    3.4976    0.0801    1.5821 C   0  0  0  0  0  0
   -4.7253    1.4415   -0.0747 H   0  0  0  0  0  0
   -7.3900    1.0574    0.0995 H   0  0  0  0  0  0
   -7.8407   -1.3547    0.2799 H   0  0  0  0  0  0
   -4.1976   -4.5773    0.2951 H   0  0  0  0  0  0
   -2.6546    1.4235   -0.7054 H   0  0  0  0  0  0
   -0.3919   -2.0708    0.3324 H   0  0  0  0  0  0
    1.8571    0.9269   -0.5518 H   0  0  0  0  0  0
    3.2130   -1.1033   -0.9238 H   0  0  0  0  0  0
    1.8646   -2.1312   -0.4936 H   0  0  0  0  0  0
    1.6476   -0.9670    1.8344 H   0  0  0  0  0  0
    1.5306    2.0712    1.7200 H   0  0  0  0  0  0
    0.3813    0.9950    2.5066 H   0  0  0  0  0  0
    2.3697    2.0984    3.9712 H   0  0  0  0  0  0
    1.9497    0.4100    4.2167 H   0  0  0  0  0  0
    4.4158    1.4925    2.9553 H   0  0  0  0  0  0
    4.1314   -0.0868    3.6671 H   0  0  0  0  0  0
    3.9955   -0.8822    1.4559 H   0  0  0  0  0  0
    3.9254    0.7624    0.8453 H   0  0  0  0  0  0
  1  2  2  0  0  0
  1  5  1  0  0  0
  1 24  1  0  0  0
  2  3  1  0  0  0
  2 25  1  0  0  0
  3  4  1  0  0  0
  3 26  1  0  0  0
  4  5  1  0  0  0
  4  9  2  0  0  0
  5  6  2  0  0  0
  6  7  1  0  0  0
  6 10  1  0  0  0
  7  8  2  0  0  0
  8  9  1  0  0  0
  8 27  1  0  0  0
 10 11  1  0  0  0
 10 14  2  0  0  0
 11 12  2  0  0  0
 11 28  1  0  0  0
 12 13  1  0  0  0
 13 14  1  0  0  0
 13 15  1  0  0  0
 14 29  1  0  0  0
 15 16  1  0  0  0
 15 19  1  0  0  0
 15 30  1  0  0  0
 16 17  1  0  0  0
 16 31  1  0  0  0
 16 32  1  0  0  0
 17 18  3  0  0  0
 19 20  1  0  0  0
 19 23  1  0  0  0
 19 33  1  0  0  0
 20 21  1  0  0  0
 20 34  1  0  0  0
 20 35  1  0  0  0
 21 22  1  0  0  0
 21 36  1  0  0  0
 21 37  1  0  0  0
 22 23  1  0  0  0
 22 38  1  0  0  0
 22 39  1  0  0  0
 23 40  1  0  0  0
 23 41  1  0  0  0
M  END
> <s_m_entry_id>
554

> <Applicants>
Incyte Corporation

> <CHEMBL_ID>
CHEMBL1789941

> <Canonical_Smiles>
[nH]1c2ncnc(c2cc1)-c1cn(nc1)[C@H](CC#N)C1CCCC1

> <Chirality>
Single Stereoisomer

> <First_Approval>
2011

> <Phase>
4

> <SC_Patent>
US-7598257-B2

> <Synonyms>
INC-424 | INC424 | INCB-018424 | INCB-18424 | INCB018424 | JAKAVI | RUXOLITINIB

> <Indications>
Treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera (post-PV) myelofibrosis and post-essential thrombocythemia (post-ET) myelofibrosis. [Lexicomp] Myeolofibrosis is the proliferation of abnormal bone marrow stem cells which cause fibrosis (the excessive formation of connective tissue).

> <Type>
1

> <targets_id>
P23458|O60674

> <inchi>
InChI=1S/C17H18N6/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16/h6,8-12,15H,1-5H2,(H,19,20,21)/t15-/m1/s1

> <stdInchikey>
HFNKQEVNSGCOJV-OAHLLOKOSA-N

> <csid>
25027389

> <Links>
|http://www.chemspider.com/Chemical-Structure.25027389.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1789941|http://pubchem.ncbi.nlm.nih.gov/compound/25126798|http://www.drugbank.ca/drugs/DB08877| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=RXT|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/RXT|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5688|http://zinc15.docking.org/substances/ZINC43207851|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=82S8X8XX8H|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50355501

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
306.2

> <HBA>
5

> <HBD>
1

> <NRB>
4

> <TPSA>
83.2

> <LogP>
3.5

> <RoF>
0

> <Targets>
JAK1; JAK2

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0000

> <r_epik_State_Penalty>
  0.0000

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
554

> <lig_pdbID>
'RXT'

> <pdbID>
4u5j 6vgl 6vnk

> <Kinase families>
Tyr

> <indicationDB>
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2,<sup class="text-reference-group"><a class="reference-popover-link" data-content="Becker H, Engelhardt M, von Bubnoff N, Wasch R: Ruxolitinib. Recent Results Cancer Res. 2014;201:249-57. doi: 10.1007/978-3-642-54490-3_16. (PubMed ID 24756798)" href="#reference-A229698">3</a></sup> which are tyrosine kinases involved in cytokine signalling and hematopoiesis.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Yang LP, Keating GM: Ruxolitinib: in the treatment of myelofibrosis. Drugs. 2012 Nov 12;72(16):2117-27. doi: 10.2165/11209340-000000000-00000. (PubMed ID 23061804)" href="#reference-A7450">2</a></sup> Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Ajayi S, Becker H, Reinhardt H, Engelhardt M, Zeiser R, von Bubnoff N, Wasch R: Ruxolitinib. Recent Results Cancer Res. 2018;212:119-132. doi: 10.1007/978-3-319-91439-8_6. (PubMed ID 30069628)" href="#reference-A229708">5</a></sup> Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Mughal TI, Girnius S, Rosen ST, Kumar S, Wiestner A, Abdel-Wahab O, Kiladjian JJ, Wilson WH, Van Etten RA: Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies. Leuk Lymphoma. 2014 Sep;55(9):1968-79. doi: 10.3109/10428194.2013.863307. Epub 2014 Feb 17. (PubMed ID 24206094)" href="#reference-A229938">15</a></sup></p><p>Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by the FDA in 2011, followed by EMA&#39;s approval in 2012.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Ajayi S, Becker H, Reinhardt H, Engelhardt M, Zeiser R, von Bubnoff N, Wasch R: Ruxolitinib. Recent Results Cancer Res. 2018;212:119-132. doi: 10.1007/978-3-319-91439-8_6. (PubMed ID 30069628)" href="#reference-A229708">5</a></sup> In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of <a href="https://go.drugbank.com/drugs/DB01005">hydroxyurea</a> and in 2019, ruxolitinib was approved for use in steroid-refractory acute graft-versus-host disease in adults and children.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Drugs.com: Jakafi FDA Approval History" href="#reference-L31958">19</a></sup> Available as oral tablets, ruxolitinib is commonly marketed under the trade name Jakafi. Ruxolitinib has been investigated to treat patients with coronavirus disease 2019 (COVID-19) accompanied by severe systemic hyperinflammation. In phase II clinical trials, ruxolitinib improved chest computed tomography and improved recovery in patients with lymphopenia.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Cao Y, Wei J, Zou L, Jiang T, Wang G, Chen L, Huang L, Meng F, Huang L, Wang N, Zhou X, Luo H, Mao Z, Chen X, Xie J, Liu J, Cheng H, Zhao J, Huang G, Wang W, Zhou J: Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial. J Allergy Clin Immunol. 2020 Jul;146(1):137-146.e3. doi: 10.1016/j.jaci.2020.05.019. Epub 2020 May 26. (PubMed ID 32470486)" href="#reference-A229713">6</a>,<a class="reference-popover-link" data-content="La Rosee F, Bremer HC, Gehrke I, Kehr A, Hochhaus

> <uniprotId>
O60674|P23458|P52333|P29597|P08684|P11712|P02768

> <BrandName>
Jakafi;Jakavi

> <Withdrawn>
|Study NCT02973711 in United States was Withdrawn during Phase 1/Phase 2 because lack of funding

> <FDA_approved>
Y

$$$$
Selumetinib
                    3D
 Structure written by MMmdl.
 42 44  0  0  1  0            999 V2000
   -3.0242    3.7672   -0.0583 C   0  0  0  0  0  0
   -3.2574    2.3521    0.1733 N   0  0  0  0  0  0
   -4.4271    1.7721    0.6097 C   0  0  0  0  0  0
   -4.3640    0.4723    0.7336 N   0  0  0  0  0  0
   -3.0806    0.1602    0.3658 C   0  0  0  0  0  0
   -2.3567    1.3191    0.0049 C   0  0  0  0  0  0
   -1.0288    1.2647   -0.4192 C   0  0  0  0  0  0
   -0.4082    0.0038   -0.4752 C   0  0  0  0  0  0
   -1.1091   -1.1666   -0.0849 C   0  0  0  0  0  0
   -2.4576   -1.0917    0.3077 C   0  0  0  0  0  0
   -3.1671   -2.2037    0.6212 F   0  0  0  0  0  0
   -0.4966   -2.4350   -0.1621 N   0  0  0  0  0  0
   -0.4517   -3.4791    0.7786 C   0  0  0  0  0  0
   -0.7536   -3.2492    2.1286 C   0  0  0  0  0  0
   -0.7171   -4.2930    3.0520 C   0  0  0  0  0  0
   -0.3789   -5.5793    2.6363 C   0  0  0  0  0  0
   -0.0752   -5.8198    1.2973 C   0  0  0  0  0  0
   -0.1088   -4.7784    0.3674 C   0  0  0  0  0  0
    0.2790   -5.1358   -1.2830 Cl  0  0  0  0  0  0
   -0.3305   -7.0059    3.8951 Br  0  0  0  0  0  0
    1.0252   -0.0508   -0.9658 C   0  0  0  0  0  0
    1.3757   -0.8875   -1.8022 O   0  0  0  0  0  0
    1.8583    0.8534   -0.4137 N   0  0  0  0  0  0
    3.2323    0.6368   -0.4981 O   0  0  0  0  0  0
    3.8300    1.6295   -1.3259 C   0  0  0  0  0  0
    5.3517    1.4186   -1.3992 C   0  0  0  0  0  0
    5.9653    1.6839   -0.1533 O   0  0  0  0  0  0
   -2.2388    4.1171    0.6122 H   0  0  0  0  0  0
   -3.9358    4.3369    0.1265 H   0  0  0  0  0  0
   -2.7114    3.9164   -1.0922 H   0  0  0  0  0  0
   -5.2908    2.3886    0.8133 H   0  0  0  0  0  0
   -0.5067    2.1662   -0.7081 H   0  0  0  0  0  0
    0.1080   -2.5642   -0.9614 H   0  0  0  0  0  0
   -1.0139   -2.2592    2.4736 H   0  0  0  0  0  0
   -0.9510   -4.1020    4.0890 H   0  0  0  0  0  0
    0.1870   -6.8185    0.9793 H   0  0  0  0  0  0
    1.6134    1.4508    0.3624 H   0  0  0  0  0  0
    3.4160    1.5559   -2.3340 H   0  0  0  0  0  0
    3.6074    2.6352   -0.9617 H   0  0  0  0  0  0
    5.5932    0.4046   -1.7205 H   0  0  0  0  0  0
    5.7849    2.0924   -2.1390 H   0  0  0  0  0  0
    6.9089    1.5277   -0.2373 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 28  1  0  0  0
  1 29  1  0  0  0
  1 30  1  0  0  0
  2  3  1  0  0  0
  2  6  1  0  0  0
  3  4  2  0  0  0
  3 31  1  0  0  0
  4  5  1  0  0  0
  5  6  1  0  0  0
  5 10  2  0  0  0
  6  7  2  0  0  0
  7  8  1  0  0  0
  7 32  1  0  0  0
  8  9  2  0  0  0
  8 21  1  0  0  0
  9 10  1  0  0  0
  9 12  1  0  0  0
 10 11  1  0  0  0
 12 13  1  0  0  0
 12 33  1  0  0  0
 13 14  1  0  0  0
 13 18  2  0  0  0
 14 15  2  0  0  0
 14 34  1  0  0  0
 15 16  1  0  0  0
 15 35  1  0  0  0
 16 17  2  0  0  0
 16 20  1  0  0  0
 17 18  1  0  0  0
 17 36  1  0  0  0
 18 19  1  0  0  0
 21 22  2  0  0  0
 21 23  1  0  0  0
 23 24  1  0  0  0
 23 37  1  0  0  0
 24 25  1  0  0  0
 25 26  1  0  0  0
 25 38  1  0  0  0
 25 39  1  0  0  0
 26 27  1  0  0  0
 26 40  1  0  0  0
 26 41  1  0  0  0
 27 42  1  0  0  0
M  END
> <s_m_entry_id>
555

> <Applicants>
Astrazeneca

> <CHEMBL_ID>
CHEMBL1614701

> <Canonical_Smiles>
Brc1cc(Cl)c(Nc2c(cc3n(cnc3c2F)C)C(=O)NOCCO)cc1

> <Chirality>
Achiral Molecule

> <First_Approval>
2020

> <Phase>
4

> <SC_Patent>
US-7425637-B2

> <Synonyms>
ARRY-142886 | ARRY-886 | AZD-6244 | AZD6244 | SELUMETINIB

> <Indications>
On April 2020 FDA approved selumetinib to treat neurofibromatosis type 1, a genetic disorder of the nervous system causing tumors to grow on nerves.

> <Type>
3

> <targets_id>
Q02750|P36507

> <inchi>
InChI=1S/C17H15BrClFN4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26)

> <stdInchikey>
CYOHGALHFOKKQC-UHFFFAOYSA-N

> <csid>
8303141

> <Links>
|http://www.chemspider.com/Chemical-Structure.8303141.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1614701|http://pubchem.ncbi.nlm.nih.gov/compound/10127622|http://www.drugbank.ca/drugs/DB11689| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=3EW|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/3EW|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5665|http://zinc15.docking.org/substances/ZINC31773258|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=6UH91I579U|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50355497

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
456

> <HBA>
6

> <HBD>
3

> <NRB>
6

> <TPSA>
88.4

> <LogP>
3.5

> <RoF>
0

> <Targets>
MAP2K1; MAP2K2

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_epik_Ionization_Penalty>
  0.0113

> <r_epik_State_Penalty>
  0.0087

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
555

> <lig_pdbID>
'3EW'

> <pdbID>
4u7z 6v32 7jut 7juz

> <Kinase families>
STE

> <indicationDB>
Activation of the Raf-MEK-ERK signaling pathway is known to be implemented in several types of malignancies, thus, mitogen-activated protein kinase kinase (MEK) inhibitors such as selumetinib are important tools that can target the problematic overactivity of this pathway.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Ciombor KK, Bekaii-Saab T: Selumetinib for the treatment of cancer. Expert Opin Investig Drugs. 2015 Jan;24(1):111-123. doi: 10.1517/13543784.2015.982275. Epub 2014 Nov 11. (PubMed ID 25385055)" href="#reference-A193611">6</a></sup>Results from clinical trials investigating earlier developed MEK inhibitors were underwhelming.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Ciombor KK, Bekaii-Saab T: Selumetinib for the treatment of cancer. Expert Opin Investig Drugs. 2015 Jan;24(1):111-123. doi: 10.1517/13543784.2015.982275. Epub 2014 Nov 11. (PubMed ID 25385055)" href="#reference-A193611">6</a></sup> However, selumetinib demonstrated impressive efficacy and tolerability in Phase I trials, leading to its continued investigation for the treatment of various types of tumors in Phase II trials.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Ciombor KK, Bekaii-Saab T: Selumetinib for the treatment of cancer. Expert Opin Investig Drugs. 2015 Jan;24(1):111-123. doi: 10.1517/13543784.2015.982275. Epub 2014 Nov 11. (PubMed ID 25385055)" href="#reference-A193611">6</a></sup></p><p>Currently, the novel MEK 1 / 2 inhibitor, selumetinib, is approved solely for the treatment of Neurofibromatosis type 1 (NF-1) in a limited age group. NF-1 is considered rare with an estimated incidence of 1/3000 individuals.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Tchernev G, Chokoeva AA, Patterson JW, Bakardzhiev I, Wollina U, Tana C: Plexiform Neurofibroma: A Case Report. Medicine (Baltimore). 2016 Feb;95(6):e2663. doi: 10.1097/MD.0000000000002663. (PubMed ID 26871793)" href="#reference-A193608">5</a></sup> It is a genetic, autosomal dominant condition resulting from mutations of the NF1 gene, which can lead to various complications including the development of multiple tumors in the nervous system.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Dombi E, Baldwin A, Marcus LJ, Fisher MJ, Weiss B, Kim A, Whitcomb P, Martin S, Aschbacher-Smith LE, Rizvi TA, Wu J, Ershler R, Wolters P, Therrien J, Glod J, Belasco JB, Schorry E, Brofferio A, Starosta AJ, Gillespie A, Doyle AL, Ratner N, Widemann BC: Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas. N Engl J Med. 2016 Dec 29;375(26):2550-2560. doi: 10.1056/NEJMoa1605943. (PubMed ID 28029918)" href="#reference-A193533">3</a>,<a class="reference-popover-link" data-content="Tchernev G, Chokoeva AA, Patterson JW, Bakardzhiev I, Wollina U, Tana C: Plexiform Neurofibroma: A Case Report. Medicine (Baltimore). 2016 Feb;95(6):e2663. doi: 10.1097/MD.0000000000002663. (PubMed ID 26871793)" href="#reference-A193608">5</a></sup> Some patients with this disorder develop plexiform neurofibromas (PN); however, this is considered to be relatively uncommon compared to other variants of NF-1.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Tchernev G, Chokoeva AA, Patterson JW, Bakardzhiev I, Wollina U, Tana C: Plexiform Neurofibroma: A Case Report. Medicine (Baltimore). 2016 Feb;95(6):e2663. doi: 10.1097/MD.0000000000002663. (PubMed ID 26871793)" href="#reference-A193608">5</a></sup> Luckily, the use of selumetinib in patients with NF-1 has shown efficacy in shrinking associated tumors and is linked to other positive clinical outcomes.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Dombi E, Baldwin A, Marcus LJ, Fisher MJ, Weiss B, Kim A, Whitcomb P, Martin S, Aschbacher-Smith LE, Rizvi TA, Wu J, Ershler R, Wolters P, Therrien J, Glod J, Belasco JB, Schorry E, Brofferio A, Starosta AJ, Gillespie A, Doyle AL, Ratner N, Widemann BC: Act

> <uniprotId>
Q02750|P36507|P33261|P08684|P11712|P05177|P10632|P05181|P20815|P22309|P35503|P02768|P02763|P19652|P08183|Q9UNQ0

> <Withdrawn>
|Study NCT03109301 in nan was Withdrawn during Phase 2 because slow accrual

> <FDA_approved>
Y

$$$$
Tucatinib
                    3D
 Structure written by MMmdl.
 60 65  0  0  1  0            999 V2000
   -2.7371   -2.4348    0.3253 C   0  0  0  0  0  0
   -2.1669   -1.0646    0.6597 C   0  0  0  0  0  0
   -0.8964   -0.7137    0.1921 C   0  0  0  0  0  0
   -0.3358    0.5333    0.4818 C   0  0  0  0  0  0
   -1.0786    1.4375    1.2525 C   0  0  0  0  0  0
   -2.3449    1.0948    1.7231 C   0  0  0  0  0  0
   -2.9067   -0.1585    1.4322 C   0  0  0  0  0  0
   -4.1478   -0.5599    1.8952 O   0  0  0  0  0  0
   -5.0139    0.3321    2.4807 C   0  0  0  0  0  0
   -5.1865    0.2988    3.8680 C   0  0  0  0  0  0
   -6.0625    1.1879    4.4870 C   0  0  0  0  0  0
   -6.7432    2.0783    3.7020 N   0  0  0  0  0  0
   -6.6083    2.1423    2.3132 C   0  0  0  0  0  0
   -5.7230    1.2461    1.6871 C   0  0  0  0  0  0
   -7.4214    3.1236    1.8499 N   0  0  0  0  0  0
   -7.9735    3.5713    2.9633 C   0  0  0  0  0  0
   -7.6286    3.0098    4.1066 N   0  0  0  0  0  0
    0.9535    0.7836   -0.0276 N   0  0  0  0  0  0
    1.8698    1.8523    0.0451 C   0  0  0  0  0  0
    3.1414    1.7362   -0.5995 C   0  0  0  0  0  0
    3.5883    0.6021   -1.3322 C   0  0  0  0  0  0
    4.8480    0.5787   -1.9526 C   0  0  0  0  0  0
    5.6875    1.6824   -1.7871 C   0  0  0  0  0  0
    5.2907    2.8124   -1.0775 C   0  0  0  0  0  0
    4.0137    2.8607   -0.4771 C   0  0  0  0  0  0
    3.6527    3.9799    0.2110 N   0  0  0  0  0  0
    2.4227    3.9722    0.7758 C   0  0  0  0  0  0
    1.5175    2.9693    0.7291 N   0  0  0  0  0  0
    5.3431   -0.5399   -2.6397 N   0  0  0  0  0  0
    4.6688   -1.1290   -3.5446 C   0  0  0  0  0  0
    5.0304   -2.2189   -4.3032 N   0  0  0  0  0  0
    4.1650   -2.4134   -5.4447 C   0  0  0  0  0  0
    2.9093   -1.7263   -4.8957 C   0  0  0  0  0  0
    3.4356   -0.7481   -4.0108 O   0  0  0  0  0  0
    4.7275   -1.6866   -6.6893 C   0  0  0  0  0  0
    3.9509   -3.9124   -5.7311 C   0  0  0  0  0  0
   -3.6698   -2.3311   -0.2303 H   0  0  0  0  0  0
   -2.9445   -2.9918    1.2396 H   0  0  0  0  0  0
   -2.0512   -3.0284   -0.2802 H   0  0  0  0  0  0
   -0.3374   -1.4245   -0.4007 H   0  0  0  0  0  0
   -0.7068    2.4140    1.5121 H   0  0  0  0  0  0
   -2.8805    1.8157    2.3226 H   0  0  0  0  0  0
   -4.6359   -0.4151    4.4632 H   0  0  0  0  0  0
   -6.2396    1.2177    5.5525 H   0  0  0  0  0  0
   -5.5885    1.2590    0.6156 H   0  0  0  0  0  0
   -8.6915    4.3783    2.9384 H   0  0  0  0  0  0
    1.3154    0.0057   -0.5593 H   0  0  0  0  0  0
    2.9398   -0.2583   -1.4121 H   0  0  0  0  0  0
    6.6744    1.6707   -2.2276 H   0  0  0  0  0  0
    5.9602    3.6549   -0.9797 H   0  0  0  0  0  0
    2.1343    4.8587    1.3217 H   0  0  0  0  0  0
    2.2952   -1.2709   -5.6742 H   0  0  0  0  0  0
    2.2724   -2.4100   -4.3292 H   0  0  0  0  0  0
    4.0492   -1.7748   -7.5387 H   0  0  0  0  0  0
    5.6879   -2.1051   -6.9935 H   0  0  0  0  0  0
    4.8799   -0.6214   -6.5069 H   0  0  0  0  0  0
    3.2326   -4.0612   -6.5382 H   0  0  0  0  0  0
    3.5714   -4.4415   -4.8556 H   0  0  0  0  0  0
    4.8818   -4.3983   -6.0266 H   0  0  0  0  0  0
    5.9189   -2.6915   -4.3774 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 37  1  0  0  0
  1 38  1  0  0  0
  1 39  1  0  0  0
  2  3  1  0  0  0
  2  7  2  0  0  0
  3  4  2  0  0  0
  3 40  1  0  0  0
  4  5  1  0  0  0
  4 18  1  0  0  0
  5  6  2  0  0  0
  5 41  1  0  0  0
  6  7  1  0  0  0
  6 42  1  0  0  0
  7  8  1  0  0  0
  8  9  1  0  0  0
  9 10  1  0  0  0
  9 14  2  0  0  0
 10 11  2  0  0  0
 10 43  1  0  0  0
 11 12  1  0  0  0
 11 44  1  0  0  0
 12 13  1  0  0  0
 12 17  1  0  0  0
 13 14  1  0  0  0
 13 15  2  0  0  0
 14 45  1  0  0  0
 15 16  1  0  0  0
 16 17  2  0  0  0
 16 46  1  0  0  0
 18 19  1  0  0  0
 18 47  1  0  0  0
 19 20  1  0  0  0
 19 28  2  0  0  0
 20 21  1  0  0  0
 20 25  2  0  0  0
 21 22  2  0  0  0
 21 48  1  0  0  0
 22 23  1  0  0  0
 22 29  1  0  0  0
 23 24  2  0  0  0
 23 49  1  0  0  0
 24 25  1  0  0  0
 24 50  1  0  0  0
 25 26  1  0  0  0
 26 27  2  0  0  0
 27 28  1  0  0  0
 27 51  1  0  0  0
 29 30  2  0  0  0
 30 31  1  0  0  0
 30 34  1  0  0  0
 31 32  1  0  0  0
 31 60  1  0  0  0
 32 33  1  0  0  0
 32 35  1  0  0  0
 32 36  1  0  0  0
 33 34  1  0  0  0
 33 52  1  0  0  0
 33 53  1  0  0  0
 35 54  1  0  0  0
 35 55  1  0  0  0
 35 56  1  0  0  0
 36 57  1  0  0  0
 36 58  1  0  0  0
 36 59  1  0  0  0
M  END
> <s_m_entry_id>
557

> <Applicants>
Array BioPharma

> <CHEMBL_ID>
CHEMBL3989868

> <Canonical_Smiles>
O1CC(N=C1Nc1cc2c(ncnc2Nc2cc(C)c(OC=3C=Cn4ncnc4C=3)cc2)cc1)(C)C

> <Chirality>
Achiral Molecule

> <First_Approval>
2020

> <Phase>
4

> <SC_Patent>
US-7452895-B2

> <Synonyms>
ARRY-380 | ONT-380 | TUCATINIB | TUKYSA

> <Indications>
On April 2020, FDA approved tucatinib to treat advanced unresectable or metastatic HER2-positive breast cancer.

> <Type>
nan

> <targets_id>
P04626

> <inchi>
InChI=1S/C26H24N8O2/c1-16-10-17(5-7-22(16)36-19-8-9-34-23(12-19)28-15-30-34)31-24-20-11-18(4-6-21(20)27-14-29-24)32-25-33-26(2,3)13-35-25/h4-12,14-15H,13H2,1-3H3,(H,32,33)(H,27,29,31)

> <stdInchikey>
SDEAXTCZPQIFQM-UHFFFAOYSA-N

> <csid>
34995558

> <Links>
|http://www.chemspider.com/Chemical-Structure.34995558.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3989868|http://pubchem.ncbi.nlm.nih.gov/compound/51039094|http://www.drugbank.ca/drugs/DB11652|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9922|http://zinc15.docking.org/substances/ZINC000068250462|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=234248D0HH

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS

> <indicationG2P>
None

> <MW>
480.2

> <HBA>
10

> <HBD>
2

> <NRB>
5

> <TPSA>
110.9

> <LogP>
5.1

> <RoF>
1

> <Targets>
ERBB2

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_epik_Ionization_Penalty>
  0.3732

> <r_epik_State_Penalty>
  0.3752

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
557

> <Kinase families>
Tyr

> <indicationDB>
Tucatinbib is a kinase inhibitor drug used with <a href="https://go.drugbank.com/drugs/DB00072">trastuzumab</a> and <a href="https://go.drugbank.com/drugs/DB01101">capecitabine</a> in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA News Release: FDA Approves First New Drug Under International Collaboration, A Treatment Option for Patients with HER2-Positive Metastatic Breast Cancer" href="#reference-L12951">8</a></sup> Tucatinib is a promising new treatment for patients with metastatic breast cancer who have not responded adequately to other chemotherapy regimens.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA approved products: Tukysa (tucatinib) oral tablets" href="#reference-L12945">7</a></sup>

> <uniprotId>
P04626|P21860|P10632|P08684|Q9HB55|P20815|P24462|P04626|Q9UNQ0|P08183|O15244|Q96FL8|Q86VL8

> <BrandName>
Tukysa

> <Melting point>
230

> <Withdrawn>
|Study NCT03846583 in nan was Withdrawn during Phase 1 because Study halted prematurely, prior to enrollment of first participant

> <FDA_approved>
Y

$$$$
Sunitinib
                    3D
 Structure written by MMmdl.
 57 59  0  0  1  0            999 V2000
   -0.0691    3.9811   -0.2416 C   0  0  0  0  0  0
   -0.3868    2.6663   -0.9728 C   0  0  0  0  0  0
   -0.4588    1.4828    0.0257 N   0  3  0  0  0  0
   -1.7836    1.4775    0.8306 C   0  0  0  0  0  0
   -1.6266    0.6944    2.1446 C   0  0  0  0  0  0
   -0.1955    0.1229   -0.6712 C   0  0  0  0  0  0
    1.2781    0.0032   -1.1302 C   0  0  0  0  0  0
    1.8365   -1.3377   -0.9637 N   0  0  0  0  0  0
    1.4584   -2.4207   -1.6682 C   0  0  0  0  0  0
    0.5817   -2.4055   -2.5338 O   0  0  0  0  0  0
    2.1568   -3.6367   -1.3205 C   0  0  0  0  0  0
    1.5834   -4.9358   -1.2830 C   0  0  0  0  0  0
    2.6113   -5.8329   -0.9721 C   0  0  0  0  0  0
    3.7559   -5.0937   -0.8570 N   0  0  0  0  0  0
    3.5309   -3.7671   -1.0890 C   0  0  0  0  0  0
    4.6875   -2.7889   -1.0601 C   0  0  0  0  0  0
    2.5836   -7.2900   -0.8080 C   0  0  0  0  0  0
    3.4883   -8.2485   -0.4807 C   0  0  0  0  0  0
    3.2523   -9.6878   -0.3803 C   0  0  0  0  0  0
    2.1167  -10.4804   -0.5727 C   0  0  0  0  0  0
    2.2086  -11.8653   -0.4015 C   0  0  0  0  0  0
    3.4273  -12.4499   -0.0406 C   0  0  0  0  0  0
    4.5597  -11.6535    0.1502 C   0  0  0  0  0  0
    4.4446  -10.2748   -0.0261 C   0  0  0  0  0  0
    5.3900   -9.2870    0.0978 N   0  0  0  0  0  0
    4.9004   -8.0590   -0.1543 C   0  0  0  0  0  0
    5.5703   -7.0305   -0.0986 O   0  0  0  0  0  0
    1.1168  -12.6413   -0.5852 F   0  0  0  0  0  0
    0.1257   -5.3043   -1.5017 C   0  0  0  0  0  0
    0.0640    4.7915   -0.9585 H   0  0  0  0  0  0
    0.8541    3.9013    0.3337 H   0  0  0  0  0  0
   -0.8636    4.2859    0.4386 H   0  0  0  0  0  0
   -1.3359    2.6827   -1.5113 H   0  0  0  0  0  0
    0.4119    2.4387   -1.6786 H   0  0  0  0  0  0
   -2.0250    2.5167    1.0496 H   0  0  0  0  0  0
   -2.5527    1.0721    0.1706 H   0  0  0  0  0  0
   -2.5249    0.7932    2.7544 H   0  0  0  0  0  0
   -0.7896    1.0708    2.7336 H   0  0  0  0  0  0
   -1.4713   -0.3714    1.9815 H   0  0  0  0  0  0
   -0.4388   -0.6440    0.0632 H   0  0  0  0  0  0
   -0.9072    0.0658   -1.4970 H   0  0  0  0  0  0
    1.3778    0.3075   -2.1740 H   0  0  0  0  0  0
    1.9156    0.6739   -0.5521 H   0  0  0  0  0  0
    2.5560   -1.4452   -0.2632 H   0  0  0  0  0  0
    4.6632   -5.4891   -0.6503 H   0  0  0  0  0  0
    4.4421   -1.8341   -1.5241 H   0  0  0  0  0  0
    5.5554   -3.1762   -1.5947 H   0  0  0  0  0  0
    5.0078   -2.5790   -0.0395 H   0  0  0  0  0  0
    1.5905   -7.6665   -1.0026 H   0  0  0  0  0  0
    1.1702  -10.0421   -0.8527 H   0  0  0  0  0  0
    3.4932  -13.5200    0.0905 H   0  0  0  0  0  0
    5.4982  -12.1097    0.4283 H   0  0  0  0  0  0
    6.3520   -9.4566    0.3525 H   0  0  0  0  0  0
   -0.1711   -6.1775   -0.9211 H   0  0  0  0  0  0
   -0.0753   -5.5293   -2.5491 H   0  0  0  0  0  0
   -0.5531   -4.5040   -1.2071 H   0  0  0  0  0  0
    0.2885    1.6194    0.6920 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 30  1  0  0  0
  1 31  1  0  0  0
  1 32  1  0  0  0
  2  3  1  0  0  0
  2 33  1  0  0  0
  2 34  1  0  0  0
  3  4  1  0  0  0
  3  6  1  0  0  0
  3 57  1  0  0  0
  4  5  1  0  0  0
  4 35  1  0  0  0
  4 36  1  0  0  0
  5 37  1  0  0  0
  5 38  1  0  0  0
  5 39  1  0  0  0
  6  7  1  0  0  0
  6 40  1  0  0  0
  6 41  1  0  0  0
  7  8  1  0  0  0
  7 42  1  0  0  0
  7 43  1  0  0  0
  8  9  1  0  0  0
  8 44  1  0  0  0
  9 10  2  0  0  0
  9 11  1  0  0  0
 11 12  1  0  0  0
 11 15  2  0  0  0
 12 13  2  0  0  0
 12 29  1  0  0  0
 13 14  1  0  0  0
 13 17  1  0  0  0
 14 15  1  0  0  0
 14 45  1  0  0  0
 15 16  1  0  0  0
 16 46  1  0  0  0
 16 47  1  0  0  0
 16 48  1  0  0  0
 17 18  2  0  0  0
 17 49  1  0  0  0
 18 19  1  0  0  0
 18 26  1  0  0  0
 19 20  2  0  0  0
 19 24  1  0  0  0
 20 21  1  0  0  0
 20 50  1  0  0  0
 21 22  2  0  0  0
 21 28  1  0  0  0
 22 23  1  0  0  0
 22 51  1  0  0  0
 23 24  2  0  0  0
 23 52  1  0  0  0
 24 25  1  0  0  0
 25 26  1  0  0  0
 25 53  1  0  0  0
 26 27  2  0  0  0
 29 54  1  0  0  0
 29 55  1  0  0  0
 29 56  1  0  0  0
M  CHG  1   3   1
M  END
> <s_m_entry_id>
560

> <Applicants>
Cp Pharmaceuticals

> <CHEMBL_ID>
CHEMBL535

> <Canonical_Smiles>
Fc1cc\2c(NC(=O)/C/2=C\c2[nH]c(C)c(C(=O)NCCN(CC)CC)c2C)cc1

> <Chirality>
Achiral Molecule

> <First_Approval>
2006

> <Phase>
4

> <SC_Patent>
US-6573293-B2

> <Synonyms>
SU-011248 | SU-11248 | SU011248 | SUNITINIB | SUTENT

> <Indications>
For the treatment of advanced renal cell carcinoma as well as the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate.

> <Type>
1

> <targets_id>
P09619|P17948|P10721|P35968|P35916|P36888|P07333|P16234

> <inchi>
InChI=1S/C22H27FN4O2/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28)/b17-12-

> <stdInchikey>
WINHZLLDWRZWRT-ATVHPVEESA-N

> <csid>
4486264

> <Links>
|http://www.chemspider.com/Chemical-Structure.4486264.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL535|http://pubchem.ncbi.nlm.nih.gov/compound/5329102|http://www.drugbank.ca/drugs/DB07417| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=B49|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/B49|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5713|http://zinc15.docking.org/substances/ZINC000003964325|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=V99T50803M|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=4814

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
398.2

> <HBA>
3

> <HBD>
3

> <NRB>
7

> <TPSA>
77.2

> <LogP>
3.3

> <RoF>
0

> <Targets>
PDGFRB; FLT1; KIT; KDR; FLT4; FLT3; CSF1R; PDGFRA

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_epik_Ionization_Penalty>
  0.0057

> <r_epik_State_Penalty>
  0.0042

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
560

> <lig_pdbID>
'B49'

> <pdbID>
2y7j 3g0e 3g0f 3miy 3ti1 4agd 4ks8 4qmz 6jok 6m11 6nfy 6nfz 6ng0 6v0x

> <Kinase families>
Tyr

> <indicationDB>
Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally available as an orally administered formulation. Sunitinib inhibits cellular signaling by targeting multiple RTKs. These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R). Sunitinib also inhibits KIT (CD117), the RTK that drives the majority of GISTs. In addition, sunitinib inhibits other RTKs including RET, CSF-1R, and flt3.

> <uniprotId>
P09619|P17948|P10721|P35968|P35916|P36888|P07333|P16234|P20815|P24462|P08684|O15439|P08183|Q92887|Q9UNQ0

> <BrandName>
Sutent

> <Withdrawn>
|Study NCT01070186 in nan was Withdrawn during Phase 2 because No participants were enrolled|Study NCT00556205 in nan was Withdrawn during Phase 2 because Toxicity of combination from other trials|Study NCT00521092 in nan was Withdrawn during Phase 2 because No participants enrolled|Study NCT03035630 in United States was Withdrawn during Phase 2 because Principal investigator left lead institution and efforts to open the protocol at another
    institution were not successful|Study NCT01441388 in nan was Withdrawn during Phase 1 because Business/Operational issues|Study NCT00748163 in nan was Withdrawn during Phase 2 because Study has been abandoned for lack of available funding|Study NCT03275558 in Singapore was Withdrawn during Phase 1 because Study halted prior to enrollment of first participant (It has been determined on 2018 May 15
    that the NCT03275558 study will be stopped by sponsor decision)|Study NCT00936832 in France was Withdrawn during Phase 2 because because the sunitinib showed futility in anotehr trial|Study NCT02400385 in United States was Withdrawn during Phase 2 because With recent advances in immunotherapy scientific question not significant|Study NCT03323710 in Poland was Withdrawn during Phase 2 because Poor patient recruitment

> <FDA_approved>
Y

$$$$
Tivozanib
                    3D
 Structure written by MMmdl.
 51 54  0  0  1  0            999 V2000
   -5.6248   10.0363   -3.7113 C   0  0  0  0  0  0
   -4.7708    8.9190   -3.1657 C   0  0  0  0  0  0
   -4.9262    7.9796   -2.1710 C   0  0  0  0  0  0
   -3.7510    7.2299   -2.1767 C   0  0  0  0  0  0
   -2.9193    7.6673   -3.1063 N   0  0  0  0  0  0
   -3.5550    8.7376   -3.7376 O   0  0  0  0  0  0
   -3.5179    6.1725   -1.3062 N   0  0  0  0  0  0
   -2.4351    5.3668   -1.2731 C   0  0  0  0  0  0
   -1.4758    5.4374   -2.0445 O   0  0  0  0  0  0
   -2.5576    4.4681   -0.2749 N   0  0  0  0  0  0
   -1.6657    3.4389    0.0898 C   0  0  0  0  0  0
   -0.2773    3.5327   -0.1026 C   0  0  0  0  0  0
    0.5629    2.4895    0.2821 C   0  0  0  0  0  0
    0.0360    1.3297    0.8679 C   0  0  0  0  0  0
   -1.3408    1.2455    1.0749 C   0  0  0  0  0  0
   -2.1918    2.2832    0.6906 C   0  0  0  0  0  0
   -3.8911    2.0976    0.9748 Cl  0  0  0  0  0  0
    0.8099    0.2646    1.2855 O   0  0  0  0  0  0
    2.0748    0.0700    0.7769 C   0  0  0  0  0  0
    3.1715    0.2709    1.6138 C   0  0  0  0  0  0
    4.4535    0.0791    1.1107 C   0  0  0  0  0  0
    4.7070   -0.3035   -0.1635 N   0  0  0  0  0  0
    3.6509   -0.5208   -0.9967 C   0  0  0  0  0  0
    2.3007   -0.3525   -0.5687 C   0  0  0  0  0  0
    1.2574   -0.6159   -1.4897 C   0  0  0  0  0  0
    1.5344   -1.0188   -2.8049 C   0  0  0  0  0  0
    2.8622   -1.1729   -3.2228 C   0  0  0  0  0  0
    3.9115   -0.9285   -2.3236 C   0  0  0  0  0  0
    3.0615   -1.5695   -4.5342 O   0  0  0  0  0  0
    4.3870   -1.6916   -5.0394 C   0  0  0  0  0  0
    0.5495   -1.2807   -3.7420 O   0  0  0  0  0  0
   -0.8194   -1.0980   -3.3948 C   0  0  0  0  0  0
   -6.5794   10.1078   -3.1900 H   0  0  0  0  0  0
   -5.8449    9.8915   -4.7691 H   0  0  0  0  0  0
   -5.1307   11.0031   -3.6132 H   0  0  0  0  0  0
   -5.7816    7.8520   -1.5242 H   0  0  0  0  0  0
   -4.2476    5.9964   -0.6317 H   0  0  0  0  0  0
   -3.4429    4.4501    0.2099 H   0  0  0  0  0  0
    0.1726    4.4147   -0.5324 H   0  0  0  0  0  0
    1.6265    2.5944    0.1271 H   0  0  0  0  0  0
   -1.7531    0.3598    1.5363 H   0  0  0  0  0  0
    3.0289    0.5797    2.6389 H   0  0  0  0  0  0
    5.3161    0.2359    1.7417 H   0  0  0  0  0  0
    0.2399   -0.4986   -1.1509 H   0  0  0  0  0  0
    4.9426   -1.0464   -2.6220 H   0  0  0  0  0  0
    4.3456   -1.9899   -6.0868 H   0  0  0  0  0  0
    4.9523   -2.4545   -4.5022 H   0  0  0  0  0  0
    4.9234   -0.7428   -4.9887 H   0  0  0  0  0  0
   -1.4428   -1.3351   -4.2569 H   0  0  0  0  0  0
   -1.0268   -0.0645   -3.1128 H   0  0  0  0  0  0
   -1.1184   -1.7605   -2.5811 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 33  1  0  0  0
  1 34  1  0  0  0
  1 35  1  0  0  0
  2  3  2  0  0  0
  2  6  1  0  0  0
  3  4  1  0  0  0
  3 36  1  0  0  0
  4  5  2  0  0  0
  4  7  1  0  0  0
  5  6  1  0  0  0
  7  8  1  0  0  0
  7 37  1  0  0  0
  8  9  2  0  0  0
  8 10  1  0  0  0
 10 11  1  0  0  0
 10 38  1  0  0  0
 11 12  1  0  0  0
 11 16  2  0  0  0
 12 13  2  0  0  0
 12 39  1  0  0  0
 13 14  1  0  0  0
 13 40  1  0  0  0
 14 15  2  0  0  0
 14 18  1  0  0  0
 15 16  1  0  0  0
 15 41  1  0  0  0
 16 17  1  0  0  0
 18 19  1  0  0  0
 19 20  2  0  0  0
 19 24  1  0  0  0
 20 21  1  0  0  0
 20 42  1  0  0  0
 21 22  2  0  0  0
 21 43  1  0  0  0
 22 23  1  0  0  0
 23 24  1  0  0  0
 23 28  2  0  0  0
 24 25  2  0  0  0
 25 26  1  0  0  0
 25 44  1  0  0  0
 26 27  2  0  0  0
 26 31  1  0  0  0
 27 28  1  0  0  0
 27 29  1  0  0  0
 28 45  1  0  0  0
 29 30  1  0  0  0
 30 46  1  0  0  0
 30 47  1  0  0  0
 30 48  1  0  0  0
 31 32  1  0  0  0
 32 49  1  0  0  0
 32 50  1  0  0  0
 32 51  1  0  0  0
M  END
> <s_m_entry_id>
561

> <Applicants>
Aveo Pharmaceuticals

> <CHEMBL_ID>
CHEMBL1289494

> <Canonical_Smiles>
Clc1cc(Oc2c3cc(OC)c(OC)cc3ncc2)ccc1NC(=O)Nc1noc(c1)C

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
4

> <SC_Patent>
None

> <Synonyms>
ASP-4130 | AV-951 | FOTIVDA | KIL-8951 | KIL8951 | KRN-951 | TIVOZANIB

> <Indications>
Tivozanib is an oral VEGF receptor tyrosine kinase inhibitor.

> <Type>
2

> <targets_id>
P17948|P35968|P35916

> <inchi>
InChI=1S/C22H19ClN4O5/c1-12-8-21(27-32-12)26-22(28)25-16-5-4-13(9-15(16)23)31-18-6-7-24-17-11-20(30-3)19(29-2)10-14(17)18/h4-11H,1-3H3,(H2,25,26,27,28)

> <stdInchikey>
SPMVMDHWKHCIDT-UHFFFAOYSA-N

> <csid>
8087481

> <Links>
|http://www.chemspider.com/Chemical-Structure.8087481.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1289494|http://pubchem.ncbi.nlm.nih.gov/compound/9911830|http://www.drugbank.ca/drugs/DB11800| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=AV9|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/AV9|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6058|http://zinc15.docking.org/substances/ZINC01489430|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=172030934T|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50331095

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
454.1

> <HBA>
7

> <HBD>
2

> <NRB>
6

> <TPSA>
107.7

> <LogP>
5.6

> <RoF>
1

> <Targets>
FLT1; KDR; FLT4

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0001

> <r_epik_State_Penalty>
  0.0000

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
561

> <lig_pdbID>
'AV9'

> <pdbID>
4ase

> <Kinase families>
Tyr

> <BrandName>
Fotivda

> <Withdrawn>
|Study NCT01728181 in nan was Withdrawn during Phase 1/Phase 2 because Stopped before approval due to ineffective drug

> <FDA_approved>
N

$$$$
Tofacitinib
                    3D
 Structure written by MMmdl.
 43 45  0  0  1  0            999 V2000
   -0.6730   -0.3298    2.5998 C   0  0  0  0  0  0
   -0.8576   -0.7234    1.1190 C   0  0  2  0  0  0
   -1.0447   -2.2488    0.9490 C   0  0  0  0  0  0
   -1.1808   -2.6850   -0.5260 C   0  0  0  0  0  0
   -0.0131   -2.1702   -1.2656 N   0  0  0  0  0  0
    0.1134   -0.6993   -1.3028 C   0  0  0  0  0  0
    0.2041   -0.1258    0.1411 C   0  0  2  0  0  0
    1.5934   -0.1541    0.6798 N   0  0  0  0  0  0
    2.3091   -1.4238    0.8133 C   0  0  0  0  0  0
    2.2146    1.0324    1.1829 C   0  0  0  0  0  0
    3.5798    1.1038    1.5929 C   0  0  0  0  0  0
    4.7352    0.2414    1.6608 C   0  0  0  0  0  0
    5.7784    0.9827    2.1798 C   0  0  0  0  0  0
    5.3490    2.2606    2.4296 N   0  0  0  0  0  0
    4.0226    2.3736    2.0797 C   0  0  0  0  0  0
    3.2830    3.4797    2.1764 N   0  0  0  0  0  0
    2.0121    3.3012    1.7461 C   0  0  0  0  0  0
    1.4551    2.1660    1.2633 N   0  0  0  0  0  0
    0.8937   -2.9724   -1.8854 C   0  0  0  0  0  0
    1.8758   -2.5285   -2.4836 O   0  0  0  0  0  0
    0.7160   -4.4968   -1.8424 C   0  0  0  0  0  0
   -0.4387   -5.0277   -2.5844 C   0  0  0  0  0  0
   -1.3472   -5.4450   -3.1669 N   0  0  0  0  0  0
    0.2349   -0.7606    3.0231 H   0  0  0  0  0  0
   -1.5114   -0.6750    3.2058 H   0  0  0  0  0  0
   -0.6132    0.7527    2.7156 H   0  0  0  0  0  0
   -1.8068   -0.2752    0.8187 H   0  0  0  0  0  0
   -0.2288   -2.7931    1.4230 H   0  0  0  0  0  0
   -1.9409   -2.5621    1.4861 H   0  0  0  0  0  0
   -1.2948   -3.7661   -0.5805 H   0  0  0  0  0  0
   -2.0813   -2.2507   -0.9619 H   0  0  0  0  0  0
    0.9591   -0.3559   -1.9010 H   0  0  0  0  0  0
   -0.7800   -0.3073   -1.7902 H   0  0  0  0  0  0
   -0.0853    0.9157    0.0159 H   0  0  0  0  0  0
    3.1094   -1.4831    0.0755 H   0  0  0  0  0  0
    1.6753   -2.2926    0.6790 H   0  0  0  0  0  0
    2.7426   -1.5215    1.8086 H   0  0  0  0  0  0
    4.8250   -0.7945    1.3723 H   0  0  0  0  0  0
    6.8023    0.7097    2.3902 H   0  0  0  0  0  0
    5.9502    2.9784    2.8070 H   0  0  0  0  0  0
    1.3663    4.1659    1.7935 H   0  0  0  0  0  0
    1.6016   -4.9816   -2.2557 H   0  0  0  0  0  0
    0.6486   -4.8334   -0.8075 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 24  1  0  0  0
  1 25  1  0  0  0
  1 26  1  0  0  0
  2  3  1  0  0  0
  2  7  1  0  0  0
  2 27  1  0  0  0
  3  4  1  0  0  0
  3 28  1  0  0  0
  3 29  1  0  0  0
  4  5  1  0  0  0
  4 30  1  0  0  0
  4 31  1  0  0  0
  5  6  1  0  0  0
  5 19  1  0  0  0
  6  7  1  0  0  0
  6 32  1  0  0  0
  6 33  1  0  0  0
  7  8  1  0  0  0
  7 34  1  0  0  0
  8  9  1  0  0  0
  8 10  1  0  0  0
  9 35  1  0  0  0
  9 36  1  0  0  0
  9 37  1  0  0  0
 10 11  1  0  0  0
 10 18  2  0  0  0
 11 12  1  0  0  0
 11 15  2  0  0  0
 12 13  2  0  0  0
 12 38  1  0  0  0
 13 14  1  0  0  0
 13 39  1  0  0  0
 14 15  1  0  0  0
 14 40  1  0  0  0
 15 16  1  0  0  0
 16 17  2  0  0  0
 17 18  1  0  0  0
 17 41  1  0  0  0
 19 20  2  0  0  0
 19 21  1  0  0  0
 21 22  1  0  0  0
 21 42  1  0  0  0
 21 43  1  0  0  0
 22 23  3  0  0  0
M  END
> <s_m_entry_id>
562

> <Applicants>
Pfizer

> <CHEMBL_ID>
CHEMBL221959

> <Canonical_Smiles>
O=C(N1C[C@H](N(C)c2ncnc3[nH]ccc23)[C@@H](CC1)C)CC#N

> <Chirality>
Single Stereoisomer

> <First_Approval>
2012

> <Phase>
4

> <SC_Patent>
US-6956041-B2

> <Synonyms>
550 | CP 690550 | CP- 690 550 | CP-690 | CP-690,550 | CP-690,550 FREE BASE | CP-690-550 | CP-690550 | CP-690550 FREE BASE | CP690,550 | CP690550 | TASOCITINIB | TOFACITINIB

> <Indications>
For the treatment of moderate to severe rheumatoid arthritis which is resistant or intolerant to methotrexate therapy. It may also be used as an adjunct to methotrexate therapy, or other non-biologic disease-modifying antirheumatic drugs (DMARDS), when methotrexate alone is not sufficient. Tofacitinib has also been investigated as a preventative therapy for kidney transplant rejections, and as a treatment for psoriasis, ulcerative colitis, and ankylosing spondylitis. It is not to be initiated in patients with a history of chronic or recurrent infections, or in the presence of active infection, even if localized, due to reports of serious and sometimes fatal infections (commonly pneumonia, herpes zoster and urinary tract infections). Use of tofacitinib is also discouraged in those who have been, or are likely to be, exposed to TB. An increased likelihood of exposure may be encountered by traveling to certain areas. In addition, tofacitinib is not to be used in patients with severe hepatic impairment, or low hemoglobin (less than 9g/dL). Cautioned is advised when using tofacitinib in patients at risk of gastrointestinal perforation, and in the elderly who are more susceptible to infection.

> <Type>
1

> <targets_id>
P23458|O60674|P52333|P29597

> <inchi>
InChI=1S/C16H20N6O/c1-11-5-8-22(14(23)3-6-17)9-13(11)21(2)16-12-4-7-18-15(12)19-10-20-16/h4,7,10-11,13H,3,5,8-9H2,1-2H3,(H,18,19,20)/t11-,13+/m1/s1

> <stdInchikey>
UJLAWZDWDVHWOW-YPMHNXCESA-N

> <csid>
8102425

> <Links>
|http://www.chemspider.com/Chemical-Structure.8102425.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL221959|http://pubchem.ncbi.nlm.nih.gov/compound/9926791|http://www.drugbank.ca/drugs/DB08895| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=MI1|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/MI1|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5677|http://zinc15.docking.org/substances/ZINC03818808|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=87LA6FU830|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50193995

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
312.2

> <HBA>
5

> <HBD>
1

> <NRB>
3

> <TPSA>
88.9

> <LogP>
1.5

> <RoF>
0

> <Targets>
JAK1; JAK2; JAK3; TYK2

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
0.999998

> <r_epik_Ionization_Penalty>
  0.0156

> <r_epik_State_Penalty>
  0.0115

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
562

> <lig_pdbID>
'MI1'

> <pdbID>
3eyg 3fup 3lxk 3lxn 4oti

> <Kinase families>
Tyr

> <indicationDB>
Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant to methotrexate.Besides rheumatoid arthritis, tofacitinib has also been studied in clinical trials for the prevention of organ transplant rejection, and is currently under investigation for the treatment of psoriasis. Known adverse effects include nausea and headache as well as more serious immunologic and hematological adverse effects. Tofacitinib is marketed under the brand name Xeljanz by Pfizer.

> <uniprotId>
P23458|O60674|P52333|P29597|P08684|P33261

> <BrandName>
Xeljanz

> <Withdrawn>
|Study NCT04412252 in United States was Withdrawn during Phase 2 because Due to the pursuit of other SARS-CoV-2-related research including alternative trials with
    tofacitinib, this trial was canceled prior to subject enrollment

> <FDA_approved>
Y

$$$$
Trametinib
                    3D
 Structure written by MMmdl.
 60 64  0  0  1  0            999 V2000
    1.0327   -2.2672    1.7188 C   0  0  0  0  0  0
   -0.3641   -2.1249    1.0875 C   0  0  0  0  0  0
   -0.9451   -0.9163    0.7855 C   0  0  0  0  0  0
   -2.3593   -0.9011    0.4024 C   0  0  0  0  0  0
   -2.9731   -2.1047    0.1762 C   0  0  0  0  0  0
   -2.3403   -3.3331    0.3725 N   0  0  0  0  0  0
   -1.0682   -3.4070    0.9023 C   0  0  0  0  0  0
   -0.5193   -4.4781    1.1880 O   0  0  0  0  0  0
   -2.9768   -4.6469    0.0887 C   0  0  0  0  0  0
   -4.2914   -2.2744   -0.2438 N   0  0  0  0  0  0
   -4.8619   -1.8491   -1.4582 C   0  0  0  0  0  0
   -4.0796   -1.3418   -2.5070 C   0  0  0  0  0  0
   -4.6764   -0.9131   -3.6918 C   0  0  0  0  0  0
   -6.0600   -0.9882   -3.8425 C   0  0  0  0  0  0
   -6.8462   -1.4927   -2.8073 C   0  0  0  0  0  0
   -6.2522   -1.9221   -1.6197 C   0  0  0  0  0  0
   -7.0379   -2.4080   -0.6288 F   0  0  0  0  0  0
   -6.9550   -0.3462   -5.6202 I   0  0  0  0  0  0
   -3.0500    0.3955    0.3974 C   0  0  0  0  0  0
   -4.2761    0.5072    0.2938 O   0  0  0  0  0  0
   -2.2291    1.4850    0.5981 N   0  0  0  0  0  0
   -0.8783    1.4997    0.9007 C   0  0  0  0  0  0
   -0.2703    2.5386    1.1906 O   0  0  0  0  0  0
   -0.2366    0.2829    0.8014 N   0  0  0  0  0  0
    1.0726    0.3212    0.2378 C   0  0  0  0  0  0
    1.2942   -0.1814   -1.0527 C   0  0  0  0  0  0
    2.5715   -0.1579   -1.6068 C   0  0  0  0  0  0
    3.6391    0.3667   -0.8810 C   0  0  0  0  0  0
    3.4450    0.8772    0.4059 C   0  0  0  0  0  0
    2.1540    0.8504    0.9619 C   0  0  0  0  0  0
    4.5951    1.3733    1.0502 N   0  0  0  0  0  0
    4.7192    1.9916    2.2439 C   0  0  0  0  0  0
    3.7996    2.2558    3.0166 O   0  0  0  0  0  0
    6.1402    2.3873    2.6342 C   0  0  0  0  0  0
   -2.8991    2.8173    0.5731 C   0  0  0  0  0  0
   -3.7035    3.2584   -0.6475 C   0  0  0  0  0  0
   -2.3948    3.9236   -0.3496 C   0  0  0  0  0  0
    1.0810   -3.0649    2.4618 H   0  0  0  0  0  0
    1.3280   -1.3716    2.2624 H   0  0  0  0  0  0
    1.7806   -2.4744    0.9526 H   0  0  0  0  0  0
   -2.3183   -5.5138    0.1539 H   0  0  0  0  0  0
   -3.3820   -4.6495   -0.9238 H   0  0  0  0  0  0
   -3.8039   -4.8139    0.7793 H   0  0  0  0  0  0
   -4.8364   -3.0003    0.1987 H   0  0  0  0  0  0
   -3.0056   -1.2747   -2.4126 H   0  0  0  0  0  0
   -4.0643   -0.5229   -4.4916 H   0  0  0  0  0  0
   -7.9185   -1.5504   -2.9235 H   0  0  0  0  0  0
    0.4773   -0.5920   -1.6289 H   0  0  0  0  0  0
    2.7355   -0.5480   -2.6006 H   0  0  0  0  0  0
    4.6225    0.3724   -1.3298 H   0  0  0  0  0  0
    1.9606    1.2170    1.9570 H   0  0  0  0  0  0
    5.4483    1.2470    0.5258 H   0  0  0  0  0  0
    6.8643    2.1092    1.8674 H   0  0  0  0  0  0
    6.4238    1.8946    3.5644 H   0  0  0  0  0  0
    6.2015    3.4653    2.7863 H   0  0  0  0  0  0
   -3.2759    3.1219    1.5504 H   0  0  0  0  0  0
   -3.7612    2.6045   -1.5185 H   0  0  0  0  0  0
   -4.6249    3.8176   -0.4858 H   0  0  0  0  0  0
   -2.4002    4.9486    0.0211 H   0  0  0  0  0  0
   -1.5538    3.7262   -1.0152 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 38  1  0  0  0
  1 39  1  0  0  0
  1 40  1  0  0  0
  2  3  2  0  0  0
  2  7  1  0  0  0
  3  4  1  0  0  0
  3 24  1  0  0  0
  4  5  2  0  0  0
  4 19  1  0  0  0
  5  6  1  0  0  0
  5 10  1  0  0  0
  6  7  1  0  0  0
  6  9  1  0  0  0
  7  8  2  0  0  0
  9 41  1  0  0  0
  9 42  1  0  0  0
  9 43  1  0  0  0
 10 11  1  0  0  0
 10 44  1  0  0  0
 11 12  1  0  0  0
 11 16  2  0  0  0
 12 13  2  0  0  0
 12 45  1  0  0  0
 13 14  1  0  0  0
 13 46  1  0  0  0
 14 15  2  0  0  0
 14 18  1  0  0  0
 15 16  1  0  0  0
 15 47  1  0  0  0
 16 17  1  0  0  0
 19 20  2  0  0  0
 19 21  1  0  0  0
 21 22  1  0  0  0
 21 35  1  0  0  0
 22 23  2  0  0  0
 22 24  1  0  0  0
 24 25  1  0  0  0
 25 26  1  0  0  0
 25 30  2  0  0  0
 26 27  2  0  0  0
 26 48  1  0  0  0
 27 28  1  0  0  0
 27 49  1  0  0  0
 28 29  2  0  0  0
 28 50  1  0  0  0
 29 30  1  0  0  0
 29 31  1  0  0  0
 30 51  1  0  0  0
 31 32  1  0  0  0
 31 52  1  0  0  0
 32 33  2  0  0  0
 32 34  1  0  0  0
 34 53  1  0  0  0
 34 54  1  0  0  0
 34 55  1  0  0  0
 35 36  1  0  0  0
 35 37  1  0  0  0
 35 56  1  0  0  0
 36 37  1  0  0  0
 36 57  1  0  0  0
 36 58  1  0  0  0
 37 59  1  0  0  0
 37 60  1  0  0  0
M  END
> <s_m_entry_id>
564

> <Applicants>
GlaxoSmithKline

> <CHEMBL_ID>
CHEMBL2105741

> <Canonical_Smiles>
Ic1cc(F)c(NC=2N(C)C(=O)C(=C3N(c4cc(NC(=O)C)ccc4)C(=O)N(C4CC4)C(=O)C=23)C)cc1

> <Chirality>
Achiral Molecule

> <First_Approval>
2013

> <Phase>
4

> <SC_Patent>
US-7378423-B2

> <Synonyms>
GSK-1120212 | GSK1120212 | JTP 74057 | JTP-74057 | MEKINIST | TMT-212 | TMT212 | TRAMETINIB

> <Indications>
Trametinib is indicated for the treatment of unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test.

> <Type>
3

> <targets_id>
P15056|Q02750|P36507

> <inchi>
InChI=1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)

> <stdInchikey>
LIRYPHYGHXZJBZ-UHFFFAOYSA-N

> <csid>
9881833

> <Links>
|http://www.chemspider.com/Chemical-Structure.9881833.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2103875|http://pubchem.ncbi.nlm.nih.gov/compound/11707110|http://www.drugbank.ca/drugs/DB08911| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=QOM|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/QOM|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6495|http://zinc15.docking.org/substances/ZINC43100709|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=33E86K87QN

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS

> <indicationG2P>
None

> <MW>
615.1

> <HBA>
8

> <HBD>
2

> <NRB>
5

> <TPSA>
107.1

> <LogP>
3.9

> <RoF>
1

> <Targets>
BRAF; MAP2K1; MAP2K2

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0000

> <r_epik_State_Penalty>
  0.0000

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
564

> <lig_pdbID>
'QOM'

> <pdbID>
6v2y 7jur 7jux

> <Kinase families>
STE<br>TKL

> <indicationDB>
Trametinib dimethyl sulfoxide is a kinase inhibitor. Each 1-mg tablet contains 1.127 mg trametinib dimethyl sulfoxide equivalent to 1 mg of trametinib non-solvated parent. FDA approved on May 29, 2013 <sup class="text-reference-group"><a class="reference-popover-link" data-content="Drugs@FDA: FDA Approved Drug Products" href="#reference-L2727">4</a></sup>.</p><p>The U.S. Food and Drug Administration approved <a href="https://go.drugbank.com/drugs/DB08912">Dabrafenib</a>(Tafilnar) and Mekinist (trametinib), administered together, for the treatment of anaplastic thyroid cancer (ATC) that cannot be removed by surgery or has spread to other parts of the body (metastatic), and has a type of abnormal gene, BRAF V600E (BRAF V600E mutation-positive) <sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA approves new uses for two drugs administered together for the treatment of BRAF-positive anaplastic thyroid cancer" href="#reference-L2726">3</a></sup>.</p><p>Thyroid cancer is a disease in which cancer cells form in the tissues of the thyroid. Anaplastic thyroid cancer is a rare, aggressive type of thyroid cancer. The National Institutes of Health (NIH) estimates there will be 53,990 new cases of thyroid cancer and an estimated 2,060 deaths from the disease in the United States in 2018. Anaplastic thyroid cancer accounts for approximately 1 to 2 percent of all thyroid cancers <sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA approves new uses for two drugs administered together for the treatment of BRAF-positive anaplastic thyroid cancer" href="#reference-L2726">3</a></sup>.

> <uniprotId>
Q02750|P36507|P10632|P08684

> <BrandName>
Mekinist

> <Melting point>
293-303

> <Withdrawn>
|Study NCT02447939 in nan was Withdrawn during Phase 1 because Change in strategy|Study NCT02939846 in nan was Withdrawn during Phase 1 because Change in strategy|Study NCT01938456 in nan was Withdrawn during Phase 1 because This study was Cancelled Before Active|Study NCT02342600 in nan was Withdrawn during Phase 2 because Supporting company withdrew interest|Study NCT02140840 in United States was Withdrawn during Phase 2 because PI left institution|Study NCT02915666 in United States was Withdrawn during Phase 1 because No subjects consented for enrollment on this study|Study NCT02672358 in nan was Withdrawn during Phase 2 because Company Decision|Study NCT03972046 in United States was Withdrawn during Phase 2 because Principal investigator leaving study site; no replacement PI will be sought|Study NCT03266159 in nan was Withdrawn during Phase 2 because Study withdrawn before active to fully evaluate impact of changing practice in target
    population|Study NCT02300935 in United States was Withdrawn during Phase 1 because Study concept was terminated|Study NCT02357732 in nan was Withdrawn during Phase 1 because PI decided not to proceed

> <FDA_approved>
Y

$$$$
Ponatinib
                    3D
 Structure written by MMmdl.
 67 71  0  0  1  0            999 V2000
   -6.5749   -0.5064   -0.2808 C   0  0  0  0  0  0
   -5.1187   -0.0657   -0.1568 C   0  0  0  0  0  0
   -4.1686   -1.0047    0.2555 C   0  0  0  0  0  0
   -2.8279   -0.6501    0.3887 C   0  0  0  0  0  0
   -2.4047    0.6574    0.1110 C   0  0  0  0  0  0
   -3.3576    1.5993   -0.2997 C   0  0  0  0  0  0
   -4.7059    1.2513   -0.4386 C   0  0  0  0  0  0
   -5.6446    2.2817   -0.8736 C   0  0  0  0  0  0
   -6.4393    3.1403   -1.2240 C   0  0  0  0  0  0
   -7.3972    4.1637   -1.6193 C   0  0  0  0  0  0
   -7.7219    4.6333   -2.8936 C   0  0  0  0  0  0
   -8.6409    5.5750   -2.9081 N   0  0  0  0  0  0
   -8.9513    5.7521   -1.6005 C   0  0  0  0  0  0
   -8.2022    4.8960   -0.7713 N   0  0  0  0  0  0
   -8.2741    4.8247    0.5755 N   0  0  0  0  0  0
   -9.1660    5.6779    1.1404 C   0  0  0  0  0  0
   -9.9619    6.5705    0.4224 C   0  0  0  0  0  0
   -9.8627    6.6173   -0.9695 C   0  0  0  0  0  0
   -0.9592    1.0651    0.2643 C   0  0  0  0  0  0
   -0.6779    2.2069    0.6319 O   0  0  0  0  0  0
   -0.0559    0.1047   -0.0375 N   0  0  0  0  0  0
    1.3496    0.1692   -0.0088 C   0  0  0  0  0  0
    2.0236   -1.0498    0.0381 C   0  0  0  0  0  0
    3.4140   -1.0844    0.0615 C   0  0  0  0  0  0
    4.1639    0.0960    0.0377 C   0  0  0  0  0  0
    3.4991    1.3408   -0.0379 C   0  0  0  0  0  0
    2.0949    1.3576   -0.0599 C   0  0  0  0  0  0
    4.2638    2.6711   -0.1172 C   0  0  0  0  0  0
    3.4557    3.7307   -0.1884 F   0  0  0  0  0  0
    5.0286    2.8271    0.9626 F   0  0  0  0  0  0
    5.0367    2.6853   -1.2036 F   0  0  0  0  0  0
    5.6873   -0.0440    0.0700 C   0  0  0  0  0  0
    6.2391   -0.6560    1.3798 N   0  3  0  0  0  0
    6.0007    0.2727    2.5919 C   0  0  0  0  0  0
    6.6159   -0.3601    3.8616 C   0  0  0  0  0  0
    8.0309   -0.7203    3.7157 N   0  0  0  0  0  0
    8.2712   -1.5886    2.5577 C   0  0  0  0  0  0
    7.7342   -1.0143    1.2258 C   0  0  0  0  0  0
    8.9087    0.4490    3.7264 C   0  0  0  0  0  0
   -7.2079    0.0812    0.3857 H   0  0  0  0  0  0
   -6.7094   -1.5580   -0.0238 H   0  0  0  0  0  0
   -6.9298   -0.3666   -1.3026 H   0  0  0  0  0  0
   -4.4669   -2.0187    0.4805 H   0  0  0  0  0  0
   -2.1265   -1.4028    0.7197 H   0  0  0  0  0  0
   -3.0452    2.6133   -0.5149 H   0  0  0  0  0  0
   -7.2816    4.2825   -3.8158 H   0  0  0  0  0  0
   -9.2373    5.6370    2.2176 H   0  0  0  0  0  0
  -10.6506    7.2218    0.9402 H   0  0  0  0  0  0
  -10.4713    7.3013   -1.5428 H   0  0  0  0  0  0
   -0.4323   -0.8013   -0.2751 H   0  0  0  0  0  0
    1.4740   -1.9804    0.0623 H   0  0  0  0  0  0
    3.9115   -2.0428    0.1040 H   0  0  0  0  0  0
    1.5886    2.3062   -0.1395 H   0  0  0  0  0  0
    6.0020   -0.7385   -0.7111 H   0  0  0  0  0  0
    6.2372    0.8859   -0.0691 H   0  0  0  0  0  0
    6.4517    1.2378    2.3585 H   0  0  0  0  0  0
    4.9227    0.4021    2.6933 H   0  0  0  0  0  0
    6.4907    0.3097    4.7139 H   0  0  0  0  0  0
    6.0591   -1.2628    4.1180 H   0  0  0  0  0  0
    9.3371   -1.8053    2.4723 H   0  0  0  0  0  0
    7.7942   -2.5511    2.7496 H   0  0  0  0  0  0
    7.8059   -1.7467    0.4206 H   0  0  0  0  0  0
    8.2607   -0.1077    0.9227 H   0  0  0  0  0  0
    9.9548    0.1408    3.7068 H   0  0  0  0  0  0
    8.7599    1.0313    4.6366 H   0  0  0  0  0  0
    8.7347    1.1059    2.8736 H   0  0  0  0  0  0
    5.7376   -1.5162    1.5513 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 40  1  0  0  0
  1 41  1  0  0  0
  1 42  1  0  0  0
  2  3  1  0  0  0
  2  7  2  0  0  0
  3  4  2  0  0  0
  3 43  1  0  0  0
  4  5  1  0  0  0
  4 44  1  0  0  0
  5  6  2  0  0  0
  5 19  1  0  0  0
  6  7  1  0  0  0
  6 45  1  0  0  0
  7  8  1  0  0  0
  8  9  3  0  0  0
  9 10  1  0  0  0
 10 11  2  0  0  0
 10 14  1  0  0  0
 11 12  1  0  0  0
 11 46  1  0  0  0
 12 13  2  0  0  0
 13 14  1  0  0  0
 13 18  1  0  0  0
 14 15  1  0  0  0
 15 16  2  0  0  0
 16 17  1  0  0  0
 16 47  1  0  0  0
 17 18  2  0  0  0
 17 48  1  0  0  0
 18 49  1  0  0  0
 19 20  2  0  0  0
 19 21  1  0  0  0
 21 22  1  0  0  0
 21 50  1  0  0  0
 22 23  1  0  0  0
 22 27  2  0  0  0
 23 24  2  0  0  0
 23 51  1  0  0  0
 24 25  1  0  0  0
 24 52  1  0  0  0
 25 26  2  0  0  0
 25 32  1  0  0  0
 26 27  1  0  0  0
 26 28  1  0  0  0
 27 53  1  0  0  0
 28 29  1  0  0  0
 28 30  1  0  0  0
 28 31  1  0  0  0
 32 33  1  0  0  0
 32 54  1  0  0  0
 32 55  1  0  0  0
 33 34  1  0  0  0
 33 38  1  0  0  0
 33 67  1  0  0  0
 34 35  1  0  0  0
 34 56  1  0  0  0
 34 57  1  0  0  0
 35 36  1  0  0  0
 35 58  1  0  0  0
 35 59  1  0  0  0
 36 37  1  0  0  0
 36 39  1  0  0  0
 37 38  1  0  0  0
 37 60  1  0  0  0
 37 61  1  0  0  0
 38 62  1  0  0  0
 38 63  1  0  0  0
 39 64  1  0  0  0
 39 65  1  0  0  0
 39 66  1  0  0  0
M  CHG  1  33   1
M  END
> <s_m_entry_id>
565

> <Applicants>
Ariad Pharmaceuticals

> <CHEMBL_ID>
CHEMBL1171837

> <Canonical_Smiles>
FC(F)(F)c1cc(NC(=O)c2cc(C#Cc3n4N=CC=Cc4nc3)c(cc2)C)ccc1CN1CCN(CC1)C

> <Chirality>
Achiral Molecule

> <First_Approval>
2012

> <Phase>
4

> <SC_Patent>
US-8114874-B2

> <Synonyms>
AP-24534 | AP24534 | ICLUSIG | PONATINIB

> <Indications>
Ponatinib is indicated for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy.

> <Type>
2

> <targets_id>
P00519|P11274|P10721|P07949|Q02763|P36888|P11362|P21802|P22607|P22455|P06239|P12931|P07948|P35968|P16234

> <inchi>
InChI=1S/C29H27F3N6O/c1-20-5-6-22(16-21(20)8-10-25-18-33-27-4-3-11-34-38(25)27)28(39)35-24-9-7-23(26(17-24)29(30,31)32)19-37-14-12-36(2)13-15-37/h3-7,9,11,16-18H,12-15,19H2,1-2H3,(H,35,39)

> <stdInchikey>
PHXJVRSECIGDHY-UHFFFAOYSA-N

> <csid>
24747381

> <Links>
|http://www.chemspider.com/Chemical-Structure.24747381.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1171837|http://pubchem.ncbi.nlm.nih.gov/compound/24826799|http://www.drugbank.ca/drugs/DB08901| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=0LI|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/0LI|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5890|http://zinc15.docking.org/substances/ZINC36701290|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=4340891KFS|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50322535

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
532.2

> <HBA>
6

> <HBD>
1

> <NRB>
4

> <TPSA>
65.8

> <LogP>
4.5

> <RoF>
1

> <Targets>
ABL1; BCR; KIT; RET; TEK; FLT3; FGFR1; FGFR2; FGFR3; FGFR4; LCK; SRC; LYN; KDR; PDGFRA

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_epik_Ionization_Penalty>
  0.0174

> <r_epik_State_Penalty>
  0.2066

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
565

> <lig_pdbID>
'0LI'

> <pdbID>
3ik3 3oxz 3zos 4c8b 4qrc 4tyj 4u0i 4uxq 4v01 4v04 6eg9 6p3d 6tu9

> <Kinase families>
Tyr<br>Atypical

> <indicationDB>
Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.

> <uniprotId>
P00519|P11274|P10721|P07949|Q02763|P36888|P11362|P21802|P22607|P22455|P06239|P12931|P07948|P35968|P16234|P08684|P10632|P10635|P20815|P08183|Q9UNQ0

> <BrandName>
Iclusig

> <Withdrawn>
|Study NCT01888562 in nan was Withdrawn during N/A because Could not obtain an IDE on the FGFR2 assay

> <FDA_approved>
Y

$$$$
Upadacitinib
                    3D
 Structure written by MMmdl.
 46 49  0  0  1  0            999 V2000
   -2.8646   -1.2371    3.5322 C   0  0  0  0  0  0
   -2.6056    0.1468    2.9165 C   0  0  0  0  0  0
   -1.8694    0.1041    1.5525 C   0  0  2  0  0  0
   -0.4854   -0.5636    1.6562 C   0  0  0  0  0  0
    0.3536    0.2192    0.7468 N   0  0  0  0  0  0
   -0.0935    1.6073    0.7688 C   0  0  0  0  0  0
   -1.6184    1.4627    0.8425 C   0  0  2  0  0  0
   -2.3156    2.6878    1.4310 C   0  0  0  0  0  0
   -1.8459    3.7540    2.2071 C   0  0  0  0  0  0
   -2.7705    4.6145    2.5762 N   0  0  0  0  0  0
   -3.9099    4.1239    2.0325 C   0  0  0  0  0  0
   -3.6678    2.9469    1.3150 N   0  0  0  0  0  0
   -4.7113    2.2606    0.6462 C   0  0  0  0  0  0
   -4.8101    1.0851   -0.1656 C   0  0  0  0  0  0
   -6.1506    0.9841   -0.4986 C   0  0  0  0  0  0
   -6.8554    2.0287    0.0603 N   0  0  0  0  0  0
   -5.9936    2.8370    0.7701 C   0  0  0  0  0  0
   -6.2887    3.9511    1.4479 N   0  0  0  0  0  0
   -5.2436    4.5777    2.0648 C   0  0  0  0  0  0
    1.4676   -0.1980    0.0951 C   0  0  0  0  0  0
    2.1665    0.5620   -0.5790 O   0  0  0  0  0  0
    1.7549   -1.5086    0.2321 N   0  0  0  0  0  0
    2.9145   -2.1951   -0.3434 C   0  0  0  0  0  0
    4.2001   -2.0744    0.4996 C   0  0  0  0  0  0
    5.1931   -2.7711   -0.0523 F   0  0  0  0  0  0
    4.6104   -0.8108    0.6100 F   0  0  0  0  0  0
    4.0165   -2.5445    1.7341 F   0  0  0  0  0  0
   -3.4189   -1.1461    4.4666 H   0  0  0  0  0  0
   -1.9340   -1.7605    3.7528 H   0  0  0  0  0  0
   -3.4516   -1.8643    2.8604 H   0  0  0  0  0  0
   -3.5714    0.6374    2.7981 H   0  0  0  0  0  0
   -2.0402    0.7565    3.6228 H   0  0  0  0  0  0
   -2.4734   -0.5069    0.8806 H   0  0  0  0  0  0
   -0.0778   -0.4703    2.6638 H   0  0  0  0  0  0
   -0.5267   -1.6247    1.4068 H   0  0  0  0  0  0
    0.3105    2.0850    1.6621 H   0  0  0  0  0  0
    0.2266    2.1835   -0.1009 H   0  0  0  0  0  0
   -1.9700    1.3916   -0.1881 H   0  0  0  0  0  0
   -0.8203    3.8924    2.5162 H   0  0  0  0  0  0
   -4.0366    0.4016   -0.4783 H   0  0  0  0  0  0
   -6.6712    0.2509   -1.0970 H   0  0  0  0  0  0
   -7.8510    2.1456   -0.0622 H   0  0  0  0  0  0
   -5.4982    5.4781    2.6040 H   0  0  0  0  0  0
    1.1362   -2.0771    0.7918 H   0  0  0  0  0  0
    2.6514   -3.2490   -0.4393 H   0  0  0  0  0  0
    3.0997   -1.8396   -1.3593 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 28  1  0  0  0
  1 29  1  0  0  0
  1 30  1  0  0  0
  2  3  1  0  0  0
  2 31  1  0  0  0
  2 32  1  0  0  0
  3  4  1  0  0  0
  3  7  1  0  0  0
  3 33  1  0  0  0
  4  5  1  0  0  0
  4 34  1  0  0  0
  4 35  1  0  0  0
  5  6  1  0  0  0
  5 20  1  0  0  0
  6  7  1  0  0  0
  6 36  1  0  0  0
  6 37  1  0  0  0
  7  8  1  0  0  0
  7 38  1  0  0  0
  8  9  2  0  0  0
  8 12  1  0  0  0
  9 10  1  0  0  0
  9 39  1  0  0  0
 10 11  2  0  0  0
 11 12  1  0  0  0
 11 19  1  0  0  0
 12 13  1  0  0  0
 13 14  1  0  0  0
 13 17  2  0  0  0
 14 15  2  0  0  0
 14 40  1  0  0  0
 15 16  1  0  0  0
 15 41  1  0  0  0
 16 17  1  0  0  0
 16 42  1  0  0  0
 17 18  1  0  0  0
 18 19  2  0  0  0
 19 43  1  0  0  0
 20 21  2  0  0  0
 20 22  1  0  0  0
 22 23  1  0  0  0
 22 44  1  0  0  0
 23 24  1  0  0  0
 23 45  1  0  0  0
 23 46  1  0  0  0
 24 25  1  0  0  0
 24 26  1  0  0  0
 24 27  1  0  0  0
M  END
> <s_m_entry_id>
571

> <Applicants>
Abbvie

> <CHEMBL_ID>
CHEMBL3622821

> <Canonical_Smiles>
FC(F)(F)CNC(=O)N1C[C@@H]([C@@H](C1)CC)c1n-2c(nc1)C=Nc1[nH]ccc1-2

> <Chirality>
Single Stereoisomer

> <First_Approval>
2019

> <Phase>
4

> <SC_Patent>
US-8962629-B2

> <Synonyms>
ABT-494 | RINVOQ | UPADACITINIB

> <Indications>
On august 2019, FDA approved fedratinib to treat adults with moderately to severely active rheumatoid arthritis

> <Type>
nan

> <targets_id>
P23458

> <inchi>
InChI=1S/C17H19F3N6O/c1-2-10-7-25(16(27)24-9-17(18,19)20)8-11(10)13-5-22-14-6-23-15-12(26(13)14)3-4-21-15/h3-6,10-11,21H,2,7-9H2,1H3,(H,24,27)/t10-,11+/m1/s1

> <stdInchikey>
WYQFJHHDOKWSHR-MNOVXSKESA-N

> <csid>
44210449

> <Links>
|http://www.chemspider.com/Chemical-Structure.44210449.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3622821|http://pubchem.ncbi.nlm.nih.gov/compound/58557659|http://www.drugbank.ca/drugs/DB15091|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9246|http://zinc15.docking.org/substances/ZINC000147180128|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=4RA0KN46E0

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS

> <indicationG2P>
None

> <MW>
380.2

> <HBA>
4

> <HBD>
2

> <NRB>
3

> <TPSA>
78.3

> <LogP>
2.9

> <RoF>
0

> <Targets>
JAK1

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_epik_Ionization_Penalty>
  0.0010

> <r_epik_State_Penalty>
  0.0006

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
571

> <Kinase families>
Tyr

> <indicationDB>
Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by synovial inflammation and hyperplasia, autoantibody production, cartilage damage and bone destruction, leading to co-morbidities.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Biggioggero M, Becciolini A, Crotti C, Agape E, Favalli EG: Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis. Drugs Context. 2019 Oct 24;8:212595. doi: 10.7573/dic.212595. eCollection 2019. (PubMed ID 31692920)" href="#reference-A189165">4</a></sup> Despite a variety of therapeutic agents available for treatment, up to 40% of the patients do not respond to current therapies, including biological therapies.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Rivellese F, Lobasso A, Barbieri L, Liccardo B, de Paulis A, Rossi FW: Novel Therapeutic Approaches in Rheumatoid Arthritis: Role of Janus Kinases Inhibitors. Curr Med Chem. 2019;26(16):2823-2843. doi: 10.2174/0929867325666180209145243. (PubMed ID 29424301)" href="#reference-A189171">6</a></sup> The etiology of the disease is mostly unknown; however, the role of JAK as a driver of immune-mediated conditions was discovered, leading to the use of JAK as therapeutic targets for rheumatoid arthritis.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O&#39;Shea JJ: JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017 Dec 28;17(1):78. doi: 10.1038/nrd.2017.267. (PubMed ID 29282366)" href="#reference-A189168">5</a></sup> To reduce dose-related toxicity (as seen with some pan-JAK inhibitors) without significantly affecting efficacy, more selective JAK1 inhibitors, upadacitinib and <a href="https://go.drugbank.com/drugs/DB14845">filgotinib</a>, were developed.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Biggioggero M, Becciolini A, Crotti C, Agape E, Favalli EG: Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis. Drugs Context. 2019 Oct 24;8:212595. doi: 10.7573/dic.212595. eCollection 2019. (PubMed ID 31692920)" href="#reference-A189165">4</a></sup></p><p>The FDA approved Upadacitinib in August 2019 for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA Approved Drug Products: Rinvoq (upadacitinib) extended-release tablets, for oral use" href="#reference-L10896">9</a></sup> In December 2019, it was additionally approved by the European Commission for the same indication in patients with inadequate response or intolerance to one or more DMARDs and can be used as monotherapy or in combination with methotrexate.<sup class="text-reference-group"><a class="reference-popover-link" data-content="AbbVie Receives European Commission Approval of RINVOQ™ (upadacitinib) for the Treatment of Adults with Moderate to Severe Active Rheumatoid Arthritis" href="#reference-L10899">10</a></sup> Upadacitinib is marketed under the brand name RINVOQ™ for oral administration.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA Approved Drug Products: Rinvoq (upadacitinib) extended-release tablets, for oral use" href="#reference-L10896">9</a></sup> It is currently being investigated in several clinical trials assessing its therapeutic effectiveness in other inflammatory diseases, such as psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, and atopic dermatitis.<sup class="text-reference-group"><a class="reference-popover-link" data-content="

> <uniprotId>
P23458|P08684|P10635|P08183|Q9UNQ0|Q9Y6L6

> <BrandName>
Rinvoq

> <Melting point>
16-19

> <FDA_approved>
Y

$$$$
Sorafenib
                    3D
 Structure written by MMmdl.
 48 50  0  0  1  0            999 V2000
   -0.8698    7.0084    2.5787 C   0  0  0  0  0  0
   -1.1506    5.8396    1.7520 N   0  0  0  0  0  0
   -0.4077    4.7151    1.7109 C   0  0  0  0  0  0
    0.6070    4.5605    2.3951 O   0  0  0  0  0  0
   -0.8749    3.6216    0.7690 C   0  0  0  0  0  0
   -0.1660    2.4133    0.6800 C   0  0  0  0  0  0
   -0.6030    1.4155   -0.2059 C   0  0  0  0  0  0
   -1.7565    1.6453   -0.9577 C   0  0  0  0  0  0
   -2.4179    2.8645   -0.8224 C   0  0  0  0  0  0
   -1.9940    3.8413    0.0175 N   0  0  0  0  0  0
    0.0257    0.1936   -0.3337 O   0  0  0  0  0  0
    1.3886    0.0689   -0.1687 C   0  0  0  0  0  0
    2.2903    0.9418   -0.7860 C   0  0  0  0  0  0
    3.6597    0.7706   -0.6071 C   0  0  0  0  0  0
    4.1442   -0.2784    0.1784 C   0  0  0  0  0  0
    3.2365   -1.1652    0.7813 C   0  0  0  0  0  0
    1.8671   -0.9904    0.5999 C   0  0  0  0  0  0
    5.5467   -0.3538    0.2948 N   0  0  0  0  0  0
    6.3154   -1.2345    0.9685 C   0  0  0  0  0  0
    5.8994   -2.1837    1.6332 O   0  0  0  0  0  0
    7.6177   -0.9282    0.7970 N   0  0  0  0  0  0
    8.7476   -1.5585    1.3510 C   0  0  0  0  0  0
    8.7286   -2.3109    2.5346 C   0  0  0  0  0  0
    9.9011   -2.8894    3.0140 C   0  0  0  0  0  0
   11.1059   -2.7222    2.3310 C   0  0  0  0  0  0
   11.1481   -1.9567    1.1511 C   0  0  0  0  0  0
    9.9601   -1.3780    0.6796 C   0  0  0  0  0  0
   12.4596   -1.7509    0.3834 C   0  0  0  0  0  0
   12.3055   -0.9900   -0.7024 F   0  0  0  0  0  0
   13.3590   -1.1580    1.1693 F   0  0  0  0  0  0
   12.9426   -2.9292   -0.0117 F   0  0  0  0  0  0
   12.5209   -3.4764    2.9842 Cl  0  0  0  0  0  0
   -0.9134    7.9095    1.9672 H   0  0  0  0  0  0
    0.1127    6.9726    3.0514 H   0  0  0  0  0  0
   -1.6215    7.0959    3.3630 H   0  0  0  0  0  0
   -1.9840    5.8828    1.1833 H   0  0  0  0  0  0
    0.7109    2.2434    1.2885 H   0  0  0  0  0  0
   -2.1300    0.8926   -1.6364 H   0  0  0  0  0  0
   -3.3107    3.0732   -1.3934 H   0  0  0  0  0  0
    1.9298    1.7532   -1.4012 H   0  0  0  0  0  0
    4.3403    1.4603   -1.0859 H   0  0  0  0  0  0
    3.5537   -1.9944    1.3918 H   0  0  0  0  0  0
    1.1741   -1.6765    1.0645 H   0  0  0  0  0  0
    6.0390    0.3706   -0.2068 H   0  0  0  0  0  0
    7.8249   -0.1791    0.1529 H   0  0  0  0  0  0
    7.8230   -2.4493    3.1048 H   0  0  0  0  0  0
    9.8723   -3.4692    3.9251 H   0  0  0  0  0  0
    9.9734   -0.7862   -0.2249 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 33  1  0  0  0
  1 34  1  0  0  0
  1 35  1  0  0  0
  2  3  1  0  0  0
  2 36  1  0  0  0
  3  4  2  0  0  0
  3  5  1  0  0  0
  5  6  1  0  0  0
  5 10  2  0  0  0
  6  7  2  0  0  0
  6 37  1  0  0  0
  7  8  1  0  0  0
  7 11  1  0  0  0
  8  9  2  0  0  0
  8 38  1  0  0  0
  9 10  1  0  0  0
  9 39  1  0  0  0
 11 12  1  0  0  0
 12 13  1  0  0  0
 12 17  2  0  0  0
 13 14  2  0  0  0
 13 40  1  0  0  0
 14 15  1  0  0  0
 14 41  1  0  0  0
 15 16  2  0  0  0
 15 18  1  0  0  0
 16 17  1  0  0  0
 16 42  1  0  0  0
 17 43  1  0  0  0
 18 19  1  0  0  0
 18 44  1  0  0  0
 19 20  2  0  0  0
 19 21  1  0  0  0
 21 22  1  0  0  0
 21 45  1  0  0  0
 22 23  1  0  0  0
 22 27  2  0  0  0
 23 24  2  0  0  0
 23 46  1  0  0  0
 24 25  1  0  0  0
 24 47  1  0  0  0
 25 26  2  0  0  0
 25 32  1  0  0  0
 26 27  1  0  0  0
 26 28  1  0  0  0
 27 48  1  0  0  0
 28 29  1  0  0  0
 28 30  1  0  0  0
 28 31  1  0  0  0
M  END
> <s_m_entry_id>
572

> <Applicants>
Bayer

> <CHEMBL_ID>
CHEMBL1336

> <Canonical_Smiles>
Clc1ccc(NC(=O)Nc2ccc(Oc3cc(ncc3)C(=O)NC)cc2)cc1C(F)(F)F

> <Chirality>
Achiral Molecule

> <First_Approval>
2005

> <Phase>
4

> <SC_Patent>
US-7235576-B1

> <Synonyms>
BAY 43-9006 | BAY-43-9006 | NEXAVAR | SORAFENIB

> <Indications>
Sorafenib is indicated for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma.

> <Type>
2

> <targets_id>
P15056|P04049|P35916|P35968|P36888|P09619|P10721|P11362|P07949|P17948

> <inchi>
InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)

> <stdInchikey>
MLDQJTXFUGDVEO-UHFFFAOYSA-N

> <csid>
187440

> <Links>
|http://www.chemspider.com/Chemical-Structure.187440.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1336|http://pubchem.ncbi.nlm.nih.gov/compound/216239|http://www.drugbank.ca/drugs/DB07438| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=BAX|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/BAX|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5711|http://zinc15.docking.org/substances/ZINC01493878|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=9ZOQ3TZI87|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=16673

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
464.1

> <HBA>
4

> <HBD>
3

> <NRB>
5

> <TPSA>
92.3

> <LogP>
5.5

> <RoF>
1

> <Targets>
BRAF; RAF1; FLT4; KDR; FLT3; PDGFRB; KIT; FGFR1; RET; FLT1

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0154

> <r_epik_State_Penalty>
  0.0121

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
572

> <lig_pdbID>
'BAX'

> <pdbID>
1uwh 1uwj 3gcs 3heg 3rgf 3wze 4asd 5hi2

> <Kinase families>
Tyr<br>TKL

> <indicationDB>
Sorafenib (rINN), marketed as Nexavar by Bayer, is a drug approved for the treatment of advanced renal cell carcinoma (primary kidney cancer). It has also received &quot;Fast Track&quot; designation by the FDA for the treatment of advanced hepatocellular carcinoma (primary liver cancer), and has since performed well in Phase III trials.Sorafenib is a small molecular inhibitor of Raf kinase, PDGF (platelet-derived growth factor), VEGF receptor 2 &amp; 3 kinases and c Kit the receptor for Stem cell factor. A growing number of drugs target most of these pathways. The originality of Sorafenib lays in its simultaneous targeting of the Raf/Mek/Erk pathway.

> <uniprotId>
P15056|P04049|P35916|P35968|P36888|P09619|P10721|P11362|P07949|P17948|P11712|P20815|P24462|P08684|P20813|P10632|P05177|P33261|P10635|O60656|P22309

> <BrandName>
Nexavar

> <Melting point>
205.6 °C

> <Withdrawn>
|Study NCT01851408 in nan was Withdrawn during Phase 2 because No progression of Phase 1 trial to Phase 2|Study NCT02227914 in United States was Withdrawn during Phase 1/Phase 2 because Study stopped due to administrative reasons|Study NCT02288507 in United States was Withdrawn during Phase 1 because Closed due to no accrual|Study NCT02599090 in nan was Withdrawn during Phase 2 because Multi phase study did not progress to Phase II Phase I registered as NCT00734526|Study NCT03780634 in China was Withdrawn during Phase 2 because No participants enrolled|Study NCT00547443 in United States was Withdrawn during Phase 1/Phase 2 because Withdrawn as the sponsor has stopped the drug for NSCLC population|Study NCT02129322 in China was Withdrawn during Phase 2 because patients not enrolled|Study NCT01801163 in United States was Withdrawn during Phase 1 because Trial had no patients accrued while open|Study NCT02747537 in nan was Withdrawn during Phase 2 because Could not recruit participants for the study|Study NCT02989870 in United States was Withdrawn during Phase 1 because No Interest Investigator was unable to enroll any participants on study|Study NCT01441388 in nan was Withdrawn during Phase 1 because Business/Operational issues|Study NCT02908165 in United States was Withdrawn during Phase 2 because A future study will be taking place using the same patient population|Study NCT02691780 in Korea, Republic of was Withdrawn during N/A because not enrolled|Study NCT00627835 in Canada was Withdrawn during Phase 1 because Site decided not to open this study|Study NCT01618253 in United States was Withdrawn during Phase 1 because Closed due to poor accrual|Study NCT00808145 in United States was Withdrawn during Phase 2 because Lack of enrollment, many screen failures and non eligible study participants|Study NCT01736878 in Germany was Withdrawn during Phase 2 because Study was withdrawn due to unanticipated hassle in patient recruitment|Study NCT03563170 in United States was Withdrawn during Phase 1/Phase 2 because Enrollment not initiated|Study NCT02406508 in United States was Withdrawn during Phase 2 because No enrollment in the study

> <FDA_approved>
Y

$$$$
Pexidartinib
                    3D
 Structure written by MMmdl.
 45 48  0  0  1  0            999 V2000
   -2.1393   -1.0266    0.1248 C   0  0  0  0  0  0
   -0.7728   -1.1829   -0.1259 C   0  0  0  0  0  0
   -0.0298   -0.0999   -0.6200 C   0  0  0  0  0  0
   -0.6635    1.0693   -0.8421 N   0  3  0  0  0  0
   -1.9782    1.2622   -0.6144 C   0  0  0  0  0  0
   -2.7546    0.2083   -0.1189 C   0  0  0  0  0  0
   -4.2416    0.4019    0.1391 C   0  0  0  0  0  0
   -5.0415    0.4912   -1.1441 C   0  0  0  0  0  0
   -5.6258    1.6167   -1.7058 C   0  0  0  0  0  0
   -6.2771    1.2962   -2.8708 N   0  0  0  0  0  0
   -6.1468   -0.0524   -3.1013 C   0  0  0  0  0  0
   -5.3777   -0.5933   -2.0302 C   0  0  0  0  0  0
   -5.1245   -1.9767   -2.0626 C   0  0  0  0  0  0
   -5.6363   -2.7157   -3.1315 C   0  0  0  0  0  0
   -6.3760   -2.0672   -4.1228 C   0  0  0  0  0  0
   -6.6486   -0.7352   -4.1352 N   0  0  0  0  0  0
   -5.3560   -4.4158   -3.2253 Cl  0  0  0  0  0  0
    1.3607   -0.1638   -0.9026 N   0  0  0  0  0  0
    2.1576   -1.3802   -0.7200 C   0  0  0  0  0  0
    3.6260   -1.1667   -1.0340 C   0  0  0  0  0  0
    4.1195   -1.3594   -2.3283 C   0  0  0  0  0  0
    5.4781   -1.1642   -2.5852 C   0  0  0  0  0  0
    6.3153   -0.7782   -1.5298 C   0  0  0  0  0  0
    5.8468   -0.5859   -0.2657 N   0  0  0  0  0  0
    4.5238   -0.7808   -0.0346 C   0  0  0  0  0  0
    7.8134   -0.5493   -1.7241 C   0  0  0  0  0  0
    8.1962   -0.7682   -2.9836 F   0  0  0  0  0  0
    8.1241    0.7089   -1.4090 F   0  0  0  0  0  0
    8.5044   -1.3711   -0.9326 F   0  0  0  0  0  0
   -2.7124   -1.8610    0.5028 H   0  0  0  0  0  0
   -0.3087   -2.1392    0.0649 H   0  0  0  0  0  0
   -2.3579    2.2488   -0.8387 H   0  0  0  0  0  0
   -4.6225   -0.4139    0.7556 H   0  0  0  0  0  0
   -4.3684    1.3096    0.7313 H   0  0  0  0  0  0
   -5.6288    2.6419   -1.3655 H   0  0  0  0  0  0
   -6.7664    1.9764   -3.4344 H   0  0  0  0  0  0
   -4.5502   -2.4570   -1.2841 H   0  0  0  0  0  0
   -6.7762   -2.6313   -4.9528 H   0  0  0  0  0  0
    1.8235    0.6536   -1.2737 H   0  0  0  0  0  0
    2.0353   -1.7105    0.3128 H   0  0  0  0  0  0
    1.7390   -2.1518   -1.3680 H   0  0  0  0  0  0
    3.4586   -1.6585   -3.1290 H   0  0  0  0  0  0
    5.8638   -1.3132   -3.5831 H   0  0  0  0  0  0
    4.1897   -0.6211    0.9804 H   0  0  0  0  0  0
   -0.1227    1.8437   -1.1997 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1  6  2  0  0  0
  1 30  1  0  0  0
  2  3  2  0  0  0
  2 31  1  0  0  0
  3  4  1  0  0  0
  3 18  1  0  0  0
  4  5  2  0  0  0
  4 45  1  0  0  0
  5  6  1  0  0  0
  5 32  1  0  0  0
  6  7  1  0  0  0
  7  8  1  0  0  0
  7 33  1  0  0  0
  7 34  1  0  0  0
  8  9  2  0  0  0
  8 12  1  0  0  0
  9 10  1  0  0  0
  9 35  1  0  0  0
 10 11  1  0  0  0
 10 36  1  0  0  0
 11 12  1  0  0  0
 11 16  2  0  0  0
 12 13  2  0  0  0
 13 14  1  0  0  0
 13 37  1  0  0  0
 14 15  2  0  0  0
 14 17  1  0  0  0
 15 16  1  0  0  0
 15 38  1  0  0  0
 18 19  1  0  0  0
 18 39  1  0  0  0
 19 20  1  0  0  0
 19 40  1  0  0  0
 19 41  1  0  0  0
 20 21  1  0  0  0
 20 25  2  0  0  0
 21 22  2  0  0  0
 21 42  1  0  0  0
 22 23  1  0  0  0
 22 43  1  0  0  0
 23 24  2  0  0  0
 23 26  1  0  0  0
 24 25  1  0  0  0
 25 44  1  0  0  0
 26 27  1  0  0  0
 26 28  1  0  0  0
 26 29  1  0  0  0
M  CHG  1   4   1
M  END
> <s_m_entry_id>
574

> <Applicants>
Daiichi Sankyo

> <CHEMBL_ID>
CHEMBL3813873

> <Canonical_Smiles>
Clc1cc2c([nH]cc2Cc2ccc(nc2)NCc2ccc(nc2)C(F)(F)F)nc1

> <Chirality>
Achiral Molecule

> <First_Approval>
2019

> <Phase>
4

> <SC_Patent>
US-7893075-B2

> <Synonyms>
CML-261 | PEXIDARTINIB | PLX-3397 | PLX3397

> <Indications>
On august 2019, FDA approved pexidartinib to treat adult patients with symptomatic tenosynovial giant cell tumor

> <Type>
2

> <targets_id>
P36888|P10721|P07333

> <inchi>
InChI=1S/C20H15ClF3N5/c21-15-6-16-14(10-28-19(16)29-11-15)5-12-2-4-18(26-7-12)27-9-13-1-3-17(25-8-13)20(22,23)24/h1-4,6-8,10-11H,5,9H2,(H,26,27)(H,28,29)

> <stdInchikey>
JGWRKYUXBBNENE-UHFFFAOYSA-N

> <csid>
35308322

> <Links>
|http://www.chemspider.com/Chemical-Structure.35308322.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3813873|http://pubchem.ncbi.nlm.nih.gov/compound/25151352|http://www.drugbank.ca/drugs/DB12978| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=P31|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/P31|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8710|http://zinc15.docking.org/substances/ZINC000115705166|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=6783M2LV5X|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50177716

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
417.1

> <HBA>
4

> <HBD>
2

> <NRB>
5

> <TPSA>
66.5

> <LogP>
5.2

> <RoF>
1

> <Targets>
FLT3; KIT; CSF1R

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
0.999992

> <r_epik_Ionization_Penalty>
  0.2266

> <r_epik_State_Penalty>
  0.2168

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
574

> <lig_pdbID>
'P31'

> <pdbID>
4r7h

> <Kinase families>
Tyr

> <indicationDB>
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA approves first therapy for rare joint tumor - FDA News Release" href="#reference-L7901">11</a></sup> Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Giustini N, Bernthal NM, Bukata SV, Singh AS: Tenosynovial giant cell tumor: case report of a patient effectively treated with pexidartinib (PLX3397) and review of the literature. Clin Sarcoma Res. 2018 Jul 10;8:14. doi: 10.1186/s13569-018-0101-2. eCollection 2018. (PubMed ID 30002809)" href="#reference-A182240">1</a>,<a class="reference-popover-link" data-content="FDA approves first therapy for rare joint tumor - FDA News Release" href="#reference-L7901">11</a></sup> Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA approves first therapy for rare joint tumor - FDA News Release" href="#reference-L7901">11</a></sup></p><p>While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence.<sup class="text-reference-group"><a class="reference-popover-link" data-content="TURALIO (PEXIDARTINIB) CAPSULES - Daiichi Sankyo, Inc. - FDA Oncologic Drugs Advisory Committee Briefing Document" href="#reference-L7895">10</a></sup> Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Tap WD, Gelderblom H, Palmerini E, Desai J, Bauer S, Blay JY, Alcindor T, Ganjoo K, Martin-Broto J, Ryan CW, Thomas DM, Peterfy C, Healey JH, van de Sande M, Gelhorn HL, Shuster DE, Wang Q, Yver A, Hsu HH, Lin PS, Tong-Starksen S, Stacchiotti S, Wagner AJ: Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial. Lancet. 2019 Jun 19. pii: S0140-6736(19)30764-0. doi: 10.1016/S0140-6736(19)30764-0. (PubMed ID 31229240)" href="#reference-A182243">2</a></sup> Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA approves first therapy for rare joint tumor - FDA News Release" href="#reference-L7901">11</a></sup>

> <uniprotId>
P07333|P10721|P36888|P09619|P08684|P22310|P20813|P11712|P22309|P02768|P02763|Q96FL8|Q86VL8|Q9Y6L6|Q9NPD5|O94956

> <BrandName>
Turalio

> <FDA_approved>
Y

$$$$
Lorlatinib
                    3D
 Structure written by MMmdl.
 49 52  0  0  1  0            999 V2000
   -0.0143   -0.0265    0.1830 C   0  0  0  0  0  0
    1.5082   -0.0071   -0.0487 C   0  0  2  0  0  0
    1.9272    0.7712   -1.3187 C   0  0  0  0  0  0
    1.2799    0.4514   -2.5222 C   0  0  0  0  0  0
    1.5859    1.1145   -3.7071 C   0  0  0  0  0  0
    2.5523    2.1130   -3.7126 C   0  0  0  0  0  0
    3.2244    2.4330   -2.5370 C   0  0  0  0  0  0
    2.9450    1.7610   -1.3367 C   0  0  0  0  0  0
    3.7458    2.1317   -0.1066 C   0  0  0  0  0  0
    3.1489    2.6177    0.8564 O   0  0  0  0  0  0
    5.0910    1.8966   -0.1059 N   0  0  0  0  0  0
    5.9307    2.2198    1.0620 C   0  0  0  0  0  0
    6.5926    1.0368    1.7774 C   0  0  0  0  0  0
    6.4470   -0.3729    1.6644 C   0  0  0  0  0  0
    7.3616   -0.9051    2.5712 C   0  0  0  0  0  0
    7.9666    0.1840    3.1539 N   0  0  0  0  0  0
    7.4998    1.3413    2.6790 N   0  0  0  0  0  0
    8.9992    0.2430    4.1841 C   0  0  0  0  0  0
    7.6847   -2.2839    2.9211 C   0  0  0  0  0  0
    7.9409   -3.3774    3.1979 N   0  0  0  0  0  0
    5.5366   -1.1550    0.7821 C   0  0  0  0  0  0
    4.1567   -0.9595    0.8373 C   0  0  0  0  0  0
    3.3111   -1.6104   -0.0730 C   0  0  0  0  0  0
    3.8931   -2.5321   -0.9562 C   0  0  0  0  0  0
    5.2281   -2.7756   -0.9898 N   0  0  0  0  0  0
    6.0273   -2.0850   -0.1383 C   0  0  0  0  0  0
    3.1095   -3.2345   -1.8707 N   0  0  0  0  0  0
    1.9511   -1.3685   -0.1223 O   0  0  0  0  0  0
    5.8403    1.3850   -1.2621 C   0  0  0  0  0  0
    0.9414    0.7902   -4.8507 F   0  0  0  0  0  0
   -0.4204    0.9853    0.2116 H   0  0  0  0  0  0
   -0.2534   -0.5009    1.1354 H   0  0  0  0  0  0
   -0.5451   -0.5789   -0.5921 H   0  0  0  0  0  0
    1.8995    0.4616    0.8494 H   0  0  0  0  0  0
    0.5278   -0.3228   -2.5487 H   0  0  0  0  0  0
    2.7872    2.6346   -4.6286 H   0  0  0  0  0  0
    3.9787    3.2068   -2.5694 H   0  0  0  0  0  0
    6.6982    2.9135    0.7155 H   0  0  0  0  0  0
    5.3599    2.7882    1.7979 H   0  0  0  0  0  0
    9.3394   -0.7557    4.4565 H   0  0  0  0  0  0
    8.5965    0.7324    5.0718 H   0  0  0  0  0  0
    9.8516    0.8135    3.8126 H   0  0  0  0  0  0
    3.7600   -0.2675    1.5642 H   0  0  0  0  0  0
    7.0872   -2.2794   -0.2179 H   0  0  0  0  0  0
    2.1107   -3.0880   -1.8810 H   0  0  0  0  0  0
    3.5504   -3.8905   -2.4986 H   0  0  0  0  0  0
    5.2477    0.6973   -1.8664 H   0  0  0  0  0  0
    6.7305    0.8395   -0.9482 H   0  0  0  0  0  0
    6.1652    2.2111   -1.8951 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 31  1  0  0  0
  1 32  1  0  0  0
  1 33  1  0  0  0
  2  3  1  0  0  0
  2 28  1  0  0  0
  2 34  1  0  0  0
  3  4  2  0  0  0
  3  8  1  0  0  0
  4  5  1  0  0  0
  4 35  1  0  0  0
  5  6  2  0  0  0
  5 30  1  0  0  0
  6  7  1  0  0  0
  6 36  1  0  0  0
  7  8  2  0  0  0
  7 37  1  0  0  0
  8  9  1  0  0  0
  9 10  2  0  0  0
  9 11  1  0  0  0
 11 12  1  0  0  0
 11 29  1  0  0  0
 12 13  1  0  0  0
 12 38  1  0  0  0
 12 39  1  0  0  0
 13 14  1  0  0  0
 13 17  2  0  0  0
 14 15  2  0  0  0
 14 21  1  0  0  0
 15 16  1  0  0  0
 15 19  1  0  0  0
 16 17  1  0  0  0
 16 18  1  0  0  0
 18 40  1  0  0  0
 18 41  1  0  0  0
 18 42  1  0  0  0
 19 20  3  0  0  0
 21 22  2  0  0  0
 21 26  1  0  0  0
 22 23  1  0  0  0
 22 43  1  0  0  0
 23 24  2  0  0  0
 23 28  1  0  0  0
 24 25  1  0  0  0
 24 27  1  0  0  0
 25 26  2  0  0  0
 26 44  1  0  0  0
 27 45  1  0  0  0
 27 46  1  0  0  0
 29 47  1  0  0  0
 29 48  1  0  0  0
 29 49  1  0  0  0
M  END
> <s_m_entry_id>
576

> <Applicants>
Pfizer

> <CHEMBL_ID>
CHEMBL3286830

> <Canonical_Smiles>
Fc1cc2c(cc1)C(=O)N(Cc1nn(C)c(c1-c1cc(O[C@@H]2C)c(nc1)N)C#N)C

> <Chirality>
Single Stereoisomer

> <First_Approval>
2018

> <Phase>
4

> <SC_Patent>
US-8680111-B2

> <Synonyms>
LORBRENA | LORLATINIB | PF-06463922

> <Indications>
On november 2, 2018, the FDA approved lorlatinib to treat patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer

> <Type>
1

> <targets_id>
Q9UM73|P08922

> <inchi>
InChI=1S/C21H19FN6O2/c1-11-15-7-13(22)4-5-14(15)21(29)27(2)10-16-19(17(8-23)28(3)26-16)12-6-18(30-11)20(24)25-9-12/h4-7,9,11H,10H2,1-3H3,(H2,24,25)/t11-/m1/s1

> <stdInchikey>
IIXWYSCJSQVBQM-LLVKDONJSA-N

> <csid>
32813339

> <Links>
|http://www.chemspider.com/Chemical-Structure.32813339.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3286830|http://pubchem.ncbi.nlm.nih.gov/compound/71731823|http://www.drugbank.ca/drugs/DB12130| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=5P8|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/5P8|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7476|http://zinc15.docking.org/substances/ZINC000098208524|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=OSP71S83EU|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50018830

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
406.2

> <HBA>
7

> <HBD>
1

> <NRB>
0

> <TPSA>
110.1

> <LogP>
2.8

> <RoF>
0

> <Targets>
ALK; ROS1

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
0.999999

> <r_epik_Ionization_Penalty>
  0.3417

> <r_epik_State_Penalty>
  0.3362

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
576

> <lig_pdbID>
'5P8'

> <pdbID>
4cli 4clj 4uxl 5a9u 5aa8 5aa9

> <Kinase families>
Tyr

> <indicationDB>
Lorlatinib has been used in trials studying the basic science and treatment of Non-small Cell Lung Cancer and anaplastic lymphoma kinase (ALK)-positive Non-Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC. Despite initial responses from the use of various ALK inhibitors, however, it is virtually almost guaranteed that all patients with the condition in question will develop tumour progression or resistance to the current therapy in use <sup class="text-reference-group"><a class="reference-popover-link" data-content="Waqar SN, Morgensztern D: Lorlatinib: a new-generation drug for ALK-positive NSCLC. Lancet Oncol. 2018 Dec;19(12):1555-1557. doi: 10.1016/S1470-2045(18)30789-7. Epub 2018 Nov 6. (PubMed ID 30413381)" href="#reference-A40086">9</a></sup>.</p><p>Considered a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic NSCLC, lorlatinib&#39;s most optimal place in the treatment sequence of this condition has most recently been identified with its latest approval by the US FDA in November of 2018 for the indication of treating those patients&#39; disease which has progressed even after the use of first and second-generation TKIs like crizotinib, alectinib, or ceritinib <sup class="text-reference-group"><a class="reference-popover-link" data-content="Drugs.com: FDA Approves Lorbrena" href="#reference-L4848">10</a>,<a class="reference-popover-link" data-content="Official drug label" href="#label-reference">Label</a></sup>. Loratinib&#39;s ability to move past the blood-brain barrier facilitates its ability to treat progressive or worsening brain metastases as well <sup class="text-reference-group"><a class="reference-popover-link" data-content="Drugs.com: FDA Approves Lorbrena" href="#reference-L4848">10</a>,<a class="reference-popover-link" data-content="Collier TL, Maresca KP, Normandin MD, Richardson P, McCarthy TJ, Liang SH, Waterhouse RN, Vasdev N: Brain Penetration of the ROS1/ALK Inhibitor Lorlatinib Confirmed by PET. Mol Imaging. 2017 Jan-Dec;16:1536012117736669. doi: 10.1177/1536012117736669. (PubMed ID 29067878)" href="#reference-A40078">5</a></sup>.

> <uniprotId>
Q9UM73

> <BrandName>
Lorbrena

> <FDA_approved>
Y

$$$$
Idelalisib
                    3D
 Structure written by MMmdl.
 49 53  0  0  1  0            999 V2000
   -0.4054    1.8035   -0.4826 C   0  0  0  0  0  0
   -0.0351    0.3234   -0.2854 C   0  0  0  0  0  0
    1.4879    0.0626   -0.1483 C   0  0  1  0  0  0
    2.1190    0.6942    1.1208 C   0  0  0  0  0  0
    1.5320    0.5002    2.2523 N   0  0  0  0  0  0
    2.0404    1.0629    3.4275 C   0  0  0  0  0  0
    1.3584    0.8175    4.6204 C   0  0  0  0  0  0
    1.8325    1.3619    5.8137 C   0  0  0  0  0  0
    2.9842    2.1499    5.8156 C   0  0  0  0  0  0
    3.6732    2.4016    4.6271 C   0  0  0  0  0  0
    3.1977    1.8544    3.4230 C   0  0  0  0  0  0
    3.9079    2.0892    2.0965 C   0  0  0  0  0  0
    4.9373    2.7669    1.9955 O   0  0  0  0  0  0
    3.2875    1.4602    1.0250 N   0  0  0  0  0  0
    3.9451    1.5943   -0.2213 C   0  0  0  0  0  0
    4.7979    0.5775   -0.6699 C   0  0  0  0  0  0
    5.4168    0.6934   -1.9111 C   0  0  0  0  0  0
    5.1854    1.8215   -2.6959 C   0  0  0  0  0  0
    4.3396    2.8371   -2.2536 C   0  0  0  0  0  0
    3.7156    2.7257   -1.0141 C   0  0  0  0  0  0
    4.7874    3.1706    4.6733 F   0  0  0  0  0  0
    1.7908   -1.3673   -0.0601 N   0  0  0  0  0  0
    2.1441   -2.1455   -1.1760 C   0  0  0  0  0  0
    2.4170   -3.5178   -1.0144 C   0  0  0  0  0  0
    2.7843   -4.2253   -2.1857 C   0  0  0  0  0  0
    2.9922   -5.5145   -1.7600 N   0  0  0  0  0  0
    2.7505   -5.5173   -0.4050 C   0  0  0  0  0  0
    2.4063   -4.3484    0.0796 N   0  0  0  0  0  0
    2.8933   -3.7102   -3.4142 N   0  0  0  0  0  0
    2.6065   -2.3802   -3.4488 C   0  0  0  0  0  0
    2.2419   -1.5779   -2.4135 N   0  0  0  0  0  0
   -1.4801    1.9186   -0.6257 H   0  0  0  0  0  0
    0.0917    2.2207   -1.3590 H   0  0  0  0  0  0
   -0.1232    2.4066    0.3809 H   0  0  0  0  0  0
   -0.5757   -0.0747    0.5753 H   0  0  0  0  0  0
   -0.4091   -0.2328   -1.1466 H   0  0  0  0  0  0
    1.9425    0.4726   -1.0478 H   0  0  0  0  0  0
    0.4654    0.2089    4.6282 H   0  0  0  0  0  0
    1.3069    1.1729    6.7380 H   0  0  0  0  0  0
    3.3446    2.5673    6.7444 H   0  0  0  0  0  0
    4.9705   -0.3009   -0.0645 H   0  0  0  0  0  0
    6.0712   -0.0896   -2.2650 H   0  0  0  0  0  0
    5.6661    1.9088   -3.6591 H   0  0  0  0  0  0
    4.1662    3.7060   -2.8707 H   0  0  0  0  0  0
    3.0540    3.5095   -0.6737 H   0  0  0  0  0  0
    1.6715   -1.8230    0.8336 H   0  0  0  0  0  0
    3.2663   -6.3284   -2.2901 H   0  0  0  0  0  0
    2.8528   -6.4357    0.1547 H   0  0  0  0  0  0
    2.6782   -1.9032   -4.4155 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 32  1  0  0  0
  1 33  1  0  0  0
  1 34  1  0  0  0
  2  3  1  0  0  0
  2 35  1  0  0  0
  2 36  1  0  0  0
  3  4  1  0  0  0
  3 22  1  0  0  0
  3 37  1  0  0  0
  4  5  2  0  0  0
  4 14  1  0  0  0
  5  6  1  0  0  0
  6  7  1  0  0  0
  6 11  2  0  0  0
  7  8  2  0  0  0
  7 38  1  0  0  0
  8  9  1  0  0  0
  8 39  1  0  0  0
  9 10  2  0  0  0
  9 40  1  0  0  0
 10 11  1  0  0  0
 10 21  1  0  0  0
 11 12  1  0  0  0
 12 13  2  0  0  0
 12 14  1  0  0  0
 14 15  1  0  0  0
 15 16  1  0  0  0
 15 20  2  0  0  0
 16 17  2  0  0  0
 16 41  1  0  0  0
 17 18  1  0  0  0
 17 42  1  0  0  0
 18 19  2  0  0  0
 18 43  1  0  0  0
 19 20  1  0  0  0
 19 44  1  0  0  0
 20 45  1  0  0  0
 22 23  1  0  0  0
 22 46  1  0  0  0
 23 24  1  0  0  0
 23 31  2  0  0  0
 24 25  2  0  0  0
 24 28  1  0  0  0
 25 26  1  0  0  0
 25 29  1  0  0  0
 26 27  1  0  0  0
 26 47  1  0  0  0
 27 28  2  0  0  0
 27 48  1  0  0  0
 29 30  2  0  0  0
 30 31  1  0  0  0
 30 49  1  0  0  0
M  END
> <s_m_entry_id>
578

> <Applicants>
Gilead Sciences

> <CHEMBL_ID>
CHEMBL2216870

> <Canonical_Smiles>
Fc1c2c(N=C(N(C2=O)c2ccccc2)[C@@H](Nc2ncnc3[nH]cnc23)CC)ccc1

> <Chirality>
Single Stereoisomer

> <First_Approval>
2014

> <Phase>
4

> <SC_Patent>
US-6800620-B2

> <Synonyms>
CAL-101 | GS-1101 | GS-11CAL-101 | IDELALISIB | ZYDELIG

> <Indications>
Idelalisib is indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies.

> <Type>
1

> <targets_id>
O00329

> <inchi>
InChI=1S/C22H18FN7O/c1-2-15(28-20-18-19(25-11-24-18)26-12-27-20)21-29-16-10-6-9-14(23)17(16)22(31)30(21)13-7-4-3-5-8-13/h3-12,15H,2H2,1H3,(H2,24,25,26,27,28)/t15-/m0/s1

> <stdInchikey>
IFSDAJWBUCMOAH-HNNXBMFYSA-N

> <csid>
9800565

> <Links>
|http://www.chemspider.com/Chemical-Structure.9800565.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2216870|http://pubchem.ncbi.nlm.nih.gov/compound/11625818|http://www.drugbank.ca/drugs/DB09054| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=40L|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/40L|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6741|http://zinc15.docking.org/substances/ZINC13986658|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=YG57I8T5M0|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50403068

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
415.2

> <HBA>
7

> <HBD>
2

> <NRB>
5

> <TPSA>
101.4

> <LogP>
3.8

> <RoF>
0

> <Targets>
PIK3CD

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
0.955582

> <r_epik_Ionization_Penalty>
  0.0022

> <r_epik_State_Penalty>
  0.0207

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
578

> <lig_pdbID>
'40L'

> <pdbID>
4xe0

> <Kinase families>
Atypical

> <indicationDB>
Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies. More specifically, idelalisib targets P110δ, the delta isoform of the enzyme phosphatidylinositol-4,5-bisphosphate 3-kinase, also known as PI-3K. The PI-3Ks are a family of enzymes involved in cellular functions such as cell growth, proliferation, differentiation, motility, survival and intracellular trafficking, which in turn are involved in cancer. In contrast to the other class IA PI3Ks p110α and p110β, p110δ is principally expressed in leukocytes (white blood cells) and is important for the function of T cells, B cell, mast cells and neutrophils. By inhibiting this enzyme, idelalisib induces apoptosis of malignant cells and inhibits several cell signaling pathways, including B-cell receptor (BCR) signaling and C-X-C chemokine receptors type 5 and type 4 signalling, which are involved in trafficking and homing of B-cells to the lymph nodes and bone marrow. Treatment of lymphoma cells with idelalisib has been shown to result in inhibition of chemotaxis and adhesion, and reduced cell viability.

> <uniprotId>
O00329

> <BrandName>
Zydelig

> <Withdrawn>
|Study NCT02662296 in United States was Withdrawn during Phase 2 because Low enrollment

> <FDA_approved>
Y

$$$$
Ripretinib
                    3D
 Structure written by MMmdl.
 54 57  0  0  1  0            999 V2000
   -3.3334   -2.3101    2.6050 C   0  0  0  0  0  0
   -2.8466   -2.4736    1.1548 C   0  0  0  0  0  0
   -2.0834   -1.3073    0.6528 N   0  0  0  0  0  0
   -2.8225   -0.1661    0.1948 C   0  0  0  0  0  0
   -4.2279   -0.0905    0.1845 C   0  0  0  0  0  0
   -4.8579    1.0682   -0.2830 C   0  0  0  0  0  0
   -4.1511    2.1411   -0.7344 N   0  0  0  0  0  0
   -2.7982    2.0715   -0.7281 C   0  0  0  0  0  0
   -2.1079    0.9475   -0.2758 C   0  0  0  0  0  0
   -0.6465    0.8773   -0.2613 C   0  0  0  0  0  0
    0.0059   -0.2114    0.2049 C   0  0  0  0  0  0
   -0.7089   -1.3789    0.7390 C   0  0  0  0  0  0
   -0.1013   -2.3383    1.2250 O   0  0  0  0  0  0
    1.4878   -0.2123    0.2116 C   0  0  0  0  0  0
    2.1752   -1.0272   -0.6969 C   0  0  0  0  0  0
    3.5784   -1.0711   -0.7132 C   0  0  0  0  0  0
    4.2951   -0.2812    0.1928 C   0  0  0  0  0  0
    3.6184    0.5227    1.1081 C   0  0  0  0  0  0
    2.2246    0.5565    1.1277 C   0  0  0  0  0  0
    1.3634    1.6590    2.4268 Br  0  0  0  0  0  0
    5.6499   -0.2905    0.1994 F   0  0  0  0  0  0
    4.3134   -1.8670   -1.6121 N   0  0  0  0  0  0
    3.9648   -3.0568   -2.1424 C   0  0  0  0  0  0
    2.9140   -3.6526   -1.8996 O   0  0  0  0  0  0
    4.9397   -3.4975   -2.9639 N   0  0  0  0  0  0
    4.9796   -4.6573   -3.7613 C   0  0  0  0  0  0
    6.2340   -5.0060   -4.2705 C   0  0  0  0  0  0
    6.3756   -6.1293   -5.0805 C   0  0  0  0  0  0
    5.2600   -6.9034   -5.3881 C   0  0  0  0  0  0
    4.0029   -6.5615   -4.8967 C   0  0  0  0  0  0
    3.8575   -5.4383   -4.0863 C   0  0  0  0  0  0
   -6.2619    1.1100   -0.2637 N   0  0  0  0  0  0
   -6.9905    2.2128   -0.8774 C   0  0  0  0  0  0
   -3.8948   -3.1883    2.9239 H   0  0  0  0  0  0
   -3.9833   -1.4429    2.7219 H   0  0  0  0  0  0
   -2.4927   -2.1905    3.2892 H   0  0  0  0  0  0
   -2.2554   -3.3886    1.0891 H   0  0  0  0  0  0
   -3.6907   -2.6701    0.4943 H   0  0  0  0  0  0
   -4.8394   -0.9075    0.5358 H   0  0  0  0  0  0
   -2.2718    2.9416   -1.0931 H   0  0  0  0  0  0
   -0.0758    1.7176   -0.6325 H   0  0  0  0  0  0
    1.6013   -1.6118   -1.4008 H   0  0  0  0  0  0
    4.1797    1.1211    1.8107 H   0  0  0  0  0  0
    5.2532   -1.5465   -1.7930 H   0  0  0  0  0  0
    5.7765   -2.9346   -3.0070 H   0  0  0  0  0  0
    7.1068   -4.4119   -4.0390 H   0  0  0  0  0  0
    7.3464   -6.3986   -5.4697 H   0  0  0  0  0  0
    5.3698   -7.7745   -6.0172 H   0  0  0  0  0  0
    3.1416   -7.1629   -5.1470 H   0  0  0  0  0  0
    2.8666   -5.1930   -3.7388 H   0  0  0  0  0  0
   -6.7510    0.2341   -0.1499 H   0  0  0  0  0  0
   -8.0505    2.1372   -0.6350 H   0  0  0  0  0  0
   -6.8849    2.1865   -1.9624 H   0  0  0  0  0  0
   -6.6307    3.1761   -0.5140 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 34  1  0  0  0
  1 35  1  0  0  0
  1 36  1  0  0  0
  2  3  1  0  0  0
  2 37  1  0  0  0
  2 38  1  0  0  0
  3  4  1  0  0  0
  3 12  1  0  0  0
  4  5  2  0  0  0
  4  9  1  0  0  0
  5  6  1  0  0  0
  5 39  1  0  0  0
  6  7  2  0  0  0
  6 32  1  0  0  0
  7  8  1  0  0  0
  8  9  2  0  0  0
  8 40  1  0  0  0
  9 10  1  0  0  0
 10 11  2  0  0  0
 10 41  1  0  0  0
 11 12  1  0  0  0
 11 14  1  0  0  0
 12 13  2  0  0  0
 14 15  1  0  0  0
 14 19  2  0  0  0
 15 16  2  0  0  0
 15 42  1  0  0  0
 16 17  1  0  0  0
 16 22  1  0  0  0
 17 18  2  0  0  0
 17 21  1  0  0  0
 18 19  1  0  0  0
 18 43  1  0  0  0
 19 20  1  0  0  0
 22 23  1  0  0  0
 22 44  1  0  0  0
 23 24  2  0  0  0
 23 25  1  0  0  0
 25 26  1  0  0  0
 25 45  1  0  0  0
 26 27  1  0  0  0
 26 31  2  0  0  0
 27 28  2  0  0  0
 27 46  1  0  0  0
 28 29  1  0  0  0
 28 47  1  0  0  0
 29 30  2  0  0  0
 29 48  1  0  0  0
 30 31  1  0  0  0
 30 49  1  0  0  0
 31 50  1  0  0  0
 32 33  1  0  0  0
 32 51  1  0  0  0
 33 52  1  0  0  0
 33 53  1  0  0  0
 33 54  1  0  0  0
M  END
> <s_m_entry_id>
580

> <Applicants>
Deciphera Pharmaceuticals

> <CHEMBL_ID>
CHEMBL4216467

> <Canonical_Smiles>
Brc1cc(F)c(NC(=O)Nc2ccccc2)cc1C1=Cc2c(N(CC)C1=O)cc(nc2)NC

> <Chirality>
Achiral Molecule

> <First_Approval>
2020

> <Phase>
4

> <SC_Patent>
US-8188113-B2

> <Synonyms>
DCC-2618 | QINLOCK | RIPRETINIB

> <Indications>
Ripretinib (DCC-2618) is an orally bioavailable, potent pan-KIT and PDGFR&alpha; kinase inhibitor being developed by Dicephera Pharmaceuticals.  It is in clinical development for the treatment of  malignancies that are driven by KIT and/or PDGFR&alpha;, for example gastrointestinal stromal tumors, glioblastoma multiforme and systemic mastocytosis. Ripretinib has activity across a broad range of resistance mutations in its target kinases, that emerge in response to imatinib treatment. Ripretinib binds to the 'switch pocket' of KIT, a domain that regulates the enzyme's catalytic conformation. Compounds that act in this way are often referred to as switch control inhibitors.

> <Type>
nan

> <targets_id>
nan

> <inchi>
InChI=1S/C24H21BrFN5O2/c1-3-31-21-12-22(27-2)28-13-14(21)9-17(23(31)32)16-10-20(19(26)11-18(16)25)30-24(33)29-15-7-5-4-6-8-15/h4-13H,3H2,1-2H3,(H,27,28)(H2,29,30,33)

> <stdInchikey>
CEFJVGZHQAGLHS-UHFFFAOYSA-N

> <csid>
67886378

> <Links>
|http://www.chemspider.com/Chemical-Structure.67886378.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4216467|http://pubchem.ncbi.nlm.nih.gov/compound/71584930|http://www.drugbank.ca/drugs/DB14840|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9175|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=9XW757O13D

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|FDA SRS

> <indicationG2P>
None

> <MW>
509.1

> <HBA>
5

> <HBD>
3

> <NRB>
5

> <TPSA>
88

> <LogP>
5.7

> <RoF>
2

> <Targets>
nan

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_epik_Ionization_Penalty>
  0.0092

> <r_epik_State_Penalty>
  0.0070

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
580

> <indicationDB>
Ripretinib is a kinase inhibitor used for the treatment of advanced gastrointestinal stromal tumor (GIST) that has not adequately responded to other kinase inhibitors such as <a href="https://go.drugbank.com/drugs/DB01268">sunitinib</a> and <a href="https://go.drugbank.com/drugs/DB00619">imatinib</a>. Ripretinib, also known as Qinlock, is manufactured by Deciphera Pharmaceuticals and was initially approved by the FDA on May 15, 2020.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA Approved Drug Products: QINLOCK (ripretinib) tablets, for oral use" href="#reference-L13769">7</a></sup> </p><p>It is the first drug approved as a fourth-line therapy in the specific setting of prior treatment with a minimum of 3 other kinase inhibitors.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA Approves First Drug for Fourth-Line Treatment of Advanced Gastrointestinal Stromal Tumors" href="#reference-L13778">8</a></sup>

> <uniprotId>
P10721|P09619|Q02763|P35968|P15056|P16234|P10632|P10721|P16234|P08684|P10635|P05181|P02768|P02763|P19652|P08183|Q9UNQ0|Q96FL8

> <BrandName>
Qinlock

> <FDA_approved>
Y

$$$$
Neratinib
                    3D
 Structure written by MMmdl.
 70 73  0  0  1  0            999 V2000
    0.8004   -4.6256    0.3146 C   0  0  0  0  0  0
   -0.3457   -3.6124    0.2407 C   0  0  0  0  0  0
    0.2076   -2.3003    0.1862 O   0  0  0  0  0  0
   -0.6293   -1.1980    0.1020 C   0  0  0  0  0  0
   -2.0275   -1.2980    0.0840 C   0  0  0  0  0  0
   -2.8429   -0.1468   -0.0002 C   0  0  0  0  0  0
   -2.2450    1.1472   -0.0614 C   0  0  0  0  0  0
   -0.8243    1.2230   -0.0404 C   0  0  0  0  0  0
   -0.0327    0.0679    0.0248 C   0  0  0  0  0  0
    1.3754    0.1293    0.0636 N   0  0  0  0  0  0
    2.1863    1.0245   -0.5410 C   0  0  0  0  0  0
    1.7978    1.9442   -1.2658 O   0  0  0  0  0  0
    3.5822    0.7905   -0.2455 C   0  0  0  0  0  0
    4.5737    1.5463   -0.7591 C   0  0  0  0  0  0
    6.0474    1.3308   -0.4717 C   0  0  0  0  0  0
    6.8504    0.8614   -1.7044 N   0  3  0  0  0  0
    6.3918   -0.5145   -2.2303 C   0  0  0  0  0  0
    8.3662    0.8677   -1.4261 C   0  0  0  0  0  0
   -3.1051    2.2951   -0.1467 C   0  0  0  0  0  0
   -4.5041    2.0765   -0.1347 C   0  0  0  0  0  0
   -4.9800    0.7681   -0.0770 C   0  0  0  0  0  0
   -4.1888   -0.3241   -0.0147 N   0  0  0  0  0  0
   -5.5025    3.1447   -0.1394 C   0  0  0  0  0  0
   -6.2934    3.9895   -0.1432 N   0  0  0  0  0  0
   -2.5205    3.5810   -0.2126 N   0  0  0  0  0  0
   -2.9112    4.6723   -1.0014 C   0  0  0  0  0  0
   -2.9300    5.9496   -0.4420 C   0  0  0  0  0  0
   -3.3165    7.0478   -1.2095 C   0  0  0  0  0  0
   -3.6847    6.8883   -2.5570 C   0  0  0  0  0  0
   -3.6509    5.6023   -3.1137 C   0  0  0  0  0  0
   -3.2638    4.5048   -2.3434 C   0  0  0  0  0  0
   -4.0901    5.3468   -4.7667 Cl  0  0  0  0  0  0
   -4.0815    7.9296   -3.3768 O   0  0  0  0  0  0
   -4.1410    9.2548   -2.8541 C   0  0  0  0  0  0
   -4.5802   10.2095   -3.9520 C   0  0  0  0  0  0
   -5.8089   10.8759   -3.8880 C   0  0  0  0  0  0
   -6.1551   11.7387   -4.9303 C   0  0  0  0  0  0
   -5.2748   11.9134   -6.0003 C   0  0  0  0  0  0
   -4.0674   11.2125   -5.9905 C   0  0  0  0  0  0
   -3.7118   10.3696   -4.9871 N   0  0  0  0  0  0
    0.4171   -5.6455    0.3552 H   0  0  0  0  0  0
    1.4112   -4.4641    1.2032 H   0  0  0  0  0  0
    1.4503   -4.5485   -0.5576 H   0  0  0  0  0  0
   -0.9502   -3.8084   -0.6467 H   0  0  0  0  0  0
   -0.9866   -3.7201    1.1176 H   0  0  0  0  0  0
   -2.5186   -2.2584    0.1353 H   0  0  0  0  0  0
   -0.3588    2.1966   -0.0637 H   0  0  0  0  0  0
    1.8193   -0.6788    0.4753 H   0  0  0  0  0  0
    3.8157   -0.0334    0.4163 H   0  0  0  0  0  0
    4.3498    2.3757   -1.4168 H   0  0  0  0  0  0
    6.5056    2.2691   -0.1550 H   0  0  0  0  0  0
    6.2171    0.5735    0.2968 H   0  0  0  0  0  0
    6.5410   -1.2435   -1.4321 H   0  0  0  0  0  0
    6.9997   -0.7469   -3.1057 H   0  0  0  0  0  0
    5.3403   -0.4296   -2.5063 H   0  0  0  0  0  0
    8.5628    0.1497   -0.6280 H   0  0  0  0  0  0
    8.6383    1.8822   -1.1318 H   0  0  0  0  0  0
    8.8677    0.5866   -2.3532 H   0  0  0  0  0  0
   -6.0414    0.5593   -0.0654 H   0  0  0  0  0  0
   -1.5199    3.5520   -0.0799 H   0  0  0  0  0  0
   -2.6539    6.0964    0.5924 H   0  0  0  0  0  0
   -3.3246    8.0181   -0.7371 H   0  0  0  0  0  0
   -3.2443    3.5208   -2.7902 H   0  0  0  0  0  0
   -4.8430    9.3002   -2.0190 H   0  0  0  0  0  0
   -3.1648    9.5722   -2.4822 H   0  0  0  0  0  0
   -6.4806   10.7292   -3.0549 H   0  0  0  0  0  0
   -7.0973   12.2663   -4.9093 H   0  0  0  0  0  0
   -5.5226   12.5752   -6.8169 H   0  0  0  0  0  0
   -3.3612   11.3214   -6.8005 H   0  0  0  0  0  0
    6.6835    1.5343   -2.4401 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 41  1  0  0  0
  1 42  1  0  0  0
  1 43  1  0  0  0
  2  3  1  0  0  0
  2 44  1  0  0  0
  2 45  1  0  0  0
  3  4  1  0  0  0
  4  5  1  0  0  0
  4  9  2  0  0  0
  5  6  2  0  0  0
  5 46  1  0  0  0
  6  7  1  0  0  0
  6 22  1  0  0  0
  7  8  2  0  0  0
  7 19  1  0  0  0
  8  9  1  0  0  0
  8 47  1  0  0  0
  9 10  1  0  0  0
 10 11  1  0  0  0
 10 48  1  0  0  0
 11 12  2  0  0  0
 11 13  1  0  0  0
 13 14  2  0  0  0
 13 49  1  0  0  0
 14 15  1  0  0  0
 14 50  1  0  0  0
 15 16  1  0  0  0
 15 51  1  0  0  0
 15 52  1  0  0  0
 16 17  1  0  0  0
 16 18  1  0  0  0
 16 70  1  0  0  0
 17 53  1  0  0  0
 17 54  1  0  0  0
 17 55  1  0  0  0
 18 56  1  0  0  0
 18 57  1  0  0  0
 18 58  1  0  0  0
 19 20  2  0  0  0
 19 25  1  0  0  0
 20 21  1  0  0  0
 20 23  1  0  0  0
 21 22  2  0  0  0
 21 59  1  0  0  0
 23 24  3  0  0  0
 25 26  1  0  0  0
 25 60  1  0  0  0
 26 27  2  0  0  0
 26 31  1  0  0  0
 27 28  1  0  0  0
 27 61  1  0  0  0
 28 29  2  0  0  0
 28 62  1  0  0  0
 29 30  1  0  0  0
 29 33  1  0  0  0
 30 31  2  0  0  0
 30 32  1  0  0  0
 31 63  1  0  0  0
 33 34  1  0  0  0
 34 35  1  0  0  0
 34 64  1  0  0  0
 34 65  1  0  0  0
 35 36  1  0  0  0
 35 40  2  0  0  0
 36 37  2  0  0  0
 36 66  1  0  0  0
 37 38  1  0  0  0
 37 67  1  0  0  0
 38 39  2  0  0  0
 38 68  1  0  0  0
 39 40  1  0  0  0
 39 69  1  0  0  0
M  CHG  1  16   1
M  END
> <s_m_entry_id>
582

> <Applicants>
Puma Biotechnology

> <CHEMBL_ID>
CHEMBL180022

> <Canonical_Smiles>
Clc1cc(Nc2c3cc(NC(=O)\C=C\CN(C)C)c(OCC)cc3ncc2C#N)ccc1OCc1ncccc1

> <Chirality>
Achiral Molecule

> <First_Approval>
2017

> <Phase>
4

> <SC_Patent>
US-7399865-B2

> <Synonyms>
CDP-820 | HKI-272 | NERATINIB | WAY-179272

> <Indications>
For use as an extended adjuvant treatment in adult patients with early stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy

> <Type>
nan

> <targets_id>
P04626|P00533

> <inchi>
InChI=1S/C30H29ClN6O3/c1-4-39-28-16-25-23(15-26(28)36-29(38)9-7-13-37(2)3)30(20(17-32)18-34-25)35-21-10-11-27(24(31)14-21)40-19-22-8-5-6-12-33-22/h5-12,14-16,18H,4,13,19H2,1-3H3,(H,34,35)(H,36,38)/b9-7+

> <stdInchikey>
JWNPDZNEKVCWMY-VQHVLOKHSA-N

> <csid>
8091392

> <Links>
|http://www.chemspider.com/Chemical-Structure.8091392.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL180022|http://pubchem.ncbi.nlm.nih.gov/compound/9915743|http://www.drugbank.ca/drugs/DB11828|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5686|http://zinc15.docking.org/substances/ZINC000003916214|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=JJH94R3PWB|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50161957

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
556.2

> <HBA>
8

> <HBD>
2

> <NRB>
11

> <TPSA>
112.4

> <LogP>
5.9

> <RoF>
2

> <Targets>
ERBB2; EGFR

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_epik_Ionization_Penalty>
  0.1681

> <r_epik_State_Penalty>
  0.1823

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
582

> <Kinase families>
Tyr

> <indicationDB>
Neratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer. Approval was granted to Puma Biotechnology Inc. for the tradename Nerlynx. Neratinib is currently under investigation for use in many other forms of cancer.

> <uniprotId>
P00533

> <BrandName>
Nerlynx

> <FDA_approved>
Y

$$$$
Pazopanib
                    3D
 Structure written by MMmdl.
 54 57  0  0  1  0            999 V2000
   -3.5120    4.0214   -0.9477 C   0  0  0  0  0  0
   -2.3200    3.1552   -0.5612 C   0  0  0  0  0  0
   -1.0359    3.6376   -0.8321 C   0  0  0  0  0  0
    0.0923    2.8875   -0.5091 C   0  0  0  0  0  0
   -0.0413    1.6293    0.0883 C   0  0  0  0  0  0
   -1.3233    1.1512    0.3706 C   0  0  0  0  0  0
   -2.4671    1.8951    0.0515 C   0  0  0  0  0  0
   -4.0836    1.1954    0.4470 S   0  0  0  0  0  0
   -4.9053    1.2901   -0.7642 O   0  0  0  0  0  0
   -3.8680   -0.0983    1.1047 O   0  0  0  0  0  0
   -4.7720    2.2766    1.6441 N   0  0  0  0  0  0
    1.0514    0.8196    0.4479 N   0  0  0  0  0  0
    2.3791    0.7434    0.0006 C   0  0  0  0  0  0
    2.8285    1.5787   -0.9713 N   0  0  0  0  0  0
    4.1182    1.4250   -1.3591 C   0  0  0  0  0  0
    4.9579    0.4606   -0.8024 C   0  0  0  0  0  0
    4.4267   -0.3706    0.2012 C   0  0  0  0  0  0
    3.1266   -0.2230    0.5901 N   0  0  0  0  0  0
    5.1866   -1.3956    0.8286 N   0  0  0  0  0  0
    6.5968   -1.5480    0.4444 C   0  0  0  0  0  0
    4.8196   -2.1429    1.9720 C   0  0  0  0  0  0
    4.9512   -3.5370    1.9698 C   0  0  0  0  0  0
    4.6041   -4.3121    3.0750 C   0  0  0  0  0  0
    4.1107   -3.6708    4.2199 C   0  0  0  0  0  0
    3.6583   -4.0847    5.5029 C   0  0  0  0  0  0
    3.3263   -2.9106    6.1514 N   0  0  0  0  0  0
    3.4869   -1.7897    5.4229 N   0  0  0  0  0  0
    3.9750   -2.2504    4.2348 C   0  0  0  0  0  0
    4.3303   -1.4903    3.1112 C   0  0  0  0  0  0
    2.8054   -2.7748    7.5048 C   0  0  0  0  0  0
    3.5578   -5.4567    6.1362 C   0  0  0  0  0  0
   -4.0951    3.5434   -1.7347 H   0  0  0  0  0  0
   -3.1993    4.9960   -1.3249 H   0  0  0  0  0  0
   -4.1606    4.2041   -0.0924 H   0  0  0  0  0  0
   -0.9031    4.6051   -1.2944 H   0  0  0  0  0  0
    1.0605    3.3140   -0.7171 H   0  0  0  0  0  0
   -1.4265    0.1837    0.8407 H   0  0  0  0  0  0
   -4.8125    1.9010    2.5951 H   0  0  0  0  0  0
   -5.6176    2.7710    1.3478 H   0  0  0  0  0  0
    0.8023    0.0455    1.0458 H   0  0  0  0  0  0
    4.4756    2.0905   -2.1314 H   0  0  0  0  0  0
    5.9769    0.3838   -1.1486 H   0  0  0  0  0  0
    6.7027   -1.6480   -0.6363 H   0  0  0  0  0  0
    7.0702   -2.4246    0.8890 H   0  0  0  0  0  0
    7.1707   -0.6820    0.7767 H   0  0  0  0  0  0
    5.3242   -4.0384    1.0881 H   0  0  0  0  0  0
    4.7134   -5.3863    3.0443 H   0  0  0  0  0  0
    4.2321   -0.4144    3.1290 H   0  0  0  0  0  0
    3.4171   -3.3634    8.1893 H   0  0  0  0  0  0
    1.7785   -3.1402    7.5310 H   0  0  0  0  0  0
    2.8224   -1.7325    7.8289 H   0  0  0  0  0  0
    3.3420   -6.2239    5.3925 H   0  0  0  0  0  0
    2.7696   -5.5174    6.8868 H   0  0  0  0  0  0
    4.4912   -5.7377    6.6242 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 32  1  0  0  0
  1 33  1  0  0  0
  1 34  1  0  0  0
  2  3  1  0  0  0
  2  7  2  0  0  0
  3  4  2  0  0  0
  3 35  1  0  0  0
  4  5  1  0  0  0
  4 36  1  0  0  0
  5  6  2  0  0  0
  5 12  1  0  0  0
  6  7  1  0  0  0
  6 37  1  0  0  0
  7  8  1  0  0  0
  8  9  2  0  0  0
  8 10  2  0  0  0
  8 11  1  0  0  0
 11 38  1  0  0  0
 11 39  1  0  0  0
 12 13  1  0  0  0
 12 40  1  0  0  0
 13 14  1  0  0  0
 13 18  2  0  0  0
 14 15  2  0  0  0
 15 16  1  0  0  0
 15 41  1  0  0  0
 16 17  2  0  0  0
 16 42  1  0  0  0
 17 18  1  0  0  0
 17 19  1  0  0  0
 19 20  1  0  0  0
 19 21  1  0  0  0
 20 43  1  0  0  0
 20 44  1  0  0  0
 20 45  1  0  0  0
 21 22  1  0  0  0
 21 29  2  0  0  0
 22 23  2  0  0  0
 22 46  1  0  0  0
 23 24  1  0  0  0
 23 47  1  0  0  0
 24 25  2  0  0  0
 24 28  1  0  0  0
 25 26  1  0  0  0
 25 31  1  0  0  0
 26 27  1  0  0  0
 26 30  1  0  0  0
 27 28  2  0  0  0
 28 29  1  0  0  0
 29 48  1  0  0  0
 30 49  1  0  0  0
 30 50  1  0  0  0
 30 51  1  0  0  0
 31 52  1  0  0  0
 31 53  1  0  0  0
 31 54  1  0  0  0
M  END
> <s_m_entry_id>
585

> <Applicants>
GlaxoSmithKline

> <CHEMBL_ID>
CHEMBL477772

> <Canonical_Smiles>
S(=O)(=O)(N)c1cc(Nc2nc(N(C)c3cc4nn(C)c(c4cc3)C)ccn2)ccc1C

> <Chirality>
Achiral Molecule

> <First_Approval>
2009

> <Phase>
4

> <SC_Patent>
US-7105530-B2

> <Synonyms>
GW786034 | PAZOPANIB | VOTRIENT

> <Indications>
Treatment of advanced renal cell cancer and advanced soft tissue sarcoma (in patients previously treated with chemotherapy)

> <Type>
1

> <targets_id>
P17948|P35968|P35916|P16234|P09619|P10721|P22607|Q08881|P11362

> <inchi>
InChI=1S/C21H23N7O2S/c1-13-5-6-15(11-19(13)31(22,29)30)24-21-23-10-9-20(25-21)27(3)16-7-8-17-14(2)28(4)26-18(17)12-16/h5-12H,1-4H3,(H2,22,29,30)(H,23,24,25)

> <stdInchikey>
CUIHSIWYWATEQL-UHFFFAOYSA-N

> <csid>
8289501

> <Links>
|http://www.chemspider.com/Chemical-Structure.8289501.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL477772|http://pubchem.ncbi.nlm.nih.gov/compound/10113978|http://www.drugbank.ca/drugs/DB06589|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5698|http://zinc15.docking.org/substances/ZINC000011617039|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=7RN5DR86CK|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=26474

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
437.2

> <HBA>
8

> <HBD>
2

> <NRB>
5

> <TPSA>
119

> <LogP>
3.1

> <RoF>
0

> <Targets>
FLT1; KDR; FLT4; PDGFRA; PDGFRB; KIT; FGFR3; ITK; FGFR1

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0466

> <r_epik_State_Penalty>
  0.0274

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
585

> <Kinase families>
Tyr

> <indicationDB>
Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.

> <uniprotId>
P17948|P35968|P35916|P16234|P09619|P10721|P22607|Q08881|P05230|Q9UQQ2|P08684|P10635|P10632|P05177|P08183|Q9UNQ0|Q9Y6L6|P22309

> <BrandName>
Votrient

> <Withdrawn>
|Study NCT02367651 in nan was Withdrawn during Phase 2 because Study cancelled: Withdrawn before enrollment of any participants|Study NCT03275558 in Singapore was Withdrawn during Phase 1 because Study halted prior to enrollment of first participant (It has been determined on 2018 May 15
    that the NCT03275558 study will be stopped by sponsor decision)|Study NCT02342600 in nan was Withdrawn during Phase 2 because Supporting company withdrew interest

> <FDA_approved>
Y

$$$$
Palbociclib
                    3D
 Structure written by MMmdl.
 64 68  0  0  1  0            999 V2000
   -4.9478   -1.2389    1.3762 C   0  0  0  0  0  0
   -4.3009    0.0659    0.8793 C   0  0  0  0  0  0
   -2.9180   -0.0780    0.3598 C   0  0  0  0  0  0
   -2.1425   -1.2466    0.4568 C   0  0  0  0  0  0
   -0.8771   -1.3365   -0.0276 N   0  0  0  0  0  0
   -0.3898   -0.2186   -0.6126 C   0  0  0  0  0  0
   -1.0436    0.9616   -0.7508 N   0  0  0  0  0  0
   -2.3143    1.0317   -0.2568 C   0  0  0  0  0  0
   -3.0319    2.2658   -0.3504 N   0  0  0  0  0  0
   -4.2357    2.4903    0.2830 C   0  0  0  0  0  0
   -4.7232    3.6200    0.4031 O   0  0  0  0  0  0
   -4.9095    1.2936    0.8206 C   0  0  0  0  0  0
   -6.2831    1.4257    1.3467 C   0  0  0  0  0  0
   -6.5715    1.1683    2.5157 O   0  0  0  0  0  0
   -7.3874    1.8952    0.3990 C   0  0  0  0  0  0
   -2.3656    3.4043   -1.0672 C   0  0  0  0  0  0
   -1.8331    4.5383   -0.1597 C   0  0  0  0  0  0
   -2.1802    5.8506   -0.8808 C   0  0  0  0  0  0
   -2.5107    5.4576   -2.3238 C   0  0  0  0  0  0
   -3.1748    4.0867   -2.1924 C   0  0  0  0  0  0
    0.9420   -0.3506   -1.1112 N   0  0  0  0  0  0
    1.7603    0.6245   -1.7634 C   0  0  0  0  0  0
    3.0477    0.2750   -2.1798 C   0  0  0  0  0  0
    3.8543    1.2228   -2.8175 C   0  0  0  0  0  0
    3.3817    2.5268   -3.0475 C   0  0  0  0  0  0
    2.0829    2.8299   -2.6032 C   0  0  0  0  0  0
    1.3391    1.8860   -1.9947 N   0  3  0  0  0  0
    4.1957    3.4692   -3.6751 N   0  0  0  0  0  0
    3.8470    4.9008   -3.6863 C   0  0  0  0  0  0
    5.0776    5.8095   -3.8965 C   0  0  0  0  0  0
    5.7902    5.4266   -5.2019 N   0  3  0  0  0  0
    6.0788    3.9199   -5.2722 C   0  0  0  0  0  0
    4.7845    3.1305   -4.9832 C   0  0  0  0  0  0
   -6.0132   -1.1688    1.5879 H   0  0  0  0  0  0
   -4.4581   -1.5745    2.2909 H   0  0  0  0  0  0
   -4.8458   -2.0232    0.6254 H   0  0  0  0  0  0
   -2.5171   -2.1430    0.9282 H   0  0  0  0  0  0
   -7.4253    1.2552   -0.4826 H   0  0  0  0  0  0
   -7.2108    2.9206    0.0757 H   0  0  0  0  0  0
   -8.3601    1.8575    0.8904 H   0  0  0  0  0  0
   -1.4878    3.0656   -1.6148 H   0  0  0  0  0  0
   -2.2636    4.5307    0.8424 H   0  0  0  0  0  0
   -0.7539    4.4366   -0.0367 H   0  0  0  0  0  0
   -3.0631    6.2959   -0.4184 H   0  0  0  0  0  0
   -1.3782    6.5875   -0.8216 H   0  0  0  0  0  0
   -3.1479    6.1882   -2.8236 H   0  0  0  0  0  0
   -1.5911    5.3712   -2.9051 H   0  0  0  0  0  0
   -3.1419    3.5207   -3.1240 H   0  0  0  0  0  0
   -4.2261    4.2229   -1.9424 H   0  0  0  0  0  0
    1.3603   -1.2605   -0.9830 H   0  0  0  0  0  0
    3.4281   -0.7222   -2.0102 H   0  0  0  0  0  0
    4.8513    0.9369   -3.1199 H   0  0  0  0  0  0
    1.5965    3.7880   -2.7158 H   0  0  0  0  0  0
    3.0894    5.0982   -4.4475 H   0  0  0  0  0  0
    3.4038    5.1749   -2.7280 H   0  0  0  0  0  0
    4.8104    6.8624   -3.9924 H   0  0  0  0  0  0
    5.8148    5.7057   -3.0985 H   0  0  0  0  0  0
    5.2016    5.6829   -5.9821 H   0  0  0  0  0  0
    6.4697    3.7335   -6.2730 H   0  0  0  0  0  0
    6.8653    3.7170   -4.5433 H   0  0  0  0  0  0
    5.0266    2.0687   -5.0328 H   0  0  0  0  0  0
    4.0510    3.3038   -5.7732 H   0  0  0  0  0  0
    6.6508    5.9485   -5.2929 H   0  0  0  0  0  0
    0.4070    2.1311   -1.6885 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 34  1  0  0  0
  1 35  1  0  0  0
  1 36  1  0  0  0
  2  3  1  0  0  0
  2 12  2  0  0  0
  3  4  1  0  0  0
  3  8  2  0  0  0
  4  5  2  0  0  0
  4 37  1  0  0  0
  5  6  1  0  0  0
  6  7  2  0  0  0
  6 21  1  0  0  0
  7  8  1  0  0  0
  8  9  1  0  0  0
  9 10  1  0  0  0
  9 16  1  0  0  0
 10 11  2  0  0  0
 10 12  1  0  0  0
 12 13  1  0  0  0
 13 14  2  0  0  0
 13 15  1  0  0  0
 15 38  1  0  0  0
 15 39  1  0  0  0
 15 40  1  0  0  0
 16 17  1  0  0  0
 16 20  1  0  0  0
 16 41  1  0  0  0
 17 18  1  0  0  0
 17 42  1  0  0  0
 17 43  1  0  0  0
 18 19  1  0  0  0
 18 44  1  0  0  0
 18 45  1  0  0  0
 19 20  1  0  0  0
 19 46  1  0  0  0
 19 47  1  0  0  0
 20 48  1  0  0  0
 20 49  1  0  0  0
 21 22  1  0  0  0
 21 50  1  0  0  0
 22 23  1  0  0  0
 22 27  2  0  0  0
 23 24  2  0  0  0
 23 51  1  0  0  0
 24 25  1  0  0  0
 24 52  1  0  0  0
 25 26  2  0  0  0
 25 28  1  0  0  0
 26 27  1  0  0  0
 26 53  1  0  0  0
 27 64  1  0  0  0
 28 29  1  0  0  0
 28 33  1  0  0  0
 29 30  1  0  0  0
 29 54  1  0  0  0
 29 55  1  0  0  0
 30 31  1  0  0  0
 30 56  1  0  0  0
 30 57  1  0  0  0
 31 32  1  0  0  0
 31 58  1  0  0  0
 31 63  1  0  0  0
 32 33  1  0  0  0
 32 59  1  0  0  0
 32 60  1  0  0  0
 33 61  1  0  0  0
 33 62  1  0  0  0
M  CHG  2  27   1  31   1
M  END
> <s_m_entry_id>
588

> <Applicants>
Pfizer

> <CHEMBL_ID>
CHEMBL189963

> <Canonical_Smiles>
O=C1N(c2nc(ncc2C(C)=C1C(=O)C)Nc1ncc(N2CCNCC2)cc1)C1CCCC1

> <Chirality>
Achiral Molecule

> <First_Approval>
2015

> <Phase>
4

> <SC_Patent>
US-6936612-B2

> <Synonyms>
IBRANCE | PALBOCICLIB | PD-0332991

> <Indications>
Palbociclib is indicated in combination with letrozole for the treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease. This indication is approved under accelerated approval based on progression-free survival (PFS). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

> <Type>
1

> <targets_id>
P11802|Q00534

> <inchi>
InChI=1S/C24H29N7O2/c1-15-19-14-27-24(28-20-8-7-18(13-26-20)30-11-9-25-10-12-30)29-22(19)31(17-5-3-4-6-17)23(33)21(15)16(2)32/h7-8,13-14,17,25H,3-6,9-12H2,1-2H3,(H,26,27,28,29)

> <stdInchikey>
AHJRHEGDXFFMBM-UHFFFAOYSA-N

> <csid>
4487437

> <Links>
|http://www.chemspider.com/Chemical-Structure.4487437.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL189963|http://pubchem.ncbi.nlm.nih.gov/compound/5330286|http://www.drugbank.ca/drugs/DB09073| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=LQQ|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/LQQ|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7380|http://zinc15.docking.org/substances/ZINC000003938686|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=G9ZF61LE7G|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=6309

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
447.2

> <HBA>
9

> <HBD>
2

> <NRB>
5

> <TPSA>
105

> <LogP>
3

> <RoF>
0

> <Targets>
CDK4; CDK6

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
0.999944

> <r_epik_Ionization_Penalty>
  0.4991

> <r_epik_State_Penalty>
  0.4069

> <i_epik_Tot_Q>
2

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
588

> <lig_pdbID>
'LQQ'

> <pdbID>
2euf 5l2i

> <Kinase families>
CMGC

> <indicationDB>
Palbociclib is a piperazine pyridopyrimidine<sup class="text-reference-group"><a class="reference-popover-link" data-content="Beaver JA, Amiri-Kordestani L, Charlab R, Chen W, Palmby T, Tilley A, Zirkelbach JF, Yu J, Liu Q, Zhao L, Crich J, Chen XH, Hughes M, Bloomquist E, Tang S, Sridhara R, Kluetz PG, Kim G, Ibrahim A, Pazdur R, Cortazar P: FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer. Clin Cancer Res. 2015 Nov 1;21(21):4760-6. doi: 10.1158/1078-0432.CCR-15-1185. Epub 2015 Aug 31. (PubMed ID 26324739)" href="#reference-A176792">3</a></sup> that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor<sup class="text-reference-group"><a class="reference-popover-link" data-content="Rocca A, Schirone A, Maltoni R, Bravaccini S, Cecconetto L, Farolfi A, Bronte G, Andreis D: Progress with palbociclib in breast cancer: latest evidence and clinical considerations. Ther Adv Med Oncol. 2017 Feb;9(2):83-105. doi: 10.1177/1758834016677961. Epub 2016 Nov 21. (PubMed ID 28203301)" href="#reference-A176798">4</a></sup> selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Cadoo KA, Gucalp A, Traina TA: Palbociclib: an evidence-based review of its potential in the treatment of breast cancer. Breast Cancer (Dove Med Press). 2014 Aug 4;6:123-33. doi: 10.2147/BCTT.S46725. eCollection 2014. (PubMed ID 25177151)" href="#reference-A176810">5</a></sup></p><p>Palbociclib was developed by Pfizer Inc after the discovery that identified the cyclin-dependent kinases as key regulators of cell growth.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Pfizer history" href="#reference-L5867">8</a></sup> It was originally FDA approved on March 2015 for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer and its indications were updated in April 2019 to include male patients based on findings from postmarketing reports and electronic health records demonstrating safety and clinical efficacy.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA Approved Drug Products: Apadaz (benzhydrocodone and acetaminophen) tablets" href="#reference-L4894">7</a></sup>

> <uniprotId>
P11802|Q00534|P08684|Q06520|P02768|P08183|Q9UNQ0|O15245

> <BrandName>
Ibrance

> <Melting point>
263-266 ºC

> <Withdrawn>
|Study NCT03123744 in United States was Withdrawn during Phase 2 because No study funding available|Study NCT03377101 in nan was Withdrawn during Phase 2 because change in study design|Study NCT04220476 in nan was Withdrawn during Phase 2 because Initiating a new study with revised Statistics

> <FDA_approved>
Y

$$$$
Osimertinib
                    3D
 Structure written by MMmdl.
 71 74  0  0  1  0            999 V2000
  -10.6500    2.9854   -1.6078 C   0  0  0  0  0  0
   -9.7305    3.0996   -0.4866 N   0  0  0  0  0  0
   -8.3692    2.9363   -0.5590 C   0  0  0  0  0  0
   -7.7752    3.1240    0.6775 C   0  0  0  0  0  0
   -8.8624    3.4065    1.5849 C   0  0  0  0  0  0
  -10.0747    3.3923    0.8204 C   0  0  0  0  0  0
  -11.3266    3.6410    1.4001 C   0  0  0  0  0  0
  -11.3570    3.8980    2.7694 C   0  0  0  0  0  0
  -10.1988    3.9061    3.5384 C   0  0  0  0  0  0
   -8.9527    3.6617    2.9663 C   0  0  0  0  0  0
   -6.3102    3.0623    0.9702 C   0  0  0  0  0  0
   -5.7102    3.7841    2.0086 C   0  0  0  0  0  0
   -4.3339    3.6308    2.1769 C   0  0  0  0  0  0
   -3.5888    2.8222    1.3817 N   0  0  0  0  0  0
   -4.2466    2.1653    0.3872 C   0  0  0  0  0  0
   -5.5816    2.2497    0.1548 N   0  0  0  0  0  0
   -3.5423    1.2943   -0.4568 N   0  0  0  0  0  0
   -2.1821    0.9386   -0.4481 C   0  0  0  0  0  0
   -1.8769   -0.4215   -0.4585 C   0  0  0  0  0  0
   -0.5494   -0.8695   -0.4186 C   0  0  0  0  0  0
    0.5061    0.0675   -0.4004 C   0  0  0  0  0  0
    0.1824    1.4346   -0.4356 C   0  0  0  0  0  0
   -1.1466    1.8878   -0.4645 C   0  0  0  0  0  0
   -1.4879    3.2284   -0.5398 O   0  0  0  0  0  0
   -0.4713    4.2239   -0.5144 C   0  0  0  0  0  0
    1.8624   -0.3525   -0.3184 N   0  0  0  0  0  0
    2.8771    0.5083   -0.9264 C   0  0  0  0  0  0
    2.2509   -0.9385    0.9708 C   0  0  0  0  0  0
    2.0767    0.0047    2.1839 C   0  0  0  0  0  0
    2.3415   -0.7410    3.5116 N   0  3  0  0  0  0
    1.8943    0.1012    4.7230 C   0  0  0  0  0  0
    3.8060   -1.1970    3.6762 C   0  0  0  0  0  0
   -0.2665   -2.2501   -0.4758 N   0  0  0  0  0  0
   -0.8816   -3.2285    0.2218 C   0  0  0  0  0  0
   -1.7856   -3.0346    1.0391 O   0  0  0  0  0  0
   -0.3688   -4.5418   -0.0957 C   0  0  0  0  0  0
   -0.8463   -5.6656    0.4712 C   0  0  0  0  0  0
  -11.3832    2.2061   -1.3962 H   0  0  0  0  0  0
  -10.1090    2.7296   -2.5202 H   0  0  0  0  0  0
  -11.1632    3.9371   -1.7511 H   0  0  0  0  0  0
   -7.9143    2.7066   -1.5119 H   0  0  0  0  0  0
  -12.2374    3.6326    0.8196 H   0  0  0  0  0  0
  -12.3062    4.0911    3.2474 H   0  0  0  0  0  0
  -10.2679    4.1021    4.5984 H   0  0  0  0  0  0
   -8.0753    3.6618    3.5941 H   0  0  0  0  0  0
   -6.2697    4.4500    2.6465 H   0  0  0  0  0  0
   -3.8083    4.1624    2.9565 H   0  0  0  0  0  0
   -4.1478    0.6522   -0.9460 H   0  0  0  0  0  0
   -2.6855   -1.1387   -0.4936 H   0  0  0  0  0  0
    0.9817    2.1581   -0.4243 H   0  0  0  0  0  0
   -0.9346    5.2092   -0.5611 H   0  0  0  0  0  0
    0.1985    4.1343   -1.3709 H   0  0  0  0  0  0
    0.1111    4.1776    0.4069 H   0  0  0  0  0  0
    2.5417    0.8778   -1.8968 H   0  0  0  0  0  0
    3.7959   -0.0523   -1.1010 H   0  0  0  0  0  0
    3.1061    1.3680   -0.2955 H   0  0  0  0  0  0
    1.6806   -1.8511    1.1400 H   0  0  0  0  0  0
    3.2874   -1.2669    0.8900 H   0  0  0  0  0  0
    2.7528    0.8613    2.1670 H   0  0  0  0  0  0
    1.0468    0.3561    2.2670 H   0  0  0  0  0  0
    2.5036    1.0063    4.7438 H   0  0  0  0  0  0
    2.0456   -0.5068    5.6160 H   0  0  0  0  0  0
    0.8362    0.3308    4.5889 H   0  0  0  0  0  0
    4.4391   -0.3096    3.6263 H   0  0  0  0  0  0
    4.0308   -1.8999    2.8747 H   0  0  0  0  0  0
    3.8857   -1.6916    4.6451 H   0  0  0  0  0  0
    0.5866   -2.4967   -0.9563 H   0  0  0  0  0  0
    0.4314   -4.6033   -0.8210 H   0  0  0  0  0  0
   -1.6453   -5.6535    1.1999 H   0  0  0  0  0  0
   -0.4353   -6.6290    0.2067 H   0  0  0  0  0  0
    1.7644   -1.5710    3.5046 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 38  1  0  0  0
  1 39  1  0  0  0
  1 40  1  0  0  0
  2  3  1  0  0  0
  2  6  1  0  0  0
  3  4  2  0  0  0
  3 41  1  0  0  0
  4  5  1  0  0  0
  4 11  1  0  0  0
  5  6  1  0  0  0
  5 10  2  0  0  0
  6  7  2  0  0  0
  7  8  1  0  0  0
  7 42  1  0  0  0
  8  9  2  0  0  0
  8 43  1  0  0  0
  9 10  1  0  0  0
  9 44  1  0  0  0
 10 45  1  0  0  0
 11 12  1  0  0  0
 11 16  2  0  0  0
 12 13  2  0  0  0
 12 46  1  0  0  0
 13 14  1  0  0  0
 13 47  1  0  0  0
 14 15  2  0  0  0
 15 16  1  0  0  0
 15 17  1  0  0  0
 17 18  1  0  0  0
 17 48  1  0  0  0
 18 19  1  0  0  0
 18 23  2  0  0  0
 19 20  2  0  0  0
 19 49  1  0  0  0
 20 21  1  0  0  0
 20 33  1  0  0  0
 21 22  2  0  0  0
 21 26  1  0  0  0
 22 23  1  0  0  0
 22 50  1  0  0  0
 23 24  1  0  0  0
 24 25  1  0  0  0
 25 51  1  0  0  0
 25 52  1  0  0  0
 25 53  1  0  0  0
 26 27  1  0  0  0
 26 28  1  0  0  0
 27 54  1  0  0  0
 27 55  1  0  0  0
 27 56  1  0  0  0
 28 29  1  0  0  0
 28 57  1  0  0  0
 28 58  1  0  0  0
 29 30  1  0  0  0
 29 59  1  0  0  0
 29 60  1  0  0  0
 30 31  1  0  0  0
 30 32  1  0  0  0
 30 71  1  0  0  0
 31 61  1  0  0  0
 31 62  1  0  0  0
 31 63  1  0  0  0
 32 64  1  0  0  0
 32 65  1  0  0  0
 32 66  1  0  0  0
 33 34  1  0  0  0
 33 67  1  0  0  0
 34 35  2  0  0  0
 34 36  1  0  0  0
 36 37  2  0  0  0
 36 68  1  0  0  0
 37 69  1  0  0  0
 37 70  1  0  0  0
M  CHG  1  30   1
M  END
> <s_m_entry_id>
591

> <Applicants>
Astrazeneca

> <CHEMBL_ID>
CHEMBL3353410

> <Canonical_Smiles>
O(C)c1cc(N(CCN(C)C)C)c(NC(=O)C=C)cc1Nc1nc(ccn1)-c1c2c(n(c1)C)cccc2

> <Chirality>
Achiral Molecule

> <First_Approval>
2015

> <Phase>
4

> <SC_Patent>
US-8946235-B2

> <Synonyms>
AZD-9291 | AZD-9291 FREE BASE | AZD9291 | OSIMERTINIB | TAGRISSO

> <Indications>
Osimertinib is indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA- approved test, who have progressed on or after EGFR-TKI therapy.

> <Type>
1

> <targets_id>
P00533

> <inchi>
InChI=1S/C28H33N7O2/c1-7-27(36)30-22-16-23(26(37-6)17-25(22)34(4)15-14-33(2)3)32-28-29-13-12-21(31-28)20-18-35(5)24-11-9-8-10-19(20)24/h7-13,16-18H,1,14-15H2,2-6H3,(H,30,36)(H,29,31,32)

> <stdInchikey>
DUYJMQONPNNFPI-UHFFFAOYSA-N

> <csid>
31042598

> <Links>
|http://www.chemspider.com/Chemical-Structure.31042598.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3353410|http://pubchem.ncbi.nlm.nih.gov/compound/71496458|http://www.drugbank.ca/drugs/DB09330| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=YY3|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/YY3|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7719|http://zinc15.docking.org/substances/ZINC000098023177|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=3C06JJ0Z2O|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50029668

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
499.3

> <HBA>
8

> <HBD>
2

> <NRB>
10

> <TPSA>
87.6

> <LogP>
4.5

> <RoF>
0

> <Targets>
EGFR

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0134

> <r_epik_State_Penalty>
  0.0077

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
591

> <lig_pdbID>
'YY3'

> <pdbID>
4zau 6jwl 6jx0 6jx4 6jxt 6lud

> <Kinase families>
Tyr

> <indicationDB>
Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals. Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved testing and which has progressed following therapy with a first-generation EGFR tyrosine kinase inhibitor. Approximately 10% of patients with NSCLC have a rapid and clinically effective response to EGFR-TKIs due to the presence of specific activating EGFR mutations within the tumour cells. More specifically, deletions around the LREA motif in exon 19 and exon 21 L858R point mutations are correlated with response to therapy. </p><p>Development of third-generation EGFR-TKIs, such as osimertinib, has been in response to altered tumour resistance patterns following treatment and toxic side effects that impact patient quality of life. Treatment with first-generation EGFR-TKIs (gefitinib and erlotinib) has been associated with the development of resistance through activating mutations in the EGFR gene. Second-generation EGFR-TKIs (afatinib and dacomitinib) were then developed to be more potent inhibitors, although their use is associated with increased toxicity through nonspecific targeting of wild-type EGFR. In contrast, third-generation inhibitors are specific for the gate-keeper T790M mutations which increases ATP binding activity to EGFR and result in poor prognosis for late-stage disease. Furthermore, osimertinib has been shown to spare wild-type EGFR during therapy, thereby reducing non-specific binding and limiting toxicity.

> <uniprotId>
P00533|P08684|P05177|P08183|Q9UNQ0

> <BrandName>
Tagrisso

> <FDA_approved>
Y

$$$$
Nintedanib
                    3D
 Structure written by MMmdl.
 74 78  0  0  1  0            999 V2000
   -0.3970   -5.9381    2.4150 C   0  0  0  0  0  0
    0.0780   -4.6255    2.8499 N   0  0  0  0  0  0
    1.2645   -4.1855    2.1113 C   0  0  0  0  0  0
    0.9713   -3.7566    0.6555 C   0  0  0  0  0  0
   -0.1647   -2.7088    0.6175 N   0  3  0  0  0  0
   -1.4027   -3.1581    1.4280 C   0  0  0  0  0  0
   -0.9821   -3.6136    2.8438 C   0  0  0  0  0  0
   -0.4675   -2.1814   -0.7536 C   0  0  0  0  0  0
   -0.8159   -0.6780   -0.6522 C   0  0  0  0  0  0
   -1.9354   -0.3454   -1.0447 O   0  0  0  0  0  0
    0.0841    0.2268   -0.1641 N   0  0  0  0  0  0
   -0.2499    1.6517   -0.0536 C   0  0  0  0  0  0
    1.3872   -0.1302    0.2143 C   0  0  0  0  0  0
    2.3644   -0.3608   -0.7574 C   0  0  0  0  0  0
    3.6456   -0.7395   -0.3670 C   0  0  0  0  0  0
    3.9661   -0.8700    0.9870 C   0  0  0  0  0  0
    2.9795   -0.6337    1.9536 C   0  0  0  0  0  0
    1.6979   -0.2513    1.5707 C   0  0  0  0  0  0
    5.2736   -1.2929    1.2929 N   0  0  0  0  0  0
    6.2089   -0.7765    2.1908 C   0  0  0  0  0  0
    7.5569   -0.7360    1.9801 C   0  0  0  0  0  0
    8.6642   -0.2542    2.8240 C   0  0  0  0  0  0
    8.7358    0.3112    4.1011 C   0  0  0  0  0  0
    9.9767    0.6703    4.6340 C   0  0  0  0  0  0
   11.1636    0.4694    3.9076 C   0  0  0  0  0  0
   11.0757   -0.1006    2.6247 C   0  0  0  0  0  0
    9.8267   -0.4503    2.1140 C   0  0  0  0  0  0
    9.5118   -1.0155    0.9045 N   0  0  0  0  0  0
    8.1926   -1.2152    0.7515 C   0  0  0  0  0  0
    7.6747   -1.7076   -0.2513 O   0  0  0  0  0  0
   12.4768    0.8710    4.5128 C   0  0  0  0  0  0
   12.5732    1.4621    5.5924 O   0  0  0  0  0  0
   13.5470    0.4943    3.7666 O   0  0  0  0  0  0
   14.8720    0.7804    4.1922 C   0  0  0  0  0  0
    5.6377   -0.2675    3.4544 C   0  0  0  0  0  0
    5.3892   -1.1479    4.5129 C   0  0  0  0  0  0
    4.8403   -0.6714    5.7001 C   0  0  0  0  0  0
    4.5412    0.6834    5.8271 C   0  0  0  0  0  0
    4.7869    1.5673    4.7786 C   0  0  0  0  0  0
    5.3364    1.0921    3.5911 C   0  0  0  0  0  0
   -1.2354   -6.2655    3.0311 H   0  0  0  0  0  0
    0.3927   -6.6833    2.5197 H   0  0  0  0  0  0
   -0.7236   -5.9374    1.3749 H   0  0  0  0  0  0
    1.7093   -3.3465    2.6488 H   0  0  0  0  0  0
    2.0214   -4.9713    2.1257 H   0  0  0  0  0  0
    1.8486   -3.2891    0.2063 H   0  0  0  0  0  0
    0.6563   -4.5903    0.0262 H   0  0  0  0  0  0
   -2.0758   -2.3010    1.4765 H   0  0  0  0  0  0
   -1.8878   -3.9536    0.8605 H   0  0  0  0  0  0
   -1.8494   -3.9836    3.3929 H   0  0  0  0  0  0
   -0.6297   -2.7485    3.4080 H   0  0  0  0  0  0
    0.4095   -2.3380   -1.3831 H   0  0  0  0  0  0
   -1.2889   -2.7810   -1.1505 H   0  0  0  0  0  0
    0.4186    2.2422   -0.6813 H   0  0  0  0  0  0
   -0.1283    1.9883    0.9766 H   0  0  0  0  0  0
   -1.2727    1.8834   -0.3540 H   0  0  0  0  0  0
    2.1316   -0.2614   -1.8081 H   0  0  0  0  0  0
    4.3913   -0.9282   -1.1267 H   0  0  0  0  0  0
    3.1727   -0.7649    3.0055 H   0  0  0  0  0  0
    0.9452   -0.0763    2.3262 H   0  0  0  0  0  0
    5.7048   -1.6728    0.4615 H   0  0  0  0  0  0
    7.8549    0.4810    4.6993 H   0  0  0  0  0  0
   10.0005    1.1056    5.6232 H   0  0  0  0  0  0
   11.9603   -0.2713    2.0279 H   0  0  0  0  0  0
   10.1925   -1.2584    0.2000 H   0  0  0  0  0  0
   15.5848    0.3947    3.4633 H   0  0  0  0  0  0
   15.0842    0.3117    5.1542 H   0  0  0  0  0  0
   15.0304    1.8558    4.2847 H   0  0  0  0  0  0
    5.6207   -2.1989    4.4150 H   0  0  0  0  0  0
    4.6478   -1.3491    6.5188 H   0  0  0  0  0  0
    4.1150    1.0528    6.7483 H   0  0  0  0  0  0
    4.5521    2.6161    4.8864 H   0  0  0  0  0  0
    5.5259    1.7779    2.7777 H   0  0  0  0  0  0
    0.1994   -1.8747    1.0570 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 41  1  0  0  0
  1 42  1  0  0  0
  1 43  1  0  0  0
  2  3  1  0  0  0
  2  7  1  0  0  0
  3  4  1  0  0  0
  3 44  1  0  0  0
  3 45  1  0  0  0
  4  5  1  0  0  0
  4 46  1  0  0  0
  4 47  1  0  0  0
  5  6  1  0  0  0
  5  8  1  0  0  0
  5 74  1  0  0  0
  6  7  1  0  0  0
  6 48  1  0  0  0
  6 49  1  0  0  0
  7 50  1  0  0  0
  7 51  1  0  0  0
  8  9  1  0  0  0
  8 52  1  0  0  0
  8 53  1  0  0  0
  9 10  2  0  0  0
  9 11  1  0  0  0
 11 12  1  0  0  0
 11 13  1  0  0  0
 12 54  1  0  0  0
 12 55  1  0  0  0
 12 56  1  0  0  0
 13 14  1  0  0  0
 13 18  2  0  0  0
 14 15  2  0  0  0
 14 57  1  0  0  0
 15 16  1  0  0  0
 15 58  1  0  0  0
 16 17  2  0  0  0
 16 19  1  0  0  0
 17 18  1  0  0  0
 17 59  1  0  0  0
 18 60  1  0  0  0
 19 20  1  0  0  0
 19 61  1  0  0  0
 20 21  2  0  0  0
 20 35  1  0  0  0
 21 22  1  0  0  0
 21 29  1  0  0  0
 22 23  1  0  0  0
 22 27  2  0  0  0
 23 24  2  0  0  0
 23 62  1  0  0  0
 24 25  1  0  0  0
 24 63  1  0  0  0
 25 26  2  0  0  0
 25 31  1  0  0  0
 26 27  1  0  0  0
 26 64  1  0  0  0
 27 28  1  0  0  0
 28 29  1  0  0  0
 28 65  1  0  0  0
 29 30  2  0  0  0
 31 32  2  0  0  0
 31 33  1  0  0  0
 33 34  1  0  0  0
 34 66  1  0  0  0
 34 67  1  0  0  0
 34 68  1  0  0  0
 35 36  1  0  0  0
 35 40  2  0  0  0
 36 37  2  0  0  0
 36 69  1  0  0  0
 37 38  1  0  0  0
 37 70  1  0  0  0
 38 39  2  0  0  0
 38 71  1  0  0  0
 39 40  1  0  0  0
 39 72  1  0  0  0
 40 73  1  0  0  0
M  CHG  1   5   1
M  END
> <s_m_entry_id>
592

> <Applicants>
Boehringer Ingelheim

> <CHEMBL_ID>
CHEMBL502835

> <Canonical_Smiles>
O=C/1Nc2cc(ccc2\C\1=C(\Nc1ccc(N(C(=O)CN2CCN(CC2)C)C)cc1)/c1ccccc1)C(OC)=O

> <Chirality>
Achiral Molecule

> <First_Approval>
2014

> <Phase>
4

> <SC_Patent>
US-6762180-B1

> <Synonyms>
BIBF 1120 | BIBF-1120 | BIBF1120 | INTEDANIB | NINTEDANIB | OFEV | VARGATEF

> <Indications>
Nintedanib is indicated for the treatment of idiopathic pulmonary fibrosis (IPF).

> <Type>
1

> <targets_id>
P17948|P35968|P35916|P11362|P21802|P22607|P36888|P06239|P07948|P12931

> <inchi>
InChI=1S/C31H33N5O4/c1-34-15-17-36(18-16-34)20-27(37)35(2)24-12-10-23(11-13-24)32-29(21-7-5-4-6-8-21)28-25-14-9-22(31(39)40-3)19-26(25)33-30(28)38/h4-14,19,32H,15-18,20H2,1-3H3,(H,33,38)/b29-28-

> <stdInchikey>
XZXHXSATPCNXJR-ZIADKAODSA-N

> <csid>
7985471

> <Links>
|http://www.chemspider.com/Chemical-Structure.7985471.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL502835|http://pubchem.ncbi.nlm.nih.gov/compound/9809715|http://www.drugbank.ca/drugs/DB09079| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=XIN|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/XIN|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5936|http://zinc15.docking.org/substances/ZINC000100014909|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=G6HRD2P839|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50026612

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
539.3

> <HBA>
7

> <HBD>
2

> <NRB>
7

> <TPSA>
94.2

> <LogP>
3.6

> <RoF>
1

> <Targets>
FLT1; KDR; FLT4; FGFR1; FGFR2; FGFR3; FLT3; LCK; LYN; SRC

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
0.5

> <r_epik_Ionization_Penalty>
  0.0410

> <r_epik_State_Penalty>
  0.8233

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
592

> <lig_pdbID>
'XIN'

> <pdbID>
3c7q 5maf 5te0 6nec

> <Kinase families>
Tyr

> <indicationDB>
Nintedanib is a small molecule kinase inhibitor used in the treatment of pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and non-small cell lung cancer (NSCLC).<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA Approved Drugs: Nintedanib" href="#reference-L8453">8</a>,<a class="reference-popover-link" data-content="EMA Approved Drugs: Nintedanib" href="#reference-L8459">9</a></sup> It was first approved for use in the United States in 2014.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA Approved Drugs: Nintedanib" href="#reference-L8453">8</a></sup> Within the spectrum of idiopathic pulmonary fibrosis treatment options, nintedanib is currently one of only two disease-modifying therapies available and indicated for the condition (the other being <a href="https://go.drugbank.com/drugs/DB04951">Pirfenidone</a>) and as such is used as a first-line treatment following diagnosis to slow down the progressive loss of lung function.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Richeldi L, Collard HR, Jones MG: Idiopathic pulmonary fibrosis. Lancet. 2017 May 13;389(10082):1941-1952. doi: 10.1016/S0140-6736(17)30866-8. Epub 2017 Mar 30. (PubMed ID 28365056)" href="#reference-A185237">6</a></sup> As a chemotherapeutic agent for NSCLC, nintedanib, in combination with <a href="https://go.drugbank.com/drugs/DB01248">Docetaxel</a>, is reserved for patients who have tried and failed first-line chemotherapeutic options.<sup class="text-reference-group"><a class="reference-popover-link" data-content="EMA Approved Drugs: Nintedanib" href="#reference-L8459">9</a></sup>

> <uniprotId>
P17948|P35968|P35916|P16234|P09619|P11362|P21802|P22607|P36888|P06239|P07948|P12931|P22309|Q9HAW7|Q9HAW9|Q9HAW8|P08684|P02768|P08183|O15245|Q9UNQ0

> <BrandName>
Ofev;Vargatef

> <Withdrawn>
|Study NCT03361319 in nan was Withdrawn during Phase 1/Phase 2 because Withdrawal of financial support from funder

> <FDA_approved>
Y

$$$$
Nilotinib
                    3D
 Structure written by MMmdl.
 61 65  0  0  1  0            999 V2000
   -4.6235   -0.2332   -0.4530 C   0  0  0  0  0  0
   -3.1137   -0.2361   -0.2372 C   0  0  0  0  0  0
   -2.4117   -1.4317   -0.4142 C   0  0  0  0  0  0
   -1.0325   -1.4802   -0.2269 C   0  0  0  0  0  0
   -0.3219   -0.3264    0.1305 C   0  0  0  0  0  0
   -1.0302    0.8687    0.3082 C   0  0  0  0  0  0
   -2.4221    0.9287    0.1434 C   0  0  0  0  0  0
   -3.1321    2.1332    0.3218 N   0  0  0  0  0  0
   -2.9180    3.2343    1.1649 C   0  0  0  0  0  0
   -3.8399    4.2259    1.0746 N   0  0  0  0  0  0
   -3.6613    5.3014    1.8833 C   0  0  0  0  0  0
   -2.5937    5.3987    2.7770 C   0  0  0  0  0  0
   -1.6912    4.3263    2.8241 C   0  0  0  0  0  0
   -1.8565    3.2429    2.0147 N   0  0  0  0  0  0
   -0.5020    4.3066    3.7312 C   0  0  0  0  0  0
    0.6457    3.5472    3.4397 C   0  0  0  0  0  0
    1.7366    3.5472    4.3102 C   0  0  0  0  0  0
    1.6591    4.3158    5.4699 C   0  0  0  0  0  0
    0.5708    5.0597    5.7864 N   0  0  0  0  0  0
   -0.4790    5.0442    4.9257 C   0  0  0  0  0  0
    1.1748   -0.3502    0.3335 C   0  0  0  0  0  0
    1.6987    0.4099    1.1510 O   0  0  0  0  0  0
    1.8499   -1.2290   -0.4421 N   0  0  0  0  0  0
    3.2375   -1.4465   -0.5111 C   0  0  0  0  0  0
    3.6560   -2.7032   -0.9578 C   0  0  0  0  0  0
    5.0175   -3.0109   -1.0710 C   0  0  0  0  0  0
    5.9658   -2.0343   -0.7463 C   0  0  0  0  0  0
    5.5621   -0.7662   -0.3152 C   0  0  0  0  0  0
    4.1992   -0.4719   -0.2019 C   0  0  0  0  0  0
    6.5240    0.2135   -0.0006 N   0  0  0  0  0  0
    6.4880    1.1490    1.0053 C   0  0  0  0  0  0
    7.6594    1.8891    0.9118 C   0  0  0  0  0  0
    8.4004    1.4535   -0.0940 N   0  0  0  0  0  0
    7.7227    0.4652   -0.6266 C   0  0  0  0  0  0
    8.1326    3.0408    1.7670 C   0  0  0  0  0  0
    5.4698   -4.3854   -1.5633 C   0  0  0  0  0  0
    6.5692   -4.2872   -2.3129 F   0  0  0  0  0  0
    5.7408   -5.1561   -0.5102 F   0  0  0  0  0  0
    4.5286   -4.9844   -2.2956 F   0  0  0  0  0  0
   -5.1371    0.0788    0.4573 H   0  0  0  0  0  0
   -5.0016   -1.2197   -0.7255 H   0  0  0  0  0  0
   -4.8916    0.4578   -1.2532 H   0  0  0  0  0  0
   -2.9344   -2.3343   -0.6962 H   0  0  0  0  0  0
   -0.5266   -2.4254   -0.3634 H   0  0  0  0  0  0
   -0.4793    1.7637    0.5561 H   0  0  0  0  0  0
   -4.0534    2.1313   -0.0900 H   0  0  0  0  0  0
   -4.3900    6.0948    1.8029 H   0  0  0  0  0  0
   -2.4781    6.2751    3.3965 H   0  0  0  0  0  0
    0.7012    2.9546    2.5378 H   0  0  0  0  0  0
    2.6190    2.9650    4.0893 H   0  0  0  0  0  0
    2.4818    4.3422    6.1693 H   0  0  0  0  0  0
   -1.3257    5.6413    5.2299 H   0  0  0  0  0  0
    1.2926   -1.8460   -1.0142 H   0  0  0  0  0  0
    2.9167   -3.4511   -1.2089 H   0  0  0  0  0  0
    7.0187   -2.2653   -0.8285 H   0  0  0  0  0  0
    3.9023    0.5197    0.1057 H   0  0  0  0  0  0
    5.6528    1.2056    1.6882 H   0  0  0  0  0  0
    8.0249   -0.1257   -1.4793 H   0  0  0  0  0  0
    7.4048    3.3024    2.5356 H   0  0  0  0  0  0
    8.3063    3.9392    1.1739 H   0  0  0  0  0  0
    9.0664    2.8062    2.2787 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 40  1  0  0  0
  1 41  1  0  0  0
  1 42  1  0  0  0
  2  3  1  0  0  0
  2  7  2  0  0  0
  3  4  2  0  0  0
  3 43  1  0  0  0
  4  5  1  0  0  0
  4 44  1  0  0  0
  5  6  2  0  0  0
  5 21  1  0  0  0
  6  7  1  0  0  0
  6 45  1  0  0  0
  7  8  1  0  0  0
  8  9  1  0  0  0
  8 46  1  0  0  0
  9 10  1  0  0  0
  9 14  2  0  0  0
 10 11  2  0  0  0
 11 12  1  0  0  0
 11 47  1  0  0  0
 12 13  2  0  0  0
 12 48  1  0  0  0
 13 14  1  0  0  0
 13 15  1  0  0  0
 15 16  1  0  0  0
 15 20  2  0  0  0
 16 17  2  0  0  0
 16 49  1  0  0  0
 17 18  1  0  0  0
 17 50  1  0  0  0
 18 19  2  0  0  0
 18 51  1  0  0  0
 19 20  1  0  0  0
 20 52  1  0  0  0
 21 22  2  0  0  0
 21 23  1  0  0  0
 23 24  1  0  0  0
 23 53  1  0  0  0
 24 25  1  0  0  0
 24 29  2  0  0  0
 25 26  2  0  0  0
 25 54  1  0  0  0
 26 27  1  0  0  0
 26 36  1  0  0  0
 27 28  2  0  0  0
 27 55  1  0  0  0
 28 29  1  0  0  0
 28 30  1  0  0  0
 29 56  1  0  0  0
 30 31  1  0  0  0
 30 34  1  0  0  0
 31 32  2  0  0  0
 31 57  1  0  0  0
 32 33  1  0  0  0
 32 35  1  0  0  0
 33 34  2  0  0  0
 34 58  1  0  0  0
 35 59  1  0  0  0
 35 60  1  0  0  0
 35 61  1  0  0  0
 36 37  1  0  0  0
 36 38  1  0  0  0
 36 39  1  0  0  0
M  END
> <s_m_entry_id>
604

> <Applicants>
Novartis

> <CHEMBL_ID>
CHEMBL255863

> <Canonical_Smiles>
FC(F)(F)c1cc(NC(=O)c2cc(Nc3nc(ccn3)-c3cccnc3)c(cc2)C)cc(-n2cc(nc2)C)c1

> <Chirality>
Achiral Molecule

> <First_Approval>
2007

> <Phase>
4

> <SC_Patent>
US-7169791-B2

> <Synonyms>
AMN 107 | AMN-107 | AMN107 | NILOTINIB | TASIGNA

> <Indications>
For the potential treatment of various leukemias, including chronic myeloid leukemia (CML).

> <Type>
2

> <targets_id>
P00519|P10721

> <inchi>
InChI=1S/C28H22F3N7O/c1-17-5-6-19(10-25(17)37-27-33-9-7-24(36-27)20-4-3-8-32-14-20)26(39)35-22-11-21(28(29,30)31)12-23(13-22)38-15-18(2)34-16-38/h3-16H,1-2H3,(H,35,39)(H,33,36,37)

> <stdInchikey>
HHZIURLSWUIHRB-UHFFFAOYSA-N

> <csid>
559260

> <Links>
|http://www.chemspider.com/Chemical-Structure.559260.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL255863|http://pubchem.ncbi.nlm.nih.gov/compound/644241|http://www.drugbank.ca/drugs/DB04868| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=NIL|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/NIL|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5697|http://zinc15.docking.org/substances/ZINC06716957|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=F41401512X|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50237710

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
529.2

> <HBA>
7

> <HBD>
2

> <NRB>
6

> <TPSA>
97.6

> <LogP>
6.4

> <RoF>
2

> <Targets>
ABL1; KIT

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.1509

> <r_epik_State_Penalty>
  0.1396

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
604

> <lig_pdbID>
'NIL'

> <pdbID>
3cs9 3gp0 5mo4

> <Kinase families>
Tyr

> <indicationDB>
Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to treatment with imatinib (Gleevec), another tyrosine kinase inhibitor used as a first-line treatment for CML.

> <uniprotId>
P00519|P10721|P08684|P10632|P11712|P10635|P20813|P08183|Q9UNQ0|P22309|Q9Y6L6

> <BrandName>
Tasigna

> <Withdrawn>
|Study NCT02973711 in United States was Withdrawn during Phase 1/Phase 2 because lack of funding

> <FDA_approved>
Y

$$$$
Netarsudil
                    3D
 Structure written by MMmdl.
 62 65  0  0  1  0            999 V2000
   -3.5437    6.8488    0.2018 C   0  0  0  0  0  0
   -3.1484    5.3858    0.1145 C   0  0  0  0  0  0
   -3.8096    4.5224   -0.7578 C   0  0  0  0  0  0
   -3.4370    3.1823   -0.8319 C   0  0  0  0  0  0
   -2.3905    2.6778   -0.0449 C   0  0  0  0  0  0
   -1.7348    3.5496    0.8577 C   0  0  0  0  0  0
   -2.1175    4.8950    0.9161 C   0  0  0  0  0  0
   -0.6263    3.0899    1.8024 C   0  0  0  0  0  0
   -2.0629    1.2230   -0.1869 C   0  0  0  0  0  0
   -2.9106    0.3511   -0.3973 O   0  0  0  0  0  0
   -0.7293    0.9972   -0.2085 O   0  0  0  0  0  0
   -0.2070   -0.3168   -0.3562 C   0  0  0  0  0  0
    1.3073   -0.2655   -0.2680 C   0  0  0  0  0  0
    2.0793   -0.4529   -1.4148 C   0  0  0  0  0  0
    3.4677   -0.4026   -1.3319 C   0  0  0  0  0  0
    4.0945   -0.1622   -0.1019 C   0  0  0  0  0  0
    3.3128    0.0270    1.0432 C   0  0  0  0  0  0
    1.9241   -0.0276    0.9614 C   0  0  0  0  0  0
    5.6234   -0.0875   -0.0009 C   0  0  1  0  0  0
    6.2976   -1.3961   -0.4988 C   0  0  0  0  0  0
    7.8243   -1.3398   -0.3445 N   0  3  0  0  0  0
    6.1393    1.1932   -0.6989 C   0  0  0  0  0  0
    6.3602    1.1732   -1.9111 O   0  0  0  0  0  0
    6.2901    2.2760    0.0958 N   0  0  0  0  0  0
    6.7326    3.5680   -0.2436 C   0  0  0  0  0  0
    6.4019    4.5860    0.6522 C   0  0  0  0  0  0
    6.7897    5.9036    0.4228 C   0  0  0  0  0  0
    7.5393    6.2286   -0.7306 C   0  0  0  0  0  0
    7.9667    7.5423   -1.0353 C   0  0  0  0  0  0
    8.6874    7.8776   -2.1308 N   0  0  0  0  0  0
    9.0193    6.8818   -2.9875 C   0  0  0  0  0  0
    8.6587    5.5471   -2.7979 C   0  0  0  0  0  0
    7.8996    5.1980   -1.6494 C   0  0  0  0  0  0
    7.4913    3.8675   -1.3863 C   0  0  0  0  0  0
   -3.7933    7.1145    1.2296 H   0  0  0  0  0  0
   -4.4095    7.0739   -0.4223 H   0  0  0  0  0  0
   -2.7189    7.4828   -0.1247 H   0  0  0  0  0  0
   -4.6139    4.8848   -1.3818 H   0  0  0  0  0  0
   -3.9693    2.5416   -1.5216 H   0  0  0  0  0  0
   -1.6157    5.5674    1.5973 H   0  0  0  0  0  0
   -0.4525    3.8084    2.6045 H   0  0  0  0  0  0
    0.3105    2.9694    1.2575 H   0  0  0  0  0  0
   -0.8793    2.1398    2.2742 H   0  0  0  0  0  0
   -0.5915   -0.9691    0.4300 H   0  0  0  0  0  0
   -0.5159   -0.7414   -1.3131 H   0  0  0  0  0  0
    1.6075   -0.6333   -2.3700 H   0  0  0  0  0  0
    4.0546   -0.5425   -2.2280 H   0  0  0  0  0  0
    3.7762    0.2197    2.0000 H   0  0  0  0  0  0
    1.3283    0.1223    1.8503 H   0  0  0  0  0  0
    5.8761   -0.0039    1.0591 H   0  0  0  0  0  0
    5.9995   -2.2696    0.0826 H   0  0  0  0  0  0
    6.1405   -1.5943   -1.5602 H   0  0  0  0  0  0
    8.2390   -2.2025   -0.6674 H   0  0  0  0  0  0
    8.0744   -1.2015    0.6242 H   0  0  0  0  0  0
    6.0057    2.1718    1.0588 H   0  0  0  0  0  0
    5.8279    4.3626    1.5407 H   0  0  0  0  0  0
    6.5196    6.6817    1.1224 H   0  0  0  0  0  0
    7.7152    8.3533   -0.3671 H   0  0  0  0  0  0
    9.5937    7.1724   -3.8550 H   0  0  0  0  0  0
    8.9466    4.7883   -3.5111 H   0  0  0  0  0  0
    7.7934    3.1037   -2.0859 H   0  0  0  0  0  0
    8.1989   -0.5763   -0.8903 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 35  1  0  0  0
  1 36  1  0  0  0
  1 37  1  0  0  0
  2  3  2  0  0  0
  2  7  1  0  0  0
  3  4  1  0  0  0
  3 38  1  0  0  0
  4  5  2  0  0  0
  4 39  1  0  0  0
  5  6  1  0  0  0
  5  9  1  0  0  0
  6  7  2  0  0  0
  6  8  1  0  0  0
  7 40  1  0  0  0
  8 41  1  0  0  0
  8 42  1  0  0  0
  8 43  1  0  0  0
  9 10  2  0  0  0
  9 11  1  0  0  0
 11 12  1  0  0  0
 12 13  1  0  0  0
 12 44  1  0  0  0
 12 45  1  0  0  0
 13 14  1  0  0  0
 13 18  2  0  0  0
 14 15  2  0  0  0
 14 46  1  0  0  0
 15 16  1  0  0  0
 15 47  1  0  0  0
 16 17  2  0  0  0
 16 19  1  0  0  0
 17 18  1  0  0  0
 17 48  1  0  0  0
 18 49  1  0  0  0
 19 20  1  0  0  0
 19 22  1  0  0  0
 19 50  1  0  0  0
 20 21  1  0  0  0
 20 51  1  0  0  0
 20 52  1  0  0  0
 21 53  1  0  0  0
 21 54  1  0  0  0
 21 62  1  0  0  0
 22 23  2  0  0  0
 22 24  1  0  0  0
 24 25  1  0  0  0
 24 55  1  0  0  0
 25 26  1  0  0  0
 25 34  2  0  0  0
 26 27  2  0  0  0
 26 56  1  0  0  0
 27 28  1  0  0  0
 27 57  1  0  0  0
 28 29  2  0  0  0
 28 33  1  0  0  0
 29 30  1  0  0  0
 29 58  1  0  0  0
 30 31  2  0  0  0
 31 32  1  0  0  0
 31 59  1  0  0  0
 32 33  2  0  0  0
 32 60  1  0  0  0
 33 34  1  0  0  0
 34 61  1  0  0  0
M  CHG  1  21   1
M  END
> <s_m_entry_id>
606

> <Applicants>
Aerie Pharmaceutical

> <CHEMBL_ID>
CHEMBL4594250

> <Canonical_Smiles>
O(C(=O)c1ccc(cc1C)C)Cc1ccc(cc1)[C@H](C(=O)Nc1cc2c(cc1)cncc2)CN

> <Chirality>
Single Stereoisomer

> <First_Approval>
2017

> <Phase>
4

> <SC_Patent>
US-8394826-B2

> <Synonyms>
AR-11324 FREE BASE|AR-13324

> <Indications>
On december 18, 2017, the FDA approved netarsudil to treat glaucoma or ocular hypertension

> <Type>
nan

> <targets_id>
nan

> <inchi>
InChI=1S/C28H27N3O3/c1-18-3-10-25(19(2)13-18)28(33)34-17-20-4-6-21(7-5-20)26(15-29)27(32)31-24-9-8-23-16-30-12-11-22(23)14-24/h3-14,16,26H,15,17,29H2,1-2H3,(H,31,32)/t26-/m1/s1

> <stdInchikey>
OURRXQUGYQRVML-AREMUKBSSA-N

> <csid>
34980598

> <Links>
|http://www.chemspider.com/Chemical-Structure.34980598.html|http://pubchem.ncbi.nlm.nih.gov/compound/66599893|http://www.drugbank.ca/drugs/DB13931|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9322|http://zinc15.docking.org/substances/ZINC000113149554|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=W6I5QDT7QI

> <LinkName>
|ChemSpider|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS

> <indicationG2P>
None

> <MW>
453.2

> <HBA>
5

> <HBD>
2

> <NRB>
7

> <TPSA>
94.3

> <LogP>
4.9

> <RoF>
0

> <Targets>
nan

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_epik_Ionization_Penalty>
  0.0179

> <r_epik_State_Penalty>
  0.0111

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
606

> <indicationDB>
A Rho kinase inhibitor with norepinephrine transport inhibitory activity that reduces production of aqueous</p><p>As of December 18, 2017 the FDA approved Aerie Pharmaceutical&#39;s Rhopressa (netarsudil ophthalmic solution) 0.02% for the indication of reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Acting as both a rho kinase inhibitor and a norepinephrine transport inhibitor, Netarsudil is a novel glaucoma medication in that it specifically targets the conventional trabecular pathway of aqueous humour outflow to act as an inhibitor to the rho kinase and norepinephrine transporters found there as opposed to affecting protaglandin F2-alpha analog like mechanisms in the unconventional uveoscleral pathway that many other glaucoma medications demonstrate.

> <uniprotId>
Q13464|O75116|P23975

> <BrandName>
Rhopressa

> <FDA_approved>
Y

$$$$
Midostaurin
                    3D
 Structure written by MMmdl.
 73 81  0  0  1  0            999 V2000
   -1.1937   -3.2475   -2.2179 C   0  0  0  0  0  0
   -0.2443   -2.4849   -1.2723 C   0  0  1  0  0  0
   -0.5697   -0.9624   -1.3105 C   0  0  1  0  0  0
    0.0670   -0.1791   -0.1071 C   0  0  1  0  0  0
   -0.5149   -0.8821    1.1499 C   0  0  0  0  0  0
   -0.2371   -2.3918    1.1622 C   0  0  1  0  0  0
   -0.6149   -3.0392   -0.0231 O   0  0  0  0  0  0
    1.1021   -2.7494    1.5665 N   0  0  0  0  0  0
    1.5549   -2.8653    2.8754 C   0  0  0  0  0  0
    0.8733   -2.6651    4.0857 C   0  0  0  0  0  0
    1.5875   -2.8536    5.2669 C   0  0  0  0  0  0
    2.9258   -3.2269    5.2593 C   0  0  0  0  0  0
    3.6090   -3.4267    4.0632 C   0  0  0  0  0  0
    2.9301   -3.2462    2.8437 C   0  0  0  0  0  0
    3.3136   -3.3515    1.4863 C   0  0  0  0  0  0
    2.1619   -3.0334    0.7268 C   0  0  0  0  0  0
    2.1905   -3.0194   -0.6708 C   0  0  0  0  0  0
    1.1727   -2.7543   -1.5915 N   0  0  0  0  0  0
    1.7785   -2.7665   -2.8619 C   0  0  0  0  0  0
    1.2739   -2.4816   -4.1454 C   0  0  0  0  0  0
    2.1338   -2.6061   -5.2355 C   0  0  0  0  0  0
    3.4577   -2.9959   -5.0849 C   0  0  0  0  0  0
    3.9816   -3.2636   -3.8263 C   0  0  0  0  0  0
    3.1476   -3.1401   -2.7030 C   0  0  0  0  0  0
    3.3958   -3.2984   -1.3378 C   0  0  0  0  0  0
    4.5405   -3.6327   -0.5958 C   0  0  0  0  0  0
    4.5063   -3.6644    0.7934 C   0  0  0  0  0  0
    5.8761   -4.0303    1.2892 C   0  0  0  0  0  0
    6.2857   -4.1609    2.4384 O   0  0  0  0  0  0
    6.6132   -4.1979    0.1790 N   0  0  0  0  0  0
    5.9208   -3.9631   -1.0742 C   0  0  0  0  0  0
    1.5202    0.2082   -0.0390 N   0  0  0  0  0  0
    1.9169    0.6881    1.3000 C   0  0  0  0  0  0
    2.3638    0.4145   -1.0994 C   0  0  0  0  0  0
    2.0011    0.4011   -2.2720 O   0  0  0  0  0  0
    3.8440    0.6414   -0.8584 C   0  0  0  0  0  0
    4.5218    1.6289   -1.5860 C   0  0  0  0  0  0
    5.8891    1.8238   -1.4053 C   0  0  0  0  0  0
    6.5870    1.0263   -0.5018 C   0  0  0  0  0  0
    5.9301    0.0355    0.2221 C   0  0  0  0  0  0
    4.5639   -0.1559    0.0414 C   0  0  0  0  0  0
   -0.4349   -0.3969   -2.6134 O   0  0  0  0  0  0
   -1.0605    0.8653   -2.8137 C   0  0  0  0  0  0
   -1.3111   -2.7554   -3.1783 H   0  0  0  0  0  0
   -2.1945   -3.3025   -1.7855 H   0  0  0  0  0  0
   -0.8401   -4.2675   -2.3762 H   0  0  0  0  0  0
   -1.6519   -0.9249   -1.1563 H   0  0  0  0  0  0
   -0.3987    0.8065   -0.1256 H   0  0  0  0  0  0
   -0.2047   -0.4497    2.1002 H   0  0  0  0  0  0
   -1.6003   -0.7686    1.1473 H   0  0  0  0  0  0
   -0.8516   -2.9012    1.9058 H   0  0  0  0  0  0
   -0.1659   -2.3728    4.1163 H   0  0  0  0  0  0
    1.0885   -2.7057    6.2132 H   0  0  0  0  0  0
    3.4445   -3.3629    6.1970 H   0  0  0  0  0  0
    4.6453   -3.7127    4.1024 H   0  0  0  0  0  0
    0.2666   -2.1513   -4.3253 H   0  0  0  0  0  0
    1.7610   -2.3883   -6.2255 H   0  0  0  0  0  0
    4.0910   -3.0796   -5.9557 H   0  0  0  0  0  0
    5.0179   -3.5482   -3.7242 H   0  0  0  0  0  0
    7.5887   -4.4567    0.2034 H   0  0  0  0  0  0
    5.9473   -4.8557   -1.7003 H   0  0  0  0  0  0
    6.3839   -3.1383   -1.6173 H   0  0  0  0  0  0
    2.8168    1.3024    1.3102 H   0  0  0  0  0  0
    2.0800   -0.1510    1.9760 H   0  0  0  0  0  0
    1.1323    1.3168    1.7223 H   0  0  0  0  0  0
    3.9945    2.2491   -2.2971 H   0  0  0  0  0  0
    6.4063    2.5880   -1.9667 H   0  0  0  0  0  0
    7.6475    1.1757   -0.3626 H   0  0  0  0  0  0
    6.4760   -0.5834    0.9191 H   0  0  0  0  0  0
    4.0677   -0.9253    0.6092 H   0  0  0  0  0  0
   -0.9358    1.1648   -3.8540 H   0  0  0  0  0  0
   -0.6117    1.6414   -2.1935 H   0  0  0  0  0  0
   -2.1303    0.8226   -2.6058 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 44  1  0  0  0
  1 45  1  0  0  0
  1 46  1  0  0  0
  2  3  1  0  0  0
  2  7  1  0  0  0
  2 18  1  0  0  0
  3  4  1  0  0  0
  3 42  1  0  0  0
  3 47  1  0  0  0
  4  5  1  0  0  0
  4 32  1  0  0  0
  4 48  1  0  0  0
  5  6  1  0  0  0
  5 49  1  0  0  0
  5 50  1  0  0  0
  6  7  1  0  0  0
  6  8  1  0  0  0
  6 51  1  0  0  0
  8  9  1  0  0  0
  8 16  1  0  0  0
  9 10  1  0  0  0
  9 14  2  0  0  0
 10 11  2  0  0  0
 10 52  1  0  0  0
 11 12  1  0  0  0
 11 53  1  0  0  0
 12 13  2  0  0  0
 12 54  1  0  0  0
 13 14  1  0  0  0
 13 55  1  0  0  0
 14 15  1  0  0  0
 15 16  2  0  0  0
 15 27  1  0  0  0
 16 17  1  0  0  0
 17 18  1  0  0  0
 17 25  2  0  0  0
 18 19  1  0  0  0
 19 20  2  0  0  0
 19 24  1  0  0  0
 20 21  1  0  0  0
 20 56  1  0  0  0
 21 22  2  0  0  0
 21 57  1  0  0  0
 22 23  1  0  0  0
 22 58  1  0  0  0
 23 24  2  0  0  0
 23 59  1  0  0  0
 24 25  1  0  0  0
 25 26  1  0  0  0
 26 27  2  0  0  0
 26 31  1  0  0  0
 27 28  1  0  0  0
 28 29  2  0  0  0
 28 30  1  0  0  0
 30 31  1  0  0  0
 30 60  1  0  0  0
 31 61  1  0  0  0
 31 62  1  0  0  0
 32 33  1  0  0  0
 32 34  1  0  0  0
 33 63  1  0  0  0
 33 64  1  0  0  0
 33 65  1  0  0  0
 34 35  2  0  0  0
 34 36  1  0  0  0
 36 37  1  0  0  0
 36 41  2  0  0  0
 37 38  2  0  0  0
 37 66  1  0  0  0
 38 39  1  0  0  0
 38 67  1  0  0  0
 39 40  2  0  0  0
 39 68  1  0  0  0
 40 41  1  0  0  0
 40 69  1  0  0  0
 41 70  1  0  0  0
 42 43  1  0  0  0
 43 71  1  0  0  0
 43 72  1  0  0  0
 43 73  1  0  0  0
M  END
> <s_m_entry_id>
608

> <Applicants>
Novartis Pharmaceuticals Corp

> <CHEMBL_ID>
CHEMBL608533

> <Canonical_Smiles>
O1[C@H]2n3c4c(c5c(CNC5=O)c5c6c(n(c45)[C@]1(C)[C@H](OC)[C@H](N(C(=O)c1ccccc1)C)C2)cccc6)c1c3cccc1

> <Chirality>
Single Stereoisomer

> <First_Approval>
2017

> <Phase>
4

> <SC_Patent>
US-7973031-B2

> <Synonyms>
CGP 41251 | CGP-41251 | MIDOSTAURIN | NVP-PKC412 | PKC 412 | PKC-412 | RYDAPT

> <Indications>
On april 28 , 2017, the FDA approved midostaurin to  treat acute myeloid leukemia

> <Type>
nan

> <targets_id>
nan

> <inchi>
InChI=1S/C35H30N4O4/c1-35-32(42-3)25(37(2)34(41)19-11-5-4-6-12-19)17-26(43-35)38-23-15-9-7-13-20(23)28-29-22(18-36-33(29)40)27-21-14-8-10-16-24(21)39(35)31(27)30(28)38/h4-16,25-26,32H,17-18H2,1-3H3,(H,36,40)/t25-,26-,32-,35+/m1/s1

> <stdInchikey>
BMGQWWVMWDBQGC-IIFHNQTCSA-N

> <csid>
8005258

> <Links>
|http://www.chemspider.com/Chemical-Structure.8005258.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL608533|http://pubchem.ncbi.nlm.nih.gov/compound/9829523|http://www.drugbank.ca/drugs/DB06595| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=2K2|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/2K2|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5702|http://zinc15.docking.org/substances/ZINC000100013130|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=ID912S5VON|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50326053

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
570.2

> <HBA>
6

> <HBD>
1

> <NRB>
3

> <TPSA>
77.7

> <LogP>
5.9

> <RoF>
2

> <Targets>
nan

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0000

> <r_epik_State_Penalty>
  0.0000

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
608

> <lig_pdbID>
'2K2'

> <pdbID>
4nct

> <indicationDB>
Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hematopoietic tumors <sup class="text-reference-group"><a class="reference-popover-link" data-content="Gallogly MM, Lazarus HM: Midostaurin: an emerging treatment for acute myeloid leukemia patients. J Blood Med. 2016 Apr 19;7:73-83. doi: 10.2147/JBM.S100283. eCollection 2016. (PubMed ID 27186148)" href="#reference-A19108">4</a></sup>. It was approved on April 28, 2017 and has shown to increase the overall survival rate in patients with AML as an adjunct therapy along with chemotherapeutic agents.

> <uniprotId>
P17252|P35968|P10721|P16234|P09619|P36888|P08684|Q9HB55|P20815|P24462|P05177|P20813|P10632|P11712|P33261|P10635|P05181|P08684|P20815|P24462|Q9HB55

> <BrandName>
Rydapt

> <Melting point>
235-260

> <Withdrawn>
|Study NCT03207334 in United States was Withdrawn during Phase 2 because Insufficient funding|Study NCT02723435 in nan was Withdrawn during Phase 2 because Logistical and administrative issues|Study NCT03760445 in nan was Withdrawn during Phase 1/Phase 2 because It was determined that the study design may not be optimal given the changing AML treatment
    landscape

> <FDA_approved>
Y

$$$$
Zanubrutinib
                    3D
 Structure written by MMmdl.
 64 68  0  0  1  0            999 V2000
   -7.5293   -4.9534   -4.6132 C   0  0  0  0  0  0
   -6.5190   -4.5892   -3.8011 C   0  0  0  0  0  0
   -5.4285   -3.7401   -4.2453 C   0  0  0  0  0  0
   -5.5864   -2.9721   -5.1992 O   0  0  0  0  0  0
   -4.2467   -3.8099   -3.5643 N   0  0  0  0  0  0
   -3.1854   -2.8114   -3.8040 C   0  0  0  0  0  0
   -3.1729   -1.8748   -2.5729 C   0  0  0  0  0  0
   -2.9941   -2.6479   -1.2383 C   0  0  0  0  0  0
   -3.9896   -3.8326   -1.1547 C   0  0  0  0  0  0
   -3.9589   -4.7089   -2.4272 C   0  0  0  0  0  0
   -3.0053   -1.7477    0.0332 C   0  0  2  0  0  0
   -4.3893   -1.1241    0.3898 C   0  0  0  0  0  0
   -4.2679    0.0995    1.3195 C   0  0  0  0  0  0
   -3.4777    1.1068    0.6159 N   0  0  0  0  0  0
   -2.1945    0.6610    0.3409 C   0  0  0  0  0  0
   -1.9919   -0.6704    0.0201 N   0  0  0  0  0  0
   -0.6986   -0.9178   -0.2224 N   0  0  0  0  0  0
   -0.0560    0.2220   -0.0701 C   0  0  0  0  0  0
   -0.9404    1.2716    0.2834 C   0  0  0  0  0  0
   -0.6004    2.6315    0.6336 C   0  0  0  0  0  0
    0.4658    2.9211    1.1728 O   0  0  0  0  0  0
   -1.5238    3.5479    0.3279 N   0  0  0  0  0  0
    1.4235    0.2582   -0.2950 C   0  0  0  0  0  0
    2.2461   -0.7319    0.2531 C   0  0  0  0  0  0
    3.6196   -0.7052    0.0281 C   0  0  0  0  0  0
    4.1803    0.3064   -0.7596 C   0  0  0  0  0  0
    3.3641    1.3019   -1.2941 C   0  0  0  0  0  0
    1.9905    1.2740   -1.0706 C   0  0  0  0  0  0
    5.5368    0.3820   -0.9918 O   0  0  0  0  0  0
    6.2659   -0.7266   -1.3720 C   0  0  0  0  0  0
    7.6017   -0.7895   -0.9721 C   0  0  0  0  0  0
    8.3972   -1.8683   -1.3489 C   0  0  0  0  0  0
    7.8565   -2.8816   -2.1369 C   0  0  0  0  0  0
    6.5291   -2.8236   -2.5547 C   0  0  0  0  0  0
    5.7344   -1.7440   -2.1780 C   0  0  0  0  0  0
   -7.5829   -4.6417   -5.6473 H   0  0  0  0  0  0
   -8.3285   -5.5797   -4.2451 H   0  0  0  0  0  0
   -6.5212   -4.9260   -2.7762 H   0  0  0  0  0  0
   -2.2276   -3.3256   -3.8947 H   0  0  0  0  0  0
   -3.3307   -2.2393   -4.7216 H   0  0  0  0  0  0
   -2.3721   -1.1448   -2.6938 H   0  0  0  0  0  0
   -4.1001   -1.3012   -2.5588 H   0  0  0  0  0  0
   -2.0008   -3.0997   -1.2850 H   0  0  0  0  0  0
   -3.7581   -4.4507   -0.2865 H   0  0  0  0  0  0
   -5.0053   -3.4650   -1.0016 H   0  0  0  0  0  0
   -4.6350   -5.5588   -2.3483 H   0  0  0  0  0  0
   -2.9599   -5.1264   -2.5608 H   0  0  0  0  0  0
   -2.7351   -2.3835    0.8789 H   0  0  0  0  0  0
   -4.9258   -0.8299   -0.5129 H   0  0  0  0  0  0
   -5.0163   -1.8766    0.8692 H   0  0  0  0  0  0
   -5.2500    0.5106    1.5542 H   0  0  0  0  0  0
   -3.7913   -0.1691    2.2642 H   0  0  0  0  0  0
   -3.9983    1.5300   -0.1391 H   0  0  0  0  0  0
   -2.3941    3.2717   -0.1020 H   0  0  0  0  0  0
   -1.3589    4.5212    0.5390 H   0  0  0  0  0  0
    1.8231   -1.5212    0.8575 H   0  0  0  0  0  0
    4.2469   -1.4690    0.4639 H   0  0  0  0  0  0
    3.7948    2.0930   -1.8904 H   0  0  0  0  0  0
    1.3694    2.0437   -1.5049 H   0  0  0  0  0  0
    8.0216   -0.0003   -0.3658 H   0  0  0  0  0  0
    9.4292   -1.9172   -1.0344 H   0  0  0  0  0  0
    8.4738   -3.7177   -2.4309 H   0  0  0  0  0  0
    6.1195   -3.6098   -3.1715 H   0  0  0  0  0  0
    4.7100   -1.6991   -2.5171 H   0  0  0  0  0  0
  1  2  2  0  0  0
  1 36  1  0  0  0
  1 37  1  0  0  0
  2  3  1  0  0  0
  2 38  1  0  0  0
  3  4  2  0  0  0
  3  5  1  0  0  0
  5  6  1  0  0  0
  5 10  1  0  0  0
  6  7  1  0  0  0
  6 39  1  0  0  0
  6 40  1  0  0  0
  7  8  1  0  0  0
  7 41  1  0  0  0
  7 42  1  0  0  0
  8  9  1  0  0  0
  8 11  1  0  0  0
  8 43  1  0  0  0
  9 10  1  0  0  0
  9 44  1  0  0  0
  9 45  1  0  0  0
 10 46  1  0  0  0
 10 47  1  0  0  0
 11 12  1  0  0  0
 11 16  1  0  0  0
 11 48  1  0  0  0
 12 13  1  0  0  0
 12 49  1  0  0  0
 12 50  1  0  0  0
 13 14  1  0  0  0
 13 51  1  0  0  0
 13 52  1  0  0  0
 14 15  1  0  0  0
 14 53  1  0  0  0
 15 16  1  0  0  0
 15 19  2  0  0  0
 16 17  1  0  0  0
 17 18  2  0  0  0
 18 19  1  0  0  0
 18 23  1  0  0  0
 19 20  1  0  0  0
 20 21  2  0  0  0
 20 22  1  0  0  0
 22 54  1  0  0  0
 22 55  1  0  0  0
 23 24  1  0  0  0
 23 28  2  0  0  0
 24 25  2  0  0  0
 24 56  1  0  0  0
 25 26  1  0  0  0
 25 57  1  0  0  0
 26 27  2  0  0  0
 26 29  1  0  0  0
 27 28  1  0  0  0
 27 58  1  0  0  0
 28 59  1  0  0  0
 29 30  1  0  0  0
 30 31  1  0  0  0
 30 35  2  0  0  0
 31 32  2  0  0  0
 31 60  1  0  0  0
 32 33  1  0  0  0
 32 61  1  0  0  0
 33 34  2  0  0  0
 33 62  1  0  0  0
 34 35  1  0  0  0
 34 63  1  0  0  0
 35 64  1  0  0  0
M  END
> <s_m_entry_id>
609

> <Applicants>
BeiGene

> <CHEMBL_ID>
CHEMBL3936761

> <Canonical_Smiles>
O(c1ccc(cc1)-c1nn2c(NCCC2C2CCN(CC2)C(=O)C=C)c1C(=O)N)c1ccccc1

> <Chirality>
Single Stereoisomer

> <First_Approval>
2019

> <Phase>
4

> <SC_Patent>
US-9447106-B2

> <Indications>
Zanubrutinib (BGB-3111) is a potent, selective and and irreversible BTK inhibitor that is being investigated for clinical utility in the treatment of hematological cancers, such as non-Hodgkin's lymphoma and chronic lymphocytic leukemia (CLL) [<a href='javascript:callRef("ReferenceDisplayForward?referenceId=34570,34571&displayId=1,2", 960, 600)' title="1. Robak P, Robak T. (2017) Expert Opin Investig Drugs. 26 (11): 1249-1265; 2. Thompson PA, Burger JA. (2018) Expert Opin Investig Drugs. 27 (1): 31-42">1-2</a>].

> <Type>
nan

> <targets_id>
nan

> <inchi>
InChI=1S/C27H29N5O3/c1-2-23(33)31-16-13-18(14-17-31)22-12-15-29-27-24(26(28)34)25(30-32(22)27)19-8-10-21(11-9-19)35-20-6-4-3-5-7-20/h2-11,18,22,29H,1,12-17H2,(H2,28,34)

> <stdInchikey>
RNOAOAWBMHREKO-UHFFFAOYSA-N

> <csid>
60600294

> <Links>
|http://www.chemspider.com/Chemical-Structure.60600294.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3973435|http://pubchem.ncbi.nlm.nih.gov/compound/135905454|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=249900

> <LinkName>
|ChemSpider|ChEMBL|PubChem|BindingDB

> <MW>
471.2

> <HBA>
6

> <HBD>
2

> <NRB>
6

> <TPSA>
102.5

> <LogP>
4.2

> <RoF>
0

> <Targets>
nan

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0001

> <r_epik_State_Penalty>
  0.0000

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
609

> <BrandName>
Brukinsa

> <FDA_approved>
Y

$$$$
Vandetanib
                    3D
 Structure written by MMmdl.
 55 58  0  0  1  0            999 V2000
   -6.4777    1.0516    0.7731 C   0  0  0  0  0  0
   -4.9698    1.3476    0.8981 N   0  3  2  0  0  0
   -4.5132    2.2512   -0.2693 C   0  0  0  0  0  0
   -3.0077    2.5374   -0.1285 C   0  0  0  0  0  0
   -2.1664    1.2453   -0.0507 C   0  0  2  0  0  0
   -2.6791    0.3342    1.0881 C   0  0  0  0  0  0
   -4.1795    0.0215    0.9590 C   0  0  0  0  0  0
   -0.6606    1.5541    0.0804 C   0  0  0  0  0  0
    0.0690    0.3296    0.0651 O   0  0  0  0  0  0
    1.4419    0.3368    0.2353 C   0  0  0  0  0  0
    2.2051    1.5119    0.3042 C   0  0  0  0  0  0
    3.6055    1.4565    0.4783 C   0  0  0  0  0  0
    4.2482    0.1874    0.5857 C   0  0  0  0  0  0
    3.4568   -0.9883    0.5102 C   0  0  0  0  0  0
    2.0665   -0.9124    0.3362 C   0  0  0  0  0  0
    1.2470   -2.0258    0.2600 O   0  0  0  0  0  0
    1.8139   -3.3270    0.3728 C   0  0  0  0  0  0
    5.6658    0.2143    0.7664 C   0  0  0  0  0  0
    6.3614    1.3794    0.8198 N   0  0  0  0  0  0
    5.6460    2.5210    0.7046 C   0  0  0  0  0  0
    4.3061    2.6241    0.5385 N   0  0  0  0  0  0
    6.3846   -0.9921    0.8724 N   0  0  0  0  0  0
    7.7388   -1.2651    1.1373 C   0  0  0  0  0  0
    8.5060   -0.4620    1.9931 C   0  0  0  0  0  0
    9.8497   -0.7561    2.2246 C   0  0  0  0  0  0
   10.4412   -1.8544    1.6026 C   0  0  0  0  0  0
    9.6873   -2.6595    0.7498 C   0  0  0  0  0  0
    8.3424   -2.3680    0.5164 C   0  0  0  0  0  0
    7.6320   -3.1656   -0.3173 F   0  0  0  0  0  0
   12.2745   -2.2562    1.9192 Br  0  0  0  0  0  0
   -6.6426    0.5073   -0.1584 H   0  0  0  0  0  0
   -6.9971    2.0107    0.7752 H   0  0  0  0  0  0
   -6.7629    0.4563    1.6416 H   0  0  0  0  0  0
   -4.7445    1.7219   -1.1956 H   0  0  0  0  0  0
   -5.1043    3.1666   -0.2141 H   0  0  0  0  0  0
   -2.6815    3.1419   -0.9761 H   0  0  0  0  0  0
   -2.8395    3.1478    0.7605 H   0  0  0  0  0  0
   -2.3020    0.7092   -0.9923 H   0  0  0  0  0  0
   -2.1254   -0.6058    1.0939 H   0  0  0  0  0  0
   -2.4888    0.8016    2.0557 H   0  0  0  0  0  0
   -4.5512   -0.5332    1.8217 H   0  0  0  0  0  0
   -4.4050   -0.5304    0.0447 H   0  0  0  0  0  0
   -0.3378    2.1834   -0.7512 H   0  0  0  0  0  0
   -0.4692    2.0992    1.0071 H   0  0  0  0  0  0
    1.7441    2.4851    0.2238 H   0  0  0  0  0  0
    3.9514   -1.9440    0.5915 H   0  0  0  0  0  0
    1.0209   -4.0711    0.2998 H   0  0  0  0  0  0
    2.3082   -3.4670    1.3354 H   0  0  0  0  0  0
    2.5255   -3.5242   -0.4301 H   0  0  0  0  0  0
    6.2008    3.4469    0.7493 H   0  0  0  0  0  0
    5.8238   -1.8169    0.7173 H   0  0  0  0  0  0
    8.0680    0.3855    2.4989 H   0  0  0  0  0  0
   10.4292   -0.1322    2.8891 H   0  0  0  0  0  0
   10.1450   -3.5111    0.2676 H   0  0  0  0  0  0
   -4.8181    1.8465    1.7639 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 31  1  0  0  0
  1 32  1  0  0  0
  1 33  1  0  0  0
  2  3  1  0  0  0
  2  7  1  0  0  0
  2 55  1  0  0  0
  3  4  1  0  0  0
  3 34  1  0  0  0
  3 35  1  0  0  0
  4  5  1  0  0  0
  4 36  1  0  0  0
  4 37  1  0  0  0
  5  6  1  0  0  0
  5  8  1  0  0  0
  5 38  1  0  0  0
  6  7  1  0  0  0
  6 39  1  0  0  0
  6 40  1  0  0  0
  7 41  1  0  0  0
  7 42  1  0  0  0
  8  9  1  0  0  0
  8 43  1  0  0  0
  8 44  1  0  0  0
  9 10  1  0  0  0
 10 11  1  0  0  0
 10 15  2  0  0  0
 11 12  2  0  0  0
 11 45  1  0  0  0
 12 13  1  0  0  0
 12 21  1  0  0  0
 13 14  2  0  0  0
 13 18  1  0  0  0
 14 15  1  0  0  0
 14 46  1  0  0  0
 15 16  1  0  0  0
 16 17  1  0  0  0
 17 47  1  0  0  0
 17 48  1  0  0  0
 17 49  1  0  0  0
 18 19  2  0  0  0
 18 22  1  0  0  0
 19 20  1  0  0  0
 20 21  2  0  0  0
 20 50  1  0  0  0
 22 23  1  0  0  0
 22 51  1  0  0  0
 23 24  1  0  0  0
 23 28  2  0  0  0
 24 25  2  0  0  0
 24 52  1  0  0  0
 25 26  1  0  0  0
 25 53  1  0  0  0
 26 27  2  0  0  0
 26 30  1  0  0  0
 27 28  1  0  0  0
 27 54  1  0  0  0
 28 29  1  0  0  0
M  CHG  1   2   1
M  END
> <s_m_entry_id>
611

> <Applicants>
Ipr Pharmaceuticals

> <CHEMBL_ID>
CHEMBL24828

> <Canonical_Smiles>
Brc1cc(F)c(Nc2ncnc3c2cc(OC)c(OCC2CCN(CC2)C)c3)cc1

> <Chirality>
Achiral Molecule

> <First_Approval>
2011

> <Phase>
4

> <SC_Patent>
US-7173038-B1

> <Synonyms>
CAPRELSA | GNF-PF-2188 | VANDETANIB | ZACTIMA | ZD-64 | ZD-6474 | ZD6474

> <Indications>
Vandetanib is currently approved as an alternative to local therapies for both unresectable and disseminated disease. Because Vandetanib can prolong the Q-T interval, it is contraindicated for use in patients with serious cardiac complications such as congenital long QT syndrome and uncompensated heart failure.

> <Type>
1.5

> <targets_id>
P15692|P00533|Q13882|Q02763|P07949

> <inchi>
InChI=1S/C22H24BrFN4O2/c1-28-7-5-14(6-8-28)12-30-21-11-19-16(10-20(21)29-2)22(26-13-25-19)27-18-4-3-15(23)9-17(18)24/h3-4,9-11,13-14H,5-8,12H2,1-2H3,(H,25,26,27)

> <stdInchikey>
UHTHHESEBZOYNR-UHFFFAOYSA-N

> <csid>
2338979

> <Links>
|http://www.chemspider.com/Chemical-Structure.2338979.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL24828|http://pubchem.ncbi.nlm.nih.gov/compound/3081361|http://www.drugbank.ca/drugs/DB08764| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=ZD6|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/ZD6|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5717|http://zinc15.docking.org/substances/ZINC000053683345|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=YO460OQ37K|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=21

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
474.1

> <HBA>
6

> <HBD>
1

> <NRB>
6

> <TPSA>
59.5

> <LogP>
5

> <RoF>
1

> <Targets>
VEGFA; EGFR; PTK6; TEK; RET

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0038

> <r_epik_State_Penalty>
  0.0000

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
611

> <lig_pdbID>
'ZD6'

> <pdbID>
2ivu

> <Kinase families>
Tyr<br>(*)

> <indicationDB>
Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types.</p><p>On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients.

> <uniprotId>
P15692|P00533|Q13882|Q02763|P07949|Q01740|P31513|P08684|P02763|P02768|P33527|Q9UNQ0|O15244|P08183

> <BrandName>
Caprelsa;Zactima

> <FDA_approved>
Y

$$$$
Lenvatinib
                    3D
 Structure written by MMmdl.
 49 52  0  0  1  0            999 V2000
   -3.0986    5.1948    0.8265 C   0  0  0  0  0  0
   -1.7697    4.6835    0.8066 O   0  0  0  0  0  0
   -1.5445    3.3410    0.5411 C   0  0  0  0  0  0
   -2.5916    2.4399    0.2878 C   0  0  0  0  0  0
   -2.3377    1.0804    0.0036 C   0  0  0  0  0  0
   -0.9923    0.6108   -0.0247 C   0  0  0  0  0  0
    0.0520    1.5331    0.2246 C   0  0  0  0  0  0
   -0.2136    2.8790    0.5102 C   0  0  0  0  0  0
    0.9435    3.8101    0.7975 C   0  0  0  0  0  0
    0.8895    4.6520    1.6925 O   0  0  0  0  0  0
    2.0248    3.6755    0.0215 N   0  0  0  0  0  0
   -0.7733   -0.7727   -0.3067 C   0  0  0  0  0  0
   -1.8727   -1.5891   -0.5676 C   0  0  0  0  0  0
   -3.1504   -1.0430   -0.5212 C   0  0  0  0  0  0
   -3.3965    0.2584   -0.2395 N   0  0  0  0  0  0
    0.4861   -1.3283   -0.3552 O   0  0  0  0  0  0
    1.2518   -1.4599    0.7871 C   0  0  0  0  0  0
    2.6185   -1.6821    0.6210 C   0  0  0  0  0  0
    3.4566   -1.8238    1.7253 C   0  0  0  0  0  0
    2.9361   -1.7565    3.0279 C   0  0  0  0  0  0
    1.5598   -1.5362    3.2007 C   0  0  0  0  0  0
    0.7290   -1.3974    2.0876 C   0  0  0  0  0  0
    0.8443   -1.4344    4.7756 Cl  0  0  0  0  0  0
    3.7439   -1.8898    4.1745 N   0  0  0  0  0  0
    4.8512   -2.6443    4.3228 C   0  0  0  0  0  0
    5.3686   -3.3342    3.4415 O   0  0  0  0  0  0
    5.3157   -2.5703    5.5803 N   0  0  0  0  0  0
    6.5319   -3.2285    6.0482 C   0  0  0  0  0  0
    6.5828   -4.7408    6.1199 C   0  0  0  0  0  0
    6.4909   -3.9276    7.3879 C   0  0  0  0  0  0
   -3.0679    6.2618    1.0466 H   0  0  0  0  0  0
   -3.7006    4.7165    1.6004 H   0  0  0  0  0  0
   -3.5893    5.0728   -0.1403 H   0  0  0  0  0  0
   -3.6220    2.7627    0.3002 H   0  0  0  0  0  0
    1.0710    1.1742    0.2016 H   0  0  0  0  0  0
    2.0401    2.9914   -0.7205 H   0  0  0  0  0  0
    2.8259    4.2732    0.1641 H   0  0  0  0  0  0
   -1.7361   -2.6359   -0.7955 H   0  0  0  0  0  0
   -4.0153   -1.6610   -0.7133 H   0  0  0  0  0  0
    3.0369   -1.7353   -0.3735 H   0  0  0  0  0  0
    4.5118   -1.9706    1.5501 H   0  0  0  0  0  0
   -0.3279   -1.2375    2.2426 H   0  0  0  0  0  0
    3.3682   -1.4669    5.0109 H   0  0  0  0  0  0
    4.9310   -1.8621    6.1884 H   0  0  0  0  0  0
    7.4486   -2.6998    5.7830 H   0  0  0  0  0  0
    5.7126   -5.3166    5.8026 H   0  0  0  0  0  0
    7.5224   -5.2411    5.8852 H   0  0  0  0  0  0
    7.3665   -3.8675    8.0345 H   0  0  0  0  0  0
    5.5568   -3.9474    7.9504 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 31  1  0  0  0
  1 32  1  0  0  0
  1 33  1  0  0  0
  2  3  1  0  0  0
  3  4  1  0  0  0
  3  8  2  0  0  0
  4  5  2  0  0  0
  4 34  1  0  0  0
  5  6  1  0  0  0
  5 15  1  0  0  0
  6  7  2  0  0  0
  6 12  1  0  0  0
  7  8  1  0  0  0
  7 35  1  0  0  0
  8  9  1  0  0  0
  9 10  2  0  0  0
  9 11  1  0  0  0
 11 36  1  0  0  0
 11 37  1  0  0  0
 12 13  2  0  0  0
 12 16  1  0  0  0
 13 14  1  0  0  0
 13 38  1  0  0  0
 14 15  2  0  0  0
 14 39  1  0  0  0
 16 17  1  0  0  0
 17 18  1  0  0  0
 17 22  2  0  0  0
 18 19  2  0  0  0
 18 40  1  0  0  0
 19 20  1  0  0  0
 19 41  1  0  0  0
 20 21  2  0  0  0
 20 24  1  0  0  0
 21 22  1  0  0  0
 21 23  1  0  0  0
 22 42  1  0  0  0
 24 25  1  0  0  0
 24 43  1  0  0  0
 25 26  2  0  0  0
 25 27  1  0  0  0
 27 28  1  0  0  0
 27 44  1  0  0  0
 28 29  1  0  0  0
 28 30  1  0  0  0
 28 45  1  0  0  0
 29 30  1  0  0  0
 29 46  1  0  0  0
 29 47  1  0  0  0
 30 48  1  0  0  0
 30 49  1  0  0  0
M  END
> <s_m_entry_id>
615

> <Applicants>
Eisai

> <CHEMBL_ID>
CHEMBL1289601

> <Canonical_Smiles>
Clc1cc(Oc2c3cc(C(=O)N)c(OC)cc3ncc2)ccc1NC(=O)NC1CC1

> <Chirality>
Achiral Molecule

> <First_Approval>
2015

> <Phase>
4

> <SC_Patent>
US-7253286-B2

> <Synonyms>
E-7080 | ER-203492-00 | KISPLYX | LENVATINIB | LENVIMA

> <Indications>
Lenvatinib is indicated for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer.

> <Type>
1.5

> <targets_id>
P17948|P35968|P35916|P11362|P21802|P22607|P22455|P10721

> <inchi>
InChI=1S/C21H19ClN4O4/c1-29-19-10-17-13(9-14(19)20(23)27)18(6-7-24-17)30-12-4-5-16(15(22)8-12)26-21(28)25-11-2-3-11/h4-11H,2-3H2,1H3,(H2,23,27)(H2,25,26,28)

> <stdInchikey>
WOSKHXYHFSIKNG-UHFFFAOYSA-N

> <csid>
7999567

> <Links>
|http://www.chemspider.com/Chemical-Structure.7999567.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1289601|http://pubchem.ncbi.nlm.nih.gov/compound/9823820|http://www.drugbank.ca/drugs/DB09078| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=LEV|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/LEV|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7426|http://zinc15.docking.org/substances/ZINC03816292|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=EE083865G2|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50331094

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
426.1

> <HBA>
5

> <HBD>
3

> <NRB>
6

> <TPSA>
115.6

> <LogP>
4.1

> <RoF>
0

> <Targets>
FLT1; KDR; FLT4; FGFR1; FGFR2; FGFR3; FGFR4; KIT

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0000

> <r_epik_State_Penalty>
  0.0000

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
615

> <lig_pdbID>
'LEV'

> <pdbID>
3wzd 5zv2

> <Kinase families>
Tyr

> <indicationDB>
Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; the platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET. These receptor tyrosine kinases (RTKs) located in the cell membrane play a central role in the activation of signal transduction pathways involved in the normal regulation of cellular processes, such as cell proliferation, migration, apoptosis and differentiation, and in pathogenic angiogenesis, lymphogenesis, tumour growth and cancer progression. In particular, VEGF has been identified as a crucial regulator of both physiologic and pathologic angiogenesis and increased expression of VEGF is associated with a poor prognosis in many types of cancers.</p><p>Lenvatinib is indicated for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine (RAI)-refractory differentiated thyroid cancer. Most patients with thyroid cancer have a very good prognosis with treatment (98% 5 year survival rate) involving surgery and hormone therapy. However, for patients with RAI-refractory thyroid cancer, treatment options are limited and the prognosis is poor, leading to a push for the development of more targeted therapies such as lenvatinib.

> <uniprotId>
P17948|P35968|P35916|P11362|P21802|P22607|P22455|P16234|P07949|P10721|P08684|Q06278|P10632|P11712|P05177|P20813|P33261|P10635

> <BrandName>
Kisplyx;Lenvima

> <Withdrawn>
|Study NCT03775707 in China was Withdrawn during Phase 2 because Protocol modification|Study NCT03005015 in Switzerland was Withdrawn during Phase 2 because supporting company (Eisai) withdrew their interest|Study NCT03919383 in China was Withdrawn during Phase 2 because No participants enrolled|Study NCT03746249 in China was Withdrawn during Phase 2 because No participants enrolled|Study NCT04044651 in China was Withdrawn during Phase 2/Phase 3 because Bristol-Myers Squibb company terminated this study|Study NCT02846766 in United States was Withdrawn during Phase 2 because Unable to execute a contract agreement with the drug manufacturer|Study NCT03803254 in China was Withdrawn during Phase 2 because No participants enrolled|Study NCT03801499 in China was Withdrawn during Phase 2 because Protocol modification|Study NCT03791918 in China was Withdrawn during Phase 3 because No participants enrolled|Study NCT03744247 in China was Withdrawn during Phase 3 because No paritcipants enrolled

> <FDA_approved>
Y

$$$$
Larotrectinib
                    3D
 Structure written by MMmdl.
 53 57  0  0  1  0            999 V2000
   -2.9536   -4.8662    4.7721 C   0  0  0  0  0  0
   -1.6533   -4.3679    4.6969 C   0  0  0  0  0  0
   -0.9252   -4.4817    3.5117 C   0  0  0  0  0  0
   -1.4958   -5.0995    2.3894 C   0  0  0  0  0  0
   -2.8032   -5.5972    2.4755 C   0  0  0  0  0  0
   -3.5290   -5.4805    3.6608 C   0  0  0  0  0  0
   -4.7903   -5.9625    3.7316 F   0  0  0  0  0  0
   -0.7088   -5.2213    1.0805 C   0  0  1  0  0  0
   -0.3925   -6.6632    0.6462 C   0  0  0  0  0  0
   -0.4206   -6.5975   -0.8738 C   0  0  0  0  0  0
   -0.5717   -5.1045   -1.1427 C   0  0  0  0  0  0
   -1.3852   -4.5675   -0.0515 N   0  0  0  0  0  0
   -1.6612   -3.1964   -0.0226 C   0  0  0  0  0  0
   -2.9852   -2.7636   -0.1506 C   0  0  0  0  0  0
   -3.2458   -1.3962   -0.1118 C   0  0  0  0  0  0
   -2.1834   -0.5483    0.0513 N   0  0  0  0  0  0
   -0.8692   -1.0280    0.1737 C   0  0  0  0  0  0
   -0.6046   -2.3423    0.1326 N   0  0  0  0  0  0
   -0.0729    0.1338    0.3292 C   0  0  0  0  0  0
   -0.9991    1.1891    0.2796 C   0  0  0  0  0  0
   -2.2476    0.7998    0.1152 N   0  0  0  0  0  0
    1.3040    0.1058    0.4899 N   0  0  0  0  0  0
    2.1177    1.1766    0.6435 C   0  0  0  0  0  0
    1.7173    2.3437    0.6454 O   0  0  0  0  0  0
    3.4330    0.8697    0.7874 N   0  0  0  0  0  0
    4.0053   -0.4848    0.8508 C   0  0  0  0  0  0
    5.4238   -0.2485    1.3630 C   0  0  0  0  0  0
    5.7879    1.1323    0.8367 C   0  0  1  0  0  0
    4.4686    1.9063    0.8924 C   0  0  0  0  0  0
    6.8272    1.7541    1.5625 O   0  0  0  0  0  0
    0.3333   -3.9864    3.4623 F   0  0  0  0  0  0
   -3.5146   -4.7754    5.6905 H   0  0  0  0  0  0
   -1.2092   -3.8919    5.5586 H   0  0  0  0  0  0
   -3.2596   -6.0723    1.6192 H   0  0  0  0  0  0
    0.2460   -4.7093    1.2228 H   0  0  0  0  0  0
    0.5825   -6.9761    1.0225 H   0  0  0  0  0  0
   -1.1298   -7.3807    1.0100 H   0  0  0  0  0  0
    0.4758   -7.0121   -1.3362 H   0  0  0  0  0  0
   -1.2829   -7.1415   -1.2631 H   0  0  0  0  0  0
    0.4029   -4.6111   -1.1660 H   0  0  0  0  0  0
   -1.0422   -4.9079   -2.1070 H   0  0  0  0  0  0
   -3.7935   -3.4702   -0.2726 H   0  0  0  0  0  0
   -4.2321   -0.9637   -0.1991 H   0  0  0  0  0  0
   -0.7701    2.2410    0.3640 H   0  0  0  0  0  0
    1.7292   -0.8101    0.4957 H   0  0  0  0  0  0
    3.4394   -1.1494    1.5051 H   0  0  0  0  0  0
    4.0243   -0.9132   -0.1523 H   0  0  0  0  0  0
    5.4182   -0.2522    2.4549 H   0  0  0  0  0  0
    6.1189   -1.0212    1.0331 H   0  0  0  0  0  0
    6.0892    1.0412   -0.2086 H   0  0  0  0  0  0
    4.3987    2.6536    0.1003 H   0  0  0  0  0  0
    4.3583    2.4171    1.8502 H   0  0  0  0  0  0
    6.5511    1.8383    2.4780 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1  6  2  0  0  0
  1 32  1  0  0  0
  2  3  2  0  0  0
  2 33  1  0  0  0
  3  4  1  0  0  0
  3 31  1  0  0  0
  4  5  2  0  0  0
  4  8  1  0  0  0
  5  6  1  0  0  0
  5 34  1  0  0  0
  6  7  1  0  0  0
  8  9  1  0  0  0
  8 12  1  0  0  0
  8 35  1  0  0  0
  9 10  1  0  0  0
  9 36  1  0  0  0
  9 37  1  0  0  0
 10 11  1  0  0  0
 10 38  1  0  0  0
 10 39  1  0  0  0
 11 12  1  0  0  0
 11 40  1  0  0  0
 11 41  1  0  0  0
 12 13  1  0  0  0
 13 14  1  0  0  0
 13 18  2  0  0  0
 14 15  2  0  0  0
 14 42  1  0  0  0
 15 16  1  0  0  0
 15 43  1  0  0  0
 16 17  1  0  0  0
 16 21  1  0  0  0
 17 18  1  0  0  0
 17 19  2  0  0  0
 19 20  1  0  0  0
 19 22  1  0  0  0
 20 21  2  0  0  0
 20 44  1  0  0  0
 22 23  1  0  0  0
 22 45  1  0  0  0
 23 24  2  0  0  0
 23 25  1  0  0  0
 25 26  1  0  0  0
 25 29  1  0  0  0
 26 27  1  0  0  0
 26 46  1  0  0  0
 26 47  1  0  0  0
 27 28  1  0  0  0
 27 48  1  0  0  0
 27 49  1  0  0  0
 28 29  1  0  0  0
 28 30  1  0  0  0
 28 50  1  0  0  0
 29 51  1  0  0  0
 29 52  1  0  0  0
 30 53  1  0  0  0
M  END
> <s_m_entry_id>
616

> <Applicants>
Array BioPharma

> <CHEMBL_ID>
CHEMBL3889654

> <Canonical_Smiles>
Fc1ccc(F)cc1[C@@H]1N(CCC1)C1=Nc2n(ncc2NC(=O)N2C[C@@H](O)CC2)C=C1

> <Chirality>
Single Stereoisomer

> <First_Approval>
2018

> <Phase>
4

> <SC_Patent>
US-8513263-B2

> <Synonyms>
ARRY-470 | BAY-2757556 | BAY2757556 | LAROTRECTINIB | LOXO-101

> <Indications>
On november 26, 2018, the FDA approved larotrectinib to treat patients whose cancers have a specific genetic feature (biomarker)

> <Type>
nan

> <targets_id>
P04629|Q16620|Q16288

> <inchi>
InChI=1S/C21H22F2N6O2/c22-13-3-4-16(23)15(10-13)18-2-1-7-28(18)19-6-9-29-20(26-19)17(11-24-29)25-21(31)27-8-5-14(30)12-27/h3-4,6,9-11,14,18,30H,1-2,5,7-8,12H2,(H,25,31)/t14-,18+/m0/s1

> <stdInchikey>
NYNZQNWKBKUAII-KBXCAEBGSA-N

> <csid>
44210503

> <Links>
|http://www.chemspider.com/Chemical-Structure.44210503.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3889654|http://pubchem.ncbi.nlm.nih.gov/compound/46188928|http://www.drugbank.ca/drugs/DB14723|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8909|http://zinc15.docking.org/substances/ZINC000118399834|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=PF9462I9HX|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=136597

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
428.2

> <HBA>
6

> <HBD>
2

> <NRB>
3

> <TPSA>
86

> <LogP>
2.9

> <RoF>
0

> <Targets>
NTRK1; NTRK2; NTRK3

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0003

> <r_epik_State_Penalty>
  0.0000

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
616

> <Kinase families>
Tyr

> <indicationDB>
Larotrectinib is an orally administered tropomyosin receptor kinase (Trk) inhibitor with demonstrated antineoplastic activity. Upon administration, larotrectinib binds to Trk, thereby preventing neurotrophin-Trk interaction and Trk activation, which results in both the induction of cellular apoptosis and the inhibition of cell growth in tumors that overexpress Trk. Trk, a receptor tyrosine kinase activated by neurotrophins, is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival.</p><p>Originally discovered by Array BioPharma, the agent was ultimately licensed to Loxo Oncology in 2013. Larotrectinib is another example of innovative new cancer therapy medications that target key, specific genetic biomarker drivers of cancer rather than particular types of tumors <sup class="text-reference-group"><a class="reference-popover-link" data-content="Larotrectinib FDA Approval Press Release" href="#reference-L4847">6</a></sup>.

> <uniprotId>
P04629|Q16620|Q16288

> <BrandName>
Vitrakvi

> <FDA_approved>
Y

$$$$
Lapatinib
                    3D
 Structure written by MMmdl.
 67 71  0  0  1  0            999 V2000
   -4.8362    3.0319   -1.6872 C   0  0  0  0  0  0
   -4.3378    3.3409    0.1052 S   0  0  0  0  0  0
   -4.5773    4.7575    0.3974 O   0  0  0  0  0  0
   -4.9664    2.3093    0.9368 O   0  0  0  0  0  0
   -2.4669    3.0587    0.1197 C   0  0  0  0  0  0
   -2.1471    1.5740   -0.1039 C   0  0  0  0  0  0
   -0.6236    1.3861   -0.0745 N   0  3  0  0  0  0
   -0.1758   -0.0716   -0.2530 C   0  0  0  0  0  0
    1.3326   -0.0948   -0.2033 C   0  0  0  0  0  0
    2.3286   -0.2162   -1.1590 C   0  0  0  0  0  0
    3.5456   -0.1737   -0.4791 C   0  0  0  0  0  0
    3.2536   -0.0199    0.8701 C   0  0  0  0  0  0
    1.9019    0.0251    1.0249 O   0  0  0  0  0  0
    4.0911    0.0859    2.0983 C   0  0  0  0  0  0
    3.5896    0.6965    3.2495 C   0  0  0  0  0  0
    4.3614    0.7989    4.4032 C   0  0  0  0  0  0
    5.6751    0.2772    4.4296 C   0  0  0  0  0  0
    6.2033   -0.3540    3.2606 C   0  0  0  0  0  0
    5.3878   -0.4346    2.0973 C   0  0  0  0  0  0
    7.5341   -0.8651    3.3706 C   0  0  0  0  0  0
    8.2541   -0.7460    4.5155 N   0  0  0  0  0  0
    7.6524   -0.1265    5.5554 C   0  0  0  0  0  0
    6.4020    0.3911    5.5763 N   0  0  0  0  0  0
    8.1366   -1.4968    2.2644 N   0  0  0  0  0  0
    9.3924   -2.0996    2.0681 C   0  0  0  0  0  0
   10.1441   -2.6704    3.1022 C   0  0  0  0  0  0
   11.3773   -3.2643    2.8376 C   0  0  0  0  0  0
   11.8875   -3.3088    1.5293 C   0  0  0  0  0  0
   11.1265   -2.7473    0.4959 C   0  0  0  0  0  0
    9.8912   -2.1552    0.7648 C   0  0  0  0  0  0
   11.6997   -2.7783   -1.1356 Cl  0  0  0  0  0  0
   13.1008   -3.8824    1.1933 O   0  0  0  0  0  0
   13.8950   -4.4923    2.2068 C   0  0  0  0  0  0
   15.1500   -5.0633    1.5694 C   0  0  0  0  0  0
   15.1378   -6.3518    1.0249 C   0  0  0  0  0  0
   16.2888   -6.8764    0.4357 C   0  0  0  0  0  0
   17.4569   -6.1153    0.3873 C   0  0  0  0  0  0
   17.4743   -4.8290    0.9275 C   0  0  0  0  0  0
   16.3235   -4.3036    1.5169 C   0  0  0  0  0  0
   18.6067   -4.0912    0.8804 F   0  0  0  0  0  0
   -5.9035    3.2251   -1.7916 H   0  0  0  0  0  0
   -4.6220    1.9958   -1.9458 H   0  0  0  0  0  0
   -4.2727    3.7046   -2.3331 H   0  0  0  0  0  0
   -2.0353    3.6926   -0.6555 H   0  0  0  0  0  0
   -2.1026    3.4006    1.0892 H   0  0  0  0  0  0
   -2.5367    0.9348    0.6906 H   0  0  0  0  0  0
   -2.4658    1.2105   -1.0817 H   0  0  0  0  0  0
   -0.2124    1.9464   -0.8077 H   0  0  0  0  0  0
   -0.6525   -0.6307    0.5535 H   0  0  0  0  0  0
   -0.5844   -0.3768   -1.2173 H   0  0  0  0  0  0
    2.1899   -0.3273   -2.2244 H   0  0  0  0  0  0
    4.5290   -0.2448   -0.9203 H   0  0  0  0  0  0
    2.5888    1.1037    3.2575 H   0  0  0  0  0  0
    3.9586    1.2765    5.2850 H   0  0  0  0  0  0
    5.7771   -0.9124    1.2098 H   0  0  0  0  0  0
    8.2295   -0.0349    6.4641 H   0  0  0  0  0  0
    7.6128   -1.3752    1.4106 H   0  0  0  0  0  0
    9.7825   -2.6840    4.1184 H   0  0  0  0  0  0
   11.9212   -3.6909    3.6663 H   0  0  0  0  0  0
    9.3221   -1.7307   -0.0506 H   0  0  0  0  0  0
   14.1697   -3.7644    2.9732 H   0  0  0  0  0  0
   13.3426   -5.2954    2.6991 H   0  0  0  0  0  0
   14.2366   -6.9472    1.0553 H   0  0  0  0  0  0
   16.2748   -7.8714    0.0161 H   0  0  0  0  0  0
   18.3473   -6.5219   -0.0692 H   0  0  0  0  0  0
   16.3451   -3.3056    1.9304 H   0  0  0  0  0  0
   -0.2737    1.7240    0.8111 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 41  1  0  0  0
  1 42  1  0  0  0
  1 43  1  0  0  0
  2  3  2  0  0  0
  2  4  2  0  0  0
  2  5  1  0  0  0
  5  6  1  0  0  0
  5 44  1  0  0  0
  5 45  1  0  0  0
  6  7  1  0  0  0
  6 46  1  0  0  0
  6 47  1  0  0  0
  7  8  1  0  0  0
  7 48  1  0  0  0
  7 67  1  0  0  0
  8  9  1  0  0  0
  8 49  1  0  0  0
  8 50  1  0  0  0
  9 10  2  0  0  0
  9 13  1  0  0  0
 10 11  1  0  0  0
 10 51  1  0  0  0
 11 12  2  0  0  0
 11 52  1  0  0  0
 12 13  1  0  0  0
 12 14  1  0  0  0
 14 15  1  0  0  0
 14 19  2  0  0  0
 15 16  2  0  0  0
 15 53  1  0  0  0
 16 17  1  0  0  0
 16 54  1  0  0  0
 17 18  1  0  0  0
 17 23  2  0  0  0
 18 19  1  0  0  0
 18 20  2  0  0  0
 19 55  1  0  0  0
 20 21  1  0  0  0
 20 24  1  0  0  0
 21 22  2  0  0  0
 22 23  1  0  0  0
 22 56  1  0  0  0
 24 25  1  0  0  0
 24 57  1  0  0  0
 25 26  1  0  0  0
 25 30  2  0  0  0
 26 27  2  0  0  0
 26 58  1  0  0  0
 27 28  1  0  0  0
 27 59  1  0  0  0
 28 29  2  0  0  0
 28 32  1  0  0  0
 29 30  1  0  0  0
 29 31  1  0  0  0
 30 60  1  0  0  0
 32 33  1  0  0  0
 33 34  1  0  0  0
 33 61  1  0  0  0
 33 62  1  0  0  0
 34 35  1  0  0  0
 34 39  2  0  0  0
 35 36  2  0  0  0
 35 63  1  0  0  0
 36 37  1  0  0  0
 36 64  1  0  0  0
 37 38  2  0  0  0
 37 65  1  0  0  0
 38 39  1  0  0  0
 38 40  1  0  0  0
 39 66  1  0  0  0
M  CHG  1   7   1
M  END
> <s_m_entry_id>
617

> <Applicants>
GlaxoSmithKline

> <CHEMBL_ID>
CHEMBL554

> <Canonical_Smiles>
Clc1cc(Nc2ncnc3c2cc(cc3)-c2oc(cc2)CNCCS(=O)(=O)C)ccc1OCc1cc(F)ccc1

> <Chirality>
Achiral Molecule

> <First_Approval>
2007

> <Phase>
4

> <SC_Patent>
US-6713485-B2

> <Synonyms>
GSK-572016 | GW-2016 | GW-572016 | GW-572016X | GW572016 | LAPATINIB | TYVERB

> <Indications>
Indicated in combination with capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress the human epidermal receptor type 2 (HER2) protein and who have received prior therapy including an anthracycline, a taxane, and trastuzuma.

> <Type>
1.5

> <targets_id>
P00533|P04626

> <inchi>
InChI=1S/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35)

> <stdInchikey>
BCFGMOOMADDAQU-UHFFFAOYSA-N

> <csid>
181006

> <Links>
|http://www.chemspider.com/Chemical-Structure.181006.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL554|http://pubchem.ncbi.nlm.nih.gov/compound/208908|http://www.drugbank.ca/drugs/DB02584| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=FMM|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/FMM|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5692|http://zinc15.docking.org/substances/ZINC000001550477|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=0VUA21238F|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=5445

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
580.1

> <HBA>
8

> <HBD>
2

> <NRB>
11

> <TPSA>
106.4

> <LogP>
6.1

> <RoF>
2

> <Targets>
EGFR; ERBB2

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
0.999978

> <r_epik_Ionization_Penalty>
  0.0160

> <r_epik_State_Penalty>
  0.0120

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
617

> <lig_pdbID>
'FMM'

> <pdbID>
1xkk 3bbt

> <Kinase families>
Tyr

> <indicationDB>
Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug Capecitabine. Lapatinib is human epidermal growth factor receptor type 2 (HER2/ERBB2) and epidermal growth factor receptor (HER1/EGFR/ERBB1) tyrosine kinases inhibitor. It binds to the intracellular phosphorylation domain to prevent receptor autophosphorylation upon ligand binding.

> <uniprotId>
P00533|P04626|P08684|P20815|P10632|P33261|P08183|Q03518

> <BrandName>
Tykerb;Tyverb

> <Withdrawn>
|Study NCT01005641 in Italy was Withdrawn during Phase 2 because Study not started for administrative reasons|Study NCT00682279 in United States was Withdrawn during Phase 1 because Cancelled before enrollment|Study NCT01700010 in United States was Withdrawn during Phase 2 because Funding issues|Study NCT01205217 in Spain was Withdrawn during Phase 2 because Data presented at SABCS 2010 showing that dual blockade is superior to monotherapy|Study NCT00513253 in United States was Withdrawn during Phase 1 because It was determined not to be needed based on the clinical development plan of Tykerb|Study NCT01985893 in Germany was Withdrawn during Phase 2 because Due to missing patient recruitment, the financial support was stopped

> <FDA_approved>
Y

$$$$
Imatinib
                    3D
 Structure written by MMmdl.
 69 73  0  0  1  0            999 V2000
   -4.2343    0.7401   -0.6955 C   0  0  0  0  0  0
   -2.7200    0.6267   -0.5494 C   0  0  0  0  0  0
   -2.1175   -0.6171   -0.7606 C   0  0  0  0  0  0
   -0.7392   -0.7682   -0.6351 C   0  0  0  0  0  0
    0.0603    0.3219   -0.2923 C   0  0  0  0  0  0
   -0.5379    1.5765   -0.1000 C   0  0  0  0  0  0
   -1.9274    1.7389   -0.2068 C   0  0  0  0  0  0
   -2.5432    2.9920   -0.0150 N   0  0  0  0  0  0
   -2.2149    4.1031    0.7763 C   0  0  0  0  0  0
   -1.0879    4.0968    1.5368 N   0  0  0  0  0  0
   -0.8495    5.1999    2.2888 C   0  0  0  0  0  0
   -1.7100    6.2975    2.2992 C   0  0  0  0  0  0
   -2.8540    6.2273    1.4917 C   0  0  0  0  0  0
   -3.1101    5.1231    0.7331 N   0  0  0  0  0  0
   -3.8572    7.3319    1.4281 C   0  0  0  0  0  0
   -5.2178    7.0884    1.1732 C   0  0  0  0  0  0
   -6.1286    8.1448    1.1217 C   0  0  0  0  0  0
   -5.6548    9.4395    1.3266 C   0  0  0  0  0  0
   -4.3503    9.7137    1.5733 N   0  0  0  0  0  0
   -3.4821    8.6709    1.6204 C   0  0  0  0  0  0
    1.4447    0.0930   -0.2070 N   0  0  0  0  0  0
    2.3567    0.7551    0.5416 C   0  0  0  0  0  0
    2.0925    1.6909    1.2998 O   0  0  0  0  0  0
    3.7854    0.2855    0.3922 C   0  0  0  0  0  0
    4.8348    1.1999    0.5527 C   0  0  0  0  0  0
    6.1578    0.7850    0.4309 C   0  0  0  0  0  0
    6.4471   -0.5517    0.1540 C   0  0  0  0  0  0
    5.4100   -1.4698   -0.0147 C   0  0  0  0  0  0
    4.0864   -1.0558    0.1089 C   0  0  0  0  0  0
    7.8929   -1.0058    0.0164 C   0  0  0  0  0  0
    8.4497   -1.7432    1.2566 N   0  3  0  0  0  0
    8.4488   -0.8349    2.5083 C   0  0  0  0  0  0
    9.0999   -1.5784    3.6977 C   0  0  0  0  0  0
   10.4347   -2.1107    3.4040 N   0  0  0  0  0  0
   10.4407   -2.9754    2.2192 C   0  0  0  0  0  0
    9.8584   -2.3027    0.9543 C   0  0  0  0  0  0
   11.4503   -1.0612    3.3357 C   0  0  0  0  0  0
   -4.4881    1.4470   -1.4860 H   0  0  0  0  0  0
   -4.6809    1.0915    0.2354 H   0  0  0  0  0  0
   -4.6962   -0.2163   -0.9442 H   0  0  0  0  0  0
   -2.7174   -1.4764   -1.0238 H   0  0  0  0  0  0
   -0.2987   -1.7407   -0.8034 H   0  0  0  0  0  0
    0.0843    2.4338    0.0979 H   0  0  0  0  0  0
   -3.4874    3.0368   -0.3680 H   0  0  0  0  0  0
    0.0462    5.1914    2.8924 H   0  0  0  0  0  0
   -1.4959    7.1561    2.9177 H   0  0  0  0  0  0
   -5.5764    6.0809    1.0196 H   0  0  0  0  0  0
   -7.1754    7.9626    0.9281 H   0  0  0  0  0  0
   -6.3273   10.2840    1.2941 H   0  0  0  0  0  0
   -2.4529    8.9394    1.8082 H   0  0  0  0  0  0
    1.7769   -0.7042   -0.7289 H   0  0  0  0  0  0
    4.6334    2.2395    0.7712 H   0  0  0  0  0  0
    6.9544    1.5041    0.5568 H   0  0  0  0  0  0
    5.6264   -2.5057   -0.2334 H   0  0  0  0  0  0
    3.3026   -1.7903   -0.0116 H   0  0  0  0  0  0
    7.9923   -1.7173   -0.8056 H   0  0  0  0  0  0
    8.5716   -0.1698   -0.1655 H   0  0  0  0  0  0
    8.9818    0.0816    2.2501 H   0  0  0  0  0  0
    7.4093   -0.5869    2.7250 H   0  0  0  0  0  0
    9.1459   -0.9250    4.5704 H   0  0  0  0  0  0
    8.4592   -2.4108    3.9925 H   0  0  0  0  0  0
   11.4550   -3.3275    2.0243 H   0  0  0  0  0  0
    9.8617   -3.8717    2.4477 H   0  0  0  0  0  0
    9.7485   -3.0181    0.1380 H   0  0  0  0  0  0
   10.4757   -1.4711    0.6101 H   0  0  0  0  0  0
   12.4407   -1.4966    3.1971 H   0  0  0  0  0  0
   11.4738   -0.4905    4.2650 H   0  0  0  0  0  0
   11.2708   -0.3638    2.5170 H   0  0  0  0  0  0
    7.8437   -2.5285    1.4479 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 38  1  0  0  0
  1 39  1  0  0  0
  1 40  1  0  0  0
  2  3  1  0  0  0
  2  7  2  0  0  0
  3  4  2  0  0  0
  3 41  1  0  0  0
  4  5  1  0  0  0
  4 42  1  0  0  0
  5  6  2  0  0  0
  5 21  1  0  0  0
  6  7  1  0  0  0
  6 43  1  0  0  0
  7  8  1  0  0  0
  8  9  1  0  0  0
  8 44  1  0  0  0
  9 10  1  0  0  0
  9 14  2  0  0  0
 10 11  2  0  0  0
 11 12  1  0  0  0
 11 45  1  0  0  0
 12 13  2  0  0  0
 12 46  1  0  0  0
 13 14  1  0  0  0
 13 15  1  0  0  0
 15 16  1  0  0  0
 15 20  2  0  0  0
 16 17  2  0  0  0
 16 47  1  0  0  0
 17 18  1  0  0  0
 17 48  1  0  0  0
 18 19  2  0  0  0
 18 49  1  0  0  0
 19 20  1  0  0  0
 20 50  1  0  0  0
 21 22  1  0  0  0
 21 51  1  0  0  0
 22 23  2  0  0  0
 22 24  1  0  0  0
 24 25  1  0  0  0
 24 29  2  0  0  0
 25 26  2  0  0  0
 25 52  1  0  0  0
 26 27  1  0  0  0
 26 53  1  0  0  0
 27 28  2  0  0  0
 27 30  1  0  0  0
 28 29  1  0  0  0
 28 54  1  0  0  0
 29 55  1  0  0  0
 30 31  1  0  0  0
 30 56  1  0  0  0
 30 57  1  0  0  0
 31 32  1  0  0  0
 31 36  1  0  0  0
 31 69  1  0  0  0
 32 33  1  0  0  0
 32 58  1  0  0  0
 32 59  1  0  0  0
 33 34  1  0  0  0
 33 60  1  0  0  0
 33 61  1  0  0  0
 34 35  1  0  0  0
 34 37  1  0  0  0
 35 36  1  0  0  0
 35 62  1  0  0  0
 35 63  1  0  0  0
 36 64  1  0  0  0
 36 65  1  0  0  0
 37 66  1  0  0  0
 37 67  1  0  0  0
 37 68  1  0  0  0
M  CHG  1  31   1
M  END
> <s_m_entry_id>
619

> <Applicants>
Novartis

> <CHEMBL_ID>
CHEMBL941

> <Canonical_Smiles>
O=C(Nc1cc(Nc2nc(ccn2)-c2cccnc2)c(cc1)C)c1ccc(cc1)CN1CCN(CC1)C

> <Chirality>
Achiral Molecule

> <First_Approval>
2001

> <Phase>
4

> <SC_Patent>
US-6958335-B2

> <Synonyms>
GLEEVEC | IMATINIB | STI-571

> <Indications>
For the treatment of Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML), Ph+ acute lymphoblastic leukaemia, myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome and/or chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans, and malignant gastrointestinal stromal tumors (GIST).

> <Type>
2

> <targets_id>
P10721|P07949|P04629|P07333|P16234|Q08345|P00519|P09619

> <inchi>
InChI=1S/C29H31N7O/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34)

> <stdInchikey>
KTUFNOKKBVMGRW-UHFFFAOYSA-N

> <csid>
5101

> <Links>
|http://www.chemspider.com/Chemical-Structure.5101.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL941|http://pubchem.ncbi.nlm.nih.gov/compound/5291|http://www.drugbank.ca/drugs/DB03261| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=STI|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/STI|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5687|http://zinc15.docking.org/substances/ZINC19632618|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=BKJ8M8G5HI|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=13530

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
493.3

> <HBA>
7

> <HBD>
2

> <NRB>
7

> <TPSA>
86.3

> <LogP>
4.6

> <RoF>
0

> <Targets>
KIT; RET; NTRK1; CSF1R; PDGFRA; DDR1; ABL1; PDGFRB

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0173

> <r_epik_State_Penalty>
  0.2066

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
619

> <lig_pdbID>
'STI'

> <pdbID>
1iep 1opj 1t46 1xbb 2hyy 2oiq 2pl0 3fw1 3gvu 3hec 3k5v 3ms9 3mss 3oez 3pyy 4bkj 4csv 4r7i 5mqt 6hd4 6hd6 6jol 6ktn 6npe 6npu 6npv 6vxh

> <Kinase families>
Tyr

> <indicationDB>
Imatinib is a small molecule kinase inhibitor used to treat certain types of cancer. It is currently marketed by Novartis as Gleevec (USA) or Glivec (Europe/Australia) as its mesylate salt, imatinib mesilate (INN). It is occasionally referred to as CGP57148B or STI571 (especially in older publications). It is used in treating chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and a number of other malignancies.</p><p>It is the first member of a new class of agents that act by inhibiting particular tyrosine kinase enzymes, instead of non-specifically inhibiting rapidly dividing cells.

> <uniprotId>
P11274|P10721|O43519|P04629|P07333|P16234|Q08345|P00519|P09619|P08684|P20815|P24462|P05177|P11712|P10635|P33261|P23219|P10632|P02768|P02763

> <BrandName>
Gleevec

> <Melting point>
226°C (mesylate salt)

> <Withdrawn>
|Study NCT02268435 in nan was Withdrawn during Phase 1 because Dovitinib Production stopped|Study NCT01188889 in United States was Withdrawn during Phase 1/Phase 2 because Unable to obtain sufficient funding|Study NCT00324077 in United States was Withdrawn during Phase 1 because Insufficient Enrollment|Study NCT02812693 in nan was Withdrawn during Phase 1/Phase 2 because poor accrual|Study NCT03688568 in United States was Withdrawn during Phase 2 because Enrollment not feasible|Study NCT00594555 in United States was Withdrawn during Phase 2 because Principal Investigator resigned position with the University of Cincinnati, closing study at
    this site will reopen study in new position|Study NCT01011998 in United States was Withdrawn during Phase 2 because Withdrawn due to lack of accrual per Center DSMP, with PI concurrence|Study NCT02129166 in nan was Withdrawn during Phase 1 because PI resigned|Study NCT00403156 in United States was Withdrawn during Phase 1 because Lack of recruitment|Study NCT02538926 in United States was Withdrawn during Phase 2 because Drugs unavailable

> <FDA_approved>
Y

$$$$
Pemigatinib
                    3D
 Structure written by MMmdl.
 62 66  0  0  1  0            999 V2000
   -2.8966    3.2149    1.4088 C   0  0  0  0  0  0
   -2.4890    2.7754   -0.0104 C   0  0  0  0  0  0
   -1.8594    1.4351   -0.0568 N   0  0  0  0  0  0
   -2.7118    0.2886   -0.1175 C   0  0  0  0  0  0
   -4.1431    0.3069   -0.0917 C   0  0  0  0  0  0
   -5.2100    1.2773    0.0009 C   0  0  0  0  0  0
   -6.4265    0.6178   -0.0261 C   0  0  0  0  0  0
   -6.1688   -0.7256   -0.1300 N   0  0  0  0  0  0
   -4.8134   -0.9507   -0.1701 C   0  0  0  0  0  0
   -4.2427   -2.1484   -0.2644 N   0  0  0  0  0  0
   -2.8910   -2.1228   -0.2824 C   0  0  0  0  0  0
   -2.1024   -0.9732   -0.2145 C   0  0  0  0  0  0
   -0.5919   -1.0780   -0.2408 C   0  0  0  0  0  0
    0.1147    0.2043   -0.0583 N   0  0  0  0  0  0
   -0.4849    1.4375    0.0185 C   0  0  0  0  0  0
    0.1929    2.4666    0.1454 O   0  0  0  0  0  0
    1.5172    0.0877   -0.0210 C   0  0  0  0  0  0
    2.2568    0.1417   -1.2092 C   0  0  0  0  0  0
    3.6490    0.0228   -1.1844 C   0  0  0  0  0  0
    4.2933   -0.1525    0.0522 C   0  0  0  0  0  0
    3.5645   -0.2118    1.2522 C   0  0  0  0  0  0
    2.1726   -0.0929    1.2034 C   0  0  0  0  0  0
    1.4576   -0.1531    2.3536 F   0  0  0  0  0  0
    4.1359   -0.3815    2.5004 O   0  0  0  0  0  0
    5.5511   -0.4872    2.6141 C   0  0  0  0  0  0
    4.3049    0.0861   -2.4005 O   0  0  0  0  0  0
    5.7224   -0.0377   -2.4380 C   0  0  0  0  0  0
    1.6234    0.3099   -2.3960 F   0  0  0  0  0  0
   -7.8497    1.1355    0.0442 C   0  0  0  0  0  0
   -8.4209    0.9917    1.3865 N   0  0  0  0  0  0
   -7.8429    1.9527    2.3356 C   0  0  0  0  0  0
   -8.4719    1.7806    3.7351 C   0  0  0  0  0  0
   -9.8920    1.8790    3.6710 O   0  0  0  0  0  0
  -10.4843    0.9631    2.7540 C   0  0  0  0  0  0
   -9.8805    1.1279    1.3425 C   0  0  0  0  0  0
   -3.4134    4.1741    1.3817 H   0  0  0  0  0  0
   -2.0202    3.3317    2.0470 H   0  0  0  0  0  0
   -3.5570    2.4940    1.8904 H   0  0  0  0  0  0
   -3.3256    2.8091   -0.7034 H   0  0  0  0  0  0
   -1.8272    3.5406   -0.4202 H   0  0  0  0  0  0
   -5.1459    2.3498    0.0882 H   0  0  0  0  0  0
   -6.9038   -1.4167   -0.1598 H   0  0  0  0  0  0
   -2.4185   -3.0919   -0.3572 H   0  0  0  0  0  0
   -0.2743   -1.7676    0.5428 H   0  0  0  0  0  0
   -0.2823   -1.5210   -1.1885 H   0  0  0  0  0  0
    5.3670   -0.2448    0.0803 H   0  0  0  0  0  0
    5.8188   -0.6066    3.6638 H   0  0  0  0  0  0
    6.0506    0.4113    2.2482 H   0  0  0  0  0  0
    5.9332   -1.3563    2.0765 H   0  0  0  0  0  0
    6.0621    0.0376   -3.4708 H   0  0  0  0  0  0
    6.0494   -1.0051   -2.0536 H   0  0  0  0  0  0
    6.2097    0.7582   -1.8727 H   0  0  0  0  0  0
   -7.8932    2.1857   -0.2509 H   0  0  0  0  0  0
   -8.4658    0.5926   -0.6752 H   0  0  0  0  0  0
   -6.7654    1.8025    2.4101 H   0  0  0  0  0  0
   -7.9918    2.9764    1.9874 H   0  0  0  0  0  0
   -8.1776    0.8267    4.1766 H   0  0  0  0  0  0
   -8.0982    2.5533    4.4069 H   0  0  0  0  0  0
  -10.3610   -0.0616    3.1096 H   0  0  0  0  0  0
  -11.5584    1.1456    2.7223 H   0  0  0  0  0  0
  -10.1653    2.0968    0.9280 H   0  0  0  0  0  0
  -10.3026    0.3682    0.6827 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 36  1  0  0  0
  1 37  1  0  0  0
  1 38  1  0  0  0
  2  3  1  0  0  0
  2 39  1  0  0  0
  2 40  1  0  0  0
  3  4  1  0  0  0
  3 15  1  0  0  0
  4  5  1  0  0  0
  4 12  2  0  0  0
  5  6  1  0  0  0
  5  9  2  0  0  0
  6  7  2  0  0  0
  6 41  1  0  0  0
  7  8  1  0  0  0
  7 29  1  0  0  0
  8  9  1  0  0  0
  8 42  1  0  0  0
  9 10  1  0  0  0
 10 11  2  0  0  0
 11 12  1  0  0  0
 11 43  1  0  0  0
 12 13  1  0  0  0
 13 14  1  0  0  0
 13 44  1  0  0  0
 13 45  1  0  0  0
 14 15  1  0  0  0
 14 17  1  0  0  0
 15 16  2  0  0  0
 17 18  1  0  0  0
 17 22  2  0  0  0
 18 19  2  0  0  0
 18 28  1  0  0  0
 19 20  1  0  0  0
 19 26  1  0  0  0
 20 21  2  0  0  0
 20 46  1  0  0  0
 21 22  1  0  0  0
 21 24  1  0  0  0
 22 23  1  0  0  0
 24 25  1  0  0  0
 25 47  1  0  0  0
 25 48  1  0  0  0
 25 49  1  0  0  0
 26 27  1  0  0  0
 27 50  1  0  0  0
 27 51  1  0  0  0
 27 52  1  0  0  0
 29 30  1  0  0  0
 29 53  1  0  0  0
 29 54  1  0  0  0
 30 31  1  0  0  0
 30 35  1  0  0  0
 31 32  1  0  0  0
 31 55  1  0  0  0
 31 56  1  0  0  0
 32 33  1  0  0  0
 32 57  1  0  0  0
 32 58  1  0  0  0
 33 34  1  0  0  0
 34 35  1  0  0  0
 34 59  1  0  0  0
 34 60  1  0  0  0
 35 61  1  0  0  0
 35 62  1  0  0  0
M  END
> <s_m_entry_id>
625

> <Applicants>
Incyte Corporation

> <CHEMBL_ID>
CHEMBL4297522

> <Canonical_Smiles>
Fc1c(N2Cc3c(N(CC)C2=O)c2cc([nH]c2nc3)CN2CCOCC2)c(F)c(OC)cc1OC

> <Chirality>
Achiral Molecule

> <First_Approval>
2020

> <Phase>
4

> <SC_Patent>
US-9611267-B2

> <Synonyms>
INCB054828 | PEMAZYRE | PEMIGATINIB

> <Indications>
On April 2020, FDA approved pemigatinib to treat certain patients with cholangiocarcinoma, a rare form of cancer that forms in bile ducts.

> <Type>
nan

> <targets_id>
nan

> <inchi>
InChI=1S/C24H27F2N5O4/c1-4-30-21-14(11-27-23-16(21)9-15(28-23)13-29-5-7-35-8-6-29)12-31(24(30)32)22-19(25)17(33-2)10-18(34-3)20(22)26/h9-11H,4-8,12-13H2,1-3H3,(H,27,28)

> <stdInchikey>
HCDMJFOHIXMBOV-UHFFFAOYSA-N

> <csid>
68007304

> <Links>
|http://www.chemspider.com/Chemical-Structure.68007304.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4297522|http://pubchem.ncbi.nlm.nih.gov/compound/86705695|http://www.drugbank.ca/drugs/DB15102|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9767|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=Y6BX7BL23K|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=301310

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
487.2

> <HBA>
6

> <HBD>
1

> <NRB>
6

> <TPSA>
83.2

> <LogP>
3.7

> <RoF>
0

> <Targets>
nan

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
0.999998

> <r_epik_Ionization_Penalty>
  0.0791

> <r_epik_State_Penalty>
  0.0670

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
625

> <indicationDB>
Pemigatinib is a small molecule kinase inhibitor with antitumour activity. It works by inhibiting fibroblast growth factor receptors (FGFRs), which are receptor tyrosine kinases that activate signalling pathways in tumour cells.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Casadei C, Dizman N, Schepisi G, Cursano MC, Basso U, Santini D, Pal SK, De Giorgi U: Targeted therapies for advanced bladder cancer: new strategies with FGFR inhibitors. Ther Adv Med Oncol. 2019 Nov 25;11:1758835919890285. doi: 10.1177/1758835919890285. eCollection 2019. (PubMed ID 31803255)" href="#reference-A193719">1</a></sup> FGFRs gained attention as potential therapeutic targets in selected cancers, as FGFR gene alterations were observed in a wide variety of cancers including those of the urinary bladder, breast, ovary, prostate, endometrium, lung, and stomach.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Roskoski R Jr: The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder. Pharmacol Res. 2020 Jan;151:104567. doi: 10.1016/j.phrs.2019.104567. Epub 2019 Nov 23. (PubMed ID 31770593)" href="#reference-A198984">4</a></sup> Deregulated FGFR signalling pathway can lead the development of oncogenes and tumour-promoting physiological processes, such as cancer cell proliferation, enhanced angiogenesis, and evasion of cell death.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Liu PCC, Koblish H, Wu L, Bowman K, Diamond S, DiMatteo D, Zhang Y, Hansbury M, Rupar M, Wen X, Collier P, Feldman P, Klabe R, Burke KA, Soloviev M, Gardiner C, He X, Volgina A, Covington M, Ruggeri B, Wynn R, Burn TC, Scherle P, Yeleswaram S, Yao W, Huber R, Hollis G: INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models. PLoS One. 2020 Apr 21;15(4):e0231877. doi: 10.1371/journal.pone.0231877. eCollection 2020. (PubMed ID 32315352)" href="#reference-A193716">2</a></sup></p><p>In April 2020, pemigatinib was approved by the FDA for the treatment of unresectable locally advanced or metastatic cholangiocarcinoma in previously treated adult patients with a fibroblast growth factor receptor 2 (FGFR2) gene fusion or other rearrangements as detected by an FDA-approved test.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA Resources for Information | Approved Drugs: FDA grants accelerated approval to pemigatinib for cholangiocarcinoma with an FGFR2 rearrangement or fusion" href="#reference-L13068">6</a></sup> Cholangiocarcinoma is the most common primary malignancy affecting the biliary tract and the second most common primary hepatic malignancy.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Blechacz B: Cholangiocarcinoma: Current Knowledge and New Developments. Gut Liver. 2017 Jan 15;11(1):13-26. doi: 10.5009/gnl15568. (PubMed ID 27928095)" href="#reference-A198963">3</a></sup> This malignancy accounts for 15% to 20% of primary hepatobiliary malignancies, which account for 13% of overall cancer-related global mortality.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Blechacz B: Cholangiocarcinoma: Current Knowledge and New Developments. Gut Liver. 2017 Jan 15;11(1):13-26. doi: 10.5009/gnl15568. (PubMed ID 27928095)" href="#reference-A198963">3</a></sup> With increasing research on the pathogenesis of cholangiocarcinoma and potential therapeutic targets for anticancer drug treatment, recent studies show that up to 45% of patients with intrahepatic cholangiocarcinoma exhibited gene rearrangements resulting in oncogenic fibroblast growth factor 2 (FGFR2) fusion proteins.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Blechacz B: Cholangiocarcinoma: Current Knowledge and New Developments. Gut Liver. 2017 Jan 15;11(1):13-26. doi: 10.5009/gnl1

> <uniprotId>
P11362|P21802|P22607|P22455|P08684|P08183|Q9UNQ0|O15244|Q96FL8

> <BrandName>
Pemazyre

> <FDA_approved>
Y

$$$$
Icotinib
                    3D
 Structure written by MMmdl.
 50 53  0  0  1  0            999 V2000
   -4.6909    1.2197    2.3591 C   0  0  0  0  0  0
   -3.7947    0.7729    1.6596 C   0  0  0  0  0  0
   -2.7231    0.2542    0.8217 C   0  0  0  0  0  0
   -2.9049   -0.9333    0.1084 C   0  0  0  0  0  0
   -1.8830   -1.4215   -0.7039 C   0  0  0  0  0  0
   -0.6768   -0.7288   -0.8013 C   0  0  0  0  0  0
   -0.4732    0.4531   -0.0825 C   0  0  0  0  0  0
   -1.5111    0.9456    0.7228 C   0  0  0  0  0  0
    0.7656    1.1016   -0.2356 N   0  0  0  0  0  0
    1.5067    1.9757    0.5843 C   0  0  0  0  0  0
    2.7756    2.4613    0.1388 C   0  0  0  0  0  0
    3.3791    2.1476   -1.1087 C   0  0  0  0  0  0
    4.6250    2.6800   -1.4428 C   0  0  0  0  0  0
    5.3049    3.5240   -0.5636 C   0  0  0  0  0  0
    4.7319    3.8498    0.6728 C   0  0  0  0  0  0
    3.4689    3.3282    1.0393 C   0  0  0  0  0  0
    2.9476    3.6690    2.2514 N   0  0  0  0  0  0
    1.7393    3.1436    2.5622 C   0  0  0  0  0  0
    0.9954    2.3156    1.7950 N   0  0  0  0  0  0
    6.5290    3.9916   -0.9944 O   0  0  0  0  0  0
    7.1610    5.0717   -0.3200 C   0  0  0  0  0  0
    8.3367    5.5237   -1.1957 C   0  0  0  0  0  0
    7.8294    6.0733   -2.4110 O   0  0  0  0  0  0
    8.3923    5.5564   -3.6139 C   0  0  0  0  0  0
    7.7312    4.2322   -4.0411 C   0  0  0  0  0  0
    6.3627    4.4623   -4.3595 O   0  0  0  0  0  0
    5.6440    3.3205   -4.8229 C   0  0  0  0  0  0
    4.5732    2.9201   -3.7969 C   0  0  0  0  0  0
    5.2142    2.3769   -2.6467 O   0  0  0  0  0  0
   -5.4733    1.6143    2.9678 H   0  0  0  0  0  0
   -3.8351   -1.4805    0.1729 H   0  0  0  0  0  0
   -2.0260   -2.3367   -1.2594 H   0  0  0  0  0  0
    0.1037   -1.1227   -1.4367 H   0  0  0  0  0  0
   -1.3956    1.8752    1.2597 H   0  0  0  0  0  0
    1.2953    0.7667   -1.0266 H   0  0  0  0  0  0
    2.8729    1.4931   -1.8031 H   0  0  0  0  0  0
    5.2420    4.4989    1.3694 H   0  0  0  0  0  0
    1.3271    3.4124    3.5240 H   0  0  0  0  0  0
    6.4663    5.9019   -0.1783 H   0  0  0  0  0  0
    7.5146    4.7507    0.6609 H   0  0  0  0  0  0
    8.9143    6.2937   -0.6836 H   0  0  0  0  0  0
    9.0136    4.6826   -1.3618 H   0  0  0  0  0  0
    8.2299    6.3001   -4.3944 H   0  0  0  0  0  0
    9.4745    5.4449   -3.5261 H   0  0  0  0  0  0
    8.2528    3.8354   -4.9137 H   0  0  0  0  0  0
    7.8144    3.4875   -3.2483 H   0  0  0  0  0  0
    5.1596    3.5940   -5.7605 H   0  0  0  0  0  0
    6.2933    2.4717   -5.0500 H   0  0  0  0  0  0
    3.9653    3.7969   -3.5594 H   0  0  0  0  0  0
    3.9028    2.1695   -4.2172 H   0  0  0  0  0  0
  1  2  3  0  0  0
  1 30  1  0  0  0
  2  3  1  0  0  0
  3  4  1  0  0  0
  3  8  2  0  0  0
  4  5  2  0  0  0
  4 31  1  0  0  0
  5  6  1  0  0  0
  5 32  1  0  0  0
  6  7  2  0  0  0
  6 33  1  0  0  0
  7  8  1  0  0  0
  7  9  1  0  0  0
  8 34  1  0  0  0
  9 10  1  0  0  0
  9 35  1  0  0  0
 10 11  1  0  0  0
 10 19  2  0  0  0
 11 12  1  0  0  0
 11 16  2  0  0  0
 12 13  2  0  0  0
 12 36  1  0  0  0
 13 14  1  0  0  0
 13 29  1  0  0  0
 14 15  2  0  0  0
 14 20  1  0  0  0
 15 16  1  0  0  0
 15 37  1  0  0  0
 16 17  1  0  0  0
 17 18  2  0  0  0
 18 19  1  0  0  0
 18 38  1  0  0  0
 20 21  1  0  0  0
 21 22  1  0  0  0
 21 39  1  0  0  0
 21 40  1  0  0  0
 22 23  1  0  0  0
 22 41  1  0  0  0
 22 42  1  0  0  0
 23 24  1  0  0  0
 24 25  1  0  0  0
 24 43  1  0  0  0
 24 44  1  0  0  0
 25 26  1  0  0  0
 25 45  1  0  0  0
 25 46  1  0  0  0
 26 27  1  0  0  0
 27 28  1  0  0  0
 27 47  1  0  0  0
 27 48  1  0  0  0
 28 29  1  0  0  0
 28 49  1  0  0  0
 28 50  1  0  0  0
M  END
> <s_m_entry_id>
628

> <Applicants>
Zhejiang Beta Pharma

> <CHEMBL_ID>
CHEMBL2087361

> <Canonical_Smiles>
O1CCOCCOc2c(OCC1)cc1c(ncnc1Nc1cc(ccc1)C#C)c2

> <Chirality>
Achiral Molecule

> <First_Approval>
2011

> <Phase>
4

> <SC_Patent>
None

> <Synonyms>
BPI-2009H | ICOTINIB

> <Indications>
Icotinib hydrochloride is a novel epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitor, exhibits encouraging efficacy and tolerability in patients with advanced non-small-cell lung cancer (NSCLC) who failed previous chemotherapy.

> <Type>
nan

> <targets_id>
P00533

> <inchi>
InChI=1S/C22H21N3O4/c1-2-16-4-3-5-17(12-16)25-22-18-13-20-21(14-19(18)23-15-24-22)29-11-9-27-7-6-26-8-10-28-20/h1,3-5,12-15H,6-11H2,(H,23,24,25)

> <stdInchikey>
QQLKULDARVNMAL-UHFFFAOYSA-N

> <csid>
10762174

> <Links>
|http://www.chemspider.com/Chemical-Structure.10762174.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2087361|http://pubchem.ncbi.nlm.nih.gov/compound/22024915|http://www.drugbank.ca/drugs/DB11737|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7641|http://zinc15.docking.org/substances/ZINC000043207566|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=9G6U5L461Q|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50391089

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
391.2

> <HBA>
7

> <HBD>
1

> <NRB>
2

> <TPSA>
74.7

> <LogP>
3.2

> <RoF>
0

> <Targets>
EGFR

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0014

> <r_epik_State_Penalty>
  0.0000

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
628

> <Kinase families>
Tyr

> <indicationDB>
Icotinib is a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)Icotinib was approved in China by the SFDA in June, 2011 and in January 2014, Beta Pharma, Inc. was given a “May Proceed” from the US FDA to conduct a Phase I study for the evaluation of icotinib as a treatment of EGFR+ Non-Small Cell Lung Cancer (NSCLC).

> <uniprotId>
P00533|P08684|P05177|P20815

> <FDA_approved>
N

$$$$
Alpelisib
                    3D
 Structure written by MMmdl.
 52 54  0  0  1  0            999 V2000
   -0.3304    2.7901   -1.0770 C   0  0  0  0  0  0
   -0.8525    1.4039   -0.7613 C   0  0  0  0  0  0
   -0.1349    0.2629   -0.3668 C   0  0  0  0  0  0
   -1.2575   -1.0611   -0.1692 S   0  0  0  0  0  0
   -2.5275    0.0215   -0.6147 C   0  0  0  0  0  0
   -2.1585    1.2456   -0.8893 N   0  0  0  0  0  0
   -3.8250   -0.4344   -0.6750 N   0  0  0  0  0  0
   -4.7065   -0.2757    0.3378 C   0  0  0  0  0  0
   -4.4464    0.3713    1.3572 O   0  0  0  0  0  0
   -5.9022   -0.8990    0.1572 N   0  0  0  0  0  0
   -6.3235   -1.6415   -1.0416 C   0  0  0  0  0  0
   -7.6678   -2.2656   -0.6855 C   0  0  0  0  0  0
   -8.2292   -1.2957    0.3399 C   0  0  0  0  0  0
   -7.0002   -0.8470    1.1483 C   0  0  1  0  0  0
   -6.7989   -1.7136    2.4121 C   0  0  0  0  0  0
   -7.6056   -1.6149    3.3337 O   0  0  0  0  0  0
   -5.7503   -2.5414    2.4615 N   0  0  0  0  0  0
    1.3174    0.0565   -0.1050 C   0  0  0  0  0  0
    1.9783   -1.0849   -0.5714 C   0  0  0  0  0  0
    3.3396   -1.2270   -0.3098 C   0  0  0  0  0  0
    4.0556   -0.3038    0.3779 N   0  0  0  0  0  0
    3.4213    0.8123    0.8371 C   0  0  0  0  0  0
    2.0500    1.0122    0.6084 C   0  0  0  0  0  0
    4.2563    1.8604    1.6213 C   0  0  0  0  0  0
    4.1676    3.2259    0.8872 C   0  0  0  0  0  0
    3.6526    2.0220    3.0426 C   0  0  0  0  0  0
    5.7735    1.4822    1.7723 C   0  0  0  0  0  0
    6.3865    1.3581    0.5927 F   0  0  0  0  0  0
    6.4512    2.4125    2.4488 F   0  0  0  0  0  0
    5.9485    0.3373    2.4365 F   0  0  0  0  0  0
    0.7574    2.8221   -1.1328 H   0  0  0  0  0  0
   -0.6322    3.5150   -0.3203 H   0  0  0  0  0  0
   -0.6971    3.1556   -2.0370 H   0  0  0  0  0  0
   -4.0885   -0.9872   -1.4773 H   0  0  0  0  0  0
   -6.4389   -0.9358   -1.8656 H   0  0  0  0  0  0
   -5.6009   -2.4020   -1.3408 H   0  0  0  0  0  0
   -8.3188   -2.4132   -1.5478 H   0  0  0  0  0  0
   -7.5067   -3.2368   -0.2153 H   0  0  0  0  0  0
   -8.6608   -0.4325   -0.1687 H   0  0  0  0  0  0
   -9.0201   -1.7429    0.9438 H   0  0  0  0  0  0
   -7.1522    0.1811    1.4826 H   0  0  0  0  0  0
   -5.0987   -2.5856    1.6923 H   0  0  0  0  0  0
   -5.5965   -3.1144    3.2783 H   0  0  0  0  0  0
    1.4530   -1.8458   -1.1302 H   0  0  0  0  0  0
    3.8797   -2.0955   -0.6572 H   0  0  0  0  0  0
    1.5563    1.8967    0.9830 H   0  0  0  0  0  0
    4.7376    4.0007    1.4014 H   0  0  0  0  0  0
    3.1425    3.5909    0.8145 H   0  0  0  0  0  0
    4.5578    3.1581   -0.1294 H   0  0  0  0  0  0
    4.2065    2.7484    3.6386 H   0  0  0  0  0  0
    3.6636    1.0786    3.5902 H   0  0  0  0  0  0
    2.6181    2.3659    3.0151 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 31  1  0  0  0
  1 32  1  0  0  0
  1 33  1  0  0  0
  2  3  2  0  0  0
  2  6  1  0  0  0
  3  4  1  0  0  0
  3 18  1  0  0  0
  4  5  1  0  0  0
  5  6  2  0  0  0
  5  7  1  0  0  0
  7  8  1  0  0  0
  7 34  1  0  0  0
  8  9  2  0  0  0
  8 10  1  0  0  0
 10 11  1  0  0  0
 10 14  1  0  0  0
 11 12  1  0  0  0
 11 35  1  0  0  0
 11 36  1  0  0  0
 12 13  1  0  0  0
 12 37  1  0  0  0
 12 38  1  0  0  0
 13 14  1  0  0  0
 13 39  1  0  0  0
 13 40  1  0  0  0
 14 15  1  0  0  0
 14 41  1  0  0  0
 15 16  2  0  0  0
 15 17  1  0  0  0
 17 42  1  0  0  0
 17 43  1  0  0  0
 18 19  2  0  0  0
 18 23  1  0  0  0
 19 20  1  0  0  0
 19 44  1  0  0  0
 20 21  2  0  0  0
 20 45  1  0  0  0
 21 22  1  0  0  0
 22 23  2  0  0  0
 22 24  1  0  0  0
 23 46  1  0  0  0
 24 25  1  0  0  0
 24 26  1  0  0  0
 24 27  1  0  0  0
 25 47  1  0  0  0
 25 48  1  0  0  0
 25 49  1  0  0  0
 26 50  1  0  0  0
 26 51  1  0  0  0
 26 52  1  0  0  0
 27 28  1  0  0  0
 27 29  1  0  0  0
 27 30  1  0  0  0
M  END
> <s_m_entry_id>
629

> <Applicants>
Novartis

> <CHEMBL_ID>
CHEMBL2396661

> <Canonical_Smiles>
s1c(-c2cc(ncc2)C(C(F)(F)F)(C)C)c(nc1NC(=O)N1CCC[C@H]1C(=O)N)C

> <Chirality>
Single Stereoisomer

> <First_Approval>
2019

> <Phase>
4

> <SC_Patent>
US-8227462-B2

> <Synonyms>
ALPELISIB | BYL-719 | NVP-BYL719 | PIQRAY

> <Indications>
On may 2019, FDA approved alpelisib to treat breast cancer

> <Type>
nan

> <targets_id>
P42336

> <inchi>
InChI=1S/C19H22F3N5O2S/c1-10-14(11-6-7-24-13(9-11)18(2,3)19(20,21)22)30-16(25-10)26-17(29)27-8-4-5-12(27)15(23)28/h6-7,9,12H,4-5,8H2,1-3H3,(H2,23,28)(H,25,26,29)/t12-/m0/s1

> <stdInchikey>
STUWGJZDJHPWGZ-LBPRGKRZSA-N

> <csid>
28424123

> <Links>
|http://www.chemspider.com/Chemical-Structure.28424123.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2396661|http://pubchem.ncbi.nlm.nih.gov/compound/56649450|http://www.drugbank.ca/drugs/DB12015| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=1LT|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/1LT|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7955|http://zinc15.docking.org/substances/ZINC000068198368|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=08W5N2C97Q|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50436459

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
441.1

> <HBA>
5

> <HBD>
2

> <NRB>
4

> <TPSA>
101.2

> <LogP>
3.8

> <RoF>
0

> <Targets>
PIK3CA

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0003

> <r_epik_State_Penalty>
  0.0000

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
629

> <lig_pdbID>
'1LT'

> <pdbID>
4jps

> <Kinase families>
Atypical

> <indicationDB>
Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. It works by selectively inhibiting class I PI3K p110α <sup class="text-reference-group"><a class="reference-popover-link" data-content="Rodon J, Curigliano G, Delord JP, Harb W, Azaro A, Han Y, Wilke C, Donnet V, Sellami D, Beck T: A Phase Ib, open-label, dose-finding study of alpelisib in combination with paclitaxel in patients with advanced solid tumors. Oncotarget. 2018 Aug 3;9(60):31709-31718. doi: 10.18632/oncotarget.25854. eCollection 2018 Aug 3. (PubMed ID 30167089)" href="#reference-A179203">2</a></sup>, which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival, differentiation, and metabolism. Alpelisib was designed to target this enzyme that appears to be mutated at a rate of nearly 30% in human cancers, leading to hyperactivation.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Yang X, Zhang X, Huang M, Song K, Li X, Huang M, Meng L, Zhang J: New Insights into PI3K Inhibitor Design using X-ray Structures of PI3Kalpha Complexed with a Potent Lead Compound. Sci Rep. 2017 Nov 6;7(1):14572. doi: 10.1038/s41598-017-15260-5. (PubMed ID 29109464)" href="#reference-A179209">3</a></sup> </p><p>There are several isoform-specific PI3K inhibitors that are under clinical development or currently approved, such as <a href="https://go.drugbank.com/drugs/DB09054">idelalisib</a> used for chronic lymphocytic leukemia (CLL).<sup class="text-reference-group"><a class="reference-popover-link" data-content="Yang X, Zhang X, Huang M, Song K, Li X, Huang M, Meng L, Zhang J: New Insights into PI3K Inhibitor Design using X-ray Structures of PI3Kalpha Complexed with a Potent Lead Compound. Sci Rep. 2017 Nov 6;7(1):14572. doi: 10.1038/s41598-017-15260-5. (PubMed ID 29109464)" href="#reference-A179209">3</a></sup> Approved by the FDA in May 2019, alpelisib is the first approved PI3K inhibitor indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer in combination with <a href="https://go.drugbank.com/drugs/DB00947">fulvestrant</a> for postmenopausal women and male patients. To initiate alpelisib therapy, it is required that the presence of a PIK3CA mutation in the tissue and/or liquid biopsy sample collection should be confirmed via FDA-approved diagnostic tests. Alpelisib is marketed under the trade name Piqray and is available as oral tablets. Studies evaluating the therapeutic effectiveness of alpelisib in other cancers, such as ovarian cancer <sup class="text-reference-group"><a class="reference-popover-link" data-content="Konstantinopoulos PA, Barry WT, Birrer M, Westin SN, Cadoo KA, Shapiro GI, Mayer EL, O&#39;Cearbhaill RE, Coleman RL, Kochupurakkal B, Whalen C, Curtis J, Farooq S, Luo W, Eismann J, Buss MK, Aghajanian C, Mills GB, Palakurthi S, Kirschmeier P, Liu J, Cantley LC, Kaufmann SH, Swisher EM, D&#39;Andrea AD, Winer E, Wulf GM, Matulonis UA: Olaparib and alpha-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. Lancet Oncol. 2019 Apr;20(4):570-580. doi: 10.1016/S1470-2045(18)30905-7. Epub 2019 Mar 14. (PubMed ID 30880072)" href="#reference-A179200">1</a></sup> and colorectal cancer <sup class="text-reference-group"><a class="reference-popover-link" data-content="Rodon J, Curigliano G, Delord JP, Harb W, Azaro A, Han Y, Wilke C, Donnet V, Sellami D, Beck T: A Phase Ib, open-label, dose-finding study of alpelisib in combination with paclitaxel in patients with advanced solid tumors. Oncotarget. 2018 Aug 3;9(60):31709-31718. doi: 10.18632/oncotarget.25854. eCollection 2018 Aug 3. (PubMed ID 30167089)" href="#reference-A179203">2</a></sup>, are under ongoing investigations.</p><p>Alpelisib was granted FDA approval on 24 May 2019.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA Approved Dr

> <uniprotId>
P42336|P08684|P11712|P10632|P33261|Q9UNQ0|P08183

> <BrandName>
Piqray

> <FDA_approved>
Y

$$$$
Gilteritinib
                    3D
 Structure written by MMmdl.
 85 89  0  0  1  0            999 V2000
   -3.6853    0.2994   -3.4241 C   0  0  0  0  0  0
   -3.8777    0.4460   -1.9081 C   0  0  0  0  0  0
   -2.5725    0.2779   -1.1336 C   0  0  0  0  0  0
   -2.1416   -0.9415   -0.5922 C   0  0  0  0  0  0
   -0.9609   -1.0031    0.0768 N   0  0  0  0  0  0
   -0.2039    0.1172    0.2245 C   0  0  0  0  0  0
   -0.6355    1.3472   -0.3350 C   0  0  0  0  0  0
   -1.8241    1.4040   -1.0081 N   0  0  0  0  0  0
    0.1542    2.6490   -0.2395 C   0  0  0  0  0  0
    1.2623    2.7112    0.2908 O   0  0  0  0  0  0
   -0.4013    3.7510   -0.7619 N   0  0  0  0  0  0
    1.0120   -0.0103    0.9268 N   0  0  0  0  0  0
    1.6211   -1.0950    1.5827 C   0  0  0  0  0  0
    0.8961   -2.1211    2.1940 C   0  0  0  0  0  0
    1.5565   -3.1655    2.8330 C   0  0  0  0  0  0
    2.9578   -3.2117    2.8861 C   0  0  0  0  0  0
    3.6984   -2.1721    2.2876 C   0  0  0  0  0  0
    3.0145   -1.1227    1.6471 C   0  0  0  0  0  0
    5.0813   -2.2320    2.3718 O   0  0  0  0  0  0
    5.8719   -1.2149    1.7658 C   0  0  0  0  0  0
    3.6168   -4.2660    3.5152 N   0  0  0  0  0  0
    4.2854   -5.2450    2.6443 C   0  0  0  0  0  0
    5.4294   -5.9672    3.3854 C   0  0  0  0  0  0
    4.9384   -6.6846    4.6687 C   0  0  0  0  0  0
    4.0332   -5.7291    5.4874 C   0  0  0  0  0  0
    2.9814   -5.0201    4.6081 C   0  0  0  0  0  0
    6.1644   -7.1187    5.5345 N   0  3  0  0  0  0
    7.1430   -8.0198    4.7353 C   0  0  0  0  0  0
    8.2914   -8.5258    5.6381 C   0  0  0  0  0  0
    7.8366   -9.1902    6.8606 N   0  0  0  0  0  0
    6.9412   -8.3337    7.6401 C   0  0  0  0  0  0
    5.7188   -7.8177    6.8466 C   0  0  0  0  0  0
    7.2684  -10.5127    6.6040 C   0  0  0  0  0  0
   -2.9083   -2.1126   -0.7484 N   0  0  0  0  0  0
   -2.5946   -3.3443   -0.0229 C   0  0  0  0  0  0
   -3.2229   -4.5437   -0.7549 C   0  0  0  0  0  0
   -3.0334   -5.8319    0.0711 C   0  0  0  0  0  0
   -3.5532   -5.6660    1.3918 O   0  0  0  0  0  0
   -2.9482   -4.6090    2.1393 C   0  0  0  0  0  0
   -3.1356   -3.2598    1.4190 C   0  0  0  0  0  0
   -4.6325    0.4225   -3.9500 H   0  0  0  0  0  0
   -3.2906   -0.6849   -3.6792 H   0  0  0  0  0  0
   -2.9928    1.0482   -3.8102 H   0  0  0  0  0  0
   -4.3076    1.4242   -1.6857 H   0  0  0  0  0  0
   -4.6179   -0.2748   -1.5593 H   0  0  0  0  0  0
   -1.3105    3.7045   -1.1980 H   0  0  0  0  0  0
    0.0882    4.6329   -0.7221 H   0  0  0  0  0  0
    1.6337    0.7700    0.7682 H   0  0  0  0  0  0
   -0.1826   -2.1194    2.1978 H   0  0  0  0  0  0
    0.9590   -3.9448    3.2827 H   0  0  0  0  0  0
    3.5618   -0.3153    1.1837 H   0  0  0  0  0  0
    6.9268   -1.4363    1.9275 H   0  0  0  0  0  0
    5.6710   -0.2364    2.2044 H   0  0  0  0  0  0
    5.7071   -1.1683    0.6881 H   0  0  0  0  0  0
    3.5569   -5.9673    2.2710 H   0  0  0  0  0  0
    4.6998   -4.7480    1.7659 H   0  0  0  0  0  0
    5.8783   -6.6809    2.6947 H   0  0  0  0  0  0
    6.2090   -5.2425    3.6293 H   0  0  0  0  0  0
    4.3929   -7.5939    4.4083 H   0  0  0  0  0  0
    3.5043   -6.2753    6.2684 H   0  0  0  0  0  0
    4.6395   -4.9766    5.9954 H   0  0  0  0  0  0
    2.4102   -4.3336    5.2355 H   0  0  0  0  0  0
    2.2720   -5.7446    4.2033 H   0  0  0  0  0  0
    6.5595   -8.8377    4.3093 H   0  0  0  0  0  0
    7.5582   -7.4227    3.9248 H   0  0  0  0  0  0
    8.9430   -9.1967    5.0758 H   0  0  0  0  0  0
    8.9219   -7.6817    5.9224 H   0  0  0  0  0  0
    6.6114   -8.8649    8.5343 H   0  0  0  0  0  0
    7.5163   -7.4813    8.0057 H   0  0  0  0  0  0
    5.1804   -7.0859    7.4472 H   0  0  0  0  0  0
    5.0342   -8.6219    6.5720 H   0  0  0  0  0  0
    7.0118  -11.0068    7.5421 H   0  0  0  0  0  0
    7.9930  -11.1463    6.0910 H   0  0  0  0  0  0
    6.3682  -10.4656    5.9907 H   0  0  0  0  0  0
   -3.8619   -1.9955   -1.0582 H   0  0  0  0  0  0
   -1.5118   -3.4793    0.0083 H   0  0  0  0  0  0
   -4.2907   -4.3783   -0.9111 H   0  0  0  0  0  0
   -2.7759   -4.6672   -1.7425 H   0  0  0  0  0  0
   -3.5502   -6.6640   -0.4076 H   0  0  0  0  0  0
   -1.9785   -6.1081    0.1216 H   0  0  0  0  0  0
   -3.4055   -4.5728    3.1284 H   0  0  0  0  0  0
   -1.8885   -4.8218    2.2928 H   0  0  0  0  0  0
   -2.6309   -2.4705    1.9775 H   0  0  0  0  0  0
   -4.1976   -3.0069    1.4120 H   0  0  0  0  0  0
    6.6677   -6.2819    5.7936 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 41  1  0  0  0
  1 42  1  0  0  0
  1 43  1  0  0  0
  2  3  1  0  0  0
  2 44  1  0  0  0
  2 45  1  0  0  0
  3  4  1  0  0  0
  3  8  2  0  0  0
  4  5  2  0  0  0
  4 34  1  0  0  0
  5  6  1  0  0  0
  6  7  2  0  0  0
  6 12  1  0  0  0
  7  8  1  0  0  0
  7  9  1  0  0  0
  9 10  2  0  0  0
  9 11  1  0  0  0
 11 46  1  0  0  0
 11 47  1  0  0  0
 12 13  1  0  0  0
 12 48  1  0  0  0
 13 14  1  0  0  0
 13 18  2  0  0  0
 14 15  2  0  0  0
 14 49  1  0  0  0
 15 16  1  0  0  0
 15 50  1  0  0  0
 16 17  2  0  0  0
 16 21  1  0  0  0
 17 18  1  0  0  0
 17 19  1  0  0  0
 18 51  1  0  0  0
 19 20  1  0  0  0
 20 52  1  0  0  0
 20 53  1  0  0  0
 20 54  1  0  0  0
 21 22  1  0  0  0
 21 26  1  0  0  0
 22 23  1  0  0  0
 22 55  1  0  0  0
 22 56  1  0  0  0
 23 24  1  0  0  0
 23 57  1  0  0  0
 23 58  1  0  0  0
 24 25  1  0  0  0
 24 27  1  0  0  0
 24 59  1  0  0  0
 25 26  1  0  0  0
 25 60  1  0  0  0
 25 61  1  0  0  0
 26 62  1  0  0  0
 26 63  1  0  0  0
 27 28  1  0  0  0
 27 32  1  0  0  0
 27 85  1  0  0  0
 28 29  1  0  0  0
 28 64  1  0  0  0
 28 65  1  0  0  0
 29 30  1  0  0  0
 29 66  1  0  0  0
 29 67  1  0  0  0
 30 31  1  0  0  0
 30 33  1  0  0  0
 31 32  1  0  0  0
 31 68  1  0  0  0
 31 69  1  0  0  0
 32 70  1  0  0  0
 32 71  1  0  0  0
 33 72  1  0  0  0
 33 73  1  0  0  0
 33 74  1  0  0  0
 34 35  1  0  0  0
 34 75  1  0  0  0
 35 36  1  0  0  0
 35 40  1  0  0  0
 35 76  1  0  0  0
 36 37  1  0  0  0
 36 77  1  0  0  0
 36 78  1  0  0  0
 37 38  1  0  0  0
 37 79  1  0  0  0
 37 80  1  0  0  0
 38 39  1  0  0  0
 39 40  1  0  0  0
 39 81  1  0  0  0
 39 82  1  0  0  0
 40 83  1  0  0  0
 40 84  1  0  0  0
M  CHG  1  27   1
M  END
> <s_m_entry_id>
630

> <Applicants>
Astellas Pharma

> <CHEMBL_ID>
CHEMBL3301622

> <Canonical_Smiles>
O1CCC(Nc2nc(Nc3cc(OC)c(N4CCC(N5CCN(CC5)C)CC4)cc3)c(nc2CC)C(=O)N)CC1

> <Chirality>
Achiral Molecule

> <First_Approval>
2018

> <Phase>
4

> <SC_Patent>
US-8969336-B2

> <Synonyms>
ASP-2215 | ASP2215 | GILTERITINIB

> <Indications>
On november 28, 2018, the FDA approved gilteritinib to treat patients who have relapsed or refractory acute myeloid leukemia (AML)

> <Type>
nan

> <targets_id>
P36888|P30530|Q9UM73

> <inchi>
InChI=1S/C29H44N8O3/c1-4-23-28(31-20-9-17-40-18-10-20)34-29(26(33-23)27(30)38)32-21-5-6-24(25(19-21)39-3)37-11-7-22(8-12-37)36-15-13-35(2)14-16-36/h5-6,19-20,22H,4,7-18H2,1-3H3,(H2,30,38)(H2,31,32,34)

> <stdInchikey>
GYQYAJJFPNQOOW-UHFFFAOYSA-N

> <csid>
32055842

> <Links>
|http://www.chemspider.com/Chemical-Structure.32055842.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3301622|http://pubchem.ncbi.nlm.nih.gov/compound/49803313|http://www.drugbank.ca/drugs/DB12141| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=C6F|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/C6F|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8708|http://zinc15.docking.org/substances/ZINC000113476229|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=66D92MGC8M|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=144315

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
552.4

> <HBA>
10

> <HBD>
3

> <NRB>
9

> <TPSA>
121.1

> <LogP>
2.7

> <RoF>
1

> <Targets>
FLT3; AXL; ALK

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_epik_Ionization_Penalty>
  0.0115

> <r_epik_State_Penalty>
  0.0264

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
630

> <lig_pdbID>
'C6F'

> <pdbID>
6jqr 7ab1

> <Kinase families>
Tyr

> <indicationDB>
Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Stone RM: What FLT3 inhibitor holds the greatest promise? Best Pract Res Clin Haematol. 2018 Dec;31(4):401-404. doi: 10.1016/j.beha.2018.09.008. Epub 2018 Sep 20. (PubMed ID 30466756)" href="#reference-A40036">1</a></sup> It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression observed in other therapies.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Lee LY, Hernandez D, Rajkhowa T, Smith SC, Raman JR, Nguyen B, Small D, Levis M: Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor. Blood. 2017 Jan 12;129(2):257-260. doi: 10.1182/blood-2016-10-745133. Epub 2016 Dec 1. (PubMed ID 27908881)" href="#reference-A40044">5</a></sup> Gilteritinib was developed by Astellas Pharma and FDA approved on November 28, 2018. This drug was approved after being designed as an orphan drug with a fast track and priority review status.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA news" href="#reference-L4830">7</a></sup>

> <uniprotId>
P36888|P08908|P28222|P28221|P28566|P30939|P28223|P41595|P28335|P46098|O95264|Q8WXA8|Q70Z44|A5X5Y0|Q13639|P50406|P34969|P30530|Q9UM73|P08684|P02768|P08183|Q96FL8|Q9UNQ0|O15245

> <BrandName>
Xospata

> <FDA_approved>
Y

$$$$
Dacomitinib
                    3D
 Structure written by MMmdl.
 59 62  0  0  1  0            999 V2000
   -0.1540   -3.3970    0.8150 C   0  0  0  0  0  0
    0.3578   -2.1063    0.4994 O   0  0  0  0  0  0
   -0.5177   -1.0680    0.2201 C   0  0  0  0  0  0
   -1.9130   -1.2150    0.2552 C   0  0  0  0  0  0
   -2.7689   -0.1282   -0.0303 C   0  0  0  0  0  0
   -2.2070    1.1415   -0.3588 C   0  0  0  0  0  0
   -0.7946    1.2743   -0.3898 C   0  0  0  0  0  0
    0.0351    0.1776   -0.1155 C   0  0  0  0  0  0
    1.4404    0.2899   -0.1106 N   0  0  0  0  0  0
    2.2167    1.0841   -0.8789 C   0  0  0  0  0  0
    1.7943    1.8360   -1.7611 O   0  0  0  0  0  0
    3.6192    0.9652   -0.5493 C   0  0  0  0  0  0
    4.5849    1.6302   -1.2145 C   0  0  0  0  0  0
    6.0640    1.5365   -0.8897 C   0  0  0  0  0  0
    6.8969    0.8478   -1.9957 N   0  3  0  0  0  0
    6.4986   -0.6417   -2.1469 C   0  0  0  0  0  0
    7.3440   -1.2836   -3.2609 C   0  0  0  0  0  0
    8.8514   -1.1158   -3.0105 C   0  0  0  0  0  0
    9.2273    0.3615   -2.8137 C   0  0  0  0  0  0
    8.4050    1.0192   -1.6922 C   0  0  0  0  0  0
   -3.1389    2.1920   -0.6290 C   0  0  0  0  0  0
   -4.4793    1.9907   -0.5666 N   0  0  0  0  0  0
   -4.8976    0.7460   -0.2470 C   0  0  0  0  0  0
   -4.1162   -0.3255    0.0236 N   0  0  0  0  0  0
   -2.6657    3.4788   -0.9546 N   0  0  0  0  0  0
   -3.2897    4.7066   -1.2438 C   0  0  0  0  0  0
   -4.6193    4.8275   -1.6754 C   0  0  0  0  0  0
   -5.1637    6.0828   -1.9471 C   0  0  0  0  0  0
   -4.3874    7.2313   -1.8001 C   0  0  0  0  0  0
   -3.0587    7.1222   -1.3835 C   0  0  0  0  0  0
   -2.5167    5.8649   -1.1112 C   0  0  0  0  0  0
   -2.0766    8.5322   -1.2030 Cl  0  0  0  0  0  0
   -4.9275    8.4429   -2.0677 F   0  0  0  0  0  0
    0.6772   -4.0791    0.9923 H   0  0  0  0  0  0
   -0.7453   -3.8055   -0.0061 H   0  0  0  0  0  0
   -0.7613   -3.3764    1.7211 H   0  0  0  0  0  0
   -2.3699   -2.1610    0.5049 H   0  0  0  0  0  0
   -0.3723    2.2422   -0.6133 H   0  0  0  0  0  0
    1.9143   -0.4133    0.4375 H   0  0  0  0  0  0
    3.8800    0.3080    0.2701 H   0  0  0  0  0  0
    4.3340    2.2920   -2.0329 H   0  0  0  0  0  0
    6.4765    2.5409   -0.7825 H   0  0  0  0  0  0
    6.2562    0.9739    0.0266 H   0  0  0  0  0  0
    6.6650   -1.1171   -1.1785 H   0  0  0  0  0  0
    5.4361   -0.6746   -2.3908 H   0  0  0  0  0  0
    7.1001   -2.3436   -3.3406 H   0  0  0  0  0  0
    7.0772   -0.8388   -4.2208 H   0  0  0  0  0  0
    9.1416   -1.6876   -2.1273 H   0  0  0  0  0  0
    9.4164   -1.5362   -3.8438 H   0  0  0  0  0  0
   10.2905    0.4436   -2.5842 H   0  0  0  0  0  0
    9.0754    0.9091   -3.7450 H   0  0  0  0  0  0
    8.6017    2.0904   -1.6303 H   0  0  0  0  0  0
    8.5919    0.5574   -0.7207 H   0  0  0  0  0  0
   -5.9658    0.5908   -0.2020 H   0  0  0  0  0  0
   -1.6655    3.5607   -0.8469 H   0  0  0  0  0  0
   -5.2484    3.9652   -1.8258 H   0  0  0  0  0  0
   -6.1891    6.1624   -2.2775 H   0  0  0  0  0  0
   -1.4868    5.7946   -0.7901 H   0  0  0  0  0  0
    6.7011    1.3182   -2.8684 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 34  1  0  0  0
  1 35  1  0  0  0
  1 36  1  0  0  0
  2  3  1  0  0  0
  3  4  1  0  0  0
  3  8  2  0  0  0
  4  5  2  0  0  0
  4 37  1  0  0  0
  5  6  1  0  0  0
  5 24  1  0  0  0
  6  7  2  0  0  0
  6 21  1  0  0  0
  7  8  1  0  0  0
  7 38  1  0  0  0
  8  9  1  0  0  0
  9 10  1  0  0  0
  9 39  1  0  0  0
 10 11  2  0  0  0
 10 12  1  0  0  0
 12 13  2  0  0  0
 12 40  1  0  0  0
 13 14  1  0  0  0
 13 41  1  0  0  0
 14 15  1  0  0  0
 14 42  1  0  0  0
 14 43  1  0  0  0
 15 16  1  0  0  0
 15 20  1  0  0  0
 15 59  1  0  0  0
 16 17  1  0  0  0
 16 44  1  0  0  0
 16 45  1  0  0  0
 17 18  1  0  0  0
 17 46  1  0  0  0
 17 47  1  0  0  0
 18 19  1  0  0  0
 18 48  1  0  0  0
 18 49  1  0  0  0
 19 20  1  0  0  0
 19 50  1  0  0  0
 19 51  1  0  0  0
 20 52  1  0  0  0
 20 53  1  0  0  0
 21 22  2  0  0  0
 21 25  1  0  0  0
 22 23  1  0  0  0
 23 24  2  0  0  0
 23 54  1  0  0  0
 25 26  1  0  0  0
 25 55  1  0  0  0
 26 27  2  0  0  0
 26 31  1  0  0  0
 27 28  1  0  0  0
 27 56  1  0  0  0
 28 29  2  0  0  0
 28 57  1  0  0  0
 29 30  1  0  0  0
 29 33  1  0  0  0
 30 31  2  0  0  0
 30 32  1  0  0  0
 31 58  1  0  0  0
M  CHG  1  15   1
M  END
> <s_m_entry_id>
642

> <Applicants>
Pfizer

> <CHEMBL_ID>
CHEMBL2110732

> <Canonical_Smiles>
Clc1cc(Nc2ncnc3c2cc(NC(=O)\C=C\CN2CCCCC2)c(OC)c3)ccc1F

> <Chirality>
Achiral Molecule

> <First_Approval>
2018

> <Phase>
4

> <SC_Patent>
US-7772243-B2

> <Synonyms>
DACOMITINIB | DACOMITINIB HYDRATE | PF-00299804

> <Indications>
On october 27, 2018, the FDA approved dacomitinib to treat metastatic non-small-cell lung cancer

> <Type>
1

> <targets_id>
P00533

> <inchi>
InChI=1S/C24H25ClFN5O2/c1-33-22-14-20-17(24(28-15-27-20)29-16-7-8-19(26)18(25)12-16)13-21(22)30-23(32)6-5-11-31-9-3-2-4-10-31/h5-8,12-15H,2-4,9-11H2,1H3,(H,30,32)(H,27,28,29)/b6-5+

> <stdInchikey>
LVXJQMNHJWSHET-AATRIKPKSA-N

> <csid>
9685914

> <Links>
|http://www.chemspider.com/Chemical-Structure.9685914.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2110732|http://pubchem.ncbi.nlm.nih.gov/compound/11511120|http://www.drugbank.ca/drugs/DB11963| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=1C9|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/1C9|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7422|http://zinc15.docking.org/substances/ZINC000072266312|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=2XJX250C20|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=112499

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
469.2

> <HBA>
6

> <HBD>
2

> <NRB>
7

> <TPSA>
79.4

> <LogP>
5.2

> <RoF>
1

> <Targets>
EGFR

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
0.999978

> <r_epik_Ionization_Penalty>
  0.0867

> <r_epik_State_Penalty>
  0.1083

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
642

> <lig_pdbID>
'1C9'

> <pdbID>
4i23 4i24

> <Kinase families>
Tyr

> <indicationDB>
Dacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors which are characterized by the irreversible binding at the ATP domain of the epidermal growth factor receptor family kinase domains.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Brzezniak C, Carter CA, Giaccone G: Dacomitinib, a new therapy for the treatment of non-small cell lung cancer. Expert Opin Pharmacother. 2013 Feb;14(2):247-53. doi: 10.1517/14656566.2013.758714. Epub 2013 Jan 7. (PubMed ID 23294134)" href="#reference-A40009">2</a></sup></p><p>Dacomitinib was developed by Pfizer Inc and approved by the FDA on September 27, 2018.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA approval" href="#reference-L4810">14</a></sup> Some evidence in the literature suggests the therapeutic potential of dacomitinib in the epithelial ovarian cancer model<sup class="text-reference-group"><a class="reference-popover-link" data-content="Momeny M, Zarrinrad G, Moghaddaskho F, Poursheikhani A, Sankanian G, Zaghal A, Mirshahvaladi S, Esmaeili F, Eyvani H, Barghi F, Sabourinejad Z, Alishahi Z, Yousefi H, Ghasemi R, Dardaei L, Bashash D, Chahardouli B, Dehpour AR, Tavakkoly-Bazzaz J, Alimoghaddam K, Ghavamzadeh A, Ghaffari SH: Dacomitinib, a pan-inhibitor of ErbB receptors, suppresses growth and invasive capacity of chemoresistant ovarian carcinoma cells. Sci Rep. 2017 Jun 23;7(1):4204. doi: 10.1038/s41598-017-04147-0. (PubMed ID 28646172)" href="#reference-A39624">1</a></sup>, although further investigations are needed.

> <uniprotId>
P00533|P10635|P08684|P11712|P22309

> <BrandName>
Vizimpro

> <Melting point>
184-187 ºC

> <FDA_approved>
Y

$$$$
Dasatinib
                    3D
 Structure written by MMmdl.
 60 63  0  0  1  0            999 V2000
   -6.5434    1.4652    1.6351 C   0  0  0  0  0  0
   -6.9764    2.8039    1.0474 C   0  0  0  0  0  0
   -8.3237    3.1707    1.1253 C   0  0  0  0  0  0
   -8.7590    4.3838    0.5979 C   0  0  0  0  0  0
   -7.8525    5.2378   -0.0242 C   0  0  0  0  0  0
   -6.5039    4.8921   -0.1164 C   0  0  0  0  0  0
   -6.0523    3.6785    0.4429 C   0  0  0  0  0  0
   -4.7069    3.2829    0.3511 N   0  0  0  0  0  0
   -3.6755    3.9049    0.9620 C   0  0  0  0  0  0
   -3.7908    4.8983    1.6831 O   0  0  0  0  0  0
   -2.3834    3.3085    0.7369 C   0  0  0  0  0  0
   -1.1931    3.5534    1.4228 C   0  0  0  0  0  0
   -0.1186    2.9245    0.9866 N   0  0  0  0  0  0
   -0.3768    2.1830   -0.0658 C   0  0  0  0  0  0
   -2.0285    2.2262   -0.5925 S   0  0  0  0  0  0
    0.5602    1.4341   -0.7203 N   0  0  0  0  0  0
    1.9543    1.2850   -0.4416 C   0  0  0  0  0  0
    2.7397    0.4543   -1.2519 C   0  0  0  0  0  0
    4.1143    0.3144   -0.9693 C   0  0  0  0  0  0
    4.6689    0.9754    0.0914 N   0  0  0  0  0  0
    3.8676    1.7687    0.8445 C   0  0  0  0  0  0
    2.5570    1.9188    0.5865 N   0  3  0  0  0  0
    4.4912    2.5024    2.0143 C   0  0  0  0  0  0
    4.9609   -0.5053   -1.7226 N   0  0  0  0  0  0
    4.6510   -0.9927   -3.0801 C   0  0  0  0  0  0
    5.2436   -2.3996   -3.3281 C   0  0  0  0  0  0
    6.7051   -2.3818   -3.1923 N   0  0  0  0  0  0
    7.0267   -1.9215   -1.8352 C   0  0  0  0  0  0
    6.4312   -0.5170   -1.5787 C   0  0  0  0  0  0
    7.2399   -3.7195   -3.4844 C   0  0  0  0  0  0
    8.7684   -3.7743   -3.7023 C   0  0  0  0  0  0
    9.5043   -3.7116   -2.4975 O   0  0  0  0  0  0
   -5.4471    5.9745   -0.9623 Cl  0  0  0  0  0  0
   -6.1263    0.8255    0.8567 H   0  0  0  0  0  0
   -7.3755    0.9307    2.0953 H   0  0  0  0  0  0
   -5.7817    1.6150    2.4012 H   0  0  0  0  0  0
   -9.0421    2.5147    1.5952 H   0  0  0  0  0  0
   -9.8019    4.6577    0.6617 H   0  0  0  0  0  0
   -8.2027    6.1680   -0.4475 H   0  0  0  0  0  0
   -4.5210    2.4364   -0.1661 H   0  0  0  0  0  0
   -1.0971    4.2131    2.2736 H   0  0  0  0  0  0
    0.2277    0.9087   -1.5159 H   0  0  0  0  0  0
    2.2691   -0.0657   -2.0708 H   0  0  0  0  0  0
    5.2828    3.1666    1.6656 H   0  0  0  0  0  0
    4.9281    1.7914    2.7165 H   0  0  0  0  0  0
    3.7578    3.1037    2.5539 H   0  0  0  0  0  0
    3.5817   -1.0554   -3.2651 H   0  0  0  0  0  0
    5.0519   -0.2798   -3.8032 H   0  0  0  0  0  0
    4.8206   -3.1109   -2.6151 H   0  0  0  0  0  0
    4.9617   -2.7363   -4.3269 H   0  0  0  0  0  0
    6.6364   -2.6339   -1.1053 H   0  0  0  0  0  0
    8.1039   -1.8622   -1.6919 H   0  0  0  0  0  0
    6.8544    0.2089   -2.2757 H   0  0  0  0  0  0
    6.7372   -0.2087   -0.5790 H   0  0  0  0  0  0
    6.9241   -4.4542   -2.7412 H   0  0  0  0  0  0
    6.7928   -4.0489   -4.4241 H   0  0  0  0  0  0
    9.0238   -4.7224   -4.1764 H   0  0  0  0  0  0
    9.0974   -2.9978   -4.3940 H   0  0  0  0  0  0
   10.4395   -3.7692   -2.7069 H   0  0  0  0  0  0
    2.0014    2.5210    1.1782 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 34  1  0  0  0
  1 35  1  0  0  0
  1 36  1  0  0  0
  2  3  1  0  0  0
  2  7  2  0  0  0
  3  4  2  0  0  0
  3 37  1  0  0  0
  4  5  1  0  0  0
  4 38  1  0  0  0
  5  6  2  0  0  0
  5 39  1  0  0  0
  6  7  1  0  0  0
  6 33  1  0  0  0
  7  8  1  0  0  0
  8  9  1  0  0  0
  8 40  1  0  0  0
  9 10  2  0  0  0
  9 11  1  0  0  0
 11 12  2  0  0  0
 11 15  1  0  0  0
 12 13  1  0  0  0
 12 41  1  0  0  0
 13 14  2  0  0  0
 14 15  1  0  0  0
 14 16  1  0  0  0
 16 17  1  0  0  0
 16 42  1  0  0  0
 17 18  1  0  0  0
 17 22  2  0  0  0
 18 19  2  0  0  0
 18 43  1  0  0  0
 19 20  1  0  0  0
 19 24  1  0  0  0
 20 21  2  0  0  0
 21 22  1  0  0  0
 21 23  1  0  0  0
 22 60  1  0  0  0
 23 44  1  0  0  0
 23 45  1  0  0  0
 23 46  1  0  0  0
 24 25  1  0  0  0
 24 29  1  0  0  0
 25 26  1  0  0  0
 25 47  1  0  0  0
 25 48  1  0  0  0
 26 27  1  0  0  0
 26 49  1  0  0  0
 26 50  1  0  0  0
 27 28  1  0  0  0
 27 30  1  0  0  0
 28 29  1  0  0  0
 28 51  1  0  0  0
 28 52  1  0  0  0
 29 53  1  0  0  0
 29 54  1  0  0  0
 30 31  1  0  0  0
 30 55  1  0  0  0
 30 56  1  0  0  0
 31 32  1  0  0  0
 31 57  1  0  0  0
 31 58  1  0  0  0
 32 59  1  0  0  0
M  CHG  1  22   1
M  END
> <s_m_entry_id>
645

> <Applicants>
Bristol Myers Squibb

> <CHEMBL_ID>
CHEMBL1421

> <Canonical_Smiles>
Clc1cccc(C)c1NC(=O)c1sc(nc1)Nc1nc(nc(N2CCN(CC2)CCO)c1)C

> <Chirality>
Achiral Molecule

> <First_Approval>
2006

> <Phase>
4

> <SC_Patent>
US-6596746-B1

> <Synonyms>
BMS-354825 | BMS-354825 HYDRATE | BMS-354825-03 | DASATINIB | DASATINIB HYDRATE | DASATINIB MONOHYDRATE | SPRYCEL

> <Indications>
For the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia with resistance or intolerance to prior therapy. Also indicated for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to prior therapy.

> <Type>
1

> <targets_id>
P00519|P12931|P29317|P06239|P07947|P10721|P09619|P42684|P06241

> <inchi>
InChI=1S/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27)

> <stdInchikey>
ZBNZXTGUTAYRHI-UHFFFAOYSA-N

> <csid>
2323020

> <Links>
|http://www.chemspider.com/Chemical-Structure.2323020.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1421|http://pubchem.ncbi.nlm.nih.gov/compound/3062316|http://www.drugbank.ca/drugs/DB01254| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=1N1|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/1N1|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5678|http://zinc15.docking.org/substances/ZINC21982951|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=X78UG0A0RN|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=13216

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
487.2

> <HBA>
9

> <HBD>
3

> <NRB>
7

> <TPSA>
106.5

> <LogP>
3.3

> <RoF>
0

> <Targets>
ABL1; SRC; EPHA2; LCK; YES1; KIT; PDGFRB; ABL2; FYN

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
0.000663724

> <r_epik_Ionization_Penalty>
  0.5179

> <r_epik_State_Penalty>
  0.1885

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
645

> <lig_pdbID>
'1N1'

> <pdbID>
2gqg 2y6o 2zva 3g5d 3k54 3lfa 3oct 3oht 3qlg 3sxr 4qms 4xey 4xli 5bvw 5h2u 5i9y 5owr 5vcv 6bsd 6fnm

> <Kinase families>
Tyr

> <indicationDB>
Dasatinib is an oral dual BCR/ABL and Src family tyrosine kinase inhibitor approved for use in patients with chronic myelogenous leukemia (CML). The main targets of Dasatinib, are BCRABL, SRC, Ephrins and GFR.

> <uniprotId>
P00519|P12931|P29317|P06239|P07947|P10721|P09619|P51692|P42684|P06241|Q06187|Q92570|P11274|P41240|P54756|P54760|P09769|P42685|P11142|P07948|Q9NYL2|Q16539|Q06203|P08684|P04798|P05177|Q16678|P20815|P31513|P08183|Q9UNQ0

> <BrandName>
Dasatinib;Sprycel

> <Melting point>
280-286 °C

> <Withdrawn>
|Study NCT00872976 in United States was Withdrawn during Phase 1 because Business Objectives Changed|Study NCT02680951 in nan was Withdrawn during Phase 1 because Withdrawn due to lack of participants|Study NCT02815059 in United States was Withdrawn during Phase 1 because Termination of Investigator Initiated Studies using Ibrutinib|Study NCT00324077 in United States was Withdrawn during Phase 1 because Insufficient Enrollment|Study NCT03414450 in United States was Withdrawn during Phase 1 because Withdrawal requested by D3|Study NCT03560908 in China was Withdrawn during Phase 1 because No enough eligable participants enrolled|Study NCT02129166 in nan was Withdrawn during Phase 1 because PI resigned|Study NCT02923986 in United States was Withdrawn during Phase 1/Phase 2 because No enrollment|Study NCT01826838 in nan was Withdrawn during Phase 1 because Lack of patients|Study NCT04439305 in United States was Withdrawn during Phase 2 because zero accrual|Study NCT00829647 in nan was Withdrawn during Phase 1/Phase 2 because Unable to enroll

> <FDA_approved>
Y

$$$$
Duvelisib
                    3D
 Structure written by MMmdl.
 47 51  0  0  1  0            999 V2000
   -0.3537   -0.9222   -1.7816 C   0  0  0  0  0  0
    0.0439   -0.1599   -0.4981 C   0  0  1  0  0  0
    1.5642   -0.0787   -0.2136 C   0  0  0  0  0  0
    2.4566   -0.1444   -1.2243 C   0  0  0  0  0  0
    3.8898   -0.0672   -0.9625 C   0  0  0  0  0  0
    4.7951   -0.0582   -2.0243 C   0  0  0  0  0  0
    6.1581    0.0506   -1.7735 C   0  0  0  0  0  0
    6.6153    0.1572   -0.4637 C   0  0  0  0  0  0
    5.7236    0.1490    0.6122 C   0  0  0  0  0  0
    4.3317    0.0246    0.3712 C   0  0  0  0  0  0
    3.3109   -0.0058    1.5188 C   0  0  0  0  0  0
    3.6282   -0.0695    2.7113 O   0  0  0  0  0  0
    1.9842    0.0469    1.1205 N   0  0  0  0  0  0
    1.0199    0.2264    2.1438 C   0  0  0  0  0  0
    0.6362    1.5213    2.5122 C   0  0  0  0  0  0
   -0.3259    1.7008    3.5020 C   0  0  0  0  0  0
   -0.8924    0.5900    4.1244 C   0  0  0  0  0  0
   -0.5036   -0.7010    3.7712 C   0  0  0  0  0  0
    0.4568   -0.8865    2.7805 C   0  0  0  0  0  0
    6.4353    0.3082    2.1868 Cl  0  0  0  0  0  0
   -0.6151    1.1461   -0.4722 N   0  0  0  0  0  0
   -1.8588    1.3705    0.1441 C   0  0  0  0  0  0
   -2.4027    2.6695    0.1662 C   0  0  0  0  0  0
   -3.6387    2.8196    0.8420 C   0  0  0  0  0  0
   -3.9373    4.1550    0.7243 N   0  0  0  0  0  0
   -2.9041    4.7203    0.0120 C   0  0  0  0  0  0
   -1.9684    3.8711   -0.3386 N   0  0  0  0  0  0
   -4.3252    1.8478    1.4506 N   0  0  0  0  0  0
   -3.7063    0.6390    1.3629 C   0  0  0  0  0  0
   -2.5270    0.3474    0.7526 N   0  0  0  0  0  0
    0.1248   -1.9013   -1.8241 H   0  0  0  0  0  0
   -0.0835   -0.3753   -2.6857 H   0  0  0  0  0  0
   -1.4308   -1.0909   -1.8182 H   0  0  0  0  0  0
   -0.3681   -0.7844    0.2927 H   0  0  0  0  0  0
    2.1219   -0.2413   -2.2462 H   0  0  0  0  0  0
    4.4461   -0.1284   -3.0446 H   0  0  0  0  0  0
    6.8603    0.0602   -2.5940 H   0  0  0  0  0  0
    7.6765    0.2505   -0.2840 H   0  0  0  0  0  0
    1.0703    2.3822    2.0244 H   0  0  0  0  0  0
   -0.6346    2.6969    3.7827 H   0  0  0  0  0  0
   -1.6407    0.7312    4.8901 H   0  0  0  0  0  0
   -0.9474   -1.5545    4.2619 H   0  0  0  0  0  0
    0.7554   -1.8872    2.5028 H   0  0  0  0  0  0
   -0.2069    1.8933   -1.0151 H   0  0  0  0  0  0
   -4.7352    4.6665    1.0714 H   0  0  0  0  0  0
   -2.9210    5.7784   -0.2060 H   0  0  0  0  0  0
   -4.2114   -0.1890    1.8387 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 31  1  0  0  0
  1 32  1  0  0  0
  1 33  1  0  0  0
  2  3  1  0  0  0
  2 21  1  0  0  0
  2 34  1  0  0  0
  3  4  2  0  0  0
  3 13  1  0  0  0
  4  5  1  0  0  0
  4 35  1  0  0  0
  5  6  1  0  0  0
  5 10  2  0  0  0
  6  7  2  0  0  0
  6 36  1  0  0  0
  7  8  1  0  0  0
  7 37  1  0  0  0
  8  9  2  0  0  0
  8 38  1  0  0  0
  9 10  1  0  0  0
  9 20  1  0  0  0
 10 11  1  0  0  0
 11 12  2  0  0  0
 11 13  1  0  0  0
 13 14  1  0  0  0
 14 15  1  0  0  0
 14 19  2  0  0  0
 15 16  2  0  0  0
 15 39  1  0  0  0
 16 17  1  0  0  0
 16 40  1  0  0  0
 17 18  2  0  0  0
 17 41  1  0  0  0
 18 19  1  0  0  0
 18 42  1  0  0  0
 19 43  1  0  0  0
 21 22  1  0  0  0
 21 44  1  0  0  0
 22 23  1  0  0  0
 22 30  2  0  0  0
 23 24  2  0  0  0
 23 27  1  0  0  0
 24 25  1  0  0  0
 24 28  1  0  0  0
 25 26  1  0  0  0
 25 45  1  0  0  0
 26 27  2  0  0  0
 26 46  1  0  0  0
 28 29  2  0  0  0
 29 30  1  0  0  0
 29 47  1  0  0  0
M  END
> <s_m_entry_id>
648

> <Applicants>
Infinity Pharmacueticals

> <CHEMBL_ID>
CHEMBL3039502

> <Canonical_Smiles>
Clc1c2c(C=C(N(C2=O)c2ccccc2)[C@@H](Nc2ncnc3[nH]cnc23)C)ccc1

> <Chirality>
Single Stereoisomer

> <First_Approval>
2018

> <Phase>
4

> <SC_Patent>
US-8193182-B2

> <Synonyms>
COPIKTRA | DUVELISIB | INK-1147 | INK-1197 | IPI-145

> <Indications>
On october 27, 2018, the FDA approved duvelisib to treat relapsed or refractory chronic lymphocytic leukemia, small lymphocytic lymphoma and follicular lymphoma

> <Type>
nan

> <targets_id>
O00329|P48736

> <inchi>
InChI=1S/C22H17ClN6O/c1-13(28-21-19-20(25-11-24-19)26-12-27-21)17-10-14-6-5-9-16(23)18(14)22(30)29(17)15-7-3-2-4-8-15/h2-13H,1H3,(H2,24,25,26,27,28)/t13-/m0/s1

> <stdInchikey>
SJVQHLPISAIATJ-ZDUSSCGKSA-N

> <csid>
28637766

> <Links>
|http://www.chemspider.com/Chemical-Structure.28637766.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3039502|http://pubchem.ncbi.nlm.nih.gov/compound/50905713|http://www.drugbank.ca/drugs/DB11952|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7795|http://zinc15.docking.org/substances/ZINC000088346058|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=610V23S0JI|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50193013

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
416.1

> <HBA>
6

> <HBD>
2

> <NRB>
4

> <TPSA>
88.5

> <LogP>
4.5

> <RoF>
0

> <Targets>
PIK3CD; PIK3CG

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
0.955582

> <r_epik_Ionization_Penalty>
  0.0023

> <r_epik_State_Penalty>
  0.0207

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
648

> <Kinase families>
Atypical

> <indicationDB>
Duvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma can produce a broad adaptative and innate immune cell inhibitory activity. All the work around duvelisib showed that this agent is a potent inhibitor of both forms.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Winkler DG, Faia KL, DiNitto JP, Ali JA, White KF, Brophy EE, Pink MM, Proctor JL, Lussier J, Martin CM, Hoyt JG, Tillotson B, Murphy EL, Lim AR, Thomas BD, Macdougall JR, Ren P, Liu Y, Li LS, Jessen KA, Fritz CC, Dunbar JL, Porter JR, Rommel C, Palombella VJ, Changelian PS, Kutok JL: PI3K-delta and PI3K-gamma inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. Chem Biol. 2013 Nov 21;20(11):1364-74. doi: 10.1016/j.chembiol.2013.09.017. Epub 2013 Nov 7. (PubMed ID 24211136)" href="#reference-A39025">1</a></sup> Duvelisib was developed by Verastem, Inc and FDA approved on September 24, 2018.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA news" href="#reference-L4585">7</a></sup>

> <uniprotId>
P48736|O00329|P08684

> <BrandName>
Copiktra

> <Melting point>
>190 ºC

> <Withdrawn>
|Study NCT03370185 in United States was Withdrawn during Phase 2 because Reassessing corporate priorities|Study NCT02640833 in United States was Withdrawn during Phase 1 because Study Stopped

> <FDA_approved>
Y

$$$$
Encorafenib
                    3D
 Structure written by MMmdl.
 63 65  0  0  1  0            999 V2000
   -4.1344    1.7018    2.1872 C   0  0  0  0  0  0
   -4.4418    2.7970    1.1486 C   0  0  1  0  0  0
   -4.1251    2.3622   -0.3049 C   0  0  0  0  0  0
   -2.6986    2.1881   -0.5674 N   0  0  0  0  0  0
   -2.0570    0.9470   -0.4456 C   0  0  0  0  0  0
   -2.7854   -0.2032   -0.3910 N   0  0  0  0  0  0
   -2.0894   -1.3602   -0.2441 C   0  0  0  0  0  0
   -0.6979   -1.3893   -0.1359 C   0  0  0  0  0  0
   -0.0329   -0.1602   -0.1951 C   0  0  0  0  0  0
   -0.7049    1.0090   -0.3684 N   0  0  0  0  0  0
    1.4449   -0.0465   -0.0249 C   0  0  0  0  0  0
    2.3960   -0.9622   -0.4484 C   0  0  0  0  0  0
    3.6163   -0.4417   -0.1134 N   0  0  0  0  0  0
    3.5010    0.7369    0.5132 N   0  0  0  0  0  0
    2.2078    0.9821    0.5839 C   0  0  0  0  0  0
    1.7165    2.2233    1.2613 C   0  0  0  0  0  0
    0.6883    2.1190    2.2048 C   0  0  0  0  0  0
    0.1844    3.2551    2.8335 C   0  0  0  0  0  0
    0.7166    4.5082    2.5373 C   0  0  0  0  0  0
    1.7525    4.6346    1.6041 C   0  0  0  0  0  0
    2.2492    3.4886    0.9682 C   0  0  0  0  0  0
    3.2404    3.6088    0.0501 F   0  0  0  0  0  0
    2.3105    5.8825    1.2880 N   0  0  0  0  0  0
    2.3907    7.2195    2.4504 S   0  0  0  0  0  0
    1.0497    7.8097    2.5190 O   0  0  0  0  0  0
    3.0347    6.6961    3.6598 O   0  0  0  0  0  0
    3.5581    8.4246    1.5925 C   0  0  0  0  0  0
   -1.1044    3.1103    3.9721 Cl  0  0  0  0  0  0
    4.9368   -1.0254   -0.3726 C   0  0  0  0  0  0
    5.6682   -1.3231    0.9520 C   0  0  0  0  0  0
    5.7584   -0.1086   -1.3013 C   0  0  0  0  0  0
   -5.8284    3.2458    1.2928 N   0  0  0  0  0  0
   -6.2869    4.4659    0.8161 C   0  0  0  0  0  0
   -5.6084    5.3298    0.2545 O   0  0  0  0  0  0
   -7.6076    4.5621    1.0648 O   0  0  0  0  0  0
   -8.3381    5.7151    0.6712 C   0  0  0  0  0  0
   -3.0818    1.4186    2.1716 H   0  0  0  0  0  0
   -4.7218    0.8013    2.0041 H   0  0  0  0  0  0
   -4.3556    2.0425    3.1995 H   0  0  0  0  0  0
   -3.7984    3.6431    1.4045 H   0  0  0  0  0  0
   -4.6881    1.4647   -0.5646 H   0  0  0  0  0  0
   -4.4709    3.1207   -1.0078 H   0  0  0  0  0  0
   -2.1149    3.0102   -0.5158 H   0  0  0  0  0  0
   -2.6675   -2.2716   -0.2007 H   0  0  0  0  0  0
   -0.1666   -2.3192    0.0032 H   0  0  0  0  0  0
    2.3146   -1.9080   -0.9636 H   0  0  0  0  0  0
    0.2665    1.1528    2.4422 H   0  0  0  0  0  0
    0.3117    5.3764    3.0351 H   0  0  0  0  0  0
    2.9786    5.9008    0.5315 H   0  0  0  0  0  0
    3.6878    9.3009    2.2268 H   0  0  0  0  0  0
    3.1252    8.7172    0.6363 H   0  0  0  0  0  0
    4.5188    7.9352    1.4336 H   0  0  0  0  0  0
    4.7755   -1.9729   -0.8898 H   0  0  0  0  0  0
    6.6173   -1.8274    0.7680 H   0  0  0  0  0  0
    5.0746   -1.9723    1.5970 H   0  0  0  0  0  0
    5.8856   -0.4106    1.5090 H   0  0  0  0  0  0
    6.7138   -0.5672   -1.5582 H   0  0  0  0  0  0
    5.9728    0.8539   -0.8346 H   0  0  0  0  0  0
    5.2295    0.0863   -2.2352 H   0  0  0  0  0  0
   -6.4966    2.6081    1.7002 H   0  0  0  0  0  0
   -9.3807    5.6105    0.9717 H   0  0  0  0  0  0
   -8.3100    5.8465   -0.4116 H   0  0  0  0  0  0
   -7.9386    6.6142    1.1429 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 37  1  0  0  0
  1 38  1  0  0  0
  1 39  1  0  0  0
  2  3  1  0  0  0
  2 32  1  0  0  0
  2 40  1  0  0  0
  3  4  1  0  0  0
  3 41  1  0  0  0
  3 42  1  0  0  0
  4  5  1  0  0  0
  4 43  1  0  0  0
  5  6  1  0  0  0
  5 10  2  0  0  0
  6  7  2  0  0  0
  7  8  1  0  0  0
  7 44  1  0  0  0
  8  9  2  0  0  0
  8 45  1  0  0  0
  9 10  1  0  0  0
  9 11  1  0  0  0
 11 12  2  0  0  0
 11 15  1  0  0  0
 12 13  1  0  0  0
 12 46  1  0  0  0
 13 14  1  0  0  0
 13 29  1  0  0  0
 14 15  2  0  0  0
 15 16  1  0  0  0
 16 17  1  0  0  0
 16 21  2  0  0  0
 17 18  2  0  0  0
 17 47  1  0  0  0
 18 19  1  0  0  0
 18 28  1  0  0  0
 19 20  2  0  0  0
 19 48  1  0  0  0
 20 21  1  0  0  0
 20 23  1  0  0  0
 21 22  1  0  0  0
 23 24  1  0  0  0
 23 49  1  0  0  0
 24 25  2  0  0  0
 24 26  2  0  0  0
 24 27  1  0  0  0
 27 50  1  0  0  0
 27 51  1  0  0  0
 27 52  1  0  0  0
 29 30  1  0  0  0
 29 31  1  0  0  0
 29 53  1  0  0  0
 30 54  1  0  0  0
 30 55  1  0  0  0
 30 56  1  0  0  0
 31 57  1  0  0  0
 31 58  1  0  0  0
 31 59  1  0  0  0
 32 33  1  0  0  0
 32 60  1  0  0  0
 33 34  2  0  0  0
 33 35  1  0  0  0
 35 36  1  0  0  0
 36 61  1  0  0  0
 36 62  1  0  0  0
 36 63  1  0  0  0
M  END
> <s_m_entry_id>
650

> <Applicants>
Novartis

> <CHEMBL_ID>
CHEMBL3301612

> <Canonical_Smiles>
Clc1cc(-c2nn(cc2-c2nc(ncc2)NC[C@@H](NC(OC)=O)C)C(C)C)c(F)c(NS(=O)(=O)C)c1

> <Chirality>
Single Stereoisomer

> <First_Approval>
2018

> <Phase>
4

> <SC_Patent>
US-8501758-B2

> <Synonyms>
BRAFTOVI | ENCORAFENIB | LGX-818 | NVP-LGX-818-NXA | NVP-LGX818 | NVP-LGX818-NXA

> <Indications>
On June 27, 2018, the Food and Drug Administration approved encorafenib and binimetinib in combination patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.

> <Type>
nan

> <targets_id>
P15056

> <inchi>
InChI=1S/C22H27ClFN7O4S/c1-12(2)31-11-16(17-6-7-25-21(28-17)26-10-13(3)27-22(32)35-4)20(29-31)15-8-14(23)9-18(19(15)24)30-36(5,33)34/h6-9,11-13,30H,10H2,1-5H3,(H,27,32)(H,25,26,28)/t13-/m0/s1

> <stdInchikey>
CMJCXYNUCSMDBY-ZDUSSCGKSA-N

> <csid>
28536139

> <Links>
|http://www.chemspider.com/Chemical-Structure.28536139.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3301612|http://pubchem.ncbi.nlm.nih.gov/compound/50922675|http://www.drugbank.ca/drugs/DB11718|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7908|http://zinc15.docking.org/substances/ZINC000068249103|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=8L7891MRB6|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=221688

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
539.2

> <HBA>
9

> <HBD>
3

> <NRB>
9

> <TPSA>
140.1

> <LogP>
3.9

> <RoF>
1

> <Targets>
BRAF

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.3904

> <r_epik_State_Penalty>
  0.3885

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
650

> <Kinase families>
TKL

> <indicationDB>
Encorafenib, also known as <em>BRAFTOVI</em>, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations <sup class="text-reference-group"><a class="reference-popover-link" data-content="Official drug label" href="#label-reference">Label</a></sup>. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and secretion. Mutations in this gene, most frequently the V600E mutation, are the most commonly identified cancer-causing mutations in melanoma, and have been isolated in various other cancers as well, including non-Hodgkin lymphoma, colorectal cancer, thyroid carcinoma, non-small cell lung carcinoma, hairy cell leukemia and adenocarcinoma of the lung <sup class="text-reference-group"><a class="reference-popover-link" data-content="BRAF B-Raf proto-oncogene, serine/threonine kinase [ Homo sapiens (human) ]" href="#reference-L3344">6</a></sup>.</p><p>On June 27, 2018, the Food and Drug Administration approved encorafenib and <a href="https://go.drugbank.com/drugs/DB11967">Binimetinib</a> (BRAFTOVI and MEKTOVI, Array BioPharma Inc.) in combination for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test <sup class="text-reference-group"><a class="reference-popover-link" data-content="Official drug label" href="#label-reference">Label</a></sup>.

> <uniprotId>
P15056|P24385|P08684|P33261|P10635

> <BrandName>
Braftovi

> <FDA_approved>
Y

$$$$
Entrectinib
                    3D
 Structure written by MMmdl.
 76 81  0  0  1  0            999 V2000
   -5.2112    0.2216   -4.5735 C   0  0  0  0  0  0
   -5.4354    0.2027   -3.0491 N   0  3  0  0  0  0
   -4.8594    1.4857   -2.4003 C   0  0  0  0  0  0
   -4.9191    1.3530   -0.8610 C   0  0  0  0  0  0
   -4.1631    0.1636   -0.4353 N   0  0  0  0  0  0
   -4.9350   -1.0037   -0.8930 C   0  0  0  0  0  0
   -4.8699   -1.1010   -2.4340 C   0  0  0  0  0  0
   -2.7836    0.1547   -0.1845 C   0  0  0  0  0  0
   -2.0782    1.3418    0.0530 C   0  0  0  0  0  0
   -0.7116    1.3326    0.3104 C   0  0  0  0  0  0
    0.0119    0.1341    0.3437 C   0  0  0  0  0  0
   -0.6714   -1.0818    0.1069 C   0  0  0  0  0  0
   -2.0525   -1.0435   -0.1500 C   0  0  0  0  0  0
    0.0338   -2.3076    0.1040 N   0  0  0  0  0  0
   -0.6024   -3.6238    0.1259 C   0  0  0  0  0  0
   -1.1678   -3.9174    1.5318 C   0  0  0  0  0  0
   -1.6758   -5.3701    1.6150 C   0  0  0  0  0  0
   -0.6451   -6.2865    1.2424 O   0  0  0  0  0  0
   -0.1408   -6.1035   -0.0817 C   0  0  0  0  0  0
    0.4460   -4.6879   -0.2484 C   0  0  0  0  0  0
    1.4938    0.1877    0.6550 C   0  0  0  0  0  0
    1.9856   -0.5931    1.4734 O   0  0  0  0  0  0
    2.1881    1.1242   -0.0314 N   0  0  0  0  0  0
    3.5522    1.3633    0.0623 C   0  0  0  0  0  0
    4.1439    2.6126   -0.3069 C   0  0  0  0  0  0
    3.6876    3.8427   -0.8071 C   0  0  0  0  0  0
    4.6157    4.8603   -1.0494 C   0  0  0  0  0  0
    5.9739    4.6588   -0.7859 C   0  0  0  0  0  0
    6.4641    3.4494   -0.2908 C   0  0  0  0  0  0
    5.5279    2.4377   -0.0589 C   0  0  0  0  0  0
    5.6535    1.1480    0.4156 N   0  0  0  0  0  0
    4.4680    0.5176    0.4816 N   0  0  0  0  0  0
    4.1421    6.2083   -1.5795 C   0  0  0  0  0  0
    4.6512    6.5363   -2.9772 C   0  0  0  0  0  0
    5.5487    7.5914   -3.1746 C   0  0  0  0  0  0
    6.0026    7.8980   -4.4580 C   0  0  0  0  0  0
    5.5588    7.1544   -5.5516 C   0  0  0  0  0  0
    4.6593    6.1052   -5.3623 C   0  0  0  0  0  0
    4.2037    5.7993   -4.0794 C   0  0  0  0  0  0
    4.2276    5.3853   -6.4223 F   0  0  0  0  0  0
    6.8722    8.9170   -4.6415 F   0  0  0  0  0  0
   -4.1358    0.2203   -4.7590 H   0  0  0  0  0  0
   -5.6845    1.1266   -4.9567 H   0  0  0  0  0  0
   -5.6907   -0.6696   -4.9806 H   0  0  0  0  0  0
   -3.8348    1.6084   -2.7571 H   0  0  0  0  0  0
   -5.4672    2.3157   -2.7628 H   0  0  0  0  0  0
   -4.5692    2.2598   -0.3720 H   0  0  0  0  0  0
   -5.9612    1.2689   -0.5459 H   0  0  0  0  0  0
   -4.6026   -1.9245   -0.4170 H   0  0  0  0  0  0
   -5.9775   -0.9109   -0.5819 H   0  0  0  0  0  0
   -5.4832   -1.9170   -2.8186 H   0  0  0  0  0  0
   -3.8452   -1.2222   -2.7914 H   0  0  0  0  0  0
   -2.5686    2.3019    0.0542 H   0  0  0  0  0  0
   -0.2214    2.2777    0.4994 H   0  0  0  0  0  0
   -2.5660   -1.9703   -0.3340 H   0  0  0  0  0  0
    0.9776   -2.2694    0.4633 H   0  0  0  0  0  0
   -1.4034   -3.6585   -0.6125 H   0  0  0  0  0  0
   -0.3954   -3.7698    2.2891 H   0  0  0  0  0  0
   -1.9789   -3.2309    1.7773 H   0  0  0  0  0  0
   -1.9968   -5.5976    2.6319 H   0  0  0  0  0  0
   -2.5476   -5.5124    0.9737 H   0  0  0  0  0  0
    0.6283   -6.8528   -0.2708 H   0  0  0  0  0  0
   -0.9354   -6.2817   -0.8085 H   0  0  0  0  0  0
    0.7856   -4.5469   -1.2756 H   0  0  0  0  0  0
    1.3280   -4.5957    0.3888 H   0  0  0  0  0  0
    1.6623    1.7767   -0.5935 H   0  0  0  0  0  0
    2.6364    3.9981   -1.0019 H   0  0  0  0  0  0
    6.6735    5.4607   -0.9737 H   0  0  0  0  0  0
    7.5180    3.3116   -0.0980 H   0  0  0  0  0  0
    6.4983    0.6717    0.6971 H   0  0  0  0  0  0
    3.0515    6.2485   -1.5949 H   0  0  0  0  0  0
    4.4511    6.9817   -0.8740 H   0  0  0  0  0  0
    5.8984    8.1749   -2.3351 H   0  0  0  0  0  0
    5.9108    7.3916   -6.5447 H   0  0  0  0  0  0
    3.5059    4.9860   -3.9413 H   0  0  0  0  0  0
   -6.4319    0.2047   -2.8808 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 42  1  0  0  0
  1 43  1  0  0  0
  1 44  1  0  0  0
  2  3  1  0  0  0
  2  7  1  0  0  0
  2 76  1  0  0  0
  3  4  1  0  0  0
  3 45  1  0  0  0
  3 46  1  0  0  0
  4  5  1  0  0  0
  4 47  1  0  0  0
  4 48  1  0  0  0
  5  6  1  0  0  0
  5  8  1  0  0  0
  6  7  1  0  0  0
  6 49  1  0  0  0
  6 50  1  0  0  0
  7 51  1  0  0  0
  7 52  1  0  0  0
  8  9  1  0  0  0
  8 13  2  0  0  0
  9 10  2  0  0  0
  9 53  1  0  0  0
 10 11  1  0  0  0
 10 54  1  0  0  0
 11 12  2  0  0  0
 11 21  1  0  0  0
 12 13  1  0  0  0
 12 14  1  0  0  0
 13 55  1  0  0  0
 14 15  1  0  0  0
 14 56  1  0  0  0
 15 16  1  0  0  0
 15 20  1  0  0  0
 15 57  1  0  0  0
 16 17  1  0  0  0
 16 58  1  0  0  0
 16 59  1  0  0  0
 17 18  1  0  0  0
 17 60  1  0  0  0
 17 61  1  0  0  0
 18 19  1  0  0  0
 19 20  1  0  0  0
 19 62  1  0  0  0
 19 63  1  0  0  0
 20 64  1  0  0  0
 20 65  1  0  0  0
 21 22  2  0  0  0
 21 23  1  0  0  0
 23 24  1  0  0  0
 23 66  1  0  0  0
 24 25  1  0  0  0
 24 32  2  0  0  0
 25 26  1  0  0  0
 25 30  2  0  0  0
 26 27  2  0  0  0
 26 67  1  0  0  0
 27 28  1  0  0  0
 27 33  1  0  0  0
 28 29  2  0  0  0
 28 68  1  0  0  0
 29 30  1  0  0  0
 29 69  1  0  0  0
 30 31  1  0  0  0
 31 32  1  0  0  0
 31 70  1  0  0  0
 33 34  1  0  0  0
 33 71  1  0  0  0
 33 72  1  0  0  0
 34 35  1  0  0  0
 34 39  2  0  0  0
 35 36  2  0  0  0
 35 73  1  0  0  0
 36 37  1  0  0  0
 36 41  1  0  0  0
 37 38  2  0  0  0
 37 74  1  0  0  0
 38 39  1  0  0  0
 38 40  1  0  0  0
 39 75  1  0  0  0
M  CHG  1   2   1
M  END
> <s_m_entry_id>
652

> <Applicants>
Ignyta

> <CHEMBL_ID>
CHEMBL1983268

> <Canonical_Smiles>
Fc1cc(cc(F)c1)Cc1cc2c([nH]nc2NC(=O)c2ccc(N3CCN(CC3)C)cc2NC2CCOCC2)cc1

> <Chirality>
Achiral Molecule

> <First_Approval>
2019

> <Phase>
4

> <SC_Patent>
US-8299057-B2

> <Synonyms>
ENTRECTINIB | NMS-E628 | ROZLYTREK | RXDX-101

> <Indications>
On august 2019, FDA approved entrectinib to treat adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive and to treat adult and pediatric patients 12 years of age and older with solid tumors

> <Type>
1

> <targets_id>
P04629|Q16620|Q16288|P08922|Q9UM73

> <inchi>
InChI=1S/C31H34F2N6O2/c1-38-8-10-39(11-9-38)25-3-4-26(29(19-25)34-24-6-12-41-13-7-24)31(40)35-30-27-17-20(2-5-28(27)36-37-30)14-21-15-22(32)18-23(33)16-21/h2-5,15-19,24,34H,6-14H2,1H3,(H2,35,36,37,40)

> <stdInchikey>
HAYYBYPASCDWEQ-UHFFFAOYSA-N

> <csid>
24808589

> <Links>
|http://www.chemspider.com/Chemical-Structure.24808589.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1983268|http://pubchem.ncbi.nlm.nih.gov/compound/25141092|http://www.drugbank.ca/drugs/DB11986| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=YMX|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/YMX|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8290|http://zinc15.docking.org/substances/ZINC000043204146|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=L5ORF0AN1I|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=158154

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
560.3

> <HBA>
6

> <HBD>
3

> <NRB>
7

> <TPSA>
85.5

> <LogP>
5

> <RoF>
2

> <Targets>
NTRK1; NTRK2; NTRK3; ROS1; ALK

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
0.980392

> <r_epik_Ionization_Penalty>
  0.0648

> <r_epik_State_Penalty>
  0.0647

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
652

> <lig_pdbID>
'YMX'

> <pdbID>
5fto 5kvt

> <Kinase families>
Tyr

> <indicationDB>
Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA Label: Rozlytrek" href="#reference-L8081">7</a></sup> It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positive solid tumors.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA Announcement: Entrectinib Approval" href="#reference-L8207">9</a></sup> Entrectinib&#39;s approved use is meant as a last line of therapy due to its accelerated approval based on early trial data. This therapy offers benefit over similar ALK inhibitors such as <a href="https://go.drugbank.com/drugs/DB11363">alectinib</a>, <a href="https://go.drugbank.com/drugs/DB09063">ceritinib</a>, and <a href="https://go.drugbank.com/drugs/DB12130">lorlatinib</a> due to a wider range of targets.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Pacenta HL, Macy ME: Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma. Drug Des Devel Ther. 2018 Oct 23;12:3549-3561. doi: 10.2147/DDDT.S147384. eCollection 2018. (PubMed ID 30425456)" href="#reference-A183929">6</a></sup>

> <uniprotId>
P04629|Q16620|Q16288|P08922|O60674|Q07912|P08684|P08183

> <BrandName>
Rozlytrek

> <FDA_approved>
Y

$$$$
Erdafitinib
                    3D
 Structure written by MMmdl.
 64 67  0  0  1  0            999 V2000
   -2.9909    3.4044    0.3026 C   0  0  0  0  0  0
   -2.7237    2.6192   -0.9951 C   0  0  0  0  0  0
   -4.0145    2.2007   -1.7158 C   0  0  0  0  0  0
   -1.9192    1.3417   -0.6886 N   0  3  0  0  0  0
   -0.4718    1.5620   -0.2190 C   0  0  0  0  0  0
    0.2298    0.1923   -0.1069 C   0  0  0  0  0  0
    1.6128    0.2118    0.4095 N   0  0  0  0  0  0
    2.4130    1.2310   -0.1464 C   0  0  0  0  0  0
    3.0473    1.0408   -1.3776 C   0  0  0  0  0  0
    3.8445    2.0378   -1.9353 C   0  0  0  0  0  0
    4.0258    3.2618   -1.2509 C   0  0  0  0  0  0
    3.3865    3.4590    0.0116 C   0  0  0  0  0  0
    2.5804    2.4302    0.5504 C   0  0  0  0  0  0
    3.5468    4.6246    0.7002 N   0  0  0  0  0  0
    4.3314    5.5865    0.1435 C   0  0  0  0  0  0
    4.9509    5.3877   -1.0935 C   0  0  0  0  0  0
    4.8065    4.2367   -1.7975 N   0  0  0  0  0  0
    4.4979    6.8425    0.9324 C   0  0  0  0  0  0
    5.1365    8.0367    0.5505 C   0  0  0  0  0  0
    5.1192    8.9649    1.4804 N   0  0  0  0  0  0
    4.4626    8.4022    2.4998 N   0  0  0  0  0  0
    4.0649    7.1209    2.2234 C   0  0  0  0  0  0
    4.2620    9.1582    3.7230 C   0  0  0  0  0  0
    2.1782   -1.0102    0.8704 C   0  0  0  0  0  0
    1.5067   -2.2428    0.7953 C   0  0  0  0  0  0
    2.0796   -3.4229    1.2698 C   0  0  0  0  0  0
    3.3601   -3.3715    1.8383 C   0  0  0  0  0  0
    4.0592   -2.1698    1.9327 C   0  0  0  0  0  0
    3.4577   -0.9988    1.4477 C   0  0  0  0  0  0
    5.3133   -2.2251    2.5101 O   0  0  0  0  0  0
    6.0823   -1.0321    2.6192 C   0  0  0  0  0  0
    1.3264   -4.5740    1.1414 O   0  0  0  0  0  0
    1.8589   -5.8073    1.6132 C   0  0  0  0  0  0
   -3.6066    4.2824    0.1039 H   0  0  0  0  0  0
   -2.0692    3.7632    0.7603 H   0  0  0  0  0  0
   -3.5162    2.7963    1.0403 H   0  0  0  0  0  0
   -2.0868    3.1864   -1.6763 H   0  0  0  0  0  0
   -4.6019    3.0739   -2.0019 H   0  0  0  0  0  0
   -4.6436    1.5725   -1.0835 H   0  0  0  0  0  0
   -3.7990    1.6427   -2.6280 H   0  0  0  0  0  0
   -2.4140    0.8005    0.0064 H   0  0  0  0  0  0
   -0.0199    2.2127   -0.9694 H   0  0  0  0  0  0
   -0.5388    2.0717    0.7423 H   0  0  0  0  0  0
   -0.3826   -0.4315    0.5453 H   0  0  0  0  0  0
    0.2373   -0.2932   -1.0847 H   0  0  0  0  0  0
    2.9210    0.1093   -1.9111 H   0  0  0  0  0  0
    4.3280    1.8806   -2.8888 H   0  0  0  0  0  0
    2.0993    2.5812    1.5068 H   0  0  0  0  0  0
    5.5779    6.1452   -1.5400 H   0  0  0  0  0  0
    5.6108    8.2216   -0.4022 H   0  0  0  0  0  0
    3.5252    6.5336    2.9518 H   0  0  0  0  0  0
    3.6653    8.5771    4.4270 H   0  0  0  0  0  0
    3.7401   10.0889    3.4967 H   0  0  0  0  0  0
    5.2295    9.3819    4.1742 H   0  0  0  0  0  0
    0.5260   -2.3193    0.3520 H   0  0  0  0  0  0
    3.8329   -4.2654    2.2163 H   0  0  0  0  0  0
    3.9852   -0.0604    1.5259 H   0  0  0  0  0  0
    7.0390   -1.2635    3.0871 H   0  0  0  0  0  0
    5.5826   -0.2890    3.2424 H   0  0  0  0  0  0
    6.2910   -0.5983    1.6400 H   0  0  0  0  0  0
    1.1356   -6.6030    1.4350 H   0  0  0  0  0  0
    2.0551   -5.7744    2.6860 H   0  0  0  0  0  0
    2.7776   -6.0740    1.0884 H   0  0  0  0  0  0
   -1.8825    0.7914   -1.5349 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 34  1  0  0  0
  1 35  1  0  0  0
  1 36  1  0  0  0
  2  3  1  0  0  0
  2  4  1  0  0  0
  2 37  1  0  0  0
  3 38  1  0  0  0
  3 39  1  0  0  0
  3 40  1  0  0  0
  4  5  1  0  0  0
  4 41  1  0  0  0
  4 64  1  0  0  0
  5  6  1  0  0  0
  5 42  1  0  0  0
  5 43  1  0  0  0
  6  7  1  0  0  0
  6 44  1  0  0  0
  6 45  1  0  0  0
  7  8  1  0  0  0
  7 24  1  0  0  0
  8  9  1  0  0  0
  8 13  2  0  0  0
  9 10  2  0  0  0
  9 46  1  0  0  0
 10 11  1  0  0  0
 10 47  1  0  0  0
 11 12  1  0  0  0
 11 17  2  0  0  0
 12 13  1  0  0  0
 12 14  2  0  0  0
 13 48  1  0  0  0
 14 15  1  0  0  0
 15 16  2  0  0  0
 15 18  1  0  0  0
 16 17  1  0  0  0
 16 49  1  0  0  0
 18 19  1  0  0  0
 18 22  2  0  0  0
 19 20  2  0  0  0
 19 50  1  0  0  0
 20 21  1  0  0  0
 21 22  1  0  0  0
 21 23  1  0  0  0
 22 51  1  0  0  0
 23 52  1  0  0  0
 23 53  1  0  0  0
 23 54  1  0  0  0
 24 25  1  0  0  0
 24 29  2  0  0  0
 25 26  2  0  0  0
 25 55  1  0  0  0
 26 27  1  0  0  0
 26 32  1  0  0  0
 27 28  2  0  0  0
 27 56  1  0  0  0
 28 29  1  0  0  0
 28 30  1  0  0  0
 29 57  1  0  0  0
 30 31  1  0  0  0
 31 58  1  0  0  0
 31 59  1  0  0  0
 31 60  1  0  0  0
 32 33  1  0  0  0
 33 61  1  0  0  0
 33 62  1  0  0  0
 33 63  1  0  0  0
M  CHG  1   4   1
M  END
> <s_m_entry_id>
655

> <Applicants>
Janssen

> <CHEMBL_ID>
CHEMBL3545376

> <Canonical_Smiles>
O(C)c1cc(N(CCNC(C)C)c2cc3nc(cnc3cc2)-c2cn(nc2)C)cc(OC)c1

> <Chirality>
Achiral Molecule

> <First_Approval>
2019

> <Phase>
4

> <SC_Patent>
US-8895601-B2

> <Synonyms>
BALVERSA | ERDAFITINIB | JNJ-42756493

> <Indications>
On april 2019, FDA approved erdafitinib to treat adult patients with locally advanced or metastatic bladder cancer

> <Type>
1

> <targets_id>
P11362

> <inchi>
InChI=1S/C25H30N6O2/c1-17(2)26-8-9-31(20-10-21(32-4)13-22(11-20)33-5)19-6-7-23-24(12-19)29-25(15-27-23)18-14-28-30(3)16-18/h6-7,10-17,26H,8-9H2,1-5H3

> <stdInchikey>
OLAHOMJCDNXHFI-UHFFFAOYSA-N

> <csid>
35308353

> <Links>
|http://www.chemspider.com/Chemical-Structure.35308353.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3545376|http://pubchem.ncbi.nlm.nih.gov/compound/67462786|http://www.drugbank.ca/drugs/DB12147| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=5SF|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/5SF|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9039|http://zinc15.docking.org/substances/ZINC000168520308|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=890E37NHMV

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS

> <indicationG2P>
None

> <MW>
446.2

> <HBA>
8

> <HBD>
1

> <NRB>
9

> <TPSA>
77.3

> <LogP>
4.2

> <RoF>
0

> <Targets>
FGFR1

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0004

> <r_epik_State_Penalty>
  0.0002

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
655

> <lig_pdbID>
'5SF'

> <pdbID>
5ew8

> <Kinase families>
Tyr

> <indicationDB>
In early April of 2019, the US FDA approved Janssen Pharmaceutical Companies&#39; brand name Balversa (erdafitinib) as the first-ever fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for patients with locally advanced or metastatic urothelial carcinoma, with susceptible FGFR3 or FGFR2 genetic alterations, that has progressed during or following platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy <sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA grants accelerated approval to erdafitinib for metastatic urothelial carcinoma: Press Release" href="#reference-L5956">4</a>,<a class="reference-popover-link" data-content="First Targeted Therapy for Metastatic Bladder Cancer Receives FDA Approval" href="#reference-L5959">5</a></sup>. At the same time, the FDA also approved the therascreen FGFR RGQ RT-PCR Kit (Qiagen) for utilization as a companion diagnostic with erdafitinib for selecting patients for the indicated therapy <sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA grants accelerated approval to erdafitinib for metastatic urothelial carcinoma: Press Release" href="#reference-L5956">4</a>,<a class="reference-popover-link" data-content="First Targeted Therapy for Metastatic Bladder Cancer Receives FDA Approval" href="#reference-L5959">5</a></sup>.</p><p>Erdafitinib&#39;s innovation lies in the fact that it is the first personalized treatment targeting susceptible FGFR genetic alterations for patients with metastatic bladder cancer, which demonstrates the design of erdafitinib in developing more personalized and precision medicines with the capacity to target cancer treatment to a patient&#39;s specific genetic mutation <sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA grants accelerated approval to erdafitinib for metastatic urothelial carcinoma: Press Release" href="#reference-L5956">4</a>,<a class="reference-popover-link" data-content="First Targeted Therapy for Metastatic Bladder Cancer Receives FDA Approval" href="#reference-L5959">5</a></sup>. Considering urothelial cancer is statistically the fourth most common kind of cancer in the world <sup class="text-reference-group"><a class="reference-popover-link" data-content="NHS Evidence Briefing On: Erdafitinib capsules for metastatic or surgically unresectable urothelial cancer with FGFR gene aberrations – second line therapy" href="#reference-F4372">7</a></sup>, the introduction of erdafitinib offers a welcome new option in the ever-expanding therapeutic tool kit to treat such prevalent medical conditions.</p><p>Nevertheless, although erdafitinib was granted Breakthrough Therapy designation and Accelerated Approval from the FDA so as to allow the agency to focus on and expedite the approval process for a medication indicated for a serious condition that fills an unmet medical need using clinical trial data that is believed to predict a genuine clinical benefit for patients with the given condition, such designations mean further ongoing clinical trials are necessary to confirm the clinical benefit of erdafitinib going forward <sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA grants accelerated approval to erdafitinib for metastatic urothelial carcinoma: Press Release" href="#reference-L5956">4</a>,<a class="reference-popover-link" data-content="First Targeted Therapy for Metastatic Bladder Cancer Receives FDA Approval" href="#reference-L5959">5</a></sup>.

> <uniprotId>
P11362|P21802|P22607|P22455|O43519|P07333|P16234|P09619|P10721|P35968|P11712|P08684|P08183|O15244

> <BrandName>
Balversa

> <FDA_approved>
Y

$$$$
Dabrafenib
                    3D
 Structure written by MMmdl.
 55 58  0  0  1  0            999 V2000
   -2.2058   -3.4567    0.0620 C   0  0  0  0  0  0
   -2.9198   -2.0797    0.0794 C   0  0  0  0  0  0
   -3.8738   -2.0148   -1.1361 C   0  0  0  0  0  0
   -3.7469   -1.9704    1.3803 C   0  0  0  0  0  0
   -1.9207   -0.9130    0.0196 C   0  0  0  0  0  0
   -0.6189   -1.0574    0.0961 N   0  0  0  0  0  0
    0.0672    0.0713    0.0390 C   0  0  0  0  0  0
   -0.7155    1.2314   -0.0936 C   0  0  0  0  0  0
   -2.3929    0.7521   -0.1254 S   0  0  0  0  0  0
   -0.3548    2.6762   -0.2377 C   0  0  0  0  0  0
   -1.1926    3.7138    0.1944 C   0  0  0  0  0  0
   -0.7340    5.0199    0.0114 C   0  0  0  0  0  0
    0.4686    5.2988   -0.5549 N   0  0  0  0  0  0
    1.2117    4.2318   -0.9410 C   0  0  0  0  0  0
    0.8540    2.9304   -0.8102 N   0  0  0  0  0  0
    2.4489    4.4928   -1.5173 N   0  0  0  0  0  0
    1.5572   -0.0023    0.1402 C   0  0  0  0  0  0
    2.2138    0.7738    1.1014 C   0  0  0  0  0  0
    3.6001    0.7230    1.2249 C   0  0  0  0  0  0
    4.3448   -0.1077    0.3909 C   0  0  0  0  0  0
    3.7082   -0.8929   -0.5782 C   0  0  0  0  0  0
    2.3130   -0.8362   -0.6991 C   0  0  0  0  0  0
    1.6909   -1.5875   -1.6419 F   0  0  0  0  0  0
    4.4253   -1.7465   -1.4303 N   0  0  0  0  0  0
    6.0314   -2.3959   -1.0387 S   0  0  0  0  0  0
    6.9911   -1.2976   -1.1988 O   0  0  0  0  0  0
    5.8945   -3.0796    0.2524 O   0  0  0  0  0  0
    6.3877   -3.6062   -2.3185 C   0  0  0  0  0  0
    6.8217   -4.9030   -2.0019 C   0  0  0  0  0  0
    7.0842   -5.8197   -3.0210 C   0  0  0  0  0  0
    6.9252   -5.4525   -4.3559 C   0  0  0  0  0  0
    6.5076   -4.1623   -4.6761 C   0  0  0  0  0  0
    6.2416   -3.2396   -3.6640 C   0  0  0  0  0  0
    5.8472   -1.9904   -4.0039 F   0  0  0  0  0  0
    7.0005   -5.2935   -0.7193 F   0  0  0  0  0  0
   -2.9199   -4.2808    0.0951 H   0  0  0  0  0  0
   -1.5385   -3.5762    0.9169 H   0  0  0  0  0  0
   -1.6060   -3.5860   -0.8403 H   0  0  0  0  0  0
   -3.3242   -2.0705   -2.0769 H   0  0  0  0  0  0
   -4.4538   -1.0913   -1.1521 H   0  0  0  0  0  0
   -4.5886   -2.8391   -1.1289 H   0  0  0  0  0  0
   -4.4647   -2.7868    1.4698 H   0  0  0  0  0  0
   -4.3128   -1.0387    1.4234 H   0  0  0  0  0  0
   -3.1067   -2.0022    2.2633 H   0  0  0  0  0  0
   -2.1506    3.5236    0.6550 H   0  0  0  0  0  0
   -1.3309    5.8646    0.3230 H   0  0  0  0  0  0
    3.0263    3.7204   -1.8150 H   0  0  0  0  0  0
    2.7470    5.4499   -1.6319 H   0  0  0  0  0  0
    1.6493    1.4208    1.7574 H   0  0  0  0  0  0
    4.0981    1.3264    1.9692 H   0  0  0  0  0  0
    5.4176   -0.1292    0.5084 H   0  0  0  0  0  0
    3.9085   -2.2060   -2.1659 H   0  0  0  0  0  0
    7.4147   -6.8184   -2.7752 H   0  0  0  0  0  0
    7.1302   -6.1655   -5.1408 H   0  0  0  0  0  0
    6.3915   -3.8761   -5.7112 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 36  1  0  0  0
  1 37  1  0  0  0
  1 38  1  0  0  0
  2  3  1  0  0  0
  2  4  1  0  0  0
  2  5  1  0  0  0
  3 39  1  0  0  0
  3 40  1  0  0  0
  3 41  1  0  0  0
  4 42  1  0  0  0
  4 43  1  0  0  0
  4 44  1  0  0  0
  5  6  2  0  0  0
  5  9  1  0  0  0
  6  7  1  0  0  0
  7  8  2  0  0  0
  7 17  1  0  0  0
  8  9  1  0  0  0
  8 10  1  0  0  0
 10 11  1  0  0  0
 10 15  2  0  0  0
 11 12  2  0  0  0
 11 45  1  0  0  0
 12 13  1  0  0  0
 12 46  1  0  0  0
 13 14  2  0  0  0
 14 15  1  0  0  0
 14 16  1  0  0  0
 16 47  1  0  0  0
 16 48  1  0  0  0
 17 18  1  0  0  0
 17 22  2  0  0  0
 18 19  2  0  0  0
 18 49  1  0  0  0
 19 20  1  0  0  0
 19 50  1  0  0  0
 20 21  2  0  0  0
 20 51  1  0  0  0
 21 22  1  0  0  0
 21 24  1  0  0  0
 22 23  1  0  0  0
 24 25  1  0  0  0
 24 52  1  0  0  0
 25 26  2  0  0  0
 25 27  2  0  0  0
 25 28  1  0  0  0
 28 29  1  0  0  0
 28 33  2  0  0  0
 29 30  2  0  0  0
 29 35  1  0  0  0
 30 31  1  0  0  0
 30 53  1  0  0  0
 31 32  2  0  0  0
 31 54  1  0  0  0
 32 33  1  0  0  0
 32 55  1  0  0  0
 33 34  1  0  0  0
M  END
> <s_m_entry_id>
656

> <Applicants>
GlaxoSmithKline

> <CHEMBL_ID>
CHEMBL2028663

> <Canonical_Smiles>
s1c(c(nc1C(C)(C)C)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F)-c1nc(ncc1)N

> <Chirality>
Achiral Molecule

> <First_Approval>
2013

> <Phase>
4

> <SC_Patent>
US-7994185-B2

> <Synonyms>
DABRAFENIB | GSK-2118436 | GSK-2118436A | GSK2118436 | GSK2118436A | TAFINLAR

> <Indications>
Dabrafenib is indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test.

> <Type>
1.5

> <targets_id>
P15056|P04049|P57059|Q8NG66|P53667

> <inchi>
InChI=1S/C23H20F3N5O2S2/c1-23(2,3)21-30-18(19(34-21)16-10-11-28-22(27)29-16)12-6-4-9-15(17(12)26)31-35(32,33)20-13(24)7-5-8-14(20)25/h4-11,31H,1-3H3,(H2,27,28,29)

> <stdInchikey>
BFSMGDJOXZAERB-UHFFFAOYSA-N

> <csid>
25948204

> <Links>
|http://www.chemspider.com/Chemical-Structure.25948204.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2028663|http://pubchem.ncbi.nlm.nih.gov/compound/44462760|http://www.drugbank.ca/drugs/DB08912| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=P06|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/P06|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6494|http://zinc15.docking.org/substances/ZINC000068153186|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=QGP4HA4G1B|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50428286

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
519.1

> <HBA>
7

> <HBD>
2

> <NRB>
5

> <TPSA>
110.9

> <LogP>
5.4

> <RoF>
2

> <Targets>
BRAF; RAF1; SIK1; NEK11; LIMK1

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.4058

> <r_epik_State_Penalty>
  0.4054

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
656

> <lig_pdbID>
'P06'

> <pdbID>
4xv2 5csw 5hie 6hj2 6v2u

> <Kinase families>
NEK<br>CAMK<br>TKL

> <indicationDB>
Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013 for the treatment of melanoma <sup class="text-reference-group"><a class="reference-popover-link" data-content="Cancer. gov Dabrafenib" href="#reference-L2718">7</a></sup>.</p><p>In May 2018, Tafinlar (dabrafenib) and Mekinist (<a href="https://go.drugbank.com/drugs/DB08911">Trametinib</a>) in combination have been approved to treat anaplastic thyroid cancer caused by an abnormal BRAF V600E gene <sup class="text-reference-group"><a class="reference-popover-link" data-content="Novartis receives FDA approval of Tafinlar® + Mekinist® for adjuvant treatment of BRAF V600-mutant melanoma" href="#reference-L2714">5</a></sup>.

> <uniprotId>
P15056|P04049|P57059|Q8NG66|P53667|P08684|P10632|P20813|P11712|P33261|P05177|P08183|Q9UNQ0|Q9Y6L6|Q9NPD5|Q4U2R8|Q8TCC7

> <BrandName>
Tafinlar

> <Withdrawn>
|Study NCT02447939 in nan was Withdrawn during Phase 1 because Change in strategy|Study NCT02915666 in United States was Withdrawn during Phase 1 because No subjects consented for enrollment on this study|Study NCT02672358 in nan was Withdrawn during Phase 2 because Company Decision|Study NCT03972046 in United States was Withdrawn during Phase 2 because Principal investigator leaving study site; no replacement PI will be sought|Study NCT02357732 in nan was Withdrawn during Phase 1 because PI decided not to proceed

> <FDA_approved>
Y

$$$$
Erlotinib
                    3D
 Structure written by MMmdl.
 52 54  0  0  1  0            999 V2000
   -4.3344    1.6743    0.4709 C   0  0  0  0  0  0
   -2.9615    1.8805    0.1752 O   0  0  0  0  0  0
   -2.1880    0.6898    0.2287 C   0  0  0  0  0  0
   -0.7276    1.0178   -0.1030 C   0  0  0  0  0  0
    0.0387   -0.1820   -0.0385 O   0  0  0  0  0  0
    1.3948   -0.1526   -0.3151 C   0  0  0  0  0  0
    2.0905    1.0212   -0.6426 C   0  0  0  0  0  0
    3.4825    0.9919   -0.9209 C   0  0  0  0  0  0
    4.1670   -0.2587   -0.8654 C   0  0  0  0  0  0
    3.4495   -1.4276   -0.5310 C   0  0  0  0  0  0
    2.0751   -1.3752   -0.2541 C   0  0  0  0  0  0
    1.3243   -2.4877    0.0852 O   0  0  0  0  0  0
    1.9552   -3.7601    0.2110 C   0  0  0  0  0  0
    0.9136   -4.7946    0.6558 C   0  0  0  0  0  0
    0.4493   -4.4642    1.9582 O   0  0  0  0  0  0
   -0.5352   -5.3592    2.4522 C   0  0  0  0  0  0
    5.5012   -0.3605   -1.1243 N   0  0  0  0  0  0
    6.1483    0.7872   -1.4346 C   0  0  0  0  0  0
    5.6082    2.0239   -1.5131 N   0  0  0  0  0  0
    4.2787    2.1302   -1.2607 C   0  0  0  0  0  0
    3.6860    3.4075   -1.3152 N   0  0  0  0  0  0
    4.1892    4.6929   -1.5855 C   0  0  0  0  0  0
    3.5045    5.7833   -1.0403 C   0  0  0  0  0  0
    3.9438    7.0865   -1.2716 C   0  0  0  0  0  0
    5.0699    7.3141   -2.0608 C   0  0  0  0  0  0
    5.7561    6.2362   -2.6259 C   0  0  0  0  0  0
    5.3138    4.9303   -2.3900 C   0  0  0  0  0  0
    6.9233    6.4722   -3.4635 C   0  0  0  0  0  0
    7.8980    6.6602   -4.1753 C   0  0  0  0  0  0
   -4.8659    2.6239    0.4098 H   0  0  0  0  0  0
   -4.4703    1.2802    1.4794 H   0  0  0  0  0  0
   -4.7965    0.9869   -0.2394 H   0  0  0  0  0  0
   -2.2487    0.2401    1.2218 H   0  0  0  0  0  0
   -2.5708   -0.0457   -0.4815 H   0  0  0  0  0  0
   -0.6685    1.4583   -1.1001 H   0  0  0  0  0  0
   -0.3464    1.7542    0.6068 H   0  0  0  0  0  0
    1.5792    1.9703   -0.6902 H   0  0  0  0  0  0
    3.9932   -2.3599   -0.4948 H   0  0  0  0  0  0
    2.3881   -4.0617   -0.7443 H   0  0  0  0  0  0
    2.7603   -3.7145    0.9469 H   0  0  0  0  0  0
    0.0812   -4.8089   -0.0505 H   0  0  0  0  0  0
    1.3614   -5.7900    0.6572 H   0  0  0  0  0  0
   -0.8380   -5.0504    3.4530 H   0  0  0  0  0  0
   -0.1502   -6.3782    2.5195 H   0  0  0  0  0  0
   -1.4246   -5.3608    1.8199 H   0  0  0  0  0  0
    7.2062    0.7074   -1.6386 H   0  0  0  0  0  0
    2.7478    3.4160   -0.9429 H   0  0  0  0  0  0
    2.6295    5.6268   -0.4257 H   0  0  0  0  0  0
    3.4109    7.9202   -0.8390 H   0  0  0  0  0  0
    5.3980    8.3299   -2.2322 H   0  0  0  0  0  0
    5.8393    4.1094   -2.8547 H   0  0  0  0  0  0
    8.7493    6.8197   -4.7983 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 30  1  0  0  0
  1 31  1  0  0  0
  1 32  1  0  0  0
  2  3  1  0  0  0
  3  4  1  0  0  0
  3 33  1  0  0  0
  3 34  1  0  0  0
  4  5  1  0  0  0
  4 35  1  0  0  0
  4 36  1  0  0  0
  5  6  1  0  0  0
  6  7  1  0  0  0
  6 11  2  0  0  0
  7  8  2  0  0  0
  7 37  1  0  0  0
  8  9  1  0  0  0
  8 20  1  0  0  0
  9 10  2  0  0  0
  9 17  1  0  0  0
 10 11  1  0  0  0
 10 38  1  0  0  0
 11 12  1  0  0  0
 12 13  1  0  0  0
 13 14  1  0  0  0
 13 39  1  0  0  0
 13 40  1  0  0  0
 14 15  1  0  0  0
 14 41  1  0  0  0
 14 42  1  0  0  0
 15 16  1  0  0  0
 16 43  1  0  0  0
 16 44  1  0  0  0
 16 45  1  0  0  0
 17 18  2  0  0  0
 18 19  1  0  0  0
 18 46  1  0  0  0
 19 20  2  0  0  0
 20 21  1  0  0  0
 21 22  1  0  0  0
 21 47  1  0  0  0
 22 23  1  0  0  0
 22 27  2  0  0  0
 23 24  2  0  0  0
 23 48  1  0  0  0
 24 25  1  0  0  0
 24 49  1  0  0  0
 25 26  2  0  0  0
 25 50  1  0  0  0
 26 27  1  0  0  0
 26 28  1  0  0  0
 27 51  1  0  0  0
 28 29  3  0  0  0
 29 52  1  0  0  0
M  END
> <s_m_entry_id>
658

> <Applicants>
Osi Pharmaceuticals

> <CHEMBL_ID>
CHEMBL553

> <Canonical_Smiles>
O(CCOC)c1cc2c(ncnc2Nc2cc(ccc2)C#C)cc1OCCOC

> <Chirality>
Achiral Molecule

> <First_Approval>
2004

> <Phase>
4

> <SC_Patent>
US-6900221-B1

> <Synonyms>
CP-358,774 | CP-358774 | CP-35877401 | ERLOTINIB | OSI-774 | R-1415 | RG-1415 | RO-508231 | TARCEVA

> <Indications>
For the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Also for use, in combination with gemcitabine, as the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.

> <Type>
1.5

> <targets_id>
P00533|O75469

> <inchi>
InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)

> <stdInchikey>
AAKJLRGGTJKAMG-UHFFFAOYSA-N

> <csid>
154044

> <Links>
|http://www.chemspider.com/Chemical-Structure.154044.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL553|http://pubchem.ncbi.nlm.nih.gov/compound/176870|http://www.drugbank.ca/drugs/DB00530| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=AQ4|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/AQ4|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4920|http://zinc15.docking.org/substances/ZINC01546066|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=J4T82NDH7E|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=5446

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
393.2

> <HBA>
7

> <HBD>
1

> <NRB>
10

> <TPSA>
74.7

> <LogP>
3.4

> <RoF>
0

> <Targets>
EGFR; NR1I2

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0014

> <r_epik_State_Penalty>
  0.0000

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
658

> <lig_pdbID>
'AQ4'

> <pdbID>
1m17 4hjo 6dwn

> <Kinase families>
Tyr<br>(*)

> <indicationDB>
Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion at the adenosine triphosphate (ATP) binding site of the receptor. Recent studies demonstrate that erlotinib is also a potent inhibitor of JAK2V617F, which is a mutant form of tyrosine kinase JAK2 found in most patients with polycythemia vera (PV) and a substantial proportion of patients with idiopathic myelofibrosis or essential thrombocythemia. This finding introduces the potential use of erlotinib in the treatment of JAK2V617F-positive PV and other myeloproliferative disorders.

> <uniprotId>
P00533|O75469|P08684|P20815|P05177|P04798|P10635|P10632|Q16678|P22309|P02768|P02763

> <BrandName>
Tarceva

> <Withdrawn>
|Study NCT00570375 in United States was Withdrawn during Phase 2 because PI left institution|Study NCT01332279 in United States was Withdrawn during Phase 1 because Pharmaceutical co withdrew support Study was never activated and did not accrue any patients|Study NCT00728000 in United States was Withdrawn during Phase 2 because study withdrawn due to lack of enrollment|Study NCT00385398 in nan was Withdrawn during Phase 2 because lack of funding and drug supply|Study NCT01006096 in United States was Withdrawn during Phase 2 because IND not obtained|Study NCT00428194 in United States was Withdrawn during Phase 1 because Withdrawn due to lack of accrual|Study NCT01013506 in nan was Withdrawn during Phase 2 because Study was abandoned before opening to accrual Replaced by another study|Study NCT01600807 in United States was Withdrawn during Phase 1/Phase 2 because Study was pending major changes and was on hold, pending activation; administratively
    withdrawn; will be submitted as a new protocol if study is revised|Study NCT02355431 in United States was Withdrawn during Phase 2 because Study withdrawn before enrolling first patient|Study NCT01728181 in nan was Withdrawn during Phase 1/Phase 2 because Stopped before approval due to ineffective drug|Study NCT01928160 in nan was Withdrawn during Phase 2 because study not accruing|Study NCT01465815 in United States was Withdrawn during Phase 1/Phase 2 because Drug manufacturer, Astellas Pharma, informed us that safety and efficacy of Erlotinib and
    OSI-906 in other oncology studies was determined to be unfavorable|Study NCT02795884 in nan was Withdrawn during Phase 3 because Because of reconsideration of using erlotinib(EGFR Tyrosine kinase inhibitor) as adjuvant aim|Study NCT02034097 in nan was Withdrawn during Phase 2 because GSK has decided to terminate the Product Development of foretinib and conclude our Development
    Agreement with Exelixis|Study NCT03529084 in nan was Withdrawn during Phase 3 because Decision by Sponsor not to continue with the trial

> <FDA_approved>
Y

$$$$
Fedratinib
                    3D
 Structure written by MMmdl.
 74 77  0  0  1  0            999 V2000
   -4.6629    0.1703   -0.5706 C   0  0  0  0  0  0
   -3.1566   -0.0114   -0.4369 C   0  0  0  0  0  0
   -2.5535   -1.2106   -0.8286 C   0  0  0  0  0  0
   -1.2173   -1.4221   -0.7374 N   0  0  0  0  0  0
   -0.4685   -0.4049   -0.2372 C   0  0  0  0  0  0
   -0.9644    0.7918    0.1630 N   0  0  0  0  0  0
   -2.3082    0.9896    0.0700 C   0  0  0  0  0  0
   -2.8491    2.2274    0.4646 N   0  0  0  0  0  0
   -2.2588    3.3849    1.0016 C   0  0  0  0  0  0
   -1.1147    3.3553    1.8118 C   0  0  0  0  0  0
   -0.5786    4.5379    2.3213 C   0  0  0  0  0  0
   -1.1828    5.7602    2.0335 C   0  0  0  0  0  0
   -2.3320    5.8013    1.2410 C   0  0  0  0  0  0
   -2.8675    4.6142    0.7313 C   0  0  0  0  0  0
   -3.1067    7.3782    0.8996 S   0  0  0  0  0  0
   -2.0337    8.2694    0.4455 O   0  0  0  0  0  0
   -4.2740    7.1330    0.0446 O   0  0  0  0  0  0
   -3.6555    7.9920    2.4714 N   0  0  0  0  0  0
   -4.6669    7.3201    3.3395 C   0  0  0  0  0  0
   -5.3035    8.4151    4.2201 C   0  0  0  0  0  0
   -3.9572    6.2914    4.2457 C   0  0  0  0  0  0
   -5.7811    6.6234    2.5265 C   0  0  0  0  0  0
    0.9249   -0.5326   -0.1364 N   0  0  0  0  0  0
    1.8127   -1.5694   -0.4736 C   0  0  0  0  0  0
    1.4393   -2.9181   -0.4963 C   0  0  0  0  0  0
    2.3700   -3.8957   -0.8353 C   0  0  0  0  0  0
    3.6835   -3.5481   -1.1486 C   0  0  0  0  0  0
    4.0614   -2.1974   -1.1119 C   0  0  0  0  0  0
    3.1309   -1.2192   -0.7712 C   0  0  0  0  0  0
    4.5322   -4.5876   -1.4748 O   0  0  0  0  0  0
    5.8955   -4.3128   -1.7848 C   0  0  0  0  0  0
    6.6464   -5.6232   -2.0832 C   0  0  0  0  0  0
    6.7973   -6.4907   -0.8130 N   0  3  0  0  0  0
    5.4939   -7.0903   -0.2434 C   0  0  0  0  0  0
    5.9147   -8.3945    0.4500 C   0  0  0  0  0  0
    7.4189   -8.5434    0.2287 C   0  0  0  0  0  0
    7.7089   -7.7107   -1.0137 C   0  0  0  0  0  0
   -4.8867    0.9659   -1.2819 H   0  0  0  0  0  0
   -5.1031    0.4347    0.3915 H   0  0  0  0  0  0
   -5.1510   -0.7400   -0.9213 H   0  0  0  0  0  0
   -3.1378   -2.0262   -1.2294 H   0  0  0  0  0  0
   -3.7839    2.3745    0.1134 H   0  0  0  0  0  0
   -0.6373    2.4230    2.0710 H   0  0  0  0  0  0
    0.3031    4.5048    2.9442 H   0  0  0  0  0  0
   -0.7634    6.6721    2.4332 H   0  0  0  0  0  0
   -3.7577    4.6462    0.1192 H   0  0  0  0  0  0
   -2.9364    8.4925    3.0005 H   0  0  0  0  0  0
   -6.0465    8.0000    4.9026 H   0  0  0  0  0  0
   -5.8063    9.1720    3.6160 H   0  0  0  0  0  0
   -4.5574    8.9283    4.8289 H   0  0  0  0  0  0
   -3.1370    6.7437    4.8053 H   0  0  0  0  0  0
   -3.5457    5.4590    3.6762 H   0  0  0  0  0  0
   -4.6470    5.8619    4.9731 H   0  0  0  0  0  0
   -6.5536    6.2198    3.1822 H   0  0  0  0  0  0
   -5.3996    5.7844    1.9444 H   0  0  0  0  0  0
   -6.2716    7.3150    1.8401 H   0  0  0  0  0  0
    1.3788    0.3461    0.0644 H   0  0  0  0  0  0
    0.4401   -3.2321   -0.2386 H   0  0  0  0  0  0
    2.0681   -4.9328   -0.8502 H   0  0  0  0  0  0
    5.0688   -1.8875   -1.3445 H   0  0  0  0  0  0
    3.4406   -0.1839   -0.7487 H   0  0  0  0  0  0
    5.9506   -3.6606   -2.6579 H   0  0  0  0  0  0
    6.3754   -3.7957   -0.9516 H   0  0  0  0  0  0
    6.1430   -6.2444   -2.8259 H   0  0  0  0  0  0
    7.6688   -5.4237   -2.4076 H   0  0  0  0  0  0
    5.0711   -6.3461    0.4327 H   0  0  0  0  0  0
    4.8240   -7.2774   -1.0845 H   0  0  0  0  0  0
    5.6673   -8.3875    1.5124 H   0  0  0  0  0  0
    5.3799   -9.2330    0.0012 H   0  0  0  0  0  0
    7.9738   -8.1440    1.0793 H   0  0  0  0  0  0
    7.7126   -9.5864    0.1045 H   0  0  0  0  0  0
    7.3843   -8.2063   -1.9311 H   0  0  0  0  0  0
    8.7407   -7.3664   -1.0969 H   0  0  0  0  0  0
    7.2168   -5.9273   -0.0866 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 38  1  0  0  0
  1 39  1  0  0  0
  1 40  1  0  0  0
  2  3  1  0  0  0
  2  7  2  0  0  0
  3  4  2  0  0  0
  3 41  1  0  0  0
  4  5  1  0  0  0
  5  6  2  0  0  0
  5 23  1  0  0  0
  6  7  1  0  0  0
  7  8  1  0  0  0
  8  9  1  0  0  0
  8 42  1  0  0  0
  9 10  1  0  0  0
  9 14  2  0  0  0
 10 11  2  0  0  0
 10 43  1  0  0  0
 11 12  1  0  0  0
 11 44  1  0  0  0
 12 13  2  0  0  0
 12 45  1  0  0  0
 13 14  1  0  0  0
 13 15  1  0  0  0
 14 46  1  0  0  0
 15 16  2  0  0  0
 15 17  2  0  0  0
 15 18  1  0  0  0
 18 19  1  0  0  0
 18 47  1  0  0  0
 19 20  1  0  0  0
 19 21  1  0  0  0
 19 22  1  0  0  0
 20 48  1  0  0  0
 20 49  1  0  0  0
 20 50  1  0  0  0
 21 51  1  0  0  0
 21 52  1  0  0  0
 21 53  1  0  0  0
 22 54  1  0  0  0
 22 55  1  0  0  0
 22 56  1  0  0  0
 23 24  1  0  0  0
 23 57  1  0  0  0
 24 25  1  0  0  0
 24 29  2  0  0  0
 25 26  2  0  0  0
 25 58  1  0  0  0
 26 27  1  0  0  0
 26 59  1  0  0  0
 27 28  2  0  0  0
 27 30  1  0  0  0
 28 29  1  0  0  0
 28 60  1  0  0  0
 29 61  1  0  0  0
 30 31  1  0  0  0
 31 32  1  0  0  0
 31 62  1  0  0  0
 31 63  1  0  0  0
 32 33  1  0  0  0
 32 64  1  0  0  0
 32 65  1  0  0  0
 33 34  1  0  0  0
 33 37  1  0  0  0
 33 74  1  0  0  0
 34 35  1  0  0  0
 34 66  1  0  0  0
 34 67  1  0  0  0
 35 36  1  0  0  0
 35 68  1  0  0  0
 35 69  1  0  0  0
 36 37  1  0  0  0
 36 70  1  0  0  0
 36 71  1  0  0  0
 37 72  1  0  0  0
 37 73  1  0  0  0
M  CHG  1  33   1
M  END
> <s_m_entry_id>
659

> <Applicants>
Sanofi

> <CHEMBL_ID>
CHEMBL1287853

> <Canonical_Smiles>
S(=O)(=O)(NC(C)(C)C)c1cc(Nc2nc(ncc2C)Nc2ccc(OCCN3CCCC3)cc2)ccc1

> <Chirality>
Achiral Molecule

> <First_Approval>
2019

> <Phase>
4

> <SC_Patent>
US-7528143-B2

> <Synonyms>
FEDRATINIB | SAR-302503 | SAR302503 | TG-101348 | TG101348

> <Indications>
On august 2019, FDA approved fedratinib to treat adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis

> <Type>
nan

> <targets_id>
O60674|P36888|O60885

> <inchi>
InChI=1S/C27H36N6O3S/c1-20-19-28-26(30-21-10-12-23(13-11-21)36-17-16-33-14-5-6-15-33)31-25(20)29-22-8-7-9-24(18-22)37(34,35)32-27(2,3)4/h7-13,18-19,32H,5-6,14-17H2,1-4H3,(H2,28,29,30,31)

> <stdInchikey>
JOOXLOJCABQBSG-UHFFFAOYSA-N

> <csid>
17626393

> <Links>
|http://www.chemspider.com/Chemical-Structure.17626393.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1287853|http://pubchem.ncbi.nlm.nih.gov/compound/16722836|http://www.drugbank.ca/drugs/DB12500| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=2TA|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/2TA|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5716|http://zinc15.docking.org/substances/ZINC000019862646|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=6L1XP550I6|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50332294

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
524.3

> <HBA>
8

> <HBD>
3

> <NRB>
10

> <TPSA>
108.5

> <LogP>
4.8

> <RoF>
1

> <Targets>
JAK2; FLT3; BRD4

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0622

> <r_epik_State_Penalty>
  0.0514

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
659

> <lig_pdbID>
'2TA'

> <pdbID>
4ogj 4ps5 6vne

> <Kinase families>
Tyr<br>(*)

> <indicationDB>
Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Jamieson C, Hasserjian R, Gotlib J, Cortes J, Stone R, Talpaz M, Thiele J, Rodig S, Pozdnyakova O: Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis. J Transl Med. 2015 Sep 10;13:294. doi: 10.1186/s12967-015-0644-4. (PubMed ID 26357842)" href="#reference-A183176">2</a>,<a class="reference-popover-link" data-content="FDA Approved Drug Products: Fedratinib Oral Capsules" href="#reference-L8090">7</a></sup> It is an anilinopyrimidine derivative.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Roskoski R Jr: Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases. Pharmacol Res. 2016 Sep;111:784-803. doi: 10.1016/j.phrs.2016.07.038. Epub 2016 Jul 26. (PubMed ID 27473820)" href="#reference-A183188">6</a></sup></p><p>Fedratinib was granted FDA approval on August 16, 2019.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA Approved Drug Products: Fedratinib Oral Capsules" href="#reference-L8090">7</a></sup>

> <uniprotId>
O60674|P36888|P23458|P08684|P33261|P31513|P10635|P08183|Q9UNQ0|Q9Y6L6|Q9NPD5|P09086|Q96FL8|Q86VL8

> <BrandName>
Inrebic

> <FDA_approved>
Y

$$$$
Flumatinib
                    3D
 Structure written by MMmdl.
 71 75  0  0  1  0            999 V2000
   -4.2253    0.1692   -0.1205 C   0  0  0  0  0  0
   -2.7096    0.0179   -0.0781 C   0  0  0  0  0  0
   -2.0440   -1.0547   -0.6988 C   0  0  0  0  0  0
   -0.6439   -1.0870   -0.6090 C   0  0  0  0  0  0
    0.0444   -0.0993    0.1145 C   0  0  0  0  0  0
   -0.7074    0.9229    0.6965 C   0  0  0  0  0  0
   -2.0579    0.9926    0.6091 N   0  0  0  0  0  0
    1.4419   -0.0435    0.2639 N   0  0  0  0  0  0
    2.3409   -1.0489    0.1530 C   0  0  0  0  0  0
    2.0564   -2.2232   -0.0909 O   0  0  0  0  0  0
    3.7861   -0.6484    0.3327 C   0  0  0  0  0  0
    4.1561    0.3763    1.2116 C   0  0  0  0  0  0
    5.4950    0.7209    1.3688 C   0  0  0  0  0  0
    6.4980    0.0589    0.6535 C   0  0  0  0  0  0
    6.1473   -0.9894   -0.2260 C   0  0  0  0  0  0
    4.7915   -1.3222   -0.3724 C   0  0  0  0  0  0
    7.2003   -1.7853   -1.0118 C   0  0  0  0  0  0
    6.6636   -2.7355   -1.7800 F   0  0  0  0  0  0
    7.8908   -0.9716   -1.8095 F   0  0  0  0  0  0
    8.0409   -2.3828   -0.1668 F   0  0  0  0  0  0
    7.9406    0.5093    0.8931 C   0  0  0  0  0  0
    8.2323    1.9623    0.4479 N   0  3  0  0  0  0
    8.1128    2.1263   -1.0840 C   0  0  0  0  0  0
    8.4643    3.5788   -1.4800 C   0  0  0  0  0  0
    9.7704    4.0254   -0.9825 N   0  0  0  0  0  0
    9.9028    3.8600    0.4692 C   0  0  0  0  0  0
    9.6149    2.4224    0.9620 C   0  0  0  0  0  0
   10.8824    3.4220   -1.7152 C   0  0  0  0  0  0
   -2.7791   -2.0304   -1.4011 N   0  0  0  0  0  0
   -2.5418   -3.3899   -1.6557 C   0  0  0  0  0  0
   -1.3975   -3.9796   -1.2182 N   0  0  0  0  0  0
   -1.2498   -5.3016   -1.4805 C   0  0  0  0  0  0
   -2.2173   -6.0408   -2.1606 C   0  0  0  0  0  0
   -3.3718   -5.3636   -2.5782 C   0  0  0  0  0  0
   -3.5358   -4.0343   -2.3192 N   0  0  0  0  0  0
   -4.4855   -6.0504   -3.3006 C   0  0  0  0  0  0
   -5.8159   -5.6048   -3.2150 C   0  0  0  0  0  0
   -6.8324   -6.2725   -3.8999 C   0  0  0  0  0  0
   -6.4945   -7.3855   -4.6676 C   0  0  0  0  0  0
   -5.2234   -7.8436   -4.7771 N   0  0  0  0  0  0
   -4.2510   -7.1792   -4.1019 C   0  0  0  0  0  0
   -4.7026   -0.6801    0.3691 H   0  0  0  0  0  0
   -4.5738    0.2089   -1.1529 H   0  0  0  0  0  0
   -4.5675    1.0771    0.3792 H   0  0  0  0  0  0
   -0.0958   -1.8563   -1.1267 H   0  0  0  0  0  0
   -0.2322    1.7175    1.2540 H   0  0  0  0  0  0
    1.8037    0.8600    0.5311 H   0  0  0  0  0  0
    3.4139    0.9105    1.7878 H   0  0  0  0  0  0
    5.7528    1.5151    2.0547 H   0  0  0  0  0  0
    4.5089   -2.1213   -1.0439 H   0  0  0  0  0  0
    8.1469    0.5042    1.9650 H   0  0  0  0  0  0
    8.6988   -0.1008    0.4039 H   0  0  0  0  0  0
    8.7874    1.4032   -1.5438 H   0  0  0  0  0  0
    7.0872    1.8760   -1.3570 H   0  0  0  0  0  0
    8.4222    3.6944   -2.5641 H   0  0  0  0  0  0
    7.7012    4.2519   -1.0864 H   0  0  0  0  0  0
   10.8974    4.1754    0.7884 H   0  0  0  0  0  0
    9.2107    4.5499    0.9546 H   0  0  0  0  0  0
    9.5821    2.3758    2.0513 H   0  0  0  0  0  0
   10.3549    1.7053    0.6025 H   0  0  0  0  0  0
   11.8320    3.8442   -1.3837 H   0  0  0  0  0  0
   10.7924    3.6252   -2.7831 H   0  0  0  0  0  0
   10.9292    2.3411   -1.5808 H   0  0  0  0  0  0
   -3.7308   -1.7602   -1.5997 H   0  0  0  0  0  0
   -0.3404   -5.7672   -1.1301 H   0  0  0  0  0  0
   -2.0722   -7.0953   -2.3411 H   0  0  0  0  0  0
   -6.0697   -4.7436   -2.6140 H   0  0  0  0  0  0
   -7.8563   -5.9352   -3.8352 H   0  0  0  0  0  0
   -7.2521   -7.9296   -5.2125 H   0  0  0  0  0  0
   -3.2545   -7.5757   -4.2289 H   0  0  0  0  0  0
    7.5369    2.5588    0.8737 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 42  1  0  0  0
  1 43  1  0  0  0
  1 44  1  0  0  0
  2  3  1  0  0  0
  2  7  2  0  0  0
  3  4  2  0  0  0
  3 29  1  0  0  0
  4  5  1  0  0  0
  4 45  1  0  0  0
  5  6  2  0  0  0
  5  8  1  0  0  0
  6  7  1  0  0  0
  6 46  1  0  0  0
  8  9  1  0  0  0
  8 47  1  0  0  0
  9 10  2  0  0  0
  9 11  1  0  0  0
 11 12  1  0  0  0
 11 16  2  0  0  0
 12 13  2  0  0  0
 12 48  1  0  0  0
 13 14  1  0  0  0
 13 49  1  0  0  0
 14 15  2  0  0  0
 14 21  1  0  0  0
 15 16  1  0  0  0
 15 17  1  0  0  0
 16 50  1  0  0  0
 17 18  1  0  0  0
 17 19  1  0  0  0
 17 20  1  0  0  0
 21 22  1  0  0  0
 21 51  1  0  0  0
 21 52  1  0  0  0
 22 23  1  0  0  0
 22 27  1  0  0  0
 22 71  1  0  0  0
 23 24  1  0  0  0
 23 53  1  0  0  0
 23 54  1  0  0  0
 24 25  1  0  0  0
 24 55  1  0  0  0
 24 56  1  0  0  0
 25 26  1  0  0  0
 25 28  1  0  0  0
 26 27  1  0  0  0
 26 57  1  0  0  0
 26 58  1  0  0  0
 27 59  1  0  0  0
 27 60  1  0  0  0
 28 61  1  0  0  0
 28 62  1  0  0  0
 28 63  1  0  0  0
 29 30  1  0  0  0
 29 64  1  0  0  0
 30 31  1  0  0  0
 30 35  2  0  0  0
 31 32  2  0  0  0
 32 33  1  0  0  0
 32 65  1  0  0  0
 33 34  2  0  0  0
 33 66  1  0  0  0
 34 35  1  0  0  0
 34 36  1  0  0  0
 36 37  1  0  0  0
 36 41  2  0  0  0
 37 38  2  0  0  0
 37 67  1  0  0  0
 38 39  1  0  0  0
 38 68  1  0  0  0
 39 40  2  0  0  0
 39 69  1  0  0  0
 40 41  1  0  0  0
 41 70  1  0  0  0
M  CHG  1  22   1
M  END
> <s_m_entry_id>
661

> <Applicants>
Jiangsu Hengrui Medicine

> <CHEMBL_ID>
CHEMBL3545413

> <Canonical_Smiles>
FC(F)(F)c1cc(ccc1CN1CCN(CC1)C)C(=O)Nc1cc(Nc2nc(ccn2)-c2cccnc2)c(nc1)C

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
4

> <SC_Patent>
None

> <Synonyms>
FLUMATINIB | HH-GV678 | HHGV-678

> <Indications>
nan

> <Type>
nan

> <targets_id>
P11274|P00519|P09619|P10721

> <inchi>
InChI=1S/C29H29F3N8O/c1-19-26(38-28-34-9-7-25(37-28)21-4-3-8-33-16-21)15-23(17-35-19)36-27(41)20-5-6-22(24(14-20)29(30,31)32)18-40-12-10-39(2)11-13-40/h3-9,14-17H,10-13,18H2,1-2H3,(H,36,41)(H,34,37,38)

> <stdInchikey>
BJCJYEYYYGBROF-UHFFFAOYSA-N

> <csid>
25069687

> <Links>
|http://www.chemspider.com/Chemical-Structure.25069687.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3545413|http://pubchem.ncbi.nlm.nih.gov/compound/46848036|http://www.drugbank.ca/drugs/DB11904|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9913|http://zinc15.docking.org/substances/ZINC000068244727|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=R4009Y24AI

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS

> <indicationG2P>
None

> <MW>
562.2

> <HBA>
8

> <HBD>
2

> <NRB>
7

> <TPSA>
99.2

> <LogP>
5

> <RoF>
2

> <Targets>
BCR; ABL1; PDGFRB; KIT

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0201

> <r_epik_State_Penalty>
  0.2066

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
661

> <Kinase families>
Tyr<br>Atypical

> <FDA_approved>
N

$$$$
Fostamatinib
                    3D
 Structure written by MMmdl.
 64 67  0  0  1  0            999 V2000
   -8.4554    2.9235    5.0432 C   0  0  0  0  0  0
   -6.9729    2.8701    4.6068 C   0  0  0  0  0  0
   -6.4559    1.3995    4.8349 C   0  0  0  0  0  0
   -6.7735    0.7470    5.8348 O   0  0  0  0  0  0
   -5.5843    0.9725    3.8726 N   0  0  0  0  0  0
   -5.2723    1.6999    2.6992 C   0  0  0  0  0  0
   -5.9901    2.8575    2.4030 C   0  0  0  0  0  0
   -5.7206    3.5627    1.2305 C   0  0  0  0  0  0
   -4.7036    3.1088    0.3883 C   0  0  0  0  0  0
   -3.9948    1.9557    0.7415 C   0  0  0  0  0  0
   -4.2816    1.2576    1.8733 N   0  0  0  0  0  0
   -2.9375    1.5398   -0.0819 N   0  0  0  0  0  0
   -2.0124    0.5041    0.1169 C   0  0  0  0  0  0
   -2.3910   -0.8149    0.4155 C   0  0  0  0  0  0
   -1.3680   -1.7559    0.5379 C   0  0  0  0  0  0
   -0.0604   -1.4396    0.3527 N   0  0  0  0  0  0
    0.2177   -0.1513    0.0278 C   0  0  0  0  0  0
   -0.7141    0.8300   -0.1161 N   0  0  0  0  0  0
    1.5809    0.1435   -0.1239 N   0  0  0  0  0  0
    2.2637    1.3474   -0.3685 C   0  0  0  0  0  0
    1.7197    2.3945   -1.1192 C   0  0  0  0  0  0
    2.4421    3.5777   -1.3385 C   0  0  0  0  0  0
    3.7334    3.6915   -0.8068 C   0  0  0  0  0  0
    4.2987    2.6519   -0.0564 C   0  0  0  0  0  0
    3.5529    1.4802    0.1471 C   0  0  0  0  0  0
    5.5743    2.8520    0.4410 O   0  0  0  0  0  0
    6.1825    1.8380    1.2335 C   0  0  0  0  0  0
    4.4461    4.8497   -1.0065 O   0  0  0  0  0  0
    5.2741    4.8276   -2.1614 C   0  0  0  0  0  0
    1.9594    4.6543   -2.0612 O   0  0  0  0  0  0
    0.6431    4.6016   -2.6001 C   0  0  0  0  0  0
   -3.6846   -1.1885    0.5562 F   0  0  0  0  0  0
   -6.9940    3.3047    3.2272 O   0  0  0  0  0  0
   -4.9635   -0.3668    4.0407 C   0  0  0  0  0  0
   -3.5704   -0.1994    4.2305 O   0  0  0  0  0  0
   -2.5214   -1.5902    4.4644 P   0  0  0  0  0  0
   -1.0846   -1.0447    4.3768 O   0  0  0  0  0  0
   -2.8701   -2.1445    5.8577 O   0  5  0  0  0  0
   -2.8590   -2.5735    3.3281 O   0  5  0  0  0  0
   -6.0384    3.8061    5.4078 C   0  0  0  0  0  0
   -8.5818    2.6906    6.1018 H   0  0  0  0  0  0
   -9.0740    2.2300    4.4710 H   0  0  0  0  0  0
   -8.8674    3.9219    4.8913 H   0  0  0  0  0  0
   -6.2794    4.4531    0.9828 H   0  0  0  0  0  0
   -4.4666    3.6535   -0.5141 H   0  0  0  0  0  0
   -2.6365    2.2418   -0.7406 H   0  0  0  0  0  0
   -1.5900   -2.7843    0.7827 H   0  0  0  0  0  0
    2.1723   -0.6022    0.2115 H   0  0  0  0  0  0
    0.7378    2.2811   -1.5484 H   0  0  0  0  0  0
    3.9643    0.6624    0.7201 H   0  0  0  0  0  0
    7.1708    2.1729    1.5478 H   0  0  0  0  0  0
    6.3127    0.9134    0.6692 H   0  0  0  0  0  0
    5.6026    1.6317    2.1346 H   0  0  0  0  0  0
    5.7911    5.7825   -2.2541 H   0  0  0  0  0  0
    4.6904    4.6762   -3.0714 H   0  0  0  0  0  0
    6.0317    4.0445   -2.0971 H   0  0  0  0  0  0
    0.4278    5.5391   -3.1123 H   0  0  0  0  0  0
   -0.1064    4.4742   -1.8172 H   0  0  0  0  0  0
    0.5423    3.7970   -3.3301 H   0  0  0  0  0  0
   -5.3536   -0.9588    4.8712 H   0  0  0  0  0  0
   -5.1413   -0.9690    3.1477 H   0  0  0  0  0  0
   -6.0515    3.5799    6.4753 H   0  0  0  0  0  0
   -6.3478    4.8458    5.2977 H   0  0  0  0  0  0
   -5.0037    3.7424    5.0665 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 41  1  0  0  0
  1 42  1  0  0  0
  1 43  1  0  0  0
  2  3  1  0  0  0
  2 33  1  0  0  0
  2 40  1  0  0  0
  3  4  2  0  0  0
  3  5  1  0  0  0
  5  6  1  0  0  0
  5 34  1  0  0  0
  6  7  1  0  0  0
  6 11  2  0  0  0
  7  8  2  0  0  0
  7 33  1  0  0  0
  8  9  1  0  0  0
  8 44  1  0  0  0
  9 10  2  0  0  0
  9 45  1  0  0  0
 10 11  1  0  0  0
 10 12  1  0  0  0
 12 13  1  0  0  0
 12 46  1  0  0  0
 13 14  1  0  0  0
 13 18  2  0  0  0
 14 15  2  0  0  0
 14 32  1  0  0  0
 15 16  1  0  0  0
 15 47  1  0  0  0
 16 17  2  0  0  0
 17 18  1  0  0  0
 17 19  1  0  0  0
 19 20  1  0  0  0
 19 48  1  0  0  0
 20 21  1  0  0  0
 20 25  2  0  0  0
 21 22  2  0  0  0
 21 49  1  0  0  0
 22 23  1  0  0  0
 22 30  1  0  0  0
 23 24  2  0  0  0
 23 28  1  0  0  0
 24 25  1  0  0  0
 24 26  1  0  0  0
 25 50  1  0  0  0
 26 27  1  0  0  0
 27 51  1  0  0  0
 27 52  1  0  0  0
 27 53  1  0  0  0
 28 29  1  0  0  0
 29 54  1  0  0  0
 29 55  1  0  0  0
 29 56  1  0  0  0
 30 31  1  0  0  0
 31 57  1  0  0  0
 31 58  1  0  0  0
 31 59  1  0  0  0
 34 35  1  0  0  0
 34 60  1  0  0  0
 34 61  1  0  0  0
 35 36  1  0  0  0
 36 37  2  0  0  0
 36 38  1  0  0  0
 36 39  1  0  0  0
 40 62  1  0  0  0
 40 63  1  0  0  0
 40 64  1  0  0  0
M  CHG  2  38  -1  39  -1
M  END
> <s_m_entry_id>
667

> <Applicants>
Rigel Pharmaceuticals

> <CHEMBL_ID>
CHEMBL2103830

> <Canonical_Smiles>
P(OCN1c2nc(Nc3nc(ncc3F)Nc3cc(OC)c(OC)c(OC)c3)ccc2OC(C)(C)C1=O)(O)(O)=O

> <Chirality>
Achiral Molecule

> <First_Approval>
2018

> <Phase>
4

> <SC_Patent>
US-7449458-B2

> <Synonyms>
FOSTAMATINIB | R-788 | R-788 FREE ACID | R-935788 | R-935788 FREE ACID | R788 FREE ACID | R935788 FREE ACID

> <Indications>
Indicated for the treatment of chronic immune thrombocytopenia (ITP) in adult patients who have had an insufficient response to a previous treatment

> <Type>
nan

> <targets_id>
P43405

> <inchi>
InChI=1S/C23H26FN6O9P/c1-23(2)21(31)30(11-38-40(32,33)34)20-14(39-23)6-7-17(28-20)27-19-13(24)10-25-22(29-19)26-12-8-15(35-3)18(37-5)16(9-12)36-4/h6-10H,11H2,1-5H3,(H2,32,33,34)(H2,25,26,27,28,29)

> <stdInchikey>
GKDRMWXFWHEQQT-UHFFFAOYSA-N

> <csid>
9846198

> <Links>
|http://www.chemspider.com/Chemical-Structure.9846198.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2103830|http://pubchem.ncbi.nlm.nih.gov/compound/11671467|http://www.drugbank.ca/drugs/DB12010| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=2RC|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/2RC|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7796|http://zinc15.docking.org/substances/ZINC000043131420|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=SQ8A3S5101|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50431381

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
580.1

> <HBA>
12

> <HBD>
4

> <NRB>
10

> <TPSA>
186.7

> <LogP>
3.1

> <RoF>
2

> <Targets>
SYK

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0741

> <r_epik_State_Penalty>
  0.0636

> <i_epik_Tot_Q>
-2

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
667

> <lig_pdbID>
'2RC'

> <pdbID>
4o75

> <Kinase families>
Tyr

> <indicationDB>
Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018 under the trade name Tavalisse for use in ITP <sup class="text-reference-group"><a class="reference-popover-link" data-content="Fostamatinib FDA Approval" href="#reference-L2644">8</a>,<a class="reference-popover-link" data-content="Official drug label" href="#label-reference">Label</a></sup>. Fostamatinib has also been granted orphan drug status by the FDA <sup class="text-reference-group"><a class="reference-popover-link" data-content="Fostamatinib FDA Approval" href="#reference-L2644">8</a></sup>.

> <uniprotId>
P43405|P0DMS8|Q99870|O00519|Q99808|P22309|O76074|P09917|P25774|P07711|P00519|P62344|P9WI81|Q9UK32|P29597|Q8NI60|P23458|P08581|Q8IY84|Q9P289|P17612|Q9Y6E0|Q13188|P42680|Q9BYT3|Q8TDR2|Q9NRP7|Q15208|Q9Y2H1|Q9UEW8|Q7L7X3|Q9UL54|Q9H2K8|Q9UHD2|Q02763|Q15569|P36897|P37173|P35590|Q9UKI8|Q86UE8|Q9UKE5|Q13470|Q07912|Q59H18|Q9BXA7|P33981|P42681|Q06418|O75385|Q8IYT8|Q6PHR2|P30291|P07947|Q56UN5|Q9NYL2|P43403|Q2M2I8|P42684|Q04771|P36896|Q96D53|Q9UM73|Q8NFD2|O14965|Q96GD4|Q9UQB9|P30530|P51451|Q9NSY1|O00238|Q13873|P51813|P15056|Q06187|Q14012|Q8IU85|Q96NX5|Q9UQM7|Q13554|Q13557|Q13555|Q8N5S9|Q96RR4|O14936|P07498|P06493|Q6DT37|P11802|Q00532|Q92772|O14757|O96017|O14578|P49759|P49760|P49761|Q9HAZ1|P07333|P41240|P48729|P68400|P19784|P53355|Q9UIK4|O43293|O15075|Q8N568|Q9C098|Q08345|Q16832|Q13627|Q9Y463|P00533|Q9BQI3|P19525|Q9P2K8|P21709|P29317|P29320|P54764|P54756|Q9UF33|Q15375|P29322|P54762|P29323|P54760|O15197|P04626|Q15303|O75460|P16591|P07332|P11362|P21802|P22607|P09769|P17948|P36888|P35916|P42345|P42685|P06241|O14976|P49840|P49841|P08631|Q9H2X6|Q9H422|Q9UPZ9|O14920|Q14164|P06213|P14616|P51617|Q9Y616|Q9NWZ3|Q08881|O60674|P52333|P35968|Q9Y2K2|P10721|O95835|P06239|P53667|P53671|Q5S007|P29376|P07948|P36507|P46734|Q13163|P52564|Q13233|Q02779|Q16584|Q12852|O43283|Q6ZN16|Q9Y2U5|Q99759|Q9Y6R4|O95382|P80192|Q92918|Q12851|Q8IVH8|O95819|Q9Y4K4|P53779|O15264|Q16539|Q8TD08|P31152|Q13164|P45984|Q8IW41|Q9P0L2|Q7KZI7|P27448|Q96L34|Q7Z460|Q9Y2H9|P42679|Q14680|Q12866|Q8N4C8|Q9BUB5|Q9HBH9|Q04912|O15146|Q15746|Q9H1R3|Q32MK0|Q86YV6|Q8NEV4|Q96PY6|Q8NG66|P51955|P51956|P51957|Q6P3R8|Q8TD19|P04629|Q16620|Q16288|O60285|Q9H093|O95747|Q13153|Q13177|O75914|O96013|Q9NQU5|Q9P286|Q00536|Q00537|P16234|P09619|O15530|Q96Q40|Q16816|Q9UBF8|O00750|O75747|O00329|P48736|P11309|Q86V86|P78356|Q8TBX8|Q99640|Q16512|Q16513|P53350|Q9NYY3|Q9H4B4|O00444|Q13131|Q13131|P54646|Q9Y478|O43741|P54619|Q9UGJ0|Q9UGI9|P22694|Q05655|Q02156|P05129|P41743|Q04759|Q15139|Q13237|Q13523|Q05397|Q14289|Q13882|P04049|P07949|Q9BRS2|Q9BVS4|O14730|Q13546|O43353|P57078|O75116|P08922|Q15418|P51812|Q52WX2|P0C264|Q96BR1|P57059|Q9H0K1|Q9H2G2|Q9NRH2|P12931|Q9H3Y6|O94804|O75716|Q9UEE5|O94768|Q8WU08|P08684|O60656

> <BrandName>
Tavalisse

> <FDA_approved>
Y

$$$$
Vemurafenib
                    3D
 Structure written by MMmdl.
 51 54  0  0  1  0            999 V2000
   -0.6101    3.8413   -1.5982 C   0  0  0  0  0  0
   -0.3041    2.3466   -1.4371 C   0  0  0  0  0  0
   -0.3657    1.8840    0.0284 C   0  0  0  0  0  0
    0.0025    0.0326    0.1681 S   0  0  0  0  0  0
    0.0117   -0.3495    1.5839 O   0  0  0  0  0  0
   -0.8262   -0.7084   -0.7893 O   0  0  0  0  0  0
    1.6788   -0.0844   -0.4044 N   0  0  0  0  0  0
    2.4645   -1.2366   -0.2460 C   0  0  0  0  0  0
    1.8918   -2.5025   -0.0711 C   0  0  0  0  0  0
    2.6984   -3.6238    0.1084 C   0  0  0  0  0  0
    4.0858   -3.4973    0.1184 C   0  0  0  0  0  0
    4.6751   -2.2369   -0.0551 C   0  0  0  0  0  0
    3.8601   -1.1090   -0.2447 C   0  0  0  0  0  0
    4.4193    0.1174   -0.4067 F   0  0  0  0  0  0
    6.1543   -2.0974   -0.0268 C   0  0  0  0  0  0
    6.8196   -2.2870   -1.0456 O   0  0  0  0  0  0
    6.7999   -1.7273    1.2363 C   0  0  0  0  0  0
    8.1654   -1.5545    1.4205 C   0  0  0  0  0  0
    8.4321   -1.1988    2.7180 N   0  0  0  0  0  0
    7.2527   -1.1292    3.4204 C   0  0  0  0  0  0
    6.1946   -1.4616    2.5257 C   0  0  0  0  0  0
    4.8937   -1.4526    3.0675 C   0  0  0  0  0  0
    4.7112   -1.1156    4.4160 C   0  0  0  0  0  0
    5.8496   -0.8068    5.1728 C   0  0  0  0  0  0
    7.1257   -0.8071    4.7090 N   0  0  0  0  0  0
    3.3489   -1.0860    5.0204 C   0  0  0  0  0  0
    3.1348   -1.5656    6.3194 C   0  0  0  0  0  0
    1.8634   -1.5384    6.8859 C   0  0  0  0  0  0
    0.7925   -1.0303    6.1552 C   0  0  0  0  0  0
    0.9864   -0.5506    4.8627 C   0  0  0  0  0  0
    2.2591   -0.5794    4.2990 C   0  0  0  0  0  0
   -0.7845   -0.9951    6.8552 Cl  0  0  0  0  0  0
    4.8440   -4.6048    0.3054 F   0  0  0  0  0  0
   -0.5621    4.1374   -2.6464 H   0  0  0  0  0  0
    0.1052    4.4541   -1.0486 H   0  0  0  0  0  0
   -1.6087    4.0827   -1.2321 H   0  0  0  0  0  0
   -1.0133    1.7710   -2.0335 H   0  0  0  0  0  0
    0.6837    2.1383   -1.8497 H   0  0  0  0  0  0
    0.3614    2.4104    0.6471 H   0  0  0  0  0  0
   -1.3568    2.0479    0.4522 H   0  0  0  0  0  0
    2.1626    0.7807   -0.5957 H   0  0  0  0  0  0
    0.8202   -2.6332   -0.0698 H   0  0  0  0  0  0
    2.2442   -4.5944    0.2442 H   0  0  0  0  0  0
    8.9842   -1.6525    0.7220 H   0  0  0  0  0  0
    9.3658   -1.0220    3.0594 H   0  0  0  0  0  0
    4.0385   -1.7048    2.4608 H   0  0  0  0  0  0
    5.7510   -0.5332    6.2134 H   0  0  0  0  0  0
    3.9543   -1.9690    6.8963 H   0  0  0  0  0  0
    1.7119   -1.9118    7.8881 H   0  0  0  0  0  0
    0.1545   -0.1560    4.2980 H   0  0  0  0  0  0
    2.3935   -0.1985    3.2967 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 34  1  0  0  0
  1 35  1  0  0  0
  1 36  1  0  0  0
  2  3  1  0  0  0
  2 37  1  0  0  0
  2 38  1  0  0  0
  3  4  1  0  0  0
  3 39  1  0  0  0
  3 40  1  0  0  0
  4  5  2  0  0  0
  4  6  2  0  0  0
  4  7  1  0  0  0
  7  8  1  0  0  0
  7 41  1  0  0  0
  8  9  1  0  0  0
  8 13  2  0  0  0
  9 10  2  0  0  0
  9 42  1  0  0  0
 10 11  1  0  0  0
 10 43  1  0  0  0
 11 12  2  0  0  0
 11 33  1  0  0  0
 12 13  1  0  0  0
 12 15  1  0  0  0
 13 14  1  0  0  0
 15 16  2  0  0  0
 15 17  1  0  0  0
 17 18  2  0  0  0
 17 21  1  0  0  0
 18 19  1  0  0  0
 18 44  1  0  0  0
 19 20  1  0  0  0
 19 45  1  0  0  0
 20 21  1  0  0  0
 20 25  2  0  0  0
 21 22  2  0  0  0
 22 23  1  0  0  0
 22 46  1  0  0  0
 23 24  2  0  0  0
 23 26  1  0  0  0
 24 25  1  0  0  0
 24 47  1  0  0  0
 26 27  1  0  0  0
 26 31  2  0  0  0
 27 28  2  0  0  0
 27 48  1  0  0  0
 28 29  1  0  0  0
 28 49  1  0  0  0
 29 30  2  0  0  0
 29 32  1  0  0  0
 30 31  1  0  0  0
 30 50  1  0  0  0
 31 51  1  0  0  0
M  END
> <s_m_entry_id>
669

> <Applicants>
Hoffmann-La Roche

> <CHEMBL_ID>
CHEMBL1229517

> <Canonical_Smiles>
Clc1ccc(cc1)-c1cc2c([nH]cc2C(=O)c2c(F)c(NS(=O)(=O)CCC)ccc2F)nc1

> <Chirality>
Achiral Molecule

> <First_Approval>
2011

> <Phase>
4

> <SC_Patent>
US-7504509-B2

> <Synonyms>
PLX-4032 | PLX4032 | RG 7204 | RG-7204 | RO 5185426 | RO-51-85426 | RO-5185426 | VEMURAFENIB | ZELBORAF

> <Indications>
Vemurafenib is approved since 2011 for the treatment of metastatic melanoma with a mutation on BRAF in the valine located in the exon 15 at codon 600, this mutation is denominated as V600E.

> <Type>
1.5

> <targets_id>
P15056

> <inchi>
InChI=1S/C23H18ClF2N3O3S/c1-2-9-33(31,32)29-19-8-7-18(25)20(21(19)26)22(30)17-12-28-23-16(17)10-14(11-27-23)13-3-5-15(24)6-4-13/h3-8,10-12,29H,2,9H2,1H3,(H,27,28)

> <stdInchikey>
GPXBXXGIAQBQNI-UHFFFAOYSA-N

> <csid>
24747352

> <Links>
|http://www.chemspider.com/Chemical-Structure.24747352.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1229517|http://pubchem.ncbi.nlm.nih.gov/compound/42611257|http://www.drugbank.ca/drugs/DB08881| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=032|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/032|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5893|http://zinc15.docking.org/substances/ZINC000052509366|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=207SMY3FQT|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50396483

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
489.1

> <HBA>
4

> <HBD>
2

> <NRB>
7

> <TPSA>
91.9

> <LogP>
5.5

> <RoF>
1

> <Targets>
BRAF

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_epik_Ionization_Penalty>
  0.3813

> <r_epik_State_Penalty>
  0.3792

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
669

> <lig_pdbID>
'032'

> <pdbID>
3og7 4rzv 5hes

> <Kinase families>
TKL

> <indicationDB>
Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Kim G, McKee AE, Ning YM, Hazarika M, Theoret M, Johnson JR, Xu QC, Tang S, Sridhara R, Jiang X, He K, Roscoe D, McGuinn WD, Helms WS, Russell AM, Miksinski SP, Zirkelbach JF, Earp J, Liu Q, Ibrahim A, Justice R, Pazdur R: FDA approval summary: vemurafenib for treatment of unresectable or metastatic melanoma with the BRAFV600E mutation. Clin Cancer Res. 2014 Oct 1;20(19):4994-5000. doi: 10.1158/1078-0432.CCR-14-0776. Epub 2014 Aug 5. (PubMed ID 25096067)" href="#reference-A31269">2</a></sup> It exerts its function by binding to the ATP-binding domain of the mutant BRAF.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Luke JJ, Hodi FS: Vemurafenib and BRAF inhibition: a new class of treatment for metastatic melanoma. Clin Cancer Res. 2012 Jan 1;18(1):9-14. doi: 10.1158/1078-0432.CCR-11-2197. Epub  2011 Nov 14. (PubMed ID 22083257)" href="#reference-A31270">3</a></sup> Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche. After approval, Roche in collaboration with Genentech launched a broad development program. <sup class="text-reference-group"><a class="reference-popover-link" data-content="Roche news" href="#reference-L1012">8</a></sup>

> <uniprotId>
P15056|P05177|P10635|P08684|P11712|P10632|P20813|P02768|P02763

> <BrandName>
Zelboraf

> <Melting point>
272°C

> <Withdrawn>
|Study NCT02145910 in nan was Withdrawn during Phase 1 because Study was never opened to accrual There is no clinical benefit to patients|Study NCT02427893 in United States was Withdrawn during Phase 3 because no patients were enrolled|Study NCT01843738 in United States was Withdrawn during Phase 1 because Competing Trials|Study NCT03005639 in United States was Withdrawn during Phase 2 because Sponsor has decided to close study

> <FDA_approved>
Y

$$$$
Abemaciclib
                    3D
 Structure written by MMmdl.
 70 74  0  0  1  0            999 V2000
   -5.5488    9.0539   -3.3022 C   0  0  0  0  0  0
   -4.4880    7.9542   -3.1233 C   0  0  0  0  0  0
   -4.9928    6.6159   -3.4610 N   0  0  0  0  0  0
   -3.9037    5.6424   -3.6075 C   0  0  0  0  0  0
   -3.2515    5.2310   -2.2667 C   0  0  0  0  0  0
   -4.3351    4.7271   -1.2846 N   0  3  0  0  0  0
   -5.5050    5.7288   -1.1535 C   0  0  0  0  0  0
   -6.0338    6.1081   -2.5558 C   0  0  0  0  0  0
   -3.7421    4.4214    0.1109 C   0  0  0  0  0  0
   -2.7081    3.3064    0.1253 C   0  0  0  0  0  0
   -3.0958    1.9658    0.2121 C   0  0  0  0  0  0
   -2.1210    0.9662    0.2446 C   0  0  0  0  0  0
   -0.7709    1.3292    0.1906 C   0  0  0  0  0  0
   -0.3860    2.6328    0.1128 N   0  0  0  0  0  0
   -1.3413    3.5945    0.0880 C   0  0  0  0  0  0
    0.1906    0.3040    0.2292 N   0  0  0  0  0  0
    1.5919    0.3079    0.1391 C   0  0  0  0  0  0
    2.1855   -0.9049    0.2793 N   0  0  0  0  0  0
    3.5402   -0.9381    0.1896 C   0  0  0  0  0  0
    4.3054    0.2070   -0.0377 C   0  0  0  0  0  0
    3.6187    1.4248   -0.1700 C   0  0  0  0  0  0
    2.2593    1.4722   -0.0846 N   0  0  0  0  0  0
    4.3007    2.7289   -0.4249 C   0  0  0  0  0  0
    5.4769    3.0523    0.2704 C   0  0  0  0  0  0
    6.0845    4.2858   -0.0023 C   0  0  0  0  0  0
    5.5394    5.1918   -0.9442 C   0  0  0  0  0  0
    4.3628    4.8608   -1.6281 C   0  0  0  0  0  0
    3.7646    3.6328   -1.3543 C   0  0  0  0  0  0
    3.8135    5.7035   -2.5331 F   0  0  0  0  0  0
    6.3011    6.3226   -1.0404 N   0  0  0  0  0  0
    7.2832    6.1392   -0.1959 C   0  0  0  0  0  0
    7.2217    4.9259    0.4732 N   0  0  0  0  0  0
    8.1756    4.4338    1.4811 C   0  0  0  0  0  0
    8.8699    3.1475    0.9931 C   0  0  0  0  0  0
    7.4840    4.2690    2.8478 C   0  0  0  0  0  0
    8.3752    7.1685    0.0149 C   0  0  0  0  0  0
    5.6523    0.1209   -0.1427 F   0  0  0  0  0  0
   -5.1022   10.0389   -3.1657 H   0  0  0  0  0  0
   -6.3576    8.9686   -2.5769 H   0  0  0  0  0  0
   -5.9848    9.0290   -4.3017 H   0  0  0  0  0  0
   -3.6552    8.1909   -3.7875 H   0  0  0  0  0  0
   -4.0871    7.9802   -2.1097 H   0  0  0  0  0  0
   -4.3012    4.7539   -4.1005 H   0  0  0  0  0  0
   -3.1463    6.0331   -4.2888 H   0  0  0  0  0  0
   -2.5449    4.4133   -2.4110 H   0  0  0  0  0  0
   -2.7331    6.0630   -1.7875 H   0  0  0  0  0  0
   -6.2753    5.2367   -0.5584 H   0  0  0  0  0  0
   -5.1382    6.5966   -0.6030 H   0  0  0  0  0  0
   -6.8497    6.8247   -2.4687 H   0  0  0  0  0  0
   -6.4833    5.2269   -3.0166 H   0  0  0  0  0  0
   -3.3298    5.3647    0.4753 H   0  0  0  0  0  0
   -4.5982    4.1549    0.7337 H   0  0  0  0  0  0
   -4.1414    1.6973    0.2546 H   0  0  0  0  0  0
   -2.4156   -0.0714    0.3113 H   0  0  0  0  0  0
   -0.9871    4.6137    0.0322 H   0  0  0  0  0  0
   -0.1978   -0.6191    0.3515 H   0  0  0  0  0  0
    4.0095   -1.9053    0.2958 H   0  0  0  0  0  0
    5.8897    2.3714    0.9988 H   0  0  0  0  0  0
    2.8592    3.3772   -1.8862 H   0  0  0  0  0  0
    8.9540    5.1864    1.6064 H   0  0  0  0  0  0
    9.6427    2.8336    1.6954 H   0  0  0  0  0  0
    9.3539    3.3018    0.0279 H   0  0  0  0  0  0
    8.1749    2.3155    0.8852 H   0  0  0  0  0  0
    8.2076    4.0045    3.6193 H   0  0  0  0  0  0
    6.7241    3.4882    2.8361 H   0  0  0  0  0  0
    7.0015    5.1959    3.1608 H   0  0  0  0  0  0
    8.2311    8.0582   -0.5996 H   0  0  0  0  0  0
    9.3576    6.7684   -0.2363 H   0  0  0  0  0  0
    8.4156    7.5056    1.0509 H   0  0  0  0  0  0
   -4.7103    3.8667   -1.6583 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 38  1  0  0  0
  1 39  1  0  0  0
  1 40  1  0  0  0
  2  3  1  0  0  0
  2 41  1  0  0  0
  2 42  1  0  0  0
  3  4  1  0  0  0
  3  8  1  0  0  0
  4  5  1  0  0  0
  4 43  1  0  0  0
  4 44  1  0  0  0
  5  6  1  0  0  0
  5 45  1  0  0  0
  5 46  1  0  0  0
  6  7  1  0  0  0
  6  9  1  0  0  0
  6 70  1  0  0  0
  7  8  1  0  0  0
  7 47  1  0  0  0
  7 48  1  0  0  0
  8 49  1  0  0  0
  8 50  1  0  0  0
  9 10  1  0  0  0
  9 51  1  0  0  0
  9 52  1  0  0  0
 10 11  1  0  0  0
 10 15  2  0  0  0
 11 12  2  0  0  0
 11 53  1  0  0  0
 12 13  1  0  0  0
 12 54  1  0  0  0
 13 14  2  0  0  0
 13 16  1  0  0  0
 14 15  1  0  0  0
 15 55  1  0  0  0
 16 17  1  0  0  0
 16 56  1  0  0  0
 17 18  1  0  0  0
 17 22  2  0  0  0
 18 19  2  0  0  0
 19 20  1  0  0  0
 19 57  1  0  0  0
 20 21  2  0  0  0
 20 37  1  0  0  0
 21 22  1  0  0  0
 21 23  1  0  0  0
 23 24  1  0  0  0
 23 28  2  0  0  0
 24 25  2  0  0  0
 24 58  1  0  0  0
 25 26  1  0  0  0
 25 32  1  0  0  0
 26 27  2  0  0  0
 26 30  1  0  0  0
 27 28  1  0  0  0
 27 29  1  0  0  0
 28 59  1  0  0  0
 30 31  2  0  0  0
 31 32  1  0  0  0
 31 36  1  0  0  0
 32 33  1  0  0  0
 33 34  1  0  0  0
 33 35  1  0  0  0
 33 60  1  0  0  0
 34 61  1  0  0  0
 34 62  1  0  0  0
 34 63  1  0  0  0
 35 64  1  0  0  0
 35 65  1  0  0  0
 35 66  1  0  0  0
 36 67  1  0  0  0
 36 68  1  0  0  0
 36 69  1  0  0  0
M  CHG  1   6   1
M  END
> <s_m_entry_id>
671

> <Applicants>
Eli Lilly

> <CHEMBL_ID>
CHEMBL3301610

> <Canonical_Smiles>
Fc1cnc(nc1-c1cc(F)c2nc(n(c2c1)C(C)C)C)Nc1ncc(cc1)CN1CCN(CC1)CC

> <Chirality>
Achiral Molecule

> <First_Approval>
2017

> <Phase>
4

> <SC_Patent>
US-7855211-B2

> <Synonyms>
ABEMACICLIB | LY-2835219 | LY2835219 | VERZENIO | VERZENIOS

> <Indications>
On September 28, 2017, the Food and Drug Administration approved abemaciclib (VERZENIO, Eli Lilly and Company) in combination with fulvestrant for women with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. In addition, abemaciclib was approved as monotherapy for  women and men with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.

> <Type>
1

> <targets_id>
P11802|Q00534

> <inchi>
InChI=1S/C27H32F2N8/c1-5-35-8-10-36(11-9-35)16-19-6-7-24(30-14-19)33-27-31-15-22(29)25(34-27)20-12-21(28)26-23(13-20)37(17(2)3)18(4)32-26/h6-7,12-15,17H,5,8-11,16H2,1-4H3,(H,30,31,33,34)

> <stdInchikey>
UZWDCWONPYILKI-UHFFFAOYSA-N

> <csid>
29340700

> <Links>
|http://www.chemspider.com/Chemical-Structure.29340700.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3301610|http://pubchem.ncbi.nlm.nih.gov/compound/46220502|http://www.drugbank.ca/drugs/DB12001| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=6ZV|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/6ZV|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7382|http://zinc15.docking.org/substances/ZINC000072318121|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=60UAB198HK|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50110183

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
506.3

> <HBA>
8

> <HBD>
1

> <NRB>
7

> <TPSA>
75

> <LogP>
4.9

> <RoF>
1

> <Targets>
CDK4; CDK6

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0469

> <r_epik_State_Penalty>
  0.2021

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
671

> <lig_pdbID>
'6ZV'

> <pdbID>
5l2s

> <Kinase families>
CMGC

> <indicationDB>
Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. On September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for the treatment of HR-positive and HER2-negative advanced or metastatic breast cancer that has progressed after unsuccessful endocrine therapy. It is either given alone in patients who has undergone endocrine therapy and chemotherapy after the metastasis of cancer, or in combination with <a href="https://go.drugbank.com/drugs/DB00947">Fulvestrant</a>. Following oral treatment in patients with HR-positive, HER2-negative breast cancer, abemaciclib demonstrated increased progression-free survival rates and objective response rates. Abemaciclib has been used in trials studying the treatment of melanoma, lymphoma, neoplasm, solid tumor, and glioblastoma.

> <uniprotId>
P11802|Q00534|P08684|P05177|P20813|P10632|P11712|P10635

> <BrandName>
Verzenio;Verzenios

> <Withdrawn>
|Study NCT04220892 in United States was Withdrawn during Early Phase 1 because One of the study drugs will no longer be supplied by manufacturer and the pembrolizumab +
    abemaciclib study arm is removed due to toxicity seen in other trials|Study NCT03846583 in nan was Withdrawn during Phase 1 because Study halted prematurely, prior to enrollment of first participant

> <FDA_approved>
Y

$$$$
Pralsetinib
                    3D
 Structure written by MMmdl.
 71 75  0  0  1  0            999 V2000
   -1.8760    7.5367   -2.2781 C   0  0  0  0  0  0
   -1.6887    6.0588   -2.0409 C   0  0  0  0  0  0
   -0.5836    5.5354   -1.4295 N   0  0  0  0  0  0
   -0.6020    4.2038   -1.3292 N   0  0  0  0  0  0
   -1.7431    3.8217   -1.8687 C   0  0  0  0  0  0
   -2.4536    4.9414   -2.3264 C   0  0  0  0  0  0
   -2.1656    2.5099   -1.9518 N   0  0  0  0  0  0
   -1.5284    1.3217   -1.5470 C   0  0  0  0  0  0
   -0.2717    1.3518   -1.0270 N   0  0  0  0  0  0
    0.2796    0.1668   -0.6554 C   0  0  0  0  0  0
   -0.3163   -1.0498   -0.7596 N   0  0  0  0  0  0
   -1.5704   -1.0553   -1.2838 C   0  0  0  0  0  0
   -2.2202    0.1140   -1.6959 C   0  0  0  0  0  0
   -2.2334   -2.4140   -1.3978 C   0  0  0  0  0  0
    1.7053    0.2139   -0.1007 C   0  0  1  0  0  0
    2.7050    0.7108   -1.1717 C   0  0  0  0  0  0
    4.1430    0.8215   -0.6252 C   0  0  0  0  0  0
    4.2757    1.7163    0.6424 C   0  0  1  0  0  0
    3.2423    1.2410    1.7188 C   0  0  0  0  0  0
    1.7940    1.0512    1.2009 C   0  0  0  0  0  0
    5.6305    1.5312    1.0918 O   0  0  0  0  0  0
    6.0436    2.1583    2.3067 C   0  0  0  0  0  0
    4.0538    3.2056    0.2180 C   0  0  0  0  0  0
    3.0125    3.8039    0.4962 O   0  0  0  0  0  0
    5.0363    3.7826   -0.5043 N   0  0  0  0  0  0
    4.9659    5.1062   -1.1377 C   0  0  2  0  0  0
    3.8368    5.2534   -2.1675 C   0  0  0  0  0  0
    3.1372    6.4592   -2.2837 C   0  0  0  0  0  0
    2.0930    6.6346   -3.1326 N   0  0  0  0  0  0
    1.7034    5.5793   -3.9042 C   0  0  0  0  0  0
    2.3553    4.3407   -3.8531 C   0  0  0  0  0  0
    3.4312    4.1847   -2.9796 C   0  0  0  0  0  0
    0.5817    5.7593   -4.7500 N   0  0  0  0  0  0
    0.2738    6.9662   -5.2638 N   0  0  0  0  0  0
   -0.8146    6.7756   -5.9738 C   0  0  0  0  0  0
   -1.2544    5.4498   -5.9499 C   0  0  0  0  0  0
   -0.3282    4.8072   -5.1511 C   0  0  0  0  0  0
   -2.3054    4.9344   -6.5444 F   0  0  0  0  0  0
    6.3243    5.4776   -1.7545 C   0  0  0  0  0  0
   -2.7935    7.7442   -2.8289 H   0  0  0  0  0  0
   -1.0536    7.9587   -2.8559 H   0  0  0  0  0  0
   -1.9297    8.0906   -1.3409 H   0  0  0  0  0  0
    0.1954    6.0827   -1.0923 H   0  0  0  0  0  0
   -3.4165    4.9350   -2.8147 H   0  0  0  0  0  0
   -3.0804    2.3297   -2.3368 H   0  0  0  0  0  0
   -3.2180    0.0830   -2.1091 H   0  0  0  0  0  0
   -3.2112   -2.3452   -1.8761 H   0  0  0  0  0  0
   -2.3712   -2.8526   -0.4088 H   0  0  0  0  0  0
   -1.6167   -3.0910   -1.9901 H   0  0  0  0  0  0
    1.9852   -0.8107    0.1546 H   0  0  0  0  0  0
    2.6953    0.0338   -2.0272 H   0  0  0  0  0  0
    2.3909    1.6824   -1.5561 H   0  0  0  0  0  0
    4.4897   -0.1842   -0.3810 H   0  0  0  0  0  0
    4.8098    1.1624   -1.4196 H   0  0  0  0  0  0
    3.5816    0.2838    2.1179 H   0  0  0  0  0  0
    3.2288    1.9212    2.5718 H   0  0  0  0  0  0
    1.3361    2.0274    1.0430 H   0  0  0  0  0  0
    1.1947    0.5780    1.9800 H   0  0  0  0  0  0
    7.1039    1.9623    2.4650 H   0  0  0  0  0  0
    5.5079    1.7597    3.1682 H   0  0  0  0  0  0
    5.9114    3.2403    2.2824 H   0  0  0  0  0  0
    5.8911    3.2647   -0.6471 H   0  0  0  0  0  0
    4.7754    5.8182   -0.3309 H   0  0  0  0  0  0
    3.4013    7.3131   -1.6768 H   0  0  0  0  0  0
    2.0404    3.5102   -4.4678 H   0  0  0  0  0  0
    3.9350    3.2307   -2.9268 H   0  0  0  0  0  0
   -1.2908    7.5874   -6.5033 H   0  0  0  0  0  0
   -0.2502    3.7803   -4.8256 H   0  0  0  0  0  0
    6.3070    6.4844   -2.1739 H   0  0  0  0  0  0
    6.6012    4.7899   -2.5549 H   0  0  0  0  0  0
    7.1185    5.4522   -1.0072 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 40  1  0  0  0
  1 41  1  0  0  0
  1 42  1  0  0  0
  2  3  1  0  0  0
  2  6  2  0  0  0
  3  4  1  0  0  0
  3 43  1  0  0  0
  4  5  2  0  0  0
  5  6  1  0  0  0
  5  7  1  0  0  0
  6 44  1  0  0  0
  7  8  1  0  0  0
  7 45  1  0  0  0
  8  9  2  0  0  0
  8 13  1  0  0  0
  9 10  1  0  0  0
 10 11  2  0  0  0
 10 15  1  0  0  0
 11 12  1  0  0  0
 12 13  2  0  0  0
 12 14  1  0  0  0
 13 46  1  0  0  0
 14 47  1  0  0  0
 14 48  1  0  0  0
 14 49  1  0  0  0
 15 16  1  0  0  0
 15 20  1  0  0  0
 15 50  1  0  0  0
 16 17  1  0  0  0
 16 51  1  0  0  0
 16 52  1  0  0  0
 17 18  1  0  0  0
 17 53  1  0  0  0
 17 54  1  0  0  0
 18 19  1  0  0  0
 18 21  1  0  0  0
 18 23  1  0  0  0
 19 20  1  0  0  0
 19 55  1  0  0  0
 19 56  1  0  0  0
 20 57  1  0  0  0
 20 58  1  0  0  0
 21 22  1  0  0  0
 22 59  1  0  0  0
 22 60  1  0  0  0
 22 61  1  0  0  0
 23 24  2  0  0  0
 23 25  1  0  0  0
 25 26  1  0  0  0
 25 62  1  0  0  0
 26 27  1  0  0  0
 26 39  1  0  0  0
 26 63  1  0  0  0
 27 28  1  0  0  0
 27 32  2  0  0  0
 28 29  2  0  0  0
 28 64  1  0  0  0
 29 30  1  0  0  0
 30 31  2  0  0  0
 30 33  1  0  0  0
 31 32  1  0  0  0
 31 65  1  0  0  0
 32 66  1  0  0  0
 33 34  1  0  0  0
 33 37  1  0  0  0
 34 35  2  0  0  0
 35 36  1  0  0  0
 35 67  1  0  0  0
 36 37  2  0  0  0
 36 38  1  0  0  0
 37 68  1  0  0  0
 39 69  1  0  0  0
 39 70  1  0  0  0
 39 71  1  0  0  0
M  END
> <s_m_entry_id>
679

> <Applicants>
Blueprint Medicines

> <CHEMBL_ID>
CHEMBL4582651

> <Canonical_Smiles>
Fc1cn(nc1)-c1ncc(cc1)[C@@H](NC(=O)C1(OC)CCC(CC1)c1nc(cc(n1)Nc1n[nH]c(c1)C)C)C

> <Chirality>
Single Stereoisomer

> <First_Approval>
2020

> <Phase>
4

> <SC_Patent>
None

> <Synonyms>
BLU-667|X581238|X-581238|BLU123244|BLU-123244

> <Indications>
Pralsetinib, also known as BLU-667, is a highly potent, selective, next generation RET inhibitor. BLU-667 is a potent and selective inhibitor of RET mutations, fusions, and predicted resistant mutants. RET fusions are key drivers of multiple cancers, including lung and thyroid cancer, and our research suggests that RET also plays a key role in some colon and breast cancers. By simultaneously targeting the primary driver and predicted resistant mutants that render cancer cells insensitive to treatment with currently approved drugs

> <Type>
nan

> <targets_id>
nan

> <inchi>
InChI=1S/C27H32FN9O2/c1-16-11-22(33-23-12-17(2)35-36-23)34-25(31-16)19-7-9-27(39-4,10-8-19)26(38)32-18(3)20-5-6-24(29-13-20)37-15-21(28)14-30-37/h5-6,11-15,18-19H,7-10H2,1-4H3,(H,32,38)(H2,31,33,34,35,36)/t18-,19-,27-/m0/s1

> <stdInchikey>
GBLBJPZSROAGMF-BATDWUPUSA-N

> <csid>
71060332

> <Links>
|http://www.chemspider.com/Chemical-Structure.71060332.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4297597| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=Q4J|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/Q4J|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=1WPE73O1WV

> <LinkName>
|ChemSpider|ChEMBL|RCSB|PDBe|FDA SRS

> <MW>
533.3

> <HBA>
9

> <HBD>
3

> <NRB>
8

> <TPSA>
135.5

> <LogP>
4.2

> <RoF>
1

> <Targets>
nan

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
0.8426

> <r_epik_Ionization_Penalty>
  0.0018

> <r_epik_State_Penalty>
  0.0915

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
679

> <lig_pdbID>
'Q4J'

> <pdbID>
7ju5

> <FDA_approved>
Y

$$$$
Fasudil
                    3D
 Structure written by MMmdl.
 38 40  0  0  1  0            999 V2000
   -2.1845   -0.9273    0.0122 C   0  0  0  0  0  0
   -2.7062    0.3555    0.1253 C   0  0  0  0  0  0
   -1.8378    1.4689    0.1881 C   0  0  0  0  0  0
   -2.3143    2.7955    0.3076 C   0  0  0  0  0  0
   -1.5250    3.8913    0.3690 N   0  0  0  0  0  0
   -0.1885    3.6963    0.3027 C   0  0  0  0  0  0
    0.4034    2.4393    0.1864 C   0  0  0  0  0  0
   -0.4203    1.2757    0.1324 C   0  0  0  0  0  0
    0.0857   -0.0600    0.0298 C   0  0  0  0  0  0
   -0.8107   -1.1314   -0.0333 C   0  0  0  0  0  0
    1.8535   -0.4132   -0.0006 S   0  0  0  0  0  0
    2.0219   -1.8706    0.0438 O   0  0  0  0  0  0
    2.4176    0.3549   -1.1166 O   0  0  0  0  0  0
    2.4850    0.2329    1.5291 N   0  0  0  0  0  0
    3.7078    1.0774    1.4783 C   0  0  0  0  0  0
    3.8929    2.0345    2.6723 C   0  0  0  0  0  0
    2.6633    2.8807    3.0776 C   0  0  0  0  0  0
    1.4082    2.0592    3.4410 N   0  3  0  0  0  0
    1.6472    0.6198    3.9318 C   0  0  0  0  0  0
    1.9590   -0.3711    2.7859 C   0  0  0  0  0  0
   -2.8527   -1.7747   -0.0379 H   0  0  0  0  0  0
   -3.7757    0.5068    0.1638 H   0  0  0  0  0  0
   -3.3784    2.9777    0.3561 H   0  0  0  0  0  0
    0.4245    4.5849    0.3445 H   0  0  0  0  0  0
    1.4773    2.3642    0.1368 H   0  0  0  0  0  0
   -0.4477   -2.1452   -0.1156 H   0  0  0  0  0  0
    4.5673    0.4090    1.4129 H   0  0  0  0  0  0
    3.7049    1.6424    0.5464 H   0  0  0  0  0  0
    4.2464    1.4674    3.5336 H   0  0  0  0  0  0
    4.7146    2.7124    2.4396 H   0  0  0  0  0  0
    2.8655    3.4601    3.9791 H   0  0  0  0  0  0
    2.3323    3.5584    2.2903 H   0  0  0  0  0  0
    0.8973    2.5666    4.1498 H   0  0  0  0  0  0
    2.4607    0.6999    4.6532 H   0  0  0  0  0  0
    0.7594    0.3268    4.4933 H   0  0  0  0  0  0
    1.0096   -0.8326    2.5130 H   0  0  0  0  0  0
    2.5658   -1.2180    3.1078 H   0  0  0  0  0  0
    0.8131    2.0075    2.6259 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 10  2  0  0  0
  1 21  1  0  0  0
  2  3  2  0  0  0
  2 22  1  0  0  0
  3  4  1  0  0  0
  3  8  1  0  0  0
  4  5  2  0  0  0
  4 23  1  0  0  0
  5  6  1  0  0  0
  6  7  2  0  0  0
  6 24  1  0  0  0
  7  8  1  0  0  0
  7 25  1  0  0  0
  8  9  2  0  0  0
  9 10  1  0  0  0
  9 11  1  0  0  0
 10 26  1  0  0  0
 11 12  2  0  0  0
 11 13  2  0  0  0
 11 14  1  0  0  0
 14 15  1  0  0  0
 14 20  1  0  0  0
 15 16  1  0  0  0
 15 27  1  0  0  0
 15 28  1  0  0  0
 16 17  1  0  0  0
 16 29  1  0  0  0
 16 30  1  0  0  0
 17 18  1  0  0  0
 17 31  1  0  0  0
 17 32  1  0  0  0
 18 19  1  0  0  0
 18 33  1  0  0  0
 18 38  1  0  0  0
 19 20  1  0  0  0
 19 34  1  0  0  0
 19 35  1  0  0  0
 20 36  1  0  0  0
 20 37  1  0  0  0
M  CHG  1  18   1
M  END
> <s_m_entry_id>
683

> <Applicants>
Asahi Kasei Pharma Corp

> <CHEMBL_ID>
CHEMBL38380

> <Canonical_Smiles>
S(=O)(=O)(N1CCCNCC1)c1c2c(ccc1)cncc2

> <Chirality>
Achiral Molecule

> <First_Approval>
nan

> <Phase>
4

> <SC_Patent>
None

> <Synonyms>
AT 877 | AT-877 | FASUDIL | HA 1077 | HA-1077 | ZK-258594

> <Indications>
Fasudil is a potent inhibitor of the Rho-kinases ROCK1 and ROCK2.

> <Type>
nan

> <targets_id>
nan

> <inchi>
InChI=1S/C14H17N3O2S/c18-20(19,17-9-2-6-15-8-10-17)14-4-1-3-12-11-16-7-5-13(12)14/h1,3-5,7,11,15H,2,6,8-10H2

> <stdInchikey>
NGOGFTYYXHNFQH-UHFFFAOYSA-N

> <csid>
3426

> <Links>
|http://www.chemspider.com/Chemical-Structure.3426.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL38380|http://pubchem.ncbi.nlm.nih.gov/compound/3547|http://www.drugbank.ca/drugs/DB08162| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=M77|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/M77|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5181|http://zinc15.docking.org/substances/ZINC000000006486|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=Q0CH43PGXS|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=14027

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
291.1

> <HBA>
4

> <HBD>
1

> <NRB>
2

> <TPSA>
62.3

> <LogP>
1.2

> <RoF>
0

> <Targets>
nan

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_epik_Ionization_Penalty>
  0.0088

> <r_epik_State_Penalty>
  0.0061

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
683

> <lig_pdbID>
'M77'

> <pdbID>
1q8w 2esm 2f2u 2gni 3tku 5lcp 5nw8 5o0e 5ok3 5vef 6em2 6emb 6ers 6erw 6i2a 6i2c 6yna

> <indicationDB>
Fasudil has been investigated in Carotid Stenosis.

> <uniprotId>
P61925|P17612|Q13464|O75116

> <FDA_approved>
N

$$$$
Ibrutinib
                    3D
 Structure written by MMmdl.
 57 61  0  0  1  0            999 V2000
   -6.9411   -4.9075   -2.9678 C   0  0  0  0  0  0
   -6.1278   -4.5220   -1.9663 C   0  0  0  0  0  0
   -4.9845   -3.6531   -2.1807 C   0  0  0  0  0  0
   -4.9510   -2.9000   -3.1587 O   0  0  0  0  0  0
   -3.9734   -3.6879   -1.2631 N   0  0  0  0  0  0
   -3.9089   -4.5762   -0.0823 C   0  0  0  0  0  0
   -4.1937   -3.6939    1.1541 C   0  0  0  0  0  0
   -3.2077   -2.5131    1.2531 C   0  0  0  0  0  0
   -3.1342   -1.7309   -0.0812 C   0  0  2  0  0  0
   -2.8985   -2.6738   -1.2962 C   0  0  0  0  0  0
   -2.0953   -0.6983    0.0013 N   0  0  0  0  0  0
   -2.2394    0.6504    0.2706 C   0  0  0  0  0  0
   -0.9290    1.1863    0.2913 C   0  0  0  0  0  0
   -0.0729    0.0667    0.0122 C   0  0  0  0  0  0
   -0.7890   -1.0273   -0.1193 N   0  0  0  0  0  0
    1.4102    0.0282   -0.1372 C   0  0  0  0  0  0
    2.0603    0.9809   -0.9259 C   0  0  0  0  0  0
    3.4447    0.9448   -1.0679 C   0  0  0  0  0  0
    4.1871   -0.0492   -0.4317 C   0  0  0  0  0  0
    3.5418   -0.9893    0.3794 C   0  0  0  0  0  0
    2.1579   -0.9521    0.5228 C   0  0  0  0  0  0
    5.5557   -0.0493   -0.5930 O   0  0  0  0  0  0
    6.2387   -1.2106   -0.8941 C   0  0  0  0  0  0
    5.6942   -2.2199   -1.7018 C   0  0  0  0  0  0
    6.4387   -3.3597   -1.9927 C   0  0  0  0  0  0
    7.7308   -3.4868   -1.4880 C   0  0  0  0  0  0
    8.2864   -2.4819   -0.6991 C   0  0  0  0  0  0
    7.5405   -1.3425   -0.4079 C   0  0  0  0  0  0
   -0.8403    2.5655    0.5691 C   0  0  0  0  0  0
   -1.9573    3.3073    0.7819 N   0  0  0  0  0  0
   -3.1494    2.6602    0.7240 C   0  0  0  0  0  0
   -3.3687    1.3411    0.4800 N   0  0  0  0  0  0
    0.3826    3.2248    0.6596 N   0  0  0  0  0  0
   -6.7852   -4.5986   -3.9924 H   0  0  0  0  0  0
   -7.7872   -5.5486   -2.7692 H   0  0  0  0  0  0
   -6.3376   -4.8570   -0.9626 H   0  0  0  0  0  0
   -4.5804   -5.4319   -0.1288 H   0  0  0  0  0  0
   -2.9001   -4.9856   -0.0142 H   0  0  0  0  0  0
   -5.2167   -3.3164    1.1072 H   0  0  0  0  0  0
   -4.1366   -4.2987    2.0597 H   0  0  0  0  0  0
   -3.4994   -1.8504    2.0692 H   0  0  0  0  0  0
   -2.2210   -2.9026    1.5105 H   0  0  0  0  0  0
   -4.0906   -1.2261   -0.2344 H   0  0  0  0  0  0
   -1.9357   -3.1799   -1.2122 H   0  0  0  0  0  0
   -2.8763   -2.1029   -2.2260 H   0  0  0  0  0  0
    1.4947    1.7433   -1.4417 H   0  0  0  0  0  0
    3.9408    1.6814   -1.6828 H   0  0  0  0  0  0
    4.1121   -1.7487    0.8939 H   0  0  0  0  0  0
    1.6688   -1.6866    1.1464 H   0  0  0  0  0  0
    4.6973   -2.1229   -2.1063 H   0  0  0  0  0  0
    6.0176   -4.1397   -2.6096 H   0  0  0  0  0  0
    8.3087   -4.3707   -1.7145 H   0  0  0  0  0  0
    9.2912   -2.5855   -0.3168 H   0  0  0  0  0  0
    7.9717   -0.5612    0.2010 H   0  0  0  0  0  0
   -4.0280    3.2647    0.8963 H   0  0  0  0  0  0
    1.2392    2.7055    0.5336 H   0  0  0  0  0  0
    0.3942    4.2108    0.8763 H   0  0  0  0  0  0
  1  2  2  0  0  0
  1 34  1  0  0  0
  1 35  1  0  0  0
  2  3  1  0  0  0
  2 36  1  0  0  0
  3  4  2  0  0  0
  3  5  1  0  0  0
  5  6  1  0  0  0
  5 10  1  0  0  0
  6  7  1  0  0  0
  6 37  1  0  0  0
  6 38  1  0  0  0
  7  8  1  0  0  0
  7 39  1  0  0  0
  7 40  1  0  0  0
  8  9  1  0  0  0
  8 41  1  0  0  0
  8 42  1  0  0  0
  9 10  1  0  0  0
  9 11  1  0  0  0
  9 43  1  0  0  0
 10 44  1  0  0  0
 10 45  1  0  0  0
 11 12  1  0  0  0
 11 15  1  0  0  0
 12 13  1  0  0  0
 12 32  2  0  0  0
 13 14  1  0  0  0
 13 29  2  0  0  0
 14 15  2  0  0  0
 14 16  1  0  0  0
 16 17  1  0  0  0
 16 21  2  0  0  0
 17 18  2  0  0  0
 17 46  1  0  0  0
 18 19  1  0  0  0
 18 47  1  0  0  0
 19 20  2  0  0  0
 19 22  1  0  0  0
 20 21  1  0  0  0
 20 48  1  0  0  0
 21 49  1  0  0  0
 22 23  1  0  0  0
 23 24  1  0  0  0
 23 28  2  0  0  0
 24 25  2  0  0  0
 24 50  1  0  0  0
 25 26  1  0  0  0
 25 51  1  0  0  0
 26 27  2  0  0  0
 26 52  1  0  0  0
 27 28  1  0  0  0
 27 53  1  0  0  0
 28 54  1  0  0  0
 29 30  1  0  0  0
 29 33  1  0  0  0
 30 31  2  0  0  0
 31 32  1  0  0  0
 31 55  1  0  0  0
 33 56  1  0  0  0
 33 57  1  0  0  0
M  END
> <s_m_entry_id>
685

> <Applicants>
Pharmacyclics

> <CHEMBL_ID>
CHEMBL1873475

> <Canonical_Smiles>
O(c1ccc(cc1)-c1nn(c2ncnc(N)c12)[C@@H]1CCCN(C1)C(=O)C=C)c1ccccc1

> <Chirality>
Single Stereoisomer

> <First_Approval>
2013

> <Phase>
4

> <SC_Patent>
US-7514444-B2

> <Synonyms>
CRA-032765 | IBRUTINIB | IMBRUVICA | PC-32765 | PCI 32765 | PCI-32765 | PCI-32765-00

> <Indications>
Ibrutinib was approved by the FDA for the treatment of mantle cell lymphoma, and later in February 2014 for the treatment of chronic lymphocytic leukemia

> <Type>
1.5

> <targets_id>
Q06187

> <inchi>
InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1

> <stdInchikey>
XYFPWWZEPKGCCK-GOSISDBHSA-N

> <csid>
26637187

> <Links>
|http://www.chemspider.com/Chemical-Structure.26637187.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1873475|http://pubchem.ncbi.nlm.nih.gov/compound/24821094|http://www.drugbank.ca/drugs/DB09053| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=1E8|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/1E8|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6912|http://zinc15.docking.org/substances/ZINC35328014|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=1X70OSD4VX|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50357312

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
440.2

> <HBA>
7

> <HBD>
1

> <NRB>
5

> <TPSA>
99.2

> <LogP>
4.2

> <RoF>
0

> <Targets>
BTK

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0006

> <r_epik_State_Penalty>
  0.0000

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
685

> <lig_pdbID>
'1E8'

> <pdbID>
4ifg 4rz7 5p9i 5yu9 6l8l 6yg2 6yz4

> <Kinase families>
Tyr

> <indicationDB>
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton&#39;s tyrosine kinase. It is designated as a targeted covalent drug and it presents a very promising activity in B cell malignancies.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Berglof A, Hamasy A, Meinke S, Palma M, Krstic A, Mansson R, Kimby E, Osterborg A, Smith CI: Targets for Ibrutinib Beyond B Cell Malignancies. Scand J Immunol. 2015 Sep;82(3):208-17. doi: 10.1111/sji.12333. (PubMed ID 26111359)" href="#reference-A32299">4</a></sup> Ibrutinib was developed by Pharmacyclics Inc and in November 2013 was FDA-approved for the treatment of mantle cell lymphoma. Later, in February 2014, ibrutinib was approved for the treatment of chronic lymphocytic leukemia and it is also indicated for the treatment of patients with Waldenström&#39;s Macroglobulinemia.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA approved drugs" href="#reference-L1926">13</a></sup> Ibrutinib has also been approved by the EMA for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Berglof A, Hamasy A, Meinke S, Palma M, Krstic A, Mansson R, Kimby E, Osterborg A, Smith CI: Targets for Ibrutinib Beyond B Cell Malignancies. Scand J Immunol. 2015 Sep;82(3):208-17. doi: 10.1111/sji.12333. (PubMed ID 26111359)" href="#reference-A32299">4</a></sup> Ibrutinib was approved for use in chronic graft versus host disease in August 2017 <sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA: Ibrutinib cGVHD approval" href="#reference-L937">12</a></sup>.

> <uniprotId>
Q06187|P08684|P20815|P10635|P02768|P02763|P19652

> <BrandName>
Imbruvica

> <Melting point>
149-158ºC

> <Withdrawn>
|Study NCT02815059 in United States was Withdrawn during Phase 1 because Termination of Investigator Initiated Studies using Ibrutinib|Study NCT02914327 in United States was Withdrawn during Phase 1 because Lack of enrollment|Study NCT02662296 in United States was Withdrawn during Phase 2 because Low enrollment|Study NCT04043845 in nan was Withdrawn during Phase 1 because Business development reasons|Study NCT02677948 in United States was Withdrawn during Phase 1/Phase 2 because FDA has placed all trials involving Pacritinib on Full Clinical Hold

> <FDA_approved>
Y

$$$$
Crizotinib
                    3D
 Structure written by MMmdl.
 53 56  0  0  1  0            999 V2000
   -2.1953    0.8222    0.3889 C   0  0  0  0  0  0
   -0.7380    1.1751    0.0485 C   0  0  2  0  0  0
   -0.6031    1.8139   -1.3528 C   0  0  0  0  0  0
   -0.3810    3.2014   -1.4835 C   0  0  0  0  0  0
   -0.2387    3.7777   -2.7456 C   0  0  0  0  0  0
   -0.3184    2.9953   -3.8915 C   0  0  0  0  0  0
   -0.5502    1.6283   -3.7840 C   0  0  0  0  0  0
   -0.6975    1.0323   -2.5272 C   0  0  0  0  0  0
   -1.0006   -0.6750   -2.4777 Cl  0  0  0  0  0  0
   -0.6328    0.8836   -4.9114 F   0  0  0  0  0  0
   -0.2754    4.2598   -0.1164 Cl  0  0  0  0  0  0
    0.0592   -0.0081    0.1833 O   0  0  0  0  0  0
    1.4395    0.0511    0.0605 C   0  0  0  0  0  0
    2.1851    1.2395    0.1501 C   0  0  0  0  0  0
    3.5755    1.2228   -0.0020 C   0  0  0  0  0  0
    4.1872   -0.0136   -0.2272 C   0  0  0  0  0  0
    3.4990   -1.1792   -0.3026 N   0  0  0  0  0  0
    2.1506   -1.1391   -0.1596 C   0  0  0  0  0  0
    1.4843   -2.3606   -0.2547 N   0  0  0  0  0  0
    4.3677    2.4829    0.0720 C   0  0  0  0  0  0
    5.7331    2.6458    0.3609 C   0  0  0  0  0  0
    6.1252    3.8994    0.3500 N   0  0  0  0  0  0
    5.0194    4.5989    0.0515 N   0  0  0  0  0  0
    3.9304    3.7852   -0.1276 C   0  0  0  0  0  0
    5.0600    6.0622   -0.0456 C   0  0  0  0  0  0
    6.0219    6.5140   -1.1698 C   0  0  0  0  0  0
    6.0988    8.0480   -1.2697 C   0  0  0  0  0  0
    6.4988    8.6243    0.1010 N   0  3  0  0  0  0
    5.5296    8.2250    1.2289 C   0  0  0  0  0  0
    5.4559    6.6902    1.3117 C   0  0  0  0  0  0
   -2.8325    1.7062    0.3490 H   0  0  0  0  0  0
   -2.2701    0.4108    1.3960 H   0  0  0  0  0  0
   -2.6107    0.0843   -0.2967 H   0  0  0  0  0  0
   -0.4131    1.8586    0.8313 H   0  0  0  0  0  0
   -0.0660    4.8399   -2.8399 H   0  0  0  0  0  0
   -0.2054    3.4508   -4.8644 H   0  0  0  0  0  0
    1.6970    2.1821    0.3383 H   0  0  0  0  0  0
    5.2572   -0.0914   -0.3553 H   0  0  0  0  0  0
    0.4784   -2.3824   -0.1692 H   0  0  0  0  0  0
    2.0152   -3.2018   -0.4263 H   0  0  0  0  0  0
    6.4296    1.8494    0.5793 H   0  0  0  0  0  0
    2.9614    4.1949   -0.3734 H   0  0  0  0  0  0
    4.0552    6.4070   -0.2995 H   0  0  0  0  0  0
    7.0257    6.1211   -0.9980 H   0  0  0  0  0  0
    5.6948    6.1067   -2.1276 H   0  0  0  0  0  0
    6.8598    8.3855   -1.9740 H   0  0  0  0  0  0
    5.1411    8.5036   -1.5259 H   0  0  0  0  0  0
    7.4273    8.3022    0.3355 H   0  0  0  0  0  0
    5.9234    8.6756    2.1404 H   0  0  0  0  0  0
    4.5697    8.6824    0.9846 H   0  0  0  0  0  0
    4.7350    6.4052    2.0796 H   0  0  0  0  0  0
    6.4228    6.3085    1.6445 H   0  0  0  0  0  0
    6.5427    9.6321    0.0397 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 31  1  0  0  0
  1 32  1  0  0  0
  1 33  1  0  0  0
  2  3  1  0  0  0
  2 12  1  0  0  0
  2 34  1  0  0  0
  3  4  2  0  0  0
  3  8  1  0  0  0
  4  5  1  0  0  0
  4 11  1  0  0  0
  5  6  2  0  0  0
  5 35  1  0  0  0
  6  7  1  0  0  0
  6 36  1  0  0  0
  7  8  2  0  0  0
  7 10  1  0  0  0
  8  9  1  0  0  0
 12 13  1  0  0  0
 13 14  1  0  0  0
 13 18  2  0  0  0
 14 15  2  0  0  0
 14 37  1  0  0  0
 15 16  1  0  0  0
 15 20  1  0  0  0
 16 17  2  0  0  0
 16 38  1  0  0  0
 17 18  1  0  0  0
 18 19  1  0  0  0
 19 39  1  0  0  0
 19 40  1  0  0  0
 20 21  1  0  0  0
 20 24  2  0  0  0
 21 22  2  0  0  0
 21 41  1  0  0  0
 22 23  1  0  0  0
 23 24  1  0  0  0
 23 25  1  0  0  0
 24 42  1  0  0  0
 25 26  1  0  0  0
 25 30  1  0  0  0
 25 43  1  0  0  0
 26 27  1  0  0  0
 26 44  1  0  0  0
 26 45  1  0  0  0
 27 28  1  0  0  0
 27 46  1  0  0  0
 27 47  1  0  0  0
 28 29  1  0  0  0
 28 48  1  0  0  0
 28 53  1  0  0  0
 29 30  1  0  0  0
 29 49  1  0  0  0
 29 50  1  0  0  0
 30 51  1  0  0  0
 30 52  1  0  0  0
M  CHG  1  28   1
M  END
> <s_m_entry_id>
686

> <Applicants>
Pfizer

> <CHEMBL_ID>
CHEMBL601719

> <Canonical_Smiles>
Clc1c([C@H](Oc2cc(cnc2N)-c2cn(nc2)C2CCNCC2)C)c(Cl)ccc1F

> <Chirality>
Single Stereoisomer

> <First_Approval>
2011

> <Phase>
4

> <SC_Patent>
US-7230098-B2

> <Synonyms>
CRIZOTINIB | PF-02341066 | PF-2341066 | XALKORI

> <Indications>
Crizotinib is used for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic-lymphoma kinase (ALK)-positive as detected by a FDA-approved test.

> <Type>
1

> <targets_id>
Q9UM73|P08581

> <inchi>
InChI=1S/C21H22Cl2FN5O/c1-12(19-16(22)2-3-17(24)20(19)23)30-18-8-13(9-27-21(18)25)14-10-28-29(11-14)15-4-6-26-7-5-15/h2-3,8-12,15,26H,4-7H2,1H3,(H2,25,27)/t12-/m1/s1

> <stdInchikey>
KTEIFNKAUNYNJU-GFCCVEGCSA-N

> <csid>
9801307

> <Links>
|http://www.chemspider.com/Chemical-Structure.9801307.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL601719|http://pubchem.ncbi.nlm.nih.gov/compound/11626560|http://www.drugbank.ca/drugs/DB08865| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=VGH|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/VGH|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4903|http://zinc15.docking.org/substances/ZINC000035902489|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=53AH36668S|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50306682

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
449.1

> <HBA>
6

> <HBD>
2

> <NRB>
5

> <TPSA>
78

> <LogP>
5

> <RoF>
1

> <Targets>
ALK; MET

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
0.999999

> <r_epik_Ionization_Penalty>
  0.3436

> <r_epik_State_Penalty>
  0.3362

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
686

> <lig_pdbID>
'VGH'

> <pdbID>
2wgj 2xp2 2yfx 3zbf 4anq 4ans 4c9w 5aaa 5aab 5aac 6imz

> <Kinase families>
Tyr

> <indicationDB>
Crizotinib an inhibitor of receptor tyrosine kinase for the treatment of non-small cell lung cancer (NSCLC). Verification of the presence of ALK fusion gene is done by Abbott Molecular&#39;s Vysis ALK Break Apart FISH Probe Kit. This verification is used to select for patients suitable for treatment. FDA approved in August 26, 2011.

> <uniprotId>
Q9UM73|P08581|P08684|P20815|P20813|P08684|Q9HB55|P20815|P24462|P08183

> <BrandName>
Xalkori

> <Withdrawn>
|Study NCT01441388 in nan was Withdrawn during Phase 1 because Business/Operational issues

> <FDA_approved>
Y

$$$$
Gefitinib
                    3D
 Structure written by MMmdl.
 55 58  0  0  1  0            999 V2000
   -0.5352    3.5512    0.7094 C   0  0  0  0  0  0
    0.0324    2.2687    0.4650 O   0  0  0  0  0  0
   -0.7968    1.1885    0.2161 C   0  0  0  0  0  0
   -2.1970    1.2823    0.1840 C   0  0  0  0  0  0
   -2.9954    0.1466   -0.0765 C   0  0  0  0  0  0
   -2.3669   -1.1126   -0.3077 C   0  0  0  0  0  0
   -0.9506   -1.1852   -0.2675 C   0  0  0  0  0  0
   -0.1734   -0.0451   -0.0105 C   0  0  0  0  0  0
    1.2110   -0.0647    0.0322 O   0  0  0  0  0  0
    1.9026   -1.2940   -0.1724 C   0  0  0  0  0  0
    3.4175   -1.0452   -0.1127 C   0  0  0  0  0  0
    4.3072   -2.3087   -0.1243 C   0  0  0  0  0  0
    4.1400   -3.1117   -1.3434 N   0  0  0  0  0  0
    5.4257   -3.6458   -1.8070 C   0  0  0  0  0  0
    5.2413   -4.4661   -3.1027 C   0  0  0  0  0  0
    4.2714   -5.4948   -2.9243 O   0  0  0  0  0  0
    3.0137   -5.0187   -2.4539 C   0  0  0  0  0  0
    3.1854   -4.2125   -1.1487 C   0  0  0  0  0  0
   -3.2394   -2.2157   -0.5676 C   0  0  0  0  0  0
   -4.5879   -2.0688   -0.5959 N   0  0  0  0  0  0
   -5.0724   -0.8287   -0.3595 C   0  0  0  0  0  0
   -4.3508    0.2874   -0.1011 N   0  0  0  0  0  0
   -2.6921   -3.4892   -0.8210 N   0  0  0  0  0  0
   -3.2348   -4.7462   -1.1447 C   0  0  0  0  0  0
   -4.5682   -5.1117   -0.9068 C   0  0  0  0  0  0
   -5.0246   -6.3842   -1.2515 C   0  0  0  0  0  0
   -4.1564   -7.3086   -1.8309 C   0  0  0  0  0  0
   -2.8245   -6.9585   -2.0637 C   0  0  0  0  0  0
   -2.3705   -5.6849   -1.7178 C   0  0  0  0  0  0
   -1.7298   -8.0890   -2.7768 Cl  0  0  0  0  0  0
   -4.6116   -8.5402   -2.1587 F   0  0  0  0  0  0
    0.2651    4.2695    0.8865 H   0  0  0  0  0  0
   -1.1732    3.5448    1.5945 H   0  0  0  0  0  0
   -1.1108    3.9041   -0.1476 H   0  0  0  0  0  0
   -2.6991    2.2229    0.3556 H   0  0  0  0  0  0
   -0.4852   -2.1429   -0.4419 H   0  0  0  0  0  0
    1.6131   -2.0131    0.5961 H   0  0  0  0  0  0
    1.6386   -1.7023   -1.1494 H   0  0  0  0  0  0
    3.7055   -0.3911   -0.9370 H   0  0  0  0  0  0
    3.6407   -0.4870    0.7975 H   0  0  0  0  0  0
    5.3401   -1.9652   -0.0404 H   0  0  0  0  0  0
    4.1322   -2.9143    0.7669 H   0  0  0  0  0  0
    6.1146   -2.8228   -2.0025 H   0  0  0  0  0  0
    5.8880   -4.2653   -1.0363 H   0  0  0  0  0  0
    4.9559   -3.8175   -3.9328 H   0  0  0  0  0  0
    6.1877   -4.9252   -3.3887 H   0  0  0  0  0  0
    2.5245   -4.4149   -3.2205 H   0  0  0  0  0  0
    2.3610   -5.8744   -2.2787 H   0  0  0  0  0  0
    3.5243   -4.8755   -0.3505 H   0  0  0  0  0  0
    2.2129   -3.8356   -0.8378 H   0  0  0  0  0  0
   -6.1467   -0.7169   -0.3795 H   0  0  0  0  0  0
   -1.6863   -3.4648   -0.8986 H   0  0  0  0  0  0
   -5.2677   -4.4366   -0.4411 H   0  0  0  0  0  0
   -6.0532   -6.6545   -1.0633 H   0  0  0  0  0  0
   -1.3370   -5.4276   -1.9029 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 32  1  0  0  0
  1 33  1  0  0  0
  1 34  1  0  0  0
  2  3  1  0  0  0
  3  4  1  0  0  0
  3  8  2  0  0  0
  4  5  2  0  0  0
  4 35  1  0  0  0
  5  6  1  0  0  0
  5 22  1  0  0  0
  6  7  2  0  0  0
  6 19  1  0  0  0
  7  8  1  0  0  0
  7 36  1  0  0  0
  8  9  1  0  0  0
  9 10  1  0  0  0
 10 11  1  0  0  0
 10 37  1  0  0  0
 10 38  1  0  0  0
 11 12  1  0  0  0
 11 39  1  0  0  0
 11 40  1  0  0  0
 12 13  1  0  0  0
 12 41  1  0  0  0
 12 42  1  0  0  0
 13 14  1  0  0  0
 13 18  1  0  0  0
 14 15  1  0  0  0
 14 43  1  0  0  0
 14 44  1  0  0  0
 15 16  1  0  0  0
 15 45  1  0  0  0
 15 46  1  0  0  0
 16 17  1  0  0  0
 17 18  1  0  0  0
 17 47  1  0  0  0
 17 48  1  0  0  0
 18 49  1  0  0  0
 18 50  1  0  0  0
 19 20  2  0  0  0
 19 23  1  0  0  0
 20 21  1  0  0  0
 21 22  2  0  0  0
 21 51  1  0  0  0
 23 24  1  0  0  0
 23 52  1  0  0  0
 24 25  1  0  0  0
 24 29  2  0  0  0
 25 26  2  0  0  0
 25 53  1  0  0  0
 26 27  1  0  0  0
 26 54  1  0  0  0
 27 28  2  0  0  0
 27 31  1  0  0  0
 28 29  1  0  0  0
 28 30  1  0  0  0
 29 55  1  0  0  0
M  END
> <s_m_entry_id>
688

> <Applicants>
Astrazeneca

> <CHEMBL_ID>
CHEMBL939

> <Canonical_Smiles>
Clc1cc(Nc2ncnc3c2cc(OCCCN2CCOCC2)c(OC)c3)ccc1F

> <Chirality>
Achiral Molecule

> <First_Approval>
2003

> <Phase>
4

> <SC_Patent>
None

> <Synonyms>
GEFITINIB | IRESSA | ZD-1839 | ZD1839

> <Indications>
For the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of either platinum-based or docetaxel chemotherapies.

> <Type>
1.5

> <targets_id>
P00533

> <inchi>
InChI=1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27)

> <stdInchikey>
XGALLCVXEZPNRQ-UHFFFAOYSA-N

> <csid>
110217

> <Links>
|http://www.chemspider.com/Chemical-Structure.110217.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL939|http://pubchem.ncbi.nlm.nih.gov/compound/123631|http://www.drugbank.ca/drugs/DB07998| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=IRE|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/IRE|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4941|http://zinc15.docking.org/substances/ZINC19632614|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=S65743JHBS|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=5447

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
446.2

> <HBA>
7

> <HBD>
1

> <NRB>
8

> <TPSA>
68.7

> <LogP>
4.3

> <RoF>
0

> <Targets>
EGFR

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
0.999978

> <r_epik_Ionization_Penalty>
  0.4080

> <r_epik_State_Penalty>
  0.4064

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
688

> <lig_pdbID>
'IRE'

> <pdbID>
2ito 2ity 2itz 3ug2 4i22 4wkq 5y7z 5y80

> <Kinase families>
Tyr

> <indicationDB>
Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa.

> <uniprotId>
P00533|P08684|P10635|P20815|P04798|P11712|P33261|P02768|P02763

> <BrandName>
Iressa

> <Withdrawn>
|Study NCT00268255 in nan was Withdrawn during Phase 1/Phase 2 because Study never moved forward with accrual|Study NCT00048087 in United States was Withdrawn during Phase 2 because Slow accrual|Study NCT00098462 in nan was Withdrawn during Phase 1/Phase 2 because Withdrawn as study never opened|Study NCT03529084 in nan was Withdrawn during Phase 3 because Decision by Sponsor not to continue with the trial

> <FDA_approved>
Y

$$$$
Ceritinib
                    3D
 Structure written by MMmdl.
 75 78  0  0  1  0            999 V2000
   -2.0230   -3.0785    0.6087 C   0  0  0  0  0  0
   -1.7088   -1.5989    0.4234 C   0  0  0  0  0  0
   -0.3695   -1.2169    0.3145 C   0  0  0  0  0  0
   -0.0086    0.1180    0.1298 C   0  0  0  0  0  0
   -1.0014    1.1142    0.1003 C   0  0  0  0  0  0
   -2.3460    0.7218    0.1937 C   0  0  0  0  0  0
   -2.7176   -0.6190    0.3540 C   0  0  0  0  0  0
   -4.2146   -0.9585    0.4598 C   0  0  0  0  0  0
   -4.9919   -0.5962   -0.8271 C   0  0  0  0  0  0
   -6.4845   -0.9571   -0.7226 C   0  0  0  0  0  0
   -7.0825   -0.2814    0.5245 N   0  3  0  0  0  0
   -6.3639   -0.6852    1.8243 C   0  0  0  0  0  0
   -4.8715   -0.3273    1.7096 C   0  0  0  0  0  0
   -0.5950    2.4372    0.0068 O   0  0  0  0  0  0
   -1.5338    3.5109   -0.0762 C   0  0  0  0  0  0
   -0.7774    4.7080   -0.6705 C   0  0  0  0  0  0
   -2.0983    3.8494    1.3177 C   0  0  0  0  0  0
    1.3622    0.4051   -0.0082 N   0  0  0  0  0  0
    2.0120    1.1506   -1.0032 C   0  0  0  0  0  0
    3.3633    1.2286   -0.9082 N   0  0  0  0  0  0
    4.0005    1.9438   -1.8717 C   0  0  0  0  0  0
    3.3203    2.5695   -2.9198 C   0  0  0  0  0  0
    1.9247    2.4262   -2.9515 C   0  0  0  0  0  0
    1.2742    1.7113   -1.9968 N   0  0  0  0  0  0
    1.1789    3.0473   -3.9682 N   0  0  0  0  0  0
   -0.2120    3.1867   -4.1310 C   0  0  0  0  0  0
   -1.0768    2.1147   -3.8641 C   0  0  0  0  0  0
   -2.4532    2.2486   -4.0307 C   0  0  0  0  0  0
   -2.9840    3.4539   -4.4796 C   0  0  0  0  0  0
   -2.1385    4.5237   -4.7630 C   0  0  0  0  0  0
   -0.7538    4.4034   -4.5918 C   0  0  0  0  0  0
    0.2857    5.8337   -4.9612 S   0  0  0  0  0  0
   -0.5968    6.9579   -5.2961 O   0  0  0  0  0  0
    1.2442    5.9688   -3.8578 O   0  0  0  0  0  0
    1.2336    5.3273   -6.5313 C   0  0  0  0  0  0
    2.2682    6.4138   -6.8617 C   0  0  0  0  0  0
    0.2441    5.0822   -7.6830 C   0  0  0  0  0  0
    4.1954    3.4795   -4.1053 Cl  0  0  0  0  0  0
   -2.5599   -3.2417    1.5437 H   0  0  0  0  0  0
   -1.1196   -3.6892    0.6408 H   0  0  0  0  0  0
   -2.6353   -3.4463   -0.2154 H   0  0  0  0  0  0
    0.4029   -1.9728    0.3540 H   0  0  0  0  0  0
   -3.1294    1.4615    0.1571 H   0  0  0  0  0  0
   -4.3099   -2.0364    0.5775 H   0  0  0  0  0  0
   -4.8998    0.4687   -1.0450 H   0  0  0  0  0  0
   -4.5572   -1.1196   -1.6800 H   0  0  0  0  0  0
   -7.0645   -0.5949   -1.5718 H   0  0  0  0  0  0
   -6.6529   -2.0283   -0.6010 H   0  0  0  0  0  0
   -7.0280    0.7215    0.4150 H   0  0  0  0  0  0
   -6.8642   -0.1447    2.6284 H   0  0  0  0  0  0
   -6.5338   -1.7559    1.9483 H   0  0  0  0  0  0
   -4.3543   -0.6656    2.6087 H   0  0  0  0  0  0
   -4.7693    0.7586    1.6902 H   0  0  0  0  0  0
   -2.3402    3.2655   -0.7690 H   0  0  0  0  0  0
   -1.4375    5.5645   -0.8107 H   0  0  0  0  0  0
   -0.3510    4.4614   -1.6417 H   0  0  0  0  0  0
    0.0444    5.0212   -0.0256 H   0  0  0  0  0  0
   -2.7886    4.6918    1.2659 H   0  0  0  0  0  0
   -1.2997    4.1186    2.0101 H   0  0  0  0  0  0
   -2.6403    3.0137    1.7582 H   0  0  0  0  0  0
    1.9822   -0.2034    0.5051 H   0  0  0  0  0  0
    5.0753    2.0128   -1.7889 H   0  0  0  0  0  0
    1.7101    3.7743   -4.4247 H   0  0  0  0  0  0
   -0.6920    1.1604   -3.5370 H   0  0  0  0  0  0
   -3.1060    1.4147   -3.8190 H   0  0  0  0  0  0
   -4.0505    3.5583   -4.6137 H   0  0  0  0  0  0
   -2.5729    5.4480   -5.1136 H   0  0  0  0  0  0
    1.7558    4.3989   -6.3014 H   0  0  0  0  0  0
    2.8600    6.1421   -7.7362 H   0  0  0  0  0  0
    2.9601    6.5616   -6.0320 H   0  0  0  0  0  0
    1.7884    7.3714   -7.0671 H   0  0  0  0  0  0
    0.7650    4.7703   -8.5887 H   0  0  0  0  0  0
   -0.3238    5.9825   -7.9200 H   0  0  0  0  0  0
   -0.4691    4.2966   -7.4329 H   0  0  0  0  0  0
   -8.0620   -0.5190    0.5967 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 39  1  0  0  0
  1 40  1  0  0  0
  1 41  1  0  0  0
  2  3  1  0  0  0
  2  7  2  0  0  0
  3  4  2  0  0  0
  3 42  1  0  0  0
  4  5  1  0  0  0
  4 18  1  0  0  0
  5  6  2  0  0  0
  5 14  1  0  0  0
  6  7  1  0  0  0
  6 43  1  0  0  0
  7  8  1  0  0  0
  8  9  1  0  0  0
  8 13  1  0  0  0
  8 44  1  0  0  0
  9 10  1  0  0  0
  9 45  1  0  0  0
  9 46  1  0  0  0
 10 11  1  0  0  0
 10 47  1  0  0  0
 10 48  1  0  0  0
 11 12  1  0  0  0
 11 49  1  0  0  0
 11 75  1  0  0  0
 12 13  1  0  0  0
 12 50  1  0  0  0
 12 51  1  0  0  0
 13 52  1  0  0  0
 13 53  1  0  0  0
 14 15  1  0  0  0
 15 16  1  0  0  0
 15 17  1  0  0  0
 15 54  1  0  0  0
 16 55  1  0  0  0
 16 56  1  0  0  0
 16 57  1  0  0  0
 17 58  1  0  0  0
 17 59  1  0  0  0
 17 60  1  0  0  0
 18 19  1  0  0  0
 18 61  1  0  0  0
 19 20  1  0  0  0
 19 24  2  0  0  0
 20 21  2  0  0  0
 21 22  1  0  0  0
 21 62  1  0  0  0
 22 23  2  0  0  0
 22 38  1  0  0  0
 23 24  1  0  0  0
 23 25  1  0  0  0
 25 26  1  0  0  0
 25 63  1  0  0  0
 26 27  1  0  0  0
 26 31  2  0  0  0
 27 28  2  0  0  0
 27 64  1  0  0  0
 28 29  1  0  0  0
 28 65  1  0  0  0
 29 30  2  0  0  0
 29 66  1  0  0  0
 30 31  1  0  0  0
 30 67  1  0  0  0
 31 32  1  0  0  0
 32 33  2  0  0  0
 32 34  2  0  0  0
 32 35  1  0  0  0
 35 36  1  0  0  0
 35 37  1  0  0  0
 35 68  1  0  0  0
 36 69  1  0  0  0
 36 70  1  0  0  0
 36 71  1  0  0  0
 37 72  1  0  0  0
 37 73  1  0  0  0
 37 74  1  0  0  0
M  CHG  1  11   1
M  END
> <s_m_entry_id>
690

> <Applicants>
Novartis

> <CHEMBL_ID>
CHEMBL2403108

> <Canonical_Smiles>
Clc1cnc(nc1Nc1ccccc1S(=O)(=O)C(C)C)Nc1cc(C)c(cc1OC(C)C)C1CCNCC1

> <Chirality>
Achiral Molecule

> <First_Approval>
2014

> <Phase>
4

> <SC_Patent>
US-7153964-B2

> <Synonyms>
CERITINIB | LDK-378 | LDK378 | NVP-LDK-378-NX | NVP-LDK378-NX | ZYKADIA

> <Indications>
Ceritinib is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. This indication is approved under accelerated approval based on tumor response rate and duration of response. An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

> <Type>
1

> <targets_id>
Q9UM73

> <inchi>
InChI=1S/C28H36ClN5O3S/c1-17(2)37-25-15-21(20-10-12-30-13-11-20)19(5)14-24(25)33-28-31-16-22(29)27(34-28)32-23-8-6-7-9-26(23)38(35,36)18(3)4/h6-9,14-18,20,30H,10-13H2,1-5H3,(H2,31,32,33,34)

> <stdInchikey>
VERWOWGGCGHDQE-UHFFFAOYSA-N

> <csid>
29315053

> <Links>
|http://www.chemspider.com/Chemical-Structure.29315053.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2403108|http://pubchem.ncbi.nlm.nih.gov/compound/57379345|http://www.drugbank.ca/drugs/DB09063| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=4MK|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/4MK|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7397|http://zinc15.docking.org/substances/ZINC000096272772|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=K418KG2GET|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50436850

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
557.2

> <HBA>
8

> <HBD>
3

> <NRB>
9

> <TPSA>
105.2

> <LogP>
6.4

> <RoF>
2

> <Targets>
ALK

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0009

> <r_epik_State_Penalty>
  0.0000

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
690

> <lig_pdbID>
'4MK'

> <pdbID>
4mkc

> <Kinase families>
Tyr

> <indicationDB>
Ceritinib is used for the treatment of adults with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) following failure (secondary to resistance or intolerance) of prior crizotinib therapy. About 4% of patients with NSCLC have a chromosomal rearrangement that generates a fusion gene between EML4 (echinoderm microtubule-associated protein-like 4) and ALK (anaplastic lymphoma kinase), which results in constitutive kinase activity that contributes to carcinogenesis and seems to drive the malignant phenotype. Ceritinib exerts its therapeutic effect by inhibiting autophosphorylation of ALK, ALK-mediated phosphorylation of the downstream signaling protein STAT3, and proliferation of ALK-dependent cancer cells. Following treatment with crizotinib (a first-generation ALK inhibitor), most tumours develop drug resistance due to mutations in key &quot;gatekeeper&quot; residues of the enzyme. This occurrence led to development of novel second-generation ALK inhibitors such as ceritinib to overcome crizotinib resistance. The FDA approved ceritinib in April 2014 due to a surprisingly high response rate (56%) towards crizotinib-resistant tumours and has designated it with orphan drug status.

> <uniprotId>
Q9UM73|P11712|P08684

> <BrandName>
Zykadia

> <Withdrawn>
|Study NCT02289144 in United States was Withdrawn during Phase 2 because study was on hold for protocol redesign; decided to not move forward with study|Study NCT02729961 in United States was Withdrawn during Phase 1/Phase 2 because Administrative closure|Study NCT02343679 in United States was Withdrawn during Phase 2 because No accrual due to rarity of disease

> <FDA_approved>
Y

$$$$
Acalabrutinib
                    3D
 Structure written by MMmdl.
 58 62  0  0  1  0            999 V2000
    1.3535    0.0368    4.3416 C   0  0  0  0  0  0
    0.5385    0.6660    3.2929 C   0  0  0  0  0  0
   -0.1161    1.1745    2.3956 C   0  0  0  0  0  0
   -0.7929    1.7933    1.2571 C   0  0  0  0  0  0
   -1.4327    2.8343    1.4128 O   0  0  0  0  0  0
   -0.6652    1.1609    0.0552 N   0  0  0  0  0  0
   -1.3303    1.6985   -1.1407 C   0  0  0  0  0  0
   -0.7639    0.8665   -2.2867 C   0  0  0  0  0  0
   -0.4558   -0.4737   -1.6448 C   0  0  0  0  0  0
    0.0156   -0.1268   -0.2270 C   0  0  1  0  0  0
    1.5395   -0.0830   -0.1084 C   0  0  0  0  0  0
    2.3109    0.8460   -0.6370 N   0  0  0  0  0  0
    3.5592    0.5882   -0.3029 C   0  0  0  0  0  0
    3.6229   -0.6122    0.4636 C   0  0  0  0  0  0
    2.2796   -1.0230    0.5752 N   0  0  0  0  0  0
    1.9265   -2.1579    1.2643 C   0  0  0  0  0  0
    2.9373   -2.9043    1.8580 C   0  0  0  0  0  0
    4.2431   -2.5600    1.7732 N   0  0  0  0  0  0
    4.5850   -1.4407    1.0859 C   0  0  0  0  0  0
    5.9456   -1.1556    1.0092 N   0  0  0  0  0  0
    4.6659    1.4970   -0.7165 C   0  0  0  0  0  0
    4.7839    1.9004   -2.0486 C   0  0  0  0  0  0
    5.8303    2.7319   -2.4378 C   0  0  0  0  0  0
    6.7760    3.1687   -1.5014 C   0  0  0  0  0  0
    6.6472    2.7666   -0.1637 C   0  0  0  0  0  0
    5.6006    1.9346    0.2236 C   0  0  0  0  0  0
    7.9052    4.0702   -1.9427 C   0  0  0  0  0  0
    7.7357    4.8608   -2.8736 O   0  0  0  0  0  0
    9.0689    3.9099   -1.2701 N   0  0  0  0  0  0
   10.2942    4.5760   -1.4544 C   0  0  0  0  0  0
   11.3358    4.2040   -0.5964 C   0  0  0  0  0  0
   12.5793    4.8256   -0.7293 C   0  0  0  0  0  0
   12.7593    5.8011   -1.7103 C   0  0  0  0  0  0
   11.6790    6.1245   -2.5311 C   0  0  0  0  0  0
   10.4642    5.5306   -2.4156 N   0  0  0  0  0  0
    1.6281    0.7788    5.0914 H   0  0  0  0  0  0
    2.2603   -0.3791    3.9018 H   0  0  0  0  0  0
    0.7878   -0.7633    4.8188 H   0  0  0  0  0  0
   -2.4066    1.5438   -1.0529 H   0  0  0  0  0  0
   -1.1423    2.7647   -1.2770 H   0  0  0  0  0  0
   -1.4550    0.7836   -3.1259 H   0  0  0  0  0  0
    0.1556    1.3227   -2.6576 H   0  0  0  0  0  0
   -1.3656   -1.0738   -1.5877 H   0  0  0  0  0  0
    0.2704   -1.0562   -2.2141 H   0  0  0  0  0  0
   -0.3521   -0.8786    0.4711 H   0  0  0  0  0  0
    0.8814   -2.4219    1.3195 H   0  0  0  0  0  0
    2.7083   -3.8024    2.4128 H   0  0  0  0  0  0
    6.2564   -0.3504    0.4852 H   0  0  0  0  0  0
    6.6044   -1.7803    1.4509 H   0  0  0  0  0  0
    4.0677    1.5674   -2.7861 H   0  0  0  0  0  0
    5.9015    3.0276   -3.4752 H   0  0  0  0  0  0
    7.3496    3.0968    0.5883 H   0  0  0  0  0  0
    5.5143    1.6386    1.2591 H   0  0  0  0  0  0
    9.0719    3.2205   -0.5334 H   0  0  0  0  0  0
   11.1924    3.4474    0.1619 H   0  0  0  0  0  0
   13.3963    4.5527   -0.0777 H   0  0  0  0  0  0
   13.7125    6.2942   -1.8313 H   0  0  0  0  0  0
   11.7772    6.8740   -3.3025 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 36  1  0  0  0
  1 37  1  0  0  0
  1 38  1  0  0  0
  2  3  3  0  0  0
  3  4  1  0  0  0
  4  5  2  0  0  0
  4  6  1  0  0  0
  6  7  1  0  0  0
  6 10  1  0  0  0
  7  8  1  0  0  0
  7 39  1  0  0  0
  7 40  1  0  0  0
  8  9  1  0  0  0
  8 41  1  0  0  0
  8 42  1  0  0  0
  9 10  1  0  0  0
  9 43  1  0  0  0
  9 44  1  0  0  0
 10 11  1  0  0  0
 10 45  1  0  0  0
 11 12  2  0  0  0
 11 15  1  0  0  0
 12 13  1  0  0  0
 13 14  2  0  0  0
 13 21  1  0  0  0
 14 15  1  0  0  0
 14 19  1  0  0  0
 15 16  1  0  0  0
 16 17  2  0  0  0
 16 46  1  0  0  0
 17 18  1  0  0  0
 17 47  1  0  0  0
 18 19  2  0  0  0
 19 20  1  0  0  0
 20 48  1  0  0  0
 20 49  1  0  0  0
 21 22  1  0  0  0
 21 26  2  0  0  0
 22 23  2  0  0  0
 22 50  1  0  0  0
 23 24  1  0  0  0
 23 51  1  0  0  0
 24 25  2  0  0  0
 24 27  1  0  0  0
 25 26  1  0  0  0
 25 52  1  0  0  0
 26 53  1  0  0  0
 27 28  2  0  0  0
 27 29  1  0  0  0
 29 30  1  0  0  0
 29 54  1  0  0  0
 30 31  1  0  0  0
 30 35  2  0  0  0
 31 32  2  0  0  0
 31 55  1  0  0  0
 32 33  1  0  0  0
 32 56  1  0  0  0
 33 34  2  0  0  0
 33 57  1  0  0  0
 34 35  1  0  0  0
 34 58  1  0  0  0
M  END
> <s_m_entry_id>
691

> <Applicants>
Astrazeneca

> <CHEMBL_ID>
CHEMBL3707348

> <Canonical_Smiles>
O=C(Nc1ncccc1)c1ccc(cc1)-c1nc(n2c1C(=NC=C2)N)[C@H]1N(CCC1)C(=O)C#CC

> <Chirality>
Single Stereoisomer

> <First_Approval>
2017

> <Phase>
4

> <SC_Patent>
US-7459554-B2

> <Synonyms>
ACALABRUTINIB | ACP-196 | CALQUENCE

> <Indications>
Acalabrutinib is currently indicated for the treatment of adult patients with Mantle Cell Lymphoma (MCL) who have received at least one prior therapy

> <Type>
nan

> <targets_id>
Q06187

> <inchi>
InChI=1S/C26H23N7O2/c1-2-6-21(34)32-15-5-7-19(32)25-31-22(23-24(27)29-14-16-33(23)25)17-9-11-18(12-10-17)26(35)30-20-8-3-4-13-28-20/h3-4,8-14,16,19H,5,7,15H2,1H3,(H2,27,29)(H,28,30,35)/t19-/m0/s1

> <stdInchikey>
WDENQIQQYWYTPO-IBGZPJMESA-N

> <csid>
36764951

> <Links>
|http://www.chemspider.com/Chemical-Structure.36764951.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3707348|http://pubchem.ncbi.nlm.nih.gov/compound/71226662|http://www.drugbank.ca/drugs/DB11703|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8912|http://zinc15.docking.org/substances/ZINC000208774715|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=I42748ELQW|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50175583

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
465.2

> <HBA>
7

> <HBD>
2

> <NRB>
4

> <TPSA>
118.5

> <LogP>
3.3

> <RoF>
0

> <Targets>
BTK

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_epik_Ionization_Penalty>
  0.0195

> <r_epik_State_Penalty>
  0.0141

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
691

> <Kinase families>
Tyr

> <indicationDB>
To date, acalabrutinib has been used in trials studying the treatment of B-All, Myelofibrosis, Ovarian Cancer, Multiple Myeloma, and Hodgkin Lymphoma, among others.</p><p>As of October 31, 2017 the FDA approved Astra Zeneca&#39;s orally administered Calquence (acalabrutinib). This Bruton Tyrosine Kinase (BTK) inhibitor indicated for the treatment of chronic lymphocytic leukemia, small lymphocytic lymphoma, and in adult patients with Mantle Cell Lymphoma (MCL) who have already received at least one prior therapy.</p><p>Also known as ACP-196, acalabrutinib is also considered a second generation BTK inhibitor because it was rationally designed to be more potent and selective than ibrutinib, theoretically expected to demonstrate fewer adverse effects owing to minimized bystander effects on targets other than BTK.</p><p>Nevertheless, acalabrutinib was approved under the FDA&#39;s accelerated approval pathway, which is based upon overall response rate and faciliates earlier approval of medicines that treat serious conditions or/and that fill an unmet medical need based on a surrogate endpoint. Continued approval for acalabrutinib&#39;s currently accepted indication may subsequently be contingent upon ongoing verification and description of clinical benefit in confimatory trials.</p><p>Furthermore, the FDA granted this medication Priority Review and Breakthrough Therapy designations. It also received Orphan Drug designation, which provides incentives to assist and encourage the development of drugs for rare diseases. At this time, more than 35 clinical trials across 40 countries with more than 2500 patients are underway or have been completed with regards to further research into better understanding and expanding the therapeutic uses of acalabrutinib <sup class="text-reference-group"><a class="reference-popover-link" data-content="Astra Zeneca Press Release: US FDA Approves Astrazeneca&#39;s Calquence for Adult Patients with Previously-Treated Mantle Cell Lymphoma" href="#reference-L1009">5</a></sup>.

> <uniprotId>
Q06187|P08684|P20815|P08684|Q9HB55|P20815|P24462|P02768|P02763|P19652

> <BrandName>
Calquence

> <FDA_approved>
Y

$$$$
Afatinib
                    3D
 Structure written by MMmdl.
 60 63  0  0  1  0            999 V2000
   -4.2975    0.3140   -1.3935 C   0  0  0  0  0  0
   -2.7848    0.6007   -1.4611 N   0  3  0  0  0  0
   -2.5108    1.9353   -2.1840 C   0  0  0  0  0  0
   -2.1324    0.5243   -0.0632 C   0  0  0  0  0  0
   -0.6167    0.5931   -0.0948 C   0  0  0  0  0  0
    0.1942   -0.4652    0.1064 C   0  0  0  0  0  0
    1.6360   -0.3638    0.0798 C   0  0  0  0  0  0
    2.2339    0.7092   -0.0382 O   0  0  0  0  0  0
    2.2375   -1.5661    0.2055 N   0  0  0  0  0  0
    3.6190   -1.8387    0.2540 C   0  0  0  0  0  0
    4.5174   -0.9768    0.8976 C   0  0  0  0  0  0
    5.9009   -1.2852    0.9566 C   0  0  0  0  0  0
    6.3597   -2.4959    0.3569 C   0  0  0  0  0  0
    5.4326   -3.3557   -0.2727 C   0  0  0  0  0  0
    4.0669   -3.0375   -0.3208 C   0  0  0  0  0  0
    3.1176   -3.8499   -0.9230 O   0  0  0  0  0  0
    3.4831   -5.0949   -1.5258 C   0  0  1  0  0  0
    3.6791   -6.1804   -0.4818 C   0  0  0  0  0  0
    2.2531   -6.6409   -0.1646 C   0  0  0  0  0  0
    1.4332   -6.1115   -1.2095 O   0  0  0  0  0  0
    2.2552   -5.6188   -2.2634 C   0  0  0  0  0  0
    7.6744   -2.8544    0.3776 N   0  0  0  0  0  0
    8.5260   -2.0032    0.9961 C   0  0  0  0  0  0
    8.2069   -0.8350    1.5963 N   0  0  0  0  0  0
    6.8985   -0.4747    1.5823 C   0  0  0  0  0  0
    6.5308    0.7442    2.1858 N   0  0  0  0  0  0
    7.2529    1.7572    2.8423 C   0  0  0  0  0  0
    6.6870    3.0356    2.8728 C   0  0  0  0  0  0
    7.3427    4.0890    3.5098 C   0  0  0  0  0  0
    8.5709    3.8732    4.1330 C   0  0  0  0  0  0
    9.1408    2.5978    4.1223 C   0  0  0  0  0  0
    8.4828    1.5453    3.4826 C   0  0  0  0  0  0
   10.6550    2.3076    4.9023 Cl  0  0  0  0  0  0
    9.1985    4.9020    4.7485 F   0  0  0  0  0  0
   -4.7592    1.0963   -0.7887 H   0  0  0  0  0  0
   -4.4226   -0.6712   -0.9423 H   0  0  0  0  0  0
   -4.6752    0.3200   -2.4167 H   0  0  0  0  0  0
   -2.9232    2.7380   -1.5707 H   0  0  0  0  0  0
   -2.9985    1.8831   -3.1582 H   0  0  0  0  0  0
   -1.4315    2.0320   -2.3026 H   0  0  0  0  0  0
   -2.5592    1.3383    0.5255 H   0  0  0  0  0  0
   -2.4679   -0.4281    0.3519 H   0  0  0  0  0  0
   -0.2014    1.5749   -0.2792 H   0  0  0  0  0  0
   -0.2275   -1.4438    0.2957 H   0  0  0  0  0  0
    1.6515   -2.3812    0.0973 H   0  0  0  0  0  0
    4.1666   -0.0718    1.3709 H   0  0  0  0  0  0
    5.8112   -4.2677   -0.7090 H   0  0  0  0  0  0
    4.3234   -4.9426   -2.2053 H   0  0  0  0  0  0
    4.2521   -7.0038   -0.9111 H   0  0  0  0  0  0
    4.2119   -5.8414    0.4068 H   0  0  0  0  0  0
    2.1774   -7.7279   -0.1215 H   0  0  0  0  0  0
    1.9096   -6.2392    0.7894 H   0  0  0  0  0  0
    1.7483   -4.8484   -2.8457 H   0  0  0  0  0  0
    2.5165   -6.4335   -2.9414 H   0  0  0  0  0  0
    9.5685   -2.2863    1.0108 H   0  0  0  0  0  0
    5.5768    1.0044    1.9837 H   0  0  0  0  0  0
    5.7355    3.2235    2.3958 H   0  0  0  0  0  0
    6.8967    5.0728    3.5197 H   0  0  0  0  0  0
    8.9366    0.5675    3.5123 H   0  0  0  0  0  0
   -2.3711   -0.1332   -2.0198 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 35  1  0  0  0
  1 36  1  0  0  0
  1 37  1  0  0  0
  2  3  1  0  0  0
  2  4  1  0  0  0
  2 60  1  0  0  0
  3 38  1  0  0  0
  3 39  1  0  0  0
  3 40  1  0  0  0
  4  5  1  0  0  0
  4 41  1  0  0  0
  4 42  1  0  0  0
  5  6  2  0  0  0
  5 43  1  0  0  0
  6  7  1  0  0  0
  6 44  1  0  0  0
  7  8  2  0  0  0
  7  9  1  0  0  0
  9 10  1  0  0  0
  9 45  1  0  0  0
 10 11  1  0  0  0
 10 15  2  0  0  0
 11 12  2  0  0  0
 11 46  1  0  0  0
 12 13  1  0  0  0
 12 25  1  0  0  0
 13 14  2  0  0  0
 13 22  1  0  0  0
 14 15  1  0  0  0
 14 47  1  0  0  0
 15 16  1  0  0  0
 16 17  1  0  0  0
 17 18  1  0  0  0
 17 21  1  0  0  0
 17 48  1  0  0  0
 18 19  1  0  0  0
 18 49  1  0  0  0
 18 50  1  0  0  0
 19 20  1  0  0  0
 19 51  1  0  0  0
 19 52  1  0  0  0
 20 21  1  0  0  0
 21 53  1  0  0  0
 21 54  1  0  0  0
 22 23  2  0  0  0
 23 24  1  0  0  0
 23 55  1  0  0  0
 24 25  2  0  0  0
 25 26  1  0  0  0
 26 27  1  0  0  0
 26 56  1  0  0  0
 27 28  2  0  0  0
 27 32  1  0  0  0
 28 29  1  0  0  0
 28 57  1  0  0  0
 29 30  2  0  0  0
 29 58  1  0  0  0
 30 31  1  0  0  0
 30 34  1  0  0  0
 31 32  2  0  0  0
 31 33  1  0  0  0
 32 59  1  0  0  0
M  CHG  1   2   1
M  END
> <s_m_entry_id>
693

> <Applicants>
Boehringer Ingelheim

> <CHEMBL_ID>
CHEMBL1173655

> <Canonical_Smiles>
Clc1cc(Nc2ncnc3c2cc(NC(=O)\C=C\CN(C)C)c(O[C@H]2CCOC2)c3)ccc1F

> <Chirality>
Single Stereoisomer

> <First_Approval>
2013

> <Phase>
4

> <SC_Patent>
US-RE43431-E1

> <Synonyms>
AFATINIB | BIBW-2992 | BIBW2992 | GILOTRIF | GIOTRIF

> <Indications>
Afatinib is a kinase inhibitor indicated for the first-line treatment of patient with metastatic non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.

> <Type>
1

> <targets_id>
P00533|P04626|Q15303

> <inchi>
InChI=1S/C24H25ClFN5O3/c1-31(2)8-3-4-23(32)30-21-11-17-20(12-22(21)34-16-7-9-33-13-16)27-14-28-24(17)29-15-5-6-19(26)18(25)10-15/h3-6,10-12,14,16H,7-9,13H2,1-2H3,(H,30,32)(H,27,28,29)/b4-3+/t16-/m0/s1

> <stdInchikey>
ULXXDDBFHOBEHA-CWDCEQMOSA-N

> <csid>
8360155

> <Links>
|http://www.chemspider.com/Chemical-Structure.8360155.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1173655|http://pubchem.ncbi.nlm.nih.gov/compound/10184653|http://www.drugbank.ca/drugs/DB08916| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=0WM|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/0WM|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5667|http://zinc15.docking.org/substances/ZINC03976838|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=41UD74L59M|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50322823

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
485.2

> <HBA>
7

> <HBD>
2

> <NRB>
8

> <TPSA>
88.6

> <LogP>
4.4

> <RoF>
0

> <Targets>
EGFR; ERBB2; ERBB4

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
0.999978

> <r_epik_Ionization_Penalty>
  0.1657

> <r_epik_State_Penalty>
  0.1823

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
693

> <lig_pdbID>
'0WM'

> <pdbID>
4g5j

> <Kinase families>
Tyr

> <indicationDB>
Afatinib is a 4-anilinoquinazoline tyrosine kinase inhibitor in the form of a dimaleate salt available as Boehringer Ingelheim&#39;s brand name Gilotrif <sup class="text-reference-group"><a class="reference-popover-link" data-content="Official drug label" href="#label-reference">Label</a></sup>. For oral use, afatinib tablets are a first-line (initial) treatment for patients with metastatic non-small cell lung cancer (NSCLC) with common epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test <sup class="text-reference-group"><a class="reference-popover-link" data-content="Boehringer Ingelheim: FDA approves new indication for Gilotrif® in EGFR mutation-positive NSCLC" href="#reference-L2939">4</a></sup>. Gilotrif (afatinib) is the first FDA-approved oncology product from Boehringer Ingelheim <sup class="text-reference-group"><a class="reference-popover-link" data-content="Boehringer Ingelheim: FDA approves new indication for Gilotrif® in EGFR mutation-positive NSCLC" href="#reference-L2939">4</a></sup>.

> <uniprotId>
P00533|P04626|Q15303

> <BrandName>
Gilotrif;Giotrif

> <Withdrawn>
|Study NCT03652233 in nan was Withdrawn during Phase 1 because Low accrual|Study NCT01480141 in United States was Withdrawn during Phase 2 because PI left MUSC, no patient enrollments|Study NCT02274012 in nan was Withdrawn during Phase 2 because Former PI left institution and had plans to continue at another institution|Study NCT02876081 in France was Withdrawn during Phase 2 because medical decision

> <FDA_approved>
Y

$$$$
Alectinib
                    3D
 Structure written by MMmdl.
 71 76  0  0  1  0            999 V2000
   -0.4850    0.6971    0.1051 C   0  0  0  0  0  0
    0.3943   -0.3797   -0.5569 C   0  0  0  0  0  0
    1.9181   -0.2541   -0.3789 C   0  0  0  0  0  0
    2.4829    0.8484    0.2718 C   0  0  0  0  0  0
    3.8693    0.9879    0.4505 C   0  0  0  0  0  0
    4.7344   -0.0193   -0.0470 C   0  0  0  0  0  0
    4.1504   -1.1177   -0.6948 C   0  0  0  0  0  0
    2.7704   -1.2562   -0.8684 C   0  0  0  0  0  0
    2.2621   -2.3655   -1.5319 N   0  0  0  0  0  0
    2.7211   -3.7145   -1.1740 C   0  0  0  0  0  0
    1.6778   -4.7780   -1.5735 C   0  0  0  0  0  0
    1.3385   -4.7308   -3.0860 C   0  0  0  0  0  0
    1.0704   -3.2658   -3.5192 C   0  0  0  0  0  0
    2.1423   -2.2886   -2.9930 C   0  0  0  0  0  0
    0.0718   -5.5995   -3.3731 N   0  3  0  0  0  0
   -0.2951   -5.5882   -4.8812 C   0  0  0  0  0  0
   -1.4906   -6.5240   -5.1408 C   0  0  0  0  0  0
   -1.2217   -7.8380   -4.6695 O   0  0  0  0  0  0
   -0.9854   -7.9001   -3.2691 C   0  0  0  0  0  0
    0.2453   -7.0603   -2.8783 C   0  0  0  0  0  0
    6.2791    0.0509    0.0921 C   0  0  0  0  0  0
    6.6687    1.3296    0.8338 C   0  0  0  0  0  0
    5.8077    2.2982    1.3145 C   0  0  0  0  0  0
    6.6181    3.3142    1.9362 C   0  0  0  0  0  0
    6.3493    4.5272    2.5932 C   0  0  0  0  0  0
    7.4102    5.2844    3.0867 C   0  0  0  0  0  0
    8.7321    4.8612    2.9403 C   0  0  0  0  0  0
    9.0451    3.6613    2.2945 C   0  0  0  0  0  0
    7.9775    2.9043    1.8004 C   0  0  0  0  0  0
    7.9597    1.7017    1.1296 N   0  0  0  0  0  0
    9.8090    5.6853    3.4696 C   0  0  0  0  0  0
   10.6656    6.3398    3.8902 N   0  0  0  0  0  0
    4.3615    2.2181    1.1698 C   0  0  0  0  0  0
    3.5946    3.0829    1.5982 O   0  0  0  0  0  0
    6.7664   -1.1590    0.9266 C   0  0  0  0  0  0
    6.9081    0.1044   -1.3218 C   0  0  0  0  0  0
   -1.5415    0.4885   -0.0655 H   0  0  0  0  0  0
   -0.2811    1.6876   -0.3028 H   0  0  0  0  0  0
   -0.3304    0.7314    1.1841 H   0  0  0  0  0  0
    0.0875   -1.3528   -0.1704 H   0  0  0  0  0  0
    0.1784   -0.3965   -1.6260 H   0  0  0  0  0  0
    1.8281    1.6194    0.6494 H   0  0  0  0  0  0
    4.7982   -1.8890   -1.0854 H   0  0  0  0  0  0
    3.6794   -3.9239   -1.6530 H   0  0  0  0  0  0
    2.8873   -3.7671   -0.0967 H   0  0  0  0  0  0
    2.0746   -5.7553   -1.2990 H   0  0  0  0  0  0
    0.7745   -4.6334   -0.9776 H   0  0  0  0  0  0
    2.1585   -5.1557   -3.6689 H   0  0  0  0  0  0
    1.0488   -3.1830   -4.6055 H   0  0  0  0  0  0
    0.0894   -2.9407   -3.1669 H   0  0  0  0  0  0
    1.8700   -1.2736   -3.2877 H   0  0  0  0  0  0
    3.1096   -2.4981   -3.4536 H   0  0  0  0  0  0
   -0.5520   -4.5677   -5.1616 H   0  0  0  0  0  0
    0.5968   -5.9112   -5.4213 H   0  0  0  0  0  0
   -2.3946   -6.1403   -4.6635 H   0  0  0  0  0  0
   -1.6984   -6.5744   -6.2099 H   0  0  0  0  0  0
   -1.8731   -7.5612   -2.7312 H   0  0  0  0  0  0
   -0.8292   -8.9422   -2.9889 H   0  0  0  0  0  0
    1.1590   -7.4397   -3.3394 H   0  0  0  0  0  0
    0.3532   -7.0407   -1.7948 H   0  0  0  0  0  0
    5.3347    4.8757    2.7184 H   0  0  0  0  0  0
    7.1883    6.2157    3.5899 H   0  0  0  0  0  0
   10.0680    3.3303    2.1795 H   0  0  0  0  0  0
    8.7543    1.1362    0.8678 H   0  0  0  0  0  0
    6.3025   -1.1789    1.9141 H   0  0  0  0  0  0
    7.8469   -1.1345    1.0744 H   0  0  0  0  0  0
    6.5403   -2.1085    0.4406 H   0  0  0  0  0  0
    6.5421    0.9600   -1.8919 H   0  0  0  0  0  0
    6.6873   -0.7921   -1.9017 H   0  0  0  0  0  0
    7.9948    0.1852   -1.2742 H   0  0  0  0  0  0
   -0.7013   -5.1935   -2.8648 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 37  1  0  0  0
  1 38  1  0  0  0
  1 39  1  0  0  0
  2  3  1  0  0  0
  2 40  1  0  0  0
  2 41  1  0  0  0
  3  4  1  0  0  0
  3  8  2  0  0  0
  4  5  2  0  0  0
  4 42  1  0  0  0
  5  6  1  0  0  0
  5 33  1  0  0  0
  6  7  2  0  0  0
  6 21  1  0  0  0
  7  8  1  0  0  0
  7 43  1  0  0  0
  8  9  1  0  0  0
  9 10  1  0  0  0
  9 14  1  0  0  0
 10 11  1  0  0  0
 10 44  1  0  0  0
 10 45  1  0  0  0
 11 12  1  0  0  0
 11 46  1  0  0  0
 11 47  1  0  0  0
 12 13  1  0  0  0
 12 15  1  0  0  0
 12 48  1  0  0  0
 13 14  1  0  0  0
 13 49  1  0  0  0
 13 50  1  0  0  0
 14 51  1  0  0  0
 14 52  1  0  0  0
 15 16  1  0  0  0
 15 20  1  0  0  0
 15 71  1  0  0  0
 16 17  1  0  0  0
 16 53  1  0  0  0
 16 54  1  0  0  0
 17 18  1  0  0  0
 17 55  1  0  0  0
 17 56  1  0  0  0
 18 19  1  0  0  0
 19 20  1  0  0  0
 19 57  1  0  0  0
 19 58  1  0  0  0
 20 59  1  0  0  0
 20 60  1  0  0  0
 21 22  1  0  0  0
 21 35  1  0  0  0
 21 36  1  0  0  0
 22 23  2  0  0  0
 22 30  1  0  0  0
 23 24  1  0  0  0
 23 33  1  0  0  0
 24 25  1  0  0  0
 24 29  2  0  0  0
 25 26  2  0  0  0
 25 61  1  0  0  0
 26 27  1  0  0  0
 26 62  1  0  0  0
 27 28  2  0  0  0
 27 31  1  0  0  0
 28 29  1  0  0  0
 28 63  1  0  0  0
 29 30  1  0  0  0
 30 64  1  0  0  0
 31 32  3  0  0  0
 33 34  2  0  0  0
 35 65  1  0  0  0
 35 66  1  0  0  0
 35 67  1  0  0  0
 36 68  1  0  0  0
 36 69  1  0  0  0
 36 70  1  0  0  0
M  CHG  1  15   1
M  END
> <s_m_entry_id>
696

> <Applicants>
Hoffmann-La Roche

> <CHEMBL_ID>
CHEMBL1738797

> <Canonical_Smiles>
O1CCN(CC1)C1CCN(CC1)c1cc2c(cc1CC)C(=O)c1c([nH]c3cc(ccc13)C#N)C2(C)C

> <Chirality>
Achiral Molecule

> <First_Approval>
2015

> <Phase>
4

> <SC_Patent>
US-9126931-B2

> <Synonyms>
AF-802 | AF802 | ALECENSA | ALECTINIB | CH-5424802 | CH5424802 | RO-5424802 | RO5424802

> <Indications>
Alectinib is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

> <Type>
1

> <targets_id>
Q9UM73

> <inchi>
InChI=1S/C30H34N4O2/c1-4-20-16-23-24(17-26(20)34-9-7-21(8-10-34)33-11-13-36-14-12-33)30(2,3)29-27(28(23)35)22-6-5-19(18-31)15-25(22)32-29/h5-6,15-17,21,32H,4,7-14H2,1-3H3

> <stdInchikey>
KDGFLJKFZUIJMX-UHFFFAOYSA-N

> <csid>
26326738

> <Links>
|http://www.chemspider.com/Chemical-Structure.26326738.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1738797|http://pubchem.ncbi.nlm.nih.gov/compound/49806720|http://www.drugbank.ca/drugs/DB11363| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=EMH|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/EMH|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7739|http://zinc15.docking.org/substances/ZINC000066166864|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=LIJ4CT1Z3Y|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50362781

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
482.3

> <HBA>
5

> <HBD>
1

> <NRB>
3

> <TPSA>
72.4

> <LogP>
4.8

> <RoF>
0

> <Targets>
ALK

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_epik_Ionization_Penalty>
  0.1628

> <r_epik_State_Penalty>
  0.1521

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
696

> <lig_pdbID>
'EMH'

> <pdbID>
3aox 5xv7

> <Kinase families>
Tyr

> <indicationDB>
Alectinib is a second generation oral drug that selectively inhibits the activity of anaplastic lymphoma kinase (ALK) tyrosine kinase. It is specifically used in the treatment of non-small cell lung cancer (NSCLC) expressing the ALK-EML4 (echinoderm microtubule-associated protein-like 4) fusion protein that causes proliferation of NSCLC cells. Inhibition of ALK prevents phosphorylation and subsequent downstream activation of STAT3 and AKT resulting in reduced tumour cell viability. </p><p>Approved under accelerated approval in 2015, alectinib is indicated for use in patients who have progressed on or were not tolerant of crizotinib, which is associated with the development of resistance.

> <uniprotId>
Q9UM73

> <BrandName>
Alecensa

> <FDA_approved>
Y

$$$$
Anlotinib
                    3D
 Structure written by MMmdl.
 53 57  0  0  1  0            999 V2000
  -11.7565    2.1978   -2.5134 C   0  0  0  0  0  0
  -10.2612    1.9911   -2.5155 C   0  0  0  0  0  0
   -9.3274    2.0435   -1.4972 C   0  0  0  0  0  0
   -8.0390    1.7646   -2.0603 C   0  0  0  0  0  0
   -8.2423    1.5446   -3.4530 C   0  0  0  0  0  0
   -9.5948    1.6913   -3.6800 N   0  0  0  0  0  0
   -7.1900    1.2446   -4.3241 C   0  0  0  0  0  0
   -5.9124    1.1654   -3.7698 C   0  0  0  0  0  0
   -5.6818    1.3703   -2.4089 C   0  0  0  0  0  0
   -6.7358    1.6760   -1.5444 C   0  0  0  0  0  0
   -6.5048    1.8798   -0.2266 F   0  0  0  0  0  0
   -4.4007    1.2811   -1.9174 O   0  0  0  0  0  0
   -3.8516    0.0603   -1.5646 C   0  0  0  0  0  0
   -4.5546   -1.1527   -1.6292 C   0  0  0  0  0  0
   -3.9226   -2.3325   -1.2541 C   0  0  0  0  0  0
   -2.6426   -2.3893   -0.8195 N   0  0  0  0  0  0
   -1.9358   -1.2286   -0.7431 C   0  0  0  0  0  0
   -2.5013    0.0300   -1.1051 C   0  0  0  0  0  0
   -1.6974    1.1920   -0.9937 C   0  0  0  0  0  0
   -0.3712    1.1174   -0.5408 C   0  0  0  0  0  0
    0.1779   -0.1220   -0.1913 C   0  0  0  0  0  0
   -0.5995   -1.2852   -0.2898 C   0  0  0  0  0  0
    1.4923   -0.1193    0.2418 O   0  0  0  0  0  0
    2.1321   -1.3458    0.5925 C   0  0  0  0  0  0
    3.6000   -1.1185    1.0144 C   0  0  0  0  0  0
    4.4082   -0.0494    0.3127 C   0  0  0  0  0  0
    3.9686    0.1514    1.7493 C   0  0  0  0  0  0
    4.3106   -2.4155    1.4128 N   0  3  0  0  0  0
    0.4542    2.2220   -0.4150 O   0  0  0  0  0  0
   -0.0432    3.5143   -0.7470 C   0  0  0  0  0  0
  -12.1302    2.4427   -1.5189 H   0  0  0  0  0  0
  -12.2874    1.3044   -2.8430 H   0  0  0  0  0  0
  -12.0521    3.0128   -3.1747 H   0  0  0  0  0  0
   -9.5554    2.2593   -0.4639 H   0  0  0  0  0  0
  -10.0763    1.6019   -4.5631 H   0  0  0  0  0  0
   -7.3492    1.0802   -5.3796 H   0  0  0  0  0  0
   -5.0768    0.9352   -4.4148 H   0  0  0  0  0  0
   -5.5804   -1.1917   -1.9637 H   0  0  0  0  0  0
   -4.4523   -3.2729   -1.2996 H   0  0  0  0  0  0
   -2.1360    2.1392   -1.2689 H   0  0  0  0  0  0
   -0.1985   -2.2520   -0.0237 H   0  0  0  0  0  0
    1.5908   -1.8188    1.4140 H   0  0  0  0  0  0
    2.1074   -2.0299   -0.2577 H   0  0  0  0  0  0
    5.4652   -0.2272    0.1126 H   0  0  0  0  0  0
    3.9371    0.5548   -0.4639 H   0  0  0  0  0  0
    3.1963    0.8931    1.9581 H   0  0  0  0  0  0
    4.7244    0.1114    2.5345 H   0  0  0  0  0  0
    5.2677   -2.2234    1.6716 H   0  0  0  0  0  0
    4.3066   -3.0653    0.6392 H   0  0  0  0  0  0
    0.7412    4.2534   -0.5843 H   0  0  0  0  0  0
   -0.8911    3.7908   -0.1185 H   0  0  0  0  0  0
   -0.3375    3.5727   -1.7960 H   0  0  0  0  0  0
    3.8402   -2.8425    2.1983 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 31  1  0  0  0
  1 32  1  0  0  0
  1 33  1  0  0  0
  2  3  2  0  0  0
  2  6  1  0  0  0
  3  4  1  0  0  0
  3 34  1  0  0  0
  4  5  1  0  0  0
  4 10  2  0  0  0
  5  6  1  0  0  0
  5  7  2  0  0  0
  6 35  1  0  0  0
  7  8  1  0  0  0
  7 36  1  0  0  0
  8  9  2  0  0  0
  8 37  1  0  0  0
  9 10  1  0  0  0
  9 12  1  0  0  0
 10 11  1  0  0  0
 12 13  1  0  0  0
 13 14  2  0  0  0
 13 18  1  0  0  0
 14 15  1  0  0  0
 14 38  1  0  0  0
 15 16  2  0  0  0
 15 39  1  0  0  0
 16 17  1  0  0  0
 17 18  1  0  0  0
 17 22  2  0  0  0
 18 19  2  0  0  0
 19 20  1  0  0  0
 19 40  1  0  0  0
 20 21  2  0  0  0
 20 29  1  0  0  0
 21 22  1  0  0  0
 21 23  1  0  0  0
 22 41  1  0  0  0
 23 24  1  0  0  0
 24 25  1  0  0  0
 24 42  1  0  0  0
 24 43  1  0  0  0
 25 26  1  0  0  0
 25 27  1  0  0  0
 25 28  1  0  0  0
 26 27  1  0  0  0
 26 44  1  0  0  0
 26 45  1  0  0  0
 27 46  1  0  0  0
 27 47  1  0  0  0
 28 48  1  0  0  0
 28 49  1  0  0  0
 28 53  1  0  0  0
 29 30  1  0  0  0
 30 50  1  0  0  0
 30 51  1  0  0  0
 30 52  1  0  0  0
M  CHG  1  28   1
M  END
> <s_m_entry_id>
698

> <Applicants>
Advenchen Laboratories

> <CHEMBL_ID>
nan

> <Canonical_Smiles>
Fc1c2cc([nH]c2ccc1Oc1c2cc(OC)c(OCC3(N)CC3)cc2ncc1)C

> <Chirality>
nan

> <First_Approval>
nan

> <Phase>
4

> <SC_Patent>
nan

> <Synonyms>
|ATCII|FU KE WEI|AL3818|APC I|ATC I|FOCUS V|APCII|ANLOTINIB|ALTN

> <Indications>
Anlotinib (AL3818) is a non-selective inhibitor of multiple receptor tyrosine kinases, including vascular endothelial growth factor receptor type 2 (VEGFR-2, FLT1) and type 3 (VEGFR-3, FLT4). It is being investigated for antineoplastic and anti-angiogenic potential. The dihydrochloride has PubChem CID: 57380530. Preparation and crystallisation of AL3818 is described in patent WO2016179123.

> <Type>
nan

> <targets_id>
P35968|P35916

> <inchi>
InChI=1S/C23H22FN3O3/c1-13-9-15-16(27-13)3-4-19(22(15)24)30-18-5-8-26-17-11-21(20(28-2)10-14(17)18)29-12-23(25)6-7-23/h3-5,8-11,27H,6-7,12,25H2,1-2H3

> <stdInchikey>
KSMZEXLVHXZPEF-UHFFFAOYSA-N

> <csid>
45743493

> <Links>
|http://www.chemspider.com/Chemical-Structure.45743493.html|http://pubchem.ncbi.nlm.nih.gov/compound/25017411|http://www.drugbank.ca/drugs/DB11885|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9601|http://zinc15.docking.org/substances/ZINC000117924202|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=GKF8S4C432

> <LinkName>
|ChemSpider|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS

> <indicationG2P>
None

> <MW>
407.2

> <HBA>
5

> <HBD>
2

> <NRB>
6

> <TPSA>
82.4

> <LogP>
4.8

> <RoF>
0

> <Targets>
KDR; FLT4

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_epik_Ionization_Penalty>
  0.2368

> <r_epik_State_Penalty>
  0.2416

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
698

> <Kinase families>
Tyr

> <FDA_approved>
N

$$$$
Apatinib
                    3D
 Structure written by MMmdl.
 53 56  0  0  1  0            999 V2000
   -6.8508   -2.1364    2.5629 N   0  0  0  0  0  0
   -6.4898   -2.3073    1.4764 C   0  0  0  0  0  0
   -6.0294   -2.5256    0.0885 C   0  0  0  0  0  0
   -6.3913   -3.9657   -0.3412 C   0  0  0  0  0  0
   -7.8917   -3.9497   -0.6602 C   0  0  0  0  0  0
   -8.2191   -2.5030   -1.0540 C   0  0  0  0  0  0
   -6.9163   -1.7090   -0.8779 C   0  0  0  0  0  0
   -4.5353   -2.1615    0.0416 C   0  0  0  0  0  0
   -3.5451   -3.1517    0.0576 C   0  0  0  0  0  0
   -2.1977   -2.8035    0.0238 C   0  0  0  0  0  0
   -1.8192   -1.4607   -0.0084 C   0  0  0  0  0  0
   -2.8046   -0.4638   -0.0324 C   0  0  0  0  0  0
   -4.1504   -0.8164   -0.0008 C   0  0  0  0  0  0
   -0.4384   -1.1973   -0.0528 N   0  0  0  0  0  0
    0.2186   -0.0867    0.3529 C   0  0  0  0  0  0
   -0.3166    0.8974    0.8670 O   0  0  0  0  0  0
    1.7178   -0.1158    0.1347 C   0  0  0  0  0  0
    2.4354   -1.2887    0.4280 C   0  0  0  0  0  0
    3.8163   -1.3352    0.2514 C   0  0  0  0  0  0
    4.4604   -0.1958   -0.2171 C   0  0  0  0  0  0
    3.7999    0.9497   -0.5078 N   0  0  0  0  0  0
    2.4490    1.0017   -0.3432 C   0  0  0  0  0  0
    1.7935    2.2097   -0.6609 N   0  0  0  0  0  0
    2.2403    3.4653   -1.1179 C   0  0  0  0  0  0
    3.3894    3.6202   -1.9092 C   0  0  0  0  0  0
    3.8266    4.8193   -2.3695 N   0  0  0  0  0  0
    3.1057    5.9203   -2.0469 C   0  0  0  0  0  0
    1.9444    5.8661   -1.2781 C   0  0  0  0  0  0
    1.5006    4.6241   -0.8088 C   0  0  0  0  0  0
    0.2296    4.5613    0.0311 C   0  0  0  0  0  0
   -5.8427   -4.2362   -1.2457 H   0  0  0  0  0  0
   -6.1484   -4.7100    0.4190 H   0  0  0  0  0  0
   -8.1451   -4.6615   -1.4468 H   0  0  0  0  0  0
   -8.4639   -4.2299    0.2258 H   0  0  0  0  0  0
   -8.5912   -2.4311   -2.0769 H   0  0  0  0  0  0
   -8.9962   -2.1063   -0.3988 H   0  0  0  0  0  0
   -7.1100   -0.6950   -0.5245 H   0  0  0  0  0  0
   -6.4203   -1.6202   -1.8467 H   0  0  0  0  0  0
   -3.8071   -4.1980    0.1000 H   0  0  0  0  0  0
   -1.4517   -3.5855    0.0332 H   0  0  0  0  0  0
   -2.5510    0.5836   -0.0881 H   0  0  0  0  0  0
   -4.8949   -0.0345   -0.0091 H   0  0  0  0  0  0
    0.1294   -1.9619   -0.3872 H   0  0  0  0  0  0
    1.9327   -2.1687    0.8035 H   0  0  0  0  0  0
    4.3736   -2.2321    0.4776 H   0  0  0  0  0  0
    5.5304   -0.1876   -0.3654 H   0  0  0  0  0  0
    0.8521    2.2358   -0.2960 H   0  0  0  0  0  0
    3.9835    2.7757   -2.2211 H   0  0  0  0  0  0
    3.4732    6.8638   -2.4225 H   0  0  0  0  0  0
    1.4027    6.7736   -1.0535 H   0  0  0  0  0  0
   -0.2075    5.5483    0.1873 H   0  0  0  0  0  0
    0.4425    4.1328    1.0111 H   0  0  0  0  0  0
   -0.5197    3.9386   -0.4590 H   0  0  0  0  0  0
  1  2  3  0  0  0
  2  3  1  0  0  0
  3  4  1  0  0  0
  3  7  1  0  0  0
  3  8  1  0  0  0
  4  5  1  0  0  0
  4 31  1  0  0  0
  4 32  1  0  0  0
  5  6  1  0  0  0
  5 33  1  0  0  0
  5 34  1  0  0  0
  6  7  1  0  0  0
  6 35  1  0  0  0
  6 36  1  0  0  0
  7 37  1  0  0  0
  7 38  1  0  0  0
  8  9  1  0  0  0
  8 13  2  0  0  0
  9 10  2  0  0  0
  9 39  1  0  0  0
 10 11  1  0  0  0
 10 40  1  0  0  0
 11 12  2  0  0  0
 11 14  1  0  0  0
 12 13  1  0  0  0
 12 41  1  0  0  0
 13 42  1  0  0  0
 14 15  1  0  0  0
 14 43  1  0  0  0
 15 16  2  0  0  0
 15 17  1  0  0  0
 17 18  1  0  0  0
 17 22  2  0  0  0
 18 19  2  0  0  0
 18 44  1  0  0  0
 19 20  1  0  0  0
 19 45  1  0  0  0
 20 21  2  0  0  0
 20 46  1  0  0  0
 21 22  1  0  0  0
 22 23  1  0  0  0
 23 24  1  0  0  0
 23 47  1  0  0  0
 24 25  1  0  0  0
 24 29  2  0  0  0
 25 26  2  0  0  0
 25 48  1  0  0  0
 26 27  1  0  0  0
 27 28  2  0  0  0
 27 49  1  0  0  0
 28 29  1  0  0  0
 28 50  1  0  0  0
 29 30  1  0  0  0
 30 51  1  0  0  0
 30 52  1  0  0  0
 30 53  1  0  0  0
M  END
> <s_m_entry_id>
702

> <Applicants>
Bukwang Pharmaceutical

> <CHEMBL_ID>
nan

> <Canonical_Smiles>
O=C(Nc1ccc(cc1)C1(CCCC1)C#N)c1cccnc1Nc1cnccc1C

> <Chirality>
nan

> <First_Approval>
2014

> <Phase>
4

> <SC_Patent>
nan

> <Synonyms>
DOCETAXEL|STUDY DRUG|CRYOABLATION||NO.|APATINIB 500MG|PLATINU|CAPECITABINE|ESYLATE APATINIB|APATINIB 750MG|NAVELBINE+AITAN|AI TAN|AITAN|ALBUMIN PACLITAXEL|CARBOPLATIN|S1|EMOZOLOMIDE|APATINIB MESYLATE|SHR-1210|ARGET THERAPY|APATINIB GROUP|S-1|REATMENT GROUP|APATINIBMESYLATE|YN968D1|H20140103|PACLITAXOL|ARM A|5-FLUOROURACIL|SPA|ATAN|YN968D1,(AITAN®|APATINIB TABLETS|EGAFUR|PEMETREXED|VP-16|OXALIPLATIN|XELOX|YEW|APATINIB MESYLAS|APATINIB|EMOZOLOMIDE（TMZ）

> <Indications>
Apatinib mesylate is an orally bioavailable, small-molecule receptor tyrosine kinase inhibitor with potential antiangiogenic and antineoplastic activities. The free-base form is also known as Rivoceranib. Apatinib selectively binds to and inhibits vascular endothelial growth factor receptor 2, which may inhibit VEGF-stimulated endothelial cell migration and proliferation and decrease tumor microvessel density. In addition, this agent mildly inhibits c-Kit and c-SRC tyrosine kinases.

> <Type>
nan

> <targets_id>
P35968

> <inchi>
InChI=1S/C24H23N5O/c1-17-10-14-26-15-21(17)29-22-20(5-4-13-27-22)23(30)28-19-8-6-18(7-9-19)24(16-25)11-2-3-12-24/h4-10,13-15H,2-3,11-12H2,1H3,(H,27,29)(H,28,30)

> <stdInchikey>
MGZNERAVOCFMCU-UHFFFAOYSA-N

> <csid>
34980756

> <Links>
|http://www.chemspider.com/Chemical-Structure.34980756.html|http://pubchem.ncbi.nlm.nih.gov/compound/66577012|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7648|http://zinc15.docking.org/substances/ZINC000083291412

> <LinkName>
|ChemSpider|PubChem|Guide to Pharmacology|ZINC

> <indicationG2P>
None

> <MW>
397.2

> <HBA>
5

> <HBD>
2

> <NRB>
5

> <TPSA>
90.7

> <LogP>
5.1

> <RoF>
1

> <Targets>
KDR

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0341

> <r_epik_State_Penalty>
  0.0267

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
702

> <Kinase families>
Tyr

> <Withdrawn>
|Study NCT03228043 in China was Withdrawn during N/A because It's not possible to complete in our hospital|Study NCT03104335 in China was Withdrawn during Phase 2 because Not enough patients|Study NCT04682249 in China was Withdrawn during Phase 2 because no patients enrolled

> <FDA_approved>
N

$$$$
Copanlisib
                    3D
 Structure written by MMmdl.
 64 68  0  0  1  0            999 V2000
    0.1822    2.7117    0.9499 C   0  0  0  0  0  0
   -0.0640    2.0129   -0.2637 O   0  0  0  0  0  0
   -0.8465    0.8892   -0.1263 C   0  0  0  0  0  0
   -0.2275   -0.3660   -0.0729 C   0  0  0  0  0  0
   -1.0135   -1.5216    0.0455 C   0  0  0  0  0  0
   -2.4008   -1.4506    0.1109 C   0  0  0  0  0  0
   -3.0511   -0.1975    0.0543 C   0  0  0  0  0  0
   -2.2671    0.9912   -0.0705 C   0  0  0  0  0  0
   -2.8602    2.2204   -0.1373 N   0  0  0  0  0  0
   -4.2169    2.2860   -0.0687 C   0  0  0  0  0  0
   -4.9987    1.1899    0.0514 N   0  3  0  0  0  0
   -4.4633   -0.0431    0.1136 C   0  0  0  0  0  0
   -5.4785   -1.0064    0.2367 N   0  0  0  0  0  0
   -6.7912   -0.3831    0.2713 C   0  0  0  0  0  0
   -6.4663    1.1115    0.1350 C   0  0  0  0  0  0
   -4.8675    3.5622   -0.1209 N   0  0  0  0  0  0
   -4.2407    4.8989   -0.1875 C   0  0  0  0  0  0
   -3.0185    5.0533   -0.2048 O   0  0  0  0  0  0
   -5.1697    6.0874   -0.2266 C   0  0  0  0  0  0
   -4.6763    7.4008   -0.2458 C   0  0  0  0  0  0
   -5.4849    8.4919   -0.2798 N   0  0  0  0  0  0
   -6.8195    8.2531   -0.2949 C   0  0  0  0  0  0
   -7.4046    7.0297   -0.2795 N   0  0  0  0  0  0
   -6.5679    5.9600   -0.2456 C   0  0  0  0  0  0
   -7.6614    9.3587   -0.3288 N   0  0  0  0  0  0
    1.1546   -0.3804   -0.1360 O   0  0  0  0  0  0
    1.8552   -1.6142   -0.0071 C   0  0  0  0  0  0
    3.3635   -1.3297   -0.0291 C   0  0  0  0  0  0
    4.2059   -2.6133    0.1227 C   0  0  0  0  0  0
    5.6356   -2.3399    0.2980 N   0  0  0  0  0  0
    6.3256   -3.5550    0.7458 C   0  0  0  0  0  0
    7.8322   -3.2868    0.9477 C   0  0  0  0  0  0
    8.4161   -2.7550   -0.2378 O   0  0  0  0  0  0
    7.7697   -1.5760   -0.7089 C   0  0  0  0  0  0
    6.2601   -1.8190   -0.9257 C   0  0  0  0  0  0
    0.8080    3.5800    0.7449 H   0  0  0  0  0  0
    0.7115    2.0839    1.6687 H   0  0  0  0  0  0
   -0.7386    3.0713    1.4115 H   0  0  0  0  0  0
   -0.5597   -2.5000    0.0882 H   0  0  0  0  0  0
   -2.9852   -2.3548    0.2030 H   0  0  0  0  0  0
   -7.3904   -0.7637   -0.5566 H   0  0  0  0  0  0
   -7.2765   -0.6260    1.2174 H   0  0  0  0  0  0
   -6.8135    1.6762    1.0019 H   0  0  0  0  0  0
   -6.9061    1.5347   -0.7696 H   0  0  0  0  0  0
   -5.8760    3.5467   -0.0971 H   0  0  0  0  0  0
   -3.6151    7.6062   -0.2333 H   0  0  0  0  0  0
   -7.0555    4.9962   -0.2345 H   0  0  0  0  0  0
   -8.6605    9.2182   -0.3405 H   0  0  0  0  0  0
   -7.2595   10.2843   -0.3417 H   0  0  0  0  0  0
    1.5871   -2.1023    0.9320 H   0  0  0  0  0  0
    1.5894   -2.2849   -0.8264 H   0  0  0  0  0  0
    3.6083   -0.8213   -0.9619 H   0  0  0  0  0  0
    3.6040   -0.6357    0.7780 H   0  0  0  0  0  0
    3.8433   -3.1458    1.0038 H   0  0  0  0  0  0
    4.0448   -3.2811   -0.7254 H   0  0  0  0  0  0
    5.8960   -3.8964    1.6887 H   0  0  0  0  0  0
    6.1872   -4.3653    0.0275 H   0  0  0  0  0  0
    7.9953   -2.6094    1.7881 H   0  0  0  0  0  0
    8.3433   -4.2153    1.2031 H   0  0  0  0  0  0
    7.9319   -0.7517   -0.0121 H   0  0  0  0  0  0
    8.2352   -1.2745   -1.6473 H   0  0  0  0  0  0
    6.1117   -2.5090   -1.7583 H   0  0  0  0  0  0
    5.7967   -0.8761   -1.2153 H   0  0  0  0  0  0
   -5.3370   -2.0044    0.3021 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 36  1  0  0  0
  1 37  1  0  0  0
  1 38  1  0  0  0
  2  3  1  0  0  0
  3  4  1  0  0  0
  3  8  2  0  0  0
  4  5  2  0  0  0
  4 26  1  0  0  0
  5  6  1  0  0  0
  5 39  1  0  0  0
  6  7  2  0  0  0
  6 40  1  0  0  0
  7  8  1  0  0  0
  7 12  1  0  0  0
  8  9  1  0  0  0
  9 10  2  0  0  0
 10 11  1  0  0  0
 10 16  1  0  0  0
 11 12  2  0  0  0
 11 15  1  0  0  0
 12 13  1  0  0  0
 13 14  1  0  0  0
 13 64  1  0  0  0
 14 15  1  0  0  0
 14 41  1  0  0  0
 14 42  1  0  0  0
 15 43  1  0  0  0
 15 44  1  0  0  0
 16 17  1  0  0  0
 16 45  1  0  0  0
 17 18  2  0  0  0
 17 19  1  0  0  0
 19 20  1  0  0  0
 19 24  2  0  0  0
 20 21  2  0  0  0
 20 46  1  0  0  0
 21 22  1  0  0  0
 22 23  2  0  0  0
 22 25  1  0  0  0
 23 24  1  0  0  0
 24 47  1  0  0  0
 25 48  1  0  0  0
 25 49  1  0  0  0
 26 27  1  0  0  0
 27 28  1  0  0  0
 27 50  1  0  0  0
 27 51  1  0  0  0
 28 29  1  0  0  0
 28 52  1  0  0  0
 28 53  1  0  0  0
 29 30  1  0  0  0
 29 54  1  0  0  0
 29 55  1  0  0  0
 30 31  1  0  0  0
 30 35  1  0  0  0
 31 32  1  0  0  0
 31 56  1  0  0  0
 31 57  1  0  0  0
 32 33  1  0  0  0
 32 58  1  0  0  0
 32 59  1  0  0  0
 33 34  1  0  0  0
 34 35  1  0  0  0
 34 60  1  0  0  0
 34 61  1  0  0  0
 35 62  1  0  0  0
 35 63  1  0  0  0
M  CHG  1  11   1
M  END
> <s_m_entry_id>
704

> <Applicants>
Bayer

> <CHEMBL_ID>
CHEMBL3218576

> <Canonical_Smiles>
O1CCN(CC1)CCCOc1ccc2c(N=C(N3C2=NCC3)NC(=O)c2cnc(nc2)N)c1OC

> <Chirality>
Achiral Molecule

> <First_Approval>
2017

> <Phase>
4

> <SC_Patent>
US-7511041-B2

> <Synonyms>
BAY 80-6946 | BAY-80-6946 | BAY80-6946 | COPANLISIB

> <Indications>
Indicated for the treatment of adult patients with relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies.

> <Type>
1

> <targets_id>
P42336|P42338

> <inchi>
InChI=1S/C23H28N8O4/c1-33-19-17(35-10-2-6-30-8-11-34-12-9-30)4-3-16-18(19)28-23(31-7-5-25-20(16)31)29-21(32)15-13-26-22(24)27-14-15/h3-4,13-14H,2,5-12H2,1H3,(H2,24,26,27)(H,28,29,32)

> <stdInchikey>
PZBCKZWLPGJMAO-UHFFFAOYSA-N

> <csid>
25069683

> <Links>
|http://www.chemspider.com/Chemical-Structure.25069683.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3218576|http://pubchem.ncbi.nlm.nih.gov/compound/24989044|http://www.drugbank.ca/drugs/DB12483| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=6E2|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/6E2|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7875|http://zinc15.docking.org/substances/ZINC000068247389|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=WI6V529FZ9|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50204093

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
480.2

> <HBA>
11

> <HBD>
2

> <NRB>
7

> <TPSA>
139.8

> <LogP>
0.7

> <RoF>
1

> <Targets>
PIK3CA; PIK3CB

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.5387

> <r_epik_State_Penalty>
  0.5211

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
704

> <lig_pdbID>
'6E2'

> <pdbID>
5g2n

> <Kinase families>
Atypical

> <indicationDB>
Copanlisib is a selective pan-Class I phosphoinositide 3-kinase (PI3K/Phosphatidylinositol-4,5-bisphosphate 3-kinase/phosphatidylinositide 3-kinase) inhibitor that was first developed by Bayer Healthcare Pharmaceuticals, Inc. The drug targets the enzyme that plays a role in regulating cell growth and survival. Copanlisib was granted accelerated approval on September 14, 2017 under the market name Aliqopa for the treatment of adult patients with relapsed follicular lymphoma and a treatment history of at least two prior systemic therapies. Follicular lymphoma is a slow-growing type of non-Hodgkin lymphoma that is caused by unregulated proliferation and growth of lymphocytes. The active ingredient in Aliquopa intravenous therapy is copanlisib dihydrochloride.

> <uniprotId>
P42336|O00329

> <BrandName>
Aliqopa

> <Withdrawn>
|Study NCT03377101 in nan was Withdrawn during Phase 2 because change in study design|Study NCT04233697 in nan was Withdrawn during Phase 1 because Investigator left institution

> <FDA_approved>
Y

$$$$
Avapritinib
                    3D
 Structure written by MMmdl.
 65 70  0  0  1  0            999 V2000
   -0.6639    1.1632   -0.4427 C   0  0  0  0  0  0
    0.0485   -0.1357    0.0201 C   0  0  2  0  0  0
   -0.6246   -0.6335    1.3222 C   0  0  0  0  0  0
    0.0572   -0.6550    2.5507 C   0  0  0  0  0  0
   -0.5743   -1.1076    3.7060 C   0  0  0  0  0  0
   -1.8953   -1.5409    3.6486 C   0  0  0  0  0  0
   -2.5899   -1.5244    2.4431 C   0  0  0  0  0  0
   -1.9574   -1.0736    1.2879 C   0  0  0  0  0  0
   -2.5083   -1.9790    4.7713 F   0  0  0  0  0  0
    1.5771    0.0613    0.1558 C   0  0  0  0  0  0
    2.1890    1.3192    0.2739 C   0  0  0  0  0  0
    3.5315    1.4792    0.3884 N   0  0  0  0  0  0
    4.2981    0.3533    0.3861 C   0  0  0  0  0  0
    3.7980   -0.9089    0.2732 N   0  0  0  0  0  0
    2.4519   -1.0355    0.1634 C   0  0  0  0  0  0
    5.6840    0.5047    0.4764 N   0  0  0  0  0  0
    6.6144   -0.6083    0.7436 C   0  0  0  0  0  0
    7.9792   -0.3950    0.0449 C   0  0  0  0  0  0
    8.6253    0.8466    0.5065 N   0  0  0  0  0  0
    7.6960    1.9437    0.1940 C   0  0  0  0  0  0
    6.3433    1.7490    0.9147 C   0  0  0  0  0  0
   10.0087    1.0225    0.5756 C   0  0  0  0  0  0
   10.5962    2.1711    1.1685 C   0  0  0  0  0  0
   10.1930    3.3516    1.8538 C   0  0  0  0  0  0
   11.3386    4.0752    2.1778 C   0  0  0  0  0  0
   12.4416    3.3584    1.7203 C   0  0  0  0  0  0
   12.0092    2.1981    1.1261 N   0  0  0  0  0  0
   12.8117    1.2555    0.6015 N   0  0  0  0  0  0
   12.1330    0.1984    0.0995 C   0  0  0  0  0  0
   10.7921    0.0298    0.0664 N   0  0  0  0  0  0
   11.3808    5.3470    2.8790 C   0  0  0  0  0  0
   12.5067    6.0490    3.3411 C   0  0  0  0  0  0
   12.2060    7.1767    3.9452 N   0  0  0  0  0  0
   10.8705    7.2380    3.8915 N   0  0  0  0  0  0
   10.3191    6.1571    3.2543 C   0  0  0  0  0  0
   10.1859    8.3755    4.4793 C   0  0  0  0  0  0
   -0.2123   -1.1323   -1.1226 N   0  3  0  0  0  0
   -0.6283    1.9367    0.3259 H   0  0  0  0  0  0
   -1.7195    0.9981   -0.6650 H   0  0  0  0  0  0
   -0.2109    1.5760   -1.3459 H   0  0  0  0  0  0
    1.0794   -0.3177    2.6343 H   0  0  0  0  0  0
   -0.0410   -1.1196    4.6453 H   0  0  0  0  0  0
   -3.6165   -1.8583    2.4044 H   0  0  0  0  0  0
   -2.5150   -1.0648    0.3628 H   0  0  0  0  0  0
    1.6192    2.2359    0.2878 H   0  0  0  0  0  0
    2.0813   -2.0477    0.0893 H   0  0  0  0  0  0
    6.7489   -0.6976    1.8232 H   0  0  0  0  0  0
    6.2066   -1.5571    0.3952 H   0  0  0  0  0  0
    8.6075   -1.2590    0.2645 H   0  0  0  0  0  0
    7.8576   -0.3533   -1.0390 H   0  0  0  0  0  0
    8.0973    2.9228    0.4380 H   0  0  0  0  0  0
    7.5400    1.9582   -0.8865 H   0  0  0  0  0  0
    5.7256    2.6254    0.7194 H   0  0  0  0  0  0
    6.4906    1.7031    1.9953 H   0  0  0  0  0  0
    9.1896    3.6606    2.1049 H   0  0  0  0  0  0
   13.4935    3.5936    1.7937 H   0  0  0  0  0  0
   12.7280   -0.5970   -0.3248 H   0  0  0  0  0  0
   13.5339    5.7322    3.2343 H   0  0  0  0  0  0
    9.2500    6.0635    3.1319 H   0  0  0  0  0  0
    9.1077    8.2660    4.3575 H   0  0  0  0  0  0
   10.5104    9.2920    3.9849 H   0  0  0  0  0  0
   10.4205    8.4320    5.5431 H   0  0  0  0  0  0
   -0.7305   -1.9262   -0.7744 H   0  0  0  0  0  0
    0.6643   -1.4602   -1.5017 H   0  0  0  0  0  0
   -0.7430   -0.6890   -1.8586 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 38  1  0  0  0
  1 39  1  0  0  0
  1 40  1  0  0  0
  2  3  1  0  0  0
  2 10  1  0  0  0
  2 37  1  0  0  0
  3  4  1  0  0  0
  3  8  2  0  0  0
  4  5  2  0  0  0
  4 41  1  0  0  0
  5  6  1  0  0  0
  5 42  1  0  0  0
  6  7  2  0  0  0
  6  9  1  0  0  0
  7  8  1  0  0  0
  7 43  1  0  0  0
  8 44  1  0  0  0
 10 11  2  0  0  0
 10 15  1  0  0  0
 11 12  1  0  0  0
 11 45  1  0  0  0
 12 13  2  0  0  0
 13 14  1  0  0  0
 13 16  1  0  0  0
 14 15  2  0  0  0
 15 46  1  0  0  0
 16 17  1  0  0  0
 16 21  1  0  0  0
 17 18  1  0  0  0
 17 47  1  0  0  0
 17 48  1  0  0  0
 18 19  1  0  0  0
 18 49  1  0  0  0
 18 50  1  0  0  0
 19 20  1  0  0  0
 19 22  1  0  0  0
 20 21  1  0  0  0
 20 51  1  0  0  0
 20 52  1  0  0  0
 21 53  1  0  0  0
 21 54  1  0  0  0
 22 23  1  0  0  0
 22 30  2  0  0  0
 23 24  2  0  0  0
 23 27  1  0  0  0
 24 25  1  0  0  0
 24 55  1  0  0  0
 25 26  2  0  0  0
 25 31  1  0  0  0
 26 27  1  0  0  0
 26 56  1  0  0  0
 27 28  1  0  0  0
 28 29  2  0  0  0
 29 30  1  0  0  0
 29 57  1  0  0  0
 31 32  1  0  0  0
 31 35  2  0  0  0
 32 33  2  0  0  0
 32 58  1  0  0  0
 33 34  1  0  0  0
 34 35  1  0  0  0
 34 36  1  0  0  0
 35 59  1  0  0  0
 36 60  1  0  0  0
 36 61  1  0  0  0
 36 62  1  0  0  0
 37 63  1  0  0  0
 37 64  1  0  0  0
 37 65  1  0  0  0
M  CHG  1  37   1
M  END
> <s_m_entry_id>
708

> <Applicants>
Blueprint Medicines

> <CHEMBL_ID>
CHEMBL4204794

> <Canonical_Smiles>
Fc1ccc(cc1)[C@@](N)(C)c1cnc(nc1)N1CCN(CC1)C1=NC=Nn2c1cc(c2)-c1cn(nc1)C

> <Chirality>
Single Stereoisomer

> <First_Approval>
2020

> <Phase>
4

> <SC_Patent>
US-9200002-B2

> <Synonyms>
70C366 | AVAPRITINIB | AYVAKIT | BLU-285 | C-366 | X-720776 | X720776

> <Indications>
On January 2020 FDA approved avapritinib to treat adults with unresectable or metastatic gastrointestinal stromal tumor (GIST)

> <Type>
nan

> <targets_id>
nan

> <inchi>
InChI=1S/C26H27FN10/c1-26(28,20-3-5-22(27)6-4-20)21-13-29-25(30-14-21)36-9-7-35(8-10-36)24-23-11-18(16-37(23)33-17-31-24)19-12-32-34(2)15-19/h3-6,11-17H,7-10,28H2,1-2H3/t26-/m0/s1

> <stdInchikey>
DWYRIWUZIJHQKQ-SANMLTNESA-N

> <csid>
58828673

> <Links>
|http://www.chemspider.com/Chemical-Structure.58828673.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4204794|http://pubchem.ncbi.nlm.nih.gov/compound/118023034|http://www.drugbank.ca/drugs/DB15233|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10368|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=513P80B4YJ

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|FDA SRS

> <indicationG2P>
None

> <MW>
498.2

> <HBA>
10

> <HBD>
1

> <NRB>
5

> <TPSA>
106.3

> <LogP>
2.6

> <RoF>
0

> <Targets>
nan

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.3902

> <r_epik_State_Penalty>
  0.3633

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
708

> <indicationDB>
Avapritinib, or BLU-285,<sup class="text-reference-group"><a class="reference-popover-link" data-content="Wu CP, Lusvarghi S, Wang JC, Hsiao SH, Huang YH, Hung TH, Ambudkar SV: Avapritinib: A Selective Inhibitor of KIT and PDGFRalpha that Reverses ABCB1 and ABCG2-Mediated Multidrug Resistance in Cancer Cell Lines. Mol Pharm. 2019 Jul 1;16(7):3040-3052. doi: 10.1021/acs.molpharmaceut.9b00274. Epub 2019 Jun 4. (PubMed ID 31117741)" href="#reference-A189327">1</a></sup> is a selective tyrosine kinase inhibitor of KIT and platelet derived growth factor receptor alpha indicated for the treatment of unresectable, metastatic gastrointestinal stromal tumors.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Mazzocca A, Napolitano A, Silletta M, Spalato Ceruso M, Santini D, Tonini G, Vincenzi B: New frontiers in the medical management of gastrointestinal stromal tumours. Ther Adv Med Oncol. 2019 May 17;11:1758835919841946. doi: 10.1177/1758835919841946. eCollection 2019. (PubMed ID 31205499)" href="#reference-A189339">2</a>,<a class="reference-popover-link" data-content="FDA Approved Drug Products: Avapritinib Oral Tablets" href="#reference-L11136">3</a></sup> It is one of the first medications available for the treatment of multidrug resistant cancers.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Wu CP, Lusvarghi S, Wang JC, Hsiao SH, Huang YH, Hung TH, Ambudkar SV: Avapritinib: A Selective Inhibitor of KIT and PDGFRalpha that Reverses ABCB1 and ABCG2-Mediated Multidrug Resistance in Cancer Cell Lines. Mol Pharm. 2019 Jul 1;16(7):3040-3052. doi: 10.1021/acs.molpharmaceut.9b00274. Epub 2019 Jun 4. (PubMed ID 31117741)" href="#reference-A189327">1</a></sup> Avapritinib shares a similar mechanism with <a href="https://go.drugbank.com/drugs/DB14840">ripretinib</a>.</p><p>Avapritinib was granted FDA approval on 9 January 2020.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA Approved Drug Products: Avapritinib Oral Tablets" href="#reference-L11136">3</a></sup>

> <uniprotId>
P10721|P08684|P11712|P08183|Q9UNQ0

> <BrandName>
Ayvakit

> <FDA_approved>
Y

$$$$
Baricitinib
                    3D
 Structure written by MMmdl.
 43 46  0  0  1  0            999 V2000
   -0.6261    2.4174   -0.8227 C   0  0  0  0  0  0
   -0.6933    1.5998    0.4748 C   0  0  0  0  0  0
   -0.2326   -0.2145    0.1746 S   0  0  0  0  0  0
   -0.4638   -0.9505    1.4221 O   0  0  0  0  0  0
   -0.8629   -0.6722   -1.0687 O   0  0  0  0  0  0
    1.5090   -0.1899   -0.0908 N   0  0  0  0  0  0
    2.4250   -1.3637    0.0235 C   0  0  0  0  0  0
    3.3210   -0.6897   -1.0384 C   0  0  0  0  0  0
    2.2256    0.3765   -1.2722 C   0  0  0  0  0  0
    4.5747   -0.0650   -0.3794 C   0  0  0  0  0  0
    5.3205    0.8459   -1.2643 C   0  0  0  0  0  0
    5.9055    1.5619   -1.9595 N   0  0  0  0  0  0
    3.7071   -1.5173   -2.1851 N   0  0  0  0  0  0
    3.6018   -1.2243   -3.5210 C   0  0  0  0  0  0
    4.1226   -2.3077   -4.2159 C   0  0  0  0  0  0
    4.5172   -3.1753   -3.1789 C   0  0  0  0  0  0
    4.2804   -2.7078   -1.9752 N   0  0  0  0  0  0
    4.2440   -2.5141   -5.6931 C   0  0  0  0  0  0
    3.8365   -1.5756   -6.6684 C   0  0  0  0  0  0
    3.2446   -0.2663   -6.7120 C   0  0  0  0  0  0
    3.1152    0.0724   -8.0462 C   0  0  0  0  0  0
    3.5920   -0.9502   -8.8299 N   0  0  0  0  0  0
    4.0403   -1.9725   -8.0235 C   0  0  0  0  0  0
    4.5719   -3.1305   -8.4282 N   0  0  0  0  0  0
    4.9223   -3.9432   -7.3981 C   0  0  0  0  0  0
    4.7904   -3.7042   -6.0692 N   0  0  0  0  0  0
   -0.9435    3.4455   -0.6469 H   0  0  0  0  0  0
   -1.2785    1.9990   -1.5897 H   0  0  0  0  0  0
    0.3851    2.4532   -1.2247 H   0  0  0  0  0  0
   -0.0181    1.9957    1.2334 H   0  0  0  0  0  0
   -1.7047    1.6113    0.8811 H   0  0  0  0  0  0
    2.8588   -1.4849    1.0166 H   0  0  0  0  0  0
    1.9501   -2.2949   -0.2894 H   0  0  0  0  0  0
    1.6482    0.2719   -2.1916 H   0  0  0  0  0  0
    2.5306    1.4151   -1.1421 H   0  0  0  0  0  0
    4.3029    0.5055    0.5097 H   0  0  0  0  0  0
    5.2642   -0.8435   -0.0507 H   0  0  0  0  0  0
    3.1758   -0.2879   -3.8439 H   0  0  0  0  0  0
    4.9788   -4.1426   -3.3133 H   0  0  0  0  0  0
    2.9445    0.3654   -5.8910 H   0  0  0  0  0  0
    2.7203    0.9641   -8.5110 H   0  0  0  0  0  0
    3.5943   -0.9145   -9.8389 H   0  0  0  0  0  0
    5.3579   -4.8939   -7.6688 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 27  1  0  0  0
  1 28  1  0  0  0
  1 29  1  0  0  0
  2  3  1  0  0  0
  2 30  1  0  0  0
  2 31  1  0  0  0
  3  4  2  0  0  0
  3  5  2  0  0  0
  3  6  1  0  0  0
  6  7  1  0  0  0
  6  9  1  0  0  0
  7  8  1  0  0  0
  7 32  1  0  0  0
  7 33  1  0  0  0
  8  9  1  0  0  0
  8 10  1  0  0  0
  8 13  1  0  0  0
  9 34  1  0  0  0
  9 35  1  0  0  0
 10 11  1  0  0  0
 10 36  1  0  0  0
 10 37  1  0  0  0
 11 12  3  0  0  0
 13 14  1  0  0  0
 13 17  1  0  0  0
 14 15  2  0  0  0
 14 38  1  0  0  0
 15 16  1  0  0  0
 15 18  1  0  0  0
 16 17  2  0  0  0
 16 39  1  0  0  0
 18 19  1  0  0  0
 18 26  2  0  0  0
 19 20  1  0  0  0
 19 23  2  0  0  0
 20 21  2  0  0  0
 20 40  1  0  0  0
 21 22  1  0  0  0
 21 41  1  0  0  0
 22 23  1  0  0  0
 22 42  1  0  0  0
 23 24  1  0  0  0
 24 25  2  0  0  0
 25 26  1  0  0  0
 25 43  1  0  0  0
M  END
> <s_m_entry_id>
712

> <Applicants>
Eli Lilly

> <CHEMBL_ID>
CHEMBL2105759

> <Canonical_Smiles>
S(=O)(=O)(N1CC(n2ncc(c2)-c2ncnc3[nH]ccc23)(C1)CC#N)CC

> <Chirality>
Achiral Molecule

> <First_Approval>
2017

> <Phase>
4

> <SC_Patent>
US-8158616-B2

> <Synonyms>
BARICITINIB | INCB-028050 | INCB-28050 | INCB028050 | LY-3009104 | LY3009104 | OLUMIANT

> <Indications>
Indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs as monotherapy or in combination with methotrexate.

> <Type>
1

> <targets_id>
P23458|O60674

> <inchi>
InChI=1S/C16H17N7O2S/c1-2-26(24,25)22-9-16(10-22,4-5-17)23-8-12(7-21-23)14-13-3-6-18-15(13)20-11-19-14/h3,6-8,11H,2,4,9-10H2,1H3,(H,18,19,20)

> <stdInchikey>
XUZMWHLSFXCVMG-UHFFFAOYSA-N

> <csid>
26373084

> <Links>
|http://www.chemspider.com/Chemical-Structure.26373084.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2105759|http://pubchem.ncbi.nlm.nih.gov/compound/44205240|http://www.drugbank.ca/drugs/DB11817| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=3JW|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/3JW|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7792|http://zinc15.docking.org/substances/ZINC000073069247|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=ISP4442I3Y|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50021656

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
371.1

> <HBA>
7

> <HBD>
1

> <NRB>
5

> <TPSA>
120.6

> <LogP>
1.1

> <RoF>
0

> <Targets>
JAK1; JAK2

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0000

> <r_epik_State_Penalty>
  0.0000

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
712

> <lig_pdbID>
'3JW'

> <pdbID>
4w9x 6vn8

> <Kinase families>
Tyr

> <indicationDB>
Baricitinib is a selective and reversible Janus kinase 1 (JAK1) and 2 (JAK2) inhibitor. Janus kinases belong to the tyrosine protein kinase family and play an important role in the proinflammatory pathway signalling that is frequently over-activated in autoimmune disorders such as rheumatoid arthritis. By blocking the actions of JAK1/2, baricitinib disrupts the activation of downstream signalling molecules and proinflammatory mediators. </p><p>Rheumatoid arthritis is a progressive autoimmune disease commonly associated with discomfort, diasability, and joint damage. Throughout disease progression, the disease may further lead to joint erosions and deformities, causing premature mortality, functional impairment, and reduced quality of life <sup class="text-reference-group"><a class="reference-popover-link" data-content="Ni H, Moe S, Myint KT, Htet A: Oral janus kinase inhibitor for the treatment of rheumatoid arthritis: tofacitinib. ISRN Rheumatol. 2013 Jul 21;2013:357904. doi: 10.1155/2013/357904. eCollection 2013. (PubMed ID 23970975)" href="#reference-A31386">3</a></sup>. While there are several disease modifying antirheumatic drugs (DMARDs) available for treatment, patients often experience inadequate threapeutic resposes to these drugs. In animal models of inflammatory arthritis, baricitinib was shown to have significant anti-inflammatory effects, but also led to preservation of cartilage and bone, with no detectable suppression of humoral immunity or adverse hematologic effects <sup class="text-reference-group"><a class="reference-popover-link" data-content="Kuriya B, Cohen MD, Keystone E: Baricitinib in rheumatoid arthritis: evidence-to-date and clinical potential. Ther Adv Musculoskelet Dis. 2017 Feb;9(2):37-44. doi: 10.1177/1759720X16687481. Epub 2017 Jan 23. (PubMed ID 28255337)" href="#reference-A31382">1</a></sup>.</p><p>In the EU, baricitinib was approved in February of 2017 as a second-line orally administered treatment for moderate to severe active rheumatoid arthritis in adults, either as a monotherapy or when combined with methotrexate. It is marketed under the trade name Olumiant.</p><p>Baricitinib in combination with <a href="https://go.drugbank.com/drugs/DB14761">remdesivir</a> for the treatment of COVID-19, was granted an FDA Emergency Use Authorization on 19 November 2020.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA: Emergency Use Authorization for Baricitinib in Combination with Remdesivir for COVID-19" href="#reference-L22619">5</a></sup>

> <uniprotId>
P23458|O60674|Q14289|P52333

> <BrandName>
Olumiant

> <FDA_approved>
Y

$$$$
Binimetinib
                    3D
 Structure written by MMmdl.
 42 44  0  0  1  0            999 V2000
   -2.9102    3.7862   -0.2473 C   0  0  0  0  0  0
   -3.1325    2.3693   -0.0156 N   0  0  0  0  0  0
   -4.3279    1.7670    0.3058 C   0  0  0  0  0  0
   -4.2495    0.4706    0.4527 N   0  0  0  0  0  0
   -2.9290    0.1840    0.2202 C   0  0  0  0  0  0
   -2.1979    1.3547   -0.0827 C   0  0  0  0  0  0
   -0.8335    1.3249   -0.3723 C   0  0  0  0  0  0
   -0.1827    0.0781   -0.3456 C   0  0  0  0  0  0
   -0.8937   -1.1036   -0.0115 C   0  0  0  0  0  0
   -2.2767   -1.0540    0.2432 C   0  0  0  0  0  0
   -2.9910   -2.1763    0.5042 F   0  0  0  0  0  0
   -0.2474   -2.3579   -0.0024 N   0  0  0  0  0  0
   -0.3715   -3.4294    0.8972 C   0  0  0  0  0  0
   -0.1310   -4.7205    0.4172 C   0  0  0  0  0  0
   -0.2069   -5.8200    1.2720 C   0  0  0  0  0  0
   -0.5045   -5.6346    2.6213 C   0  0  0  0  0  0
   -0.7160   -4.3485    3.1168 C   0  0  0  0  0  0
   -0.6403   -3.2454    2.2649 C   0  0  0  0  0  0
   -0.8171   -2.0075    2.7849 F   0  0  0  0  0  0
   -0.6097   -7.1342    3.7887 Br  0  0  0  0  0  0
    1.2952    0.0524   -0.6837 C   0  0  0  0  0  0
    1.7513   -0.7879   -1.4638 O   0  0  0  0  0  0
    2.0416    0.9921   -0.0701 N   0  0  0  0  0  0
    3.4313    0.8574   -0.0630 O   0  0  0  0  0  0
    4.0370    1.8164   -0.9288 C   0  0  0  0  0  0
    3.9053    3.2622   -0.4072 C   0  0  0  0  0  0
    4.6099    4.1457   -1.2536 O   0  0  0  0  0  0
   -2.1424    4.1480    0.4375 H   0  0  0  0  0  0
   -3.8315    4.3458   -0.0808 H   0  0  0  0  0  0
   -2.5789    3.9356   -1.2752 H   0  0  0  0  0  0
   -5.2215    2.3652    0.4120 H   0  0  0  0  0  0
   -0.3045    2.2348   -0.6197 H   0  0  0  0  0  0
    0.4751   -2.4688   -0.7000 H   0  0  0  0  0  0
    0.1057   -4.8797   -0.6254 H   0  0  0  0  0  0
   -0.0323   -6.8139    0.8867 H   0  0  0  0  0  0
   -0.9313   -4.2042    4.1655 H   0  0  0  0  0  0
    1.7095    1.5918    0.6710 H   0  0  0  0  0  0
    5.0925    1.5510   -1.0004 H   0  0  0  0  0  0
    3.6303    1.7269   -1.9388 H   0  0  0  0  0  0
    2.8622    3.5782   -0.3697 H   0  0  0  0  0  0
    4.3118    3.3491    0.6011 H   0  0  0  0  0  0
    4.5287    5.0361   -0.9038 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 28  1  0  0  0
  1 29  1  0  0  0
  1 30  1  0  0  0
  2  3  1  0  0  0
  2  6  1  0  0  0
  3  4  2  0  0  0
  3 31  1  0  0  0
  4  5  1  0  0  0
  5  6  1  0  0  0
  5 10  2  0  0  0
  6  7  2  0  0  0
  7  8  1  0  0  0
  7 32  1  0  0  0
  8  9  2  0  0  0
  8 21  1  0  0  0
  9 10  1  0  0  0
  9 12  1  0  0  0
 10 11  1  0  0  0
 12 13  1  0  0  0
 12 33  1  0  0  0
 13 14  1  0  0  0
 13 18  2  0  0  0
 14 15  2  0  0  0
 14 34  1  0  0  0
 15 16  1  0  0  0
 15 35  1  0  0  0
 16 17  2  0  0  0
 16 20  1  0  0  0
 17 18  1  0  0  0
 17 36  1  0  0  0
 18 19  1  0  0  0
 21 22  2  0  0  0
 21 23  1  0  0  0
 23 24  1  0  0  0
 23 37  1  0  0  0
 24 25  1  0  0  0
 25 26  1  0  0  0
 25 38  1  0  0  0
 25 39  1  0  0  0
 26 27  1  0  0  0
 26 40  1  0  0  0
 26 41  1  0  0  0
 27 42  1  0  0  0
M  END
> <s_m_entry_id>
713

> <Applicants>
Novartis

> <CHEMBL_ID>
CHEMBL3187723

> <Canonical_Smiles>
Brc1cc(F)c(Nc2c(cc3n(cnc3c2F)C)C(=O)NOCCO)cc1

> <Chirality>
Achiral Molecule

> <First_Approval>
2018

> <Phase>
4

> <SC_Patent>
US-7777050-B2

> <Synonyms>
ARRY 438162 | ARRY-162 | ARRY-438162 | BINIMETINIB | MEK-162 | MEK162 | MEKTOVI | NVP-MEK162

> <Indications>
On June 27, 2018, the Food and Drug Administration approved encorafenib and binimetinib in combination patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.

> <Type>
nan

> <targets_id>
Q02750

> <inchi>
InChI=1S/C17H15BrF2N4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26)

> <stdInchikey>
ACWZRVQXLIRSDF-UHFFFAOYSA-N

> <csid>
8463660

> <Links>
|http://www.chemspider.com/Chemical-Structure.8463660.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3187723|http://pubchem.ncbi.nlm.nih.gov/compound/10288191|http://www.drugbank.ca/drugs/DB11967| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=QO7|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/QO7|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7921|http://zinc15.docking.org/substances/ZINC000038460704|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=181R97MR71

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS

> <indicationG2P>
None

> <MW>
440

> <HBA>
6

> <HBD>
3

> <NRB>
6

> <TPSA>
88.4

> <LogP>
3

> <RoF>
0

> <Targets>
MAP2K1

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_epik_Ionization_Penalty>
  0.0113

> <r_epik_State_Penalty>
  0.0087

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
713

> <lig_pdbID>
'QO7'

> <pdbID>
6v2x

> <Kinase families>
STE

> <indicationDB>
Binimetinib, also known as <em>Mektovi</em>, is a potent is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK 1/2) inhibitor which is combined with <a href="https://go.drugbank.com/drugs/DB11718">Encorafenib</a> <sup class="text-reference-group"><a class="reference-popover-link" data-content="Bendell JC, Javle M, Bekaii-Saab TS, Finn RS, Wainberg ZA, Laheru DA, Weekes CD, Tan BR, Khan GN, Zalupski MM, Infante JR, Jones S, Papadopoulos KP, Tolcher AW, Chavira RE, Christy-Bittel JL, Barrett E, Patnaik A: A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor. Br J Cancer. 2017 Feb 28;116(5):575-583. doi: 10.1038/bjc.2017.10. Epub 2017 Feb 2. (PubMed ID 28152546)" href="#reference-A34275">4</a></sup>,<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA approves encorafenib and binimetinib in combination for unresectable or metastatic melanoma with BRAF mutations" href="#reference-L3335">8</a></sup>.</p><p>On June 27, 2018, the Food and Drug Administration approved the combination of <a href="https://go.drugbank.com/drugs/DB11718">Encorafenib</a> and binimetinib (BRAFTOVI and MEKTOVI, from Array BioPharma Inc.) in combination for patients with unresectable or metastatic melanoma with the BRAF V600E or V600K mutations, as detected by an FDA-approved test <sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA approves encorafenib and binimetinib in combination for unresectable or metastatic melanoma with BRAF mutations" href="#reference-L3335">8</a></sup>.

> <uniprotId>
P05231|P01375|P01584|Q13233|P36507|P22309|P05177|P33261

> <BrandName>
Mektovi

> <Withdrawn>
Study NCT02263898 in United States was Withdrawn during Phase 2 because closed without enrollment|

> <FDA_approved>
Y

$$$$
Bosutinib
                    3D
 Structure written by MMmdl.
 66 69  0  0  1  0            999 V2000
   -5.0426   -2.9629    3.7104 C   0  0  0  0  0  0
   -3.6021   -2.5635    3.3353 N   0  3  0  0  0  0
   -3.1029   -1.4242    4.2505 C   0  0  0  0  0  0
   -1.7004   -0.9626    3.7893 C   0  0  0  0  0  0
   -1.6412   -0.5914    2.3700 N   0  0  0  0  0  0
   -2.0921   -1.6949    1.5094 C   0  0  0  0  0  0
   -3.5182   -2.1914    1.8391 C   0  0  0  0  0  0
   -2.2956    0.6995    2.1069 C   0  0  0  0  0  0
   -2.0164    1.2930    0.7046 C   0  0  0  0  0  0
   -0.5314    1.5444    0.3800 C   0  0  0  0  0  0
    0.1449    0.2983    0.2400 O   0  0  0  0  0  0
    1.5143    0.2686    0.0522 C   0  0  0  0  0  0
    2.2886    1.4151   -0.1672 C   0  0  0  0  0  0
    3.6850    1.3228   -0.3614 C   0  0  0  0  0  0
    4.3245    0.0464   -0.3445 C   0  0  0  0  0  0
    3.5107   -1.0948   -0.0972 C   0  0  0  0  0  0
    2.1250   -0.9880    0.0886 C   0  0  0  0  0  0
    1.3008   -2.0772    0.3182 O   0  0  0  0  0  0
    1.8539   -3.3894    0.3353 C   0  0  0  0  0  0
    5.7479   -0.0022   -0.5667 C   0  0  0  0  0  0
    6.4342    1.2194   -0.7388 C   0  0  0  0  0  0
    5.7103    2.4091   -0.7272 C   0  0  0  0  0  0
    4.3729    2.4777   -0.5545 N   0  0  0  0  0  0
    7.8789    1.3061   -0.9524 C   0  0  0  0  0  0
    9.0215    1.3742   -1.1214 N   0  0  0  0  0  0
    6.4689   -1.2174   -0.6013 N   0  0  0  0  0  0
    6.1502   -2.3913   -1.3051 C   0  0  0  0  0  0
    6.3330   -3.6066   -0.6390 C   0  0  0  0  0  0
    6.0409   -4.8322   -1.2613 C   0  0  0  0  0  0
    5.5834   -4.8185   -2.5840 C   0  0  0  0  0  0
    5.4300   -3.6134   -3.2672 C   0  0  0  0  0  0
    5.7169   -2.3999   -2.6437 C   0  0  0  0  0  0
    5.5372   -0.9510   -3.5762 Cl  0  0  0  0  0  0
    5.2060   -6.2948   -3.4019 Cl  0  0  0  0  0  0
    6.1754   -6.0629   -0.6438 O   0  0  0  0  0  0
    6.6187   -6.1234    0.7075 C   0  0  0  0  0  0
   -5.6889   -2.0984    3.5492 H   0  0  0  0  0  0
   -5.0299   -3.2659    4.7582 H   0  0  0  0  0  0
   -5.3225   -3.7995    3.0687 H   0  0  0  0  0  0
   -3.8367   -0.6176    4.2045 H   0  0  0  0  0  0
   -3.0818   -1.8218    5.2661 H   0  0  0  0  0  0
   -1.3555   -0.1313    4.4062 H   0  0  0  0  0  0
   -0.9823   -1.7660    3.9624 H   0  0  0  0  0  0
   -2.0231   -1.4163    0.4583 H   0  0  0  0  0  0
   -1.3895   -2.5220    1.6248 H   0  0  0  0  0  0
   -3.7705   -3.0911    1.2763 H   0  0  0  0  0  0
   -4.2752   -1.4302    1.6428 H   0  0  0  0  0  0
   -3.3720    0.6192    2.2613 H   0  0  0  0  0  0
   -1.9372    1.4198    2.8444 H   0  0  0  0  0  0
   -2.4659    0.6751   -0.0728 H   0  0  0  0  0  0
   -2.5403    2.2473    0.6416 H   0  0  0  0  0  0
   -0.4540    2.1056   -0.5528 H   0  0  0  0  0  0
   -0.0777    2.1469    1.1693 H   0  0  0  0  0  0
    1.8366    2.3957   -0.1948 H   0  0  0  0  0  0
    3.9787   -2.0623   -0.0447 H   0  0  0  0  0  0
    1.0565   -4.1121    0.5073 H   0  0  0  0  0  0
    2.5825   -3.5064    1.1390 H   0  0  0  0  0  0
    2.3253   -3.6393   -0.6167 H   0  0  0  0  0  0
    6.2006    3.3631   -0.8669 H   0  0  0  0  0  0
    7.4672   -1.0707   -0.5538 H   0  0  0  0  0  0
    6.6884   -3.5847    0.3807 H   0  0  0  0  0  0
    5.0900   -3.6209   -4.2929 H   0  0  0  0  0  0
    6.6538   -7.1648    1.0272 H   0  0  0  0  0  0
    5.9366   -5.5968    1.3768 H   0  0  0  0  0  0
    7.6226   -5.7109    0.8185 H   0  0  0  0  0  0
   -3.0033   -3.3636    3.4861 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 37  1  0  0  0
  1 38  1  0  0  0
  1 39  1  0  0  0
  2  3  1  0  0  0
  2  7  1  0  0  0
  2 66  1  0  0  0
  3  4  1  0  0  0
  3 40  1  0  0  0
  3 41  1  0  0  0
  4  5  1  0  0  0
  4 42  1  0  0  0
  4 43  1  0  0  0
  5  6  1  0  0  0
  5  8  1  0  0  0
  6  7  1  0  0  0
  6 44  1  0  0  0
  6 45  1  0  0  0
  7 46  1  0  0  0
  7 47  1  0  0  0
  8  9  1  0  0  0
  8 48  1  0  0  0
  8 49  1  0  0  0
  9 10  1  0  0  0
  9 50  1  0  0  0
  9 51  1  0  0  0
 10 11  1  0  0  0
 10 52  1  0  0  0
 10 53  1  0  0  0
 11 12  1  0  0  0
 12 13  1  0  0  0
 12 17  2  0  0  0
 13 14  2  0  0  0
 13 54  1  0  0  0
 14 15  1  0  0  0
 14 23  1  0  0  0
 15 16  2  0  0  0
 15 20  1  0  0  0
 16 17  1  0  0  0
 16 55  1  0  0  0
 17 18  1  0  0  0
 18 19  1  0  0  0
 19 56  1  0  0  0
 19 57  1  0  0  0
 19 58  1  0  0  0
 20 21  2  0  0  0
 20 26  1  0  0  0
 21 22  1  0  0  0
 21 24  1  0  0  0
 22 23  2  0  0  0
 22 59  1  0  0  0
 24 25  3  0  0  0
 26 27  1  0  0  0
 26 60  1  0  0  0
 27 28  1  0  0  0
 27 32  2  0  0  0
 28 29  2  0  0  0
 28 61  1  0  0  0
 29 30  1  0  0  0
 29 35  1  0  0  0
 30 31  2  0  0  0
 30 34  1  0  0  0
 31 32  1  0  0  0
 31 62  1  0  0  0
 32 33  1  0  0  0
 35 36  1  0  0  0
 36 63  1  0  0  0
 36 64  1  0  0  0
 36 65  1  0  0  0
M  CHG  1   2   1
M  END
> <s_m_entry_id>
715

> <Applicants>
Wyeth

> <CHEMBL_ID>
CHEMBL288441

> <Canonical_Smiles>
Clc1cc(Cl)c(OC)cc1Nc1c2cc(OC)c(OCCCN3CCN(CC3)C)cc2ncc1C#N

> <Chirality>
Achiral Molecule

> <First_Approval>
2012

> <Phase>
4

> <SC_Patent>
US-7417148-B2

> <Synonyms>
BOSULIF | BOSUTINIB | BOSUTINIB MONOHYDRATE | SK-606 | SKI-606

> <Indications>
Treatment of chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapy in adult patients.

> <Type>
1

> <targets_id>
P11274|P00519|P07948|P08631|P12931|P24941|Q02750|P36507|Q9Y2U5|Q13555

> <inchi>
InChI=1S/C26H29Cl2N5O3/c1-32-6-8-33(9-7-32)5-4-10-36-25-13-21-18(11-24(25)35-3)26(17(15-29)16-30-21)31-22-14-23(34-2)20(28)12-19(22)27/h11-14,16H,4-10H2,1-3H3,(H,30,31)

> <stdInchikey>
UBPYILGKFZZVDX-UHFFFAOYSA-N

> <csid>
4486102

> <Links>
|http://www.chemspider.com/Chemical-Structure.4486102.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL288441|http://pubchem.ncbi.nlm.nih.gov/compound/5328940|http://www.drugbank.ca/drugs/DB06616| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=DB8|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/DB8|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5710|http://zinc15.docking.org/substances/ZINC000022448983|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=5018V4AEZ0|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=4552

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
529.2

> <HBA>
8

> <HBD>
1

> <NRB>
9

> <TPSA>
82.9

> <LogP>
5.2

> <RoF>
2

> <Targets>
BCR; ABL1; LYN; HCK; SRC; CDK2; MAP2K1; MAP2K2; MAP3K2; CAMK2G

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_epik_Ionization_Penalty>
  0.0297

> <r_epik_State_Penalty>
  0.1132

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
715

> <lig_pdbID>
'DB8'

> <pdbID>
3soa 3ue4 4mxo 4mxx 4mxy 4mxz 4qmn 5ajq 5i9x 5vc3 5vcy 6fdy 6op9

> <Kinase families>
Atypical<br>CAMK<br>Tyr<br>STE<br>CMGC

> <indicationDB>
Bosutinib is a Bcr-Abl kinase inhibitor for the treatment of Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML). Compared to other tyrosine kinase inhibitors, it has a more favourable hematologic toxicity profile. FDA approved on September 4, 2012.

> <uniprotId>
P11274|P00519|P07948|P08631|P12931|P24941|Q02750|P36507|Q9Y2U5|Q13555|P08684|P10632|P08183

> <BrandName>
Bosulif

> <FDA_approved>
Y

$$$$
Brigatinib
                    3D
 Structure written by MMmdl.
 80 84  0  0  1  0            999 V2000
  -10.8472   -1.0760    2.7899 C   0  0  0  0  0  0
  -10.9355   -0.9677    1.3343 N   0  0  0  0  0  0
  -10.2168    0.2008    0.8143 C   0  0  0  0  0  0
   -8.6783    0.0492    0.8438 C   0  0  0  0  0  0
   -8.2751   -1.2503    0.1029 N   0  3  0  0  0  0
   -9.0244   -2.4784    0.6699 C   0  0  0  0  0  0
  -10.5475   -2.2098    0.6572 C   0  0  0  0  0  0
   -6.7474   -1.5254   -0.0150 C   0  0  0  0  0  0
   -6.0243   -1.4925    1.3498 C   0  0  0  0  0  0
   -4.4978   -1.6269    1.1556 C   0  0  0  0  0  0
   -3.9608   -0.5710    0.2741 N   0  0  0  0  0  0
   -4.5824   -0.7218   -1.0564 C   0  0  0  0  0  0
   -6.1126   -0.5255   -0.9998 C   0  0  0  0  0  0
   -2.6191   -0.1975    0.3217 C   0  0  0  0  0  0
   -1.6414   -0.9861    0.9434 C   0  0  0  0  0  0
   -0.3104   -0.5801    0.9741 C   0  0  0  0  0  0
    0.0812    0.6189    0.3776 C   0  0  0  0  0  0
   -0.8828    1.4484   -0.2257 C   0  0  0  0  0  0
   -2.2217    1.0182   -0.2502 C   0  0  0  0  0  0
   -0.4693    2.6669   -0.7388 O   0  0  0  0  0  0
   -1.4174    3.5429   -1.3389 C   0  0  0  0  0  0
    1.4430    0.9622    0.4417 N   0  0  0  0  0  0
    2.3170    1.3446   -0.5853 C   0  0  0  0  0  0
    3.5798    1.6568   -0.2009 N   0  0  0  0  0  0
    4.4425    2.0206   -1.1839 C   0  0  0  0  0  0
    4.0730    2.0684   -2.5297 C   0  0  0  0  0  0
    2.7494    1.7205   -2.8444 C   0  0  0  0  0  0
    1.8738    1.3501   -1.8712 N   0  0  0  0  0  0
    2.3357    1.7253   -4.1887 N   0  0  0  0  0  0
    1.1951    1.2050   -4.8309 C   0  0  0  0  0  0
   -0.0632    1.2222   -4.2109 C   0  0  0  0  0  0
   -1.1841    0.7016   -4.8524 C   0  0  0  0  0  0
   -1.0644    0.1616   -6.1287 C   0  0  0  0  0  0
    0.1744    0.1491   -6.7653 C   0  0  0  0  0  0
    1.3092    0.6733   -6.1324 C   0  0  0  0  0  0
    2.9221    0.6362   -7.0062 P   0  0  0  0  0  0
    3.6488    1.9338   -6.9379 O   0  0  0  0  0  0
    3.8168   -0.7644   -6.2243 C   0  0  0  0  0  0
    2.6247    0.0529   -8.7272 C   0  0  0  0  0  0
    5.2339    2.5302   -3.7291 Cl  0  0  0  0  0  0
  -11.4657   -1.8992    3.1498 H   0  0  0  0  0  0
  -11.2130   -0.1645    3.2642 H   0  0  0  0  0  0
   -9.8261   -1.2473    3.1315 H   0  0  0  0  0  0
  -10.5406    0.3714   -0.2136 H   0  0  0  0  0  0
  -10.5174    1.0935    1.3650 H   0  0  0  0  0  0
   -8.1968    0.8868    0.3419 H   0  0  0  0  0  0
   -8.3095   -0.0100    1.8671 H   0  0  0  0  0  0
   -8.7719   -3.3311    0.0383 H   0  0  0  0  0  0
   -8.6474   -2.6631    1.6762 H   0  0  0  0  0  0
  -11.0827   -3.0533    1.0959 H   0  0  0  0  0  0
  -10.8917   -2.1548   -0.3768 H   0  0  0  0  0  0
   -6.6634   -2.5238   -0.4496 H   0  0  0  0  0  0
   -6.2113   -0.5585    1.8785 H   0  0  0  0  0  0
   -6.3821   -2.2924    1.9980 H   0  0  0  0  0  0
   -4.0274   -1.5569    2.1375 H   0  0  0  0  0  0
   -4.2474   -2.6098    0.7518 H   0  0  0  0  0  0
   -4.1702    0.0025   -1.7600 H   0  0  0  0  0  0
   -4.3415   -1.7075   -1.4589 H   0  0  0  0  0  0
   -6.5402   -0.6519   -1.9952 H   0  0  0  0  0  0
   -6.3152    0.5051   -0.7096 H   0  0  0  0  0  0
   -1.8959   -1.9301    1.4016 H   0  0  0  0  0  0
    0.4207   -1.2157    1.4535 H   0  0  0  0  0  0
   -2.9799    1.6403   -0.7019 H   0  0  0  0  0  0
   -0.9034    4.4355   -1.6949 H   0  0  0  0  0  0
   -2.1757    3.8621   -0.6226 H   0  0  0  0  0  0
   -1.9053    3.0806   -2.1981 H   0  0  0  0  0  0
    1.9090    0.7199    1.3036 H   0  0  0  0  0  0
    5.4467    2.2724   -0.8754 H   0  0  0  0  0  0
    3.1126    1.8597   -4.8208 H   0  0  0  0  0  0
   -0.1971    1.6515   -3.2316 H   0  0  0  0  0  0
   -2.1455    0.7220   -4.3602 H   0  0  0  0  0  0
   -1.9325   -0.2422   -6.6286 H   0  0  0  0  0  0
    0.2304   -0.2715   -7.7566 H   0  0  0  0  0  0
    3.2243   -1.6780   -6.2711 H   0  0  0  0  0  0
    4.0299   -0.5494   -5.1773 H   0  0  0  0  0  0
    4.7640   -0.9451   -6.7319 H   0  0  0  0  0  0
    2.1736   -0.9389   -8.7382 H   0  0  0  0  0  0
    3.5660   -0.0054   -9.2733 H   0  0  0  0  0  0
    1.9689    0.7405   -9.2611 H   0  0  0  0  0  0
   -8.6061   -1.1464   -0.8459 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 41  1  0  0  0
  1 42  1  0  0  0
  1 43  1  0  0  0
  2  3  1  0  0  0
  2  7  1  0  0  0
  3  4  1  0  0  0
  3 44  1  0  0  0
  3 45  1  0  0  0
  4  5  1  0  0  0
  4 46  1  0  0  0
  4 47  1  0  0  0
  5  6  1  0  0  0
  5  8  1  0  0  0
  5 80  1  0  0  0
  6  7  1  0  0  0
  6 48  1  0  0  0
  6 49  1  0  0  0
  7 50  1  0  0  0
  7 51  1  0  0  0
  8  9  1  0  0  0
  8 13  1  0  0  0
  8 52  1  0  0  0
  9 10  1  0  0  0
  9 53  1  0  0  0
  9 54  1  0  0  0
 10 11  1  0  0  0
 10 55  1  0  0  0
 10 56  1  0  0  0
 11 12  1  0  0  0
 11 14  1  0  0  0
 12 13  1  0  0  0
 12 57  1  0  0  0
 12 58  1  0  0  0
 13 59  1  0  0  0
 13 60  1  0  0  0
 14 15  1  0  0  0
 14 19  2  0  0  0
 15 16  2  0  0  0
 15 61  1  0  0  0
 16 17  1  0  0  0
 16 62  1  0  0  0
 17 18  2  0  0  0
 17 22  1  0  0  0
 18 19  1  0  0  0
 18 20  1  0  0  0
 19 63  1  0  0  0
 20 21  1  0  0  0
 21 64  1  0  0  0
 21 65  1  0  0  0
 21 66  1  0  0  0
 22 23  1  0  0  0
 22 67  1  0  0  0
 23 24  1  0  0  0
 23 28  2  0  0  0
 24 25  2  0  0  0
 25 26  1  0  0  0
 25 68  1  0  0  0
 26 27  2  0  0  0
 26 40  1  0  0  0
 27 28  1  0  0  0
 27 29  1  0  0  0
 29 30  1  0  0  0
 29 69  1  0  0  0
 30 31  1  0  0  0
 30 35  2  0  0  0
 31 32  2  0  0  0
 31 70  1  0  0  0
 32 33  1  0  0  0
 32 71  1  0  0  0
 33 34  2  0  0  0
 33 72  1  0  0  0
 34 35  1  0  0  0
 34 73  1  0  0  0
 35 36  1  0  0  0
 36 37  2  0  0  0
 36 38  1  0  0  0
 36 39  1  0  0  0
 38 74  1  0  0  0
 38 75  1  0  0  0
 38 76  1  0  0  0
 39 77  1  0  0  0
 39 78  1  0  0  0
 39 79  1  0  0  0
M  CHG  1   5   1
M  END
> <s_m_entry_id>
721

> <Applicants>
Ariad Pharmaceuticals

> <CHEMBL_ID>
CHEMBL3545311

> <Canonical_Smiles>
Clc1cnc(nc1Nc1ccccc1P(=O)(C)C)Nc1ccc(N2CCC(N3CCN(CC3)C)CC2)cc1OC

> <Chirality>
Achiral Molecule

> <First_Approval>
2017

> <Phase>
4

> <SC_Patent>
US-9012462-B2

> <Synonyms>
ALUNBRIG | AP-26113 | AP26113 | BRIGATINIB

> <Indications>
The anaplastic lymphoma kinase positive, metastatic non-small cell lung cancer (ALK+ NSCLC), represents only 3-5% of the NSCLC cancer cases, but the ALK mutation, overexpression and presence in several oncogenic fusion proteins in solid and hematologic tumors have pointed out the importance as well as its potential as a cancer therapy target. The ALK-related cases of NSCLC are associated with the presence of the fusion gene EML4-ALK which fused the ALK protein with the echinoderm microtubule-associated protein like-4 whose original function is the correct formation of microtubules. The presence of the aberrant fusion protein results in abnormal signaling that provokes increased cell growth, proliferation and survival. Crizotinib is indicated for the treatment of such cases but the presence of ALK kinase domain mutations confer resistance to the treatment. Thus, brigatinib is indicated for the treatment of patients with ALK+ NSCLC with intolerance to Crizotinib.

> <Type>
1

> <targets_id>
Q9UM73|P00533

> <inchi>
InChI=1S/C29H39ClN7O2P/c1-35-15-17-37(18-16-35)21-11-13-36(14-12-21)22-9-10-24(26(19-22)39-2)33-29-31-20-23(30)28(34-29)32-25-7-5-6-8-27(25)40(3,4)38/h5-10,19-21H,11-18H2,1-4H3,(H2,31,32,33,34)

> <stdInchikey>
AILRADAXUVEEIR-UHFFFAOYSA-N

> <csid>
34982928

> <Links>
|http://www.chemspider.com/Chemical-Structure.34982928.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3545311|http://pubchem.ncbi.nlm.nih.gov/compound/68165256|http://www.drugbank.ca/drugs/DB12267| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=6GY|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/6GY|http://zinc15.docking.org/substances/ZINC000148723177|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=HYW8DB273J|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50185140

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|ZINC|FDA SRS|BindingDB

> <MW>
583.3

> <HBA>
9

> <HBD>
2

> <NRB>
8

> <TPSA>
85.9

> <LogP>
5.1

> <RoF>
2

> <Targets>
ALK; EGFR

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0088

> <r_epik_State_Penalty>
  0.0135

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
721

> <lig_pdbID>
'6GY'

> <pdbID>
6mx8

> <Kinase families>
Tyr

> <indicationDB>
Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Ceccon M, Mologni L, Bisson W, Scapozza L, Gambacorti-Passerini C: Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors. Mol Cancer Res. 2013 Feb;11(2):122-32. doi: 10.1158/1541-7786.MCR-12-0569. Epub 2012 Dec 13. (PubMed ID 23239810)" href="#reference-A31311">1</a></sup> It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the EML4-ALK fusion gene, which is a pivotal player in the transformation of susceptible lung parenchyma.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Iragavarapu C, Mustafa M, Akinleye A, Furqan M, Mittal V, Cang S, Liu D: Novel ALK inhibitors in clinical use and development. J Hematol Oncol. 2015 Feb 27;8:17. doi: 10.1186/s13045-015-0122-8. (PubMed ID 25888090)" href="#reference-A31313">2</a></sup> Brigatinib was developed by Ariad Pharmaceuticals, a subsidiary of Takeda Pharmaceutical Company Limited, and FDA-approved on April 28, 2017.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA News and Events" href="#reference-L1026">9</a></sup>

> <uniprotId>
Q9UM73|P00533|P00519|P08069|P36888|P06213|P08581|Q15303|P04626|P10632|P08684|P08684|Q9HB55|P20815|P24462|Q2M3G0|Q9UNQ0|O15245|Q96FL8|Q86VL8

> <BrandName>
Alunbrig

> <FDA_approved>
Y

$$$$
Capmatinib
                    3D
 Structure written by MMmdl.
 48 52  0  0  1  0            999 V2000
   -5.8861    0.3020   -1.9452 C   0  0  0  0  0  0
   -4.4737    0.2569   -1.5836 N   0  0  0  0  0  0
   -3.8209    1.2112   -0.8950 C   0  0  0  0  0  0
   -4.3495    2.2527   -0.5018 O   0  0  0  0  0  0
   -2.3607    0.9378   -0.6251 C   0  0  0  0  0  0
   -1.9251   -0.3538   -0.2948 C   0  0  0  0  0  0
   -0.5765   -0.6119   -0.0517 C   0  0  0  0  0  0
    0.3808    0.4069   -0.1333 C   0  0  0  0  0  0
   -0.0605    1.6953   -0.4709 C   0  0  0  0  0  0
   -1.4068    1.9642   -0.7159 C   0  0  0  0  0  0
   -1.7627    3.2281   -1.0511 F   0  0  0  0  0  0
    1.8253    0.1274    0.1279 C   0  0  0  0  0  0
    2.4303   -1.1008   -0.1826 C   0  0  0  0  0  0
    3.7554   -1.3480    0.0151 N   0  0  0  0  0  0
    4.4769   -0.3392    0.5223 C   0  0  0  0  0  0
    5.8034   -0.3064    0.7993 N   0  0  0  0  0  0
    6.0008    0.9112    1.2638 C   0  0  0  0  0  0
    4.8525    1.7069    1.3103 C   0  0  0  0  0  0
    3.8574    0.8833    0.8312 N   0  0  0  0  0  0
    2.5498    1.1513    0.6618 N   0  0  0  0  0  0
    4.6115    3.1372    1.7701 C   0  0  0  0  0  0
    3.9504    4.0079    0.7070 C   0  0  0  0  0  0
    4.6604    4.3736   -0.4375 C   0  0  0  0  0  0
    4.0588    5.1269   -1.4432 C   0  0  0  0  0  0
    2.7076    5.5293   -1.3196 C   0  0  0  0  0  0
    1.9780    5.1639   -0.1472 C   0  0  0  0  0  0
    2.6211    4.4086    0.8618 C   0  0  0  0  0  0
    0.6233    5.5703   -0.0521 C   0  0  0  0  0  0
    0.0551    6.3017   -1.0923 C   0  0  0  0  0  0
    0.8388    6.6174   -2.1988 C   0  0  0  0  0  0
    2.1379    6.2498   -2.3269 N   0  0  0  0  0  0
   -5.9903    0.4971   -3.0125 H   0  0  0  0  0  0
   -6.4402    1.0689   -1.4020 H   0  0  0  0  0  0
   -6.3506   -0.6602   -1.7300 H   0  0  0  0  0  0
   -3.9543   -0.5460   -1.9065 H   0  0  0  0  0  0
   -2.6290   -1.1701   -0.2124 H   0  0  0  0  0  0
   -0.2829   -1.6171    0.2129 H   0  0  0  0  0  0
    0.6485    2.5060   -0.5558 H   0  0  0  0  0  0
    1.8633   -1.9104   -0.6181 H   0  0  0  0  0  0
    6.9861    1.2285    1.5725 H   0  0  0  0  0  0
    3.9957    3.1276    2.6709 H   0  0  0  0  0  0
    5.5535    3.6056    2.0585 H   0  0  0  0  0  0
    5.6876    4.0599   -0.5565 H   0  0  0  0  0  0
    4.6182    5.3980   -2.3270 H   0  0  0  0  0  0
    2.0602    4.1224    1.7403 H   0  0  0  0  0  0
    0.0400    5.3062    0.8182 H   0  0  0  0  0  0
   -0.9766    6.6171   -1.0420 H   0  0  0  0  0  0
    0.4209    7.1831   -3.0185 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 32  1  0  0  0
  1 33  1  0  0  0
  1 34  1  0  0  0
  2  3  1  0  0  0
  2 35  1  0  0  0
  3  4  2  0  0  0
  3  5  1  0  0  0
  5  6  1  0  0  0
  5 10  2  0  0  0
  6  7  2  0  0  0
  6 36  1  0  0  0
  7  8  1  0  0  0
  7 37  1  0  0  0
  8  9  2  0  0  0
  8 12  1  0  0  0
  9 10  1  0  0  0
  9 38  1  0  0  0
 10 11  1  0  0  0
 12 13  1  0  0  0
 12 20  2  0  0  0
 13 14  2  0  0  0
 13 39  1  0  0  0
 14 15  1  0  0  0
 15 16  2  0  0  0
 15 19  1  0  0  0
 16 17  1  0  0  0
 17 18  2  0  0  0
 17 40  1  0  0  0
 18 19  1  0  0  0
 18 21  1  0  0  0
 19 20  1  0  0  0
 21 22  1  0  0  0
 21 41  1  0  0  0
 21 42  1  0  0  0
 22 23  1  0  0  0
 22 27  2  0  0  0
 23 24  2  0  0  0
 23 43  1  0  0  0
 24 25  1  0  0  0
 24 44  1  0  0  0
 25 26  1  0  0  0
 25 31  2  0  0  0
 26 27  1  0  0  0
 26 28  2  0  0  0
 27 45  1  0  0  0
 28 29  1  0  0  0
 28 46  1  0  0  0
 29 30  2  0  0  0
 29 47  1  0  0  0
 30 31  1  0  0  0
 30 48  1  0  0  0
M  END
> <s_m_entry_id>
725

> <Applicants>
Novartis

> <CHEMBL_ID>
CHEMBL3188267

> <Canonical_Smiles>
Fc1cc(ccc1C(=O)NC)C1=Nn2c(ncc2Cc2cc3c(nccc3)cc2)N=C1

> <Chirality>
Achiral Molecule

> <First_Approval>
2020

> <Phase>
4

> <SC_Patent>
US-7767675-B2

> <Synonyms>
CAPMATINIB | INC-280 | INC280 | INCB-28060 | INCB-28060 FREE BASE | NVP-INC280 | NVP-INC280-NX | NYP-INC280-NX

> <Indications>
On may 2020 FDA approved capmatinib to treat patients with non small cell lung cancer

> <Type>
nan

> <targets_id>
P08581

> <inchi>
InChI=1S/C23H17FN6O/c1-25-22(31)18-6-5-16(11-19(18)24)21-13-28-23-27-12-17(30(23)29-21)10-14-4-7-20-15(9-14)3-2-8-26-20/h2-9,11-13H,10H2,1H3,(H,25,31)

> <stdInchikey>
LIOLIMKSCNQPLV-UHFFFAOYSA-N

> <csid>
25069712

> <Links>
|http://www.chemspider.com/Chemical-Structure.25069712.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3188267|http://pubchem.ncbi.nlm.nih.gov/compound/25145656|http://www.drugbank.ca/drugs/DB11791|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7904|http://zinc15.docking.org/substances/ZINC000043195321|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=TY34L4F9OZ|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50146167

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
412.1

> <HBA>
6

> <HBD>
1

> <NRB>
4

> <TPSA>
85.1

> <LogP>
3.4

> <RoF>
0

> <Targets>
MET

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_epik_Ionization_Penalty>
  0.0075

> <r_epik_State_Penalty>
  0.0056

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
725

> <Kinase families>
Tyr

> <indicationDB>
Capmatinib is a small molecule kinase inhibitor targeted against c-Met (a.k.a. hepatocyte growth factor receptor [HGFR]), a receptor tyrosine kinase that, in healthy humans, activates signaling cascades involved in organ regeneration and tissue repair.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Kim S, Kim TM, Kim DW, Kim S, Kim M, Ahn YO, Keam B, Heo DS: Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib. Cancer Res Treat. 2019 Jul;51(3):951-962. doi: 10.4143/crt.2018.052. Epub 2018 Oct 10. (PubMed ID 30309221)" href="#reference-A199122">2</a></sup> Aberrant c-Met activation - via mutations, amplification, and/or overexpression - is known to occur in many types of cancer, and leads to overactivation of multiple downstream signaling pathways such as STAT3, PI3K/ATK, and RAS/MAPK.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Kim S, Kim TM, Kim DW, Kim S, Kim M, Ahn YO, Keam B, Heo DS: Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib. Cancer Res Treat. 2019 Jul;51(3):951-962. doi: 10.4143/crt.2018.052. Epub 2018 Oct 10. (PubMed ID 30309221)" href="#reference-A199122">2</a></sup> Mutations in <em>MET</em> have been detected in non-small cell lung cancer (NSCLC), and the prevalence of <em>MET</em> amplification in epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI)-naive patients with NSCLC has been reported to be 1.4% - 21%.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Kim S, Kim TM, Kim DW, Kim S, Kim M, Ahn YO, Keam B, Heo DS: Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib. Cancer Res Treat. 2019 Jul;51(3):951-962. doi: 10.4143/crt.2018.052. Epub 2018 Oct 10. (PubMed ID 30309221)" href="#reference-A199122">2</a></sup> This co-occurrence has made c-Met a desirable target in the treatment of NSCLC.</p><p>Manufactured by Novartis and marketed under the brand name Tabrecta, capmatinib was granted accelerated approval by the FDA on May 6, 2020,<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA Approvals and Databases: FDA grants accelerated approval to capmatinib for metastatic non-small cell lung cancer" href="#reference-L13380">4</a></sup> for the treatment of NSCLC in patients whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA Approved Drug Products: Tabrecta (capmatinib) oral tablets" href="#reference-L13347">3</a></sup> The presence of the mutation must be confirmed by an FDA-approved test, such as the FoundationOne CDx assay (manufactured by Foundation Medicine, Inc.), which was approved by the FDA on the same day.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA Approvals and Databases: FDA grants accelerated approval to capmatinib for metastatic non-small cell lung cancer" href="#reference-L13380">4</a></sup> As this indication was granted under an accelerated approval, its continued approval is contingent upon verification of capmatinib&#39;s benefit in confirmatory trials.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA Approved Drug Products: Tabrecta (capmatinib) oral tablets" href="#reference-L13347">3</a></sup>

> <uniprotId>
P08581|P08684|Q06278|P05177|P08183|Q96FL8|Q86VL8|Q9UNQ0

> <FDA_approved>
Y

$$$$
Cobimetinib
                    3D
 Structure written by MMmdl.
 52 55  0  0  1  0            999 V2000
   -0.9688   -3.4104    3.9445 C   0  0  0  0  0  0
   -0.0848   -4.4694    4.1453 C   0  0  0  0  0  0
    0.9145   -4.7295    3.2081 C   0  0  0  0  0  0
    1.0382   -3.9262    2.0739 C   0  0  0  0  0  0
    0.1539   -2.8592    1.8640 C   0  0  0  0  0  0
   -0.8514   -2.6098    2.8089 C   0  0  0  0  0  0
    0.3076   -2.0617    0.7174 N   0  0  0  0  0  0
   -0.5453   -1.0833    0.1664 C   0  0  0  0  0  0
   -1.8871   -1.4005   -0.1118 C   0  0  0  0  0  0
   -2.7185   -0.4731   -0.7395 C   0  0  0  0  0  0
   -2.2186    0.7674   -1.1228 C   0  0  0  0  0  0
   -0.8853    1.0855   -0.8810 C   0  0  0  0  0  0
   -0.0384    0.1761   -0.2355 C   0  0  0  0  0  0
    1.3948    0.5870    0.0001 C   0  0  0  0  0  0
    2.1516    0.7761   -0.9514 O   0  0  0  0  0  0
    1.7875    0.7146    1.2815 N   0  0  0  0  0  0
    1.0497    0.7444    2.5699 C   0  0  0  0  0  0
    2.4342    0.7535    3.2480 C   0  0  0  0  0  0
    3.1148    0.9885    1.8805 C   0  0  0  0  0  0
    2.6299    1.7853    4.1996 O   0  0  0  0  0  0
    2.7856   -0.6303    3.8783 C   0  0  1  0  0  0
    4.2928   -0.6269    4.2245 N   0  3  0  0  0  0
    4.7858   -1.9491    4.8404 C   0  0  0  0  0  0
    3.9671   -2.2569    6.1059 C   0  0  0  0  0  0
    2.4599   -2.3051    5.8101 C   0  0  0  0  0  0
    1.9717   -1.0046    5.1461 C   0  0  0  0  0  0
   -4.0112   -0.7820   -0.9920 F   0  0  0  0  0  0
   -2.3928   -2.6179    0.2028 F   0  0  0  0  0  0
    2.0276   -4.1885    1.1867 F   0  0  0  0  0  0
   -0.2402   -5.6514    5.8625 I   0  0  0  0  0  0
   -1.7423   -3.2048    4.6698 H   0  0  0  0  0  0
    1.6019   -5.5479    3.3654 H   0  0  0  0  0  0
   -1.5411   -1.7889    2.6776 H   0  0  0  0  0  0
    1.2122   -2.1329    0.2736 H   0  0  0  0  0  0
   -2.8625    1.4809   -1.6162 H   0  0  0  0  0  0
   -0.5165    2.0521   -1.1952 H   0  0  0  0  0  0
    0.4630    1.6578    2.6770 H   0  0  0  0  0  0
    0.4365   -0.1393    2.7393 H   0  0  0  0  0  0
    3.8709    0.2610    1.5828 H   0  0  0  0  0  0
    3.4443    2.0092    1.6819 H   0  0  0  0  0  0
    2.3835    2.6225    3.7982 H   0  0  0  0  0  0
    2.6904   -1.4198    3.1294 H   0  0  0  0  0  0
    4.8252   -0.4337    3.3882 H   0  0  0  0  0  0
    4.6688   -2.7089    4.0662 H   0  0  0  0  0  0
    5.8462   -1.8070    5.0508 H   0  0  0  0  0  0
    4.2896   -3.2093    6.5284 H   0  0  0  0  0  0
    4.1714   -1.5019    6.8667 H   0  0  0  0  0  0
    2.2521   -3.1501    5.1544 H   0  0  0  0  0  0
    1.9017   -2.4896    6.7291 H   0  0  0  0  0  0
    2.0278   -0.1966    5.8774 H   0  0  0  0  0  0
    0.9159   -1.1048    4.8929 H   0  0  0  0  0  0
    4.4746    0.1269    4.8724 H   0  0  0  0  0  0
  1  2  2  0  0  0
  1  6  1  0  0  0
  1 31  1  0  0  0
  2  3  1  0  0  0
  2 30  1  0  0  0
  3  4  2  0  0  0
  3 32  1  0  0  0
  4  5  1  0  0  0
  4 29  1  0  0  0
  5  6  2  0  0  0
  5  7  1  0  0  0
  6 33  1  0  0  0
  7  8  1  0  0  0
  7 34  1  0  0  0
  8  9  2  0  0  0
  8 13  1  0  0  0
  9 10  1  0  0  0
  9 28  1  0  0  0
 10 11  2  0  0  0
 10 27  1  0  0  0
 11 12  1  0  0  0
 11 35  1  0  0  0
 12 13  2  0  0  0
 12 36  1  0  0  0
 13 14  1  0  0  0
 14 15  2  0  0  0
 14 16  1  0  0  0
 16 17  1  0  0  0
 16 19  1  0  0  0
 17 18  1  0  0  0
 17 37  1  0  0  0
 17 38  1  0  0  0
 18 19  1  0  0  0
 18 20  1  0  0  0
 18 21  1  0  0  0
 19 39  1  0  0  0
 19 40  1  0  0  0
 20 41  1  0  0  0
 21 22  1  0  0  0
 21 26  1  0  0  0
 21 42  1  0  0  0
 22 23  1  0  0  0
 22 43  1  0  0  0
 22 52  1  0  0  0
 23 24  1  0  0  0
 23 44  1  0  0  0
 23 45  1  0  0  0
 24 25  1  0  0  0
 24 46  1  0  0  0
 24 47  1  0  0  0
 25 26  1  0  0  0
 25 48  1  0  0  0
 25 49  1  0  0  0
 26 50  1  0  0  0
 26 51  1  0  0  0
M  CHG  1  22   1
M  END
> <s_m_entry_id>
726

> <Applicants>
Hoffmann-La Roche

> <CHEMBL_ID>
CHEMBL2146883

> <Canonical_Smiles>
Ic1cc(F)c(Nc2c(F)c(F)ccc2C(=O)N2CC(O)(C2)[C@H]2NCCCC2)cc1

> <Chirality>
Single Stereoisomer

> <First_Approval>
2015

> <Phase>
4

> <SC_Patent>
US-7803839-B2

> <Synonyms>
COBIMETINIB | COTELLIC | GDC-0623 | GDC-0973 | RG 7420 | RG-7420 | RG-7421 | RG7420 | XL-518

> <Indications>
For the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. Cobimetinib is used in combination with vemurafenib, a BRAF inhibitor.

> <Type>
3

> <targets_id>
Q02750

> <inchi>
InChI=1S/C21H21F3IN3O2/c22-14-6-5-13(19(18(14)24)27-16-7-4-12(25)9-15(16)23)20(29)28-10-21(30,11-28)17-3-1-2-8-26-17/h4-7,9,17,26-27,30H,1-3,8,10-11H2/t17-/m0/s1

> <stdInchikey>
BSMCAPRUBJMWDF-KRWDZBQOSA-N

> <csid>
17349374

> <Links>
|http://www.chemspider.com/Chemical-Structure.17349374.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2146883|http://pubchem.ncbi.nlm.nih.gov/compound/16222096|http://www.drugbank.ca/drugs/DB05239| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=EUI|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/EUI|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7626|http://zinc15.docking.org/substances/ZINC000060325170|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=ER29L26N1X|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50391802

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
531.1

> <HBA>
4

> <HBD>
3

> <NRB>
4

> <TPSA>
64.6

> <LogP>
3.8

> <RoF>
1

> <Targets>
MAP2K1

> <chiral flag>
1

> <version>
0

> <i_f3d_flags>
0

> <r_epik_Ionization_Penalty>
  0.0039

> <r_epik_State_Penalty>
  0.0028

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
726

> <lig_pdbID>
'EUI'

> <pdbID>
4an2 4lmn 6v2z 7juy

> <Kinase families>
STE

> <indicationDB>
Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment of patients with unresectable or metastatic BRAF V600 mutation-positive melanoma.

> <uniprotId>
Q02750|P08684|P08183|Q9Y6L6|Q9NPD5|Q9UNQ0|P08183

> <BrandName>
Cotellic

> <Withdrawn>
|Study NCT02427893 in United States was Withdrawn during Phase 3 because no patients were enrolled|Study NCT03005639 in United States was Withdrawn during Phase 2 because Sponsor has decided to close study

> <FDA_approved>
Y

$$$$
Axitinib
                    3D
 Structure written by MMmdl.
 46 49  0  0  1  0            999 V2000
    0.5229    4.2623   -2.0262 C   0  0  0  0  0  0
   -0.1758    3.0966   -1.4966 N   0  0  0  0  0  0
    0.1870    2.4103   -0.3975 C   0  0  0  0  0  0
    1.1587    2.6993    0.3028 O   0  0  0  0  0  0
   -0.6865    1.2230   -0.0645 C   0  0  0  0  0  0
   -2.0807    1.3930   -0.0365 C   0  0  0  0  0  0
   -2.9279    0.3323    0.2788 C   0  0  0  0  0  0
   -2.3959   -0.9195    0.5719 C   0  0  0  0  0  0
   -1.0169   -1.1106    0.5474 C   0  0  0  0  0  0
   -0.1563   -0.0553    0.2307 C   0  0  0  0  0  0
    1.5850   -0.4128    0.1892 S   0  0  0  0  0  0
    1.7332   -1.2087   -1.3791 C   0  0  0  0  0  0
    1.6096   -0.4536   -2.5463 C   0  0  0  0  0  0
    1.7161   -1.0466   -3.8039 C   0  0  0  0  0  0
    1.9567   -2.4284   -3.8823 C   0  0  0  0  0  0
    2.0831   -3.1703   -2.6817 C   0  0  0  0  0  0
    1.9753   -2.5837   -1.4169 C   0  0  0  0  0  0
    2.3127   -4.4660   -3.0847 N   0  0  0  0  0  0
    2.3350   -4.5752   -4.4234 N   0  0  0  0  0  0
    2.1246   -3.3844   -4.9394 C   0  0  0  0  0  0
    2.0744   -3.1178   -6.3680 C   0  0  0  0  0  0
    2.2557   -4.0023   -7.3709 C   0  0  0  0  0  0
    2.1942   -3.7141   -8.8187 C   0  0  0  0  0  0
    2.4261   -4.7445   -9.7383 C   0  0  0  0  0  0
    2.3603   -4.4624  -11.1043 C   0  0  0  0  0  0
    2.0673   -3.1646  -11.5247 C   0  0  0  0  0  0
    1.8489   -2.1861  -10.5548 C   0  0  0  0  0  0
    1.9084   -2.4439   -9.2234 N   0  0  0  0  0  0
    0.7389    4.1106   -3.0838 H   0  0  0  0  0  0
    1.4666    4.4637   -1.5176 H   0  0  0  0  0  0
   -0.1081    5.1461   -1.9328 H   0  0  0  0  0  0
   -0.9946    2.7956   -2.0044 H   0  0  0  0  0  0
   -2.5219    2.3566   -0.2506 H   0  0  0  0  0  0
   -3.9974    0.4827    0.2985 H   0  0  0  0  0  0
   -3.0513   -1.7423    0.8166 H   0  0  0  0  0  0
   -0.6164   -2.0894    0.7695 H   0  0  0  0  0  0
    1.4275    0.6092   -2.4825 H   0  0  0  0  0  0
    1.6156   -0.4486   -4.6977 H   0  0  0  0  0  0
    2.0720   -3.1623   -0.5097 H   0  0  0  0  0  0
    2.4550   -5.2793   -2.5035 H   0  0  0  0  0  0
    1.8647   -2.0849   -6.6059 H   0  0  0  0  0  0
    2.4669   -5.0294   -7.1083 H   0  0  0  0  0  0
    2.6529   -5.7470   -9.4054 H   0  0  0  0  0  0
    2.5346   -5.2432  -11.8298 H   0  0  0  0  0  0
    2.0107   -2.9236  -12.5760 H   0  0  0  0  0  0
    1.6191   -1.1697  -10.8391 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 29  1  0  0  0
  1 30  1  0  0  0
  1 31  1  0  0  0
  2  3  1  0  0  0
  2 32  1  0  0  0
  3  4  2  0  0  0
  3  5  1  0  0  0
  5  6  1  0  0  0
  5 10  2  0  0  0
  6  7  2  0  0  0
  6 33  1  0  0  0
  7  8  1  0  0  0
  7 34  1  0  0  0
  8  9  2  0  0  0
  8 35  1  0  0  0
  9 10  1  0  0  0
  9 36  1  0  0  0
 10 11  1  0  0  0
 11 12  1  0  0  0
 12 13  1  0  0  0
 12 17  2  0  0  0
 13 14  2  0  0  0
 13 37  1  0  0  0
 14 15  1  0  0  0
 14 38  1  0  0  0
 15 16  2  0  0  0
 15 20  1  0  0  0
 16 17  1  0  0  0
 16 18  1  0  0  0
 17 39  1  0  0  0
 18 19  1  0  0  0
 18 40  1  0  0  0
 19 20  2  0  0  0
 20 21  1  0  0  0
 21 22  2  0  0  0
 21 41  1  0  0  0
 22 23  1  0  0  0
 22 42  1  0  0  0
 23 24  1  0  0  0
 23 28  2  0  0  0
 24 25  2  0  0  0
 24 43  1  0  0  0
 25 26  1  0  0  0
 25 44  1  0  0  0
 26 27  2  0  0  0
 26 45  1  0  0  0
 27 28  1  0  0  0
 27 46  1  0  0  0
M  END
> <s_m_entry_id>
727

> <Applicants>
Pfizer

> <CHEMBL_ID>
CHEMBL1289926

> <Canonical_Smiles>
S(c1ccccc1C(=O)NC)c1cc2[nH]nc(c2cc1)\C=C\c1ncccc1

> <Chirality>
Achiral Molecule

> <First_Approval>
2012

> <Phase>
4

> <SC_Patent>
US-6534524-B1

> <Synonyms>
AG-013736 | AG-13736 | AXITINIB | INLYTA

> <Indications>
Used in kidney cell cancer and investigated for use/treatment in pancreatic and thyroid cancer.

> <Type>
2

> <targets_id>
P17948|P35968|P35916

> <inchi>
InChI=1S/C22H18N4OS/c1-23-22(27)18-7-2-3-8-21(18)28-16-10-11-17-19(25-26-20(17)14-16)12-9-15-6-4-5-13-24-15/h2-14H,1H3,(H,23,27)(H,25,26)/b12-9+

> <stdInchikey>
RITAVMQDGBJQJZ-FMIVXFBMSA-N

> <csid>
4953153

> <Links>
|http://www.chemspider.com/Chemical-Structure.4953153.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1289926|http://pubchem.ncbi.nlm.nih.gov/compound/6450551|http://www.drugbank.ca/drugs/DB06626| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=AXI|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/AXI|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5659|http://zinc15.docking.org/substances/ZINC03816287|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=C9LVQ0YUXG|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=25117

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
386.1

> <HBA>
4

> <HBD>
2

> <NRB>
5

> <TPSA>
70.7

> <LogP>
4.6

> <RoF>
0

> <Targets>
FLT1; KDR; FLT4

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_epik_Ionization_Penalty>
  0.0045

> <r_epik_State_Penalty>
  0.0032

> <i_epik_Tot_Q>
0

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
727

> <lig_pdbID>
'AXI'

> <pdbID>
4ag8 4agc 4twp 4wa9

> <Kinase families>
Tyr

> <indicationDB>
Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3).<sup class="text-reference-group"><a class="reference-popover-link" data-content="DRUG NAME: Axitinib - BC Cancer" href="#reference-L6676">7</a></sup> Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is reported to exhibit potency that is 50-450 times higher than that of the first generation VEGFR inhibitors.<sup class="text-reference-group"><a class="reference-popover-link" data-content="DRUG NAME: Axitinib - BC Cancer" href="#reference-L6676">7</a></sup> Axitinib is an indazole derivative.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Gross-Goupil M, Francois L, Quivy A, Ravaud A: Axitinib: a review of its safety and efficacy in the treatment of adults with advanced renal cell carcinoma. Clin Med Insights Oncol. 2013 Oct 29;7:269-77. doi: 10.4137/CMO.S10594. (PubMed ID 24250243)" href="#reference-A179398">6</a></sup> It is most commonly marketed under the name Inlyta® and is available in oral formulations.

> <uniprotId>
P17948|P35968|P35916|P08684|P20815|P05177|P33261|P22309|P08183|Q9Y6L6

> <BrandName>
Inlyta

> <Withdrawn>
|Study NCT03275558 in Singapore was Withdrawn during Phase 1 because Study halted prior to enrollment of first participant (It has been determined on 2018 May 15
    that the NCT03275558 study will be stopped by sponsor decision)|Study NCT04197219 in nan was Withdrawn during Phase 2 because PI is leaving institution|Study NCT01441388 in nan was Withdrawn during Phase 1 because Business/Operational issues

> <FDA_approved>
Y

$$$$
Cabozantinib
                    3D
 Structure written by MMmdl.
 62 66  0  0  1  0            999 V2000
    1.8719    3.5735   -1.7287 C   0  0  0  0  0  0
    0.5145    3.8982   -1.4453 O   0  0  0  0  0  0
   -0.3036    2.9592   -0.8402 C   0  0  0  0  0  0
    0.1515    1.6956   -0.4261 C   0  0  0  0  0  0
   -0.7233    0.7584    0.1776 C   0  0  0  0  0  0
   -0.3117   -0.5426    0.6087 C   0  0  0  0  0  0
   -1.2444   -1.3854    1.2170 C   0  0  0  0  0  0
   -2.5621   -0.9702    1.3814 C   0  0  0  0  0  0
   -2.9325    0.2509    0.9603 N   0  3  0  0  0  0
   -2.0800    1.1515    0.3628 C   0  0  0  0  0  0
   -2.5361    2.4203   -0.0452 C   0  0  0  0  0  0
   -1.6447    3.3224   -0.6471 C   0  0  0  0  0  0
   -2.0165    4.5855   -1.0750 O   0  0  0  0  0  0
   -3.3620    5.0195   -0.9056 C   0  0  0  0  0  0
    0.9849   -0.9859    0.4747 O   0  0  0  0  0  0
    1.5115   -1.3103   -0.7612 C   0  0  0  0  0  0
    2.8920   -1.4945   -0.8291 C   0  0  0  0  0  0
    3.5006   -1.8378   -2.0326 C   0  0  0  0  0  0
    2.7333   -1.9956   -3.1880 C   0  0  0  0  0  0
    1.3416   -1.8280   -3.1238 C   0  0  0  0  0  0
    0.7364   -1.4874   -1.9169 C   0  0  0  0  0  0
    3.4316   -2.3645   -4.3521 N   0  0  0  0  0  0
    3.0596   -2.2338   -5.6444 C   0  0  0  0  0  0
    2.0093   -1.7108   -6.0209 O   0  0  0  0  0  0
    4.0651   -2.7855   -6.6788 C   0  0  0  0  0  0
    3.7777   -4.2175   -7.1210 C   0  0  0  0  0  0
    3.5245   -3.0777   -8.0756 C   0  0  0  0  0  0
    5.5462   -2.3493   -6.6563 C   0  0  0  0  0  0
    6.4394   -3.1969   -6.6053 O   0  0  0  0  0  0
    5.7584   -1.0163   -6.7193 N   0  0  0  0  0  0
    6.9822   -0.3242   -6.6949 C   0  0  0  0  0  0
    6.9958    0.9387   -7.2928 C   0  0  0  0  0  0
    8.1637    1.6968   -7.2989 C   0  0  0  0  0  0
    9.3160    1.1971   -6.6966 C   0  0  0  0  0  0
    9.3089   -0.0537   -6.0840 C   0  0  0  0  0  0
    8.1434   -0.8156   -6.0772 C   0  0  0  0  0  0
   10.4491    1.9348   -6.7015 F   0  0  0  0  0  0
    2.3459    4.4178   -2.2289 H   0  0  0  0  0  0
    1.9481    2.7119   -2.3943 H   0  0  0  0  0  0
    2.4353    3.3743   -0.8158 H   0  0  0  0  0  0
    1.1833    1.4101   -0.5609 H   0  0  0  0  0  0
   -0.9438   -2.3657    1.5570 H   0  0  0  0  0  0
   -3.3366   -1.5696    1.8378 H   0  0  0  0  0  0
   -3.5738    2.6706    0.1183 H   0  0  0  0  0  0
   -3.4647    6.0306   -1.2992 H   0  0  0  0  0  0
   -3.6452    5.0463    0.1478 H   0  0  0  0  0  0
   -4.0603    4.3824   -1.4505 H   0  0  0  0  0  0
    3.4969   -1.3722    0.0577 H   0  0  0  0  0  0
    4.5722   -1.9773   -2.0595 H   0  0  0  0  0  0
    0.7096   -1.9757   -3.9857 H   0  0  0  0  0  0
   -0.3368   -1.3718   -1.8891 H   0  0  0  0  0  0
    4.3493   -2.7524   -4.1880 H   0  0  0  0  0  0
    4.6003   -4.9011   -7.3364 H   0  0  0  0  0  0
    2.9191   -4.7477   -6.7056 H   0  0  0  0  0  0
    2.4922   -2.8308   -8.3275 H   0  0  0  0  0  0
    4.1812   -2.9696   -8.9404 H   0  0  0  0  0  0
    4.9432   -0.4340   -6.8448 H   0  0  0  0  0  0
    6.1067    1.3361   -7.7618 H   0  0  0  0  0  0
    8.1755    2.6695   -7.7681 H   0  0  0  0  0  0
   10.2035   -0.4301   -5.6102 H   0  0  0  0  0  0
    8.1588   -1.7719   -5.5771 H   0  0  0  0  0  0
   -3.8957    0.5231    1.0969 H   0  0  0  0  0  0
  1  2  1  0  0  0
  1 38  1  0  0  0
  1 39  1  0  0  0
  1 40  1  0  0  0
  2  3  1  0  0  0
  3  4  1  0  0  0
  3 12  2  0  0  0
  4  5  2  0  0  0
  4 41  1  0  0  0
  5  6  1  0  0  0
  5 10  1  0  0  0
  6  7  2  0  0  0
  6 15  1  0  0  0
  7  8  1  0  0  0
  7 42  1  0  0  0
  8  9  2  0  0  0
  8 43  1  0  0  0
  9 10  1  0  0  0
  9 62  1  0  0  0
 10 11  2  0  0  0
 11 12  1  0  0  0
 11 44  1  0  0  0
 12 13  1  0  0  0
 13 14  1  0  0  0
 14 45  1  0  0  0
 14 46  1  0  0  0
 14 47  1  0  0  0
 15 16  1  0  0  0
 16 17  1  0  0  0
 16 21  2  0  0  0
 17 18  2  0  0  0
 17 48  1  0  0  0
 18 19  1  0  0  0
 18 49  1  0  0  0
 19 20  2  0  0  0
 19 22  1  0  0  0
 20 21  1  0  0  0
 20 50  1  0  0  0
 21 51  1  0  0  0
 22 23  1  0  0  0
 22 52  1  0  0  0
 23 24  2  0  0  0
 23 25  1  0  0  0
 25 26  1  0  0  0
 25 27  1  0  0  0
 25 28  1  0  0  0
 26 27  1  0  0  0
 26 53  1  0  0  0
 26 54  1  0  0  0
 27 55  1  0  0  0
 27 56  1  0  0  0
 28 29  2  0  0  0
 28 30  1  0  0  0
 30 31  1  0  0  0
 30 57  1  0  0  0
 31 32  1  0  0  0
 31 36  2  0  0  0
 32 33  2  0  0  0
 32 58  1  0  0  0
 33 34  1  0  0  0
 33 59  1  0  0  0
 34 35  2  0  0  0
 34 37  1  0  0  0
 35 36  1  0  0  0
 35 60  1  0  0  0
 36 61  1  0  0  0
M  CHG  1   9   1
M  END
> <s_m_entry_id>
728

> <Applicants>
Exelixis

> <CHEMBL_ID>
CHEMBL2105717

> <Canonical_Smiles>
Fc1ccc(NC(=O)C2(CC2)C(=O)Nc2ccc(Oc3c4cc(OC)c(OC)cc4ncc3)cc2)cc1

> <Chirality>
Achiral Molecule

> <First_Approval>
2012

> <Phase>
4

> <SC_Patent>
US-7579473-B2

> <Synonyms>
BMS-907351 | BMS-907351 FREE BASE | CABOMETYX | CABOZANTINIB | COMETRIQ | XL-184 | XL-184 FREE BASE | XL184

> <Indications>
For the treatment of metastatic medullary thyroid cancer and for the treatment of patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy.

> <Type>
2

> <targets_id>
P08581|P35968|P07949

> <inchi>
InChI=1S/C28H24FN3O5/c1-35-24-15-21-22(16-25(24)36-2)30-14-11-23(21)37-20-9-7-19(8-10-20)32-27(34)28(12-13-28)26(33)31-18-5-3-17(29)4-6-18/h3-11,14-16H,12-13H2,1-2H3,(H,31,33)(H,32,34)

> <stdInchikey>
ONIQOQHATWINJY-UHFFFAOYSA-N

> <csid>
25948202

> <Links>
|http://www.chemspider.com/Chemical-Structure.25948202.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2105717|http://pubchem.ncbi.nlm.nih.gov/compound/25102847|http://www.drugbank.ca/drugs/DB08875|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5887|http://zinc15.docking.org/substances/ZINC000070466416|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=1C39JW444G|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50021574

> <LinkName>
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

> <indicationG2P>
None

> <MW>
501.2

> <HBA>
6

> <HBD>
2

> <NRB>
8

> <TPSA>
98.8

> <LogP>
5.5

> <RoF>
2

> <Targets>
MET; KDR; RET

> <chiral flag>
0

> <version>
0

> <i_f3d_flags>
0

> <r_lp_tautomer_probability>
1

> <r_epik_Ionization_Penalty>
  0.0524

> <r_epik_State_Penalty>
  0.0450

> <i_epik_Tot_Q>
1

> <chiral flag>
1

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
728

> <Kinase families>
Tyr

> <indicationDB>
Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA Approved Drug Products: Cometriq (cabozantinib) oral capsules" href="#reference-L15123">6</a></sup> In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced renal cell carcinoma, and this same formulation gained additional approval in both the US and Canada in 2019 for the treatment of hepatocellular carcinoma in previously treated patients.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA Approved Drug Products: Cabometyx (cabozantinib) oral tablets" href="#reference-L15128">7</a>,<a class="reference-popover-link" data-content="Health Canada Product Monograph: Cabometyx (cabozantinib) oral tablets" href="#reference-L15133">8</a></sup>

> <uniprotId>
P08581|P35968|P07949|P08684|P11712|P10632

> <BrandName>
Cabometyx;Cometriq

> <Withdrawn>
|Study NCT04149275 in United States was Withdrawn during Phase 2 because Funding withdrawn by sponsor

> <FDA_approved>
Y

$$$$
gefitinib
                    3D
 Structure written by MMmdl.
 55 58  0  0  1  0            999 V2000
    7.3930    5.9834   -3.6531 Cl  0  0  0  0  0  0
    5.8768    8.3622   -2.6932 F   0  0  0  0  0  0
   -6.3937   -1.0488    2.3761 O   0  0  0  0  0  0
    0.0117   -0.0378   -0.0146 O   0  0  0  0  0  0
    1.2815   -2.2900    0.5975 O   0  0  0  0  0  0
   -4.0820    0.3545    1.4315 N   0  0  0  0  0  0
    3.7493    3.5178   -0.8913 N   0  0  0  0  0  0
    5.5866   -0.0938    0.0640 N   0  0  0  0  0  0
    5.6997    2.2083   -0.5353 N   0  0  0  0  0  0
   -2.6406    0.4991    1.2351 C   0  0  0  0  0  0
   -4.6309   -0.8050    0.7306 C   0  0  0  0  0  0
   -4.4049    0.2459    2.8505 C   0  0  0  0  0  0
   -2.2111    0.8585   -0.1985 C   0  0  0  0  0  0
   -6.1418   -0.9638    0.9773 C   0  0  0  0  0  0
   -5.9168    0.0882    3.0880 C   0  0  0  0  0  0
   -0.7100    1.1518   -0.3039 C   0  0  0  0  0  0
    1.3904    0.0070   -0.0117 C   0  0  0  0  0  0
    3.5517    1.1443   -0.2892 C   0  0  0  0  0  0
    2.1396    1.1707   -0.3131 C   0  0  0  0  0  0
    2.0648   -1.1901    0.3127 C   0  0  0  0  0  0
    4.2357   -0.0574    0.0369 C   0  0  0  0  0  0
    3.4812   -1.2094    0.3326 C   0  0  0  0  0  0
    4.3498    2.2830   -0.5828 C   0  0  0  0  0  0
    4.3291    4.7100   -1.3548 C   0  0  0  0  0  0
    6.2411    1.0319   -0.2205 C   0  0  0  0  0  0
    1.9263   -3.5130    0.9213 C   0  0  0  0  0  0
    5.4700    4.7399   -2.1914 C   0  0  0  0  0  0
    3.7072    5.9265   -1.0033 C   0  0  0  0  0  0
    5.9955    5.9681   -2.6397 C   0  0  0  0  0  0
    4.2306    7.1550   -1.4504 C   0  0  0  0  0  0
    5.3773    7.1777   -2.2659 C   0  0  0  0  0  0
   -2.2770    1.2880    1.8951 H   0  0  0  0  0  0
   -2.1326   -0.4129    1.5529 H   0  0  0  0  0  0
   -4.4622   -0.7153   -0.3420 H   0  0  0  0  0  0
   -4.1159   -1.7110    1.0544 H   0  0  0  0  0  0
   -3.8822   -0.6079    3.2849 H   0  0  0  0  0  0
   -4.0491    1.1308    3.3797 H   0  0  0  0  0  0
   -2.4623    0.0547   -0.8904 H   0  0  0  0  0  0
   -2.7660    1.7372   -0.5289 H   0  0  0  0  0  0
   -6.5120   -1.8674    0.4929 H   0  0  0  0  0  0
   -6.6932   -0.1234    0.5525 H   0  0  0  0  0  0
   -6.4552    0.9808    2.7650 H   0  0  0  0  0  0
   -6.1219   -0.0431    4.1506 H   0  0  0  0  0  0
   -0.4398    1.9484    0.3912 H   0  0  0  0  0  0
   -0.4774    1.4904   -1.3146 H   0  0  0  0  0  0
    1.6377    2.0909   -0.5668 H   0  0  0  0  0  0
    4.0216   -2.1111    0.5774 H   0  0  0  0  0  0
    2.7671    3.5782   -0.6657 H   0  0  0  0  0  0
    7.3196    0.9869   -0.1914 H   0  0  0  0  0  0
    5.9465    3.8260   -2.5117 H   0  0  0  0  0  0
    2.8253    5.9238   -0.3792 H   0  0  0  0  0  0
    1.1723   -4.2756    1.1155 H   0  0  0  0  0  0
    2.5365   -3.4167    1.8203 H   0  0  0  0  0  0
    2.5480   -3.8665    0.0976 H   0  0  0  0  0  0
    3.7507    8.0804   -1.1681 H   0  0  0  0  0  0
  1 29  1  0  0  0
  2 31  1  0  0  0
  3 14  1  0  0  0
  3 15  1  0  0  0
  4 16  1  0  0  0
  4 17  1  0  0  0
  5 20  1  0  0  0
  5 26  1  0  0  0
  6 10  1  0  0  0
  6 11  1  0  0  0
  6 12  1  0  0  0
  7 23  1  0  0  0
  7 24  1  0  0  0
  7 48  1  0  0  0
  8 21  1  0  0  0
  8 25  2  0  0  0
  9 23  2  0  0  0
  9 25  1  0  0  0
 10 13  1  0  0  0
 10 32  1  0  0  0
 10 33  1  0  0  0
 11 14  1  0  0  0
 11 34  1  0  0  0
 11 35  1  0  0  0
 12 15  1  0  0  0
 12 36  1  0  0  0
 12 37  1  0  0  0
 13 16  1  0  0  0
 13 38  1  0  0  0
 13 39  1  0  0  0
 14 40  1  0  0  0
 14 41  1  0  0  0
 15 42  1  0  0  0
 15 43  1  0  0  0
 16 44  1  0  0  0
 16 45  1  0  0  0
 17 19  1  0  0  0
 17 20  2  0  0  0
 18 19  2  0  0  0
 18 21  1  0  0  0
 18 23  1  0  0  0
 19 46  1  0  0  0
 20 22  1  0  0  0
 21 22  2  0  0  0
 22 47  1  0  0  0
 24 27  2  0  0  0
 24 28  1  0  0  0
 25 49  1  0  0  0
 26 52  1  0  0  0
 26 53  1  0  0  0
 26 54  1  0  0  0
 27 29  1  0  0  0
 27 50  1  0  0  0
 28 30  2  0  0  0
 28 51  1  0  0  0
 29 31  2  0  0  0
 30 31  1  0  0  0
 30 55  1  0  0  0
M  END
> <s_m_entry_id>
763

> <r_lp_tautomer_probability>
0.999978000241998

> <r_epik_Ionization_Penalty>
  0.4080

> <r_epik_State_Penalty>
  0.4064

> <i_epik_Tot_Q>
0

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
763

> <i_f3d_flags>
0

> <s_pdb_PDB_TITLE>
gefitinib

$$$$
Cimetidine
                    3D
 Structure written by MMmdl.
 33 33  0  0  1  0            999 V2000
    2.2939   -0.9199   -3.4400 S   0  0  0  0  0  0
   -0.2868   -4.7361   -2.5329 N   0  0  0  0  0  0
    0.3434   -0.1577   -0.9926 N   0  0  0  0  0  0
   -0.1377   -3.0389   -3.9601 N   0  0  0  0  0  0
   -1.9110    0.4698   -0.4353 N   0  0  0  0  0  0
   -0.0892    1.6881    0.3698 N   0  0  0  0  0  0
   -2.7769   -1.4458   -1.7653 N   0  0  0  0  0  0
    1.1432   -3.3875   -3.5211 C   0  0  0  0  0  0
    2.3576   -2.6467   -3.9992 C   0  0  0  0  0  0
    2.5181   -1.1200   -1.6477 C   0  0  0  0  0  0
    1.7878   -0.0272   -0.8602 C   0  0  0  0  0  0
    1.0630   -4.4440   -2.6368 C   0  0  0  0  0  0
    2.1204   -5.1872   -1.8910 C   0  0  0  0  0  0
   -0.9402   -3.8864   -3.3290 C   0  0  0  0  0  0
   -0.6227    0.6391   -0.3691 C   0  0  0  0  0  0
   -0.8719    2.6510    1.1268 C   0  0  0  0  0  0
   -2.3687   -0.5538   -1.1508 C   0  0  0  0  0  0
    2.4050   -2.6589   -5.0882 H   0  0  0  0  0  0
    3.2757   -3.1081   -3.6350 H   0  0  0  0  0  0
    2.1568   -2.0957   -1.3259 H   0  0  0  0  0  0
    3.5862   -1.0959   -1.4318 H   0  0  0  0  0  0
    2.1030    0.9586   -1.2046 H   0  0  0  0  0  0
    2.0527   -0.1010    0.1953 H   0  0  0  0  0  0
   -0.7028   -5.4582   -1.9625 H   0  0  0  0  0  0
    0.0633   -0.9255   -1.5877 H   0  0  0  0  0  0
    2.6457   -4.5255   -1.2026 H   0  0  0  0  0  0
    2.8534   -5.6087   -2.5787 H   0  0  0  0  0  0
    1.6940   -6.0060   -1.3107 H   0  0  0  0  0  0
   -2.0141   -3.8859   -3.4449 H   0  0  0  0  0  0
   -0.2156    3.4006    1.5688 H   0  0  0  0  0  0
   -1.4173    2.1557    1.9307 H   0  0  0  0  0  0
   -1.5881    3.1609    0.4815 H   0  0  0  0  0  0
    0.9084    1.8341    0.4226 H   0  0  0  0  0  0
  1  9  1  0  0  0
  1 10  1  0  0  0
  2 12  1  0  0  0
  2 24  1  0  0  0
  2 14  1  0  0  0
  3 11  1  0  0  0
  3 15  1  0  0  0
  3 25  1  0  0  0
  4 14  2  0  0  0
  4  8  1  0  0  0
  5 15  2  0  0  0
  5 17  1  0  0  0
  6 15  1  0  0  0
  6 16  1  0  0  0
  6 33  1  0  0  0
  7 17  3  0  0  0
  8  9  1  0  0  0
  8 12  2  0  0  0
  9 18  1  0  0  0
  9 19  1  0  0  0
 10 11  1  0  0  0
 10 20  1  0  0  0
 10 21  1  0  0  0
 11 22  1  0  0  0
 11 23  1  0  0  0
 12 13  1  0  0  0
 13 26  1  0  0  0
 13 27  1  0  0  0
 13 28  1  0  0  0
 14 29  1  0  0  0
 16 30  1  0  0  0
 16 31  1  0  0  0
 16 32  1  0  0  0
M  END
> <s_m_entry_id>
774

> <r_lp_tautomer_probability>
0.499999999999999

> <r_epik_Ionization_Penalty>
  0.2918

> <r_epik_State_Penalty>
  0.5243

> <i_epik_Tot_Q>
0

> <s_m_Source_Path>
/media/4tb_disk1/SijieChen/TKI/pharmacophore_hypothesis-2

> <s_m_Source_File>
screening_tkis_ligprep.maegz

> <i_m_Source_File_Index>
774

> <i_f3d_flags>
0

> <s_pdb_PDB_TITLE>
cimetidine

$$$$
